Drug ID	Drug Name	Drug Class	Synonymous	Drug Status	Drug Status Class	PubChem CID	DrugBank ID	TTD Drug ID	Molecular Weight	Polararea	Complexity	xlogp	Heavycnt	Hbonddonor	Hbondacc	Rotbonds	Formula	iupacname	canonicalsmiles	isosmiles	InChI	InChIKey
D53YOE	Hydroxyprogesterone caproate	Small molecule	HYDROXYPROGESTERONE CAPROATE; 630-56-8; Delalutin; Primolut Depot; Hydroxyprogesterone hexanoate; Hormofort; Proge; Syngynon; Depo-Proluton; Proluton Depot; Hylutin; Teralutil; Makena; Estralutin; Hyproval; Kaprogest; Neolutin; Lutate; Relutin; Progesterone caproate; Neolutin forte; 17-Caproxyprogesterone; Idrogestene; Duraluton; Hyroxon; Luteocrin; Lutopron; Luteocrin depot; Hyproval-PA; 17alpha-Hydroxyprogesterone caproate; NSC-17592; 17-alpha-hydroxy-progesterone caproate; Corlutin L.A.; Gesterol LA 250; 17-OHPC; Procyte depo; Progesterone retard pharlon; 17alpha-Caproyloxypregn-4-ene-3,20-dione; 17-alpha-Hydroxyprogesterone caproate; 17-((1-Oxohexyl)oxy)pregn-4-ene-3,20-dione; MLS000028438; 17a-hydroxyprogesterone caproate; Oxiprogesterone Caproate; 17 alpha-hydroxyprogesterone caproate; 17alpha-Hydroxyprogesterone hexanoate; 17.alpha.-caproyloxy-p4; Progesterone, 17-hydroxy-, hexanoate; SMR000058336; MLS001148643; CHEBI:5812; DTXSID6043915; 17-Hydroxypregn-4-ene-3,20-dione hexanoate; 17a-Hydroxyprogesterone hexanoate; Pregn-4-ene-3,20-dione, 17-hydroxy-, hexanoate; Pregn-4-ene-3,20-dione, 17-((1-oxohexyl)oxy)-; 17.alpha.-Hydroxyprogesterone caproate; 276F2O42F5; (8R,9S,10R,13S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl hexanoate; 17.alpha.-Hydroxyprogesterone hexanoate; NCGC00021268-03; 17.alpha.-Hydroxyprogesterone n-caproate; 3,20-Dioxopregn-4-en-17.alpha.-yl caproate; [(8R,9S,10R,13S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate; 17.alpha.-Hydroxypregn-4-ene-3,20-dione hexanoate; Pregn-4-ene-3,20-dione, 17-[(1-oxohexyl)oxy]-; DTXCID4023915; Gestiva; Hexanoic acid, ester with 17-hydroxypregn-4-ene-3,20-dione; Delalutin (TN); CAS-630-56-8; 17; A-Hydroxyprogesterone caproate; Idroprogesterone caproato; Hydroxyprogesteroni caproas; Lewntogest; Caproate d'hydroxyprogesterone; Caproato de hidroxiprogesterona; UNII-276F2O42F5; Idroprogesterone caproato [DCIT]; 17; A-Hydroxyprogesterone hexanoate; Hyproval P.A.; EINECS 211-138-8; Hylutin (TN); Makena (TN); 17-alpha-Hydroxyprogesterone hexanoate; 17alpha-Hydroxyprogesterone n-caproate; Hydroxyprogesteroni caproas [INN-Latin]; Progesterone, hexanoate; 17-alpha-Hydroxy progesterone n-caproate; 17-Caproyloxyprogesterone; 3,20-Dioxo-4-pregnen-17alpha-yl hexanoat; 3,20-Dioxopregn-4-en-17alpha-yl caproate; Caproate d'hydroxyprogesterone [INN-French]; Hydroxyprogesterone caproate [USP:INN:JAN]; Opera_ID_1479; 17alpha-Hydroxyprogesterone-17alpha caproate; 17-alpha-Hexanoyloxypregn-4-ene-3,20-dione; Caproato de hidroxiprogesterona [INN-Spanish]; Deluteval 2X (Salt/Mix); SCHEMBL5330; MLS002207289; 17alpha-Caproyloxyprogesterone; 17-hydroxyprogesterone-caproate; Caproic acid hydroxyprogesterone; cid_169870; CHEMBL1200848; BDBM70293; 17alpha-Hydroxyprogesteron-Caproat; HMS2230L08; BCP16081; HY-B0742; NSC17592; Tox21_113502; Tox21_302333; 17-alpha hydroxyprogesterone caproate; MFCD00072134; s4674; AKOS005267159; Tox21_113502_1; 17 alpha -Hydroxyprogesterone Caproate; CCG-268987; DB06789; GS-3233; NCGC00021268-04; NCGC00255784-01; (1S,11S,15S,2R,10R,14R)-14-acetyl-2,15-dimethyl-5-oxotetracyclo[8.7.0.0<2,7>.0 <11,15>]heptadec-6-en-14-yl hexanoate; HYDROXYPROGESTERONE CAPROATE [INN]; HYDROXYPROGESTERONE CAPROATE [JAN]; Pregn-4-ene-3, 17-hydroxy-, hexanoate; 17alpha-hexanoyloxy-4pregnene-3,20-dione; Hydroxyprogesterone caproate (JAN/USP/INN); HYDROXYPROGESTERONE CAPROATE [MART.]; HYDROXYPROGESTERONE CAPROATE [VANDF]; Pregn-4-ene-3, 17-[(1-oxohexyl)oxy]-; 17-Hydroxypregn-4-ene-3,20-dione caproate; H0994; HYDROXYPROGESTERONE CAPROATE [USP-RS]; HYDROXYPROGESTERONE CAPROATE [WHO-DD]; 17alpha-Hydroxyprogesterone hexanoate, >=98%; C08148; D00949; H10189; 17-.alpha.-Hexanoyloxypregn-4-ene-3,20-dione; 17alpha-Hydroxypregn-4-ene-3,20-diene Caproate; EN300-7422372; 17alpha-Hydroxyprogesterone caproate [Progestins]; 3,20-Dioxopregn-4-en-17.alpha.-yl hexanoate #; A834188; HYDROXYPROGESTERONE CAPROATE [ORANGE BOOK]; SR-01000003075; 17.alpha.-Hydroxypregn-4-ene-3,20-dione caproate; 17.ALPHA.-HYDROXYPROGESTERONE CAPROATE [MI]; HYDROXYPROGESTERONE CAPROATE [USP MONOGRAPH]; Q-201222; Q3792032; SR-01000003075-3; 17-Hydroxyprogesterone hexanoate;17-Hydroxyprogesterone caproate; Hydroxyprogesterone caproate, United States Pharmacopeia (USP) Reference Standard; (1R,3aS,3bR,9aR,9bS,11aS)-1-acetyl-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl hexanoate; (1S,2R,10R,11S,14R,15S)-14-acetyl-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl hexanoate; [(10R,13S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate; [(8R,9S,10R,13S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate;17-Caproxyprogesterone	Approved	Approved Drug(s)	169870	DB06789	D00AEQ	428.6	60.4	797	5.7	31	0	4	7	C27H40O4	[(8R,9S,10R,13S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate	CCCCCC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)C(=O)C	CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C	InChI=1S/C27H40O4/c1-5-6-7-8-24(30)31-27(18(2)28)16-13-23-21-10-9-19-17-20(29)11-14-25(19,3)22(21)12-15-26(23,27)4/h17,21-23H,5-16H2,1-4H3/t21-,22+,23+,25+,26+,27+/m1/s1	DOMWKUIIPQCAJU-LJHIYBGHSA-N
DVC29Q	Goserelin	Small molecule	goserelin; 65807-02-5; Zoladex; Decapeptide I; ICI 118630; ICI-118630; ICI 118,630; 0F65R8P09N; 1-(5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-O-tert-butyl-D-seryl-L-leucyl-L-arginyl-L-prolyl)semicarbazide; 1233494-97-7; Goserelina; Gosereline; Goserelinum; (S)-N-((6S,9S,12R,15S,18S,21S,24S)-21-((1H-indol-3-yl)methyl)-1-amino-12-(tert-butoxymethyl)-6-((S)-2-(2-carbamoylhydrazine-1-carbonyl)pyrrolidine-1-carbonyl)-15-(4-hydroxybenzyl)-18-(hydroxymethyl)-25-(1H-imidazol-4-yl)-1-imino-9-isobutyl-8,11,14,17,20,23-hexaoxo-2,7,10,13,16,19,22-heptaazapentacosan-24-yl)-5-oxopyrrolidine-2-carboxamide; Gosereline [French]; Goserelinum [Latin]; Goserelina [Spanish]; Goserelin [USAN:INN:BAN]; UNII-0F65R8P09N; goserelin-acetate; HSDB 7606; 4-D-Ser-goserelin; HS-2015; ZD-9393; GOSERELIN [INN]; GOSERELIN [MI]; Goserelin (USAN/INN); GOSERELIN [HSDB]; GOSERELIN [USAN]; D-Ser(t-Bu)(sup 6)aza-gly(sup 10)-GNRH; GOSERELIN [MART.]; GOSERELIN [WHO-DD]; SCHEMBL8643; CHEBI:5523; GTPL3879; CHEMBL1201247; DTXSID7048297; GOSERELIN [EP MONOGRAPH]; SCHEMBL19712239; SCHEMBL20459194; HMS2089D16; MFCD00867894; AKOS015994653; AKOS030213245; DB00014; NCGC00390804-01; HY-13673; (D-Ser(tBu)6,Azagly10)-LHRH (free base); D04405; AB01275466-01; EN300-7480905; Q1992653; (2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(TERT-BUTOXY)-2-[(2S)-2-[(2S)-3-HYDROXY-2-[(2S)-2-[(2S)-3-(1H-IMIDAZOL-4-YL)-2-{[(2S)-5-OXOPYRROLIDIN-2-YL]FORMAMIDO}PROPANAMIDO]-3-(1H-INDOL-3-YL)PROPANAMIDO]PROPANAMIDO]-3-(4-HYDROXYPHENYL)PROPANAMIDO]PROPANAMIDO]-4-METHYLPENTANAMIDO]-5-CARBAMIMIDAMIDOPENTANOYL]-N-(CARBAMOYLAMINO)PYRROLIDINE-2-CARBOXAMIDE	Approved	Approved Drug(s)	5311128	DB00014	D00BCG	1269.4	496	2560	-1.5	91	17	16	32	C59H84N18O14	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide	CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6	InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1	BLCLNMBMMGCOAS-URPVMXJPSA-N
DA2M4L	Chlorpropamide	Small molecule	chlorpropamide; 94-20-2; Chloropropamide; Diabinese; Glucamide; Meldian; Chlorpropamid; Diabenese; Chlorodiabina; Chloronase; Diabeneza; Diabetoral; Adiaben; Catanil; Diabaril; Dynalase; Insulase; Melitase; Diabechlor; Diabenal; Mellinese; Millinese; Asucrol; Glisema; Oradian; Diabet-Pages; Diamel Ex; 1-(4-Chlorophenylsulfonyl)-3-propylurea; Clorpropamide; Diabexan; Prodiaben; 4-chloro-N-(propylcarbamoyl)benzenesulfonamide; Chlorpropamidum; Clorpropamida; 1-(p-Chlorobenzenesulfonyl)-3-propylurea; 1-(4-chlorophenyl)sulfonyl-3-propylurea; 1-Propyl-3-(p-chlorobenzenesulfonyl)urea; N-(4-Chlorophenylsulfonyl)-N'-propylurea; N-(p-Chlorobenzenesulfonyl)-N'-propylurea; N-Propyl-N'-(p-chlorobenzenesulfonyl)urea; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide; 1-(p-Chlorophenylsulfonyl)-3-propylurea; 1-p-Chlorophenyl-3-(propylsulfonyl)urea; NCI-C01752; 4-Chloro-N-((propylamino)carbonyl)benzenesulfonamide; N-Propyl-N'-p-chlorphenylsulfonylcarbamide; 1-((p-Chlorophenyl)sulfonyl)-3-propylurea; n-Propyl-N'-p-chlorophenylsulfonylcarbamide; 1-[(4-chlorobenzene)sulfonyl]-3-propylurea; P 607; NSC 44634; Benzenesulfonamide, 4-chloro-N-((propylamino)carbonyl)-; U-9818; 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide; Benzenesulfonamide, 4-chloro-N-[(propylamino)carbonyl]-; Clorpropamid; MFCD00079004; NSC-44634; WTM2C3IL2X; CHEMBL498; NSC-626720; 1-(4-chlorobenzenesulfonyl)-3-propylurea; MLS000028395; CHEBI:3650; Bioglumin; DTXSID9020322; Insogen; Urea, 1-((p-chlorophenyl)sulfonyl)-3-propyl-; NSC626720; CAS-94-20-2; NCGC00015216-11; Chlorporpamide; SMR000058364; Clorpropamide [DCIT]; chlorpropamide, alpha-form; Clorpropamide [Italian]; Urea, 1-[(p-chlorophenyl)sulfonyl]-3-propyl-; chlorpropamide, epsilon-form; chlorpropamide, epsilon`-form; DTXCID30322; Chlorpropamidum [INN-Latin]; Clorpropamida [INN-Spanish]; Diabinese (TN); CCRIS 155; 1-(p-Chlorobenzensulfonyl)-3-propylurea; HSDB 2051; 4-chloro-n-(propylaminocarbonyl)benzenesulfonamide; SR-01000000060; 4-chloro-N-((propylaminocarbonyl)benzenesulfonamide; EINECS 202-314-5; UNII-WTM2C3IL2X; U-3818; NSC 626720; BRN 2218363; Urea, 1-((p-chloropenyl)sulfonyl)-3-propyl-; Prestwick_684; Chlorpropamide [USP:INN:BAN:JAN]; Chlorpropamide B.P.; Chlorpropamide-[d4]; Spectrum_000144; 1-(4-chlorophenyl)sulfonyl-3-propyl-urea; Opera_ID_359; ADENYLOSUCCINICACID; Prestwick0_000323; Prestwick1_000323; Prestwick2_000323; Prestwick3_000323; Spectrum2_000089; Spectrum3_000347; Spectrum4_000284; Spectrum5_000719; WLN: GR DSWMVM3; Lopac-C-1290; chlorpropamide, delta-form; 1-(4-chloro-benzenesulfonyl)-3-n-propyl-urea; C 1290; CHLORPROPAMIDE [MI]; CHLORPROPAMIDE [INN]; CHLORPROPAMIDE [JAN]; Lopac0_000229; SCHEMBL23947; BSPBio_000325; BSPBio_002013; CHLORPROPAMIDE [HSDB]; KBioGR_000808; KBioGR_002273; KBioSS_000624; KBioSS_002274; MLS001148665; CHLORPROPAMIDE [VANDF]; DivK1c_000513; SPECTRUM1500185; SPBio_000018; SPBio_002246; CHLORPROPAMIDE [MART.]; BPBio1_000359; GTPL6801; CHLORPROPAMIDE [USP-RS]; CHLORPROPAMIDE [WHO-DD]; HMS501J15; KBio1_000513; KBio2_000624; KBio2_002273; KBio2_003192; KBio2_004841; KBio2_005760; KBio2_007409; KBio3_001233; KBio3_002753; Chlorpropamide (JP17/USP/INN); cMAP_000007; NINDS_000513; HMS1569A07; HMS1920M05; HMS2091E08; HMS2096A07; HMS2233L19; HMS3259A17; HMS3260N19; HMS3373D09; HMS3428C03; HMS3652L03; HMS3713A07; Pharmakon1600-01500185; BCP09162; HY-B1429; NSC44634; CHLORPROPAMIDE [EP IMPURITY]; CHLORPROPAMIDE [ORANGE BOOK]; Tox21_110102; Tox21_201391; Tox21_302789; Tox21_500229; AC8695; BDBM50344965; CCG-38905; NSC756690; NSC813219; s4166; STK857458; CHLORPROPAMIDE [USP MONOGRAPH]; AKOS001482739; Tox21_110102_1; CS-4917; DB00672; KS-5316; LP00229; NC00503; NSC-756690; NSC-813219; SDCCGSBI-0050217.P005; IDI1_000513; MRF-0000539; NCGC00015216-01; NCGC00015216-02; NCGC00015216-03; NCGC00015216-04; NCGC00015216-05; NCGC00015216-06; NCGC00015216-07; NCGC00015216-08; NCGC00015216-09; NCGC00015216-10; NCGC00015216-12; NCGC00015216-13; NCGC00015216-14; NCGC00015216-17; NCGC00015216-18; NCGC00015216-23; NCGC00021451-03; NCGC00021451-04; NCGC00021451-05; NCGC00021451-06; NCGC00021451-07; NCGC00021451-08; NCGC00256414-01; NCGC00258942-01; NCGC00260914-01; SY052508; SBI-0050217.P004; AB00051944; C1220; Chlorpropamide, analytical standard, >=97%; EU-0100229; P-607; SW196839-3; A16447; D00271; Urea, 1-propyl-3-(p-chloro-benzenesulfonyl)-; AB00051944_16; AB00051944_17; EN300-7388134; Q1075324; SR-01000000060-2; SR-01000000060-4; SR-01000000060-6; W-100205; 4-Chloro-N-[(propylamino)-carbonyl]benzenesulfonamide; BRD-K97746869-001-05-6; BRD-K97746869-001-15-5; Z276509110; 1-Chloro-4-(([(propylamino)carbonyl]amino)sulfonyl)benzene #; Chlorpropamide, European Pharmacopoeia (EP) Reference Standard; Chlorpropamide, United States Pharmacopeia (USP) Reference Standard; Chlorpropamide, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	2727	DB00672	D00BCP	276.74	83.6	345	2.3	17	2	3	4	C10H13ClN2O3S	1-(4-chlorophenyl)sulfonyl-3-propylurea	CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl	CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl	InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)	RKWGIWYCVPQPMF-UHFFFAOYSA-N
DR6DI4	Niraparib	Small molecule	Niraparib; 1038915-60-4; MK-4827; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; MK4827; Niraparib [USAN]; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827; HMC2H89N35; CHEMBL1094636; C19H20N4O; Niraparib (USAN); ZL-2306; JNJ-64091742; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide;MK-4827; Niraparib [USAN:INN]; UNII-HMC2H89N35; MK 4827 (Base); 3JD; Zejula (TN); NIRAPARIB [INN]; NIRAPARIB [MI]; MK-4827(Niraparib); NIRAPARIB [WHO-DD]; GTPL8275; SCHEMBL1421875; AMY4192; DTXSID50146129; EX-A290; CHEBI:176844; MK-4827 (PARP-1); BDBM50316226; MFCD17779309; NSC754355; NSC800020; s2741; AKOS016004869; BCP9000940; CCG-267709; compound 56 [PMID 19873981]; CS-0780; DB11793; MK-4827/MK4827; NSC-754355; NSC-800020; NCGC00346435-01; NCGC00346435-04; AC-28447; AS-35248; HY-10619; BCP0726000077; D10140; EN300-7364833; A857972; Q25326660; 2-[4-(3S)-3-Piperidinylphenyl]-2H-indazole-7-carboxamide; 2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]; 2H-INDAZOLE-7-CARBOXAMIDE, 2-(4-(3S)-3-PIPERIDINYLPHENYL)-	Approved	Approved Drug(s)	24958200	DB11793	D00BMF	320.4	72.9	449	2.2	24	2	3	3	C19H20N4O	2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide	C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N	C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N	InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1	PCHKPVIQAHNQLW-CQSZACIVSA-N
D17HXI	Tazemetostat	Small molecule	Tazemetostat; 1403254-99-8; EPZ-6438; EPZ6438; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Tazemetostat [INN]; E7438; E-7438; Tazverik; Tazemetostat [USAN]; EPZ 6438; Tazemetostat(EPZ-6438); Tazemetostat (EPZ-6438); Q40W93WPE1; N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide; MFCD24849415; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-; N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide; UNII-Q40W93WPE1; TAZEMETOSTAT [MI]; Tazemetostat (USAN/INN); Tazemetostat [USAN:INN]; E 7438; TAZEMETOSTAT [WHO-DD]; GTPL7011; CHEMBL3414621; SCHEMBL13276848; SCHEMBL19325409; SCHEMBL22210809; EX-A509; DTXSID201025831; HMS3653O07; HMS3747A09; BCP07409; NSC777109; NSC791066; s7128; AKOS026750211; CCG-264672; CS-1758; DB12887; NSC-777109; NSC-791066; SB22955; NCGC00381562-01; NCGC00381562-10; AC-30931; AS-55991; DA-34776; HY-13803; SY040988; FT-0700193; SW220030-1; A12712; D11444; J-690163; J-690164; Q27088941; EPZ-6438; EPZ 6438; E7438; Tazemetostat; E-7438; E 7438; (R,Z)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((2-hydroxy-4-methoxy-6-methylpyridin-3-yl)methyl)-2-methyl-1H-indole-3-carbimi dic acid; 5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((2-hydroxy-4,6-dimethylpyridin-3-yl)methyl)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl) methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)biphenyl-3-carboxamide; N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-5-[ethyl(oxan-4-yl)amino]-4-methyl-4'-[(morpholin-4-yl)methyl]-[1,1'-biphenyl]-3-carboxamide; N-[(4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-5-[ethyl(tetrahydropyran-4-yl)amino]-4-methyl-4 inverted exclamation mark -(morpholinomethyl)biphenyl-3-carboxamide	Approved	Approved Drug(s)	66558664	DB12887	D00EQL	572.7	83.1	992	4.2	42	2	6	9	C34H44N4O4	N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide	CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5	CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5	InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)	NSQSAUGJQHDYNO-UHFFFAOYSA-N
DO6B7N	Agalsidase beta	Small molecule	Eliglustat tartrate; 928659-70-5; eliglustat hemitartrate; Cerdelga; Agalsidase beta; Eliglustat (hemitartrate); GENZ-112638; 104138-64-9; Eliglustat tartrate [USAN]; Eliglustat (Tartrate); Genz 112638; 928659-70-5 (tartrate); Eliglustat hemitartrate (Genz-112638); N0493335P3; N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide;(2R,3R)-2,3-dihydroxybutanedioic acid; N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide hemi((2R,3R)-2,3-dihydroxysuccinate); Genz-112638;Eliglustat tartrate; UNII-N0493335P3; Cerdelga (TN); eliglustat L-tartrate; ELIGLUSTAT TARTRATE [MI]; CHEBI:83353; Eliglustat tartrate (JAN/USAN); DTXSID50239166; ELIGLUSTAT TARTRATE [JAN]; Eliglustat tartrateGenz-112638; ELIGLUSTAT TARTRATE [WHO-DD]; HY-14885A; Genz-112638;Eliglustat hemitartrate; CS-5423; EX-A2301-1; ELIGLUSTAT TARTRATE [ORANGE BOOK]; AC-35333; bis(N-((1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(pyrrolidin-1- ylmethyl)ethyl)octanamide) (2R,3R)-2,3-dihydroxybutanedioate; MS-31794; Octanamide, N-((1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1- pyrrolidinylmethyl)ethyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); CERDELGA COMPONENT ELIGLUSTAT TARTRATE; S4433; C16736; D09894; ELIGLUSTAT TARTRATE COMPONENT OF CERDELGA; Q27156779; (1R,2R)-OCTANOIC ACID(2-(2',3'-DIHYDRO-BENZO(1,4) DIOXIN-6'-YL)-2-HYDROXY-1-PYRROLIDIN-1-YLMETHYL-ETHYL)-AMIDE-L-TARTARIC ACID SALT; bis{1-[(2R,3R)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-hydroxy-2-(octanoylamino)propyl]pyrrolidinium} (2R,3R)-2,3-dihydroxysuccinate; bis{N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]octanamide} (2R,3R)-2,3-dihydroxysuccinic acid; N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide ((2R,3R)-2,3-dihydroxysuccinate)(2:1); OCTANAMIDE, N-((1R,2R)-2-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-2-HYDROXY-1-(1-PYRROLIDINYLMETHYL)ETHYL)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (2:1)	Approved	Approved Drug(s)	52918379	DB00103	D00FIX	959.2	257	617	.	68	8	16	25	C50H78N4O14	N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide;(2R,3R)-2,3-dihydroxybutanedioic acid	CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O.C(C(C(=O)O)O)(C(=O)O)O	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O	InChI=1S/2C23H36N2O4.C4H6O6/c2*1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h2*10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t2*19-,23-;1-,2-/m111/s1	KUBARPMUNHKBIQ-VTHUDJRQSA-N
DUID31	Capecitabine	Small molecule	CAPECITABINE; 154361-50-9; Xeloda; Capiibine; Capecitibine; Captabin; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Capecytabine; Ro 09-1978; Capecitabine Sun; Capecitabine Teva; Capecitabine Medac; Capecitabine Accord; Ro 09-1978/000; Ecansya; Pentyl (1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate; C15H22FN3O6; Cytidine, 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; Ro-091978000; DTXSID3046451; CHEBI:31348; 6804DJ8Z9U; NSC-759853; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; Caxeta; Xabine; Capecitabine [USAN]; RO-09-1978000; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; pentyl 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-ylcarbamate; Cytidine, 5'-deoxy-5-fluoro-N-((pentyloxy)carbonyl)-; DTXCID1026451; capecitabina; capecitabinum; Capecitabin; Capecitabine (Xeloda); SMR002530052; Xeloda (TN); CAS-154361-50-9; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Cpecitabine; R340; UNII-6804DJ8Z9U; HSDB 7656; NCGC00164569-01; Capecitabine [USAN:USP:INN:BAN]; RG-340; Capecitabine- Bio-X; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Ro-09-1978; CAPECITABINE [MI]; R-340; CAPECITABINE [INN]; CAPECITABINE [JAN]; CAPECITABINE [HSDB]; Xelox component capecitabine; SCHEMBL8153; CAPECITABINE [VANDF]; CHEMBL1773; CAPECITABINE [MART.]; MLS003915642; MLS004774137; pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate; CAPECITABINE [USP-RS]; CAPECITABINE [WHO-DD]; Capecitabine (JAN/USP/INN); GTPL6799; CAPECITABINE [EMA EPAR]; Capecitabine, analytical standard; Capecitabine, >=98% (HPLC); EX-A835; BCPP000300; CAPECITABINE [ORANGE BOOK]; CAPECITABINE [EP MONOGRAPH]; CAPECITABINE [USP IMPURITY]; HY-B0016; XELIRI COMPONENT CAPECITIBINE; CAPECITABINE [USP MONOGRAPH]; Tox21_112198; MFCD00930626; s1156; AKOS015920130; Tox21_112198_1; AM84502; BCP9000483; BS-1000; CCG-264841; CS-0768; DB01101; NSC 759853; NCGC00164569-02; NCGC00164569-05; BC164277; BP-58647; 3-(2-HYDROXYETHYL)THIAZOLIUMBROMIDE; RO-9-1978; Ro-09-1978-000; D01223; n4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; AB01274776-01; AB01274776-02; AB01274776_04; 5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine; 5-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Q420207; SR-01000931255; 5-Deoxy-5-fluoro-N4-[(pentyloxy)carbonyl]cytidine; J-700154; Q-200788; SR-01000931255-3; BRD-K61192372-001-08-9; Z1501480421; Capecitabine, European Pharmacopoeia (EP) Reference Standard; Capecitabine, United States Pharmacopeia (USP) Reference Standard; Capecitabine, Pharmaceutical Secondary Standard; Certified Reference Material; CARBAMIC ACID, (1-(5-DEOXY-.BETA.-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINYL)-, PENTYL ESTER; PENTYL 1-(5-DEOXY-.BETA.-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINECARBAMATE	Approved	Approved Drug(s)	60953	DB01101	D00HCQ	359.35	121	582	0.6	25	3	7	7	C15H22FN3O6	pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate	CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O	CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O	InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1	GAGWJHPBXLXJQN-UORFTKCHSA-N
DNZ3V9	Moexipril	Small molecule	MOEXIPRIL; 103775-10-6; Uniretic; Univasc; Moexiprilum [INN-Latin]; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; Moexipril (INN); CI-925; 109715-88-0; RS-10085; CHEMBL1165; WT87C52TJZ; CHEBI:6960; Moexiprilum; MOEXIPRIL [INN]; Moexipril [INN:BAN]; (3S)-2-((2S)-N-((1S)-1-Carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, 2-ethyl ester; (3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (S)-2-((S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (S)-2-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; 3-Isoquinolinecarboxylic acid,2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-, (3S)-; UNII-WT87C52TJZ; MOEXIPRIL [MI]; MOEXIPRIL [VANDF]; MOEXIPRIL [WHO-DD]; SCHEMBL34030; BIDD:GT0007; GTPL6571; DTXSID9023330; [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, monohydrochloride;[3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, monohydrochloride; BDBM50084673; AKOS015843317; DB00691; NCGC00263546-03; (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; HY-117281; CS-0064930; C07704; D08225; AB01565830_02; A800803; EN300-19766737; Q2291605; BRD-K34441861-003-01-3; 4-(4-OXOPIPERIDINE-1-CARBONYL)PHENYLBORONICACID; (3S)-2-((2S)-2-(((1S)-1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-3-ISOQUINOLINECARBOXYLIC ACID; 1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-indole-2-carboxylic acid(moexipril); 3-ISOQUINOLINECARBOXYLIC ACID, 2-(2-((1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-, (3S-(2(R*(R*)),3R*))-	Approved	Approved Drug(s)	91270	DB00691	D00HDU	498.6	114	742	1.2	36	2	8	12	C27H34N2O7	(3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid	CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC(=C(C=C3CC2C(=O)O)OC)OC	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC	InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1	UWWDHYUMIORJTA-HSQYWUDLSA-N
D2GD1J	Trimipramine	Small molecule	trimipramine; Trimeprimine; 739-71-9; Surmontil; Trimeproprimine; Sapilent; beta-Methylimipramine; Trimeprimina [Italian]; (+)-Trimipramine; (-)-Trimipramine; Trimeprimina; Trimipraminum; Trimipraminum [INN-Latin]; Trimipramina [INN-Spanish]; 7162 RP; IL 6001; FI 6120; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine; IL-6001; RP-7162; 5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; Surmontyl; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile; CHEMBL644; 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; BRN 1321466; QJ9MUH57H8; 1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine; 10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 6S082C9NDT; CHEBI:9738; Trimeproprimin; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-; 5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-, (-)-; 9K5931C1H5; 3564-66-7; 3564-75-8; 7162-RP; Trimipramina; Rhotrimine; 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,.beta.-trimethyl-; 5-20-08-00099 (Beilstein Handbook Reference); Trimipramine [USAN:INN:BAN]; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-; 5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-; 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-; EINECS 212-008-3; Trimipramine (USAN/INN); UNII-QJ9MUH57H8; UNII-6S082C9NDT; 10633 RP; 10645 RP; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian]; UNII-9K5931C1H5; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethyl-1-propanamine; 5H-DIBENZ(B,F)AZEPINE-5-PROPANAMINE, 10,11-DIHYDRO-N,N,.BETA.-TRIMETHYL-; Spectrum_001422; .beta.-Methylimipramine; Prestwick0_000806; Prestwick1_000806; Prestwick2_000806; Prestwick3_000806; Spectrum2_001530; Spectrum3_001151; Spectrum4_000759; Spectrum5_001052; TRIMIPRAMINE [MI]; TRIMIPRAMINE [INN]; TRIMIPRAMINE [USAN]; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, (+)-; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, (-)-; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-, (+)-; TRIMIPRAMINE [VANDF]; Lopac0_001156; Oprea1_375679; SCHEMBL35144; BSPBio_000671; BSPBio_002701; KBioGR_001118; KBioSS_001902; TRIMIPRAMINE [MART.]; DivK1c_000093; TRIMIPRAMINE [WHO-DD]; TRIMIPRAMINE, (+)-; TRIMIPRAMINE, (-)-; SPBio_001320; SPBio_002592; BPBio1_000739; GTPL7317; DTXSID8023715; HY-B1213A; KBio1_000093; KBio2_001902; KBio2_004470; KBio2_007038; KBio3_002201; NINDS_000093; BCP06247; Trimipramine 1.0 mg/ml in Methanol; BDBM50240410; STL483796; AKOS015962182; 10645RP; CCG-205230; DB00726; FI-6120; SDCCGSBI-0051123.P004; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-; IDI1_000093; NCGC00016013-02; NCGC00016013-03; NCGC00016013-11; NCGC00162356-01; AC-15969; RP-10663; SBI-0051123.P003; AB00053646; CS-0013853; FT-0764503; D00394; AB00053646_10; AB00053646_11; A847268; EN300-24410256; L000969; Q423498; J-525116; BRD-A19195498-050-05-9; BRD-A19195498-050-09-1; (+)-5-[3-(Dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethyl-1-propanamine #; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethyl-propan-1-amine; 5-(.gamma.-Dimethylamino-.beta.-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5H-DIBENZ(B,F)AZEPINE, 5-(3-(DIMETHYLAMINO)-2-METHYLPROPYL)-10,11-DIHYDRO-, D-; 5H-DIBENZ(B,F)AZEPINE-5-PROPANAMINE, 10,11-DIHYDRO-N,N,.BETA.-TRIMETHYL-, (+)-; 5H-DIBENZ(B,F)AZEPINE-5-PROPANAMINE, 10,11-DIHYDRO-N,N,.BETA.-TRIMETHYL-, (-)-; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)-; (3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}-2-methylpropyl)dimethylamine; (3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}-2-methylpropyl)dimethylamine; 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,beta.-trimethyl-, (2Z)-2-butenedioate (1:1)	Approved	Approved Drug(s)	5584	DB00726	D00HZV	294.4	6.5	317	5.8	22	0	2	4	C20H26N2	3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine	CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C	CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C	InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3	ZSCDBOWYZJWBIY-UHFFFAOYSA-N
D6GX9O	Piroxicam	Small molecule	piroxicam; 36322-90-4; Feldene; Piroxicamum; Pyroxycam; Roxicam; Piroftal; BAXO; CP-16171; C15H13N3O4S; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 4-Hydroxy-2-methyl-N-(pyridin-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide; CP 16171; CHF 1251; NSC 666076; Piroxicam (Feldene); 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; NSC-666076; 13T4O6VMAM; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; CP-16,171; MLS000069644; CHEBI:8249; DTXSID5021170; NSC666076; 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; NCGC00015823-02; Artroxicam; Bruxicam; Caliment; Flogobene; Geldene; Improntal; Larapam; Piroflex; Reudene; Roxiden; Sasulen; SMR000035997; Solocalm; Erazon; Pirkam; piroxicam usp; Riacen; Zunden; Roxam; CAS-36322-90-4; 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; Piroxicamum [INN-Latin]; 1044566-76-8; DTXCID401170; Piroxicam D3 (N-methyl D3); Rosiden; Felden; Feldene Fast; Feldene Gel; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-Dioxide; 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; (3Z)-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1lambda6,2-benzothiazine-1,1,4-trione; (Z)-3-(hydroxy(pyridin-2-ylamino)methylene)-2-methyl-2H-benzo[e][1,2]thiazin-4(3H)-one 1,1-dioxide; Feldene (TN); CCRIS 3719; SR-01000000199; EINECS 252-974-3; AK1015; UNII-13T4O6VMAM; BRN 0627692; 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1?^{6},2-benzothiazine-3-carboxamide; Piroxicam,(S); Prestwick_573; MFCD00057317; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid [German]; Piroxicam [USAN:USP:INN:BAN:JAN]; piroxicam:malonic acid; Spectrum_001115; Tocris-0960; Piroxicam-(methyl-d3); Opera_ID_442; PIROXICAM [INN]; PIROXICAM [JAN]; Piroxicam: Form Alpha1; Piroxicam: Form Alpha2; PIROXICAM [MI]; PIROXICAM [USAN]; Prestwick0_000211; Prestwick1_000211; Prestwick2_000211; Prestwick3_000211; Spectrum2_001287; Spectrum3_000780; Spectrum4_000968; Spectrum5_001445; Lopac-P-5654; PIROXICAM [VANDF]; PIROXICAM ANHYDROUS; CHEMBL527; PIROXICAM [MART.]; P 5654; PIROXICAM [USP-RS]; PIROXICAM [WHO-DD]; BIDD:PXR0154; Lopac0_000900; Oprea1_714707; SCHEMBL13462; SCHEMBL21350; BSPBio_000221; BSPBio_001030; BSPBio_002460; KBioGR_000370; KBioGR_001315; KBioSS_000370; KBioSS_001595; MLS000038002; MLS001148207; MLS001304054; MLS004774122; DivK1c_000369; SPECTRUM1500491; SPBio_001293; SPBio_002142; Piroxicam (JP17/USP/INN); BPBio1_000245; GTPL7273; Piroxicam, >=98% (TLC); SCHEMBL3703617; PIROXICAM [ORANGE BOOK]; Piroxicam for system suitability; CHEMBL1518938; PIROXICAM [EP MONOGRAPH]; BCBcMAP01_000176; BDBM85245; HMS501C11; KBio1_000369; KBio2_000370; KBio2_001595; KBio2_002938; KBio2_004163; KBio2_005506; KBio2_006731; KBio3_000719; KBio3_000720; KBio3_001680; PIROXICAM [USP MONOGRAPH]; NINDS_000369; Piroxicam 1.0 mg/ml in Methanol; Bio1_000363; Bio1_000852; Bio1_001341; Bio2_000355; Bio2_000835; GLXC-26155; GLXC-26156; HMS1362D11; HMS1568L03; HMS1792D11; HMS1920H22; HMS1990D11; HMS2089B06; HMS2092A05; HMS2095L03; HMS2231G03; HMS3262D22; HMS3267I03; HMS3369B07; HMS3403D11; HMS3414H17; HMS3429L03; HMS3655C04; HMS3678H15; HMS3712L03; HMS3884C08; Pharmakon1600-01500491; BCP02919; HY-B0253; NSC_4856; Tox21_110231; Tox21_200151; Tox21_500900; CCG-36403; NSC757284; s1713; STK177288; AKOS000714958; AKOS025312555; AKOS026749939; Tox21_110231_1; AM84917; DB00554; KS-5322; LP00900; NSC-757284; SDCCGSBI-0050875.P005; (4-hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamid e; (4-Hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamide; 2H-1,2-Benzothiazine-3-carboxamide,4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3,4-Dihydro-2-methyl-4-oxo-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; IDI1_000369; IDI1_002110; NCGC00015823-01; NCGC00015823-03; NCGC00015823-04; NCGC00015823-05; NCGC00015823-06; NCGC00015823-07; NCGC00015823-08; NCGC00015823-09; NCGC00015823-10; NCGC00015823-11; NCGC00015823-12; NCGC00015823-13; NCGC00015823-14; NCGC00015823-15; NCGC00015823-17; NCGC00015823-18; NCGC00015823-20; NCGC00015823-29; NCGC00021244-03; NCGC00021244-05; NCGC00021244-06; NCGC00021244-07; NCGC00021244-08; NCGC00021244-09; NCGC00188982-01; NCGC00257705-01; NCGC00261585-01; AC-24190; NCI60_022912; BCP0726000299; SBI-0050875.P004; CAS_36322-90-4; Piroxicam, meets USP testing specifications; EU-0100900; FT-0630590; FT-0673949; P1905; SW219862-1; EN300-70724; A19556; C01608; D00127; D70554; AB00052074-21; AB00052074-22; AB00052074_23; AB00052074_24; Q408676; SR-01000000199-3; SR-01000000199-5; SR-01000000199-9; W-106626; SR-01000000199-12; F0001-2399; Piroxicam, British Pharmacopoeia (BP) Reference Standard; Z1137167677; Piroxicam, European Pharmacopoeia (EP) Reference Standard; Piroxicam, United States Pharmacopeia (USP) Reference Standard; Piroxicam, Pharmaceutical Secondary Standard; Certified Reference Material; 4-hydroxy-2-methyl-1,1-dioxo-N-(2-pyridyl)-1$l^{6},2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1$l^{6},2-benzothiazine-3-carboxamide; 4-Hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-2H-1,2-benzothiazine 1,1-Dioxide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzo-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-(pyridin-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide1,1-dioxide; N-(2-pyridyl)-4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1$l^{6},2-benzothiazine-1,1,4-trione; 3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1lambda6,2-benzothiazine-1,1,4-trione; 4-hydroxy-2-methyl-1,1-dioxo-N-(2-pyridyl)-1,2-dihydro-1lambda,2-benzothiazine-3-carboxamide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine -3-carboxamide-1,1-dioxide malonic acid	Approved	Approved Drug(s)	54676228	DB00554	D00IBN	331.3	108	611	3.1	23	2	6	2	C15H13N3O4S	4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide	CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3	CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3	InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)	QYSPLQLAKJAUJT-UHFFFAOYSA-N
DQH5T6	Pimozide	Small molecule	pimozide; 2062-78-4; Orap; Opiran; Pimozidum; McN-JR-6238; Pimozidum [INN-Latin]; R-6238; R 6238; R6238; NSC 170984; McN-JR 6238; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 2H-Benzimidazol-2-one, 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-; NSC-170984; 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1HIZ4DL86F; CHEMBL1423; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; MLS000028410; MLS002702058; CHEBI:8212; DTXSID8023474; NSC170984; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 2H-Benzimidazol-2-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro-; pimozida; NCGC00015802-08; NCGC00015802-18; Primozida; SMR000058385; CAS-2062-78-4; R 623; R-623; 1-(1-(4,4-bis(4-fluorophenyl)butyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; Primozida [INN-Spanish]; DTXCID803474; Primozide; Pimozida [INN-Spanish]; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one; CCRIS 9172; Orap (TN); SR-01000075392; EINECS 218-171-7; UNII-1HIZ4DL86F; BRN 0729089; Prestwick_395; MFCD00055081; Pimozide [USAN:USP:INN:BAN:JAN]; Spectrum_000445; Tocris-0937; PIMOZIDE [USAN]; PIMOZIDE [INN]; PIMOZIDE [JAN]; PIMOZIDE [MI]; PIMOZIDE [VANDF]; Opera_ID_1580; Prestwick0_000308; Prestwick1_000308; Prestwick2_000308; Prestwick3_000308; Spectrum2_001026; Spectrum3_001451; Spectrum4_000420; Spectrum5_001308; Lopac-P-1793; PIMOZIDE [MART.]; GTPL90; PIMOZIDE [USP-RS]; PIMOZIDE [WHO-DD]; NCIMech_000356; P 1793; Lopac0_000946; SCHEMBL41584; BSPBio_000276; BSPBio_001439; BSPBio_002941; KBioGR_000720; KBioSS_000925; 5-24-02-00367 (Beilstein Handbook Reference); MLS001077311; BIDD:GT0435; DivK1c_000386; Methyl-(2-m-tolylethyl)amine; SPECTRUM1501134; Pimozide (JP17/USP/INN); SPBio_001211; SPBio_002495; PIMOZIDE [ORANGE BOOK]; BPBio1_000304; SCHEMBL7519553; PIMOZIDE [EP MONOGRAPH]; PIMOZIDE [USP MONOGRAPH]; BCBcMAP01_000043; HMS501D08; KBio1_000386; KBio2_000925; KBio2_003493; KBio2_006061; KBio3_002441; NINDS_000386; HMS1568N18; HMS1791H21; HMS1921H19; HMS1989H21; HMS2089C11; HMS2092F09; HMS2095N18; HMS2231P23; HMS3262N14; HMS3267E19; HMS3370N13; HMS3402H21; HMS3411J16; HMS3675J16; HMS3712N18; Pharmakon1600-01501134; Tox21_110224; Tox21_301586; Tox21_500946; BDBM50334150; CCG-35918; CCG-36461; CCG-39728; NSC757854; s4358; 2-Benzimidazolinone, 1-[1-[4,4-bis(p-fluorophenyl)butyl]-4-piperidyl]-; 3-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidyl]-1H-benzimidazol-2-one; AKOS024458706; Tox21_110224_1; DB01100; LP00946; NSC-757854; SDCCGSBI-0050920.P004; IDI1_000386; SMP1_000241; NCGC00015802-01; NCGC00015802-02; NCGC00015802-03; NCGC00015802-04; NCGC00015802-05; NCGC00015802-06; NCGC00015802-07; NCGC00015802-09; NCGC00015802-10; NCGC00015802-11; NCGC00015802-12; NCGC00015802-13; NCGC00015802-14; NCGC00015802-15; NCGC00015802-16; NCGC00015802-26; NCGC00015802-29; NCGC00016601-01; NCGC00022282-03; NCGC00024888-01; NCGC00024888-02; NCGC00024888-03; NCGC00024888-04; NCGC00024888-05; NCGC00024888-06; NCGC00024888-07; NCGC00255294-01; NCGC00261631-01; AS-13916; HY-12987; SBI-0050920.P003; AB00052215; CS-0012921; EU-0100946; FT-0673903; SW196639-3; C07566; D00560; EN300-127038; F70142; AB00052215-06; AB00052215_07; AB00052215_08; L000494; Q144085; WLN: T56 BMVNJ D- DT6NTJ A3YR DF&R DF; J-013477; SR-01000075392-1; SR-01000075392-3; SR-01000075392-4; SR-01000075392-6; BRD-K01292756-001-06-0; BRD-K01292756-001-13-6; Pimozide, European Pharmacopoeia (EP) Reference Standard; 2-Benzimidazolinone,4-bis(p-fluorophenyl)butyl]-4-piperidyl]-; N-benzyl-N-(3-isobutoxy-2-(pyrrolidin-1-yl)propyl)benzenamine; Pimozide, United States Pharmacopeia (USP) Reference Standard; 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[1-[4,4-Bis(p-flurophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-(1-(4,4-bis(4-fluorophenyl)butyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one; 1-{1-[4,4-bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one; 2H-Benzimidazol-2-one,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-; 1-{1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one(Pimozide); 2H-BENZIMIDAZOL-2-ONE, 1-(1-(4,4-BIS(4-FLUOROPHENYL)BUTYL)-4-PIPERIDINYL)-1,3-DIHYDRO; Pimozide (1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidaol-2-one); PIMOZIDE1-{1-[4,4-BIS-(4-FLUORO-PHENYL)-BUTYL]-PIPERIDIN-4-YL}-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONE	Approved	Approved Drug(s)	16362	DB01100	D00KHM	461.5	35.6	632	6.3	34	1	4	7	C28H29F2N3O	3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one	C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F	C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F	InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)	YVUQSNJEYSNKRX-UHFFFAOYSA-N
DXPY20	Protriptyline	Small molecule	protriptyline; Protryptyline; Amimetilina; 438-60-8; Vivactil; Triptil; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; Vivactyl; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; Protriptyline (INN); PROTRYPTYLINE HYDROCHLORIDE; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; CHEMBL668; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; 5H-Dibenzo(a,d)cycloheptene-5-propanamine, N-methyl-; CHEBI:8597; 3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; 4NDU154T12; 5H-Dibenzo(a,d)cycloheptene-5-propylamine, N-methyl-; 5H-Dibenzo[a,d]cycloheptene-5-propanamine, N-methyl-; Protriptilina; Protriptylinum; MK-240; 3-(11H-dibenzo[1,2-a:1',2'-e][7]annulen-11-yl)-N-methylpropan-1-amine; PROTRIPTYLINE [INN]; N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenyl)propan-1-amine; Protriptyline [INN:BAN]; Protriptylinum [INN-Latin]; Protriptilina [INN-Spanish]; NSC169912; HSDB 3391; NCGC00015851-02; EINECS 207-119-9; CAS-1225-55-4; 5H-Dibenzo[a,d]cycloheptene-5-propylamine, N-methyl-; BRN 2217411; UNII-4NDU154T12; 5H-Dibenzo(a,d)cycloheptene-5-propanamine, N-methyl-, hydrochloride; Vivactil (Salt/Mix); Concordin (Salt/Mix); Prestwick0_000930; Prestwick1_000930; Prestwick2_000930; Prestwick3_000930; Lopac-P-8813; PROTRIPTYLINE [MI]; PROTRIPTYLINE [HSDB]; BIDD:PXR0157; Lopac0_000974; SCHEMBL34267; BSPBio_000840; PROTRIPTYLINE [VANDF]; SPBio_003019; PROTRIPTYLINE [WHO-DD]; BPBio1_000924; GTPL7285; DTXSID0023535; HY-B0949A; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; BDBM50176062; MK 240; PDSP1_001390; PDSP2_001374; AKOS015962184; CCG-205054; DB00344; SDCCGSBI-0050947.P003; NCGC00015851-01; NCGC00015851-03; NCGC00015851-04; NCGC00015851-05; NCGC00015851-06; NCGC00015851-07; NCGC00015851-15; NCGC00024439-03; AC-15971; SBI-0050947.P002; AB00489964; CS-0013761; C07408; D08447; AB00489964_10; EN300-18552820; L000913; Q408432; BRD-K42098891-003-03-1; 3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine #; 3-(11H-dibenzo[[?],[?]][7]annulen-11-yl)-N-methyl-propan-1-amine; methyl(3-{tricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-yl}propyl)amine; methyl(3-{tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-yl}propyl)amine	Approved	Approved Drug(s)	4976	DB00344	D00MYQ	263.4	12	296	4.4	20	1	1	4	C19H21N	N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenyl)propan-1-amine	CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13	CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13	InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3	BWPIARFWQZKAIA-UHFFFAOYSA-N
D64LYP	Venetoclax	Small molecule	Venetoclax; 1257044-40-8; ABT-199; Venclexta; GDC-0199; ABT199; ABT 199; RG7601; Venetoclax (ABT199); GDC 0199; RG-7601; Venetoclax; Abt-199; Venetoclax(ABT-199); 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; Venetoclax (ABT-199); N54AIC43PW; ABT-199 (GDC-0199); 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-; venclyxto; BDBM189459; UNII-N54AIC43PW; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(oxan-4-ylmethyl)amino]benzene}sulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; Venetoclax [USAN:INN]; Venclexta (TN); Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-; VENETOCLAX [MI]; VENETOCLAX [INN]; VENETOCLAX [JAN]; VENETOCLAX [USAN]; VENETOCLAX [WHO-DD]; 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide; MLS006010298; SCHEMBL523816; Venetoclax (JAN/USAN/INN); AMY343; GTPL8318; CHEMBL3137309; SCHEMBL19236295; VENETOCLAX [ORANGE BOOK]; BDBM60828; DTXSID30154863; EX-A168; CHEBI:133021; HMS3653J06; HMS3745E07; BCP06811; BDBM50162774; MFCD23160052; NSC766270; AKOS025289539; CCG-270543; CS-1155; DB11581; KS-1470; NSC-766270; SB16499; NCGC00345789-01; NCGC00345789-05; NCGC00345789-10; NCGC00345789-11; AC-28754; DA-35360; HY-15531; SMR004701366; FT-0699586; S8048; SW219672-1; J3.516.625D; D10679; US9174982, 5; EN300-7399830; A850921; US9174982, 369; J-005269; Q23671272; Z2037279542; 2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2HPYRAN-4-YLMETHYL) AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzenesulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide; 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(tetrahydropyran-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	Approved	Approved Drug(s)	49846579	DB11581	D00PBX	868.4	183	1640	8.2	61	3	11	12	C45H50ClN7O7S	4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C	CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C	InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)	LQBVNQSMGBZMKD-UHFFFAOYSA-N
DVC3A9	Eltrombopag	Small molecule	Eltrombopag; 496775-61-2; (Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; SB497115; Eltrombopag [INN]; SB 497115; UNII-S56D65XJ9G; (ZE)-Eltrombopag; Eltrombopag free base; SB-497115; CHEMBL461101; S56D65XJ9G; 3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; DTXSID5057753; CHEBI:85010; Eltrombopag (SB-497115-GR); 496775-61-2 (free base); 1807882-48-9; 376591-99-0; NCGC00274067-01; (1,1'-Biphenyl)-3-carboxylic acid, 3'-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-; (Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,; 3'-{2-[(4E)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; AMG531; HSDB 8212; 3'-((2Z)-2-(1-(3,4-DIMETHYLPHENYL)-3-METHYL-5-OXO-1,5-DIHYDRO-4H-PYRAZOL-4-YLIDENE)DIAZANYL)-2'-HYDROXYBIPHENYL-3-CARBOXYLIC ACID; 3'-{(2z)-2-(1-[3,4-dimethylphenyl]-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)diazanyl}-2'-hydroxybiphenyl-3-carboxylic acid; Eltrombopag- Bio-X; ELTROMBOPAG [MI]; SB-497 115; ELTROMBOPAG [VANDF]; ELTROMBOPAG [MART.]; SCHEMBL18910; ELTROMBOPAG [WHO-DD]; MLS006010024; SCHEMBL164270; SCHEMBL211081; SCHEMBL211082; ELTROMBOPAG [EMA EPAR]; CHEMBL478463; GTPL6961; CHEMBL3186485; DTXCID6031542; EX-A443; BCPP000243; HMS3655B14; HMS3743O17; AMY10836; BCP01884; Tox21_113965; BDBM50248106; MFCD20926253; MFCD21090400; s4502; AKOS015920246; AKOS026750537; AKOS037515498; BCP9000641; CCG-269152; CS-1565; DB06210; EX-7216; SB19101; NCGC00274067-02; 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid; AS-19180; AS-35176; BE164406; HY-15306; SMR004701208; CAS-496775-61-2; FT-0660417; SW219608-1; SB-497115-GR;SB497115; A12686; A25156; C75316; EN300-260743; AB01274808-01; AB01274808_02; EN300-1709152; EN300-23586760; Q411588; Z2568748600; (1,1'-BIPHENYL)-3-CARBOXYLIC ACID, 3'-(2-(1-(3,4-DIMETHYLPHENYL)-4,5-DIHYDRO-3-METHYL-5-OXO-1H-PYRAZOL-4-YL)DIAZENYL)-2'-HYDROXY-; (E)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; (Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxybiphenyl-3-carboxylic acid; 2097678-09-4; 3'-[(2Z)- [1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazinyl}-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid; 3'-{2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-(3-{2-[(4Z)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2-hydroxyphenyl)benzoic acid; 3-[(5E)-5-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid; 3-[(5E)-5-{2-[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]hydrazin-1-ylidene}-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid; 3-[(5Z)-5-{2-[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]hydrazin-1-ylidene}-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid; 3-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2-hydroxy-[1,1-biphenyl]-3-carboxylic acid; 3-[3-[2-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazole-4-ylidene]hydrazino]-2-hydroxyphenyl]benzoic acid; SB 497115; SB497115GR;3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid	Approved	Approved Drug(s)	135449332	DB06210	D00PEH	442.5	115	812	5.4	33	3	7	5	C25H22N4O4	3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid	CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C	CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C	InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33)	SVOQIEJWJCQGDQ-UHFFFAOYSA-N
DI5ZJ8	Trametinib	Small molecule	Trametinib; 871700-17-3; GSK1120212; Mekinist; GSK-1120212; JTP 74057; JTP-74057; GSK 1120212; Trametinib (GSK1120212); N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide; GSK212; TMT212; Trametinib [USAN]; CHEBI:75998; TMT-212; 33E86K87QN; Trametinib (USAN); N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide; N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide; N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide; Acetamide, N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-3,4,6,7-tetrahydro-6,8- dimethyl-2,4,7-trioxopyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)-; UNII-33E86K87QN; Trametinib [USAN:INN]; trametinibum; JTP74057; N-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)acetamide; N-(3-{3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2H)-yl}phenyl)acetamide; QOM; TRAMETINIB [MI]; TRAMETINIB [INN]; TRAMETINIB [VANDF]; TRAMETINIB [WHO-DD]; SCHEMBL170938; GTPL6495; GSK1120212 (Trametinib); CHEMBL2103875; EX-A022; BCPP000218; DTXSID901007381; HMS3295I05; HMS3656J11; BCP02307; BDBM50531540; MFCD17215075; NSC758246; NSC800956; s2673; AKOS015850628; AM90271; CCG-264976; CS-0060; DB08911; EX-5957; NSC-758246; NSC-800956; SB16553; NCGC00263180-01; NCGC00263180-07; NCGC00263180-14; AC-25891; AS-19382; HY-10999; N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide; FT-0688438; SW218089-2; A25168; D10175; GSK1120212 - JTP-74057; EN300-25299821; GSK1120212,JTP-74057, GSK212; SR-01000941589; A1-01871; J-523325; Q7833138; SR-01000941589-1; BRD-K12343256-001-01-4; Acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-; N-(3-(3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide; N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-1H,2H,3H,4H,6H,7H-pyrido[4,3-d]pyrimidin-1-yl}phenyl)acetamide; N-[3-[3-Cyclopropyl-5-[(2-Fluoro-4-Iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phe nyl]acetamide; N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide; N-{3-[3-Cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl}ethanimidic acid; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide	Approved	Approved Drug(s)	11707110	DB08911	D00QDJ	615.4	102	1090	3.4	37	2	6	5	C26H23FIN5O4	N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide	CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5	CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5	InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)	LIRYPHYGHXZJBZ-UHFFFAOYSA-N
DTH5D4	Enalapril	Small molecule	enalapril; 75847-73-3; Vasotec; Enalaprilum; Enalaprila; Olinapril; Enalaprilum [INN-Latin]; Enalaprila [INN-Spanish]; Enalapril (INN); Epaned; CHEMBL578; 1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester; Bonuten; 69PN84IO1A; CHEBI:4784; DTXSID5022982; C09AA02; (S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline; NCGC00021569-04; ENALAPRIL [INN]; ((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-L-proline; L-Proline, N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-; Enalapril Richet; MK-421; (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid; (2S)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]pyrrolidine-2-carboxylic acid; (S)-1-{(S)-2-[1-((S)-Ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid; DTXCID202982; Gadopril; HSDB 6529; Enalapril (TN); CAS-75847-73-3; Enalapril [INN:BAN]; analapril; UNII-69PN84IO1A; Enaladex; L-Proline, N-((1S)-1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl-; Enalapril, AldrichCPR; Spectrum_001307; ENALAPRIL [MI]; SCHEMBL18; Prestwick3_000314; Spectrum2_001455; Spectrum3_001478; Spectrum4_000008; Spectrum5_001107; ENALAPRIL [VANDF]; Enalapril Maleate Usp Xxi; ENALAPRIL [MART.]; ENALAPRIL [WHO-DD]; BSPBio_000308; BSPBio_003035; KBioGR_000355; KBioSS_001787; BIDD:GT0751; DivK1c_000408; SPBio_001349; BPBio1_000340; GTPL6322; KBio1_000408; KBio2_001787; KBio2_004355; KBio2_006923; KBio3_002535; NINDS_000408; HMS2090E08; HY-B0331; N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline; Tox21_110872; BDBM50017129; MFCD00865774; N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline; AKOS025310615; Tox21_110872_1; DB00584; IDI1_000408; NCGC00016932-01; NCGC00021569-05; NCGC00021569-06; NCGC00021569-09; SBI-0051691.P002; CAS-76095-16-4; C06977; D07892; H10947; AB00053615-17; AB00053615-18; AB00053615_19; AB00053615_20; EN300-7481394; A838525; A838609; Q422185; BRD-K57545991-050-16-5; N-(1(S)-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline; N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline; N-[(2S)-1-Ethoxy-1-oxo-4-phenyl-2-butanyl]-L-alanyl-L-proline; Nalpha -[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline; L-Proline, 1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-, (S)-; (s)-1-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-l-proline;Enalapril maleate salt; (SSS)1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid; 1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid; (2S)-1-[(2S)-2-[[(1R)-1-ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]pyrrolidine-2-carboxylic acid; maleic acid; (S)-1-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)pyrrolidine-2-carboxylic acid; (S)-1-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)pyrrolidine-2-carboxylicacid; (S)-1-((S)-2-((R)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)pyrrolidine-2-carboxylic acid; (S)-1-[(R)-2-((R)-1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid; (S,S,S)-1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid; 1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid (Enalapril); 1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid(enalapril); 2-[2-(1-Carboxy-3-phenyl-propylamino)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid(enalapril)	Approved	Approved Drug(s)	5388962	DB00584	D00SEB	376.4	95.9	519	-0.1	27	2	6	10	C20H28N2O5	(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid	CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O	InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1	GBXSMTUPTTWBMN-XIRDDKMYSA-N
D3O2LQ	Umeclidinium	Small molecule	UMECLIDINIUM; Umeclidinium [USAN]; Umeclidinium ion; Umeclidinium cation; UNII-GE2T1418SV; GSK573719; GE2T1418SV; 869185-19-3; GSK-573719; Umeclidinium (USAN); CHEMBL523299; 1-(2-(Benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)-1-azoniabicyclo(2.2.2)octane; 1-[2-(benzyloxy)ethyl]-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane; 1-Azoniabicyclo(2.2.2)octane, 4-(hydroxydiphenylmethyl)-1-(2-(phenylmethoxy)ethyl)-; 1-(2-(BENZYLOXY)ETHYL)-4-(HYDROXY(DIPHENYL)METHYL)-1-AZONIABICYCLO(2.2.2)OCTANE; UMECLIDINIUM [VANDF]; UMECLIDINIUM [WHO-DD]; GTPL7354; SCHEMBL2033192; CHEMBL1187833; CHEBI:79041; DTXSID00235971; BDBM50267614; DB09076; NCGC00379061-01; D10180; Q21011235; di(phenyl)-[1-[2-(phenylmethoxy)ethyl]-1-azoniabicyclo[2.2.2]octan-4-yl]methanol	Approved	Approved Drug(s)	11519070	DB09076	D00SLY	428.6	29.5	543	4.7	32	1	2	8	C29H34NO2+	diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol	C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5	C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5	InChI=1S/C29H34NO2/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25/h1-15,31H,16-24H2/q+1	FVTWTVQXNAJTQP-UHFFFAOYSA-N
DA27OM	Nilotinib	Small molecule	Nilotinib; 641571-10-0; Tasigna; AMN107; AMN 107; AMN-107; Nilotinib free base; Nilotinib (AMN-107); MFCD09833716; 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide; NSC-747599; CHEMBL255863; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; CHEBI:52172; 641571-10-0 (free base); NSC747599; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; F41401512X; 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-{(4-(pyridin-3-yl)pyrimidin-2-yl)amino}benzamide; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-; Nilotinib & its intermediates; nilotinibum; Nilotinib(AMN-107); 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide; Nilotinib,AMN107,Tasigna;4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; SMR002544680; Nilotinib [USAN]; C28H22F3N7O; Nilotinib [USAN:INN:BAN]; HSDB 7842; UNII-F41401512X; Nilotinib- Bio-X; 4-METHYL-N-(3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; BENZAMIDE, 4-METHYL-N-(3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINO)-; 3gp0; NILOTINIB [INN]; NILOTINIB [MI]; Nilotinib (USAN/INN); NILOTINIB [HSDB]; NILOTINIB [VANDF]; NILOTINIB [MART.]; EC 700-544-5; NILOTINIB [USP-RS]; NILOTINIB [WHO-DD]; SCHEMBL7901; NILOTINIB [EMA EPAR]; MLS003915611; MLS006010160; GTPL5697; DTXSID5042663; BCPP000149; HMS3244A13; HMS3244A14; HMS3244B13; HMS3295A23; HMS3654M07; HMS3748E11; BCP01367; AC-647; BDBM50237710; NSC800804; s1033; AKOS005063561; BCP9000989; CCG-264784; CS-0102; DB04868; NSC 747599; NSC-800804; SB17315; NCGC00183285-01; NCGC00183285-03; NCGC00183285-04; NCGC00183285-09; NCGC00183285-15; 4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; 4-Methyl-N-[3-(4-methyl-1-imidazolyl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]benzamide; AS-16214; BN164654; HY-10159; N-(3-(3-(1H-Imidazolyl)propoxy)phenyl)-4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)benzamide; SY024415; AM20090651; FT-0654026; SW218083-2; EC-000.2344; D08953; N-8207; AB01273978-01; AB01273978-02; AB01273978_03; EN300-7381984; A834657; Q412327; SR-01000931150; Q-101348; SR-01000931150-2; BRD-K81528515-001-04-7; Z1741976994; 1353151-22-0; 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide; 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino] benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[5-(3-pyridyl)pyrimidin-2-yl]amino]benzamide; Benzamide, 4-methyl-N-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (9CI)	Approved	Approved Drug(s)	644241	DB04868	D00STL	529.5	97.6	817	4.9	39	2	9	6	C28H22F3N7O	4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5	InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)	HHZIURLSWUIHRB-UHFFFAOYSA-N
DW28XV	Lutetium-177 vipivotide tetraxetan	Small molecule	177Lu-Psma-617; G6UF363ECX; Lutetium Lu-177 vipivotide tetraxetan; Vipivotide tetraxetan Lu-177; 177Lu-Labeled PSMA-617; PSMA-617 Lu-177; UNII-G6UF363ECX; Vipivotide tetraxetan lutetium Lu-177; Lutetium (177Lu) vipivotide tetraxetan; lutetium lu 177 vipivotide tetraxetan [USAN]; WHO 11429; PLUVICTO; lutetium ((1)Lu) vipivotide tetraxetan [INN]; Lutetium (177Lu) vipivotide tetraxetan [INN]; LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN [WHO-DD]; 1703749-62-5; LUTETATE(3-)-177LU, (N-((((1S)-1-CARBOXY-5-(((2S)-3-(2-NAPHTHALENYL)-1-OXO-2-(((TRANS-4-(((2-(4,7,10-TRIS((CARBOXY-.KAPPA.O)METHYL)-1,4,7,10-TETRAAZACYCLODODEC-1-YL-.KAPPA.N1,.KAPPA.N4,.KAPPA.N7,.KAPPA.N10)ACETYL-.KAPPA.O)AMINO)METHYL)CYCLOHEXYL)CARBONYL)AMINO)PROPYL)AMINO)PENTYL)AMINO)CARBONYL)-L-GLUTAMATO(6-))-, HYDROGEN (1:3); LUTETATE(3-)-177LU, (N2-((((1S)-1,3-DICARBOXYPROPYL)AMINO)CARBONYL)-N6-(3-(2-NAPHTHALENYL)-N-((TRANS-4-(((2-(4,7,10-TRIS((CARBOXY-.KAPPA.O)METHYL)-1,4,7,10-TETRAAZACYCLODODEC-1-YL-.KAPPA.N1,.KAPPA.N4,.KAPPA.N7,.KAPPA.N10)ACETYL-.KAPPA.O)AMINO)METHYL)CYCLOHEXYL)CARBONYL)-L-ALANYL)-L-LYSINATO(6-))-, HYDROGEN (1:3	Approved	Approved Drug(s)	122706785	DB16778	DGQW52	1216.1	374	1860	.	75	8	20	24	C49H68LuN9O16	2-[4-[2-[[4-[[(2S)-1-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]cyclohexyl]methylamino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+)	C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)NC(CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O.[Lu+3]	C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O.[177Lu+3]	InChI=1S/C49H71N9O16.Lu/c59-40(28-55-17-19-56(29-42(62)63)21-23-58(31-44(66)67)24-22-57(20-18-55)30-43(64)65)51-27-32-8-12-35(13-9-32)45(68)52-39(26-33-10-11-34-5-1-2-6-36(34)25-33)46(69)50-16-4-3-7-37(47(70)71)53-49(74)54-38(48(72)73)14-15-41(60)61;/h1-2,5-6,10-11,25,32,35,37-39H,3-4,7-9,12-24,26-31H2,(H,50,69)(H,51,59)(H,52,68)(H,60,61)(H,62,63)(H,64,65)(H,66,67)(H,70,71)(H,72,73)(H2,53,54,74);/q;+3/p-3/t32?,35?,37-,38-,39-;/m0./s1/i;1+2	RSTDSVVLNYFDHY-IOCOTODDSA-K
DG2E1T	Rosiglitazone	Small molecule	rosiglitazone; 122320-73-4; Avandia; Rosiglizole; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; Brl-49653; Brl 49653; Rezult; BRL49653; Avandaryl; TDZ 01; Gaudil; rosiglitazone (Avandia); Rosvel; C18H19N3O3S; Avandamet; DTXSID7037131; CHEBI:50122; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; MFCD00871760; NSC-758698; Rosigilitazone; 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; 05V02F2KDG; TDZ-01; Rosiglitazone (INN); NCGC00095124-01; BRL 49653C; 5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; ROSIGLITAZONE [INN]; 2,4-thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; DTXCID5017131; 5-[4-[2-[Methyl(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; Rosiglitazone [INN:BAN]; 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; CAS-122320-73-4; SR-01000763023; rosiglitazona; rosiglitazonum; UNII-05V02F2KDG; Rosigltazone; Rosi; HSDB 7555; Rosiglitazone base; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; RGZ; Gaudil (TN); Rosiglitazone- Bio-X; Spectrum_001703; 1217260-35-9; Spectrum2_001241; Spectrum3_000997; Spectrum4_001125; Spectrum5_001464; ROSIGLITAZONE [MI]; SCHEMBL5169; Dioxopromethazinehydrochloride; ROSIGLITAZONE [HSDB]; ROSIGLITAZONE [IARC]; BSPBio_002693; KBioGR_001609; KBioSS_002183; ROSIGLITAZONE [VANDF]; ROSIGLITAZONE [MART.]; SPECTRUM1504263; SPBio_001142; ROSIGLITAZONE [WHO-DD]; GTPL1056; ROSIGLITAZONE [EMA EPAR]; SCHEMBL14383595; KBio2_002183; KBio2_004751; KBio2_007319; KBio3_001913; Rosiglitazone, >=98% (HPLC); HMS1922J11; HMS2094O13; HMS3649G08; HMS3656K16; HMS3744M11; HMS3871L03; HMS3884N08; Pharmakon1600-01504263; ACT04332; BCP03047; Tox21_111434; BDBM50030474; CCG-39102; HB2556; NSC758698; STL350047; AKOS015894872; Tox21_111434_1; AC-3459; BCP9000017; CS-1088; DB00412; NSC 758698; SB17326; NCGC00095124-02; NCGC00095124-03; NCGC00095124-04; NCGC00095124-05; NCGC00095124-06; NCGC00095124-08; BR164372; HY-17386; SY031184; BCP0726000232; FT-0602578; R0106; S2556; SW197573-6; 6P-065; D08491; S00306; AB00698473-15; AB00698473-17; AB00698473-18; AB00698473-19; AB00698473_20; AB00698473_21; AB00698473_22; AB00698473_23; Q424771; Q-201681; SR-01000763023-5; SR-01000763023-6; BRD-A97437073-001-02-3; BRD-A97437073-001-03-1; BRD-A97437073-001-04-9; SR-01000763023-12; (RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)-benzyl)thiazolidine-2,4-dione; 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4dione; IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin); (+/-)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI); 5-(4-(2-(N-METHYL-N-(2-PYRIDINYL)AMINO)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE; 5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione; 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(Methyl-2-pyridinylamino)e thoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(methyl-pyridin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]phenyl methyl]thiazolidine-2,4-dione	Approved	Approved Drug(s)	77999	DB00412	D0K5ER	357.4	96.8	469	3.1	25	1	6	7	C18H19N3O3S	5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione	CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3	CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3	InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)	YASAKCUCGLMORW-UHFFFAOYSA-N
DW18BD	Simeprevir	Small molecule	SIMEPREVIR; TMC435; 923604-59-5; TMC435350; TMC 435; Olysio; TMC 435350; TMC-435; Simeprevir sodium; TMC-435350; CHEMBL501849; (1R,4R,6S,7Z,15R,17R)-N-cyclopropylsulfonyl-17-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxamide; Simeprevir [USAN]; SIMEPREVIR SODIUM [JAN]; HCV-PI; SIMEPREVIR [MI]; SIMEPREVIR [INN]; SIMEPREVIR [JAN]; SIMEPREVIR [VANDF]; SIMEPREVIR [WHO-DD]; SCHEMBL826061; GTPL7367; DTXSID20919221; CHEBI:134743; 1217263-04-1; N-cyclopropylsulfonyl-[[2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methyl-4-quinolyl]oxy]-methyl-dioxo-[?]carboxamide; BDBM50336504; s5015; AKOS025401966; CCG-270435; AC-27651; AS-56205; TMC-00435350; TMC-435, TMC-435350; US8741926, 47; US8754106, 47; Q7517689; (2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-({7-methoxy-8-methyl-2-[4-(1-methylethyl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide; (2R,3aR,10Z,11aS,12aR,14aR)-N-(Cyclopropylsulfonyl)-2-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide; (2R,3aR,10Z,12S,13R,15aR)-N-(Cyclopropylsulfonyl)-2-[[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methyl-4-quinolyl]oxy]-5-methyl-4,15-dioxo-2,3,3a,4,5,6,7,8,9,12,13,14,15,15a-tetradecahydro-12,13-methano-5,14-diaza-1H-cyclopentacyclotetradecene-13-carboxamide; (2R,3aR,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-(2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-5-methyl-4,14-dioxo-1,2,3,3a,4,5,6,7,8,9,11a,12,12a,13,14,14a-hexadecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a-carboxamide; (2R,3aR,11aS,12aR,14aR,Z)-N-(cyclopropylsulfonyl)-2-((2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-yl)oxy)-5-methyl-4,14-dioxo-1,2,3,3a,4,5,6,7,8,9,11a,12,12a,13,14,14a-hexadecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a-carboxamide; (2R,3aR,11aS,12aR,14aR,Z)-N-(Cyclopropylsulfonyl)-2-((2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-yl)oxy)-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide; (2R,3aR,11aS,12aR,14aR,Z)-N-(cyclopropylsulfonyl)-2-(2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-5-methyl-4,14-dioxo-1,2,3,3a,4,5,6,7,8,9,11a,12,12a,13,14,14a-hexadecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a-carboxamide; N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo [13.3.0.0''4,6]octadec-7-ene-4-carbonyl](cyclopropyl)sulfonamide	Approved	Approved Drug(s)	24873435	DB06290	D00TLP	749.9	194	1490	4.8	52	2	10	8	C38H47N5O7S2	(1R,4R,6S,7Z,15R,17R)-N-cyclopropylsulfonyl-17-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxamide	CC1=C(C=CC2=C1N=C(C=C2OC3CC4C(C3)C(=O)N(CCCCC=CC5CC5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC	CC1=C(C=CC2=C1N=C(C=C2O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(CCCC/C=C\[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC	InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1	JTZZSQYMACOLNN-VDWJNHBNSA-N
D2H9WB	Carfilzomib	Small molecule	Carfilzomib; 868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; Carfilzomib (PR171); UNII-72X6E3J5AR; NSC-758252; 72X6E3J5AR; CHEMBL451887; DTXSID4048690; CHEBI:65347; NCGC00249613-01; (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide; (alphaS)-alpha-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide; DTXCID0028616; C40H57N5O7; (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide; (S)-4-Methyl-N-((S)-1-((S)-4-Methyl-1-((R)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylaMino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-MorpholinoacetaMido)-4-phenylbutanaMido)pentanaMide; (S)-4-methyl-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; Carfilzomib [USAN]; CAS-868540-17-4; Carfilzomib [USAN:INN]; MFCD11040997; Kyprolis (TN); (2S)-N-[(1S)-1-Benzyl-2-[[(1S)-3-methyl-1-[[(2R)-2-methyloxiran-2-yl]carbonyl]butyl]amino]-2-oxoethyl]-4-methyl-2-[[(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide; Carfilzomib; PR171; CARFILZOMIB [MI]; CARFILZOMIB [INN]; CARFILZOMIB [JAN]; CARFILZOMIB [VANDF]; SCHEMBL85165; CARFILZOMIB [WHO-DD]; MLS006011102; Carfilzomib (JAN/USAN/INN); GTPL7420; AMY4357; CARFILZOMIB [ORANGE BOOK]; EX-A2037; ONO-7057; Tox21_113079; BDBM50277889; NSC756640; NSC758252; s2853; AKOS025401910; Tox21_113079_1; CCG-270405; CS-0984; CS-W004540; DB08889; NSC 758252; NSC-756640; NCGC00249613-02; NCGC00249613-03; NCGC00249613-08; NCGC00249613-11; NCGC00249613-13; AC-27051; AS-17059; HY-10455; SMR004660024; SW218090-2; D08880; AB01565867_02; SR-01000941582; J-501773; SR-01000941582-1; Q15366934; (Alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phe nylalaninamide; L-PHENYLALANINAMIDE, (.ALPHA.S)-.ALPHA.-((4-MORPHOLINYLACETYL)AMINO)BENZENEBUTANOYL-L-LEUCYL-N-((1S)-3-METHYL-1-(((2R)-2-METHYLOXIRANYL)CARBONYL)BUTYL)-; L-Phenylalaninamide, (alphaS)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-L-leucyl-N-((1S)-3-methyl-1-(((2R)-2-methyloxiranyl)carbonyl)butyl)-	Approved	Approved Drug(s)	11556711	DB08889	D00UVA	719.9	159	1180	4.7	52	4	8	20	C40H57N5O7	(2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide	CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4	CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4	InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1	BLMPQMFVWMYDKT-NZTKNTHTSA-N
D6F1ZR	Palbociclib	Small molecule	Palbociclib; 571190-30-2; PD-0332991; Ibrance; PD0332991; PD 0332991; Palbociclib free base; UNII-G9ZF61LE7G; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; PD-332991; 571190-30-2 (free base); MFCD11840850; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; G9ZF61LE7G; Palbociclib(PD0332991); PD 332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; CHEBI:85993; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; LQQ; 2euf; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-; Palbociclib [USAN]; 571190-30-2 pound not827022-32-2; Palbociclib [USAN:INN]; [d8]-Palbociclib; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-((5-(PIPERAZIN-1-YL)PYRIDIN-2-YL)AMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE; Ibrance (TN); Palbociclib- Bio-X; Kinome_3823; Kinome_3824; PALBOCICLIB [MI]; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one hydrochloride; PALBOCICLIB [INN]; PALBOCICLIB [JAN]; Palbociclib (JAN/USAN); PALBOCICLIB [WHO-DD]; SCHEMBL462630; BDBM6309; CHEMBL189963; GTPL7380; PD 0332991 (Palbociclib); DTXSID40972590; EX-A408; PALBOCICLIB [ORANGE BOOK]; 2euf; PD 0332991; OTAVA-BB 1115529; BCPP000125; HMS3265M09; HMS3265M10; HMS3265N09; HMS3265N10; HMS3744G13; AMY14886; BCP09274; BCP18381; NSC758247; NSC772256; NSC800815; s4482; AKOS022205241; BCP9001058; DB09073; NSC-758247; NSC-772256; NSC-800815; SB40426; Pyrido-[2,3-d]-pyrimidin-7-one 43; NCGC00263129-01; NCGC00263129-08; NCGC00263129-21; NCGC00263129-22; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one; AC-25485; AS-17016; BP166224; HY-50767; SY026143; A8153; FT-0697059; A14427; D10372; EN300-18531248; PD 0332991,PD0332991; BRD-K51313569-001-01-1; Q15269707; Z2216894329; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-((5-(PIPERAZIN-1-YL)PYRIDIN-2-YL)AMINO(PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[6,5-d]pyrimidin-7-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)-pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 8-cyclopentyl-6-acetyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one	Approved	Approved Drug(s)	5330286	DB09073	D00UZR	447.5	103	775	1.8	33	2	8	5	C24H29N7O2	6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one	CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C	CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C	InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)	AHJRHEGDXFFMBM-UHFFFAOYSA-N
D4CS3J	Dolutegravir	Small molecule	Dolutegravir; 1051375-16-6; GSK1349572; S/GSK1349572; Tivicay; GSK-1349572; GSK 1349572; Dolutegravir (GSK1349572); S-349572; Dolutegravir  DTG; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; Dolutegravir [USAN]; CHEBI:76010; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; DKO1W9H7M1; Dolutegravir (USAN); 1051375-16-6 (free); Tivicay (TN); (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-diene-13-carboxamide; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide; S-GSK1349572; Dolutegravir [USAN:INN]; UNII-DKO1W9H7M1; Soltegravir; HSDB 8152; 3s3m; 3s3n; 3s3o; (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[[?]:[?]]pyrazino[[?]][1,3]oxazine-9-carboxamide; DOLUTEGRAVIR [MI]; DOLUTEGRAVIR [INN]; DOLUTEGRAVIR [VANDF]; SCHEMBL82071; MLS006011137; DOLUTEGRAVIR [WHO-DD]; GTPL7365; CHEMBL1229211; DTXSID90909356; EX-A1695; BDBM50062551; MFCD20488027; s2667; AKOS025396657; S/GSK-1349572; BCP9000620; CCG-268876; CS-0454; DB08930; NCGC00346629-01; NCGC00346629-02; 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-; AC-28371; AS-75277; HY-13238; SMR004702915; S/GSK1349572,GSK1349572; D10066; EN300-7409916; A854801; Q937224; J-501471; Z2235801952; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0(3),?]tetradeca-10,13-diene-13-carboxamide; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0,3,8]tetradeca-10,13-diene-13-carboxamide; (4R,12.ALPHA.S)-N-((2,4-DIFLUOROPHENYL)METHYL)-7-HYDROXY-4-METHYL-6,8-DIOXO-3,4,6,8,12,12.ALPHA.-HEXAHYDRO-2H-PYRIDO(1',2':4,5)PYRAZINO(2,1-.BETA.)(1,3)OXAZINE-9-CARBOXAMIDE; (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-a]pyrido[1,2-d]pyrazine-9-carboxamide; (4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxamide; (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1,2:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1 ,3]oxazine-9-carboxamide; (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide	Approved	Approved Drug(s)	54726191	DB08930	D00YZD	419.4	99.2	829	2.4	30	2	8	3	C20H19F2N3O5	(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide	CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O	C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O	InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1	RHWKPHLQXYSBKR-BMIGLBTASA-N
D2LP0M	Fostemsavir	Small molecule	Fostemsavir; 864953-29-7; BMS-663068; BMS-663068 free acid; BMS 663068; Fostemsavir [USAN]; Fostemsavir(BMS-663068); Rukobia; 97IQ273H4L; 864953-29-7(free base); Fostemsavir (USAN); [3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate; BMS663068; Piperazine, 1-benzoyl-4-((4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-((phosphonooxy)methyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)oxoacetyl)-; ({3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl}methoxy)phosphonic acid; (3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)methyl dihydrogen phosphate; UNII-97IQ273H4L; fostemsavir & N6; [3-[2-(4-benzoylpiperazin-1-yl)-2-oxo-acetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate; 1,2-Ethanedione, 1-(4-benzoyl-1-piperazinyl)-2-(4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-((phosphonooxy)methyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-; 1,2-Ethanedione, 1-(4-benzoyl-1-piperazinyl)-2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-; GSK3684934; fostemsavir & PG16; fostemsavir & 4Dm2m; fostemsavir & VRC03; fostemsavir & CH106; fostemsavir & 35O22; fostemsavir & PGT128; FOSTEMSAVIR [MI]; FOSTEMSAVIR [INN]; fostemsavir & 3BNC117; fostemsavir & PG16-iMab; FOSTEMSAVIR [WHO-DD]; fostemsavir & PGT128-iMab; fostemsavir & VRC07-523; SCHEMBL754395; Fostemsavir; BMS-663068; CHEMBL3301594; GTPL11100; DTXSID40235596; fostemsavir & NIH45-46G54W; BCP13226; EX-A1973; BMS-626529 & 4Dm2m; HY-15440A; s7220; BMS-626529 & PG16-iMab; BMS-663038; CS-1059; DB11796; SB11250; BMS-626529 & PGT128-iMab; BMS626-529 & VRC03; GSK-3684934; BMS-626529 & N6; BMS-626529 & PG16; compound 35 [PMID: 29271653]; NCGC00510187-01; AC-30663; BMS-626529 & PGT128; BMS-626529 & CH106; BMS-626529 & 3BNC117; BMS-626529 & 35O22; BMS-626529 & VRC07-523; BMS626-529 & NIH45-46G54W; D10707; A863152; EN300-20207550; Q17001240; (3-((4-Benzoyl-1-piperazinyl)(oxo)acetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo(2,3-c)pyridin-1-yl)methyl dihydrogen phosphate; (3-((4-BENZOYLPIPERAZIN-1-YL)-OXOACETYL)-4-METHOXY- 7-(3-METHYL-1H-1,2,4-TRIAZOL-1-YL)-1H-PYRROLO(2,3-C)PYRIDIN- 1-YL)METHYL DIHYDROGEN PHOSPHATE; 1-(4-Benzoyl-1-piperazinyl)-2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-ethanedione	Approved	Approved Drug(s)	11319217	DB11796	D00ZCT	583.5	182	1020	-0.1	41	2	11	8	C25H26N7O8P	[3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate	CC1=NN(C=N1)C2=NC=C(C3=C2N(C=C3C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5)COP(=O)(O)O)OC	CC1=NN(C=N1)C2=NC=C(C3=C2N(C=C3C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5)COP(=O)(O)O)OC	InChI=1S/C25H26N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38)	SWMDAPWAQQTBOG-UHFFFAOYSA-N
DWS24C	Duloxetine	Small molecule	duloxetine; 116539-59-4; (S)-Duloxetine; Yentreve; (S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine; LY 248686; LY248686; Duloxetine (INN); LY-248686; methyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine; Yentreve (TN); (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; O5TNM5N07U; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (gammaS)-; CHEBI:36795; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; Duloxetine Boehringer Ingelheim; DULOXETINE [INN]; Duloxetine [INN:BAN]; (3s)-N-Methyl-3-(Naphthalen-1-Yloxy)-3-(Thiophen-2-Yl)propan-1-Amine; SMR000449282; HSDB 7368; NCGC00164559-01; UNII-O5TNM5N07U; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine; 29E; MFCD06801358; CPD000449282; DRIZALMA SPRINKLE; DULOXETINE [MI]; DULOXETINE [HSDB]; DULOXETINE [VANDF]; SCHEMBL8291; CHEMBL1175; DULOXETINE [WHO-DD]; GTPL202; MLS000758267; MLS001423946; DULOXETINE [EMA EPAR]; (S)-Duloxetine;LY248686; DTXSID6048385; N-Methyl-gama-(1-naphthalenyloxy)-2-thiophenepropanamine; BDBM84745; (+)-(S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine monohydrochloride; HMS2051I05; HMS3886K11; HY-B0161; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (S)-; PDSP1_000969; PDSP1_001385; PDSP2_000953; PDSP2_001369; s5071; AKOS015851058; CCG-100763; DB00476; NC00013; NCGC00164559-02; NCGC00164559-04; AC-15704; AS-35259; SBI-0206832.P001; CAS_136434-34-9; D07880; EN300-150640; AB00639911-13; AB00639911_15; AB00639911_16; Q411932; J-003455; J-523680; (+)-(S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamin; (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine; (S)-N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1 amine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1-amine; (3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1amine; (S)-(+)-N-methyl-3-(1-naphthaleneoxy)-3-(2-thienyl)propanamine; (+)-(S)-N-METHYL-.GAMMA.(1-NAPHTHYLOXY)-2-THIOPHENEPROPYLAMINE; 2-THIOPHENEPROPANAMINE, N-METHYL-.GAMMA.-(1-NAPHTHALENYLOXY)-, (S)-	Approved	Approved Drug(s)	60835	DB00476	D01AXB	297.4	49.5	312	4.3	21	1	3	6	C18H19NOS	(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine	CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32	CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32	InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1	ZEUITGRIYCTCEM-KRWDZBQOSA-N
DW08BY	Terbinafine	Small molecule	terbinafine; 91161-71-6; Lamisil; Lamasil; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; SF-86-327; Lamisil AT; SF 86-327; terbinafin; Terbinex; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; Terbinafina; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; Terbinafine free base; TDT 067; TDT-067; G7RIW8S0XP; CHEMBL822; CHEBI:9448; DTXSID2023640; Lamisil Tablet; 91161-71-6 (free base); Terbinafinum; Zabel; 1-NAPHTHALENEMETHANAMINE, N-(6,6-DIMETHYL-2-HEPTEN-4-YNYL)-N-METHYL-, (E)-; NCGC00159346-02; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine; (2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; N-[(2E)-6,6-dimethyl-2-hepten-4-yn-1-yl]-N-methyl-1-naphthalenemethanamine; DTXCID703640; [(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)[(naphthalen-1-yl)methyl]amine; Lamasil (TN); CAS-91161-71-6; UNII-G7RIW8S0XP; Terbinafine (USAN/INN); BRN 4256376; Corbinal; Terbinafine [USAN:INN:BAN]; N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine hydrochloride; erbinafine hydrochloride; TERBINAFINE [MI]; Terbinafine, SF-86-327, Lamisil, TBNF; TERBINAFINE [INN]; TERBINAFINE [USAN]; EC 618-706-8; TERBINAFINE [VANDF]; TERBINAFINE [MART.]; SCHEMBL36794; SCHEMBL37843; TERBINAFINE [WHO-DD]; MLS006011885; BIDD:GT0825; Terbinafine (Lamisil, Terbinex); TERBINAFINE [GREEN BOOK]; CHEBI:94705; TERBINAFINE [ORANGE BOOK]; HMS2089B20; HMS3715L08; BCP22896; OSURNIA COMPONENT TERBINAFINE; Tox21_111591; (E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine; BBL010959; BDBM50018518; HY-17395A; MFCD00242672; s1725; STK802069; AKOS001451917; Tox21_111591_1; AC-8561; CCG-221253; CS-1944; DB00857; GS-3099; TERBINAFINE COMPONENT OF OSURNIA; (E)-N,6,6-trimethyl-N-(naphthalen-1; NCGC00159346-03; NCGC00159346-04; NCGC00188975-01; TERBINAFINE [EMA EPAR VETERINARY]; SF86-327; SMR004703509; SBI-0206829.P001; SW197656-3; T3677; C08079; D02375; EN300-832786; AB00698510-07; AB00698510-09; AB00698510-10; AB00698510-11; AB00698510_12; AB00698510_13; AB00698510_14; A843743; EN300-25297578; Q415259; BRD-K68132782-003-05-4; Z2315576259; (6,6-Dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine; N,6,6-Trimethyl-N-(1-naphthylmethyl)-2-heptene-4-yne-1-amine; SF 86-327; SF-86-327; SF86-327; Lamasil; Lamisil AT; ((E)-6,6-Dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine; (6,6-dimethylhept-2-en-4-yn-1-yl)(methyl)[(naphthalen-1-yl)methyl]amine; 1N,6,6-trimethyl-1N-(1-naphthylmethyl)-(E)-2-hepten-4-yn-1-amine; (6,6-Dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine(Terbinafine); [(E)-6,6-dimethyl-hept-2-en-4-ynyl]-methyl-(naphthalen-1-yl-methyl)-amine; 1-Naphthalenemethanamine, N-[(2E)-6,6-dimethyl-2-hepten-4-yn-1-yl]-N-methyl-	Approved	Approved Drug(s)	1549008	DB00857	D01AYJ	291.4	3.2	428	5.6	22	0	1	5	C21H25N	(E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine	CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21	CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21	InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+	DOMXUEMWDBAQBQ-WEVVVXLNSA-N
D2TW8V	Melphalan flufenamide	Small molecule	Melphalan flufenamide; Melflufen; Prodrug J-1; Prodrug J 1; J-1 (prodrug); J 1 (prodrug); 380449-51-4; UNII-F70C5K4786; F70C5K4786; Melphalan flufenamide [USAN:INN]; WHO 9493; 380449-51-4 (free base); J-1; L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-l-phenylalanyl-4-fluoro-, ethyl ester; Ethyl (2S)-2-((2S)-2-amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanamido)-3-(4-fluorophenyl)propanoate; J1; MFF; ethyl (2S)-2-[[(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate; ethyl (S)-2-((S)-2-amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanamido)-3-(4-fluorophenyl)propanoate; Melphalan flufenamide [INN]; Pepaxti; PRODRUG J1; J1 (PRODRUG); CHEMBL4303060; SCHEMBL18239898; GTPL11605; DTXSID40191461; GLXC-25713; Melphalan flufenamide (USAN/INN); MELPHALAN FLUFENAMIDE [USAN]; MELPHALAN FLUFENAMIDE [WHO-DD]; J 1; HY-105019; CS-0024709; D11865; Q27277739	Approved	Approved Drug(s)	9935639	DB16627	D01HPY	498.4	84.7	579	3.2	33	2	6	14	C24H30Cl2FN3O3	ethyl (2S)-2-[[(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate	CCOC(=O)C(CC1=CC=C(C=C1)F)NC(=O)C(CC2=CC=C(C=C2)N(CCCl)CCCl)N	CCOC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)[C@H](CC2=CC=C(C=C2)N(CCCl)CCCl)N	InChI=1S/C24H30Cl2FN3O3/c1-2-33-24(32)22(16-18-3-7-19(27)8-4-18)29-23(31)21(28)15-17-5-9-20(10-6-17)30(13-11-25)14-12-26/h3-10,21-22H,2,11-16,28H2,1H3,(H,29,31)/t21-,22-/m0/s1	YQZNKYXGZSVEHI-VXKWHMMOSA-N
D2FYA8	Memantine	Small molecule	memantine; 19982-08-2; 3,5-dimethyladamantan-1-amine; 1-Amino-3,5-dimethyladamantane; 1,3-Dimethyl-5-adamantanamine; 3,5-Dimethyl-1-adamantanamine; Memantina; Memantine [INN]; Memantinum [INN-Latin]; Memantina [INN-Spanish]; Memantinum; 3,5-Dimethyl-1-aminoadamantane; 3,5-Dimethyl-1-adamantylamine; 3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine; Tricyclo[3.3.1.13,7]decan-1-amine, 3,5-dimethyl-; D-145; DRG-0267; CHEMBL807; W8O17SJF3T; DTXSID5045174; CHEBI:64312; Memantine (INN); NSC-757843; alzantin; NCGC00015705-04; DTXCID3025174; D 145; nemdatine; Memantine [INN:BAN]; CAS-19982-08-2; HSDB 7327; 3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine; UNII-W8O17SJF3T; DMAA [Antiparkinson Agent]; 3,5-dimethyladamantanylamine; Retyliumtosylate; 1,3-Dimethyl-5-aminoadamantane; DRG 0267; Exiba (TN); Spectrum_000607; MEMANTINE [MI]; MEMANTINE [HSDB]; Prestwick0_000978; Prestwick1_000978; Prestwick2_000978; Prestwick3_000978; Spectrum2_001408; Spectrum3_000923; Spectrum4_001022; Spectrum5_001355; MEMANTINE [VANDF]; CBMicro_020348; Biomol-NT_000209; MEMANTINE [WHO-DD]; SCHEMBL2688; Lopac0_000861; Oprea1_480562; BSPBio_001015; KBioGR_001543; KBioSS_001087; DivK1c_000068; SPBio_001456; SPBio_002926; 1-amino-3,5-dimethyladamantan; BPBio1_001117; BPBio1_001270; GTPL4253; SCHEMBL13213676; HMS500D10; KBio1_000068; KBio2_001087; KBio2_003655; KBio2_006223; KBio3_001926; 1-amino-3,5-dimethyl adamantane; 1-amino-3,5-dimethyl-adamantane; Tricyclo(3.3.1.1(3,7))decan-1-amine, 3,5-dimethyl-; NINDS_000068; 3,5-Dimethyl-adamantan-1-ylamine; BCP29702; Tox21_110199; 3,5-Dimethyl-1-aminoadamantane HCl; BBL000737; BDBM50062599; STK520682; AKOS000113995; AKOS015953276; AKOS016340748; Tox21_110199_1; CCG-204092; DB01043; DS-3152; NSC 757843; SDCCGSBI-0020417.P005; IDI1_000068; NCGC00015705-03; NCGC00015705-05; NCGC00015705-07; NCGC00015705-09; NCGC00015705-16; NCGC00024782-02; NCGC00024782-03; D145 pound>>D 145 pound>>D-145; SBI-0020417.P004; AB00053600; BB 0216388; EU-0053634; FT-0649142; D08174; D94592; EN300-103626; AB00053600-13; AB00053600_14; AB00053600_15; A814131; Q412189; 3,5-DIMETHYLTRICYCLO(3.3.1.1(SUP 3,7))DECAN-1-AMINE; TRICYCLO(3.3.1.1(SUP 3,7))DECAN-1-AMINE, 3,5-DIMETHYL-	Approved	Approved Drug(s)	4054	DB01043	D01JEU	179.3	26	240	3.3	13	1	1	0	C12H21N	3,5-dimethyladamantan-1-amine	CC12CC3CC(C1)(CC(C3)(C2)N)C	CC12CC3CC(C1)(CC(C3)(C2)N)C	InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3	BUGYDGFZZOZRHP-UHFFFAOYSA-N
D6IEN8	Selpercatinib	Small molecule	Selpercatinib; 2152628-33-4; Retevmo; Selpercatinib [INN]; CEGM9YBNGD; Selpercatinib [USAN]; LY3527723; Ret inhibitor loxo-292; Selpercatinib(LOXO-292); LOXO292; 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile; 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile; LY-3527723; 6-(2-Hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]pyrazolo[1,5-a]pyridine-3-carbonitrile; 6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile; Pyrazolo(1,5-a)pyridine-3-carbonitrile, 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxy-3-pyridinyl)methyl)-3,6-diazabicyclo(3.1.1)hept-3-yl)-3-pyridinyl)-; Serpercatinib; 6-(2-hydroxy-2-methylpropoxy)-4-(6-{6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl}pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile; Retevmo (TN); UNII-CEGM9YBNGD; SELPERCATINIB [MI]; SELPERCATINIB [JAN]; LOXO-292; Selpercatinib; Selpercatinib [USAN:INN]; SELPERCATINIB [WHO-DD]; CHEMBL4559134; SCHEMBL20071478; Selpercatinib (JAN/USAN/INN); GTPL10318; BDBM296429; DTXSID901026442; SELPERCATINIB [ORANGE BOOK]; BCP29047; CLD62833; EX-A2859; NSC818434; s8781; WHO 10967; ZB1574; US10112942, Example 163; US10112942, Example 166; US10112942, Example 183; AKOS037649115; NSC-818434; AC-31588; BS-16622; LOXO-292;LOXO 292;LOXO292; Selpercatinib (LOXO-292, ARRY-192); example 163 [WO2018071447A1]; HY-114370; CS-0084279; D11713; D77980; A929273; EN300-27032767	Approved	Approved Drug(s)	134436906	DB15685	D01KOA	525.6	112	885	2.5	39	1	9	8	C29H31N7O3	6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile	CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O	CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O	InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3	XIIOFHFUYBLOLW-UHFFFAOYSA-N
D72MRE	Carmustine	Small molecule	carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Gliadel; Carmubris; Carmustin; Nitrumon; BiCNU; Becenun; Bischloroethyl nitrosourea; Bi CNU; Carmustinum; 1,3-Bis(2-chloroethyl)nitrosourea; Bischlorethylnitrosurea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bischlorethylnitrosourea; Carmustina; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; NSC-409962; Bis(2-chloroethyl)nitrosourea; FDA 0345; SRI 1720; BiCNU (TN); DTI 015; NCI-C04773; SK 27702; Carmustine (98%); Bis(chloroethyl)nitrosourea; NSC 409962; bis-chloroethylnitrosourea; NSC409962; CHEMBL513; 1,3-bis(2-chloroethyl)-1-nitroso-urea; CHEBI:3423; Urea, 1,3-bis(2-chloroethyl)-1-nitroso-; Becenum; DTXSID8022743; DTI-015; U68WG3173Y; FDA-0345; SRI-1720; 1,3-bis(2-chloroethyl)-3-nitrosourea; NCGC00015204-05; SK-27702; 1,3-Bis(.beta.-chloroethyl)-1-nitrosourea; Gliadel Wafer; Bischloroethylnitrosourea; Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTXCID002743; Bis(2-chloroethyl)1-nitrosourea; Bis-N,N'-(chloroethyl)nitrosourea; CAS-154-93-8; CCRIS 810; 1,3-Bis(beta-chloroethyl)-1-nitrosourea; BCNU [Chloroethyl nitrosoureas]; SR-01000075736; EINECS 205-838-2; BRN 2049744; Camustine; Carustine; UNII-U68WG3173Y; AI3-52216; HSDB 7761; BiCNU; Nitrumon; Carmustine [USAN:USP:INN:BAN]; Carmustine- Bio-X; Prestwick_997; Gliadel (TN); Bischloroethyl nitrosourea [Chloroethyl nitrosoureas]; MFCD00057706; Gliadel (MGI Pharm); Spectrum_000265; Carmustine, >=98%; CARMUSTINE [MI]; CARMUSTINE [INN]; CARMUSTINE [JAN]; Spectrum4_000888; Spectrum5_000920; CAMUSTINE [VANDF]; CARMUSTINE [HSDB]; CARMUSTINE [USAN]; Lopac-C-0400; WLN: ONN2GVM2G; C 0400; CARMUSTINE [MART.]; SCHEMBL4503; CARMUSTINE [USP-RS]; CARMUSTINE [WHO-DD]; Lopac0_000188; Carmustine (JAN/USP/INN); KBioGR_001296; KBioSS_000745; MLS001333962; DivK1c_000835; AMY382; GTPL6800; CARMUSTINE [EP IMPURITY]; CARMUSTINE [ORANGE BOOK]; HMS502J17; KBio1_000835; KBio2_000745; KBio2_003313; KBio2_005881; CARMUSTINE [EP MONOGRAPH]; NINDS_000835; CARMUSTINE [USP MONOGRAPH]; HMS2092J22; HMS2230I05; HMS3260F17; HMS3369D17; Pharmakon1600-01503110; BCP27690; Tox21_110097; Tox21_500188; BDBM50015950; CCG-39925; NSC758392; STK624770; AKOS005558013; Tox21_110097_1; BCP9000490; DB00262; LP00188; NSC-758392; SDCCGSBI-0050176.P004; IDI1_000835; Urea,3-bis(2-chloroethyl)-1-nitroso-; BISCHLOROETHYL NITROSOUREA [IARC]; NCGC00015204-01; NCGC00015204-02; NCGC00015204-03; NCGC00015204-04; NCGC00015204-06; NCGC00015204-07; NCGC00015204-08; NCGC00015204-09; NCGC00015204-18; NCGC00093665-01; NCGC00093665-02; NCGC00093665-03; NCGC00093665-04; NCGC00260873-01; Urea,N'-bis(2-chloroethyl)-N-nitroso-; AC-24196; AS-12106; BC164289; HY-13585; N,N''-Bis(2-chloroethyl)-N-nitrosourea; NCI60_003931; SMR000058426; SBI-0050176.P003; C2634; EU-0100188; FT-0602937; S3669; BCNU; 1,3-Bis(2-chloroethyl)-1-nitrosourea; C06873; D00254; EN300-123541; AB00052431-07; AB00052431_08; A809590; Q415869; SR-01000075736-1; SR-01000075736-3; W-108025; Z1269141329; Carmustine, United States Pharmacopeia (USP) Reference Standard; 1-(2-Chloroethyl)-1-([(2-chloroethyl)amino]carbonyl)-2-oxohydrazine #	Approved	Approved Drug(s)	2578	DB00262	D01OXI	214.05	61.8	156	1.5	12	1	3	4	C5H9Cl2N3O2	1,3-bis(2-chloroethyl)-1-nitrosourea	C(CCl)NC(=O)N(CCCl)N=O	C(CCl)NC(=O)N(CCCl)N=O	InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)	DLGOEMSEDOSKAD-UHFFFAOYSA-N
D2RVS9	Rucaparib	Small molecule	RUCAPARIB; 283173-50-2; Rubraca; AG-14447; Rucaparib free base; Rucaparib (free base); Kinome_3180; 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one; 8237F3U7EH; 283173-50-2 (free base); 8-FLUOR-2-{4-[(METHYLAMINO)METHYL]FENYL}-1,3,4,5-TETRAHYDRO-6HAZEPINO[5,4,3-CD]INDOOL-6-ON; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one; 6H-Azepino(5,4,3-cd)indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-; 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-; C19H18FN3O; Rucaparib [INN]; Rucaparib [USAN:INN]; PF 01367338; UNII-8237F3U7EH; 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one; RPB; RUCAPARIB [MI]; Rucaparib (USAN/INN); RUCAPARIB [USAN]; RUCAPARIB [WHO-DD]; Rucaparib(AG-014447); 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; SCHEMBL844585; GTPL7736; CHEMBL1173055; CHEBI:94311; DTXSID10182563; CHEBI:134689; BCP07633; EX-A2700; BDBM50446130; HY-10617A; NSC756644; s4948; AKOS015898427; AG14447; DB12332; NSC-756644; SB16538; NCGC00263173-01; NCGC00263173-03; NCGC00263173-09; NCGC00263173-13; 6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one; AC-24390; AS-74779; FT-0696622; A14182; C74459; D10079; Rucaparib; AG 014699; PF-01367338; A856084; Q7376558; BRD-K88560311-011-01-4; 6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.0^{4,13]trideca-1,4,6,8(13)-tetraen-9-one; 6-fluoro-2-{4-[(methylamino)methyl]phenyl}-3,10-diazatricyclo[6.4.1.0?,(1)(3)]trideca-1,4,6,8(13)-tetraen-9-one; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]; 8-fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-one	Approved	Approved Drug(s)	9931954	DB12332	D01SHZ	323.4	56.9	466	2.5	24	3	3	3	C19H18FN3O	6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one	CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2	CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2	InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)	HMABYWSNWIZPAG-UHFFFAOYSA-N
DSU46K	Desipramine	Small molecule	desipramine; Norimipramine; 50-47-5; Desmethylimipramine; Monodemethylimipramine; Demethylimipramine; Desipramin; Desimipramine; Dimethylimipramine; Dezipramine; Methylaminopropyliminodibenzyl; Imipramine, demethyl-; desipraminum; Desimpramine; Desipramina; Norpramine; Sertofran; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; DMI (pharmaceutical); N-(3-Methylaminopropyl)iminobibenzyl; 5-(gamma-Methylaminopropyl)iminodibenzyl; DMI 50475; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; Desipramine (INN); N-desmethylimipramine; CHEMBL72; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N-methyl-; 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N-methyl-; CHEBI:47781; TG537D343B; Desipramine (D4); Pertrofane; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)-; DESIPRAMINE [INN]; Desipramine [INN:BAN]; Desipraminum [INN-Latin]; Desipramina [INN-Spanish]; Desmethylimipramine;Imipramine,demethyl-;Methylaminopropyliminodibenzyl; CCRIS 7091; HSDB 3052; CAS-58-28-6; NCGC00015340-02; EINECS 200-040-0; BRN 1432747; Treyzafagit; UNII-TG537D343B; 5H-Dibenz[b,f]azepine, 10,11-dihydro-5-[3-(methylamino)propyl]-; Imipramine-M Nor; Desipramine;Norpramin; (3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; Pertofran (Salt/Mix); Spectrum_000441; Pertofrane (Salt/Mix); DESIPRAMINE [MI]; Prestwick0_000343; Prestwick1_000343; Prestwick2_000343; Prestwick3_000343; Spectrum2_000091; Spectrum3_000379; Spectrum4_000314; Spectrum5_000833; Lopac-D-3900; DESIPRAMINE [HSDB]; DESIPRAMINE [VANDF]; Lopac0_000358; SCHEMBL34384; BSPBio_000405; BSPBio_002137; DESIPRAMINE [WHO-DD]; KBioGR_000928; KBioSS_000921; DivK1c_000190; SPBio_000042; SPBio_002326; BPBio1_000447; GTPL2399; DTXSID6022896; BDBM35229; HY-B1272A; KBio1_000190; KBio2_000921; KBio2_003489; KBio2_006057; KBio3_001357; NINDS_000190; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; HMS3430H03; HMS3742I19; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methyl-propan-1-amine; STK735144; AKOS001681456; CCG-118231; CS-8193; DB01151; SDCCGSBI-0050346.P005; 4-(2H-Tetrazol-5-yl)phenylboronicacid; IDI1_000190; NCGC00015340-01; NCGC00015340-03; NCGC00015340-04; NCGC00015340-05; NCGC00015340-06; NCGC00015340-07; NCGC00015340-08; NCGC00015340-09; NCGC00015340-10; NCGC00015340-11; NCGC00015340-13; NCGC00015340-22; NCGC00024375-04; AC-15977; SBI-0050346.P004; AB00053450; FT-0666024; C06943; D07791; AB00053450_14; EN300-18293453; L001089; Q423288; BRD-K60762818-003-15-3; IMIPRAMINE HYDROCHLORIDE IMPURITY A [EP IMPURITY]; 5-(3-methylaminopropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; [3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]methylamine; 10,11-dihydro-5-(3-(methylamino)propyl)-5h-dibenz(b,f)azepine; 5H-Dibenzo[b, f]azepine, N-(3-methylaminopropyl)-, 10,11-Dihydro; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methyl-1-propanamine #; (3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine; (3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)(methyl)amine	Approved	Approved Drug(s)	2995	DB01151	D01UTL	266.4	15.3	267	4.9	20	1	2	4	C18H22N2	3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine	CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31	CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31	InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3	HCYAFALTSJYZDH-UHFFFAOYSA-N
DMGA79	Pitolisant	Small molecule	Pitolisant; 362665-56-3; TIPROLISANT; wakix; 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine; BF2.649; HBS-101; 1-(3-(3-(4-Chlorophenyl)propoxy)propyl)piperidine; 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine; Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-; 4BC83L4PIY; CHEMBL462605; 3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether; BF-2649; BF-2.649; Wakix (TN); Pitolisant (BF2.649); 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]-piperidinehydrochloride; Pitolisant [INN]; UNII-4BC83L4PIY; Tirolisant; Ozawade; PIPERIDINE, 1-(3-(3-(4-CHLOROPHENYL)PROPOXY)PROPYL)-; tiprolisant [USAN]; PITOLISANT [MI]; Pitolisant (USAN/INN); Pitolisant [USAN:INN]; PITOLISANT [USAN]; PITOLISANT [WHO-DD]; SCHEMBL117648; GTPL8924; DTXSID30957654; CHEBI:134709; HMS3743C05; BCP13114; EX-A3601; BDBM50247053; MFCD18782650; AKOS028108820; CS-0666; DB11642; SB17037; NCGC00370823-03; AS-57273; HY-12199; DB-115766; D10749; BF2649; BF-2649; BF 2649; Pitolisant; EN300-7385525; A855975; Q426044; 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine	Approved	Approved Drug(s)	9948102	DB11642	D01UUD	295.8	12.5	235	4.3	20	0	2	8	C17H26ClNO	1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine	C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl	C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl	InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2	NNACHAUCXXVJSP-UHFFFAOYSA-N
DA8PN3	Atenolol	Small molecule	atenolol; 29122-68-7; Tenormin; Blokium; Myocord; Normiten; Prenormine; Tenormine; (RS)-Atenolol; Duraatenolol; Betacard; Corotenol; Tenoblock; Atehexal; Betablok; Cuxanorm; Juvental; Selobloc; Antipressan; Atcardil; Atenblock; Evitocor; Farnormin; Internolol; Normalol; Premorine; Prenolol; Tenoprin; Tensimin; Vascoten; Vericordin; Alinor; Anselol; Atecard; Atendol; Atenet; Atenil; Atereal; Aterol; Hipres; Hypoten; Ibinolo; Lotenal; Oraday; Serten; Stermin; Tenidon; Tenolol; Tredol; Uniloc; Wesipin; Altol; Ateni; Noten; Xaten; Seles beta; Apo-Atenolol; Felo-Bits; Lo-ten; Atenolin; Atenomel; Blocotenol; Cardaxen; Cardiopress; Jenatenol; Panapres; Plenacor; Servitenol; Tenobloc; Aircrit; Betasyn; Ormidol; Prinorm; Unibloc; Loten; Atenol acis; Atenol Cophar; Atenol Fecofar; Atenol Heumann; Atenol Nordic; Atenol Quesada; Atenol Gador; Atenol Stada; Atenol-Mepha; Atenol-Wolff; Atenol Atid; Atenol ct; Atenol Tika; Atenol Trom; Atenol Genericon; Betatop Ge; Atenol von ct; Atenol-ratiopharm; Atenol AL; Atenol PB; Atenol GNR; Atenol MSD; Atenol NM Pharma; Scheinpharm Atenol; Atenol 1A pharma; Atenololum; 2-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; Tenormine [French]; (r,s)-atenolol; Atenololum [INN-Latin]; ICI 66082; 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; Tenormin (TN); ICI-66082; Novaten; 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; ICI 66,082; 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; MFCD00057645; Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-; CHEMBL24; duratenol; 60966-51-0; NSC-757832; 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; Benzeneacetamide, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-; 50VV3VW0TI; MLS000069622; CHEBI:2904; Atenolol Bp; DTXSID2022628; C07AB03; SMR000036768; Atenol; 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; Acetamide, 2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)-; Teno-basan; Neatenol; Tensotin; Atcard; dl-Atenolol; (+/-)-2-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide; CCRIS 4196; (+/-)-Atenolol; HSDB 6526; SR-01000000159; 1309283-20-2; EINECS 249-451-7; EINECS 262-544-7; UNII-50VV3VW0TI; BRN 2739235; 2-(4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl)acetamide; Artrenolol; 2-(4-(2-Hydroxy-3-(Isopropylamino)propoxy)phenyl)ethanamide; 4-(2-Hydroxy-3-[(1-methylethyl)amino]propoxy)benzeneacetamide; 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid; phenyl)acetamide; Atenolol [USAN:BAN:INN:JAN]; (y)-Atenolol; Atenalol (RS); Atenolol,(S); (?)-Atenolol; Atenolol [USAN:USP:INN:BAN:JAN]; (A+/-)-Atenolol; Tenoretic (Salt/Mix); Atenolol (JAN/USP); Spectrum_001364; ATENOLOL [HSDB]; ATENOLOL [USAN]; ATENOLOL [INN]; ATENOLOL [JAN]; ATENOLOL [MI]; ATENOLOL [VANDF]; Opera_ID_1283; Spectrum2_001411; Spectrum3_001448; Spectrum4_000435; Spectrum5_001509; ATENOLOL [MART.]; ATENOLOL [USP-RS]; ATENOLOL [WHO-DD]; ATENOLOL [WHO-IP]; A 7655; SCHEMBL4362; Lopac0_000121; Oprea1_448775; BSPBio_002915; GTPL548; KBioGR_000790; KBioSS_001844; MLS001066372; MLS001074163; MLS001304038; DivK1c_000057; SPECTRUM1501127; Atenolol (JP17/USP/INN); SPBio_001482; ATENOLOL [ORANGE BOOK]; DTXCID202628; ATENOLOL [EP MONOGRAPH]; ATENOLOL [USP IMPURITY]; ATENOLOL [USP MONOGRAPH]; BDBM25753; HMS500C19; KBio1_000057; KBio2_001844; KBio2_004412; KBio2_006980; KBio3_002415; METKIMKYRPQLGS-UHFFFAOYSA-; ATENOLOLUM [WHO-IP LATIN]; NINDS_000057; S-Atenolol-D7 (Iso-propyl-d7); 2-{4-[2-Hydroxy-3-(isopropylamino)propoxy]-phenyl}acetamide; HMS1569L13; HMS1921H09; HMS2090I19; HMS2092D19; HMS2233E06; HMS3259K08; HMS3260I04; HMS3266K13; HMS3369B14; HMS3369D20; HMS3369P20; HMS3411G21; HMS3675G21; HMS3886G03; Pharmakon1600-01501127; ( inverted question mark)-Atenolol; TENORETIC COMPONENT ATENOLOL; BCP12899; Atenolol 1.0 mg/ml in Acetonitrile; Atenolol, >=98% (TLC), powder; Tox21_302426; Tox21_500121; 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; BBL009276; CCG-39010; GEO-03413; NSC757832; s4817; STK528649; AKOS005111050; ATENOLOL COMPONENT OF TENORETIC; AC-8245; Atenolol, analytical reference material; DB00335; KS-5341; LP00121; NC00548; NSC 757832; SDCCGSBI-0050109.P004; IDI1_000057; MRF-0000571; NCGC00015007-06; NCGC00015007-07; NCGC00015007-08; NCGC00015007-09; NCGC00015007-10; NCGC00015007-11; NCGC00015007-13; NCGC00015007-24; NCGC00024566-03; NCGC00024566-04; NCGC00024566-05; NCGC00024566-06; NCGC00024566-07; NCGC00255122-01; NCGC00260806-01; BA166036; HY-17498; SBI-0050109.P003; CAS-29122-68-7; DB-072177; DB-079552; EU-0100121; FT-0662315; FT-0662316; FT-0693045; 2-(4-(2-hydroxy-3-(isopropylamino)propoxy); BIM-0050109.0001; D00235; EN300-119532; O10469; AB00052208-13; AB00052208-15; AB00052208_16; L000116; Q411325; Q-200656; SR-01000000159-2; SR-01000000159-4; SR-01000000159-5; SR-01000000159-8; BRD-A20239487-001-02-5; BRD-A20239487-001-15-7; Atenolol, European Pharmacopoeia (EP) Reference Standard; Z1521553991; Atenolol, United States Pharmacopeia (USP) Reference Standard; (+)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; (RS)-2-{4-[2-Hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; (RS)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; 2-(P-(HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ACETAMIDE; (+/-)-4-(2-Hydroxy-3-[(1-methylethyl)amino]propoxy)benzeneacetamide; 2-(4-{[(2S)-2-hydroxy-3-(propan-2-ylamino)propyl]oxy}phenyl)acetamide; Atenolol, Pharmaceutical Secondary Standard; Certified Reference Material; 2-(P-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ACETAMIDE (RACEMATE); 106020-65-9	Approved	Approved Drug(s)	2249	DB00335	D01UXC	266.34	84.6	263	0.2	19	3	4	8	C14H22N2O3	2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide	CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O	CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O	InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)	METKIMKYRPQLGS-UHFFFAOYSA-N
DE8CK6	Metolazone	Small molecule	metolazone; 17560-51-9; Zaroxolyn; Diulo; Mykrox; Oldren; Metenix; Microx; Metalozone; Metolazona; Metolazonum; 7-Chloro-2-methyl-4-oxo-3-(o-tolyl)-1,2,3,4-tetrahydroquinazoline-6-sulfonamide; Metolazonum [INN-Latin]; Metolazona [INN-Spanish]; SR-720-22; metozalone; Metolazone (Zaroxolyn); 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide; SR 720-22; 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-; Metazoline; Normelan; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide; 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone; 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide; Metolazone, (+)-; Metolazone, (-)-; NSC-759581; NM7V2Y3G0U; TZ7V40X7VX; 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide; DTXSID6045167; CHEBI:64354; 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-; NN9U607695; NCGC00093985-07; Metalazone; Xuret; 6-Quinazolinesulfonamide, 1,2,3,4-tetrahydro-7-chloro-2-methyl-4-oxo-3-o-tolyl-; DTXCID4025167; Zaroxolyn (TN); 56436-31-8; 56436-32-9; 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-, (+)-; 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-, (-)-; SMR001230730; HSDB 3367; SR-05000001765; EINECS 241-539-3; UNII-TZ7V40X7VX; BRN 0965506; Metolazone (JAN/USP/INN); Prestwick_333; CAS-17560-51-9; MFCD00069304; Metolazone [USAN:USP:INN:BAN:JAN]; Spectrum_000456; METOLAZONE [MI]; METOLAZONE [INN]; METOLAZONE [JAN]; Prestwick0_000112; Prestwick1_000112; Prestwick2_000112; Prestwick3_000112; Spectrum2_001741; Spectrum4_000229; Spectrum5_001237; METOLAZONE [HSDB]; METOLAZONE [USAN]; METOLAZONE [VANDF]; CHEMBL878; UNII-NM7V2Y3G0U; METOLAZONE [MART.]; (non-labelled)Metolazone-d7; METOLAZONE [USP-RS]; METOLAZONE [WHO-DD]; SCHEMBL40558; BSPBio_000124; BSPBio_002422; KBioGR_000897; KBioSS_000936; 5-25-09-00212 (Beilstein Handbook Reference); MLS002153316; MLS002154200; DivK1c_000275; SPECTRUM2300325; SPBio_001842; SPBio_002063; BPBio1_000138; GTPL4838; METOLAZONE [EP IMPURITY]; METOLAZONE [ORANGE BOOK]; UNII-NN9U607695; BDBM25899; HMS500N17; KBio1_000275; KBio2_000936; KBio2_003504; KBio2_006072; METOLAZONE [EP MONOGRAPH]; NINDS_000275; BCPP000166; HMS1568G06; HMS1922L16; HMS2093P14; HMS2095G06; HMS2230J15; HMS3261J22; HMS3373C11; HMS3655M09; HMS3712G06; HMS3744I19; METOLAZONE [USP MONOGRAPH]; Pharmakon1600-02300325; BCP21574; HY-B0209; Tox21_110186; Tox21_113526; Tox21_500610; CCG-39450; NSC759581; s1610; AKOS015897109; Metolazone, >=98% (HPLC), solid; Tox21_110186_1; BCP9000920; DB00524; KS-5139; LP00610; NSC 759581; SDCCGSBI-0051460.P003; IDI1_000275; NCGC00093985-01; NCGC00093985-02; NCGC00093985-03; NCGC00093985-04; NCGC00093985-05; NCGC00093985-06; NCGC00093985-08; NCGC00093985-10; NCGC00093985-11; NCGC00093985-20; NCGC00261295-01; AS-13016; SBI-0051460.P002; DB-044227; AB00052055; SW196612-3; D00431; 7-chloro-2-methyl-4-oxo-3-o-tolyl-1,2,3,4; AB00052055-08; AB00052055_09; AB00052055_10; EN300-23818025; Q-201399; Q1169561; SR-05000001765-1; SR-05000001765-4; SR-05000001765-7; BRD-A61793559-001-05-7; BRD-A61793559-001-08-1; Metolazone, European Pharmacopoeia (EP) Reference Standard; Metolazone, United States Pharmacopeia (USP) Reference Standard; 7-Chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydro-6-quinazolinesulfonamide #; Metolazone for system suitability, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	4170	DB00524	D01WLC	365.8	101	594	4.1	24	2	5	2	C16H16ClN3O3S	7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide	CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl	CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl	InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)	AQCHWTWZEMGIFD-UHFFFAOYSA-N
DM35YI	Raloxifene	Small molecule	raloxifene; 84449-90-1; Keoxifene; Raloxifenum; Raloxifenum [Latin]; Raloxifeno [Spanish]; Raloxifeno; LY 139481; LY-139481; Pharoxifene; Raloxiphene; Eviden; Raxeto; CHEMBL81; (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone; NSC-747974; (2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone; Keoxifene; LY 139481;; CHEBI:8772; YX9162EO3I; DTXSID3023550; Raloxifene (INN); 2-(4-hydroxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]benzoyl}-1-benzothiophen-6-ol; Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-; J22.982B; LY139481; RALOXIFENE [INN]; Raloxifene [INN:BAN]; 2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol; Methanone, [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-; CCRIS 7129; HSDB 7460; NCGC00015889-05; CAS-82640-04-8; UNII-YX9162EO3I; Raloxifene, 6; [2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methanone; [2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl]{4-[(2-piperidin-1-ylethyl)oxy]phenyl}methanone; Eviden (TN); Raxeto (TN); RALOXIFENE [MI]; Prestwick0_000862; Prestwick1_000862; Prestwick2_000862; Prestwick3_000862; Lopac-R-1402; RALOXIFENE [HSDB]; RALOXIFENE [VANDF]; SCHEMBL6144; RALOXIFENE [WHO-DD]; Lopac0_001051; BSPBio_000903; KBioGR_002361; KBioSS_002364; BIDD:ER0216; BIDD:GT0795; SPBio_002824; BPBio1_000995; DTXCID803550; GTPL2820; BDBM19441; KBio2_002361; KBio2_004929; KBio2_007497; KBio3_002840; cid_11071264; cMAP_000032; HMS2089F06; HMS3742O11; BCP09772; Tox21_202603; MFCD00866415; NSC747974; NSC761389; s5781; AKOS015896267; AC-8399; CCG-205128; DB00481; NSC 747974; NSC-761389; SDCCGSBI-0051021.P003; [6-hydroxy-2-(4-hydroxyphenyl)benzothiophen-3-yl]-[4-[2-(1-piperidyl)ethoxy]phenyl]methanone; MRF-0000684; SMP2_000095; NCGC00015889-01; NCGC00015889-02; NCGC00015889-04; NCGC00015889-06; NCGC00015889-07; NCGC00015889-08; NCGC00015889-10; NCGC00015889-22; NCGC00092353-02; NCGC00092353-04; NCGC00260151-01; [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone; AS-35086; HY-13738; SBI-0051021.P002; CAS-84449-90-1; CS-0007764; FT-0674305; EN300-58333; VU0155042-3; C07228; D08465; A916152; Q425223; BRD-K63828191-003-11-5; 6-hydroxy-2-(4-hydoxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene; 6-hydroxy-2-(4-hydoxyphenyl)-3[-4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene; 6-Hydroxy-2-(4-Hydroxyphenyl)-3-[4(2-Piperidinoethoxy)benzoyl]benzo[b]thiophene; 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]-thiophene; 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene; 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2piperidinoethoxy)-benzoyl]benzo[b]thiophene; 6-hydroxy-2-(4-hydroxyphenyl)-3[-4-(2-piperidinoethoxy)benzoyl]benzo [b]thiophene; 6-hydroxy-2-(4-hydroxyphenyl)-3[-4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene; 6-hydroxy-2-(4-hydroxyphenyl)-3[-4-(2piperidinoethoxy)benzoyl]benzo[b]thiophene; 6-hydroxy-2-(4-hyroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene; [2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]methanone; Raloxifeno; [6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone; [6-hydroxy-2-(4-hydroxyphenyl)benzo-[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone; [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone; [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1piperidinyl)ethoxy]phenyl]methanone; 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl methanone	Approved	Approved Drug(s)	5035	DB00481	D01XBA	473.6	98.2	655	6.1	34	2	6	7	C28H27NO4S	[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone	C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O	C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O	InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2	GZUITABIAKMVPG-UHFFFAOYSA-N
D7QK5R	Omeprazole	Small molecule	omeprazole; 73590-58-6; Losec; Prilosec; Esomeprazole; Antra; Omeprazon; Audazol; Omapren; Omepral; Parizac; Zegerid; Mopral; Miol; Belmazol; Ceprandal; Dizprazol; Dudencer; Emeproton; Epirazole; Gastrimut; Gastroloc; Gibancer; Indurgan; Inhibitron; Inhipump; Logastric; Pepticum; Peptilcer; Prazidec; Sanamidol; Secrepina; Ulcometion; Mepral; Miracid; Omeprol; Omezol; Omisec; Omizac; Ompanyt; Ozoken; Prysma; Ramezol; Ulceral; Ulcesep; Ulcozol; Zefxon; Zoltum; Desec; Elgam; Lomac; Ulsen; Ultop; Zimor; Ocid; Omed; Omid; OMEP; Demeprazol; Nopramin; Omezolan; Paprazol; Pepticus; Prazentol; Prazolit; Procelac; Regulacid; Danlox; Erbolin; Lensor; Morecon; Nilsec; Olexin; Omegast; Omesek; Ortanol; Osiren; Proclor; Result; Ulcsep; Victrix; Zepral; Exter; Gasec; Ulzol; Omebeta 20; Tedec Ulceral; AULCER; Antra MUPS; Omerprazole; Omeprazol; 119141-88-7; Omez; Omepradex; Omeprazolum; H 168/68; Gastrogard; Nuclosina; Omesec; MFCD00083192; Prestwick_808; 6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; H-168/68; OMZ; CHEBI:77260; Omeprazole 13CD3; Esomeprazole sodium salt; 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole; 1H-Benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-; Aisi'aomeilazuona Esomeprazole Sodium; NSC-751450; NSC-759192; CHEMBL1503; Nexiam; 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole; 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; MLS000069373; DTXSID6021080; KG60484QX9; 73590-58-6 (free form); 5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-3H-benzoimidazole; 326602-80-6; Omeprazol [INN-Spanish]; Omeprazolum [INN-Latin]; NCGC00016925-06; Esomperazole; SMR000058847; Emilok; CAS-73590-58-6; 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole; 2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl}-1H-1,3-benzodiazole; ( -)-Omeprazole; (R)-5-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; DTXCID501080; 1261395-28-1; Omeprazone; Omeprazen; Omeprazole delayed-release; Omeprazole Pellets; 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole; Prilosec (TN); (+-)-Omeprazole; CCRIS 7099; HSDB 3575; SR-01000003003; UNII-KG60484QX9; Omeprazole, solid; 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole; AGI-010; Omeprazole,(S); Omeprazole-[d3]; (RS)-6-METHOXY-2-((4-METHOXY-3,5-DIMETHYLPYRIDIN-2-YL) METHYLSULFINYL)-1H-BENZO(D)IMIDAZOLE; (RS)-6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl) methylsulfinyl)-1H-benzo[d]imidazole; Omeprazole S-Isomer; 2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole; Omeprazole - Bio-X; DM-3458; Omeprazole [USAN:USP:INN:BAN:JAN]; Omeprazole (Prilosec); OMEPRAZOLE [MI]; OMEPRAZOLE [INN]; OMEPRAZOLE [JAN]; Maybridge4_002645; Opera_ID_1863; Prestwick0_000493; Prestwick1_000493; Prestwick2_000493; Prestwick3_000493; (.+/-.)-Omeprazole; OMEPRAZOLE [HSDB]; OMEPRAZOLE [USAN]; O0359; OMEPRAZOLE [VANDF]; UPCMLD-DP075; cid_4594; OMEPRAZOLE [MART.]; SCHEMBL1191; OMEPRAZOLE [USP-RS]; OMEPRAZOLE [WHO-DD]; H 16868; BSPBio_000385; MLS001076112; MLS001424148; MLS006010400; MLS006011759; BIDD:GT0189; SPBio_002306; BPBio1_000425; GTPL4279; Omeprazole (JP17/USP/INN); OMEPRAZOLE [GREEN BOOK]; OMEPRAZOLE [ORANGE BOOK]; SCHEMBL11995456; UPCMLD-DP075:001; CHEBI:91766; OMEPRAZOLE [USP IMPURITY]; HMS1528I05; HMS1569D07; HMS2052G17; HMS2090E16; HMS2090F11; HMS2096D07; HMS2232B21; HMS3269D17; HMS3394G17; HMS3413J07; HMS3651A11; HMS3677J07; HMS3713D07; OMEPRAZOLE [USP MONOGRAPH]; Pharmakon1600-01505693; ZEGERID COMPONENT OMEPRAZOLE; AMY30573; BCP05852; BCP13592; BCP21299; HY-B0113; YOSPRALA COMPONENT OMEPRAZOLE; 2,3,5-Trimethylpyridine/Omeprazole; Tox21_110686; Tox21_200509; AC-401; BBL028172; BDBM50103597; BDBM50241343; DL-462; MFCD23135254; NSC751450; NSC759192; s1389; STK623746; AKOS005066653; AKOS015895343; OMEPRAZOLE COMPONENT OF ZEGERID; Tox21_110686_1; AC-4676; CCG-101130; CCG-213517; CS-1868; DB00338; HS-0055; NC00380; NSC 751450; NSC 759192; OMEPRAZOLE COMPONENT OF YOSPRALA; (S)-5-Methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-3H-benzoimidazole; IDI1_032523; NCGC00016925-01; NCGC00016925-02; NCGC00016925-03; NCGC00016925-04; NCGC00016925-05; NCGC00016925-07; NCGC00016925-08; NCGC00016925-10; NCGC00016925-11; NCGC00021522-03; NCGC00021522-04; NCGC00021522-05; NCGC00258063-01; Omeprazole, analytical reference material; BO164173; SY009746; SY077145; SBI-0206896.P001; FT-0601585; FT-0652860; FT-0653294; FT-0673283; FT-0689771; H 199; SW196942-4; A19447; C07324; D00455; EN300-117238; A837865; A892647; A937349; Q422210; SR-01000003003-4; SR-01000003003-7; SR-01000003003-8; 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl); BRD-A55962179-001-04-9; BRD-A55962179-001-08-0; BRD-A55962179-001-20-5; BRD-A88691025-001-07-4; F0001-2386; Z1501475006; Omeprazole, British Pharmacopoeia (BP) Reference Standard; Omeprazole, European Pharmacopoeia (EP) Reference Standard; Omeprazole, United States Pharmacopeia (USP) Reference Standard; 2-(3-methoxy-2,4-dimethylbenzylsulfinyl)-6-methoxy-1H-benzo[d]imidazole; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-; Omeprazole, Pharmaceutical Secondary Standard; Certified Reference Material; (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1h-benzimidazole; (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1h-benzimidazole; (RS)-5-Methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridylmethylsulphinyl)benzimidazole; 1H-Benzimidazole,5-methoxy-2-[(R)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-; 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyrdinyl)-methyl]sulfinyl]-1H-benzimidazole; 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole; 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole; 5-methoxy-2-(2-(4-methoxy-3,5-dimethylpyridin-2-yl)ethylsulfinyl)-1H-benzo[d]imidazole; 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl- 1H-benzimidazole; 5-methoxy-2-[[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole; 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulphinyl]-1H-benzimidazole; 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-benzimidazole; 5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulphinyl]1H-benzimidazole; 6-methoxy-2-(((4-methoxy-3,5-dimethyl pyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole; 6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; 6-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-1H-benzimidazole; 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4-methoxy-3,5dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4-methoxy3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4methoxy-3,5-dimethyl2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole; Omeprazole for peak identification, European Pharmacopoeia (EP) Reference Standard; (omeprazole)5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole; 1H-BENZIMIDAZOLE,6-METHOXY-2-[(R)-[(4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL]SULFINYL]-; 5-METHOXY-2-(((4-METHOXY-3,5,-DIMETHYL-2-PYRIDINYL)-METHYL)SULPHINYL)-1H-BENZIMIDAZOLE; 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole (omeprazole); 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole(Omeprazole)	Approved	Approved Drug(s)	4594	DB00338	D01XNB	345.4	96.3	453	2.2	24	1	6	5	C17H19N3O3S	6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole	CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC	CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC	InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)	SUBDBMMJDZJVOS-UHFFFAOYSA-N
D9P3SB	Zidovudine	Small molecule	zidovudine; Azidothymidine; 30516-87-1; 3'-Azido-3'-deoxythymidine; Retrovir; AZT; Zidovudinum; Thymidine, 3'-azido-3'-deoxy-; Compound S; Trizivir; ZIDOVUDINE [AZT]; Zidovudina; BW A509U; zidovudin; BWA509U; ZDV; 3'-Deoxy-3'-azidothymidine; Azidothymidine (AZT); BW-A509U; BW-A-509U; NSC 602670; 3'-azt; 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; 1-((2R,4S,5S)-4-AZIDO-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE; CHEMBL129; 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine; MLS000028548; 4B9XT59T7S; DTXSID8020127; CHEBI:10110; NCGC00023945-05; Zidovudinum [Latin]; SMR000058351; Zidovudina [Spanish]; DTXCID60127; 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione; Propolis+AZT; NSC-602670; 3'-Azido-2',3'-Dideoxythymidine; DRG-0004; Retrovir(TM); AZT & Li & EPO; Retrovir (TN); CCRIS 105; Cpd S; Intron A & AZT; HSDB 6515; Racemic Liposomal AZT; Liposomal AZT-SN-1; Liposomal AZT-SN-3; Zidovudine+PRO 140; PC-SOD+AZT; AZT & srCD4; AZT & rIFN.alpha.2; AZT & rsT4; rIFN-beta seron & AZT; MFCD00006536; 3'-Azido-3'-deoxythymidine (AIDS); AZT & EPO; AZT & GM-CSF; AZT & HPA; AZT & sCD4; AZT & SST; zudovidine; UNII-4B9XT59T7S; AZT & Li & GM-CSF; AZT+PRO 140; Met-SDF-1.beta. & AZT; AZT & Li & IL-1; AZT & Li & IL-6; AZT & IL-1; AZT & IL-2; AZT & IL-6; AZT & Interferon-.alpha.-2; AZT & Concanavalin A (ConA); AZT & Lymphoblastoid Interferon; AZT & PM-19; Met-SDF-1.beta. & Zidovudine; 4lhm; 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (AZT); 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione [AZT]; AZT & rsCD4 & rIFN.alpha.A; 3'-azido-3'-deoxythymidine, AZT; DS-4152 & AZT; 1-((2R,4R,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; 5-methyl-1-[rac-(2R,4S,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione; AZT & Colony-stimulating factor 2; AZT & NP (from PHCA or HSA); 3''-azido-thymidine; K7 [P Ti2 W10 O40]; Zidovudine [USAN:USP:INN:BAN:JAN]; Zidovudine & IFNL1; Zidovudine & IFNL2; Zidovudine & IFNL3; Zidovudine (Retrovir); COMPOUND-S; Spectrum_001348; AZT & CD4(178)-PE 40; AZT & IFN.alpha.; Zidovudine & IL-29; ZIDOVUDINE [MI]; Zidovudine & IL-28A; Zidovudine & IL-28B; ZIDOVUDINE [INN]; ZIDOVUDINE [JAN]; AZT & Interleukin 29; Opera_ID_1602; Prestwick3_000333; Spectrum2_000927; Spectrum3_001507; Spectrum4_000332; Spectrum5_001101; 3'azido-3'deoxythymidine; ZIDOVUDINE [HSDB]; ZIDOVUDINE [IARC]; ZIDOVUDINE [USAN]; 3'-Azido-3'-deoxythymidine & Erythropoietin; 3'-Azido-3'-deoxythymidine & Sho-Saiko-To; Azidothymidine; Zidovudine; Interferon AD + 3'-azido-3'-deoxythymidine; AZT & Interleukin 28A; AZT & Interleukin 28B; 3'-Azido-3'-deoxythymidine & Concanavalin A; 3'-Azido-3'-deoxythymidine & Interleukin-1; 3'-Azido-3'-deoxythymidine & Interleukin-2; 3'-Azido-3'-deoxythymidine & Interleukin-6; ZIDOVUDINE [VANDF]; 3'-azido3'-deoxythymidine; AZT & IFNL1; AZT & IFNL2; AZT & IFNL3; ZIDOVUDINE [MART.]; 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)-5-methylpyrimidine-2,4-(1H,3H)-dione; AZT & Interferon lambda-1; AZT & Interferon lambda-2; AZT & Interferon lambda-3; ZIDOVUDINE [USP-RS]; ZIDOVUDINE [WHO-DD]; ZIDOVUDINE [WHO-IP]; 3''-Deoxy-3-azidothymidine; BSPBio_000365; BSPBio_003153; KBioGR_000703; KBioSS_001828; MLS001055351; MLS001076358; MLS002153202; MLS002222249; Zidovudine & Interleukin 29; DivK1c_000524; SPECTRUM1502109; ZIDOVUDINE [EMA EPAR]; 3'-deoxy-3'-azido-thymidine; SPBio_000834; Zidovudine & Interleukin 28A; Zidovudine & Interleukin 28B; AZT & IL-28A; AZT & IL-28B; BPBio1_000403; GTPL4825; Zidovudine (JP17/USP/INN); 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon; SCHEMBL14615088; SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle); SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle); ZIDOVUDINE [EP IMPURITY]; ZIDOVUDINE [ORANGE BOOK]; AZT & IL-29; HMS501K06; KBio1_000524; KBio2_001828; KBio2_004396; KBio2_006964; KBio3_002653; racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle); ZIDOVUDINE [EP MONOGRAPH]; 3''-Azido-3''-deoxy-thymidine; NINDS_000524; Zidovudine & Interferon lambda-1; Zidovudine & Interferon lambda-2; Zidovudine & Interferon lambda-3; HMS1921J20; HMS2090G11; HMS2092D06; HMS2096C07; HMS2234K17; HMS3259H17; HMS3713C07; Pharmakon1600-01502109; ZIDOVUDINE [USP MONOGRAPH]; ZIDOVUDINUM [WHO-IP LATIN]; COMBIVIR COMPONENT ZIDOVUDINE; TRIZIVIR COMPONENT ZIDOVUDINE; 3''azido-2''3''-dideoxythymidine; Tox21_110062; Tox21_110894; Tox21_202203; Tox21_300578; BBL033764; BDBM50002692; CCG-39924; NSC758185; STK801891; AKOS005622576; AKOS015842610; Tox21_110062_1; 3''-azido-2'',3''-dideoxythymidine; DB00495; NC00666; NSC-758185; ZIDOVUDINE COMPONENT OF COMBIVIR; ZIDOVUDINE COMPONENT OF TRIZIVIR; IDI1_000524; NCGC00014918-01; NCGC00023945-03; NCGC00023945-04; NCGC00023945-06; NCGC00023945-07; NCGC00023945-08; NCGC00023945-09; NCGC00023945-10; NCGC00023945-12; NCGC00023945-13; NCGC00023945-24; NCGC00023945-25; NCGC00178237-01; NCGC00178237-02; NCGC00254276-01; NCGC00259752-01; 1-((2R,4S,5S)-4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; AS-13019; SBI-0051731.P002; Propolis & Thymidine, 3'-azido-3'-deoxy-; S2579; SW198799-2; EN300-52518; 3'-Azido-3'-deoxythymidine, >=98% (HPLC); C07210; D00413; D88500; 3'-Azido-3'deoxythymidine & Interferon .alpha.; 3'-Azido-3'-deoxythymidine, >=99.0% (HPLC); A820413; Q198504; SR-01000000098; SR-05000001587; J-700147; SR-01000000098-3; SR-05000001587-1; BRD-K72903603-001-04-6; BRD-K72903603-001-14-5; LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT ZIDOVUDINE; Z754931264; ZIDOVUDINE COMPONENT OF LAMIVUDINE/ZIDOVUDINE TEVA; Zidovudine, European Pharmacopoeia (EP) Reference Standard; 3'-Azido-3'-deoxythymidine & Recombinant Interferon-.alpha.-2; Zidovudine, United States Pharmacopeia (USP) Reference Standard; 3'-Azido-3'-deoxythymidine & CD4-Pseudomonas exotoxin A hybrid; Beta interferon(rIFN-beta seron) & 3'-Azido-3'-deoxythymidine(AZT); Lecithinized superoxide dismutase & Thymidine, 3'-azido-3'-deoxy-; 3'-Azido-2',3'-dideoxythymidine & sCD4(soluble recombinant protein); Thymidine, 3'-azido-3'-deoxy- & PRO 140 (Anti-CCR5 monoclonal antibody); Zidovudine, Pharmaceutical Secondary Standard; Certified Reference Material; (AZT) 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; (AZT)1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(AZT); 3'-Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor; 3'-Azido-3'-deoxythymidine & Lithium & Granulocyte-macrophage colony-stimulating factor; 3'-Azido-3'deoxythymidine & Recombinant Soluble CD4 & Recombinant Interferon.alpha.A; 4-(4-Azido-5-hydroxy-tetrahydro-furan-2-yl)-5-methyl-3H-pyrazine-2,6-dione; Met-Stromal Cell-derived Factor-1.beta. (Human) & 3'-Azido-3'-deoxythymidine; 1-((2R,4S,5S)-4-(diazoamino)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-((2R,4S,5S)-4-azido-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-((2R,5S)-4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; 1-((2S,4R,5R)-4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (AzddThd, AZT); 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (N3ddThd); 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(3''-azido-2'',3''-dideoxythymidine); 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(azidothymidine, AZT); 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(Zidovudine, AZT); 146426-54-2; 3-((2S,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)triaz-1-en-2-ium-1-ide; 3-Azido-1,2,3-trideoxy-1-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-D-erythro- pentofuranuronic acid	Approved	Approved Drug(s)	35370	DB00495	D01XYJ	267.24	93.2	484	0	19	2	6	3	C10H13N5O4	1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione	CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-]	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-]	InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1	HBOMLICNUCNMMY-XLPZGREQSA-N
DA53IN	Futibatinib	Small molecule	Futibatinib; TAS-120; 1448169-71-8; FGFR-IN-1; TAS120; Futibatinib [USAN]; Lytgobi; UNII-4B93MGE4AL; 4B93MGE4AL; TAS 120 [WHO-DD]; TAS 120; WHO 10879; (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one; 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one; 2-Propen-1-one, 1-((3S)-3-(4-amino-3-(2-(3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-pyrrolidinyl)-; 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one; 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one; FUTIBATINIB [INN]; FUTIBATINIB [JAN]; FUTIBATINIB [WHO-DD]; Futibatinib (JAN/USAN/INN); GTPL9786; CHEMBL3701238; SCHEMBL15345470; BDBM161389; AMY16930; BCP17213; EX-A1862; NSC813488; CS-6031; DB15149; Example 2 [WO2013108809]; NSC-813488; AC-35460; BS-15425; HY-100818; D11725; D77976; US9108973, 2; 1814961-20-0	Approved	Approved Drug(s)	71621331	DB15149	D01ZLU	418.4	108	723	2	31	1	7	6	C22H22N6O3	1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one	COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC	COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)[C@H]4CCN(C4)C(=O)C=C)OC	InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1	KEIPNCCJPRMIAX-HNNXBMFYSA-N
D4AN0M	Axitinib	Small molecule	Axitinib; 319460-85-0; AG-013736; Inlyta; AG 013736; (E)-N-Methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide; AG-13736; AG013736; C9LVQ0YUXG; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; MFCD09837898; NSC757441; NSC-757441; DTXSID3049049; CHEBI:66910; (E)-N-methyl-2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)benzamide; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide; NCGC00241108-01; S1005; DTXCID8028975; N-methyl-2-({3-[(E)-2-(pyridin-2-yl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide; N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)-BENZAMIDE; Axitinib [USAN]; CAS-319460-85-0; UNII-C9LVQ0YUXG; axitinibum; Axitinib [USAN:INN:JAN]; Axitinib (AG 013736); 4agc; BENZAMIDE, N-METHYL-2-((3-((1E)-2-(2-PYRIDINYL)ETHENYL)-1H-INDAZOL-6-YL)THIO)-; Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-; N-methyl-2-({3-[(1E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide; Inlyta (TN); AG13736; 4ag8; Axitinib (JAN/USAN); AXITINIB [INN]; AXITINIB [JAN]; AXITINIB [MI]; AXITINIB [VANDF]; AXITINIB [MART.]; AG-013736;Axitinib; AXITINIB [WHO-DD]; Axitinib,AG-013736; MLS006010164; SCHEMBL172918; AXITINIB [ORANGE BOOK]; GTPL5659; Axitinib, >=98% (HPLC); CHEMBL1289926; N-methyl-2-[[3-[2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide; SCHEMBL22930506; BDBM25117; CHEBI:94568; EX-A337; BCPP000372; BCP01371; Tox21_113597; NSC799341; AKOS015902898; N-methyl-2-[[3-[(E)-2-(2-pyridyl)vinyl]-1H-indazol-6-yl]sulfanyl]benzamide; Tox21_113597_1; AC-1539; BCP9000345; CCG-264772; CS-0116; DB06626; KS-1448; NSC 757441; NSC-799341; Benzamide, N-methyl-2-((3-((E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)-; NCGC00241108-04; NCGC00241108-06; HY-10065; SMR002530046; AM20090673; SW219464-1; D03218; AB01274739-01; AB01274739_02; EN300-26869010; SR-01000941566; J-502064; Q-200662; Q4830631; SR-01000941566-1; BRD-K29905972-001-01-4; BRD-K29905972-001-02-2; Z2216885372; Benzamide, N-methyl-2-((3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazo)-6-yl)thio)-; N-Methyl-[[3[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide; N-METHYL-2((3-((1E0-2-(PYRIDIN-2-YL)ETHENYL)-1H-INAZOL-6-YLSUFANYL)BENZAMIDE; N-methyl-2-[[3-[(E)-2-(2-pyridyl)vinyl]-2H-indazol-6-yl]sulfanyl]benzamide	Approved	Approved Drug(s)	6450551	DB06626	D01ZRI	386.5	96	557	4.2	28	2	4	5	C22H18N4OS	N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide	CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4	CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4	InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+	RITAVMQDGBJQJZ-FMIVXFBMSA-N
DR4B1Q	Tretinoin	Small molecule	Retinoic acid; tretinoin; 302-79-4; all-trans-Retinoic acid; Vitamin A acid; trans-Retinoic acid; ATRA; Retin-A; Vesanoid; Aberel; Eudyna; Renova; Airol; All-trans Retinoic Acid; all-trans-Vitamin A acid; Dermairol; Aknoten; Aknefug; Cordes vas; Epi-aberel; TRETINON; Tretin M; Retin A; Atralin; all-trans-Vitamin A1 acid; all-trans-Tretinoin; Retionic acid; All Trans Retinoic Acid; Vitamin A1 acid, all-trans-; Retin-A Micro; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; beta-Retinoic acid; all-(E)-Retinoic acid; Vitamin A acid, all-trans-; Retinoic acid, all-trans-; Alltrans-retinoic acid; NSC-122758; Retinoate; Retacnyl; Vesnaroid; Ro 1-5488; Tretinoin, all-trans-; all trans-Retinoic acid; Stieva-A; Tretinoine; Solage; all-trans-beta-Retinoic acid; Effederm; .beta.-Retinoic acid; Kerlocal; Oristar rna; RETINOIC ACID, ALL TRANS; Tretinoin/All-Trans Retinoic Acid; Aberela [Norway]; Avitoin [Norway]; Effederm [France]; A-Acido (Argentina); 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; MLS000028588; b-Retinoic acid; DTXSID7021239; Retinoic acid (GMP); Tretinoine [INN-French]; Tretinoinum [INN-Latin]; AT-RA; Tretinoina [INN-Spanish]; Tretinoino [INN-Spanish]; CHEMBL38; (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-; 11-cis,13-cis-; NSC122758; Atragen; Retinova; SMR000058245; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid; CHEBI:15367; 15-Apo-beta-caroten-15-oic acid; 5688UTC01R; Tretinoin (TN); beta-Ra; Acnavit [Denmark]; AGN 100335; 9-cis-RA; Retin A (TN); NCGC00017280-10; Tretinoinum; Aberela; Acnavit; Avitoin; Betarretin; Tretinoina; Tretinoino; A-Vitaminsyre; MFCD00001551; all-trans-b-Retinoic acid; Cordes VAS [Germany]; A-Vitaminsyre [Denmark]; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL); trans-Retinoate; beta-Retinoate; DTXCID001239; tretinoine (French) (EINECS); cis-Retinoic acid; Acide retinoique (French) (DSL); Refissa; Nexret; Vitamin a acid, trans-; Retisol-A; LGD 100057; Acid A Vit (Belgium, Netherlands); 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid; 3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2E,4E,6E,8E-tetraenoic acid; (11Z)-retinoic acid; Isotretinoin;(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; [3H]Retinoic acid; Renova (TN); CCRIS 3294; Avita (TN); HSDB 2169; SR-01000000239; EINECS 206-129-0; NSC 122758; BRN 2057223; retinoicacid; Tretinoin (JAN/USP/INN); Retinoic acid, cis-9,trans-13-; Tretinion; TNP00194; UNII-5688UTC01R; BML2-E05; 1cbr; [3H]tretinoin; [All-E]-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; Tretinoin [USAN:USP:INN:BAN]; (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; CAS-302-79-4; Prestwick_424; all-(E)-Retinoate; Tretinoine (French); ALTRENO; Retinoic acid, cis-; (5E)-Retinoic acid; [3H]Vitamin A acid; 1n4h; CPD000058245; Retinoic acid all trans; TRETINOIN [INN]; TRETINOIN [JAN]; 6-s-trans-retinoic acid; TRETINOIN [HSDB]; TRETINOIN [USAN]; Vitamin-A-sA currencyure; Opera_ID_1055; Prestwick2_000257; Prestwick3_000257; Spectrum5_001746; Spectrum5_001933; TRETINOIN [VANDF]; acide retinoique (French); Vesanoid (TN) (Roche); Tretinoin - Retinoic Acid; bmse000562; TRETINOIN [MART.]; UPCMLD-DP097; R 2625; Renova (0.02% cream); RETINOIC ACID [MI]; SCHEMBL3145; TRETINOIN [USP-RS]; TRETINOIN [WHO-DD]; (9Z,13Z)-Retinoic acid; 3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-all-trans-tetraenoic acid; Altreno (0.05% lotion); BIDD:PXR0081; Lopac0_001061; Avita (0.025% gel); BSPBio_000074; BSPBio_001500; RETINOIC ACID [INCI]; MLS001076515; MLS002207234; MLS002222211; MLS002548861; MLS006010222; BIDD:GT0483; SPECTRUM1502016; 9-cis-retinoic acid (9cRA); LGD 1057; NSC 659772; Panretin; Panretyn; Panrexin; Toctino; [3H]RA; BPBio1_000082; cid_444795; GTPL2644; .beta.-all-trans-Retinoic acid; TRETINOIN [ORANGE BOOK]; ZIANA COMPONENT TRETINOIN; all-trans-retinoic acid (ATRA); SCHEMBL19091395; TRETINOIN [EP MONOGRAPH]; BDBM31883; HMS502N05; SOLAGE COMPONENT TRETINOIN; TWYNEO COMPONENT TRETINOIN; VELTIN COMPONENT TRETINOIN; TRETINOIN [USP MONOGRAPH]; BCPP000036; BDBM323588; HMS1361K22; HMS1568D16; HMS1791K22; HMS1921D14; HMS1989K22; HMS2089D20; HMS2092N11; HMS2095D16; HMS2236N03; HMS3259E11; HMS3263E04; HMS3402K22; HMS3411B09; HMS3675B09; HMS3712D16; Pharmakon1600-01502016; Retinoic acid, all-trans- (8CI); 124510-04-9; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (2E,4E,6Z,8E)-; ACT00012; BCP01405; TRETINOIN COMPONENT OF ZIANA; TRI-LUMA COMPONENT TRETINOIN; US10188615, at-RA; Tox21_110812; Tox21_202330; Tox21_300305; Tox21_501061; TRETINOIN COMPONENT OF SOLAGE; TRETINOIN COMPONENT OF TWYNEO; TRETINOIN COMPONENT OF VELTIN; All-trans Retinoic Acid (Tretinoin); CCG-39912; HY-14649G; LMPR01090019; NSC759631; s1653; AKOS000280845; Tox21_110812_1; AC-6824; CS-1269; DB00755; GS-3578; LP01061; NC00481; NSC-759631; SDCCGSBI-0051031.P004; TRETINOIN COMPONENT OF TRI-LUMA; IDI1_000903; IDI1_033970; NCGC00017280-05; NCGC00017280-06; NCGC00017280-07; NCGC00017280-08; NCGC00017280-09; NCGC00017280-12; NCGC00017280-15; NCGC00017280-16; NCGC00017280-17; NCGC00017280-18; NCGC00017280-19; NCGC00017280-20; NCGC00017280-23; NCGC00017280-38; NCGC00021808-04; NCGC00021808-05; NCGC00021808-06; NCGC00021808-07; NCGC00021808-09; NCGC00021808-11; NCGC00021808-14; NCGC00021808-15; NCGC00254179-01; NCGC00259879-01; NCGC00261746-01; BP-20401; BR164493; HY-14649; Retinoic acid, >=98% (HPLC), powder; SBI-0051031.P003; CS-0626116; EU-0101061; ISOTRETINOIN IMPURITY A [EP IMPURITY]; R0064; SW203749-4; C00777; D00094; Q29417; AB00052318-15; AB00052318-16; AB00052318-17; AB00052318_18; AB00052318_19; A899883; EN300-27107561; L000833; Q-200610; SR-01000000239-3; SR-01000000239-4; SR-01000000239-6; SR-01000000239-7; BRD-K06926592-001-01-7; BRD-K71879491-001-15-0; BRD-K71879491-001-22-6; SR-01000000239-12; SR-01000000239-13; SR-01000000239-14; SR-01000000239-15; WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1; Tretinoin, European Pharmacopoeia (EP) Reference Standard; WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1; Tretinoin, United States Pharmacopeia (USP) Reference Standard; 3,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; Tretinoin, Pharmaceutical Secondary Standard; Certified Reference Material; (2E,4E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraenoic acid; (4E,6E,8E)-9-(2,6,6-Trimethyl-1-cyclohexenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; (8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate; 2,4,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-; 2,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2E,4E,6E,8E,-nonatetraenoic acid; all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid; 2,4, 6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6, 6-trimethyl-1-cyclohexen-1-yl)-, (2E, 4E, 6E, 8E)-; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)--, (all trans)-; 2,4,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all trans)-; 2,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid-, (all trans)-; 97950-17-9	Approved	Approved Drug(s)	444795	DB00755	D02DGU	300.4	37.3	567	6.3	22	1	2	5	C20H28O2	(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid	CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+	SHGAZHPCJJPHSC-YCNIQYBTSA-N
DKNU74	Amphotericin B	Small molecule	amphotericin b; Amphotericin; 1397-89-3; Ambisome; Amphotericine B; Fungizone; Halizon; Ampho-Moronal; Amphotericinum B; Liposomal Amphotericin B; Amfotericina B; AMPH-B; Abelcet; Amphotericin-B; Amphotec; Fungilin; Amphotocerin; Ambil; Amphotericin B liposome; amphotericin B liposomal; MFCD00877763; 7XU7A7DROE; NSC 527017; CHEBI:2682; ABELCET, LIPOSOMAL AMPHOTERICIN B; NSC-527017; ABLC; Abelecet; Amphortericin B; Anfotericine B; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-(((2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; Amphotericin B trihydrate; IAB; UNII-7XU7A7DROE; DTXSID9022601; Fungisome; Amfotericina B [INN-Spanish]; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; CCRIS 5963; HSDB 3008; Amphotericin B [USP:INN:JAN]; Fungizone (TN); NCGC00090808-01; Amphotec (TN); (1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylic acid; AmBisome (TN); Amp B; EINECS 215-742-2; NS 718; BRN 0078342; Amphotericin b, liposome; AI3-26528; Prestwick3_000410; Amphotericin B (85%); Amphotericin B solubilized; AMPHOTERICIN B [MI]; SCHEMBL17973; AMPHOTERICIN B [INN]; AMPHOTERICIN B [JAN]; BSPBio_000340; 5-18-10-00525 (Beilstein Handbook Reference); AMPHOTERICIN B [HSDB]; BIDD:GT0351; AMPHOTERICIN B [VANDF]; BPBio1_000374; CHEMBL267345; NKTR-024; AMPHOTERICIN B [MART.]; AMPHOTERICIN B [USP-RS]; AMPHOTERICIN B [WHO-DD]; AMPHOTERICIN B [WHO-IP]; HMS2096A22; HMS3713A22; Amphotericin B (JP17/USP/INN); HY-B0221; Amphotericin b, liposome [WHO-DD]; Amphotericin B, Streptomyces nodosus; AMPHOTERICIN B [ORANGE BOOK]; LMPK06000002; s1636; AMPHOTERICIN B [EP MONOGRAPH]; AKOS024464746; AMPHOTERICIN B [USP MONOGRAPH]; AMPHOTERICIN B LIPOSOME [VANDF]; CCG-220410; DB00681; AMPHOTERICINUM B [WHO-IP LATIN]; (1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E,25E,27E,29E,31E,33R*,35S*,36R*,37S*))-33-((3-Amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; 14,39-Dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,2 7,29,31-heptaene-36-carboxylic acid, 33-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-(1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E, 25E-27E,29E,31E,33R*,35S*,36R*,37S*))-; AB00513832; C06573; D00203; AB00513832_02; Q412223; 1397-89-3, C47H73NO17; Amphotericin B from Streptomyces sp., ~80% (HPLC), powder; Amphotericin B from Streptomyces sp., BioReagent, suitable for cell culture, ~80% (HPLC); Amphotericin B solubilized, powder, gamma-irradiated, BioXtra, suitable for cell culture; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-Amino-3,6-dideoxy-?-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-he; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-hept; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,33R,35S,36R,37S)-33-{[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carbo; (1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-; 23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylic acid; Amphotericin B from Streptomyces sp., Vetec(TM) reagent grade, BioReagent, suitable for cell culture, ~80%	Approved	Approved Drug(s)	5280965	DB00681	D02DWM	924.1	320	1670	0	65	12	18	3	C47H73NO17	(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid	CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O	C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O	InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1	APKFDSVGJQXUKY-INPOYWNPSA-N
DUF62Z	Perphenazine	Small molecule	perphenazine; 58-39-9; Trilafon; Perphenazin; Etaperazine; Perfenazine; Ethaperazine; Etaperazin; Fentazin; Chlorpiprazine; Perphenan; Thilatazin; Decentan; Chlorperphenazine; Emesinal; Perfenazina; Tranquisan; Trifaron; Trilifan; Triphenot; F-mon; Perphenazinum; 2-(4-(3-(2-Chloro-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; Sch 3940; 2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol; 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol; PZC; gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine; NSC 150866; 4-(3-(2-Chlorophenothiazin-10-yl)propyl)-1-piperazineethanol; 4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol; 1-(2-Hydroxyethyl)-4-(3-(2-chloro-10-phenothiazinyl)propyl)piperazine; FTA7XXY4EZ; CHEMBL567; NSC-150866; 2-Chloro-10-3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl phenothiazine; 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol; 2-Chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine; 2-Chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine; 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethan-1-ol; MLS000069637; CHEBI:8028; DTXSID1023441; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina; 1-Piperazineethanol, 4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-; 1-Piperazineethanol, 4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-; 2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol; NSC150866; CAS-58-39-9; NCGC00015826-02; Perfenil; SMR000058180; Perfenazina [Italian]; 1-Piperazineethanol, 4-(3-(2-chlorophenothiazin-10-yl)propyl)-; 1-(2-Hydroxyethyl)-4-[3-(2-chloro-10-phenothiazinyl)propyl]piperazine; Piperazineethanol, 4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-; Perfenazina [INN-Spanish]; Perphenazinum [INN-Latin]; DTXCID703441; Perphenazine maleate [JAN]; 1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-; 2-Chloro-10-3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl phenothiazine; HSDB 3379; SR-01000000137; UNII-FTA7XXY4EZ; EINECS 200-381-5; MFCD00056798; AI3-50151; Piperazineethanol, 4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-; .gamma.-(4-(.beta.-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine; .gamma.-[4-(.beta.-Hydroxyethyl)piperazin-1-yl]propyl-2-chlorophenothiazine; 2-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethan-1-ol; Perphenazine [USP:INN:BAN:JAN]; 2-Chloro-10-(3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; SCH-3940; Prestwick_536; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina [Italian]; Etrafon (Salt/Mix); Spectrum_001610; Opera_ID_1161; Prestwick0_000125; Prestwick1_000125; Prestwick2_000125; Prestwick3_000125; Spectrum2_001602; Spectrum3_000758; Spectrum4_000843; Spectrum5_001493; Lopac-P-6402; PERPHENAZINE [MI]; PERPHENAZINE [INN]; PERPHENAZINE [JAN]; P 6402; PERPHENAZINE [HSDB]; PERPHENAZINE [VANDF]; Lopac0_000930; Oprea1_603835; REGID_for_CID_4748; SCHEMBL42125; BSPBio_000170; BSPBio_002376; GTPL209; KBioGR_001445; KBioSS_002090; PERPHENAZINE [MART.]; MLS001146929; MLS002548897; 5,7-EICOSADIYNOICACID; BIDD:GT0150; DivK1c_000880; PERPHENAZINE [USP-RS]; PERPHENAZINE [WHO-DD]; SPECTRUM1503934; SPBio_001603; SPBio_002109; BPBio1_000188; component of Triavil (Salt/Mix); HMS502L22; KBio1_000880; KBio2_002090; KBio2_004658; KBio2_007226; KBio3_001596; Perphenazine (JP17/USP/INN); NINDS_000880; HMS1568I12; HMS1922M14; HMS2093M15; HMS2095I12; HMS2232D21; HMS3259C09; HMS3262J22; HMS3370O14; HMS3712I12; HMS3885H20; PERPHENAZINE [ORANGE BOOK]; Pharmakon1600-01503934; PERPHENAZINE [EP MONOGRAPH]; HY-A0077; PERPHENAZINE [USP MONOGRAPH]; Perphenazine 1.0 mg/ml in Methanol; Tox21_110233; Tox21_500930; 1-Piperazineethanol, trihydrochloride; BDBM50130273; CCG-39060; NSC758649; s4731; STK019818; AKOS000664046; Tox21_110233_1; CS-5137; DB00850; ETRAFON-A COMPONENT PERPHENAZINE; KS-5105; LP00930; NC00472; NSC-758649; SDCCGSBI-0050904.P004; IDI1_000880; MRF-0000509; NCGC00015826-01; NCGC00015826-03; NCGC00015826-04; NCGC00015826-05; NCGC00015826-06; NCGC00015826-07; NCGC00015826-08; NCGC00015826-09; NCGC00015826-10; NCGC00015826-13; NCGC00015826-20; NCGC00024092-03; NCGC00024092-04; NCGC00024092-05; NCGC00024092-06; NCGC00261615-01; AC-12196; PERPHENAZINE COMPONENT OF ETRAFON-A; SBI-0050904.P003; DB-053200; AB00052390; EU-0072164; EU-0100930; FT-0603244; P1970; C07427; D00503; D82041; EN300-120640; AB00052390_17; A831863; L000919; Q423520; SR-01000000137-2; SR-01000000137-4; SR-01000000137-5; SR-01000000137-8; W-105390; BRD-K10995081-001-05-5; BRD-K10995081-001-15-4; WLN: T C666 BN ISJ EG B3- AT6N DNTJ D2Q; Z1530532754; Perphenazine, British Pharmacopoeia (BP) Reference Standard; FLUPHENAZINE DIHYDROCHLORIDE IMPURITY E [EP IMPURITY]; Perphenazine, European Pharmacopoeia (EP) Reference Standard; Perphenazine, United States Pharmacopeia (USP) Reference Standard; 2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]-piperazin-1-yl]ethanol; 2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol #; Perphenazine for system suitability, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	4748	DB00850	D02HED	404	55.2	463	4.2	27	1	5	6	C21H26ClN3OS	2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol	C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO	C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO	InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2	RGCVKNLCSQQDEP-UHFFFAOYSA-N
DR3A9M	Pralatrexate	Small molecule	Pralatrexate; 146464-95-1; Folotyn; 10-Propargyl-10-deazaaminopterin; HSDB 7786; PDX; Pralatrexate(Folotyn); CHEBI:71223; (2S)-2-(4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzamido)pentanedioic acid; N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid; NSC-754230; DTXSID3048578; A8Q8I19Q20; 146464-95-1 (racemic); NSC754230; L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-; (2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid; NCGC00242596-01; (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid; (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid; N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid; L-Glutamic acid, N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-; N -(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid; (2S)-2-[[4-[(1RS)-1-[(2,4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid; Folotyn (TN); Pralatrexate [USAN]; Pralatrexate [USAN:INN]; pralatrexato; pralatrexatum; Pralatrexat; Pralatrexte; UNII-A8Q8I19Q20; PRALATREXATE [MI]; PRALATREXATE [INN]; PRALATREXATE [JAN]; PRALATREXATE [HSDB]; PRALATREXATE [VANDF]; SCHEMBL21633; PRALATREXATE [MART.]; PRALATREXATE [WHO-DD]; GTPL6840; Pralatrexate (JAN/USAN/INN); CHEMBL1201746; DTXCID3028504; SCHEMBL15075302; BCPP000101; PRALATREXATE [ORANGE BOOK]; EX-A2142; Tox21_112906; BDBM50457437; MFCD00920897; s1497; AKOS015966891; AM84423; CCG-269517; CS-0504; DB06813; NSC 754230; (2S)-2-[[4-[1-[(2,4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid; s11194; 10-Propargyl-10-deazaaminopterin, 95%; NCGC00386226-01; AC-28388; BS-15438; HY-10446; CAS-146464-95-1; P2645; SW220187-1; D05589; AB00443251-02; AB00443251_04; A884505; EN300-26509071; Q637059; SR-01000941578; J-008227; SR-01000941578-1; (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]phenyl}formamido)pentanedioic acid; N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid;Pralatrexate	Approved	Approved Drug(s)	148121	DB06813	D02LWU	477.5	207	809	-0.9	35	5	11	10	C23H23N7O5	(2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid	C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O	C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O	InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1	OGSBUKJUDHAQEA-WMCAAGNKSA-N
DE18TH	Topotecan	Small molecule	topotecan; 123948-87-8; Hycamptamine; Topotecan lactone; Hycamptin; Nogitecan; Topotecane; Topotecanum; Topotecane [INN-French]; Topotecanum [INN-Latin]; (S)-Topotecan; 9-Dimethylaminomethyl-10-hydroxycamptothecin; CHEMBL84; NSC609699; Hycamtin (TN); NSC-641007; 7M7YKX2N15; Hycamtamine; CHEBI:63632; FF-10850 (liposomal topotecan); SK-S-104864-A; SKF-104864; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin; Topotecan [INN:BAN]; (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)-; SKF-104864-A; SK&F-104864-A; TOPOTECANHYDROCHLORIDE; CHEMBL1607; Topophore C; TopoCED; Topotecan (BAN); (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 10-((dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-, (S)-; SK&F-S-104864A; NSC 609669; SR-01000763672; SK&F 104864 A; 9-Dimethylaminomethyl-10-hydroxycamptothecin.; UNII-7M7YKX2N15; CCRIS 8163; HSDB 8213; 1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 10-((DIMETHYLAMINO)METHYL)-4-ETHYL-4,9-DIHYDROXY-, (4S)-; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (S)-; SKF-S 104864; SKF 104864; TOPOTECAN [INN]; TOPOTECAN [MI]; TOPOTECAN [VANDF]; SCHEMBL3836; TOPOTECAN [WHO-DD]; NCIStruc1_001659; NCIStruc2_001796; BSPBio_002348; TOPOTECAN [EMA EPAR]; cid_60699; GTPL7101; DTXSID3042685; EX-A834; HMS2090B20; HMS3715L03; BDBM50008935; BDBM50034026; HSCI1_000228; MFCD00870670; NSC641007; s9321; AKOS015966792; CCG-221171; DB01030; SK&F-104864; SMP2_000312; SMP2_000327; NCGC00014925-02; NCGC00014925-03; NCGC00014925-04; NCGC00014925-07; NCGC00014925-10; NCGC00014925-24; NCGC00178695-01; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; AC-11592; AC-34812; AS-75098; BP-29353; HY-13768; NCI60_004771; dimethylaminomethyl-ethyl-dihydroxy-[?]dione; T-161; dihydroxy(oxo)silane; dioxido(dioxo)molybdenum; A16815; D08618; EN300-117268; AB00641837-09; AB00641837-11; AB00641837-12; AB00641837-13; AB00641837-14; AB00641837_15; AB00641837_16; A805171; A892572; Q419953; SR-01000763672-3; SR-01000763672-4; BRD-K55696337-001-03-2; BRD-K55696337-003-08-7; Z1501485359; Topotecan hydrochloride hydrate, >=98% (HPLC and enzymatic); 10-HYDROXY-9-((DIMETHYLAMINO)METHYL)-(20S)-CAMPTOTHECIN; (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0(2),(1)(1).0?,?.0(1)?,(2)?]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione; (20S)-10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; (4-Ethyl-4,9-dihydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-10-ylmethyl)-dimethyl-ammonium; (alphaS)-alpha,8-Dihydroxy-1(11H)-oxo-alpha-ethyl-2-(hydroxymethyl)-9-(dimethylaminomethyl)-5,11a-diaza-11aH-benzo[b]fluorene-3-acetic acid 3,2-lactone; (alphaS)-alpha-Hydroxy-8-oxylato-1(11H)-oxo-alpha-ethyl-2-(hydroxymethyl)-9-(dimethylaminiomethyl)-5,11a-diaza-11aH-benzo[b]fluorene-3-acetic acid 3,2-lactone; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3'''',4'''':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione monohydrochloride; Nogitecan hydrochloride; Hycamtin; (S)-10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; (S)-10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; hydrochloride; (S)-11-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; (S)-11-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; hydrochloride; 10-dimethylaminomethyl-4-ethyl-4,9-dihydroxy-(4S)-3,4,12,14-tetrahydro-1H-pyrano[3'''',4'''':6,7]indolizino[1,2-b]quinoline-3,14-dione; 10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (Topotecan); 10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione(Topotecan); 10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; hydrochloride; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline- 3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)-	Approved	Approved Drug(s)	60700	DB01030	D02PMO	421.4	103	867	0.5	31	2	7	3	C23H23N3O5	(19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione	CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O	InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1	UCFGDBYHRUNTLO-QHCPKHFHSA-N
D7CX9J	Pravastatin	Small molecule	pravastatin; 81093-37-0; Pravastatina; Pravastatine; Pravastatinum; Pravachol; Pravastatin acid; PRAVASTATIN SODIUM; Pravator; Pravastatin (INN); (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; KXO2KT9N0G; CHEMBL1144; Eptastatin; CHEBI:63618; C10AA03; Pravastatine [French]; Pravastatinum [Latin]; Pravastatina [Spanish]; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; PRAVASTATIN [INN]; Pravastatin [INN:BAN]; (betaR,deltaR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-beta,delta,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-1-naphthaleneheptanoic acid; Mevalothin; Pravator (TN); (+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid; CCRIS 7557; UNII-KXO2KT9N0G; Pravastatin-3H; 3beta-Hydroxycompactin; KS-5015; PRAVASTATIN [VANDF]; SCHEMBL1117; PRAVASTATIN [WHO-DD]; BIDD:GT0773; PRAVASTATIN [EMA EPAR]; GTPL2953; DTXSID6023498; BDBM20688; HSDB 8368; HMS3715P11; ACT02637; HY-B0165; 1,4-Butanedisulfonicaciddisodiumsalt; LMFA05000695; s5713; AKOS015895229; CCG-221195; DB00175; NCGC00188962-01; NCGC00188962-02; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid; 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-((2S)-2-methyl-1-oxobutoxy)-, (betaR,deltaR,1S,2S,6S,8S,8aR)-; 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betas*,deltas*),2alpha,6alpha,8beta(R*),8aalpha))-; C01844; D08410; H12037; EN300-6481366; A840039; SR-01000781259; Q1240093; SR-01000781259-2; BRD-K60511616-236-01-4; BRD-K60511616-236-02-2; BRD-K60511616-236-08-9; (3R,5R)-3,5-dihydroxy-7-((1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-((S)-2-methylbutanoyloxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoic acid; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-.beta.,.delta.,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (.beta.R,.delta,R,1S,2S,6S,8S,8aR)-	Approved	Approved Drug(s)	54687	DB00175	D02RQU	424.5	124	656	1.6	30	4	7	11	C23H36O7	(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid	CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O	InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1	TUZYXOIXSAXUGO-PZAWKZKUSA-N
DNV2P6	Urofollitropin	Small molecule	Urofollitropin; 97048-13-0; 146479-72-3; Follicle-stimulating hormone; 1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide; 26995-91-5; Fertinex; Fertinorm; Metrodin; Orgafol; Urofollitrophin; SCHEMBL19712185; DTXSID10869286; AT36867; Q4006490; 1-{19-Amino-7-(2-amino-2-oxoethyl)-13-(butan-2-yl)-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl}prolylleucylglycinamide	Approved	Approved Drug(s)	62819	DB00094	D02SBQ	980.2	427	1790	-1.5	67	12	15	15	C42H65N11O12S2	1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide	CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O	CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O	InChI=1S/C42H65N11O12S2/c1-6-21(4)33-40(63)52-34(22(5)54)41(64)49-28(16-31(44)56)37(60)50-29(19-67-66-18-25(43)35(58)47-27(38(61)51-33)15-23-9-11-24(55)12-10-23)42(65)53-13-7-8-30(53)39(62)48-26(14-20(2)3)36(59)46-17-32(45)57/h9-12,20-22,25-30,33-34,54-55H,6-8,13-19,43H2,1-5H3,(H2,44,56)(H2,45,57)(H,46,59)(H,47,58)(H,48,62)(H,49,64)(H,50,60)(H,51,61)(H,52,63)	ZDRRIRUAESZNIH-UHFFFAOYSA-N
DQNW72	Ifosfamide	Small molecule	ifosfamide; Isophosphamide; 3778-73-2; Iphosphamide; Isofosfamide; Ifex; Ifosfamid; Mitoxana; Iphosphamid; Isoendoxan; Naxamide; I-Phosphamide; Holoxan; Cyfos; Ifsofamide; Holoxan 1000; ASTA Z 4942; MJF 9325; Ifosfamida; Ifosfamidum; MJF-9325; isosfamide; NSC-109724; NCI-C01638; Z4942; Z-4942; ifomide; NSC 109724; A 4942; Z 4942; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; NSC109724; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide; ISOCYCLOPHOSPHAMIDE; UM20QQM95Y; 3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide; CHEBI:5864; Ifosphamide; DTXSID7020760; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 3-(2-Chloroethyl)-2-(2-chloroethylamino)tetrahydro-2H-1,3,2-oxaazaphosphorin 2-oxide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide; NCGC00016639-01; CAS-3778-73-2; Ifosfamide Sterile; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; Ifosfamidum [INN-Latin]; Ifosfamida [INN-Spanish]; DTXCID90760; (R)-Ifosfamide; (S)-Ifosfamide; 66849-34-1; (R)-3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide; 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2lambda5-oxazaphosphinan-2-one; (2-CHLORO-ETHYL)-[(R)-3-(2-CHLORO-ETHYL)-2-OXO-2LAMBDA5-[1,3,2]OXAZAPHOSPHINAN-2-YL]-AMINE; CCRIS 352; HSDB 7023; SR-05000002022; EINECS 223-237-3; IFEX (TN); UNII-UM20QQM95Y; BRN 0611835; Ifosfamide (JAN/USP/INN); N,3-bis(2-chloroethyl)-2-oxo-1,3,2?^{5}-oxazaphosphinan-2-amine; Ifosfamid A; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorineoxide; Ifosfamide in bulk; 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd; Isophosphamide,(S); N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; MFCD00057374; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]; Ifosfamide - Bio-X; Ifosfamide [USAN:USP:INN:BAN:JAN]; starbld0001221; Ifosfamide, >=98%; IFOSFAMIDE [MI]; IFOSFAMIDE [INN]; IFOSFAMIDE [JAN]; Prestwick0_000833; Prestwick1_000833; Prestwick2_000833; Prestwick3_000833; IFOSFAMIDE [HSDB]; IFOSFAMIDE [USAN]; Intermediate of Ifosfamide; IFOSFAMIDE [VANDF]; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid; IFOSFAMIDE [MART.]; SCHEMBL4885; CHEMBL1024; IFOSFAMIDE [USP-RS]; IFOSFAMIDE [WHO-DD]; BSPBio_000785; ISOPHOSPHAMIDE [IARC]; MLS002154021; Ifex (TN) (Bristol Meyers); SPBio_002706; BPBio1_000865; GTPL7201; IFOSFAMIDE [EP IMPURITY]; IFOSFAMIDE [ORANGE BOOK]; IFOSFAMIDE [EP MONOGRAPH]; (S)-3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide; BDBM189358; HMS1570H07; HMS2090M12; HMS2093N07; HMS2097H07; HMS2232O10; HMS3374B08; HMS3654B15; HMS3714H07; IFOSFAMIDE [USP MONOGRAPH]; Pharmakon1600-01505480; {3-(2-Chloroethyl)-2-[(2-; BCP06596; WLN: T6NPOTJ AM2G BO B2G; Tox21_110539; Tox21_201815; Tox21_302775; BBL028071; N,3-bis(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine; N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine; NSC759154; s1302; STL058690; AKOS005711213; N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide; Tox21_110539_1; AB02316; AC-2113; CCG-213464; CS-1424; DB01181; NSC-759154; N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine; Ifosfamide, analytical reference material; NCGC00179435-01; NCGC00179435-02; NCGC00179435-03; NCGC00179435-06; NCGC00179435-07; NCGC00256413-01; NCGC00259364-01; AS-10978; BI166243; HY-17419; NCI60_000233; SMR001233348; SBI-0206804.P001; DB-049196; AB00513932; FT-0603650; FT-0670282; I0713; SW197177-4; C07047; D00343; AB00513932-06; AB00513932-07; AB00513932-08; AB00513932_09; AB00513932_10; EN300-7476797; A823873; Q418560; Q-101874; SR-05000002022-1; SR-05000002022-3; SR-05000002022-5; BRD-A67097164-001-11-2; Ifosfamide, British Pharmacopoeia (BP) Reference Standard; Ifosfamide, European Pharmacopoeia (EP) Reference Standard; Ifosfamide, United States Pharmacopeia (USP) Reference Standard; 2,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxy-; 2,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd; N,3-bis(2-chloroethyl)-2-oxo-1,3,2$l;{5}-oxazaphosphinan-2-amine; {3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,} 2-oxazaphosphorine oxide; 1,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 2H-1,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; 2H-1,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 3-(2-Chloroethyl)-2-(2-chloroethylamino)tetrahydro-2H-1,3,2-oxazaphosphorin-2-one; 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2$l^{5}-oxazaphosphinan-2-one; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,2-oxazaphosphorineoxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,2-oxazaphosphorine 2-oxide; N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphinan-2-amine 2-oxide #; 3-(2-chloroethyl)-2-[(2-chloroethyl)amino][(perhydrochloroethyl)amino]perhydro-2h-1,3,2-oxazaphospho	Approved	Approved Drug(s)	3690	DB01181	D02TLO	261.079	41.6	218	0.9	14	1	4	5	C7H15Cl2N2O2P	N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine	C1CN(P(=O)(OC1)NCCCl)CCCl	C1CN(P(=O)(OC1)NCCCl)CCCl	InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)	HOMGKSMUEGBAAB-UHFFFAOYSA-N
D8I9VZ	Metaproterenol	Small molecule	metaproterenol; ORCIPRENALINE; 586-06-1; Alupent; Orciprenalinum; Orciprenalinum [INN-Latin]; Orciprenalina [INN-Spanish]; Orciprenaline [INN]; Prometa; 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol; Orciprenaline (INN); (RS)-1-(3,5-Dihydroxyphenyl)-2-isopropylaminoethanol; CHEMBL776; CHEBI:6792; 5-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,3-diol; 1,3-Benzenediol, 5-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-; 53QOG569E0; NSC-757089; Orciprenalina; 1,3-Benzenediol, 5-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-; CCRIS 9017; TH-152; SR-01000075168; EINECS 209-569-1; Orciprenaline [INN:BAN]; BRN 2807247; Orciprenalin; UNII-53QOG569E0; 3,5-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; Spectrum_000925; Prestwick0_000505; Prestwick1_000505; Prestwick2_000505; Prestwick3_000505; Spectrum2_000096; Spectrum3_000492; Spectrum4_000044; Spectrum5_000952; M-3070; METAPROTERENOL [MI]; SCHEMBL4270; Lopac0_000734; BSPBio_000429; BSPBio_001983; KBioGR_000507; KBioSS_001405; DivK1c_000645; METAPROTERENOL [VANDF]; SPECTRUM1500390; SPBio_000052; SPBio_002350; ORCIPRENALINE [WHO-DD]; BPBio1_000473; GTPL7250; DTXSID8048529; CHEBI:83329; HMS502A07; HY-B1276A; KBio1_000645; KBio2_001405; KBio2_003973; KBio2_006541; KBio3_001483; NINDS_000645; HMS1920L09; HMS2091D04; HMS3259J13; Pharmakon1600-01500390; Benzyl alcohol, 3,5-dihydroxy-alpha-((isopropylamino)methyl)-; BDBM50295572; CCG-38914; NSC757089; DB00816; NC00651; NSC 757089; SDCCGSBI-0050712.P005; IDI1_000645; NCGC00015655-02; NCGC00015655-03; NCGC00015655-04; NCGC00015655-05; NCGC00015655-06; NCGC00015655-14; NCGC00094718-01; NCGC00094718-02; NCGC00094718-03; SBI-0050712.P004; AB00052037; CS-0013668; C07144; D08300; EN300-142650; 1-(3,5-Dihydroxyphenyl)-2-isopropylaminoethanol; AB00052037_09; AB00052037_10; L000678; Q416473; SR-01000075168-1; SR-01000075168-4; BRD-A07780951-001-06-3; 5-(1-Hydroxy-2-(isopropylamino)ethyl)benzene-1,3-diol; 5-(1-Hydroxy-2-isopropylamino-ethyl)-benzene-1,3-diol; 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol; 5-[1-Hydroxy-2-(isopropylamino)ethyl]-1,3-benzenediol #; [2-(3,5-Dihydroxy-phenyl)-2-hydroxy-ethyl]-isopropyl-ammonium; 3,5-Dihydroxy-.alpha.-((isopropylamino)methyl)benzyl alcohol; 5-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,3-diol, 6; Benzyl alcohol, 3,5-dihydroxy-.alpha.-((isopropylamino)methyl)-; [2-(3,5-Dihydroxy-phenyl)-2-hydroxy-ethyl]-isopropyl-ammonium (orciprenaline)	Approved	Approved Drug(s)	4086	DB00816	D02UFG	211.26	72.7	177	0.7	15	4	4	4	C11H17NO3	5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol	CC(C)NCC(C1=CC(=CC(=C1)O)O)O	CC(C)NCC(C1=CC(=CC(=C1)O)O)O	InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8/h3-5,7,11-15H,6H2,1-2H3	LMOINURANNBYCM-UHFFFAOYSA-N
DEB1V0	Semaglutide	Small molecule	Semaglutide; NN9535; Ozempic; Rybelsus; 910463-68-2; NN 9535; NNC 0113-0217; NN-9535; UNII-53AXN4NNHX; Semaglutide [USAN:INN]; Wegovy; 53AXN4NNHX; Rybelsus (oral semaglutide); GTPL9724; Ozempic (injectable semaglutide); CHEBI:167574; EX-A2424; AC-32580; NNC-0113-0217; Rybelsus;Ozempic;NN9535;OG217SC;NNC 0113-0217	Approved	Approved Drug(s)	56843331	DB13928	D02ULU	4114	1650	9590	-5.8	291	57	63	151	C187H291N45O59	18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid	CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N	InChI=1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1	DLSWIYLPEUIQAV-CCUURXOWSA-N
D05NYS	Pirfenidone	Small molecule	PIRFENIDONE; 53179-13-8; 5-methyl-1-phenylpyridin-2(1H)-one; Esbriet; AMR-69; Deskar; Pirespa; 5-Methyl-1-phenyl-2-(1H)-pyridone; Pirfenidonum; Pirfenidona; 2(1H)-Pyridinone, 5-methyl-1-phenyl-; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-methyl-1-phenylpyridin-2-one; AMR 69; 5-methyl-1-phenyl-2(1H)-pyridinone; 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-methyl-1-phenyl-2-pyridinone; MFCD00866047; D7NLD2JX7U; NSC-748456; AMR69; DTXSID4045183; CHEBI:32016; S-7701; NCGC00015806-03; Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; Pirfenidona [INN-Spanish]; DTXCID2025183; CAS-53179-13-8; SR-01000076061; UNII-D7NLD2JX7U; BRN 1526549; Prfendone; Pirfenidone (JAN/USAN/INN); 5-methyl-1-phenyl-pyridin-2-one; Pirfenidone-[d3]; Esbriet (TN); Pirfenidone- Bio-X; Pirfenidone(AMR69); KS-5041; 2(1H)-Pyridone, 5-methyl-1-phenyl-; Tocris-1093; PIRFENIDONE [MI]; Lopac-P-2116; PIRFENIDONE [INN]; PIRFENIDONE [JAN]; F-647; PIRFENIDONE [USAN]; P 2116; PIRFENIDONE [VANDF]; SCHEMBL4708; PIRFENIDONE [MART.]; Lopac0_000907; PIRFENIDONE [WHO-DD]; 5-21-07-00197 (Beilstein Handbook Reference); MLS000860042; PIRFENIDONE [EMA EPAR]; 5-Methyl-1-phenyl-2-pyridone; GTPL7532; CHEMBL1256391; 1-phenyl-5-methyl-2-pyridinone; HSDB 8340; Pirfenidone, >=97% (HPLC); PIRFENIDONE [ORANGE BOOK]; Bio1_000397; Bio1_000886; Bio1_001375; HMS2234G24; HMS3262F16; HMS3267I06; HMS3372A08; HMS3412G13; HMS3651P08; HMS3676G13; PIRFENIDONE [EP MONOGRAPH]; BCP04473; ESBRIET COMPONENT PIRFENIDONE; HY-B0673; Tox21 110225; Tox21_110225; Tox21_500907; BDBM50005201; NSC748456; s2907; AKOS006273697; S-7701,AMR-69; Tox21_110225_1; AB07515; AC-6797; AM84939; CCG-204989; DB04951; LP00907; NSC 748456; PIRFENIDONE COMPONENT OF ESBRIET; SDCCGSBI-0050882.P002; NCGC00015806-01; NCGC00015806-02; NCGC00015806-04; NCGC00015806-05; NCGC00015806-06; NCGC00015806-17; NCGC00024992-01; NCGC00024992-02; NCGC00024992-03; NCGC00261592-01; BM164275; SMR000326900; SY034783; EU-0100907; FT-0602686; FT-0672092; P1871; SW220156-1; D01583; 5-Methyl-N-phenyl-2-1H-pyridone [Pirfenidone]; EN300-7366392; A829431; J-523979; Q2060696; SR-01000076061-1; SR-01000076061-3; 5-METHYL-1-PHENYL-1,2-DIHYDROPYRIDIN-2-ONE; 5-Methyl-N-phenyl-2-1H-pyridone-d5(pirfenidone-d5); BRD-K96862998-001-03-1; BRD-K96862998-001-09-8; Pirfenidone, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	40632	DB04951	D02WCI	185.22	20.3	285	1.9	14	0	1	1	C12H11NO	5-methyl-1-phenylpyridin-2-one	CC1=CN(C(=O)C=C1)C2=CC=CC=C2	CC1=CN(C(=O)C=C1)C2=CC=CC=C2	InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3	ISWRGOKTTBVCFA-UHFFFAOYSA-N
DXW3H9	Octreotide	Small molecule	Octreotide; Octreotide acetate; 83150-76-9; SMS 201-995; Sandostatin; 79517-01-4; Longastatin; SMS-201-995; RWM8CCW8GP; CHEMBL1680; SMS995; SMS-995; 83150-76-9 (free base); Octreotidum [Latin]; Octreotida [Spanish]; Octrotide; (4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide; [R-(R*,R*)]-D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxy-methyl)propyl]-cysteinamide cyclic(2-->7)-disulfide; Octreotida; Octreotidum; DRG-0115; Octreotide-LAR; UNII-RWM8CCW8GP; DTXSID0048682; Octreotide [USAN:INN:BAN]; Octreotide CRS; Octreotode Acetate; (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; MFCD00871400; OCTREOTIDE [MI]; OCTREOTIDE [INN]; OCTREOTIDE [USAN]; OCTREOTIDE [VANDF]; OCTREOTIDE [WHO-DD]; Octreotide, >=98% (HPLC); SCHEMBL10044649; OCTREOTIDE [EP MONOGRAPH]; HMS2090C09; 10-(4-Amino-butyl)-19-(2-amino-3-phenyl-propionylamino)-16-benzyl-7-(1-hydroxy-ethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloicosane-4-carboxylic acid (2-hydroxy-1-hydroxymethyl-propyl)-amide; EX-A4865; BDBM50272772; AKOS015994656; CCG-270610; DB00104; HS-2020; AC-28733; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2-7)-disulfide, (R-(R*,R*))-; 10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate; AB01275486-01; Q419935; Q-201501; (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenyl-propanoyl]amino]-16-benzyl-7-[(1R)-1-hydroxyethyl]-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; 10-(4-Amino-butyl)-19-(2-amino-3-phenyl-propionylamino)-16-benzyl-7-(1-hydroxy-ethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloicosane-4-carboxylic acid (2-hydroxy-1-; 2-{[(13R,16S,19R)-10-(4-Amino-butyl)-19-((S)-2-amino-3-phenyl-propionylamino)-16-benzyl-7-(1-hydroxy-ethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloicosane-4-carbonyl]-amino}-3-hydroxy-butyric acid; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide; D-PHENYLALANYL-L-HEMICYSTYL-L-PHENYLALANYL-D-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-HEMICYSTYL-L-THREONINOL CYCLIC (2->7)-DISULFIDE; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*,R*))-; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*,R*))-	Approved	Approved Drug(s)	448601	DB00104	D02XIY	1019.2	383	1740	1	71	13	14	17	C49H66N10O10S2	(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide	CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O	C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O	InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1	DEQANNDTNATYII-OULOTJBUSA-N
DTD5B0	Midodrine	Small molecule	midodrine; Midodrin; 42794-76-3; Midodrina; Midodrinum; Midodrinum [INN-Latin]; Midodrina [INN-Spanish]; St 1085; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; ProAmatine; Midodrine free base; ST-1085; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; Midodrine (INN); Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-; 6YE7PBM15H; CHEBI:6933; 42794-76-3 (free base); 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; MIDODRINE [INN]; 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide; Midodrine [INN:BAN]; 133163-28-7; 97476-58-9; EINECS 255-945-3; UNII-6YE7PBM15H; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; HSDB 7854; Spectrum_001641; MIDODRINE [MI]; MIDODRINE [HSDB]; Prestwick0_000191; Prestwick1_000191; Prestwick2_000191; Prestwick3_000191; Spectrum2_001545; Spectrum3_001585; Spectrum4_000192; Spectrum5_000962; MIDODRINE [VANDF]; MIDODRINE [WHO-DD]; BSPBio_000141; BSPBio_003150; KBioGR_000763; KBioSS_002121; DivK1c_000955; SCHEMBL131436; SPBio_001390; SPBio_002062; BPBio1_000157; GTPL7240; CHEMBL1201212; DTXSID0023321; SCHEMBL20996761; KBio1_000955; KBio2_002121; KBio2_004689; KBio2_007257; KBio3_002650; NINDS_000955; HMS3886M20; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; 2-AMINO-N-[2-(2,5-DIMETHOXYPHENYL)-2-HYDROXY-ETHYL]ACETAMIDE; s5735; AKOS015967099; CS-4688; DB00211; ( inverted exclamation markA)-Midodrine; IDI1_000955; NCGC00178238-01; NCGC00178238-02; DA-05918; HY-12749; SBI-0051934.P002; AB00053715; FT-0740719; C07890; D08220; AB00053715_08; A913477; EN300-25893675; Q415051; BRD-A79981887-003-05-7; BRD-A79981887-003-09-9; rac-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; (+-)-2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide; (+/-)-2-amino-n-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]ethanimidic acid; (+/-)-2-AMINO-N-(.BETA.-HYDROXY-2,5-DIMETHOXYPHENETHYL)ACETAMIDE; ACETAMIDE, 2-AMINO-N-(2-(2,5-DIMETHOXYPHENYL)-2-HYDROXYETHYL)-, (+/-)-	Approved	Approved Drug(s)	4195	DB00211	D02XJY	254.28	93.8	263	-0.6	18	3	5	6	C12H18N2O4	2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide	COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O	COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O	InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)	PTKSEFOSCHHMPD-UHFFFAOYSA-N
D97INJ	Levalbuterol	Small molecule	Levalbuterol; Levosalbutamol; 34391-04-3; (-)-Salbutamol; (-)-Albuterol; (R)-salbutamol; R-Salbutamol; Xopenex; 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Levosalbutamol [INN]; EDN2NBH5SS; (-)-Albuterol sulfate (1; CHEBI:8746; ASF-1096; Levosalbutamol (INN); (R)-albuterol; R-Albuterol; (r)-(-)-salbutamol; (R)-4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; 324000-04-6; Salbutamol (hemisulfate); UNII-EDN2NBH5SS; Levolin; 68H; (R) - Albuterol; Albuterol (r)-form; CAS-18559-94-9; (R)-Albuterol;(R)-Salbutamol;Levosalbutamol; Tocris-0634; Albuterol (hemisulfate);AH-3365 (hemisulfate); Lopac-S-5013; Lopac-S-8260; SCHEMBL4003; (-)-alpha(sup 1)-(((1,1-Dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol; CHEMBL1002; LEVALBUTEROL [VANDF]; m-Xylene-alpha,alpha'-diol, alpha(sup 1)-((tert-butylamino)methyl)-4-hydroxy-, (R)-(-)-; Levosalbutamol (Levalbuterol); BIDD:GT0508; LEVOSALBUTAMOL [MART.]; GTPL9816; LEVOSALBUTAMOL [WHO-DD]; DTXSID80187964; ALBUTEROL (R)-FORM [MI]; GLXC-25242; BCP28425; HY-B1675; BBL010806; BDBM50361247; STK618645; (R)-alpha1-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; 4-[(1R)-2-(tert-butylamino)-1-hydroxy-ethyl]-2-(hydroxymethyl)phenol; AKOS005552518; AC-1542; DB13139; (R)-alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; 1,3-Benzenedimethanol, alpha(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (-)-; 1,3-Benzenedimethanol, alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (alpha1R)-; NCGC00015955-01; NCGC00015955-02; NCGC00015955-03; NCGC00016736-01; NCGC00024698-01; SBI-0206903.P001; CS-0013639; D08124; EN300-1699072; A822211; Q408709; J-019582; BRD-K34469523-003-01-4; F2173-0564; Albuterol; AH-3365; (R)-albuterol; R-albuterol; R albuterol; alpha-1-[[(1,1-Dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol; (R)-.ALPHA.(SUP 1)-((TERT-BUTYLAMINO)METHYL)-4-HYDROXY-M-XYLENE-.ALPHA.,.ALPHA.'-DIOL	Approved	Approved Drug(s)	123600	DB13139	D02ZJI	239.31	72.7	227	0.3	17	4	4	5	C13H21NO3	4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol	CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O	CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)O)CO)O	InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/m0/s1	NDAUXUAQIAJITI-LBPRGKRZSA-N
D25YZW	Sulfasalazine	Small molecule	sulfasalazine; 599-79-1; Salicylazosulfapyridine; Azulfidine; Salazosulfapyridine; Sulphasalazine; Salazopyrin; Asulfidine; Benzosulfa; Salazopyridin; Accucol; Azopyrin; Sulcolon; Colo-Pleon; Salazopiridazin; Azopyrine; Reupirin; Salisulf; Salazosulfapyridin; Sulfasalazinum; w-t Sasp oral; Azulfidine EN; Sulfasalazin; Sulfasalazina; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Salazosulfapyridinum; Sas-500; SASP; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; NSC 667219; S.A.S.-500; 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid; 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene; 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid; 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid; 5-[4-(2-Pyridylsulfamoyl)phenylazo]salicylic Acid; CHEBI:9334; NSC 203730; S.A.S. 500; (E)-2-hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid; Sulfasalazopyridine; MFCD00057363; Benzoic acid, 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]-; 3XC8GUZ6CB; Sulfasalazine (Azulfidine); NSC-203730; NSC-667219; Benzoic acid, 2-hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)-; S.A.S.; 737754-28-8; Azosulfidin; DTXSID0021256; 2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid; 5-[p-(2-Pyridylsulfamoyl)phenylazo]salicylic acid; 2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID; NSC203730; NSC667219; Salicylic acid, 5-((p-(2-pyridylsulfamoyl)phenyl)azo)-; NCGC00090903-01; Salazo-sulfapyridinum; CAS-599-79-1; 2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid; 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid; 2-hydroxy-5-[(E)-{4-[(pyridin-2-ylamino)sulfonyl]phenyl}diazenyl]benzoic acid; 5-[p-(2-Pyridylsulfamyl)phenylazo]salicylic acid; (3Z)-6-Oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid; 5-(p-(2-Pyridylsulfamoyl)phenylazo)salicylic acid; DTXCID401256; Sulfasalazinum [INN-Latin]; Sulfasalazina [INN-Spanish]; Salicylic acid, 5-[[p-(2-pyridylsulfamoyl)phenyl]azo]-; 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid; Salazosulfapyridinum [INN-Latin]; Salazosulfapiridina [INN-Spanish]; SI-88; 2-Hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid; 2-hydroxy-5-(2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl)benzoic acid; 2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid; Azulfidine (TN); SMR000059146; Sulphasalazine, N-; CCRIS 4713; HSDB 3395; 13gs; SR-05000001721; EINECS 209-974-3; UNII-3XC8GUZ6CB; 5-[[p-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid; Sulfasalazine (USP/INN); BRN 0356241; Iwata; Prestwick_848; Sulfasalazine [USAN:USP:INN:BAN]; SSZ; Spectrum_000998; Prestwick0_000520; Prestwick1_000520; Prestwick2_000520; Prestwick3_000520; Spectrum2_001216; Spectrum3_001364; Spectrum4_000347; Spectrum5_001443; SULFASALAZINE [MI]; CHEMBL421; Epitope ID:122672; SULFASALAZINE [INN]; SCHEMBL4514; SCHEMBL4515; Salazosulfapyridine (JP17); SULFASALAZINE [HSDB]; SULFASALAZINE [IARC]; SULFASALAZINE [USAN]; SCHEMBL18490; BSPBio_000479; BSPBio_002888; KBioGR_000753; KBioGR_002314; KBioSS_001478; KBioSS_002316; SULFASALAZINE [VANDF]; 5-22-08-00433 (Beilstein Handbook Reference); MLS000759399; MLS001424109; MLS006011702; BIDD:GT0161; DivK1c_000860; SPECTRUM1500552; SULFASALAZINE [MART.]; SPBio_001032; SPBio_002400; SULFASALAZINE [USP-RS]; SULFASALAZINE [WHO-DD]; SULFASALAZINE [WHO-IP]; BPBio1_000527; CHEMBL100848; CHEMBL242373; GTPL4840; SCHEMBL1079598; SCHEMBL1229516; CHEMBL1206016; SCHEMBL10289061; CHEBI:94500; HMS502K22; KBio1_000860; KBio2_001478; KBio2_002314; KBio2_004046; KBio2_004882; KBio2_006614; KBio2_007450; KBio3_002108; KBio3_002794; SALAZOSULFAPYRIDINE [JAN]; cMAP_000018; NINDS_000860; HMS1569H21; HMS1921C05; HMS2051J21; HMS2090P13; HMS2092K07; HMS2096H21; HMS2232H07; HMS3370D16; HMS3393J21; HMS3655G07; HMS3713H21; HMS3871J13; HMS3884E21; Pharmakon1600-01500552; SULFASALAZINE [ORANGE BOOK]; ALBB-033361; BCP13311; SULFASALAZINE [EP MONOGRAPH]; Tox21_111037; Tox21_201239; Tox21_300541; BDBM50097125; BDBM50103596; CCG-39145; DL-510; NSC757330; s1576; SULFASALAZINE [USP MONOGRAPH]; SULFASALAZINUM [WHO-IP LATIN]; AKOS002311709; AKOS025116975; AKOS026749974; AKOS037515748; Tox21_111037_1; WLN: T6NJ BSWMR DNUNR DQ CVQ; CCG-100987; DB00795; HS-0062; NC00237; NSC-757330; IDI1_000860; SMP2_000059; NCGC00016518-01; NCGC00090903-02; NCGC00090903-03; NCGC00090903-04; NCGC00090903-05; NCGC00090903-06; NCGC00090903-07; NCGC00090903-08; NCGC00090903-09; NCGC00090903-11; NCGC00186644-01; NCGC00254313-01; NCGC00258791-01; AC-20497; HY-14655; SMR004703430; SY052318; SBI-0051526.P003; DB-017797; FT-0603483; FT-0674746; S0580; SW196979-4; C07316; D00448; EN300-119546; H10652; AB00052101-04; AB00052101-06; AB00052101_07; AB00052101_08; A832559; Q420035; Q-201769; SR-05000001721-1; SR-05000001721-2; SR-05000001721-3; Sulfasalazine, analytical standard, >=98% (HPLC); 5-[[4-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid; BRD-K10670311-001-06-4; BRD-K10670311-001-08-0; Q27166356; Q63398427; Sulphasalazine, Antibiotic for Culture Media Use Only; F2173-1125; Z1521554012; 4-(Pyridyl-2-amidosulfonyl)-3''-carboxy-4''-hydroxyazobenzene; Sulfasalazine, European Pharmacopoeia (EP) Reference Standard; 2-hydroxy-5-[(E)-[4-(2-pyridylsulfamoyl)phenyl]azo]benzoic acid; 5-{4-[(2-pyridylideneamino)sulfonyl]phenyldiazenyl}salicylic acid; Sulfasalazine, United States Pharmacopeia (USP) Reference Standard; (E)-2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid; 2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid; 2-Hydroxy-5-((4-[(2-pyridinylamino)sulfonyl]phenyl)diazenyl)benzoic acid #; 2-HYDROXY-5-((4-((2-PYRIDINYLAMINO)SULFONYL)PHENYL)AZO)BENZOIC ACID [WHO-IP]; 6-oxo-3-(2-[4-(n-pyridin-2-ylsulfamoyl)phenyl]hydrazono)cyclohexa-1,4-dienecarboxylic acid; BENZOIC ACID, 2-HYDROXY-5-(2-(4-((2-PYRIDINYLAMINO)SULFONYL)PHENYL)DIAZENYL)-; 6-oxo-3-((4-(pyridin-2-ylsulfamoyl)phenyl) hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid; 6-oxo-3-[[4-(2-pyridinylsulfamoyl)phenyl]hydrazinylidene]-1-cyclohexa-1,4-dienecarboxylic acid	Approved	Approved Drug(s)	5339	DB00795	D02ZTJ	398.4	150	657	-0.7	28	3	9	6	C18H14N4O5S	2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid	C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O	C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O	InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)	NCEXYHBECQHGNR-UHFFFAOYSA-N
DL14MC	Sodium zirconium cyclosilicate	Small molecule	UXSI-9; DTXSID601026629; SODIUM ZIRCONIUM CYCLOSILICATE [MI]; SODIUM ZIRCONIUM CYCLOSILICATE [WHO-DD]; SODIUM ZIRCONIUM CYCLOSILICATE [ORANGE BOOK]	Approved	Approved Drug(s)	155804812	DB14048	D03AZK	365.45	166	131	.	15	0	9	0	Na2O9Si3Zr	disodium;2,2,4,4,6,6-hexaoxido-1,3,5,2,4,6-trioxatrisilinane;zirconium(4+)	[O-][Si]1(O[Si](O[Si](O1)([O-])[O-])([O-])[O-])[O-].[Na+].[Na+].[Zr+4]	[O-][Si]1(O[Si](O[Si](O1)([O-])[O-])([O-])[O-])[O-].[Na+].[Na+].[Zr+4]	InChI=1S/2Na.O9Si3.Zr/c;;1-10(2)7-11(3,4)9-12(5,6)8-10;/q2*+1;-6;+4	QMLIRKACNOVYNW-UHFFFAOYSA-N
D9C6TL	Quinine sulfate	Small molecule	quinine sulfate; 804-63-7; Quinine sulphate; M4XCR57IWG; QUININE SULFATE (2:1); Quinine (sulfate) (2:1); Quinine hydrogen sulphate; Quinine sulfate anhydrous; Aflukin; Quinine bisulfate; Quinine, sulfate (2:1) (salt); Quinine hydrogen sulfate; Anhydrous quinine sulfate; Quinine hemisulfate anhydrous; Quine; Coco-Quinine; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol sulfate (2:1); Quinine, sulfate; NSC 5362; NSC-5362; 549-56-4; Legatrin; (R)-(6-methoxy-4-quinolyl)-[(2S,4S,5R)-5-vinylquinuclidin-2-yl]methanol; sulfuric acid; Quinine sulfate (VAN); UNII-M4XCR57IWG; SCHEMBL41278; HY-B0433B; DTXSID50859000; QUININE SULFATE [WHO-DD]; EINECS 212-359-2; AKOS017343635; QUININE SULFATE ANHYDROUS [MI]; ANHYDROUS QUININE SULFATE [MART.]; CS-0009645; A864691; W-105183; Q27123328; Cinchonan-9-ol, 6'-methoxy-, (8alpha,9R)-, sulfate (2:1); Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate (2:1); Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate (2:1) (salt); Cinchonan-9-ol, 6'-methoxy-, (8alpha,9R)-, sulfate (2:1) (salt); (R)-(6-Methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol hemisulfate; (R)-(6-methoxyquinolin-4-yl)((2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol hemisulfate	Approved	Approved Drug(s)	16051948	DB00468	D03DDR	746.9	174	538	.	53	4	12	8	C40H50N4O8S	(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid	COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.OS(=O)(=O)O	COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.OS(=O)(=O)O	InChI=1S/2C20H24N2O2.H2O4S/c2*1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;1-5(2,3)4/h2*3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;(H2,1,2,3,4)/t2*13-,14-,19-,20+;/m00./s1	RONWGALEIBILOG-VMJVVOMYSA-N
DDGO76	Indacaterol	Small molecule	Indacaterol; 312753-06-3; Onbrez; QAB-149; QAB149; Arcapta; QAB 149; Indacterol; UNII-8OR09251MQ; Indacaterol [USAN:INN:BAN]; 8OR09251MQ; 753498-25-8; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; CHEMBL1095777; CHEBI:68575; 312753-06-3 (free base); QABI49; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; (R)-5-[2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin-2-one; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; Indacaterol [INN]; Indacaterol (USAN/INN); 5-{(1R)-2-((5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; INDACATEROL [MI]; INDACATEROL [USAN]; INDACATEROL [VANDF]; INDACATEROL [MART.]; SCHEMBL48098; INDACATEROL [WHO-DD]; GTPL7455; DTXSID90185198; HMS3886I14; BCP03766; EX-A6067; BDBM50318159; MFCD18782702; s5654; AKOS024463516; BCP9000787; CCG-268560; CS-0744; DB05039; NCGC00386216-07; 5-[(1R)-2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-2(1H)-quinolinone Maleic Acid; AC-27668; AS-56318; HY-14299; BCP0726000140; D09318; AB01565805_02; A855441; A900064; EN300-20321622; Q425654; J-521526; (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1h-quinolin-2-one; 8-Hydroxy-5-[(R)-1-hydroxy-2-(5,6-diethylindan-2-ylamino)-ethyl]-1H-quinolin-2-one; 5-[(1R)-2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one; QAB 149; Benzyl hydrogen (3-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)-4-morpholinyl]methyl}-5-oxo-2,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonate	Approved	Approved Drug(s)	6918554	DB05039	D03DJL	392.5	81.6	589	3.3	29	4	4	6	C24H28N2O3	5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one	CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC	CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC	InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1	QZZUEBNBZAPZLX-QFIPXVFZSA-N
DIY5M0	Amisulpride	Small molecule	amisulpride; 71675-85-9; Solian; Aminosultopride; Deniban; Amisulprida; DAN 2163; Amisulpridum; Socian; Amisulpride [INN]; Barhemsys; C17H27N3O4S; DAN-2163; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide; APD421; Sulamid; Amisulpride (INN); 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; Amisulpride free base; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; NSC-760085; 4-amino-N-((1-ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; DTXSID5042613; CHEBI:64045; APD-421; 71675-85-9 (free base); 8110R61I4U; NCGC00092310-03; Amisulpiride; Benzamide, 4-amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-; Amisulpridum [INN-Latin]; Amisulprida [INN-Spanish]; DTXCID3022613; Sulpitac; 4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2-methoxybenzamide; 4-amino-5-(ethanesulfonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide; SMR000449309; Deniban (TN); CAS-71675-85-9; Solian (TN); Amisulpride [INN:BAN]; EINECS 275-831-7; UNII-8110R61I4U; Barhemsys (TN); 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; Amisulpride- Bio-X; (plusmn)-amisulpride; MFCD00866691; AMISULPRIDE [MI]; SL-91.1077; AMISULPRIDE [MART.]; SCHEMBL34126; (+/-)-AMISULPRIDE; AMISULPRIDE [WHO-DD]; GTPL963; MLS000758258; MLS000759450; MLS001424039; MLS006011769; CHEMBL243712; Amisulpride, >=98% (HPLC); BDBM81790; AMISULPRIDE [ORANGE BOOK]; Amisulpride for system suitability; AMISULPRIDE [EP MONOGRAPH]; BCPP000404; HMS2051K10; HMS2235M16; HMS3263D07; HMS3268L09; HMS3369K09; HMS3393K10; HMS3413G07; HMS3657E11; HMS3677G07; HMS3713N06; HMS3884A09; Pharmakon1600-01502285; BCP02089; NSC_2159; Tox21_113392; Tox21_501133; HB1879; NSC760085; STK635172; STL454297; AKOS005567252; Tox21_113392_1; AC-6820; BCP9000294; CCG-100860; CCG-220622; CCG-222437; CS-1791; DB06288; LP01133; NC00110; NSC 760085; SDCCGSBI-0633795.P001; NCGC00092310-01; NCGC00092310-02; NCGC00092310-04; NCGC00092310-06; NCGC00092310-16; NCGC00261818-01; AS-13890; BA164158; HY-14545; Amisulpride 100 microg/mL in Acetonitrile; CAS_71675-85-9; FT-0630805; S1280; SW197490-3; D07310; AB00639933-07; AB00639933-09; AB00639933_10; A837282; EN300-18166870; L000106; Q418785; SR-01000759303; SR-01000759303-5; W-104511; BRD-A60197193-001-05-4; Amisulpride, British Pharmacopoeia (BP) Reference Standard; Amisulpride, European Pharmacopoeia (EP) Reference Standard; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl) methyl]-5-(ethylsulfonyl)-2-benzamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-benzamide; 4-amino-5-ethanesulfonyl-n-(1-ethyl-pyrrolidin-2-ylmethyl)-2-methoxy-benzamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulf onyl)-2-benzamide DAN 2163; 4-Amino-N-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)- 2-methoxybenzamide; 4-azanyl-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide; Amisulpride for system suitability, European Pharmacopoeia (EP) Reference Standard; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzenecarboximidic acid	Approved	Approved Drug(s)	2159	DB06288	D03ELL	369.5	110	549	1.5	25	2	6	7	C17H27N3O4S	4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide	CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC	CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC	InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)	NTJOBXMMWNYJFB-UHFFFAOYSA-N
DBTW93	Lamotrigine	Small molecule	lamotrigine; 84057-84-1; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; Lamictal; Lamictal Cd; Lamictal XR; Lamotrigina; Lamotriginum; BW 430C; Lamotriginum [Latin]; Lamotrigina [Spanish]; BW-430C; Labileno; Lamitor; Lamictal ODT; 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; C9H7Cl2N5; 1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)-; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; BW430C; LTG;BW430C; MFCD00865333; CHEMBL741; NSC-759171; MLS000069685; CHEBI:6367; DTXSID2023195; U3H27498KS; NCGC00015605-06; SMR000058464; DTXCID203195; Lamictal (TN); LTg; CAS-84057-84-1; SR-01000000187; EINECS 281-901-8; Epilepax; UNII-U3H27498KS; HSDB 7526; EUR-1048; Lamotrigine [USAN:USP:INN:BAN]; zine-3,5-diamine; Lamotrigine- Bio-X; Opera_ID_12; Tocris-1611; hydroxymethyl progesterone; LAMOTRIGINE [MI]; LAMOTRIGINE [INN]; LAMOTRIGINE [JAN]; Lopac-L-3791; LAMOTRIGINE [HSDB]; LAMOTRIGINE [USAN]; L 3791; LAMOTRIGINE [MART.]; Lopac0_000688; SCHEMBL35439; LAMOTRIGINE [USP-RS]; LAMOTRIGINE [WHO-DD]; MLS000759486; MLS001077325; MLS001423991; BIDD:GT0794; Lamotrigine (JAN/USP/INN); Lamotrigine, >=98%, powder; GTPL2622; LAMOTRIGINE [EP IMPURITY]; LAMOTRIGINE [ORANGE BOOK]; HMS2051C10; HMS2089M08; HMS2093P21; HMS2230L04; HMS3262I17; HMS3268G17; HMS3371O16; HMS3393C10; HMS3657A17; HMS3715H21; HMS3885M03; LAMOTRIGINE [EP MONOGRAPH]; LAMOTRIGINE [USP IMPURITY]; Pharmakon1600-01505610; LAMOTRIGINE [USP MONOGRAPH]; AMY40805; BCP12156; HY-B0495; Lamotrigine 1.0 mg/ml in Methanol; Tox21_110179; Tox21_500688; BDBM50031299; HB0368; NSC746307; NSC759171; s3024; STK628377; AKOS005561147; Tox21_110179_1; 6-(2,2,4-triazine-3,5-diyldiamine; CCG-100856; DB00555; KS-1074; LP00688; NC00106; NSC 746307; NSC 759171; NSC-746307; SDCCGSBI-0050666.P003; SMP2_000303; NCGC00015605-01; NCGC00015605-02; NCGC00015605-03; NCGC00015605-04; NCGC00015605-05; NCGC00015605-07; NCGC00015605-08; NCGC00015605-09; NCGC00015605-10; NCGC00015605-23; NCGC00015605-24; NCGC00022936-02; NCGC00022936-04; NCGC00022936-05; NCGC00261373-01; AC-10298; AC-32483; BL166799; Lamotrigine 100 microg/mL in Acetonitrile; SBI-0050666.P002; 6-(2,3-Dichloro-phenyl)-[1,2,4]tria; DB-014839; EU-0100688; FT-0602546; FT-0670713; FT-0670714; L-205; L0241; SW197486-3; A11873; D00354; EN300-120680; W13018; AB00384359-16; AB00384359_17; AB00384359_18; A840709; Q410346; 3,5-diamino-(2,3-dichlorophenyl)-1,2,4-triazine; Q-201221; SR-01000000187-2; SR-01000000187-4; SR-01000000187-7; BRD-K93460210-071-01-6; SR-01000000187-10; 3,5-diamino-6-(2,3,-dichlorophenyl)-1,2,4-triazine; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine.; F2173-0540; Z1532338577; 6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine; 6-[2,3-bis(chloranyl)phenyl]-1,2,4-triazine-3,5-diamine; Lamotrigine, British Pharmacopoeia (BP) Reference Standard; Lamotrigine, European Pharmacopoeia (EP) Reference Standard; 1,2,4-TRIAZINE-3,5-DIAMINE, 6-(2,3-DICHLOROPHENYL); 6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine(lamotrigine); GI 267119X; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine; Lamotrigine, United States Pharmacopeia (USP) Reference Standard; Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material; Lamotrigine for peak identification, European Pharmacopoeia (EP) Reference Standard; Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	3878	DB00555	D03FLC	256.089	90.7	242	1.4	16	2	5	1	C9H7Cl2N5	6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine	C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N	C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N	InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)	PYZRQGJRPPTADH-UHFFFAOYSA-N
DZTG60	Menadione	Small molecule	menadione; 58-27-5; Vitamin K3; 2-Methyl-1,4-naphthoquinone; 2-methylnaphthalene-1,4-dione; Menaphthone; Kayquinone; 2-Methylnaphthoquinone; 2-Methyl-1,4-naphthalenedione; Thyloquinone; Kappaxin; Klottone; Panosine; Kanone; Kayklot; Kolklot; Menaphthon; Menadion; Kipca; Aquinone; Kaergona; Kativ-G; Mitenone; Prokayvit; Aquakay; Hemodal; Karcon; Kareon; Kaykot; Koaxin; Mitenon; Synkay; Vitamin K 3; K-Thrombyl; K-Vitan; Juva-K; Vitamin K2(0); Vitamin K0; 2-Methyl-1,4-naphthochinon; Menaquinone 0; Menaphtone; Usaf ek-5185; 3-Methyl-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-methyl-; Menaphthene; Kaynone; 2-methyl-1,4-dihydronaphthalene-1,4-dione; 2-Methyl-1,4-naftochinon; Menadione (Vitamin K3); 1,4-Naphthoquinone, 2-methyl-; Menaquinone O; NSC 4170; MFCD00001681; Methyl-1,4-naphthoquinone; NSC4170; NSC-4170; MNQ; CHEMBL590; 2-Methyl-1,4-naphthalendione; MLS000069420; 723JX6CXY5; 1,4-Dihydro-2-methylnaphthalene-1,4-dione; Menadionum; DTXSID4021715; Memodol; 1,4-naphthalenedione, 2-methyl; CHEBI:28869; Menadione (Vitamin K3) 10 microg/mL in Acetonitrile; Kappaxan (VAN); VK3; CAS-58-27-5; Menadione semiquinone; NCGC00016258-02; SMR000059102; DTXCID801715; 2-Methyl-1,4-naftochinon [Czech]; Menadione (USP); Kappaxin (TN); 2-Methyl-1,4-naphthochinon [German]; CCRIS 6672; HSDB 3354; Menadione [USP:BAN]; SR-01000712386; EINECS 200-372-6; 2-Methyl-1,4-naphthodione; Methyl-1,4-naphthalenedione; UNII-723JX6CXY5; Mendione; AI3-14700; 2-methyl-1,4-naphthoquinone, 5; Menadione, 9; Menadione,(S); Prestwick_313; Menadione, 98%; Menadione, crystalline; Spectrum_001228; SpecPlus_000191; MENADIONE [MI]; MENADIONE [HSDB]; MENADIONE [INCI]; Opera_ID_1802; Prestwick0_000459; Prestwick1_000459; Prestwick2_000459; Prestwick3_000459; Spectrum2_001194; Spectrum4_000722; Spectrum5_001764; MENADIONE [VANDF]; M0373; MENADIONE [MART.]; NCIMech_000105; cid_4055; MENADIONE [USP-RS]; MENADIONE [WHO-DD]; 2-methyl-1,4-napthoquinone; SCHEMBL25970; BSPBio_000538; KBioGR_000984; KBioGR_002527; KBioSS_001708; KBioSS_002535; 2-methyl-1,4 naphthoquinone; 34524-96-4; MLS001148443; BIDD:ER0556; DivK1c_000080; DivK1c_006287; SPECTRUM1502254; SPBio_001267; SPBio_002477; 3-methyl-1,4-naphthalenedione; BPBio1_000592; MENADIONE [ORANGE BOOK]; MENADIONE [EP MONOGRAPH]; 2-Methyl-[1,4]-naphthoquinone; BDBM24778; HMS500D22; KBio1_000080; KBio1_001231; KBio2_001708; KBio2_002527; KBio2_004276; KBio2_005095; KBio2_006844; KBio2_007663; KBio3_003005; WLN: L66 BV EVJ C1; MENADIONE [USP MONOGRAPH]; cMAP_000077; NINDS_000080; Bio1_000471; Bio1_000960; Bio1_001449; HMS1569K20; HMS1921P06; HMS2092F12; HMS2096K20; HMS2232A09; HMS2234J16; HMS3371M08; HMS3373A12; HMS3655P03; HMS3869N03; Pharmakon1600-01502254; AMY31055; BCP25699; HY-B0332; STR01143; Tox21_110334; Tox21_301367; BBL027351; CCG-35354; Menadione (K3), analytical standard; NSC758200; s1949; STL377874; AKOS004910447; AKOS025244105; Tox21_110334_1; DB00170; FS-2556; NSC-758200; SB17255; IDI1_000080; QTL1_000056; NCGC00016258-01; NCGC00016258-03; NCGC00016258-04; NCGC00016258-06; NCGC00016258-07; NCGC00016258-08; NCGC00094978-01; NCGC00094978-02; NCGC00255225-01; AC-34841; NCI60_003945; SMR000653532; SY018303; SBI-0051776.P002; Menadione, meets USP testing specifications; FT-0612893; FT-0675843; SW219798-1; C05377; D02335; EN300-125382; PHYTOMENADIONE IMPURITY A [EP IMPURITY]; A831816; Q192471; 1,4-Naphthalenedione, 2-methyl-, radical ion(1-); Q-201350; SR-01000712386-2; SR-01000712386-5; SR-01000712386-6; VITAMIN K3; 2-METHYL-1,4-NAPHTHALENEDIONE; BRD-K78126613-001-16-0; Vitamin K3; 2-Methyl-1,4-naphthoquinone; Menaphthone; Vitamin K3: 1,4-Dihydro-1,4-dioxo-2-methylnaphthalene; Z1255430959; Menadione, European Pharmacopoeia (EP) Reference Standard; 03AAE1E9-B215-45AF-976C-91E61894A467; Menadione, United States Pharmacopeia (USP) Reference Standard; Menadione, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	4055	DB00170	D03GET	172.18	34.1	289	2.2	13	0	2	0	C11H8O2	2-methylnaphthalene-1,4-dione	CC1=CC(=O)C2=CC=CC=C2C1=O	CC1=CC(=O)C2=CC=CC=C2C1=O	InChI=1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3	MJVAVZPDRWSRRC-UHFFFAOYSA-N
DDM7P6	Liraglutide	Small molecule	Liraglutide; NN2211; victoza; 204656-20-2; NN-2211; Liraglutida; Liraglutidum; NN 2211; CHEMBL4084119; Saxenda; NNC 90-1170; Liraglutidum [INN-Latin]; Liraglutida [INN-Spanish]; Liraglutide recombinant; UNII-839I73S42A; HSDB 8205; Liraglutide [USAN:INN:BAN:JAN]; Liraglutide (rDNA origin); GTPL1133; CHEBI:71193; DTXSID60174433; EX-A2418; BDBM50240819; NN9924; AKOS037435224; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide; 839I73S42A; NN-9924; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide; NNC-90-1170; AS-56276; A16115; Arg34Lys26-(N-epsilon-(gamma-Glu(N-alpha-hexadecanoyl)))-GLP-1(7-37); N(sup 26)-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide	Approved	Approved Drug(s)	16134956	DB06655	D03GOI	3751	1510	8760	-3.4	266	54	55	132	C172H265N43O51	(2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid	CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O	InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1	YSDQQAXHVYUZIW-QCIJIYAXSA-N
D7JX0S	Darunavir	Small molecule	Darunavir; 206361-99-1; TMC114; TMC-114; Prezista; UIC-94017; TMC 114; Darunavirum; Darunavirum [INN-Latin]; Derunavir; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate; UIC 94017; (-)-DARUNAVIR; CHEMBL1323; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; DTXSID0046779; CHEBI:367163; TMC-41629; YO603Y8113; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide; Darunavir [USAN]; NCGC00168773-01; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; DRV; Prezista(TM); Darunavir [INN]; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl-isobutyl-amino]-1-benzyl-2-hydroxy-propyl]carbamate; AIDS073035; Darunavir (USAN/INN); Darunavir [USAN:INN:BAN]; Prezista Naive; UNII-YO603Y8113; HSDB 7788; 2idw; 2ien; 3bvb; 3cyw; 3ekt; 3ggu; 3lzs; 3lzu; 3lzv; 3ogp; 3pwm; 3qoz; 3tkw; 3ttp; 4hla; Darunavir (DRV); (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; TMC41629; MFCD09260006; TMC 41629; UIC-96017; 2f8g; 2hs1; 2hs2; 3d1z; 3so9; 3t3c; 3u7s; 4ll3; DARUNAVIR [MI]; DARUNAVIR [HSDB]; DARUNAVIR [VANDF]; DARUNAVIR [MART.]; DRV & AAG; DRV & HSA; DARUNAVIR [WHO-DD]; DARUNAVIR [EMA EPAR]; SCHEMBL118546; AMY373; BDBM8125; UIC-940T; DARUNAVIR [ORANGE BOOK]; Darunavir, >=98% (HPLC); DTXCID8026779; GTPL11243; 2f80; 2f81; 3d20; 3s53; 3s54; HMS3715I13; (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ((2S,3R)-4-((4-AMINO-N-ISOBUTYLPHENYL)SULFONAMIDO)-3-HYDROXY-1-PHENYLBUTAN-2-YL)CARBAMATE; EX-A4009; Tox21_112634; Darunavir & alpha1-acid glycoprotein; MC-114; s5250; 206361-99-1 (free); AKOS015966592; BCP9000587; CCG-269991; CS-0749; DB01264; KS-1469; NCGC00388284-07; NCGC00388284-08; NCGC00388284-12; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; AC-26778; HY-17040; BCP0726000058; CAS-206361-99-1; D03656; AB01565837_02; EN300-20600172; J-013483; Q3765251; Z2301684748; 3-(4-AMINO-PHENOXY)-PYRROLIDINE-1-CARBOXYLICACIDTERT-BUTYLESTER; ((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-carbamic acid (3R,3aS,6aR)-hexahydrofurano(2,3-b)furan-3-yl ester; ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-CARBAMIC ACID (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ESTER; (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(ISOBUTYL)AMINO)-1-BENZYL-2-HYDROXYPROPYL)CARBAMATE; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(sup 1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl N-[(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)(4-aminobenzene)sulfonamido]-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)-4-aminobenzenesulfonamido]-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-[(2S,3R)-4-[(4-aminobenzene)(2-methylpropyl)sulfonamido]-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate; [(3R,3aS,6aR)-2,3,3a,4,5,6a-hexahydrofuro[5,4-b]furan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3R,3aS,6aR)-hexahydrofurano(2,3-b)furan-3-yl ester	Approved	Approved Drug(s)	213039	DB01264	D03IGH	547.7	149	853	2.9	38	3	9	12	C27H37N3O7S	[(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate	CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N	InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1	CJBJHOAVZSMMDJ-HEXNFIEUSA-N
D19LJU	Perindopril	Small molecule	PERINDOPRIL; 82834-16-0; S-9490; Perindoprilum; McN-A-2833; Coversyl; CHEBI:8024; (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; Y5GMK36KGY; DTXSID6023440; (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid; DTXCID303440; Prestarium; Coverex; Coversum; Coverene Cor; (2S,3aS,7aS)-1-((S)-N-((S)-1-Carboxybutyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid; CAS-82834-16-0; Perindoprilum [Latin]; UNII-Y5GMK36KGY; Perindopril (USAN/INN); Perindopril [USAN:INN:BAN]; McN-A 2833; S 9490; NCGC00159509-02; (2S,3aS,7aS)-1-[(S)-N-[(S)-1-Carboxybutyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; SED-9490; DW-7950; BRN 4300272; Spectrum_001948; PERINDOPRIL [MI]; Spectrum2_001108; Spectrum3_001683; Spectrum4_000775; Spectrum5_001689; PERINDOPRIL [INN]; PERINDOPRIL [USAN]; PERINDOPRIL [VANDF]; CHEMBL1581; PERINDOPRIL [MART.]; SCHEMBL16205; BSPBio_003206; KBioGR_001190; KBioSS_002502; PERINDOPRIL [WHO-DD]; MLS002154153; BIDD:GT0786; SPBio_001216; GTPL6367; KBio2_002494; KBio2_005062; KBio2_007630; KBio3_002426; HMS2098M04; HMS2232M24; HMS3715M04; EX-A6377; HY-B0130; Tox21_113087; BDBM50493988; AKOS025311315; Tox21_113087_1; CCG-221101; CS-1903; DB00790; NCGC00274070-01; (2S)-2-[(1S)-1-Carbethoxybutylamino]-1-oxopropyl-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid; ethyl N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvalinate; SMR001233453; SBI-0206736.P001; C07706; D03753; AB00918721_06; EN300-7481397; Q277785; S-90652; SR-01000841817; J-523913; SR-01000841817-2; BRD-K92731339-227-02-3; BRD-K92731339-227-03-1; (2S,3aS,7aS)-1-((S)-N-((S)-1-carboxybutyl)alanyl)hexahydro-2-indolinecarboxylicacid1-ethylester; (2s,3as,7as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-2-pent-yl]amino]propanoyl]-octahydro-1h-indole-2-carboxylic acid; (2S,3aS,7aS)-1-{(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl}octahydro-1H-indole-2-carboxylic acid; 11H-Indole-2-carboxylic acid, octahydro-1-(2-((1-ethoxycarbonyl)butyl)amino)-1-oxopropyl)-, (2S-(1(R*(R*)),2-alpha,3a-beta,7a-beta))-; 1H-INDOLE-2-CARBOXYLIC ACID, 1-(2-((1-(ETHOXYCARBONYL)BUTYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S-(1(R*(R*)),2.ALPHA.,3A.BETA.,7A.BETA.))-; 1H-Indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R*(R*)),2alpha,3abeta,7abeta))-	Approved	Approved Drug(s)	107807	DB00790	D03KYG	368.5	95.9	524	0.9	26	2	6	9	C19H32N2O5	(2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid	CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O	CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O	InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1	IPVQLZZIHOAWMC-QXKUPLGCSA-N
DC60RN	Infigratinib	Small molecule	NVP-BGJ398; Infigratinib; 872511-34-7; BGJ398; BGJ-398; BGJ 398; Truseltiq; Infigratinib [INN]; Infigratinib free base; 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea; Infigratinib [USAN]; BGJ398 (NVP-BGJ398); MVP-BGJ398; NVP-BGJ398(Infigratinib); A4055ME1VK; CHEBI:63451; 872511-34-7 (free base); 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-1-methylurea; 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea; Urea, N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(6-((4-(4-ethyl-1-piperazinyl)phenyl)amino)-4-pyrimidinyl)-N-methyl-; CHEMBL1834657; 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea.; 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea; UNII-A4055ME1VK; Infigratinib (BGJ398); Infigratinib (USAN/INN); Infigratinib [USAN:INN]; NVP-BGJ389; 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)-1-methylurea; MLS006010953; INFIGRATINIB [WHO-DD]; SCHEMBL374435; GTPL7877; CHEMBL1852688; DTXSID70236238; EX-A057; HMS3295O21; AMY10737; BCP03602; BGJ398 - NVP-BGJ398; BDBM50355393; FD5035; MFCD22123241; NSC764487; s2183; WHO 10032; AKOS025149513; AKOS032949944; BCP9000399; CS-0586; DB11886; NSC-764487; SB16612; NCGC00274030-01; NCGC00274030-11; 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea; AC-28417; AS-16290; HY-13311; SMR004702757; BCP0726000187; FT-0699366; D11589; J-510477; BRD-K42728290-001-01-8; Q27075200; 07J; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; N'-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-N-(6-((4-(4-ETHYL-1- PIPERAZINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-N-METHYLUREA	Approved	Approved Drug(s)	53235510	DB11886	D03LWG	560.5	95.1	724	4.7	38	2	8	8	C26H31Cl2N7O3	3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea	CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl	CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl	InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)	QADPYRIHXKWUSV-UHFFFAOYSA-N
D0AC4H	Doxazosin	Small molecule	doxazosin; 74191-85-8; Doxazosine; Doxazosinum; Doxazosina; R-Doxazosin; Doxazosin (INN); [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; UK 33274; UK-33274; 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin; CHEBI:4708; (RS)-2-{4-[(2,3-Dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine; C02CA04; NW1291F1W8; (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone; Doxazosine [French]; Doxazosinum [Latin]; DOXAZOSIN [INN]; Doxazosina [Spanish]; Doxazosin [INN:BAN]; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine; Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](2,3-dihydro-1,4-benzodioxin-2-yl)-; Cardura XL (TN); supress; UNII-NW1291F1W8; METHANONE, (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)-; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-, (S)-; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; CPD000097306; DOXAZOSIN [MI]; Prestwick0_000858; Prestwick1_000858; Prestwick2_000858; Prestwick3_000858; DOXAZOSIN [VANDF]; ChemDiv2_005017; CHEMBL707; EC 616-059-6; DOXAZOSIN [WHO-DD]; (+/-)-DOXAZOSIN; Lopac0_000474; Oprea1_259518; SCHEMBL34111; BSPBio_000875; 2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine; SPBio_002796; BPBio1_000963; GTPL7170; DTXSID7022964; BDBM86731; HMS1383E01; HMS2090C20; HMS3259N21; HMS3372L09; HMS3886J03; BCP12228; HY-B0098; ZCA19185; (4-Benzylmorpholin-2-yl)-aceticacid; NSC768144; NSC768145; s5782; AKOS001681453; AKOS017343634; CCG-118218; CS-1831; DB00590; NC00685; NSC-768144; NSC-768145; SDCCGSBI-0050459.P003; IDI1_003732; NCGC00018158-02; NCGC00018158-03; NCGC00018158-05; NCGC00018158-06; NCGC00018158-08; NCGC00018158-11; NCGC00018158-20; NCGC00089775-02; 2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; AC-11062; AS-77104; SBI-0050459.P002; CAS_74191-85-8; DB-055848; UK 33,274; FT-0630831; UK-3327427; EN300-53055; C06970; D07874; A838054; L000738; Q419939; BRD-A13188892-066-03-3; BRD-A13188892-066-13-2; (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)METHANONE; (4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydro-1,4-benzodioxin-2-yl)methanone; [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methanone; 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(1,4-BENZODIOXAN-2-YLCARBONYL)PIPERAZINE; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine; 137888-77-8; 2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxy-3,4-dihydroquinazolin-4-imine	Approved	Approved Drug(s)	3157	DB00590	D03MIR	451.5	112	678	2.5	33	1	9	4	C23H25N5O5	[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC	InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)	RUZYUOTYCVRMRZ-UHFFFAOYSA-N
D7TWQ3	Sevelamer	Small molecule	Sevelamer; 52757-95-6; 2-(chloromethyl)oxirane;prop-2-en-1-amine; 2-Propen-1-amine, polymer with (chloromethyl)oxiraneOTHER CA INDEX NAMES:Oxirane, (chloromethyl)-, polymer with 2-propen-1-amine; Sevelamer anhydrous; Sevelamer (INN); 2-(chloromethyl)oxirane; prop-2-en-1-amine; SCHEMBL726092; 3-(Trifluoromethoxy)cinnamicacid; CHEMBL1201798; DB00658; NCGC00522026-01; 1392212-84-8; D08512; EN300-25310384; 2-Propen-1-amine - 2-(chloromethyl)oxirane (1:1)	Approved	Approved Drug(s)	3085017	DB00658	D03MZQ	149.62	38.6	55.1	.	9	1	2	2	C6H12ClNO	2-(chloromethyl)oxirane;prop-2-en-1-amine	C=CCN.C1C(O1)CCl	C=CCN.C1C(O1)CCl	InChI=1S/C3H5ClO.C3H7N/c4-1-3-2-5-3;1-2-3-4/h3H,1-2H2;2H,1,3-4H2	ZNSIZMQNQCNRBW-UHFFFAOYSA-N
DNH3F4	Pioglitazone	Small molecule	Pioglitazone; 111025-46-8; Actos; Glustin; 105355-27-9; Zactos; Pioglitazona; Pioglitazonum; Pioglitazonum [INN-Latin]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; Pioglitazona [INN-Spanish]; AD-4833; U 72107; Pioglitazone (Actos); 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; pioglitazone (INN); 105390-47-4; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; CHEBI:8228; C19H20N2O3S; U-72107; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; 2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-; X4OV71U42S; 5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione; MFCD00865504; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; PIOGLITAZONE [INN]; 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; Pioglitazone [BAN:INN]; Pioglitazone [INN:BAN]; Piozone; Pioglu; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-; HSDB 7322; UNII-X4OV71U42S; SR-01000763737; 5-(4-(2-(5-ETHYL-2-PYRIDYL)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, (+/-)-; [( inverted exclamation markA)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochlorid; 2,4-THIAZOLIDINEDIONE, 5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-, (+/-)-; Pioglitazone-[d4]; Pioglitazone- Bio-X; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione; HS-0047; Spectrum_001623; Spectrum2_001679; Spectrum3_001002; Spectrum4_001130; Spectrum5_001480; Spectrum5_002067; PIOGLITAZONE [MI]; PIOGLITAZONE [HSDB]; PIOGLITAZONE [IARC]; SCHEMBL4121; PIOGLITAZONE [VANDF]; BSPBio_002723; KBioGR_001619; KBioSS_002103; MLS006011848; PIOGLITAZONE [WHO-DD]; SPBio_001897; GTPL2694; PIOGLITAZONE [EMA EPAR]; DTXSID3037129; KBio2_002103; KBio2_004671; KBio2_007239; KBio3_001943; HMS2089H14; HMS3651D09; HMS3712E16; HMS3884L10; Pharmakon1600-01504401; ACT02635; BCP26474; BBL029068; BDBM50103521; HB4139; NSC758876; s2590; STL309607; STL373406; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; AKOS015894953; AKOS022109420; AC-1021; CCG-220107; CS-1700; DB01132; SB17323; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, (+-)-; NCGC00163128-01; NCGC00163128-02; NCGC00163128-03; NCGC00163128-04; NCGC00163128-05; NCGC00163128-06; NCGC00163128-07; BP164273; HY-13956; SMR002204015; SY017473; SBI-0206791.P001; DB-027350; FT-0601906; FT-0645030; SW197561-3; C07675; D08378; EN300-117258; AB00698454-10; AB00698454_11; AB00698454_12; AB00698454_13; A802277; Q417765; J-002506; J-516181; SR-01000763737-5; BRD-A48430263-003-02-4; BRD-A48430263-003-06-5; Z1501480426; 5-[4-[2-(5-ethyl-2-pyridyl) ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(5-ethyl-2-pyridyl)eth-oxy]benzyl]-2,4-thiazolidinedione; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4thiazolidinedione; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)-thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl-2,4-thiazolidinedione; 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy] phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-(P-(2-(5-ETHYL-2-PYRIDYL)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE; (5S)-5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione;Pioglitazone; (RS)-5-(4-(2-(5-ETHYLPYRIDIN-2-YL)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI); 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-4-hydroxy-1,3-thiazol-2(5H)-one; [()-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochlorid; 198077-89-3	Approved	Approved Drug(s)	4829	DB01132	D03OFF	356.4	93.6	466	3.8	25	1	5	7	C19H20N2O3S	5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione	CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3	CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3	InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)	HYAFETHFCAUJAY-UHFFFAOYSA-N
D3D1IF	Triptorelin	Small molecule	TRIPTORELIN; 57773-63-4; Triptoreline; Arvekap; (D-Trp6)-GnRH; Decapeptyl; Triptorelina; Triptorelinum; Trelstar; Triptodur; Diphereline; CL 118532; CL-118532; pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2; AY-25650; CL 118,532; CHEBI:63633; Wy 42462; AY 25650; Pamorelin; Salvacyl; Trelstar depot; 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide; Trelstar LA; BIM 21003; Wy 42422; tryptorelin; Diferelin; D-Tryptophan-LH-RH; Triptoreline [INN-French]; Triptorelinum [INN-Latin]; Triptorelina [INN-Spanish]; Trellasar; Moapar; Triptorelin [USAN:INN:BAN]; Decapeptyl SR; Pamorelin LA; UNII-9081Y98W2V; Triptorelin (swine); Wy-42462; D-Trp6-LHRH; Debio-8206; Triptorelin (USAN/INN); (D-Trp6)-LH-RH; GTPL1177; SCHEMBL5079698; CHEMBL1201334; DTXSID2048375; SCHEMBL22289009; HMS2090C17; EX-A3857; BIM-21003; AKOS030213249; 9081Y98W2V; CS-5745; DB06825; NCGC00167301-01; NCGC00167301-02; AS-71149; BN-52014; HY-12551; C75704; D06247; [D-Trp6]-LH-RH, >=97% (HPLC), powder; AB01275488-01; A936467; EN300-18527985; pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-GlyNH2; Q1992452; (S)-1-((3S,6S,9S,12S,15R,18S,21S)-3-((1H-imidazol-5-yl)methyl)-6,15-bis((1H-indol-3-yl)methyl)-21-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-18-isobutyl-1,4,7,10,13,16,19-heptaoxo-1-((S)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-N-(2-amino-2-oxoethyl)pyrrolidine-2-carboxamide; Glycinamide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolyl-	Approved	Approved Drug(s)	25074470	DB06825	D03QRS	1311.4	490	2710	-0.3	95	17	15	33	C64H82N18O13	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide	CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8	InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1	VXKHXGOKWPXYNA-PGBVPBMZSA-N
DEY59P	Betaxolol	Small molecule	betaxolol; 63659-18-7; Betaxololum; Betoptic; Kerlone; Betaxololum [INN-Latin]; SL 75212; Betaxolol (INN); 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; O0ZR1R6RZ2; 2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-; CHEBI:3082; DTXSID2022674; ALO-140102 FREE BASE; SL-7521210 FREE BASE; KERLEDEX; NCGC00015159-06; BETAXOLOL [INN]; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; Betaxolol [INN:BAN]; Dextrobetaxolol; DTXCID102674; Betaxolol S; 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)propan-2-ol; 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol; Betaxolol (TN); CAS-63659-18-7; UNII-O0ZR1R6RZ2; (R)-Betaxolol; (+)-Betaxolol; SL-75212-10; 2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-; Betaxolol (Betoptic); BETAXOLOL [MI]; Prestwick0_000382; Prestwick1_000382; Prestwick2_000382; Prestwick3_000382; BETAXOLOL [VANDF]; CHEMBL423; BETAXOLOL [WHO-DD]; Lopac0_000193; SCHEMBL23530; BSPBio_000563; GTPL549; SPBio_002484; BPBio1_000621; HMS2089I07; HMS3655P17; HMS3884L05; HY-B0381; Tox21_110091; BDBM50405521; s2091; (R)-1-[4-(2-Cyclopropylmethoxy-ethyl)-phenoxy]-3-isopropylamino-propan-2-ol; AKOS015841671; Tox21_110091_1; AC-1115; CCG-204288; DB00195; SDCCGSBI-0050181.P002; 1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol; MRF-0000336; NCGC00015159-04; NCGC00015159-05; NCGC00015159-08; NCGC00015159-09; NCGC00015159-11; NCGC00015159-13; NCGC00015159-14; NCGC00015159-23; NCGC00024863-03; NCGC00024863-04; 108008-51-1; AS-14125; Cobalt,[(1,2,5,6-h)-1,5-cyclooctadiene][(1,2,3,4,5-h)-1-(trifluoroacetyl)-2,4-cyclopentadien-1-yl]-; FT-0773524; SW196917-5; C06849; C75987; D07526; A834454; EN300-18552812; L000125; Q794162; Q-200713; BRD-A02759312-003-03-9; BRD-A02759312-003-11-2; (+/-)-1-(Isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; (.+/-.)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol; 1-(4-[2-(Cyclopropylmethoxy)ethyl]phenoxy)-3-(isopropylamino)-2-propanol #; 1-[4-(2-(Cyclopropylmethyloxy)ethyl]-phenoxy]-3-[(1-methylethyl)amino]-2-propanol; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)propan-2-ol;Betaxolol; 1-{4-[2-(Cyclopropylmethoxy)ethyl]phenoxy}-3-[(propan-2-yl)amino]propan-2-ol	Approved	Approved Drug(s)	2369	DB00195	D03ROX	307.4	50.7	286	2.8	22	2	4	11	C18H29NO3	1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol	CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O	CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O	InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3	NWIUTZDMDHAVTP-UHFFFAOYSA-N
D4LJY9	Trabectedin	Small molecule	Trabectedin; Yondelis; Ecteinascidin; ecteinascidin 743; ET-743; 114899-77-3; Ect 743; ET743; ID0YZQ2TCP; Et 743; Ecteinascidins trabectedin; DTXSID2046880; CHEBI:84050; NSC-648766; [(1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2H-isoquinoline]-22-yl] acetate; Trabectedin [INN]; Ecteinascidine 743; DTXCID0026880; (1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxo-3',4'-dihydro-2'H-17,19,28-trioxa-24-thia-13,30-diazaspiro[heptacyclo[12.9.6.1^{3,11}.0^{2,13}.0^{4,9}.0^{15,23}.0^{16,20}]triacontane-26,1'-isoquinoline]-4(9),5,7,15(23),16(20),21-hexaen-22-yl acetate; Ecteinascidin-743; CAS-114899-77-3; UNII-ID0YZQ2TCP; NSC 648766; NSC 684766; Trabectedin [USAN:INN:BAN]; CCRIS 8133; NCGC00181159-01; NCGC00181159-02; TRABECTEDIN [JAN]; TRABECTEDIN [USAN]; TRABECTEDIN [MART.]; TRABECTEDIN [WHO-DD]; TRABECTEDIN [EMA EPAR]; CHEMBL450449; GTPL2774; SCHEMBL12119916; TRABECTEDIN [ORANGE BOOK]; EX-A4317; Tox21_112762; Tox21_113236; NSC813783; CS-1608; DB05109; ECTEINASCIDINS TRABECTEDIN [MI]; NSC-684766; NSC-813783; (1'R,6R,6aR,7R,13S,14S,16R)-6',8,14-Trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydrospiro(6,16-(epithiopropanooxymethano)-7,13-imino-6aH-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-5-yl acetate; AC-27767; Ecteinascidin 743;ET-743;Ecteinascidin; HY-50936; MS-31361; Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 3',4',6,6a,7,13,14,16-octahydro-5-(acetyloxy)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (6R-(6-alpha,6a-beta,7-beta,13-beta,14-beta,16-alpha,20R*))-; Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)-; F81329; EN300-19768451; Q2637746; (6R,6aR,7R,13S,14S,16R,20R)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydro-2'H,6aH-spiro[7,13-epimino-6,16-(epithiopropanooxymethano)[1,3]dioxolo[7,8]isoquinolino[3,2-b][3]benzazocine-20,1'-isoquinolin]-5-yl acetate	Approved	Approved Drug(s)	108150	DB05109	D03RTK	761.8	194	1450	3.4	54	4	15	4	C39H43N3O11S	[(1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2H-isoquinoline]-22-yl] acetate	CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O	CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O	InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1	PKVRCIRHQMSYJX-AIFWHQITSA-N
DIT89U	Celecoxib	Small molecule	celecoxib; 169590-42-5; Celebrex; Celebra; Onsenal; Celocoxib; Celecox; SC 58635; SC-58635; 184007-95-2; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; YM177; YM 177; p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; HSDB 7038; MFCD00941298; 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; SC58635; 194044-54-7; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide; CHEMBL118; NSC-719627; NSC-758624; DFN15; JCX84Q7J1L; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonami de; DFN-15; DTXSID0022777; CHEBI:41423; 4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-; Celecoxib [USAN]; NCGC00091455-01; Xilebao; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide; DTXCID502777; 544686-20-6; Solexa; Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-; Celebrex (TN); SMR000550473; CAS-169590-42-5; SR-01000837528; YM-177; UNII-JCX84Q7J1L; Celecoxibum; Celecoxib [USAN:INN:BAN]; CCRIS 9330; TPI-336; Celecoxib- Bio-X; Celecoxib-[d4]; Onsenal (TN); AI-525; CEP-33222; CELEBCOXIB; ELYXYB; Spectrum_000432; 1oq5; CELECOXIB [INN]; CELECOXIB [JAN]; CELECOXIB [MI]; CELECOXIB [HSDB]; Spectrum2_001576; Spectrum3_001996; Spectrum4_000182; Spectrum5_001324; CELECOXIB [VANDF]; CELECOXIB [MART.]; CELECOXIB [USP-RS]; CELECOXIB [WHO-DD]; cid_2662; SCHEMBL3708; Celecoxib (JAN/USP/INN); BSPBio_003596; CELECOXIB [EMA EPAR]; KBioGR_000723; KBioGR_002351; KBioSS_000912; KBioSS_002354; MLS001165684; MLS001195656; MLS001304708; MLS006011862; BIDD:GT0408; DivK1c_000893; SPECTRUM1503678; SPBio_001512; GTPL2892; CELECOXIB [ORANGE BOOK]; CELECOXIB [EP MONOGRAPH]; Celecoxib, >=98% (HPLC); BDBM11639; HMS502M15; KBio1_000893; KBio2_000912; KBio2_002351; KBio2_003480; KBio2_004919; KBio2_006048; KBio2_007487; KBio3_002830; KBio3_003037; CELECOXIB [USP MONOGRAPH]; EX-A175; cMAP_000027; NINDS_000893; BCPP000290; HMS1922G14; HMS2089L18; HMS2093I07; HMS2234N18; HMS3259L08; HMS3261A14; HMS3373A09; HMS3654H09; HMS3715F11; HMS3867I03; HMS3884M07; Pharmakon1600-01503678; CONSENSI COMPONENT CELECOXIB; ACT02648; ALBB-033772; BCP02156; Tox21_111135; Tox21_201964; Tox21_300599; Tox21_500406; US8741944, Comparative Compound; 4-[5-(p-tolyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; BBL029086; CCG-39354; NSC719627; NSC758624; s1261; STL373576; Celecoxib 1.0 mg/ml in Acetonitrile; AKOS015842517; CELECOXIB COMPONENT OF CONSENSI; Tox21_111135_1; AC-4228; AM84588; BCP9000507; CS-0570; DB00482; KS-1041; NC00708; NSC 719627; NSC 758624; SB19318; IDI1_000893; NCGC00091455-02; NCGC00091455-03; NCGC00091455-04; NCGC00091455-05; NCGC00091455-06; NCGC00091455-07; NCGC00091455-08; NCGC00091455-09; NCGC00091455-13; NCGC00254540-01; NCGC00259513-01; NCGC00261091-01; BC164295; BP-30217; HY-14398; NCI60_041049; SY064976; SBI-0051875.P002; UNM-0000305813; C2816; FT-0601628; FT-0623536; FT-0700357; SW199611-3; A25046; C07589; D00567; EN300-119504; AB00052396-07; AB00052396-08; AB00052396-09; AB00052396_10; AB00052396_11; Q408801; J-010566; J-520011; Q-200816; SR-01000837528-2; SR-01000837528-3; BRD-K02637541-001-02-4; BRD-K02637541-001-06-5; Z1258938406; Celecoxib, European Pharmacopoeia (EP) Reference Standard; Celecoxib, United States Pharmacopeia (USP) Reference Standard; 4-[5-(p-Tolyl)-3-(trifluoromethyl)-1-pyrazolyl]benzenesulfonamide; 4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-pyrazol-1-yl]benzenesulfonamide; 5-(4-Methylphenyl)-1-(4-sulfamoylphenyl)-3-(trifluoromethyl)pyrazole; Celecoxib, Pharmaceutical Secondary Standard; Certified Reference Material; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyazol-1-yl]benezenesulfonamide; Benzenesulfonamide,4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-; 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-pyrazol-1-yl]benzenesulfonamide;4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide	Approved	Approved Drug(s)	2662	DB00482	D03RTS	381.4	86.4	577	3.4	26	1	7	3	C17H14F3N3O2S	4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F	InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)	RZEKVGVHFLEQIL-UHFFFAOYSA-N
DB9XH6	Clonidine	Small molecule	clonidine; 4205-90-7; Clonidin; Catapres; Duraclon; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; Chlornidinum; Catapres-TTS; Adesipress; Catarpres; Catarpresan; ST-155-BS; ST 155BS; Catapresan; Clonidinum [INN-Latin]; CATAPRES-TTS-1; CATAPRES-TTS-2; CATAPRES-TTS-3; Clonidinhydrochlorid; 2-(2,6-Dichloroanilino)-2-imidazoline; clonidine (amino form); Catarpres-TTS; SKF 34427; M-5041T; CLORPRES; 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2); CCRIS 7787; Combipres; 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; HSDB 3040; 734571A; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; M 5041T; CHEBI:3757; ST-155BS; Benzenamine, 2,6-dichloro-N-2-imidazolidinylidene-; 2-Imidazoline, 2-(2,6-dichloroanilino)-; Catapressan; Clonidine extended release; CLONIDINE(200MG); MN3L5RMN02; 2-[(2,6-Dichlorophenyl)imino]imidazoline; DTXSID6022846; 4205-90-7 (free base); NCGC00015268-05; Clonidina; Clonidinum; 2-[(2,6-Dichlorophenyl)imino]imidazolidine; Catapres- TTS; Clonidina [INN-Spanish]; DTXCID402846; Nexiclon XR; CAS-4205-90-7; Catarpres-TTS (TN); EINECS 224-119-4; CAS-4205-91-8; UNII-MN3L5RMN02; Chlofazoline; Nexiclon; Kapvay&reg; SR-01000759380; 3h-clonidine; [3H]clonidine; Clonidine [USAN:USP:INN:BAN]; Clonidine(200 mg); clonidine (imino form); Spectrum_001341; Tocris-0690; 2-(2,6-Dichlorophenylimino)imidazolidine; starbld0009556; CLONIDINE [INN]; CLONIDINE [JAN]; CLONIDINE [MI]; CLONIDINE [HSDB]; CLONIDINE [USAN]; Prestwick0_000248; Prestwick1_000248; Prestwick2_000248; Prestwick3_000248; Spectrum2_001187; Spectrum3_000358; Spectrum4_000956; Spectrum5_000759; CLONIDINE [VANDF]; Lopac-C-7897; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; CHEMBL134; CLONIDINE [MART.]; D00281; CLONIDINE [USP-RS]; CLONIDINE [WHO-DD]; SCHEMBL5982; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; Clonidine (JAN/USP/INN); Lopac0_000268; BSPBio_000036; BSPBio_001588; BSPBio_002055; GTPL516; KBioGR_000308; KBioGR_001572; KBioSS_000308; KBioSS_001821; MLS006011925; BIDD:GT0547; DivK1c_000774; SPBio_001233; SPBio_002255; BPBio1_000040; CLONIDINE [ORANGE BOOK]; BDBM14062; CHEBI:46632; KBio1_000774; KBio2_000308; KBio2_001821; KBio2_002876; KBio2_004389; KBio2_005444; KBio2_006957; KBio3_000615; KBio3_000616; KBio3_001275; CLONIDINE [USP MONOGRAPH]; NINDS_000774; Bio1_000470; Bio1_000959; Bio1_001448; Bio2_000308; Bio2_000788; HMS1361P10; HMS1791P10; HMS1989P10; HMS2089G11; HMS3402P10; BCP07223; CLONIDINE, Clonidine hydrochloride; Tox21_110118; BBL025137; BDBM50016897; BDBM50225285; STL355995; AKOS001595470; AKOS015960367; Tox21_110118_1; CCG-204363; DB00575; SDCCGSBI-0050256.P005; IDI1_000774; IDI1_034058; MRF-0000018; NCGC00015268-01; NCGC00015268-02; NCGC00015268-03; NCGC00015268-04; NCGC00015268-06; NCGC00015268-07; NCGC00015268-08; NCGC00015268-12; NCGC00024734-01; NCGC00024734-02; NCGC00024734-03; NCGC00024734-04; NCGC00024734-05; NCGC00179680-01; NCGC00179680-02; NCGC00179680-03; NCGC00179680-05; HY-12721; SMR001550184; 2-(2,6-dichlorophenylimino)-imidazolidine; SBI-0050256.P004; 2-(2,6-dichlorophenyl-imino)-imidazolidine; AB00514634; CS-0012297; FT-0741246; N-(2,6-dichlorophenyl)imidazolidin-2-imine; 2-(2',6'-dichlorophenylamino)-2-imidazoline; 2-[(2,6-dichlorophenyl)imino]-imidazolidine; F74813; AB00053441_03; AB00514634-07; AB00514634-08; AB00514634_09; EN300-8686697; (2,6-Dichlorophenyl)imidazolidin-2-ylidene amine; L000193; Q412221; (2,6-dichloro-phenyl)-imidazolidin-2-ylidene-amine; SR-01000759380-4; 2-IMIDAZOLINE, 2-(2,6-DICHLOROPHENYLAMINO)-; BRD-K98530306-001-02-1; BRD-K98530306-003-05-0; BRD-K98530306-003-07-6; 2-Imidazoline, 2-(2,6-dichloroanilino)- (7CI,8CI); N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine #; 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- (9CI); 57066-25-8	Approved	Approved Drug(s)	2803	DB00575	D03SKR	230.09	36.4	222	1.6	14	2	1	2	C9H9Cl2N3	N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine	C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl	C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl	InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)	GJSURZIOUXUGAL-UHFFFAOYSA-N
D6X0EY	Aliskiren	Small molecule	Aliskiren; 173334-57-1; Rasilez; SPP100; SPP 100; Aliskiren(CGP 60536); Aliskiren fumarate; CHEMBL1639; (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide; CHEBI:601027; SPP-100; 502FWN4Q32; CGP60536B; CGP 60536; (2S,4S,5S,7S)-5-AMINO-N-(2-CARBAMOYL-2-METHYLPROPYL)-4-HYDROXY-2-ISOPROPYL-7-[4-METHOXY-3-(3-METHOXYPROPOXY)BENZYL]-8-METHYLNONANAMIDE; Benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis-(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-; 5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide fumarate; Aliskiren [INN]; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; NCGC00186464-01; 173334-58-2; CGP 60536;CGP60536B;SPP 100; Aliskiren [USAN:INN:BAN]; UNII-502FWN4Q32; HSDB 7843; (2s,4s,5s,7s)-5-amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide; (2S,4S,5S,7S)-5-amino-N-[2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide; CGP-060536B; Rasilez (TN); Aliskiren-hemifumarate; ALISKIREN [MI]; Aliskiren (USAN/INN); ALISKIREN [HSDB]; ALISKIREN [USAN]; ALISKIREN [VANDF]; ALISKIREN [WHO-DD]; ALISKIREN [EMA EPAR]; SCHEMBL455490; GTPL4812; BDBM17950; DTXSID40891494; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; MFCD09839018; s5767; STL386835; AKOS015852572; AKOS015888741; CS-0443; DB09026; NCGC00186464-02; 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid hemifumarate; AS-80517; HY-12176; SBI-0206888.P001; D03208; EN300-708809; AB01274865-01; AB01274865_02; AB01274865_03; Q414904; BRD-K30020243-051-01-7; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl)-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonamide; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxo-propyl)-4-hydroxy-2-isopropyl-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-nonanamide; (2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamide; (2s,4s,5s,7s)-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide; 1327153-71-8; 5(S)-Amino-4(S)-hydroxy-2(S),7(S)-diisopropyl-8-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-octanoic acid N-(2-carbamoyl-2,2-dimethyl-ethyl)-amide; Benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-; C41	Approved	Approved Drug(s)	5493444	DB09026	D03SVX	551.8	146	717	3.5	39	4	7	19	C30H53N3O6	(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide	CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N	CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N	InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1	UXOWGYHJODZGMF-QORCZRPOSA-N
D5JBO2	Vortioxetine	Small molecule	VORTIOXETINE; 508233-74-7; 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine; Lu AA21004; 1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine; Vortioxetine free base; 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine; LuAA21004; Lu-AA21004; Vortioxetine [USAN]; 3O2K1S3WQV; Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-; Vortioxetine (Lu AA21004); CHEBI:76016; 508233-74-7 (free base); Vortioxetine (USAN); Brintellix (TN); 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine; Piperazine, 1-(2-((2,4-dimethylphenyl)thio)phenyl)-; 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine; CHEMBL2204360; 1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine; 1-(2-((2,4-Dimethylphenyl)sulfanyl)phenyl}piperazine; Vortioxetine [USAN:INN]; UNII-3O2K1S3WQV; vortioxetina; vortioxetinum; Lu AA 21004; VORTIOXETINE [MI]; VORTIOXETINE [INN]; VORTIOXETINE [VANDF]; Vortioxetine, Lu AA21004; SCHEMBL236115; VORTIOXETINE [WHO-DD]; GTPL7351; CHEMBL2104993; HSDB 8250; DTXSID80965062; HMS3886M08; AMY38899; BCP05996; BDBM50400902; MFCD22380814; s5506; STL483777; AKOS016008748; CCG-229998; CS-1471; DB09068; GG-0052; SB16506; NCGC00386237-08; AC-27648; DA-42264; HY-15414; FT-0686961; D10184; EN300-746942; A853366; AR-270/43507985; Q3563148; 1-[2-(2,4-Dimethylphenylsulfanyl)-phenyl]piperazine; 1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL)PIPERAZINE HYDROCHLRIDE; Lu AA 21004 pound>>LuAA21004 pound>> Lu-AA21004 pound>> Lu AA21004 pound>> AA21004	Approved	Approved Drug(s)	9966051	DB09068	D03WEX	298.4	40.6	316	4.2	21	1	3	3	C18H22N2S	1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine	CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C	CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C	InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3	YQNWZWMKLDQSAC-UHFFFAOYSA-N
DRQ39X	Cinacalcet	Small molecule	Cinacalcet; 226256-56-0; AMG 073; AMG073; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; AMG-073; Cinacalcet (USAN); KRN1493; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; UAZ6V7728S; CHEBI:48390; KRN-1493; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-[(1r)-1-(naphthalen-1-yl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; CINACALCET [USAN]; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine; Cinacalcet [INN]; [(1R)-1-(naphthalen-1-yl)ethyl]({3-[3-(trifluoromethyl)phenyl]propyl})amine; CNC; NCGC00181002-01; UNII-UAZ6V7728S; Cinacalcet [USAN:INN:BAN]; HSDB 7318; CINACALCET [MI]; CINACALCET [HSDB]; CINACALCET [VANDF]; CINACALCET [WHO-DD]; SCHEMBL71876; CINACALCET [EMA EPAR]; GTPL3308; CHEMBL1201284; DTXSID8048286; ACT06726; AMY13665; BCP07181; BDBM50416875; s5191; AKOS015909821; AC-8974; CS-0287; DB01012; NCGC00181002-02; NCGC00181002-03; NCGC00181002-05; BS-16242; HY-70037; D03504; EN300-220098; AB01274759-01; AB01274759_02; Q193978; J-520046; (R)-N-(3-(3-trifluoromethylphenyl)propyl)-1-(1-naphthyl)ethylamine; 1-Naphthalenemethanamine, alpha-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-, (alphaR)-; 1-NAPHTHALENEMETHANAMINE, .ALPHA.-METHYL-N-(3-(3-(TRIFLUOROMETHYL)PHENYL)PROPYL)-, (.ALPHA.R)-; 1025064-29-2; YP4	Approved	Approved Drug(s)	156419	DB01012	D03YGR	357.4	12	422	6.1	26	1	4	6	C22H22F3N	N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine	CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F	C[C@H](C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F	InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1	VDHAWDNDOKGFTD-MRXNPFEDSA-N
D18WAS	Crizotinib	Small molecule	Crizotinib; 877399-52-5; Xalkori; PF-02341066; (R)-crizotinib; PF-2341066; PF 2341066; Crizotinib (PF-02341066); (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine; PF 02341066; Crizotinib (PF-2341066); PF2341066; CHEMBL601719; CHEBI:64310; 877399-52-5 (free base); 53AH36668S; NSC-756645; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine; 2-Pyridinamine, 3-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1H-pyrazol-4-yl)-; 3-[(1r)-1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-Yl-1h-Pyrazol-4-Yl)pyridin-2-Amine; (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; Xalkori (TN); Crizotinib [USAN]; Crizotinib [USAN:INN]; crizotinibum; UNII-53AH36668S; 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; VGH; Crizotinib- Bio-X; CRIZOTINIB [MI]; CRIZOTINIB [INN]; CRIZOTINIB [JAN]; PF02341066; CRIZOTINIB [VANDF]; CRIZOTINIB [MART.]; CRIZOTINIB [WHO-DD]; SCHEMBL93829; PF-2341066,Crizotinib; 3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-[1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL]PYRIDIN-2-AMINE; Crizotinib (JAN/USAN/INN); GTPL4903; CRIZOTINIB [ORANGE BOOK]; Crizotinib, >=98% (HPLC); PF-2341066 - Crizotinib; EX-A096; BCPP000116; DTXSID701009329; AMY10313; PF 2341066;(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; BDBM50306682; MFCD12407409; NSC749005; NSC749769; NSC800080; AKOS015901233; AKOS015995207; CCG-264803; DB08865; GS-6178; NSC 756645; NSC-749005; NSC-749769; NSC-800080; NCGC00250400-01; NCGC00250400-02; NCGC00250400-09; NCGC00250400-12; BC164334; HY-50878; BB 0261738; SW202555-3; D09731; J-510370; Q5186964; BRD-K78431006-001-01-1; BRD-K78431006-001-03-7; 877399-52-5, 877399-53-6 (acetate); Z2065417924; 3-(2,6-dichloro-3-fluorobenzyloxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-am ine; 3-(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy-5-1-(4-piperidinyl)-1H-pyrazol-4-yl-2-Pyridinamine; 3-[(R)-1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine	Approved	Approved Drug(s)	11626560	DB08865	D03ZBT	450.3	78	558	3.7	30	2	6	5	C21H22Cl2FN5O	3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine	CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N	C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N	InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1	KTEIFNKAUNYNJU-GFCCVEGCSA-N
DB5IN0	Cidofovir	Small molecule	Cidofovir; 113852-37-2; Vistide; HPMPC; Cidofovir anhydrous; (S)-HPMPC; GS-504; anhydrous cidofovir; Cidofovir [INN]; Cidofovir (Vistide); Cidofovir hydrate; GS 0504; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; CDV; [1-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-propan-2-yl]oxymethylphosphonic acid; GS-0504; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine; (S)-(((1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonic acid; CHEBI:3696; DTXSID3043734; Hpmpc dihydrate; ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine; 768M1V522C; NSC-742135; NCGC00184994-01; Phosphonic acid, ((2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, (S)-; ({[(2S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine; 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine; Cidofovir (anhydrous); Cidofovir hydrate (1:2); Cidofovirum; Forvade; (S)-(3-(4-amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid; [(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid; HSDB 7115; GS504; 1-((S)-3-HYDROXY-2-(PHOSPHONOMETHOXY)PROPYL)CYTOSINE; Cidofovir gel; UNII-768M1V522C; Cidofovir,Vistide; [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; Cidofovir(Vistide); (((S)-2-(4-AMINO-2-OXO-1(2H)-PYRIMIDINYL)-1-(HYDROXYMETHYL)ETHOXY)METHYL)PHOSPHONIC ACID; Forvade (TM); CIDOFOVIR [MI]; CIDOFOVIR [HSDB]; CHEMBL152; CIDOFOVIR [WHO-DD]; Cidofovir anhydrous- Bio-X; SCHEMBL3948; (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; MLS003915629; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; DTXCID1023734; BDBM31915; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate; BCP03734; EX-A4209; Tox21_112994; MFCD00866936; NSC742135; s1516; AKOS005145721; AKOS015854828; AC-1666; BCP9000528; CCG-267235; CS-1669; DB00369; GS-6438; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; [(1S)-1-[(4-amino-2-oxo-pyrimidin-1-yl)methyl]-2-hydroxy-ethoxy]methylphosphonic acid; NCGC00184994-02; NCGC00184994-03; BC164304; HY-17438; SMR002544687; BCP0726000147; CAS-113852-37-2; AB01566823_01; EN300-7479747; Q423445; SR-01000931969; J-502695; SR-01000931969-2; (S)-(((1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonicacid; ({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; L8P; Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-; Phosphonic acid,[[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-	Approved	Approved Drug(s)	60613	DB00369	D04AAW	279.19	146	417	-3.6	18	4	6	6	C8H14N3O6P	[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid	C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O	C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O	InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1	VWFCHDSQECPREK-LURJTMIESA-N
DD31ZH	Ferric citrate	Small molecule	FERRIC CITRATE; Iron(III) citrate; Iron citrate; Zerenex; 3522-50-7; 6043-74-9; 28633-45-6; ferrum citricum; Citric acid, iron(3+) salt; FERRICCITRATE; Iron(III) citrate tribasic; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt (1:1); ferric citrate anhydrous; KRX-0502; iron(iii)citrate; Iron citrate, FeC6H5O7; Auryxia; iron(3+) citrate; 63G354M39Z; 2338-05-8; Iron, (hydrogen citrato(3-))-; Citric acid, iron(3+) salt (1:1); FERROUS CITRATE; iron(III) 2-hydroxypropane-1,2,3-tricarboxylate; 2-hydroxy-1,2,3-propanetricarboxylic acid iron salt; Ferric citrate [USAN]; Ferric citrate tetrahydrate; Iron(III) citrate; Zerenex; JTT-751; Ferric citrate (VAN); 2-hydroxypropane-1,2,3-tricarboxylate;iron(3+); NSC-112227; Fexeric; iron(3+) 2-hydroxypropane-1,2,3-tricarboxylate; UNII-63G354M39Z; JTT 751; EINECS 222-536-6; EINECS 249-117-0; Iron(III)-citrate; Iron (III) citrate; NSC 112227; Citric acid, iron salt; 1185-57-5; Citric acid,iron(3+)salt; FERRIC CITRATE [MI]; SCHEMBL42945; FERRIC CITRATE [FCC]; 2-hydroxypropane-1,2,3-tricarboxylate; iron(3+); FERRIC CITRATE [INCI]; FERRUM CITRICUM [HPUS]; CCRIS 6843; DTXSID0037657; FERRIC CITRATE [WHO-DD]; Iron(III) citrate;Iron citrate; HY-N1428C; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt; BCP30645; FERRIC CITRATE [ORANGE BOOK]; AKOS015918266; DB09162; DB-119245; CS-0030977; FT-0626407; FT-0627304; FT-0652224; Iron 2-hydroxy-1,2,3-propanetricarboxylate; A832727; iron(3+); 2-oxidanylpropane-1,2,3-tricarboxylate; Q15628111; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron salt (1:?); 1,2,3-propanetricarboxylic acid, 2-hydroxy-, iron(2+) salt (2:3)	Approved	Approved Drug(s)	61300	DB14520	D04CJL	244.94	141	211	.	14	1	7	2	C6H5FeO7	2-hydroxypropane-1,2,3-tricarboxylate;iron(3+)	C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Fe+3]	C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Fe+3]	InChI=1S/C6H8O7.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3	NPFOYSMITVOQOS-UHFFFAOYSA-K
D15EAV	Glatiramer acetate	Small molecule	Glatiramer acetate; 147245-92-9; acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid; Glatirameracetat; DTXSID30163637; AM84438; AC-28732; L-alanine compound with L-glutamic acid and L-lysine and L-tyrosine and acetic acid (1:1:1:1:1); Q418274; (2S)-2,6-diaminohexanoic acid; (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid; (2S)-2-aminopentanedioic acid; (2S)-2-aminopropanoic acid; acetic acid	Approved	Approved Drug(s)	3081884	DB05259	D04CRL	623.7	374	519	.	43	12	18	13	C25H45N5O13	acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid	CC(C(=O)O)N.CC(=O)O.C1=CC(=CC=C1CC(C(=O)O)N)O.C(CCN)CC(C(=O)O)N.C(CC(=O)O)C(C(=O)O)N	C[C@@H](C(=O)O)N.CC(=O)O.C1=CC(=CC=C1C[C@@H](C(=O)O)N)O.C(CCN)C[C@@H](C(=O)O)N.C(CC(=O)O)[C@@H](C(=O)O)N	InChI=1S/C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2.C2H4O2/c10-8(9(12)13)5-6-1-3-7(11)4-2-6;7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;1-2(3)4/h1-4,8,11H,5,10H2,(H,12,13);5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1H3,(H,3,4)/t8-;5-;3-;2-;/m0000./s1	FHEAIOHRHQGZPC-KIWGSFCNSA-N
D4S3HQ	Atomoxetine	Small molecule	Atomoxetine; 83015-26-3; Tomoxetine; (-)-Tomoxetine; Strattera; Tomoxetina; Tomoxetinum; Tomoxetinum [Latin]; Tomoxetina [Spanish]; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine; HSDB 7352; methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine; ASW034S0B8; CHEBI:127342; (R)-Tomoxetine; (R)-N-methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine; Benzenepropanamine, N-methyl-gamma-(2-methylphenoxy)-, (gammaR)-; Tomoxetine [INN]; (R)-N-Methyl-gamma-(2-methylphenoxy)benzenepropanamine; (R)-Atomoxetine; Atomoxetine [INN]; CHEMBL641; Atomoxetine [INN:BAN]; UNII-ASW034S0B8; Ginseng america; Tocris-2011; Atomoxetine (USP/INN); ATOMOXETINE [MI]; ATOMOXETINE [HSDB]; ATOMOXETINE [VANDF]; SCHEMBL34268; ATOMOXETINE [WHO-DD]; (R)-N-methyl-3-(2-methylphenoxy)benzenepropanamine; GTPL7118; HSDB7352; DTXSID9044297; HSDB-7352; AD109 COMPONENT ATOMOXETINE; BDBM50366567; PDSP1_000504; PDSP2_000502; AD-109 COMPONENT ATOMOXETINE; AKOS015961834; AC-5316; DB00289; NCGC00025345-01; AC-25548; HY-107370; D07473; AB00698501_08; EN300-17832026; N-methyl-3-(3-(o-tolyloxy)phenyl)propan-1-amine; Q417240; Q-200658; BRD-K20141153-003-03-8; 1027094-45-6	Approved	Approved Drug(s)	54841	DB00289	D04CRN	255.35	21.3	237	3.7	19	1	2	6	C17H21NO	(3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine	CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2	CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2	InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1	VHGCDTVCOLNTBX-QGZVFWFLSA-N
DWVE72	Propranolol	Small molecule	propranolol; Propanolol; 525-66-6; beta-Propranolol; Euprovasin; Betalong; Proprasylyt; Reducor; Anapriline; Propanalol; Propanix; propranololo; Sawatal; dl-propranolol; Sumial; Propranololum; .beta.-Propranolol; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; hemangiol; Bedranol; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; CHEMBL27; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-; 9Y8NXQ24VQ; 2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-; CHEBI:8499; Betadren; Corpendol; 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-; Inderex; Inderol; Pranolol; Propranolol (INN); Racemic propranolol; 1-Isopropylamino-3-(naphthalen-1-yloxy)-propan-2-ol; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; AY-64043-; PROPRANOLOL [INN]; Inderal hydrochloride; D,L-Propranolol; (+-)-Propranolol; Propranololo [DCIT]; Propranalol; [2-hydroxy-3-(naphthalen-1-yloxy)propyl](propan-2-yl)amine; 1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; Propranolol [INN:BAN]; AY 20694; Propanolol [INN-Spanish]; Propranololum [INN-Latin]; racemic-Propranolol; NSC91523; CCRIS 3082; EINECS 208-378-0; EINECS 235-867-6; UNII-9Y8NXQ24VQ; b-Propranolol; Propranolol (TN); Dociton (Salt/Mix); Inderal (Salt/Mix); Obsidan (Salt/Mix); (+/-)-propranolol; Propanolol,(+/-); PROPRANOLOL, d; Avlocardyl (Salt/Mix); beta-Propranolol;Dociton; 2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-, (+-)-; PROPANOLOL(-); PROPRANOLOL [MI]; Prestwick0_000952; Prestwick1_000952; Prestwick2_000952; Prestwick3_000952; PROPRANOLOL,(+); PROPRANOLOL,(-); Spectrum2_001301; Spectrum2_001699; Spectrum3_000883; Spectrum3_001071; Spectrum4_000974; Spectrum4_001222; Spectrum5_000751; (.+/-.)-Propranolol; PROPRANOLOL [VANDF]; SCHEMBL3955; 3-[(methylethyl)amino]-1-naphthyloxypropan-2-ol; Lopac0_000896; Oprea1_304193; BSPBio_000944; BSPBio_002682; CBDivE_006180; GTPL564; KBioGR_001347; KBioGR_001684; KBioGR_002515; KBioSS_002523; PROPRANOLOL [WHO-DD]; DivK1c_000023; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; SPBio_001361; SPBio_001658; SPBio_003093; (+)-Propranolol hydrochloride; (R)-(+)-Propranolol hydrochloride; 1-(Isopropylamino)-3-(naphthalen-1-yloxy)propan-2-ol; BPBio1_001040; ICI 45520 (Salt/Mix); NSC 91523 (Salt/Mix); DTXSID6023525; SCHEMBL12264958; BDBM25761; HY-B0573B; KBio1_000023; KBio2_002515; KBio2_005083; KBio2_007651; KBio3_001766; KBio3_001902; KBio3_002993; cMAP_000071; NINDS_000023; (A+/-)-Propranolol hydrochloride; Bio1_000367; Bio1_000856; Bio1_001345; HMS2090L21; HMS3428G03; BCP26001; BCP31343; BBL023437; PDSP1_000767; PDSP1_001607; PDSP1_001608; PDSP2_000755; PDSP2_001591; PDSP2_001592; STK735510; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-; AKOS000588816; AKOS016050338; CCG-103643; DB00571; FE-0204; SDCCGSBI-0050871.P004; IDI1_000023; NCGC00015798-04; NCGC00015798-05; NCGC00015798-06; NCGC00015798-07; NCGC00015798-08; NCGC00015798-09; NCGC00015798-15; NCGC00015798-19; NCGC00024690-02; NCGC00024690-03; 13013-17-7; SBI-0050871.P003; AB00053537; CS-0069968; FT-0650563; FT-0674088; EN300-40731; C07407; D08443; AB00053537-10; AB00053537_11; AB00053537_12; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; L000679; Q423364; 1(-alpha-naphthoxy)-3-(iso-propylamino)-2-propanol; 1-(alpha-naphthoxy)-3-(iso-propylamino)-2-propanol; 1-(alpha-naphthoxy)-3-(isopropylamino)-2-propanol; 1-isopropylamino-3-(naphthalen-1-yloxy)propan-2-ol; W-109550; 1-(isopropylamino)-3-naphthalen-1-yloxy-propan-2-ol; BRD-A10070317-003-06-9; BRD-A10070317-003-17-6; 1-((1-Methylethyl)amino)-3-(1-naphthyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; F0001-3681; 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-methyl-3-(trifluoromethyl)-, ethyl ester	Approved	Approved Drug(s)	4946	DB00571	D04JEE	259.339	41.5	257	3	19	2	3	6	C16H21NO2	1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol	CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O	CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O	InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3	AQHHHDLHHXJYJD-UHFFFAOYSA-N
D2VW3Y	Lomustine	Small molecule	lomustine; 13010-47-4; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; CCNU; Belustine; CeeNU; Cecenu; CINU; Chloroethylcyclohexylnitrosourea; Urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso-; Lomustina; Lomustinum; Lomustinum [INN-Latin]; Lomustina [INN-Spanish]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea; NSC 79037; NSC-79037; Gleostine; Cyclohexyl chloroethyl nitrosourea; SRI 2200; ICIG 1109; NCI-C04740; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; RB 1509; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; NSC79037; Lomustine (CeeNU); 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-; CHEBI:6520; Urea, 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-; CCN-U; 7BRF0Z81KG; CCNU; NSC 79037; DTXSID2023222; 3-(2-chloroethyl)-1-cyclohexyl-3-nitrosourea; 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea; MFCD00012392; NCGC00167466-01; DTXCID103222; CCRIS 860; CAS-13010-47-4; CCNU [Chloroethyl nitrosoureas]; HSDB 6519; SR-05000001497; EINECS 235-859-2; UNII-7BRF0Z81KG; BRN 2125058; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian]; Lomustine [USAN:INN:BAN]; AI3-52779; Gleostine (TN); Lomustine- Bio-X; Lomustine, >=98%; Lomustine (USP/INN); LOMUSTINE [INN]; LOMUSTINE [MI]; LOMUSTINE [HSDB]; LOMUSTINE [USAN]; LOMUSTINE [VANDF]; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; CHEMBL514; LOMUSTINE [MART.]; NCIMech_000220; LOMUSTINE [USP-RS]; LOMUSTINE [WHO-DD]; SCHEMBL3995; WLN: L6TJ AMVNNO&2G; GTPL7214; LOMUSTINE [ORANGE BOOK]; LOMUSTINE [EP MONOGRAPH]; LOMUSTINE [USP MONOGRAPH]; HMS2090A17; HMS3655I16; Pharmakon1600-01502301; BCP06551; Tox21_112470; BDBM50247919; NSC759635; s1840; AKOS005766022; Tox21_112470_1; AC-8062; CCG-213022; CS-1461; DB01206; DS-1269; NSC-759635; NCGC00167466-02; NCGC00167466-03; BL164634; HY-13669; NCI60_041743; DB-017097; AM20070540; FT-0627972; L0251; SW220040-1; C07079; D00363; EN300-118685; AB00173884-02; AB00173884-03; AB00173884-04; AB00173884_05; AB00173884_06; A806019; Q415378; SR-05000001497-1; SR-05000001497-3; Urea, 1-(2-chloroethyl)-3-cyclohexyl)-1-nitroso-; W-108355; Lomustine, European Pharmacopoeia (EP) Reference Standard; 1-(2-CHLOROETHYL)-3-CYCLOHEXYL-1-NITROSOUREA [IARC]; Lomustine, United States Pharmacopeia (USP) Reference Standard; 1-(2-Chloroethyl)-1-[(cyclohexylamino)carbonyl]-2-oxohydrazine #; 2-chloro-N-(cyclohexyl-C-hydroxycarbonimidoyl)-N-nitrosoethan-1-amine; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea13010-47-4NCI60_0417431-(2-Chloroethyl)-3-cyclohexylnitrosourea1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-Be	Approved	Approved Drug(s)	3950	DB01206	D04JPJ	233.69	61.8	219	2.8	15	1	3	3	C9H16ClN3O2	1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea	C1CCC(CC1)NC(=O)N(CCCl)N=O	C1CCC(CC1)NC(=O)N(CCCl)N=O	InChI=1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)	GQYIWUVLTXOXAJ-UHFFFAOYSA-N
D7KC8E	Formoterol	Small molecule	formoterol; 73573-87-2; 128954-45-0; n-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; Foradil; Formoterol-D6 (Major); Formoterolum [INN-Latin]; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; FORMOTEROL FUMARATE; CHEBI:63082; Formoterol (INN); 2'-hydroxy-5'-(1-hydroxy-2-((p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; 2'-hydroxy-5'-{1-hydroxy-2-[(p-methoxy-alpha-methylphenethyl)amino]ethyl}formanilide; N-[2-hydroxy-5-(1-hydroxy-2-{[2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl)phenyl]formamide; Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, [R-(R*,S*)]-; Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, [S-(R*,S*)]-; Oxis (TN); Oxeze/Oxis; BD-40A; n-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide; CGP-25827A; NCGC00181126-01; SCHEMBL349579; GTPL3465; CHEMBL1256786; SCHEMBL15856256; BDBM86453; DTXSID20860603; Formoterol Fumarate Dihydrate EP Impurity I (R,S-isomer) ((R,S)-Formoterol); AC-459; MFCD05662345; STL450992; AKOS015961179; AT22502; DB00983; SB17482; NSC_3083544; AS-14186; CAS_73573-87-2; Formoterol Fumarate Dihydrate EP Impurity I; C07805; D07990; EN300-7480042; L000259; Q637247; 126587-85-7; N-[2-hydroxy-5-[(1rs)-1-hydroxy-2-[[(1rs)-2(4methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl] formamide	Approved	Approved Drug(s)	3410	DB00983	D04KJO	344.4	90.8	388	1.8	25	4	5	8	C19H24N2O4	N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide	CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O	CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O	InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)	BPZSYCZIITTYBL-UHFFFAOYSA-N
DKXN52	Allopurinol	Small molecule	allopurinol; 315-30-0; 1H-Pyrazolo[3,4-d]pyrimidin-4-ol; Zyloprim; Lopurin; Zyloric; Suspendol; Atisuril; Bleminol; Caplenal; Takanarumin; Uripurinol; Embarin; Foligan; Milurit; Progout; Urosin; Anoprolin; Cellidrin; Epidropal; Ailural; Allopur; Allural; Alositol; Bloxanth; Cosuric; Hamarin; Ledopur; Lysuron; Uricemil; Uriprim; Xanturat; Aloral; Anzief; Apurin; Apurol; Geapur; Gotax; Remid; Urbol; Urolit; Urtias; 4-Hydroxypyrazolo[3,4-d]pyrimidine; Ketobun-A; Apulonga; Dabrosin; Dabroson; Ketanrift; Miniplanor; Nektrohan; Adenock; Allozym; Aluline; Gichtex; Monarch; Riball; 1H-Pyrazolo[3,4-d]pyrimidin-4(5H)-one; Hexanuret; Epuric; Allo-Puren; 4-HPP; Allopurinol(I); Dura Al; Allopurinolum; 1H-Pyrazolo(3,4-d)pyrimidin-4-ol; Urtias 100; 4-Hydroxypyrazolopyrimidine; 4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine; Alopurinol; Aloprim; 180749-06-8; 180749-08-0; 1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one; 4-Hydroxy-3,4-pyrazolopyrimidine; 73334-58-4; NSC-1390; 4-Hydroxypyrazolo(3,4-d)pyrimidine; Alopurinol [INN-Spanish]; Allopurinolum [INN-Latin]; 2H-Pyrazolo[3,4-d]pyrimidin-4-ol; 1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one; 4-Hydroxypyrazolyl(3,4-d)pyrimidine; 4H-Pyrazolo(3,4-d)pyrimidin-4-one; BW 56-158; 4'-Hydroxypyrazolol(3,4-d)pyrimidine; AL-100; Zyloprim (TN); 180749-09-1; 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one; BW-56-158; B. W. 56-158; 1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one; 4H-Pyrazolo(3,4-d)pyrimidin-4-one, 1,5-dihydro-; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-; 1,5-Dihydropyrazolo[3,4-d]pyrimidin-4-one; MFCD00599413; MLS000069453; 180749-07-9; 184789-03-5; 916980-04-6; CHEBI:40279; NSC-101655; 63CZ7GJN5I; SMR000059083; 4-Hydroxy-1H-pyrazolo[3,4-d]pyrimidine; 1H-Pyrazolo[3,4-d]pyrimidin-4-ol (9CI); 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,7-dihydro- (9CI); 1H,2H,4H-pyrazolo[3,4-d]pyrimidin-4-one; 1H,4H,7H-pyrazolo[3,4-d]pyrimidin-4-one; DTXSID4022573; NSC1390; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,2-dihydro-; NSC101655; 9002-17-9; NCGC00015094-02; NCGC00094580-04; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 2,5-dihydro- (9CI); 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 2,7-dihydro- (9CI); BW 56158; BW-56158; Sigapurol; Uritas; 1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one; 1,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-one; DTXCID502573; 4H-Pyrazolo[3, 1,5-dihydro-; Ailurial; WLN: T56 BMN GN INJ FQ; Xanthine oxidase; 4-Hydroxypyrazolyl[3,4-d]pyrimidine; 4'-Hydroxypyrazolol[3,4-d]pyrimidine; NSC 1390; CAS-315-30-0; CCRIS 626; NSC 101655; HSDB 3004; SR-05000001983; EINECS 206-250-9; UNII-63CZ7GJN5I; Hexanurat; Uricto; ATH008; 4-Hydroxypyrazol[3,4-D]pyrimidine; Prestwick_511; Xanthomax-100; Xanthomax-300; 4H-Pyrazolo[3,4-d]pyrimidin-4-one,1,2-dihydro-; Aluline 100; Aluline 300; Hamarin 100; Hamarin 300; Zyloric-300; Allopurinol [USAN:USP:INN:BAN:JAN]; Allopurinol (Zyloprim); Spectrum_000026; ALLOPURINOL [MI]; Opera_ID_1680; Spectrum2_000098; Spectrum3_000289; Spectrum4_000135; Spectrum5_000768; ALLOPURINOL [INN]; ALLOPURINOL [JAN]; Lopac-A-8003; 1,4-d]pyrimidin-4-one; ALLOPURINOL [HSDB]; ALLOPURINOL [USAN]; A 8003; cid_2094; SCHEMBL4627; ALLOPURINOL [MART.]; CHEMBL1467; NCIOpen2_001825; Lopac0_000102; ALLOPURINOL [USP-RS]; ALLOPURINOL [WHO-DD]; ALLOPURINOL [WHO-IP]; BSPBio_001798; KBioGR_000550; KBioSS_000386; MLS001148183; US9138393, Allopurinol; US9144538, Allopurinol; DivK1c_000685; SPECTRUM1500108; SPBio_000056; ALLOPURINOLUM [WHO-IP]; GTPL6795; SCHEMBL1128219; Allopurinol (JP17/USP/INN); BDBM35440; HMS502C07; KBio1_000685; KBio2_000386; KBio2_002954; KBio2_005522; KBio3_001298; ALLOPURINOL [EP IMPURITY]; ALLOPURINOL [ORANGE BOOK]; NINDS_000685; ALLOPURINOL [EP MONOGRAPH]; BDBM181133; HMS1920A15; HMS2091G15; HMS2234M09; HMS3259K13; HMS3260E06; HMS3371I11; HMS3651O13; HMS3714L22; Pharmakon1600-01500108; ALLOPURINOL [USP MONOGRAPH]; ACT02732; AMY18272; BCP26973; DUZALLO COMPONENT ALLOPURINOL; HY-B0219; STR05189; Tox21_110082; Tox21_200922; Tox21_500102; 4-Hydroxy-pyrazolo[3,4-d]pyrimidin; AC-019; BBL009959; BDBM50016784; BDBM50140241; CCG-38916; NSC755858; s1630; SC1118; SC2251; STK378584; STK711106; AKOS000267490; AKOS000269759; AKOS024255717; Tox21_110082_1; Allopurinol, xanthine oxidase inhibitor; CCG-204197; CCG-221406; CCG-266128; DB00437; LP00102; NC00492; NSC-755858; SB10164; SDCCGSBI-0050090.P005; IDI1_000685; NCGC00015094-01; NCGC00015094-03; NCGC00015094-04; NCGC00015094-05; NCGC00015094-06; NCGC00015094-07; NCGC00015094-08; NCGC00015094-22; NCGC00091134-01; NCGC00091134-02; NCGC00091134-03; NCGC00094580-01; NCGC00094580-02; NCGC00094580-05; NCGC00188948-01; NCGC00258476-01; NCGC00260787-01; TS-00028; SBI-0050090.P004; DB-065332; 2H-Pyrazolo[3,4-d]pyrimidin-4-ol (9CI); A0907; EU-0100102; FT-0602537; FT-0661492; FT-0685730; FT-0764079; SW199406-4; 1,5-dihydropyrazolo[3,4-d]-pyrimidin-4-one; EN300-34144; VU0611037-1; BIM-0061756.0001; D00224; F18007; AB00173448-03; AB00173448-04; AB00173448_05; AB01274719-01; AB01274719_02; 4h-pyrazolo[3,4-d]pyrimidin-4-one,1,7-dihydro-; 4h-pyrazolo[3,4-d]pyrimidin-4-one,2,5-dihydro-; 4h-pyrazolo[3,4-d]pyrimidin-4-one,2,7-dihydro-; AB-323/25048497; Allopurinol (4-Hydroxypyrazolo[3,4-d]pyrimidine); Q412486; SR-01000075595; 4H-pyrazolo[3,4-d]pyrimidin-4-one, 1,7-dihydro-; J-504736; SR-01000075595-1; SR-05000001983-1; SR-05000001983-2; W-106892; F2173-0394; F3329-0375; Z104486670; Allopurinol, British Pharmacopoeia (BP) Reference Standard; Allopurinol, European Pharmacopoeia (EP) Reference Standard; Allopurinol, United States Pharmacopeia (USP) Reference Standard; 1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one Synonym:  Allopurinol; Allopurinol, Pharmaceutical Secondary Standard; Certified Reference Material; 1H-Pyrazolo[3,4-d]pyrimidin-4-ol;1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE; 184856-42-6	Approved	Approved Drug(s)	135401907	DB00437	D04KYY	136.11	70.1	190	-0.7	10	2	3	0	C5H4N4O	1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one	C1=NNC2=C1C(=O)NC=N2	C1=NNC2=C1C(=O)NC=N2	InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)	OFCNXPDARWKPPY-UHFFFAOYSA-N
D7S5OG	Gilteritinib	Small molecule	Gilteritinib; 1254053-43-4; ASP2215; ASP-2215; Xospata; ASP 2215; Gilteritinib(ASP2215); 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; 66D92MGC8M; Gilteritinib HCl; 2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-; 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; 6-ethyl-3-[[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide; 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide; Gilteritinib [USAN:INN]; Gilteritinib (ASP2215); gilteritinibum; UNII-66D92MGC8M; 2-Pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-; C6F; GILTERITINIB [MI]; Gilteritinib (USAN/INN); GILTERITINIB [INN]; GILTERITINIB [USAN]; Gilteritinib (ASP-2215); GILTERITINIB [WHO-DD]; SCHEMBL282229; GTPL8708; CHEMBL3301622; CHEBI:145372; BDBM144315; DTXSID701027949; BCP28756; EX-A2775; MFCD28144685; NSC787846; NSC787854; NSC788454; NSC800106; s7754; CCG-270016; CS-3885; DB12141; NSC-787846; NSC-787854; NSC-788454; NSC-800106; SB16988; NCGC00481652-01; NCGC00481652-02; AC-29030; AS-35199; BG166434; HY-12432; DB-108103; A14411; D10709; A901674; US8969336, 547; US8969336, 577; Q27077802; 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-2-pyrazinecarboxamide; 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide; 6-Ethyl-3-[3-methoxy-4-[4-(4-methylpiperazine-1-yl)piperidino]anilino]-5-[(tetrahydro-2H-pyran-4-yl)amino]pyrazine-2-carboxamide; 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide; 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide	Approved	Approved Drug(s)	49803313	DB12141	D04KZY	552.7	121	785	3.5	40	3	10	9	C29H44N8O3	6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide	CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5	CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5	InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)	GYQYAJJFPNQOOW-UHFFFAOYSA-N
DYOF03	Ceritinib	Small molecule	ceritinib; LDK378; 1032900-25-6; ZYKADIA; LDK-378; NVP-LDK378-NX; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; LDK 378; Ceritinib(LDK378); Ceritinib (LDK378); K418KG2GET; NVP-LDK-378-NX; CHEMBL2403108; CHEBI:78432; 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine; 2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-; 5-chloro-2-N-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-4-N-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine; 5-Chloro-N~2~-[5-Methyl-4-(Piperidin-4-Yl)-2-(Propan-2-Yloxy)phenyl]-N~4~-[2-(Propan-2-Ylsulfonyl)phenyl]pyrimidine-2,4-Diamine; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrimidine-2,4-diamine; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine; 5-Chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; 5-Chloro-N4-[2-[(1methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine;5-Chloro-N4-[2-[(1methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; Ceritinib [USAN:INN]; UNII-K418KG2GET; ceritinibum; C28H36ClN5O3S; Ceritinib[mi]; Zykadia (TN); LDK378 Certinib; Ceritinib; LDK378; LDK378(Ceritinib); CERITINIB [INN]; CERITINIB [JAN]; CERITINIB [MI]; CERITINIB [USAN]; CERITINIB [VANDF]; CERITINIB [WHO-DD]; Ceritinib (JAN/USAN/INN); GTPL7397; SCHEMBL1014329; CERITINIB [ORANGE BOOK]; DTXSID10725373; EX-A187; HMS3652H22; HMS3673I17; HMS3747A11; AMY10314; BCP07611; BDBM50436850; MFCD26142648; NSC776422; NSC777193; NSC800072; AKOS025396438; CCG-264762; CS-1406; DB09063; GS-6356; NSC-776422; NSC-777193; NSC-800072; SB16490; compound 15b [PMID 23742252]; NCGC00351603-10; NCGC00351603-13; NCGC00351603-15; AC-27469; HY-15656; FT-0697208; S7083; SW219725-1; D10551; EN300-7404145; A852144; J-690011; Q21011233; Z2235802104; N-{2-Methyl-5-[(methylamino)methyl]phenyl}-4-[(4-phenyl-2-quinazolinyl)amino]benzamide; 4MK; 5-chloro-N(2)-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N(4)-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine; 5-Chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-CHLORO-N2-(5-METHYL-4-(PIPERIDIN-4-YL)-2-(PROPAN-2-YLOXY)PHENYL)-N4-(2-(PROPANE-2- SULFONYL)PHENYL)PYRIMIDINE-2,4-DIAMINE; 5-CHLORO-N4-(2-((1-METHYLETHYL)SULFONYL)PHENYL)-N2-(5-METHYL-2-(1-METHYLETHOXY)-4- (PIPERIDIN-4-YL)PHENYL)PYRIMIDINE-2,4-DIAMINE; Ceritinib;5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine;Ceritinib; N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide	Approved	Approved Drug(s)	57379345	DB09063	D04LVK	558.1	114	835	6.4	38	3	8	9	C28H36ClN5O3S	5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl	CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl	InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)	VERWOWGGCGHDQE-UHFFFAOYSA-N
DFGU82	Carbamazepine	Small molecule	carbamazepine; 298-46-4; Tegretol; Carbamazepen; Finlepsin; Biston; 5H-Dibenzo[b,f]azepine-5-carboxamide; Equetro; Tegretal; 5H-Dibenz[b,f]azepine-5-carboxamide; Carbazepine; Neurotol; Epitol; Timonil; Carbamezepine; Carbatrol; Karbamazepin; Stazepine; Telesmin; Lexin; Tegretol-Xr; benzo[b][1]benzazepine-11-carboxamide; Carbamazepinum; Teril; Geigy 32883; 5H-Dibenz(b,f)azepine-5-carboxamide; Carbamazepin; Carbamazepina; Amizepin; Bipotrol; Carnexiv; Sirtal; 5-Carbamyl-5H-dibenzo(b,f)azepine; 5-Carbamoyl-5H-dibenzo(b,f)azepine; Calepsin; Carbamazepine Anhydrous; 5-Carbamoyl-5H-dibenz(b,f)azepine; 5-Carbamoyl-5H-dibenz[b,f]azepine; G-32883; G 32883; Karbelex; Neurotop; NSC 169864; MFCD00005073; CHEBI:3387; CHEMBL108; NSC-169864; Carbamazepine extended release; 5-Carbamyldibenzo(b,f)azepine; MLS000069652; 5-Carbamoyldibenzo(b,f)azepine; CBZ; DTXSID4022731; NSC169864; 33CM23913M; NCGC00015234-11; CAS-298-46-4; SMR000058201; Stazepin; DTXCID902731; 5H-dibenzo[b,f]azepine-5-carboxamide;Oxcarbazepine IMpurity A; Carbelan; Tegretol Cr; Carbamazepinum [INN-Latin]; Carbamazepina [INN-Spanish]; SMR001227191; HSDB 3019; SR-01000000229; Carbatrol extended-release; EINECS 206-062-7; BRN 1246090; Carbmazepine; Trimonil; Neurotop retard; UNII-33CM23913M; dibenzo[b,f]azepine-5-carboxamide; Tegretol (TN); Prestwick_104; Equetro (TN); Carbamazepine-[d2]; Carbamazepine, powder; Opera_ID_72; Spectrum_000096; Carbamazepine [USAN:USP:INN:BAN:JAN]; Prestwick0_000052; Prestwick1_000052; Prestwick2_000052; Prestwick3_000052; Spectrum2_000125; Spectrum3_000325; Spectrum4_000262; Spectrum5_000936; Carbamazepine (Carbatrol); Lopac-C-4024; ChemDiv1_018966; CARBAMAZEPINE [MI]; CBChromo1_000350; Epitope ID:174842; Iminostilbene-N-carboxamide; CARBAMAZEPINE [INN]; CARBAMAZEPINE [JAN]; CARBAMAZEPINE [HSDB]; CARBAMAZEPINE [USAN]; Carbamazepine-[13C,15N]; Lopac0_000292; Oprea1_790775; SCHEMBL21639; BSPBio_000203; BSPBio_001929; CARBAMAZEPINE [VANDF]; KBioGR_000724; KBioSS_000516; MLS001055475; MLS001074172; MLS002548877; BIDD:GT0479; CARBAMAZEPINE [MART.]; DivK1c_000388; DivK1c_003750; SPECTRUM1500159; SPBio_000170; SPBio_002124; CARBAMAZEPINE [USP-RS]; CARBAMAZEPINE [WHO-DD]; CARBAMAZEPINE [WHO-IP]; BPBio1_000225; GTPL5339; SCHEMBL19838283; HMS501D10; HMS640O02; KBio1_000388; KBio2_000516; KBio2_003084; KBio2_005652; KBio3_001149; WLN: T C676 BNJ BVZ; Carbamazepine (JP17/USP/INN); CBZ;NSC 169864; SPD-417; Carbamazepine, analytical standard; NINDS_000388; HMS1568K05; HMS1920I17; HMS2090M07; HMS2091O19; HMS2095K05; HMS2233G16; HMS3039K09; HMS3259B21; HMS3260L06; HMS3372J13; HMS3657G03; HMS3712K05; HMS3747E03; Pharmakon1600-01500159; CARBAMAZEPINE [ORANGE BOOK]; ACT02606; BCP21380; HY-B0246; 5-Carbomoyl-5H-dibenzo(b,f)azepine; CARBAMAZEPINE [EP MONOGRAPH]; CARBAMAZEPINE [USP IMPURITY]; Tox21_110104; Tox21_202273; Tox21_300195; Tox21_500292; AC2074; BDBM50003659; CARBAMAZEPINE [USP MONOGRAPH]; CCG-38931; NSC755920; s1693; STK177357; STL453548; 11-benzo[b][1]benzazepinecarboxamide; 5H-Dibenz[b,f]azepine-5-carboxamine; Carbamazepine 1.0 mg/ml in Methanol; CARBAMAZEPINUM [WHO-IP LATIN]; AKOS003235644; AKOS025397243; Tox21_110104_1; AC-9538; DB00564; KS-5146; LP00292; NC00679; NSC-755920; SDCCGSBI-0050280.P005; 2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene-2-carboxamide; 5H-Dibenz[ b, f]azepine-5-carboxamide; CDS1_002710; IDI1_000388; 5H-Dibenzo[b,f]azepine-5-carboxamide #; NCGC00015234-01; NCGC00015234-02; NCGC00015234-03; NCGC00015234-04; NCGC00015234-05; NCGC00015234-06; NCGC00015234-07; NCGC00015234-08; NCGC00015234-09; NCGC00015234-10; NCGC00015234-12; NCGC00015234-13; NCGC00015234-14; NCGC00015234-15; NCGC00015234-16; NCGC00015234-18; NCGC00015234-19; NCGC00015234-33; NCGC00023877-03; NCGC00023877-04; NCGC00023877-05; NCGC00023877-06; NCGC00023877-07; NCGC00023877-08; NCGC00253982-01; NCGC00259822-01; NCGC00260977-01; BC166161; SY002823; (z)-5h-dibenzo[b,f]azepine-5-carboxamide; SBI-0050280.P004; 5H-dibenzo[b,f]azepine-5-carboximidic acid; DB-047659; Dibenzo[b,f]azepine-5-carboxylic acid amide; EU-0100292; FT-0602927; FT-0696814; SW220141-1; EN300-21678; OXCARBAZEPINE IMPURITY A [EP IMPURITY]; BIM-0050280.0001; C 4024; C06868; Carbamazepine, meets USP testing specifications; D00252; 5H-Dibenz(b,f)azepine-5-carboxamide maleic acid; 5H-Dibenz(b,f)azepine-5-carboxamide oxalic acid; AB00051931-17; AB00051931-18; AB00051931_19; AB00051931_20; A820074; Q410412; carbamazepine host structure with maleic acid removed; carbamazepine host structure with oxalic acid removed; Q-200792; SR-01000000229-2; SR-01000000229-4; SR-01000000229-7; 5H-Dibenz(b,f)azepine-5-carboxamide DL-tartaric acid; BRD-K71799949-001-06-7; F0348-2551; Z104508594; carbamazepine host structure with DL-tartaric acid removed; Dibenzo[b,f]azepine-5-carboxylic acid amide(Carbamazepine); carbamazepine host structure with 4-hydroxybenzoic acid removed; Carbamazepine, British Pharmacopoeia (BP) Reference Standard; Carbamazepine, European Pharmacopoeia (EP) Reference Standard; Carbamazepine, United States Pharmacopeia (USP) Reference Standard; 2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carboxamide; Carbamazepine, Pharmaceutical Secondary Standard; Certified Reference Material; N6W	Approved	Approved Drug(s)	2554	DB00564	D04MSM	236.27	46.3	326	2.5	18	1	1	0	C15H12N2O	benzo[b][1]benzazepine-11-carboxamide	C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N	C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N	InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)	FFGPTBGBLSHEPO-UHFFFAOYSA-N
DB3CK8	Nifedipine	Small molecule	nifedipine; 21829-25-4; Adalat; Procardia; Procardia XL; Adalat CC; Cordipin; Corinfar; Fenihidine; Citilat; Oxcord; Bay-a-1040; dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Coracten; Fenihidin; Afeditab CR; Adalate; Nifediac; Hexadilat; Introcar; Kordafen; Nifedical; Nifedipinum; Tibricol; Adapine; Anifed; Pidilat; Sepamit; Zenusin; Orix; Adalat LA; BAY A 1040; Nifedipino; 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester; Adipine XL; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester; MFCD00057326; Nifedipine-d4; CCRIS 6074; CHEBI:7565; Nifedipine slow release; 3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; CHEMBL193; NSC-757242; I9ZF7L6G2L; MLS000028521; DTXSID2025715; Dimethyl 1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-3,5-pyridinedicarboxylate; Dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate; Dimethyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate; NCGC00015748-11; Chronadalate; Dignokonstant; Adapress; Afeditab; Aldipin; Alfadal; Angipec; Aprical; Bonacid; Calcibloc; Calcigard; Calcilat; Cardifen; Cardilat; Cardionorm; Cordafen; Cordaflex; Cordalat; Cordicant; Cordilan; Corotrend; Corynphar; Dilafed; Dipinkor; Duranifin; Ecodipi; Ecodipin; Fenamon; Hadipin; Macorel; Megalat; Myogard; Nifecard; Nifecor; Nifedicor; Nifedin; Nifedipres; Nifelan; Nifelat; Nificard; SMR000058291; Alonix; Anpine; Camont; Fedcor; Glopir; Coral; Depin; 1219798-99-8; Alat; Adalat Retard; CAS-21829-25-4; Fedcor Retard; Adalat Crono; Chronadalate LP; Adalat Oros; 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine; Ecodipin E; Apo-Nifed; Nifensar XL; Alonix S; Fenamon SR; Adalat CR; Adalat FT; Adalat LP; Adalat PA; Adalat GITS; Adalat 5; Adalat 10; Adalat 20; DTXCID205715; Adalat GITS 30; Alpha-Nifedipine Retard; Emaberin; Dilcor; Aprical long; Slofedipine XL; Fortipine LA; Nifedical XL; Nifedipinum [INN-Latin]; Tensipine MR; 4-(2-Nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine; Adalate LP; Nifedipino [INN-Spanish]; Adalat XL; 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethylester; Dimethyl 4-(2-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; Procardia (TN); 193689-82-6; Adalat (TN); Afeditab CR (TN); 1173023-46-5; SR-01000075332; BAYa1040; Nifedipine,(S); BAY 1040; KB-1712P; Prestwick_357; EINECS 244-598-3; Nifedipine (Adalat); BRN 0497773; Nifedipine-[13C8]; Spectrum_000979; Tocris-1075; NIFEDIPINE [MI]; NIFEDIPINE [INN]; NIFEDIPINE [JAN]; Opera_ID_1816; Prestwick0_000063; Prestwick1_000063; Prestwick2_000063; Prestwick3_000063; Spectrum2_001058; Spectrum3_000516; Spectrum4_000074; Spectrum5_001278; Lopac-N-7634; NIFEDIPINE [HSDB]; NIFEDIPINE [INCI]; NIFEDIPINE [USAN]; NIFEDIPINE [VANDF]; UNII-I9ZF7L6G2L; Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate; N 7634; cid_4485; NIFEDIPINE [MART.]; SCHEMBL3968; NIFEDIPINE [USP-RS]; NIFEDIPINE [WHO-DD]; NIFEDIPINE [WHO-IP]; BIDD:PXR0034; CBiol_001826; Lopac0_000819; Oprea1_788617; BSPBio_000245; BSPBio_001391; BSPBio_002071; KBioGR_000111; KBioGR_000627; KBioGR_002400; KBioSS_000111; KBioSS_001459; KBioSS_002405; MLS000758222; MLS001148146; MLS001401371; BIDD:GT0442; DivK1c_000313; SPECTRUM1500431; SPBio_001016; SPBio_002166; BPBio1_000271; GTPL2514; Nifedipine (JP17/USP/INN); BAY-a 1040; NIFEDIPINE [ORANGE BOOK]; BCBcMAP01_000046; HMS500P15; HSDB 7775; KBio1_000313; KBio2_000111; KBio2_001459; KBio2_002400; KBio2_002679; KBio2_004027; KBio2_004968; KBio2_005247; KBio2_006595; KBio2_007536; KBio3_000221; KBio3_000222; KBio3_001571; KBio3_002879; NIFEDIPINE [EP MONOGRAPH]; NIFEDIPINE [USP IMPURITY]; cMAP_000042; NINDS_000313; Bio1_000112; Bio1_000601; Bio1_001090; Bio2_000111; Bio2_000591; HMS1361F13; HMS1568M07; HMS1791F13; HMS1920P19; HMS1989F13; HMS2051O03; HMS2089H11; HMS2091H20; HMS2095M07; HMS2233B22; HMS3262D19; HMS3267G06; HMS3393O03; HMS3412E17; HMS3651M19; HMS3676E17; HMS3712M07; HMS3748O21; NIFEDIPINE [USP MONOGRAPH]; Pharmakon1600-01500431; NIFEDIPINUM [WHO-IP LATIN]; ACT02669; BCP21147; HY-B0284; L-Type Calcium Channel Blocker III; Tox21_110212; Tox21_200304; Tox21_500819; BBL023163; BDBM50000778; BDBM50101817; CCG-40115; HB1228; NSC757242; NSC786036; s1808; STK735567; AKOS002942507; AKOS037515769; Nifedipine - CAS 21829-25-4; Nifedipine, >=98% (HPLC), powder; Tox21_110212_1; AC-8061; CCG-100758; DB01115; KS-1456; LP00819; NC00008; Nifedipine [USAN:USP:INN:BAN:JAN]; NSC 757242; NSC-786036; SDCCGSBI-0050796.P005; 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethylester [German]; IDI1_000313; IDI1_033861; Bay-1040;Bay 1040;Bay1040; NCGC00015748-01; NCGC00015748-02; NCGC00015748-03; NCGC00015748-04; NCGC00015748-05; NCGC00015748-06; NCGC00015748-07; NCGC00015748-08; NCGC00015748-09; NCGC00015748-10; NCGC00015748-12; NCGC00015748-13; NCGC00015748-14; NCGC00015748-15; NCGC00015748-17; NCGC00015748-33; NCGC00021710-02; NCGC00024983-01; NCGC00024983-02; NCGC00024983-03; NCGC00024983-04; NCGC00024983-05; NCGC00024983-06; NCGC00024983-07; NCGC00024983-08; NCGC00091707-01; NCGC00091707-02; NCGC00091707-03; NCGC00257858-01; NCGC00261504-01; BN166183; CPD000058291; SY074220; SBI-0050796.P004; EU-0100819; FT-0630478; FT-0653833; FT-0672727; N0528; SW219724-1; BIM-0050796.0001; C07266; D00437; EN300-120627; Q39111; AB00052051-05; AB00052051_06; AB00052051_07; 5-22-04-00268 (Beilstein Handbook Reference); A899873; L001054; Q-201471; SR-01000075332-1; SR-01000075332-3; SR-01000075332-4; SR-01000075332-6; BRD-K96354014-001-01-3; BRD-K96354014-001-10-4; Z90350374; F2173-0802; Nifedipine, British Pharmacopoeia (BP) Reference Standard; Nifedipine, European Pharmacopoeia (EP) Reference Standard; Nifedipine, United States Pharmacopeia (USP) Reference Standard; 2,6-Dimethyl-3,5-dicarbomethoxy-4-(2-nitrophenyl)-1,4-dihydropyridine; 4-(2'-nitrophenyl)-2,6 dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridine; 4-(2'-nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridine; Nifedipine, Pharmaceutical Secondary Standard; Certified Reference Material; 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylicaciddimethylester; 2,6-dimethyl-4-(2nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3,5-dimethyl ester; Dimethyl (4-(2-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate); Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate #; dimethyl2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 101539-70-2; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester (9CI); 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-, dimethyl ester (8CI)	Approved	Approved Drug(s)	4485	DB01115	D04OSE	346.3	110	608	2.2	25	1	7	5	C17H18N2O6	dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate	CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC	CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC	InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3	HYIMSNHJOBLJNT-UHFFFAOYSA-N
DKNX46	Olodaterol	Small molecule	OLODATEROL; 868049-49-4; Olodaterol Free Base; BI 1744; BI-1744; Striverdi; CHEBI:82700; VD2YSN1AFD; 6-Hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one; 868049-49-4 (free base); (R)-6-hydroxy-8-(1-hydroxy-2-((1-(4-methoxyphenyl)-2-methylpropan-2-yl)amino)ethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one; 6-Hydroxy-8-((1R)-1-hydroxy-2-((2-(4-methoxyphenyl)-1,1-dimethylethyl)amino)ethyl)-2H-1,4-benzoxazin-3(4H)-one; 6-hydroxy-8-[(1R)-1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4H-1,4-benzoxazin-3-one; Striverdi respimat (TN); 6-hydroxy-8-[(1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino}ethyl]-3,4-dihydro-2H-1,4-benzoxazin-3-one; UNII-VD2YSN1AFD; Olodaterol [USAN:INN]; 6-HYDROXY-8-((1R)-1-HYDROXY-2-((1-(4-METHOXYPHENYL)-2-METHYLPROPAN-2-YL)AMINO)ETHYL)-2H-1,4-BENZOXAZIN-3(4H)-ONE; 6-hydroxy-8-[(1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino}ethyl]-2H-1,4-benzoxazin-3(4H)-one; OLODATEROL [MI]; OLODATEROL [INN]; Olodaterol (USAN/INN); OLODATEROL [USAN]; OLODATEROL [VANDF]; Olodaterol (BI 1744); OLODATEROL [WHO-DD]; SCHEMBL560926; CHEMBL605846; GTPL7543; DTXSID601024792; AMY16614; BCP11473; EX-A1729; BDBM50569861; BI1744; s4485; OLODATEROL HYDROCHLORIDE [JAN]; CS-6275; DB09080; NCGC00522533-01; AC-29048; AS-74944; HY-14301; C76830; D10145; EN300-20331067; Q7088466; 2H-1,4-Benzoxazin-3(4H)-one, 6-hydroxy-8-((1R)-1-hydroxy-2-((2-(4-methoxyphenyl)- 1,1-dimethylethyl)amino)ethyl)-; 2H-1,4-BENZOXAZIN-3(4H)-ONE, 6-HYDROXY-8-((1R)-1-HYDROXY-2-((2-(4-METHOXYPHENYL)-1,1-DIMETHYLETHYL)AMINO)ETHYL)-; 6-hydroxy-8-(1-hydroxy-2-((2-(4-methoxyphenyl)-1,1-dimethylethyl)amino)ethyl)-2H-1,4-benzoxazin-3(4H)-one	Approved	Approved Drug(s)	11504295	DB09080	D04UTT	386.4	100	521	1.8	28	4	6	7	C21H26N2O5	6-hydroxy-8-[(1R)-1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4H-1,4-benzoxazin-3-one	CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=C3C(=CC(=C2)O)NC(=O)CO3)O	CC(C)(CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C(=CC(=C2)O)NC(=O)CO3)O	InChI=1S/C21H26N2O5/c1-21(2,10-13-4-6-15(27-3)7-5-13)22-11-18(25)16-8-14(24)9-17-20(16)28-12-19(26)23-17/h4-9,18,22,24-25H,10-12H2,1-3H3,(H,23,26)/t18-/m0/s1	COUYJEVMBVSIHV-SFHVURJKSA-N
DQ8G9M	Lithium Carbonate	Small molecule	LITHIUM CARBONATE; 554-13-2; Dilithium carbonate; Lithonate; Lithobid; Lithane; Carbonic acid, dilithium salt; Eskalith; Lithotabs; Carbonic acid lithium salt; Liskonum; Lithizine; Micalith; Priadel; Limas; Eskalith CR; Camcolit; Carbolitium; Neurolepsin; Lithium carbonicum; NSC-16895; Candamide; Carbolith; Eutimin; Hypnorex; Lithicarb; Lithinate; Lithionate; Liticar; Manialith; Maniprex; Litard; Lithea; Plenur; Quilonum retard; Pfi-lithium; Lithium Phasal; Pfl-Lithium; Litho-Carb; CP-15467-61; Lithium carbonate (Li2CO3); CP-15,467-61; MFCD00011084; 2BMD2GNA4V; CHEBI:6504; Carbonic acid lithium salt (Li2CO3); Lithium carbonate (2:1); CP 15467-61; Ceglution; Phasal; CP-1546761; Teralithe [French]; Carbolithium; Teralithe; dilithium;carbonate; Li2 (C O3); Carbonic Acid Dilithium Salt; CCRIS 3153; HSDB 3351; EINECS 209-062-5; UNII-2BMD2GNA4V; Carbolithium IFI; Lithium QD; Eskalith (TN); Lithobid (TN); Lithium carbonate [USAN:USP:JAN]; starbld0023766; Lithium Carbonate Powder; Li2CO3; dilithium trioxidocarbonate; EC 209-062-5; LITHIUM CARBONATE [MI]; LITHIUM CARBONATE [JAN]; CHEMBL1200826; DTXSID1023784; Lithium carbonate (JP17/USP); LITHIUM CARBONATE [HSDB]; LITHIUM CARBONATE [INCI]; LITHIUM CARBONATE [USAN]; LITHIUM CARBONATE [VANDF]; LITHIUM CARBONICUM [HPUS]; LITHIUM CARBONATE [MART.]; LITHIUM CARBONATE [USP-RS]; LITHIUM CARBONATE [WHO-DD]; LITHIUM CARBONATE [WHO-IP]; STR02638; Carbonic acid, lithium salt (1:2); DILITHIUM CARBONATE [WHO-IP]; Lithium carbonate, ACS reagent grade; AKOS015904647; ANGC-554-13-2; DB14509; LITHII CARBONAS [WHO-IP LATIN]; LITHIUM CARBONATE [ORANGE BOOK]; LITHIUM CARBONATE [EP MONOGRAPH]; LITHIUM CARBONATE [USP MONOGRAPH]; FT-0627895; L0224; C07964; D00801; Dilithium Carbonate, Dilithium Salt, Carbonic Acid; Q410174; Z608344424	Approved	Approved Drug(s)	11125	DB14509	D04UUH	73.9	63.2	18.8	.	6	0	3	0	CLi2O3	dilithium;carbonate	[Li+].[Li+].C(=O)([O-])[O-]	[Li+].[Li+].C(=O)([O-])[O-]	InChI=1S/CH2O3.2Li/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2	XGZVUEUWXADBQD-UHFFFAOYSA-L
D70GRS	Menotropins	Small molecule	Human Menopausal Gonadotrophin; 6,6-dimethylheptanal; Menotrophin; 61489-71-2; MENOTROPINS; SCHEMBL1784550; AKOS013847259; Gonadotropin from human menopausal urine; EN300-1838362; 187244-57-1	Approved	Approved Drug(s)	21888462	DB00032	D04WBY	142.24	17.1	89.4	3	10	0	1	5	C9H18O	6,6-dimethylheptanal	CC(C)(C)CCCCC=O	CC(C)(C)CCCCC=O	InChI=1S/C9H18O/c1-9(2,3)7-5-4-6-8-10/h8H,4-7H2,1-3H3	CBUWTGCATVNMJE-UHFFFAOYSA-N
DHK6X4	Nortriptyline	Small molecule	nortriptyline; Aventyl; 72-69-5; Desitriptilina; Noramitriptyline; Lumbeck; Desmethylamitriptyline; Noritren; Sensaval; Ateben; Avantyl; Demethylamitriptyline; Sesaval; Pamelor; Demethylamitryptyline; Nortrilen; Nortriptylinum; Amitryptyline, demethyl-; Psychostyl; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methyl-; Aventyl;Desitriptilina; Nortriptyline (INN); 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine; Nortryptiline; Nortryptyline; BL03SY4LXB; Pamelor hydrochloride; NSC-757234; 5-(3-Methylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; CHEBI:7640; Nortriptylene hydrochloride; 5-(3-(Methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene; 10,11-Dihydro-5-(3-methylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptene; 10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methylpropylamine; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-; NCI-169453; Nortriptilina; Nortriptilina [DCIT]; NSC169453; NORTRIPTYLINE [INN]; Nortriptyline [INN:BAN]; Demethylamitriptylene; Nortriptylinum [INN-Latin]; 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine; Nortrilen (TN); NSC78248; CCRIS 9175; CAS-894-71-3; EINECS 200-788-8; UNII-BL03SY4LXB; BRN 2216786; nortriptylina; 5-[3-(Methylamino)propylidene]dibenzo[a,E]cyclohepta[1,5]diene; HSDB 3371; Triptyline-M nor; 10,11-Dihydro-5-(3-methylaminopropylidene)-5H-dibenzo[a,d][1,4]cycloheptene; 3-(10,11-DIHYDRO-5H-DIBENZO(A,D)(7)ANNULEN-5-YLIDENE)-N-METHYLPROPAN-1-AMINE; 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methylpropylamine; 5-(alpha-Methylaminopropylidene)dibenzo(a,d)cyclohepta(1,4)diene; N-Methyl-3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)propylamin; NCI169453; Spectrum_001041; Psychostyl (Salt/Mix); Prestwick0_000254; Prestwick1_000254; Prestwick2_000254; Prestwick3_000254; Spectrum2_000997; Spectrum3_000526; Spectrum4_000455; Spectrum5_001377; Lopac-N-7261; NORTRIPTYLINE [MI]; CHEMBL445; NCIStruc1_000856; NCIStruc2_000700; 5H-Dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-N-methyl-; NCIOpen2_004361; BIDD:PXR0187; Lopac0_000868; SCHEMBL34527; BSPBio_000068; BSPBio_002111; KBioGR_000870; KBioSS_001521; NORTRIPTYLINE [VANDF]; DivK1c_000151; SPECTRUM1500442; SPBio_001093; SPBio_002287; NORTRIPTYLINE [WHO-DD]; BPBio1_000076; GTPL2404; DTXSID9023384; HMS500H13; KBio1_000151; KBio2_001521; KBio2_004089; KBio2_006657; KBio3_001611; NINDS_000151; BDBM112777; HMS1920B20; HMS2091J20; KUC112478N; Pharmakon1600-01500442; CCG-38266; NCGC00014483; NSC757234; PDSP1_001805; PDSP2_001788; DB00540; NSC 757234; SDCCGSBI-0050843.P006; (2)10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-.delta.5.gamma.-propylamine; IDI1_000151; MRF-0000480; QTL1_000063; NCGC00014483-02; NCGC00014483-03; NCGC00014483-04; NCGC00014483-05; NCGC00014483-06; NCGC00014483-07; NCGC00014483-08; NCGC00014483-09; NCGC00014483-10; NCGC00014483-11; NCGC00014483-12; NCGC00014483-14; NCGC00014483-16; NCGC00014483-23; NCGC00024261-03; NCGC00024261-04; NCGC00024261-05; NCGC00024261-06; KSC-315-028-; methyl({3-[(2E)-tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene]propyl})amine; MS-23718; N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine; NCI60_001354; SBI-0050843.P004; US8629135, SW-02; HY-118620; AB00052061; CS-0067638; EN300-57709; C07274; D08288; F82279; Q61387; AB00052061_16; SR-01000000223-4; BRD-K91263825-003-03-2; AMITRIPTYLINE HYDROCHLORIDE IMPURITY C [EP IMPURITY]; 10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptane-.DELTA.,.gamma.-propylamine; 10,11-DIHYDRO-N-METHYL-5H-DIBENZO(A,D)CYCLOHEPTENE-D(SUP5,.GAMMA.)-PROPYLAMINE; 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta5,gamma-propylamine; 3-(5,6-dihydrodibenzo[[?],[?]][7]annulen-11-ylidene)-N-methyl-propan-1-amine; 5H-Dibenzo[a,d]cycloheptene-.DELTA.5,.gamma.-propylamine, 10,11-dihydro-N-methyl-; 21B; methyl({3-[(2E)-tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene]propyl})amine; methyl(3-{tricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine	Approved	Approved Drug(s)	4543	DB00540	D04WFD	263.4	12	307	4.5	20	1	1	3	C19H21N	N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine	CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31	CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31	InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3	PHVGLTMQBUFIQQ-UHFFFAOYSA-N
DVS4X9	Benznidazole	Small molecule	BENZNIDAZOLE; 22994-85-0; Radanil; Benznidazol; Benzonidazole; benzonidazol; Benznidazolum; Rochagan; Ro 07-1051; N-benzyl-2-(2-nitroimidazol-1-yl)acetamide; 1H-Imidazole-1-acetamide, 2-nitro-N-(phenylmethyl)-; N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide; N-Benzyl-2-nitroimidazole-1-acetamide; N-Benzyl-2-nitro-1H-imidazole-1-acetamide; N-Benzyl-2-nitroimidazol-1-yl-acetamide; 2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamide; Ro 71051; Imidazole-1-acetamide, N-benzyl-2-nitro-; YC42NRJ1ZD; CHEMBL110; NSC-299972; Ro-7-1051; DTXSID9046570; MMV688773; NSC299972; NCGC00166238-01; Ro 07-1051;Ro 71051; RO-07-1051; Benznidazol (Ro 07-1051; Ro 71051); Benznidazole [INN]; DTXCID7026570; Benznidazol [INN-Spanish]; Benznidazolum [INN-Latin]; SMR000857153; NSC 299972; CAS-22994-85-0; CCRIS 2200; SR-01000841264; UNII-YC42NRJ1ZD; N-benzyl-2-nitro-1-imidazoleacetamide; BRN 0551486; Ragonil; Acetamide, N-benzyl-2-(nitroimidazol-1-yl)-; benznidazole (TN); Rochagan (TN); Radanil (TN); BENZNIDAZOLE [MI]; Benznidazole (USAN/INN); Benznidazole [USAN:INN]; BENZNIDAZOLE [USAN]; SCHEMBL45081; BENZNIDAZOLE [MART.]; MLS001332409; MLS001332410; MLS001360496; BENZNIDAZOLE [WHO-DD]; BENZNIDAZOLE [WHO-IP]; SCHEMBL22493029; CHEBI:133833; BENZNIDAZOLE [ORANGE BOOK]; HMS2233G13; HMS3369C11; HY-B1548; Tox21_112364; BDBM50089916; BENZNIDAZOLUM [WHO-IP LATIN]; MFCD00243089; s3741; AKOS015916722; AKOS024283499; Tox21_112364_1; CCG-267054; DB11989; NCGC00166238-02; AS-68694; CS-0013411; FT-0662547; C74184; D02489; N-Benzyl-2-(2-nitro-imidazol-1-yl)-acetamide; EN300-1716737; N-benzyl-2-(2-nitro-1Himidazol-1-yl)acetamide; A912716; N-benzyl-2-(2-nitro-1H-imidazol-5-yl)acetamide; N-Benzyl-2-nitro-1H-imidazole-1-acetamide, 97%; Q425300; 2-(2-nitroimidazol-1-yl)-N-(phenylmethyl)acetamide; J-014932; SR-01000841264-3; SR-01000841264-4; 1H-Imidazole-1-acetamide,2-Nitro-n-(phenylmethyl)-; BRD-K56156805-001-05-4; 1H-Imidazole-1-acetamide, 2-nitro-N-(phenylmethyl)- [; Z2044771577; N-Benzyl-2-(2-nitro-imidazol-1-yl)-acetamide (Benznidazole); Pyridinium,1-dodecyl-2-[(hydroxyimino)methyl]-,iodide(1:1)	Approved	Approved Drug(s)	31593	DB11989	D04XGT	260.25	92.7	325	0.9	19	1	4	4	C12H12N4O3	N-benzyl-2-(2-nitroimidazol-1-yl)acetamide	C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-]	C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-]	InChI=1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)	CULUWZNBISUWAS-UHFFFAOYSA-N
D9ELO0	Hypertonic saline	Small molecule	sodium chloride; 7647-14-5; Salt; Table salt; Halite; Saline; Rock salt; Common salt; Dendritis; Purex; Sodium chloric; Iodized salt; Top flake; Sodium chloride (NaCl); Hyposaline; Sodium monochloride; Flexivial; Gingivyl; Slow Sodium; Sea salt; NaCl; SS salt; sodiumchloride; Natriumchlorid; Adsorbanac; Hypersal; sodium;chloride; Trisodium trichloride; White crystal; H.G. blending; Salt (ingredient); Colyte; Isotonic saline; Sodium chloride (Na4Cl4); Caswell No. 754; Normal saline; Natrum Muriaticum; Extra Fine 200 Salt; Extra Fine 325 Salt; Sodium chloride brine, purified; Arm-A-Vial; CCRIS 982; Dendritic salt; HSDB 6368; EPA Pesticide Chemical Code 013905; 14762-51-7; MFCD00003477; NSC-77364; Sodium chloride, hypertonic; LS-1700; 10% Sodium Chloride Injection; CHEBI:26710; 451W47IQ8X; Ayr; Sodium chloride, ultra dry; Natriumchlorid [German]; Broncho saline; Halite (NaCl); Sodium chloride, ACS reagent, >=99.0%; Sodium-36 chloride; EINECS 231-598-3; NSC 77364; Sodium chloride (Na36Cl); Sodium chloride [USP:JAN]; Isotonic; Kochsalz; Mafiron; Rocksalt; Titrisol; cloruro sodico; sodium-chloride; Solsel; UNII-451W47IQ8X; natrii chloridum; Sea water; Watesal A; Uzushio Biryuu M; chlorure de sodium; Adsorbanac (TN); Brinewate Superfine; Sodium chloride in plastic container; sodium chloride salt; Canners 999; Sodium Chloride ACS; NaCl Solution, 1M; 0.9% saline; Sodium chloride 3% in plastic container; Sodium chloride 5% in plastic container; SUPRASEL NITRITE; Saline, sodium chloride; Sodium chloride, tablet; Sodium chloride (8CI); Sodium chloride 0.9% in plastic container; mono-sodium chloride salt; 0.9% nacl; Sodium chloride 0.45% in plastic container; Sodium chloride 23.4% in plastic container; Sodium chloride, isotonic; UNII-VR5Y7PDT5W; Salt (6CI,7CI); VR5Y7PDT5W; Special Salt 100/95; Nacl 0.9%; WLN: NA G; EC 231-598-3; SODIUM CHLORIDE [II]; SODIUM CHLORIDE [MI]; Sodium chloride 0.9% in sterile plastic container; Sodium chloride, ACS reagent; B1655 [LANGUAL]; SODIUM CHLORIDE [JAN]; RNS60 COMPONENT SALINE; Sodium chloride (JP17/USP); SODIUM CHLORIDE [HSDB]; SODIUM CHLORIDE [INCI]; Sodium chloride, Optical Grade; SODIUM CHLORIDE [VANDF]; SODIUM CHLORIDE ANHYDROUS; Bacteriostatic sodium chloride 0.9% in plastic container; CHEMBL1200574; DTXSID3021271; NATRUM MURIATICUM [HPUS]; RNS-60 COMPONENT SALINE; Isotonic sodium chloride solution; Sodium chloride biochemical grade; 7647-14-5 (solid); SODIUM CHLORIDE [USP-RS]; SODIUM CHLORIDE [WHO-DD]; SODIUM CHLORIDE [WHO-IP]; SODIUM CHLORIDE, ANHYDROUS; NSC77364; Sodium chloride, AR, >=99.9%; Sodium chloride, LR, >=99.5%; Sodium chloride, Spectroscopy Grade; STR02627; Sodium chloride, MANAC Incorporated; SODIUM CHLORIDE [GREEN BOOK]; Sodium chloride, >=99%, AR grade; SODIUM CHLORIDE [ORANGE BOOK]; AKOS024438089; AKOS024457457; SODIUM CHLORIDE [EP MONOGRAPH]; SODIUM CHLORIDE, BACTERIOSTATIC; DB09153; SODIUM CHLORIDE [USP MONOGRAPH]; Sodium chloride, technical grade, 95%; Sodium chloride, technical grade, 97%; NATRII CHLORIDUM [WHO-IP LATIN]; Sodium chloride, Ph. Eur., USP grade; Sodium chloride, p.a., 99-100.5%; 32343-72-9; Sodium chloride, NIST(R) SRM(R) 919b; Sodium chloride, ReagentPlus(R), >=99%; Sodium chloride, USP, 99.0-100.5%; Sodium chloride, USP, 99.0-101.0%; FT-0645114; Q2314; S0572; Sodium chloride, BioXtra, >=99.5% (AT); Sodium chloride, SAJ first grade, >=99.0%; Sodium chloride, tested according to Ph.Eur.; D02056; Sodium chloride, 99.999% trace metals basis; Sodium chloride, JIS special grade, >=99.5%; Sodium chloride, Trace metals grade, 99.99%; Isotopic standard for chlorine, NIST SRM 975a; Sodium chloride, Vetec(TM) reagent grade, 99%; Sodanylium and hydrochloric acid, ion(1-) (1:1); Sodium chloride, puriss. p.a., >=99.5% (AT); Sodium chloride, NIST(R) SRM(R) 2201, ion-selective; Sodium chloride crystal optic disc, 13mm x 2mm, unpolished; Sodium chloride crystal optic disc, 25mm x 5mm, unpolished; Sodium chloride crystal optic disc, 32mm x 3mm, unpolished; Sodium chloride crystal optic disc, 13mm x 1mm, polished both sides; Sodium chloride crystal optic disc, 13mm x 2mm, polished both sides; Sodium chloride crystal optic disc, 22mm x 4mm, polished both sides; Sodium chloride crystal optic disc, 25mm x 2mm, polished both sides; Sodium chloride crystal optic disc, 25mm x 4mm, polished both sides; Sodium chloride crystal optic disc, 32mm x 3mm, polished both sides; Sodium chloride crystal optic disc, 38mm x 6mm, polished both sides; Sodium chloride, BioUltra, for molecular biology, >=99.5% (AT); Sodium chloride, puriss. p.a., >=99.5% (AT), powder or crystals; Sodium chloride, reagent grade, >=98%, +80 mesh particle size; Sodium chloride, United States Pharmacopeia (USP) Reference Standard; Sodium standard for AAS, ready-to-use, traceable to BAM, in H2O; Sodium chloride crystal optic rectangle, 30mm x 15mm x 4mm, unpolished; Sodium chloride crystal optic rectangle, 38.5mm x 19.5mm x 4mm, unpolished; Sodium chloride crystal optic rectangle, 41mm x 23mm x 6mm, unpolished; Sodium chloride, anhydrous, beads, -10 mesh, 99.99% trace metals basis; Sodium chloride, anhydrous, beads, -10 mesh, 99.999% trace metals basis; Sodium chloride, p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.5%; Sodium chloride, random crystals, optical grade, 99.98% trace metals basis; Sodium chloride crystal optic disc, 32mm x 3mm (drilled), polished both sides; Sodium chloride crystal optic rectangle, 30mm x 15mm x 4mm (drilled), polished both sides; Sodium chloride crystal optic rectangle, 30mm x 15mm x 4mm, polished both sides; Sodium chloride crystal optic rectangle, 38.5mm x 19.5mm x 4mm, polished both sides; Sodium chloride, anhydrous, free-flowing, Redi-Dri(TM), ReagentPlus(R), >=99%; Sodium chloride, anhydrous, Redi-Dri(TM), free-flowing, ACS reagent, >=99%; Sodium chloride, BioPerformance Certified, >=99% (titration), Cell Culture Tested; Sodium chloride, meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%; Sodium chloride, Pharmaceutical Secondary Standard; Certified Reference Material; Sodium chloride, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., >=99.5%; Sodium chloride crystal optic rectangle, 38.5mm x 19.5mm x 4mm (drilled), polished both sides; Sodium chloride, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=99%; Sodium chloride, certified reference material for titrimetry, certified by BAM, according to ISO 17025, >=99.5%; Sodium chloride, for molecular biology, DNase, RNase, and protease, none detected, >=98% (titration)	Approved	Approved Drug(s)	5234	DB09153	D04YZL	58.44	0	2	.	2	0	1	0	ClNa	sodium;chloride	[Na+].[Cl-]	[Na+].[Cl-]	InChI=1S/ClH.Na/h1H;/q;+1/p-1	FAPWRFPIFSIZLT-UHFFFAOYSA-M
DIJ21E	Azilsartan	Small molecule	Azilsartan; 147403-03-0; TAK-536; TAK 536; Azilsartan (TAK-536); CHEMBL57242; F9NUX55P23; TAK536; 2-ethoxy-3-[[4-[2-(5-oxo-2H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid; CHEBI:68850; 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylic acid; 1H-Benzimidazole-7-carboxylic acid, 1-((2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol- 3-yl)(1,1'-biphenyl)-4-yl)methyl)-2-ethoxy-; 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid; 2-Ethoxy-3-[2'-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid; Azilsartan [USAN]; Azilsartan [USAN:INN]; UNII-F9NUX55P23; HSDB 8208; Azilsartan- Bio-X; Azilsartan free acid; Azilva (TN); AZILSARTAN [MI]; AZILSARTAN [INN]; AZILSARTAN [JAN]; AZILSARTAN [VANDF]; AZILSARTAN [MART.]; AZILSARTAN [WHO-DD]; 2-Ethoxy-1-[[2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic Acid; Azilsartan (JAN/USAN/INN); SCHEMBL167538; GTPL6901; Azilsartan, >=98% (HPLC); AMY4360; DTXSID70163712; HMS3651J16; HMS3747I09; BCP03826; WDC59945; BDBM50055441; CX1016; MFCD20278186; s3046; AKOS007930882; AKOS024458220; AM84439; BCP9000002; CCG-269296; CS-1396; KS-5381; SB20804; NCGC00386206-03; NCGC00386206-04; 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic Acid; 2-Ethoxy-1-((2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylic acid; AC-25912; BA164233; HY-14914; BCP0726000135; DB-063707; FT-0662457; FT-0662458; SW219493-1; D08864; AB01566867_01; EN300-6482027; L001451; Q27074832; Z1575099375; 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl) [1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid; 2-ETHOXY-1-((2'-(5-OXO-2,5-DIHYDRO-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-YL)METHYL)-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID; 2-Ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)- 1H-benzimidazole-7-carboxylic acid; 2-Ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid; 2-Ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl4-yl]methyl]benzimidazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-1,3-benzodiazole-7-carboxylic acid; 2-Ethoxy-3-[2''-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid; 2-Ethoxy-3-[2'-(5-oxo-2,5-dihydro-[1,2,4]oxadiazol-3-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid	Approved	Approved Drug(s)	135415867	DB08822	D05FGG	456.4	115	783	4.4	34	2	7	7	C25H20N4O5	2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid	CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O	CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O	InChI=1S/C25H20N4O5/c1-2-33-24-26-20-9-5-8-19(23(30)31)21(20)29(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-25(32)34-28-22/h3-13H,2,14H2,1H3,(H,30,31)(H,27,28,32)	KGSXMPPBFPAXLY-UHFFFAOYSA-N
DYC3N6	Tramadol	Small molecule	Tramadol; (+)-Tramadol; 27203-92-5; 123154-38-1; Tramadolum [INN-Latin]; cis-Tramadol; 181289-58-7; Tramadol, (+)-; 0NG5TTM63P; (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol; 39J1LGJ30J; CHEBI:75725; Ralivia flashtab; (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol; Tramadol (INN); Ralivia ER; Ryzolt; Tramadon; Zytram; TRAMADOL [INN]; (+)-trans-2-(Dimethylaminomethyl)-1-(m-methoxyphenyl)cyclohexanol; Racemic tramadol; Amanda; Tramadolum; Biomadol; Contramid; Labesfal; Tradolan; Tramadis; Tramadol [INN:BAN]; Tramaliv; Trapidol; CHEMBL201531; Tradonal odis; (1R,2R)-2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol; Tramadol Contramid; CG-315E; (+-)-Tramadol; (+/-)-tramadol; NCGC00159343-02; EINECS 248-319-6; (+)-(R,R)-trans-; ETS6103; UNII-39J1LGJ30J; Tiparol; cis tramadol; ETS-6103; (+)-trans-Tramadol free base; Rel-Tramadol; (1R,2R)-2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexan-1-ol; CG 315E; (r,r)-tramadol; U-26255A; (R,R) tramadol; Amanda (TN); E-265; U 26255A; Cyclohexanol, 2-((dimethylamino)methyl)-1-(m-methoxyphenyl)-; TRAMADOL [JAN]; TRAMADOL [MI]; TRAMADOL [VANDF]; sustained-release tramadol; E 265; E 382; TRAMADOL [WHO-DD]; UNII-0NG5TTM63P; Cyclohexanol, 2-((dimethylamino)methyl)-1-(3-methoxyphenyl)-, cis-(+-)-; SCHEMBL7464; CHEMBL1066; MLS000333190; BIDD:GT0075; (+)-(R,R)-TRAMADOL; HSDB 7047; DTXSID90858931; DTXSID401167150; HMS2090D10; HMS2803D04; BDBM50176259; Cyclohexanol, 2-((dimethylamino)-1-(3-methoxyphenyl)-, cis-(+-)-; AKOS005066335; Cyclohexanol, 2-(dimethylaminomethyl)-1-(m-methoxyphenyl)-, (+)-(E)-; Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, (1R,2R)-rel-; DB00193; SMR000436547; FT-0604438; FT-0675346; C07153; D08623; AB00640024-11; Q407592; (1R,2R)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol; (1R,2R)-2-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexanol; (1R,2R)-2-[(dimethylamino)methyl]-1-[3-(methyloxy)phenyl]cyclohexanol; Cyclohexanol-2-((dimethylamino)methyl)-1-(3-methoxyphenyl)-, trans-(+-)-; (+/-)-CIS-2-((DIMETHYLAMINO)METHYL)-1-(M-METHOXYPHENYL)CYCLOHEXANOL	Approved	Approved Drug(s)	33741	DB00193	D05GKD	263.37	32.7	282	2.6	19	1	3	4	C16H25NO2	(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol	CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O	CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O	InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1	TVYLLZQTGLZFBW-ZBFHGGJFSA-N
DFN30Z	Linagliptin	Small molecule	Linagliptin; 668270-12-0; Tradjenta; BI 1356; BI-1356; Ondero; Linagliptin (BI-1356); Trajenta; Trazenta; BI-1356-BS; BS 1356 BS; ione; 3X29ZEJ4R2; CHEMBL237500; (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione; BI-1356BS; CHEBI:68610; BI 1356 BS; BS-1356-BS; (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-ynyl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione; (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione; 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione; 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione; 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione; 8-[(3r)-3-Aminopiperidin-1-Yl]-7-But-2-Yn-1-Yl-3-Methyl-1-[(4-Methylquinazolin-2-Yl)methyl]-3,7-Dihydro-1h-Purine-2,6-Dione; C25H28N8O2; UNII-3X29ZEJ4R2; Linaglitpin; Linagliptin [USAN:INN:JAN]; HSDB 8204; Tradjenta (TN); 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione; LINAGLIPTIN [MI]; LINAGLIPTIN [INN]; LINAGLIPTIN [JAN]; LINAGLIPTIN [USAN]; LINAGLIPTIN [VANDF]; LINAGLIPTIN [MART.]; LINAGLIPTIN [WHO-DD]; MLS006010217; SCHEMBL160188; Linagliptin (JAN/USAN/INN); GTPL6318; AMY8953; EX-A076; LINAGLIPTIN [ORANGE BOOK]; BCPP000185; DTXSID201021653; BCP02462; BDBM50228403; GLYXAMBI COMPONENT LINAGLIPTIN; MFCD14635356; s3031; AKOS015951179; AKOS015995251; AC-8761; BCP9000854; CCG-269463; CS-0637; DB08882; LINAGLIPTIN COMPONENT OF GLYXAMBI; TRIJARDY XR COMPONENT LINAGLIPTIN; NCGC00346655-01; NCGC00346655-02; 1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-; AS-35080; BL164627; HY-10284; JENTADUETO COMPONENT OF LINAGLIPTIN; LINAGLIPTIN COMPONENT OF JENTADUETO; SMR004701306; LINAGLIPTIN COMPONENT OF TRIJARDY XR; SW219813-1; D09566; AB01563307_01; AB01563307_03; EN300-6481354; Q909745; J-519354; Z2235801970; (R)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione; (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione; 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)xanthine; 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)aminopiperidin-1-yl)xanthine; 1-[(4-methyl-quinazolin-2yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R) amino-piperidin-1-yl]-xanthine; 1-[(4-Methylquinazolin-2-yl)-methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine; 1-[(4-Methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine; 1233245-11-8; 1H-PURINE-2,6-DIONE, 8-((3R)-3-AMINO-1-PIPERIDINYL)-7-(2-BUTYNYL)-3,7-DIHYDRO-3-METHYL-1-((4-METHYL-2- QUINAZOLINYL)METHYL)-; 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 8-[(3R)-3-Aminopiperidin-1-yl]-7-but-2-yn-1-yl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-d ione; Linagliptin; (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione	Approved	Approved Drug(s)	10096344	DB08882	D05JAC	472.5	114	885	1.9	35	1	7	4	C25H28N8O2	8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione	CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C	CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C	InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1	LTXREWYXXSTFRX-QGZVFWFLSA-N
D3VMZ0	Ticlopidine	Small molecule	ticlopidine; 55142-85-3; 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; Ticlid; Ticlopidinum; Ticlopidina; Ticlopidin-Puren; PCR 5332; 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine; Ticlopidine (INN); 5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine; 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; OM90ZUW7M1; CHEBI:9588; DTXSID5023669; 5-[(2-chlorophenyl)methyl]-4H,5H,6H,7H-thieno[3,2-c]pyridine; Thieno(3,2-c)pyridine, 4,5,6,7-tetrahydro-5-((2-chlorophenyl)methyl)-; Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-; PCR 5332; Ticlid; Ticlop;Tiklyd; NCGC00016872-06; TICLOPIDINE [INN]; Ticlopidine [INN:BAN]; Ticlopidinum [INN-Latin]; Ticlopidina [INN-Spanish]; DTXCID903669; Thieno(3,2-c)pyridine, 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydro-; UNII-OM90ZUW7M1; SMR000641861; CAS-55142-85-3; Ticlopidin-Puren (TN); EINECS 259-498-5; BRN 1216802; TICLOPIDINE [MI]; Prestwick0_000047; Prestwick1_000047; Prestwick2_000047; Prestwick3_000047; CHEMBL833; TICLOPIDINE [VANDF]; SCHEMBL4204; BIDD:PXR0169; BSPBio_000173; TICLOPIDINE [WHO-DD]; MLS001201825; MLS006011439; SPBio_002094; BPBio1_000191; GTPL7307; BDBM85509; HMS2089I18; HMS2962E14; BCP25528; NSC_5472; Tox21_110658; BBL028843; MFCD00661081; STK589340; AKOS005511613; Tox21_110658_1; DB00208; DS-6623; NCGC00016872-01; NCGC00016872-02; NCGC00016872-03; NCGC00016872-04; NCGC00016872-05; NCGC00016872-07; NCGC00016872-09; NCGC00016872-10; NCGC00016872-12; NCGC00024361-04; AC-15204; SBI-0206813.P001; CAS-53885-35-1; CAS_55142-85-3; HY-100386; UNM-0000345023; CS-0018717; FT-0619727; FT-0675227; S0721; C07140; D08594; EN300-1692883; A918120; L001108; Q420571; BRD-K00603606-003-03-4; BRD-K00603606-003-13-3; Z231745614; 5-(2-chlorobenzyl)-4,5,6,7tetrahydrothieno[3,2-c]pyridine; 5-(O-Chlorobenzyl)-4,5,6,7-tetrahydrothieno-[3,2-c]pyridine; 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine #	Approved	Approved Drug(s)	5472	DB00208	D05LBU	263.8	31.5	261	3.6	17	0	2	2	C14H14ClNS	5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine	C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl	C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl	InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2	PHWBOXQYWZNQIN-UHFFFAOYSA-N
DBM0Y9	Fluorouracil	Small molecule	5-Fluorouracil; fluorouracil; 51-21-8; 5-FU; Fluoroplex; Efudex; Adrucil; Carac; Fluracil; 5-fluoropyrimidine-2,4(1H,3H)-dione; Fluoroblastin; Queroplex; Kecimeton; Phthoruracil; Carzonal; Timazin; Arumel; Efudix; Fluril; 5-Fluoracil; Fluracilum; Ulup; 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilum; Fluro Uracil; 5 Fluorouracil; 5-Fluoruracil; Ftoruracil; Efurix; Fluri; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; 5-Fluoropyrimidine-2,4-dione; Effluderm (free base); Fluorouracilo; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; 2,4-Dihydroxy-5-fluoropyrimidine; Ro 2-9757; Uracil, 5-fluoro-; 5-fluoropyrimidine-2,4-diol; 5-Fluor-2,4-pyrimidindiol; 5-fluoro uracil; 5-fluoro-uracil; 5-Ftouracyl; 2,4-Dioxo-5-fluoropyrimidine; NSC 19893; NSC-19893; Fluorouracil, 5-; 5-Fluoro-2,4-pyrimidinedione; Fluorouricil; Ro-2-9757; Tolak; 5-Fluor-2,4-dihydroxypyrimidin; U-8953; 5-Fluorouracil-6-d1; 191047-65-1; FU; CHEMBL185; 2,4-Pyrimidinediol, 5-fluoro- (9CI); MLS000069498; 5 FU; 5FU; Fluroblastin; Phtoruracil; DTXSID2020634; CHEBI:46345; Fluoro-uracile; Fluoro-uracilo; U3P01618RT; NSC19893; 5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione; 5-Faracil; Cinco FU; Ro-29757; 191047-64-0; 191115-88-5; URF; NCGC00015442-02; Fluorouracile; Effluderm; SMR000038082; Fluorouracile [DCIT]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoruracil [German]; 1004-03-1; DTXCID40634; Fluorouracilum [INN-Latin]; Fluorouracilo [INN-Spanish]; 5-Fluoropyrimidin-2,4-diol; Fluorouracil (Adrucil); Fluorouracil Cream; CAS-51-21-8; Fluoroplex (TN); 5-Fluor-2,4-pyrimidindiol [Czech]; Adrucil (TN); CCRIS 2582; Carac (TN); 5-Fluor-2,4-dihydroxypyrimidin [Czech]; HSDB 3228; SR-01000075881; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; EINECS 200-085-6; 5-Fluor-2,4(1H,3H)-pyrimidindion; Fluouracil; inhibits thymilidate synthetase; UNII-U3P01618RT; 2,4-Dioxo-5-fluoropryimidine; 5-fluorourasil; AI3-25297; Fluoro Uracil; 5-florouracil; 5-fluorouacil; 5-FU (TN); 5-Fluracil; 1upf; 5F-uracil; U 8953; 1-fluoro-1h-pyrimidine-2,4-dione; Adrucil (ICN); MFCD00006018; Adrucil (Fluorouracil); Fluorouracil - Adrucil; Fluorouracil [USAN:USP:INN:BAN:JAN]; Spectrum_000841; Opera_ID_134; 5-Fluorouracil, 99%; Spectrum2_000076; Spectrum3_000434; Spectrum4_000557; Spectrum5_000718; WLN: T6MVMVJ EF; FLUOROURACIL [MI]; Lopac-F-6627; F0151; FLUOROURACIL [INN]; FLUOROURACIL [JAN]; UPCMLD-DP130; EC 200-085-6; F 6627; FLUOROURACIL [HSDB]; FLUOROURACIL [USAN]; SCHEMBL3646; 5-fluorpyrimidin-2,4-diol; FLUOROURACIL [VANDF]; Folfox component fluorouracil; Lopac0_000536; BSPBio_002048; FLUOROURACIL [MART.]; KBioGR_001253; KBioSS_001321; 2(1H)-Pyrimidinone, 5-fluoro-4-hydroxy- (9CI); 4(3H)-Pyrimidinone, 5-fluoro-2-hydroxy- (9CI); MLS002415705; DivK1c_000054; FLUOROURACIL [USP-RS]; FLUOROURACIL [WHO-DD]; FLUOROURACIL [WHO-IP]; SPECTRUM1500305; SPBio_000291; 5-FLUOROURACIL [IARC]; 5-fluoro-2,4-dioxo-pyrimidin; 5-fluoro-pyrimidine-2,4-diol; GTPL4789; UPCMLD-DP130:001; Fluorouracil (JP17/USP/INN); HMS500C16; KBio1_000054; KBio2_001321; KBio2_003889; KBio2_006457; KBio3_001268; 5-Fluoro-2,3H)-pyrimidinedione; 5-FLUOROURACIL [WHO-IP]; 2,4-Pyrimidinedione, 5-fluoro-; NINDS_000054; BCPP000428; FLUOROURACIL [ORANGE BOOK]; HMS1920O18; HMS2090I04; HMS2091F19; HMS3259O03; HMS3261L13; HMS3654K22; HMS3715H03; HMS3865L03; Pharmakon1600-01500305; FLUOROURACIL [EP MONOGRAPH]; 5-Fluorouracil, analytical standard; BCP02083; 2,3H)-Pyrimidinedione, 5-fluoro-; Fluorouracil (5-Fluoracil, 5-FU); Fluorouracil (5-Fluoracil; 5-FU); FLUOROURACIL [USP MONOGRAPH]; Tox21_110150; Tox21_202335; Tox21_300112; Tox21_500536; BDBM50340677; CCG-39879; DL-399; NSC757036; NSC816997; s1209; STK297802; STL367375; FLUOROURACILUM [WHO-IP LATIN]; AKOS000119162; AKOS003237897; AKOS008044307; Tox21_110150_1; BCP9000239; CS-0993; DB00544; KS-5129; LP00536; NC00454; NSC-757036; NSC-816997; SDCCGSBI-0050519.P005; FLUCYTOSINE IMPURITY A [WHO-IP]; IDI1_000054; NCGC00015442-01; NCGC00015442-03; NCGC00015442-04; NCGC00015442-05; NCGC00015442-06; NCGC00015442-07; NCGC00015442-08; NCGC00015442-09; NCGC00015442-10; NCGC00015442-11; NCGC00015442-12; NCGC00015442-15; NCGC00015442-16; NCGC00015442-24; NCGC00015442-30; NCGC00091349-01; NCGC00091349-02; NCGC00091349-03; NCGC00091349-04; NCGC00091349-05; NCGC00091349-07; NCGC00091349-08; NCGC00254023-01; NCGC00259884-01; NCGC00261221-01; 5-Fluoro-2,4-(1H,3H)-pyrimidinedione; AC-11201; BF166014; EMTRICITABINE IMPURITY F [WHO-IP]; HY-90006; NCI60_001652; SRI-10792-04; SRI-10792-05; SRI-10792-06; SRI-10792_07; SRI-10792_08; 5-Fluoro-1H-pyrimidine-2,4-dione(5FU); 5-Fluorouracil, >=99% (HPLC), powder; SBI-0050519.P004; 5-Fluoro-1H-pyrimidine-2,4-dione(5-FU); DB-051923; DB-065735; 5-Fluoro-1H-pyrimidine-2,4-dione (5-FU); A7567; AM20100252; EU-0100536; FLUCYTOSINE IMPURITY A [EP IMPURITY]; FT-0601511; FT-0668745; FT-0695666; FT-0695667; FT-0707652; SW199617-3; 5-Fluoro-1H-pyrimidine-2,4-dione(5-FUra); EN300-33909; Fluorouracil, meets USP testing specifications; C07649; D00584; 5-Fluorouracil, Vetec(TM) reagent grade, >=99%; Q238512; W-60379; (5-fluorouracil)5-Fluoro-1H-pyrimidine-2,4-dione; 5-Fluoro-1H-pyrimidine-2,4-dione(5-fluoro uracil); SR-01000075881-1; SR-01000075881-3; SR-01000075881-5; W-202929; 5-Fluoro-1H-pyrimidine-2,4-dione (5-Fluorouracil); BRD-K24844714-001-02-1; 5-FLUOROPYRIMIDIN-2,4(1H,3H)-DIONE [WHO-IP]; Z275128052; 5-Fluoro-1H-pyrimidine-2,4-dione(5-fluorouracil)(5-FU); 5-Fluorouracil, certified reference material, TraceCERT(R); Fluorouracil, British Pharmacopoeia (BP) Reference Standard; Fluorouracil, European Pharmacopoeia (EP) Reference Standard; Fluorouracil, United States Pharmacopeia (USP) Reference Standard; pyrimidine antimetabolite: inhibits nucleic acid replication; tetratogen; Fluorouracil, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	3385	DB00544	D05LEO	130.08	58.2	199	-0.9	9	2	3	0	C4H3FN2O2	5-fluoro-1H-pyrimidine-2,4-dione	C1=C(C(=O)NC(=O)N1)F	C1=C(C(=O)NC(=O)N1)F	InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)	GHASVSINZRGABV-UHFFFAOYSA-N
DJZV32	Sulfadiazine	Small molecule	sulfadiazine; 68-35-9; Sulphadiazine; Sulfapyrimidine; Sulfadiazin; Adiazine; Sulfazine; Sulfadiazene; Adiazin; Debenal; Pyrimal; Liquadiazine; Sulfapyrimidin; 2-Sulfanilamidopyrimidine; Coco-Diazine; Cremodiazine; Spofadrizine; Theradiazine; Cremotres; Deltazina; Diazolone; Eskadiazine; Microsulfon; Neotrizine; Palatrize; Piridisir; Quadetts; Quadramoid; Sanodiazine; Sterazine; Sulfatryl; Sulfolex; Sulfonsol; Terfonyl; Trifonamide; Truozine; Diazin; Neazine; Pirimal; Sulfose; Trisem; Sulfanilamidopyrimidine; Honey diazine; Lipo-Levazine; Tri-Sulfameth; Triple Sulfas; Lipo-Diazine; Metha-Meridiazine; Sulfadiazinum; Diazovit; Sulfadiazina; Sulphadiazine E; Sulfapirimidin; 4-amino-N-(pyrimidin-2-yl)benzenesulfonamide; Di-Azo-Mul; Thi-Di-Mer; 2-Sulfanilylaminopyrimidine; Codiazine; Silvadene; 4-amino-N-pyrimidin-2-ylbenzenesulfonamide; Pecta-diazine, suspension; Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-; RP 2616; Pyrimidine, 2-sulfanilamido-; 2-Sulfapyrimidine; N(1)-2-pyrimidylsulfanilamide; N(1)-2-pyrimidinylsulfanilamide; 4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDE; N(sup 1)-2-Pyrimidinylsulfanilamide; Sulfanilamide, N1-2-pyrimidinyl-; 4-amino-N-pyrimidin-2-yl-benzenesulfonamide; 4-amino-N-(pyrimidin-2-yl)benzene-1-sulfonamide; CHEBI:9328; Sulfanilamide, N(sup 1)-2-pyrimidinyl-; 4-Amino-N-2-pyrimidinyl-benzenesulfonamide; N(sup1)-2-Pyrimidylsulfanilamide; Sulfanilamide, N1-2(1H)-pyrimidinylidene-; silver sulfadiazine; A-306; N(sup1)-2-Pyrimidinylsulfanilamide; CHEMBL439; S. N. 112; DTXSID7044130; NSC35600; NSC-35600; CAS-68-35-9; NCGC00016305-01; Solfadiazina; CocoDiazine; Solfadiazina [DCIT]; Sulfadiazine 100 microg/mL in Acetonitrile; 0N7609K889; 2-Sulfanilamidopyrimidin; NSC117870; Sulfapyrimidin [German]; SDZ; Sulfadiazinum [INN-Latin]; Sulfadiazina [INN-Spanish]; Sildaflo; S.N. 112; 2-Sulfanilamidopyrimidin [German]; A-306 (VAN); A 306; SMR000059113; Sulfadiazine (TN); N-(2-Pyrimidinyl)sulfanilamide; rBPI21 & Sulfa; RP-2616; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide; SR-01000002973; SSD; EINECS 200-685-8; MFCD00006065; NSC 35600; 2-Sulfanilamido-pyrimidine; BRN 0235192; diazine; CRL-8131 & Sulfadiazine; N1-2-Pyrimidinylsulfanilamide; Sulfadiazine (JAN/USP/INN); AI3-01047; Sulfadiazine,(S); Trisulfapyrimidine, oral suspension; UNII-0N7609K889; Sulfadiazine [USP:INN:BAN:JAN]; Prestwick_428; Spectrum_000986; Sulfadiazina Reig Jofre; Sulfacombin (Salt/Mix); Prestwick0_000023; Prestwick1_000023; Prestwick2_000023; Prestwick3_000023; Spectrum2_001319; Spectrum3_001362; Spectrum4_000342; Spectrum5_000992; SULFADIAZINE [MI]; [(4-aminophenyl)sulfonyl]pyrimidin-2-ylamine; SULFADIAZINE [INN]; SULFADIAZINE [JAN]; Epitope ID:140083; N1-2-Pyrimidylsulfanilamide; Sulfadiazine, >=99.0%; SULFADIAZINE [VANDF]; Oprea1_081078; SCHEMBL24176; BSPBio_000085; BSPBio_002884; KBioGR_000743; KBioSS_001466; SULFADIAZINE [MART.]; 5-25-10-00067 (Beilstein Handbook Reference); MLS000069423; MLS006011457; DivK1c_000543; SPECTRUM1500546; SULFADIAZINE [USP-RS]; SULFADIAZINE [WHO-DD]; SPBio_001417; SPBio_002006; BPBio1_000095; WLN: T6N CNJ BMSWR DZ; DTXCID5024130; GTPL12635; HMS501L05; KBio1_000543; KBio2_001466; KBio2_004034; KBio2_006602; KBio3_002104; SULFADIAZINE [GREEN BOOK]; NINDS_000543; GLXC-25873; HMS1568E07; HMS1921A13; HMS2090P09; HMS2092I15; HMS2095E07; HMS2235D19; HMS3371L19; HMS3655I10; HMS3712E07; Pharmakon1600-01500546; SULFADIAZINE [ORANGE BOOK]; SULFADIAZINE [EP MONOGRAPH]; SULFADIAZINE [USP IMPURITY]; AMY33423; BCP12140; HY-B0273; SULFADIAZINE [USP MONOGRAPH]; Tox21_110360; BBL013169; BDBM50166571; CCG-39257; NSC757324; Recombinant bactericidal/permeability-increasing protein & Sulfadiazine; s1770; STK317797; SULFOSE COMPONENT SULFADIAZINE; TERFONYL COMPONENT SULFADIAZINE; 2-(p-Aminobenzenesulfonamido)pyrimidin; AKOS000119073; LANTRISUL COMPONENT SULFADIAZINE; SULFALOID COMPONENT SULFADIAZINE; DB00359; KS-1144; NSC-757324; 2-(4-Aminobenzenesulfonamido)pyrimidine; 4-amino-N-2-pyrimidylbenzenesulfonamide; IDI1_000543; NEOTRIZINE COMPONENT SULFADIAZINE; SULFADIAZINE COMPONENT OF SULFOSE; NCGC00016305-02; NCGC00016305-03; NCGC00016305-04; NCGC00016305-05; NCGC00016305-06; NCGC00016305-09; NCGC00016305-10; NCGC00016305-11; NCGC00023291-03; NCGC00023291-04; SULFADIAZINE (TRISULFAPYRIMIDINES); SULFADIAZINE COMPONENT OF TERFONYL; TRISULFAPYRIMIDINES (SULFADIAZINE); 2-(4-Aminobenzenesulfonylamino)pyrimidine; AC-26817; SULFADIAZINE COMPONENT OF LANTRISUL; SULFADIAZINE COMPONENT OF SULFALOID; 4-amino-N-2-pyrimidinyl benzenesulfonamide; SBI-0051520.P003; SULFADIAZINE COMPONENT OF NEOTRIZINE; TRIPLE SULFOID COMPONENT SULFADIAZINE; 4-[[(Pyrimidin-2-yl)amino]sulfonyl]aniline; AB00052095; Benzenesulfonamide,4-amino-N-2-pyrimidinyl-; FT-0674739; FT-0674740; FT-0674741; S0579; Sulfadiazine 1000 microg/mL in Acetonitrile; Sulfadiazine for identification of impurity F; SW196657-3; 4-amino-N-(2-pyrimidinyl) benzenesulfonamide; EN300-19076; SULFADIMIDINE IMPURITY B [EP IMPURITY]; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide #; C07658; D00587; D92267; SULFADIAZINE COMPONENT OF TRIPLE SULFOID; Trisulfapyrimidine, oral suspension (Salt/Mix); AB00052095-13; AB00052095-14; AB00052095_15; AB00052095_16; Benzenesulfonamide, 4-amino-N-(2-pyrimidinyl)-; Sulfadiazine, VETRANAL(TM), analytical standard; A836115; Q-201759; Q2555060; SR-01000002973-2; SR-01000002973-3; BRD-K32273377-001-05-4; BRD-K32273377-001-09-6; F1657-1720; Sulfadiazine, certified reference material, TraceCERT(R); TRISULFAPYRIMIDINES (SULFADIAZINE) [ORANGE BOOK]; Z104472626; Sulfadiazine, European Pharmacopoeia (EP) Reference Standard; Sulfadiazine, United States Pharmacopeia (USP) Reference Standard; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide, N1-(Pyrimidin-2-yl)sulfanilamide; Sulfadiazine, Pharmaceutical Secondary Standard; Certified Reference Material; 141582-64-1; Sulfadiazine for identification of impurity F, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	5215	DB00359	D05LKP	250.28	106	327	-0.1	17	2	6	3	C10H10N4O2S	4-amino-N-pyrimidin-2-ylbenzenesulfonamide	C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N	C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N	InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)	SEEPANYCNGTZFQ-UHFFFAOYSA-N
D2WG6F	Glyburide	Small molecule	glyburide; Glibenclamide; 10238-21-8; Glybenclamide; Glynase; Diabeta; Micronase; Daonil; Euglucon; Maninil; Glybenzcyclamide; Semi-daonil; Apo-Glibenclamide; Euglucon 5; Azuglucon; Bastiverit; Benclamin; Betanase; Duraglucon; Euglucan; Euglykon; Glibenil; Glucolon; Orabetic; Prodiabet; Renabetic; Yuglucon; Dibelet; Gilemal; Glibens; Glibil; Glimel; Glimide; Humedia; Libanil; Suraben; Tiabet; Adiab; Melix; Pira; Med-Glionil; Glibenclamidum; Glibenclamida; 5-Chloro-N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-methoxybenzamide; HB 419; Glibenclamidum [INN-Latin]; Glibenclamida [INN-Spanish]; C23H28ClN3O5S; glyburide (glibenclamide); HB-419; UR 606; Cirara; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; Neogluconin; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide; 5-Chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide; Glibenclamide [INN]; U 26452; Gewaglucon; Glibenbeta; Glidiabet; Glucobene; Glucohexal; Glucoremed; Hexaglucon; Lederglib; Lisaglucon; Normoglucon; Praeciglucon; Calabren; Cytagon; Euclamin; Glamide; Glibesyn; Glibetic; Gliboral; Glisulin; Glitisol; Glubate; Glucomid; Glucoven; Glycomin; Miglucan; Debtan; Gliban; Gliben; Glibet; Glicem; Gluben; Glyben; Nadib; Sugril; SX6K58TVWC; CHEMBL472; Novo-Glyburide; NSC-759618; Glibenclamid AL; 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; Gen-Glybe; Norglicem 5; Betanese 5; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; Glibenclamid Fabra; 5-chloro-N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-2-methoxybenzamide; Benzamide, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxy-; MLS000069721; CHEBI:5441; Glibenclamid Basics; Glibenclamid-Cophar; DTXSID0037237; Glibenclamid Heumann; Semi-Euglucon; Glibenclamid Genericon; Hemi-Daonil; U-26452; Glibenclamid-Ratiopharm; U-26,452; Urea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexyl-; Benzamide, 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy-; Glyburide [USAN]; NCGC00015467-11; Abbenclamide; Diabiphage; Glibadone; SMR000058229; Semi-Gliben-Puren N; GBN 5; CAS-10238-21-8; Glibenclamid Riker M.; Glyburide (micronized); Urea, 1-((p-(2-(chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexyl-; U-26,45; Micronized glyburide; DTXCID8017237; Glycron; 1-[[p-[2-(5-Chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohexylurea; 5-chloro-N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-2-methoxybenzamide; 5-chloro-N-(2-{4-[N-(N-cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-2-methoxybenzamide; 5-Chloro-N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)-phenethyl)-2-methoxybenzamide; Glyburide (USP); Micronase (TN); 1-{4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulfonyl}-3-cyclohexylurea;1-{4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulfonyl}-3-cyclohexylurea; Diabeta (TN); Glynase (TN); SR-01000000196; Glyburide [USAN:USP]; EINECS 233-570-6; UNII-SX6K58TVWC; BRN 2230085; Amglidia; Delmide; 5-chloro-N-(4-[N-(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-2-methoxybenzamide; Glibenclamide,(S); GBM; Prestwick_569; Glibenclamide B.P.; MFCD00056625; RP-1127; Spectrum_000250; Tocris-0911; Glibenclamide - Bio-X; Glybenzcyclamide, 99%; Opera_ID_801; GLYBURIDE [MI]; Prestwick0_000316; Prestwick1_000316; Prestwick2_000316; Prestwick3_000316; Spectrum2_001816; Spectrum3_001327; Spectrum4_001199; Spectrum5_001631; GLYBURIDE [VANDF]; Lopac-G-0639; Probes1_000431; Probes2_000378; UPCMLD-DP006; G 0639; GLIBENCLAMIDE [JAN]; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; GLYBURIDE [USP-RS]; GLYBURIDE [WHO-IP]; Glibenclamide (JP17/INN); N-(4-(beta-(2-Methoxy-5-chlorbenzamido)-aethyl)-benzolsulfonyl)-N'-cyclohexyl-harnstoff; CBiol_001790; Lopac0_000499; Oprea1_764617; SCHEMBL22009; BSPBio_000312; BSPBio_001351; BSPBio_003053; KBioGR_000071; KBioGR_001897; KBioSS_000071; KBioSS_000730; MLS001077262; BIDD:GT0239; DivK1c_000481; GLIBENCLAMIDE [MART.]; SPECTRUM2300229; SPBio_001831; SPBio_002531; GLIBENCLAMIDE [WHO-DD]; GLIBENCLAMIDE [WHO-IP]; BPBio1_000344; GTPL2414; GLYBURIDE [ORANGE BOOK]; UPCMLD-DP006:001; HMS501I03; KBio1_000481; KBio2_000071; KBio2_000730; KBio2_002639; KBio2_003298; KBio2_005207; KBio2_005866; KBio3_000141; KBio3_000142; KBio3_002273; GLYBURIDE [USP MONOGRAPH]; Glybenclamide, >=99% (HPLC); NINDS_000481; Bio1_000076; Bio1_000565; Bio1_001054; Bio2_000071; Bio2_000551; HMS1361D13; HMS1568P14; HMS1791D13; HMS1922L08; HMS1989D13; HMS2089L06; HMS2093P04; HMS2095P14; HMS3259O12; HMS3261D19; HMS3267A15; HMS3402D13; HMS3411F16; HMS3428D15; HMS3651E17; HMS3675F16; HMS3712P14; Pharmakon1600-02300229; BCP05327; GLIBENCLAMIDE [EP MONOGRAPH]; Glibenclamide for peak identification; Tox21_110158; Tox21_300758; Tox21_500499; BDBM50012957; CCG-39618; GLUCOVANCE COMPONENT GLYBURIDE; HD 419; NSC759618; NSC813214; STK362992; GLIBENCLAMIDUM [WHO-IP LATIN]; Glyburide - CAS 10238-21-8; AKOS001487495; Tox21_110158_1; BCP9000729; CS-1075; DB01016; KS-5326; LP00499; NC00566; NSC 759618; NSC-813214; SB17414; SDCCGSBI-0050483.P004; GLYBURIDE COMPONENT OF GLUCOVANCE; IDI1_000481; IDI1_033821; Glibenclamide 1.0 mg/ml in Acetonitrile; NCGC00015467-01; NCGC00015467-02; NCGC00015467-03; NCGC00015467-04; NCGC00015467-05; NCGC00015467-06; NCGC00015467-07; NCGC00015467-08; NCGC00015467-09; NCGC00015467-10; NCGC00015467-12; NCGC00015467-13; NCGC00015467-14; NCGC00015467-15; NCGC00015467-16; NCGC00015467-17; NCGC00015467-18; NCGC00015467-20; NCGC00015467-21; NCGC00015467-36; NCGC00015467-37; NCGC00016689-01; NCGC00023447-02; NCGC00023447-04; NCGC00023447-05; NCGC00023447-06; NCGC00023447-07; NCGC00023447-08; NCGC00023447-09; NCGC00023447-10; NCGC00023447-11; NCGC00023447-12; NCGC00254662-01; NCGC00261184-01; BG166164; HY-15206; SBI-0050483.P003; Glyburide, meets USP testing specifications; AB00051949; EU-0100499; FT-0601608; G-150; G0382; S1716; SW195828-5; A19539; C07022; D00336; D81733; EN300-117270; M01823; AB00051949-16; AB00051949-17; AB00051949_18; AB00051949_19; Q420626; SR-01000000196-2; SR-01000000196-4; SR-01000000196-5; SR-01000000196-6; SR-01000000196-8; W-108874; BRD-K36927236-001-06-0; BRD-K36927236-001-17-7; Z277540138; Glybenclamide, European Pharmacopoeia (EP) Reference Standard; Glyburide, United States Pharmacopeia (USP) Reference Standard; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexyl urea; 5-Chloro-N-[4-(3-cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide.; 5-chloro-N-[4-({[(cyclohexylamino)carbonyl]amino}sulfonyl)phenethyl]-2-methoxybenzamide; Glibenclamide for peak identification, European Pharmacopoeia (EP) Reference Standard; Glyburide (Glibenclamide), Pharmaceutical Secondary Standard; Certified Reference Material; N-(4-(.beta.-(2-Methoxy-5-chlorbenzamido)-aethyl)-benzolsulfonyl)-N'-cyclohexyl-harnstoff; N1-[4-({[(cyclohexylamino)carbonyl]amino}sulfonyl)phenethyl]-5-chloro-2-methoxybenzamide; 5-Chloro-N-(2-[4-(([(cyclohexylamino)carbonyl]amino)sulfonyl)phenyl]ethyl)-2-methoxybenzamide #; 5-Chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]-amino]sulfonyl]phenyl]-ethyl]-2-methoxybenzamide; 5-Chloro-N-[2-[4-[[[(Cylcohexylamino)carbonyl]amino]sulphonyl]phenyl]ethyl]-2-methoxybenzamide	Approved	Approved Drug(s)	3488	DB01016	D05LYX	494	122	746	4.8	33	3	5	8	C23H28ClN3O5S	5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide	COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3	COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3	InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)	ZNNLBTZKUZBEKO-UHFFFAOYSA-N
DA9L7S	Abrocitinib	Small molecule	Abrocitinib; 1622902-68-4; PF-04965842; Cibinqo; N-[cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide; Abrocitinib [USAN]; 73SM5SF3OR; CHEMBL4101725; PF-04965842 (Abrocitinib); N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide; N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide; 1-Propanesulfonamide, N-(cis-3-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclobutyl)-; N-(3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide, cis-; N-[cis-3-(Methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide; UNII-73SM5SF3OR; N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide; D7D; N-((1S,3S)-3-(METHYL(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)AMINO)CYCLOBUTYL)PROPANE-1-SULFONAMIDE; N-((1s,3s)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide; ABROCITINIB [INN]; ABROCITINIB [JAN]; Abrocitinib (JAN/USAN); ABROCITINIB [WHO-DD]; GTPL9991; CHEMBL3655081; SCHEMBL15970412; SCHEMBL15970413; PF-04965842(Abrocitinib); BDBM159748; DTXSID301126581; BCP30441; EX-A3037; XPC90268; AC8575; BDBM50243847; MFCD30187577; s8765; ZB1566; DB14973; SB18849; compound 25 [PMID: 29298069]; NCGC00601823-02; AC-36318; AS-84437; SY248874; HY-107429; CS-0028460; PF04965842; D11400; US9035074, 2; A936574; PF-04965842, >=98% (HPLC); PF-04965842PF-04965842; PF-04965842; PF 04965842; PF04965842; N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide; N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide; Abrocitinib;N-[cis-3-(Methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide	Approved	Approved Drug(s)	78323835	DB14973	D05PCM	323.42	99.4	474	1.7	22	2	6	6	C14H21N5O2S	N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide	CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3	CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3	InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)	IUEWXNHSKRWHDY-UHFFFAOYSA-N
D7WK9B	Carisoprodol	Small molecule	carisoprodol; 78-44-4; Isomeprobamate; Carisoprodate; SOMA; Carisoprodatum; Carisoma; Isobamate; Isoprotane; Isoprothane; Sanoma; Isopropyl meprobamate; Atonalyt; Flexartal; Miolisodal; Mioratrina; Skutamil; Somalgit; Apesan; Arusal; Flexal; Mioril; Nospasm; Relasom; Somanil; Carlsoprol; Brianil; Calenfa; Caprodat; Carisol; Carlsodol; Carlsoma; Carsodal; Diolene; Domarax; Isoprotan; Izoprotan; Mediquil; Mioriodol; Somadril; Stialgin; RELA; Carisoprodolum; Carsodol; Carisoprodolum [INN-Latin]; Tonolyt isopropyl meprobamate; NCI-C56235; SCH 7307; Miolisodol; Flexartel; CB 8019; Carisoprodol civ; 2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate; [2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate; (1-Methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester; NSC-172124; Isopropylcarbamic acid, ester with 2-(hydroxymethyl)-2-methylpentyl carbamate; MLS000028401; CHEBI:3419; Artifar; Caridolin; Chinchen; DTXSID8024733; Fibrosona; Flexagilt; Flexagit; Flexidon; Listaflex; Meprodat; Neotica; Muslax; Scutamil-C; Carbamic acid, ester with 2-methyl-2-propyl-1,3-propanediol isopropylcarbamate; Carbamic acid, (1-methylethyl)-, 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester; Carbamic acid, isopropyl-, 2-(hydroxymethyl)-2-methylpentyl ester carbamate (ester); NCGC00015278-09; SMR000058433; 21925K482H; (+-)-2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate; Carbamic acid, (1-methylethyl)-, 2-[[(aminocarbonyl)oxy]methyl]-2-methylpentyl ester; Isopropylmeprobamate; DTXCID904733; 2-((Carbamoyloxy)methyl)-2-methylpentyl isopropylcarbamate; 2-methyl-2-propyltrimethylene carbamate isopropylcarbamate; Carisoprodolo [DCIT]; N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate; Carisoprodolo; Prazolamine; Carbamic acid 2-isopropylcarbamoyloxymethyl-2-methyl-pentyl ester; (+/-)-2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate; Carbamic acid, ester with 2-(hydroxymethyl)-2-methylpentylisopropyl carbamate; CCRIS 4764; HSDB 3021; SR-01000000076; EINECS 201-118-7; NSC 172124; BRN 1791537; Carisoprodol [USP:INN:BAN]; 2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate; CAS-78-44-4; Prestwick_50; UNII-21925K482H; MFCD00057661; Soma (TN); N-Isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate; Spectrum_000102; Opera_ID_1100; Prestwick0_000423; Prestwick1_000423; Prestwick2_000423; Prestwick3_000423; Spectrum2_001153; Spectrum3_000328; Spectrum4_000265; Spectrum5_000661; CARISOPRODOL [MI]; CARISOPRODOL [INN]; CARISOPRODOL [JAN]; 1,3-Propanediol, 2-methyl-2-propyl-, carbamate isopropylcarbamate (ester); Carbamic acid, ester with 2-(hydroxymethyl)-2-methylpentyl isopropylcarbamate; CARISOPRODOL [HSDB]; CARISOPRODOL [VANDF]; CHEMBL1233; Lopac0_000319; SCHEMBL33286; BSPBio_000406; BSPBio_001935; CARISOPRODOL [MART.]; KBioGR_000730; KBioSS_000542; MLS001148409; MLS002454391; CARISOPRODOL [WHO-DD]; DivK1c_000816; SPECTRUM1500162; Carisoprodol (JAN/USP/INN); SPBio_001105; SPBio_002345; BPBio1_000448; GTPL7610; DEA No. 8192; HMS502I18; KBio1_000816; KBio2_000542; KBio2_003110; KBio2_005678; KBio3_001155; CARISOPRODOL CIV [USP-RS]; NINDS_000816; CARISOPRODOL [EP IMPURITY]; CARISOPRODOL [ORANGE BOOK]; HMS1569E08; HMS1920K03; HMS2091A06; HMS2096E08; HMS2234F13; HMS3259O15; HMS3372H19; HMS3713E08; Pharmakon1600-01500162; HY-B1380; CARISOPRODOL [USP MONOGRAPH]; Carisoprodol 1.0 mg/ml in Methanol; Tox21_110122; Tox21_200623; AC-212; CCG-40092; NSC172124; NSC756671; AKOS015842914; Tox21_110122_1; WLN: ZVO1X3&1&1OVMY1&1; CS-4819; DB00395; LP00319; NC00502; NSC-756671; SDCCGSBI-0050307.P005; IDI1_000816; NCGC00015278-03; NCGC00015278-04; NCGC00015278-05; NCGC00015278-06; NCGC00015278-07; NCGC00015278-08; NCGC00015278-11; NCGC00015278-12; NCGC00015278-14; NCGC00015278-15; NCGC00089734-02; NCGC00089734-03; NCGC00089734-04; NCGC00089734-05; NCGC00089734-06; NCGC00089734-07; NCGC00258177-01; SBI-0050307.P004; SOMA COMPOUND COMPONENT CARISOPRODOL; AB00051932; C3573; EU-0100319; FT-0601536; FT-0656125; Carbamic acid,3-propanediol isopropylcarbamate; CARISOPRODOL COMPONENT OF SOMA COMPOUND; C 8759; D00768; N-Isopropyl-2-methyl-2-propyl-1, dicarbamate; AB00051932_15; CARISOPRODOL COMPOUND COMPONENT CARISOPRODOL; Q416905; SR-01000000076-2; SR-01000000076-4; SR-01000000076-6; W-104280; 1, 2-methyl-2-propyl-, carbamate isopropylcarbamate; CARISOPRODOL COMPONENT OF CARISOPRODOL COMPOUND; N-Isopropyl-2-methyl-2-propyl-1,3-propanediol, dicarbamate; 2-[(carbamoyloxy)methyl]-2-methylpentyl propan-2-ylcarbamate; Carisoprodol, European Pharmacopoeia (EP) Reference Standard; 1,3-Propanediol, 2-methyl-2-propyl-, carbamate isopropylcarbamate; Carisoprodol, United States Pharmacopeia (USP) Reference Standard; (RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate; Carbamic acid, isopropyl-, 2-(hydroxymethyl)-2-methylpentyl ester carbamate; Carbamic acid, isopropyl-, 2-(hydroxymethyl)-2-methylpentyl ester, carbamate	Approved	Approved Drug(s)	2576	DB00395	D05PLH	260.329	90.6	281	1.9	18	2	4	9	C12H24N2O4	[2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate	CCCC(C)(COC(=O)N)COC(=O)NC(C)C	CCCC(C)(COC(=O)N)COC(=O)NC(C)C	InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)	OFZCIYFFPZCNJE-UHFFFAOYSA-N
D7AV8Z	Acitretin	Small molecule	Acitretin; 55079-83-9; Etretin; Soriatane; Neotigason; Acitretine; all-trans-Acitretin; Retinoid etretin; Ro 10-1670; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; Acitretina; Acitretinum; TMMP; Ro 10-1670/000; 54757-46-9; 9-cis Acitretin; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; CHEBI:50173; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E)-; Ro-101670000; LCH760E9T7; DTXSID6022553; Ro-10-1670/000; 13-CIS-ACITRETIN-D3; NCGC00163127-02; Acitretine [French]; Acitretinum [Latin]; Acitretina [Spanish]; Acitretin 100 microg/mL in Acetonitrile:Acetone; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-, (all-E)-; Acetretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; Soriatane CK; Soriatane (TN); CCRIS 5534; Ro-10-1670; HSDB 7187; 419534-31-9; Isoacitretin;Ro 13-7652; EINECS 259-474-4; CHEBI:50172; UNII-LCH760E9T7; U0279; all-trans-Etretin; Acitretin [USAN:USP:INN:BAN]; 13-is Acitretin; Acitretin,(S); Acitretin- Bio-X; Acitretin (USP/INN); ACITRETIN [INN]; ACITRETIN [MI]; ACITRETIN [HSDB]; ACITRETIN [USAN]; Spectrum5_002065; ACITRETIN [VANDF]; ACITRETIN [MART.]; ACITRETIN [USP-RS]; ACITRETIN [WHO-DD]; SCHEMBL3759; CHEMBL1131; MLS001076667; BIDD:GT0617; DTXCID902553; GTPL7598; ACITRETIN [ORANGE BOOK]; ACITRETIN [EP MONOGRAPH]; ACITRETIN [USP IMPURITY]; ACITRETIN [USP MONOGRAPH]; BCPP000437; HMS2234L17; HMS3259J12; HMS3714E17; Acitretin, >=98.0% (HPLC); HY-B0107; Tox21_112012; BDBM50088429; MFCD00866632; s1368; STL565770; AKOS015889991; AC-4702; BCP9000229; CCG-220668; CS-1855; DB00459; KS-5246; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-; NCGC00163127-01; NCGC00163127-03; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; AS-12644; BA164136; SMR000499573; CAS-55079-83-9; CS-0368934; SW199134-2; C75579; D02754; EN300-117242; AB00698376-08; AB00698376_09; EN300-1273239; A830475; Q341500; SR-01000763200; SR-01000763200-3; BRD-K90699611-001-01-4; Acitretin, British Pharmacopoeia (BP) Reference Standard; Z2312273468; Acitretin, European Pharmacopoeia (EP) Reference Standard; Acitretin, United States Pharmacopeia (USP) Reference Standard; Acitretin, Pharmaceutical Secondary Standard; Certified Reference Material; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (2E,4E,6E,8E)-	Approved	Approved Drug(s)	5284513	DB00459	D05QDC	326.4	46.5	539	6.1	24	1	3	6	C21H26O3	(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid	CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC	CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC	InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+	IHUNBGSDBOWDMA-AQFIFDHZSA-N
DCK7Z2	Dabrafenib	Small molecule	Dabrafenib; 1195765-45-7; Tafinlar; Dabrafenib (GSK2118436); GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; GSK-2118436; GSK-2118436A; QGP4HA4G1B; 1195765-45-7 (free base); N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; Dabrafenib (USAN); N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; DABRAFENIB [USAN]; Dabrafenib (Free Base); Dabrafenib [USAN:INN]; BENZENESULFONAMIDE, N-(3-(5-(2-AMINO-4-PYRIMIDINYL)-2-(1,1-DIMETHYLETHYL)-4-THIAZOLYL)-2-FLUOROPHENYL)-2,6-DIFLUORO-; Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-; N-(3-(5-(2-AMINOPYRIMIDIN-4-YL)-2-TERT-BUTYL-1,3-THIAZOL-4-YL)-2-FLUOROPHENYL)-2,6-DIFLUOROBENZENESULFONAMIDE; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; P06; DABRAFENIB [MI]; DABRAFENIB [INN]; DABRAFENIB [VANDF]; DABRAFENIB [WHO-DD]; MLS006011052; SCHEMBL806377; GTPL6494; CHEMBL2028663; DABRAFENIB, KB-57246; DTXSID20152499; HMS3656D12; HMS3672G05; AMY10291; BCP09341; EX-A1320; BDBM50428286; FD5028; GSK 2118436A; MFCD17215684; NSC764134; NSC800083; (GSK2118436) pound notDabrafenib; AKOS024463285; AKOS032950004; CCG-264736; CS-0692; DB08912; NSC-764134; NSC-800083; SB13355; NCGC00346716-01; NCGC00346716-02; NCGC00346716-14; AC-25889; AS-19634; HY-14660; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfo; SMR004702844; S2807; SW219503-1; D10064; AB01565833_02; A852141; J-004153; Q3011604; BRD-K09951645-066-01-2; N-{3-(5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl)-2-fluorophenyl}-2,6- difluorobenzenesulfonamide; N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide	Approved	Approved Drug(s)	44462760	DB08912	D05ROI	519.6	148	817	4.8	35	2	11	6	C23H20F3N5O2S2	N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F	InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)	BFSMGDJOXZAERB-UHFFFAOYSA-N
D6J2KZ	Abemaciclib	Small molecule	Abemaciclib; 1231929-97-7; LY2835219; Verzenio; LY2835219 free base; LY-2835219; N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine; UNII-60UAB198HK; N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine; Abemaciclib (ly2835219); 60UAB198HK; LY 2835219; HY-16297A; LY2835219 free base (Abemaciclib); CS-1230; 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl); N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-1,3-benzodiazol-5-yl)pyrimidin-2-amine; N-{5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-amine; LY2835219 (free base); Abemaciclib [USAN:INN]; Verzenios; rimidin-2-amine; C27H32F2N8; Verzenio (TN); 6ZV; N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]py rimidin-2-amine; CDK4/6 dual inhibitor; LY2835210; ABEMACICLIB [MI]; ABEMACICLIB [INN]; ABEMACICLIB [JAN]; Abemaciclib (JAN/USAN); ABEMACICLIB [USAN]; ABEMACICLIB [WHO-DD]; GTPL7382; SCHEMBL2487229; CHEMBL3301610; ABEMACICLIB [ORANGE BOOK]; DTXSID20673119; EX-A521; LY 2835219 (free base); HMS3673I05; BCP13079; EX-A1588; BDBM50110183; MFCD22665744; NSC768073; NSC783671; s5716; 1231929-97-7, Verzenio,; AKOS025404907; CCG-269750; DB12001; NSC-768073; NSC-783671; SB16476; NCGC00351599-02; NCGC00351599-06; 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine; 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)pyrimidin-2-yl)amine; AC-30666; AS-10230; DA-33422; LY2835219 Ms salt, Abemaciclib Ms salt; FT-0700134; LY 2835210; A12989; D10688; EN300-7406007; J-690083; Q23901483; [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine; 2-Pyrimidinamine, N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-; 2-Pyrimidinamine,N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-; N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-1,3-benzodiazol-6-yl]pyrimidin-2-amine	Approved	Approved Drug(s)	46220502	DB12001	D05SBO	506.6	75	723	3.8	37	1	9	7	C27H32F2N8	N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine	CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F	CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F	InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)	UZWDCWONPYILKI-UHFFFAOYSA-N
DTE75I	Nadolol	Small molecule	nadolol; Corgard; 42200-33-9; Solgol; (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; SQ-11725; Anabet; (2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; Nadolol [MI]; Nadolol [HSDB]; Nadolol [INN]; Nadolol [JAN]; Nadolol [USAN]; Nadolol [VANDF]; Nadolol [MART.]; Nadolol [WHO-DD]; Corzide component nadolol; CHEMBL649; Nadolol [ORANGE BOOK]; NSC-758430; Nadolol component of corzide; Nadolol [USP MONOGRAPH]; MLS000028580; FEN504330V; SMR000058975; 1403-22-1; Corgard;Solgol; DTXCID903342; cis-5-(3-((1,1-Dimethylethyl)amino)-2-hydroxy-propoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol; 1-(tert-Butylamino)-3-((5,6,7,8-tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy)-2-propanol; SR-01000000251; 2,3-Naphthalenediol, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, cis-; DTXSID3023342; SQ11725; UNII-FEN504330V; Candidin B; 1-(tert-butylamino)-3-[(5,6,7,8-tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy]-2-propanol; NCGC00016851-01; 220045-89-6; Prestwick_108; Nadolol [EP]; Nadolol [USP]; CAS-42200-33-9; Nadolol [USP-RS]; Spectrum_001643; Opera_ID_1099; Prestwick0_000818; Prestwick1_000818; Prestwick2_000818; Spectrum2_001546; Spectrum3_001586; Spectrum4_000193; Spectrum5_001255; SCHEMBL4177; Nadolol, analytical standard; BSPBio_003152; GTPL554; KBioGR_000765; KBioSS_002123; cid_39147; MLS001148087; MLS002548875; DivK1c_000427; Nadolol (JP17/USP/INN); NADOLOL [EP IMPURITY]; SPECTRUM1503260; SPBio_001392; SPBio_002636; NADOLOL [EP MONOGRAPH]; INV102; Nadolol 1.0 mg/ml in Methanol; BDBM25766; HMS501F09; KBio1_000427; KBio2_002123; KBio2_004691; KBio2_007259; KBio3_002652; INV-102; NINDS_000427; HMS1570D17; HMS1922O05; HMS2093A15; HMS2233E12; HMS3259C07; HMS3714D17; Pharmakon1600-01503260; Nadolol [USAN:INN:JAN:WHO-DD]; Tox21_110646; CCG-39324; NSC758430; s5023; AKOS015895037; Tox21_110646_1; DB01203; NC00464; IDI1_000427; SMP1_000203; NCGC00021623-03; NCGC00021623-05; NCGC00089811-02; (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; SBI-0051806.P002; EN300-50860; VU0239635-6; A12516; D00432; AB00052338_13; Q424952; SR-01000000251-2; SR-01000000251-3; BRD-A87606379-001-03-4; BRD-A87606379-001-13-3; Nadolol, European Pharmacopoeia (EP) Reference Standard; Z608060832; Nadolol, United States Pharmacopeia (USP) Reference Standard; 1164498-31-0	Approved	Approved Drug(s)	39147	DB01203	D05SHK	309.4	82	344	0.7	22	4	5	6	C17H27NO4	(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol	CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O	CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O	InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1	VWPOSFSPZNDTMJ-UCWKZMIHSA-N
DAUJ38	Methotrexate	Small molecule	methotrexate; 59-05-2; Amethopterin; Rheumatrex; Methylaminopterin; Abitrexate; Trexall; Mexate; Metatrexan; Hdmtx; Methylaminopterinum; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexatum; Rasuvo; 4-Amino-10-methylfolic acid; Methotrexate hydrate; Metotrexato; Maxtrex; NSC-740; Mexate-Aq; N-Bismethylpteroylglutamic acid; Folex; NCI-C04671; CL-14377; Antifolan; 133073-73-1; Methotrexate Lpf; Xatmep; Amethopterine; Farmitrexat; EMT 25,299; L-Amethopterin; CL 14377; Methotrexat-Ebewe; TCMDC-125858; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid; R 9985; YL5FZ2Y5U1; Methotextrate; Methotrexat; CHEMBL34259; NSC740; DTXSID4020822; CHEBI:44185; ADX-2191; N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid; CL14377; NCGC00025060-04; NSC 740; 4-amino-N(10)-methylpteroylglutamic acid; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; R-9985; (2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid; Methotrexate, L-; N-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)carbonyl]-L-glutamic acid; DTXCID80822; X 133; Metotressato [DCIT]; Methotrexate, d-; Fauldexato; Medsatrexate; Methoblastin; Metotressato; Brimexate; Emthexat; Emthexate; Lantarel; Lumexon; Metrotex; Novatrex; Otrexup; Tremetex; Trexeron; Trixilem; Metex; Texate; MLS001401431; Methotrexatum [INN-Latin]; Metotrexato [INN-Spanish]; [3H]methotrexate; Methotrexate (hydrate); SMR000112001; [3H]-methotrexate; folic acid antagonist; CCRIS 1109; 4-Aminomethylpteroylglutamic acid; HSDB 3123; L-(+)-N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)glutamic acid; N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-(+)-glutamic acid; SR-01000075682; SMR000449324; EINECS 200-413-8; UNII-YL5FZ2Y5U1; Metolate; Nordimet; AI3-25299; Intradose-MTX; 4-Amino-N(sup 10)-methylpteroylglutamic acid; 1dhi; 1dhj; 2drc; 4ocx; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid; CAS-59-05-2; Glutamic acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, L-; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova; MPI-2505; Prestwick_322; Otrexup (TN); Xatmep (TN); JYLAMVO; REDITREX; Kyselina 4-amino-N(sup 10)-methylpteroylglutamova [Czech]; Methylaminopterin; MTX; Methotrexate [USAN:USP:INN:BAN:JAN]; Spectrum_001836; Tocris-1230; 4kn0; WR-19039; Prestwick0_000135; Prestwick1_000135; Prestwick2_000135; Spectrum2_001077; Spectrum3_000497; Spectrum4_000616; Spectrum5_000958; Abitrexate (Methotrexate); Methotrexate - Abitrexate; METHOTREXATE [MI]; N-(p-(((2,4-Diamino-6-pteridyl)methyl)methylamino)benzoyl)glutamic acid; METHOTREXATE [INN]; METHOTREXATE [JAN]; L(+)-Amethopterin hydrate; METHOTREXATE [HSDB]; METHOTREXATE [IARC]; METHOTREXATE [INCI]; METHOTREXATE [USAN]; N-(4-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-glutamicacid; NCIMech_000767; SCHEMBL3711; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova [Czech]; METHOTREXATE [VANDF]; Methotrexate hydrate (1:x); BIDD:PXR0175; Lopac0_000020; KBioGR_001172; KBioSS_002341; METHOTREXATE [MART.]; Kyselina 4-amino-N(sup 10)-methylpteroylglutamova; MLS000049968; MLS002154208; DivK1c_000114; METHOTREXATE [USP-RS]; METHOTREXATE [WHO-DD]; METHOTREXATE [WHO-IP]; SPBio_001094; SPBio_002149; Amethopterin (hydrate); CL14377 (hydrate); WR19039 (hydrate); AMY235; cid_126941; cid_165528; GTPL4674; GTPL4815; SCHEMBL12421860; SCHEMBL23111732; BDBM18050; BDBM66082; HMS500F16; KBio1_000114; KBio2_002338; KBio2_004906; KBio2_007474; KBio3_001493; Methotrexate (JP17/USP/INN); g301; NINDS_000114; Bio1_000486; Bio1_000975; Bio1_001464; HMS1568K12; HMS2095K12; HMS2233O18; HMS3260C21; HMS3414L09; HMS3678L07; HMS3712K12; METHOTREXATE [ORANGE BOOK]; METHOTREXATE [EP MONOGRAPH]; METHOTREXATE [USP IMPURITY]; ACT03341; APC-2002; BCP13701; MPI-5004; METHOTREXATE [USP MONOGRAPH]; Tox21_110944; Tox21_300269; Tox21_500020; CCG-35800; EMT-25299; METHOTREXATUM [WHO-IP LATIN]; MFCD00064370; s1210; STL535338; (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-glutamic acid; AKOS016340329; Tox21_110944_1; CS-1732; DB00563; KS-5093; LP00020; SDCCGSBI-0050009.P003; WR19039; IDI1_000114; SMP2_000020; (methyl)amino)benzamido)pentanedioic acid; NCGC00025060-01; NCGC00025060-02; NCGC00025060-03; NCGC00025060-05; NCGC00025060-06; NCGC00025060-07; NCGC00025060-08; NCGC00025060-09; NCGC00025060-10; NCGC00025060-11; NCGC00025060-12; NCGC00025060-13; NCGC00025060-15; NCGC00025060-16; NCGC00254216-01; NCGC00260705-01; HY-14519; EU-0100020; G-301; SW198601-3; Methotrexate 1.0 mg/ml in Dimethyl Sulfoxide; A10021; C01937; D00142; EN300-119523; Q422232; SR-01000597411; W-60383; (S)-2-(4-(((2,4-diaminopteridin-6-yl)methyl); Q-201366; SR-01000075682-1; SR-01000075682-2; SR-01000075682-6; SR-01000597411-1; W-105347; BRD-K59456551-001-09-3; BRD-K59456551-001-11-9; WLN: T66 BN DN GN JNJ CZ EZ H1N1&R DVMYVQ2VQ; Z1521553982; N,N,N,N-ETHYLENEDIAMINETETRA(METHYLENEPHOSPHONICACID); Methotrexate, European Pharmacopoeia (EP) Reference Standard; Methotrexate, United States Pharmacopeia (USP) Reference Standard; Glutamic acid,4-diamino-6-pteridinyl)methyl] methylamino]benzoyl]-, L-(+)-; L-Glutamic acid,4-diamino-6-pteridinyl)methyl]- methylamino]benzoyl]-; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)-(methyl)amino)benzamido)pentanedioic acid; L-Glutamic acid,N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-,hydrate(9ci); Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard; Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard; Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material; N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-L-glutamic acid; N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino]benzoyl]-L-glutamic acid; (2S)-2-((4-(((2,4-DIAMINOPTERIDIN-6-YL)METHYL)(METHYL)AMINO)BENZOYL)AMINO)PENTANEDIOIC ACID; (2S)-2-[[[4-[(2,4-diamino-6-pteridinyl)methyl-methylamino]phenyl]-oxomethyl]amino]pentanedioic acid;hydrate; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]glutaric acid;hydrate; (2S)-2-[[4-[[2,4-bis(azanyl)pteridin-6-yl]methyl-methyl-amino]phenyl]carbonylamino]pentanedioic acid;hydrate; 102613-64-9	Approved	Approved Drug(s)	126941	DB00563	D05TMW	454.4	211	704	-1.8	33	5	12	9	C20H22N8O5	(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid	CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O	CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O	InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1	FBOZXECLQNJBKD-ZDUSSCGKSA-N
D9P1YD	Afatinib	Small molecule	Afatinib; 439081-18-2; 850140-72-6; Tovok; BIBW2992; Tomtovok; BIBW 2992; BIBW-2992; Afatinib (BIBW2992); (S,E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; Afatinib, Free Base; BIBW2992 (Tovok); Afatinib free base; C24H25ClFN5O3; (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; NSC-750691; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; CHEMBL1173655; CHEBI:61390; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-Butenamide; 41UD74L59M; 850140-72-6 (free base); NSC750691; (2E)-N-(4-(3-chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; S1011; (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; (S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide.; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; Afatinib [USAN]; Afatinib [USAN:INN]; afatinibum; UNII-41UD74L59M; MFCD12407405; Afatinib- Bio-X; (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl)-amide; (E)-4-Dimethylamino-but-2-enoic acid-[4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl]-amide; 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-, (2E)-; (E/Z)-Afatinib; BIBW2992,Afatinib; Afatinib (USAN/INN); AFATINIB [INN]; AFATINIB [MI]; AFATINIB [VANDF]; AFATINIB [MART.]; BIBW2992 - Afatinib; AFATINIB [WHO-DD]; MLS006010000; GTPL5667; CHEBI:94698; DTXSID20893451; EX-A065; BCPP000338; BCP01779; BDBM50322823; NSC799327; Afatinib(cis-trans isomerismtautomers); AKOS015850681; AKOS015904219; AKOS025149636; BCP9000407; CCG-264776; DB08916; EX-8656; NSC-799327; NCGC00185000-01; (2e)-n-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3s)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-2-butenamide; (E)-N-[4-(3-chloro-4-fluoro-anilino)-7-[(3S)-tetrahydrofuran-3-yl]oxy-quinazolin-6-yl]-4-(dimethylamino)but-2-enamide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)- 6-quinazolinyl)-4-(dimethylamino)-, (2E)-; AC-26079; AC-27018; AM808098; AS-80916; BA164141; DS-14172; SMR004701084; CS-0020030; SW219248-1; A15572; D09724; AB01565886_02; EN300-6487482; EN300-19625328; SR-01000941576; J-500781; J-502300; Q4688818; SR-01000941576-1; BRD-K66175015-001-01-7; Z2568727518; (2E)-N-[4-(3-Chloro-4-fluoroanilino)-7-[[(3S)-oxolane-3-yl]oxy]quinazoline-6-yl]-4-(dimethylamino)-2-buteneamide; (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6yl)-amide; (R,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; (S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide	Approved	Approved Drug(s)	10184653	DB08916	D05UFG	485.9	88.6	702	3.6	34	2	8	8	C24H25ClFN5O3	(E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide	CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4	CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4	InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1	ULXXDDBFHOBEHA-CWDCEQMOSA-N
DUP9Q2	Nintedanib	Small molecule	Nintedanib; Vargatef; 656247-17-5; BIBF-1120; Intedanib; 928326-83-4; BIBF 1120; BIBF1120; Nintedanib (BIBF 1120); (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; 1160294-26-7; CID 9809715; G6HRD2P839; Methyl (3Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate; CHEBI:85164; (Z)-Methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)-phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1h-indole-6-carboxylate; methyl (3Z)-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate; methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate; methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate; Nintedanib [INN]; Nintedanib [USAN]; Nintedanib [USAN:INN]; BIBF1120 (Vargatef); UNII-G6HRD2P839; Vargatef Base; Nintedanib- Bio-X; Nintedanib, Free Base; BIBF1120,Vargatef; Nintedanib (Intedanib); INTEDANIB [MI]; Bibf1120 - Vargatef; Nintedanib (USAN/INN); NINTEDANIB [VANDF]; NINTEDANIB [WHO-DD]; MLS006010165; SCHEMBL431006; SCHEMBL431007; US10669235, Nintedanib; GTPL5936; SCHEMBL1535871; OFEV COMPONENT NINTEDANIB; CHEMBL2136735; CHEBI:91413; HSDB 8339; AMY9163; DTXSID20918936; EX-A341; BDBM445209; DTXSID201025948; HMS3244B06; HMS3244B10; HMS3244B14; HMS3295K01; HMS3654A05; BCP01744; BCP09316; EX-A2818; NINTEDANIB COMPONENT OF OFEV; BDBM50026612; MFCD11974012; NSC756659; NSC757442; NSC800805; s1010; AKOS005145820; AKOS025401745; AKOS026750205; AM84929; BCP9000405; CCG-264775; CS-0104; DB09079; KS-1434; NSC-756659; NSC-757442; NSC-800805; SB11190; NCGC00263156-01; NCGC00263156-02; NCGC00263156-13; NCGC00263156-14; NCGC00389321-03; AC-25071; BN164249; HY-50904; SMR004701273; FT-0670358; FT-0772497; SW218301-2; EC-000.2311; D10481; EN300-188528; J-502642; BRD-K49075727-001-01-0; Q15149723; Q27163267; Z2756516920; (Z)-Methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester; 3-[[4-[methyl-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylic acid methyl ester; 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone; Methyl 2-hydroxy-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-3H-indole-6-carboxylate; methyl 3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate	Approved	Approved Drug(s)	135423438	DB09079	D05USQ	539.6	102	892	4.3	40	2	7	8	C31H33N5O4	methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate	CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O	CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O	InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3	CPMDPSXJELVGJG-UHFFFAOYSA-N
D7BY9M	Nalmefene	Small molecule	nalmefene; Nalmetrene; 55096-26-9; Selincro; JF-1; Revex; Nalmefeno; ORF-11676; ORF 11676; Nalmefene - d3; Nalmetrenum; Nalmefenum; Nalmetreno; TOV02TDP9I; CHEMBL982; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol; MLS000069366; CHEBI:7457; SRD174; DTXSID8023347; JKB-121; SRD-174; ORF 1167; ORF-1167; NCGC00021666-03; SMR000058884; Selincro (TN); JF 1; Nalmefenum [INN-Latin]; Nalmefeno [INN-Spanish]; Nalmetrenum [INN-Latin]; Nalmetreno [INN-Spanish]; DTXCID903347; Alcofene; Arthene; Cervene; Incystene; Soberal; Cessal; (4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylene-1,2,3,4,5,6,7,7a-octahydro-4aH-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol; CAS-55096-26-9; HSDB 6761; Nalmefene (USAN/INN); UNII-TOV02TDP9I; Nalmefene [USAN:INN:BAN]; Nalmefene hydrochloride hydrate; 9a-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylen-3,14-morphinandiol; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinon-3,14-diol; NIH-10365; NALMEFENE [INN]; Opera_ID_468; NALMEFENE [MI]; NALMEFENE [HSDB]; NALMEFENE [USAN]; NALMEFENE [VANDF]; NALMEFENE [MART.]; NALMEFENE [WHO-DD]; SCHEMBL35230; GTPL1628; Revex (nalmefene hydrochloride); cid_5284594; Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, (5.alpha.)-; HMS2232D07; BCP16723; Tox21_110873; BDBM50045776; PDSP2_001543; (5alpha)-17-(cyclopropylmethyl)-6-methylidene-4,5-epoxymorphinan-3,14-diol; Tox21_110873_1; BN36715; DB06230; Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, (5alpha)-; NCGC00021666-04; C08027; D05111; AB00384250_10; EN300-18384909; Q4353252; (1S,5R,13S,17S)-4-(cyclopropylmethyl)-14-methylidene-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-triene-10,17-diol; (1S,5R,13S,17S)-4-(cyclopropylmethyl)-14-methylidene-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18)-triene-10,17-diol; (4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol	Approved	Approved Drug(s)	5284594	DB06230	D05VIL	339.4	52.9	618	2.7	25	2	4	2	C21H25NO3	(4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol	C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O	C=C1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O	InChI=1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1	WJBLNOPPDWQMCH-MBPVOVBZSA-N
D8X4HU	Empagliflozin	Small molecule	Empagliflozin; 864070-44-0; JARDIANCE; BI 10773; BI10773; BI-10773; Empagliflozin (BI 10773); (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; HDC1R2M35U; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; CHEBI:82720; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-CHLORO-3-[[4-[(3S)-OXOLAN-3-YL]OXYPHENYL]METHYL]PHENYL]-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL; Empagliflozin  (BI-10773;BI 10773;BI10773); (1S)-1,5-anhydro-1-C-{4-chloro-3-((4-{((3S)-oxolan-3-yl)oxy}phenyl)methyl)phenyl}-D-glucitol; (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(((3S)-tetrahydro-3-furanyl)oxy)phenyl)methyl)phenyl)-, (1S)-; Empagliflozin [INN]; UNII-HDC1R2M35U; Empagliflozin [USAN:INN]; C23H27ClO7; MFCD22566222; Jardiance (TN); (S)-Empagliflozin D4; EMPAGLIFLOZIN [MI]; BI-10773;Empagliflozin; EMPAGLIFLOZIN [JAN]; EMPAGLIFLOZIN [USAN]; Empagliflozin (BI10773); EMPAGLIFLOZIN [VANDF]; SCHEMBL899986; EMPAGLIFLOZIN [WHO-DD]; GTPL4754; CHEMBL2107830; Empagliflozin (JAN/USAN/INN); AMY1858; EX-A414; BDBM150162; DTXSID601026093; EMPAGLIFLOZIN [ORANGE BOOK]; BBL104150; HB4638; s8022; STL557964; US8980829, EMPAGLIFLOZIN; AKOS024464680; GLYXAMBI COMPONENT EMPAGLIFLOZIN; CCG-269242; CS-0940; DB09038; DS-9824; PB23119; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol; AC-27643; EMPAGLIFLOZIN COMPONENT OF GLYXAMBI; EMPAGLIFLOZIN COMPONENT OF SYNJARDY; HY-15409; TRIJARDY XR COMPONENT EMPAGLIFLOZIN; EMPAGLIFLOZIN COMPONENT OF TRIJARDY XR; SW219120-1; C22194; D10459; EN300-7422890; A852380; AU-004/43508285; Q5373824; Z2235802079; 1,5-anhydro-1-{4-chloro-3-[4-(tetrahydro-3-furanyloxy)benzyl]phenyl}hexitol; (1S)-1,5-ANHYDRO-1-C-(4-CHLORO-3-((4-(((3S)-OXAN-3-YL)OXY)PHENYL)METHYL)PHENYL)-D-GLUCITOL; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxyMethyl)-tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-tetrahydrofuran-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; 7R3	Approved	Approved Drug(s)	11949646	DB09038	D06ALD	450.9	109	558	2	31	4	7	6	C23H27ClO7	(2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol	C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl	C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl	InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1	OBWASQILIWPZMG-QZMOQZSNSA-N
D64IDG	Buprenorphine	Small molecule	buprenorphine; Temgesic; Probuphine; Buprenex; 52485-79-7; Buprenophine; Buprenorfina; Buprenorphinum; Butrans; Buprenorfina [INN-Spanish]; Buprenorphinum [INN-Latin]; (-)-buprenorphine; buprenorphin; Sublocade; CHEBI:3216; DEA No. 9064; 40D3SCR4GZ; CAM2038; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; RX 6029M; Brixadi; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; Probuphenine; Temgesic (TN); (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol; 2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol; 6029-M; Buprenorphine (JAN/INN); CHEMBL560511; UNII-40D3SCR4GZ; Buvidal; Buprenorphine [INN:BAN:JAN]; ALKS-5461 COMPONENT BUPRENORPHINE; EINECS 257-950-6; BEMA; [5alpha,7alpha(S)]-; BUPRENORPHINE [MI]; BUPRENORPHINE [INN]; BUPRENORPHINE [JAN]; SCHEMBL15821; BUPRENORPHINE [VANDF]; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; BUPRENORPHINE [MART.]; BUPRENORPHINE [WHO-DD]; GTPL1670; BUPRENORPHINE [EMA EPAR]; DTXSID2022705; BUPRENORPHINE [EP IMPURITY]; BUPRENORPHINE [ORANGE BOOK]; Sixmo (buprenorphine hydrochloride); RBP-6000; BUPRENORPHINE [EP MONOGRAPH]; BDBM50026603; DB00921; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-.alpha.-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-.alpha.-methyl-, (.alpha.S,5.alpha.,7.alpha.)-; C08007; D07132; Q407721; (1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7(12),8,10-trien-11-ol; (1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7,9,11-trien-11-ol; (2S)-2-[(5R,6R,7R,14S)-9alpha-Cyclopropylmethyl-3-hydroxy-6-methoxy-4,5-epoxy-6,14-ethanomorphinan-7-yl]-3,3-dimethylbutan-2-ol; 6,14-ethenomorphinan-3-ol, 17-(cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-7-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-, (5alpha,7alpha)-; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-,; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5-alpha,7-alpha-(S))-; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)- (9CI)	Approved	Approved Drug(s)	644073	DB00921	D06AWE	467.6	62.2	869	5	34	2	5	5	C29H41NO4	(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol	CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O	C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O	InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1	RMRJXGBAOAMLHD-IHFGGWKQSA-N
D3CJ9O	Ferumoxytol	Small molecule	Magnetic oxide; iron(ii; MFCD00011010; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; Eisen(II,III)-oxid; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; ferro ferric oxide; EINECS 215-169-8; KN 320; Ferumoxytol [USAN]; KBC 100 (mineral); Code 7228; DTXSID2052780; CHEBI:50821; NSC 729745; Iron Oxide Powder, 97+% Nano, 50-100nm particle size; Iron Oxide, Fe3O4, 98+%, 20-30 nm, coated with 1% PVP(Molecular Weight 30K)	Approved	Approved Drug(s)	14789	DB06215	D06CTM	233.55	74.6	27.9	.	7	2	4	0	Fe3H2O4	hydroxy(oxo)iron;iron	O[Fe]=O.O[Fe]=O.[Fe]	O[Fe]=O.O[Fe]=O.[Fe]	InChI=1S/3Fe.2H2O.2O/h;;;2*1H2;;/q;2*+1;;;;/p-2	UCNNJGDEJXIUCC-UHFFFAOYSA-L
D84VLM	Verapamil	Small molecule	VERAPAMIL; 52-53-9; Iproveratril; Vasolan; Dilacoran; Isoptin; Falicard; Finoptin; Isoptine; Calan; Lekoptin; Verapamilo; Verapamilum; Isotopin; Securon; Calcan; Tarka; D-365; (+/-)-VERAPAMIL; CP-16533-1; Cardibeltin; Izoptin; Verelan; Covera-HS; Verpamil; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile; Verelan PM; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Cardiagutt; Berkatens; Dignover; Geangin; Veramex; Quasar; Univer; Novo-Veramil; Verapamil slow release; Apo-Verap; Isoptin SR; Nu-Verap; C27H38N2O4; Calan SR; Isoptimo; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; CJ0O37KU29; DTXSID9041152; CHEBI:77733; CP-16,533-1; Cardiabeltin; Cardioprotect; Durasoptin; Hexasoptin; Veratensin; Veroptinstada; Calaptin; Caveril; Civicor; Coraver; Corpamil; Harteze; Hormitol; Ikapress; Inselon; Isoptino; Jenapamil; Lodixal; Magotiron; Praecicor; Robatelan; Vasomil; Vasopten; Verabeta; Veracor; Verahexal; Veraloc; Veramil; Verapin; Verasal; Verasifar; Verdilac; Vetrimil; Akilen; Elthon; Flamon; Ikacor; Univex; Vortac; Anpec; Ormil; Rapam; Civicor Retard; Isoptin Retard; Manidon Retard; Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-; Vera-Sanorania; Verapamil Acis; Verapamil Atid; Verapamil Ebewe; Verapamil Riker; Verapamil Verla; Verapamil Basics; Verapamil Nordic; Verapamil-AbZ; Novapamyl LP; Verapamil AL; Verapamil NM; Verapamil PB; Verapamil SR; Cordilox SR; Dilacoran HTA; Veracaps SR; Verapamil MSD; Verapamilum [INN-Latin]; Arpamyl LP; Hexasoptin Retard; Verapamil Henning; Verelan SR; NCGC00016083-09; Verapamilo [INN-Spanish]; CP-165331; Verapamil Injection; Verapamil NM Pharma; Calaptin 240 SR; Verapress 240 SR; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-; (+/-)-Verapamil hydrochlorid; DTXCID7021152; ()-Verapamil hydrochlorid; Verapamil [USAN:INN:BAN]; dl-Verapamil; r,s-verapamil; (+/-)-Verapamil;CP-16533-1; CAS-52-53-9; CCRIS 6749; NSC272366; Verapamil (USAN/INN); EINECS 200-145-1; UNII-CJ0O37KU29; Ansyr; NSC 272306NA; EINECS 260-462-6; Calan (Salt/Mix); Akilen (Salt/Mix); alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Isoptin (Salt/Mix); alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Cordilox (Salt/Mix); delta-365; VERAPAMIL [INN]; VERAPAMIL [MI]; Covera-HS (Salt/Mix); VERAPAMIL [USAN]; Prestwick0_000141; Prestwick1_000141; Prestwick2_000141; Prestwick3_000141; Spectrum2_001740; Spectrum4_000906; Spectrum5_001786; VERAPAMIL [VANDF]; CP 16533-1; D 365; VERAPAMIL [WHO-DD]; CHEMBL6966; Lopac0_001237; SCHEMBL16742; BSPBio_000242; BSPBio_001513; BSPBio_002358; KBioGR_000233; KBioGR_001372; KBioGR_002343; KBioSS_000233; KBioSS_002346; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino) propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-; MLS006011414; DivK1c_000399; SPBio_001820; SPBio_002181; BPBio1_000268; GTPL2406; CP 16533-1 (Verapamil); SCHEMBL13287282; (A+/-)-Verapamil hydrochloride; BDBM81939; HSDB 3928; KBio1_000399; KBio2_000233; KBio2_002343; KBio2_002801; KBio2_004911; KBio2_005369; KBio2_007479; KBio3_000465; KBio3_000466; KBio3_002823; ()-Verapamil;CP-16533-1; cMAP_000023; NINDS_000399; NSC-272306NA; Bio1_000425; Bio1_000914; Bio1_001403; Bio2_000233; Bio2_000713; HMS1791L15; HMS1989L15; HMS2089H17; HMS3402L15; Tox21_110300; MFCD00056240; NSC_62969; STK538085; AKOS005468962; Tox21_110300_1; CCG-205311; DB00661; SDCCGSBI-0051204.P005; CAS_52-53-9; IDI1_000399; IDI1_033983; NCGC00016083-04; NCGC00016083-05; NCGC00016083-06; NCGC00016083-07; NCGC00016083-08; NCGC00016083-10; NCGC00016083-11; NCGC00016083-13; NCGC00016083-14; NCGC00016083-15; NCGC00016083-16; NCGC00016083-17; NCGC00016083-18; NCGC00016083-20; NCGC00016083-25; NCGC00016083-34; NCGC00024710-04; NCGC00024710-05; NCGC00024710-06; NCGC00024710-07; NCGC00024710-08; NCGC00024710-09; NCGC00344584-01; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-isopropyl-pentanenitrile; 56949-77-0; AC-16016; BP-21223; HY-14275; NCI60_020143; SMR001550201; SBI-0051204.P003; AB00053495; CS-0002967; FT-0603225; FT-0675801; C07188; D02356; E75969; EN300-708774; AB00053495-20; AB00053495_21; A829133; L001330; Q410291; BRD-A09533288-001-02-7; BRD-A09533288-003-05-6; CP-165331 /  CP-16533-1; F2173-0851; VERAPAMIL, Dexverapamil, Verapamyl hydrochloride, VERAPAMIL HYDROCHLORIDE; .alpha.-((N-Methyl-N-homoveratryl)-.gamma.-aminopropyl)-3,4-dimethoxyphenylacetonitrile; (+/-)-5-((3,4-DIMETHOXYPHENETHYL)METHYLAMINO)-2-(3,4-DIMETHOXYPHENYL)-2-ISOPROPYLVALERONITRILE; (?)-alpha-[3-[[2-(3,4-Dimethoxyphenyl)ethyl](methyl)amino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; 2-(3,4-Dimethoxyphenyl)-5-((2-(3,4-dimethoxyphenyl)ethyl)(methyl)amino)-2-isopropylpentanenitrile, (+/-)-; 2-(3,4-Dimethoxyphenyl)-5-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-2-isopropylpentanenitrile #	Approved	Approved Drug(s)	2520	DB00661	D06ECJ	454.6	64	606	3.8	33	0	6	13	C27H38N2O4	2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile	CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC	CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC	InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3	SGTNSNPWRIOYBX-UHFFFAOYSA-N
DY3S7P	Oliceridine	Small molecule	Oliceridine; TRV130; 1401028-24-7; TRV-130; Olinvyk; Oliceridine [USAN]; N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine; MCN858TCP0; [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine; Olinvo; 6-Oxaspiro(4.5)decane-9-ethanamine, N-((3-methoxy-2-thienyl)methyl)-9-(2-pyridinyl)-, (9R)-; 6-Oxaspiro[4.5]decane-9-ethanamine, N-[(3-methoxy-2-thienyl)methyl]-9-(2-pyridinyl)-, (9R)-; N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethan-1-amine; TRV 130; UNII-MCN858TCP0; TRV130A; N-((3-methoxythiophen-2-yl)methyl)-2-((9R)-9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethanamine; N-[(3-Methoxythiophen-2-yl)methyl]-2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethanamine; Olinvyk (TN); OLICERIDINE [MI]; Oliceridine; TRV-130; OLICERIDINE [INN]; Oliceridine (USAN/INN); OLICERIDINE [WHO-DD]; GTPL7334; CHEMBL2443262; SCHEMBL12542370; OLICERIDINE [ORANGE BOOK]; DTXSID201031292; BCP14196; BGC02824; EX-A2170; BDBM50493818; AKOS030526482; Oliceridine;Olinvo;TRV 130;TRV130; CS-3571; DB14881; NCGC00390659-01; AC-35966; HY-16655; A14337; D11214; A935006; EN300-20351935; Q17142898; (9R)-N-[(3-Methoxy-2-thienyl)methyl]-9-(2-pyridinyl)-6-oxaspiro[4.5]decane-9-ethanamine hydrochlorid; (R)-N-((3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine; [(3-methoxythiophen-2-yl)methyl]({2-[(9r)-9-(pyridine-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine; WH2	Approved	Approved Drug(s)	66553195	DB14881	D06ENM	386.6	71.6	471	3.5	27	1	5	7	C22H30N2O2S	N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine	COC1=C(SC=C1)CNCCC2(CCOC3(C2)CCCC3)C4=CC=CC=N4	COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4	InChI=1S/C22H30N2O2S/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3/t21-/m1/s1	DMNOVGJWPASQDL-OAQYLSRUSA-N
DP78TH	Didanosine	Small molecule	didanosine; 2',3'-Dideoxyinosine; 69655-05-6; DIDEOXYINOSINE; Videx; Videx EC; Inosine, 2',3'-dideoxy-; ddIno; Didanosinum; Didanosina; DDI; 2,3-dideoxyinosine; BMY-40900; (-)-didanosine; NSC-612049; K3GDH6OH08; DTXSID6022927; 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one; CHEBI:490877; 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; NSC 612049; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; NCGC00090691-03; NCGC00159514-02; Didanosine 100 microg/mL in Acetonitrile; 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; 9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one; 2',3'-Dideoxyinosine (ddI); DTXCID402927; 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one; Hypoxanthine ddN; Didanosinum [INN-Latin]; NSC612049; Didanosina [INN-Spanish]; 9-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6,9-DIHYDRO-3H-PURIN-6-ONE; D2I; SMR000058576; Videx(TM); Intron A & Videx; CAS-69655-05-6; Videx (TN); PC-SOD+ddI; Dideoxyinosine (DDI); LOA & ddI; ddI + d4T combination; ddI & GM-CSF; SR-05000001487; DRG-0016; DDI and rIFN.alpha.2; BMY 40900; ddI & sCD4(rsCD4); UNII-K3GDH6OH08; CCRIS 805; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one; DS-4152 & ddI; HSDB 6548; Didanosine,(S); Didanosine [USAN:USP:INN:BAN]; Didanosine (DDI); 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; Didanosine (Videx); Didanosine and Interferon-.alpha.-2; MFCD00077728; Videx EC(TM)(slow-release capsules); KS-1049; BRN 3619529; 2',3'-didesoxyinosin; 2',3'-Dideoxyinosine (AIDS Initiative); ddI & IFN-.alpha.; DIDANOSINE [MI]; DIDANOSINE [INN]; DIDANOSINE [JAN]; 2', 3'-dideoxyinosine; DIDANOSINE [HSDB]; DIDANOSINE [USAN]; DIDANOSINE [VANDF]; DIDANOSINE [MART.]; SCHEMBL3363; CHEMBL1460; DIDANOSINE [USP-RS]; DIDANOSINE [WHO-DD]; DIDANOSINE [WHO-IP]; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine; Listera ovata agglutinin & 2',3'-Dideoxyinosine; Didanosine (JAN/USP/INN); MLS000759469; MLS001055350; MLS001424118; MLS002154216; MLS006011561; 3'-Azido-3'-deoxythymidine + 2',3'-Dideoxyinosine; GTPL4833; DIDANOSINE [EP IMPURITY]; DIDANOSINE [ORANGE BOOK]; Didanosine for system suitability; 2',3'-Dideoxyinosine & sCD4(soluble recombinant protein); DIDANOSINE [EP MONOGRAPH]; DIDANOSINE [USP IMPURITY]; DIDANOSINE [USP MONOGRAPH]; HMS2051J11; HMS2089N20; HMS2095O08; HMS2232P22; HMS3712O08; HMS3884M06; DIDANOSINUM [WHO-IP LATIN]; HY-B0249; Tox21_111732; Tox21_202333; Tox21_300575; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-3H-purin-6-one; BDBM50404252; 2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor; 2',3'-DIDEOXYINOSINE; Didanosine; AKOS015833088; AKOS015901454; AKOS015963259; AKOS026750545; Tox21_111732_1; CCG-100947; CCG-220153; DB00900; NC00197; 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,9-dihydro-6H-purin-6-one; SRI-7013-04; SRI-7013-05; SRI-7013_07; NCGC00090691-01; NCGC00090691-02; NCGC00090691-14; NCGC00159514-03; NCGC00159514-04; NCGC00164280-01; NCGC00188983-01; NCGC00254496-01; NCGC00259882-01; NCGC00390773-01; 2DI; AC-12026; AC-32186; BP-58651; SMR004703324; 2',3'-Dideoxyinosine, >=98% (HPLC); 2',3'-Dideoxyinosine & Interferon-.alpha.; D3066; SW198619-2; 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran; C06953; D00296; EN300-123032; T71244; Q422606; J-700356; SR-05000001487-1; SR-05000001487-2; W-203551; Z1546616193; Didanosine, European Pharmacopoeia (EP) Reference Standard; Didanosine, United States Pharmacopeia (USP) Reference Standard; Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2; Lecithinized superoxide dismutase & Inosine, 2',3'-dideoxy-; 9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol; 2 inverted exclamation mark ,3 inverted exclamation mark -Dideoxyinosine; 9-((2R,5S)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-1H-PURIN-6(9H)-ONE; Didanosine for system suitability, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	135398739	DB00900	D06FDR	236.23	88.7	348	-1.2	17	2	5	2	C10H12N4O3	9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one	C1CC(OC1CO)N2C=NC3=C2N=CNC3=O	C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O	InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1	BXZVVICBKDXVGW-NKWVEPMBSA-N
DX26OG	Doxepin	Small molecule	doxepin; (e)-doxepin; Doxepine; 1668-19-5; trans-doxepin; Doxepin, (E)-; Sinequan; Doxepinum [INN-Latin]; Doxepina [INN-Spanish]; Sinequan (TN); 3607-34-9; 851NLB57HQ; Doxepin [USAN]; Doxepina; Doxepinum; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; Deptran; 1-Propanamine, 3-dibenz(b,e)oxepin-11(6H)-ylidene-N,N-dimethyl-; MF 10; (3e)-3-(Dibenzo[b,E]oxepin-11(6h)-Ylidene)-N,N-Dimethylpropan-1-Amine; Doxepin (INN); [11C]doxepin; 3-(Dibenzo[b,e]oxepin-11(6H)-ylidene)-N,N-dimethylpropan-1-amine; [11C]-doxepin; CCRIS 9176; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; HSDB 3069; Doxepin [INN:BAN]; NCGC00015344-03; UNII-5ASJ6HUZ7D; CAS-1229-29-4; UNII-851NLB57HQ; Methyllactate; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; NSC 108160; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; E-DOXEPIN; Tocris-0508; P-3693A; Prestwick2_000263; Prestwick3_000263; DOXEPIN, E-ISOMER; Lopac-D-4526; 5ASJ6HUZ7D; CHEMBL860; Doxepin [USAN:INN:BAN]; Lopac0_000339; BSPBio_000106; SCHEMBL116895; BPBio1_000118; GTPL1225; GTPL3958; HY-B0725A; DTXSID90859605; (3E)-3-DIBENZO(B,E)OXEPIN-11(6H)-YLIDENE-N,N-DIMETHYLPROPAN-1-AMINE; BDBM112780; Dibenz(b,e)oxepin-delta(sup 11(6H)),gamma-propylamine, N,N-dimethyl-; CCG-204434; SDCCGSBI-0050327.P002; NCGC00015344-01; NCGC00015344-02; NCGC00015344-04; NCGC00015344-12; NCGC00024623-01; NCGC00162127-01; US8629135, SW-07; CS-0013584; C06971; D07875; L000699; BRD-K36616567-003-01-5; BRD-K54462405-003-03-3; BRD-K54462405-003-16-5; Q27077103; 1-PROPANAMINE, 3-DIBENZ(B,E)OXEPIN-11(6H)-YLIDENE-N,N-DIMETHYL-, (3E)-; 5EH	Approved	Approved Drug(s)	667477	DB01142	D06FES	279.4	12.5	363	4.3	21	0	2	3	C19H21NO	(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine	CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31	CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31	InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+	ODQWQRRAPPTVAG-GZTJUZNOSA-N
DM8OW2	Enfuvirtide	Small molecule	Enfuvirtide; Pentafuside; Fuzeon; DP178; DP-178; T-20; CHEBI:608828; T 20; Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2; Dp 178; Fuzeon (TM); Fuzeon T-20; T 20 (peptide); Enfurvitide (T-20); Enfuvirtide+PRO 140; Enfuvirtide + T1144; TNX-355 & Efuvirtide; UNII-19OWO1T3ZE; 19OWO1T3ZE; T20-LAI; Enfuvirtide [USAN:INN:BAN]; CHEMBL525076; HSDB 7341; DTXSID20166672; GNA & G-20; HHA & T-20; PENTAFUSIDE (TRIVIAL NAME); BDBM50023615; T-20+PRO 140; GP41 127-162 AA; 5A8 & T-20; R-698; T20 + T1144; Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2 & PRO 140 (Anti-CCR5 monoclonal antibody); Humanized monoclonal antibody to CD4 & Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2; Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2 & Galanthus nivalis agglutinin (GNA); Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2 & Hippeastrum hybrid agglutinin( HHA); Acetyl-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2; AcTyrThrSerLeuIleHisSerLeuIleGluGluSerGlnAsnGlnGlnGluLysAsnGluGlnGluLeuLeuGluLeuAspLysTrpAlaSerLeuTrpAsnTrpPheNH2; T-20-LAI [Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2]	Approved	Approved Drug(s)	16130199	DB00109	D06GBQ	4492	1900	11200	-14.7	319	63	67	151	C204H301N51O64	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid	CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(C)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(=O)N)C(=O)NC(CC5=CNC6=CC=CC=C65)C(=O)NC(CC7=CC=CC=C7)C(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(CC8=CN=CN8)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)C	InChI=1S/C204H301N51O64/c1-20-102(15)166(253-195(310)137(75-100(11)12)239-200(315)150(93-258)251-190(305)143(82-112-90-215-95-219-112)248-203(318)167(103(16)21-2)254-196(311)138(76-101(13)14)240-201(316)151(94-259)252-204(319)168(105(18)260)255-197(312)139(221-106(19)261)78-108-45-47-113(262)48-46-108)202(317)233-131(58-68-164(280)281)178(293)228-130(57-67-163(278)279)182(297)250-149(92-257)198(313)232-125(52-62-155(210)266)179(294)245-145(84-157(212)268)191(306)229-124(51-61-154(209)265)175(290)224-122(49-59-152(207)263)173(288)226-126(53-63-159(270)271)176(291)222-120(43-31-33-69-205)172(287)244-144(83-156(211)267)192(307)231-127(54-64-160(272)273)177(292)225-123(50-60-153(208)264)174(289)227-128(55-65-161(274)275)180(295)235-134(72-97(5)6)185(300)237-133(71-96(3)4)184(299)230-129(56-66-162(276)277)181(296)236-135(73-98(7)8)187(302)247-147(86-165(282)283)194(309)223-121(44-32-34-70-206)171(286)241-140(79-109-87-216-117-40-28-25-37-114(109)117)183(298)220-104(17)170(285)249-148(91-256)199(314)238-136(74-99(9)10)186(301)242-142(81-111-89-218-119-42-30-27-39-116(111)119)189(304)246-146(85-158(213)269)193(308)243-141(80-110-88-217-118-41-29-26-38-115(110)118)188(303)234-132(169(214)284)77-107-35-23-22-24-36-107/h22-30,35-42,45-48,87-90,95-105,120-151,166-168,216-218,256-260,262H,20-21,31-34,43-44,49-86,91-94,205-206H2,1-19H3,(H2,207,263)(H2,208,264)(H2,209,265)(H2,210,266)(H2,211,267)(H2,212,268)(H2,213,269)(H2,214,284)(H,215,219)(H,220,298)(H,221,261)(H,222,291)(H,223,309)(H,224,290)(H,225,292)(H,226,288)(H,227,289)(H,228,293)(H,229,306)(H,230,299)(H,231,307)(H,232,313)(H,233,317)(H,234,303)(H,235,295)(H,236,296)(H,237,300)(H,238,314)(H,239,315)(H,240,316)(H,241,286)(H,242,301)(H,243,308)(H,244,287)(H,245,294)(H,246,304)(H,247,302)(H,248,318)(H,249,285)(H,250,297)(H,251,305)(H,252,319)(H,253,310)(H,254,311)(H,255,312)(H,270,271)(H,272,273)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)/t102-,103-,104-,105+,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,166-,167-,168-/m0/s1	PEASPLKKXBYDKL-FXEVSJAOSA-N
D9WG8U	Paroxetine	Small molecule	paroxetine; 61869-08-7; Paxil; Frosinor; Paxil CR; Casbol; Motivan; PaxPar; Seroxat; Paroxetina; Paroxetinum; Aropax; Paroxetinum [INN-Latin]; Paroxetina [INN-Spanish]; BRL 29060; Paxetil; BRL-29060; (-)-Paroxetine; FG 7051; FG-7051; (3s,4r)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; Arketis; Besitram; Daparox; Parogen; Xetanor; Arotin; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; [3H]Paroxetine; (+/-)-Paroxetine; (-)3s,4r-paroxetine; (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; Paroxetine, (+/-)-; CHEMBL490; Paroxetine, trans-(+/-)-; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S,4R)-; 32Q7TW8BX7; CHEBI:7936; DTXSID3023425; 41VRH5220H; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)-; (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; 110429-35-1; Paroxetine (TN); DTXCID703425; Paroxetine [USAN:INN:BAN]; CHEMBL1708; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3R,4S)-rel-; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, trans-; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, trans-(+/-)-; Rel-(3R,4S)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; PAROXETINE HCL HEMIHYDRATE; 130855-15-1; CAS-61869-08-7; Paroxetine (USP/INN); UNII-41VRH5220H; 3h-paroxetine; Paroxetine.HCl; (3S,4R)-3-((1,3-BENZODIOXOL-5-YLOXY)METHYL)-4-(4-FLUOROPHENYL)PIPERIDINE; piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)-; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)-; NCGC00182968-01; 8PR; NNC-20-7051; Spectrum_001752; PAROXETINE [MI]; SpecPlus_000788; PAROXETINE [INN]; Prestwick3_000851; Spectrum5_001665; PAROXETINE [USAN]; PAROXETINE [VANDF]; PAROXETINE [MART.]; PAROXETINE [WHO-DD]; UNII-32Q7TW8BX7; SCHEMBL27799; BSPBio_000861; KBioSS_002232; BIDD:GT0673; DivK1c_006884; BPBio1_000949; GTPL4790; BDBM22416; HSDB 7175; KBio1_001828; KBio2_002232; KBio2_004800; KBio2_007368; HMS2090H05; Tox21_113123; BDBM50331515; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine; AKOS015888636; Tox21_113123_1; AC-8185; DB00715; SDCCGSBI-0051908.P003; (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine; (3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine; NCGC00025355-02; NCGC00025355-03; NCGC00025355-04; NCGC00025355-05; NCGC00025355-06; NCGC00025355-07; NCGC00025355-08; NCGC00025355-09; NCGC00025355-12; NCGC00025355-22; SBI-0051908.P002; HY-122272; AB00514724; CS-0083299; C07415; D02362; EN300-150199; AB00053704-21; AB00053704_22; AB00053704_23; Paroxetine Hydrochloride Anhydrous EP Impurity E; paroxetine hydrochloride (anhydrous or hemihydrate); Q408471; BRD-K37991163-003-02-7; BRD-K37991163-050-05-1; (3S,4R)-3-[(1,3-dioxaindan-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (-)-TRANS-4-(P-FLUOROPHENYL)-3-((3,4-(METHYLENEDIOXY)PHENOXY)METHYL)PIPERIDINE; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-,(3S,4R)-	Approved	Approved Drug(s)	43815	DB00715	D06GDY	329.4	39.7	402	3.5	24	1	5	4	C19H20FNO3	(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine	C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4	C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4	InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1	AHOUBRCZNHFOSL-YOEHRIQHSA-N
DKV28R	Deferoxamine	Small molecule	deferoxamine; Desferrioxamine B; 70-51-9; DESFERRIOXAMINE; Deferoxamine B; Deferrioxamine B; Deferrioxamine; Deferoxamin; Deferoxaminum; Desferin; DFOM; Desferan; Desferex; Desferral; Desferrin; N-Benzoylferrioxamine B; Desferal; DF B; DFOA; Deferoxamide B; NSC-527604; Deferoxamina; Ferrioxamine B, N-benzoyl-; Desferoxamine b; N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide; Dfo-b; J06Y7MXW4D; CHEBI:4356; Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy-; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide; Ba-33112; NSC527604; 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-; 30-Amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone; Deferoxamine (USAN); Desferal mesylate; DEFEROXAMINE [USAN]; N-(5-(3-((5-Aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid; N-(5-aminopentyl)-N-hydroxy-N'-[5-(N-hydroxy-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propanamido)pentyl]butanediamide; Propionohydroxamic acid, N-(5-(3-((5-aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)-; Deferoxamine B; Deferriferrioxamine B; Deferrioxamine; Desferriferrioxamin B; MLS002702118; Deferoxamine [USAN:INN]; Deferoxaminum [INN-Latin]; Deferoxamina [INN-Spanish]; Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-; Ba 29837; NSC268993; NSC644468; HSDB 3311; SMR000058548; EINECS 200-738-5; Ba 33112; UNII-J06Y7MXW4D; BRN 2514118; Cordaneurin; Desferrioxamin; Perineurin; Desferioxamine B; desferrioxamine-B; N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide; N-[5-(3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido)pentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)propionohydroxamic acid; N-[5-{3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido}pentyl]-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propionohydroxamic acid; Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-; deferoxamine-mesylate; Desferal (Salt/Mix); Spectrum_000892; Prestwick0_000725; Prestwick1_000725; Prestwick2_000725; Prestwick3_000725; Spectrum2_001155; Spectrum3_000376; Spectrum4_000311; Spectrum5_000827; DEFEROXAMINE [MI]; DEFEROXAMINE [INN]; CHEMBL556; DEFEROXAMINE [HSDB]; EC 200-738-5; DEFEROXAMINE [VANDF]; SCHEMBL34571; BSPBio_000650; BSPBio_002131; KBioGR_000922; KBioGR_002429; KBioSS_001372; KBioSS_002435; 1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetyl hydroxylamino)-6,11,17,22-tetraazaheptaeicosane; cid_62881; N'-(5-((4-((5-(Acetylhydroxamino)pentyl)amino)-1,4-dioxobutyl) hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxybutanediamide; DEFEROXAMINE [WHO-DD]; DivK1c_000082; Ba 29837 (Salt/Mix); SPBio_001109; SPBio_002589; BPBio1_000716; CGH-749B; ICL-749B; DTXSID7022887; BDBM47715; KBio1_000082; KBio2_001372; KBio2_002429; KBio2_003940; KBio2_004997; KBio2_006508; KBio2_007565; KBio3_001351; KBio3_002908; cMAP_000047; NINDS_000082; HMS3604E17; BCP16524; HY-B1625; LMFA08020169; WLN: Z5NQV/2VM5NQV/ 21; DEFEROXAMINE, Deferoxamine Mesylate; AKOS016004824; DB00746; IDI1_000082; SMP2_000121; NCGC00178802-01; NCGC00178802-02; NCGC00178802-03; MS-30181; NCI60_002181; SMR001550278; SBI-0051332.P003; AB00053447; CS-0013559; C06940; D03670; F11488; AB00053447_14; EN300-19748908; Q419618; Q-200933; BRD-K09821361-066-05-0; BRD-K09821361-066-06-8; BRD-K09821361-066-08-4; BRD-K09821361-066-13-4; BRD-K09821361-066-15-9; BRD-K09821361-066-16-7; 3,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-; 30-Amino-3,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone; Butanediamide,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-; N''''-(5-azanylpentyl)-N-[5-[[4-[5-[ethanoyl(oxidanyl)amino]pentylamino]-4-oxidanylidene-butanoyl]-oxidanyl-amino]pentyl]-N''''-oxidanyl-butanediamide;methanesulfonic acid; N'-[5-(acetyl-hydroxy-amino)pentyl]-N-[5-[3-(5-aminopentyl-hydroxy-carbamoyl)propanoylamino]pentyl]-N-hydroxy-butane diamide; N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-1,4-dioxobutyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-keto-butanoyl]-hydroxy-amino]pentyl]-N''-(5-aminopentyl)-N''-hydroxy-succinamide;mesylic acid; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid; N~1~-(5-(Acetyl(hydroxy)amino)pentyl)-N~4~-(5-((4-((5-aminopentyl)(hydroxy)amino)-4-oxobutanoyl)amino)pentyl)-N~4~-hydroxysuccinamide; Propionohydroxamic acid, N-[5-(3-[(5-aminopentyl)hydroxycarbamoyl]propionamido)phentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)-; Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[(5-N-hydroxyacetamido)pentyl]carbamoyl]-	Approved	Approved Drug(s)	2973	DB00746	D06GKR	560.7	206	739	-2.1	39	6	9	23	C25H48N6O8	N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide	CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O	CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O	InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)	UBQYURCVBFRUQT-UHFFFAOYSA-N
D9BH7U	Etoposide	Small molecule	etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; VP-16; Zuyeyidal; Etoposidum; Etoposido; Etoposidum [INN-Latin]; VP-16-213; Etoposide (VP16); VP 16-213; Vepesid J; Sintopozid; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; NSC-141540; DTXSID5023035; Etoposide (VP-16); VP 16 (pharmaceutical); 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); VP 16; 6PLQ3CP4P3; Epipodophyllotoxin VP-16213; CHEMBL44657; CHEBI:4911; NK 171; Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; NSC 141540; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); Etosid; [1,3]benzodioxol-8-one; Etoposido [INN-Spanish]; (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one; Etopophos (phosphate salt); DTXCID601473876; Etopol; VP 16213; NSC141540; (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one; (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one; SMR000112002; CCRIS 2392; HSDB 6517; VePESID (TN); EINECS 251-509-1; MFCD00869325; UNII-6PLQ3CP4P3; 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside; Etoposide,(S); NCGC00016821-01; (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f]; (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; EVP; Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); CAS-33419-42-0; Etoposide [USAN:USP:INN:BAN:JAN]; Etoposide; VP-16; CPD000112002; Epipodophyllotoxin-beta-D-ethyliden-glucoside, 4'-demethyl-; ETOPOSIDE [INN]; ETOPOSIDE [JAN]; ETOPOSIDE [MI]; ETOPOSIDE [HSDB]; ETOPOSIDE [IARC]; ETOPOSIDE [USAN]; Prestwick3_000396; ETOPOSIDE [VANDF]; ETOPOSIDE [MART.]; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; ETOPOSIDE [USP-RS]; ETOPOSIDE [WHO-DD]; ETOPOSIDE [WHO-IP]; SCHEMBL4259; BSPBio_000611; 9-((4,6-O-Ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-; 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4- hydroxy-3,4-dimethyloxyphenyl)furo (3',4'':6,7) naptho-(2,3-d)-1,3-dioxol-6 (5aH)-one; MLS000049957; MLS001074951; MLS001424283; MLS002153463; MLS002207239; MLS002222184; Etoposide (JP17/USP/INN); BPBio1_000673; GTPL6815; ETOPOSIDE [EP IMPURITY]; ETOPOSIDE [ORANGE BOOK]; ETOPOSIDE [EP MONOGRAPH]; ETOPOSIDE [USP IMPURITY]; ETOPOSIDE [USP MONOGRAPH]; ETOPOSIDUM [WHO-IP LATIN]; etoposide4-o-b-d-galactopyranoside; HMS2052N05; HMS2089F14; HMS2096O13; HMS2232L03; HMS3713O13; (5R,5aR,8aR,9S)-9-(((4aR,6R,7R,8R,8aS)-7,8-Dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one; EX-A1207; Tox21_110630; Tox21_302201; BDBM50127140; s1225; Etoposide - CAS 33419-42-0; AKOS007930275; BCP9000669; CCG-101165; CS-1774; DB00773; Etoposide, synthetic, >=98%, powder; NC00415; SDCCGSBI-0050405.P002; 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; NCGC00179504-02; NCGC00255126-01; AS-35312; BE164434; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 9-((4,6-O-(1R)-ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one-, 9-((4,6-O-ethylidene-beta-D-glucopyranosyl)oxy)5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl), (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-; HY-13629; SBI-0051910.P002; AB00438905; EN300-97099; C01576; D00125; AB00438905-17; AB00438905-18; AB00438905_19; Q418817; SR-01000763196; SR-01000763196-3; BRD-K37798499-001-02-5; BRD-K37798499-001-05-8; BRD-K37798499-001-10-8; BRD-K37798499-001-14-0; BRD-K37798499-001-27-2; Etoposide, British Pharmacopoeia (BP) Reference Standard; Z1304065033; Etoposide, European Pharmacopoeia (EP) Reference Standard; Etoposide, United States Pharmacopeia (USP) Reference Standard; 4''-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); 4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-(R)-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSIDE); Etoposide for system suitability, European Pharmacopoeia (EP) Reference Standard; (5R,5AR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahy; (5R,5aR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one; (5R,5AR,8AR,9S)-9-((4,6-O-((1R)-ETHANE-1,1-DIYL)-.ALPHA.-D-GLUCOPYRANOSYL)OXY)-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDRO(2)BENZOFURO(5,6-F)(1,3)BENZODIOXOL-6(5AH)-ONE; (5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-Ethylidene-beta-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one; (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxy-phenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[5,6-f][1,3]benzodioxol-8-one; (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3'',4'':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; [5R-[5?,5a?,8a?,9?(R*)]]-9-[(4,6-?-Ethylidene-?-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6-(5aH)-one; 121471-01-0; 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3'',4'''':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one; FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE-, 9-((4,6-O-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSYL)OXY)5,8,8A,9-TETRAHYDRO-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL), (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.BETA.(R*)))-	Approved	Approved Drug(s)	36462	DB00773	D06GMG	588.6	161	969	0.6	42	3	13	5	C29H32O13	(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one	CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O	C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O	InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1	VJJPUSNTGOMMGY-MRVIYFEKSA-N
DJ8W7L	Pilocarpine	Small molecule	pilocarpine; 92-13-7; Pilokarpin; Pilocarpol; Syncarpine; Pilocarpin; (+)-Pilocarpine; Ocusert pilo; Spersacarpine; Isoptocarpine; Epicar; ocucarpine; Pilocarpine chloride; Ocusert P 20; (3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; (3S,4R)-3-Ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydrofuran-2(3H)-one; Pilokarpol; CHEMBL550; (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one; Ocusert pilo-20; 01MI4Q9DI3; CHEBI:8207; Ocusert Pilo-40; DTXSID1021162; (3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone; 2(3H)-Furanone, 3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-, (3S,4R)-; 92-13-7 (FREE BASE); NCGC00023339-09; Pilocarpine 100 microg/mL in Acetonitrile; (3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]oxolan-2-one; beta-Pilocarpine hydrochloride; (3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; 2(3H)-Furanone, 3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S,4R)-; Pilocarpine nitrate salt; DTXCID901162; CAS-92-13-7; NSC5746; HSDB 3163; Pilocarpine (JAN/USP); EINECS 202-128-4; Ocusert pilo-20 (TN); UNII-01MI4Q9DI3; Pilocarpinum; Pilocarpine [USP:BAN:JAN]; AI3-50523; Ocucarpine; Ocusert P 20; Ocusert Pilo; Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone; pilocarpine, Cytokine; Spectrum_001107; Tocris-0694; PILOCARPINE [MI]; Prestwick0_000449; Prestwick1_000449; Prestwick2_000449; Prestwick3_000449; Spectrum2_001284; Spectrum3_000546; Spectrum4_000478; Spectrum5_001379; PILOCARPINE [JAN]; PILOCARPINE [HSDB]; PILOCARPINE [VANDF]; PILOCARPINUM [HPUS]; PILOCARPINE [MART.]; Lopac0_000950; Lopac0_000960; SCHEMBL15146; BSPBio_000498; BSPBio_002191; GTPL305; KBioGR_000956; KBioSS_001587; PILOCARPINE [USP-RS]; PILOCARPINE [WHO-DD]; BIDD:GT0217; DivK1c_000358; SPBio_001287; SPBio_002437; BPBio1_000548; HY-B0726A; KBio1_000358; KBio2_001587; KBio2_004155; KBio2_006723; KBio3_001691; PILOCARPINE [ORANGE BOOK]; NINDS_000358; HMS2089K17; PILOCARPINE [USP MONOGRAPH]; Tox21_110887; BDBM50008072; MFCD00153042; (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]tetrahydrofuran-2-one; AKOS016010311; Tox21_110887_1; CCG-205031; DB01085; SDCCGMLS-0003164.P005; SDCCGSBI-0050924.P006; IDI1_000358; NCGC00023339-03; NCGC00023339-06; NCGC00023339-07; NCGC00023339-08; NCGC00023339-10; NCGC00023339-11; NCGC00023339-12; NCGC00023339-13; NCGC00023339-14; NCGC00023339-16; NCGC00023339-27; NCGC00023339-28; BS-18966; NCI60_004403; SBI-0050924.P004; CS-0013746; C07474; D00525; E87145; AB00053525-27; AB00053525_28; AB00053525_29; EN300-19632236; Q411461; BRD-K85090592-008-05-2; BRD-K85090592-008-15-1; SR-01000075339-11; 102282-25-7	Approved	Approved Drug(s)	5910	DB01085	D06HLY	208.26	44.1	245	1.1	15	0	3	3	C11H16N2O2	(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one	CCC1C(COC1=O)CC2=CN=CN2C	CC[C@H]1[C@H](COC1=O)CC2=CN=CN2C	InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1	QCHFTSOMWOSFHM-WPRPVWTQSA-N
D8LX0F	Mycophenolate sodium	Small molecule	MYCOPHENOLATE SODIUM; 37415-62-6; Sodium mycophenolate; Mycophenolic acid sodium salt; Mycophenolic acid monosodium salt; ERL 080; Mycophenolate sodium [USAN]; Mycophenolic acid (sodium); Sodium mycophenalate; ERL-080; Mycophenolic acid, sodium salt; WX877SQI1G; CHEBI:67155; sodium;(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate; NSC-116072; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, sodium salt(1:1) , (4E)-; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, monosodium salt, (4E)-; Sodium 4(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate; Mycophenolate (sodium); Sodium (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate; UNII-WX877SQI1G; NSC 116072; Femulan; ERL 080A; Mycophenolic sod; Mycophenolic sodium; Myfortic (TN); EC-MPS; starbld0043375; MYCOPHENOLATESODIUM; Mycophenolate sodium (USP); 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, monosodium salt, (E)-; ERL-080A; SCHEMBL1649229; CHEMBL2106643; HY-B0421A; MYCOPHENOLATE SODIUM [VANDF]; MYCOPHENOLATE SODIUM [MART.]; MYCOPHENOLATE SODIUM [USP-RS]; MYCOPHENOLATE SODIUM [WHO-DD]; AKOS015969286; 4-Hexenoic acid, 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-, sodium salt; AS-17786; MYCOPHENOLATE SODIUM [EP MONOGRAPH]; MYCOPHENOLIC ACID SODIUM SALT [MI]; MYCOPHENOLATE SODIUM [USP MONOGRAPH]; CS-0103129; D05095; D93087; Q27135653; 23288-62-2; sodium (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; sodium;(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid	Approved	Approved Drug(s)	23665584	DB01024	D06MRY	342.3	95.9	492	.	24	1	6	6	C17H19NaO6	sodium;(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate	CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)[O-])O.[Na+]	CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)[O-])O.[Na+]	InChI=1S/C17H20O6.Na/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3;/h4,20H,5-8H2,1-3H3,(H,18,19);/q;+1/p-1/b9-4+;	DOZYTHNHLLSNIK-JOKMOOFLSA-M
D3WT6L	Tolbutamide	Small molecule	tolbutamide; 64-77-7; Orinase; Arkozal; Willbutamide; Butamide; Diabetamid; Ipoglicone; Artosin; Tolbutamid; Aglicid; Diabetol; Dolipol; Glyconon; Rastinon; Tolumid; Diaben; Orabet; 1-Butyl-3-tosylurea; 1-Butyl-3-(p-tolylsulfonyl)urea; Tolylsulfonylbutylurea; Diabuton; Diasulfon; Dirastan; Pramidex; Tolbusal; Artozin; Butamid; Drabet; Mobenol; Oralin; Orezan; Orinaz; Oterben; Toluina; Toluvan; Tolbutamidum; Sk-tolbutamide; N-(Butylcarbamoyl)-4-methylbenzenesulfonamide; N-n-Butyl-N'-tosylurea; Tolbutamida; 1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-p-Toluenesulfonyl-3-butylurea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-Butyl-N'-p-toluenesulfonylurea; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; HLS 831; Orinase (TN); 1-butyl-3-(4-methylphenyl)sulfonylurea; N-(Sulfonyl-p-methylbenzene)-N'-N-butylurea; N-(p-Tolylsulfonyl)-N'-butylcarbamide; Benzenesulfonamide, N-[(butylamino)carbonyl]-4-methyl-; NCI-C01763; N-4-Methylbenzolsulfonyl-N-butylurea; N-[(butylamino)carbonyl]-4-methylbenzenesulfonamide; D 860; Urea, 1-butyl-3-(p-tolylsulfonyl)-; 1-Butyl-3-(4-methylphenylsulfonyl)urea; N-Butyl-N'-toluene-p-sulfonylurea; 3-butyl-1-(4-methylbenzenesulfonyl)urea; N-(p-Methylbenzenesulfonyl)-N'-butylurea; 3-butyl-1-[(4-methylbenzene)sulfonyl]urea; Benzenesulfonamide, N-((butylamino)carbonyl)-4-methyl-; NSC-23813; 1-BUTYL-3-(4-METHYLBENZENESULFONYL)UREA; CHEMBL782; 982XCM1FOI; MLS000028399; Arcosal; Beglucin; Butamidum; Diabesan; DTXSID8021359; Tarasina; Tolbutone; CHEBI:27999; Tolbet; N-((Butylamino)carbonyl)-4-methylbenzenesulfonamide; NSC-87833; CAS-64-77-7; NCGC00015999-10; SMR000058363; Tolbutamide form I^L^; Tolbutamidum [INN-Latin]; Tolbutamida [INN-Spanish]; DTXCID801359; Tolumide; CCRIS 592; N-4-(Methylbenzolsulfonyl)-n-butylurea; HSDB 3393; SR-01000003059; EINECS 200-594-3; MFCD00027169; NSC 23813; U 2043; UNII-982XCM1FOI; BRN 1984428; N-(Sulfonyl-p-methylbenzene)-N'-butylurea; tolbutamide IL; tolbutamide III; Tolbutamide [USP:INN:BAN:JAN]; Prestwick_471; Spectrum_000447; Tolbutamide form I^H^; Opera_ID_112; TOLBUTAMIDE [MI]; Prestwick0_000190; Prestwick1_000190; Prestwick2_000190; Prestwick3_000190; Spectrum2_001210; Spectrum3_000599; Spectrum4_000358; Spectrum5_001272; Lopac-T-0891; TOLBUTAMIDE [INN]; TOLBUTAMIDE [JAN]; N-n-Butyl-N''-tosylurea; TOLBUTAMIDE [HSDB]; WLN: 4MVMSWR D1; T 0891; TOLBUTAMIDE [VANDF]; NCIOpen2_009592; TOLBUTAMIDE [MART.]; BIDD:PXR0179; CBiol_001920; Lopac0_001154; SCHEMBL15918; BSPBio_000119; BSPBio_001507; BSPBio_002078; KBioGR_000227; KBioGR_000795; KBioGR_002275; KBioSS_000227; KBioSS_000927; KBioSS_002276; TOLBUTAMIDE [USP-RS]; TOLBUTAMIDE [WHO-DD]; TOLBUTAMIDE [WHO-IP]; 4-11-00-00396 (Beilstein Handbook Reference); MLS001148399; MLS002152944; DivK1c_000341; SPECTRUM1500581; SPBio_001000; SPBio_002040; BPBio1_000131; GTPL6848; Tolbutamide (JP17/USP/INN); Tolbutamide, analytical standard; HMS501B03; KBio1_000341; KBio2_000227; KBio2_000927; KBio2_002275; KBio2_002795; KBio2_003495; KBio2_004843; KBio2_005363; KBio2_006063; KBio2_007411; KBio3_000453; KBio3_000454; KBio3_001578; KBio3_002755; TOLBUTAMIDE [ORANGE BOOK]; cMAP_000008; NINDS_000341; Bio1_000206; Bio1_000695; Bio1_001184; Bio2_000227; Bio2_000707; HMS1361L09; HMS1568F21; HMS1791L09; HMS1989L09; HMS2089C17; HMS2092M21; HMS2095F21; HMS2232H16; HMS3259A08; HMS3263H09; HMS3402L09; HMS3651N03; HMS3712F21; Pharmakon1600-01500581; TOLBUTAMIDE [EP MONOGRAPH]; TOLBUTAMIDE [USP MONOGRAPH]; BCP09192; HY-B0401; NSC23813; TOLBUTAMIDUM [WHO-IP LATIN]; N-Butyl-N''-(p-tolylsulfonyl)urea; Tox21_110279; Tox21_201612; Tox21_302795; Tox21_501154; BDBM50027886; CCG-39141; NSC757354; NSC813220; s2443; 1-Butyl-3-(para-tolylsulfonyl)-urea; AKOS015894999; Tox21_110279_1; DB01124; LP01154; NC00543; NSC-757354; NSC-813220; SDCCGSBI-0051121.P004; Tolbutamide 1.0 mg/ml in Acetonitrile; IDI1_000341; IDI1_033977; N-(n-Butyl)-N'-p-toluene-sulfonylurea; NCGC00015999-01; NCGC00015999-02; NCGC00015999-03; NCGC00015999-04; NCGC00015999-05; NCGC00015999-06; NCGC00015999-07; NCGC00015999-08; NCGC00015999-09; NCGC00015999-11; NCGC00015999-12; NCGC00015999-13; NCGC00015999-14; NCGC00015999-15; NCGC00015999-16; NCGC00015999-17; NCGC00015999-19; NCGC00015999-20; NCGC00015999-29; NCGC00022721-03; NCGC00022721-04; NCGC00022721-05; NCGC00022721-06; NCGC00022721-07; NCGC00022721-08; NCGC00022721-09; NCGC00022721-10; NCGC00256548-01; NCGC00259161-01; NCGC00261839-01; AC-12490; AS-14136; N-(4-Methylphenylsulfonyl)-N''-butylurea; N-Butyl-N''-(4-methylphenylsulfonyl)urea; SBI-0051121.P003; DB-054728; AB00052110; EU-0101154; FT-0603265; SW196681-3; T3690; BIM-0051121.0001; C07148; D00380; D87667; EN300-124678; U-2043; AB00052110-16; AB00052110_17; AB00052110_18; Tolbutamide, VETRANAL(TM), analytical standard; A834879; Q414275; SR-01000003059-2; SR-01000003059-4; SR-01000003059-7; W-104820; BRD-K85119730-001-06-5; BRD-K85119730-001-17-2; N'-butyl-N-(p-tolylsulfonyl)carbamimidate;Tolbutamide; Z44591715; Tolbutamide, European Pharmacopoeia (EP) Reference Standard; 1-(([(Butylamino)carbonyl]amino)sulfonyl)-4-methylbenzene #; Tolbutamide, United States Pharmacopeia (USP) Reference Standard	Approved	Approved Drug(s)	5505	DB01124	D06OIV	270.35	83.6	354	2.3	18	2	3	5	C12H18N2O3S	1-butyl-3-(4-methylphenyl)sulfonylurea	CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C	CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C	InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)	JLRGJRBPOGGCBT-UHFFFAOYSA-N
DA3CW2	Tacrolimus	Small molecule	tacrolimus; Fujimycin; 104987-11-3; Prograf; Tsukubaenolide; Protopic; FK506; Tacrolimus anhydrous; Anhydrous Tacrolimus; Modigraf; Fk-506; Protopy; LCP-Tacro; FK 506; Advagraf; tacrolimus (fk506); FR-900506; Tacrolimus, anhydrous; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN; Tacrolimus (INN); FR900506; Astagraf XL; Envarsus XR; (-)-FK 506; FK-506 (Tacrolimus); Prograf (TN); Tacrolimus [USAN]; CHEMBL269732; DTXSID5046354; CHEBI:61049; Y5L2157C4J; NSC-758659; K506; NCGC00163470-03; Prograft; TACROLIMUS [INN]; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propen-1-yl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)tetrone; Avagraf; Envarsus; Graceptor; Tacrolimus (anhydrous); SR-05000001879; Tacrolimus [USAN:INN]; Hecoria; Talymus; UNII-Y5L2157C4J; CCRIS 7124; MFCD00869853; HSDB 8195; L 679934; PROGRAPH; TACRO; TACROLIMUS [MI]; SCHEMBL3088; TACROLIMUS [MART.]; TACROLIMUS [WHO-DD]; BSPBio_001279; CHEMBL66247; L-679934; GTPL6784; DTXCID3026354; CHEBI:93221; HMS503O21; C44H69NO12.H2O; HMS1792O21; HMS1990O21; HMS2093M19; HMS3403O21; Pharmakon1600-01503968; EX-A1677; Tox21_112056; BDBM50030448; BDBM50079777; HB0289; LMPK04000003; NSC758659; s5003; AKOS005145901; AC-1182; AM81227; CCG-270494; CS-1507; DB00864; IDI1_001040; NCGC00163470-01; NCGC00163470-02; NCGC00163470-04; NCGC00163470-05; NCGC00163470-06; NCGC00163470-07; NCGC00163470-27; HY-13756; SBI-0052894.P002; CAS-104987-11-3; M2258; C01375; D08556; EN300-221601; AB01209746-01; AB01209746_03; Q411648; Q-201775; SR-05000001879-1; SR-05000001879-2; SR-05000001879-5; BRD-K35452788-001-02-1; BRD-K69608737-001-03-7; BRD-K69608737-001-10-2; Z2242006187; [(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,; (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone; (1R,9S,12S,13R,14S,17R,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-{1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-4-azatricyclo[22.3.1.0,4,9]octacos-18-ene-2,3,10,16-tetrone; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26AS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26A-HEXADECAHYDRO-5,19-DIHYDROXY-3-[(1E)-2-[(1R,3R,4R)-4-HYDROXY-3-METHOXYCYCLOHEXYL]-1-METHYLETHENYL]-14,16-DIMETHOXY-4,10,12,18-TETRAMETHYL-8-(2-PROPEN-1-YL)-15,19; (E)-(1R,9S,12S,13R,14R,21S,23S,24R,25S,27R)-17-Allyl-1,14-dihydroxy-12-[(E)-2-((3R,4R)-4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.0*4,9*]octacos-18-ene-2,3,10,16-tetraone; 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-, (3S-(3R*(E(1S*,3S*,4S*)),4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*))-; 15,19-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyc; 15,19-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propen-1-yl)-, (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-; 15,19-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycycl ohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propen-1-yl)-, (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-; 4,5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-heptadecahydro-5,19-dihydroxy-3-; dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-,(3S,4R,5S,8R,12S,14S,15R,16S,18R,19R,26aS)-; lohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propen-1-yl)-, (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-	Approved	Approved Drug(s)	445643	DB00864	D06OMK	804	178	1480	2.7	57	3	12	7	C44H69NO12	(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone	CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC	C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC	InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1	QJJXYPPXXYFBGM-LFZNUXCKSA-N
D3JUK0	Rasagiline	Small molecule	rasagiline; 136236-51-6; (R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine; Azilect; (R)-N-2-Propynyl-1-indanamine; (R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine; 1-Indanamine, N-2-propynyl-, (R)-; TV-1030; (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; Azilect (TN); RAS; CHEMBL887; NSC-759639; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)-; (1R)-N-propargylindan-1-amine; CHEBI:63620; 003N66TS6T; (R)-Indan-1-yl-prop-2-ynyl-amine; Rasagiline [INN]; (R)-N-(Prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; TVP1012; Rasagiline [USAN]; (R)-(+)-Rasagiline; Rasagiline [USAN:INN]; UNII-003N66TS6T; MFCD00866571; HSDB 7699; (1R)-N-prop-2-ynylindan-1-amine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R); TV 1030; RASAGILINE [MI]; Rasagiline (USAN/INN); RASAGILINE [HSDB]; RASAGILINE [VANDF]; RASAGILINE [WHO-DD]; SCHEMBL74699; MLS006012042; N-propargyl-1-(R)aminoindan; RASAGILINE [EMA EPAR]; GTPL6641; SCHEMBL2029054; DTXSID3041112; RASAGILINE [ORANGE BOOK]; BDBM10989; HMS3264K12; HMS3715L12; HMS3886N03; Pharmakon1600-01502333; AC-723; HY-14605A; NSC759639; NSC789038; s5795; AKOS006271452; AKOS015837675; AM84542; CCG-213034; DB01367; FS-3130; NSC 759639; NSC-789038; SMR002533187; (1R)-N-(prop-2-yn-1-yl)indan-1-amine; DB-001111; A2916; D08469; EN300-150047; AB01562963_01; AB01562963_02; Q420685; SR-00000006359; SR-00000006359-3; (R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine; (1R)-2,3-DIHYDRO-N-2-PROPYN-1-YL-1H-INDEN-1-AMINE; 1H-INDEN-1-AMINE, 2,3-DIHYDRO-N-2-PROPYNYL-, (R)-; 1H-INDEN-1-AMINE, 2,3-DIHYDRO-N-2-PROPYN-1-YL-, (1R)-; (R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine;(R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine; 1204184-69-9	Approved	Approved Drug(s)	3052776	DB01367	D06OMW	171.24	12	212	1.8	13	1	1	2	C12H13N	(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine	C#CCNC1CCC2=CC=CC=C12	C#CCN[C@@H]1CCC2=CC=CC=C12	InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1	RUOKEQAAGRXIBM-GFCCVEGCSA-N
DNA1B2	Ketamine	Small molecule	ketamine; dl-Ketamine; Ketaject; Ketalar; Special K; CI 581 base; (+-)-Ketamine; Calypsol; Ketaminum; CLSTA 20; 6740-88-1; Ketanest; Ketalar base; (+/-)-Ketamine; narketan; Tekam; KETAMINE HCL; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone; Ketolar; 2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone; Ursotamin; Vetaket; Anaket v; NSC 70151; Ketamine (INN); Clorketam 1000; Ketasol 100; Imalgene 1000; NSC-70151; CHEMBL742; 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-; CHEBI:6121; 100477-72-3; DTXSID8023187; PMI-150; 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; 690G0D6V8H; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-; (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; DEA No. 7285; NCGC00159480-02; NCGC00159480-03; Cetamina; KETAMINE [INN]; Ketamine Base; Ketamine [INN:BAN]; Ketaminum [INN-Latin]; Cetamina [INN-Spanish]; Special K [street name]; DTXCID703187; Ketoject; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+/-)-; CAS-6740-88-1; Tekam (TN); EINECS 229-804-1; BRN 2216965; ketamina; UNII-690G0D6V8H; HSDB 2180; Ketolar (Salt/Mix); Vetalar (Salt/Mix); Kalipsol (Salt/Mix); Ketanest (Salt/Mix); Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+-)-; KETAMINE [HSDB]; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)-; KETAMINE [MI]; KETAMINE [VANDF]; (.+/-.)-Ketamine; KETAMINE [WHO-DD]; EC 229-804-1; Cyclohexanone, (.+-.)-; SCHEMBL16103; MLS001331674; DivK1c_000217; GTPL4233; (+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; SCHEMBL17084881; KBio1_000217; KETAFOL COMPONENT KETAMINE; NINDS_000217; HMS2272G05; NSC70151; Tox21_111703; Tox21_111704; BDBM50044140; DB01221; IDI1_000217; SMR000238141; C07525; D08098; Q243547; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone #; J-505587; (.+/-.)-2-(O-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone(Ketamine); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (.+/-.)-; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (.+/-.)-; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)	Approved	Approved Drug(s)	3821	DB01221	D06ORI	237.72	29.1	269	2.2	16	1	2	2	C13H16ClNO	2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one	CNC1(CCCCC1=O)C2=CC=CC=C2Cl	CNC1(CCCCC1=O)C2=CC=CC=C2Cl	InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3	YQEZLKZALYSWHR-UHFFFAOYSA-N
DJ1WG6	Nateglinide	Small molecule	nateglinide; 105816-04-4; Starlix; senaglinide; Starsis; Fastic; AY-4166; Nateglinide [INN]; Trazec; A-4166; SDZ-DJN-608; D-Nateglinide; 105816-06-6; DJN 608; DJN-608; AY4166; MFCD00875706; SDZ DJN 608; SDZ-DJN 608; AY 4166; (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine; A 4166; XTM4DQP5S5; CHEMBL783; 41X3PWK4O2; 105746-37-0; A4166; DTXSID9040687; CHEBI:31897; n-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-d-phenylalanine; NSC-758695; (-)-N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; D-phenylalanine, N-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-; D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis-; D-Phenylalanine, N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-; (r)-2-((1r,4r)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid; N-[[cis-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine(Nateglinide Impurity); DTXCID7020687; N-((cis-4-Isopropylcyclohexyl)carbonyl)-D-phenylalanine; N-(Trans-4-Isopropylcyclohexylcarbonyl)-D-Phenyl Alanine; D-Phenylalanine, N-((cis-4-(1-methylethyl)cyclohexyl)carbonyl)-; N-((cis-4-(1-Methylethyl)cyclohexyl)carbonyl)-D-phenylalanine; trans-N-((4-(1-Methylethyl)cyclohexyl)carbonyl)-D-phenylalanine; D-Phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, cis-; (R)-2-rel-((1r,4R)-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid; SMR000466372; CAS-105816-04-4; nateglinida; nateglinidum; UNII-41X3PWK4O2; trans-N-{[4-(1-methylethyl)cyclohexyl]carbonyl}-D-phenylalanine; (2R)-3-phenyl-2-{[(1r,4r)-4-(propan-2-yl)cyclohexyl]formamido}propanoic acid; NCGC00095121-01; Nateglinide [USAN:USP:INN:BAN]; Starsis (TN); Nateglinide, Starlix; YM-026; Nateglinide (Starlix); Nateglinide impurity C; Nateglinide cis Impurity; NATEGLINIDE [MI]; UNII-XTM4DQP5S5; NATEGLINIDE [JAN]; NATEGLINIDE [USAN]; NATEGLINIDE [VANDF]; NATEGLINIDE [MART.]; SCHEMBL22088; NATEGLINIDE [USP-RS]; NATEGLINIDE [WHO-DD]; Nateglinide impurity C [EP]; MLS000759500; MLS001424043; MLS003915639; MLS006011429; BIDD:GT0257; Nateglinide cis-isomer [USP]; SCHEMBL303827; NATEGLINIDE [EMA EPAR]; GTPL6833; SCHEMBL7880361; SCHEMBL9232138; Nateglinide (JP17/USP/INN); CHEMBL2114389; SCHEMBL13753829; CHEBI:94617; NATEGLINIDE [ORANGE BOOK]; HMS2051G20; HMS2089A10; HMS2235O08; HMS3675G17; HMS3715F12; n-(trans-4-Isopropylcylolohexylcarboxyl)-d-phenylpropylicacid; NATEGLINIDE [EP MONOGRAPH]; NATEGLINIDE [USP MONOGRAPH]; BCP28400; carboxamido)-3-phenylpropanoic acid; HY-B0422; Tox21_111432; BBL033469; BDBM50344967; s2489; STK647123; AKOS005577723; AKOS015841612; AKOS015960899; Nateglinide, >=98% (HPLC), solid; Tox21_111432_1; AC-1690; CCG-100898; DB00731; KS-5143; NC00148; NSC 758695; NCGC00178741-03; NCGC00271534-02; NCGC00271534-03; (R)-2-((1r,4R)-4-isopropylcyclohexane; N0912; NATEGLINIDE CIS-ISOMER [USP IMPURITY]; NATEGLINIDE IMPURITY C [EP IMPURITY]; SW197528-2; D01111; EN300-303645; AB00639979-06; AB00639979-08; AB00639979-09; AB00639979-11; AB00639979_12; A801324; EN300-27126236; A1-02996; Q-201449; Q2254797; Q27166439; n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine; Z1514053266; (trans-4-isopropylcyclohexane-1-carbonyl)-D-phenylalanine; N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine; Nateglinide, European Pharmacopoeia (EP) Reference Standard; ((1r,4R)-4-isopropylcyclohexane-1-carbonyl)-D-phenylalanine; 2-[(4-Isopropyl-cyclohexanecarbonyl)-amino]-3-phenyl-propionic acid; N-(4alpha-Isopropylcyclohexane-1alpha-yl)carbonyl-D-phenylalanine; Nateglinide, United States Pharmacopeia (USP) Reference Standard; (2R)-2-[(4-isopropylcyclohexanecarbonyl)amino]-3-phenyl-propanoic acid; (2R)-3-phenyl-2-{[4-(propan-2-yl)cyclohexyl]formamido}propanoic acid; D-Phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-; (2R)-2-[(4-isopropylcyclohexanecarbonyl)amino]-3-phenyl-propanoic acid;Nateglinide; (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid; (R)-2-rel-((1r,4R)-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoicacid; N-[[cis-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine (Nateglinide Impurity)	Approved	Approved Drug(s)	5311309	DB00731	D06PSS	317.4	66.4	393	3.2	23	2	3	6	C19H27NO3	(2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid	CC(C)C1CCC(CC1)C(=O)NC(CC2=CC=CC=C2)C(=O)O	CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O	InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15?,16?,17-/m1/s1	OELFLUMRDSZNSF-OFLPRAFFSA-N
DND95Y	Vosoritide	Small molecule	Vosoritide; Voxzogo; BMN 111; BMN-111; Vosoritide [USAN:INN]; UNII-7SE5582Q2P; 1480724-61-5; GTPL9068; 7SE5582Q2P	Approved	Approved Drug(s)	119058036	DB11928	D06QAK	4103	1820	9600	-20.6	286	61	64	112	C176H290N56O51S3	(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,43S,49S,52R)-52-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-5-amino-5-oxo-2-[[2-[[(2S)-pyrrolidine-2-carbonyl]amino]acetyl]amino]pentanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]hexanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-[(2S)-butan-2-yl]-31-(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,22-bis(hydroxymethyl)-10,37,43-tris(2-methylpropyl)-19-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carboxylic acid	CCC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CN=CN5)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO	CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@@H]6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO	InChI=1S/C176H290N56O51S3/c1-14-95(10)143-172(280)201-84-138(245)209-125(86-234)168(276)221-113(54-65-284-13)159(267)229-124(85-233)152(260)200-81-135(242)206-114(66-91(2)3)150(258)198-83-140(247)211-128(174(282)283)89-286-285-88-127(170(278)224-118(70-98-34-16-15-17-35-98)151(259)199-80-137(244)207-115(67-92(4)5)162(270)217-108(41-23-29-60-182)155(263)223-117(69-94(8)9)164(272)226-122(75-142(250)251)167(275)219-110(160(268)231-143)44-32-63-193-176(188)189)210-139(246)82-197-149(257)105(38-20-26-57-179)215-169(277)126(87-235)230-163(271)116(68-93(6)7)208-136(243)79-196-147(255)103(36-18-24-55-177)213-153(261)106(39-21-27-58-180)218-166(274)121(74-132(185)239)222-144(252)96(11)203-133(240)77-195-148(256)104(37-19-25-56-178)214-165(273)119(71-99-46-48-101(236)49-47-99)225-156(264)107(40-22-28-59-181)216-154(262)109(43-31-62-192-175(186)187)212-145(253)97(12)204-161(269)120(73-131(184)238)227-171(279)129-45-33-64-232(129)173(281)123(72-100-76-190-90-202-100)228-158(266)112(51-53-141(248)249)220-157(265)111(50-52-130(183)237)205-134(241)78-194-146(254)102-42-30-61-191-102/h15-17,34-35,46-49,76,90-97,102-129,143,191,233-236H,14,18-33,36-45,50-75,77-89,177-182H2,1-13H3,(H2,183,237)(H2,184,238)(H2,185,239)(H,190,202)(H,194,254)(H,195,256)(H,196,255)(H,197,257)(H,198,258)(H,199,259)(H,200,260)(H,201,280)(H,203,240)(H,204,269)(H,205,241)(H,206,242)(H,207,244)(H,208,243)(H,209,245)(H,210,246)(H,211,247)(H,212,253)(H,213,261)(H,214,273)(H,215,277)(H,216,262)(H,217,270)(H,218,274)(H,219,275)(H,220,265)(H,221,276)(H,222,252)(H,223,263)(H,224,278)(H,225,264)(H,226,272)(H,227,279)(H,228,266)(H,229,267)(H,230,271)(H,231,268)(H,248,249)(H,250,251)(H,282,283)(H4,186,187,192)(H4,188,189,193)/t95-,96-,97-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,143-/m0/s1	IGYWDDBBJPSOTG-WBAGYEQSSA-N
D1RBQ7	Leflunomide	Small molecule	leflunomide; 75706-12-6; Arava; lefunamide; Leflunomida; Leflunomidum; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; HWA 486; HWA-486; Repso; Leflunomidum [INN-Latin]; leflunomide medac; SU101; 5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide; Arava (TN); SU-101; 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; Leflunomide teva; 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-; alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; Leflunomide winthrop; SULOL; HWA486; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide; Leflunomide ratiopharm; RS-34821; CHEMBL960; NSC-677411; NSC-759864; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); MLS000069648; CHEBI:6402; G162GK9U4W; DTXSID9023201; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)-; L04AA13; NCGC00015610-02; SMR000058209; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; Leflunomide 100 microg/mL in Acetonitrile; CAS-75706-12-6; Leflunomida [INN-Spanish]; SU 101 (pharmaceutical); DTXCID103201; Lefunomide [Inn-Spanish]; Leflunomide [INN]; HSDB 7289; SR-01000000191; UNII-G162GK9U4W; Arabloc; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Prestwick_87; Leflunomide [USAN:USP:INN:BAN]; MFCD00867593; SU 101; Spectrum_000322; LEFLUNOMIDE [MI]; Opera_ID_1709; Prestwick0_000772; Prestwick1_000772; Prestwick2_000772; Prestwick3_000772; Spectrum5_000850; LEFLUNOMIDE [JAN]; Lopac-L-5025; LEFLUNOMIDE [HSDB]; LEFLUNOMIDE [USAN]; L 5025; LEFLUNOMIDE [VANDF]; SCHEMBL5057; LEFLUNOMIDE [MART.]; BIDD:PXR0189; Lopac0_000649; BSPBio_000844; KBioSS_000802; LEFLUNOMIDE [USP-RS]; LEFLUNOMIDE [WHO-DD]; Leflunomide, Immunosuppressant; MLS001076267; DivK1c_000916; Leflunomide (JAN/USP/INN); SPECTRUM1503927; SPBio_002783; LEFLUNOMIDE [EMA EPAR]; BPBio1_000930; GTPL6825; HMS502N18; KBio1_000916; KBio2_000802; KBio2_003370; KBio2_005938; LEFLUNOMIDE [EP IMPURITY]; LEFLUNOMIDE [ORANGE BOOK]; NINDS_000916; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; HMS1570K06; HMS1922M06; HMS2090O12; HMS2097K06; HMS2235C07; HMS3262A19; HMS3268D12; HMS3371F21; HMS3414P03; HMS3654F07; HMS3673M17; HMS3678N21; HMS3714K06; HMS3865I13; LEFLUNOMIDE [EP MONOGRAPH]; Leflunomide for peak identification; Pharmakon1600-01503927; LEFLUNOMIDE [USP MONOGRAPH]; ALBB-019233; BCP22241; HY-B0083; Tox21_110182; Tox21_301873; Tox21_500649; BDBM50054601; DL-433; NSC677411; NSC759864; s1247; STL426823; AKOS000265193; Tox21_110182_1; AC-6796; BCP9000846; CCG-204736; CS-1781; DB01097; KS-1076; LP00649; NSC 677411; NSC 759864; SB17287; SDCCGSBI-0050629.P003; IDI1_000916; NCGC00015610-01; NCGC00015610-03; NCGC00015610-04; NCGC00015610-05; NCGC00015610-06; NCGC00015610-07; NCGC00015610-08; NCGC00015610-09; NCGC00015610-10; NCGC00015610-11; NCGC00015610-12; NCGC00015610-13; NCGC00015610-14; NCGC00015610-17; NCGC00015610-18; NCGC00015610-30; NCGC00022625-03; NCGC00022625-04; NCGC00022625-05; NCGC00022625-06; NCGC00022625-07; NCGC00022625-08; NCGC00255370-01; NCGC00261334-01; BM164612; A9622; AB00052389; EU-0100649; FT-0621959; L0250; SW196399-3; C07905; D00749; EN300-119495; MLS-0003109.0001; AB00052389-17; AB00052389-18; AB00052389_19; AB00052389_21; Q248550; Q-201289; SR-01000000191-2; SR-01000000191-4; SR-01000000191-7; BRD-K78692225-001-03-9; BRD-K78692225-001-11-2; Z228668542; 5-methyl-4-(4-trifluoromethyl-phenyl)aminocarbonylisoxazole; 5-methyl-4-(4-trifluoromethylphenyl)aminocarbonylisoxazole; Leflunomide, European Pharmacopoeia (EP) Reference Standard; N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; 5-Methyl-N-[4-(trifluoromethyl)-phenyl]isoxazole-4-carboxamide; 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)-anilide; N-(4-trifluoromethylphenyl)-5-methylisoxa-zole-4-carboxamide; Isoxazole-4-carboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-; Leflunomide, United States Pharmacopeia (USP) Reference Standard; 5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide;Leflunomide; HWA486; RS-34821; SU101;HWA 486; RS 34821; SU 101; Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material; N-(4-(TRIFLUOROMETHYL)PHENYL) 5 METHYLISOXAZOLE-4-CARBOXAMIDE; Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	3899	DB01097	D06VRI	270.21	55.1	327	2.5	19	1	6	2	C12H9F3N2O2	5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide	CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F	CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F	InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)	VHOGYURTWQBHIL-UHFFFAOYSA-N
DR28FH	Captopril	Small molecule	captopril; 62571-86-2; Capoten; L-Captopril; Lopirin; Captopryl; Garranil; Cesplon; Captolane; Tensoprel; Acepress; Captoril; Dilabar; Hypertil; Tenosbon; Alopresin; Captoprilum; Acepril; Apopril; Lopril; Acediur; Aceplus; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; SQ-14225; Farcopril; Hypopress; Tensiomin; Tensobon; Zapto; Captoprilum [INN-Latin]; SQ 14225; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; SQ 14,225; C9H15NO3S; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; SA 333; D-3-Mercapto-2-methylpropionylproline; Captomax; Mepha; L-Proline, 1-[(2S)-3-mercapto-2-methyl-1-oxopropyl]-; (2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; Hipertil; CHEBI:3380; L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)-; NSC-757419; 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; (S)-1-((S)-3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylic acid; 9G64RSX1XD; CHEMBL1560; 1-[(2S)-3-Mercapto-2-methyl-1-oxopropyl]-L-proline; MLS000069484; Asisten; DTXSID1037197; Isopresol; C09AA01; (-)-Captopril; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; SA-333; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; L-Proline, 1-((2S)-3-mercapto-2-methyl-1-oxopropyl)-; NCGC00023654-04; SMR000059061; SQ -14225; Lopirin [Switzerland]; 1-Pyrrolidinecarboxylic acid, 1-(D-3-mercapto-2-methyl-1-propionyl)-, L-(S,S)-; DTXCID9017197; Novocaptopril; Captril; Captopril (Capoten); Capozide (Salt/Mix); 3-Mercapto-2-methylpropionyl-proline; X8Z; Apopril (TN); Capoten (TN); HSDB 6527; 1-[(2s)-3-mercapto-2-methylpropionyl]-l-proline; SR-01000075603; EINECS 263-607-1; UNII-9G64RSX1XD; component of Captea (Salt/Mix); component of Acezide (Salt/Mix); component of Ecazide (Salt/Mix); 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); Captopril,(S); Prestwick_103; Capoten;L-Captopril; MFCD00168073; Captopril [USAN:USP:INN:BAN:JAN]; SQ14534; SCHEMBL4; Spectrum_000688; CAPTOPRIL [INN]; CAPTOPRIL [JAN]; CAPTOPRIL [MI]; CAPTOPRIL [HSDB]; CAPTOPRIL [USAN]; Opera_ID_1041; Prestwick3_000019; Spectrum2_001211; Spectrum3_001388; Spectrum4_000811; Spectrum5_001587; CAPTOPRIL [VANDF]; Lopac-C-4042; 1-((2S)-2-Methyl-3-sulfanylpropanoyl)-L-proline #; CAPTOPRIL [MART.]; Epitope ID:114065; UPCMLD-DP003; C 4042; CAPTOPRIL [USP-RS]; CAPTOPRIL [WHO-DD]; CAPTOPRIL [WHO-IP]; Lopac0_000302; BSPBio_000057; BSPBio_002976; KBioGR_001321; KBioSS_001168; MLS001076488; DivK1c_000208; SPECTRUM1500682; SPBio_001022; Captopril (JP17/USP/INN); (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; BPBio1_000063; GTPL5158; CAPTOPRIL [ORANGE BOOK]; Captopril for system suitability; CAPTOPRIL [EP MONOGRAPH]; CAPTOPRIL [USP IMPURITY]; UPCMLD-DP003:001; BDBM21642; HMS500K10; KBio1_000208; KBio2_001168; KBio2_003736; KBio2_006304; KBio3_002196; CAPTOPRIL [USP MONOGRAPH]; 1j37; NINDS_000208; HMS1921C12; HMS2089P19; HMS2092I12; HMS2095C19; HMS2233I04; HMS3259G10; HMS3260N06; HMS3712C19; Pharmakon1600-01500682; SA333; CAPTOPRILUM [WHO-IP LATIN]; HY-B0368; Tox21_110890; Tox21_500302; BBL033600; CCG-39104; EI-213; HB3636; NSC757419; s2051; STK802012; AKOS005622581; Captopril, >=98% (HPLC), powder; Tox21_110890_1; BCP9000485; CS-2425; DB01197; KS-5025; LP00302; NC00554; NSC 757419; SDCCGSBI-0050290.P006; IDI1_000208; SMP1_000056; NCGC00015235-01; NCGC00015235-02; NCGC00023654-03; NCGC00023654-05; NCGC00023654-06; NCGC00023654-07; NCGC00023654-08; NCGC00023654-09; NCGC00023654-10; NCGC00023654-11; NCGC00023654-13; NCGC00023654-25; NCGC00023654-26; NCGC00260987-01; AC-12047; AC-32120; SBI-0050290.P004; Captopril, meets USP testing specifications; EU-0100302; ((S)-3-mercapto-2-methylpropanoyl)-L-proline; BIM-0050290.0001; C06867; D00251; EN300-118718; AB00052156-16; AB00052156_17; AB00052156_18; Q421119; SR-01000000039; 1-[(2S)-3-Mercapto-2-methylpropionyl]- L-proline; SR-01000000039-2; SR-01000075603-1; SR-01000075603-3; 1-[(S)-3-mercapto-2-methyl-1-oxopropyl]-L-proline; BRD-K54529596-001-04-0; BRD-K54529596-001-15-6; Captopril, British Pharmacopoeia (BP) Reference Standard; Z1269124804; Captopril, European Pharmacopoeia (EP) Reference Standard; Captopril, United States Pharmacopeia (USP) Reference Standard; (S)-1-((S)-3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylicacid; Captopril, Pharmaceutical Secondary Standard; Certified Reference Material; L-?Proline, 1-?[(2S)?-?3-?mercapto-?2-?methyl-?1-?oxopropyl]?-; 1-[(2S)-3-Mercapto-2-methyl-1-oxopropyl]-<span class='DL'>L</span>-proline; Captopril for system suitability, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	44093	DB01197	D06VSD	217.29	58.6	244	0.3	14	2	4	3	C9H15NO3S	(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid	CC(CS)C(=O)N1CCCC1C(=O)O	C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O	InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1	FAKRSMQSSFJEIM-RQJHMYQMSA-N
D8SM9H	Lovastatin	Small molecule	lovastatin; 75330-75-5; mevinolin; Mevacor; Altoprev; Mevlor; Sivlor; MK-803; Monacolin K; Lovalord; Nergadan; Artein; 6alpha-Methylcompactin; Lovalip; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Mevinacor; Altocor; Hipovastin; Lovasterol; Cholestra; Closterol; Colevix; Hipolip; Lestatin; Lipivas; Lipofren; Lovastin; Lozutin; Paschol; Rodatin; Rovacor; Tecnolip; Teroltrat; Belvas; Lipdip; Taucor; Lovastatin [USAN]; MLS000069585; 6.alpha.-Methylcompactin; MSD 803; Lovastatin (MK-803); 9LHU78OQFD; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; NSC-758662; L-154803; MK 803; 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; SMR000058779; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-; Lovastatine; DTXSID5020784; CHEBI:40303; C10AA02; Lovastatin (Mevacor); (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; HSDB 6534; NCGC00023509-03; Lovastatina; Lovastatinum; DTXCID50784; Liposcler; 6 alpha-Methylcompactin; Rextat; Monakolin K; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate; (S)-(1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2-methylbutanoate; Mevacor (TN); CHEMBL503; Lovastatin & Primycin; Lovastatin (USP/INN); SR-05000001880; (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-2-Methylbutanoic acid 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (S)-2-Methylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; 1,2,6,7,8,8a-Hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone; UNII-9LHU78OQFD; BRN 3631989; Mevinolin from Aspergillus sp.; CCRIS 8092; 1cqp; Lovastatin,(S); ML-530B; Lovastatin [USAN:USP:INN:BAN]; (+)-mevinolin; (2S)-2-METHYLBUTANOIC ACID (1S,3R,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-((2R,4R)-TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL ESTER; (2S)-2-Methylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; (S)-((1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl) 2-methylbutanoate; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (2S)-; Lovastatin- Bio-X; Prestwick_819; CAS-75330-75-5; MFCD00072164; Mevinolin (lovastatin); Lovastatin (Mevinolin); LOVASTATIN [MI]; LOVASTATIN [INN]; Opera_ID_1578; Prestwick0_000516; Prestwick1_000516; Prestwick2_000516; Prestwick3_000516; Spectrum3_001873; Spectrum5_001294; LOVASTATIN [HSDB]; LOVASTATIN [VANDF]; EC 616-212-7; LOVASTATIN [MART.]; SCHEMBL3136; LOVASTATIN [USP-RS]; LOVASTATIN [WHO-DD]; US9115116, lovastatin; BIDD:PXR0113; BSPBio_000471; BSPBio_001265; BSPBio_003346; Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-; cid_53232; MLS001055358; MLS006011867; US9353061, Lovastatina; BIDD:GT0749; DivK1c_001032; SPECTRUM1503977; SPBio_002392; BPBio1_000519; GTPL2739; MEGxm0_000398; LOVASTATIN [ORANGE BOOK]; SCHEMBL14227102; ACon0_000534; ACon1_000390; BDBM34168; HMS503O05; KBio1_001032; KBio3_002848; LOVASTATIN [EP MONOGRAPH]; Simvastatin impurity, lovastatin-; Lovastatin for peak identification; NINDS_001032; HMS1569H13; HMS1792O07; HMS1923O13; HMS1990O07; HMS2089M06; HMS2093O03; HMS2096H13; HMS2236F07; HMS3039N16; HMS3259F10; HMS3268C03; HMS3403O07; HMS3412H19; HMS3676H19; HMS3713H13; HMS3884B03; LOVASTATIN [USP MONOGRAPH]; Pharmakon1600-01503977; ADVICOR COMPONENT LOVASTATIN; (S)-2-Methylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one; ACT02620; ALBB-027272; HY-N0504; MK-803; LOVALIP; MEVACOR; Tox21_110888; Tox21_201475; Tox21_300268; BBL024473; CCG-39627; NSC633781; NSC758662; NSC779704; s2061; STK801953; AKOS005267139; LOVASTATIN COMPONENT OF ADVICOR; Tox21_110888_1; CS-1990; DB00227; KS-1082; Mevinolin from Aspergillus sp., powder; NC00713; NSC 758662; NSC-633781; NSC-779704; IDI1_001032; NCGC00023509-04; NCGC00023509-05; NCGC00023509-06; NCGC00023509-07; NCGC00023509-08; NCGC00023509-09; NCGC00023509-10; NCGC00023509-11; NCGC00023509-13; NCGC00023509-14; NCGC00023509-16; NCGC00254157-01; NCGC00259026-01; 74133-25-8; AC-13961; BL164644; Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (2S)-; G226; SMR000673570; SBI-0051881.P002; L0214; SIMVASTATIN IMPURITY E [EP IMPURITY]; EN300-52515; C07074; D00359; AB00052400-17; AB00052400_18; AB00052400_19; Mevinolin from Aspergillus sp., >=98% (HPLC); A838030; A838383; Q417740; SR-01000000123; SR-01000000123-3; SR-05000001880-1; SR-05000001880-2; BRD-K09416995-001-06-8; BRD-K09416995-001-21-7; Mevacor;Monacolin K;mevinolin;6-alpha-Methylcompactin; SIMVASTATIN IMPURITY, LOVASTATIN- [USP IMPURITY]; Z754931258; (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-8-(2-((4R,6R)-4-hydroxy-2-oxo-2H-pyran-6-yl)ethyl)-3,7-dimethylnaphtyl(S)-2-methylbutyrat; (2S)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl-2-methyl butanoate; (2S)-2-methylbutanoic acid [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-2-oxanyl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] ester; (S)-((1S,3R,7S,8S,8AR)-8-(2-((2R,4R)-4-HYDROXY-6-OXO-TETRAHYDRO-2H-PYRAN-2-YL)ETHYL)-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL) 2-METHYLBUTANOATE; (S)-2-Methyl-butyric acid (1S,3R,7S,8S,8aR)-8-[2-((3R,5R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl ester; [(1S,3R,7S,8S,8aR)-3,7-dimethyl-8-[2-[(2R,4R)-4-oxidanyl-6-oxidanylidene-oxan-2-yl]ethyl]-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-Hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2-methylbutanoate; 1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; 8-[2-(4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydro-1-naphthale; Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-- oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-; BUTANOIC ACID, 2-METHYL-, 1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-(TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL ESTER, (1S-(1.ALPHA.(R*),3.ALPHA.,7.BETA.,8.BETA.(2S*,4S*),8.ALPHA..BETA.))-	Approved	Approved Drug(s)	53232	DB00227	D06WTZ	404.5	72.8	666	4.3	29	1	5	7	C24H36O5	[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate	CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C	CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C	InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1	PCZOHLXUXFIOCF-BXMDZJJMSA-N
DI15AY	Testosterone	Small molecule	testosterone; 58-22-0; Androderm; Testim; Testosteron; Virosterone; Mertestate; Sustanon; Testoderm; AndroGel; Androlin; Homosterone; Oreton; Testiculosterone; Synandrol F; Andropatch; Homosteron; Orquisteron; Perandren; Primotest; Primoteston; Sustanone; Testandrone; Testobase; Testopropon; Testosteroid; Andronaq; Andrusol; Relibra; Testogel; Testrone; Testryl; Teslen; Cristerona T; Testoviron T; Malerone; Neotestis; Testoviron; trans-Testosterone; Testoviron Schering; Cristerone T; Geno-cristaux gremy; Testostosterone; Testolin; 17beta-Hydroxyandrost-4-en-3-one; LibiGel; Sustason 250; Percutacrine androgenique; Oreton-F; Testoject-50; Testosterona; Testosteronum; Intrinsa; Striant; Andro 100; Testex; Testosterone hydrate; Virormone; beta testosterone; Testro AQ; Malestrone (amps); Malogen, aquaspension injection; Testosteronum [INN-Latin]; Testosterona [INN-Spanish]; Natesto; Vogelxo; Neo-Hombreol F; Androst-4-en-17beta-ol-3-one; 17beta-Hydroxy-4-androsten-3-one; 7-beta-Hydroxyandrost-4-en-3-one; COL 1621; delta4-Androsten-17beta-ol-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 4-Androsten-17beta-ol-3-one; Testosterone ciii; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; delta(sup 4)-Androsten-17(beta)-ol-3-one; (+)-testosterone; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; Androst-4-en-3-one, 17beta-hydroxy-; Androst-4-en-3-one, 17-hydroxy-, (17beta)-; Androst-4-en-3-one, 17-beta-hydroxy-; CHEBI:17347; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; Neo-testis; Testoderm Tts; (17beta)-17-Hydroxyandrost-4-en-3-one; 3XMK78S47O; DTXSID8022371; Androst-4-en-3-one, 17-hydroxy-, (17b)-; NSC-9700; Testopel Pellets; CDB 111C; Halotensin; Fortesta; Livensa; Nasobol; Axiron; Tefina; Androst-4-en-3-one, 17-hydroxy-, (17.beta.)-; CompleoTRT; CP 601B; Androderm (TN); Androgel 1%; 17.beta.-Testosterone; Androgel (TN); SMR000058344; CCRIS 574; Striant (TN); Bio-T-Gel; AA 2500; Testim (TN); Androgel 1.62%; HSDB 3398; NSC 9700; EINECS 200-370-5; Testosterone (JAN/USP); Androst-4-en-3-on-17B-ol; CHEMBL386630; component of Duogen (Salt/Mix); component of Tostrex (Salt/Mix); component of Di-Met (Salt/Mix); UNII-3XMK78S47O; component of Intrinsa (Salt/Mix); Epitestosteron; Lumitestosteron; 4-Androsten-17.beta.-ol-3-one; 4-Androsten-3-one-17.beta.-ol; Tostrelle; Tostrex; Viatrel; component of Di-Genik (Salt/Mix); 4-Androsten-3-one, 17b-hydroxy-; Testosterone [USP:INN:BAN]; 9b-testosterone; component of Mal-O-Fem (Salt/Mix); 4-androstene-17beta-ol-3-one; 17b-hydroxy-4-androsten-3-one; delta4-androsten-17b-ol-3-one; LPCN 1021; Testosterone, 1; 3kdm; 17b-Testosterone; 17-.beta.-Hydroxyandrost-4-en-3-one; NCGC00091018-01; 8-iso-testosterone; Androst-4-en-3-one, 17-hydroxy-, (17-beta)-; (+-)-testosterone; Axiron (TN); CMC_13449; 13-iso-testosterone; ANDROLAN; mpp10; TESTSTERONE; 9b,10a-testosterone; 17.beta.-Hydroxy-.DELTA.4-androsten-3-one; ANDROID-T; 17-Hydroxyandrost-4-en-3-one, (17.beta.)-; (+-)-retrotestosterone; Testosterone, >=98%; TESTOSTERONE [MI]; TESTOSTERONE [INN]; TESTOSTERONE [JAN]; Epitope ID:135865; EC 200-370-5; TESTOSTERONE [HSDB]; TESTOSTERONE [INCI]; Testosterone EP Impurity C; (+-)-8-iso-testosterone; SCHEMBL8452; TESTOSTERONE [VANDF]; TESTOSTERONE [MART.]; 4-Androsten-3-one-17b-ol; MLS000563091; MLS001032098; MLS001306401; MLS001424262; MLS002174283; BIDD:ER0555; TESTOSTERONE [WHO-DD]; D4-Androsten-17b-ol-3-one; Androst-4-en-17b-ol-3-one; BDBM8885; DTXCID302371; GTPL2858; Androst-4-ene-17b-ol-3-one; TESTOSTERONE [EMA EPAR]; 17-hydroxy-D4-androsten-3-one; 17-hydroxy-androst-4-en-3-one; 17beta-hydroxy-4-androsten-3one; TESTOSTERONE [GREEN BOOK]; Testosterone, cell culture tested; 17b-Hydroxy-androst-4-en-3-on; 17b-Hydroxy-D4-androsten-3-one; 17b-Hydroxyandrost-4-ene-3-one; 1i37; 17a-hydroxy-androst-4-en-3-one; 17b-hydroxy-androst-4-en-3-one; HMS2052N11; HMS2272B03; HMS2272P03; TESTOSTERONE [EP IMPURITY]; TESTOSTERONE [ORANGE BOOK]; TESTOSTERONE [EP MONOGRAPH]; (8R,9S,10R,13S,14S,17S)-17-Hydroxy-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; 17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one; TESTOSTERONE [USP MONOGRAPH]; Tox21_200689; HY-15554A; LMST02020002; RB3046; 17b-hydroxy-8a-androst-4-en-3-one; rac-17b-hydroxy-androst-4-en-3-one; AKOS015894897; 17a-hydroxy-13a-androst-4-en-3-one; 17a-hydroxy-14b-androst-4-en-3-one; 17b-hydroxy-13a-androst-4-en-3-one; CCG-101189; CS-1415; DB00624; NC00439; CAS-58-22-0; Testosterone 1.0 mg/ml in Acetonitrile; (17?)-17-Hydroxyandrost-4-en-3-one; 17b-hydroxy-(8a)-androst-4-en-3-one; 17b-hydroxy-(9b)-androst-4-en-3-one; NCGC00258243-01; (17b)-17-hydroxy-androst-4-en-3-one; 17a-hydroxy-(13a)-androst-4-en-3-one; 17b-hydroxy-(10a)-androst-4-en-3-one; 17b-hydroxy-(13a)-androst-4-en-3-one; AC-14899; CPD000058344; SMR001261453; Testosterone, purum, >=99.0% (HPLC); Testosterone 100 microg/mL in Acetonitrile; rac-17b-hydroxy-(13a)androst-4-en-3-one; rac-17b-hydroxy-(8a)-androst-4-en-3-one; T0027; 17b-hydroxy-(8a,10a)-androst-4-en-3-one; 17b-hydroxy-(9b,10a)-androst-4-en-3-one; BIM-0061761.0001; C00535; D00075; rac-17b-hydroxy-(9b,10a)androst-4-en-3-one; S00309; AB00973630-03; Testosterone, VETRANAL(TM), analytical standard; Androst-4-en-3-one, 17-hydroxy, (17.beta.)-; Q-101251; Q1318776; B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E; TESTOSTERONE ENANTATE IMPURITY D [EP IMPURITY]; TESTOSTERONE PROPIONATE IMPURITY C [EP IMPURITY]; Testosterone, European Pharmacopoeia (EP) Reference Standard; (8alpha,10alpha,13alpha,14beta,17alpha)-17-hydroxyandrost-4-en-3-one; Testosterone;  4-Androsten-17?-ol-3-one;  17?-Hydroxy-4-androsten-3-one; Testosterone for impurity D identification, European Pharmacopoeia (EP) Reference Standard; Testosterone for system suitability, European Pharmacopoeia (EP) Reference Standard; (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-6-en-5-one; 1050678-68-6; 17?-hydroxyandrost-4-en-3-one; epitestosterone; 17-epi-Testosterone; 17?-cis-Testosterone; 4-Androstene-17?-ol-3-one; Isotestosterone	Approved	Approved Drug(s)	6013	DB00624	D06XMU	288.4	37.3	508	3.3	21	1	2	0	C19H28O2	(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one	CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1	MUMGGOZAMZWBJJ-DYKIIFRCSA-N
D7G6TY	Dacomitinib	Small molecule	Dacomitinib; 1110813-31-4; PF-00299804; PF299804; Dacomitinib (PF299804, PF299); Dacomitinib anhydrous; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide; (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide; PF-299804; Dacomitinib (PF299804); 2XJX250C20; PF 00299804-03; Dacomitinib (INN); (2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide; DACOMITINIB [INN]; PF-299804 (Dacomitinib PF-00299804); (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide; Dacomitinib [USAN:INN]; dacomitinibum; UNII-2XJX250C20; PF299; (E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide; PF-299; DACOMITINIB [WHO-DD]; MLS006011275; GTPL7422; CHEMBL2110732; CHEBI:91466; DTXSID50149493; EX-A030; CHEBI:132268; BDBM112499; Dacomitinib (PF-00299804); AMY21292; BCP02530; MFCD19443734; NSC765888; NSC800084; s2727; AKOS025401818; CCG-264987; CS-0500; DB11963; NSC-765888; NSC-800084; US8623883, No. 2; NCGC00263185-09; NCGC00263185-10; AC-25915; AS-57686; HY-13272; SMR004703025; D5450; SW219155-1; D09883; Dacomitinib (PF299804, PF-00299804); EN300-7406881; J-500784; Q17130597; (2E)-N-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-METHOXYQUINAZOLIN-6-YL)-4-PIPERIDIN-1-YLBUT-2-ENAMIDE; (2E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide; (E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide; (E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, (2E)-	Approved	Approved Drug(s)	11511120	DB11963	D06XXH	469.9	79.4	665	4.4	33	2	7	7	C24H25ClFN5O2	(E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4	InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+	LVXJQMNHJWSHET-AATRIKPKSA-N
D6U3SM	Lansoprazole	Small molecule	lansoprazole; 103577-45-3; Prevacid; Agopton; Limpidex; Lanzor; Bamalite; Monolitum; Takepron; Ogastro; Opiren; Zoton; Prevacid SoluTab; Lansoprazol; Lanzopral; AG-1749; Lanproton; Lansopep; Lasoprol; Mesactol; Aprazol; Blason; Ketian; Lancid; Lanston; Ogast; Lanz; lanzoprazole; Lansoprazolum; Lansox; Prevacid Iv; PrevOnco; AG 1749; A-65006; Lanzo; Prevacid 24HR; Lansoprazole-13C6; Ogastoro; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; CHEBI:6375; Prezal; 1261394-42-6; Pro Ulco; Compraz; Ilsatec; Prosogan; Suprecid; Dakar; Promp; Zoprol; NSC-758638; TAK-390MR; 0K5C5T2QPG; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole; MLS000069705; DTXSID4023200; Lanzol-30; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; NCGC00015615-02; SMR000058469; Lansoprazol [INN-Spanish]; Lansoprazolum [INN-Latin]; CAS-103577-45-3; MLS-0003247.0001; Prevacid NapraPAC; 1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-; 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole; Prevacid I.V.; DTXCID703200; TAK 390MR; Lansophed; Lanzol; Lanzul; 2-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; Prevacid (TN); 2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole;2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole; HSDB 7204; SR-01000000169; A 65006; UNII-0K5C5T2QPG; BRN 4333393; Lanfast; Lapraz; 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl}-1H-benzimidazole; ABT-006; Lansoprazole,(S); 2-(((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE; Lansoprazole [USAN:USP:INN:BAN]; MFCD00866873; CG-4801; Spectrum_001580; CPD000058469; Prevacid Delayed Release; Opera_ID_1676; Prestwick0_001072; Prestwick1_001072; Prestwick2_001072; Prestwick3_001072; Spectrum2_000444; Spectrum3_000295; Spectrum4_000856; Spectrum5_001521; Dexlansoprazole-[13C6]; LANSOPRAZOLE [MI]; Lopac-L-8533; LANSOPRAZOLE [INN]; LANSOPRAZOLE [JAN]; CHEMBL480; L 8533; LANSOPRAZOLE [HSDB]; LANSOPRAZOLE [USAN]; cid_3883; LANSOPRAZOLE [VANDF]; Lopac0_000709; SCHEMBL22365; BSPBio_001084; BSPBio_001830; KBioGR_001491; KBioSS_002060; LANSOPRAZOLE [MART.]; Lansoprazole impurity standard; MLS000759405; MLS001074170; MLS001424235; (+/-)-LANSOPRAZOLE; BIDD:GT0006; DivK1c_000920; LANSOPRAZOLE [USP-RS]; LANSOPRAZOLE [WHO-DD]; SPECTRUM1503926; SPBio_000488; SPBio_002992; BPBio1_001194; GTPL7208; BDBM47032; HMS502N22; KBio1_000920; KBio2_002060; KBio2_004628; KBio2_007196; KBio3_001330; Lansoprazole (JP17/USP/INN); 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; 2-[(S)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; Levolansoprazole;(-)-Lansoprazole; NINDS_000920; HMS1571G06; HMS1922M04; HMS2052F05; HMS2093M07; HMS2098G06; HMS2234B10; HMS3262M19; HMS3264E12; HMS3269D15; HMS3371E21; HMS3394F05; HMS3413J05; HMS3654J17; HMS3677J05; HMS3715G06; LANSOPRAZOLE [ORANGE BOOK]; Pharmakon1600-01503926; Pharmakon1600-01504282; LANSOPRAZOLE [EP MONOGRAPH]; ACT03358; BCP22331; BCP34129; Lansoprazole for peak identification; LANSOPRAZOLE [USP MONOGRAPH]; Tox21_110184; Tox21_301023; Tox21_500709; BBL029072; BDBM50070208; CCG-39952; NSC758638; NSC758710; PREVPAC COMPONENT LANSOPRAZOLE; s1354; STK621169; AKOS005554811; Tox21_110184_1; AC-1233; CS-1847; DB00448; KS-1075; Lansoprazole, >=98% (TLC), powder; LP00709; NC00411; NSC 758638; SB19127; SDCCGSBI-0050687.P004; 2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole; 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole; IDI1_000920; LANSOPRAZOLE COMPONENT OF PREVPAC; NCGC00015615-01; NCGC00015615-03; NCGC00015615-04; NCGC00015615-05; NCGC00015615-06; NCGC00015615-07; NCGC00015615-08; NCGC00015615-09; NCGC00015615-10; NCGC00015615-11; NCGC00015615-12; NCGC00015615-14; NCGC00015615-15; NCGC00023826-03; NCGC00023826-04; NCGC00023826-05; NCGC00023826-06; NCGC00023826-07; NCGC00254925-01; NCGC00261394-01; NCGC00381720-13; BL166173; HY-13662; SBI-0050687.P003; AB00052388; EU-0100709; FT-0610894; FT-0670721; FT-0670722; L0233; SW197226-4; D00355; F20528; AB00052388-17; AB00052388_18; AB00052388_19; A800764; A921066; Q254296; J-007154; SR-01000000169-2; SR-01000000169-6; SR-01000000169-9; BRD-A49172652-001-05-7; BRD-A49172652-001-13-1; F2173-0222; Z1501485356; Lansoprazole, British Pharmacopoeia (BP) Reference Standard; Lansoprazole, European Pharmacopoeia (EP) Reference Standard; Lansoprazole, United States Pharmacopeia (USP) Reference Standard; (+)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole; 2-[[ [3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]-sulfinyl]1H-benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methylsulfinyl]-1H-benzimidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]methylsulfinyl]benzimidazole; 2-[[3-methyl-4-[2,2,2-tris(fluoranyl)ethoxy]pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; 2-[3-Methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-1H-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)pyridin-2-ylmethanesulfinyl]-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl-methanesulfinyl]-1H-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-ylmethanesulfinyl]-1H-benzimidazole; Lansoprazole for peak identification, European Pharmacopoeia (EP) Reference Standard; 1H-Benzimidazole, 2-[(S)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-; 2-[[[3-METHYL-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDIN-2-YL]METHYL]SULFINYL]-1H-BENZO[D]IMIDAZOLE	Approved	Approved Drug(s)	3883	DB00448	D06YYD	369.4	87.1	480	2.8	25	1	8	5	C16H14F3N3O2S	2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole	CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F	CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F	InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)	MJIHNNLFOKEZEW-UHFFFAOYSA-N
DNZ57Q	Dexlansoprazole	Small molecule	dexlansoprazole; (R)-Lansoprazole; 138530-94-6; Kapidex; R-(+)-LANSOPRAZOLE; dexilant; Dexilant Solutab; TAK 390; TAK-390; Lansoprazole r-form; Lansoprazole, (r)-; T 168390; (r)-(+)-lansoprazole; T-168390; UYE4T5I70X; (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; NSC-758710; 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; TAK-390MR; 1H-Benzimidazole, 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-; Dexlansoprazole [USAN]; UNII-UYE4T5I70X; Dexlansoprazole (INN/USAN); Dexlansoprazole [USAN:INN]; (+)-lansoprazol; 2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; Dexilant (TN); (+)-2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE; (+)-2-((R)-{(3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl}sulfinyl)-1H-benzimidazole; 1H-Benzimidazole, 2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-; SCHEMBL44975; DEXLANSOPRAZOLE [INN]; DEXLANSOPRAZOLE [VANDF]; GTPL5487; DEXLANSOPRAZOLE [MART.]; CHEMBL1201863; DEXLANSOPRAZOLE [WHO-DD]; LANSOPRAZOLE R-FORM [MI]; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; CHEBI:135931; HMS3652C14; AMY25226; BDBM50247930; DEXLANSOPRAZOLE [ORANGE BOOK]; HY-13662B; MFCD13196699; s4099; AKOS025290765; CCG-213301; DB05351; NSC 758710; PB33188; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; NCGC00386267-03; AC-26449; AS-18086; SW219466-1; D08903; AB01563023_01; AB01563023_02; Q5268339; (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]benzimidazole; (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole; (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole; (R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzimidazole; 2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl]-1H-1,3-benzodiazole	Approved	Approved Drug(s)	9578005	DB05351	D06YYD	369.4	87.1	480	2.8	25	1	8	5	C16H14F3N3O2S	2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole	CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F	CC1=C(C=CN=C1C[S@@](=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F	InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1	MJIHNNLFOKEZEW-RUZDIDTESA-N
DSA9V1	Imipramine	Small molecule	imipramine; Melipramine; 50-49-7; Antideprin; Berkomine; Imidobenzyle; Dimipressin; Melipramin; Tofranil; Intalpram; Nelipramin; Dynaprin; Timolet; Irmin; Dpid; Dyna-zina; Impramine; Promiben; Censtim; Censtin; Imiprin; Iramil; Janimine; Imipramina; Declomipramine; Eupramin; Imipraminum; Psychoforin; Imavate; Surplix; Imizin; Tofranil, base; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; Imipramin; Imizinum; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; Tofranil (free base); SK-Pramine; Cristalia; Sermonil; Imipramine (INN); NSC 169866; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; CHEMBL11; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; NSC-169866; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-; OGG85SX4E4; N-(.gamma.-Dimethylaminopropyl)iminodibenzyl; DTXSID1043881; CHEBI:47499; 5,e)azepine; 5,e]azepine; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)propyl)-; N,N-Dimethyl-10,11-dihydro-5H-dibenzo[b,f]azepine-5-propanamine-2,8-D2; ORG-2463; Imidol; 2241983-10-6; NCGC00015563-07; Imipramina [Italian]; IMIPRAMINE [INN]; Tofranil (TN); 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 3-(5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE; 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)-10,11-dihydro-; Imipramine [INN:BAN]; IMIPRAMINE-D3 HYDROCHLORIDE 98 ATOM % D; Imipraminum [INN-Latin]; Imipramina [INN-Spanish]; DTXCID9023881; 3-(10,11-dihydro-5h-dibenz[b,f]azepin-5-yl)propyldimethylamine; 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; CAS-50-49-7; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine;3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; CCRIS 9173; HSDB 3100; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethyl-propan-1-amine; Janimine (hydrochloride); Tofranil (hydrochloride); CAS-113-52-0; EINECS 200-042-1; UNII-OGG85SX4E4; BRN 0256892; 5H-Dibenz(b, 5-(3-(dimethylamino)propyl)-10,11-dihydro-; 5H-Dibenz[b, 5-[3-(dimethylamino)propyl]-10,11-dihydro-; Tofranil base; 5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)propyl]-10,11-dihydro-; IXX; Imizin (Salt/Mix); Imavate (Salt/Mix); Imizine (Salt/Mix); Surplix (Salt/Mix); Eupramin (Salt/Mix); Imizinum (Salt/Mix); Tofranil (Salt/Mix); Spectrum_000915; IMIPRAMINE [MI]; Psychoforin (Salt/Mix); Prestwick0_000072; Prestwick1_000072; Prestwick2_000072; Prestwick3_000072; SK-Pramine (Salt/Mix); Spectrum2_000990; Spectrum3_000466; Spectrum4_000016; Spectrum5_000864; IMIPRAMINE [HSDB]; Lopac-I-7379; IMIPRAMINE [VANDF]; IMIPRAMINE [MART.]; IMIPRAMINE [WHO-DD]; Lopac0_000702; Oprea1_200908; SCHEMBL34282; BSPBio_000283; BSPBio_002172; GTPL357; KBioGR_000391; KBioSS_001395; BIDD:GT0116; DivK1c_000559; SPBio_001059; SPBio_002204; G-22355 (Salt/Mix); BPBio1_000313; Clomipramine HCl EP Impurity B; HY-B1490A; KBio1_000559; KBio2_001395; KBio2_003963; KBio2_006531; KBio3_001392; NINDS_000559; HMS2089G08; Tox21_110174; BDBM50010859; CCG-36485; MFCD31699979; NSC169866; STL416211; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; AKOS016010320; Tox21_110174_1; DB00458; SDCCGSBI-0050680.P005; IDI1_000559; MRF-0000592; NCGC00015563-01; NCGC00015563-02; NCGC00015563-03; NCGC00015563-04; NCGC00015563-05; NCGC00015563-06; NCGC00015563-08; NCGC00015563-09; NCGC00015563-10; NCGC00015563-11; NCGC00015563-13; NCGC00015563-25; NCGC00024253-03; NCGC00024253-04; 5-(3-Dimethylaminopropyl)-10,f)azepine; SY246340; Trimipramine maleate impurity, imipramine-; SBI-0050680.P004; WLN: T C676 BN&T&J B3N1&1; 5-(3-(Dimethylamino)propyl)-10,f)azepine; AB00053486; CS-0013621; FT-0670319; FT-0697093; 5H-Dibenz[b, 10,11-dihydro-N,N-dimethyl-; C07049; D08070; EN300-708790; Q58396; AB00053486-15; AB00053486_16; AB00053486_17; 1-(3-Dimethylaminopropyl)-4,3,6,7-dibenzazepine; L000739; W-109253; BRD-K38436528-003-05-5; BRD-K38436528-003-15-4; TRIMIPRAMINE MALEATE IMPURITY D [EP IMPURITY]; 5H-Dibenz(b, 10,11-dihydro-5-(3-(dimethylamino)propyl)-; CLOMIPRAMINE HYDROCHLORIDE IMPURITY B [EP IMPURITY]; TRIMIPRAMINE MALEATE IMPURITY, IMIPRAMINE- [USP IMPURITY]; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine #; Clomipramine EP Impurity B; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; (3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine; (3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine	Approved	Approved Drug(s)	3696	DB00458	D06ZUK	280.4	6.5	291	4.8	21	0	2	4	C19H24N2	3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine	CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31	CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31	InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3	BCGWQEUPMDMJNV-UHFFFAOYSA-N
DN72OM	Duvelisib	Small molecule	Duvelisib; 1201438-56-3; IPI-145; INK-1197; (S)-3-(1-((9H-Purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one; IPI 145; UNII-610V23S0JI; IPI145; (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one; INK-1147; IPI-145 (INK1197); Duvelisib (IPI-145, INK1197); 610V23S0JI; 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one; Duvelisib hydrate; Copiktra (TN); 1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-((1S)-1-(9H-purin-6-ylamino)ethyl)-; Duvelisib [USAN]; Duvelisib [USAN:INN]; IPI-145;INK1197; 1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-; INK1197; DUVELISIB [INN]; DUVELISIB [MI]; Duvelisib (USAN/INN); Duvelisib (IPI-145); DUVELISIB [WHO-DD]; SCHEMBL153543; GTPL7795; DUVELISIB [ORANGE BOOK]; CHEMBL3039502; SCHEMBL18343557; SCHEMBL19670020; SCHEMBL20580104; DTXSID80152697; CHEBI:131169; AMY24208; BCP07042; EX-A1562; BDBM50193013; MFCD15144635; NSC772469; s7028; AKOS022186370; AKOS037515795; IPI-145, INK 1197, Duvelisib; CCG-268854; CS-0888; DB11952; NSC-772469; 8-chloro-2-phenyl-3-((1S)-1-(9H-purin-6-ylamino)ethyl)-1(2H)-isoquinolinone; NCGC00351482-01; AC-30239; AS-16309; compound 4904 [Patent US8193182]; HY-17044; SW219822-1; D10555; EN300-18167128; Q27077129; IPI-145 pound>>INK1197; IPI 145; IPI145; INK-1197; INK 1197; 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one; 8-chloro-2-phenyl-3-[(1S)-1-[(9H-purin-6-yl)amino]ethyl]-1,2-dihydroisoquinolin-1-one	Approved	Approved Drug(s)	50905713	DB11952	D06ZVZ	416.9	86.8	668	4.1	30	2	5	4	C22H17ClN6O	8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one	CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5	C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5	InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1	SJVQHLPISAIATJ-ZDUSSCGKSA-N
DG8AK7	Ceftriaxone	Small molecule	ceftriaxone; Biotrakson; Rocephin; 73384-59-5; Ceftriaxon; Ceftriazone; Rocefin; Ceftriaxonum [INN-Latin]; Ceftriaxona [INN-Spanish]; Ceftriaxona; Ceftriaxonum; Rocephine; CEFTRIAXONE SODIUM; Rocephalin; Ceftriaxone (INN); CHEBI:29007; CHEMBL161; CTRX; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CEFTRIAXONE [INN]; 75J73V1629; Ceftriaxone and Dextrose in Duplex Container; (E)-Ceftriaxone; 74578-69-1; Ro 139904; Rophex; DRG-0071; Ceftriaxone (TN); (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; EINECS 277-405-6; Ceftriaxone [USAN:INN:JAN]; UNII-75J73V1629; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CEFTRIAXONE [MI]; CEFTRIAXONE [VANDF]; SCHEMBL23354; CEFTRIAXONE [WHO-DD]; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6R-(6alpha,7beta(Z)))-; DTXSID0022773; HY-B0712; BDBM50049707; BDBM50103601; AKOS015960618; AC-1592; DB01212; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid; AS-56320; C06683; D07659; A899928; EN300-23582312; Cefatriaxone, Antibiotic for Culture Media Use Only; W-104454; (6R,7R)-7-[[(2Z)-2-(2-Amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7^2-(Z)-(O-; (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-3-(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R,)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2-AMINO-4-THIAZOLYL)(METHOXYIMINO)ACETYL)AMINO)-8-OXO-3-(((1,2,5,6-TETRAHYDRO-2-METHYL-5,6-DIOXO-1,2,4-TRIAZIN-3-YL)THIO)METHYL)-, (6R-(6.ALPHA.,7.BETA.(Z)))-; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6R,7R)-; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, (6R,7R)-; 7-[2-(2-Amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid (Ceftriaxone); 7-[2-(2-Amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid(Ceftriaxone)	Approved	Approved Drug(s)	5479530	DB01212	D07ACT	554.6	288	1110	-1.3	36	4	13	8	C18H18N8O7S3	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid	CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O	CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)O	InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1	VAAUVRVFOQPIGI-SPQHTLEESA-N
D7Q9NV	Ascorbic acid	Small molecule	ascorbic acid; l-ascorbic acid; vitamin C; 50-81-7; L-ascorbate; L(+)-Ascorbic acid; ascorbate; Ascoltin; Ascorbicap; Cevitamic acid; Cenolate; Hybrin; Allercorb; Ascorbajen; Ascorbutina; Ascorteal; Cescorbat; Cetemican; Cevitamin; Citriscorb; Laroscorbine; Lemascorb; Natrascorb; Proscorbin; Roscorbic; Secorbate; Testascorbic; Vitacimin; Vitamisin; Vitascorbol; Ascorin; Ascorvit; Cantaxin; Cebicure; Cebione; Cegiolan; Ceglion; Celaskon; Cemagyl; Cenetone; Cergona; Cetamid; Cevatine; Cevimin; Cevital; Cevitan; Cevitex; Colascor; Concemin; Redoxon; Vicelat; Viforcit; Viscorin; Vitacee; Vitacin; Adenex; Ascorb; Cantan; Cebid; Cebion; Cecon; Cemill; Cereon; Cevex; Ciamin; Cipca; Hicee; Ribena; Vitace; Xitix; Davitamon C; Arco-cee; Planavit C; Catavin C; Ce lent; Liqui-Cee; Vicomin C; Cee-Vite; Cevi-Bid; Scorbu-C; C-Level; C-Vimin; Cetane-Caps TD; Duoscorb; Scorbacid; Cewin; Antiscorbic vitamin; C-Long; C-Quin; C-Span; Meri-C; Cee-Caps TD; 3-Oxo-L-gulofuranolactone; L-Lyxoascorbic acid; L-Xyloascorbic acid; Cevalin; Antiscorbutic vitamin; Cetane-Caps TC; 3-Keto-L-gulofuranolactone; Ce-Mi-Lin; IDO-C; Natrascorb injectable; Acidum ascorbicum; L-(+)-Ascorbic Acid; CE-VI-Sol; Ferrous ascorbate; Acidum ascorbinicum; Ascor-B.I.D.; (R)-5-((S)-1,2-dihydroxyethyl)-3,4-dihydroxyfuran-2(5H)-one; Celin; Dora-C-500; Kyselina askorbova; Cortalex; Ferancee; Stuartinic; Tolfrinic; Acido ascorbico; L-Threoascorbic acid; Acide ascorbique; L-3-Ketothreohexuronic acid lactone; Chromagen; Kyselina askorbova [Czech]; Caswell No. 061B; FEMA No. 2109; Acide ascorbique [INN-French]; Acido ascorbico [INN-Spanish]; Acidum ascorbicum [INN-Latin]; Sodascorbate; Ascorbicin; NCI-C54808; L-threo-Hex-2-enonic acid, gamma-lactone; L-threo-Ascorbic acid; 3-Oxo-L-gulofuranolactone (enol form); Ascor; Ascorbicum acidum; Ascorbic acid, l-; Cetebe; Ascorbin; (+)-Ascorbic acid; Hex-2-enonic acid gamma-lactone, L-threo-; L-Ascorbic acid (GMP); MFCD00064328; Iron(II) ascorbate; PQ6CK8PD0R; component of E and C-Level; component of Endoglobin Forte; Vitamin c (as ascorbic acid); INS NO.300; Ascorbicab; DTXSID5020106; E-300; CHEBI:29073; INS-300; CCRIS 57; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2,5-dihydrofuran-2-one; NSC-33832; component of Cortalex; component of Ferancee; HSDB 818; NSC-218455; 6730-29-6; Antiscorbutic factor; NCGC00164357-01; E300; Ester-C; (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; hex-1-enofuranos-3-ulose; L-Ascorbic acid 1000 microg/mL in Acetonitrile; Kangbingfeng; Chewcee; Citrovit; Juvamine; Ceklin; DTXCID90106; Vasc; Rovimix C; Scorbu C; Ascorbinsaeure; Parentrovite; Cell C; Viscorin 100M; Ronotec 100; Suncoat VC 40; Rontex 100; Ascorbicap (TN); Xyloascorbic acid, L-; Ascoltin (TN); [14C]ascorbic acid; Ascorbic acid [BAN:INN:JAN]; [14C]-ascorbic acid; ascorbic acid (vit C); L-Ascorbic acid, meets USP testing specifications; 2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one; EINECS 200-066-2; UNII-PQ6CK8PD0R; NSC 33832; Cevitamate; L-lyxoascorbate; L-xyloascorbate; .Ascorbinsaure; (5R)-5-((1S)-1,2-DIHYDROXYETHYL)-3,4-DIHYDROXYFURAN-2(5H)-ONE; 3eka; Ester C; (+)-ascorbate; L(+)-ascorbate; L-threo-hex-2-enono-1,4-lactone; L-Ascorbic acid, free radical form; L-(+)-ascorbate; Ascorbic acid [USP:INN:BAN:JAN]; Vitamin C,(S); E 300; 178101-88-7; Ascorbic Acid DC97SF; (2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; Prestwick3_000325; L-Ascorbic acid, 99%; ASCOR (TN); SCHEMBL785; bmse000182; VITAMIN C [VANDF]; Vitamin C (Ascorbic acid); ASCORBIC ACID [II]; ASCORBIC ACID [MI]; SCHEMBL4430; ASCORBIC ACID [FCC]; ASCORBIC ACID [INN]; ASCORBIC ACID [JAN]; L-Ascorbic acid, FCC, FG; L-Ascorbic Acid, Free Acid; ASCORBIC ACID [FHFI]; ASCORBIC ACID [HSDB]; ASCORBIC ACID [INCI]; BSPBio_000329; (r)-5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5h-furan-2-one; MLS002153776; ASCORBIC ACID [VANDF]; CHEMBL40274; L-Ascorbic acid, cell culture; ASCORBIC ACID [MART.]; BPBio1_000363; GTPL4532; GTPL4781; L-Ascorbic acid, reagent grade; ASCORBIC ACID [USP-RS]; ASCORBIC ACID [WHO-DD]; ASCORBIC ACID [WHO-IP]; L-Ascorbic acid, >=99.0%; HY-B0166G; DTXSID50986567; Ascorbic acid (JP17/USP/INN); HMS2096A11; HMS2231N16; HMS3713A11; L-Ascorbic acid ACS reagent grade; (2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one; ASCORBIC ACID [ORANGE BOOK]; BCP27915; HY-B0166; L-Threoascorbic acid,Antiscorbutic factor,Vitamin C;(R)-5-((S)-1,2-Dihydroxyethyl)-3,4-dihydroxyfuran-2(5H)-one; Tox21_110315; Tox21_112104; Tox21_202127; Tox21_302958; ASCORBIC ACID [EP MONOGRAPH]; gamma-lactone L-threo-Hex-2-enonate; HB1238; L-Ascorbic acid, analytical standard; L-Ascorbic acid, AR, >=99.5%; s3114; ASCORBIC ACID [USP MONOGRAPH]; AKOS016843589; Tox21_112104_1; CCG-207946; DB00126; L-Ascorbic acid, mixt. with vitamin B; NSC 218455; ACIDUM ASCORBICUM [WHO-IP LATIN]; gamma-lactone L-threo-Hex-2-enonic acid; L-Ascorbic acid, ACS reagent, >=99%; NCGC00091517-01; NCGC00091517-02; NCGC00091517-03; NCGC00091517-06; NCGC00188972-01; NCGC00256504-01; NCGC00259676-01; 53262-66-1; BP-12831; SMR001233160; L-Ascorbic acid, plant cell culture tested; L-Ascorbic acid, reagent grade, crystalline; A0537; AB00376923; Ascorbic Acid (L-Ascorbic Acid; Vitamin C); CS-0626121; SW198791-2; L-Ascorbic acid, BioUltra, >=99.5% (RT); L-Ascorbic acid, tested according to Ph.Eur.; C 1000; C00072; D00018; E80759; EN300-708766; L-Ascorbic acid, p.a., ACS reagent, 99.0%; 2,3-DEHYDRO-L-THREO-HEXONO-1,4-LACTONE; AB00376923_04; AB00376923_05; L-Ascorbic acid, JIS special grade, >=99.0%; L-Ascorbic acid, Vetec(TM) reagent grade, 99%; L-Ascorbic acid, BioXtra, >=99.0%, crystalline; Q199678; L-Ascorbic acid, puriss. p.a., >=99.0% (RT); Q27101942; 47A605F0-4187-47A8-B0CE-F9E7DA1B0076; L-Ascorbic acid, p.a., ACS reagent, reag. ISO, 99.7%; Ascorbic acid, British Pharmacopoeia (BP) Reference Standard; Ascorbic acid, European Pharmacopoeia (EP) Reference Standard; L-Ascorbic acid, certified reference material, TraceCERT(R); L-Ascorbic acid, powder, cell culture tested, gamma-irradiated; 3,4-Dihydroxy-5beta-[(S)-1,2-dihydroxyethyl]furan-2(5H)-one; Ascorbic acid, United States Pharmacopeia (USP) Reference Standard; (2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxy-2,3-dihydrofuran-3-one; 4-((E)-2-[(2-HYDROXYETHYL)SULFANYL]DIAZENYL)BENZENECARBOXYLICACID; L-Ascorbic acid, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=99%; L-Ascorbic acid, suitable for cell culture, suitable for plant cell culture, >=98%; L-Ascorbic acid, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.7-100.5% (oxidimetric)	Approved	Approved Drug(s)	54670067	DB00126	D07AHW	176.12	107	232	-1.6	12	4	6	2	C6H8O6	(2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one	C(C(C1C(=C(C(=O)O1)O)O)O)O	C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O	InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1	CIWBSHSKHKDKBQ-JLAZNSOCSA-N
DO1RH5	Tobramycin	Small molecule	tobramycin; 32986-56-4; Nebramycin factor 6; Nebramycin VI; Nebramycin 6; Tobi; 3'-Deoxykanamycin B; Tobramicin; Tobrex; Aktob; Nebcin; Deoxykanamycin B; Tobramycin Base; Tobi Podhaler; vantobra; Tobradistin; Bethkis; Kitabis Pak; TOBRAMYCIN SULFATE; NEBRAMYCIN; Distobram; Tobralex; Tobracin (TN); NSC 180514; Tobrex (TN); C18H37N5O9; VZ8RRZ51VK; (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol; DTXSID8023680; Obramycin; CHEBI:28864; 1-Epitobramycin; NSC-180514; Tobramicina; Tobramycine; Tobramycinum; Gotabiotic; Nebicin; Tobacin; Tobrased; (2S,3R,4S,5S,6R)-4-amino-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine; Tobramycine [INN-French]; Tobramycinum [INN-Latin]; Tobramicina [INN-Spanish]; (2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine; TOY; Nebramycin factir 6; HSDB 3259; SR-05000001726; EINECS 251-322-5; UNII-VZ8RRZ51VK; SPRC-AB01; BRN 1357507; torbamycin; Kitabis; Nebramycin Factor 6;Deoxykanamycin B; Tobramycin,(S); Nebcin (Sulfate); NCGC00016814-01; (1S,2S,3R,4S,6R)-4,6-diamino-3-[(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (2S,3R,4S,5S,6R)-4-amino-2-((1S,2S,3R,4S,6R)-4,6-diamino-3-((2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yloxy)-2-hydroxycyclohexyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol; D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1->4))-2-DEOXY-; D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[2,6-diamino-2,3,6-trideoxy-.alpha.-D-ribo-hexopyranosyl-(1->4)]-2-deoxy-; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4)]-2-deoxy-D-streptamine; Bethkis (TN); CAS-32986-56-4; Tobramycin Deuterated; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy-; Tobramycin [USAN:USP:INN:BAN:JAN]; Tobi (TN); Spectrum_001072; TOBRAMYCIN [MI]; TOBRAMYCIN [INN]; TOBRAMYCIN [JAN]; Prestwick3_000544; Spectrum2_000078; Spectrum3_000588; Spectrum4_000752; Spectrum5_001038; TOBRAMYCIN [HSDB]; TOBRAMYCIN [USAN]; TOBRAMYCIN [VANDF]; Tobramycin (JP17/USP); SCHEMBL2838; TOBRAMYCIN [MART.]; CHEMBL1747; TOBRAMYCIN [USP-RS]; TOBRAMYCIN [WHO-DD]; BSPBio_000587; BSPBio_002036; KBioGR_001104; KBioSS_001552; 4-(2,6-Diamino-2,3,6-trideoxy-alpha-D-glycopyranosyl)-6-(3-amino-3-deoxy-alpha-D-glycopyranosyl)-2-deoxystreptamine; MLS000069544; Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-tyrideoxy-alpha-D-ribohexopyranosyl-(1-6))-2-deoxy-, D-; BIDD:GT0503; SPECTRUM1500579; SPBio_000295; BPBio1_000647; DTXCID903680; TOBRAMYCIN [ORANGE BOOK]; GTPL10930; KBio2_001552; KBio2_004120; KBio2_006688; KBio3_001536; ZYLET COMPONENT TOBRAMYCIN; TOBRAMYCIN [EP MONOGRAPH]; HMS2090B16; HMS2092M17; HMS2096N09; HMS3713N09; Pharmakon1600-01500579; TOBRAMYCIN [USP MONOGRAPH]; HY-B0441; TOBRADEX COMPONENT TOBRAMYCIN; TOBRAMYCIN COMPONENT OF ZYLET; Tox21_110626; BDBM50366778; CCG-39936; HB4564; NSC757352; s2514; TOBRASONE COMPONENT TOBRAMYCIN; Tobradex (tobramycin + dexamethasone); AKOS016339662; DB00684; KS-1405; NSC-757352; TOBRADEX ST COMPONENT TOBRAMYCIN; TOBRAMYCIN COMPONENT OF TOBRADEX; TOBRAMYCIN COMPONENT OF TOBRASONE; NCGC00178852-01; NCGC00178852-02; (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxy-tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-6-(hydroxymethyl)tetrahydropyran-3,5-diol; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-6))-2-deoxy-L-streptamine; SMR000058793; Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-6))-2-deoxy-, D-; SBI-0051915.P003; TOBRAMYCIN COMPONENT OF TOBRADEX ST; AB00513858; T2503; C00397; D00063; AB00052438-12; AB00052438_13; AB00052438_14; EN300-7480857; SR-01000721898; Tobramycin, Antibiotic for Culture Media Use Only; Q-201837; Q1758380; SR-01000721898-2; SR-05000001726-1; SR-05000001726-2; BRD-K05619559-001-12-7; (1S,2S,3R,4S,6R)-4,6-diamino-3-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[2,6-diamino-2,3,6-trideoxy-.alpha.-D-ribohexopyranosyl-(1->4)]-2-deoxy-; D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1?6)-O-[2,6-diamino-2,3,6-trideoxy-.alpha.-D-ribo-hexopyranosyl-(1?4)]-2-deoxy-; O-[3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)]-O-[2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1->4)]-2-deoxy-D-streptamine; O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1.ALPHA.6))-2-DEOXY-L-STREPTAMINE; O-3-Amino-3-deoxy-?-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,6-trideoxy-?-D-ribohexopyranosyl-(1-4)]-2-deoxy-D-streptamine	Approved	Approved Drug(s)	36294	DB00684	D07BCT	467.5	268	609	-6.2	32	10	14	6	C18H37N5O9	(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol	C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N	C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N	InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1	NLVFBUXFDBBNBW-PBSUHMDJSA-N
DV7M8O	Ivosidenib	Small molecule	Ivosidenib; 1448347-49-6; AG-120; Tibsovo; Ivosidenib [INN]; AG120; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; Q2PCN8MAM6; UNII-Q2PCN8MAM6; Ivosidenib [USAN:INN:WHO-DD]; (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; Glycinamide, 1-(4-cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)-, (2S)-; (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; RG120; ivosidenibum; Tibsovo (TN); IVOSIDENIB [MI]; Ivosidenib (USAN/INN); GTPL9217; CHEMBL3989958; IVOSIDENIB [ORANGE BOOK]; SCHEMBL15122512; EX-A992; CHEBI:145430; BDBM363689; DTXSID801027928; AMY38924; US9850277, Compound 176; MFCD29036964; NSC789102; s8206; CCG-270141; CS-5122; DB14568; NSC-789102; NCGC00476170-04; NCGC00476170-06; (S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-; (S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; AC-32624; AS-35058; HY-18767; A14386; D11090; A900315; EN300-21623926; Q27895417; (2S)-1-(4-Cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chloroPh)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)-glycinamide; (2S)-2-(2-CHLOROPHENYL)-2-{1-[(2S)-1-(4-CYANOPYRIDIN-2-YL)-5-OXOPYRROLIDIN-2-YL]-N-(5-FLUOROPYRIDIN-3-YL)FORMAMIDO}-N-(3,3-DIFLUOROCYCLOBUTYL)ACETAMIDE; (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide;AG-120; N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxo-L-prolinamide	Approved	Approved Drug(s)	71657455	DB14568	D07DCG	583	119	1050	3.4	41	1	9	7	C28H22ClF3N6O3	(2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide	C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N	C1CC(=O)N([C@@H]1C(=O)N(C2=CC(=CN=C2)F)[C@@H](C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N	InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1	WIJZXSAJMHAVGX-DHLKQENFSA-N
DD18MT	Beclomethasone	Small molecule	beclomethasone; Beclometasone; 4419-39-0; Beclometasona; Beclometasonum; Beclometasone [INN]; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; MLS000028668; KGZ1SLC28Z; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; SMR000058899; MLS001076089; CHEBI:3001; DTXSID5040750; Beclometasone (INN); 9alpha-Chloro-16beta-methylprednisolone; NCGC00164402-01; Beclometasonum [INN-Latin]; Beclometasona [INN-Spanish]; DTXCID3020750; (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione (Beclometasone); (8~{S},9~{R},10~{S},11~{S},13~{S},14~{S},16~{S},17~{R})-9-chloranyl-10,13,16-trimethyl-11,17-bis(oxidanyl)-17-(2-oxidanylethanoyl)-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; CAS-4419-39-0; BMJ 5800; EINECS 224-585-9; UNII-KGZ1SLC28Z; Beclometasone [INN:BAN]; pulvinal; Beclometason; Pregna-1,4-diene-3,20-dione, 9-chloro-11,17,21-trihydroxy-16-methyl-, (11.beta.,16.beta.)-; Beclometason (TN); Opera_ID_1081; BECLOMETHASONE [MI]; SCHEMBL3183; Beclometasone-17-Propionate; Beclometasone-21-Propionate; CHEMBL1586; cid_20469; BECLOMETHASONE [VANDF]; BIDD:GT0556; BECLOMETASONE PROPIONATE; BECLOMETASONE [WHO-DD]; GTPL7059; BCBcMAP01_000159; BDBM53488; AMY7469; HMS2233A18; EX-A4423; HY-B1540; Tox21_112116; AKOS037645177; Tox21_112116_1; CS-5872; 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 9-chloro-11,17,21-trihydroxy-16-methyl-, (11beta,16beta)-; SMP1_000039; NCGC00179392-03; AS-58067; C06842; D07495; F85436; A905224; SR-01000000273; SR-01000000273-4; Beclometasone. Short expiry date due to chemical nature of component(s); 9-CHLORO-11.BETA.,17,21-TRIHYDROXY-16.BETA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE; Pregna-1,4-diene-3,20-dione,9-chloro-11,17,21-trihydroxy-16-methyl-, (11b,16b)-; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloranyl-10,13,16-trimethyl-11,17-bis(oxidanyl)-17-(2-oxidanylethanoyl)-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-17-glycoloyl-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; Beclometasone; (1R,2S,10S,11S,13S,14R,15S,17S)-1-Chloro-14-(2-glycoloyl)-14,17-dihydroxy-2,13,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one; GXR	Approved	Approved Drug(s)	20469	DB00394	D07DVK	408.9	94.8	805	2.2	28	3	5	2	C22H29ClO5	(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one	CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)Cl)C	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C	InChI=1S/C22H29ClO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1	NBMKJKDGKREAPL-DVTGEIKXSA-N
D74VYT	Naltrexone	Small molecule	naltrexone; 16590-41-3; Vivitrol; ReVia; Celupan; N-Cyclopropylmethylnoroxymorphone; Vivitrex; Naltrexona; Nemexin; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; N-Cyclopropylmethyl-14-hydroxydihydromorphinone; 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one; 5S6W795CQM; CHEBI:7465; EN-1639A FREE BASE; DTXSID4046313; NSC-758439; (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one; UM-792; EN-1639A [AS HYDROCHLORIDE]; Naltrexonum [INN-Latin]; (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one; (4R,4As,7aR)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one; Naltrexona [INN-Spanish]; DTXCID2026313; Naltrexonum; Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5.alpha.)-; Naltrexone [USAN:INN:BAN]; Naltrexone base anhydrous; CAS-16590-41-3; CCRIS 3506; HSDB 6750; EINECS 240-649-9; BRN 3596648; UNII-5S6W795CQM; (-)naltrexone; PTI-555; NCGC00162274-02; (-)-Naltrexone; Vivitrol (TN); NALTREXONE [MI]; NALTREXONE [INN]; (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride; Naltrexone (USAN/INN); Prestwick0_000116; Prestwick1_000116; Prestwick2_000116; Prestwick3_000116; NALTREXONE [HSDB]; NALTREXONE [USAN]; NALTREXONE [VANDF]; Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-; NALTREXONE [MART.]; NALTREXONE [USP-RS]; NALTREXONE [WHO-DD]; US9107954, naltrexone; SCHEMBL34681; BSPBio_000132; BIDD:GT0405; CHEMBL19019; SPBio_002071; BPBio1_000146; GTPL1639; NALTREXONE [ORANGE BOOK]; BDBM60212; cid_5485201; cyclopropylmethyl(dihydroxy)[?]one; HMS2089O11; BCP07022; EX-A4863; Tox21_112007; BDBM50000787; MFCD00242996; PDSP2_000847; AKOS015994596; Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-; Tox21_112007_1; CS-0880; DB00704; HS-0002; NALTREXONE COMPONENT OF CONTRAVE; NSC 758439; SMP1_000206; NCGC00024427-03; NCGC00024427-04; NCGC00024427-05; AC-36726; HY-76711; C07253; D05113; AB00174152-14; AB00174152_17; AR-270/43507956; EN300-19748946; Q409587; BRD-K88172511-003-21-1; BRD-K88172511-310-03-8; 3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one; 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxmorphinan-6-one, (5.alpha.)-; (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-bis(oxidanyl)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride; (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one; (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one; 4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0~1,13~.0~5,17~.0~7,18~]octadeca-7(18),8,10-trien-14-one	Approved	Approved Drug(s)	5360515	DB00704	D07EUO	341.4	70	621	1.9	25	2	5	2	C20H23NO4	(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one	C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O	C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O	InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1	DQCKKXVULJGBQN-XFWGSAIBSA-N
DW5X6F	Siponimod	Small molecule	Siponimod; 1230487-00-9; BAF312; BAF312 (Siponimod); Mayzent; BAF-312; Siponimod [INN]; NVP-BAF312-NX; Siponimod [WHO-DD]; Siponimod [USAN]; BAF-312(SiponiMod); 1230487-85-0; RR6P8L282I; CHEMBL2336071; 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid; 1-((4-((1E)-1-(((4-Cyclohexyl- 3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)- 2-ethylphenyl)methyl)azetidine-3-carboxylic acid; 3-Azetidinecarboxylic acid, 1-((4-((1E)-1-(((4-cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)methyl)-; UNII-RR6P8L282I; 3-Azetidinecarboxylic acid, 1-[[4-[(1E)-1-[[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]imino]ethyl]-2-ethylphenyl]methyl]-; J8C; SIPONIMOD [MI]; Siponimod (USAN/INN); SCHEMBL641699; AMY595; BAF 312; DTXSID40153847; Siponimod [USAN:INN:WHO-DD]; C29H35F3N2O3; (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid; 1-[[4-[(~{E})-~{N}-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-~{C}-methyl-carbonimidoyl]-2-ethyl-phenyl]methyl]azetidine-3-carboxylic acid; 1-{4-[1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid; WHO 9491; BDBM50428142; MFCD26142651; AKOS037645089; CCG-269825; CS-3876; DB12371; 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethylbenzyloxyimino)-ethyl)-2-ethylbenzyl)-azetidine-3-carboxylic acid; AC-32779; AS-56983; HY-12355; S7179; D11460; EN300-25360071; J-690082; Z2568751224; (E)-1-(4-(1-(4-cyclohexyl-3-(trifluoromethyl)benzyloxyimino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid; (Z)-4-Cyano-5-((3,5-dichloropyridin-4-yl)thio)-N-(4-(methylsulfonyl)phenyl)thiophene-2-carbimidic acid; 1-({4-[(1E)-1-({[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid; 2(1H)-Isoquinolinebutanoic acid, beta-(((4,5-dihydro-5-(2-(1H-imidazol-2-ylamino)ethyl)-3-isoxazolyl)carbonyl)amino)-3,4-dihydro-gamma-oxo-	Approved	Approved Drug(s)	44599207	DB12371	D07FKQ	516.6	62.1	777	4.8	37	1	8	9	C29H35F3N2O3	1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid	CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O	CCC1=C(C=CC(=C1)/C(=N/OCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)/C)CN4CC(C4)C(=O)O	InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+	KIHYPELVXPAIDH-HNSNBQBZSA-N
DPL64J	Ramipril	Small molecule	ramipril; 87333-19-5; Tritace; Altace; Ramace; Triatec; Delix; Carasel; Vesdil; Cardace; Hoe-498; Pramace; Ramiprilum [Latin]; Ramiprilum; Unipril; HOE 498; Quark; Altace (TN); Corpril; Ramipres; Ecator; Hopace; Acovil; Lostapres; Hytren; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; NSC-758933; CHEMBL1168; L35JN3I7SJ; CHEBI:8774; DTXSID8023551; C09AA05; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; Ramipro; Naprix; MFCD00865775; (2S,3aS,6aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3As,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]azaniumyl]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylate; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; DTXCID203551; HOE498; Ramipril (Altace); (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,6aS)-; SMR000466386; Ramipril (USP/INN); SR-05000001908; UNII-L35JN3I7SJ; Ramipril [USAN:USP:INN:BAN]; NCGC00016955-01; (2S,3aS,6aS)-1-[(S)-N-[(S)-1-Carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid, 1-ethyl ester; CYCLOPENTA(B)PYRROLE-2-CARBOXYLIC ACID, 1-((2S)-2-(((1S)-1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S,3AS,6AS)-; CAS-87333-19-5; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; Spectrum_001958; RAMIPRIL [USAN]; RAMIPRIL [INN]; RAMIPRIL [JAN]; RAMIPRIL [MI]; RAMIPRIL [VANDF]; Spectrum3_001794; Spectrum4_001269; Spectrum5_001721; RAMIPRIL [MART.]; RAMIPRIL [USP-RS]; RAMIPRIL [WHO-DD]; SCHEMBL16059; BSPBio_003347; KBioGR_001858; KBioSS_002512; RAMIPRIL, (+)-; Cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-; MLS000759523; MLS001216547; MLS001423965; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; BIDD:GT0803; SPECTRUM1505214; RAMIPRIL [ORANGE BOOK]; GTPL6339; RAMIPRIL [EP MONOGRAPH]; Ramipril, >=98% (HPLC); RAMIPRIL [USP MONOGRAPH]; HSDB 8393; KBio2_002504; KBio2_005072; KBio2_007640; KBio3_002849; NPD2431; HMS2051E04; HMS2090L11; HMS2093M10; HMS2231M05; HMS3259J07; HMS3715M16; Pharmakon1600-01505214; CYCLOPENTA(B)PYRROLE-2-CARBOXYLIC ACID, 1-(2-((1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S-(1(R*(R*)),2.ALPHA.,3A.BETA.,6A.BETA.))-; HY-B0279; Tox21_110708; BBL033964; BDBM50084681; NSC758933; s1793; STK801937; AKOS005622534; Tox21_110708_1; AC-1347; CCG-100833; DB00178; KS-1103; NC00083; NC00627; NSC 758933; NCGC00178127-01; NCGC00178127-02; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; BR164319; SBI-0206728.P001; R0219; D00421; EN300-118695; AB00698339-07; AB00698339-08; AB00698339_09; AB00698339_10; Q412666; SR-05000001908-1; SR-05000001908-2; Ramipril, British Pharmacopoeia (BP) Reference Standard; Ramipril, European Pharmacopoeia (EP) Reference Standard; Z1515381509; Ramipril, United States Pharmacopeia (USP) Reference Standard; Ramipril, Pharmaceutical Secondary Standard; Certified Reference Material; (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[d]pyrrole-2-carboxylic acid; 1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]pyrrole-2-carboxylic acid(Ramipril); 1-[2-(1-ethoxycarbonyl-3-phenylpropylamino)propionyl]octahydrocyclopenta[b]- pyrrole-2-carboxylic acid; 1028843-43-7	Approved	Approved Drug(s)	5362129	DB00178	D07FRV	416.5	95.9	619	1.4	30	2	6	10	C23H32N2O5	(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid	CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O	InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1	HDACQVRGBOVJII-JBDAPHQKSA-N
DL57DM	Irinotecan	Small molecule	irinotecan; 97682-44-5; (+)-Irinotecan; Camptosar; Irinotecanum; Biotecan; Irinotecanum [INN-Latin]; Irinotecan lactone; Campto; Irinotecan Hcl; Irinophore C; Irinotecan mylan; CPT-11; Irinotecan Free base; (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate; Irinotecan (INN); HSDB 7607; CHEMBL481; NSC-728073; CHEBI:80630; 97682-44-5 (Free base); (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; IRINOTECAN [INN]; Irinotecan [INN:BAN]; 1,4'-Bipiperidine-1'-carboxylic acid (S)-4,11-diethyl-3,4,12,14- tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester; CPT-11 hydrochloride;Camptothecin 11 hydrochloride; Biotecan (TN); MFCD00866307; 1,4'-bipiperidine-1'-carboxylic acid (s)-4,11-diethyl-3,4,12,14- tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester; UNII-7673326042; IRINOTECAN [MI]; IRINOTECAN [HSDB]; IRINOTECAN [VANDF]; SCHEMBL4034; IRINOTECAN [WHO-DD]; IRINOTECAN; CPT-11; BSPBio_002346; GTPL6823; DTXSID1041051; AMY4227; 1u65; BCP02860; BDBM50128267; NSC728073; s1198; AKOS015894969; AB07527; AC-7469; BCP9000793; CS-1138; DB00762; NSC 728073; NCGC00178697-02; NCGC00178697-05; (1,4'-Bipiperidine)-1'-carboxylic acid, 4,11-diethyl-3,4,12-14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester, (S)-; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; AS-14323; HY-16562; NCI60_005051; D08086; EN300-708800; AB00698464-07; AB00698464-09; AB00698464-10; AB00698464-11; AB00698464_12; AB00698464_13; AB00698464_14; A845740; Q412197; BRD-K08547377-003-02-4; (diethyl-hydroxy-dioxo-[?]yl) 4-(1-piperidyl)piperidine-1-carboxylate; 3-tert-Butoxycarbonylamino-5-(4-fluorophenyl)thiophene-2-carboxylicacid; 2-methoxy-5-[2-(3-sulfophenyl)-5-(4-sulfophenyl)pyrylium-4-yl]benzenesulfonic acid; (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate; (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl 4-(piperidin-1-yl)piperidine-1-carboxylate; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3'',4'':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4''-BIPIPERIDINE-1''-CARBOXYLATE; (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate; (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl[1,4'-bipiperidine]-1'-carboxylate; [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate; [1,4'']bipiperidinyl-1''-carboxylic acid (S)-4,11-diethyl-4-hydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-9-yl ester; [1,4'']Bipiperidinyl-1''-carboxylic acid 4,11-diethyl-4-hydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-9-yl ester	Approved	Approved Drug(s)	60838	DB00762	D07HOB	586.7	113	1200	3	43	1	8	5	C33H38N4O6	[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7	InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1	UWKQSNNFCGGAFS-XIFFEERXSA-N
D9P5ZT	Efavirenz	Small molecule	efavirenz; 154598-52-4; Sustiva; Stocrin; DMP-266; DMP 266; (-)-Efavirenz; EFV; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; L-743726; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; Viraday; Efavirenz teva; (Rac)-Efavirenz; L-743,726; (S)-Efavirenz; (4S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; NSC-742403; (-)-6-CHLORO-4-CYCLOPROPYLETHYNYL-4-TRIFLUOROMETHYL-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one; JE6H2O27P8; DTXSID9046029; CHEBI:119486; NSC742403; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one; (S)-6-CHLORO-4-(CYCLOPROPYLETHYNYL)-4-(TRIFLUOROMETHYL)-1H-BENZO[D][1,3]OXAZIN-2(4H)-ONE; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one; (Rac)-DMP 266; (Rac)-EFV; (Rac)-L-743726; DTXCID7026029; Eravirenz; MFCD05662344; SMR000466351; Strocin (TM); Sustiva (TM); Sustiva (TN); CAS-154598-52-4; L 743726; HSDB 7163; SR-01000759360; Efavirenz [USP:INN:BAN]; UNII-JE6H2O27P8; Efavirenzum; Met-SDF-1.beta. & Efavirenz; 1ikv; 1ikw; Efavirenz- Bio-X; NCGC00159337-02; Efavirenz, (S); Efavirenz & PLGA; Efavirenz & IFNL1; Efavirenz & IFNL2; Efavirenz & IFNL3; Efavirenz & IL-29; EFAVIRENZ [INN]; EFAVIRENZ [JAN]; DMP-266; Efavirenz; Efavirenz & IL-28A; Efavirenz & IL-28B; EFAVIRENZ [MI]; EFAVIRENZ [HSDB]; EFAVIRENZ [USAN]; EFV & Interleukin 29; EFAVIRENZ [VANDF]; EFV & Interleukin 28A; EFV & Interleukin 28B; EFV & PLGA; EFAVIRENZ [MART.]; EFAVIRENZ [USP-RS]; EFAVIRENZ [WHO-DD]; EFAVIRENZ [WHO-IP]; EFV & IFNL1; EFV & IFNL2; EFV & IFNL3; Efavirenz (JAN/USP/INN); EFV & Interferon lambda-1; EFV & Interferon lambda-2; EFV & Interferon lambda-3; Efavirenz & Interleukin 29; SCHEMBL37762; EFAVIRENZ [EMA EPAR]; Efavirenz & Interleukin 28A; Efavirenz & Interleukin 28B; MLS000759465; MLS001424087; BIDD:GT0383; AMY229; BDBM2483; CHEMBL223228; DMP266; EFV & IL-28A; EFV & IL-28B; EFAVIRENZ [ORANGE BOOK]; Efavirenz, >=98% (HPLC); Efavirenz & Interferon lambda-1; Efavirenz & Interferon lambda-2; Efavirenz & Interferon lambda-3; EFV & IL-29; GTPL11287; TELURA COMPONENT EFAVIRENZ; EFAVIRENZ [USP MONOGRAPH]; ATRIPLA COMPONENT EFAVIRENZ; BCPP000245; HMS2051J08; HMS2090N16; HMS3393J08; HMS3713M14; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; EFAVIRENZUM [WHO-IP LATIN]; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-; BCP27719; Tox21_111582; DL-535; s4685; EFAVIRENZ COMPONENT OF ATRIPLA; AKOS015894951; Tox21_111582_1; AB21723; BCP9000636; CCG-101011; DB00625; KS-5380; NC00261; NSC 742403; (s)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one; Efavirenz 100 microg/mL in Acetonitrile; NCGC00159337-04; NCGC00159337-12; NCGC00271713-05; NCGC00271713-08; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; AC-25006; BC164402; HY-10572; E0997; C08088; D00896; EN300-219935; F17329; AB00639956-06; AB00639956-08; A809555; Q422645; J-520431; SR-01000759360-4; SR-01000759360-5; Z2177953192; Efavirenz, United States Pharmacopeia (USP) Reference Standard; (4S)-6-chloranyl-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; 2H-3, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-; (S)-6-Chloro-4-(cyclopropyl-ethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazine-2-one; (S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-ben zoxazin-2-one; (S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one	Approved	Approved Drug(s)	64139	DB00625	D07HVY	315.67	38.3	519	4	21	1	5	1	C14H9ClF3NO2	(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one	C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F	C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F	InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1	XPOQHMRABVBWPR-ZDUSSCGKSA-N
D2P5BG	Atazanavir	Small molecule	Atazanavir; 198904-31-3; Latazanavir; Zrivada; Reyataz; BMS-232632; CGP 73547; BMS 232632; CGP-73547; Atazanavir (INN); ATV; Reyataz (TN); CHEMBL1163; QZU4H47A3S; methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; DTXSID9048691; CHEBI:37924; NCGC00182552-01; ATAZANAVIR [INN]; Atazanavir [INN:BAN]; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; DR7; methyl N-[(1S)-1-{N'-[(2S,3S)-2-hydroxy-3-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethylbutanamido]-4-phenylbutyl]-N'-{[4-(pyridin-2-yl)phenyl]methyl}hydrazinecarbonyl}-2,2-dimethylpropyl]carbamate; methyl N-[1-[2-[2-hydroxy-3-[[2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; DTXCID5028617; atazanavirum; Atazanavir Base; 1,14-Dimethyl (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate; methyl N-[(1S)-1-[[(1S,2S)-1-benzyl-2-hydroxy-3-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethyl-butanoyl]amino]-[[4-(2-pyridyl)phenyl]methyl]amino]propyl]carbamoyl]-2,2-dimethyl-propyl]carbamate; methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-[(4-pyridin-2-ylphenyl)methyl]amino]-1-phenylbutan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; CAS-198904-31-3; HSDB 7339; UNII-QZU4H47A3S; 2aqu; Reyataz(TM) (*1:1 sulfate*); (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5, 6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; ATAZANAVIR [MI]; ATAZANAVIR [HSDB]; ATAZANAVIR [VANDF]; ATV & AAG; ATV & HSA; ATAZANAVIR [WHO-DD]; SCHEMBL41696; ATAZANAVIR,BISULFATESALT; Atazanavir, >=98% (HPLC); BDBM13934; GTPL11138; HMS2089P22; ACT06755; AMY31160; Tox21_113081; MFCD08435966; Atazanavir & alpha1-acid glycoprotein; AKOS025396423; Tox21_113081_1; CCG-270390; CS-0945; DB01072; NCGC00182552-02; NCGC00182552-03; NCGC00182552-14; (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide; 2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3S-(3R*,8R*,9R*,12R*))-; BS-16315; dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate; HY-17367; S4662; A25022; D07471; AB01274792-01; AB01274792-02; AB01274792-03; AB01274792_04; EN300-20600002; Q423467; SR-01000930924; J-519602; SR-01000930924-2; Z1258932192; 6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; 2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID, 3-12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-((-4-(2-PYRIDINYL)PHENYL)METHYL)-, DIMETHYL ESTER, (3S,8S,9S,12S)-; Atazanavir;(2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide; DIMETHYL (3S,8S,9S,12S)-9-BENZYL-3,12,DI-TERT-BUTYL-8-HYDROXY-4,11-DIOXO-6-(P-2-PYRIDYLBENZYL)-2,5,6,10,13-PENTAAZATETRADECANEDIOATE; methyl N-[(1S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethyl-butanoyl]amino]-[(4-pyridin-2-ylphenyl)methyl]amino]-1-phenyl-butan-2-yl]carbamoyl]-2,2-dimethyl-propyl]carbamate; methyl N-[(1S)-1-{[(2S,3S)-3-hydroxy-4-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethyl-N''-{[4-(pyridin-2-yl)phenyl]methyl}butanehydrazido]-1-phenylbutan-2-yl]carbamoyl}-2,2-dimethylpropyl]carbamate; Methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-[(4-pyridin-2-ylphenyl)methyl]amino]-1-phenylbutan-2-yl]ami	Approved	Approved Drug(s)	148192	DB01072	D07IQS	704.9	171	1110	5.6	51	5	9	18	C38H52N6O7	methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate	CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC	CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC	InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1	AXRYRYVKAWYZBR-GASGPIRDSA-N
DTWB48	Thalidomide	Small molecule	thalidomide; 50-35-1; Thalomid; 2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; (+/-)-THALIDOMIDE; Contergan; Distaval; Pantosediv; Softenon; Sedoval; Kevadon; Corronarobetin; Psycholiquid; Psychotablets; Theophilcholine; Algosediv; Asmadion; Bonbrain; Calmorex; Ectiluran; Enterosediv; Gastrinide; Glutanon; Hippuzon; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Nevrodyn; Noctosediv; Profarmil; Quetimid; Quietoplex; Sandormin; Sedimide; Sedisperil; Shinnibrol; Softenil; Talargan; Talismol; Telargean; Tensival; Thalinette; Valgraine; Asmaval; Calmore; Glupan; Grippex; Imidene; Isomin; Nibrol; Noxodyn; Pangul; Sleepan; Slipro; Talimol; Telagan; Thalin; Valgis; Yodomin; N-Phthaloylglutamimide; Sedin; Predni-Sediv; Imida-lab; N-Phthalylglutamic acid imide; Sedalis sedi-lab; Shin-naito S; Neaufatin; Asidon 3; Pro-ban M; 3-Phthalimidoglutarimide; Imidan (peyta); Neurosedyn; Ulcerfen; alpha-Phthalimidoglutarimide; K-17; Bonbrrin; Distaxal; Distoval; Talidomida; Kedavon; Thaled; (+-)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; NSC-66847; N-(2,6-Dioxo-3-piperidyl)phthalimide; Thalidomide Celgene; alpha-N-Phthalylglutaramide; Celgene; Pharmion; Glutarimide, 2-phthalimido-; N-Phthalyl-glutaminsaeure-imid; alpha-(N-Phthalimido)glutarimide; K 17; .alpha.-Phthalimidoglutarimide; E-217; Myrin; 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline; .alpha.-N-Phthalylglutaramide; 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-; Phthalimide, N-(2,6-dioxo-3-piperidyl)-; .alpha.-(N-Phthalimido)glutarimide; 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione; 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione; MFCD00153873; CHEMBL468; Thalidomide (soluble form); NSC-527179; 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; 4Z8R6ORS6L; ENMD 0995; DTXSID9022524; Thalomide; (+-)-N-(2,6-Dioxo-3-piperidyl)phthalimide; CHEBI:74947; 2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione; NSC66847; Pro-Bam M; N-(2,6-dioxo-3-piperidinyl)phthalimide; NCGC00015989-09; Talidomide [DCIT]; Thalidomidum; Sedalis; Talidomide; Telargan; (+/-)-N-(2,6-dioxo-3-piperidyl)phthalimide; 1012310-87-0; Talidomida [INN-Spanish]; Thalidomidum [INN-Latin]; Thalidomine USP26; 2-(2,6-Dioxo-piperidin-3-yl)-isoindole-1,3-dione; DTXCID402524; Synovir; Talizer; (?)-Thalidomide; Phthalimide,6-dioxo-3-piperidyl)-; WLN: T56 BVNVJ C- DT6VMVTJ; Thalomid (TM); Thalomid (TN); Thalidomide Pharmion; Thaled (TN); N-Phthalyl-glutaminsaeure-imid [German]; N-Phthalimidoglutamic acid imide; HSDB 3586; 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-; SR-01000076184; EINECS 200-031-1; UNII-4Z8R6ORS6L; NSC 527179; BRN 0030233; Talinol; Thalidomide (JAN/USP/INN); AI3-50606; CCRIS 8148; NSC-91729; NSC-91730; (y)-Thalidomide; Thalidomide,(S); CAS-50-35-1; Prestwick_463; Thalidomide [USAN:USP:INN:BAN:JAN]; (A+/-)-Thalidomide; THALIDOMIDE [MI]; (+/-)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione; Prestwick0_000192; Prestwick1_000192; Prestwick2_000192; Prestwick3_000192; Spectrum2_000707; Spectrum3_001715; Spectrum4_001087; Spectrum5_001791; THALIDOMIDE [INN]; THALIDOMIDE [JAN]; (.+/-.)-Thalidomide; THALIDOMIDE [HSDB]; THALIDOMIDE [USAN]; UPCMLD-DP139; THALIDOMIDE [VANDF]; Thalomid (TN) (Celgene); SCHEMBL7581; NCIOpen2_003188; THALIDOMIDE [MART.]; Lopac0_001224; BSPBio_000143; BSPBio_001156; BSPBio_003330; KBioGR_000496; KBioGR_001474; KBioGR_002322; KBioSS_000496; KBioSS_002324; THALIDOMIDE [USP-RS]; THALIDOMIDE [WHO-DD]; 2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione; MLS000069353; DivK1c_000051; SPECTRUM1503607; SPBio_000893; SPBio_002064; THALIDOMIDE [EMA EPAR]; BPBio1_000159; GTPL7327; SCHEMBL15197560; UPCMLD-DP139:001; HMS500C13; KBio1_000051; KBio2_000496; KBio2_002322; KBio2_003064; KBio2_004890; KBio2_005632; KBio2_007458; KBio3_000911; KBio3_000912; KBio3_002550; KBio3_002802; THALIDOMIDE [ORANGE BOOK]; cMAP_000022; NINDS_000051; Bio1_000387; Bio1_000876; Bio1_001365; Bio2_000418; Bio2_000898; HMS1362J17; HMS1568H05; HMS1792J17; HMS1922E12; HMS1990J17; HMS2090O05; HMS2093G15; HMS2095H05; HMS2234C07; HMS3259C22; HMS3263F10; HMS3266F13; HMS3373E06; HMS3373G15; HMS3403J17; HMS3414F19; HMS3654A20; HMS3678F19; HMS3712H05; HMS3884I05; Pharmakon1600-01503607; THALIDOMIDE [USP MONOGRAPH]; BCP19772; NSC91729; NSC91730; Tox21_110275; Tox21_300580; Tox21_501224; 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, (+-)-; AC-917; BBL023439; BDBM50070114; CCG-39878; NSC527179; NSC758479; STL356025; ( inverted question mark)-Thalidomide; AKOS009529198; Tox21_110275_1; CS-1084; DB01041; LP01224; NC00600; NSC-758479; SDCCGSBI-0051191.P004; (+/-)-Thalidomide, >=98%, powder; IDI1_000051; IDI1_002173; NCGC00015989-03; NCGC00015989-04; NCGC00015989-05; NCGC00015989-06; NCGC00015989-07; NCGC00015989-08; NCGC00015989-10; NCGC00015989-11; NCGC00015989-12; NCGC00015989-13; NCGC00015989-14; NCGC00015989-16; NCGC00015989-17; NCGC00015989-29; NCGC00024708-02; NCGC00024708-03; NCGC00024708-04; NCGC00024708-05; NCGC00024708-06; NCGC00024708-07; NCGC00024708-08; NCGC00024708-09; NCGC00024708-10; NCGC00024708-11; NCGC00254343-01; NCGC00261909-01; AS-12367; BP-30256; BT164465; HY-14658; NCI60_023904; SMR000058524; SY052614; WLN: T56 BVNVJ C- DT6VMVTJ -D; WLN: T56 BVNVJ C- DT6VMVTJ -L; SBI-0051191.P003; DB-051759; Phthalimide,6-dioxo-3-piperidyl)-, (+)-; Phthalimide,6-dioxo-3-piperidyl)-, (-)-; AB00052362; EU-0101224; FT-0600001; FT-0602275; FT-0631211; FT-0675130; S1193; SW196678-4; T2524; EN300-60005; isopropyl (3,4-dichlorophenyl)carbamodithioate; Phthalimide,6-dioxo-3-piperidyl)-, D-(+)-; Phthalimide,6-dioxo-3-piperidyl)-, L-(-)-; C07910; D00754; AB00052362-11; AB00052362-12; AB00052362-13; AB00052362_14; AB00052362_15; Q203174; SR-01000076184-1; SR-01000076184-3; SR-01000076184-5; SR-01000076184-8; Thalidomide N-(2,6-Dioxopiperidin-3-yl)phthalimide; W-105969; BRD-A93255169-001-04-4; BRD-A93255169-001-06-9; BRD-A93255169-001-24-2; Z905162656; 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-, (R)-; 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-, (S)-; 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione #; [(R,S)-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione; Thalidomide, United States Pharmacopeia (USP) Reference Standard; ( inverted question mark)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione; 1H-ISOINDOLE-1,3(2H)-DIONE, 2-(2,6-DIOXO-3-PIPERIDINYL)-, (+/-)-; 2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione	Approved	Approved Drug(s)	5426	DB01041	D07ISX	258.23	83.6	449	0.3	19	1	4	1	C13H10N2O4	2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione	C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O	C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O	InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)	UEJJHQNACJXSKW-UHFFFAOYSA-N
DNC1D3	Nalidixic acid	Small molecule	nalidixic acid; 389-08-2; Nalidixate; Nalidixin; Nevigramon; Uronidix; NegGram; Innoxalon; Nalidixan; Nalitucsan; Sicmylon; Unaserus; Nalidic acid; Nalidixinic acid; Wintomylon; Dixiben; Dixinal; Jicsron; Nalurin; Naxuril; Nogram; Urisal; Cybis; Nalix; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; Uroman; Nalidicron; Betaxina; Kusnarin; Narigix; Nicelate; Specifen; Specifin; Uralgin; Uriclar; Urodixin; Negram; Poleon; Uriben; Uroneg; Uropan; Acide nalidixique; Eucistin; Acide nalidixico; Acido nalidixico; NSC-82174; Acidum nalidixicum; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; WIN 18,320; Nalidixane; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one; NCI-C56199; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; MFCD00006884; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; Nalidixic acid (NegGram); WIN-18320; MLS000028504; 3B91HWA56M; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Win 18320; DTXSID3020912; CHEBI:100147; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; NSC82174; NCGC00018181-08; SMR000058264; Wintron; Acido nalidissico; Nalidixic acid 100 microg/mL in Acetonitrile; Acido nalidissico [DCIT]; Acide nalidixico [Italian]; Acide nalidixique [French]; DTXCID70912; Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; CAS-389-08-2; NegGram (TN); CCRIS 2365; HSDB 3241; EINECS 206-864-7; BRN 0750515; UNII-3B91HWA56M; Innoxalomn; Eucisten; nalidixic-acid; SR-01000003086; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; NALIDIXICACID; WIN 183203; CHEMBL5; Spectrum_000918; Nalidixic acid [USAN:USP:INN:BAN:JAN]; Maybridge1_007101; Opera_ID_1064; Prestwick0_000187; Prestwick1_000187; Prestwick2_000187; Prestwick3_000187; Spectrum2_001360; Spectrum3_000075; Spectrum4_000817; Spectrum5_001540; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; Nalidixic acid, >=98%; UPCMLD-DP129; N-1200; NALIDIXIC ACID [MI]; NCIOpen2_004342; Lopac0_000837; Oprea1_010545; SCHEMBL21736; BSPBio_000113; BSPBio_001889; KBioGR_001333; KBioSS_001398; NALIDIXIC ACID [INN]; NALIDIXIC ACID [JAN]; 5-25-07-00384 (Beilstein Handbook Reference); MLS001148578; MLS002303041; MLS004820190; MLS006011875; 1-ethyl-7-methyl-4-oxo-1; BIDD:GT0529; DivK1c_000058; NALIDIXIC ACID [HSDB]; NALIDIXIC ACID [USAN]; SPECTRUM1500756; SPBio_001579; SPBio_002034; NALIDIXIC ACID [VANDF]; BPBio1_000125; NALIDIXIC ACID [MART.]; NALIDIXIC ACID [WHO-DD]; UPCMLD-DP129:001; BDBM21691; HMS500C20; HMS561K17; KBio1_000058; KBio2_001398; KBio2_003966; KBio2_006534; KBio3_001109; NINDS_000058; HMS1921G10; HMS2092K04; HMS2232H24; HMS3259O13; HMS3374G11; HMS3656K05; Pharmakon1600-01500756; Nalidixic acid (JP17/USP/INN); Nalidixic acid, analytical standard; ALBB-021275; HY-B0398; Tox21_110835; Tox21_201477; Tox21_302754; BBL012279; CCG-39298; NALIDIXIC ACID [EP IMPURITY]; NALIDIXIC ACID [ORANGE BOOK]; NSC757432; STK735579; NALIDIXIC ACID [USP IMPURITY]; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; AKOS000120074; Tox21_110835_1; DB00779; NC00494; NSC-757432; SDCCGSBI-0050814.P004; IDI1_000058; NCGC00018181-01; NCGC00018181-02; NCGC00018181-03; NCGC00018181-04; NCGC00018181-05; NCGC00018181-06; NCGC00018181-07; NCGC00018181-09; NCGC00018181-10; NCGC00018181-12; NCGC00018181-13; NCGC00021730-03; NCGC00021730-04; NCGC00021730-05; NCGC00021730-06; NCGC00021730-07; NCGC00256581-01; NCGC00259028-01; AS-13289; NCI60_041807; SMR004703506; WLN: T66 BN EV JNJ B2 DVQ I1; SBI-0050814.P003; DB-049349; Nalidixic acid 1000 microg/mL in Methanol; 1, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; BB 0242389; FT-0603390; N0490; S2328; SW219624-1; 1-Ethyl-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,8-naphthyridine-3-carboxylic acid; EN300-20573; VU0239598-6; C05079; D00183; D91720; Nalidixic acid, meets USP testing specifications; Q281082; SR-01000003086-4; SR-01000003086-6; BRD-K47886988-323-03-0; Nalidixic acid, Antibiotic for Culture Media Use Only; SR-01000003086-10; F0850-6751; Z104478940; 1-Ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1-ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid; Nalidixic acid, European Pharmacopoeia (EP) Reference Standard; Nalidixic acid, United States Pharmacopeia (USP) Reference Standard; 1,8-Naphthyridine-3-carboxylic acid,1-ethyl-1,4-dihydro-7-methyl-4-oxo-; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naph thyridine-3-carboxylic acid; N-benzyl-4-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methyl]-N-ethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonamide	Approved	Approved Drug(s)	4421	DB00779	D07JGT	232.23	70.5	378	1.4	17	1	5	2	C12H12N2O3	1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid	CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O	CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O	InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)	MHWLWQUZZRMNGJ-UHFFFAOYSA-N
DM53VH	Diazepam	Small molecule	diazepam; Valium; 439-14-5; Ansiolisina; Diazemuls; Apaurin; Faustan; Relanium; Seduxen; Sibazon; Stesolid; Alboral; Methyldiazepinone; Ansiolin; Apozepam; Atensine; Bensedin; Bialzepam; Calmocitene; Calmpose; Ceregulart; Condition; Diacepan; Diazepan; Diazetard; Dipezona; Domalium; Kiatrium; Liberetas; Neurolytril; Paranten; Quetinil; Quiatril; Quievita; Relaminal; Renborin; Ruhsitus; Seduksen; Serenack; Serenamin; Serenzin; Stesolin; Tensopam; Tranimul; Tranqdyn; Tranquirit; Unisedil; Valitran; Valrelease; Aliseum; Amiprol; Armonil; Assival; Atilen; Cercine; Dialag; Diapam; Diastat; Dienpax; Duksen; Eridan; Eurosan; Freudal; Frustan; Gihitan; Lembrol; Levium; Morosan; Paxate; Plidan; Saromet; Sedipam; Setonil; Sonacon; Umbrium; Vatran; Velium; Duxen; Lamra; Paxel; Solis; Valeo; Vival; Vivol; Zipan; Noan; Usempax ap; Methyl diazepinone; Q-pam; Centrazepam; Kabivitrum; La-Iii; Evacalm; Gewacalm; Horizon; Novazam; Tranquase; Valaxona; Valiquid; Dialar; Dizac; Paceum; LA III; An-Ding; e-Pam; Jinpanfan; Servizepam; Simasedan; Antenex; Arzepam; Diapax; Drenian; Ducene; Kratium; Nellium; Nerozen; Zepaxid; Doval; Paxum; Sipam; Vazen; Placidox 5; Ro 5-2807; WY-3467; 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; D-Pam; NSC-77518; 7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Diacepin; Diazepam civ; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-; Faustan,; 7-Chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one; 7-Chloro-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepine; 7-Chloro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; CHEMBL12; Q3JTX2Q7TU; NSC-169897; 1-Methyl-5-phenyl-7-chloro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; NRL-1; RO-5-2807; DZP; DTXSID4020406; Methyldiazepinone, pharmaceutical; CHEBI:49575; Apo-diazepam; Wy 3467; Diazepam Intensol; Diazepam-d8; LA 111; Ro-52807; 7-Chloro-1-methyl-5-3H-1,4-benzodiazepin-2(1H)-one; NCGC00178168-02; Calmociteno; Alupram; Ansilive; Anxicalm; Anxionil; Benzopin; Betapam; Britazepam; Calmaven; Chuansuan; Desconet; Desloneg; Diaceplex; Diapine; Diaquel; Diatran; Diazepin; Disopam; Faustal; Gradual; Iazepam; Medipam; Mentalium; Metamidol; Nervium; Nivalen; Nixtensyn; Notense; Novodipam; Ortopsique; Paralium; Prozepam; Psychopax; Radizepam; Reliver; Sedapam; Trankinon; Trazepam; Valuzepam; Vanconin; Baogin; Calmod; Caudel; Diazem; Lovium; Mandro; Parzam; Dipaz; Dupin; Gubex; Lizan; Pomin; Winii; Diazepam Nordic; Diazepam-Lipuro; Diazepan leo; Diazepam Elmu; Diazepam Fabra; Diazepam Stada; Metil Gobanal; Diazepam Dak; Tranquo-tablinen; Diazepam Desitin; Euphorin P; Mandro-Zep; Sico Relax; Diazepam Rectubes; S.a. r.l.; Elcion CR; Placidox 2; Kratium 2; Diazepam-ratiopharm; Placidox 10; Diazepamu [Polish]; DTXCID20406; Diazepam-Eurogenerics; Diazepamum; Diazepamu; Mandrozep; Plumiaz; Tensium; Tranquo-puren; Diastat Acudial; Diazepamum [INN-Latin]; 7-chloro-1-methyl-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one; 7-chloro-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one; WLN: T67 GNV JN IHJ CG G1 KR; CAS-439-14-5; SMR000058398; CCRIS 6009; Best [Pharaceutical]; HSDB 3057; Methyldiazepinone (pharmaceutical); 2H-1, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-; EINECS 207-122-5; UNII-Q3JTX2Q7TU; LA-111; 1-Methyl-5-phenyl-7-chloro-1,4-benzodiazepin-2-one; 7-Chloro-1-methyl-5-phenyl-1,4-benzodiazepin-2-one; NSC 169897; BRN 0754371; Anlin; DEA No. 2765; Pro pam; Diastat (TN); Valium (TN); VALTOCO; Diazepam [USAN:USP:INN:BAN:JAN]; 83056-50-2; DIAZEPAM [HSDB]; DIAZEPAM [IARC]; DIAZEPAM [USAN]; DIAZEPAM [INN]; DIAZEPAM [JAN]; DIAZEPAM [MI]; DIAZEPAM [VANDF]; Spectrum3_001780; Spectrum4_000576; Spectrum5_001890; DIAZEPAM [MART.]; DIAZEPAM [WHO-DD]; BIDD:PXR0158; Oprea1_126223; SCHEMBL21442; BSPBio_003279; KBioGR_001012; 5-24-04-00300 (Beilstein Handbook Reference); MLS000759402; MLS001424086; BIDD:GT0105; DIAZEPAM [GREEN BOOK]; DivK1c_000967; Diazepam (JP17/USP/INN); DIAZEPAM [ORANGE BOOK]; DIAZEPAM CIV [USP-RS]; Mono (2-ethylhexyl) phthalate; GTPL3364; S.A.R.L.; DIAZEPAM [EP MONOGRAPH]; DIAZEPAM [USP MONOGRAPH]; HMS503A15; KBio1_000967; KBio3_002780; Diazepam 0.1 mg/ml in Methanol; Diazepam 1.0 mg/ml in Methanol; CHEBI:194180; NINDS_000967; HMS2051N04; HMS3393N04; BCP23002; NSC77518; Tox21_113071; Tox21_202458; 7-Chloro-1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one; BDBM50000766; NSC169897; STK735517; AKOS003367969; Diazepam 1000 microg/mL in Methanol; Tox21_113071_1; AB02310; BCP9000199; CCG-100997; CS-0653; DB00829; NC00247; Ro 5-2805; IDI1_000967; NCGC00178168-01; NCGC00178168-03; NCGC00178168-04; NCGC00260007-01; AC-10561; HY-17027; BCP0726000176; DB-051179; C06948; D00293; A826456; Q210402; Valium; Ansiolisina; Diazemuls; Apaurin; Faustan; BRD-K16508793-001-01-8; Diazepam, European Pharmacopoeia (EP) Reference Standard; 7-chloranyl-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one; 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one.; 7-chloro-1-methyl-5-phenyl-1H-1,4-benzodiazepine-2(3H)on; Diazepam, United States Pharmacopeia (USP) Reference Standard; 7-chloro-1-methyl-5-phenyl-1,3-dihydro-[1,4]benzodiazepin-2-one; 7 -chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H -1,4-benzodiazepin-2-one; 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2h-1,4-benzodiazepine-2-one; 7-chloro-1-methyl-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-methyl-5-phenyl-2-oxo-2,3-dihydro-1H-benzo[f]-1,4-diazepine; 7-chloro-1,3-dihydro-1-(methyl-d3)-5-(phenyl-d5)-2H-1,4-benzodiazepin-2-one; 7-chloro-1-((2)H3)methyl-5-((2)H5)phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Diazepam for system suitability, European Pharmacopoeia (EP) Reference Standard; 11100-37-1; 7-chloro-5-(2,3,4,5,6-pentadeuteriophenyl)-1-(trideuteriomethyl)-3H-1,4-benzodiazepin-2-one	Approved	Approved Drug(s)	3016	DB00829	D07JVL	284.74	32.7	403	3	20	0	2	1	C16H13ClN2O	7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one	CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3	CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3	InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3	AAOVKJBEBIDNHE-UHFFFAOYSA-N
DA0V5X	Tamoxifen	Small molecule	tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Diemon; Tamoxifene; Novaldex; Tamoxifeno; Tamoxifenum; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Mammaton; Tamoplex; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; Tamoxifen (INN); 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; CHEMBL83; Citofen; ICI-47699; Istubol; Oncomox; Retaxim; Tamizam; Tamoxen; NSC-727681; (2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine; C26H29NO; cis-Tamoxifen; DTXSID1034187; CHEBI:41774; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl-; (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; Tamoxifen (Z); 094ZI81Y45; TAMOXIFEN [INN]; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-n,n-dimethylethanamine; Tamoxifen [INN:BAN]; DTXCID9014187; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine; (E/Z)-Tamoxifen; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethyl-ethanamine; [3H]tamoxifen; Tamoxifen (TN); [3H]-tamoxifen; Tamoplex (TN); SMR000059172; CAS-10540-29-1; TRANS FORM OF TAMOXIFEN; CCRIS 3275; Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-; HSDB 6782; EINECS 234-118-0; ICI 47699; trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; Z-Tamoxifen; Ethanamine, 2-(4-((1Z)-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-; Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl-; UNII-094ZI81Y45; Ethylamine, N,N-dimethyl-2-(p-(1,2-diphenyl-1-butenyl)phenoxy)-, (Z)-; ETHANAMINE, 2-(4-((1Z)-1,2-DIPHENYL-1-BUTEN-1-YL)PHENOXY)-N,N-DIMETHYL-; Tamoxifen, 7; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); MFCD00010454; Tocris-0999; 1ya4; Tamoxifen, >=99%; TAMOXIFEN [MI]; TAMOXIFEN [HSDB]; TAMOXIFEN [IARC]; Prestwick2_000146; Prestwick3_000146; Spectrum5_001417; Spectrum5_002043; TAMOXIFEN [VANDF]; UPCMLD-DP027; EC 234-118-0; SCHEMBL4084; TAMOXIFEN [WHO-DD]; BIDD:PXR0003; Lopac0_001203; BSPBio_000252; BSPBio_001150; BSPBio_001982; MLS001332535; MLS001332536; BIDD:ER0008; BIDD:GT0009; Tamoxifen, analytical standard; BPBio1_000278; GTPL1016; GTPL5384; BDBM20607; cid_2733526; cMAP_000044; HMS1362J11; HMS1792J11; HMS1990J11; HMS2090N08; HMS2232C12; HMS3261D09; HMS3403J11; HMS3411P04; 7728-73-6; ICI47699; Tox21_201243; Tox21_300539; Tox21_500494; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; HB0601; HY-13757A; NSC727681; AKOS022143035; AM84324; CCG-205277; DB00675; FD12063; KS-1472; LP00494; SDCCGSBI-0051170.P007; ICI47699;Z-Tamoxifen;trans-Tamoxifen; IDI1_000258; IDI1_002170; QTL1_000079; NCGC00024928-01; NCGC00024928-03; NCGC00024928-04; NCGC00024928-05; NCGC00024928-07; NCGC00024928-08; NCGC00024928-09; NCGC00024928-10; NCGC00024928-11; NCGC00024928-12; NCGC00024928-13; NCGC00024928-14; NCGC00024928-15; NCGC00024928-16; NCGC00024928-17; NCGC00024928-18; NCGC00024928-19; NCGC00024928-39; NCGC00024928-40; NCGC00254455-01; NCGC00258795-01; NCGC00261179-01; AC-35768; BT164438; SBI-0051170.P004; C07108; D08559; AB00053547-16; AB00053547-17; AB00053547-18; AB00053547_19; AB00053547_20; EN300-1273241; A801229; L024126; Q412178; W-108788; BRD-K93754473-001-02-9; BRD-K93754473-048-04-6; BRD-K93754473-048-05-3; BRD-K93754473-048-10-3; ETHYL3-(4-HYDROXY-3-METHOXYPHENYL)PROPIONATE; Tamoxifen, certified reference material, TraceCERT(R); Z2527624834; 1-[4-(2-Dimethylaminoethoxy)phenyl]-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-amine; (Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine; 2-[4-[(1Z)-1,2-Diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethylethanamine; 2-[4-[(Z)-1,2-di(phenyl)but-1-enyl]phenoxy]-N,N-dimethylethanamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene, trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine	Approved	Approved Drug(s)	2733526	DB00675	D07KSG	371.5	12.5	463	7.1	28	0	2	8	C26H29NO	2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine	CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3	CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3	InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-	NKANXQFJJICGDU-QPLCGJKRSA-N
D3VG9X	Elacestrant	Small molecule	Elacestrant; 722533-56-4; RAD1901; RAD-1901; Elacestrant [INN]; Elacestrant [USAN]; ER-306323; FM6A2627A8; (6R)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; ORSERDU; (6R)-6-{2-[ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol; (2R)-2-(2-(Ethyl-((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxy-phenyl)tetralin-6-ol; (6R)-6-(2-(Ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-ol; 2-Naphthalenol, 6-(2-(ethyl((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydro-, (6R)-; Elacestrant (USAN/INN); Elacestrant [USAN:INN]; ELACESTRANT [WHO-DD]; SCHEMBL229431; UNII-FM6A2627A8; CHEMBL4297509; GTPL12339; BDBM349630; DTXSID901045846; GLXC-26208; EX-A5070; US10208011, Compound RAD-; MFCD30532693; WHO 10247; CS-6306; DB06374; AC-37208; ER306323; HY-19822; MS-28398; D11671; Q27278069; (R)-6-(2-(Ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol; I0V	Approved	Approved Drug(s)	23642301	DB06374	D07KUN	458.6	44.7	578	6.3	34	2	4	10	C30H38N2O2	(6R)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol	CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)C3CCC4=C(C3)C=CC(=C4)O	CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)[C@@H]3CCC4=C(C3)C=CC(=C4)O	InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1	SIFNOOUKXBRGGB-AREMUKBSSA-N
D62GDK	Selinexor	Small molecule	Selinexor; KPT-330; 1393477-72-9; Xpovio; Selinexor (KPT-330); Selinexor free base; (Z)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide; KPT 330; 31TZ62FO8F; 2-Propenoic acid, 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-, 2-(2-pyrazinyl)hydrazide, (2Z)-; (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide; 1621865-82-4; 2-Propenoic acid, 3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]-, 2-(2-pyrazinyl)hydrazide, (2Z)-; Selinexor [USAN:INN]; KPT330; UNII-31TZ62FO8F; Nexpovio; Selinexor [INN]; KPT330;Selinexor; Xpovio (TN); KPT-330(Selinexor); SELINEXOR [MI]; Selinexor (USAN/INN); SELINEXOR [USAN]; SELINEXOR [WHO-DD]; SELINEXOR [ORANGE BOOK]; CHEMBL3545185; SCHEMBL14678327; GTPL10036; EX-A870; DTXSID801026013; BDBM50527778; MFCD27987944; NSC780203; NSC781780; CCG-269161; DB11942; NSC-780203; NSC-781780; NCGC00386310-01; NCGC00386310-03; AC-33645; BS-15022; compound 70 [WO2013019561A1]; N-Hydroxy-N'-(2-phenylethyl)isophthalamide; S7252; SW219336-1; D11222; EN300-7360494; A857179; J-690156; Q27256082; (2Z)-2-(2-Pyrazinyl)hydrazide-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]-2-propenoic acid; (2Z)-3-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}-N'-(pyrazin-2-yl)prop-2-enehydrazide; Selinexor;(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide	Approved	Approved Drug(s)	71481097	DB11942	D07KVV	443.3	97.6	621	3	31	2	12	5	C17H11F6N7O	(Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide	C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F	C1=CN=C(C=N1)NNC(=O)/C=C\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F	InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-	DEVSOMFAQLZNKR-RJRFIUFISA-N
DS7NF1	Chloroprocaine	Small molecule	CHLOROPROCAINE; Chloroprocain; 2-Chloroprocaine; 133-16-4; Chlorprocaine; Halestyn; 2-(Diethylamino)ethyl 4-amino-2-chlorobenzoate; Piocaine; Chloroprocainum; Cloroprocaina; Chloroprocaine [INN]; Nesacaine; 2-Diethylaminoethyl 4-amino-2-chloro-benzoate; Benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester; Chloroprocaine (INN); 5YVB0POT2H; Chlor-procaine; 4-amino-2-chlorobenzoic acid 2-(diethylamino)ethyl ester; CHEBI:3636; Chlorprocainum; Chloroprocainum [INN-Latin]; Cloroprocaina [INN-Spanish]; HSDB 3301; UNII-5YVB0POT2H; 2-(Diethylaminoethyl)-4-amino-2-chlorobenzoate; BRN 2808071; CHLOROPROCAINE [MI]; SCHEMBL6676; CHLOROPROCAINE [HSDB]; 4-14-00-01273 (Beilstein Handbook Reference); CHLOROPROCAINE [VANDF]; GTPL7145; CHLOROPROCAINE [WHO-DD]; CHEMBL1179047; DTXSID8022799; HY-B1604A; AKOS010575135; DB01161; NCGC00183273-04; CS-0013537; FT-0713386; C07877; D07678; EN300-1590375; SR-01000944416; Q2964133; SR-01000944416-1; Z802864938	Approved	Approved Drug(s)	8612	DB01161	D07NAJ	270.75	55.6	259	2.9	18	1	4	7	C13H19ClN2O2	2-(diethylamino)ethyl 4-amino-2-chlorobenzoate	CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl	CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl	InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3	VDANGULDQQJODZ-UHFFFAOYSA-N
DV0A5Y	Insulin glargine	Small molecule	Insulin glargine; 160337-95-1; Basaglar; Glargine; Lantus Solostar; Optisulin; Toujeo; SoloStar; Toujeo Solostar; Lantus R; HOE 901; A21-Gly-B31-Arg-B32-Arg-insulin; UNII-2ZM8CX04RZ; Lusduna Nexvue; Insulin, glycyl(A21)-arginyl(B31,B32)-; SoloStar [Insulin delivery pen]; Insulin glargine [USAN:INN:BAN]; LY 2963016; HOE 71GT; 2ZM8CX04RZ; MK-1293; 21(sup A)-Glycine-30(sup B)a-L-arginine-30(sup B)b-L-arginine insulin (human); 21(sup A)-glycine-30(supp B)a-L-arginine-30(supp B)b-L-arginineinsulin (human); Insulin (human), 21(sup A)-glycine-30(sup B)a-L-arginine-30(sup B)b-L-arginine-	Approved	Approved Drug(s)	118984454	DB00047	D07NGZ	6063	2590	15300	-14.1	423	85	92	191	C267H404N72O78S6	(4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-47-(carboxymethylcarbamoyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid	CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NCC(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN	CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NCC(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN	InChI=1S/C267H404N72O78S6/c1-29-137(23)212(330-199(355)109-269)260(412)334-211(136(21)22)256(408)305-166(79-86-206(365)366)226(378)298-163(75-82-196(273)352)230(382)326-190-122-421-422-123-191-251(403)322-185(117-341)249(401)312-170(94-129(7)8)234(386)313-176(101-146-57-65-152(346)66-58-146)237(389)299-161(73-80-194(271)350)227(379)308-169(93-128(5)6)232(384)301-165(78-85-205(363)364)229(381)320-182(107-197(274)353)244(396)316-178(103-148-61-69-154(348)70-62-148)240(392)325-188(222(374)290-115-207(367)368)120-418-420-121-189(221(373)288-112-200(356)294-160(76-83-203(359)360)225(377)297-157(53-42-88-284-265(276)277)219(371)287-113-201(357)295-174(99-144-48-36-32-37-49-144)236(388)315-175(100-145-50-38-33-39-51-145)239(391)317-179(104-149-63-71-155(349)72-64-149)247(399)338-216(142(28)345)263(415)339-91-45-56-193(339)254(406)302-158(52-40-41-87-268)231(383)336-214(140(26)343)261(413)303-159(54-43-89-285-266(278)279)224(376)306-167(264(416)417)55-44-90-286-267(280)281)328-258(410)210(135(19)20)333-245(397)172(96-131(11)12)310-238(390)177(102-147-59-67-153(347)68-60-147)314-233(385)168(92-127(3)4)307-217(369)139(25)293-223(375)164(77-84-204(361)362)304-255(407)209(134(17)18)332-246(398)173(97-132(13)14)311-242(394)181(106-151-111-283-126-292-151)319-248(400)184(116-340)296-202(358)114-289-220(372)187(119-419-423-124-192(327-252(190)404)253(405)337-215(141(27)344)262(414)323-186(118-342)250(402)335-213(138(24)30-2)259(411)329-191)324-235(387)171(95-130(9)10)309-241(393)180(105-150-110-282-125-291-150)318-228(380)162(74-81-195(272)351)300-243(395)183(108-198(275)354)321-257(409)208(133(15)16)331-218(370)156(270)98-143-46-34-31-35-47-143/h31-39,46-51,57-72,110-111,125-142,156-193,208-216,340-349H,29-30,40-45,52-56,73-109,112-124,268-270H2,1-28H3,(H2,271,350)(H2,272,351)(H2,273,352)(H2,274,353)(H2,275,354)(H,282,291)(H,283,292)(H,287,371)(H,288,373)(H,289,372)(H,290,374)(H,293,375)(H,294,356)(H,295,357)(H,296,358)(H,297,377)(H,298,378)(H,299,389)(H,300,395)(H,301,384)(H,302,406)(H,303,413)(H,304,407)(H,305,408)(H,306,376)(H,307,369)(H,308,379)(H,309,393)(H,310,390)(H,311,394)(H,312,401)(H,313,386)(H,314,385)(H,315,388)(H,316,396)(H,317,391)(H,318,380)(H,319,400)(H,320,381)(H,321,409)(H,322,403)(H,323,414)(H,324,387)(H,325,392)(H,326,382)(H,327,404)(H,328,410)(H,329,411)(H,330,355)(H,331,370)(H,332,398)(H,333,397)(H,334,412)(H,335,402)(H,336,383)(H,337,405)(H,338,399)(H,359,360)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,416,417)(H4,276,277,284)(H4,278,279,285)(H4,280,281,286)/t137-,138-,139-,140+,141+,142+,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,208-,209-,210-,211-,212-,213-,214-,215-,216-/m0/s1	COCFEDIXXNGUNL-RFKWWTKHSA-N
D62YQW	Midostaurin	Small molecule	Midostaurin; 120685-11-2; PKC412; Cgp 41251; PKC-412; 4'-N-Benzoylstaurosporine; PKC 412; RYDAPT; CGP-41251; Benzoylstaurosporine; N-Benzoylstaurosporine; ID912S5VON; NVP-PKC412; CHEMBL608533; CHEBI:63452; NSC-656576; N-((9S,10R,11R,13R)-10-methoxy-9-methyl-1-oxo-2,3,10,11,12,13-hexahydro-9,13-epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-N-methylbenzamide; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; Midostaurin [INN]; Cgp 41 251; Midostaurin [USAN:INN]; UNII-ID912S5VON; PKC412;CGP 41251; CGP 41231; Rydapt (TN); Midostaurin(PKC412); 4-N-benzoylstaurosporine; MIDOSTAURIN [MI]; Staurosporine, N-Benzoyl; MIDOSTAURIN [JAN]; MIDOSTAURIN [USAN]; MIDOSTAURIN [MART.]; MIDOSTAURIN [WHO-DD]; Midostaurin (JAN/USAN/INN); GTPL5702; SCHEMBL8295379; MIDOSTAURIN [ORANGE BOOK]; HMS3229K17; EX-A1741; BDBM50326053; CGP-41521; MFCD00871372; NSC800791; s8064; AKOS024457372; CCG-101288; CS-3331; DB06595; NSC 656576; NSC-800791; NCGC00241102-01; NCGC00241102-02; NCGC00241102-05; NCGC00484987-03; AC-31929; Benzamide, N-(2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-1-oxo-8,12-epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-10-yl)-N-methyl-, (8alpha,9beta,10beta,12alpha)-; HY-10230; C71714; D05029; J-004379; Q6842945; BRD-K13646352-001-01-2; [9S-(9?,10?,11?,13?)]-N-(2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methylbenzamide; Benzamide, N-((9S,10R,11R,13R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-N-methyl-; N-((5S,6R,7R,9R)-6-Methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide; N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-4-yl]-N-methylbenzamide; N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl]-N-methyl-benzamide; N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide	Approved	Approved Drug(s)	9829523	DB06595	D07NVU	570.6	77.7	1140	4.8	43	1	4	3	C35H30N4O4	N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide	CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC	C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC	InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1	BMGQWWVMWDBQGC-IIFHNQTCSA-N
DU82AQ	Capmatinib	Small molecule	capmatinib; 1029712-80-8; INCB28060; INC280; INC-280; NVP-INC280-NX; INCB-28060; NVP-INC280; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; Tabrecta; Capmatinib (INCB28060); Capmatinib [USAN]; INCB-28060 FREE BASE; 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; Capmatinib(INCB28060); TY34L4F9OZ; INCB 28060; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide; 2-fluoro-N-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide; Benzamide, 2-fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-;Benzamide, 2-fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-; Capmatinib [INN]; INC28060; UNII-TY34L4F9OZ; benzamide hcl; BENZAMIDE, 2-FLUORO-N-METHYL-4-(7-(6-QUINOLINYLMETHYL)IMIDAZO(1,2-B)(1,2,4)TRIAZIN-2-YL)-; CAPMATINIB [MI]; Capmatinib (USAN/INN); Capmatinib [USAN:INN]; INCB28060(Capmatinib); NYP-INC280-NX; CAPMATINIB [WHO-DD]; MLS006010965; GTPL7904; SCHEMBL1426819; CHEMBL3188267; DTXSID90145595; EX-A446; AMY18553; BCP23444; BDBM50146167; MFCD18633285; NSC777878; NSC800067; s2788; AKOS025396439; BCP9000785; CCG-268791; CS-1541; DB11791; NSC-777878; NSC-800067; SB16608; NCGC00346702-01; NCGC00346702-02; NCGC00346702-05; AC-25890; AS-74142; DA-33530; HY-13404; SMR004702769; FT-0746310; D10696; EN300-18166640; J-509516; Q27075685; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2- yl)benzamide; 2-Fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazolo[1,2-b][1,2,4]triazin-2-yl]benzamide	Approved	Approved Drug(s)	25145656	DB11791	D07OJZ	412.4	85.1	637	2.9	31	1	6	4	C23H17FN6O	2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide	CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F	CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F	InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)	LIOLIMKSCNQPLV-UHFFFAOYSA-N
DXY71I	Erlotinib	Small molecule	Erlotinib; 183321-74-6; Tarceva; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; Erlotinib free base; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; OSI-774; 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-; Erlotinib, Free Base; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; 183321-74-6 (free base); NSC 718781; CHEMBL553; J4T82NDH7E; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; CP358774; CP-358,774; DTXSID8046454; CHEBI:114785; MFCD02089651; RG-1415; NCGC00164574-01; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; CP-35877401; R-1415; DTXCID6026454; Erlotinib(Tarceva); OSI-744; CAS-183321-74-6; NSC718781; Erlotinib [INN:BAN]; SR-05000001460; UNII-J4T82NDH7E; erlotinibum; Erotinib; HSDB 8082; OSI 744; nchembio866-comp3; Kinome_3317; n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine monohydrochloride; ERLOTINIB [MI]; ERLOTINIB [VANDF]; R 1415; ERLOTINIB [WHO-DD]; SCHEMBL8413; ERLOTINIB [EMA EPAR]; BDBM5446; cid_176870; GTPL4920; HMS2089F05; HMS3244M19; HMS3244M20; HMS3244N19; HMS3295A19; HMS3713C22; HMS3745M05; Tox21_112202; AC-399; NSC800097; s7786; STK623143; AKOS000282911; Tox21_112202_1; CCG-220420; CS-0620; DB00530; NSC-800097; Ro-508231; SB16916; NCGC00164574-03; NCGC00164574-05; NCGC00164574-06; NCGC00164574-14; NCGC00164574-25; AS-35132; BCB03_000783; BE164419; HY-50896; SY028059; AM20090621; FT-0651539; R1415; EN300-708808; K00241; AB01273955-01; AB01273955-02; AB01273955-03; Q418369; SR-05000001460-1; SR-05000001460-2; SR-05000001460-3; SR-05000001460-6; BRD-K70401845-003-04-7; Z2588038919; 1429636-49-6	Approved	Approved Drug(s)	176870	DB00530	D07POC	393.4	74.7	525	3.3	29	1	7	11	C22H23N3O4	N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine	COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC	COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC	InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)	AAKJLRGGTJKAMG-UHFFFAOYSA-N
DFX24Q	Azathioprine	Small molecule	azathioprine; 446-86-6; Imuran; Azothioprine; Azathioprin; Azamun; Azanin; Azatioprin; Azasan; Imurel; Azathiopurine; Ccucol; Imurek; Muran; Rorasul; BW 57-322; Azathioprinum; NSC-39084; BW-57-322; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; NCI-C03474; Imuran (TN); 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; NSC 39084; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-9H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; Azathioprine (Azasan, Imuran); 1H-Purine, 6-((1-methyl-4-nitro-1H-imidazol-5-yl)thio)-; Purine, 6-(1-methyl-4-nitro-5-imidazolylthio)-; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; 1H-Purine, 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-; MRK240IY2L; BW 57322; Azamun [Czech]; 6-((1-methyl-4-nitro-1H-imidazol-5-yl)thio)-7H-purine; CHEBI:2948; DTXSID4020119; B. W. 57-322; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; NSC39084; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; Purine, 6-((1-methyl-4-nitroimidazol-5-yl)thio)-; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine; NCGC00015060-06; NCGC00015060-14; Azatioprina; CAS-446-86-6; Azathioprinum [INN-Latin]; Azatioprina [INN-Spanish]; DTXCID00119; Azamune; Methylnitroimidazolylmercaptopurine; CCRIS 62; Azasan (TN); HSDB 7084; SR-01000075537; Purine, 6-[(1-methyl-4-nitroimidazol-5-yl)thio]-; EINECS 207-175-4; MFCD00069203; UNII-MRK240IY2L; 6-(1-methyl-4-nitro-1H-imidazol-5-ylthio)-9H-purine; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; azanine; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; Azothioprin; Jayempi; Azoran; AI3-50290; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; Prestwick_41; Azathiopurine,(S); [Methyl(nitroimidazolyl)mercaptopurine]; Azathioprine [USAN:USP:INN:BAN:JAN]; Spectrum_000064; Azathioprine, >=98%; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; Prestwick0_000094; Prestwick1_000094; Prestwick2_000094; Prestwick3_000094; Spectrum2_000068; Spectrum3_000308; Spectrum4_000243; Spectrum5_000848; AZATHIOPRINE [MI]; Lopac-A-4638; ChemDiv1_002659; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; AZATHIOPRINE [INN]; AZATHIOPRINE [JAN]; A 4638; AZATHIOPRINE [HSDB]; AZATHIOPRINE [IARC]; AZATHIOPRINE [USAN]; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); SCHEMBL4278; AZATHIOPRINE [VANDF]; CHEMBL1542; Lopac0_000027; Oprea1_375441; Oprea1_533384; Oprea1_633462; AZATHIOPRINE [MART.]; BSPBio_000048; BSPBio_001876; CBDivE_013132; KBioGR_000646; KBioGR_002427; KBioSS_000464; KBioSS_002433; AI-981/34845012; MLS001049307; AZATHIOPRINE [USP-RS]; AZATHIOPRINE [WHO-DD]; AZATHIOPRINE [WHO-IP]; DivK1c_000586; SPECTRUM1500133; SPBio_000255; SPBio_001987; BPBio1_000054; GTPL7120; Azathioprine (JP17/USP/INN); HMS501N08; HMS594I19; KBio1_000586; KBio2_000464; KBio2_002427; KBio2_003032; KBio2_004995; KBio2_005600; KBio2_007563; KBio3_001376; KBio3_002906; cMAP_000046; NINDS_000586; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; AZATHIOPRINE [EP IMPURITY]; AZATHIOPRINE [ORANGE BOOK]; HMS1568C10; HMS1920E17; HMS2091K19; HMS2095C10; HMS2802J03; HMS3259P03; HMS3260E15; HMS3655M04; HMS3712C10; Pharmakon1600-01500133; AZATHIOPRINE [EP MONOGRAPH]; ACT02232; BCP09492; HY-B0256; AZATHIOPRINE [USP MONOGRAPH]; Tox21_110074; Tox21_400024; Tox21_500027; AZATHIOPRINUM [WHO-IP LATIN]; BDBM50373919; CCG-16168; CCG-39877; NSC755900; s1721; STK831906; AKOS005609209; AKOS028108935; Tox21_110074_1; AC-4230; CCG-220094; DB00993; KS-1146; LP00027; NC00614; NSC-755900; SDCCGMLS-0065415.P001; SDCCGSBI-0050016.P005; IDI1_000586; NCGC00015060-01; NCGC00015060-02; NCGC00015060-03; NCGC00015060-04; NCGC00015060-05; NCGC00015060-07; NCGC00015060-08; NCGC00015060-09; NCGC00015060-10; NCGC00015060-11; NCGC00015060-12; NCGC00015060-13; NCGC00015060-15; NCGC00015060-16; NCGC00015060-18; NCGC00015060-19; NCGC00015060-29; NCGC00090836-01; NCGC00090836-02; NCGC00090836-03; NCGC00090836-04; NCGC00090836-05; NCGC00090836-06; NCGC00094593-01; NCGC00094593-02; NCGC00094593-03; NCGC00260712-01; BA166065; SMR000427366; 6-1'-Methyl,5'-imidazolyl mercaptopurine; SBI-0050016.P003; Azathioprine 100 microg/mL in Acetonitrile; 6-(1-Methyl-4-nitromidazol-5-ylthio)purine; AB00443544; EU-0100027; FT-0602904; FT-0662375; SW198560-2; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purine; Azathioprine, meets USP testing specifications; C06837; D00238; D70170; EN300-118702; Q18939; AB00443544-03; AB00443544-11; AB00443544_12; AB00443544_13; A826664; SR-01000762955; 6-(1-Methyl-4-nitro-5-imidazolythio)-9H-pur-ine; SR-01000075537-1; SR-01000075537-4; SR-01000762955-2; BRD-K32821942-001-05-6; BRD-K32821942-001-10-6; BRD-K60324116-001-01-5; WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW; Z57063156; 6-((1-methyl-4-nitro-1h-imidazol-5-yl)thio)-1h-purin; 6-(3-methyl-5-nitro-imidazol-4-yl)sulfanyl-9H-purine; 6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-1H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-9H-purine; 9H-Purine, 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-; Azathioprine, European Pharmacopoeia (EP) Reference Standard; 1H-PURINE, 6-((1-METHYL-4-NITRO-1H-IMIDAZOL-5-YL)THIO); 6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-1H-purine #; Azathioprine, United States Pharmacopeia (USP) Reference Standard; Azathioprine, Pharmaceutical Secondary Standard; Certified Reference Material; 6-((1-METHYL-4-NITROIMIDAZOL-5-YL)THIO)PURINE6-((1-METHYL-4-NITRO-1H-IMIDAZOL-5-YL)THIO)-1H-PURINE	Approved	Approved Drug(s)	2265	DB00993	D07QCE	277.27	143	354	0.1	19	1	7	2	C9H7N7O2S	6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine	CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]	CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]	InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)	LMEKQMALGUDUQG-UHFFFAOYSA-N
D8O1SC	Teriflunomide	Small molecule	Teriflunomide; 163451-81-8; 108605-62-5; Aubagio; Flucyamide; A77 1726; HMR1726; (Z)-2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide; HMR-1726; HMR 1726; A 771726; A-771726; SU 20; A771726; (Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide; A 77-1726; (E/Z)-Teriflunomide; CHEBI:68540; Teriflunomide(Random Configuration); 2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide; (2z)-2-Cyano-3-Hydroxy-N-[4-(Trifluoromethyl)phenyl]but-2-Enamide; (Z)-2-cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-p-crotonotoluidide; 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-; 1C058IKG3B; 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide; A77-1726; Teriflunomide (USAN); Teriflunomide [INN]; 2-Butenamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-; TERIFLUNOMIDE [USAN]; 2-Cyano-3-OH-N-(4-trifluoromethylphenyl)croton amide; 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-; (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide.; MFCD00910058; RS 61980; Teriflunomide [USAN:INN]; teriflunomida; teriflunomidum; UNII-1C058IKG3B; 2-cyano-3-hydroxy-n-[4-(trifluoromethyl)phenyl]-2-butenamide; 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide; Malononitrilamide; N-(4-Trifluoromethylphenyl)-2-cyano-2-hydroxycrotonamide; 2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide; 2-BUTENAMIDE, 2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHYL)PHENYL)-, (2Z)-; A 1726; A26; Aubagio (TN); SU-0020; RS-61980; Leflunomide EP Impurity B; TERIFLUNOMIDE [MI]; (2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile; DIMETHYL APROBARBITAL; SCHEMBL22661; TERIFLUNOMIDE [VANDF]; Teriflunomide(A-771726); Teriflunomide, A77 1726; TERIFLUNOMIDE [WHO-DD]; GTPL6844; DTXSID80893457; A77 1726 (E/Z) Mixture; TERIFLUNOMIDE [ORANGE BOOK]; TERIFLUNOMIDE [EP MONOGRAPH]; BDBM50018011; NSC766118; s4169; AKOS015994773; CCG-267145; DB08880; LE-0275; NSC-766118; NCGC00263218-07; NCGC00263218-13; AC-26446; HY-110159; CS-0033021; LEFLUNOMIDE IMPURITY B [EP IMPURITY]; SW219377-1; T3287; D10172; EN300-189832; AB01565775_02; A801897; A882574; J-010046; Q3077133; N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide; Z1878131003; N-[4-(Trifluoromethyl)phenyl]-2-cyano-3-hydroxycrotonamide; 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2Z-butenamide; (Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide; 2-Butenamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-, (Z)-; A 77-1726;A771726;HMR1726;CAS# 108605-62-5; (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide (Teriflunomide); A 1726, A77-1726, A771726, Flucyamide, HMR 1726, N-(4-Trifluoromethylphenyl)-2-cyano-3-hydroxycrotoamide, SU 20; Teriflunomide; Leflunomide USP RC B; Cyano Keto leflunomide impurity; N-(4-Trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide; 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-beuteamide	Approved	Approved Drug(s)	54684141	DB08880	D07QFP	270.21	73.1	426	3.3	19	2	6	2	C12H9F3N2O2	(Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide	CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O	C/C(=C(\C#N)/C(=O)NC1=CC=C(C=C1)C(F)(F)F)/O	InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-	UTNUDOFZCWSZMS-YFHOEESVSA-N
D3GWD9	Chloroquine	Small molecule	chloroquine; 54-05-7; Aralen; Chlorochin; Chloraquine; Artrichin; Chloroquinium; Chloroquina; Reumachlor; Capquin; Chemochin; Chlorquin; Clorochina; Malaquin; Bemaco; Arthrochin; Bemasulph; Benaquin; Bipiquin; Chingamin; Cidanchin; Cocartrit; Dichinalex; Gontochin; Heliopar; Iroquine; Klorokin; Lapaquin; Mesylith; Pfizerquine; Quinachlor; Quinercyl; Quinilon; Quinoscan; Sanoquin; Silbesan; Solprina; Sopaquin; Tresochin; Amokin; Elestol; Imagon; Malaren; Malarex; Neochin; Roquine; Siragan; Trochin; Nivaquine B; Bemaphate; Resoquine; Nivaquine; Chlorochine; Chloroquinum; Cloroquina; Quingamine; Ronaquine; Khingamin; N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine; Avlochlor; Nivachine; Quinagamin; Quinagamine; Resochen; Resoquina; Reumaquin; Avloclor; Delagil; Tanakan; WIN 244; RP 3377; 1,4-Pentanediamine, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-; W 7618; Chloroin; Miniquine; Rivoquine; Tanakene; Arolen; 7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline; CHEBI:3638; N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine; {4-[(7-chloroquinolin-4-yl)amino]pentyl}diethylamine; Gontochin phosphate; CHEMBL76; NSC-187208; 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine; SN 6718; Ipsen 225; 886U3H6UFF; Chlorochinum; 7-Chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline; N(sup 4)-(7-Chloro-4-quinolinyl)-N(sup 1),N(sup 1)-diethyl-1,4-pentanediamine; MFCD00024009; NSC187208; SN 7618; Chloroquine (VAN); Clorochina [DCIT]; Quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-; 3377 RP; CQ; 1,4-Pentanediamine, N(sup 4)-(7-chloro-4-quinolinyl)-N(sup 1),N(sup 1)-diethyl-; ST 21 (pharmaceutical); Chloroquinum [INN-Latin]; Cloroquina [INN-Spanish]; 3377 RP opalate; Chloroquin; Quinoline, 7-chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]-; N(4)-(7-chloro-4-quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine; ST 21; (+-)-Chloroquine; NSC14050; CCRIS 3439; 1246815-14-4; HSDB 3029; Chloroquine (USP/INN); EINECS 200-191-2; Malaquin (*Diphosphate*); NSC 187208; BRN 0482809; UNII-886U3H6UFF; Cloroquine; Chloroquine [USP:INN:BAN]; Chloroquine, 17; Chloroquine-[d4]; 4,7-Dichloroquine; Arechin (Salt/Mix); Delagil (Salt/Mix); Tanakan (Salt/Mix); RP-3377; Bemaphate (Salt/Mix); Resoquine (Salt/Mix); Spectrum_000132; Chloroquine + Proveblue; CHLOROQUINE [MI]; Prestwick0_000548; Prestwick1_000548; Prestwick2_000548; Prestwick3_000548; Spectrum2_000127; Spectrum3_000341; Spectrum4_000279; Spectrum5_000707; CHLOROQUINE [INN]; (.+/-.)-Chloroquine; 1,4-Pentanediamine, N(4)-(7-chloro-4-quinolinyl)-N(1),N(1)-diethyl-; CHLOROQUINE [HSDB]; Epitope ID:131785; MolMap_000009; CHLOROQUINE [VANDF]; SCHEMBL8933; CHLOROQUINE [MART.]; Lopac0_000296; BSPBio_000595; BSPBio_002001; CHLOROQUINE [WHO-DD]; KBioGR_000778; KBioSS_000592; DivK1c_000404; CU-01000012392-2; SPBio_000174; SPBio_002516; GNF-Pf-4216; BPBio1_000655; GTPL5535; DTXSID2040446; BDBM22985; KBio1_000404; KBio2_000592; KBio2_003160; KBio2_005728; KBio3_001221; NINDS_000404; CHLOROQUINE [USP IMPURITY]; HMS2090O03; CHLOROQUINE [USP MONOGRAPH]; HY-17589A; s6999; AKOS015935106; CCG-204391; CS-W004760; DB00608; KH-0005; SB73098; SDCCGSBI-0050284.P005; IDI1_000404; SMP2_000034; NCGC00015256-02; NCGC00015256-03; NCGC00015256-04; NCGC00015256-05; NCGC00015256-06; NCGC00015256-07; NCGC00015256-08; NCGC00015256-09; NCGC00015256-10; NCGC00015256-13; NCGC00015256-17; NCGC00015256-28; NCGC00162120-01; NCI60_000894; SY086904; WLN: T66 BNJ EMY1&3N2&2 IG; SBI-0050284.P004; AB00053436; C3730; CS-0021871; FT-0623612; C07625; D02366; EN300-120683; MLS-0466768.0001; AB00053436-05; AB00053436_06; AB00053436_07; 1, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-; Q422438; BRD-A91699651-065-01-1; BRD-A91699651-316-06-7; n(sup4)-(7-chloro-4-quinolinyl)-n(sup1),4-pentanediamine; N'-(7-chloroquinolin-4-yl)-N,N-diethylpentane-1,4-diamine; N4-(7-chloro-4-quinolyl)-N1,N1-diethyl-pentane-1,4-diamine; Quinoline, 7-chloro-4-(4-diethylamino-1-methyl-butylamino)-; 7-CHLORO-N-[5-(DIETHYLAMINO)PENTAN-2-YL]QUINOLIN-4-AMINE; N(4)-(7-chloroquinolin-4-yl)-N(1),N(1)-diethylpentane-1,4-diamine; 1,4-PENTANEDIAMINE, N(SUP 4)-(7-CHLORO-4-QUINOLINYL)-N(SUP 1),N (SUP 1)-DIETHYL-; N(sup4)-(7-chloro-4-quinolinyl)-N(sup1),N(sup1)-diethyl-1,4-pentanediamine; 117399-83-4; Chloroquine; Chloroquine Sulphate; 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine	Approved	Approved Drug(s)	2719	DB00608	D07QYQ	319.9	28.2	309	4.6	22	1	3	8	C18H26ClN3	4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl	InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)	WHTVZRBIWZFKQO-UHFFFAOYSA-N
DN9DE8	Etelcalcetide	Small molecule	etelcalcetide; Velcalcetide; 1262780-97-1; Parsabiv; KAI-4169; AMG-416; Telcalcetide; 60ME133FJB; ONO-5163; Etelcalcetide Hydrochloride(AMG-416); D-Argininamide, N-acetyl-D-cysteinyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-, disulfide with L-cysteine; Etelcalcetide [USAN:INN]; UNII-60ME133FJB; KAI 4169; Amg416; ETELCALCETIDE [MI]; ETELCALCETIDE [INN]; Etelcalcetide (USAN/INN); ETELCALCETIDE [USAN]; ETELCALCETIDE [WHO-DD]; GTPL8375; CHEMBL3545184; SCHEMBL21982605; DTXSID70155132; CHEBI:134700; ETELCALCETIDE [ORANGE BOOK]; HY-P1955; AKOS037648615; DB12865; BS-14875; CS-0030931; J3.559.823E; D10676; D71178; EN300-25975978; Q21098973; (2R)-2-amino-3-{[(2S)-2-{[(1R)-1-{[(1R)-4-carbamimidamido-1-{[(1R)-4-carbamimidamido-1-{[(1R)-4-carbamimidamido-1-{[(1R)-1-{[(1R)-4-carbamimidamido-1-carbamoylbutyl]carbamoyl}ethyl]carbamoyl}butyl]carbamoyl}butyl]carbamoyl}butyl]carbamoyl}ethyl]carbamoyl}-2-acetamidoethyl]disulfanyl}propanoic acid; N-ACETYL-D-CYSTEINYL-D-ALANYL-D-ARGINYL-D-ARGINYL-D-ARGINYL-D-ALANYL-D-ARGININAMIDE DISULFIDE WITH L-CYSTEINE; S-(((S)-2-acetamido-3-(((R)-1-(((R)-1-(((R)-1-(((R)-1-(((R)-1-(((R)-1-amino-5-guanidino-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)-L-cysteine	Approved	Approved Drug(s)	71511839	DB12865	D07RYI	1048.3	618	1910	-10.7	71	18	17	36	C38H73N21O10S2	(2R)-3-[[(2S)-2-acetamido-3-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]disulfanyl]-2-aminopropanoic acid	CC(C(=O)NC(CCCN=C(N)N)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CSSCC(C(=O)O)N)NC(=O)C	C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@@H](C(=O)O)N)NC(=O)C	InChI=1S/C38H73N21O10S2/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52)/t18-,19-,21+,22-,23-,24-,25-,26-/m1/s1	ANIAZGVDEUQPRI-ZJQCGQFWSA-N
D7G1XH	Busulfan	Small molecule	busulfan; 55-98-1; Myleran; Busulphan; Sulphabutin; Leucosulfan; Busulfex; Myelosan; Citosulfan; Mielucin; Misulban; Mitostan; Myeloleukon; Mylecytan; Sulfabutin; Mablin; Mielevcin; Milecitan; Mielosan; Mileran; Buzulfan; 1,4-Dimesyloxybutane; butane-1,4-diyl dimethanesulfonate; 1,4-BUTANEDIOL DIMETHANESULFONATE; Myeleukon; Busulfanum; Myelosanum; 1,4-Dimethanesulfonoxybutane; Tetramethylene dimethane sulfonate; 1,4-Butanediol, dimethanesulfonate; Busilvex; Busulfano; Busulphane; 1,4-Dimethylsulfonyloxybutane; NCI-C01592; 1,4-Dimethanesulfonyloxybutane; 1,4-Bis(methanesulfonoxy)butane; 1,4-Butanediol dimethylsulfonate; 1,4-Dimethylsulfonoxybutane; 1,4-Bis(methanesulfonyloxy)butane; GT 41; 4-methylsulfonyloxybutyl methanesulfonate; NSC-750; CB 2041; 1,4-Butanediol dimethanesulphonate; AN 33501; Methanesulfonic acid, tetramethylene ester; Tetramethylene bis(methanesulfonate); 1,4-Dimethanesulphonyloxybutane; NSC 750; Tetramethylenester kyseliny methansulfonove; C.B. 2041; X 149; GT 2041; Tetramethylene bis[methanesulfonate]; 1,4-Butanediol, dimethanesulphonate; NSC750; 1,4-Bis[methanesulfonoxy]butane; CHEBI:28901; 2041 C. B.; G.T. 41; G1LN9045DK; 4-(methanesulfonyloxy)butyl methanesulfonate; DTXSID3020910; NCGC00090905-06; Mitosan; Busulfanum [INN-Latin]; Busulfano [INN-Spanish]; DTXCID10910; Methanesulfonic; CAS-55-98-1; CCRIS 418; SR-01000765405; EINECS 200-250-2; BRN 1791786; UNII-G1LN9045DK; Bisulfex; AI3-25012; Busulfan;; Busulfan/Myleran; Busulfex IV; Busulfan [USP:INN:BAN:JAN]; HSDB 7605; Tetramethylenester kyseliny methansulfonove [Czech]; Prestwick_989; MFCD00007562; Tetramethylene {bis[methanesulfonate]}; Spectrum_000092; BUSULFAN [HSDB]; BUSULFAN [IARC]; BUSULFAN [INN]; BUSULFAN [JAN]; 2041 C.B.; BUSULFAN [MI]; BUSULFAN [VANDF]; Spectrum2_000067; Spectrum3_000320; Spectrum4_000259; Spectrum5_000928; BUSULFAN [MART.]; BUSULFAN [WHO-DD]; BUSULFAN [WHO-IP]; CHEMBL820; NCIMech_000192; SCHEMBL4373; BUSULFAN [EMA EPAR]; MYELOSANUM [WHO-IP]; WLN: WS1&O4OSW1; BSPBio_001920; KBioGR_000698; KBioSS_000512; MLS001076666; Busulfan (Myleran, Busulfex); BUSULFAN FRESENIUS KABI; DivK1c_000847; SPECTRUM1500152; Busulfan (JP17/USP/INN); SPBio_000253; BUSULFAN [EP IMPURITY]; BUSULFAN [ORANGE BOOK]; GTPL7136; BUSULFAN [EP MONOGRAPH]; BUSULFAN [USP MONOGRAPH]; COVZYZSDYWQREU-UHFFFAOYSA-; HMS502K09; KBio1_000847; KBio2_000512; KBio2_003080; KBio2_005648; KBio3_001420; butane-1,4-diyldimethanesulfonate; BUSULFANUM [WHO-IP LATIN]; NINDS_000847; HMS1920I07; HMS2091O09; HMS2233H04; HMS3259G15; HMS3370E11; HMS3655A21; HMS3712A20; Pharmakon1600-01500152; AMY33355; HY-B0245; Tox21_111038; Tox21_201848; Tox21_300318; 1, {4-Bis[methanesulfonoxy]butane}; 2041CB; AC-198; BDBM50237623; CCG-35458; NSC755916; s1692; AKOS003614975; Tox21_111038_1; DB01008; KS-5212; NC00498; NSC-755916; IDI1_000847; NCGC00090905-01; NCGC00090905-02; NCGC00090905-03; NCGC00090905-04; NCGC00090905-05; NCGC00090905-07; NCGC00090905-08; NCGC00090905-09; NCGC00090905-10; NCGC00090905-11; NCGC00090905-12; NCGC00254038-01; NCGC00259397-01; NCI60_041640; SMR000058613; TETRAMETHYLENE DI(METHANESULFONATE); SBI-0051300.P003; B1022; FT-0623291; FT-0663910; SW198555-3; C06862; D00248; D88731; EN300-118686; 4-[(Methylsulfonyl)oxy]butyl methanesulfonate #; AB00051929-10; AB00051929-11; AB00051929_12; AB00051929_14; Busulfan, analytical standard, for drug analysis; Q348922; SR-01000765405-2; SR-01000765405-3; SR-01000765405-7; Busulfan, European Pharmacopoeia (EP) Reference Standard; Z276508890; 129316-96-7	Approved	Approved Drug(s)	2478	DB01008	D07SUG	246.3	104	294	-0.5	14	0	6	7	C6H14O6S2	4-methylsulfonyloxybutyl methanesulfonate	CS(=O)(=O)OCCCCOS(=O)(=O)C	CS(=O)(=O)OCCCCOS(=O)(=O)C	InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3	COVZYZSDYWQREU-UHFFFAOYSA-N
DV90AG	Larotrectinib	Small molecule	Larotrectinib; LOXO-101; 1223403-58-4; ARRY-470; (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide; Vitrakvi; LOXO 101; BAY2757556; BAY-2757556; LOXO101; PF9462I9HX; (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide; Larotrectinib (LOXO-101 free base); 1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-; ARRY 470; (3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxypyrrolidine-1-carboxamide; 1-Pyrrolidinecarboxamide, N-[5-[(2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-, (3S)-; Larotrectinib [INN]; LAROTRECTINIB [MI]; ARRY-470; larotrectinib; Larotrectinib (USAN/INN); Larotrectinib [USAN:INN]; LAROTRECTINIB [USAN]; UNII-PF9462I9HX; ARRY470; LAROTRECTINIB [WHO-DD]; AMY264; GTPL8909; SCHEMBL2241012; CHEMBL3889654; BDBM136597; DTXSID101020707; BCP16262; EX-A1981; MFCD28902192; NSC785570; NSC801004; s5860; example 14 [US8865698 B2]; CS-5722; DB14723; NSC-785570; NSC-801004; AC-33660; AS-35231; HY-12866; J3.628.138C; D11137; EN300-7411765; US8865698, 14; Q27081513; ARRY-470;ARRY 470 : LOXO-101; LOXO101; Larotrectinib; ARRY470;ARRY-470;ARRY 470;LOXO 101;LOXO101;Larotrectinib; (3S)-N-(5-((2R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDIN- 1-YL)PYRAZOLO(1,5-A)PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE- 1-CARBOXAMIDE; (3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide; (S)-N-(5 -((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide; (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin -1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide; (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide; (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3 yl)-3-hydroxypyrrolidine-1-carboxamide	Approved	Approved Drug(s)	46188928	DB14723	D07TOK	428.4	86	659	1.7	31	2	7	3	C21H22F2N6O2	(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide	C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F	C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@@H](C4)O)C5=C(C=CC(=C5)F)F	InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1	NYNZQNWKBKUAII-KBXCAEBGSA-N
D9YQG4	Lamivudine	Small molecule	lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; 136891-12-8; 3TC; BCH-189; Heptodin; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; (-)-2'-Deoxy-3'-thiacytidine; VIROLAM; GR-109714X; 3'-Thia-2',3'-dideoxycytidine; GR109714X; GR 109714X; (-)-BCH-189; beta-L-2',3'-Dideoxy-3'-thiacytidine; beta-L-3'-Thia-2',3'-dideoxycytidine; 2',3'-Dideoxy-3'-thiacytidine; CIS-LAMIVUDINE; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; Lamivudine teva; (-)NGPB-21; BCH 189, (-)-; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 4-Amino-1-(cis-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE; Hepitec; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-2(1H)-PYRIMIDINONE; CHEBI:63577; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-; 2T8Q726O95; NSC-760061; Heptivir; Lamivir; Zefix; BCH 189; Lamivudine [USAN:BAN:INN]; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; 2(1H)-Pyrimidinone, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-; 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-; Epivir(TM); HHA & Lamivudine; Lamivudine & GNA; SMR000466319; Epivir (TN); (-)-BCH 189; DTHC; CHEMBL141; HSDB 7155; DRG-0126; 3TC and NV-01; (-)-SddC; DTXSID7023194; Lamivudeine; Lamivudinum; Lamivudine (JAN/USP/INN); 3TC & GNA; 3TC & SST; HHA & 3TC; (+/-)-SddC; CCRIS 9274; NSC620753; UNII-2T8Q726O95; BCH-790; Lamivudine [USAN:USP:INN:BAN]; rac-cis-Lamivudine; NCGC00159341-04; Lamivudine- Bio-X; GG-714; MFCD00869739; Lamivudine (EPIVIR); CPD000466319; LAMIVUDINE [MI]; (+/-)-3TC; (+/-)-BCH-189; LAMIVUDINE [INN]; LAMIVUDINE [JAN]; LAMIVUDINE [HSDB]; LAMIVUDINE [USAN]; LAMIVUDINE [VANDF]; LAMIVUDINE [MART.]; LAMIVUDINE [USP-RS]; LAMIVUDINE [WHO-DD]; LAMIVUDINE [WHO-IP]; MLS000759424; MLS001424097; MLS006011910; BIDD:GT0033; LAMIVUDINE [EMA EPAR]; SCHEMBL109675; AMY384; LAMIVUDINE [EP IMPURITY]; LAMIVUDINE [ORANGE BOOK]; LAMIVUDINE [EP MONOGRAPH]; KIVEXA COMPONENT LAMIVUDINE; HMS2051D21; HMS3259F08; HMS3713C16; LAMIVUDINE [USP MONOGRAPH]; EPZICOM COMPONENT LAMIVUDINE; LAMIVUDINUM [WHO-IP LATIN]; TEMIXYS COMPONENT LAMIVUDINE; TRIUMEQ COMPONENT LAMIVUDINE; COMBIVIR COMPONENT LAMIVUDINE; HY-B0250; LAMIVUDINE TEVA PHARMA B.V.; TRIZIVIR COMPONENT LAMIVUDINE; BBL033871; BDBM50366817; DELSTRIGO COMPONENT LAMIVUDINE; MFCD00870542; s1706; STK801940; lamivudine & TNF-alpha & IFN-gamma; TELURA COMPONENT OF LAMIVUDINE; AKOS005622556; AKOS015854841; LAMIVUDINE COMPONENT OF EPZICOM; LAMIVUDINE COMPONENT OF TEMIXYS; LAMIVUDINE COMPONENT OF TRIUMEQ; Lamivudine, >=98% (HPLC), powder; (-)-BCH189; AC-1416; CCG-100984; DB00709; KS-1073; LAMIVUDINE COMPONENT OF COMBIVIR; LAMIVUDINE COMPONENT OF DUTREBIS; LAMIVUDINE COMPONENT OF TRIZIVIR; NC00234; NC00705; NSC 760061; LAMIVUDINE COMPONENT OF DELSTRIGO; NCGC00159341-05; NCGC00159341-18; NCGC00159341-20; BL164607; EMTRICITABINE IMPURITY C [WHO-IP]; L0217; rac-cis-Lamivudine ((2RS,5SR)-Lamivudine); SW197614-3; C07065; D00353; EN300-123034; P17147; AB00639995-06; AB00639995-08; AB00639995_09; Lamivudeine 100 microg/mL in Acetonitrile:Water; Q422631; SR-01000759420; J-700183; Q-201275; SR-01000759420-5; LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT LAMIVUDINE; LAMIVUDINE COMPONENT OF LAMIVUDINE/ZIDOVUDINE TEVA; Z1509637175; Lamivudine, British Pharmacopoeia (BP) Reference Standard; Lamivudine, European Pharmacopoeia (EP) Reference Standard; (2R,5S)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; .beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; Lamivudine, United States Pharmacopeia (USP) Reference Standard; (+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-L-2',3'-DIDEOXY-3'-THIACYTIDINE; LAMIVUDINE; EPIVIR; Lamivudine, 1.0 mg/mL in methanol, certified reference material; Lamivudine, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-(cis)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis); 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-[1,3]-oxathiolan-5-yl]-(1H)-pyrimidin-2-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-Oxathiolan-5-yl]-(1H)-pyrimidin-2-one; cis(+/-)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard; Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard; 1117764-41-6; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA); 4-AMINO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDIN-2(1H)-ONE [WHO-IP]	Approved	Approved Drug(s)	60825	DB00709	D07TQV	229.26	113	331	-0.9	15	2	4	2	C8H11N3O3S	4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one	C1C(OC(S1)CO)N2C=CC(=NC2=O)N	C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N	InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1	JTEGQNOMFQHVDC-NKWVEPMBSA-N
DAD30O	Atorvastatin	Small molecule	atorvastatin; 134523-00-5; Cardyl; Lipitor; Torvast; ATORVASTATIN CALCIUM; 110862-48-1; rel-Atorvastatin; (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid; Atorvastatin (INN); CI 981; Lipitor (TN); Tozalip; Xavator; A0JWA85V8F; CHEMBL1487; (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; DTXSID8029868; CHEBI:39548; ATORVASTATIN [INN]; 134523-03-8; Atorvastatin [INN:BAN]; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (R-(R*,R*))-; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID; Atorvastatin calcium salt; atorvastatina; atorvastatine; atrovastin; Atofast; Atorcor; Atorlip; Lipilou; Lipinon; Atorin; Ator; Lipitor(TM); (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; Sortis (TN); CCRIS 7159; HSDB 7039; NCGC00159458-03; UNII-A0JWA85V8F; atorvastatinum; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; Atorvastatin & Primycin; ATORVASTATIN [MI]; ATORVASTATIN [HSDB]; SCHEMBL3831; ATORVASTATIN [VANDF]; ATORVASTATIN [WHO-DD]; BIDD:GT0336; Atorvastatin (Relative Stereo); DTXCID509868; GTPL2949; BDBM22164; DTXSID60274003; HMS3715L05; HMS3886C20; Lipilou; Tozalip; Torvast; Cardyl; (3S,5S)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; ACT03225; HY-B0589; Tox21_302417; MFCD00899261; s5715; AKOS000281127; AC-9386; CCG-221172; DB01076; MRF-0000761; NCGC00159458-02; NCGC00159458-20; NCGC00255181-01; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (betaR,deltaR)-; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; AS-35260; CAS-134523-00-5; C06834; D07474; A802259; A806791; A806793; EN300-18527331; Q668093; SR-01000872702; SR-01000872702-1; BRD-K69726342-001-02-6; Atorvastatin is known as an HMG-CoA reductase inhibitor.; (.BETA.R,.DELTA.R)-2-(P-FLUOROPHENYL)-.BETA.,.DELTA.-DIHYDROXY-5-ISOPROPYL-3-PHENYL-4-(PHENYLCARBAMOYL)PYRROLE-1-HEPTANOIC ACID; (3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-PROPAN-2-YL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-PYRROLE-1-HEPTANOIC ACID, 2-(4-FLUOROPHENYL)-.BETA.,.DELTA.-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-, (R-(R*,R*))-; sodium 7-[5-(4-fluorophenyl)-2-isopropyl-4-phenyl-3-(phenylcarbamoyl)-2,3-dihydropyrrol-1-yl]-3,5-dihydroxy-heptanoate	Approved	Approved Drug(s)	60823	DB01076	D07TSV	558.6	112	822	5	41	4	6	12	C33H35FN2O5	(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid	CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4	CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4	InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1	XUKUURHRXDUEBC-KAYWLYCHSA-N
DGNE23	Tafenoquine	Small molecule	Tafenoquine; 106635-80-7; Etaquine; Arakoda; Krintafel; WR 238605; SB-252263-AAB; Tafenoquine free base; WR238605; 262P8GS9L9; 106635-80-7 (free base); 4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine; Tafenoquine (USAN); TAFENOQUINE [USAN]; N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine; 1,4-Pentanediamine, N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-8-quinolinyl)-; SB-252263; UNII-262P8GS9L9; Tafenoquine [USAN:INN:BAN]; 1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]-; N4-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine; N(4)-(2,6-Dimethoxy-4-methyl-5-((3-trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine; TAFENOQUINE [MI]; TAFENOQUINE [INN]; (R)-N3-(2,6-Dimethoxy-4-methyl-5-(3-trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine; TAFENOQUINE [MART.]; TAFENOQUINE [WHO-DD]; SCHEMBL347388; CHEMBL298470; GTPL9722; DTXSID90869466; CHEBI:141487; EX-A3146; DB06608; SB16555; (RS)-N(sup 3)-(2,6-Dimethoxy-4-methyl-5-(3-trifluoro-methylphenoxy)quinolin-8-yl)pentane-1,4-diamine; HY-111529; CS-0042381; FT-0775258; D10490; D87160; EN300-19754461; Q2387553; N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolyl]pentane-1,4-diamine; (+/-)-8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-(3-trifluoromethylphenoxy) quinoline; (4-Amino-1-methylbutyl){2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy](8-quinolyl)}amine; N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine	Approved	Approved Drug(s)	115358	DB06608	D07TWN	463.5	78.6	597	5.4	33	2	9	9	C24H28F3N3O3	4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine	CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC	CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC	InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3	LBHLFPGPEGDCJG-UHFFFAOYSA-N
DM5Y3A	Olmesartan	Small molecule	Olmesartan; 144689-24-7; Olmesartan Acid; RNH-6270; RNH 6270; 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid; CS-088; NSC-759810; CHEMBL1516; 8W1IQP3U10; 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid; CHEBI:48416; Votum; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-; Olmesartan [USAN]; omesartan; Olme sartan; 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole-5-carboxylic Acid (Olmesartan); 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid; 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; SMR000466337; UNII-8W1IQP3U10; Olmesartan [USAN:INN:BAN]; Benicar;Olmetec; HSDB 8214; 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid; Olmesartan medoximil; CS 088; Diclofenacdiethylamine; MFCD00914967; OLMESARTAN [MI]; OLMESARTAN [INN]; Olmesartan (USAN/INN); OLMESARTAN [VANDF]; EC 646-413-5; OLMESARTAN [WHO-DD]; SCHEMBL94037; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; MLS000759446; MLS001424016; MLS006011945; DTXSID2040571; Olmesartan, >=98% (HPLC); HMS2051K12; HMS2235O24; HMS3369I09; HMS3393K12; HMS3604J06; Pharmakon1600-01505206; BCP12007; BDBM50241364; DE-092; NSC759810; s5581; AKOS015900241; AKOS024458255; AC-9385; CCG-100868; CCG-269198; CS-0576; DB00275; NC00118; NSC 759810; NCGC00246968-01; NCGC00246968-02; NCGC00246968-04; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid; 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylic acid; AS-10242; HY-17004; Olmesartan medoxomil impurity, olmesartan-; SMR004703526; DB-042742; FT-0631169; O-125; O0507; C21543; D05246; EN300-122328; A853148; L001097; Olmesartan 100 microg/mL in Acetonitrile:Methanol; Q421156; W-201270; OLMESARTAN MEDOXOMIL IMPURITY A [EP IMPURITY]; Z1541758605; OLMESARTAN MEDOXOMIL IMPURITY, OLMESARTAN- [USP IMPURITY]; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate; 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid; 1H-IMidazole-5-carboxylicacid,4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-; 4-(1-hydroxy-1-methylethyl) -2-propyl-1-{4-[2-(tetrazole -5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl) -2-propyl-1-{4-[2-(tetrazole-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazole-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid; 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1H-tetrazol-5-yl)-1,1''-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid.; OLM	Approved	Approved Drug(s)	158781	DB00275	D07UBG	446.5	130	656	3.2	33	3	7	8	C24H26N6O3	5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid	CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)C(C)(C)O	CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)C(C)(C)O	InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)	VTRAEEWXHOVJFV-UHFFFAOYSA-N
D94CHP	Arsenic trioxide	Small molecule	arsenic trioxide; Arsenic oxide (As2O3); Arsenic(III) trioxide; arsenic(3+);oxygen(2-); Trisenox; Arsenic oxidearsenous trioxide; DTXSID0020103; Arsenous oxide [ISO]; Arsenox; Trixenox; Arsenious Acid Anhydride; Oxyde Arsenieux; Caswell No. 059; Rcra waste number P012; RCRA waste no. P012; Trixonex; CCRIS 5455; HSDB 419; EINECS 215-481-4; UN1561; EPA Pesticide Chemical Code 007001; UN 1561; AI3-01163; UNII-S7V92P67HO; Arsenic trioxide [USAN:JAN]; S7V92P67HO; DTXCID60820620; Tox21_112255; NSC 92859; NSC 759274; Arsenic trioxide [UN1561]  [Poison]; CAS-1327-53-3; EC 215-481-4; SR-01000944371; SR-01000944371-1	Approved	Approved Drug(s)	14888	DB01169	D07VIK	197.841	3	0	.	5	0	3	0	As2O3	arsenic(3+);oxygen(2-)	[O-2].[O-2].[O-2].[As+3].[As+3]	[O-2].[O-2].[O-2].[As+3].[As+3]	InChI=1S/2As.3O/q2*+3;3*-2	QTLQKAJBUDWPIB-UHFFFAOYSA-N
DA2PC3	Doxorubicin	Small molecule	doxorubicin; Adriamycin; 23214-92-8; Adriablastin; Doxil; Adriblastina; Doxorubicine; Hydroxydaunorubicin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicine [INN-French]; Doxorubicinum [INN-Latin]; Doxorubicina [INN-Spanish]; Adriamycin semiquinone; FI 106; CHEMBL53463; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; Doxorubicina; CHEBI:28748; NSC-759155; NDC 38242-874; NCI-C01514; 80168379AG; ADM; NSC-123127; (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; Doxorubicin [USAN:INN:BAN]; ThermoDox; DOX; MLS000028393; DM2; Doxorubicin-hLL1; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (8S-cis)-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione; Adriblastina (TN); CCRIS 739; Doxorubicin-P4/D10; HSDB 3070; EINECS 245-495-6; Doxorubicin (USAN/INN); Doxorubicin-hLL1 conjugate; Doxorubicin-P4/D10 conjugate; UNII-80168379AG; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-; DOXORUBICIN [MI]; (8S,10S)-10-(((2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracen; Prestwick0_000438; Prestwick1_000438; Prestwick2_000438; Prestwick3_000438; DOXORUBICIN [INN]; ADR; DOXORUBICIN [HSDB]; DOXORUBICIN [USAN]; Probes1_000151; Probes2_000129; DOXORUBICIN [VANDF]; SCHEMBL3243; DOXORUBICIN [MART.]; BSPBio_000456; BSPBio_001031; DOXORUBICIN [WHO-DD]; (1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-(3-amino-2,3,6-tridesoxy-alpha-L-lyxo-hexopyranosid); (8S,10S)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 1,2,3,4,6,11-Hexahydro-4beta,5,12-trihydroxy-4-(hydroxyacetyl)-10-methoxy-6,11-dioxonaphthacen-1beta-yl-3-amino-2,3,6-trideoxy-alpha-L-lyxohexopyranoside; 10-((3-Amino-2,3,6-trideoxy-D-lyxohexopyranosyl)oxy)-8-glycolcyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Caelyx (liposomal doxorubicin); SPBio_002395; BPBio1_000502; cid_443939; GTPL7069; Valrubicin impurity, doxorubicin; DTXSID8021480; BDBM22984; BDBM32022; HMS2089H06; (8S,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-8-GLYCOLOYL-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPHTHACENEDIONE; 5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-, (8S-CIS)-; GR-319; HY-15142A; LMPK13050001; MFCD00869292; AKOS015951330; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DB00997; SMP1_000106; NCGC00024415-35; NCGC00024415-37; NCGC00024415-38; NCGC00024415-40; NCGC00024415-41; NCGC00024415-42; NCGC00024415-61; BP-23114; A14403; C01661; D03899; EN300-120698; Epirubicin hydrochloride impurity, doxorubicin-; H11954; Q18936; A816625; BRD-K92093830-003-04-3; BRD-K92093830-003-25-8; VALRUBICIN IMPURITY, DOXORUBICIN [USP IMPURITY]; EPIRUBICIN HYDROCHLORIDE IMPURITY C [EP IMPURITY]; DAUNORUBICIN HYDROCHLORIDE IMPURITY D [EP IMPURITY]; EPIRUBICIN HYDROCHLORIDE IMPURITY, DOXORUBICIN- [USP IMPURITY]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (7S,9R)-7-[(2S,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-9-glycoloyl-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride; (7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (7S,9S)-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione;(7S,9S)-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S,10S)-10-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione; 1392315-46-6; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-; 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-	Approved	Approved Drug(s)	31703	DB00997	D07VLY	543.5	206	977	1.3	39	6	12	5	C27H29NO11	(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione	CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O	InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1	AOJJSUZBOXZQNB-TZSSRYMLSA-N
DN3LX1	Olutasidenib	Small molecule	Olutasidenib; 1887014-12-1; FT-2102; Rezlidhia; Olutasidenib [USAN]; 5-[[(1S)-1-(6-chloro-2-oxo-1H-quinolin-3-yl)ethyl]amino]-1-methyl-6-oxopyridine-2-carbonitrile; Olutasidenib (FT-2102); 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; FT2102; 5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 5-[[(1S)-1-(6-Chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino]-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; OLUTASIDENIB [INN]; UNII-0T4IMT8S5Z; OLUTASIDENIB [WHO-DD]; CHEMBL4297610; SCHEMBL17603134; GTPL10319; AMY16919; EX-A4523; BDBM50506474; example 26 [US9834539B2]; NSC818621; s8949; FT-2102FT-2102; NSC-818621; AC-36556; MS-25542; HY-114226; CS-0080183; D87221; 5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; PWV	Approved	Approved Drug(s)	118955396	DB16267	D07VYP	354.8	85.2	745	2.5	25	2	4	3	C18H15ClN4O2	5-[[(1S)-1-(6-chloro-2-oxo-1H-quinolin-3-yl)ethyl]amino]-1-methyl-6-oxopyridine-2-carbonitrile	CC(C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N	C[C@@H](C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N	InChI=1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1	NEQYWYXGTJDAKR-JTQLQIEISA-N
DFC4Y3	Fenofibrate	Small molecule	fenofibrate; 49562-28-9; Procetofen; Lipantil; Tricor; Lipanthyl; Antara; Lipidil; Fenobrate; Secalip; Triglide; Fenoglide; Finofibrate; Lipoclar; Lipofene; Proctofene; Fenogal; Lipirex; Lipofen; Sedufen; Elasterin; Fenotard; Protolipan; Ankebin; Lipidex; Lipifen; Liposit; Lipsin; Nolipax; Fenofibratum [INN-Latin]; Fenofibrato [INN-Spanish]; Lipantil (TN); Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate; Tricor (TN); propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; LF-178; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester; NSC 281319; Fenofibrate micronized; Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate; FNF; Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester; Elasterate; Procetofene; Luxacor; MFCD00133314; Fenofibrate delayed release; CHEMBL672; MLS000028515; CHEBI:5001; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate; isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; DTXSID2029874; Lofibra; U202363UOS; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-, 1-methylethyl ester; NSC-281319; NCGC00015437-10; Fenofibrato; Fenofibratum; SMR000058299; Supralip; CAS-49562-28-9; C20H21ClO4; propan-2-yl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate; TRICOR (MICRONIZED); Antara (micronized); DTXCID209874; Fenomax; Isopropyl 2-[p-(p-chlorobenzoyl)phenoxy]-2-methylpropionate; Pharmavit; FENOFIBRATE (MICRONIZED); Fulcro; CIP-Fenofibrate; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methylethyl ester; LCP-FenoChol; LCP-Feno; Triglide (TN); Fenofibrate IDD-P; Lipofen (TN); Antara (TN); CCRIS 7282; SR-01000000091; EINECS 256-376-3; LF 178; BRN 2062462; Procetoken; Isopropyl 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionate; UNII-U202363UOS; HSDB 7736; Fenofibrate,(S); GRS-027; Fenofibrate [USAN:USP:INN:BAN]; Prestwick_217; Spectrum_001250; Opera_ID_328; FENOFIBRATE [MI]; Prestwick0_000275; Prestwick1_000275; Prestwick2_000275; Prestwick3_000275; Spectrum2_001390; Spectrum3_001431; Spectrum4_000413; Spectrum5_001479; FENOFIBRATE [INN]; FENOFIBRATE [JAN]; Lopac-F-6020; FENOFIBRATE [HSDB]; FENOFIBRATE [USAN]; EC 256-376-3; F 6020; FENOFIBRATE [VANDF]; SCHEMBL4670; FENOFIBRATE [MART.]; Lopac0_000486; BSPBio_000150; BSPBio_003162; FENOFIBRATE [USP-RS]; FENOFIBRATE [WHO-DD]; KBioGR_000706; KBioSS_001730; MLS001148191; MLS002548878; BIDD:GT0574; DivK1c_000557; Fenofibrate (JAN/USP/INN); SPECTRUM1501010; SPBio_001380; SPBio_002369; FENOFIBRATE [EMA EPAR]; Fenofibrate, >=99%, powder; BPBio1_000166; Fenofibrate (Tricor, Trilipix); GTPL7186; HMS501L19; KBio1_000557; KBio2_001730; KBio2_004298; KBio2_006866; KBio3_002382; FENOFIBRATE [ORANGE BOOK]; NINDS_000557; FENOFIBRATE [EP MONOGRAPH]; FENOFIBRATE [USP IMPURITY]; HMS1568H12; HMS1921B17; HMS2090G20; HMS2092B05; HMS2095H12; HMS2231B14; HMS3259K03; HMS3261B13; HMS3369M13; HMS3649D20; HMS3655K12; HMS3712H12; isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate; Pharmakon1600-01501010; FENOFIBRATE [USP MONOGRAPH]; ALBB-028958; BCP21243; Tox21_110147; Tox21_300151; Tox21_500486; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid isopropyl ester; BDBM50085042; CCG-38996; NSC281319; NSC757822; s1794; AKOS005107777; Tox21_110147_1; AB03716; AC-4227; CS-0892; DB01039; LP00486; MS-2223; NC00452; NSC-757822; SDCCGSBI-0050470.P004; IDI1_000557; NCGC00015437-01; NCGC00015437-02; NCGC00015437-03; NCGC00015437-04; NCGC00015437-05; NCGC00015437-06; NCGC00015437-07; NCGC00015437-08; NCGC00015437-09; NCGC00015437-11; NCGC00015437-12; NCGC00015437-13; NCGC00015437-14; NCGC00015437-16; NCGC00015437-17; NCGC00015437-31; NCGC00021475-03; NCGC00021475-04; NCGC00021475-05; NCGC00021475-06; NCGC00021475-07; NCGC00021475-08; NCGC00253945-01; NCGC00261171-01; FENOFIBRATE (MICRONIZED) (fenofibrate; Fenofibrate, analytical reference material; HY-17356; SY052561; SBI-0050470.P003; DB-051642; AB00052196; EU-0100486; F0674; FT-0626400; FT-0654669; SW196525-4; C07586; D00565; AB00052196-15; AB00052196-16; AB00052196_17; AB00052196_18; A827746; Q419724; Q-201111; SR-01000000091-2; SR-01000000091-5; SR-01000000091-6; SR-01000000091-8; BRD-K50388907-001-05-6; BRD-K50388907-001-18-9; BRD-K50388907-001-20-5; SR-01000000091-16; Z1501485369; Fenofibrate, European Pharmacopoeia (EP) Reference Standard; Isopropyl 2-(4-(4-chlorobenzoyl)-phenoxy)-2-methylpropanoate; 1-methylethyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoicacidisopropylester; Fenofibrate, United States Pharmacopeia (USP) Reference Standard; Isopropyl (4''-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methyl-ethyl ester; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid Isopropyl Ester; Fenofibrate, Pharmaceutical Secondary Standard; Certified Reference Material; isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate;Fenofibrate; Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethylester	Approved	Approved Drug(s)	3339	DB01039	D07XGR	360.8	52.6	458	5.2	25	0	4	7	C20H21ClO4	propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate	CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl	CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl	InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3	YMTINGFKWWXKFG-UHFFFAOYSA-N
DA96HL	Telmisartan	Small molecule	Telmisartan; 144701-48-4; Micardis; Pritor; Kinzalmono; BIBR 277; Semintra; 4'-((1,7'-Dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid; BIBR-277; tolura; BIBR 277SE; Telmisartan [INN]; Telmisartan Teva; Telmisartan Actavis; C33H30N4O2; BIBR-277-SE; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid; BIBR-277SE; BIBR 277 SE; 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid; MFCD00918125; 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid; CHEMBL1017; U5SYW473RQ; BIBR-277 SE; CHEBI:9434; 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid; DTXSID8023636; C09CA07; (1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-; [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-; NCGC00095150-01; Telmisattan; Targit; 1261396-33-1; 2-(4-{[4-methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid; 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propyl-benzimidazol-1-yl]methyl]phenyl]benzoic acid; 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid; 4'[(1,4'-DIMETHYL-2'-PROPYL[2,6'-BI-1H-BENZIMIDAZOL]-1'-YL)METHYL][1,1'-BIPHENYL]-2-CARBOXYLIC ACID; DTXCID803636; Kinzal; Tazlok; Kinzal/Pritor; Micardis (TN); 4'-((1,7'-DIMETHYL-2'-PROPYL-1H,3'H-2,5'-BIBENZO[D]IMIDAZOL-3'-YL)METHYL)BIPHENYL-2-CARBOXYLIC ACID; SMR000466326; CAS-144701-48-4; Bay 68-9291; SR-01000759355; UNII-U5SYW473RQ; Telmisartana; Telmisartar; Telsite; Telday; HSDB 7590; 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid; 4'-[[4-METHYL-6-(1-METHYL-2-BENZIMIDAZOLYL)-2-PROPYL-1-BENZIMIDAZOLYL]METHYL]-2-BIPHENYLCARBOXYLIC ACID; Telmisartan [USAN:USP:INN:BAN]; Telmisartan- Bio-X; YM-086; BAY68-9291; Telmisartan (Micardis); CPD000466326; TELMISARTAN [MI]; Spectrum2_001976; Spectrum3_001089; Spectrum4_001261; Spectrum5_001053; TELMISARTAN [JAN]; TELMISARTAN [HSDB]; TELMISARTAN [USAN]; TELMISARTAN [VANDF]; SCHEMBL4464; TELMISARTAN [MART.]; BSPBio_002738; GTPL592; KBioGR_001842; TELMISARTAN [USP-RS]; TELMISARTAN [WHO-DD]; MLS000759432; MLS001076687; MLS001424174; MLS006011851; BIDD:GT0365; SPECTRUM1505261; TELMISARTAN TEVA PHARMA; SPBio_002131; TELMISARTAN [EMA EPAR]; Telmisartan (JP17/USP/INN); TELMISARTAN [GREEN BOOK]; KBio3_001958; TELMISARTAN [EP IMPURITY]; TELMISARTAN [ORANGE BOOK]; Telmisartan for system suitability; HMS1922P07; HMS2051P16; HMS2090P17; HMS2093M22; HMS2231P07; HMS3393P16; HMS3655C08; HMS3715L17; HMS3750E19; Pharmakon1600-01505261; TELMISARTAN [EP MONOGRAPH]; Telmisartan for peak identification; TELMISARTAN [USP MONOGRAPH]; ALBB-028954; BCP04513; ONDUARP COMPONENT TELMISARTAN; TWYNSTA COMPONENT TELMISARTAN; Tox21_111452; BBL029085; BDBM50043280; CCG-39514; DL-511; HB2558; NSC759811; s1738; STK624049; TOLUCOMBI COMPONENT TELMISARTAN; AKOS005557501; KINZALKOMB COMPONENT TELMISARTAN; PRITORPLUS COMPONENT TELMISARTAN; Telmisartan, >=98% (HPLC), solid; Tox21_111452_1; AB07687; AC-2013; AM90292; CS-1699; DB00966; KS-1215; NC00296; NSC 759811; NSC-759811; TELMISARTAN COMPONENT OF ONDUARP; TELMISARTAN COMPONENT OF TWYNSTA; BAY-68-9291; MICARDIS HCT COMPONENT TELMISARTAN; MICARDISPLUS COMPONENT TELMISARTAN; NCGC00095150-02; NCGC00095150-03; NCGC00095150-04; NCGC00095150-06; NCGC00095150-07; NCGC00095150-08; TELMISARTAN [EMA EPAR VETERINARY]; TELMISARTAN COMPONENT OF TOLUCOMBI; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid; BT164444; HY-13955; SY052776; TELMISARTAN COMPONENT OF KINZALKOMB; TELMISARTAN COMPONENT OF PRITORPLUS; BCP0726000055; SBI-0206733.P001; TELMISARTAN COMPONENT OF MICARDIPLUS; TELMISARTAN COMPONENT OF MICARDISPLUS; FT-0631170; FT-0674836; SW197676-3; T-170; T2861; C07710; D00627; EN300-123532; AB00639941-06; AB00639941-07; AB00639941_08; AB00639941_09; A808270; L001035; Q733186; Q-101933; SR-01000759355-4; SR-01000759355-5; BRD-K73999723-001-02-2; Z1551967334; Telmisartan, European Pharmacopoeia (EP) Reference Standard; Telmisartan, United States Pharmacopeia (USP) Reference Standard; Telmisartan, Pharmaceutical Secondary Standard; Certified Reference Material; 4-(1,4-Dimethyl-2-propyl-2,6-bi-1H-benzimidazol-1-yl)methyl-1,1-biphenyl-2-carboxylicacid; Telmisartan for peak identification, European Pharmacopoeia (EP) Reference Standard; Telmisartan for system suitability, European Pharmacopoeia (EP) Reference Standard; 2-[4-[[4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]phenyl]benzoic acid; 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid.; 4''-((1,4''-dimethyl-2''-propyl(2,6''-bi-1H-benzimidazol)-1''-yl)methyl)-(1,1''-biphenyl)-2-carboxylic acid; 4''-((4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid; 4''-[(1,4''-dimethyl-2''propyl[2,6''-bi-1H-benzimidazol]-1''-yl)methyl]-[1,1''-biphenyl]-2-carboxylic acid; 4''-[(1,7''-dimethyl-2''-propyl-1H,3''H-2,5''-bibenzimidazol-3''-yl)methyl][1,1''-biphenyl]-2-carboxylic acid; 4''-[(1,7''-dimethyl-2''-propyl-1H,3''H-2,5''-bibenzimidazol-3''-yl)methyl]biphenyl-2-carboxylic acid; 4'-((1,7'-Dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl)methyl)-[1,1'-biphenyl]-2-carboxylicacid; 4'-(1,7'-DIMETHYL-2'-PROPYL-1H-[2,5']BIBENZOIMIDAZOLYL-3'-YLMETHYL)-BIPHENYL-2-CARBOXYLIC ACID; 4'-[[2-n-Propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid; 4'-[[4-Methyl-6-(1-methyl-1H-benzimidazol-2-yl)-2-propyl-1H-benzimidazol-1-yl]methyl]biphenyl-2-carboxylic Acid; 4'-[2-n-propyl-4-methyl-6-(1-methyl benzimidazol-2-yl)benzimidazol-1-yl methyl]biphenyl-2-carboxylic acid; 4'-{[4-methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}-[1,1'-biphenyl]-2-carboxylic acid; TLS	Approved	Approved Drug(s)	65999	DB00966	D07XRU	514.6	72.9	831	6.9	39	1	4	7	C33H30N4O2	2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid	CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C	CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C	InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)	RMMXLENWKUUMAY-UHFFFAOYSA-N
DQ9U0S	Acalabrutinib	Small molecule	Acalabrutinib; 1420477-60-6; ACP-196; Calquence; Acalabrutinib (ACP-196); Acalabrutinib [INN]; Acalabrutinib(ACP196); I42748ELQW; 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide; Benzamide, 4-(8-amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl-; (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide; 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide; Acalabrutinib [USAN:INN]; acalabrutinibum; UNII-I42748ELQW; Calquence (TN); Benzamide, 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-; ACP-196;Acalabrutinib; ACALABRUTINIB [MI]; ACALABRUTINIB [JAN]; ACALABRUTINIB [USAN]; ACALABRUTINIB [WHO-DD]; ACP196; GTPL8912; Acalabrutinib (JAN/USAN/INN); CHEMBL3707348; SCHEMBL14637368; ACP 196; AMY5290; EX-A881; CHEBI:167707; DTXSID401026209; ACALABRUTINIB [ORANGE BOOK]; BDBM50175583; MFCD29472294; NSC791164; NSC800976; s8116; CCG-269407; CS-5356; DB11703; DS-3326; NSC-791164; NSC-800976; NCGC00479074-01; HY-17600; Example 6 [US20140155385 A1]; D10893; EN300-7369651; A857446; J-690166; Q23668732; Z2238902271; (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide;Acalabrutinib; (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide; 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-Benzamide; 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide	Approved	Approved Drug(s)	71226662	DB11703	D08ABQ	465.5	119	845	3	35	2	6	4	C26H23N7O2	4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide	CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5	CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5	InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1	WDENQIQQYWYTPO-IBGZPJMESA-N
D4IP9F	Lapatinib	Small molecule	Lapatinib; 231277-92-2; Lapatinib Ditosylate; Tykerb; GW572016; GW 572016; Lapatinib [INN]; Lapatinib base; Tyverb; 388082-78-8; Lapatinib (INN); Lapatinib free base; N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; Lapatinib (free base); 231277-92-2 (free base); GSK572016; FMM; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine; CHEMBL554; GW-572016; DTXSID7046675; CHEBI:49603; 0VUA21238F; NSC745750; GSK-572016; GW-572016X; 1210608-87-9; NCGC00167507-01; DTXCID5026675; 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-; 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-; N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine; n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine; GSK 572016; CAS-231277-92-2; GW-2016; Lapatinib [INN:BAN]; MFCD09264194; GW 282974X; C29H26ClFN4O4S; UNII-0VUA21238F; HSDB 8209; 1xkk; N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; Lapatinib, Free base; nchembio866-comp20; Kinome_3684; Kinome_3685; Lapatinib base- Bio-X; LAPATINIB [MI]; LAPATINIB [VANDF]; LAPATINIB [WHO-DD]; SCHEMBL8100; Lapatinib (GW572016); LAPATINIB [EMA EPAR]; BDBM5445; cid_208908; GTPL5692; EX-A402; BCPP000188; BCPP000189; HMS2089H10; HMS3244N06; HMS3244N10; HMS3244N14; HMS3744K11; Tykerb (TN) (Glaxo Smith Kline); BCP01874; Tox21_112505; NSC800780; AKOS005145766; Tox21_112505_1; AC-1314; BCP9000837; BCP9000838; CCG-270133; DB01259; NSC-745750; NSC-800780; SB16918; NCGC00167507-02; NCGC00167507-03; NCGC00167507-04; NCGC00167507-09; 913989-15-8; AS-14065; BC164610; HY-50898; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; AM20090641; FT-0659650; L0360; SW199101-5; A25184; D08108; EN300-117254; AB01273965-01; AB01273965-02; AB01273965-03; AB01273965_04; AB01273965_05; Q420323; Q-101353; SR-05000001472-1; BRD-K19687926-001-01-7; BRD-K19687926-379-02-5; GW572016;GW-572016;GW 572016; 1092929-10-6; GW-2016;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl] quinazolin-4-amine; N-{3-chloro-4-[(3-fluoro-benzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N3-Chloro-4-(3-fluorophenyl)methoxyphenyl-6-5-(2-methylsulfonylethylamino)methyl-2-furylquinazolin-4-amine	Approved	Approved Drug(s)	208908	DB01259	D08CDI	581.1	115	898	5.1	40	2	9	11	C29H26ClFN4O4S	N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl	InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)	BCFGMOOMADDAQU-UHFFFAOYSA-N
DS9G4P	Mipomersen	Small molecule	Mipomerson; Mipomersen [INN]; UNII-9GJ8S4GU0M; 9GJ8S4GU0M; DB05528	Approved	Approved Drug(s)	118984467	DB05528	D08CVQ	7177	2980	20600	-12	457	45	157	156	C230H324N67O122P19S19	1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione	CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1C(OC(C1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=O)(OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)O)S	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=S)(O)O[C@H]6C[C@@H](O[C@@H]6COP(=S)(O)O[C@H]7C[C@@H](O[C@@H]7COP(=S)(O)O[C@H]8C[C@@H](O[C@@H]8COP(=S)(O)O[C@H]9C[C@@H](O[C@@H]9COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=O)(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)O)S	InChI=1S/C230H324N67O122P19S19/c1-97-55-278(217(309)256-177(97)231)141-45-111(122(381-141)70-362-422(325,441)404-116-50-146(283-66-108(12)196(302)275-228(283)320)387-128(116)76-368-427(330,446)410-120-54-150(294-93-253-154-191(294)266-214(243)270-200(154)306)390-130(120)78-370-428(331,447)408-118-52-148(292-91-250-151-186(240)246-89-248-188(151)292)388-131(118)79-371-430(333,449)412-159-134(394-204(169(159)354-37-27-344-17)286-59-101(5)181(235)260-221(286)313)83-375-435(338,454)417-164-138(398-209(174(164)359-42-32-349-22)291-68-110(14)198(304)277-230(291)322)87-377-434(337,453)415-162-136(396-207(172(162)357-40-30-347-20)289-62-104(8)184(238)263-224(289)316)85-376-433(336,452)414-161-133(393-206(171(161)356-39-29-346-19)288-61-103(7)183(237)262-223(288)315)82-374-432(335,451)411-158-121(69-298)391-211(168(158)353-36-26-343-16)296-95-254-155-192(296)267-215(244)271-201(155)307)401-420(323,439)365-74-127-117(51-147(386-127)284-67-109(13)197(303)276-229(284)321)406-425(328,444)369-77-129-119(53-149(389-129)293-92-252-153-190(293)265-213(242)269-199(153)305)409-426(329,445)367-71-123-112(46-142(382-123)279-56-98(2)178(232)257-218(279)310)402-421(324,440)364-73-125-115(49-145(384-125)282-65-107(11)195(301)274-227(282)319)405-424(327,443)366-75-126-114(48-144(385-126)281-64-106(10)194(300)273-226(281)318)403-423(326,442)363-72-124-113(47-143(383-124)280-57-99(3)179(233)258-219(280)311)407-429(332,448)373-81-139-166(176(361-44-34-351-24)212(400-139)297-96-255-156-193(297)268-216(245)272-202(156)308)419-438(341,457)379-86-137-163(173(358-41-31-348-21)208(397-137)290-63-105(9)185(239)264-225(290)317)416-436(339,455)380-88-140-165(175(360-43-33-350-23)210(399-140)295-94-251-152-187(241)247-90-249-189(152)295)418-437(340,456)378-84-135-160(170(355-38-28-345-18)205(395-135)287-60-102(6)182(236)261-222(287)314)413-431(334,450)372-80-132-157(299)167(352-35-25-342-15)203(392-132)285-58-100(4)180(234)259-220(285)312/h55-68,89-96,111-150,157-176,203-212,298-299H,25-54,69-88H2,1-24H3,(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H,341,457)(H2,231,256,309)(H2,232,257,310)(H2,233,258,311)(H2,234,259,312)(H2,235,260,313)(H2,236,261,314)(H2,237,262,315)(H2,238,263,316)(H2,239,264,317)(H2,240,246,248)(H2,241,247,249)(H,273,300,318)(H,274,301,319)(H,275,302,320)(H,276,303,321)(H,277,304,322)(H3,242,265,269,305)(H3,243,266,270,306)(H3,244,267,271,307)(H3,245,268,272,308)/t111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,203+,204+,205+,206+,207+,208+,209+,210+,211+,212+,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?/m0/s1	XLTMQWVJFPYGMC-QVKFEXRMSA-N
DW8R0B	Fluvastatin	Small molecule	fluvastatin; 93957-54-1; Lescol; (3R,5S)-fluvastatin; 155229-75-7; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Cranoc; (+)-3R,5S-Fluvastatin sodium salt; (+)-(3R,5S)-fluvastatin; (3R,5S,E)-7-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; XU-62320; CHEBI:38565; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEMBL1078; Fluvastatin & Primycin; XU 62-320 (free acid); DTXSID2020636; NSC-758896; (-)-fluvastatin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-isopropyl-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; Prestwick2_000859; SCHEMBL2846; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; SCHEMBL556754; GTPL2951; DTXCID0065309; BDBM86704; CHEBI:93160; DTXSID201020962; HMS2089P06; HMS3259J15; Pharmakon1600-01504911; 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]- 3,5-dihydroxy-, (3R,5S,6E)-rel-; ACT03305; Tox21_302765; DL-108; HY-14664B; NSC758896; CCG-213323; NC00659; NCGC00256490-01; CAS-93957-54-1; CAS_93957-54-1; CS-0019897; EN300-51915; H11963; EN300-21702553; Q417942; SR-05000001489-1; BRD-K66296774-001-02-0; (3R,5S)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E)-(3R,5S)-7-[3-(4-Fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-; Fluvastatin sodium                                                      L1483	Approved	Approved Drug(s)	446155	DB01095	D08GHB	411.5	82.7	590	3.5	30	3	5	8	C24H26FNO4	(E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid	CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F	CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F	InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1	FJLGEFLZQAZZCD-MCBHFWOFSA-N
D8LFH2	Procarbazine	Small molecule	procarbazine; 671-16-9; Procarbazin; Ibenzmethyzin; Ibenzmethyzine; Procarbazin [German]; Procarbazina; Procarbazinum; Procarbazinum [INN-Latin]; N-Isopropyl-4-((2-methylhydrazinyl)methyl)benzamide; Procarbazina [INN-Spanish]; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; Procarbazine free base; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; Procarbacine; Ro 4-6467; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide; CB 400-497; 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide; Procarbazine (INN); Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-; MIH; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide; N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide; PCX; 671-16-9 (free base); DTXSID4021189; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-; CHEBI:71417; RO-4-6467 FREE BASE; 35S93Y190K; CB 400-497; Ibenzmethyzine; MIH; p-Toluamide, N-isopropyl-.alpha.-(2-methylhydrazino)-; 4-[(2-methylhydrazin-1-yl)methyl]-N-(propan-2-yl)benzamide; RO-4-6467; PROCARBAZINE [INN]; Procarbazine [INN:BAN]; N-Isopropyl-.alpha.-(2-methylhydrazino)-p-toluamide; CCRIS 2389; NSC 77213; HSDB 3250; NCGC00016438-01; Ro-4646711; CAS-366-70-1; IBZ; Ro-4-6467/1; EINECS 211-582-2; p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide; BRN 0958270; SR-01000763375; UNII-35S93Y190K; Procarbazine-[d3]; p-Toluamide, N-isopropyl-alpha-(2-methylhydrazino)-; SRI-10847; MBH (Salt/Mix); Matulane (Salt/Mix); Nathulane (Salt/Mix); Natunalar (Salt/Mix); Prestwick0_001112; Prestwick1_001112; Prestwick2_001112; Prestwick3_001112; PROCARBAZINE [MI]; PROCARBAZINE [HSDB]; SCHEMBL4656; CHEMBL1321; NCIOpen2_004074; PROCARBAZINE [VANDF]; BSPBio_001244; BIDD:GT0183; PROCARBAZINE [WHO-DD]; SPBio_003112; BPBio1_001369; DTXCID301189; GTPL7278; HMS2090J09; Pharmakon1600-01502326; BCP12198; Tox21_301738; HY-13733A; NSC759626; STL483417; AKOS015891211; AC-4547; CCG-213031; DB01168; NSC-759626; NCGC00016438-02; NCGC00016438-05; NCGC00255280-01; CAS-671-16-9; NCI60_041703; SRI-10847-09; SRI-10847-10; SRI-10847_11; SRI-10847_13; DB-082065; CS-0012387; FT-0737820; C07402; D08423; EN300-708801; A917829; Q418656; SR-01000763375-3; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide #; 4-[(2-methylhydrazinyl)methyl]-N-(propan-2-yl)benzamide	Approved	Approved Drug(s)	4915	DB01168	D08GYO	221.3	53.2	210	0.1	16	3	3	5	C12H19N3O	4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide	CC(C)NC(=O)C1=CC=C(C=C1)CNNC	CC(C)NC(=O)C1=CC=C(C=C1)CNNC	InChI=1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)	CPTBDICYNRMXFX-UHFFFAOYSA-N
DVXJ69	Levodopa	Small molecule	levodopa; L-dopa; 59-92-7; Dopar; 3,4-dihydroxy-L-phenylalanine; 3-Hydroxy-L-tyrosine; Bendopa; Larodopa; Levopa; 3,4-Dihydroxyphenylalanine; Brocadopa; Cidandopa; Insulamina; Maipedopa; Dopaidan; Dopalina; Dopasol; Eldopal; Eldopar; Pardopa; Prodopa; Syndopa; 3-(3,4-Dihydroxyphenyl)-L-alanine; (-)-Dopa; Dihydroxy-L-phenylalanine; Helfo-Dopa; Dopaflex; Deadopa; Dopal-fher; Doparkine; Dopaston; Dopastral; Eldopatec; Eurodopa; Doparl; Doprin; Veldopa; L-3,4-Dihydroxyphenylalanine; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; Dopa; Levedopa; Levodopum; L-o-Hydroxytyrosine; L-Tyrosine, 3-hydroxy-; (-)-3-(3,4-Dihydroxyphenyl)-L-alanine; Ledopa; 3,4-Dihydroxyphenyl-L-alanine; Dopaston SE; beta-(3,4-Dihydroxyphenyl)-L-alanine; L-(o-Dihydroxyphenyl)alanine; L-(-)-Dopa; L-3-Hydroxytyrosine; L-beta-(3,4-Dihydroxyphenyl)alanine; Weldopa; Parda; L-Dihydroxyphenylalanine; L-3-(3,4-Dihydroxyphenyl)alanine; C9H11NO4; (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; Ro 4-6316; beta-(3,4-Dihydroxyphenyl)alanine; Inbrija; CVT-301; alanine, 3-(3,4-dihydroxyphenyl)-, L-; dihydroxyphenylalanine; component of Sinemet; Dopar (TN); CHEBI:15765; beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine; L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine; Alanine, 3-(3,4-dihydroxyphenyl)-, (-)-; L(-)-Dopa; (-)-(3,4-Dihydroxyphenyl)alanine; NSC-118381; L-.beta.-(3,4-Dihydroxyphenyl)alanine; CHEMBL1009; .beta.-(3,4-Dihydroxyphenyl)-L-alanine; DTXSID9023209; L-(3,4-Dihydroxyphenyl)alanine; NSC118381; .beta.-(3,4-Dihydroxyphenyl)alanine; CAS-59-92-7; NCGC00016270-04; Biodopa; Cerepap; Laradopa; Sobiodopa; L-(3,4-Dihydroxyphenyl)-.alpha.-alanine; 46627O600J; MFCD00002598; V-1512; Helfo DOPA; beta-(3,4-Dihydroxyphenyl)-alpha-alanine; Atamet; Levodopum [INN-Latin]; BDBM50130192; L-O-Dihydroxyphenylalanine; L Dopa; L-3; CCRIS 3766; HSDB 3348; WLN: QVYZ1R CQ DQ; 3,4-Dihydroxyphenylalanine (VAN); SR-01000075384; EINECS 200-445-2; NSC 118381; L-3,4-Dihydrophenylalanine; Dopastone; Dopicar; Prolopa; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate; UNII-46627O600J; Prestwick_185; Levodopa (Sinemet); L-DOPA; Levodopa; Madopa (Salt/Mix); Levodopa [USAN:USP:INN:BAN:JAN]; Spectrum_000454; 4-dihydroxyphenylalanine; LEVODOPA [HSDB]; LEVODOPA [USAN]; LEVODOPA [INN]; LEVODOPA [JAN]; Carbidopa EP Impurity A; LEVODOPA [MI]; LEVODOPA [VANDF]; Prestwick0_000017; Prestwick1_000017; Prestwick2_000017; Prestwick3_000017; Spectrum2_000496; Spectrum4_000539; Spectrum5_001899; Lopac-D-9628; Levodopa (JP15/USP); LEVODOPA [MART.]; bmse000322; Epitope ID:150927; LEVODOPA [USP-RS]; LEVODOPA [WHO-DD]; LEVODOPA [WHO-IP]; DOPA, L-; 3, 4-Dihydroxyphenylalanine; Alanine,4-dihydroxyphenyl)-; LEVODOPA [EMA EPAR]; Lopac0_000454; SCHEMBL22655; BSPBio_000053; BSPBio_002354; KBioGR_001177; KBioSS_000934; L-4-5-Dihydroxyphenylalanine; MLS000028514; BIDD:GT0158; DivK1c_000452; SPECTRUM2300205; Levodopa (JP17/USP/INN); SPBio_000391; SPBio_001974; DHIVY COMPONENT LEVODOPA; DUOPA COMPONENT LEVODOPA; LEVODOPA [EP IMPURITY]; LEVODOPA [ORANGE BOOK]; BPBio1_000059; DTXCID303209; GTPL3639; LEVODOPA [EP MONOGRAPH]; RYTARY COMPONENT LEVODOPA; b-(3,4-Dihydroxyphenyl)alanine; LEVODOPA [USP MONOGRAPH]; WLN: QVYZ1R CQ DQ -L; 3, 4-Dihydroxy-L-phenylalanine; BDBM60928; HMS501G14; KBio1_000452; KBio2_000934; KBio2_003502; KBio2_006070; PARCOPA COMPONENT LEVODOPA; STALEVO COMPONENT LEVODOPA; LEVODOPUM [WHO-IP LATIN]; Alanine,4-dihydroxyphenyl)-, L-; CARBILEV COMPONENT LEVODOPA; CORBILTA COMPONENT LEVODOPA; DOPASNAP COMPONENT LEVODOPA; IPX203 COMPONENT LEVODOPA; L-(3, 4-Dihydroxyphenyl)alanine; NINDS_000452; HMS1568C15; HMS1922J14; HMS2090O08; HMS2093N04; HMS2095C15; HMS2230B04; HMS3261K10; HMS3712C15; LEVODOPA COMPONENT OF DHIVY; LEVODOPA COMPONENT OF DUOPA; Pharmakon1600-02300205; H-Phe{3,4-(OH)2}-OH; HY-N0304; IPX-203 COMPONENT LEVODOPA; LEVODOPA COMPONENT OF RYTARY; Levodopa;3,4-Dihydroxyphenylalanine; b-(3,4-Dihydroxyphenyl)-L-alanine; Inbrija (levodopa inhalation powder); LEVODOPA COMPONENT OF PARCOPA; LEVODOPA COMPONENT OF SINEMET; LEVODOPA COMPONENT OF STALEVO; Tox21_110338; Tox21_500454; CCG-39571; HB1925; L-3-(3,4-dihydroxy-phenyl)alanine; L-3-(3,4-dihydroxyphenyl)-Alanine; NSC759573; PDSP1_001541; PDSP2_001525; s1726; Alanine, 3-(3,4-dihydroxyphenyl)-; Alanine,4-dihydroxyphenyl)-, (-)-; LEVODOPA COMPONENT OF CARBILEV; LEVODOPA COMPONENT OF CORBILTA; LEVODOPA COMPONENT OF DOPASNAP; AKOS010396267; b-(3,4-Dihydroxyphenyl)-a-L-alanine; L-b-(3,4-Dihydroxyphenyl)-a-alanine; L-DOPA (3,4-Dihydroxyphenylalanine); .beta.-(3, 4-Dihydroxyphenyl)alanine; AC-8432; AM82124; CS-1945; DB01235; LP00454; NSC-759573; SDCCGMLS-0066924.P001; SDCCGSBI-0050439.P004; IDI1_000452; NCGC00015384-01; NCGC00016270-01; NCGC00016270-06; NCGC00016270-07; NCGC00016270-09; NCGC00016270-10; NCGC00016270-22; NCGC00093869-04; NCGC00261139-01; AS-13287; BP-12850; SMR000058312; SBI-0050439.P003; L-(3, 4-Dihydroxyphenyl)-.alpha.-alanine; D0600; D9628; EU-0100454; EN300-52637; Alanine, 3-(3, 4-dihydroxyphenyl)-, (-)-; C00355; D 9628; D00059; D70595; 3,4-Dihydroxy-L-phenylalanine, >=98% (TLC); AB00052418-06; AB00052418-07; AB00052418_08; AB00052418_09; A832543; Q300989; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoicacid; Q-201294; SR-01000075384-1; SR-01000075384-4; SR-01000075384-6; SR-01000075384-7; (S)-2-Amino-3-(3,4-dihydroxy-phenyl)-propionic acid; F0347-4695; Levodopa, British Pharmacopoeia (BP) Reference Standard; Levodopa, European Pharmacopoeia (EP) Reference Standard; Z756440064; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acidL-dopa; 1E83F927-C221-46AA-B90A-81B33C5F3868; 3,4-Dihydroxy-L-phenylalanine, Vetec(TM) reagent grade, 98%; LEVODOPA COMPONENT OF LEVODOPA/CARBIDOPA/ENTACAPONE ORION; Levodopa, United States Pharmacopeia (USP) Reference Standard; LEVODOPA/CARBIDOPA/ENTACAPONE ORION COMPONENT LEVODOPA; 3,4-Dihydroxy-L-phenylalanine, certified reference material, TraceCERT(R); Levodopa, Pharmaceutical Secondary Standard; Certified Reference Material; 122769-74-8; 65170-01-6; L-Methyldopa ; (2S)-2-Amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; 3-(3,4-Dihydroxyphenyl)-?-methyl-L-alanine; 3-Hydroxy-a-methyl-L-tyrosine	Approved	Approved Drug(s)	6047	DB01235	D08HVR	197.19	104	209	-2.7	14	4	5	3	C9H11NO4	(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid	C1=CC(=C(C=C1CC(C(=O)O)N)O)O	C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O	InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1	WTDRDQBEARUVNC-LURJTMIESA-N
DR36KO	Tofacitinib	Small molecule	Tofacitinib; Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; 1259404-17-5; rac-Tofacitinib; CP-690,550; Tofacitinib (CP-690550,Tasocitinib); 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; Tofacitinib [USAN]; Cp-690 free base; CP690550; CHEMBL221959; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; C16H20N6O; CHEBI:71200; racemic-Tasocitinib; 87LA6FU830; CP-690550 FREE BASE; CP-690,550 FREE BASE; 477600-75-2 (free base); Tofacitinib (USAN); CP690,550; CP-690-550; 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile; MFCD11035919; 3-[(3R*,4R*)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo(2,3-d)pyrimidin-4-yl-, (3R,4R)-; Tofacitinib [USAN:INN]; tofacitinibum; UNII-87LA6FU830; 3eyg; 3fup; 3lxk; 4oti; 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile; MI1; TOFACITINIB [MI]; (+)-TOFACITINIB; TOFACITINIB [INN]; TOFACITINIB [VANDF]; TOFACITINIB [WHO-DD]; SCHEMBL322753; Tofacitinib (CP-690550); GTPL5677; HSDB 8311; AMY3992; DTXSID90197271; EX-A205; BCPP000274; BDBM50193995; NSC782351; NSC800953; s2789; AKOS005145814; AKOS005258733; AC-8193; BCP9000550; CCG-264998; CS-0050; DB08895; GS-6106; NSC-782351; NSC-800953; NCGC00229511-02; NCGC00229511-04; NCGC00229511-10; NCGC00244463-01; Tofacitinib (CP-690550, Tasocitinib); HY-40354; A7301; CP- 690 550; D09970; AB01565786_02; EN300-1718468; AR-270/43507983; J-524314; Q3530324; BRD-K31283835-001-01-9; BRD-K31283835-048-04-4; 3-((3R,4R)-4-Methyl(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yi)Amino)Piperidin-1-Yl-3-Oxopropaneni; (3R,4R)-3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine propanenitrile; 1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-.BETA.-OXO-, (3R,4R)-; 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidyl]-3-oxo-propanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]piperidin-1-yl}-3-oxo-propionitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; 3-{4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidinyl}-3-oxopropanenitrile; Tofacitinib;3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile	Approved	Approved Drug(s)	9926791	DB08895	D08ICX	312.37	88.9	488	1.5	23	1	5	3	C16H20N6O	3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile	CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1	UJLAWZDWDVHWOW-YPMHNXCESA-N
D8EI2Z	Amlodipine	Small molecule	amlodipine; 88150-42-9; Norvasc; AMLODIPINE BASE; Amlodipino; Amlodipinum; Caduet; Istin; Amlodipine Free Base; Amvaz; Amlodis; CHEBI:2668; 3-ethyl 5-methyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; Norvasc (TN); Amlocard; Coroval; Lipinox; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; UK-4834011; Amlodipinum [Latin]; HGP0904; Amlodipino [Spanish]; 88150-42-9 (free base); HGP-0904; Amdepin; Amdipin; Amlodin; Pelmec; CKD-330 COMPONENT AMLODIPINE; MFCD00864687; (R)-Amlodipine-d4; (S)-Amlodipine-d4; 1J444QC288; 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; Amlodipine [INN:BAN]; Racemic Amlodipine; (RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; SR-05000001461; NCGC00165957-04; Amlodipine 100 microg/mL in Acetonitrile; UNII-1J444QC288; HSDB 7079; 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 2-[2-aminoethoxymethyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; amlodipine (NORVASC); AMLODIPINE [MI]; Amlodipine (USP/INN); AMLODIPINE [INN]; Spectrum2_000486; Spectrum3_001004; Spectrum4_001132; Spectrum5_001550; AMLODIPINE [VANDF]; EC 425-820-1; AMLODIPINE [MART.]; AMLODIPINE [WHO-DD]; CHEMBL1491; SCHEMBL26478; BSPBio_002727; KBioGR_001643; MLS001401409; AMLODIPINE [EMA EPAR]; BIDD:GT0810; SPBio_000351; GTPL6981; AMLODIPINE [ORANGE BOOK]; CHEMBL3211346; CHEMBL3304444; DTXSID7022596; KBio3_001947; Copalia (amlodipine + valsartan); Morphine Sulfate Pentahydrate USP; BCPP000403; HMS2052N03; HMS2089H07; HMS2231K08; HMS3370G17; HMS3394N03; HMS3651I04; HMS3713C10; BCP02420; HY-B0317; BDBM50088383; s1905; STL356053; AKOS015843475; AC-4535; BCP9000295; CCG-101157; CCG-220414; DB00381; NC00407; NCGC00165957-01; NCGC00165957-02; NCGC00165957-03; NCGC00165957-05; NCGC00165957-07; 3-Ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; 3-Ethyl-5-methyl (+-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; AS-13747; BA164164; CPD000469198; O3-ethyl O5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; SMR000469198; SY104813; UK-48340; FT-0602653; FT-0657130; FT-0662111; FT-0662112; SW220228-1; C06825; D07450; EN300-708796; AB01209618-01; AB01274726-01; AB01274726-02; AB01274726_03; AB01274726_04; AB01274726_05; A842481; Q411347; Katerzia&reg (amlodipine oral suspension, 1 mg/mL); SR-05000001461-3; SR-05000001461-4; SR-05000001461-5; BRD-A22032524-074-02-4; BRD-A22032524-074-03-2; BRD-A22032524-074-04-0; 2-(2-aminoethoxy)methyl-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 2-[(2-Aminoethoxy)-methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5- pyridinedicarboxylic acid 3-ethyl 5-methyl ester benzene sulfonate; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methylester; 2-[2-Aminoethoxymethyl]-3-ethoxycarbonyl-4-(2-chlorophenyl)-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 3,5-PYRIDINEDICARBOXYLIC ACID, 2-((2-AMINOETHOXY)METHYL)-4-(2-CHLOROPHENYL)-1,4-DIHYDRO-6-METHYL-, 3-ETHYL 5-METHYL ESTER, (+/-)-; 3-ETHYL 5-METHYL (+/-)-2-((2-AMINOETHOXY)METHYL)-4-(O-CHLOROPHENYL)-1,4-DIHYDRO-6-METHYL-3,5-PYRIDINEDICARBOXYLATE; 3-ethyl 5-methyl ester 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid; 3-Ethyl 5-methylester, (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (.+/-.)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-ethyl5-methyl2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-ethyl 5-O-methyl 4-(2-chlorophenyl)-1-deuterio-2-[2-(dideuterioamino)ethoxymethyl]-6-methyl-4H-pyridine-3,5-dicarboxylate	Approved	Approved Drug(s)	2162	DB00381	D08JIV	408.9	99.9	647	3	28	2	7	10	C20H25ClN2O5	3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN	InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3	HTIQEAQVCYTUBX-UHFFFAOYSA-N
D7CHN2	Minocycline	Small molecule	minocycline; 10118-90-8; Minocyclin; Minociclina; Dynacin; Minocin; Minomycin; CL 59806; MINO; Minocyn; 7-Dimethylamino-6-demethyl-6-deoxytetracycline; CHEBI:50694; FYY3R43WGO; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; Tri-minocycline; (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; Minocyclinum; DTXSID1045033; Minocyclinum [INN-Latin]; NCGC00183044-01; Borymycin; Minociclina [INN-Spanish]; 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-; MIY; minociclinum; Minocline; Minoz; UNII-FYY3R43WGO; HSDB 3130; NSC-141993; Minocin (Hydrochloride); Vectrin (Hydrochloride); Minocycline (USAN/INN); BRN 3077644; Lactoferrin B & Minocycline; Lactoferrin H & Minocycline; Minocycline [USAN:INN:BAN]; SR-05000001675; (minocycline); (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2- CARBOXAMIDE; (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; NSC141993; Spectrum_000967; MINOCYCLINE [MI]; Prestwick0_000315; Prestwick1_000315; Prestwick2_000315; Spectrum2_001047; Spectrum3_000508; Spectrum4_000062; Spectrum5_001293; MINOCYCLINE [INN]; MINOCYCLINE [HSDB]; MINOCYCLINE [USAN]; MINOCYCLINE [VANDF]; SCHEMBL4042; CHEMBL1434; MINOCYCLINE [MART.]; SCHEMBL24315; BSPBio_002035; KBioGR_000583; KBioSS_001447; MINOCYCLINE [WHO-DD]; 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S-(4alpha,4aalpha,5aalpha,12aalpha))-; CHEMBL69484; DivK1c_000450; SPBio_000974; SPBio_002529; DTXCID9025033; SCHEMBL16681149; BCBcMAP01_000027; GTPL10831; KBio1_000450; KBio2_001447; KBio2_004015; KBio2_006583; KBio3_001535; NINDS_000450; HMS2090D03; KUC106429N; (4S,4aS,5aR,12aS)4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide;(4S,4aS,5aR,12aS)4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide; 2-NAPHTHACENECARBOXAMIDE, 4,7-BIS(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-, (4S-(4.ALPHA.,4A.ALPHA.,5A.ALPHA.,12A.ALPHA.))-; KSC-12-231B; Tox21_113643; BDBM50103599; HY-17412A; LMPK07000002; AKOS015969674; BCP9000928; CL59806; DB01017; IDI1_000450; SMP1_000191; NCGC00178854-01; NCGC00178854-02; NCGC00188954-01; AC-30184; CL-59806; SBI-0051449.P003; CAS-10118-90-8; AM20090714; CS-0009521; TIGECYCLINE IMPURITY C [EP IMPURITY]; C07225; D05045; D78303; AB00053501-03; AB00053501_04; AB00053501_05; EN300-7481098; Q415336; J-500789; SR-05000001675-3; (2E,4S,4aR,5aS,12aR)-2-(amino-hydroxy-methylidene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3 ,12-trione	Approved	Approved Drug(s)	54675783	DB01017	D08LTU	457.5	165	971	-0.6	33	5	9	3	C23H27N3O7	(4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide	CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C	InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1	FFTVPQUHLQBXQZ-KVUCHLLUSA-N
DG2C6D	Ribociclib	Small molecule	Ribociclib; 1211441-98-3; LEE011; Ribociclib (LEE011); LEE-011; Kisqali; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; LEE 011; LEE011A; UNII-TK8ERE8P56; TK8ERE8P56; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; LEE-011A; 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; 7-Cyclopentyl-N,N-dimethyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-Cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; Ribociclib [INN]; Ribociclib, LEE011; Ribociclib [USAN:INN]; Ribociclib-[d6]; RIBOCICLIB [MI]; Ribociclib (USAN/INN); RIBOCICLIB [USAN]; NVP-LEE011; RIBOCICLIB [WHO-DD]; SCHEMBL302310; GTPL7383; CHEMBL3545110; EX-A304; BDBM148264; DTXSID201021027; HMS3653N03; HMS3673I19; HMS3748M05; example 74 [US8962630]; AMY16792; BCP08804; MFCD27976795; NSC778909; NSC794613; NSC800867; s7440; AKOS025404915; AKOS032949987; CCG-269070; CS-1750; DB11730; NSC-778909; NSC-794613; NSC-800867; SB18480; NCGC00386317-10; NCGC00386317-11; AC-30029; AS-10159; DA-35904; HY-15777; LEE-011; LEE 011;LEE011; FT-0700117; SW220101-1; D10883; EN300-7409093; US8962630, 74; A858033; J-690066; Q27088552; 6-(1H-Indazol-6-yl)-N-[4-(4-morpholinyl)phenyl]-Imidazo[1,2-a]pyrazin-8-amine; 6ZZ; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; 7H-PYRROLO(2,3-D)PYRIMIDINE-6-CARBOXAMIDE, 7-CYCLOPENTYL-N,N-DIMETHYL-2-((5-(1-PIPERAZINYL)-2-PYRIDINYL)AMINO)-	Approved	Approved Drug(s)	44631912	DB11730	D08MXP	434.5	91.2	636	2.2	32	2	7	5	C23H30N8O	7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide	CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5	CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5	InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)	RHXHGRAEPCAFML-UHFFFAOYSA-N
D9N5PC	Brigatinib	Small molecule	Brigatinib; 1197953-54-0; ALUNBRIG; AP-26113; Brigatinib [USAN]; Brigatinib (AP-26113); HYW8DB273J; AP 26113; (2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine; 2,4-Pyrimidinediamine, 5-chloro-N4-(2-(dimethylphosphinyl)phenyl)-N2-(2-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)-; 5-Chloro-N4-(2-(dimethylphosphoryl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1- yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-; 5-Chloro-N~4~-[2-(Dimethylphosphoryl)phenyl]-N~2~-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl)piperidin-1-Yl]phenyl}pyrimidine-2,4-Diamine; 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine; UNII-HYW8DB273J; Brigatiib; Alunbrig (TN); 5-Chloro-N4-(2-(dimethylphosphoryl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; 6GY; BRIGATINIB [MI]; BRIGATINIB [INN]; BRIGATINIB [JAN]; Brigatinib (JAN/USAN); Brigatinib [USAN:INN]; Brigatinib; AP26113; Brigatinib (AP26113); BRIGATINIB [WHO-DD]; GTPL7741; BRIGATINIB [ORANGE BOOK]; CHEMBL3545311; SCHEMBL11916361; EX-A775; DTXSID501027929; AMY10294; BCP17214; BDBM50185140; MFCD29472221; NSC784728; NSC787457; AKOS030257612; CS-4278; DB12267; NSC-784728; NSC-787457; SB40412; compound 11q [PMID: 27144831]; NCGC00483924-01; (2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone; 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-Pyrimidinediamine; AC-29958; AS-75176; HY-12857; DB-118419; FT-0700112; S8229; J3.535.964H; D10866; EN300-6477855; Q27456393; Z2512157852; (2-((5-CHLORO-2-((2-METHOXY-4-(4-(4-METHYLPIPERAZIN-1-YL)PIPERIDIN-1-YL)PHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)PHENYL)DIMETHYL-,.DELTA.5-PHOSPHANONE	Approved	Approved Drug(s)	68165256	DB12267	D08PIE	584.1	85.9	835	4.6	40	2	9	8	C29H39ClN7O2P	5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine	CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC	CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC	InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)	AILRADAXUVEEIR-UHFFFAOYSA-N
DVT5A1	Ethambutol	Small molecule	ethambutol; 74-55-5; Ethambutolum; Tibutol; Myambutol; Aethambutolum; D-Ethambutol; (+)-S,S-Ethambutol; Ethambutol Hydrochloride; (+)-ethambutol; (S,S)-ethambutol; (2S,2'S)-2,2'-(Ethane-1,2-diylbis(azanediyl))bis(butan-1-ol); Etambutolo [DCIT]; Etambutol [INN-Spanish]; Ethambutolum [INN-Latin]; S,S-Ethambutol; Diambutol; CHEBI:4877; (+)-2,2'-(Ethylenediimino)di-1-butanol; EMB; Purderal; (+)-N,N'-Bis(1-(hydroxymethyl)propyl)ethylenediamine; (2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; Ethambutol (INN); 8G167061QZ; (2R)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (2S,2'S)-; 1-Butanol,2,2'-(1,2-ethanediyldiimino)bis-, (2S,2'S)-; ETHAMBUTOL [INN]; (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol; (2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; Etambutolo; (2S)-2-[(2-{[(2S)-1-hydroxybutan-2-yl]amino}ethyl)amino]butan-1-ol; D-2,2'-(Ethylenediimino)di-1-butanol; D-2,2'-(Ethylenediimino)bis(1-butanol); 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (S-(R*,R*))-; 1-Butanol, 2,2'-(ethylenediimino)di-, (+)-; d,N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; Ethambutol [INN:BAN]; (R)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; NCGC00178864-03; UNII-8G167061QZ; HSDB 3078; Servambutol (TN); 95E; EINECS 200-810-6; Spectrum_001058; ETHAMBUTOL [MI]; Spectrum2_001014; Spectrum3_000426; Spectrum4_000545; Spectrum5_000702; ETHAMBUTOL [HSDB]; ETHAMBUTOL [VANDF]; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (R)-; Myambutol (dihydrochloride); SCHEMBL3399; ETHAMBUTOL [WHO-DD]; BSPBio_002012; KBioGR_001209; KBioSS_001538; CHEMBL44884; DivK1c_000561; SPBio_001167; CL 40881 (dihydrochloride); DTXSID8023006; KBio1_000561; KBio2_001538; KBio2_004106; KBio2_006674; KBio3_001232; NINDS_000561; DTXSID901028179; HY-B0535; BDBM50448407; DB00330; IDI1_000561; NCGC00178864-01; NCGC00178864-04; SBI-0051375.P003; C06984; D07925; D94801; E-3950; EN300-150035; AB00053473_04; AB00053473_05; Q412318; (S,S)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; BRD-K93231391-300-03-1; (+)-(S,S)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (2R*,2'R*)-2,2'-(Ethane-1,2-diyldiimino)dibutan-1-ol; (2S,2S)-2,2-(ETHANE-1,2-DIYLDIIMINO)DIBUTAN-1-OL; Ethambutol dihydrochloride, Antibiotic for Culture Media Use Only; (2S)-2-[2-[[(1S)-1-(hydroxymethyl)propyl]amino]ethylamino]butan-1-ol	Approved	Approved Drug(s)	14052	DB00330	D08QME	204.31	64.5	109	-0.1	14	4	4	9	C10H24N2O2	(2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol	CCC(CO)NCCNC(CC)CO	CC[C@@H](CO)NCCN[C@@H](CC)CO	InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1	AEUTYOVWOVBAKS-UWVGGRQHSA-N
D09KZO	Escitalopram	Small molecule	Escitalopram; 128196-01-0; (S)-Citalopram; S(+)-Citalopram; (+)-Citalopram; Seroplex; S-(+)-Citalopram; Esertia; Cipralex; Escitalopram [INN]; Esitol; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; Escitalopram (INN); CHEMBL1508; (s)-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile; 4O4S742ANY; CHEBI:36791; (+)-(S)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; LU-26-054; 5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-; 5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-; Esertia (TN); Escitalopram [INN:BAN]; escitalopramum; UNII-4O4S742ANY; 68P; Spectrum_001401; Tocris-1427; Spectrum2_000551; Spectrum3_001062; Spectrum4_001212; Spectrum5_001693; ESCITALOPRAM [MI]; Lopac-C-7861; ESCITALOPRAM [VANDF]; BIDD:PXR0135; SCHEMBL34948; BSPBio_002644; KBioGR_001644; KBioSS_001881; ESCITALOPRAM [WHO-DD]; SPBio_000621; GTPL7177; DTXSID8048440; HSDB 8410; KBio2_001881; KBio2_004449; KBio2_007017; KBio3_001864; HMS2089O08; ESCITALOPRAM [EP MONOGRAPH]; (S)-Citalopram;S-(+)-Citalopram; BCP12154; BDBM50302225; AKOS017343470; 2-METHOXYETHYLP-TOLUENESULFONATE; AC-1594; AC-4508; CS-2053; DB01175; SB17453; (1r)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-3h-isobenzofuran-5-carbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-isobenzofuran-5-carbonitrile; MRF-0000226; NCGC00015267-01; NCGC00015267-02; NCGC00015267-03; NCGC00015267-06; NCGC00025160-01; NCGC00178555-01; NCGC00178555-07; HY-14258; D07913; AB00698374-07; AB00698374-09; AB00698374_10; A805793; EN300-18530974; Q423757; J-005570; BRD-K70301876-034-02-0; (s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5 carbonitrile; S-(+)-1-(3-(DIMETHYLAMINO)PROPYL)-1-(P-FLUOROPHENYL)-5-PHTHALANCARBONITRILE; (S)-(+)-1-[3-(dimethylamino) propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile; (S)-(+)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile; S-(+)-5-ISOBENZOFURANCARBONITRILE, 1-(3-(DIMETHYLAMINO)PROPYL)-1-(4-FLUOROPHENYL)-1,3-DIHYDRO-	Approved	Approved Drug(s)	146570	DB01175	D08RBC	324.4	36.3	466	3.2	24	0	4	5	C20H21FN2O	(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile	CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F	CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F	InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1	WSEQXVZVJXJVFP-FQEVSTJZSA-N
DL82KO	Ibandronic acid	Small molecule	Ibandronic Acid; Ibandronate; 114084-78-5; Bonviva; Boniva; Bondenza; Ibandronic Acid Teva; Ibandronic Acid Accord; Ibandronic Acid Sandoz; (1-Hydroxy-3-(methyl(pentyl)amino)propane-1,1-diyl)diphosphonic acid; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid; {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid; Ibandronic acid (INN); CHEMBL997; UMD7G2653W; (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid; Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-; NSC-722623; Phosphonic acid, (1-hydroxy-3-(methylpentylamino)propylidene)bis-; Acid ibandronico; BFQ; IBANDRONIC ACID [INN]; Ibandronic acid [INN:BAN]; Iasibon; Bisphosphonate 2; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphono-propyl]phosphonic acid; SR-05000001496; UNII-UMD7G2653W; R484; 1-hydroxy-3-(methylpentylamino)propylidene bisphosphonic acid; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID; IBANDRONATE [VANDF]; SCHEMBL9183; IBANDRONIC ACID [MI]; BPH 24; GTPL3059; JMC515594 Compound 53; DTXSID5048340; IBANDRONIC ACID [MART.]; BDBM12577; HY-B0515A; IBANDRONIC ACID [WHO-DD]; HMS2090A13; IBANDRONIC ACID [EMA EPAR]; ACT05527; BCP13798; AC-521; MFCD00868772; AKOS015855723; DB00710; NSC 722623; AS-12948; FT-0602640; FT-0670253; D08056; EN300-304883; AB01275485-01; A803131; Q166825; J-003052; SR-05000001496-1; SR-05000001496-2; BRD-K08681769-323-01-1; 1-hydroxy-3-(methyl(pentyl)amino)propane-1,1-diyldiphosphonic acid; P,P'-[1-Hydroxy-3-(methylpentylamino)propylidene]bisphosphonic Acid; Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphono-propyl]phosphonic acid; sodium	Approved	Approved Drug(s)	60852	DB00710	D08SJZ	319.23	139	342	-4.1	19	5	8	9	C9H23NO7P2	[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid	CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O	CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O	InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)	MPBVHIBUJCELCL-UHFFFAOYSA-N
DDSZ48	Metoclopramide	Small molecule	metoclopramide; 364-62-5; Methochlopramide; Metochlopramide; Metaclopramide; Primperan; Reliveran; Reglan; Metaclopromide; Metoclol; Moriperan; Elieten; Plasil; Terperan; Maxolon; 2-Methoxy-5-chloroprocainamide; 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; Methoclopramide; Metoclopramida; Metoclopramidum; Plasil (pharmaceutical); Metoclopramidum [INN-Latin]; Metoclopramida [INN-Spanish]; 5-Chloro-2-methoxyprocainamide; Clopra; Gastromax; Maxeran; Metocobil; Metramid; Parmid; DEL 1267; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide; Methoxyclopramide; Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-; Metadrate; 4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide; CLOPRA-'YELLOW'; N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide; Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-; L4YEB44I46; DTXSID6045169; CHEBI:107736; 2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethyl)benzamide; NCGC00015643-07; 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide; o-Anisamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-; DTXCID4025169; o-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-; Megaldrate; Metoclopramide [INN:BAN:JAN]; Terperan (TN); CAS-364-62-5; Elieten (TN); EINECS 206-662-9; BRN 1884366; UNII-L4YEB44I46; Gimoli; Regla; Metochloropramide; HSDB 7841; Reglan (Salt/Mix); Maxolon (Salt/Mix); Paspertin (Salt/Mix); Spectrum_001638; 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide; CHEMBL86; Prestwick0_000209; Prestwick1_000209; Prestwick2_000209; Prestwick3_000209; Spectrum2_001720; Spectrum3_000504; Spectrum4_000964; Spectrum5_001449; Lopac-M-0763; Biomol-NT_000082; bmse000779; METOCLOPRAMIDE [MI]; METOCLOPRAMIDE [INN]; METOCLOPRAMIDE [JAN]; Lopac0_000762; SCHEMBL18629; BSPBio_000197; BSPBio_002027; GTPL241; KBioGR_001307; KBioSS_002118; Metoclopramide (JP17/INN); METOCLOPRAMIDE [HSDB]; cid_23659; DivK1c_000069; METOCLOPRAMIDE [VANDF]; SPBio_001740; SPBio_002118; METOCLOPRAMIDE [MART.]; US9132134, Metoclopramide; BPBio1_000217; BPBio1_001100; METOCLOPRAMIDE [WHO-DD]; Primperan (tablet) (Salt/Mix); BDBM48320; KBio1_000069; KBio2_002118; KBio2_004686; KBio2_007254; KBio3_001527; AMY8975; NINDS_000069; HMS2089G16; HMS3886P05; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; BCP30761; Gimoti (metoclopramide nasal spray); Tox21_110188; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (Mcp); METOCLOPRAMIDE [EP MONOGRAPH]; MFCD00211338; s5862; STL257058; (metaclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; (metoclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide(Metoclopramide); AKOS000280832; Tox21_110188_1; CCG-204847; CS-1064; DB01233; KS-5055; SDCCGSBI-0050740.P005; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide); IDI1_000069; NCGC00015643-01; NCGC00015643-02; NCGC00015643-03; NCGC00015643-04; NCGC00015643-05; NCGC00015643-06; NCGC00015643-08; NCGC00015643-09; NCGC00015643-11; NCGC00015643-13; NCGC00015643-18; NCGC00024440-03; NCGC00024440-04; AC-37197; HY-17382; NCI60_003185; CAS-7232-21-5; SBI-0050740.P004; AB00053498; FT-0628931; M2218; C07868; D00726; EN300-119507; AB00053498-13; AB00053498_14; A823256; L001078; Metoclopramide, VETRANAL(TM), analytical standard; Q421095; BRD-K75641298-001-01-5; BRD-K75641298-003-05-2; BRD-K75641298-003-16-9; Z2196779550; 2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethylbenzamide; Metoclopramide, European Pharmacopoeia (EP) Reference Standard; N-(2-diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide; 4-Amino-5-chloro-2-methoxy-N-(.beta.-diethylaminoethyl)benzamide; 4-amino-5-chloro-N-[2-(diethylamino)-ethyl]-2-methoxybenzamide; 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-benzamide;hydrochloride; 4-azanyl-5-chloranyl-N-[2-(diethylamino)ethyl]-2-methoxy-benzamide;hydrochloride	Approved	Approved Drug(s)	4168	DB01233	D08VYV	299.79	67.6	300	2.6	20	2	4	7	C14H22ClN3O2	4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide	CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl	CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl	InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)	TTWJBBZEZQICBI-UHFFFAOYSA-N
DD8GO3	Nafarelin	Small molecule	NAFARELIN; 76932-56-4; Nafareline; NAFARELIN ACETATE; 1X0094V6JV; Nafarelinum; Nafarelina; Nafareline [French]; Nafarelinum [Latin]; Nafarelina [Spanish]; Nafarelin [INN:BAN]; (S)-1-(((R)-2-((S)-2-((S)-2-((S)-2-((S)-3-(1H-imidazol-4-yl)-2-((S)-5-oxopyrrolidine-2-carboxamido)propanamido)-3-(1H-indol-3-yl)propanamido)-3-hydroxypropanamido)-3-(4-hydroxyphenyl)propanamido)-3-(naphthalen-2-yl)propanoyl)-L-leucyl-L-arginyl)-N-(2-amino-2-oxoethyl)pyrrolidine-2-carboxamide; NAFARELIN [INN]; UNII-1X0094V6JV; LHRH, Ala(2-naphthyl)(6)-; HS-2018; NAFARELIN [MI]; NAFARELIN [VANDF]; NAFARELIN [WHO-DD]; (D-2-Nal6)-LHRH; SCHEMBL22518; BIDD:GT0760; GTPL3902; BDBM84707; DTXSID001031284; AKOS015895038; CCG-270673; DB00666; C76463; EN300-7480908; Q3869873; 5-OXOPRO-HIS-TRP-SER-TYR-D-NAL(2)-LEU-ARG-PRO-GLY-NH2; (S)-1-((3S,6S,9S,12S,15R,18S,21S)-3-((1H-imidazol-5-yl)methyl)-6-((1H-indol-3-yl)methyl)-21-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-18-isobutyl-15-(naphthalen-2-ylmethyl)-1,4,7,10,13,16,19-heptaoxo-1-((S)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-N-(2-amino-2-oxoethyl)pyrrolidine-2-carboxamide	Approved	Approved Drug(s)	25077405	DB00666	D08WYM	1322.5	475	2730	0.8	96	16	15	33	C66H83N17O13	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide	CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC3=CC=CC=C3C=C2)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CC3=CC=CC=C3C=C2)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8	InChI=1S/C66H83N17O13/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71)/t46-,47-,48-,49-,50+,51-,52-,53-,54-/m0/s1	RWHUEXWOYVBUCI-ITQXDASVSA-N
D2UDZ4	Tolazamide	Small molecule	tolazamide; 1156-19-0; Tolinase; Norglycin; Tolanase; Diabewas; Tolazolamide; Tolazamida; Tolazamidum; 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea; U-17835; N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea; NSC-70762; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea; 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide; NCI-C03327; 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea; U 17835; CCRIS 591; Urea, 1-(hexahydroazepin-1-yl)-3-p-tolylsulfonyl-; EINECS 214-588-3; Urea, 1-(hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)-; BRN 1323565; Benzenesulfonamide, N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-; N-(azepan-1-ylcarbamoyl)-4-methylbenzenesulfonamide; 9LT1BRO48Q; Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methyl-; MLS000028534; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-toluenesulfonyl)urea; CHEBI:9613; N-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide; DTXSID3021358; N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide; NSC70762; NCGC00016009-10; SMR000058290; CAS-1156-19-0; Tolazamidum [INN-Latin]; Tolazamida [INN-Spanish]; DTXCID401358; 1-(((((4-Methylphenyl)sulfonyl)amino)carbonyl)amino)azepane; Tolinase (TN); HSDB 3192; SR-01000003105; NSC 70762; UNII-9LT1BRO48Q; 1-[(Azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide; 1-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]azepane; Ronase; AI3-50826; N-{[(hexahydro-1H-azepin-1-yl)-amino]carbonyl}-4-methylbenzenesulfonamide; Prestwick_865; Tolazamide [USAN:USP:INN:BAN:JAN]; Spectrum_001269; TOLAZAMIDE [MI]; TOLAZAMIDE [INN]; TOLAZAMIDE [JAN]; Opera_ID_1740; Prestwick0_000554; Prestwick1_000554; Prestwick2_000554; Prestwick3_000554; Spectrum2_001449; Spectrum3_001473; Spectrum4_000240; Spectrum5_001204; Lopac-T-2408; TOLAZAMIDE [HSDB]; TOLAZAMIDE [USAN]; TOLAZAMIDE [VANDF]; CHEMBL817; Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methyl-; T 2408; TOLAZAMIDE [MART.]; 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea; NCIOpen2_008361; TOLAZAMIDE [USP-RS]; TOLAZAMIDE [WHO-DD]; CBiol_001918; Lopac0_001195; Oprea1_061180; SCHEMBL34417; BSPBio_000627; BSPBio_001505; BSPBio_003025; KBioGR_000225; KBioGR_000939; KBioSS_000225; KBioSS_001749; Tolazamide (JAN/USP/INN); 1-(azepan-1-yl)-3-(4-methylbenzenesulfonyl)urea; 5-20-04-00062 (Beilstein Handbook Reference); MLS001076161; DivK1c_000212; SPECTRUM1501201; SPBio_001317; SPBio_002548; BPBio1_000691; GTPL6847; WLN: T7NTJ AMVMSWR D1; TOLAZAMIDE [ORANGE BOOK]; BCBcMAP01_000061; HMS500K14; KBio1_000212; KBio2_000225; KBio2_001749; KBio2_002793; KBio2_004317; KBio2_005361; KBio2_006885; KBio3_000449; KBio3_000450; KBio3_002525; NINDS_000212; Bio1_000204; Bio1_000693; Bio1_001182; Bio2_000225; Bio2_000705; HMS1361L07; HMS1569P09; HMS1791L07; HMS1921P19; HMS1989L07; HMS2089L10; HMS2092L09; HMS2096P09; HMS2232L21; HMS3259O18; HMS3263P11; HMS3369L04; HMS3402L07; HMS3713P09; Pharmakon1600-01501201; TOLAZAMIDE [USP MONOGRAPH]; BCP23550; HY-B0920; Tox21_110281; Tox21_201507; Tox21_300416; Tox21_501195; CCG-39178; NSC758149; AKOS015913823; N-[[(Hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methylbenzenesulfonamide; Tox21_110281_1; DB00839; KS-1438; LP01195; NC00590; NSC-758149; SDCCGSBI-0051162.P004; Benzenesulfonamide, {N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-}; IDI1_000212; IDI1_033975; NCGC00016009-01; NCGC00016009-02; NCGC00016009-03; NCGC00016009-04; NCGC00016009-05; NCGC00016009-06; NCGC00016009-07; NCGC00016009-08; NCGC00016009-09; NCGC00016009-11; NCGC00016009-12; NCGC00016009-13; NCGC00016009-14; NCGC00016009-15; NCGC00016009-16; NCGC00016009-17; NCGC00016009-19; NCGC00016009-24; NCGC00023701-03; NCGC00023701-04; NCGC00023701-05; NCGC00023701-06; NCGC00023701-07; NCGC00023701-08; NCGC00023701-09; NCGC00023701-10; NCGC00254501-01; NCGC00259058-01; NCGC00261880-01; 1-(azepan-1-yl)-3-(p-tolylsulfonyl)urea; SBI-0051162.P003; AB00052247; EU-0101195; FT-0675268; SW196991-3; TOLBUTAMIDE IMPURITY C [EP IMPURITY]; C71499; D00379; AB00052247-15; AB00052247_16; AB00052247_17; A921617; 1-(azepan-1-yl)-3-[(4-methylbenzene)sulfonyl]urea; 3-(Azepan-1-yl)-1-(4-methylphenyl)Sulfonyl-Urea; Q7814101; SR-01000003105-2; SR-01000003105-4; SR-01000003105-5; SR-01000003105-8; W-109110; BRD-K32164935-001-06-8; BRD-K32164935-001-17-5; BRD-K32164935-001-28-2; F2173-1137; Z1575267190; 1-(4-Methylphenylsulfonyl)-3-(hexahydro-1H-azepin-1-yl)urea; 1-[(([(4-Methylphenyl)sulfonyl]amino)carbonyl)amino]azepane #; Tolazamide, United States Pharmacopeia (USP) Reference Standard; Benzenesulfonamide, N-[[(hexahydro-1-azepinyl)amino]carbonyl]-4-methyl-	Approved	Approved Drug(s)	5503	DB00839	D09FJB	311.4	86.9	431	1.5	21	2	4	3	C14H21N3O3S	1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2	InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)	OUDSBRTVNLOZBN-UHFFFAOYSA-N
D65TPD	Regorafenib	Small molecule	Regorafenib; 755037-03-7; BAY 73-4506; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; Regorafenibum; Regorafenib (BAY 73-4506); BAY73-4506; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; Regorafenib-13C-d3; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; REGORAFENIB ANHYDROUS; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Bay-734506; Stivarga (TN); Regorafenib (BAY73-4506,Fluoro-Sorafenib); 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide; Regorafenib [INN]; Regorafenib [USAN:INN]; UNII-24T2A1DOYB; C21H15ClF4N4O3; Fluoro-Sorafenib; 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl}amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide; REGORAFENIB [MI]; Regorafenib (USAN/INN); REGORAFENIB [VANDF]; REGORAFENIB [WHO-DD]; MLS006010303; Regorafenib crystalline form I; SCHEMBL432230; Regorafenib,BAY 73-4506; GTPL5891; DTXSID60226441; EX-A058; Regorafenib - BAY 73-4506; BCPP000352; HMS3654K16; HMS3672E15; BCP02105; BKD17855; BDBM50363397; MFCD16038047; NSC763932; NSC800865; s1178; AKOS015951107; AM81251; BAY 734506; BCP9000384; CCG-269571; CS-0170; DB08896; NSC-763932; NSC-800865; SB16819; NCGC00263138-01; NCGC00263138-13; NCGC00263138-19; 2-Pyridinecarboxamide,4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-; 835621-08-4; AC-25075; AC-31116; AS-16304; HY-10331; SMR004701370; FT-0674338; R0142; SW218097-2; cas:835621-07-3;Regorafenib hydrochloride; A25020; D10138; AB01565826_02; SR-01000941571; Q3891664; SR-01000941571-1; BRD-K16730910-001-02-4; Z2235801830; 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-; 4-[4-({[4-Chloro-3-(trifluoromethy)phenyl]carbamoyl}amino)-3-fluorophenoxy]-1-methylpyridine-2-carboxamide; 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide; Regorafenib;1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea	Approved	Approved Drug(s)	11167602	DB08896	D09GDD	482.8	92.4	686	4.2	33	3	8	5	C21H15ClF4N4O3	4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide	CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F	CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F	InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)	FNHKPVJBJVTLMP-UHFFFAOYSA-N
DG57XL	Tucatinib	Small molecule	Tucatinib; Irbinitinib; 937263-43-9; ONT-380; Tukysa; 6-DIAMINE; Irbinitinib(ARRY-380); N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 234248D0HH; Irbinitinib; ARRY-380; ONT-380; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine; Tucatinib [INN]; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine; UNII-234248D0HH; ONT 380; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine; Tukysa (TN); ONT-380;Tucatinib; TUCATINIB [MI]; Tucatinib (USAN/INN); Tucatinib [USAN:INN]; TUCATINIB [USAN]; Irbinitinib; ARRY-380; TUCATINIB [WHO-DD]; GTPL9922; SCHEMBL1193050; TUCATINIB [ORANGE BOOK]; CHEMBL3989868; BDBM471617; DTXSID601027958; BCP15983; EX-A1031; MFCD22380467; NSC764581; NSC799335; s8362; ARRY-380 (ONT-380); AKOS026750449; CCG-264747; CS-3906; DB11652; MK-7119; NSC-764581; NSC-799335; SB17126; US10822334, Compound ONT380; NCGC00482879-02; AC-33037; AS-56109; BT177688; HY-16069; Example 11 [WO2007059257A2]; DB-130430; A16413; D11141; A857335; EN300-24438049; Q25100690; 4,6-QuinazolinediaMine,N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; N6-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-N4-(3-methyl-4-{[1,2,4]triazolo[1,5-a]pyridin-7-yloxy}phenyl)quinazoline-4,6-diamine; N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine;; N6-(4,5-dihydro-4,4-dmethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-A)pyridin-7-Yloxy)phenyl)-4,6-quinazolinediamine	Approved	Approved Drug(s)	51039094	DB11652	D09GRX	480.5	111	796	4	36	2	8	6	C26H24N8O2	6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine	CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5	CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5	InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)	SDEAXTCZPQIFQM-UHFFFAOYSA-N
D6R7DU	Amoxapine	Small molecule	amoxapine; 14028-44-5; Asendin; Demolox; Moxadil; Amoxan; Desmethylloxapin; Amoxapina; Amoxapinum; Amoxepine; CL-67772; Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)-; CL 67772; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine; CL-67,772; CL 67,772; Asendis; NSC-759559; DIBENZ(b,f)(1,4)OXAZEPINE, 2-CHLORO-11-(1-PIPERAZINYL)-; CHEMBL1113; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; MLS000069371; 2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; CHEBI:2675; R63VQ857OT; DTXSID7022598; 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine; NCGC00015004-09; Ascendin; SMR000058416; CAS-14028-44-5; Amoxapinum [INN-Latin]; Amoxapina [INN-Spanish]; DTXCID102598; (E)-2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; Asendin (TN); SR-01000003001; EINECS 237-867-1; MFCD00069210; amoxipine; BRN 0832057; UNII-R63VQ857OT; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; Amoxapine-[d8]; Prestwick_503; Amoxapine [USAN:USP:INN:BAN:JAN]; KS-1197; Opera_ID_33; Spectrum_000446; CPD000058416; AMOXAPINE [INN]; AMOXAPINE [JAN]; AMOXAPINE [MI]; Lopac-A-129; AMOXAPINE [USAN]; Prestwick0_000102; Prestwick1_000102; Prestwick2_000102; Prestwick3_000102; Spectrum2_001245; Spectrum3_001067; Spectrum4_001218; Spectrum5_001284; AMOXAPINE [VANDF]; A-129; AMOXAPINE [MART.]; AMOXAPINE [USP-RS]; AMOXAPINE [WHO-DD]; Lopac0_000116; REGID_for_CID_2170; SCHEMBL33950; BSPBio_000084; BSPBio_002654; GTPL201; KBioGR_001656; KBioSS_000926; MALEICACIDMONOSODIUMSALT; DivK1c_000236; SPECTRUM2300161; SPBio_001150; SPBio_002023; Amoxapine (JP17/USP/INN); BPBio1_000094; AMOXAPINE [ORANGE BOOK]; 2-Chloro-11-(1-piperazinyl)dibenzo[b,f][1,4]oxazepine; 8-chloro-6-piperazin-1-yl-benzo[b][1,4]benzoxazepine; AMOXAPINE [USP IMPURITY]; BDBM22870; HMS500L18; KBio1_000236; KBio2_000926; KBio2_003494; KBio2_006062; KBio3_001874; AMOXAPINE [USP MONOGRAPH]; NINDS_000236; HMS1568E06; HMS2089G10; HMS2093N08; HMS2095E06; HMS2231E13; HMS3259G08; HMS3260G14; HMS3370P03; HMS3712E06; Pharmakon1600-02300161; HY-B0991; Tox21_110064; Tox21_302352; Tox21_500116; CCG-39135; NSC759559; PDSP1_001609; PDSP2_001593; s4218; AKOS015895092; Tox21_110064_1; AC-5495; CS-4485; DB00543; LP00116; NC00546; NSC 759559; SDCCGSBI-0050104.P004; IDI1_000236; NCGC00015004-01; NCGC00015004-02; NCGC00015004-03; NCGC00015004-04; NCGC00015004-05; NCGC00015004-06; NCGC00015004-07; NCGC00015004-08; NCGC00015004-10; NCGC00015004-11; NCGC00015004-13; NCGC00015004-16; NCGC00015004-22; NCGC00023887-03; NCGC00023887-04; NCGC00023887-05; NCGC00023887-06; NCGC00255124-01; NCGC00260801-01; 13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene; BA164170; SBI-0050104.P003; EU-0100116; FT-0659871; FT-0662122; A16406; D00228; EN300-123014; Q58356; T70258; AB00052421-13; AB00052421_14; AB00052421_15; A807639; L001293; J-007373; SR-01000003001-2; SR-01000003001-4; SR-01000003001-6; 8-chloro-6-piperazin-1-ylbenzo[b][1,5]benzoxazepine; BRD-K02265150-001-05-9; BRD-K02265150-001-15-8; 2-Chloro-11-(1-piperazinyl)dibenz[b,f]-1,4-oxazepine; 2-Chloro-11-(1-piperazinyl)dibenzo[b,f]-1,4-oxazepine; 2-Chloro-11-piperazin-1-yl-dibenzo[b,f][1,4]oxazepine; 8-chloro-6-(1-piperazinyl)benzo[b][1,4]benzoxazepine; 2-Chloro-11-(1-piperazinyl)dibenzo[b,f][1,4]oxazepine #; 8-chloranyl-6-piperazin-1-yl-benzo[b][1,4]benzoxazepine; Amoxapine, 1.0 mg/mL in methanol, certified reference material; Amoxapine, United States Pharmacopeia (USP) Reference Standard; Dibenzo[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)-; LOXAPINE SUCCINATE IMPURITY, AMOXAPINE- [USP IMPURITY]; Amoxapine, Pharmaceutical Secondary Standard; Certified Reference Material; 13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene; 13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,9,12,14-heptaene	Approved	Approved Drug(s)	2170	DB00543	D09IOI	313.8	36.9	424	2.6	22	1	3	1	C17H16ClN3O	8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine	C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl	C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl	InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2	QWGDMFLQWFTERH-UHFFFAOYSA-N
D1JM9W	Alendronic acid	Small molecule	ALENDRONIC ACID; alendronate; 66376-36-1; Fosamax; (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid; Arendal; Acido alendronico; Acide alendronique; Acidum alendronicum; bisphosphonate; (4-Amino-1-hydroxybutane-1,1-diyl)diphosphonic acid; (4-Amino-1-hydroxybutylidene)bisphosphonic acid; ABDP; (4-Amino-1-hydroxybutylidene)diphosphonic acid; 4-Amino-1-hydroxybutane-1,1-diphosphonic Acid; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-; MK 217; Alendronic acid (INN); (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid); MK-217; ALENDRONIC-D6 ACID; CHEMBL870; CHEBI:2567; X1J18R4W8P; Alendronate acid; (4-amino-1-hydroxy-1-phosphono-butyl)phosphonic acid; Acide alendronique [INN-French]; Acido alendronico [INN-Spanish]; Acidum alendronicum [INN-Latin]; ALENDRONIC ACID [INN]; P,P'-(4-Amino-1-hydroxybutylidene)bisphosphonic acid; Alendronic acid [INN:BAN]; Phosphonic acid, P,P'-(4-amino-1-hydroxybutylidene)bis-; bisphosphonate, 65; NCGC00096054-03; 4-Amino-1-hydroxybutylidene-1,1-bisphosphonate; UNII-X1J18R4W8P; 4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid); SR-05000001906; HSDB 7990; 1yhm; ABDP-d6; 4-Amino-1-hydroxybutane-1,1-diphosphonate; ALENDRONATE [VANDF]; ALENDRONATE [MART.]; BPH 1; Oprea1_422906; SCHEMBL18898; ALENDRONIC ACID [MI]; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis; BIDD:GT0180; SPECTRUM1505166; GTPL3141; DTXSID5022568; BDBM25313; 66376-36-1 (unlabeled); ALENDRONIC ACID [WHO-DD]; ALENDRONIC ACID [EMA EPAR]; HY-B0631; HSCI1_000337; MFCD00868112; s5536; AKOS001015793; DB00630; NCGC00096054-01; NCGC00096054-04; AS-10963; SBI-0206778.P001; CS-0009566; FT-0641064; 4-amino-1-hydroxybutylidene-bisphosphonic acid; C07752; D07119; D88506; 4-Amino-1- hydroxybutane-1,1-diphosphonate-d6; AB01274863-01; (4-Amino-1-Hydroxybutylidene)-Bisphosphonic Acid; 4-amino-1-hydroxybutane-1,1-diyldiphosphonic acid; A835441; Q420057; 2-BUTYLDECAHYDRONAPHTHALENE-1-CARBOXYLICACID; Q-200607; SR-05000001906-1; (4-amino-1-hydroxybutane-1,1-diyl)bisphosphonic acid; BRD-K75527158-323-01-3; Z56771118; (4-azanyl-1-oxidanyl-1-phosphono-butyl)phosphonic acid; .ALPHA.-HYDROXY-.DELTA.-AMINOBUTYLIDENEDIPHOSPHONIC ACID	Approved	Approved Drug(s)	2088	DB00630	D09KLR	249.1	161	257	-6.5	14	6	8	5	C4H13NO7P2	(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid	C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN	C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN	InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)	OGSPWJRAVKPPFI-UHFFFAOYSA-N
D0IJM3	Ezetimibe	Small molecule	Ezetimibe; 163222-33-1; Zetia; Ezetrol; Ezedoc; Sch 58235; (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; SCH58235; SCH-58235; Ezetimibe (Zetia); (3R,4S)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one; EOR26LQQ24; DTXSID1044223; CHEBI:49040; MK0653; NSC-758923; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone; DTXCID9024223; Zient; C24H21F2NO3; (-)-Sch 58235; (3~{R},4~{S})-1-(4-fluorophenyl)-3-[(3~{S})-3-(4-fluorophenyl)-3-oxidanyl-propyl]-4-(4-hydroxyphenyl)azetidin-2-one; 2-Azetidinone, 1-(4-fluorophenyl)-3-((3S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3R,4S)-; 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)-; SMR000466334; CAS-163222-33-1; Zetia (TN); UNII-EOR26LQQ24; ezetimiba; ezetimibum; Ezetimibe [USAN:INN:BAN]; Ezetimibe); MFCD00937872; HSDB 7737; ezetimibe anhydrate; Ezetimibe- Bio-X; NCGC00095134-01; Ezetimibe [USAN]; MK-0653; EZETIMIBE [INN]; EZETIMIBE [JAN]; EZETIMIBE [MI]; EZETIMIBE [HSDB]; EZETIMIBE [VANDF]; EZETIMIBE [MART.]; EZETIMIBE [USP-RS]; EZETIMIBE [WHO-DD]; SCHEMBL2871; CHEMBL1138; Ezetimibe (JAN/USP/INN); MLS000759443; MLS001424125; MLS006011921; GTPL6816; EZETIMIBE [ORANGE BOOK]; Ezetimibe, >=98% (HPLC); ROSZET COMPONENT EZETIMIBE; EX-A795; EZETIMIBE [USP MONOGRAPH]; VYTORIN COMPONENT EZETIMIBE; HMS2051K16; HMS2236A04; HMS3715D06; NEXLIZET COMPONENT EZETIMIBE; (3R,4S)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone; ACT03511; EZETIMIBE COMPONENT OF ROSZET; Tox21_111443; BDBM50371521; s1655; STK640490; EZETIMIBE COMPONENT OF VYTORIN; AKOS005572111; EZETIMIBE COMPONENT OF NEXLIZET; Tox21_111443_1; AC-1057; AM84560; CCG-100884; DB00973; KS-1170; NC00134; NSC 758923; NCGC00263575-01; NCGC00263575-07; (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)azetidin-2-one; 2-Azetidinone, 1-(4-fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3R-(3alpha(S*),4beta))-; BE164439; HY-17376; E1449; D01966; EN300-122361; AB00639916-06; AB00639916-08; AB00639916_09; AR-270/43507897; Q417997; 3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one; BRD-K42260897-001-09-2; Z1541759501; (3R,4S)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-; Ezetimibe, United States Pharmacopeia (USP) Reference Standard; Ezetimibe, Pharmaceutical Secondary Standard; Certified Reference Material; (3R,4S)-1-(4-fluorophenyl)-3-[(3 S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)- 3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(4-Fluorophenyl)-3-[(S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-azetidin-2-one; 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone; 2-AZETIDINONE, 1-(4-FLUOROPHENYL)-3-(3-(4-FLUOROPHENYL)-3-HYDROXYPROPYL)-4-(4-HYDROXYPHENYL)-, (3R-(3.ALPHA.(S*),4.BETA.))-; H56	Approved	Approved Drug(s)	150311	DB00973	D09LWS	409.4	60.8	567	4	30	2	5	6	C24H21F2NO3	(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one	C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O	C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O	InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1	OLNTVTPDXPETLC-XPWALMASSA-N
D64OVX	Chlorthalidone	Small molecule	chlorthalidone; 77-36-1; Chlortalidone; Phthalamudine; Chlorphthalidolone; Hygroton; Chlorthalidon; Phthalamodine; Natriuran; Thalitone; Chlorothalidone; Chlorphthalidone; Saluretin; Zambesil; Igroton; Isoren; Oradil; Renon; Hydro-Long; Chlortalidonum; Oxodolin; Oksodolin (oxodolin); Racemic chlorthalidone; 2-Chloro-5-(1-hydroxy-3-oxoisoindolin-1-yl)benzenesulfonamide; Demi-Regroton; G-33182; 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide; 1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline; 3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine; 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide; 3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine; 1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline; G 33182; NSC-69200; Benzenesulfonamide, 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)-; Chlortalidone [INN]; Benzenesulfonamide, 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)-; Chlorthalidone (Chlortalidone); MLS000069531; CHEBI:3654; Q0MQD1073Q; Clortalidone; DTXSID4022812; Famolin; Higroton; Urolin; 2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide; Clortalidona; SMR000058635; (+-)-Hygroton; Clortalidone [DCIT]; (+-)-Chlorthalidone; 2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzene-1-sulfonamide; Chlortalidonum [INN-Latin]; Clortalidona [INN-Spanish]; DTXCID902812; Thalitone (TN); Hygroton (TN); Chlorthalidone (USP); HSDB 3035; SR-01000721929; EINECS 201-022-5; NSC 69200; Chlortalidone (JAN/INN); BRN 0312295; Chlorthalidone [USAN:USP]; UNII-Q0MQD1073Q; Oksodolin; CAS-77-36-1; NCGC00016317-01; Prestwick_759; Regroton (Salt/Mix); Combipres (Salt/Mix); Spectrum_000146; Opera_ID_138; (.+/-.)-Hygroton; Prestwick0_000351; Prestwick1_000351; Prestwick2_000351; Prestwick3_000351; Spectrum2_000099; Spectrum3_000349; Spectrum4_000957; Spectrum5_000743; (.+/-.)-Chlorthalidone; CHLORTALIDONE [JAN]; CHLORTHALIDONE [MI]; CHEMBL1055; SCHEMBL26234; BSPBio_000441; BSPBio_002017; CHLORTHALIDONE [HSDB]; CHLORTHALIDONE [USAN]; KBioGR_001574; KBioSS_000626; 5-22-07-00602 (Beilstein Handbook Reference); CHLORTALIDONE [MART.]; CHLORTHALIDONE [VANDF]; DivK1c_000731; SPECTRUM1500187; SPBio_000058; SPBio_002362; CHLORTALIDONE [WHO-DD]; CHLORTALIDONE [WHO-IP]; BPBio1_000487; GTPL7147; CHLORTHALIDONE [USP-RS]; BDBM25900; HMS502E13; KBio1_000731; KBio2_000626; KBio2_003194; KBio2_005762; KBio3_001237; NINDS_000731; HMS1569G03; HMS1920M09; HMS2091E12; HMS2096G03; HMS2236D07; HMS3259H04; HMS3372A07; HMS3713G03; Pharmakon1600-01500187; CHLORTALIDONE [EP IMPURITY]; BCP27835; NSC69200; CHLORTALIDONE [EP MONOGRAPH]; CHLORTHALIDONE [ORANGE BOOK]; Tox21_110369; CCG-38917; MFCD00036257; NSC756692; s3074; STK686335; Chlortalidone 1.0 mg/ml in Methanol; CHLORTALIDONUM [WHO-IP LATIN]; CHLORTHALIDONE [USP MONOGRAPH]; AKOS005599810; Tox21_110369_1; DB00310; KS-1342; NC00690; NSC-756692; CLORPRES COMPONENT CHLORTHALIDONE; IDI1_000731; KERLEDEX COMPONENT CHLORTHALIDONE; REGROTON COMPONENT CHLORTHALIDONE; COMBIPRES COMPONENT CHLORTHALIDONE; NCGC00094616-01; NCGC00094616-02; NCGC00094616-03; NCGC00094616-04; NCGC00094616-07; TENORETIC COMPONENT CHLORTHALIDONE; AC-11367; HY-15833; CHLORTHALIDONE COMPONENT OF CLORPRES; CHLORTHALIDONE COMPONENT OF KERLEDEX; CHLORTHALIDONE COMPONENT OF REGROTON; SBI-0051313.P003; CHLORTHALIDONE COMPONENT OF COMBIPRES; CHLORTHALIDONE COMPONENT OF TENORETIC; DB-056211; LOPRESSIDONE COMPONENT CHLORTHALIDONE; [(3,5-Difluorophenyl)amino](oxo)aceticacid; AB00051946; DEMI-REGROTON COMPONENT CHLORTHALIDONE; C76474; CHLORTHALIDONE COMPONENT OF LOPRESSIDONE; D00272; AB00051946_12; CHLORTHALIDONE COMPONENT OF DEMI-REGROTON; A839067; EN300-18527725; Q425289; SR-01000721929-2; SR-01000721929-3; W-104322; BRD-A26384407-001-05-3; BRD-A26384407-001-15-2; Z1741981513; 2-Chloro-5-(1-hydroxy-3-oxo-1H-isoindolinyl)benzenesulfonamide; Chlorthalidone, European Pharmacopoeia (EP) Reference Standard; 2-chloro-5-(1,3-dihydroxy-1H-isoindol-1-yl)benzene-1-sulfonamide; Benzenesulfonamide,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)-; Chlorthalidone, United States Pharmacopeia (USP) Reference Standard; 2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide #; 2-chloro-5-[(1S)-1-hydroxy-3-oxo-isoindolin-1-yl]benzenesulfonamide;Chlorthalidone; Chlortalidone for peak identification, European Pharmacopoeia (EP) Reference Standard; 74658-80-3	Approved	Approved Drug(s)	2732	DB00310	D09NIA	338.8	118	564	0.9	22	3	5	2	C14H11ClN2O4S	2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide	C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O	C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O	InChI=1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)	JIVPVXMEBJLZRO-UHFFFAOYSA-N
DTF80S	Tetrabenazine	Small molecule	TETRABENAZINE; 58-46-8; Nitoman; 718635-93-9; Rubigen; Tetrabenzaine; Tetrabenzine; tetra Benazin; Tetrabenazine Racemate; Xenazine; Tetrabenazine (Racemate); 3-isobutyl-9,10-dimethoxy-3,4,6,7-tetrahydro-1H-pyrido[2,1-a]isoquinolin-2(11bH)-one; Ro 1-9569 Racemate; Tetrabenazinum; Ro 1-9569; Tetrabenazinum [INN-Latin]; Tetrabenazina [INN-Spanish]; 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one; Deutetrabenazine; 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; 9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-one; MLS003106727; Ro 1-9569/12; CHEMBL117785; CHEBI:64028; Ro-19569; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; NSC-169886; NSC 169886; 1,2,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; 3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; (-)-tetrabenazine; 2-oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzoquinolizine; Xenazine (TN); SMR000718664; Nitoman (TN); WLN: T B666 DV GNTT&J E1Y1&1 LO1 MO1; Tetrabenazin; Revocon; 2-Oxo-3-isobutyl-9,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; 2-Oxo-3-isobutyl-9,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine; 1,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; 2H-Benzo[a]quinolizin-2-one,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; 2H-Benzo[a]quinolizin-2-one,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; 2H-Benzo[a]quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-; NCGC00160421-01; RO-1-9569; Tetrabenazine- Bio-X; Nitoman;Ro 1-9569; Tetrabenazine (JAN/INN); TimTec1_002217; 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-Benzo[a]quinolizin-2-one; Oprea1_264344; SCHEMBL62026; MLS001249426; MLS001249497; GTPL4834; HY-B0590A; DTXSID501127442; HMS1540E17; HMS2966E06; HMS3263I14; HMS3430F03; HMS3884E10; Tetrabenazine (Nitoman, Xenazine); ACT06890; BCP15831; BCP24156; EX-A2361; Tox21_501086; BDBM50017701; MFCD00042740; MFCD11519951; NSC169886; NSC172187; s1789; STK678061; AKOS001681311; AKOS016347602; CCG-118217; CS-5700; DB04844; LP01086; NSC-172187; PB21652; PB25061; PB38735; SB49797; SDCCGSBI-0633786.P001; NCGC00160421-02; NCGC00160421-06; NCGC00261771-01; AS-35785; BT164463; SY055407; FT-0674921; FT-0700948; FT-0771873; FT-0772314; D08575; EN300-122639; A856325; A917912; Q413050; SR-01000833864; SR-01000833864-4; BRD-A47564106-001-01-8; Z1544404943; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7,11b-hexahydro-2H-benzo(a)quinolizine; 2H-Benzo[a]quinolizin-2-one, 1,3,4,6,7, 11b-hexahydro-3-isobutyl-9,10-dimethoxy-,; 3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one #; 3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-pyrido[2,1-a]isoquinolin-2-one; 3-isobutyl-9-,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizin-2-one; Tetrabenazine (3r,11br)-rel-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one	Approved	Approved Drug(s)	6018	DB04844	D09PJX	317.4	38.8	425	2.9	23	0	4	4	C19H27NO3	9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one	CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC	CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC	InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3	MKJIEFSOBYUXJB-UHFFFAOYSA-N
DOD1Y7	Vincristine	Small molecule	vincristine; 22-Oxovincaleukoblastine; Leurocristine; 57-22-7; Vinkristin; Vincrystine; leucristine; vincristin; Vincristina [DCIT]; rel-Vincristine; Vincristinum [INN-Latin]; Tecnocris; DTXSID1032278; CHEBI:28445; NSC-67574; Kyocristine; Vincristine (INN); VIN; NCGC00163700-01; Vincrstine; Oncotcs; DTXCID9012278; (+)-Vincristine; CAS-57-22-7; Tecnocris (TN); LCR; VCR; 1217704-92-1; Vincasar (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincrex (1:1 sulfate salt); oncovin (brand name); Leurocristine;NSC-67574;22-Oxovincaleukoblastine; 22-oxo-vincaleukoblastine; Vincristine (Leurocristine); SCHEMBL3709; CHEMBL90555; GTPL6785; HMS2090E19; Tox21_112067; BDBM50139772; Lilly 37231 (1:1 sulfate salt); Tox21_112067_1; NCGC00163700-02; NCGC00163700-04; NCGC00263543-01; NCI60_026703; SRI-10749-04; SRI-10749-05; C07204; D08679; Q408977; Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine; methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2(7),3,5,13-tetraene-10-carboxylate; methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate	Approved	Approved Drug(s)	5978	DB00541	D09QVV	825	171	1750	2.8	60	3	12	10	C46H56N4O10	methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate	CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O	CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O	InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1	OGWKCGZFUXNPDA-XQKSVPLYSA-N
D89PXC	Vincristine sulfate	Small molecule	Vincristine sulfate; 2068-78-2; Kyocristine; Vincristine sulphate; Leurocristine sulfate; Vincrisul; Oncovin; Onkovin; Marqibo; 22-oxovincaleukoblastine sulfate; VCR sulfate; rel-Vincristine  Sulfate; NSC 67574; Lilly 37231; NSC67574; NSC-67574; Leurocristine, sulfate (1:1) (salt); Novopharm; CHEBI:79401; 1217704-93-2; MLS002702994; LILLY-37231; Vincristini sulfas; Oncovin (Lilly); Vincasar (TN); Marqibo (TN); Oncovin (TN); Vincrex (TN); Vincristine, sulfate; Leurocristine, sulfate; Vincristine sulphate Salt; Vincristine sulfate liposome; SCHEMBL3710; Leurocristine sulfate (1:1); CHEMBL501867; DTXSID8044331; Leurocristine (sulfate);NSC-67574 (sulfate);22-Oxovincaleukoblastine (sulfate); Vincristine sulfate (JP17/USP); HMS3414L13; HMS3678L11; MFCD08706469; AKOS015895862; V0129; LCR; VCR; D02197; A936684; methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((3S,5S,7S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-6-formyl-5-hydroxy-8-methoxy-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate sulfate	Approved	Approved Drug(s)	249332	DB00541	D09QVV	923	254	1830	.	65	5	16	10	C46H58N4O14S	methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate;sulfuric acid	CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O	CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O	InChI=1S/C46H56N4O10.H2O4S/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6;1-5(2,3)4/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3;(H2,1,2,3,4)/t28-,37+,38-,39-,42+,43-,44-,45+,46+;/m1./s1	AQTQHPDCURKLKT-JKDPCDLQSA-N
D5N9BK	Ropivacaine	Small molecule	Ropivacaine; 84057-95-4; (S)-Ropivacaine; Naropin; Ropivacaine [INN]; Ropivacaine hydrochloride; Ropivacaina; Ropivacainum; Ropivacaina [Spanish]; (S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide; Ropivacainum [INN-Latin]; Ropivacaina [INN-Spanish]; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide; Ropivicaine; Ropivacaine base; (2S)-N-(2,6-dimethylphenyl)-1-propyl-piperidine-2-carboxamide; 7IO5LYA57N; (-)-1-Propyl-2',6'-pipecoloxylidide; LEA 103; CHEBI:8890; TLC590; (2S)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide; TLC-590; Ropivacaine (INN); MFCD00864425; L-N-n-propylpipecolic acid-2,6-xylidide; LEA-103; 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)-; S-Ropivacaine; (S)-(-)-1-propyl-2',6'-pipecoloxylidide; 1-propyl-2',6'-pipecoloxylidide; Noropine; Narop; LEA-103 HCl; Naropin (TN); NCGC00164597-01; Ropivacaine [INN:BAN]; 98717-15-8; UNII-7IO5LYA57N; AL-381; ROPIVACAINE [MI]; ROPIVACAINE [VANDF]; SCHEMBL33292; ROPIVACAINE [USP-RS]; ROPIVACAINE [WHO-DD]; BIDD:GT0203; Narop; Noropine; LEA-103; GTPL7602; (-)-1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilid; CHEMBL1077896; DTXSID4040187; HY-B0563; BBL102321; s5504; STL556120; AKOS017343283; CCG-267197; DB00296; AS-35173; CS-0009514; R0251; C07532; D08490; AB00698466-07; AB00698466_10; EN300-7436767; A840710; Q279504; (S)-(-)-1-PROPYL-2',6'-PIPECOLOXYLIDINE; Q-201677; (-)-1-propyl-2',6'-dimethyl-2-piperidylcarboxyanilide; Z2235811359; (s)-n-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide; (S)-(-)-1-PROPYLPIPERIDINE-2-CARBOXYLIC ACID (2,6-DIMETHYLPHENYL)AMIDE	Approved	Approved Drug(s)	175805	DB00296	D09RHQ	274.4	32.299	308	2.9	20	1	2	4	C17H26N2O	(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide	CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C	CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C	InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1	ZKMNUMMKYBVTFN-HNNXBMFYSA-N
DKU35L	Voxelotor	Small molecule	Voxelotor; 1446321-46-5; Oxbryta; GBT440; GBT 440; GBT-440; GTX-011; Hemoglobin Modulators-1; Voxelotor [USAN]; 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; GBT-440(Voxelotor); 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde; CHEMBL4101807; 3ZO554A4Q8; Voxelotor (USAN); 2-hydroxy-6-({2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl}methoxy)benzaldehyde; Benzaldehyde, 2-hydroxy-6-((2-(1-(1-methylethyl)-1H-pyrazol-5-yl)-3-pyridinyl)methoxy)-; 2-hydroxy-6-((2-(1-(propan-2-yl)-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; Oxbryta (TN); VOXELOTOR [INN]; VOXELOTOR [MI]; VOXELOTOR [WHO-DD]; UNII-3ZO554A4Q8; VOXELOTOR [ORANGE BOOK]; SCHEMBL15065529; GTPL10559; Voxelotor(GBT440, GTx011); DTXSID801027954; BCP20182; EX-A2980; BDBM50235297; CCG-267884; CS-5317; DB14975; SB19656; 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-3-pyridinyl)methoxy)benzaldehyde; compound 36 [PMID: 28337324]; AC-36867; AS-57911; DA-44587; HY-18681; FT-0702904; S8540; D11330; EN300-21636492; GBT-440;GBT440;Voxelotor;GTx-011;GTx011;GTx 011; 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY) BENZALDEHYDE	Approved	Approved Drug(s)	71602803	DB14975	D09RII	337.4	77.2	434	2.7	25	1	5	6	C19H19N3O3	2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde	CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O	CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O	InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3	FWCVZAQENIZVMY-UHFFFAOYSA-N
D3EB4N	Daclatasvir	Small molecule	Daclatasvir; 1009119-64-5; Daclatasvir (BMS-790052); BMS-790052; Daklinza; EBP 883; 1214735-16-6; BMS790052; BMS 790052; Daclatasvir [USAN]; Daclatasvir dihydrochloride; methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; CHEBI:82977; EBP-883; Daclatasvir (USAN); Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester; Carbamic acid, N,N'-((1,1'-biphenyl)-4,4'-diylbis(1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl ester; Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dica; methyl N-[(2S)-1-[(2S)-2-[5-(4'-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl}-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; LI2427F9CI; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; DACLATASVIR [MI]; DACLATASVIR [INN]; DACLATASVIR [WHO-DD]; dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate; MLS006011140; EBP883; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; GTPL11266; EX-A410; DTXSID901026404; AMY36655; dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate; Dimethyl N,N'-(biphenyl-4,4'-diylbis{1H-imidazole-5,2-diyl-((2S)-pyrrolidine-2,1- diyl)((1S)-1-(1-methylethyl)-2-oxoethane-2,1-diyl)})dicarbamate; BDBM50387084; MFCD17129086; s1482; CCG-270425; CS-0588; DB09102; NCGC00346533-07; NCGC00346533-09; AC-28958; AS-75298; HY-10466; SMR004702917; SW219754-1; D10065; EN300-27736661; J-520204; Q5207712; DIMETHYL N,N'-((1,1'-BIPHENYL)-4,4'-DIYLBIS(1H-IMIDAZOLE-5,2-DIYL-((2S)-PYRROLIDINE-2,1-DIYL)((1S)-3-METHYL-1-OXOBUTANE-1,2-DIYL)))DICARBAMATE; methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate; methyl [(2s)-1-{(2s)-2-[4-(4'-{2-[(2s)-1-{(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1h-imidazol-4-yl}-4-biphenylyl)-1h-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate; methyl [(2S)-1-{(2S)-2-[4-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate; Methyl [(2S)-1-{(2S)-2-[5-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate; methyl-N-[(2s)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl] pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1himidazol-2-yl]pyrrolidin-1-yl]3-methyl-1-oxobutan-2-yl]carbamate	Approved	Approved Drug(s)	25154714	DB09102	D09SGV	738.9	175	1190	5.1	54	4	8	13	C40H50N8O6	methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate	CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC	CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC	InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1	FKRSSPOQAMALKA-CUPIEXAXSA-N
DC8GA4	Isoniazid	Small molecule	isoniazid; 54-85-3; Isonicotinic acid hydrazide; Isonicotinohydrazide; pyridine-4-carbohydrazide; Isoniazide; Nydrazid; Rimifon; Cotinazin; Hydrazid; Iscotin; Isonicotinic hydrazide; Mybasan; Isonicotinylhydrazine; Armazid; Armazide; Atcotibine; Dinacrin; Ditubin; Ertuban; Hidrasonil; Isidrina; Isobicina; Isonicotan; Laniazid; Neumandin; Eralon; Cedin; Hyzyd; Andrazide; Neoteben; Nicizina; Nicotibina; Nicozide; Pycazide; Stanozide; Tubazide; Isolyn; Isonex; Niconyl; Isonicotinhydrazid; Antimicina; Chemiazid; Hidranizil; Isocidene; Isohydrazide; Isonicotil; Isonidrin; Isonikazid; Isonindon; Isonizide; Isotebezid; Pyricidin; Pyrizidin; Teebaconin; Cemidon; Chemidon; Defonin; Diforin; Ebidene; Eutizon; Fimalene; Hidrulta; Hycozid; Idrazil; Ismazide; Isocotin; Isonerit; Isonicid; Isonico; Isonide; Isonilex; Isonirit; Isoniton; Isozide; Niadrin; Nicetal; Nidaton; Nidrazid; Nikozid; Nitadon; Nyscozid; Pelazid; Raumanon; Retozide; Rimicid; Rimitsid; Tubazid; Azuren; Evalon; Hidrun; Inizid; Isocid; Isonin; Isozyd; Neoxin; Nevin; Niplen; Antituberkulosum; Inah; Ido-tebin; Tisiodrazida; Bacillin; Isoniacid; Isotinyl; Nicazide; Nicotibine; Nicotisan; Phthisen; Pyreazid; Rimiphone; Tubilysin; Isotebe; Percin; Razide; Tyvid; Isoniazid SA; Neo-Tizide; 4-Pyridinecarboxylic acid, hydrazide; GINK; Armacide; Cortinazine; Cotinizin; Isonicazide; Isotamine; Robisellin; Sauterazid; Tibinide; Unicozyde; Vazadrine; Zonazide; Dibutin; Hyozid; Isonicotinoyl hydrazide; Tebecid; Tekazin; Tubeco; Tubicon; Tubomel; Vederon; Zinadon; Dow-Isoniazid; Preparation 6424; Isonicotinyl hydrazide; TB-Razide; INH; Sanohidrazina; Laniozid; Niteban; Pyridicin; Robiselin; Roxifen; Sauterzid; Tebenic; Tebexin; Tebilon; Tibazide; Tibison; Tibivis; Tibizide; Tibusan; Tuberian; Tubizid; Unicocyde; Tebos; Tisin; Tizide; 4-Pyridinecarboxylic acid hydrazide; FSR 3; TB-Vis; Inh-Burgthal; TB-Phlogin; Isoniazidum; Zidafimia; Isokin; Nitebannsc 9659; In-73; RU-EF-Tb; Isonicotinoylhydrazine; 4-Pyridinecarbonylhydrazine; BP 5015; FSR-3; Isonicotinsaeurehydrazid; 4-(Hydrazinocarbonyl)pyridine; 4-pyridinecarbohydrazide; 4-Pyridylcarbonylhydrazide; isonicotinoylhydrazide; NSC 9659; Dianicotyl; Ipcazide; HIA; RP-5015; pyridine-4-carboxylic acid hydrazide; MFCD00006426; Isonicotinylhydrazide; L 1945; 5015 RP; CHEBI:6030; 5015 R.P.; NSC-9659; CHEMBL64; V83O1VOZ8L; MLS000069444; DTXSID8020755; Isozid; NSC9659; Cedin (Aerosol); CAS-54-85-3; bacillen; tebemid; tubercid; NCGC00016244-09; Continazine; Tubecotubercid; Abdizide; Anidrasona; Isoniazida; Isonizida; SMR000059082; Tibemid; Tibiazide; Fetefu; Hydra; DTXCID20755; LANIZID; 4-Pyridinecarboxylic hydrazide; RY-EF-Tb; Isoniazidum [INN-Latin]; Isoniazida [INN-Spanish]; AZT + Isoniazid; FRS-3; Laniazid (TN); CCRIS 351; Usaf cb-2; HSDB 1647; Isonicotinsaeurehydrazid [German]; INHd20; SR-01000003025; EINECS 200-214-6; UNII-V83O1VOZ8L; RP 5015; Mayambutol; AI3-23936; I.A.I.; Idrazide dell'acido isonicotinico [Italian]; isoniazid (inh); Idrazide dell'acido isonicotinico; Isoniazid [USP:INN:BAN:JAN]; isonicotinhydrazide; Isoniazid(Tubizid); Soniazid,(S); NIZ; Prestwick_578; Isoniazid (Tubizid); Rifater (Salt/Mix); isonicotinate hydrazide; Isonicotinic acid hydrazide (Isoniazid); Isonicotinicacidhydrazide; Spectrum_000853; ISONIAZID [INN]; ISONIAZID [JAN]; Opera_ID_454; ISONIAZID [MI]; isonicotinicacid hydrazide; ISONIAZID [HSDB]; isonicotinic acid hydrazid; Prestwick0_000161; Prestwick1_000161; Prestwick2_000161; Prestwick3_000161; Spectrum2_000107; Spectrum3_000472; Spectrum4_000022; Spectrum5_000876; ISONIAZID [VANDF]; I0138; WLN: T6NJ DVMZ; isonicotinic acid hydrazone; SCHEMBL228; Biomol-NT_000288; Epitope ID:141801; ISONIAZID [MART.]; 4-Pyridylcarbonyl hydrazide; ISONIAZID [USP-RS]; ISONIAZID [WHO-DD]; ISONIAZID [WHO-IP]; Oprea1_396155; BSPBio_000021; BSPBio_002204; KBioGR_000423; KBioSS_001333; MLS001055327; BIDD:GT0140; DivK1c_000070; SPECTRUM1500355; SPBio_000094; SPBio_001942; Isoniazid (JP17/USP/INN); BPBio1_000025; BPBio1_001322; SCHEMBL2998929; ISONIAZID [EP IMPURITY]; ISONIAZID [ORANGE BOOK]; component of Niadox (Salt/Mix); ISONIAZID [EP MONOGRAPH]; HMS500D12; KBio1_000070; KBio2_001333; KBio2_003901; KBio2_006469; KBio3_001424; ISONIAZID [USP MONOGRAPH]; NINDS_000070; RIFATER COMPONENT ISONIAZID; HMS1568B03; HMS1920H09; HMS2089I16; HMS2091N19; HMS2095B03; HMS2234G04; HMS3259E19; HMS3373O01; HMS3655L03; HMS3712B03; KUC109571N; Pharmakon1600-01500355; 4-pyridinecarbohydrazide(Isoniazid); ISONIAZIDUM [WHO-IP LATIN]; RIFAMATE COMPONENT ISONIAZID; BCP13791; HY-B0329; STR00210; [(4-Pyridinylcarbonyl)oxy]hydrazine; Anti-TNF monoclonal antibody & INH; Tox21_113640; Tox21_201367; Tox21_300193; BBL008409; BDBM50336507; CCG-39710; NSC757078; s1937; STK086288; ISONIAZID COMPONENT OF RIFATER; AKOS000119062; ISONIAZID COMPONENT OF RIFAMATE; Isonicotinic acid hydrazide(Isoniazid); Tox21_113640_1; DB00951; KSC-27-048; NC00513; NSC-757078; PS-4129; IDI1_000070; UPCMLD0ENAT5791176:001; NCGC00016244-01; NCGC00016244-02; NCGC00016244-03; NCGC00016244-04; NCGC00016244-05; NCGC00016244-06; NCGC00016244-07; NCGC00016244-08; NCGC00016244-10; NCGC00016244-11; NCGC00016244-12; NCGC00016244-14; NCGC00016244-15; NCGC00022648-03; NCGC00022648-04; NCGC00022648-05; NCGC00022648-06; NCGC00022648-07; NCGC00254094-01; NCGC00258919-01; ISONICOTINIC ACID HYDRAZIDE [IARC]; SY010614; Isoniazid, Vetec(TM) reagent grade, 98%; SBI-0051419.P003; AB00052025; BB 0240534; FT-0627424; FT-0670476; ISONICOTINIC ACID HYDRAZIDE [WHO-IP]; SW196752-3; EN300-18498; ISONICOTINIC ACID HYDRAZIDE(ISONIAZIDE); C07054; D00346; D70582; Isoniazid, analytical standard, >=99% (TLC); AB00052025-20; AB00052025-21; AB00052025_22; AB00052025_23; AB00052025_24; AB00052025_25; A830384; AE-641/02310003; Q423169; 4-PYRIDINECARBOXYLIC ACID HYDRAZIDE [WHO-IP]; SR-01000003025-2; SR-01000003025-3; BRD-K87202646-001-26-8; Isoniazid, certified reference material, TraceCERT(R); Z58981801; F0391-0007; Isoniazid, European Pharmacopoeia (EP) Reference Standard; Isoniazid, United States Pharmacopeia (USP) Reference Standard; Isoniazid, Pharmaceutical??Secondary??Standard;??Certified??Reference??Material	Approved	Approved Drug(s)	3767	DB00951	D09XQF	137.14	68	120	-0.7	10	2	3	1	C6H7N3O	pyridine-4-carbohydrazide	C1=CN=CC=C1C(=O)NN	C1=CN=CC=C1C(=O)NN	InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)	QRXWMOHMRWLFEY-UHFFFAOYSA-N
DT60XW	Gefitinib	Small molecule	Gefitinib; 184475-35-2; Iressa; ZD1839; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; Irressat; gefitinib (zd1839); ZD 1839; ZD-1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; Gefitinib (GMP); N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; MFCD04307832; CHEMBL939; NSC-759856; S65743JHBS; DTXSID8041034; CHEBI:49668; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; Gefitinib [USAN]; NCGC00159455-02; N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; 3-Chloro-4-Fluoro-N-[(4z)-7-Methoxy-6-(3-Morpholin-4-Ylpropoxy)quinazolin-4(1h)-Ylidene]aniline; DTXCID6021034; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-; Iressa(TM); IRE; Iressa (TN); CCRIS 9011; CAS-184475-35-2; SR-00000000262; gefitinibum; UNII-S65743JHBS; Gefitinib (JAN/USAN/INN); Gefitinib [USAN:INN:BAN]; Gefitini; Iressa; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine; gefitinib (iressa); Gefitinib - Iressa; Iressa (AstraZeneca); nchembio866-comp14; Kinome_3321; Kinome_3322; GEFITINIB [INN]; GEFITINIB [JAN]; GEFITINIB [MI]; GEFITINIB [VANDF]; GEFITINIB [MART.]; GEFITINIB [WHO-DD]; SCHEMBL7866; Gefitinib,ZD-1839,Iressa; GEFITINIB [EMA EPAR]; KBioSS_002241; MLS003899193; CU-00000000396-1; BDBM5447; cid_123631; GTPL4941; GEFITINIB [ORANGE BOOK]; GEFITINIB [EP MONOGRAPH]; Gefitinib, >=98% (HPLC); BCPP000221; HMS2089B19; HMS3244M21; HMS3244M22; HMS3244N21; HMS3295A21; HMS3413H08; HMS3654A07; HMS3677H08; HMS3714A05; HMS3748E17; Pharmakon1600-01502274; BCP01365; Tox21_111683; HY-50895G; NSC715055; NSC759856; NSC800105; s1025; STK621310; AKOS000280752; Tox21_111683_1; AB20814; AC-1556; BCP9000718; CCG-220642; CS-0124; DB00317; KS-1204; NSC 759856; NSC-715055; NSC-800105; 4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-4-morpholin)propoxy)-; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine; NCGC00159455-03; NCGC00159455-04; NCGC00159455-05; NCGC00159455-06; NCGC00159455-08; NCGC00159455-09; NCGC00159455-14; BCB03_000781; BG164498; HY-50895; SMR002204119; SY002154; AM20090619; CS-0622782; FT-0602325; G0546; SW199108-4; EC-000.2409; D01977; EN300-123024; G-4408; K00240; AB01273954-01; AB01273954-02; AB01273954-03; AB01273954_04; A812870; Q417824; Q-201149; SR-00000000262-2; SR-00000000262-3; Gefitinib, EuropePharmacopoeia (EP) Reference Standard; Z1546610485; 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)-quinazoline; Gefitinib for system suitability, EuropePharmacopoeia (EP) Reference Standard; (3-CHLORO-4-FLUORO-PHENYL)-[7-METHOXY-6-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-4-YL]-AMINE	Approved	Approved Drug(s)	123631	DB00317	D09XZB	446.9	68.7	545	4.1	31	1	8	8	C22H24ClFN4O3	N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4	InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)	XGALLCVXEZPNRQ-UHFFFAOYSA-N
D39COD	Everolimus	Small molecule	001, RAD; 40-O-(2-hydroxyethyl)-rapamycin; 40-O-(2-Hydroxyethyl)rapamycin; Afinitor; Certican; Everolimus; RAD; RAD 001; RAD, SDZ; RAD001; SDZ RAD; SDZ-RAD; Zortress; 159351-69-6; Votubia; 42-O-(2-Hydroxyethyl)rapamycin; RAD-001; Afinitor Disperz; CHEBI:68478; Rapamycin, 42-O-(2-hydroxyethyl)-; 9HW64Q8G6G; DTXSID0040599; RAD 666; RAD-666; Everolimus (INN); NCGC00167512-01; Everolimus (RAD001); EVEROLIMUS [INN]; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-dihydroxy-12-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; Everolimus [USAN]; everolimusum; NSC733504; SDZRAD; XIENCE V; EVEROLIMUS [MI]; Everolimus - RAD001; EVEROLIMUS [JAN]; EVEROLIMUS [VANDF]; EVEROLIMUS [MART.]; SCHEMBL4378; EVEROLIMUS [USP-RS]; EVEROLIMUS [WHO-DD]; NVP-RAD001; UNII-9HW64Q8G6G; EVEROLIMUS [EMA EPAR]; Everolimus [USAN:INN:BAN]; NVP-RAD-001; Everolimus, analytical standard; GTPL5889; RAD-001C; CHEMBL1908360; DTXCID8020599; EVEROLIMUS [ORANGE BOOK]; HSDB 8255; EVEROLIMUS [EP MONOGRAPH]; Everolimus; RAD001; SDZ-RAD; 42-O-(2-Hydroxyethyl)-rapamycin; EX-A2057; Tox21_112510; BDBM50088378; AKOS015850977; CS-0064; DB01590; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; AS-16971; HY-10218; CAS-159351-69-6; Q421052; Q-101413; BRD-K13514097-001-01-2; BRD-K13514097-001-05-3; dihydroxy-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxy-cyclohexyl]-1-methyl-ethyl]-dimethoxy-hexamethyl-[?]pentone	Approved	Approved Drug(s)	6442177	DB01590	D09ZSC	958.2	205	1810	5.9	68	3	14	9	C53H83NO14	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC	InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1	HKVAMNSJSFKALM-GKUWKFKPSA-N
DU6BZ1	Bupivacaine	Small molecule	bupivacaine; 2180-92-9; 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; DL-Bupivacaine; 38396-39-3; Marcaine; Bupivacaina; Anekain; (+-)-Bupivacaine; Bupivacainum; Sensorcaine; 1-Butyl-2',6'-pipecoloxylidide; Exparel; Bupivacainum [INN-Latin]; Bupivacaina [INN-Spanish]; dl-1-Butyl-2',6'-pipecoloxylidide; AH 250; Bucaine; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-; Win 11318; Bloqueina; (+/-)-Bupivacaine; Posimir; SKY0402; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; 2',6'-Pipecoloxylidide, 1-butyl-; 1-butyl-N-(2,6-dimethylphenyl)-piperidine-2-carboxamide; Marcain; LIQ865; (1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CHEBI:77431; LIQ-865; SKY-0402; Xaracoll; LAC-43; Y8335394RO; cBupivacaine; Bupivacaine HCL KIT; bupivacaine base; (R)-Bupivacaine HCl; Bucaine (TN); DUR-843; EINECS 218-553-3; EINECS 253-911-2; Bupivacaine [USAN:INN:BAN]; UNII-Y8335394RO; HSDB 7790; racemic bupivacaine; (RS)-bupivacaine; Bupivacaine liposome; SKY 0402; Exparel (TN); Liposomal bupivacaine; Bupivacaine Free Base; Bupivacaine-[13C]; Spectrum_001524; Bupivacaine liposome injectable suspension; Marcaine and Sensorcaine; BUPIVACAINE [MI]; Prestwick0_000305; Prestwick1_000305; Prestwick2_000305; Prestwick3_000305; Spectrum2_001589; Spectrum3_000974; Spectrum4_001098; Spectrum5_001483; BUPIVACAINE [INN]; (.+/-.)-1-Butyl-2',6'-pipecoloxylidide; (.+/-.)-Bupivacaine; Bupivacaine (USAN/INN); BUPIVACAINE [HSDB]; BUPIVACAINE [USAN]; LAC-43 (Salt/Mix); Epitope ID:122662; BUPIVACAINE [VANDF]; Marcaine spinal (Salt/Mix); CHEMBL1098; SCHEMBL25438; BSPBio_000270; BSPBio_002607; BUPIVACAINE [WHO-DD]; KBioGR_001516; KBioSS_002004; DivK1c_000758; SPBio_001558; SPBio_002489; BPBio1_000298; CHEBI:3215; GTPL2397; BUPIVACAINE [GREEN BOOK]; DTXSID2022703; KBio1_000758; KBio2_002004; KBio2_004572; KBio2_007140; KBio3_001827; BUPIVACAINE [ORANGE BOOK]; dl-1-Butyl-2,6-pipecoloxylidide; NINDS_000758; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboximidic acid; AH250; HMS2090F12; HMS3428P06; Marcaine hydrochloride (Salt/Mix); 1217442-06-2; 3-Ethyl-2-methylbenzoxazoliumiodide; BCP12242; BCP21825; HY-B0405; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (+-)-; AH-250; BDBM50350790; MFCD00243007; STL484283; ZYNRELEF COMPONENT BUPIVACAINE; AKOS001637202; AKOS016842516; AC-2096; BS-5224; CS-W023182; DB00297; BUPIVACAINE COMPONENT OF ZYNRELEF; IDI1_000758; NCGC00178579-01; NCGC00178579-02; BB166160; SBI-0051846.P002; DB-119016; AB00053674; FT-0623286; FT-0660567; FT-0699781; FT-0771900; C07529; D07552; Ropivacaine hydrochloride impurity, bupivacaine-; AB00053674-08; AB00053674-09; AB00053674_10; AB00053674_11; A873847; EN300-18292932; L000695; Q422806; Q-100271; BRD-A01636364-003-05-2; BRD-A01636364-003-08-6; (plusmn)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (+/-)-; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (.+/-.)-; ROPIVACAINE HYDROCHLORIDE IMPURITY, BUPIVACAINE- [USP IMPURITY]; 119427-31-5	Approved	Approved Drug(s)	2474	DB00297	D0A0FL	288.4	32.299	321	3.4	21	1	2	5	C18H28N2O	1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide	CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C	CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C	InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)	LEBVLXFERQHONN-UHFFFAOYSA-N
D9CPJ0	Flurbiprofen	Small molecule	flurbiprofen; 5104-49-4; Ansaid; Froben; Antadys; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; Cebutid; Flurofen; 3-Fluoro-4-phenylhydratropic acid; Ocufen; Flurbiprofene [INN-French]; Flurbiprofenum [INN-Latin]; Flurbiprofeno [INN-Spanish]; C15H13FO2; BTS 18322; BTS-18322; FP 70; U-27182; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; MFCD00079303; Stayban; Zepolas; Adfeed; U 27182; 2-(2-FLUORO-[1,1'-BIPHENYL]-4-YL)PROPANOIC ACID; 51543-38-5; CHEMBL563; BTS 18,322; NSC-757037; 5GRO578KLP; 2-(2-Fluoro-4-biphenylyl)propionic acid; MLS000040873; CHEBI:5130; Flubiprofen; DTXSID0037231; Flugalin; U-27,182; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; Ocuflur; SMR000042823; DTXCID8017231; Anmetarin; Yakuban; dl-Flurbiprofen; [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-a-methyl-, (A+/-)-; Flurbiprofen (Ansaid); Ansaid (TN); CCRIS 3708; SR-01000003043; FLP; (R)-Flurbiprofen;MPC7869; EINECS 225-827-6; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; UNII-5GRO578KLP; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; MPC7869; U 27,182; Flurbiprofen O; MKS-11; rac-Flurbiprofen; Flurbiprofen,(S); NCGC00016654-01; (+-)Flurbiprofen; CAS-5104-49-4; EINECS 257-262-6; Ocufen (Salt/Mix); [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-?-methyl-; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; Flurbiprofen (NSAID); Flurbiprofen [USAN:USP:INN:BAN:JAN]; Spectrum_001096; Opera_ID_777; Prestwick0_000917; Prestwick1_000917; Prestwick2_000917; Prestwick3_000917; Spectrum2_001025; Spectrum3_000435; Spectrum4_000558; Spectrum5_000720; FLURBIPROFEN [MI]; 2-(3-fluoro-4-phenyl-phenyl)propanoic acid; F0371; (.+/-.)-Flurbiprofen; FLURBIPROFEN [INN]; FLURBIPROFEN [JAN]; 4-Biphenylacetic acid, 2-fluoro-alpha-methyl-; FLURBIPROFEN [USAN]; SCHEMBL2248; FLURBIPROFEN [VANDF]; 4-Biphenylacetic acid, 2-fluoro-.alpha.-methyl-; BSPBio_000794; BSPBio_002050; FLURBIPROFEN [MART.]; KBioGR_001255; KBioSS_001576; MLS000028441; MLS000758198; MLS001201729; MLS001401361; MLS006011431; MLS006011931; DivK1c_000804; FLURBIPROFEN [USP-RS]; FLURBIPROFEN [WHO-DD]; SPECTRUM1500308; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; SPBio_001209; SPBio_002983; BPBio1_000874; GTPL4194; SCHEMBL10029029; Flurbiprofen (JP17/USP/INN); HMS502I06; KBio1_000804; KBio2_001576; KBio2_004144; KBio2_006712; KBio3_001270; SYTBZMRGLBWNTM-UHFFFAOYSA-; [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-; NINDS_000804; FLURBIPROFEN [ORANGE BOOK]; HMS1570H16; HMS1920O20; HMS2051A05; HMS2090I06; HMS2091F21; HMS2097H16; HMS2232I08; HMS3259I12; HMS3268E10; HMS3370N14; HMS3371I05; HMS3393A05; HMS3414N17; HMS3649K11; HMS3655G19; HMS3678N15; HMS3714H16; Pharmakon1600-01500308; FLURBIPROFEN [EP MONOGRAPH]; (1,1'-Biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, (+-)-; BCP09086; BCP13426; FLURBIPROFEN [USP MONOGRAPH]; Tox21_110547; Tox21_302353; BBL010980; BDBM50074922; CCG-40243; Flurbiprofen - CAS 5104-49-4; HB3049; NSC685701; NSC755404; NSC757037; STK802101; Flurbiprofen, cyclooxygenase inhibitor; AKOS004119934; AKOS016340701; AC-8106; CCG-100759; DB00712; KS-5035; NC00009; NC00563; NSC 757037; NSC-685701; NSC-755404; 2(2-Fluoro-4-biphenylyl)propionic acid; IDI1_000804; NCGC00018157-03; NCGC00018157-04; NCGC00018157-05; NCGC00018157-08; NCGC00018157-11; NCGC00018157-13; NCGC00025287-03; NCGC00025287-04; NCGC00255457-01; HY-10582; NCI60_030812; 2 -(2-fluoro-4-biphenylyl)propionic acid; 2-(2-fluoro-4-biphenylyl)-propionic acid; 2-(2-fluoro-biphenyl-4-yl)propionic acid; SBI-0051387.P003; DB-051888; 2-(2-fluoro-biphenyl-4-yl)-propionic acid; AB00051999; FT-0603668; FT-0660285; FT-0668760; FT-0771103; alpha-methyl-2-fluoro-4-biphenylylacetic acid; (RS)-2-(2-fluorobiphenyl-4-yl)propionic acid; 2-Fluoro-.alpha.-methyl-4-biphenylacetic acid; BIM-0051387.0001; C07013; D00330; AB00051999-17; AB00051999_18; EN300-7479231; 2-(2-Fluoro-1,1'-biphenyl-4-yl)propanoic acid; 2-(2-Fluoro[1,1'-biphenyl]-4-yl)propanoic acid; 2-fluoro--methyl-(1,1'-biphenyl)-4-acetic acid; AO-295/42284050; Q419890; (.+/-.)-2-(2-Fluoro-4-biphenylyl)propionic acid; (r/s)-2-fluoro-alpha-methyl-4-biphenylacetic acid; 2-Fluoro-?-methyl-[1,1'-biphenyl]-4-acetic acid; Flurbiprofen, Antibiotic for Culture Media Use Only; Q-201129; SR-01000003043-2; SR-01000003043-5; SR-01000003043-6; (S)-(+)-2-Fluoro-alpha-methyl-4-biphenylaceticacid; 2-(2-fluoro-[1,1''-biphenyl-4-yl])propanoic acid; 2-(2-Fluoro[1,1'-biphenyl]-4-yl)propanoic acid #; BRD-A86044036-001-05-9; SR-01000003043-14; (+/-)-2-(2-FLUORO-4-BIPHENYLYL)PROPIONIC ACID; (.+/-.)-2-Fluoro-.alpha.-methyl-4-biphenylacetic acid; 2-Fluoro-.alpha.-methyl(1,1'-biphenyl)-4-acetic acid; 2-fluoro-alpha-methyl-(1,1''-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-[1,1'-biphenyl]-4-a cetic acid; Z2216885233; (+/-)-2-FLUORO-.ALPHA.-METHYL-4-BIPHENYLACETIC ACID; Flurbiprofen, European Pharmacopoeia (EP) Reference Standard; (1,1'-Biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, (+/-)-; Flurbiprofen, United States Pharmacopeia (USP) Reference Standard; [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-, (.+/-.)-; (1,1'-BIPHENYL)-4-ACETIC ACID, 2-FLUORO-.ALPHA.-METHYL-, (+/-)-; Flurbiprofen, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	3394	DB00712	D0A1PX	244.26	37.3	286	4.2	18	1	3	3	C15H13FO2	2-(3-fluoro-4-phenylphenyl)propanoic acid	CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O	CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O	InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)	SYTBZMRGLBWNTM-UHFFFAOYSA-N
D0BSK5	Pomalidomide	Small molecule	Pomalidomide; 19171-19-8; Actimid; 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; CC-4047; Pomalyst; Imnovid; 4-Aminothalidomide; 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione; IMiD 3; 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide; CC 4047; 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-; (S)-pomalidomide; IMID-3; 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; (R)-pomalidomide; D2UX06XLB5; CHEBI:72690; MFCD12756407; 4-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione; 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; 4-amino-2-(2,6-dioxo-3-piperidinyl)-1H-Isoindole-1,3(2H)-dione; 4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione; Pomalidomide (CC-4047); Pomalidomide [USAN:INN]; UNII-D2UX06XLB5; HSDB 8222; Pomalyst (TN); CC4047; Pomalidomide- Bio-X; IMiD1; POMALIDOMIDE [MI]; POMALIDOMIDE [INN]; POMALIDOMIDE [JAN]; 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide; POMALIDOMIDE [USAN]; 3-Aminophthalimidoglutarimide; POMALIDOMIDE [VANDF]; MLS006011261; CHEMBL43452; POMALIDOMIDE [WHO-DD]; SCHEMBL369172; GTPL7348; Pomalidomide (JAN/USAN/INN); POMALIDOMIDE [EMA EPAR]; 3-aminio-phthalimido-glutarimide; SCHEMBL19250920; BDBM65456; IMID-4047; CDC-394; DTXSID40893458; Pomalidomide, >=98% (HPLC); s-3-amino-phthalimido-glutarimide; HMS3655G05; HMS3744K07; POMALIDOMIDE [ORANGE BOOK]; BCP02890; BCP09107; CFC83849; AM9718; NSC767909; NSC775351; s1567; AKOS013400288; CCG-264684; CS-0165; DB08910; NSC-767909; NSC-775351; SB16552; NCGC00346551-01; NCGC00346551-03; AC-26970; AS-17905; BP-24477; BP164278; DA-21486; HY-10984; SMR004703012; SY054807; BCP0726000263; 3-(3-AMINO)-PHTALAMIDO-GLUTARIMIDE; FT-0697903; P2074; SW218099-2; D08976; EN300-317097; AB01565777_02; SR-01000941573; J-012392; J-514302; Phthalimide, 3-amino-N-(2,6-dioxo-3-piperidyl)-; Q7227206; SR-01000941573-1; Z1269642575; 4-amino-2-(2,6-dioxo(3-piperidyl))isoindoline-1,3-dione; 4-Amino-2-(2,6-dioxo-3-piperidinyl)isoindole-1,3-dione; 4-Amino-2-(2,6-dioxo-3-piperidyl) isoindoline -1,3-dione; 4-Amino-2-[(3RS)-2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione	Approved	Approved Drug(s)	134780	DB08910	D0A3ZU	273.24	110	504	0.2	20	2	5	1	C13H11N3O4	4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione	C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N	C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N	InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)	UVSMNLNDYGZFPF-UHFFFAOYSA-N
DVT1Y4	Abacavir	Small molecule	abacavir; 136470-78-5; Ziagen; Abacavir sulfate; Abacavir [INN]; 1592U89; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; Abacavir (INN); CHEBI:421707; WR2TIP26VS; ((1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol; ABC; [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; NSC-742406; [(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl]methanol; [(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]-1-cyclopent-2-enyl]methanol; 2-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-, (1S,4R)-; Avacavir; 136777-48-5; (1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol; 2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S-cis)-; (+/-)-Abacavir; Abacavir [INN:BAN]; UNII-WR2TIP26VS; DTXSID4046444; NSC742406; Ziagen (TM)(*Succinate salt*); {(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; 2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S,4R)-; NCGC00164560-01; MFCD00903850; ABACAVIR [MI]; ABACAVIR [VANDF]; AVACAVIR [VANDF]; ABACAVIR [MART.]; ABACAVIR [WHO-DD]; Epitope ID:137341; ABACAVIR [EMA EPAR]; CHEMBL1380; SCHEMBL38632; MLS006010117; GTPL11152; SRCA-00004; ACT03218; BCP07728; BDBM50366816; s5215; AKOS024464970; AC-1299; CCG-267342; CS-1354; DB01048; DT-0030; NSC 742406; (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (-)-CIS-4-(2-AMINO-6-(CYCLOPROPYLAMINO)-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL; NCGC00164560-02; NCGC00164560-05; NCGC00164560-17; BA166801; HY-17423; SMR004701251; C07624; D07057; EN300-258000; AB01566826_01; A807079; A905952; Q304330; J-700136; ((1s,4r)-4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)cyclopent-2-enyl)methanol; (+/-)-cis-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol;Abacavir	Approved	Approved Drug(s)	441300	DB01048	D0A4IJ	286.33	102	414	0.9	21	3	6	4	C14H18N6O	[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol	C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO	C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO	InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1	MCGSCOLBFJQGHM-SCZZXKLOSA-N
D03PXI	Febuxostat	Small molecule	Febuxostat; 144060-53-7; Adenuric; Uloric; 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid; Tei 6720; Feburic; Tei-6720; TMX 67; TMX-67; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid; Zurig; C16H16N2O3S; Febuxostat (Uloric); NSC-758874; 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID; CHEMBL1164729; DTXSID8048650; 101V0R1N2E; 5-Thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl-; Febuxostat [USAN]; NCGC00182059-02; DTXCID1028576; 5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-; SMR002529566; Uloric (TN); CAS-144060-53-7; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazolecarboxylic acid; 2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid; Donifoxate; Febuxostatum; Febuday; Goturic; Febric; Goutex; Febuxostat (JAN/USAN/INN); Febuxostat [USAN:INN:BAN]; UNII-101V0R1N2E; Febuxostat- Bio-X; Feburic (TN); SPIRAMYCINADIPATE; 111GE013; FEBUXOSTAT [MI]; FEBUXOSTAT [INN]; FEBUXOSTAT [JAN]; S1547; FEBUXOSTAT [VANDF]; 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid; FEBUXOSTAT [MART.]; FEBUXOSTAT [WHO-DD]; Febuxostat,Uloric, TMX-67; MLS004774136; MLS006011568; FEBUXOSTAT [EMA EPAR]; SCHEMBL249339; GTPL6817; thyl-thiazole-5-carboxylic acid; FEBUXOSTAT [ORANGE BOOK]; Febuxostat, >=98% (HPLC); CHEBI:31596; BCPP000233; HMS3264C20; HMS3655C03; HMS3673M21; HMS3743I09; HMS3868J03; MX-67; Pharmakon1600-01504286; ACT06289; BCP02342; WZB81950; Tox21_113004; AC-425; BBL036503; BDBM50320491; FD7322; MFCD00871598; NSC758874; STL559020; AKOS015841695; Tox21_113004_1; BCP9000679; BS-1018; CCG-213303; CS-0403; DB04854; NSC 758874; PB33929; 2-(3-Cyano-4-isobutoxy-phenyl)-4-me; NCGC00182059-03; BC164443; HY-14268; AM20090760; F0847; FT-0601639; SW219283-1; D01206; EN300-122360; AB01274796-01; AB01274796_02; AB01274796_03; Q417296; SR-01000940023; Q-100164; SR-01000940023-2; BRD-K48367671-001-01-8; Z1541759499; 2-(3-cyano-4-isobutyloxy)-phenyl-4-methyl-5-thiazolecarboxylic acid; 2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid; 2-(3-CYANO-4-ISOBUTOXYPHENYL)-4-METHYL-1,3-THIAZOLE-5-CARBOXYLIC ACID	Approved	Approved Drug(s)	134018	DB04854	D0A5SE	316.4	111	448	3.9	22	1	6	5	C16H16N2O3S	2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid	CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O	CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O	InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)	BQSJTQLCZDPROO-UHFFFAOYSA-N
D0AF4K	Haloperidol	Small molecule	haloperidol; 52-86-8; Haldol; Serenace; Aloperidin; Eukystol; Aloperidol; Serenelfi; Brotopon; Serenase; Dozic; Linton; Einalon S; Aloperidolo; Galoperidol; Halojust; Halopoidol; Ulcolind; Uliolind; Halopal; Keselan; Mixidol; Pernox; Sernas; Sernel; Aldo; Lealgin compositum; Bioperidolo; Sigaperidol; Peluces; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one; McN-JR-1625; Haloperidolum; Aloperidon; 177716-59-5; 4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one; R-1625; NSC 170973; R 1625; 1-(3-p-Fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine; Haloperidol (Haldol); 4'-Fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone; 4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone; CHEMBL54; Haldol (TN); Haldol Solutab; NSC-170973; NSC-615296; 4-(4-Hydroxy-4'-chloro-4-phenylpiperidino)-4'-fluorobutyrophenone; 1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-; 4-(4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone; 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone; MLS000028450; CHEBI:5613; DTXSID4034150; Fortunan; Halosten; 4-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone; J6292F8L3D; Butyrophenone, 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-; 1-Butanone, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-; NSC170973; NSC615296; CAS-52-86-8; NCGC00015500-10; Aloperidolo [DCIT]; Halidol; Halopidol; Pekuces; SMR000058303; Halol; Aloperidolo [Italian]; 4-(4-(para-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; Butyrophenone, 4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-4'-fluoro-; gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorobutyrophenone; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one; Haloperidolum [INN-Latin]; DTXCID2014150; Neurodol; Butyrophenone, 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4'-fluoro-; gamma-(4-(p-Chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone; CCRIS 1630; HSDB 3093; SR-01000003076; EINECS 200-155-6; NSC 615296; BRN 0331267; Duraperidol; UNII-J6292F8L3D; Epoxy resins; 4'-Fluoro-4-[4-hydroxy-4-(4'-chlorophenyl)piperidino]butyrophenone; gamma-[4-(p-chlorophenyl)-4-hydroxypiperidino]-p-fluorobutyrophenone; 4-[4-(para-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone; Picroside-III; Haloperidol, 1; Haloperidol, powder; Prestwick_250; Haloperidol [USAN:USP:INN:BAN:JAN]; Spectrum_000861; Tocris-0931; starbld0018801; Opera_ID_446; 4'-Fluoro-4-(4-hydroxy-4-p-chlorophenylpiperidino)butyrophenone; HALOPERIDOL [MI]; 4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one;propionate(HCl); 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone; gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorbutyrophenone; Prestwick0_000115; Prestwick1_000115; Prestwick2_000115; Prestwick3_000115; Spectrum2_001268; Spectrum3_000448; Spectrum4_000570; Spectrum5_000788; HALOPERIDOL [INN]; HALOPERIDOL [JAN]; Lopac-H-1512; HALOPERIDOL [HSDB]; HALOPERIDOL [USAN]; Biomol-NT_000035; GTPL86; Probes1_000255; Probes2_000296; H 1512; HALOPERIDOL [VANDF]; SCHEMBL8264; HALOPERIDOL [MART.]; Lopac0_000583; Oprea1_509923; BSPBio_000130; BSPBio_002096; HALOPERIDOL [USP-RS]; HALOPERIDOL [WHO-DD]; HALOPERIDOL [WHO-IP]; KBioGR_000980; KBioGR_002390; KBioSS_001341; KBioSS_002395; 5-21-02-00377 (Beilstein Handbook Reference); MLS001146904; BIDD:GT0128; DivK1c_000654; SPECTRUM1500325; Haloperidol-[Chlorophenyl-d4]; SPBio_001236; SPBio_002069; McM-JR-1625; BPBio1_000144; BPBio1_001231; Haloperidol (JP17/USP/INN); BDBM21398; HMS502A16; KBio1_000654; KBio2_001341; KBio2_002390; KBio2_003909; KBio2_004958; KBio2_006477; KBio2_007526; KBio3_001316; KBio3_002869; LNEPOXFFQSENCJ-UHFFFAOYSA-; HALOPERIDOL [ORANGE BOOK]; cMAP_000037; Haloperidol for system suitability; NINDS_000654; AC250; HALOPERIDOL [EP MONOGRAPH]; HALOPERIDOL [USP IMPURITY]; Haloperidol for peak identification; HMS1568G12; HMS1920D03; HMS2089M15; HMS2091J09; HMS2095G12; HMS2234P08; HMS3261F08; HMS3370H11; HMS3657I13; HMS3712G12; Pharmakon1600-01500325; HALOPERIDOL [USP MONOGRAPH]; BCP33202; CHA71659; Haloperidol 1.0 mg/ml in Methanol; STR04750; Tox21_110162; Tox21_300475; Tox21_500583; CCG-36042; CCG-39111; HALOPERIDOLUM [WHO-IP LATIN]; NSC757054; STL417208; VESALIUM COMPONENT HALOPERIDOL; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one; AKOS000280660; Tox21_110162_1; AT13670; CS-1971; DB00502; LP00583; NSC-757054; SDCCGSBI-0050565.P005; HALOPERIDOL COMPONENT OF VESALIUM; IDI1_000654; MRF-0000027; QTL1_000042; WLN: T6NTJ A3VR DF& DQ DR DG; NCGC00015500-01; NCGC00015500-02; NCGC00015500-03; NCGC00015500-04; NCGC00015500-05; NCGC00015500-06; NCGC00015500-07; NCGC00015500-08; NCGC00015500-09; NCGC00015500-11; NCGC00015500-12; NCGC00015500-13; NCGC00015500-14; NCGC00015500-15; NCGC00015500-16; NCGC00015500-17; NCGC00015500-19; NCGC00015500-24; NCGC00015500-32; NCGC00016234-01; NCGC00023875-02; NCGC00023875-04; NCGC00023875-05; NCGC00023875-06; NCGC00023875-07; NCGC00023875-08; NCGC00023875-09; NCGC00254503-01; NCGC00261268-01; AC-19691; BH166165; HY-14538; SBI-0050565.P004; Haloperidol decanoate impurity, haloperidol-; SC 170973; AB00052008; EU-0100583; FT-0669100; FT-0669101; FT-0697842; H0912; S1920; SW196557-4; C01814; D00136; VU0239704-10; AB00052008-21; AB00052008-22; AB00052008_23; AB00052008_24; A899749; L000288; Q251347; SR-01000003076-2; SR-01000003076-8; W-105791; BRD-K67783091-001-04-8; BRD-K67783091-001-05-5; BRD-K67783091-003-03-6; HALOPERIDOL DECANOATE IMPURITY G [EP IMPURITY]; SR-01000003076-11; Z1590789254; Haloperidol, European Pharmacopoeia (EP) Reference Standard; .gamma.-[4-(p-Chlorphenyl)-4-hydroxpiperidino]-p-fluorbutyrophenone; HALOPERIDOL DECANOATE IMPURITY, HALOPERIDOL- [USP IMPURITY]; Haloperidol, United States Pharmacopeia (USP) Reference Standard; .gamma.-(4-(p-Chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone; Haloperidol, Pharmaceutical Secondary Standard; Certified Reference Material; 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl) -1-butanone; Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard; Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	3559	DB00502	D0A6NU	375.9	40.5	451	3.2	26	1	4	6	C21H23ClFNO2	4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one	C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F	C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F	InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2	LNEPOXFFQSENCJ-UHFFFAOYSA-N
DD6U4A	Tiopronin	Small molecule	tiopronin; 1953-02-2; N-(2-Mercaptopropionyl)glycine; Acadione; Captimer; Thiopronine; Mucolysin; Capen; Thiola; Tiopronine; Epatiol; 2-(2-sulfanylpropanoylamino)acetic acid; Thiosol; Glycine, N-(2-mercapto-1-oxopropyl)-; Tiopronin (Thiola); A-MERCAPTOPROPIONYL GLYCINE; 2-(2-sulfanylpropanamido)acetic acid; 2-(2-Mercaptopropanamido)acetic acid; NSC-760416; CHEMBL1314; C5W04GO61S; N-(2-mercaptopropanoyl)glycine; Thiopronin; DTXSID4023678; CHEBI:32229; NCGC00159422-02; NCGC00159422-04; Sutilan; Glycine, N-(2-mercapto-1-oxopropyl)- (9CI); Thiolpropionamidoacetic acid; DTXCID803678; Tioglis; Vincol; CAS-1953-02-2; Meprin (detoxicant); N-(2-Mercapto-1-oxopropyl)glycine; Tiopronine [INN-French]; Tioproninum [INN-Latin]; Tiopronino [INN-Spanish]; (2-Mercaptopropionyl)glycine; Tiopronin [INN:DCF:JAN]; Tiopronino; Tioproninum; CCRIS 1935; (S)-2-(2-Mercaptopropanamido)acetic Acid; EINECS 217-778-4; Thiola (TN); BRN 1859822; THIOLA EC; Tiopronin (JAN/INN); TIOPRONIN [INN]; TIOPRONIN [JAN]; TIOPRONIN [MI]; GLYCINE, N-(2-MERCAPTOPROPIONYL)-; TIOPRONIN [VANDF]; 2-mercapto-propionylglycine; TIOPRONIN [MART.]; TIOPRONIN [WHO-DD]; (2-mercaptopropanoyl)glycine; UNII-C5W04GO61S; SCHEMBL19989; MLS006010632; alpha-mercaptopropionyl glycine; MERCAPTOPROPIONYLGLYCINE-; N-(2-Sulfanylpropanoyl)glycine; TIOPRONIN [ORANGE BOOK]; n-(2-mercaptopropionyl) glycine; N-(2-mercaptopropanoyl) glycine; Acadione; Capen; Epatiol; Vincol; HMS3264B11; HMS3655L15; Pharmakon1600-01506190; AMY39003; BCP13354; HY-B0373; 2-(2-Mercaptopropanamido)aceticacid; Tox21_111654; BDBM50020805; MFCD00004861; MFCD30157366; NSC760416; s2062; (2-Mercaptopropionylamino)acetic acid; AKOS015895408; N-(2-Mercaptopropionyl)glycine, 99%; Tox21_111654_1; AC-2087; CCG-214007; DB06823; NSC 760416; (2-Mercapto-propionylamino)-acetic acid; NCGC00159422-03; AS-12522; SMR001550282; SY262996; FT-0603530; FT-0653686; SW219206-1; T2614; Tiopronin, VETRANAL(TM), analytical standard; C73708; D01430; AB00376096_02; EN300-7408657; A813794; Q414456; SR-01000942263; J-012651; SR-01000942263-1; Z2681891170; TIOPRONIN, Dextiopronin, Tiopronin (n-2-mercaptopropionyl glycine)	Approved	Approved Drug(s)	5483	DB06823	D0A8CJ	163.2	67.4	148	-0.1	10	3	4	3	C5H9NO3S	2-(2-sulfanylpropanoylamino)acetic acid	CC(C(=O)NCC(=O)O)S	CC(C(=O)NCC(=O)O)S	InChI=1S/C5H9NO3S/c1-3(10)5(9)6-2-4(7)8/h3,10H,2H2,1H3,(H,6,9)(H,7,8)	YTGJWQPHMWSCST-UHFFFAOYSA-N
D46WNV	Labetalol	Small molecule	labetalol; 36894-69-6; Labetolol; Albetol; Ibidomide; Labetalolum; Normodyne; Trandate; 2-Hydroxy-5-(1-hydroxy-2-((4-phenylbutan-2-yl)amino)ethyl)benzamide; Labetalolum [INN-Latin]; AH 5158; 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide; 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide; Labetalol (INN); 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol; 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide; 2-Hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide; Benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)-; AH-5158A FREE BASE; CHEBI:6343; SCH-15719W FREE BASE; 36894-69-6 (free base); Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-; R5H8897N95; LABETALOL [INN]; Labetalol [INN:BAN]; 2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide; Apo-Labetalol; HSDB 6537; EINECS 253-258-3; 2-Hydroxy-5-(1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl)benzamide; UNII-R5H8897N95; Amipress (Salt/Mix); Trandate (Salt/Mix); Normodyne (Salt/Mix); Spectrum_001607; LABETALOL [MI]; LABETALOL [HSDB]; Prestwick0_000277; Prestwick1_000277; Prestwick2_000277; Prestwick3_000277; Spectrum2_000863; Spectrum3_001581; Spectrum4_000184; Spectrum5_001010; LABETALOL [VANDF]; CHEMBL429; EC 253-258-3; (non-labelled)Labetalol-d6; LABETALOL [WHO-DD]; SCHEMBL4582; Lopac0_000687; BSPBio_000154; BSPBio_003142; KBioGR_000727; KBioSS_002087; DivK1c_000474; SPBio_000905; SPBio_002373; BPBio1_000170; GTPL7207; DTXSID2023191; BDBM25758; KBio1_000474; KBio2_002087; KBio2_004655; KBio2_007223; KBio3_002642; CHEBI:167638; NINDS_000474; Labetalol hydrochloride (Salt/Mix); BCP31095; AH5158;Sch-15719W free base; MFCD00242941; AKOS015908406; CCG-204772; DB00598; DS-4652; SDCCGSBI-0050665.P004; IDI1_000474; NCGC00015595-03; NCGC00015595-04; NCGC00015595-06; NCGC00015595-07; NCGC00015595-12; NCGC00015595-14; NCGC00015595-19; NCGC00089800-02; AC-18747; Labetolol;Albetol;Normodyne;Apo-Labetalol; SBI-0050665.P003; HY-121383; AB00053659; CS-0081835; FT-0670696; C07063; C74903; D08106; AB00053659_13; EN300-1272609; A823444; L001344; Q958087; Q-201273; BRD-A07440155-003-05-6; BRD-A07440155-003-16-3; 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzene-1-carboximidic acid; 3-Carboxamido-4-hydroxy-.alpha.-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol; 32780-40-8	Approved	Approved Drug(s)	3869	DB00598	D0A8XN	328.4	95.6	385	3.1	24	4	4	8	C19H24N2O3	2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide	CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O	CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O	InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)	SGUAFYQXFOLMHL-UHFFFAOYSA-N
D21SFY	Indinavir	Small molecule	indinavir; 150378-17-9; Compound J; Indinavir anhydrous; MK-639; CHEBI:44032; (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; 9MG78X43ZT; Indinavir [USAN:INN:BAN]; D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-, (1(1S,2R),5(S))-; L-735524; (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide; D-erythro-Pentonamide, 2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-; Indinavir System Suitability; D-erythro-Pentonamide, 2,3,5-trideoxy-N-((1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-((2S)-2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-; N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; NSC697197; MK639; UNII-9MG78X43ZT; 1hsg; 1hsh; 1sdt; 1sdu; 1sdv; 1sgu; 2avo; 2avs; 2avv; 2bpx; Propolis+Indinavir; Crixivan (TM); (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxyindan-1-yl]amino]-5-oxo-pentyl]-N-tert-butyl-4-(3-pyridylmethyl)piperazine-2-carboxamide; (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide; L735,524; Indinavir & IFNL1; Indinavir & IFNL2; Indinavir & IFNL3; 1c6y; 1k6c; Indinavir & IL-29; INDINAVIR [INN]; Indinavir & IL-28A; Indinavir & IL-28B; INDINAVIR [MI]; CHEMBL115; INDINAVIR [WHO-DD]; SCHEMBL6317; BIDD:PXR0141; Indinavir & Interleukin 29; Indinavir & Interleukin 28A; Indinavir & Interleukin 28B; BIDD:GT0378; DTXSID4043802; Indinavir & Interferon lambda-1; Indinavir & Interferon lambda-2; Indinavir & Interferon lambda-3; Indinavir (*1:1 Sulfate salt*); HY-B0689; BDBM50067593; RS-253; AKOS000280989; AM84463; AT13874; DB00224; KS-5060; NCGC00159460-01; NCGC00159460-03; NCGC00159460-10; NCGC00159460-13; AC-20034; C07051; AB00698241-07; EN300-19767270; Q425490; J-008694; (.ALPHA.R,.GAMMA.S,2S)-.ALPHA.-BENZYL-2-(TERT-BUTYLCARBAMOYL)-.GAMMA.-HYDROXY-N-((1S,2R)-2-HYDROXY-1-INDANYL)-4-(3-PYRIDYLMETHYL)-1-PIPERAZINEVALERAMIDE; (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide; (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tert-butyl-4-[(pyridin-3-yl)methyl]piperazine-2-carboxamide; (S)-1-((2S,4R)-4-benzyl-2-hydroxy-5-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-ylamino)-5-oxopentyl)-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide; 2,3,5-Trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-D-erythro-pentonamide sulfate; 2-benzyl-5-[(2S)-2-(tert-butylcarbamoyl)-4-(pyridin-3-ylmethyl)piperazin-1-yl]-2,3,5-trideoxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-D-erythro-pentonamide; BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; D-erythro-Pentonamide,2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide	Approved	Approved Drug(s)	5362440	DB00224	D0A9NN	613.8	118	952	2.8	45	4	7	12	C36H47N5O4	(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide	CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5	CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5	InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1	CBVCZFGXHXORBI-PXQQMZJSSA-N
DE4DV9	Acarbose	Small molecule	acarbose; 56180-94-0; Glucobay; Precose; Bay g 5421; Acarbosum; Prandase; CHEBI:2376; BAY-g 5421; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; SMR000466376; SR-01000759407; xan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol; Glucobay;; Prandase;; Precose;; NSC-758915; Acarbose,(S); (3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)o; Precose (TN); MFCD00869592; Acarbose for identification; Acarbose (JAN/USAN/INN); MLS000759506; MLS001424056; MLS006011898; SPECTRUM1505172; CHEMBL404271; SCHEMBL5316305; Acarbose for peak identification; CHEMBL3734896; BDBM23406; HMS2051F03; HMS2093I22; HMS2236P06; Pharmakon1600-01505172; C25H43NO18;; BBL030515; BDBM50180587; NSC758915; STK801930; AKOS005622515; CCG-100913; CCG-213345; MD-0230; NC00163; NCGC00160515-01; (3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol; SBI-0206777.P001; C06802; D00216; AB00639959-06; AB00639959_08; Abamectin, Antibiotic for Culture Media Use Only; Q-200574; SR-01000759407-4; SR-01000759407-5; SR-01000759407-6; BRD-A16444946-001-07-1; (3R,4R,5S,6R)-5-(((2R,3R,4R,5S,6R)-5-(((2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl)amino)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4-triol; (3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4-triol; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; Precose (TN);; WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2122h-1a_1-5][a2122m-1a_1-5_4*NC^SC^SC^SC^RCCO/7=^ZC$3/6O/5O/4O]/1-2-3/a4-b1_b4-c1	Approved	Approved Drug(s)	41774	DB00284	D0AD5C	645.6	321	962	-8.5	44	14	19	9	C25H43NO18	(3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol	CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO	C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO	InChI=1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23?,24-,25-/m1/s1	XUFXOAAUWZOOIT-UGEKTDRHSA-N
DSCK32	Lorlatinib	Small molecule	Lorlatinib; 1454846-35-5; PF-06463922; Loratinib; Lorbrena; PF06463922; PF 06463922; OSP71S83EU; PF06463922(Lorlatinib); CHEMBL3286830; C21H19FN6O2; (10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile; (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile; 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-; Lorviqua; MFCD28144520; (10r)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2h-8,4-(Metheno)pyrazolo[4,3-H][2,5,11]benzoxadiazacyclotetradecine-3-Carbonitrile; UNII-OSP71S83EU; lorlatinibum; PF-6463922; 4cli; 4clj; Lorbrena (TN); 2H-4,8-Methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-; LORLATINIB [MI]; LORLATINIB [INN]; LORLATINIB [JAN]; Lorlatinib [USAN:INN]; LORLATINIB [USAN]; PFE-PKIS 10; LORLATINIB [WHO-DD]; 7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile; Lorlatinib (JAN/USAN/INN); GTPL7476; LORLATINIB [ORANGE BOOK]; PF-06463922  Lorlatinib; SCHEMBL15261807; AMY3295; EX-A828; CHEBI:143117; DTXSID201027944; BCP10287; BDBM50018830; NSC780108; NSC800990; s7536; AKOS027250753; CCG-268718; CS-3983; DB12130; NSC-780108; NSC-800990; NCGC00386417-02; NCGC00386417-13; AC-30881; HY-12215; A14207; D11012; A857523; J-690185; Q27285820; (10R)-7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15,16,17-TETRAHYDRO-2H-4,8- METHENOPYRAZOLO(4,3-H)(2,5,11)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE; (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile; (R)-26-Amino-55-fluoro-11,4,7-trimethyl-6-oxo-11H-3-oxa-7-aza-2(3,5)-pyridina-1(4,3)-pyrazola-5(1,2)-benzenacyclooctaphane-15-carbonitrile	Approved	Approved Drug(s)	71731823	DB12130	D0AF6O	406.4	110	700	1.5	30	1	7	0	C21H19FN6O2	(16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile	CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C	C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C	InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1	IIXWYSCJSQVBQM-LLVKDONJSA-N
D6OUV0	Gemcitabine	Small molecule	gemcitabine; 95058-81-4; 2',2'-Difluorodeoxycytidine; 2'-Deoxy-2',2'-difluorocytidine; Cytidine, 2'-deoxy-2',2'-difluoro-; dFdC; GEMCITABINE HYDROCHLORIDE; Gemcitabine free base; 103882-84-4; 2',2'-difluoro-2'-deoxycytidine; LY188011; 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one; LY-188011; 95058-81-4 (free base); 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; NSC 613327; B76N6SBZ8R; LY 188011; 4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; Gamcitabine; CHEBI:175901; NSC-613327; Gemcitabina; Gemcitabinum; Folfugem; Gemcel; Zefei; GemLip; 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; Gemcitabinum [INN-Latin]; Gemcitabina [INN-Spanish]; C9H11F2N3O4; Gemzar (hydrochloride); SR-05000001491; Gemcitabine (USAN/INN); UNII-B76N6SBZ8R; 2',2'-DiF-dC; Gemcitabine [USAN:INN:BAN]; CCRIS 8984; MFCD00869720; HSDB 7567; 2vpp; gemcitabine (Gemzar); 4pd5; GEMCITABINE [MI]; GEMCITABINE [INN]; 2'-Deoxy-.beta.-D-2',2'-difluorocytidine; GEMCITABINE [HSDB]; GEMCITABINE [USAN]; CHEMBL888; GEMCITABINE [VANDF]; SCHEMBL4295; GEMCITABINE [WHO-DD]; GTPL4793; DTXSID3040487; 2'deoxy-2',2'-difluorocytidine; BCPP000219; BDBM429521; HMS2089P10; HMS3715N07; 2`-Deoxy-2`,2`-difluorocytidine; med.21724, Compound Gemcitabine; DL-215; s1714; AKOS015920303; Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine; BCP9000721; CCG-221183; CS-0643; DB00441; GS-3582; 4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one; NCGC00168784-02; NCGC00168784-08; NCGC00168784-12; BP-58640; HY-17026; G0544; SW199649-2; C07650; D02368; EN300-267822; AB01274777-01; AB01274777-02; AB01274777_05; AB01274777_06; Q414143; J-001056; SR-05000001491-1; SR-05000001491-2; BRD-K15108141-001-04-1; Z1741982024; 1-(2-deoxy-2,2-difluoro-; A-D-erythropentofuranosyl)cytosine; 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one	Approved	Approved Drug(s)	60750	DB00441	D0AJ3K	263.2	108	426	-1.5	18	3	6	2	C9H11F2N3O4	4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one	C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F	C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F	InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1	SDUQYLNIPVEERB-QPPQHZFASA-N
D8Z7NK	Irbesartan	Small molecule	irbesartan; 138402-11-6; Avapro; Aprovel; Karvea; SR-47436; BMS-186295; Irbesartan BMS; SR 47436; BMS 186295; Irbesartan Zentiva; Irbesartan D4; Sarbevel; Irbesartan teva; Irbesartan-d3; Irbesartan free base; NSC-758696; CHEMBL1513; 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one; CHEBI:5959; DTXSID0023169; J0E2756Z7N; 138402-11-6 (free base); 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one; 1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; NCGC00095122-01; 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; DTXCID903169; Irbetan; Irbesartan Krka; [3H]irbesartan; 3-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one; Irbesartan Winthrop; SMR000466306; Avapro (TN); CAS-138402-11-6; 1185120-76-6; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; UNII-J0E2756Z7N; 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one; HSDB 8215; Irbesartan [USAN:USP:INN:BAN]; Irbesartan ,(S); 2-butyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one; 3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one; Irbesartan- Bio-X; Irbesartan (Avapro); MFCD00864464; Spectrum_001751; IRBESARTAN [MI]; IRBESARTAN [INN]; IRBESARTAN [JAN]; Spectrum2_001675; Spectrum3_000994; Spectrum4_001122; Spectrum5_001288; IRBESARTAN [USAN]; IRBESARTAN [VANDF]; IRBESARTAN [MART.]; SCHEMBL4246; IRBESARTAN [USP-RS]; IRBESARTAN [WHO-DD]; BSPBio_002687; GTPL589; KBioGR_001603; KBioSS_002231; MLS000759408; MLS001424099; BIDD:GT0347; IRBESARTAN [EMA EPAR]; SPECTRUM1504259; SPBio_001889; GTPL6908; Irbesartan (JP17/USP/INN); IRBESARTAN [EP IMPURITY]; IRBESARTAN [ORANGE BOOK]; KBio2_002231; KBio2_004799; KBio2_007367; KBio3_001907; IRBESARTAN [EP MONOGRAPH]; IRBESARTAN [USP IMPURITY]; BCPP000202; HMS1922J05; HMS2051L08; HMS2093E16; HMS2232F23; HMS3370B06; HMS3393L08; HMS3715L04; IRBESARTAN [USP MONOGRAPH]; Pharmakon1600-01504259; AVALIDE COMPONENT IRBESARTAN; BCP02004; HY-B0202; Tox21_111433; AC-537; BDBM50042235; CCG-39091; COAPROVEL COMPONENT IRBESARTAN; NSC758696; STK645362; AKOS005576396; AKOS015895353; IFIRMACOMBI COMPONENT IRBESARTAN; IRBESARTAN COMPONENT OF AVALIDE; Irbesartan, >=98% (HPLC), powder; Tox21_111433_1; AB07472; AM90289; BCP9000792; CCG-101012; DB01029; KS-1151; NC00262; NSC 758696; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one; IRBESARTAN COMPONENT OF COAPROVEL; IRBESARTAN COMPONENT OF KARVEZIDE; NCGC00095122-02; NCGC00095122-03; NCGC00095122-04; NCGC00095122-05; NCGC00095122-14; 2-BUTYL-3-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE; BI164582; IRBESARTAN COMPONENT OF IFIRMACOMBI; SBI-0206769.P001; FT-0601598; FT-0670413; I0859; S1507; SR-47436;BMS-186295; C07469; D00523; AB00639954-06; AB00639954_07; AB00639954_08; A807387; EN300-37158602; L000319; Q947266; SR-05000001997; Q-201249; SR-05000001997-1; BRD-K60038276-001-02-5; BRD-K60038276-001-03-3; IBERSARTAN/HYDROCHLOROTHIAZIDE COMPONENT IBERSARTAN; Irbesartan, European Pharmacopoeia (EP) Reference Standard; IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA COMPONENT IBERSARTAN; Irbesartan, United States Pharmacopeia (USP) Reference Standard; IBERSARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA; IBERSARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA; IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA COMPONENT IBERSARTAN; Irbesartan, Pharmaceutical Secondary Standard; Certified Reference Material; 2-(n-butyl)-3-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one; 2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[4.4]non-1-en-4-one; 2-butyl-3-{[2''-(1H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; 2-butyl-3-{[2''-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; 2-butyl-3-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)-methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one; 8-butyl-7-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one	Approved	Approved Drug(s)	3749	DB01029	D0AL2K	428.5	87.1	682	4.1	32	1	5	7	C25H28N6O	2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5	InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)	YOSHYTLCDANDAN-UHFFFAOYSA-N
D3W6KY	Pegfilgrastim	Small molecule	Pefloxacin mesylate; 70458-95-6; Pefloxacin methanesulfonate; Pegfilgrastim; pefloxacin mesilate; PEFLOXACINE MESYLATE; Pefloxacin mesylate [USAN]; Pefloxacin (mesylate); 41 982 RP; 208265-92-3; 5IAD0UV3FH; NSC-758944; Pefloxacinium mesylate; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;methanesulfonic acid; DTXSID8045935; Pefloxacinium mesylate dihydrate; NCGC00095159-01; 41-982-RP; Pefloxacin mesylate (USAN); 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-, monomethanesulfonate; 3-Quinolinecarboxylic acid,1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-,monomethanesulfonate; DTXCID6025935; MLS001049009; CHEBI:50194; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound with methanesulfonic acid (1:1); CAS-70458-95-6; 1589 mR.B.; SMR000387024; EINECS 274-613-9; UNII-5IAD0UV3FH; 3-Carboxy-1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxoquinoline monomethanesulphonate; 1-Ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, monomethanesulfonate; MLS001401444; SCHEMBL135085; SPECTRUM1505305; CHEMBL1428564; HY-B0147A; HMS1922B14; HMS2051H19; HMS2093B03; HMS2267K05; HMS3393H19; HMS3655C18; Pharmakon1600-01505305; BCP07819; PEFLOXACIN MESILATE [MART.]; Tox21_111458; CCG-39994; NSC758944; PEFLOXACIN MESILATE [WHO-DD]; s1855; AKOS015918261; Tox21_111458_1; CS-1962; NC00228; NSC 758944; NCGC00095159-02; NCGC00177986-02; AC-13996; AS-16015; 5-AMINO-1H-INDOLE-3-CARBOXYLICACID; DB-055418; FT-0630799; FT-0673546; SW197608-3; D02307; PEFLOXACIN METHANESULFONATE ANHYDROUS [MI]; Q-201538; SR-01000356843-5; Q27121975; Pefloxacin mesylate, Antibiotic for Culture Media Use Only; 1-ETHYL-6-FLUORO-1,4-DIHYDRO-7-(4-METHYL-1-PIPERAZINYL)-4-OXO-3-QUINOLINECARBOXYLIC MESILATE; 1-ETHYL-6-FLUORO-1,4-DIHYDRO-7-(4-METHYL-1-PIPERAZINYL)-4-OXO-3-QUINOLINECARBOXYLIC MESYLATE; 1-Ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid monomethanesulfonate; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; methanesulfonic acid; 3-QUINOLINECARBOXYLIC ACID, 1-ETHYL-6-FLUORO-1,4-DIHYDRO-7-(4-METHYL-1-PIPERAZINYL)-4-OXO-, MONOMETHANESULPHONATE	Approved	Approved Drug(s)	119525	DB00019	D0AT8C	429.5	127	638	.	29	2	10	3	C18H24FN3O6S	1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;methanesulfonic acid	CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O.CS(=O)(=O)O	CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O.CS(=O)(=O)O	InChI=1S/C17H20FN3O3.CH4O3S/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21;1-5(2,3)4/h8-10H,3-7H2,1-2H3,(H,23,24);1H3,(H,2,3,4)	HQQSBEDKMRHYME-UHFFFAOYSA-N
DVYB50	Vancomycin	Small molecule	VANCOMYCIN; Vancocin; Vancoled; 1404-90-6; Vancomycinum; Vancomicina; Vancomycine; VANCOR; Vancomycin HCL; 6Q205EH1VU; CHEMBL262777; CHEBI:28001; Vancomycin (USP); Vancomycine [INN-French]; Vancomycinum [INN-Latin]; Vancomicina [INN-Spanish]; HSDB 3262; EINECS 215-772-6; vancomicin; vanomycin; UNII-6Q205EH1VU; Vancomycin [USP:INN:BAN]; Vancomycin hydrochloride from Streptomyces orientalis; Viomycin derivative; [(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-(2-amino-2-oxo-ethyl)-dichloro-pentahydroxy-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-pentaoxo-[?]carboxylic acid; Glycopeptide Antibiotic; C06689; D00212; VANCOMYCIN [MI]; VANCOMYCIN [INN]; Prestwick0_000497; Prestwick1_000497; Prestwick2_000497; VANCOMYCIN [HSDB]; SCHEMBL3177; VANCOMYCIN [MART.]; VANCOMYCIN [WHO-DD]; Chloroorienticin B derivative; Lopac0_001267; N-demethylvancomycin derivative; SPBio_002314; CHEMBL3735877; DTXSID0042664; VANCOMYCIN [ORANGE BOOK]; GTPL10932; VANCOMYCIN [USP IMPURITY]; VANCOMYCIN [USP MONOGRAPH]; ACT02696; HY-B0671; N-(3-benzoylpyridin-4-yl)acetamide; BDBM50335519; s5784; AKOS030526092; CCG-205340; CS-3242; DB00512; SDCCGSBI-0051233.P002; NCGC00162383-04; NCGC00162383-11; 4-Naphthalen-2-ylmethyl-4,5-dihydro-1H-imidazole; A929942; Q424027; SR-01000076194-5; BRD-K91065602-003-05-5; (2.2Sp,3.5Sa,2.6Sp)-O4.2,C3.4:C5.4,O4.6:C3.5,C2.7-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-beta-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-beta-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]; (S)-3,6-Diamino-hexanoic acid {(3S,9S,12S,15S)-3-((S)-6-hydroxy-2-imino-hexahydro-pyrimidin-4-yl)-9,12-bis-hydroxymethyl-2,5,8,11,14-pentaoxo-6-[1-ureido-meth-(Z)-ylidene]-1,4,7,10,13pentaaza-cyclohexadec-15-yl}-amide; 22H-8,11:18,21-Dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno-1H,16H-[1,6,9]oxadiazacyclohexadecino[4,5-m][10,2,16]benzoxadiazacyclotetracosine,vancomycin deriv.	Approved	Approved Drug(s)	14969	DB00512	D0B1IV	1449.2	531	2960	-2.6	101	19	26	13	C66H75Cl2N9O24	(1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid	CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O	C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O	InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1	MYPYJXKWCTUITO-LYRMYLQWSA-N
D2FYL3	Glimepiride	Small molecule	glimepiride; 93479-97-1; Amaryl; Amarel; Glimepirid; Glimepirida; Glimepiridum; cis-Glimepiride; Hoe-490; Glimepride; HOE 490; 684286-46-2; Glimepiride, cis-; GLIMPERIDE; Glimepiride Impurity A; 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide; CHEBI:5383; 1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea; Endial; NSC-759809; 24T6XIR2MZ; 261361-60-8; DTXSID5040675; 6KY687524K; NCGC00016960-03; Glimepiridum [Latin]; Roname; Glimepirida [Spanish]; CAS-93479-97-1; Glista OD; 1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-(2-(4-(((((4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-, trans-; 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; DTXCID3020675; Glymepirid; Glorion; Glemax; Glimer; Solosa; 3-ethyl-4-methyl-N-{2-[4-({[(4-methylcyclohexyl)carbamoyl]amino}sulfonyl)phenyl]ethyl}-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; SMR000466368; Amaryl (TN); CCRIS 7083; SR-05000001508; UNII-24T6XIR2MZ; BRN 5365754; gimepiride; vitamine; Niddaryl; Sugral; HOE490; UNII-6KY687524K; Glimepiride,(S); 1-[[4-[2-[[(3-Ethyl-4-methyl-2-oxo-2,3-dihydro-1H-pyrrol-1-yl)carbonyl]amino]ethyl]phenyl]sulphonyl]-3-(cis-4-methylcyclohexyl)urea (cis-Glimepiride); 3-ethyl-4-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-2-oxo-5H-pyrrole-1-carboxamide; Glimepiride [USAN:USP:INN:BAN]; Amaryl, Glista OD; Glimepiride- Bio-X; MFCD00878417; CPD000466368; GLIMEPIRIDE [MI]; Prestwick0_000651; Prestwick1_000651; Prestwick2_000651; Prestwick3_000651; GLIMEPIRIDE [INN]; GLIMEPIRIDE [JAN]; GLIMEPIRIDE [USAN]; GLIMEPIRIDE [VANDF]; CHEMBL1481; GLIMEPIRIDE [MART.]; Oprea1_382896; SCHEMBL16084; SCHEMBL16086; BSPBio_000681; GLIMEPIRIDE [USP-RS]; GLIMEPIRIDE [WHO-DD]; GLIMEPIRIDE CIS-ISOMER; MLS000759495; MLS001076674; MLS001401419; MLS003915622; MLS006011260; SPBio_002602; GLIMEPIRIDE [EMA EPAR]; BPBio1_000751; CHEMBL149223; GTPL6820; SCHEMBL8738802; Glimepiride (JP17/USP/INN); SCHEMBL14371714; SCHEMBL14965363; CHEBI:92609; DTXSID20861130; GLIMEPIRIDE [ORANGE BOOK]; Glimepiride for system suitability; GLIMEPIRIDE [EP MONOGRAPH]; GLIMEPIRIDE [USP IMPURITY]; HMS1570C03; HMS2052L03; HMS2090K18; HMS2097C03; HMS2235L07; HMS3269A09; HMS3372O07; HMS3394L03; HMS3413K06; HMS3654F17; HMS3677K06; HMS3714C03; Pharmakon1600-01504915; GLIMEPIRIDE [USP MONOGRAPH]; BCP05331; DUETACT COMPONENT GLIMEPIRIDE; HY-B0104; Tox21_110713; AC-476; BDBM50237590; NSC759809; NSC813217; s1344; STL451059; STL453194; AKOS015894919; AKOS015969663; Glimepiride, >=98% (HPLC), solid; Tox21_110713_1; AB07644; BCP9000728; CCG-101156; CS-1844; DB00222; GLIMEPIRIDE COMPONENT OF DUETACT; KS-5238; NC00406; NSC 759809; NSC-813217; NCGC00016960-01; NCGC00016960-02; NCGC00016960-04; NCGC00016960-05; NCGC00016960-07; NCGC00161404-01; NCGC00161404-02; NCGC00181757-01; NCGC00371061-02; NCGC00371061-06; 1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea; 1H-Pyrrole-1-carboxamide, 2,5-dihydro-3-ethyl-4-methyl-N-(2-(4-(((((4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-, trans-; 3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro; BG164507; SMR001550123; Glimepiride 100 microg/mL in Acetonitrile; AB00513874; CS-0165191; FT-0626713; FT-0668978; G0395; GLIMEPIRIDE IMPURITY A [EP IMPURITY]; SW196369-4; C07669; D00593; AB00513874-06; AB00513874-08; AB00513874-09; AB00513874_10; AB00513874_11; A844609; A899888; EN300-19873446; Q425027; Q-201158; SR-05000001508-1; SR-05000001508-2; SR-05000001508-3; BRD-K34776109-001-03-4; BRD-K42693031-001-01-8; Q27253874; Z1501475009; Glimepiride, British Pharmacopoeia (BP) Reference Standard; Glimepiride, European Pharmacopoeia (EP) Reference Standard; 3-ethyl-4-methyl-N-(4-(N-((1r,4r)-4-methylcyclohexylcarbamoyl); Glimepiride, United States Pharmacopeia (USP) Reference Standard; sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; Glimepiride for system suitability, European Pharmacopoeia (EP) Reference Standard; 1-((4-(2-(((3-ETHYL-4-METHYL-2-OXO-2,3-DIHYDRO-1H-PYRROL-1-YL)CARBONYL)AMINO)ETHYL)PHENYL)SULFONYL)-3-(CIS-4-METHYLCYCLOHEXYL)UREA; 1H-PYRROLE-1-CARBOXAMIDE, 3-ETHYL-2,5-DIHYDRO-4-METHYL-N-(2-(4-(((((CIS-4-METHYLCYCLOHEXYL)AMINO)CARBONYL)AMINO)SULFONYL)PHENYL)ETHYL)-2-OXO-; 1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(trans- 4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-; 3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide; 3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-2-oxo-N-(2-{4-[({[(1r,4r)-4-methylcyclohexyl]carbamoyl}amino)sulfonyl]phenyl}ethyl)-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-N-(4-(N-(((1r,4r)-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-N-(4-(N-(((1s,4s)-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide? (Glimepiride Impurity pound(c); 3-ETHYL-4-METHYL-N-(4-(N-((1R,4R)-4-METHYLCYCLOHEXYLCARBAMOYL)SULFAMOYL)PHENETHYL)-2-OXO-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE; 3-Ethyl-4-methyl-N-(4-(N-((rel-(1r,4r)-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-N-(4-(N-((trans-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-N-[2-(4-{[(4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-Ethyl-4-Methyl-N-[2-(4-{[(Cis-4-Methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-Oxo-2,5-Dihydro-1h-Pyrrole-1-Carboxamide; 3-Ethyl-4-methyl-N-[2-[4-[[3-(4-methylcyclohexyl)ureido]sulfonyl]phenyl]ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; N'-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-N-(4-methylcyclohexyl)carbamimidic acid; N-(4-ethyl-3-methyl-5-oxo-2H-pyrrol-1-yl)-3-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]propanamide;GLIMEPIRIDE; N-[4-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)-ethyl]-benzenesulfonyl]-N'-4-methylcyclohexylurea; trans-1-(4-(2-(3-ethyl-4-Me-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamido)ethyl)phenylsulfonyl)-3-(4-methylcyclohexyl)urea; trans-3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methyl cyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide; Trans-3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide; trans-3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxyamide	Approved	Approved Drug(s)	3476	DB00222	D0B2GI	490.6	133	895	3.9	34	3	5	7	C24H34N4O5S	4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide	CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C	CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C	InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)	WIGIZIANZCJQQY-UHFFFAOYSA-N
DK5E3I	Nelarabine	Small molecule	Nelarabine; Nelzarabine; 121032-29-9; Arranon; Atriance; 506U78; GW-506U78; 506U; GW 506U78; Attriance; NSC-686673; (2R,3S,4S,5R)-2-(2-Amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine; Nelarabine (Arranon); CHEBI:63612; (2R,3S,4S,5R)-2-(2-amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; NSC-755985; MAY; DTXSID6046842; 2-Amino-6-methoxypurine arabinoside; NSC-759876; NCGC00181098-01; 60158CV180; S1213; Nelarabine [USAN]; DTXCID4026842; ArranonG; GW506U78; SMR002544682; Arranon (TN); Nelzarabine (USAN); CAS-121032-29-9; compound 506U78; C11H15N5O5; Nelarabine [USAN:INN:BAN]; GW-506U; UNII-60158CV180; Nelarabine [INN]; 9beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine; 9-beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine; NSC 686673; NELARABINE [MI]; NELARABINE [JAN]; NELARABINE [VANDF]; NELARABINE [MART.]; NELARABINE [WHO-DD]; SCHEMBL18820; MLS003915614; MLS004774135; MLS006010906; Nelarabine (JAN/USAN/INN); NELARABINE [EMA EPAR]; GTPL7090; CHEMBL1201112; NELARABINE [ORANGE BOOK]; BCPP000392; HMS3715I16; Tox21_112714; BDBM50247985; MFCD00871078; NSC755985; 2-(2-Amino-6-methoxy-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol; AKOS015852325; AKOS015920191; Tox21_112714_1; BCP9000318; CCG-267441; CS-1607; DB01280; NCGC00274059-01; NCGC00274059-02; AS-47664; BP-58633; HY-13701; N1144; SW218086-2; D05134; F15095; AB01274773-01; AB01274773_02; EN300-7361965; A804639; A935144; SR-01000931847; 9-?-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine; Q1216264; SR-01000931847-3; 2-Amino-6-methoxy-9-b-D-arabinofuranosyl-9 H-purine; 2-Amino-6-methoxy-9-b-D-arabinofuranosyl-9H-purine; 9H-Purin-2-amine, 9-b-D-arabinofuranosyl-6-methoxy-; BRD-K84466663-001-01-3; 2-Amino-6-methoxy-9-beta-D-arabinofuranosyl-9H-purine; 9-(beta-D-arabinofuranosyl)-6-methoxy-9H-purin-2-amine; 9-beta -D-arabinofuranosyl-2-amino-6-methoxy-9H-purine; 9-beta-D-arabinofuranosyl-2-amino-6-methoxy-9 H-purine; 9H-Purin-2-amine, 9beta-D-arabinofuranosyl-6-methyl-; 2-Amino-6-methoxy-9-(beta-D-arabinofuranosyl)-9H-purine; 2-AMINO-9-.BETA.-D-ARABINOFURANOSYL-6-METHOXY-9H-PURINE; 9-.BETA.-D-ARABINOFURANOSYL-6-METHOXY-9H-PURIN-2-AMINE; 9H-PURIN-2-AMINE, 9-.BETA.-D-ARABINOFURANOSYL-6-METHOXY-; (2R,3S,4S,5R)-2-(2-amino-6-methoxy-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3S,4S,5R)-2-(2-azanyl-6-methoxy-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(hydroxymethyl)-5-(2-imino-6-methoxy-3,9-dihydro-2H-purin-9-yl)oxolane-3,4-diol	Approved	Approved Drug(s)	3011155	DB01280	D0B8UJ	297.27	149	377	-0.7	21	4	9	3	C11H15N5O5	(2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol	COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N	COC1=NC(=NC2=C1N=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N	InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1	IXOXBSCIXZEQEQ-UHTZMRCNSA-N
DO2TV6	Levonorgestrel	Small molecule	Levonorgestrel; norgestrel; 797-63-7; D-Norgestrel; Mirena; (-)-Norgestrel; Levonova; Microval; Postinor; Plan B; NORPLANT; Jadelle; dl-Norgestrel; Follistrel; 18-Methylnorethisterone; Levonorgestrelum; Ovrette; 6533-00-2; d(-)-Norgestrel; Levonelle; Neogest; Levonorgestrelum [INN-Latin]; Liletta; Fallback Solo; Monovar; Wy-5104; Norgestrel-(-)-D; 17-Ethynyl-18-methyl-19-nortestosterone; 17alpha-Ethynyl-18-homo-19-nortestosterone; 18-Methyl-17-alpha-ethynyl-19-nortestosterone; 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one; 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one; Norgestrelum; 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol; 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one; BAY86-5028; Norgestrel, (-)-; Norgestrel (-)-form; Norplant 2; Microlution; Ovranette; Triagynon; Triciclor; Microgyn; Microlut; 5W7SIA7YZW; Nordet; Trigoa; Wy 3707; Wy-3707; 17-alpha-Ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one; NSC-744007; Microgynon CD; Microgest ED; Norplant II; (-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one; Logynon ED; Ovral-Lo; Levlen ED; Microgynon 21; Microgynon 28; Trinordiol 21; Trinordiol 28; MLS000069491; CHEBI:6443; Minivlar 30; Monofeme 28; Neogynon 21; Nordette 21; Nordette 28; Stediril 30; Trifeme 28; DTXSID3036496; DTXSID3047477; Preven; Levora-21; Levora-28; Microgynon 30 ED; Tri-Levlen 21; 17-alpha-Ethynyl-13-ethyl-19-nortestosterone; Rigevidon 21+7; FH 122-A; NorLevo; 13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one; SH 850; Triquilar ED; LD norgestrel [French]; Triphasil 21; Triphasil 28; 3J8Q1747Z2; (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one; SH 70850; NCGC00159349-02; Norgestrelum [INN-Latin]; 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; SMR000059117; Levonorgestrel implants; E-Gen-C; Norgestrel [Progestins]; Ovoplex 30-150; (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one; (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; DTXCID1016496; Microluton; Levogel; Levosert; Skyla; 13-ethyl-17alpha-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one; Next choice; Norplant System in Plastic Container; Plan B One Step; Plan B One-Step; Norplant (TN); rel-(8R,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-17-hydroxy-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; Ovrette (TN); Mirena (TN); CCRIS 6525; CCRIS 9033; Levonorgestrel (Levonelle); HSDB 3595; HSDB 6483; LNG-IUS; 17alpha-Ethynyl-13-ethyl-19-nortestosterone; 13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; EINECS 212-349-8; EINECS 229-433-5; UNII-5W7SIA7YZW; BRN 2391114; FH-122A; 13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one; Kyleena; dl-13-beta-Ethyl-17-alpha-ethynyl-19-nortestosterone; SH-850; 19-Nortestosterone, 17-ethynyl-18-methyl-; Levonorgestrel (JAN/USP/INN); UNII-3J8Q1747Z2; 1lhv; NSC-757251; Oral levonorgestrel; CAS-797-63-7; LNG; SH-70850; Prestwick_109; (+-)-Norgestrel; 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)-; (-)-Levonorgestrel; Levonorgestrel [USAN:USP:INN:BAN]; MFCD00199013; Levonorgestrel implant; Skyla (TN); Norgestrel [USAN:USP:INN:BAN:JAN]; BAY 86-5028; NORGESTREL [MI]; Opera_ID_552; Levonorgestrel(Levonelle); NORGESTREL [INN]; NORGESTREL [JAN]; dl-13-beta-Ethyl-17-alpha-ethynyl-17-beta-hydroxygon-4-en-3-one; Prestwick0_000773; Prestwick1_000773; Prestwick2_000773; Prestwick3_000773; NORGESTREL [HSDB]; NORGESTREL [USAN]; Intrauterine levonorgestrel; 17-beta-Hydroxy-18-methyl-19-nor-17-alpha-pregn-4-en-20-yn-3-one; NORGESTREL [VANDF]; (+-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one; (-)-Norgestrel, 98%; 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(-)-; NORGESTREL [MART.]; CHEMBL1389; LEVONORGESTREL [INN]; LEVONORGESTREL [JAN]; NORGESTREL [USP-RS]; NORGESTREL [WHO-DD]; BIDD:PXR0194; SCHEMBL27597; BSPBio_000846; LEVONORGESTREL [HSDB]; LEVONORGESTREL [USAN]; MLS000759484; MLS001074069; MLS001423967; LEVONORGESTREL [VANDF]; SPBio_002785; LEVONORGESTREL [MART.]; 13-Ethyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one; BPBio1_000932; GTPL2881; Norgestrel (JP17/USP/INN); LEVONORGESTREL [USP-RS]; LEVONORGESTREL [WHO-DD]; LEVONORGESTREL [WHO-IP]; NORGESTREL [ORANGE BOOK]; OVRAL COMPONENT NORGESTREL; 17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one; NORGESTREL [EP MONOGRAPH]; IMPLANT WITH LEVONORGESTREL; DTXCID401079284; HMS1570K08; HMS2051M08; HMS2090O06; HMS2097K08; HMS2232H06; HMS2232K12; HMS3649J10; HMS3714K08; HMS3886K18; NORGESTREL [USP MONOGRAPH]; AMY40476; CRYSELLE COMPONENT NORGESTREL; HY-B0257; NORGESTREL (-)-FORM [MI]; D-(-)-Norgestrel (Levonorgestrel); LEVONORGESTREL [ORANGE BOOK]; NORGESTREL COMPONENT OF OVRAL; Tox21_111593; Tox21_202872; Tox21_303623; Tox21_303658; BDBM50410522; LEVONORGESTREL [EP MONOGRAPH]; LEVONORGESTREL [USP IMPURITY]; LMST02030119; NSC744007; s1727; s5709; ALESSE COMPONENT LEVONORGESTREL; AVIANE COMPONENT LEVONORGESTREL; D(-)-Norgestrel, analytical standard; LEVONORGESTREL [USP MONOGRAPH]; LEVORA COMPONENT LEVONORGESTREL; LYBREL COMPONENT LEVONORGESTREL; PORTIA COMPONENT LEVONORGESTREL; PREVEN COMPONENT LEVONORGESTREL; TWIRLA COMPONENT LEVONORGESTREL; VIENVA COMPONENT LEVONORGESTREL; 18,19-Dinor-17-alpha-pregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-; AKOS015894913; KURVELO COMPONENT LEVONORGESTREL; KYLEENA COMPONENT LEVONORGESTREL; LESSINA COMPONENT LEVONORGESTREL; LEVLITE COMPONENT LEVONORGESTREL; MYZILRA COMPONENT LEVONORGESTREL; PLASTIC IUD WITH LEVONORGESTREL; Tox21_111593_1; TRIVORA COMPONENT LEVONORGESTREL; BCP9000852; CCG-100853; DB00367; Levonorgestrel for system suitability 1; Levonorgestrel for system suitability 2; LEVONORGESTRELUM [WHO-IP LATIN]; NC00103; NORGESTREL COMPONENT OF CRYSELLE; NSC 744007; NSC 757251; NSC 759653; 18,19-Dinor-17-alpha-pregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (+-)-; ALTAVERA COMPONENT LEVONORGESTREL; ELIFEMME COMPONENT LEVONORGESTREL; ENPRESSE COMPONENT LEVONORGESTREL; LEVONEST COMPONENT LEVONORGESTREL; MARLISSA COMPONENT LEVONORGESTREL; NORDETTE COMPONENT LEVONORGESTREL; ORSYTHIA COMPONENT LEVONORGESTREL; QUASENSE COMPONENT LEVONORGESTREL; SETLAKIN COMPONENT LEVONORGESTREL; [18,(17.alpha.)-(-)-]; AFIRMELLE COMPONENT LEVONORGESTREL; INTROVALE COMPONENT LEVONORGESTREL; LEVONORGESTREL COMPONENT OF ALESSE; LEVONORGESTREL COMPONENT OF LYBREL; LEVONORGESTREL COMPONENT OF PREVEN; LEVONORGESTREL COMPONENT OF TWIRLA; NCGC00159349-03; NCGC00159349-05; NCGC00256735-01; NCGC00257283-01; NCGC00260418-01; QUARTETTE COMPONENT LEVONORGESTREL; SEASONALE COMPONENT LEVONORGESTREL; TRIPHASIL COMPONENT LEVONORGESTREL; LEVONORGESTREL COMPONENT OF KYLEENA; LEVONORGESTREL COMPONENT OF LEVLITE; SEASONIQUE COMPONENT LEVONORGESTREL; SMR000653526; CAS-6533-00-2; CLIMARA PRO COMPONENT LEVONORGESTREL; LEVONORGESTREL COMPONENT OF ALTAVERA; LEVONORGESTREL COMPONENT OF LEVONEST; LEVONORGESTREL COMPONENT OF QUASENSE; LEVONORGESTREL COMPONENT OF SETLAKIN; LEVONORGESTREL COMPONENT OF INTROVALE; LEVONORGESTREL COMPONENT OF SEASONALE; LOSEASONIQUE COMPONENT LEVONORGESTREL; LEVONORGESTREL COMPONENT OF SEASONIQUE; N0889; NORGESTIMATE IMPURITY B [EP IMPURITY]; Levonorgestrel 100 microg/mL in Acetonitrile; LEVONORGESTREL COMPONENT OF CLIMARA PRO; C08149; C08153; D00950; D00954; EN300-122613; L-4455; LEVONORGESTREL COMPONENT OF LOSEASONIQUE; OPCICON ONE-STEP COMPONENT LEVONORGESTREL; Q416950; SR-01000759218; SR-01000946725; (-)-17alpha-Ethynyl-18-methyl-19-nortestosterone; LEVONORGESTREL COMPONENT OF OPCICON ONE-STEP; SR-01000759218-5; SR-01000946725-1; BRD-K35189033-001-03-0; 13-ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; Z1544404028; 13beta-ethyl-17alpha-ethynyl-17-hydroxy-gon-4-en-3-one; (17?)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-yn-3-one; 13beta-ethyl-17alpha-ethynyl-17beta-hydroxy-gon-4-en-3-one; Levonorgestrel, British Pharmacopoeia (BP) Reference Standard; Levonorgestrel, European Pharmacopoeia (EP) Reference Standard; Levonorgestrel, United States Pharmacopeia (USP) Reference Standard; (-)-18,19-Dinor-13beta-ethyl-17beta-hydroxy-4-pregnen-20-yn-3-one; [(-)-13-ethyl-17-hydroxy-18,19-dinor-17a-pregn-4-en-20-yn-3-one; (+/-)-13-ETHYL-17-HYDROXY-18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YN-3-ONE; (-)-13-ETHYL-17-HYDROXY-18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YN-3-ONE; [18,19-Dinorpregn-4-en-20-yn-3-one-13-ethyl-17-hydroxy-,(17..)-(-)-]; 18,19-DINORPREGN-4-EN-20-YN-3-ONE, 13-ETHYL-17-HYDROXY-, (17.ALPHA.)-(+/-)-; 18,19-DINORPREGN-4-EN-20-YN-3-ONE, 13-ETHYL-17-HYDROXY-, (17.ALPHA.)-(-)-; Levonorgestrel for system suitability 2, European Pharmacopoeia (EP) Reference Standard; Levonorgestrel, Pharmaceutical Secondary Standard; Certified Reference Material; (1R,3aS,3bR,9aR,9bS,11aS)-11a-ethyl-1-ethynyl-1-hydroxy-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one; (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one	Approved	Approved Drug(s)	13109	DB00367	D0BA9U	312.4	37.3	609	3.3	23	1	2	2	C21H28O2	(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one	CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34	CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34	InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1	WWYNJERNGUHSAO-XUDSTZEESA-N
DGF68L	Pamidronic acid	Small molecule	PAMIDRONIC ACID; pamidronate; 40391-99-9; Aredia; Amidronate; (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid; Aminomux; Ribodroat; Acide pamidronique [INN-French]; Acido pamidronico [INN-Spanish]; Acidum pamidronicum [INN-Latin]; PAMIDRONATE DISODIUM; Disodium pamidronate; (3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid); (3-Amino-1-hydroxypropylidene)diphosphonic acid; (3-Amino-1-hydroxypropylidene)bisphosphonic acid; Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-; Pamidronic acid (INN); 3-amino-1-hydroxypropane-1,1-diphosphonic acid; CHEMBL834; OYY3447OMC; DTXSID4023414; (3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID; CGP-23339AE; NCGC00159433-02; Acido pamidronico; Acide pamidronique; Acidum pamidronicum; 1159812-33-5; PAMIDRONIC ACID [INN]; (3-Amino-1-hydroxypropane-1,1-diyl)diphosphonic acid; DTXCID003414; Pamidronic acid [INN:BAN]; 57248-88-1; Bisphosphonate 6; Ribodroat (TN); CAS-40391-99-9; EINECS 254-905-2; UNII-OYY3447OMC; starbld0044121; 106437-12-1; ChemDiv1_025240; PAMIDRONATE [VANDF]; 3-Amino-1-hydroxypropylidene-1,1-diphosphonate; PAMIDRONATE [MART.]; SCHEMBL18361; PAMIDRONIC ACID [MI]; BIDD:GT0538; CHEBI:7903; GTPL7259; JMC515594 Compound 62; BDBM12581; HMS658L06; PAMIDRONIC ACID [WHO-DD]; HMS2090C13; HMS3749A11; BCP17709; CCG-2075; HY-B0012; Tox21_111664; HSCI1_000312; MFCD00168777; s2063; STL510914; AKOS003599275; Tox21_111664_1; CS-7787; DB00282; NCGC00159433-03; NCGC00165862-02; DB-049579; FT-0630610; C07395; C75045; D07281; EN300-119514; A825084; Propane-1-hydroxy-3-amino-1,1-diphosphonic acid; Q627499; SR-01000514873; 3-amino-1-hydroxypropane-1,1-diyldiphosphonic acid; SR-01000514873-1; (3-Amino-1-hydroxy-1-phosphono-propyl)-phosphonic acid; Phosphonic acid, P,P'-(3-amino-1-hydroxypropylidene)bis-; DIHYDROGEN (3-AMINO-1-HYDROXYPROPYLIDENE)DIPHOSPHONATE	Approved	Approved Drug(s)	4674	DB00282	D0BF8G	235.07	161	243	-6.9	13	6	8	4	C3H11NO7P2	(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid	C(CN)C(O)(P(=O)(O)O)P(=O)(O)O	C(CN)C(O)(P(=O)(O)O)P(=O)(O)O	InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)	WRUUGTRCQOWXEG-UHFFFAOYSA-N
D9I2BZ	Thioguanine	Small molecule	6-Thioguanine; thioguanine; 154-42-7; Tioguanine; 2-Amino-6-mercaptopurine; 6-Mercaptoguanine; Tabloid; 2-Amino-6-purinethiol; Tioguanin; Lanvis; 2-Amino 6MP; 2-Aminopurin-6-thiol; 2-Aminopurine-6-thiol; 2-Aminopurine-6(1H)-thione; Wellcome U3B; 6-Mercapto-2-aminopurine; 2-Amino-9H-purine-6-thiol; 6-TG; 2-Amino-6-merkaptopurin; Tioguaninum; Guanine, thio-; 2-amino-1H-purine-6(7H)-thione; Tioguanina; 6H-Purine-6-thione, 2-amino-1,7-dihydro-; 2-Amino-1,7-dihydro-6H-purine-6-thione; Thioguanine Anhydrous; NSC-752; BW 5071; Purine-6-thiol, 2-amino-; Purine-6(1H)-thione, 2-amino-; 2-Amino-1,9-Dihydro-6h-Purine-6-Thione; TG; Thioguanine, anhydrous; THG; NSC 752; 2-Amino-1,7-dihydro-6H-purin-6-thion; X 27; 6-TG/Thioguanine; Tioguanine (INN); Tioguanine [INN]; 2-amino-6,7-dihydro-3H-purine-6-thione; 2-amino-1,9-dihydropurine-6-thione; CHEMBL727; WIX31ZPX66; 2-amino-3,7-dihydro-6H-purine-6-thione; CHEBI:9555; NSC752; DTXSID6023652; Thioguanine2-Amino-6-purinethiol; 2-Thioguanine; 2-amino-1H-purine-6(9H)-thione; 2-amino-1,7-dihydropurine-6-thione; NSC-76504; NCGC00094792-01; 2-Amino-6-MP; Tioguanine hemihydrate; Tioguaninum [INN-Latin]; DTXCID803652; C5H5N5S; 2-Aminopurin-6-thiol [Czech]; Guanine, thio- (VAN); 2-Amino-6-merkaptopurin [Czech]; 6-Tioguanine; Tioguanina [INN-Spanish]; CAS-154-42-7; DX4; SMR000857244; Lanvis (TN); CCRIS 8997; 9H-Purine-6-thiol, 2-amino-; HSDB 2504; SR-05000002077; EINECS 205-827-2; Thioguanine [USAN:USP]; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; UNII-WIX31ZPX66; Thioquanine; AI3-26078; 6-thioguano-sine; MFCD00233553; 1330266-29-9; Spectrum_000235; THIOGUANINE [MI]; Spectrum2_000695; Spectrum3_000577; Spectrum4_000926; Spectrum5_001455; purine antimetabolite: antimetabolite: inhibits nucleic acid replication; THIOGUANINE [HSDB]; 2-Amino-6-mercapto-purin; 6-Thioguanine, >=98%; SCHEMBL3701; SCHEMBL5898; NCIOpen2_004153; TIOGUANINE [WHO-DD]; BSPBio_001994; KBioGR_001452; KBioGR_002476; KBioSS_000715; KBioSS_002483; MLS001333131; MLS001333132; MLS006010896; DivK1c_000428; SPECTRUM1500573; SPBio_000849; 154-42-7; 6-Thioguanine; 2-amino-6-mercapto-9H-purine; GTPL6845; Thioguanine (TN) (GlaxoSmith); HMS501F10; KBio1_000428; KBio2_000715; KBio2_002476; KBio2_003283; KBio2_005044; KBio2_005851; KBio2_007612; KBio3_001494; KBio3_002954; cMAP_000061; NINDS_000428; BCPE000001; HMS1921E09; HMS2092M11; HMS2235F05; HMS3865G13; Pharmakon1600-01500573; ALBB-023493; BCP27718; Tox21_111035; Tox21_113184; Tox21_202401; Tox21_300275; BDBM50200099; CCG-39890; HB1379; NSC757348; s1774; AKOS003389499; AKOS015901298; Tox21_111035_1; 2-Amino-1,7-dihydro-purine-6-thione; 2-Amino-1,9-dihydro-purine-6-thione; AC-8421; BCP9000197; CCG-213953; CCG-266338; CS-1497; DB00352; NSC-757348; PS-5007; WLN: T56 BNM FYM INJ FUS HZ; IDI1_000428; SMP2_000326; NCGC00094792-02; NCGC00094792-03; NCGC00094792-05; NCGC00094792-06; NCGC00094792-17; NCGC00188976-01; NCGC00188976-02; NCGC00254082-01; NCGC00259950-01; NCGC00263442-01; NCGC00263442-02; NCGC00263442-05; AC-23020; BT166463; HY-13765; NCI60_041643; SMR004701808; SBI-0051533.P003; FT-0611217; T0212; 2-Amino-1,7-dihydro-6H-purine-6-thione #; C07648; D08603; EN300-119530; T71841; AB00174074_06; AB00918694_06; AB01273926-01; AB01273926-02; AB01273926_03; A809532; Q385347; SR-05000002077-1; SR-05000002077-5; W-108030; W-205813; Z2299468139; 6-Thioguanine;6-TG;2-Amino-6-mercaptopurine;2-Amino-6-purinethiol; Thioguanine, United States Pharmacopeia (USP) Reference Standard; Thioguanine;6-TG; 2-Amino-6-mercaptopurine; 2-Amino-6-purinethiol; 6-Thioguanine, Hybri-Max(TM), 50 x, gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma	Approved	Approved Drug(s)	2723601	DB00352	D0BK1N	167.19	111	225	-0.1	11	3	2	0	C5H5N5S	2-amino-3,7-dihydropurine-6-thione	C1=NC2=C(N1)C(=S)N=C(N2)N	C1=NC2=C(N1)C(=S)N=C(N2)N	InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)	WYWHKKSPHMUBEB-UHFFFAOYSA-N
D98HLI	Etravirine	Small molecule	Etravirine; 269055-15-4; Intelence; TMC-125; TMC125; Etravirine (TMC125); TMC 125; R165335; R-165335; 4-((6-Amino-5-bromo-2-((4-cyanophenyl)amino)pyrimidin-4-yl)oxy)-3,5-dimethylbenzonitrile; 4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE; 4-[[6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]-4-PYRIMIDINYL]OXY]-3,5-DIMETHYLBENZONITRILE; 0C50HW4FO1; CHEMBL308954; CHEBI:63589; Etravirine-d8; 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrile; 4-(6-Amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yloxy)-3,5-dimethylbenzonitrile; Benzonitrile, 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-; Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-; Benzonitrile,4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-; 65B; Intelence(TM); DAPY deriv; 4-(6-amino-5-bromo-2-(4-cyanophenylamino)pyrimidin-4-yloxy)-3,5-dimethylbenzonitrile; Intelence (TN); Diaminopyrimidine deriv; TMC125 cpd; UNII-0C50HW4FO1; Etravirine (JAN/USAN/INN); 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-benzonitrile; Etravirine [USAN:INN:BAN:JAN]; Etravirine [INN]; Etravirine- Bio-X; R 165335; Etravine; Etravirine; 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile; R165335-TMC125; 3m8p; ETRAVIRINE [MI]; TMC-125/R-165335; ETRAVIRINE [JAN]; ETRAVIRINE [USAN]; ETRAVIRINE [VANDF]; ETRAVIRINE [MART.]; ETRAVIRINE [WHO-DD]; SCHEMBL52691; ETRAVIRINE [EMA EPAR]; ETRAVIRINE [ORANGE BOOK]; DTXSID30181412; HMS3651P20; BCP03562; EX-A4282; BDBM50103642; s3080; 4-({6-amino-5-bromo-2-[(4-; AKOS015896355; AC-8503; BCP9000006; CCG-269074; CS-0435; DB06414; HE-0088; PB32778; 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile; 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethyl-benzonitrile; NCGC00345885-02; NCGC00345885-04; BA164437; HY-90005; BCP0726000193; DB-067700; AM20080899; cyanophenyl)amino]pyrimidin-4-yl}oxy)-3,5-; FT-0658058; FT-0668442; FT-0668443; SW219570-1; A26965; D04112; AB01566873_01; A818671; EN300-23542752; Q414762; SR-01000944895; J-513179; SR-01000944895-1; 4-(6-amino-5-bromo-2-(4-cyanophenylamino)pyrimidin-4-ylamino)-3,5-dimethylbenzonitrile; 4-[[4-amino 5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile; 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]-amino]benzonitrile; 4-[[6-amino-5-bromo-2-(4-cyanoanilino)-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile; 4-[6-amino-5-bromo-2-(4-cyano-phenylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile; 4-((6-amino-5-bromo-2-((4-cyanophenyl) amino) pyrimidin-4-yl) oxy)-3, 5-dimethylbenzonitrile; 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3, 5  Cdimethylbenzonitrile; 4-[[6-Amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl -benzonitrile; 4-[6-azanyl-5-bromanyl-2-[(4-cyanophenyl)amino]pyrimidin-4-yl]oxy-3,5-dimethyl-benzenecarbonitrile	Approved	Approved Drug(s)	193962	DB06414	D0BP9C	435.3	121	609	4.5	28	2	7	4	C20H15BrN6O	4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile	CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N	CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N	InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)	PYGWGZALEOIKDF-UHFFFAOYSA-N
DP5VQ0	Letrozole	Small molecule	letrozole; 112809-51-5; Femara; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; Letrozol; CGS 20267; CGS-20267; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile; LETRAZOLE; Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-; Femera; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; NSC-759652; CHEMBL1444; 4-[(4-CYANOPHENYL)(1H-1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 7LKK855W8I; CHEBI:6413; DTXSID4023202; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; NCGC00016973-01; Letoval; CAS-112809-51-5; DTXCID503202; SMR000466343; Femara (TN); HSDB 7461; SR-01000759382; Letrozole (JAN/USP/INN); UNII-7LKK855W8I; CCRIS 8822; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; FEM-345; Femara, Letrozole; Letrozole [USAN:USP:INN:BAN]; Letrozole- Bio-X; CGS20267; MFCD00866241; LETROZOLE [INN]; LETROZOLE [JAN]; LETROZOLE [MI]; LETROZOLE [HSDB]; LETROZOLE [USAN]; Prestwick0_001025; Prestwick1_001025; Prestwick2_001025; Prestwick3_001025; Femara (TN) (Novartis); LETROZOLE [MART.]; LETROZOLE [USP-RS]; LETROZOLE [WHO-DD]; SCHEMBL4331; 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; BIDD:PXR0130; BSPBio_001209; MLS000759455; MLS001424038; MLS002584991; MLS006010040; BIDD:GT0015; SPBio_003070; BPBio1_001331; GTPL5209; LETROZOLE [EP IMPURITY]; LETROZOLE [ORANGE BOOK]; LETROZOLE [EP MONOGRAPH]; Letrozole, >=98% (HPLC); BDBM13061; EX-A965; LETROZOLE [USP MONOGRAPH]; HMS1571M11; HMS2051E08; HMS2089L22; HMS2098M11; HMS2233C23; HMS3369E11; HMS3393E08; HMS3651K05; HMS3715M11; Pharmakon1600-01502354; AMY32541; BCP23354; Tox21_110719; Tox21_303572; NSC719345; NSC759652; s1235; STL451047; AKOS005145822; AB07525; AC-1193; BCP9000848; CCG-100849; CS-1776; DB01006; KS-1269; NC00099; NSC 759652; NSC-719345; NCGC00016973-02; NCGC00016973-03; NCGC00016973-06; NCGC00257460-01; BL164620; HY-14248; BCP0726000213; 1-Bis(4-cyanophenyl)methyl-1,2,4-triazole; 4,2,4-Triazol-1-ylmethylene)dibenzonitrile; AB00514009; L0248; SW197294-4; A25380; C08163; D00964; EN300-264820; AB00514009-05; AB00514009-07; AB00514009-08; AB00514009-09; AB00514009_10; AB00514009_11; KISQALI FEMARA CO-PACK COMPONENT LETROZOLE; Q194974; W-60273; 4,4'-(1,2,4-Triazol-1-ylmethylene)dibenzonitrile; LETROZOLE COMPONENT OF KISQALI FEMARA CO-PACK; Q-201291; SR-01000759382-4; SR-01000759382-5; BRD-K88789588-001-03-2; 4,4 -(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)-bisbenzonitrile; F2173-0288; Z1741968261; 4,4'-((1H-1,2,4-Triazol-1-yl)-methylene)dibenzonitrile; Letrozole, European Pharmacopoeia (EP) Reference Standard; Letrozole, United States Pharmacopeia (USP) Reference Standard; 4-[1-(4-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE; Letrozole, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	3902	DB01006	D0C1WH	285.3	78.3	420	2.7	22	0	4	3	C17H11N5	4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile	C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3	C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3	InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H	HPJKCIUCZWXJDR-UHFFFAOYSA-N
DMS53O	Lesinurad	Small molecule	LESINURAD; 878672-00-5; RDEA594; RDEA 594; Zurampic; RDEA-594; 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid; Lesinurad free acid; (+)-Lesinurad; (-)-Lesinurad; Lesinurad, (+)-; Lesinurad, (-)-; Lesinurad, (4R)-; Lesinurad, (4S)-; Lesinurad (RDEA594; Q59CAT99RS; 09ERP08I3W; 73WY698HZ7; 878672-00-5 (free acid); 2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid; 2-{[5-broMo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid; {[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid; 2-(((4R)-5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)acetic acid; 2-(((4S)-5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)acetic acid; Acetic acid, 2-((5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)-; 1890222-25-9; 1890222-26-0; Acetic acid, 2-(((4R)-5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)-; Acetic acid, 2-(((4S)-5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)-; Lesinurad [USAN]; Lesinurad [USAN:INN]; UNII-09ERP08I3W; Zurampic (TN); LESINURAD [INN]; LESINURAD [MI]; Lesinurad (USAN/INN); Lesinurad (RDEA594); UNII-Q59CAT99RS; LESINURAD [WHO-DD]; SCHEMBL842962; UNII-73WY698HZ7; GTPL7673; LESINURAD [ORANGE BOOK]; CHEMBL2105720; Lesinurad, >=98% (HPLC); BDBM37953; CHEBI:90929; DUZALLO COMPONENT LESINURAD; DTXSID201026091; HMS3874M03; AMY27876; BCP06435; EX-A1289; US10093631, Compound Lesinurad; MFCD22572730; s4640; AKOS027327368; CCG-268685; CS-1389; DB11560; SB16705; AC-29310; AS-56014; HY-15258; RDEA 594;RDEA-594;RDEA594; FT-0776044; D09921; EN300-7399813; A857828; Q21820633; (5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid; 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid; 2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-acetic acid; 2-((5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3- YL)SULFANYL)ACETIC ACID; RDEA 594;sodium 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetate	Approved	Approved Drug(s)	53465279	DB11560	D0C3SW	404.3	93.3	479	4.7	24	1	5	5	C17H14BrN3O2S	2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid	C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O	C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O	InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)	FGQFOYHRJSUHMR-UHFFFAOYSA-N
DD3WB6	Pramlintide	Small molecule	AC0137; Triproamylin; TRIPRO-AMYLIN; UNII-D3FM8FA78T; Pramlintide [USAN:INN:BAN]; D3FM8FA78T; CHEMBL2103758; CHEBI:135922; AC137; AC-0137; Amylin (human) , 25-L-proline-28-L-proline-29-L-proline-	Approved	Approved Drug(s)	70691388	DB01278	D0C4AM	3949	1740	9660	-15.7	277	56	59	110	C171H267N51O53S2	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[(2S,3R)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-16-(2-amino-2-oxoethyl)-19-[[(2S)-2,6-diaminohexanoyl]amino]-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]pentanediamide	CCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N)NC(=O)C4CCCN4C(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC6=CNC=N6)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C8CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N8)C(C)O)C)C(C)O)CC(=O)N)NC(=O)C(CCCCN)N	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N	InChI=1S/C171H267N51O53S2/c1-21-81(12)130(163(268)207-110(56-78(6)7)169(274)222-53-33-42-118(222)170(275)221-52-32-41-117(221)160(265)219-135(89(20)230)167(272)206-109(66-125(180)238)151(256)212-128(79(8)9)161(266)186-68-126(239)192-111(70-223)154(259)203-107(64-123(178)236)152(257)218-134(88(19)229)166(271)195-98(136(181)241)57-92-43-45-94(231)46-44-92)214-159(264)116-40-31-51-220(116)127(240)69-187-141(246)101(58-90-34-24-22-25-35-90)199-148(253)105(62-121(176)234)201-149(254)106(63-122(177)235)202-155(260)112(71-224)209-156(261)113(72-225)208-146(251)103(60-93-67-184-75-188-93)205-162(267)129(80(10)11)213-150(255)100(55-77(4)5)198-145(250)102(59-91-36-26-23-27-37-91)200-147(252)104(61-120(175)233)196-137(242)82(13)189-144(249)99(54-76(2)3)197-142(247)96(39-30-50-185-171(182)183)193-143(248)97(47-48-119(174)232)194-165(270)132(86(17)227)215-138(243)83(14)190-157(262)114-73-276-277-74-115(210-140(245)95(173)38-28-29-49-172)158(263)204-108(65-124(179)237)153(258)217-131(85(16)226)164(269)191-84(15)139(244)216-133(87(18)228)168(273)211-114/h22-27,34-37,43-46,67,75-89,95-118,128-135,223-231H,21,28-33,38-42,47-66,68-74,172-173H2,1-20H3,(H2,174,232)(H2,175,233)(H2,176,234)(H2,177,235)(H2,178,236)(H2,179,237)(H2,180,238)(H2,181,241)(H,184,188)(H,186,266)(H,187,246)(H,189,249)(H,190,262)(H,191,269)(H,192,239)(H,193,248)(H,194,270)(H,195,271)(H,196,242)(H,197,247)(H,198,250)(H,199,253)(H,200,252)(H,201,254)(H,202,260)(H,203,259)(H,204,263)(H,205,267)(H,206,272)(H,207,268)(H,208,251)(H,209,261)(H,210,245)(H,211,273)(H,212,256)(H,213,255)(H,214,264)(H,215,243)(H,216,244)(H,217,258)(H,218,257)(H,219,265)(H4,182,183,185)/t81-,82-,83-,84-,85+,86+,87+,88+,89+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,128-,129-,130-,131-,132-,133-,134-,135-/m0/s1	TZIRZGBAFTZREM-MKAGXXMWSA-N
DMG78N	Binimetinib	Small molecule	Binimetinib; 606143-89-9; MEK162; ARRY-162; Mektovi; ARRY-438162; MEK-162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; Binimetinib (MEK-162); ARRY 438162; NVP-MEK162; MEK162(Binimetinib); MEK162 (ARRY-162, ARRY-438162); MFCD22124525; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide; 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aa,5a,6aa)-octahydro- 2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-; 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide.; 5-(4-Bromo-2-fluoroanilino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide; 6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; Binimetinib [USAN:INN]; binimetinibum; UNII-181R97MR71; Mektovi (TN); ARRY-162; ARRY-438162; MEK 162; ARRY 162; ARRY 438162; Binimetinib; Mek162; BINIMETINIB [MI]; Binimetinib (MEK162); BINIMETINIB [INN]; BINIMETINIB [JAN]; Binimetinib (JAN/USAN); BINIMETINIB [USAN]; BINIMETINIB [WHO-DD]; MLS006011180; SCHEMBL570088; GTPL7921; CHEMBL3187723; AMY9056; BINIMETINIB [ORANGE BOOK]; DTXSID70209422; ARRY-162,MEK-162; CHEBI:145371; BDBM520649; HMS3652J14; HMS3747G09; BCP06780; EX-A1024; NSC764042; NSC788187; NSC799361; s7007; AKOS026750517; CCG-269133; CS-0627; DB11967; NSC-764042; NSC-788187; NSC-799361; SB16501; NCGC00345804-01; NCGC00345804-10; 1073666-70-2; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methylbenzimidazole-6-carboxamide; 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; AC-29023; AS-16706; DA-35030; HY-15202; SMR004702949; SY284756; cas:606143-89-9;MEK162; FT-0697088; SW219910-1; D10604; EN300-7411873; Binimetinib;MEK-162; ARRY-162;ARRY-438162; J-516581; Q19903515; US11147816, Binimetinib (ARRY-162, ARRY-438162); 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; 5-(4-Bromo-2-fluorophenylamino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide; 5-[(4-Bromo-2-Fluorophenyl)Amino]-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H-Benzimidazole-6-Carboxami; 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide; N-(2-hydroxyethoxy)-4-fluoro-5-(2-fluoro-4-bromophenylamino)-1-methyl-1H-benzoimidazole-6-carboxamide; QO7	Approved	Approved Drug(s)	10288191	DB11967	D0C4LF	441.2	88.4	521	3.1	27	3	7	6	C17H15BrF2N4O3	6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO	InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)	ACWZRVQXLIRSDF-UHFFFAOYSA-N
D60WBA	Paclitaxel	Small molecule	33069-62-4; P88XT4IS4D; Paclitaxel; Taxol; Taxol A; Yewtaxan; Abraxane; Plaxicel; Genaxol; Ebetaxel; Genetaxyl; Capxol; Paxene; Onxol; OncoGel; Cyclopax; Genexol; Intaxel; Mitotax; Pacliex; Paxceed; TaxAlbin; EmPAC; ABI-007; Onxal; Zisu; LipoPac; Taxus Liberte; Taxus stent; EndoTAG 1; LEP-ETU; Genexol-PM; Tocosol Paclitaxel; NSC-125973; (-)-Paclitaxel; Taxus; ABI 007; BMS 181339-01; MBT 0206; Paclitaxel (Taxol); NSC 125973; BMS-181339-01; HSDB 6839; DHP 107; DHP-107; DRG-0190; NK 105; NSC125973; QW 8184; Liposome-entrapped paclitaxel easy-to-use; Paclitaxel (taxus canadensis); CHEMBL428647; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetate; 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; DTXSID9023413; CHEBI:45863; nab-paclitaxel; MBT-0206; ABI-007 COMPONENT PACLITAXEL; NK-105; (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; QW-8184; NCGC00164367-01; Padexol; MFCD00869953; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; Cynviloq; Nanoxel; Sindaxel; Xorane; Cypher select; Coroflex Please; Taxus Express; 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.; (NAB)-Paclitaxel; SMR000857385; EndoTAG-1; SR-01000075350; Abraxane I.V. Suspension; UNII-P88XT4IS4D; Anzatax; Infinnium; Nanotaxel; Paclical; Pacligel; Paxoral; CCRIS 8143; Paclitaxel,(S); Paclitaxel [USAN:USP:INN:BAN]; Abraxane (TN); (2alpha,5beta,7beta,10beta,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; [diacetoxy-[(2R,3S)-3-benzamido-2-hydroxy-3-phenyl-propanoyl]oxy-dihydroxy-tetramethyl-oxo-[?]yl] benzoate; 5?,20-Epoxy-1,7?-dihydroxy-9-oxotax-11-ene-2?,4,10?,13?-tetrayl 4,10-diacetate 2-benzoate 13-[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoate]; Taxol (Paclitaxel); CAS-33069-62-4; IG 001; BMS-181339; Paclitaxel-SSMM-VIP; P-SSMM-VIP; PACLITAXEL [MI]; PACLITAXEL [INN]; PACLITAXEL [JAN]; Prestwick3_000155; PACLITAXEL [HSDB]; PACLITAXEL [USAN]; TAXOL (TN); PACLITAXEL [VANDF]; PACLITAXEL [MART.]; SCHEMBL3976; 3PPC5TL76P; Nova-12005; PACLITAXEL [USP-RS]; PACLITAXEL [WHO-DD]; Paclitaxel, Taxus brevifolia; BIDD:PXR0046; BSPBio_000290; KBioGR_002509; KBioSS_002517; Paclitaxel (JAN/USP/INN); MLS002154218; MLS002695976; OAS-PAC-100; PACLITAXEL [EMA EPAR]; BPBio1_000320; DTXCID603413; GTPL2770; MEGxp0_001940; Taxol (TN) (Bristol Meyers); PACLITAXEL [GREEN BOOK]; PACLITAXEL [ORANGE BOOK]; ACon1_002231; KBio2_002509; KBio2_005077; KBio2_007645; KBio3_002987; ANX-513; DHP-208; DTS-301; PACLITAXEL [EP MONOGRAPH]; PACLITAXEL [USP IMPURITY]; SDP-013; cMAP_000068; ORAXOL COMPONENT PACLITAXEL; HMS2090D07; HMS2095O12; HMS2231A16; HMS3712O12; PACLITAXEL [USP MONOGRAPH]; Abraxane (albumin-bound suspension); ABRAXANE COMPONENT PACLITAXEL; ACT02709; HY-B0015; MPI-5018; Tox21_112107; BDBM50001839; NSC745099; ABI 007 COMPONENT PACLITAXEL; AKOS007930675; AKOS015969673; AKOS025312303; CCG-220155; CS-1145; DB01229; GS-6554; NSC-745099; NCGC00164367-02; NCGC00164367-03; NCGC00164367-04; NCGC00164367-05; NCGC00164367-10; Paclitaxel, From Taxus brevifolia, 95%; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; NAB-PACLITAXEL COMPONENT PACLITAXEL; NCI60_000601; Paclitaxel, from Taxus yannanensis, powder; PACLITAXEL IMPURITY L [EP IMPURITY]; AB00513812; D00491; EN300-117275; M02242; N88686; AB00513812-02; AB00513812-03; Paclitaxel, Antibiotic for Culture Media Use Only; Q423762; 7,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.; Q-201533; SR-01000075350-1; SR-01000075350-3; SR-01000075350-6; SR-01000075350-7; SR-01000075350-9; BRD-K62008436-001-03-1; BRD-K62008436-001-05-6; BRD-K62008436-001-22-1; Paclitaxel, from semisynthetic (from Taxus sp.), >=97%; Paclitaxel, European Pharmacopoeia (EP) Reference Standard; Paclitaxel, from Taxus brevifolia, >=95% (HPLC), powder; Paclitaxel, United States Pharmacopeia (USP) Reference Standard; 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; Paclitaxel, Pharmaceutical Secondary Standard; Certified Reference Material; Paclitaxel natural for peak identification, European Pharmacopoeia (EP) Reference Standard; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro 4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano 5Hcyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate,; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-Tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (alphaR,betaS)-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-(benzoylamino)-a-hydroxybenzenepropanoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate; (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl]benzoate; 1203669-79-7; 4,7beta,10beta-tris(acetyloxy)-13alpha-[[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy]-1-hydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; 4alpha,10beta-bis(acetyloxy)-13alpha-[(2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy]-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-6,12B-BIS(ACETYLOXY)-12-(BENZOYLOXY)-2A,3,4,4A,5,6,9,10,11,12,12A,12B-DODECAHYDRO-4,11-DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO-7,11-METHANO-1H-CYCLODECA(3,4)BENZ(1,2-B)OXET-9-YL ESTER, (.ALPHA.R,.BETA.S)-; Benzenepropanoic acid, 6,12b-bis(acetyl oxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b,- dodecahydro-4,11- dihydroxy-4a,8,13,13-tetramethyl-5-oxo- 7,11-methano- 1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR- [2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(alpha. R*,.beta.S*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-; Benzenepropanoic acid, b-(benzoylamino)-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,bS)-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 4,6,12b-tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha]]-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2a-alpha,4-beta,4a-beta,6-beta,9-alpha(alpha-R*,beta-S*),11-alpha,12-alpha,12a-alpha, 12b-alpha))-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-; Paclitaxel semi-synthetic for peak identification, European Pharmacopoeia (EP) Reference Standard; Paclitaxel semi-synthetic for system suitability, European Pharmacopoeia (EP) Reference Standard; Tax-11-en-9-one, 5	Approved	Approved Drug(s)	36314	DB01229	D0C4RB	853.9	221	1790	2.5	62	4	14	14	C47H51NO14	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C	InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1	RCINICONZNJXQF-MZXODVADSA-N
DXNL26	5-aminosalicylic acid	Small molecule	5-Aminosalicylic acid; mesalamine; Mesalazine; 89-57-6; 5-Amino-2-hydroxybenzoic acid; Pentasa; Asacol; Canasa; 5-ASA; Claversal; Rowasa; Salofalk; m-Aminosalicylic acid; Lialda; Mesasal; Benzoic acid, 5-amino-2-hydroxy-; Fisalamine; Apriso; Lixacol; sfRowasa; p-Aminosalicylsaeure; Asacolitin; Mesalazina; Mesalazinum; Iialda; 5-amino-2-hydroxy-benzoic acid; Asacol HD; Mesalamine [USAN]; 5-Amino Salicylic Acid; 2-Hydroxy-5-aminobenzoic acid; MAX-002; 3-carboxy-4-hydroxyaniline; SALICYLIC ACID, 5-AMINO-; MFCD00007877; NSC 38877; NSC-38877; Mesalazine [INN]; MESALAMINE-D3; MLS001424012; 4Q81I59GXC; CHEBI:6775; DTXSID5024506; mesalamine (USAN); 5-?Aminosalicylic Acid (Mesalazine); CAS-89-57-6; NCGC00016344-03; Mesalazinum [Latin]; SMR000145728; DTXCID804506; Mesalazina [Spanish]; 1309283-32-6; p-Aminosalicylsaeure [German]; Mesavancol; Delzicol; Mesavance; Mezavant; Mesalazine MMX; Mezavant XL; Mesalamine (USP); Pentasa (TN); Salofalk Granu-Stix; Apriso (TN); Asacol (TN); Canasa (TN); Lialda (TN); Rowasa (TN); 5-AS; CCRIS 7334; SR-01000763486; Mesalamine [USAN:USP]; EINECS 201-919-1; BRN 2090421; UNII-4Q81I59GXC; AI3-15564; 5-Amino 2-hydroxy benzoic acid; HSDB 7512; AJG-501; SPD 476; SPD-476; SPD-480; Mesalamine (TN); Delzicol (TN); Sfrowasa (TN); Mesalamine (Lialda); 5-aminosalicylic_acid; MD-0901; 5-Aminosalicyclic acid; 5-amino-salicylic acid; MESALAMINE [MI]; MESALAZINE [JAN]; Prestwick0_001069; Prestwick1_001069; Prestwick2_001069; Prestwick3_001069; MESALAMINE [HSDB]; WLN: ZR DQ CVQ; Z-206; MESALAMINE [VANDF]; CHEMBL704; Mesalazine (JP17/INN); EC 201-919-1; cid_4075; MESALAZINE [MART.]; MESALAMINE [USP-RS]; MESALAZINE [WHO-DD]; Oprea1_847633; SCHEMBL31297; 3amino-6-hydroxybenzoic acid; BSPBio_001058; KBioGR_002425; KBioSS_002431; 4-14-00-02058 (Beilstein Handbook Reference); MLS000758287; 5-Aminosalicylic acid, 95%; 5-Aminosalicylic acid, tablet; BIDD:GT0811; 3-amino-6-hydroxybenzoic acid; SPBio_002969; BPBio1_001164; GTPL2700; MESALAMINE [ORANGE BOOK]; MESALAZINE [EP IMPURITY]; SCHEMBL18038934; 5-Aminosalicylic acid, >=99%; BDBM60918; KBio2_002425; KBio2_004993; KBio2_007561; KBio3_002904; MESALAZINE [EP MONOGRAPH]; cMAP_000045; HMS1571E20; HMS2051M21; HMS2090I09; HMS2098E20; HMS3393M21; HMS3649K15; HMS3651M15; HMS3715E20; MESALAMINE [USP MONOGRAPH]; Pharmakon1600-01505993; BCP05326; NSC38877; Tox21_110384; Tox21_201610; Tox21_303125; AC8101; BBL013046; NSC759301; s1681; STK301678; AKOS000118959; Tox21_110384_1; AC-2764; BCP9000175; CCG-100829; DB00244; HS-0100; NC00079; NSC-759301; NCGC00016344-01; NCGC00016344-02; NCGC00016344-04; NCGC00016344-05; NCGC00016344-07; NCGC00090934-01; NCGC00090934-02; NCGC00257142-01; NCGC00259159-01; 5-amino-2-hydroxobenzoic acid monohydrate; 51481-17-5; BP-13074; HY-15027; SY002854; 5-Aminosalicylic acid, analytical standard; A0317; AB00374979; AM20060091; FT-0619950; SW197303-4; EN300-18389; C07138; D00377; AB00374979-09; AB00374979-10; AB00374979_11; AB00374979_12; Q412479; 5-amino-2-hydroxybenzoic acid,5-Aminosalicylic acid; Q-201355; SR-01000763486-3; SR-01000763486-4; SR-01000763486-9; Z57127471; F1918-0003; Mesalazine, European Pharmacopoeia (EP) Reference Standard; Mesalamine, United States Pharmacopeia (USP) Reference Standard; Mesalamine, Pharmaceutical Secondary Standard; Certified Reference Material; Mesalazine for system suitability, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	4075	DB00244	D0C4YC	153.14	83.6	160	1.3	11	3	4	1	C7H7NO3	5-amino-2-hydroxybenzoic acid	C1=CC(=C(C=C1N)C(=O)O)O	C1=CC(=C(C=C1N)C(=O)O)O	InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)	KBOPZPXVLCULAV-UHFFFAOYSA-N
D0V5RQ	Temozolomide	Small molecule	temozolomide; 85622-93-1; Methazolastone; Temodar; Temodal; Temozolamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; Sch 52365; CCRG-81045; Temozolomidum [Latin]; Temozolodida [Spanish]; Temozolomidum; CCRG 81045; NSC 362856; Sch-52365; M&B 39831; M&B-39831; NSC-362856; C6H6N6O2; CCRIS 8996; MB 39831; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; M & B 39831; BRN 5547136; M-39831; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; NSC362856; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; CHEMBL810; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; MLS002701861; YF1K15M17Y; DTXSID5043714; CHEBI:72564; Mk-7365; Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; TMZ; NCGC00167429-01; Temozolodida; 3-methyl-4-oxo-3H,4H-imidazo[4,3-d][1,2,3,5]tetrazine-8-carboxamide; 8-CARBAMOYL-3-METHYLIMIDAZO[5,1-D]-1,2,3,5-TETRAZIN-4(3H)-ONE; DTXCID3023714; 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo-[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide.; 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide; SMR000466338; Temodal (TN); Temodar (TN); CAS-85622-93-1; Temozolomide, VETRANAL(TM), analytical standard; SR-01000759347; temozolomida; UNII-YF1K15M17Y; Temozolomide (JAN/USAN/INN); Temozolomide [USAN:INN:BAN]; 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide; IMIDAZO(5,1-D)-1,2,3,5-TETRAZINE-8-CARBOXAMIDE, 3,4-DIHYDRO-3-METHYL-4-OXO-; MFCD00866492; Temozolomide- Bio-X; TEMOZOLOMIDE [MI]; TEMOZOLOMIDE [INN]; TEMOZOLOMIDE [JAN]; Temodar (TN) (Schering); TEMOZOLOMIDE [USAN]; SCHEMBL3739; 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide; TEMOZOLOMIDE [VANDF]; TEMOZOLOMIDE [MART.]; MLS000759447; MLS001424028; BIDD:GT0204; TEMOZOLOMIDE [USP-RS]; TEMOZOLOMIDE [WHO-DD]; GTPL7301; TEMOZOLOMIDE [EMA EPAR]; Temozolomide, >=98% (HPLC); HMS2051O12; HMS2090B08; HMS2232N13; HMS3264I14; HMS3269P05; HMS3372K13; HMS3393O12; HMS3413D06; HMS3654N05; HMS3677D06; HMS3713H16; Pharmakon1600-01502289; TEMOZOLOMIDE [ORANGE BOOK]; TEMOZOLOMIDE [EP MONOGRAPH]; 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; ALBB-021358; BCP03692; TEMOZOLOMIDE [USP MONOGRAPH]; Tox21_112433; AC-758; BDBM50034562; DL-190; NSC759883; s1237; STK623541; 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; AKOS005557098; Tox21_112433_1; CCG-100870; CS-0943; DB00853; KS-1216; NC00120; NSC-759883; Imidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; NCGC00167429-02; NCGC00167429-04; NCGC00167429-05; BP-25388; BT164447; HY-17364; NCI60_003316; BCP0726000154; Temozolomide 100 microg/mL in Acetonitrile; AM20110227; FT-0630936; FT-0674845; SW197500-4; T2744; D06067; EN300-122324; AB00639915-06; AB00639915-08; AB00639915-09; AB00639915_10; AB00639915_11; A841386; Q425088; Q-201786; SR-01000759347-4; SR-01000759347-5; BRD-K32107296-001-04-5; Z1201620684; 3-methyl-4-oxo-8-imidazo[5,1-d][1,2,3,5]tetrazinecarboxamide; Temozolomide, United States Pharmacopeia (USP) Reference Standard; 3-methyl-4-oxidanylidene-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-Methyl-8-aminocarbonyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one; Imidazo[5,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; {Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide,} 3, 4-dihydro-3-methyl-4-oxo-; Temozolomide, Pharmaceutical Secondary Standard; Certified Reference Material; 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (Temozolomide); 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide(Temozolomide)	Approved	Approved Drug(s)	5394	DB00853	D0C8EU	194.15	106	315	-1.1	14	1	5	1	C6H6N6O2	3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N	InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)	BPEGJWRSRHCHSN-UHFFFAOYSA-N
DHB28G	Epirubicin	Small molecule	Epirubicin; Epiadriamycin; Epidoxorubicin; 4'-Epiadriamycin; 56420-45-2; Ellence; Epirubicine; 4'-epidoxorubicin; Epirubicinum; Pidorubicina; Pidorubicine; Pidorubicinum; Epirubicina; Farmorubicin; 4-Epidoxorubicin; Epirubicin free base; Epirubicin (INN); Pidorubicin; NSC-256942; Ridorubicin; NSC 256942; CHEBI:47898; Epi-DX; Epirubicine [French]; Epirubicinum [Latin]; 3Z8479ZZ5X; Epirubicina [Spanish]; (8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; IMI 28; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Epirubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; 56420-45-2 (FREE BASE); Pidorubicina [INN-Spanish]; EPIRUBICIN [INN]; Epirubicin [INN:BAN]; WP 697; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (8S,10S)-10-(((2R,4S,5R,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; Farmorubicin (TN); CCRIS 2261; HSDB 6962; NSC256942; BRN 1445813; Epi-doxorubicin; UNII-3Z8479ZZ5X; DM6; Acid, 8; EPIRUBICIN [MI]; EPIRUBICIN [HSDB]; EPIRUBICIN [VANDF]; CHEMBL417; SCHEMBL8582; EPIRUBICIN [WHO-DD]; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; DTXSID0022987; EPIRUBICIN(Hydrochloride form); BDBM43839; DM2; DB00445; NCGC00263918-04; NCGC00263918-08; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-; HY-13624; SBI-0206890.P001; D07901; AB00698552-11; AB00698552-13; AB00698552-14; AB00698552_15; AB00698552_16; EN300-7410311; A831042; Q425122; BRD-K04548931-003-16-5; (1S,3S)-3-GLYCOLOYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-ARABINO-HEXOPYRANOSIDE; (7S,9S)-7-[(2R,4S,5R,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-ARABINO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-, (8S-CIS)-; 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-; 5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-	Approved	Approved Drug(s)	41867	DB00445	D0C9XJ	543.5	206	977	1.3	39	6	12	5	C27H29NO11	(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione	CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O	C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O	InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1	AOJJSUZBOXZQNB-VTZDEGQISA-N
DIP1B3	Telbivudine	Small molecule	Telbivudine; 3424-98-4; 2'-Deoxy-L-thymidine; Epavudine; L-Thymidine; beta-L-Thymidine; Tyzeka; L-dT; Telbivudin; Sebivo; L-Deoxythymidine; NV-02B; LDT600; beta-L-2'-Deoxythymidine; LdT; NV 02B; LDT-600; CHEBI:63624; 2OC4HKD3SF; 1-((2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; 26879-47-0; 1-(2-deoxy-beta-L-ribofuranosyl)-5-methyluracil; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; Telbivudine [USAN]; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione; MFCD02683612; LLT; Tyzeka (TN); UNII-2OC4HKD3SF; Telbivudine (USAN/INN); Telbivudine [USAN:INN:BAN]; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; TELBIVUDINE [MI]; b-L-2'-deoxy-thymidine; TELBIVUDINE [INN]; TELBIVUDINE [VANDF]; TELBIVUDINE [MART.]; TELBIVUDINE [WHO-DD]; SCHEMBL124279; Telbivudine (Sebivo, Tyzeka); TELBIVUDINE [EMA EPAR]; CHEMBL374731; Epavudine;L-Thymidine;NV 02B; Thymine, 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-; Telbivudine, >=98% (HPLC); DTXSID30187813; TELBIVUDINE [ORANGE BOOK]; AMY23971; HY-B0017; BDBM50088372; s1651; AKOS025117349; AC-5632; CCG-266887; CS-1934; DB01265; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-b-L-erythro-pentofuranosyl)-5-methyl-; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-5-methyl-; NCGC00346560-01; NCGC00346560-06; NCGC00346560-12; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; AS-35209; BP-58605; SW220236-1; D06675; EN300-123027; AB01274717-01; AB01274717_02; Q413621; BRD-K15976406-001-01-7; Thymine, 1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-; Z1546610488; 1-[(2R,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; 1-[(2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione; 2,4(1H,3H)-PYRIMIDINEDIONE,1-(2-DEOXY-.BETA.-L-ERYTHRO-PENTOFURANOSYL)-5-METHYL-; 1-((2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione	Approved	Approved Drug(s)	159269	DB01265	D0CL9S	242.23	99.1	381	-1.2	17	3	5	2	C10H14N2O5	1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione	CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O	CC1=CN(C(=O)NC1=O)[C@@H]2C[C@H]([C@@H](O2)CO)O	InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1	IQFYYKKMVGJFEH-CSMHCCOUSA-N
DZ42UO	Brivaracetam	Small molecule	Brivaracetam; 357336-20-0; Briviact; UCB-34714; UCB 34714; (2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide; UCB34714; 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide; U863JGG2IA; (2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide; Rikelta; Brivaracetam [USAN:INN]; UNII-U863JGG2IA; compound 83alpha; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-; Briviact (TN); BRIVARACETAM [MI]; BRIVARACETAM [INN]; BRIVARACETAM [JAN]; BRIVARACETAM [USAN]; BRIVARACETAM [MART.]; BRIVARACETAM [WHO-DD]; SCHEMBL122081; Brivaracetam (JAN/USAN/INN); CHEMBL607400; GTPL9041; DTXSID00905081; CHEBI:133013; BRIVARACETAM [ORANGE BOOK]; EX-A2748; BDBM50422531; MFCD25976668; AKOS027324306; CCG-266666; CS-3418; DB05541; NCGC00390779-02; AC-29289; AS-35277; BB161996; HY-14449; D08879; Q408099; (S)-2-((R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide; (2S)-2-((4R)-2-oxo-4-n-propyl-1-pyrrolidinyl)butanamide; (2S)-2-((4R)-2-OXO-4-PROPYLTETRAHYDRO-1H-PYRROL-1-YL) BUTANAMIDE; 1-PYRROLIDINEACETAMIDE, .ALPHA.-ETHYL-2-OXO-4-PROPYL (.ALPHA.S,4R)-	Approved	Approved Drug(s)	9837243	DB05541	D0CT4D	212.29	63.4	253	1	15	1	2	5	C11H20N2O2	(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide	CCCC1CC(=O)N(C1)C(CC)C(=O)N	CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N	InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1	MSYKRHVOOPPJKU-BDAKNGLRSA-N
DE6YG0	Cyclophosphamide	Small molecule	cyclophosphamide; 50-18-0; Cytoxan; Cyclophosphamid; Cyclophosphane; Cytophosphan; Procytox; Sendoxan; Clafen; Endoxan; Cyclophosphan; Cyclostin; Neosar; Cyclophosphamidum; Cytophosphane; Claphene; Endoxana; Endoxanal; Genoxal; Endoxan-Asta; Endoxan R; Zyklophosphamid; Mitoxan; (RS)-Cyclophosphamide; Cyclophosphoramide; Cyklofosfamid; Endoxane; Enduxan; Semdoxan; Senduxan; (+-)-Cyclophosphamide; Cyclophosphamide anhydrous; Cyclophosphanum; Rcra waste number U058; Asta B 518; 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide; NSC 26271; NSC-26271; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; B 518; CB 4564; NCI-C04900; SK 20501; Cyclofosphamide; CHEBI:4027; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (-)-Cyclophosphamide; Cyclophosphamide (INN); N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; NSC26271; Anhydrous cyclophosphamide; Cytoxan (TN); 50-18-0 (anhydrous); 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide; Ciclophosphamide; 2-(Bis(2-chloroethyl)amino)-2H-1,3,2-oxazaphosphorine 2-oxide; ASTA; 6UXW23996M; N,N-Bis(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; N,N-Di(2-chloroethyl)-N,O-propylene-phosphoric acid ester diamide; 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-,2-oxide; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, intramol. ester; Lyophilized Cytoxan; CY; Cyclophosphamide-d4; Ciclofosfamida; D,L-Cyclophosphamide; Cyklofosfamid [Czech]; N,N-bis(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine; Ciclophosphamide [INN]; 2-[Bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; Zyklophosphamid [German]; CYCLOPHOSPHAMIDE [INN]; Cyclophosphamide (anhydrous); ASTA B518; Ciclofosfamida [INN-Spanish]; Cyclophosphamidum [INN-Latin]; Occupation, cyclophosphamide exposure; CCRIS 188; 4-Hydroxy-cyclophosphan-mamophosphatide; Cyclophosphamide (anhydrous form); Cyclophosphamide (TN); HSDB 3047; SR-01000075737; NCGC00015209-05; EINECS 200-015-4; RCRA waste no. U058; BRN 0011744; Cyclophosphamide [USP:INN]; 2-(Bis(2-chloroethyl)amino)-2H-1,2-oxazaphosphorine 2-oxide; 2-[Bis(2-chloroethyl)amino]-2H-1,2-oxazaphosphorine 2-oxide; UNII-6UXW23996M; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; AI3-26198; (Bis(chloro-2-ethyl)amino)-2-tetrahydro-3,5,6-oxazaphosphorine-1,3,2-oxide-2 hydrate; [Bis(chloro-2-ethyl)amino]-2-tetrahydro-3,5,6-oxazaphosphorine-1,3,2-oxide-2 hydrate; 173547-45-0; CB-4564; Cyclophosphamide-[d4]; Spectrum_000858; CHEMBL88; Spectrum2_001146; Spectrum3_000370; Spectrum4_000304; Spectrum5_000795; Lopac-C-0768; N,N-Bis(beta-chloroethyl)-N',O-propylenephosphoric acid ester diamide; N,N-Bis(beta-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide; Epitope ID:131782; 2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazophosphorine 2-oxide; C 0768; N,N-Bis-(beta-chloraethyl)-N',O-propylen-phosphorsaeure-ester-diamid [German]; SCHEMBL4346; (.+/-.)-Cyclophosphamide; Lopac0_000238; BSPBio_002099; KBioGR_000888; KBioSS_001338; DivK1c_000246; SPBio_001071; CYCLOPHOSPHAMIDE [HSDB]; GTPL7154; SCHEMBL4345553; DTXSID5020364; SCHEMBL10262910; CMSMOCZEIVJLDB-UHFFFAOYSA-; KBio1_000246; KBio2_001338; KBio2_003906; KBio2_006474; KBio3_001319; CYCLOPHOSPAMIDE MONOHYDRATE; CYCLOPHOSPHAMIDE [WHO-DD]; WLN: T6MPOTJ BO BN2G2G; CYCLOPHOSPHAMIDE, ANHYDROUS; NINDS_000246; 2-(bis(2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide; CYCLOPHOSPHAMIDE LYOPHILIZED; HMS2090A12; HMS3260P17; HMS3715J05; Pharmakon1600-01500213; AMY33449; BCP02139; Tox21_500238; 2-CHLORO-5-METHYLBENZANILIDE; BDBM50237604; N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine; N,N-Bis-(beta-chloraethyl)-N',O-propylen-phosphorsaeure-ester-diamid; NSC273033; NSC273034; NSC756711; STK177249; 2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide; AKOS005410738; CS-1425; CYCLOPHOSPHAMIDE ANHYDROUS [MI]; DB00531; LP00238; NSC-273033; NSC-273034; SDCCGSBI-0050226.P004; IDI1_000246; N,3,2-oxazaphosphorin-2-amine-2-oxide; N,O-propylen-phosphorsaeure-ester-diamid; NCGC00015209-01; NCGC00015209-02; NCGC00015209-03; NCGC00015209-04; NCGC00015209-06; NCGC00015209-07; NCGC00015209-08; NCGC00015209-09; NCGC00015209-12; NCGC00015209-28; NCGC00091741-02; NCGC00091741-03; NCGC00260923-01; AS-73255; BP-25411; HY-17420; NCI60_002097; N,O-propylenephosphoric acid ester diamide; SBI-0050226.P003; DB-082057; N,O-propylene-phosphoric acid ester diamide; C2236; EU-0100238; FT-0624276; FT-0665387; N,O-trimethylenephosphoric acid ester diamide; EN300-74526; C07888; D07760; AB00053446-09; AB00053446-11; AB00053446-12; AB00053446_13; AB00053446_14; AB00053446_15; Q408524; W-60377; N,O-propylenephosphoric acid ester amide monohydrate; SR-01000075737-1; SR-01000075737-6; W-105248; BRD-A09722536-002-02-4; Z276509078; 2-(bis(2-chloroethyl)amino)-1,3,2-oxazaphosphinane2-oxide; 2-[bis(2-chloroethyl)amino]-1,3,2??-oxazaphosphinan-2-one; 2-[bis(2-chloroethyl)amino]-1,3,2$l^{5}-oxazaphosphinan-2-one; 2-[bis(2-chloroethyl)amino]-1,3,2lambda5-oxazaphosphinan-2-one; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide #; 2-(Di(2-chloroethyl)amino)-2-phospha(V)-tetrahydro-2H-1,3-oxazine-2-one; 2-[Bis(2-chloroethyl)amino]tetrahydro-1,3,2-oxazaphosphorin-2-oxide; 2H-1,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-,2-oxide; N,N-Bis(.beta.-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide; N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide; N,N-Bis-(.beta.-chloraethyl)-N',O-propylen-phosphorsaeure-ester-diamid; (+/-)-2-(BIS(2-CHLOROETHYL)AMINO)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE 2-OXIDE; (+/-)-2-[Bis(2-chloroethyl)amino]tetrahydro-2 H-1,3,2-oxazaphosphorine 2-oxide; (R)-2-[Bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide; (S)-2-[Bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; 2H-1,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide; 2H-1,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide, (+)-; 2H-1,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide, (-)-; 2H-1,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate; N,N-bis(2-chloroethyl)-2-oxo-1-oxa-3-aza-2$l^{5}-phosphacyclohexan-2-amine; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, intramol. ester	Approved	Approved Drug(s)	2907	DB00531	D0CT9C	261.079	41.6	212	0.6	14	1	4	5	C7H15Cl2N2O2P	N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine	C1CNP(=O)(OC1)N(CCCl)CCCl	C1CNP(=O)(OC1)N(CCCl)CCCl	InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)	CMSMOCZEIVJLDB-UHFFFAOYSA-N
DV4F3G	Miglitol	Small molecule	MIGLITOL; 72432-03-2; Glyset; (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol; Bay-m-1099; Bay m 1099; Miglitol (Glyset); Seibule; CHEMBL1561; (2R,3R,4R,5S)-1-(2-Hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol; 0V5436JAQW; CHEBI:6935; Diastabol; DTXSID0023323; NSC-758702; Plumarol; DTXCID703323; Miglitolum; N-(2-Hydroxyethyl)-1-deoxynojirimycin; SMR000466381; Miglitolum [Latin]; CAS-72432-03-2; Glyset (TN); UNII-0V5436JAQW; Miglitol [USAN:INN:BAN]; BAY1099;BAY-m1099; Bay 1099; HSDB 8022; NCGC00095127-01; EINECS 276-661-6; MFCD00867240; SK-983; baym1099; MIGLITOL [USAN]; MIGLITOL [INN]; MIGLITOL [JAN]; MIGLITOL [MI]; MIGLITOL [VANDF]; MIGLITOL [MART.]; Bay m1009; MIGLITOL [WHO-DD]; SCHEMBL22593; MLS000759514; MLS001424128; MLS006011963; BIDD:GT0732; BAY-m1099; MIGLITOL [ORANGE BOOK]; cid_441314; GTPL4842; Miglitol (JP17/USAN/INN); BAY1099; HMS2051D05; HMS3713J07; N-hydroxylethyl-1-deoxynojirimycin; HY-B0481; Tox21_111436; BDBM50242271; AKOS015969689; Tox21_111436_1; CCG-100920; DB00491; KS-1242; NC00170; NSC 758702; NCGC00270540-02; M2302; S2589; C07708; C76308; D00625; EN300-119541; AB00639982-06; AB00639982_08; A837526; Q772735; SR-01000759413; SR-01000759413-4; W-104490; 1,5-Dideoxy-1,5-((2-hydroxyethyl)imino)-D-glucitol; BRD-K44779798-001-06-5; Z1269163651; (2R,3R,4R,5S)-1-ethoxy-2-(hydroxymethyl)piperidine-3,4,5-triol; (4R,5R)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-Hydroxyethyl)-2-(2-hydroxymethyl)-3,4,5-piperidinetriol; 1204250-58-7; 3,4,5-PIPERIDINETRIOL, 1-(2-HYDROXYETHYL)-2-(HYDROXYMETHYL)-, (2R-(2.ALPHA.,3.BETA.,4.ALPHA.,5.BETA.))-; 3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-	Approved	Approved Drug(s)	441314	DB00491	D0D0ZD	207.22	104	179	-2.6	14	5	6	3	C8H17NO5	(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol	C1C(C(C(C(N1CCO)CO)O)O)O	C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O	InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1	IBAQFPQHRJAVAV-ULAWRXDQSA-N
DAS8E5	Boceprevir	Small molecule	Boceprevir; 394730-60-0; Victrelis; SCH 503034; EBP 520; SCH-503034; SCH503034; EBP-520; 89BT58KELH; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide; CHEBI:68621; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; (1R,2S,5S)-N-(4-AMINO-1-CYCLOBUTYL-3,4-DIOXOBUTAN-2-YL)-3-[(2S)-2-(TERT-BUTYLCARBAMOYLAMINO)-3,3-DIMETHYLBUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; (1S,4S,5R)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxo-propyl]-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethyl-butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-4-carboxamide; Boceprevir [USAN]; Boceprevir [USAN:INN]; UNII-89BT58KELH; HSDB 8081; Victrelis(TM); Victrelis (TN); (1R,2S,5S)-N-(3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2S)-2-(((1,1-dimethylethyl)carbamoyl)amino)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexane-2-carboxamide; (1R,2S,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[(1,1-dimethylethyl)carbamoyl]amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-AZABICYCLO(3.1.0)HEXANE-2-CARBOXAMIDE, N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-((2S)-2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-, (1R,2S,5S)-; 3-azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-, (1R,2S,5S)-; Boceprevir & NM107; BOCEPREVIR [MI]; BOCEPREVIR [INN]; Boceprevir (INN/USAN); BOCEPREVIR [VANDF]; BOCEPREVIR [MART.]; BOCEPREVIR [WHO-DD]; BOCEPREVIR [EMA EPAR]; SCHEMBL640836; CHEMBL218394; EBP520; GTPL7876; BOCEPREVIR [ORANGE BOOK]; BDBM12311; DTXSID30960103; BCP02502; EX-A1336; MFCD22208555; s3733; AKOS005145787; EBP-520;SCH503034; CCG-269852; CS-0361; DB08873; DT-0021; NCGC00378631-01; BOC; HY-10237; SCH 503034 & NM107; D08876; EN300-7410986; Q410551; J-519910; (1r,5s)-n-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(s)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(s)-carboxamide; 3-Azabicyclo(3.1.0)hexane-2-carboxamide, N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2S)-2-((((1,1- dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6- dimethyl-, (1R,2S,5S)-; N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; N-(4-Amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-{N-[(tert-butylamino)(hydroxy)methylidene]-3-methylvalyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboximidic acid	Approved	Approved Drug(s)	10324367	DB08873	D0D1CS	519.7	151	959	3.1	37	4	5	10	C27H45N5O5	(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C	CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C	InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1	LHHCSNFAOIFYRV-DOVBMPENSA-N
D8RJQ5	Arformoterol	Small molecule	Arformoterol; (R,R)-Formoterol; formoterol; 67346-49-0; (-)-Formoterol; Oxis; 73573-87-2; Arformoterol [INN]; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; eformoterol; Atimos; Arformoterol (INN); Foradil; 5ZZ84GCW8B; CHEMBL1363; F91H02EBWT; CHEBI:408174; N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide; Formoterolum [INN-Latin]; FORMOTEROL FUMARATE; Formoterolum; Innovair; Fluir; Racemic formoterol; Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-; (+-)-Formoterol; FORMOTEROL [INN]; 1254575-18-2; YM-08316; UNII-5ZZ84GCW8B; UNII-F91H02EBWT; Formoterol [USAN:INN:BAN]; HSDB 7287; Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-; H98; Formoterol r,r-form; FORMOTEROL [MI]; FORMOTEROL [HSDB]; FORMOTEROL [VANDF]; SCHEMBL4247; ARFORMOTEROL [VANDF]; FORMOTEROL [WHO-DD]; ARFORMOTEROL [WHO-DD]; GTPL7479; cid_9912089; HY-B0010A; DTXSID40110071; FORMOTEROL R,R-FORM [MI]; BDBM50151720; AKOS015969668; CS-1413; DB01274; N-{2-hydroxy-5-[(1R)-1-hydroxy-2-({(1R)-1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)ethyl]phenyl}formamide; (-)-Formoterol;Arformoterol;(R,R)-Formoterol; D07463; D87655; EN300-174504; Q4789167; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; (-)-N-(2-HYDROXY-5-((1R)-1-HYDROXY-2-(((1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENYL)FORMAMIDE HYDROGEN (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE; FORMAMIDE, N-(2-HYDROXY-5-(1-HYDROXY-2-((2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENYL)-; Formamide, N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, (R-(R*,R*))-; N-(2-hydroxy-5-((R)-1-hydroxy-2-((R)-1-(4-methoxyphenyl)propan-2-ylamino)ethyl)phenyl)formamide; N-(2-Hydroxy-5-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1-methyl-ethylamino]-ethyl}-phenyl)-formamide; n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide; rel-n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide	Approved	Approved Drug(s)	3083544	DB01274	D0D1DI	344.4	90.8	388	1.8	25	4	5	8	C19H24N2O4	N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide	CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O	C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O	InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1	BPZSYCZIITTYBL-YJYMSZOUSA-N
D1ZGS7	Carvedilol	Small molecule	carvedilol; 72956-09-3; Coreg; Dilatrend; Eucardic; Kredex; Carvedilolum [Latin]; Carvedilolum; Querto; BM 14190; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; BM-14190; Dimitone; Artist; SKF 105517; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; 1-((9H-Carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol; Coronis; Korvasan; Talliton; DQ 2466; DQ-2466; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-Carvedilol-d4; CHEMBL723; NSC-758694; SK&F-105517; BM 14.190; BM-14-190; BM-14.190; CHEBI:3441; C07AG02; 0K47UL67F2; [3-(9H-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine; SKF-105517; Carvedilol-methyl-d3; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol; Coropress; Dibloc; R-(+)-Carvedilol; S-(-)-Carvedilol; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; SMR000449280; Artist (TN); Coreg (TN); HSDB 7044; SR-01000759289; UNII-0K47UL67F2; MFCD00869663; 1-(9H-Carbazol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol; EG-P042; (R)-BM 14190; (S)-BM 14190; MFCD00864692; Carvedilol - Bio-X; BM14190; Carvedilol [USAN:USP:INN:BAN:JAN]; Spectrum_001665; CARVEDILOL [MI]; CARVEDILOL [INN]; CARVEDILOL [JAN]; Spectrum2_001673; Spectrum3_001182; Spectrum4_000636; Spectrum5_001436; CARVEDILOL [HSDB]; CARVEDILOL [USAN]; CARVEDILOL [VANDF]; CARVEDILOL [MART.]; CARVEDILOL [USP-RS]; CARVEDILOL [WHO-DD]; SCHEMBL22293; GTPL551; KBioGR_001252; KBioSS_002145; MLS000758299; MLS000759508; MLS001424092; MLS006011886; SPBio_001885; Carvedilol (JP17/USP/INN); CARVEDILOL [ORANGE BOOK]; DTXSID8022747; SCHEMBL10082334; SCHEMBL13287211; BDBM25759; KBio2_002145; KBio2_004713; KBio2_007281; KBio3_002323; CARVEDILOL [EP MONOGRAPH]; (R)-1-[(4-Carbazolyl)oxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; CARVEDILOL [USP MONOGRAPH]; HMS2051N03; HMS2089B09; HMS2093E12; HMS3261E15; HMS3269N11; HMS3393N03; HMS3413B14; HMS3655O14; HMS3677B14; HMS3715D15; HMS3750I15; HMS3884E12; Pharmakon1600-01504257; Carvedilol 1.0 mg/ml in Methanol; AMY40801; BCP23386; EX-A5746; HY-B0006; Tox21_500347; BBL029064; MFCD00869664; NSC758694; s1831; STK621453; AKOS005554967; Carvedilol, >=98% (HPLC), solid; AC-1641; BCP9000493; CCG-100917; CCG-207952; CS-1194; DB01136; KS-1037; LP00347; NC00167; NSC 758694; SB17441; SDCCGSBI-0206771.P002; 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)-; NCGC00167832-01; NCGC00167832-02; NCGC00167832-03; NCGC00167832-04; NCGC00167832-19; NCGC00261032-01; BC164291; SY129821; SY283162; BCP0726000253; SBI-0206771.P001; DB-055704; DB-057556; DB-057557; C2260; FT-0603055; FT-0603057; FT-0652640; FT-0664397; SW197547-3; C06875; D00255; F19969; AB00639903-07; AB00639903-09; AB00639903_10; AB00639903_11; AB00639903_12; L001243; Q412534; Q-200801; SR-01000759289-5; SR-01000759289-6; SR-01000759289-9; BRD-A10977446-001-04-8; BRD-A10977446-001-05-5; BRD-A10977446-045-01-1; Z1515383337; Carvedilol, European Pharmacopoeia (EP) Reference Standard; Ethyl 2-(9-(pyridin-4-ylmethyl)-9H-fluoren-9-yl)acetate; Carvedilol, United States Pharmacopeia (USP) Reference Standard; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol; Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-1-CARBAZOL-4-YLOXY)-3-((2-(O-METHOXYPHENOXY)ETHYL)AMINO)-2-PROPANOL; 1-(CARBAZOL-4-YLOXY)-3-((2-(O-METHOXY-PHENOXY)ETHYL)AMINO)-2-PROPANOL; Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard; 107741-96-8; 2-PROPANOL, 1-(9H-CARBAZOL-4-YLOXY)-3-((2-(2-METHOXYPHENOXY)ETHYL)AMINO)-, (+/-)-	Approved	Approved Drug(s)	2585	DB01136	D0D1HH	406.5	75.7	508	4.2	30	3	5	10	C24H26N2O4	1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol	COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O	COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O	InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3	OGHNVEJMJSYVRP-UHFFFAOYSA-N
D6XTI8	Prednisolone	Small molecule	prednisolone; 50-24-8; Metacortandralone; Hydroretrocortine; Predonine; Delta-Cortef; Deltacortril; Meticortelone; Deltahydrocortisone; Codelcortone; Cortalone; Prenolone; Sterane; Hydroretrocortin; Meti-Derm; PRDL; Deltacortenol; Hydrodeltalone; Hydrodeltisone; Cotogesic; Decaprednil; Delcortol; Deltisilone; Dicortol; Donisolone; Dydeltrone; Erbacort; Erbasona; Estilsona; Fernisolone; Hydeltra; Hydeltrone; Lentosone; Paracortol; Paracotol; Precortancyl; Precortilon; Precortisyl; Prednelan; Prednicen; Predniliderm; Predonin; Rolisone; Scherisolon; Sterolone; Cordrol; Prednis; Prelone; Steran; Ulacort; Fernisolone P; Hostacortin H; Ultracorten H; Ultracortene-H; Delta-stab; Predne-Dome; Decortin H; CO-Hydeltra; Eazolin D; Di-adreson F; Delta F; Derpo PD; 1-Dehydrohydrocortisone; Solone; delta(1)-Hydrocortisone; Fernisolone-P; delta(1)-Dehydrocortisol; Delta-Ef-Cortelan; Dexa-Cortidelt hostacortin H; 1,2-Dehydrohydrocortisone; Panafcortelone; Prednisolona; Prednisolonum; Prednisolonum [INN-Latin]; Prednisolona [INN-Spanish]; 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione; Ultracortene-hydrogen; (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione; Delta(1)-dehydrohydrocortisone; 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol; 11beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione; 3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene; K 1557; .DELTA.1-Cortisol; NSC-9120; NSC-9900; .DELTA.1-Hydrocortisone; 9PHQ9Y1OLM; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; .DELTA.1-Dehydrocortisol; CHEMBL131; CHEBI:8378; .DELTA.1-Dehydrohydrocortisone; 11beta,17alpha,21-Trihydroxypregna-1,4-diene-3,20-dione; Predniretard; DTXSID9021184; .delta.-Cortef; Neo-Delta-Cortef; .delta.-Stab; component of Ataraxoid; Cotolone; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11b)-; component of K-Predne-Dome; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; delta(1)-Cortisol; DTXCID301184; Deltasolone; Klismacort; Supercortisol; delta(sup 1)-Cortisol; Bubbli-Pred; delta(sup 1)-Hydrocortisone; delta(sup 1)-Dehydrocortisol; SMR000718761; CCRIS 980; Prednisolone [INN:BAN:JAN]; HSDB 3385; delta(sup 1)-Dehydrohydrocortisone; MLS002638110; NSC 9120; Pregna-1,20-dione, 11.beta.,17,21-trihydroxy-; EINECS 200-021-7; UNII-9PHQ9Y1OLM; MFCD00003649; Predisolone Sodium Phosphate; BRN 1354103; prednisolon; Preflam; Pregna-1,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; CAS-50-24-8; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-; NCGC00094764-01; Prednisolone Powder; delta-hydrocortisone; Prestwick_404; delta-dehydrocortisol; DELTA.1-Cortisol; APREDNISLON; EQUISOLON; VETSOLONE; Delta-Cortef (TN); 11-beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione; T-Pred (Salt/Mix); 1,4-Pregnadien-11-beta,17-alpha,21-triol-3,20-dione; 1,4-Pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; 1,4-Pregnadiene-3,20-dione-11-beta,17-alpha,21-triol; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-; Prednisolone, >=99%; Prestwick0_000274; Prestwick1_000274; Prestwick2_000274; Prestwick3_000274; delta-dehydrohydrocortisone; PREDNISOLONE [EP]; PREDNISOLONE [MI]; (+)-PREDNISOLONE; PREDNISOLONE [INN]; PREDNISOLONE [JAN]; EC 200-021-7; PREDNISOLONE [HSDB]; SCHEMBL3233; K-Predne-Dome (Salt/Mix); PREDNISOLONE [VANDF]; PREDNISOLONE ANHYDROUS; .DELTA.(sup 1)-Cortisol; BSPBio_000148; PREDNISOLONE [MART.]; 4-08-00-03467 (Beilstein Handbook Reference); MLS001304083; MLS002154250; MLS002207037; MLS002548883; PREDNISOLONE [USP-RS]; PREDNISOLONE [WHO-DD]; PREDNISOLONE [WHO-IP]; SPBio_002367; BPBio1_000164; GTPL2866; .DELTA.(sup 1)-Hydrocortisone; BDBM19190; Prednisolone (JP17/USP/INN); NSC9120; NSC9900; PREDNISOLONE [GREEN BOOK]; .DELTA.(sup 1)-Dehydrocortisol; HMS1568H10; HMS2090J05; HMS2095H10; HMS2230P10; HMS3259E09; HMS3712H10; PREDNISOLONE [ORANGE BOOK]; PREDNISOLONE [EP MONOGRAPH]; PREDNISONE IMPURITY B [EP]; BCP09053; PREDNISOLONE [USP MONOGRAPH]; Tox21_111327; Tox21_201673; Tox21_302987; LMST02030179; PREDNISOLONUM [WHO-IP LATIN]; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; s1737; .DELTA.(sup 1)-Dehydrohydrocortisone; AKOS015894935; Tox21_111327_1; AC-1773; CCG-220274; DB00860; NC00473; NCGC00179649-01; NCGC00179649-02; NCGC00179649-03; NCGC00179649-04; NCGC00179649-06; NCGC00256577-01; NCGC00259222-01; (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one; AS-13665; HY-17463; PREDNISOLONE (EMA EPAR: VETERINARY); P0637; EN300-53017; PREDNICARBATE IMPURITY A [EP IMPURITY]; C07369; D00472; D91990; HYDROCORTISONE IMPURITY A [EP IMPURITY]; Prednisolone, VETRANAL(TM), analytical standard; A929791; CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE; METHYLPREDNISOLONE IMPURITY K [EP IMPURITY]; SR-01000837502; Q-201616; SR-01000837502-2; 11b,17,21-Trihydroxypregna-1,4-diene-3,20-dione; BRD-K98039984-001-03-0; BRD-K98039984-001-06-3; PREDNISOLONE ACETATE IMPURITY B [EP IMPURITY]; PREDNISOLONE COMPONENT OF CHLOROPTIC-P S.O.P.; Q11426176; 11beta,17,21-trihydroxy-1,4-pregnadiene-3,20-dione; delta-1-Cortisol; Prednicarbate EP Imp A; Supercortisol; Prednisolone, British Pharmacopoeia (BP) Assay Standard; Z778141968; 11-.beta.,17,21-Trihydroxypregna-1,4-diene-3,20-dione; 1,4-Pregnadien-11-.beta.,17-.alpha.,21-triol-3,20-dione; 1,4-Pregnadiene-11-.beta.,17-.alpha.,21-triol-3,20-dione; 1,4-Pregnadiene-3,20-dione-11-.beta.,17-.alpha.,21-triol; Prednisolone, European Pharmacopoeia (EP) Reference Standard; Pregna-1,4-diene-3,20-dione, 11.beta.,17,21-trihydroxy-; 11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, (11.beta.)-; 11-.beta.,17-.alpha.,21-Trihydroxy-1,4-pregnadiene-3,20-dione; 11-.beta.,17-.alpha.,21-Trihydroxypregna-1,4-diene-3,20-dione; 11.BETA.,17,21-TRIHYDROXYPREGNA-1,4-DIENE-3,20-DIONE.; 11.beta.,17.alpha.,21-Trihydroxypregna-1,4-diene-3,20-dione; Prednisolone, United States Pharmacopeia (USP) Reference Standard; Prednisolone for peak identification, European Pharmacopoeia (EP) Reference Standard; Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard; Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material; PREGNA-1,4-DIENE-3,20-DIONE, 11,17,21-TRIHYDROXY-, (11.BETA)-; (1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one; (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-5-one; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-8,10,13-trimethyl-3-oxo-6,7,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carboxylic acid;Prednisolone; 8056-11-9; TUA	Approved	Approved Drug(s)	5755	DB00860	D0D1SG	360.4	94.8	724	1.6	26	3	5	2	C21H28O5	(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one	CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O	C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O	InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1	OIGNJSKKLXVSLS-VWUMJDOOSA-N
D15XZY	Mavacamten	Small molecule	Mavacamten; Camzyos; MYK-461; 1642288-47-8; 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione; Mavacamten [INN]; Mavacamten [USAN]; Mavacamten [WHO-DD]; SAR-439152; QX45B99R3J; (S)-3-isopropyl-6-((1-phenylethyl)amino)pyrimidine-2,4(1H,3H)-dione; SAR439152; 2,4(1H,3H)-Pyrimidinedione, 3-(1-methylethyl)-6-(((1S)-1-phenylethyl)amino)-; 2,4(1H,3H)-Pyrimidinedione, 3-(1-methylethyl)-6-[[(1S)-1-phenylethyl]amino]-; Mavacamten (MYK-461); UNII-QX45B99R3J; MYK461; CHEMBL4297517; SCHEMBL16320785; GTPL11265; Mavacamten [USAN:INN:WHO-DD]; EX-A2072; BDBM50575174; s8861; WHO 10492; DB14921; MYK-461; Mavacamten; SAR439152; MS-23884; SAR-439152; MYK-461; HY-109037; CS-0031211; E83742; (S)-3-Isopropyl-6-((1-phenylethyl)amino) pyrimidine-2,4(1H,3H)-dione; (S)-3-Isopropyl-6-((1-phenylethyl)amino)pyrimidine-2, 4(1H,3H)-dione; (S)-3-Isopropyl-6-(1-phenylethylamino)pyrimidine-2,4(1H,3H)-dione; 3-(1-Methylethyl)-6-[[(1S)-1-phenylethyl]amino]-2,4(1H,3H)-pyrimidinedione; 6-(((1S)-1-Phenylethyl)amino)-3-(propan-2-yl)-1,2,3,4 tetrahydropyrimidine-2,4-dione; 6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione; 6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)pyrimidine-2,4(1H,3H)-dione	Approved	Approved Drug(s)	117761397	DB14921	D0D1ZF	273.33	61.4	411	2.1	20	2	3	4	C15H19N3O2	6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione	CC(C)N1C(=O)C=C(NC1=O)NC(C)C2=CC=CC=C2	C[C@@H](C1=CC=CC=C1)NC2=CC(=O)N(C(=O)N2)C(C)C	InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1	RLCLASQCAPXVLM-NSHDSACASA-N
DQ5N1E	Sofosbuvir	Small molecule	SOFOSBUVIR; 1190307-88-0; PSI-7977; SOVALDI; GS-7977; PSI 7977; GS7977; GS 7977; WJ6CA3ZU8B; SofosbuvirPSI7977GS-7977; CHEBI:85083; propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate; L-Alanine, N-((P(S),2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl)-, 1-methylethyl ester; Sofosbuvir [USAN]; Sofosbuvir [USAN:INN]; UNII-WJ6CA3ZU8B; C22H29FN3O9P; Hepcinat; Hepcvir; Resof; SoviHep; HSDB 8226; PSI7977; Sovaldi (TN); SOFOSBUVIR [MI]; SOFOSBUVIR [INN]; SOFOSBUVIR [JAN]; Sofosbuvir (JAN/USAN); SOFOSBUVIR [VANDF]; Sofosbuvir(PSI-7977); Sofosbuvir (GS-7977); SOFOSBUVIR [WHO-DD]; 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester; GTPL7368; SCHEMBL2010114; CHEMBL1259059; SOFOSBUVIR [ORANGE BOOK]; EX-A389; VOSEVI COMPONENT SOFOSBUVIR; DTXSID701027632; EPCLUSA COMPONENT SOFOSBUVIR; HARVONI COMPONENT SOFOSBUVIR; (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate; isopropyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate; MFCD18782704; s2794; SOFOSBUVIR COMPONENT OF VOSEVI; AKOS024464753; SOFOSBUVIR COMPONENT OF EPCLUSA; SOFOSBUVIR COMPONENT OF HARVONI; AM84279; CCG-269909; CS-0554; DB08934; GI 7977; GI-7977; Sofosbuvir (PSI-7977, GS-7977); Sofosbuvir (PSI-7977; GS-7977); BS165550; HY-15005; SW219116-1; D10366; EN300-19897652; Q2502747; Z2235802138; (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-h; (S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; isopropyl ((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate; isopropyl (2S)-2-{[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate; propan-2-yl (2S)-2-{[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate; S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)- (phenoxy)phosphorylamino)propanoate; WG6	Approved	Approved Drug(s)	45375808	DB08934	D0D4YZ	529.5	153	913	1	36	3	11	11	C22H29FN3O9P	propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate	CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3	C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3	InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1	TTZHDVOVKQGIBA-IQWMDFIBSA-N
D4WE5S	Candesartan	Small molecule	candesartan; 139481-59-7; Blopress; CV-11974; 1-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid; CV 11974; 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid; C24H20N6O3; 2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid; NSC-759858; CHEMBL1016; S8Q36MD2XX; CHEBI:3347; DTXSID0022725; NCGC00167474-01; 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; DTXCID202725; [3H]candesartan; 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid; 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid; Candesartan [INN]; CAS-139481-59-7; SR-05000001447; Candesartan (USAN/INN); UNII-S8Q36MD2XX; Candesartan [USAN:INN:BAN]; HSDB 7520; 2-ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid; 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-benzimidazolecarboxylic acid; Candesartan-[d5]; 2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylic acid; 2-ethoxy-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid; Candesartan- Bio-X; CANDEMORE; CELEXETIL; candesartan (Atacand); KS-5003; Candesartan - Atacand; CANDESARTAN [MI]; TCV-116 (prodrug); CANDESARTAN [HSDB]; CANDESARTAN [USAN]; CANDESARTAN [VANDF]; EC 604-138-8; SCHEMBL3938; 2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid; CANDESARTAN [WHO-DD]; GTPL587; MLS003915631; MLS004774041; BIDD:GT0350; GTPL6907; BCPP000302; HMS2089M22; HMS3651C13; HMS3715F13; Pharmakon1600-01502288; ACT02607; BCP01137; HY-B0205; STR09609; Tox21_112478; BDBM50240609; MFCD00864463; NSC755311; NSC759858; s1578; AKOS015888154; AKOS025117340; Tox21_112478_1; AB07470; AM84369; BCP9000479; CCG-213059; CCG-269122; DB13919; NSC 759858; NSC-755311; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; NCGC00167474-02; NCGC00167474-04; NCGC00167474-06; 2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid; BC164271; SMR002203608; SMR003500711; C-266; FT-0602912; SW199612-2; C07468; D00522; AB01275447-01; AB01275447_02; AB01275447_03; EN300-6491073; A807545; A808309; L000156; Q415970; Candesartan 100 microg/mL in Acetonitrile:Methanol; J-007281; SR-05000001447-1; SR-05000001447-2; SR-05000001447-5; CANDESARTAN CILEXETIL IMPURITY G [EP IMPURITY]; Z1741968269; 2-Ethoxy-1-[[2'-(1 H-tetrazol-5-yl)biphenyl-4-yl]methyl]-benzimidazole-7-carboxylic acid; 2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-benzimidazole-7-carboxylic acid; 2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic Acid; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl]}-1H-benzimidazole-7-carboxylic acid; 2-Ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid.; 2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzimidazole-4-carboxylic acid; 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylicacid; 2-Ethoxy-1-((2-(1H-tetrazole-5-yl)biphenyl-4-yl)methyl)-1H-benzamidazole-7-carboxylic acid.; 2-ethoxy-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylic acid; 2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic Acid (Candesartan); 2-ethoxy-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-1,3-benzodiazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-1,3-benzodiazole-7-carboxylic acid; 2-ethoxy-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid; 2-Ethoxy-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid(CV-11974); 2-Ethoxy-3-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid; 2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid	Approved	Approved Drug(s)	2541	DB13919	D0D5SQ	440.5	119	660	4.1	33	2	7	7	C24H20N6O3	2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid	CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O	CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O	InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)	HTQMVQVXFRQIKW-UHFFFAOYSA-N
DT1N8G	Sufentanil	Small molecule	SUFENTANIL; Sufentanyl; 56030-54-7; Sufentanilum; Sufentanilum [INN-Latin]; Zalviso; R-30730; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide; CHEBI:9316; AFE2YW0IIZ; N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide; Chronogesic; IDS-NS-001; R 30,730; Propanamide, N-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenyl-; N-[4-(Methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidyl]propionanilide; Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl-; R 30730; HSDB 6760; UNII-AFE2YW0IIZ; Sufentanil (USAN/INN); Sufentanil [USAN:INN:BAN]; Sufentanil Base; N-[4-(Methoxymethyl)-1-{2-(2-thienyl)ethyl}-4-piperidinyl]-N-phenylpropanamide; Dsuvia (brand name); Sufenta (brand name); SUFENTANIL [MI]; SUFENTANIL [INN]; SUFENTANIL [HSDB]; SUFENTANIL [USAN]; SUFENTANIL [VANDF]; CHEMBL658; Epitope ID:153513; SUFENTANIL [MART.]; ARX04; SUFENTANIL [WHO-DD]; Oprea1_120838; Oprea1_246787; SCHEMBL26728; cid_65494; ARX 04; GTPL3534; DTXSID6023604; BDBM94503; SUFENTANIL [EP MONOGRAPH]; PDSP1_001741; PDSP2_001724; DB00708; N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; NCGC00247355-01; HY-13754; C08022; D05938; L000580; Q417915; N-[4-(Methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]propionalnalide; citric acid;N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidyl]-N-phenyl-propionamide; N-(4-(methoxymethyl)-1-(2-(thiophen-2-yl)ethyl)piperidin-4-yl)-N-phenylpropionamide; N-(4-(Methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl)-N-phenylpropanamide #; N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide; 2-hydroxypropane-1,2,3-tricarboxylic acid;N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)-4-piperidinyl]-N-phenylpropanamide; N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenyl-propanamide;2-oxidanylpropane-1,2,3-tricarboxylic acid	Approved	Approved Drug(s)	41693	DB00708	D0D8DD	386.6	61	459	4	27	0	4	8	C22H30N2O2S	N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC	InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3	GGCSSNBKKAUURC-UHFFFAOYSA-N
D5BSU8	Metformin	Small molecule	metformin; 657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Fluamine; Metiguanide; Dimethylbiguanide; Haurymelin; Metformine; Flumamine; Gliguanid; Melbin; Imidodicarbonimidic diamide, N,N-dimethyl-; N,N-Dimethylbiguanide; N1,N1-Dimethylbiguanide; DMGG; NNDG; N,N-Dimethyldiguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; 1,1-Dimethyl biguanide; BIGUANIDE, 1,1-DIMETHYL-; LA-6023; Metformin extended release; CHEMBL1431; CHEBI:6801; DTXSID2023270; Glifage; Islotin; Siofor; Dimethyldiguanide; Diaformin; 9100L32L2N; Metformina [DCIT]; Metforminum; Metformina; Metformina [Spanish]; Metformine [INN-French]; Metforminum [INN-Latin]; Metformin [USAN:INN:BAN]; C4H11N5; MLS000028493; [14C]metformin; [14C]-metformin; Metformin (USAN/INN); NCGC00016564-01; SMR000058277; EINECS 211-517-8; CAS-1115-70-4; Dianben; Obimet; Dimethylbiguanid; CCRIS 9321; UNII-9100L32L2N; N-dimethylbiguanide; DMBG; Glucophage (Salt/Mix); METFORMIN [INN]; n',n'-dimethylbiguanide; METFORMIN [MI]; METFORMIN [USAN]; Imidodicarbonimidic diamide-, N,N-dimethyl-; Prestwick0_000004; Prestwick1_000004; Prestwick2_000004; Prestwick3_000004; METFORMIN [VANDF]; N,N-Dimethylguanylguanidin; METFORMIN [WHO-DD]; SCHEMBL8944; BSPBio_000007; BSPBio_002314; KBioGR_002310; KBioSS_002312; cid_14219; LA 6023 (Salt/Mix); BIDD:GT0697; SPBio_001928; BPBio1_000009; DTXCID803270; GTPL4503; GTPL4779; SCHEMBL9913821; SCHEMBL10276396; BDBM57047; KBio2_002310; KBio2_004878; KBio2_007446; KBio3_002790; cMAP_000016; HMS2089D19; HY-B0627; Tox21_302370; BBL012337; BDBM50229665; HSCI1_000295; MFCD00242652; NSC813213; s5958; STK011633; STL483693; STL484070; AKOS000121065; AKOS005206848; AKOS015966566; CCG-102605; DB00331; NSC-813213; 3-carbamimidoyl-1,1-dimethyl-guanidine; NCGC00016564-02; NCGC00016564-03; NCGC00016564-05; NCGC00016564-07; NCGC00188959-01; NCGC00255255-01; AC-32484; AS-65365; CAS-657-24-9; SBI-0206876.P001; 1-carbamimidamido-N,N-dimethylmethanimidamide; CS-0009563; FT-0628266; EN300-23696; A19551; C07151; D04966; D72476; EN300-746417; Q19484; (E)-3-[Amino(dimethylamino)methylidene]guanidine; 1-[(E)-amino(dimethylamino)methylidene]guanidine; W-109589; {[amino(dimethylamino)methylidene]amino}methanimidamide; BRD-K79602928-003-04-1; BRD-K79602928-003-08-2; 3-(diaminomethylene)-1,1-dimethyl-guanidine;hydrochloride; [(E)-[AMINO(DIMETHYLAMINO)METHYLIDENE]AMINO]METHANIMIDAMIDE; 3-[bis(azanyl)methylidene]-1,1-dimethyl-guanidine;hydrochloride; MF8	Approved	Approved Drug(s)	4091	DB00331	D0D8RC	129.16	91.5	132	-1.3	9	3	1	2	C4H11N5	3-(diaminomethylidene)-1,1-dimethylguanidine	CN(C)C(=N)N=C(N)N	CN(C)C(=N)N=C(N)N	InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)	XZWYZXLIPXDOLR-UHFFFAOYSA-N
D96NDM	Tenofovir	Small molecule	Tenofovir; 147127-20-6; (R)-9-(2-Phosphonomethoxypropyl)adenine; Truvada; (R)-PMPA; tenofovir (anhydrous); PMPA gel; (R)-(((1-(6-AMINO-9H-PURIN-9-YL)PROPAN-2-YL)OXY)METHYL)PHOSPHONIC ACID; Apropovir; GS-1275; anhydrous tenofovir; Tenofovir anhydrous; tenofovir (anh.); CHEBI:63625; PMP-A; [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid; ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid; W4HFE001U5; (R)-(1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonic acid; 147127-20-6 (Tenofovir); C9H14N5O4P; GS-1278; 9-[(R)-2-(phosphonomethoxy)propyl]adenine; Phosphonic acid, P-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-; D,L-Tenofovir; Tenofovir gel; [(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methylphosphonic acid; (((1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy)methyl)phosphonic acid; (R)-[[2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid; GNA & Tenofovir; HHA & Tenofovir; TFV gel; GS 1275; PMPA-(R); UNII-W4HFE001U5; Tenofovir [USAN:INN:BAN]; Rac tenofovir; anh. tenofovir; Viread (prodrug for Tenofovir); {[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl}phosphonic acid; Phosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)-; Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-; PHOSPHONIC ACID, P-(((1R)-2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)-; Tenofovir- Bio-X; Tenofovir (Viread); (R)-9-(Phosphonomethoxypropyl)adenine; GS 1278; KS-5021; TENOFOVIR [INN]; TENOFOVIR [MI]; 9-PMPA; CHEMBL483; EC 604-571-2; TENOFOVIR [WHO-DD]; SCHEMBL39724; Tenofovir gel (GS-1278); DTXSID9040132; Tenofovir, >=98% (HPLC); GTPL10948; BCPP000049; HMS3264H05; AC-760; BDBM50450813; MFCD00943794; AKOS015856701; AKOS015894941; CCG-267345; CS-1609; DB14126; Phosphonic acid, ((2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)-, (R)-; NCGC00167535-16; BT164455; HY-13910; (R)-9-(2-Phosphonoylmethoxypropyl)adenine; AM20090678; T3006; (R)-9-[2-(phosphonomethoxy) propyl] adenine; C17407; EN300-123033; AB01274787-01; AB01274787_02; AB01274787_03; A808613; Q155954; SR-01000883934; Q-201787; SR-01000883934-1; BRD-K15891719-001-02-8; Z1546616194; [(2R)-3-(6-aminopurin-9-yl)-2-methyl-propyl] dihydrogen phosphate; [[(1R)-2(6-Amino-9H-Purin-9-Yl)-1-Methylethoxy]Methyl]Phosphonic Acid; [2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY]METHYLPHOSPHONIC ACID; Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)	Approved	Approved Drug(s)	464205	DB14126	D0D9HW	287.21	136	354	-1.6	19	3	8	5	C9H14N5O4P	[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid	CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O	C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O	InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1	SGOIRFVFHAKUTI-ZCFIWIBFSA-N
D9DGP2	Dapagliflozin	Small molecule	Dapagliflozin; 461432-26-8; BMS-512148; Forxiga; Dagagflozin; BMS 512148; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol; 1ULL0QJ8UC; CHEMBL429910; (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol; CHEBI:85078; LYN-045; Dapagliflozin [USAN:INN]; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; BMS512148; Forxiga (TN); CHEMBL3125458; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; Dapagliflozin [USAN]; UNII-1ULL0QJ8UC; S1548_Selleck; C-aryl glucoside, 6; DAPAGLIFLOZIN [MI]; DAPAGLIFLOZIN [INN]; Dapagliflozin (USAN/INN); 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; DAPAGLIFLOZIN [VANDF]; SCHEMBL157820; DAPAGLIFLOZIN [WHO-DD]; GTPL4594; BDBM20880; DTXSID20905104; EX-A005; BCPP000265; DAPAGLIFLOZIN [ORANGE BOOK]; AMY18541; BDBM50448923; MFCD13182359; s1548; QTERNMET COMPONENT DAPAGLIFOZIN; AKOS005145763; DAPAGLIFLOZIN COMPONENT QTERNMET; BCP9000583; BL-0052; BMS5121458; CCG-229917; CS-0781; DB06292; EX-7214; NCGC00250402-09; AC-24699; BD164346; HY-10450; QTERNMET XR COMPONENT DAPAGLIFLOZIN; DAPAGLIFLOZIN COMPONENT OF QTERNMET XR; A25150; C22193; D08897; EN300-7407160; Q409898; J-500392; BRD-K58160573-001-01-3; BRD-K58160573-001-05-4; Z2235801883; 1-[3-(beta-D-Glucopyranosyl)-6-chlorobenzyl]-4-ethoxybenzene; (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol; (2S, 3R, 4R, 5S, 6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;BMS-512148; (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol	Approved	Approved Drug(s)	9887712	DB06292	D0DN1V	408.9	99.4	472	2.3	28	4	6	6	C21H25ClO6	(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl	InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1	JVHXJTBJCFBINQ-ADAARDCZSA-N
D3YJ5V	Lorazepam	Small molecule	lorazepam; Ativan; 846-49-1; o-Chloroxazepam; o-Chlorooxazepam; Temesta; Loraz; Tavor; Delormetazepam; Almazine; Anxiedin; Bonatranquan; Duralozam; Emotival; Lorabenz; Sedatival; Laubeel; Orfidal; Punktyl; Lorax; Quait; Wypax; Apo-Lorazepam; Lorazepam Intensol; Norlormetazepam; Anzepam; Aplacasse; Azurogen; Efasedan; Equitam; Kalmalin; Larpose; Lorapam; Lorazene; Lorazep; Lorazin; Lorenin; Loridem; Lorsedal; Lozepam; Novhepar; Renaquil; Rocosgen; Sedizepan; Sidenar; Silence; Tranqipam; Anxira; Aripax; Bonton; Loram; Lorat; Merlit; Stapam; Trapax; Upan; Nervistop L; Wy-4036; Demethyllormetazepam; Lorazepamum; Wy 4036; (+/-)-Lorazepam; 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one; Lorazepam preservative free; Lorazepam civ; 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-; NSC 289758; Idalprem; 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; Aplacassee; Sinestron; Donix; Tolid; CHEMBL580; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1H-1,4-benzodiazepin-2(3H)-one; Lorazepam Medical; Nu Loraz; O26FZP769L; Nervistopl; Novolorazem; DTXSID7023225; Emotion; Lomesta; Lorafen; Lorazon; Lorivan; Somagerol; Vigiten; Lorans; Lorzem; Lopam; Lorazepam Fabra; Lorazepam-Efeka; Lorazepan Chobet; Lorazepan Richet; Max Pax; NSC289758; Lorazepam Genericon; Lorazepam Lannacher; NSC-289758; NCGC00159439-02; Lorsilan; Securit; Sedazin; Pro dorm; 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-; Lorazepamum [INN-Latin]; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Ativan (TN); EINECS 212-687-6; BRN 0759084; UNII-O26FZP769L; DEA No. 2885; Lorazepam [USAN:USP:INN:BAN:JAN]; LOREEV XR; LORAZEPAM [INN]; LORAZEPAM [JAN]; LORAZEPAM [MI]; LORAZEPAM [USAN]; (.+/-.)-Lorazepam; LORAZEPAM [VANDF]; LORAZEPAM [MART.]; LORAZEPAM [WHO-DD]; (+-)-7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; SCHEMBL26961; 5-25-02-00248 (Beilstein Handbook Reference); MLS001424236; DivK1c_000965; Lorazepam (JP17/USP/INN); CHEBI:6539; DTXCID303225; GTPL5884; LORAZEPAM [EP IMPURITY]; LORAZEPAM [ORANGE BOOK]; LORAZEPAM CIV [USP-RS]; LORAZEPAM [EP MONOGRAPH]; HMS503A11; KBio1_000965; LORAZEPAM [USP MONOGRAPH]; NINDS_000965; HMS2052H07; HMS3394H07; BCP13713; Tox21_111669; BDBM50292627; Lorazepam 0.1 mg/ml in Acetonitrile; Lorazepam 1.0 mg/ml in Acetonitrile; AKOS015904303; CCG-101170; DB00186; NC00420; 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-, (+-)-; IDI1_000965; CAS-846-49-1; SMR000058410; WLN: T67 GMV JN IHJ CG IQ KR BG; L-230; D00365; A840886; Q408265; 7-Chloro-5-(o-chlorophenyl)-1,4-benzodiazepin-2-one; BRD-A11990600-001-01-8; Lorazepam, British Pharmacopoeia (BP) Reference Standard; Lorazepam, European Pharmacopoeia (EP) Reference Standard; 2H-1, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-; 2H-1, 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-; Lorazepam, United States Pharmacopeia (USP) Reference Standard; O-Chloroxazepam; O-Chlorooxazepam; Almazine; WY 4036; WY-4036; WY4036; 7-chloranyl-5-(2-chlorophenyl)-3-oxidanyl-1,3-dihydro-1,4-benzodiazepin-2-one; 7-chloro-3-hydroxy-5-(2'-chloro-phenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one; 7-chloro-3-hydroxy-5-(2'-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one; 7-Chloro-5-(2-chloro-phenyl)-3-hydroxy-1,3-dihydro-benzo[e][1,4]diazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepine-2-one; 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one.; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one #; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1H-benzo[e][1,4]diazepin-2(3H)-one; 7-chloro-5-(2-chlorophenyl)-3-hydroxy-2,3-dihydro-1H-1,4-benzodiazepin-2-one; Lorazepam for system suitability, European Pharmacopoeia (EP) Reference Standard; LORAZEPAM7-Chloro-5-(2-chloro-phenyl)-3-hydroxy-1,3-dihydro-benzo[e][1,4]diazepin-2-one; (+/-)-7-CHLORO-5-(O-CHLOROPHENYL)-1,3-DIHYDRO-3-HYDROXY-2H-1,4-BENZODIAZEPIN-2-ONE; (RS)-9-chloro-6-(2-chlorophenyl)-4-hydroxy-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one; 2H-1,4-BENZODIAZEPIN-2-ONE, 7-CHLORO-5-(2-CHLOROPHENYL)-1,3-DIHYDRO-3-HYDROXY-, (+/-)-; 7-Chloro-5-(2-chloro-phenyl)-3-hydroxy-1,3-dihydro-benzo[e][1,4]diazepin-2-one (lorazepam)	Approved	Approved Drug(s)	3958	DB00186	D0E0OG	321.2	61.7	443	2.4	21	2	3	1	C15H10Cl2N2O2	7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one	C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl	C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl	InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)	DIWRORZWFLOCLC-UHFFFAOYSA-N
D8BCX4	Fentanyl	Small molecule	fentanyl; Phentanyl; Fentanil; Fentanest; Fentora; 437-38-7; Duragesic; Sublimaze; Fentanylum; Fentanila; Sentonil; Sublimase; Duragesic-100; Matrifen; IONSYS; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; Duragesic-12; Duragesic-25; Duragesic-50; Duragesic-75; Fentanyl-12; Fentanyl-25; Fentanyl-50; Fentanyl-75; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Recuvyra; PecFent; Fentanyl CII; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; 1-Phenethyl-4-(N-phenylpropionamido)piperidine; R 4263; N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide; Fendrop; Abstral-; N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide; Durogesic d-trans; N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide; CHEBI:119915; N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide; Propionanilide, N-(1-phenethyl-4-piperidyl)-; Durogesic; CHEMBL596; IDS-NF-001; DTXSID9023049; R4263; En3267; Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)-; Propanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-; N02AB03; UF599785JZ; AD 923; AD-923; EN-3267; NCGC00168252-01; Subsys; Fentanil [DCIT]; Durotep MT; HSDB 3329; EINECS 207-113-6; Fentanyl Transdermal System; JNS020QD; BRN 0494484; UNII-UF599785JZ; Fentanyl [USAN:USP:INN:BAN]; Duragesic (TN); 7V7; Subsys (TN); FENTANYL-HCl; Tranq component fentanyl; FENTANYL [HSDB]; FENTANYL [USAN]; FENTANYL [INN]; FENTANYL [JAN]; FENTANYL [MI]; FENTANYL [VANDF]; FENTANYL [MART.]; Epitope ID:153507; FENTANYL [WHO-DD]; SCHEMBL8804; Fentanyl (JAN/USP/INN); FENTANYL [EMA EPAR]; Oprea1_152073; Oprea1_207148; 5-22-08-00049 (Beilstein Handbook Reference); BIDD:GT0555; FENTANYL [GREEN BOOK]; FENTANYL [EP IMPURITY]; FENTANYL [ORANGE BOOK]; FENTANYL CII [USP-RS]; DTXCID103049; GTPL1626; FENTANYL [EP MONOGRAPH]; FENTANYL [USP MONOGRAPH]; Fentanyl 0.1 mg/ml in Methanol; Fentanyl 1.0 mg/ml in Methanol; N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide; Tox21_112611; BDBM50008984; HY-U00158; PDSP1_000860; PDSP2_000846; FENTANYL [EMA EPAR VETERINARY]; CS-7211; DB00813; CAS-437-38-7; N-(1-Phenylethyl-4-piperidinyl)propionanilide; D00320; 1-(2-Phenylethyl)-4-(N-propananilido)piperidine; L001275; Q407541; N-Phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide #; N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide(Fentanyl); PROPANAMIDE, N-PHENYL-N-(1-(2-PHENYLETHYL)-4-PIPERIDINYL)	Approved	Approved Drug(s)	3345	DB00813	D0E1WI	336.5	23.6	391	4	25	0	2	6	C22H28N2O	N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide	CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3	CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3	InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3	PJMPHNIQZUBGLI-UHFFFAOYSA-N
D38IOX	Levetiracetam	Small molecule	Levetiracetam; 102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; ucb L059; UCB-L 059; matever; UCB-L059; Levetiracetame; Levetiracetamum; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; Elepsia; Levetiracetam sun; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; Levetiracetam teva; UCB-22059; Levetiracetam accord; Levetiracetam [INN]; Levetiracetam actavis; Levetiracetam hospira; UCB 22059; Levetiracetamum [INN-Latin]; NSC-760119; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; CHEBI:6437; Levetiracetam In Sodium Chloride; AGB-101; N03AX14; 44YRR34555; Levroxa; (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide; Leviteracetam; Levipil; Torleva; Elepsia XR; (S)-Levetiracetam; SMR000466303; Keppra (TN); Levesam 500; Etiracetam levo-isomer; SR-01000759400; MFCD03265610; UNII-44YRR34555; E Keppra; HSDB 7528; Levetiracetam [USAN:USP:INN:BAN]; E keppra (TN); Levetiracetam- Bio-X; (S)-2-(2-Oxo-1-pyrrolidinyl)butyramide; L-059; LEVETIRACETAM [MI]; LEVETIRACETAM [JAN]; CHEMBL1286; LEVETIRACETAM [HSDB]; LEVETIRACETAM [USAN]; LEVETIRACETAM [VANDF]; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (S)-; MLS000759403; MLS001424069; MLS006010215; BIDD:GT0242; LEVETIRACETAM [MART.]; SCHEMBL118843; LEVETIRACETAM RATIOPHARM; LEVETIRACETAM [USP-RS]; LEVETIRACETAM [WHO-DD]; GTPL6826; Levetiracetam (JAN/USP/INN); DTXSID9023207; LEVETIRACETAM [EMA EPAR]; LEVETIRACETAM ACTAVIS GROUP; Levetiracetam, >=98% (HPLC); Levetiracetam, analytical standard; HMS2051D07; HMS2089L20; HMS2235I18; HMS3262H11; HMS3713P16; HMS3884O11; Pharmakon1600-01502265; LEVETIRACETAM [EP IMPURITY]; LEVETIRACETAM [ORANGE BOOK]; ACT02712; ALBB-027275; BCP11856; HY-B0106; LEVETIRACETAM [EP MONOGRAPH]; LEVETIRACETAM [USP IMPURITY]; Tox21_500835; BDBM50422542; LEVETIRACETAM [USP MONOGRAPH]; NSC760119; s1356; STL388027; Levetiracetam 1.0 mg/ml in Methanol; AKOS015841981; AC-1479; CCG-100928; CS-1854; DB01202; KS-1176; LP00835; NC00178; NSC 760119; SDCCGSBI-0633760.P001; (2S)-(2-Oxopyrrolidin-1-yl)butyramide; NCGC00186028-01; NCGC00186028-13; NCGC00261520-01; (S)-2-(2-oxopyrrolidin-1-yl)butyramide; BL164623; (s)-2-(2-oxopyrrolidin-1-yl) butyramide; AM20070676; L0234; SW197558-3; C07841; D00709; EN300-244575; AB00639945-06; AB00639945_07; AB00639945_08; A800616; (S)-2-(2-OXO-PYRROLIDIN-1-YL)-BUTYRAMIDE; Q-201292; SR-01000759400-4; SR-01000759400-5; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide;Levetiracetam; Z1255435426; (-)-(S)-.ALPHA.-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE; 1-Pyrrolidineacetamide, .alpha.-ethyl-2-oxo-, (.alpha.S)-; Levetiracetam, European Pharmacopoeia (EP) Reference Standard; Levetiracetam, United States Pharmacopeia (USP) Reference Standard; (-)-(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide (2S)-2-(2-Oxo-pyrrolidin-1-yl)butanamide; Levitiracetam, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	5284583	DB01202	D0E1XL	170.21	63.4	203	-0.3	12	1	2	3	C8H14N2O2	(2S)-2-(2-oxopyrrolidin-1-yl)butanamide	CCC(C(=O)N)N1CCCC1=O	CC[C@@H](C(=O)N)N1CCCC1=O	InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1	HPHUVLMMVZITSG-LURJTMIESA-N
DCE1Y9	Prednisone	Small molecule	prednisone; 53-03-2; Dehydrocortisone; Decortin; Deltasone; Meticorten; Orasone; Supercortil; Metacortandracin; Decortisyl; Rectodelt; Sterapred; Ultracorten; Dacortin; Encorton; Paracort; Cortan; 1,2-Dehydrocortisone; Liquid Pred; Deltacortisone; Deltacortone; Ancortone; Colisone; Decortancyl; Deltison; Encortone; Prednilonga; Prednison; Servisone; Lodotra; Prednicen-M; Delta-Dome; Di-Adreson; Bicortone; Cortidelt; Dekortin; Diadreson; Enkorton; Hostacortin; Lisacort; Panafcort; Prednisonum; Prednizon; Pronison; Ultracortene; Zenadrid; Adasone; Cotone; Deltra; Juvason; Nurison; Winpred; Wojtab; Prednisone Intensol; Delta-Cortelan; Delta E; In-Sone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; Cartancyl; Deltisona; SK-Prednisone; Prednisona; Prednisonum [INN-Latin]; Prednisona [INN-Spanish]; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy-; prednisone anhydrous; Deltisone; Rayos; Zenadrid (veterinary); Fernisone; Prednisone tablets; 1-Dehydrocortisone; 3en3hg4wsw; NSC-10023; NCI-C04897; NSC 10023; Prednisone(Adasone); U 6020; Prednidib; CHEBI:8382; Panasol; delta-Cortisone; Sone; Zenadrid [veterinary]; Apo-Prednisone; Novoprednisone; Dellacort; Deltacortene; Econosone; Incocortyl; Parmenison; Predeltin; Prednicorm; Prednicort; Prednicot; Prednitone; Prednovister; Retrocortine; Dacorten; Fiasone; Pehacort; Presone; delta cortelan; Nisona; Nizon; Dellacort A; VB0R961HZT; Me-Korti; Origen Prednisone; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; DTXSID4021185; .delta.-Cortisone; 1-Cortisone; .delta.1-Cortisone; delta-1-Cortisone; NCGC00090766-01; Precort; .delta.1-Dehydrocortisone; Meticorten (Veterinary); delta(sup 1)-Cortisone; delta-1-Dehydrocortisone; (8S,9S,10R,13S,14S,17R)-17-Hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthrene-3,11(6H)-dione; DTXCID701185; delta(sup 1)-Dehydrocortisone; Lodtra; SMR000718760; SMR001227202; Delta E.; CCRIS 2646; HSDB 3168; MLS002638114; EINECS 200-160-3; MFCD00003608; UNII-VB0R961HZT; Prednisone [USP:INN:BAN]; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; AI3-52939; .delta.sone; .delta.-Cortone; .delta.-Cortelan; CAS-53-03-2; Deltadehydrocortisone; Prestwick_405; .delta. E; .delta.-E; Prednisone (Adasone); Prednisone, >=98%; PREDNISONE [MI]; PREDNISONE [INN]; Prestwick0_000077; Prestwick1_000077; Prestwick2_000077; Prestwick3_000077; PREDNISONE [HSDB]; PREDNISONE [IARC]; .delta.(sup1)-Cortisone; P1276; PREDNISONE [VANDF]; CHEMBL635; PREDNISONE [MART.]; SCHEMBL3288; PREDNISONE [USP-RS]; PREDNISONE [WHO-DD]; BSPBio_000293; MLS001061265; MLS001304073; MLS001335907; MLS001335908; MLS002154191; MLS002207083; MLS002548880; SPBio_002214; BPBio1_000323; GTPL7096; MEGxm0_000443; PREDNISONE [GREEN BOOK]; PREDNISONE [ORANGE BOOK]; ACon0_000082; ACon1_000297; PREDNISONE [EP MONOGRAPH]; HMS1568O15; HMS2090J13; HMS2095O15; HMS2231I24; HMS3039K07; HMS3259I09; HMS3712O15; HMS3884C04; PREDNISONE [USP MONOGRAPH]; 1,21-diol-3,11,20-trione; BCP09049; HY-B0214; NSC10023; PREDNISONE TABLETS [USP-RS]; Pregna-1,4-diene-3,11,20-trione monohydrate, 17,21-dihydroxy-; Tox21_111014; Tox21_201564; Tox21_300196; BDBM50550126; LMST02030180; s1622; AKOS005267096; AKOS007930684; Tox21_111014_1; CCG-220077; DB00635; NC00475; NCGC00090766-02; NCGC00090766-03; NCGC00090766-04; NCGC00090766-05; NCGC00090766-07; NCGC00254096-01; NCGC00259113-01; Prednisone, tested according to Ph.Eur.; AC-11112; AS-11685; NCI60_000008; PREDNISOLONE IMPURITY B [EP IMPURITY]; Pregna-1,11,20-trione, 17,21-hydroxy-; EN300-52605; Pregna-1,11,20-trione, 17,21-dihydroxy-; C07370; Q424972; SR-01000837536; SR-01000837536-3; BRD-K85883481-001-04-2; BRD-K85883481-001-08-3; BRD-K85883481-001-25-7; 17alpha,21-dihydroxypregna-1,4-diene-3,11,20-trione; WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ; Z756390288; Prednisone, British Pharmacopoeia (BP) Reference Standard; Prednisone, European Pharmacopoeia (EP) Reference Standard; Prednisone, United States Pharmacopeia (USP) Reference Standard; Prednisone, Pharmaceutical Secondary Standard; Certified Reference Material; Prednisone for peak identification, European Pharmacopoeia (EP) Reference Standard; Prednisone, pharmaceutical secondary standard; traceable to USP, PhEur and BP; (1R,3aS,3bS,9aR,9bS,11aS)-1-hydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-7,10-dione; (8S,10R,13S,17R)-17-Hydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-7,8,9,10,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,11-dione	Approved	Approved Drug(s)	5865	DB00635	D0E3JP	358.4	91.7	764	1.5	26	2	5	2	C21H26O5	(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione	CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C	C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C	InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1	XOFYZVNMUHMLCC-ZPOLXVRWSA-N
DKQ42H	Warfarin	Small molecule	warfarin; 81-81-2; Coumadin; Coumafene; Prothromadin; Coumafen; Zoocoumarin; Coumarins; Coumefene; Panwarfin; Warfarine; Brumolin; Dethmor; Dethnel; Kumader; Kypfarin; Maveran; Solfarin; Kumadu; Rosex; Athrombine-K; Frass-Ratron; Vampirinip II; Mar-Frin; Rattentraenke; Rattunal; Rodafarin; Temus W; Warfarat; Kumatox; Ratorex; Ratron; Vampirinip iii; D-Con; Rats-no-more; Tox-hid; Ratten-Koederrohr; Rat-Gard; Rat-Kill; Rat-Trol; Rat-Mix; Rat-Ola; Ro-Deth; Coumaphene; Rat-a-way; Rat & mice bait; Ratoxin; Martin's mar-frin; Rat-B-gon; Maag Rattentod Cum; Warfarin plus; Rodex blox; CO-Rax; Fasco fascrat powder; Liqua-tox; Mouse pak; Place-pax; Twin light rat away; Warfarin Q; Dicusat E; Ratron G; Eastern states duocide; Compound 42; Ratox; Cov-R-Tox; rac-Warfarin; Rodafarin C; Rough & ready mouse mix; WARF compound 42; 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; Rat-o-cide #2; Latka 42; Arab Rat Death; Spray-trol brand roden-trol; Warf 42; 200 coumarin; Rattenstreupulver Neu Schacht; Coumaphen; Warficide; Sorexa plus; Arab rat deth; 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-; Rodex; 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin; 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one; Rattenstreupulver new schacht; 2-hydroxy-3-(3-oxo-1-phenylbutyl)-4h-chromen-4-one; W.A.R.F. 42; Rcra waste number P001; Athrombin-K; Sakarat; Sewarin; Waran; 3-(1'-Phenyl-2'-acetylethyl)-4-hydroxycoumarin; 4-Hydroxy-3-(3-oxo-1-fenyl-butyl) cumarine; 4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-cumarin; Warfarin (INN); 4OH-Coumarin deriv.; RAX; 1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone; Rat-o-cide No. 2; 3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin; R-(+)-Warfarin-d5; S-(-)-Warfarin-d5; 4-Idrossi-3-(3-oxo-1-fenil-butil)-cumarine; DL-3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin; NSC-59813; 951658-59-6; 4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one; (Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarine; 3-(alpha-Phenyl-beta-acetylethyl)-4-hydroxycoumarin; 5Q7ZVV76EI; CHEMBL1464; (R)-(+)-Warfarin; DTXSID5023742; 3-(.alpha.-Acetonylbenzyl)-4-hydroxycoumarin; CHEBI:87732; NSC59813; 3-(Acetonylbenzyl)-4-hydroxycoumarin; 3-(alpha-Phenyl-beta-acetylaethyl)-4-hydroxycumarin; Coumafene [French]; NCGC00094810-01; Warfarina; Warfarinum; WARFARIN [INN]; Zoocoumarin [Russian]; Latka 42 [Czech]; Warfarin [INN:BAN]; 4-Idrossi-3-(3-oxo-)-fenil-butil)-cumarine; Warfarine [INN-French]; Warfarine [ISO-French]; Warfarinum [INN-Latin]; (Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarin; Coumarin, 3-(.alpha.-acetonylbenzyl)-4-hydroxy-; Warfarina [INN-Spanish]; Warfarin, analytical standard; 773005-79-1; DTXCID703742; Warfarin plus [discontinued]; Caswell No. 903; 3-(.alpha.-Phenyl-.beta.-acetylethyl)-4-hydroxycoumarin; Warfarin [BSI:ISO]; Choice; Zoocoumarin [Netherlands and USSR]; CAS-81-81-2; Warfarin [ISO]; Choice (TN); HSDB 1786; SR-01000195154; 791013-22-4; NCGC00094810-04; EINECS 201-377-6; NSC 59813; RCRA waste no. P001; CBKinase1_000192; CBKinase1_012592; UNII-5Q7ZVV76EI; EPA Pesticide Chemical Code 086002; BRN 1293536; wafarin; delta-con; Athrombine K; Rat-alpha-way; Rat-beta-gon; Coumarin, 3-(alpha-acetonylbenzyl)-4-hydroxy-; Killgerm sewarin p; Rat and mice bait; (RS)-Warfarin; 4-Hydroxy-3-(3-oxo-1-fenyl-butyl) cumarine [Dutch]; 4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-cumarin [German]; 4-Idrossi-3-(3-oxo-1-fenil-butil)-cumarine [Italian]; Rattentraenke (German); Spectrum_000194; (Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarine [French]; 3-(alpha-Phenyl-beta-acetylaethyl)-4-hydroxycumarin [German]; WARFARIN [HSDB]; WARFARIN [MI]; WARFARIN [VANDF]; (.+/-.)-Warfarin; Spectrum2_000935; Spectrum3_000583; Spectrum4_000381; Spectrum5_001751; Rough and ready mouse mix; WARFARIN [USP-RS]; WARFARIN [WHO-DD]; EC 201-377-6; Ratten-Koederrohr (German); SCHEMBL3689; CHEMBL7252; BSPBio_002026; CBDivE_002127; CBDivE_013236; KBioGR_000901; KBioSS_000674; 5-18-04-00162 (Beilstein Handbook Reference); MLS001304042; DivK1c_000444; SCHEMBL136434; SPECTRUM1500613; SPBio_000870; GTPL6853; HMS501G06; KBio1_000444; KBio2_000674; KBio2_003242; KBio2_005810; KBio3_001526; NINDS_000444; HMS1921K07; HMS2092C20; HMS2233L10; HMS3372L19; HMS3648B15; HMS3714G21; Pharmakon1600-01500613; HY-B0687; Tox21_113185; Tox21_202182; Tox21_300531; Warfarin 1.0 mg/ml in Acetonitrile; BBL027615; BDBM50343352; CCG-39672; NSC757385; s4545; STK364490; WLN: T66 BOVJ DYR&1V1 EQ; AKOS005430103; AKOS026749956; DB00682; NSC-757385; Rattenstreupulver Neu Schacht (German); SB48255; SB48256; 3-(a-acetonylbenzyl)-4-hydroxycoumarin; IDI1_000444; SMP1_000316; Warfarin 100 microg/mL in Acetonitrile; NCGC00094810-02; NCGC00094810-03; NCGC00094810-05; NCGC00094810-06; NCGC00159398-03; NCGC00178855-01; NCGC00188986-01; NCGC00188986-02; NCGC00254457-01; NCGC00259731-01; AC-15978; SMR000718754; SBI-0051556.P002; DB-052729; DB-052730; DL-3-(a-Acetonylbenzyl)-4-hydroxycoumarin; FT-0635767; FT-0635768; Warfarin, PESTANAL(R), analytical standard; EN300-51918; 4-Hydroxy-3- (3-oxo-1-fenyl-butyl) cumarine; 4-Hydroxy-3- (3-oxo-1-phenyl-butyl)-cumarin; 4-Idrossi-3- (3-oxo-)-fenil-butil)-cumarine; C01541; D08682; H10432; AB00052125_02; AB00876255-06; Q407431; 4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-chromen-2-one; 4-hydroxy-3-(3-oxo-1-phenyl-butyl)chromen-2-one; SR-01000195154-3; SR-01000195154-4; BRD-A24514565-001-02-2; BRD-A24514565-236-01-6; SR-01000195154-10; 3-(.alpha.-Phenyl-.beta.-acetylaethyl)-4-hydroxycumarin; 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one; Warfarin, British Pharmacopoeia (BP) Reference Standard; Z732250592; 4-(4-hydroxy-2-oxo-2H-3-chromenyl)-4-phenyl-2-butanone; 4-HYDROXY-3-((1RS)-3-OXO-1-PHENYLBUTYL)COUMARIN; 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one #; Warfarin4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-chromen-2-one; Warfarin, United States Pharmacopeia (USP) Reference Standard; 2-Hydroxy-3-(alpha-(2-oxopropyl)benzyl)-4H-1-benzopyran-4-one; (+/-)-4-HYDROXY-3-(3-OXO-1-PHENYLBUTYL)-2H-1-BENZOPYRAN-2-ONE	Approved	Approved Drug(s)	54678486	DB00682	D0E3OF	308.3	63.6	502	2.7	23	1	4	4	C19H16O4	4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one	CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O	CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O	InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3	PJVWKTKQMONHTI-UHFFFAOYSA-N
DC0DI4	Panobinostat	Small molecule	Panobinostat; 404950-80-7; LBH589; LBH-589; Farydak; Panobinostat (LBH589); Faridak; LBH 589; (E)-N-Hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide; NVP-LBH589; NVP-LBH-589; LBH-589B; Panobinostat(LBH589); (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; CHEBI:85990; 9647FM7Y3Z; 404950-80-7 (free base); (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide; Farydak (TN); (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide; 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)-, (2E)-; 2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)-; Panobinostat [INN]; Panobinostat [USAN:INN]; UNII-9647FM7Y3Z; PANOBINOSTAT [MI]; LBH589 - Panobinostat; Panobinostat (USAN/INN); PANOBINOSTAT [USAN]; N-Hydroxy-3-[4-[2-(2-methyl-1H-indol-3-yl)ethylaminomethyl]phenyl]-2(E)-propenamide; PANOBINOSTAT [MART.]; MLS006011216; NVP-LBH 589; PANOBINOSTAT [WHO-DD]; SCHEMBL164801; SCHEMBL183197; CHEMBL483254; GTPL7489; SCHEMBL22773814; BDBM29589; CHEBI:93774; DTXSID40193506; EX-A169; N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide; BCPP000187; BDBM198124; BCP01816; LBH58,9NVP-LBH589,Panobinostat; (LBH-589); MFCD09833242; NSC761190; s1030; AKOS005146046; BCP9000844; CCG-208762; CS-0267; DB06603; EX-8456; NSC-761190; (2E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide; (E)-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enehydroxamic acid; (E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide; NCGC00263117-05; NCGC00263117-07; 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2E)-; AC-28652; AM808102; AS-17046; HY-10224; SMR004702978; DB-025426; SW219369-1; EC-000.2287; A25218; D10319; EN300-7395075; J-523585; Q7131441; BRD-K02130563-001-07-2; (E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indole-3-yl)ethyl]amino]methyl]phenyl]acrylamide; N-hydroxy-3 -[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide; N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide; Panobinostat;(E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide	Approved	Approved Drug(s)	6918837	DB06603	D0E3SH	349.4	77.2	474	3	26	4	3	7	C21H23N3O2	(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide	CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO	CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO	InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+	FPOHNWQLNRZRFC-ZHACJKMWSA-N
DO94LA	Phenytoin	Small molecule	phenytoin; 5,5-DIPHENYLHYDANTOIN; 57-41-0; Diphenylhydantoin; Dilantin; 5,5-diphenylimidazolidine-2,4-dione; Phenytoine; Zentropil; Epamin; Lepitoin; Dihydantoin; Aleviatin; Dilabid; Diphantoin; Diphenylan; Diphedan; Fenylepsin; Phentytoin; Sodanton; Difenin; Dihycon; Lehydan; Diphenylhydatanoin; Dantoinal; Di-Hydan; Dilantine; Dillantin; Diphenine; Diphentyn; Ditoinate; Elepsindon; Epilantin; Fenitoina; Fenytoine; Hidantilo; Hidantina; Hidantomin; Hydantoinal; Kessodanten; Phanantin; Phanatine; Phenatoine; Sodantoin; Sylantoic; Thilophenyl; Zentronal; Auranile; Dantinal; Dantoine; Difetoin; Difhydan; Dintoin; Dintoina; Diphedal; Diphenin; Enkelfel; Epifenyl; Epihydan; Fentoin; Hidantal; Hydantal; Idantoil; Idantoin; Labopal; Phentoin; Ritmenal; Saceril; Sanepil; Silantin; Solantin; Danten; Denyl; Epelin; Epinat; Epised; Eptal; Hidan; Lepsin; Ekko; Ictalis simple; Toin unicelles; Dilantin acid; Dantoinal klinos; Om-Hydantoine; Di-Phetine; Epdantoine simple; Hidantina vitoria; Gerot-epilan-D; Epilan-D; Neosidantoina; Comitoina; Hidantina senosian; Hydantol; Minetoin; Novantoina; Causoin; Convul; Di-Lan; Ekko capsules; Neos-Hidantoina; 2,4-Imidazolidinedione, 5,5-diphenyl-; Om hidantoina simple; TOIN; Phenhydanin; Phenytex; Phenytoinum; Sinergina; Sodanthon; Iphenylhydantoin; Phenytoin-Gerot; Difenilhidantoina; Fenytoin Dak; Didan TDC 250; Dilantin-125; Epdantoin Simple; Phenytoin AWD; Epilan D; 5,5-Diphenyl-2,4-imidazolidinedione; Diphenat; Hindatal; Hydantin; Epanutin; Fenitoina [INN-Spanish]; Phenytoine [INN-French]; Phenytoinum [INN-Latin]; Difenilhidantoina [Spanish]; Diphenylhydantoine [French]; 5,5-Dwufenylohydantoina; Antisacer; Fenantoin Mn Pharma; Diphenylhydantoine; Di-Lan (VAN); PHENYTOIN SODIUM; Diphenylhydantoin (VAN); Diphentoin; DILANTIN-30; Solantoin; Solantyl; Eptoin; DPH (VAN); 5,5-Diphenylimidazolidin-2,4-dione; 5,5-Diphenyl-imidazolidine-2,4-dione; 5,5-Diphenylhydantoin (IUPAC); PHENYTEK; 5,5-Dwufenylohydantoina [Polish]; Hydantoin, 5,5-diphenyl-; CCRIS 515; CHEBI:8107; 5,5-diphenyl hydantoin; NCI-C55765; 5,5-Diphenylhydantoin (phenytoin); Diphenylan sodium; AI3-52498; NSC-8722; Dilantin (TN); Novophenytoin; MLS000069789; Citrulliamon; DTXSID8020541; Phenitoin; 5,5-diphenyltetrahydro-1H-2,4-imidazoledione; Fenidantoin s; NSC8722; SM-88 COMPONENT PHENYTOIN; 6158TKW0C5; Epasmir 5; NCGC00021139-03; SMR000059026; Fenidantoin 's'; 5,5-DIPHENYLHYDANTOIN-D5 98 ATOM % D; DTXCID60541; Epasmir '5'; Didan-tdc-250; CAS-57-41-0; phenytoin (PHN); component of Mebroin; fenidantoin ''s''; epasmir ''5''; NSC 8722; 630-93-3; EINECS 200-328-6; MFCD00005264; UNII-6158TKW0C5; SR-01000075211; IFLab1_000214; Fenidantoin 's'; HSDB 3160; Episar (Salt/Mix); Epasmir '5'; Aladdin (Salt/Mix); Alepsin (Salt/Mix); Epsolin (Salt/Mix); Phenytoin (Lepitoin); Tacosal (Salt/Mix); Phenytoin [USAN:USP:INN:BAN:JAN]; Antisacer (Salt/Mix); Epdantoin (Salt/Mix); Epileptin (Salt/Mix); Hydantoin,5-diphenyl-; Spectrum_001105; Fenigramon (Salt/Mix); Citrullamon (Salt/Mix); Opera_ID_394; PHENYTOIN [INN]; PHENYTOIN [JAN]; 2, 5,5-diphenyl-; PHENYTOIN [MI]; CHEMBL16; PHENYTOIN [HSDB]; PHENYTOIN [IARC]; PHENYTOIN [USAN]; Spectrum2_001281; Spectrum3_000890; Spectrum4_000984; Spectrum5_001369; Lopac-D-4007; PHENYTOIN [VANDF]; Epitope ID:117723; PHENYTOIN [MART.]; D 4007; PHENYTOIN [USP-RS]; PHENYTOIN [WHO-DD]; PHENYTOIN [WHO-IP]; SCHEMBL3440; BIDD:PXR0090; Lopac0_000329; Lopac0_000378; Oprea1_373280; BSPBio_001437; KBioGR_001387; KBioSS_001585; MLS001074087; MLS002454401; BIDD:GT0625; DivK1c_000507; Soluble phenytoin (Salt/Mix); SPBio_001281; Phenytoin (JP17/USP/INN); GTPL2624; PHENYTOIN [ORANGE BOOK]; 2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one; PHENYTOIN [EP MONOGRAPH]; PHENYTOIN [USP IMPURITY]; KBio1_000507; KBio2_001585; KBio2_004153; KBio2_006721; KBio3_001780; PHENYTOIN [USP MONOGRAPH]; WLN: T5MVMV EHJ ER& ER; 5,5-Diphenylhydantoin, >=99%; NINDS_000507; Phenytoin 1.0 mg/ml in Methanol; HMS1412J16; HMS1694O05; HMS1791H19; HMS1989H19; HMS2089E11; HMS2236J06; HMS3261K17; HMS3402H19; HMS3657O03; PHENYTOINUM [WHO-IP LATIN]; BCP05960; HY-B0448; Hydantoin, 5,5-diphenyl- (8CI); Tox21_110861; Tox21_202299; Tox21_300281; Tox21_500378; AC-376; BDBM50003655; BDBM50101816; s2525; STK058029; STK182871; STL454130; AKOS000416887; AKOS003245432; Tox21_110861_1; 5,5-diphenylimidazolidine-2,4-dione.; CCG-104011; CCG-221682; DB00252; LP00378; Phenytoin 1000 microg/mL in Methanol; 5,5-di(phenyl)imidazolidine-2,4-dione; IDI1_000507; IDI1_008433; NCGC00015342-01; NCGC00015342-02; NCGC00015342-03; NCGC00015342-04; NCGC00015342-05; NCGC00015342-06; NCGC00015342-07; NCGC00015342-08; NCGC00015342-09; NCGC00015342-10; NCGC00015342-11; NCGC00015342-12; NCGC00021139-01; NCGC00021139-02; NCGC00021139-04; NCGC00021139-05; NCGC00021139-06; NCGC00021139-07; NCGC00021139-08; NCGC00021139-09; NCGC00021139-10; NCGC00021139-11; NCGC00091492-01; NCGC00091492-02; NCGC00091492-03; NCGC00091492-04; NCGC00091492-05; NCGC00093810-01; NCGC00093810-02; NCGC00254135-01; NCGC00259848-01; NCGC00261063-01; 5,5-?Diphenyl-?2,4-?imidazolidinedione; 5,5-Diphenyl-1H-imidazolidine-2,4-dione; D0894; EU-0100378; FT-0667653; FT-0699999; P-235; SW203757-2; EN300-16818; 5,5-diphenylimidazolidine-2,4-dione;Phenytoin; C07443; D00512; E76094; 2,4-Imidazolidinedione, 5,5-diphenyl- (9CI); 5,5-diphenyl-1H-imidazole-2,4(3H,5H)-dione; AB00374253-10; AB00374253-11; AB00374253_13; A831435; Q410400; SR-01000003141; SR-01000003141-8; SR-01000075211-2; W-105468; BRD-K55930204-001-02-7; BRD-K55930204-236-11-0; Z56786458; 4-hydroxy-5,5-diphenyl-1,5-dihydro-2H-imidazol-2-one; F0020-1370; Phenytoin, European Pharmacopoeia (EP) Reference Standard; Phenytoin, United States Pharmacopeia (USP) Reference Standard; Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material; Phenytoin for system suitability, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	1775	DB00252	D0E4DW	252.27	58.2	350	2.5	19	2	2	2	C15H12N2O2	5,5-diphenylimidazolidine-2,4-dione	C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3	C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3	InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)	CXOFVDLJLONNDW-UHFFFAOYSA-N
DAL5M8	Deutetrabenazine	Small molecule	Tetrabenazine-d6; 1392826-25-3; Deutetrabenazine; Tetrabenazine D6; SD809; Ro 1-9569 D6; (3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one; rel-(3R,11bR)-3-isobutyl-9,10-bis(methoxy-d3)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; Austedo (TN); Deutetrabenazine (USAN/INN); GTPL8707; SCHEMBL16227993; HY-B0590S; DTXSID601027934; EX-A4770; MS-24810; D10701; Q27077026	Approved	Approved Drug(s)	73437646	DB12161	D0E7ZU	323.5	38.8	425	2.9	23	0	4	4	C19H27NO3	(3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one	CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC	[2H]C([2H])([2H])OC1=C(C=C2[C@H]3CC(=O)[C@@H](CN3CCC2=C1)CC(C)C)OC([2H])([2H])[2H]	InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1/i3D3,4D3	MKJIEFSOBYUXJB-VFJJUKLQSA-N
DJAT62	Potassium chloride	Small molecule	potassium chloride; 7447-40-7; Sylvite; Klotrix; Enseal; Slow-K; Klor-Con; Muriate of potash; Neobakasal; Potassium monochloride; Chlorvescent; Kalitabs; Kaochlor; Potavescent; Kloren; Pfiklor; Rekawan; Chloropotassuril; KCl-retard Zyma; Klor-Lyte; K-Contin; Kay Ciel; Monopotassium chloride; K-Lease; Kaon Cl; Kaon-Cl; Micro-K; Potassium chloride (KCl); Chloride of potash; K-Lor; K-Tab; Ten-K; Kay-EM; Potassiumchloride; Kaliumchlorid; Micro-K LS; Kali muriaticum; Emplets potassium chloride; Kaon-Cl 10; potassium;chloride; Sylvite (KCl); Kaon Cl-10; Micro-K 10; KCL; Sylvine; K+10; Chloride (as potassium); Steropotassium; Acronitol; Kaliduron; Kaliglutol; Kalilente; Kaliolite; Miopotasio; Durekal; Durules; Kadalex; Kalcorid; Kaleorid; Kalinorm; Kalipor; Kalipoz; Keylyte; Klorvess; MFCD00011360; NSC-77368; Potasion; Potasol; Celeka; Enpott; 14336-88-0; Natural sylvite; Kato; Kalium Duriles; Kalium Durules; Kalium-Durettes; Rekawan Retard; Kalium Retard; Lento-Kalium; Peter-kal; Kalitrans Retard; Potassium muriate; Durules-K; Kalium-R; Kay-Ciel; Repone K; Diffu-K; Kalinor-Retard P; Kalium SR; Lento-K; Super K; Ultra K Chlor; Ultra-K-Chlor; KCL Retard; Addi-K; Cena-K; INS NO.508; K-Care; K-Grad; K-Norm; Span-K; Clor-K-Zaf; Potassium chloride,AR,99.5%; Micro-K Extentcaps; Plus Kalium Retard; Potassium chloride, ACS reagent; Infalyte; Kayciel; Apo-K; CHEBI:32588; K Tab; K-Dur; K-Lyte Cl; K-Sol; Kay-Cee-L; Leo-K; Micro-Kalium Retard; Rum-K; INS-508; Nu-K; Slow-K tablets; Kalinorm Depottab; Tripotassium trichloride; 660YQ98I10; K+8; K-SR; Chlorid draselny [Czech]; Super K (salt); Kaon-Cl TABS; Kalium S.R.; Klor-Con M20; Chlorid draselny; Potassium Cl; E 508; E-508; Potassium chloride [JAN]; Potassium chloride, ultra dry; Klor-Con M10; Klor-Con M15; Potassium chloride (K3Cl3); Caswell No. 686; Epiklor; Kali Chloratum; Kali Chloridum; Potassii Chloridum; Klotrix (TN); Klor-con (TN); CCRIS 1962; Klor-Con 10; K-10; HSDB 1252; Kaon-Cl (TN); K-dur (TN); Potassium Chloride 10meq in Plastic Container; Potassium thallium chloride (KTlCl); [KCl]; EINECS 231-211-8; NSC 77368; EPA Pesticide Chemical Code 013904; KCL (TN); Potassium Chloride in Plastic Container; Kalii chloridum; Potassium chloride [USP:JAN]; UNII-660YQ98I10; Potassium chloride 30meq in plastic container; Potassium chloride 40meq in plastic container; potassium chloride salt; Potassium Chloride,(S); Potassium (as chloride); Potassium chloride 20meq in plastic container; WLN: KA G; EC 231-211-8; POTASSIUM(I) CHLORIDE; B1653 [LANGUAL]; KALI MURIATICUM [HPUS]; Potassium Chloride, Food Grade; POTASSIUM CHLORIDE [II]; POTASSIUM CHLORIDE [MI]; CHEMBL1200731; DTXSID5021178; Potassium Chloride (FRU Grade); POTASSIUM CHLORIDE [FCC]; Potassium chloride solution, 1M; Potassium chloride (JP17/USP); POTASSIUM CHLORIDE [HSDB]; POTASSIUM CHLORIDE [INCI]; Potassium chloride, Optical Grade; POTASSIUM CHLORIDE [VANDF]; Potassium chloride, LR, >=99%; POTASSIUM CHLORIDE [MART.]; AMY37139; CS-B1714; HY-Y0537; NSC77368; POTASSIUM CHLORIDE [USP-RS]; POTASSIUM CHLORIDE [WHO-DD]; POTASSIUM CHLORIDE [WHO-IP]; Potassium chloride, ACS, 99.5%; STR03715; Potassium Chloride - Drilling Grade; Potassium chloride, AR, >=99.5%; AKOS015902779; AKOS024438069; AKOS024457458; DB00761; KALII CHLORIDUM [WHO-IP LATIN]; POTASSIUM CHLORIDE [ORANGE BOOK]; CHLORIDE (AS POTASSIUM) [VANDF]; POTASSIUM (AS CHLORIDE) [VANDF]; POTASSIUM CHLORIDE [EP MONOGRAPH]; Potassium chloride, BioXtra, >=99.0%; Potassium chloride, BP, Ph. Eur. grade; E508; POTASSIUM CHLORIDE [USP MONOGRAPH]; THAM-E COMPONENT POTASSIUM CHLORIDE; Potassium chloride Biochemical Grade = 99%; FT-0645107; P1757; Potassium chloride, ACS reagent, >=99.0%; Potassium chloride, p.a., 99.0-100.5%; HALFLYTELY COMPONENT POTASSIUM CHLORIDE; Potassium Chloride (Technical Grade, Type A); Potassium Chloride (Technical Grade, Type B); POTASSIUM CHLORIDE COMPONENT OF THAM-E; Potassium chloride, 99.997% (metals basis); TIS-U-SOL COMPONENT POTASSIUM CHLORIDE; D02060; Potassium chloride, BioUltra, >=99.5% (AT); Potassium chloride, ReagentPlus(R), >=99.0%; POTASSIUM CHLORIDE COMPONENT OF HALFLYTELY; POTASSIUM CHLORIDE COMPONENT OF TIS-U-SOL; Potassium chloride, 99.999% trace metals basis; Potassium chloride, SAJ first grade, >=99.0%; Potassium chloride, tested according to Ph.Eur.; Potassium chloride, Trace metals grade 99.99%; Potassium chloride, >=99.99% trace metals basis; Potassium chloride, 0.85M, Conductivity Standard; Potassium chloride, ACS reagent, 99.0-100.5%; Potassium chloride, JIS special grade, >=99.5%; Potassium chloride, Spectroscopy Grade, Ultrapure; Potassium chloride, USP special, 99.0-100.5%; Potassium chloride, Vetec(TM) reagent grade, 99%; Q184630; Potassium chloride, 0.005M, Conductivity Standard; Potassium chloride, 0.007M, Conductivity Standard; Potassium chloride, 0.010M, Conductivity Standard; Potassium chloride, 0.0145M, Conductivity Standard; Potassium chloride, 0.0375M, Conductivity Standard; Potassium chloride, 0.0765M, Conductivity Standard; Potassium chloride, 0.117M, Conductivity Standard; Potassium chloride, 0.159M, Conductivity Standard; Potassium chloride, puriss. p.a., >=99.5% (AT); Potassium chloride, 0.00017M, Conductivity Standard; Potassium chloride, 0.00068M, Conductivity Standard; Potassium chloride, for molecular biology, >=99.0%; Potassium chloride, ~0.000027M, Conductivity Standard; Potassium chloride, meets EP, USP testing specifications; Potassium chloride crystal optic disc, 13mm x 2mm, unpolished; Potassium chloride crystal optic disc, 25mm x 5mm, unpolished; Potassium chloride crystal optic disc, 32mm x 3mm, unpolished; Potassium chloride, BioUltra, for molecular biology, >=99.5% (AT); Potassium standard for AAS, ready-to-use, traceable to BAM, in H2O; Potassium chloride crystal optic disc, 13mm x 1mm, polished both sides; Potassium chloride crystal optic disc, 13mm x 2mm, polished both sides; Potassium chloride crystal optic disc, 22mm x 4mm, polished both sides; Potassium chloride crystal optic disc, 25mm x 2mm, polished both sides; Potassium chloride crystal optic disc, 25mm x 4mm, polished both sides; Potassium chloride crystal optic disc, 32mm x 3mm, polished both sides; Potassium chloride crystal optic disc, 38mm x 6mm, polished both sides; Potassium chloride crystal optic rectangle, 30mm x 15mm x 4mm, unpolished; Potassium chloride crystal optic rectangle, 41mm x 23mm x 6mm, unpolished; Potassium chloride, anhydrous, beads, -10 mesh, 99.99% trace metals basis; Potassium chloride, United States Pharmacopeia (USP) Reference Standard; Potassium chloride crystal optic disc, 32mm x 3mm (drilled), polished both sides; Potassium chloride crystal optic rectangle, 30mm x 15mm x 4mm, polished both sides; Potassium chloride crystal optic rectangle, 38.5mm x 19.5mm x 4mm, unpolished; Potassium chloride, anhydrous, beads, -10 mesh, 99.999% trace metals basis; Potassium chloride, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=99%; Potassium chloride, anhydrous, free-flowing, Redi-Dri(TM), ReagentPlus(R), >=99%; Potassium Chloride, Pharmaceutical Secondary Standard; Certified Reference Material; Potassium chloride, puriss. p.a., reag. ISO, reag. Ph. Eur., 99.5-100.5%; Potassium chloride crystal optic rectangle, 30mm x 15mm x 4mm, (drilled), polished both sides; Potassium chloride crystal optic rectangle, 38.5mm x 19.5mm x 4mm, (drilled), polished both sides; Potassium chloride, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, >=99.0%; Potassium chloride, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E508, 99-100.5% (AT), <=0.0001% Al	Approved	Approved Drug(s)	4873	DB00761	D0E9JM	74.55	0	2	.	2	0	1	0	ClK	potassium;chloride	[Cl-].[K+]	[Cl-].[K+]	InChI=1S/ClH.K/h1H;/q;+1/p-1	WCUXLLCKKVVCTQ-UHFFFAOYSA-M
DORN21	Clopidogrel	Small molecule	clopidogrel; 113665-84-2; Zyllt; Plavix; (S)-Clopidogrel; Clopidogrel bisulfate; CLOPIDOGREL SULFATE; Thrombo; Clopidogrel Acino; Clopidogrel Hexal; (+)-(S)-Clopidogrel; (+)-Clopidogrel; SR 25990; R 130964; methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate; CHEBI:37941; SR-25990C; A74586SNO7; (S)-Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate; NSC-758613; SR-25990; Clopidogrel (TN); Plavix (TN); methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate; R-130964; Clopidogrel [INN:BAN]; CHEMBL1083385; methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate; SMR000550475; Clopidogrel Winthrop; Clopidogrel 1A Pharma; HSDB 7430; UNII-A74586SNO7; Plavix&reg; (+) clopidogrel; Methyl 2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno(3,2-c)pyridin-5-yl)acetate; CGE; Clopidogrel Teva (hydrogen sulphate); Spectrum_000105; CPD000550475; Clopidogrel (USP/INN); CLOPIDOGREL [MI]; Spectrum2_000512; Spectrum3_001606; Spectrum4_000175; CLOPIDOGREL [INN]; CLOPIDOGREL [HSDB]; CLOPIDOGREL [VANDF]; SCHEMBL4769; THIAMINELAURYLSULPHATE; CHEMBL1771; BSPBio_003211; CLOPIDOGREL [WHO-DD]; KBioGR_000689; KBioSS_000545; MLS001165708; MLS001195633; MLS001304711; MLS006011891; BIDD:GT0284; DivK1c_000787; SPBio_000463; CLOPIDOGREL [EMA EPAR]; GTPL7150; DTXSID6022848; HMS502H09; KBio1_000787; KBio2_000545; KBio2_003113; KBio2_005681; KBio3_002431; AMY8913; NINDS_000787; HMS2090O21; HMS2234N16; HMS3259B08; HMS3715J08; (+)-(S)-Methyl 2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno[3,2-c ] pyridin-5-yl) acetate monosulfate; BBL010770; BDBM50318910; BDBM50397662; MFCD05662337; NSC748298; STK580572; AKOS005504280; CCG-221243; CS-0656; DB00758; NC00703; NSC 758613; NSC-748298; IDI1_000787; Methyl (+)-(S)-alpha-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4H)-acetate; methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate; NCGC00163329-02; NCGC00163329-04; AC-19024; DS-13362; HY-15283; Thieno(3,2-c)pyridine-5(4H)-acetic acid, alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (S)-; SBI-0052755.P002; D07729; N11780; AB00053786-07; AB00053786-08; AB00053786_09; AB00053786_10; EN300-7388859; Q410237; BRD-K27721098-065-02-9; BRD-K27721098-065-05-2; methyl (2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate; (S)-(+)-Methyl (2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate; (S)-(+)-Methyl (2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate; (S)-Methyl2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate; methyl (+)-(S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate; methyl (+)-(s)-alpha-(o-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4h)-acetate; Methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate sulfate; methyl (S)-(+)-alpha-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-acetate; methyl(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h) acetate; methyl-(S)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl)-acetate; (+)-(S)-(2-Chlorophenyl) (6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetic acid methyl ester; (+)-(S)-2-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetic acid methyl ester; (S)-METHYL .ALPHA.-(4,5,6,7-TETRAHYDROTHIENO(3,2-C)PYRIDIN-5-YL)-.ALPHA.-(O-CHLOROPHENYL)ACETATE; Thieno[3,2-c]pyridine-5(4H)-acetic acid, .alpha.-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (.alpha.S)-; Thieno[3,2-c]pyridine-5(4H)-acetic acid, alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (alphaS)-	Approved	Approved Drug(s)	60606	DB00758	D0ED3R	321.8	57.8	381	3.8	21	0	4	4	C16H16ClNO2S	methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate	COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3	COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3	InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1	GKTWGGQPFAXNFI-HNNXBMFYSA-N
DL0MR6	Valsartan	Small molecule	valsartan; 137862-53-4; Diovan; Tareg; CGP 48933; Provas; Exforge; CGP-48933; (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid; Prexxartan; 137863-60-6; C24H29N5O3; MFCD00865840; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; L-Valsartan; NSC-758927; CHEMBL1069; L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; 80M03YXJ7I; CHEBI:9927; L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; Kalpress; Miten; Nisis; Vals; (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid; N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine; Valzaar; Valtan; [3H]valsartan; (2~{S})-3-methyl-2-[pentanoyl-[[4-[2-(2~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; SMR000466318; Diovan (TN); DTXSID6023735; UNII-80M03YXJ7I; Valpression; Valsartana; Varexan; HSDB 7519; Valsartan [USAN:USP:INN:BAN]; Valsartan,(S); Valsartan- Bio-X; (2S)-3-Methyl-2-(pentanoyl-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)amino)butanoic acid; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; U35; valsartan (Diovan); Spectrum_001796; VALSARTAN [INN]; VALSARTAN [JAN]; VALSARTAN [MI]; VALSARTAN [HSDB]; VALSARTAN [USAN]; Spectrum2_001120; Spectrum3_001831; Spectrum4_000749; Spectrum5_001582; VALSARTAN [VANDF]; VALSARTAN [MART.]; EC 604-045-2; SCHEMBL2542; VALSARTAN [USP-RS]; VALSARTAN [WHO-DD]; BSPBio_003501; GTPL593; KBioGR_001078; KBioSS_002289; VALSARTAN [EMA EPAR]; MLS000759423; MLS001424088; BIDD:GT0345; SPECTRUM1505209; SPBio_001260; Valsartan (JP17/USP/INN); GTPL3937; VALSARTAN [EP IMPURITY]; VALSARTAN [ORANGE BOOK]; VALSARTAN [EP MONOGRAPH]; Valsartan, >=98% (HPLC); DAFIRO COMPONENT VALSARTAN; KBio2_002287; KBio2_004855; KBio2_007423; KBio3_003006; EZR-104; VAL-489; VALSARTAN [USP MONOGRAPH]; COPALIA COMPONENT VALSARTAN; EXFORGE COMPONENT VALSARTAN; IMPRIDA COMPONENT VALSARTAN; HMS1922L21; HMS2051L12; HMS2093K22; HMS2232F05; HMS3651E04; HMS3715P12; Pharmakon1600-01505209; ENTRESTO COMPONENT VALSARTAN; VALTURNA COMPONENT VALSARTAN; (2R)-3-Methyl-2-[pentanoyl[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]amino]butanoic Acid (Valsartan (R)-Enantiomer); ACT02671; BCP05184; AGSAV301 COMPONENT VALSARTAN; BDBM50049186; HB3381; NSC758927; s1894; DAFIRO-HCT COMPONENT VALSARTAN; DIOVAN HCT COMPONENT VALSARTAN; VALSARTAN COMPONENT OF COPALIA; VALSARTAN COMPONENT OF EXFORGE; AKOS015914315; AKOS015994698; BYVALSON COMPONENT OF VALSARTAN; COPALIA-HCT COMPONENT VALSARTAN; EXFORGE HCT COMPONENT VALSARTAN; IMPRIDA-HCT COMPONENT VALSARTAN; VALSARTAN COMPONENT OF BYVALSON; VALSARTAN COMPONENT OF ENTRESTO; VALSARTAN COMPONENT OF IMMPRIDA; VALSARTAN COMPONENT OF VALTURNA; AC-4543; AM90287; CCG-101028; CCG-221275; CS-1967; DB00177; DS-1248; KS-1194; NC00278; NSC 758927; N-(1-OXOPENTYL)-N-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-L-VALINE; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine; NCGC00178027-08; NCGC00178027-11; VALSARTAN COMPONENT OF DAFIRO-HCT; VALSARTAN COMPONENT OF DIOVAN HCT; BV164506; HY-18204; VALSARTAN COMPONENT OF COPALIA-HCT; VALSARTAN COMPONENT OF EXFORGE HCT; VALSARTAN COMPONENT OF IMPRIDA-HCT; SBI-0206738.P001; SW197658-2; V-120; V0112; D00400; AB00639940-06; AB00639940-08; AB00639940_09; AB00639940_11; EN300-6482022; Q155472; SR-05000001928; J-007068; SR-05000001928-1; BRD-K45158365-001-02-3; BRD-K45158365-001-05-6; Z1379303659; Valsartan, European Pharmacopoeia (EP) Reference Standard; N-Valeryl-N-[2'-(5-tetrazolyl)biphenyl-4-ylmethyl]-L-valine; Valsartan, United States Pharmacopeia (USP) Reference Standard; N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine; Valsartan, Pharmaceutical Secondary Standard; Certified Reference Material; (5)-2-{N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]pentanamido}-3-methylbutanoic acid; (S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid; 3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-yl]-amino}-butyric acid; L-Valine,N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]- (9CI); L-Valine,N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]-(9ci); N-(1-oxopentyl)-N-[[2'-(1h-tetrazol-5-yl) [1,1'-bi-phenyl]-4-yl]methyl]-l-valine; N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(L)-valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-L-valine; Valsartan for peak identification, European Pharmacopoeia (EP) Reference Standard; Valsartan for system suitability, European Pharmacopoeia (EP) Reference Standard; (2S)-3-methyl-2-(N-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}pentanamido)butanoic acid; (2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid.; (2S)-3-Methyl-2-{N-pentanoyl-N'-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butanoic acid; (2S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid; (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoicacid; (S)-2-(N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid; (S)-3-methyl-2-(N-{[2'-(2H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl}pentanamido)butanoic acid; (s)-3-methyl-2-[N-({4-[2-(2h-1,2,3,4-tetrazol-5-yl) phenyl]phenyl}methyl)pentanamido]butanoic acid; (S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid; (s)-3-methyl-2-{pentanoyl-[-2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid; (S)-3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid; (S)-3-Methyl-2-{pentanoyl-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid; (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine; (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amine; (S)-N-(1-Carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine; 2-{[2''-(2,3-Dihydro-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-pentanoyl-amino}-3-methyl-butyric acid; 3-Methyl-2-{((S)-pentanoyl)-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid	Approved	Approved Drug(s)	60846	DB00177	D0EO8K	435.5	112	608	4.4	32	2	6	10	C24H29N5O3	(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid	CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O	CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O	InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1	ACWBQPMHZXGDFX-QFIPXVFZSA-N
D3PL8S	Spironolactone	Small molecule	spironolactone; 52-01-7; Aldactone; Spirolactone; Verospirone; Verospiron; Euteberol; Spirolang; Spiroctan; Acelat; Aldactone A; Spironocompren; Melarcon; Spiresis; Spiridon; Uractone; Urusonin; Alderon; Spirone; Xenalon; Dira; Spiro-Tablinen; Spironolactone A; spironolattone; Aquareduct; Spironolactonum; Aldopur; Espironolactona; Abbolactone; Aldace; Almatol; Deverol; Altex; Berlactone; SC 9420; SC-9420; SC9420; Spironolactone ceva; C24H32O4S; NSC-150399; CHEMBL1393; CHEBI:9241; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); DTXSID6034186; Spironolattone [DCIT]; 17-Hydroxy-7alpha-mercapto-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone acetate; 27O7W4T232; S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate; Aldactide; Spironolactonum [INN-Latin]; Espironolactona [INN-Spanish]; SC 15983; 17-Hydroxy-7-alpha-mercapto-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid-gamma-lactone-7-acetate; DTXCID4014186; Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Diatense; Aldactone (TN); (1'S,2R,2'R,9'R,10'R,11'S,15'S)-9'-(acetylsulfanyl)-2',15'-dimethylspiro[oxolane-2,14'-tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan]-6'-ene-5,5'-dione; SMR000471892; HSDB 3184; EINECS 200-133-6; MFCD00082250; NSC 150399; BRN 0057767; spirotone; Spiranolactone; Carospir; UNII-27O7W4T232; 2oax; 3vhu; CAS-52-01-7; NCGC00015948-02; 3-(3-Keto-7.alpha.-acetylthio-17.beta.-hydroxy-4-androsten-17.alpha.-yl)propionic acid lactone; 7-.alpha.-(acetylthio)-17-.alpha.-hydroxy-3-oxopregn-4-ene-21-carboxylic acid, .gamma.-lactone; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; S-((7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl) ethanethioate; S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl] ethanethioate; Spironolactone [USP:INN:BAN:JAN]; Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, gamma-lactone, (7alpha,17alpha)-; Prestwick0_000128; Prestwick1_000128; Prestwick2_000128; Prestwick3_000128; SPIRONOLACTONE [MI]; 3'-(3-Oxo-7-alpha-acetylthio-17-beta-hydroxyandrost-4-en-17-beta-yl)propionic acid lactone; 3-(3-Keto-7-alpha-acetylthio-17-beta-hydroxy-4-androsten-17-alpha-yl)propionic acid lactone; SPIRONOLACTONE [INN]; SPIRONOLACTONE [JAN]; BIDD:PXR0071; SCHEMBL20939; BSPBio_000176; SPIRONOLACTONE [HSDB]; SPIRONOLACTONE [IARC]; SPIRONOLACTONE [INCI]; 17alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7alpha-mercapto-3-oxo-, gamma-lactone, acetate; 4-18-00-01601 (Beilstein Handbook Reference); MLS001074672; MLS001333253; MLS001333254; MLS002153245; MLS002207058; MLS002548846; SPIRONOLACTONE [VANDF]; SPBio_002115; SPIRONOLACTONE [MART.]; BPBio1_000194; GTPL2875; SPIRONOLACTONE [USP-RS]; SPIRONOLACTONE [WHO-DD]; SPIRONOLACTONE [WHO-IP]; Spironolactone (JP17/USP/INN); HMS1568I18; HMS2090N21; HMS2095I18; HMS2236E06; HMS3259G11; HMS3712I18; ACT02596; AMY40521; HY-B0561; Spironolactone, 97.0-103.0%; SPIRONOLACTONE [ORANGE BOOK]; Tox21_113047; Tox21_302154; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone; BDBM50228080; HB2799; NSC150399; s4054; SPIRONOLACTONE [EP MONOGRAPH]; SPIRONOLACTONE [USP MONOGRAPH]; AKOS015896401; SPIRONOLACTONUM [WHO-IP LATIN]; AC-4214; CCG-220128; DB00421; KS-5234; NC00482; 7-alpha-(acetylthio)-17-alpha-hydroxy-3-oxopregn-4-ene-21-carboxylic acid, gamma-lactone; CARDALIS COMPONENT SPIRONOLACTONE; SPIRONOLACTONE COMPONENT CARDALIS; NCGC00164397-01; NCGC00164397-02; NCGC00164397-03; NCGC00164397-05; NCGC00255229-01; 17-alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7-alpha-mercapto-3-oxo-, gamma-lactone acetate; BS166385; CPD000471892; Spironolactone 1.0 mg/ml in Acetonitrile; ALDACTAZIDE COMPONENT SPIRONOLACTONE; SPIRONOLACTONE [EMA EPAR VETERINARY]; AB00513806; S0260; SPIRONOLACTONE COMPONENT OF ALDACTAZIDE; C07310; C75438; D00443; EN300-123035; AB01275520-01; AB01275520_02; Q422188; SR-01000765419; SR-05000000452; Q-201737; SR-01000765419-2; SR-05000000452-2; BRD-K90027355-001-03-4; BRD-K90027355-001-19-0; Z1546616196; Spironolactone, European Pharmacopoeia (EP) Reference Standard; WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ; 17.alpha.-Pregn-4-ene-21-carboxylic acid, .gamma.-lactone acetate; Spironolactone, United States Pharmacopeia (USP) Reference Standard; 17.alpha.-Pregn-4-ene-21-carboxylic acid, .gamma.-lactone, acetate; Pregn-4-ene-21-carboxylic acid, .gamma.-lactone, (7.alpha.,17.alpha.)-; (7?,17?)-7-(Acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic acid ?-lactone; Spironolactone for system suitability, European Pharmacopoeia (EP) Reference Standard; (1R,3aS,3bR,4R,9aR,9bS,11aS)-4-(acetylsulfanyl)-9a,11a-dimethyl-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydrospiro[cyclopenta[a]phenanthrene-1,2'-oxolane]-5',7-dione; (7<span class='symbol'>alpha</span>,17<span class='symbol'>alpha</span>)-7-(Acetylthio)-17-hydroxy-3- oxopregn-4-ene-21-carboxylic acid <span class='symbol'>gamma</span>-lactone; 2'',15''-dimethyl-5,5''-dioxo-(9''R)-spiro[tetrahydrofuran-2,14''-tetracyclo[8.7.0.02,7.011,15]heptadec-6''-ene]-9-yl ethanethioate; 2'',15''-dimethyl-5,5''-dioxospiro[tetrahydrofuran-2,14''-tetracyclo[8.7.0.02,7.011,15]heptadec-6''-ene]-9-yl ethanethioate; 2'',15''-dimethyl-5,5''-dioxospiro[tetrahydrofuran-2,14''-tetracyclo[8.7.0.02,7.011,15]heptadec-6''-ene]-9-yl ethanethioate(Spiranolactone); PREGN-4-ENE-21-CARBOXYLIC ACID, 7-(ACETYLTHIO)-17-HYDROXY-3-OXO-,.GAMMA.-LACTONE, (7.ALPHA.,17.ALPHA.)-; S-(2''R,7R,8R,9S,10R,13S,14S)-10,13-dimethyl-3,5''-dioxo-1,2,3,4'',5'',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3''H-spiro[cyclopenta[a]phenanthrene-17,2''-furan]-7-yl ethanethioate	Approved	Approved Drug(s)	5833	DB00421	D0EP0C	416.6	85.7	818	2.9	29	0	5	2	C24H32O4S	S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate	CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C	InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1	LXMSZDCAJNLERA-ZHYRCANASA-N
DI3UQ4	Sodium oxybate	Small molecule	Sodium oxybate; 502-85-2; Anetamin; Sodium 4-hydroxybutyrate; Somsanit; Oxybate sodium; 4-Hydroxybutyric acid sodium salt; Sodium Oxybutyrate; Gamma OH; Sodium Oxybate [USAN]; 4-Hydroxybutyrate sodium; Catabate; Sodium oxybat; sodium 4-hydroxybutanoate; Sodium gamma-hydroxybutyrate; Butanoic acid, 4-hydroxy-, monosodium salt; Oxybate (sodium); LUMRYZ; WY-3478; gamma-Hydroxybutyrate sodium; sodium;4-hydroxybutanoate; gamma-Hydroxy sodium butyrate; Butanoic acid, 4-hydroxy-, sodium salt; EB 27; Hydroxybutyric acid monosodium salt; DTXSID3048940; 4-Hydroxybutyric acid monosodium salt; WY 3478; .gamma.-hydroxybutyrate sodium salt; NSC-84223; Sodium oxybate (USAN); 7G33012534; Butyric acid, 4-hydroxy-, monosodium salt; BUTYRIC ACID, 4-HYDROXY-, SODIUM SALT; Natrium 4-hydroxybutyrat; Sodium-4-hydroxybutyrate; Sodium Oxybate (Sodium 4-Hydroxybutanoate); GHB Sodium Salt (Sodium Gammahydroxybutyrate); 4-Hydroxybuttersaeure natriumsalz; gamma-Hydroxybutyrate sodium salt; NCGC00247714-01; EINECS 207-953-3; NSC 84223; gamma-Hydroxybutyric acid, sodium salt; JZP-6; SODIUM4-HYDROXYBUTYRATE; Acetamide,2,2-dichloro-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-,rel-; UNII-7G33012534; Xyrem (TN); Sodium gammahydroxybutyrate; SCHEMBL61823; SODIUM OXYBATE [HSDB]; SODIUM OXYBATE [VANDF]; DEA No. 2012; SODIUM OXYBATE [MART.]; CHEMBL1200682; DTXCID6028866; OXYBATE SODIUM [WHO-DD]; SODIUM OXYBATE [EMA EPAR]; HMS2091E15; HY-B1187; Tox21_112871; SODIUM OXYBATE [ORANGE BOOK]; Gamma Hydroxybutyric Acid preparations; XYWAV COMPONENT SODIUM OXYBATE; AKOS006221428; CCG-212465; CS-4796; DB09072; SODIUM OXYBATE COMPONENT OF XYWAV; CAS-502-85-2; DB-071156; FT-0626615; D05866; H-4040; SODIUM SALT OF GAMMA-HYDROXYBUTYRIC ACID; .GAMMA.-HYDROXYBUTYRATE SODIUM SALT [MI]; Butanoic acid, 4-hydroxy-, sodium salt (1:1); Q7553347; 90318-49-3	Approved	Approved Drug(s)	23663870	DB09072	D0EP8X	126.09	60.4	64.3	.	8	1	3	3	C4H7NaO3	sodium;4-hydroxybutanoate	C(CC(=O)[O-])CO.[Na+]	C(CC(=O)[O-])CO.[Na+]	InChI=1S/C4H8O3.Na/c5-3-1-2-4(6)7;/h5H,1-3H2,(H,6,7);/q;+1/p-1	XYGBKMMCQDZQOZ-UHFFFAOYSA-M
DN14UG	Temsirolimus	Small molecule	Temsirolimus; Torisel; CCI-779; 162635-04-3; 624KN6GM2T; CHEMBL1201182; DTXSID2040945; Cci 779; NCGC00167518-01; Rapamycin 42-(2,2-bis(hydroxymethyl)propionate); Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]; Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate); CHEBI:79699; Temserolimus; NSC-683864; MFCD00934421; Temsirolimus (CCI-779, NSC 683864); Temsirolimus [USAN]; Temsirolimus - Torisel; TEMSIROLIMUS [MI]; TEMSIROLIMUS [INN]; TEMSIROLIMUS [JAN]; TEMSIROLIMUS [VANDF]; UNII-624KN6GM2T; SCHEMBL18792; TEMSIROLIMUS [MART.]; 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin; TEMSIROLIMUS [WHO-DD]; WAY-CCI 779; GTPL5892; TEMSIROLIMUS [EMA EPAR]; DTXCID0020945; HSDB 7931; Temsirolimus, >=98% (HPLC); TEMSIROLIMUS [ORANGE BOOK]; 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin; Temsirolimus [USAN:INN:BAN:JAN]; Tox21_112515; BDBM50343413; s1044; AKOS025142069; AM84554; CCG-264790; CS-0129; NCGC00167518-02; NCGC00167518-05; NCGC00167518-09; HY-50910; CAS-162635-04-3; T3574; AB01274736-01; AB01274736_02; SR-01000898799; J-009958; Q7699074; SR-01000898799-3; BRD-K08177763-001-02-6; (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,30S,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate; A4I	Approved	Approved Drug(s)	6918289	DB06287	D0ES1Q	1030.3	242	2010	5.6	73	4	16	11	C56H87NO16	[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate	CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC	InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1	CBPNZQVSJQDFBE-FUXHJELOSA-N
DH68ZY	Tipranavir	Small molecule	Tipranavir; 174484-41-4; Aptivus; PNU-140690; TPV; Tipranavir (INN); U-140690; CHEBI:63628; ZZT404XD09; 3'-((1R)-1-((6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2H-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide; DTXSID6048622; 2-Pyridinesulfonamide, N-[3-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-; N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE; TIPRANAVIR [INN]; PNU 140690; Aptivus(TM); N-(3-{(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide; N-[3-[(1R)-1-[(2R)-4-hydroxy-6-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide; N-{3-[(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulfonamide; Aptivus (TN); Tipranavir [INN:BAN]; UNII-ZZT404XD09; HSDB 8083; NCGC00182028-01; 2-Pyridinesulfonamide, N-(3-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl)propyl)phenyl)-5-(trifluoromethyl)-; U 140690; 1d4y; 2o4l; 2o4n; 2o4p; TIPRANAVIR [MI]; TIPRANAVIR [VANDF]; TIPRANAVIR [MART.]; TIPRANAVIR [WHO-DD]; SCHEMBL40629; SCHEMBL40630; N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide; TIPRANAVIR [EMA EPAR]; CHEMBL183041; CHEMBL222559; DTXCID9028548; TIPRANAVIR [ORANGE BOOK]; EX-A4113; Tox21_112962; BDBM50479982; AKOS030254403; CS-1210; DB00932; NCGC00379087-01; NCGC00379087-02; AS-79082; HY-15148; N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide; N-[3-[(1R)-1-[(6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide; CAS-174484-41-4; D08605; F84910; A811642; EN300-19769351; Q423404; J-010991; 2-Pyridinesulfonamide, N-(3-(1-(5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl)propyl)phenyl)-5-(trifluoromethyl)-, (R-(R*,R*))-; N-[3-[(1R)-1-[(2R)-4-hydroxy-6-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide; N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide; N-[3-[(1R)-1-[(2R)-6-oxidanyl-4-oxidanylidene-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide	Approved	Approved Drug(s)	54682461	DB00932	D0EV6T	602.7	114	1050	7	42	2	10	11	C31H33F3N2O5S	N-[3-[(1R)-1-[(2R)-4-hydroxy-6-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide	CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4	CCC[C@]1(CC(=C(C(=O)O1)[C@H](CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4	InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1	SUJUHGSWHZTSEU-FYBSXPHGSA-N
DJL67U	Pazopanib	Small molecule	Pazopanib; 444731-52-6; GW786034; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; GW 786034; 790713-33-6; NSC-752782; 7RN5DR86CK; GW 78603; GW-786034; 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide; DTXSID8048733; CHEBI:71219; NCGC00188865-01; 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide; 5-[4-[(2,3-Dimethyl-2H-indazol-6-yl)-methyl-amino]-pyrimidin-2-ylamino]-2-methyl-benzenesulfonamide; DTXCID1028659; Pazopanib [INN]; 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide; Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-; Pazopanib (GW-786034); CAS-444731-52-6; Pazopanib [INN:BAN]; UNII-7RN5DR86CK; pazopanibum; HSDB 8210; Pazopanib- Bio-X; Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-; MFCD11616589; GW 786034B; indazolylpyrimidine 13; Pazopanib (free base); Kinome_3790; GW780604; PAZOPANIB [MI]; GW-780604; PAZOPANIB [VANDF]; PAZOPANIB [WHO-DD]; PAZOPANIB [EMA EPAR]; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; SCHEMBL588608; CHEMBL477772; GTPL5698; JMC514632 Compound 13; BDBM26474; cid_10113978; BCPP000129; HMS3244C21; HMS3244C22; HMS3244D21; HMS3656L14; HMS3745G05; BCP01839; EX-A1241; Tox21_113174; NSC752782; NSC800839; s3012; AKOS005145819; Tox21_113174_1; AC-8522; BCP9001053; CCG-265010; CS-0269; DB06589; NSC 752782; NSC-800839; SB17290; NCGC00188865-02; NCGC00188865-03; NCGC00188865-10; AS-11066; BD164238; HY-10208; AM20090659; FT-0659928; FT-0684794; SW218082-3; EN300-57325; A19406; P-6706; AB01273967-01; AB01273967-02; AB01273967_05; AB01273967_06; A839572; AR-270/43507999; Q-101400; Q7157043; BRD-K74514084-003-02-7; Z1541638525; 5-(3-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)phenylamino)-2-methylbenzenesulfonamide; 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]-pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide; 5-[[4-[(2,3-dimethyl-6-indazolyl)-methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide	Approved	Approved Drug(s)	10113978	DB06589	D0F0ZY	437.5	127	717	3.1	31	2	8	5	C21H23N7O2S	5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide	CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N	CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N	InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)	CUIHSIWYWATEQL-UHFFFAOYSA-N
D0P7AY	Calcium acetate	Small molecule	Calcium acetate; 62-54-4; Calcium diacetate; Acetic acid, calcium salt; Lime acetate; PhosLo; Lime pyrolignite; Acetate of lime; Brown acetate; acetic acid calcium salt; Gray Acetate of Lime; Brown Acetate of Lime; Phoslyra; calcium;diacetate; calcium ethanoate; FEMA No. 2228; Calcarea acetica; calcium(II) acetate; Acetic acid, calcium salt (2:1); Calcium acetate anhydrous; Calcium acetate, anhydrous; CHEBI:3310; INS NO.263; Y882YXF34X; Teltozan; Sorbo-calcion; Gray acetate; INS-263; Phoslo Gelcaps; E-263; Calcium di(acetate); Ca(OAc)2; Eliphos; Sanopan; CCRIS 4921; HSDB 928; EINECS 200-540-9; Calcium acetate [USP:JAN]; UNII-Y882YXF34X; AI3-02903; calcium acetate salt; Phoslo (TN); Calcium Acetate, FCC; Calcium acetate (USP); EC 200-540-9; Calcium Acetate 23% 10M; SCHEMBL23872; CALCIUM ACETATE [II]; CALCIUM ACETATE [MI]; CALCIUM ACETATE [FCC]; CALCIUM ACETATE [FHFI]; CALCIUM ACETATE [HSDB]; CALCIUM ACETATE [INCI]; CALCAREA ACETICA [HPUS]; CALCIUM ACETATE [VANDF]; CALCIUM ACETATE [MART.]; CHEMBL1200800; DTXSID0020234; CALCIUM ACETATE [USP-RS]; CALCIUM ACETATE [WHO-DD]; Calcium Acetate (Fragrance Grade); AMY23411; MFCD00012448; CALCIUM ACETATE [ORANGE BOOK]; AKOS015904560; CALCIUM ACETATE [EP MONOGRAPH]; CALCIUM ACETATE [USP MONOGRAPH]; DB00258; E263; FT-0623376; FT-0623377; D00931; CALCIUM ACETATE, ANHYDROUS [EP IMPURITY]; CIS,CIS-1,3,5-CYCLOHEXANETRICARBOXYLICACID; Q409251; calcium diacetate, CAc - acetic acid, calcium salt; J-519530	Approved	Approved Drug(s)	6116	DB00258	D0F1GS	158.17	80.3	25.5	.	9	0	4	0	C4H6CaO4	calcium;diacetate	CC(=O)[O-].CC(=O)[O-].[Ca+2]	CC(=O)[O-].CC(=O)[O-].[Ca+2]	InChI=1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2	VSGNNIFQASZAOI-UHFFFAOYSA-L
DOS57I	Pindolol	Small molecule	pindolol; 13523-86-9; Visken; Betapindol; Prinodolol; Carvisken; Durapindol; Pinbetol; Calvisken; Decreten; Pectobloc; Pynastin; LB-46; Blocklin L; Glauco-visken; Pindololum; Blocklin-L; DL-Pindolol; Blockin L; LB 46; (rs)-pindolol; 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol; 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol; Apo-pindol; 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol; 4-(3-(Isopropylamino)-2-hydroxypropoxy)indole; 2-Propanol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]-; Dl-lb-46; 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol; BJ4HF6IU1D; NSC-757276; 2-Propanol, 1-(4-indolyloxy)-3-(isopropylamino)-; CHEBI:8214; 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol; DTXSID8023476; 2-Propanol, 1-(1H-indol-4-yloxy)-3-((1-methylethyl)amino)-; Glauco-Viskin; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol; NCGC00015786-11; 1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; 2-Propanol, 1-(1H-indol-4-yloxy)-3-(1-methylethyl)amino-; (+-)-Pindolol; Pindololum [INN-Latin]; DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole; DTXCID603476; Blocklin; Carvisken (TN); SMR000059120; Blocklin-L (TN); Visken (TN); CCRIS 9215; HSDB 6539; SR-01000000027; EINECS 236-867-9; EINECS 244-623-8; UNII-BJ4HF6IU1D; BRN 1536506; DL-4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)INDOLE; DL-LB 46; Prestwick_397; CAS-13523-86-9; Pindolol [USAN:USP:INN:BAN:JAN]; Spectrum_001109; (-)-Pindolol; (S)-(-)-Pindolol; S-Pindolol; (1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol; PINDOLOL [HSDB]; PINDOLOL [USAN]; PINDOLOL [INN]; PINDOLOL [JAN]; PINDOLOL [MI]; PINDOLOL [VANDF]; (.+/-.)-Pindolol; Prestwick0_000090; Prestwick1_000090; Prestwick2_000090; Prestwick3_000090; Spectrum2_001285; Spectrum3_000547; Spectrum4_000479; Spectrum5_001266; PINDOLOL [MART.]; CHEMBL500; GTPL91; PINDOLOL [USP-RS]; PINDOLOL [WHO-DD]; PINDOLOL,(-); P 0778; P-6820; SCHEMBL5219; Lopac0_000955; Oprea1_770884; (+/-)-PINDOLOL; BSPBio_000020; BSPBio_002193; KBioGR_000958; KBioSS_001589; 5-21-03-00017 (Beilstein Handbook Reference); MLS000069496; MLS002548891; DivK1c_000837; SPECTRUM1500488; Pindolol (JP17/USP/INN); SPBio_001289; SPBio_001959; PINDOLOL [ORANGE BOOK]; 2-Propanol, 1-(indol-4-yloxy)-3-(isopropylamino)-; BPBio1_000022; PINDOLOL [EP MONOGRAPH]; 1-((1H-indol-4-yl)oxy)-3-(isopropylamino)propan-2-ol; PINDOLOL [USP MONOGRAPH]; HMS502J19; KBio1_000837; KBio2_001589; KBio2_004157; KBio2_006725; KBio3_001693; NINDS_000837; 2-Propanol, 1-(indol-4-yloxy)-3-(isopropylamino)-, (+-)-; HMS1568A22; HMS1920H16; HMS2089I21; HMS2091P20; HMS2095A22; HMS3259I07; HMS3262P12; HMS3267K17; HMS3369E14; HMS3414J03; HMS3678H21; HMS3712A22; HMS3742C07; HMS3885N04; Pharmakon1600-01500488; VISKAZIDE COMPONENT PINDOLOL; HY-B0982; Pindolol, >=98% (TLC), powder; Tox21_110221; Tox21_500955; BDBM50019443; CCG-39223; NSC757276; PDSP1_000771; PDSP1_000772; PDSP2_000759; PDSP2_000760; (+/-)-Pindolol-d7(iso-propyl-d7); AKOS015969756; PINDOLOL COMPONENT OF VISKAZIDE; Tox21_110221_1; CS-4473; DB00960; LP00955; NC00467; NSC 757276; SB17015; SDCCGSBI-0050929.P005; IDI1_000837; NCGC00015786-06; NCGC00015786-07; NCGC00015786-08; NCGC00015786-09; NCGC00015786-10; NCGC00015786-13; NCGC00015786-14; NCGC00015786-16; NCGC00015786-20; NCGC00015786-22; NCGC00024925-03; NCGC00024925-04; NCGC00024925-05; NCGC00024925-06; NCGC00024925-07; NCGC00261640-01; BS-42390; SBI-0050929.P004; 4-(3-Isopropylamino-2-hydroxypropoxy)indole; AB00052072; EU-0100955; FT-0673907; SW196641-3; (+/-)-LB-46; C07445; C90604; D00513; AB00052072-11; AB00052072_12; AB00052072_13; 1-(4-Indolyloxy)-3-(isopropylamino)-2-propanol; EN300-18518413; L000006; Q418101; 4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDOLE; SR-01000000027-2; SR-01000000027-4; SR-01000000027-5; SR-01000000027-7; 1-(1H-Indol-4-yloxy)-3-isopropylamino-propan-2-ol; BRD-A97701745-001-05-3; BRD-A97701745-001-09-5; 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol #; Pindolol, European Pharmacopoeia (EP) Reference Standard; (+/-)-4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)INDOLE; 1-(1H-Indol-4-yloxy)-3-isopropylamino-propan-2-ol(pindolol); Pindolol, United States Pharmacopeia (USP) Reference Standard; 1-(1H-Indol-4-yloxy)-3-isopropylamino-propan-2-ol((-)-Pindolol); N-(2-HYDROXY-3-(1H-INDOL-4-YLOXY)PROPYL)-N-ISOPROPYLAMINE	Approved	Approved Drug(s)	4828	DB00960	D0F2PO	248.32	57.3	248	1.8	18	3	3	6	C14H20N2O2	1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol	CC(C)NCC(COC1=CC=CC2=C1C=CN2)O	CC(C)NCC(COC1=CC=CC2=C1C=CN2)O	InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3	JZQKKSLKJUAGIC-UHFFFAOYSA-N
DAP1F9	Fludarabine	Small molecule	Fludarabine; 21679-14-1; F-Ara-A; (2R,3S,4S,5R)-2-(6-Amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 2-Fluoro Ara-A; Fludarabine [INN]; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; Fludarabinum; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; NSC 118218; 2-F-ara-A; Fludarabine (INN); CCRIS 3382; 2-Fluoro-9-beta-D-arabinofuranosyladenine; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-F-ARAA; 9-b-d-arabinofuranosyl-2-fluoroadenine; MLS000028687; DTXSID4039657; P2K93U8740; Fludarabine (Fludara); SMR000058874; 2-Fluoroadenine-9-beta-D-arabinofuranoside; Fludarabinum [Latin]; DTXCID2019657; Fludarabina [Spanish]; Fludarabina; FaraA; NSC-118218; Fluradosa (TN); CAS-21679-14-1; 2-FLUORO-9-ARABINOADENINE; MFCD00132942; F-ara-A;NSC 118218; UNII-P2K93U8740; HSDB 6964; NCGC00181336-01; EINECS 244-525-5; NSC 118218H; Fludarabine free base; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-; 2F-Ara-A; FLUDARABINE [MI]; 2-FLUORO-ARA-A; Adenine, 9-beta-D-arabinofuranosyl-2-fluoro-; FLUDARABINE [HSDB]; FLUDARABINE [VANDF]; SCHEMBL3510; CHEMBL1568; FLUDARABINE [WHO-DD]; MLS006011578; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; cid_657237; GTPL4802; BDBM68391; CHEBI:94701; EX-A833; BCPP000227; HMS2232K13; HMS3259F09; HMS3413N14; HMS3677N14; HMS3715F15; BCP01383; HY-B0069; Tox21_112795; Tox21_113419; HG1007; s1491; AKOS015854911; AKOS015916481; Tox21_113419_1; BCP9000693; CCG-221147; DB01073; DS-1271; NC00633; 9-ss-D-Arabinofuranosyl-2-fluoroadenine; NCGC00021920-04; NCGC00181336-03; NCGC00182047-03; BP-25389; BP-55389; AM20090199; F0658; EN300-52641; C21550; D07966; AB00383071-11; AB00383071_13; SR-01000000270; 2-FLUORO-9-.BETA.-D-ARABINOFURANOSYLADENINE; 9-.BETA.-D-ARABINOFURANOSYL-2-FLUOROADENINE; 9-?-D-Arabinofuranosyl-2-fluoro-9H-purin-6-amine; 9-; A-D-Arabinofuranosyl-2-fluoro-9H-purin-6-amine; SR-01000000270-2; 9-(?-D-Arabinofuranosyl)-2-fluoro-9H-purin-6-amine; FLUDARABINE PHOSPHATE IMPURITY E [EP IMPURITY]; Z756440078; 9-.BETA.-D-ARABINOFURANOSYL-2-FLUORO-9H-PURIN-6-AMINE; FLUDARABINE PHOSPHATE IMPURITY, 2-FLUORO-ARA-ADENINE- [USP IMPURITY]; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-purin-9-yl)-5-methylol-tetrahydrofuran-3,4-diol; (2R,3S,4S,5R)-2-(6-azanyl-2-fluoranyl-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-Fluoroadenine-9-beta-D-arabinofuranoside, DNA synthesis and methylation inhibitor	Approved	Approved Drug(s)	657237	DB01073	D0F2XQ	285.23	140	367	-0.6	20	4	9	2	C10H12FN5O4	(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol	C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N	C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N	InChI=1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1	HBUBKKRHXORPQB-FJFJXFQQSA-N
D6LS4P	Fosamprenavir	Small molecule	Fosamprenavir; 226700-79-4; Fosamprenavir [INN]; GW433908; FOS-APV; GW-433908; VX 175; VX-175; Fosamprenavir (INN); WOU1621EEG; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate; CHEBI:82941; GW433908A; fos-amprenavir; Amprenavir phosphate; GW 433908; Telzir(TM); Lexiva (TM); HSDB 7340; UNII-WOU1621EEG; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); GW 908; GW-908; GW908 cpd; VX175 cpd; FOSAMPRENAVIR [MI]; CHEMBL1664; FOSAMPRENAVIR [HSDB]; SCHEMBL34080; FOSAMPRENAVIR [VANDF]; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; FOSAMPRENAVIR [WHO-DD]; DTXSID2048296; DTXSID20861514; CS-M2417; EX-A6824; AKOS032960329; DB01319; ((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; [(3S)-tetrahydrofuran-3-yl] N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl-isobutyl-amino]-1-benzyl-2-phosphonooxy-propyl]carbamate; AS-56492; FPV; HY-78726; C12723; D02497; EN300-19659831; Q1385311; (3S)-TETRAHYDRO-3-FURYL ((.ALPHA.S)-.ALPHA.-((1R)-1-HYDROXY-2-(N1-ISOBUTYLSULFANILAMIDO)ETHYL)PHENETHYL)CARBAMATE PHOSPHATE (ESTER); (3S)-tetrahydrofuran-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-phenyl-3-(phosphonooxy)butan-2-yl]carbamate; (S)-TETRAHYDROFURAN-3-YL ((2S,3R)-4-(4-AMINO-N-ISOBUTYLPHENYLSULFONAMIDO)-1-PHENYL-3-(PHOSPHONOOXY)BUTAN-2-YL)CARBAMATE; {[(2R,3S)-1-[N-(2-methylpropyl)(4-aminobenzene)sulfonamido]-3-({[(3S)-oxolan-3-yloxy]carbonyl}amino)-4-phenylbutan-2-yl]oxy}phosphonic acid; {[(2R,3S)-1-[N-(2-methylpropyl)-4-aminobenzenesulfonamido]-3-({[(3S)-oxolan-3-yloxy]carbonyl}amino)-4-phenylbutan-2-yl]oxy}phosphonic acid; 1257693-05-2; CARBAMIC ACID, ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2-(PHOSPHONOOXY)PROPYL)-, C-(3S)-TETRAHYDRO-3-FURANYL) ESTER; N-[3-[N-(4-aminophenylsulfonyl)-N-isobutylamino]-1(s)-benzyl-2(r)-(phosphonooxyl)propyl]carbamic acid tetrahydrofuran-3(s)-yl ester; rel-(3R)-Tetrahydro-3-furanyl N-[(1R,2S)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)-2-(phosphonooxy)propyl]carbamate	Approved	Approved Drug(s)	131536	DB01319	D0F5MT	585.6	186	912	1.8	39	4	11	14	C25H36N3O9PS	[(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate	CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N	InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1	MLBVMOWEQCZNCC-OEMFJLHTSA-N
DI07NQ	Amoxicillin	Small molecule	amoxicillin; Amoxycillin; 26787-78-0; Amoxicillin anhydrous; Amoxicilline; p-Hydroxyampicillin; Amopenixin; Amolin; Moxal; D-Amoxicillin; Clamoxyl; Amoxil; Amoxicillinum; Amoxicilina; Imacillin; Hiconcil; Robamox; Amoxicilina [INN-Spanish]; Amoxicilline [INN-French]; Amoxicillinum [INN-Latin]; Amoxicillin (anhydrous); Moxatag; alpha-Amino-p-hydroxybenzylpenicillin; Histocillin; Amoclen; Flemoxin; Unicillin; Amoxicillin [INN]; Amoxycillin Trihydrate; AMOXICILLIN CRYSTALLINE; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; BRL-2333; Amoxicillin (INN); CHEBI:2676; Amoxicillin hydrate; Bristamox; Delacillin; Amoxiden; Amoxivet; Anemolin; Aspenil; Cemoxin; Efpenix; Piramox; Vetramox; Amoxi; Sumox; NSC-277174; Amoxi-Mast; Sawamox PM; Metafarma capsules; Metifarma capsules; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; DTXSID3037044; Ospamox; Amopen; Topramoxin; Amoxyke; Atoksilin; Demoksil; Largopen; Moksilin; Promoxil; Remoxil; Damoxy; 9EM05410Q9; Amoxicaps; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; Apo-Amoxi; AMOX; (2S,5R,6R)-6-((R)-2-Amino-2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; AX; AMOXICILLIN PEDIATRIC; DTXCID1017044; amoxicillanyl; Amoxicillin (as trihydrate); BLP 1410; D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; Amoxicillin (TN); SMR000058707; Amoxicillin (trihydrate); Amoxycillin (trihydrate); Amoxicillin (Amoxycillin); Ro 10-8756; HSDB 3204; 61336-70-7; EINECS 248-003-8; BL-P 1410; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; NSC 277174; amoxycilin; AMOXICILLINTRIHYDRATE; Amoxi-Inject; Amoxi-Tabs; NSC277174; UNII-9EM05410Q9; notoginsenoside-fe; 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; NCGC00016797-02; NCGC00094586-01; Prestwick_713; CAS-26787-78-0; (-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; MFCD00056860; Amoxicillinum trihydricum; AMOXICILLIN [MI]; Prestwick0_000357; Prestwick1_000357; Prestwick2_000357; Prestwick3_000357; Epitope ID:114241; Epitope ID:116054; EC 248-003-8; SCHEMBL3427; AMOXICILLIN [MART.]; CHEMBL1082; AMOXICILLIN [WHO-DD]; BSPBio_000453; MLS000028632; MLS002222248; SPBio_002374; BPBio1_000499; CHEBI:53712; GTPL10895; HY-B0467A; HMS1569G15; HMS2096G15; HMS2231K23; HMS3259P17; HMS3713G15; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; AMOXICILLIN ANHYDROUS [HSDB]; Tox21_111302; BDBM50350464; s3015; AKOS025395540; Tox21_111302_1; CCG-220357; DB01060; DS-3835; NC00670; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid; NCGC00179554-01; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2R)-amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D-; 4-Thia-1-azobicyclo(3.2.0)heptane-2-carboxylic acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S)))-; AC-12263; Amoxicillin, potency: >=900 mug per mg; co-amoxiclav (amoxicillin + clavulanic acid); C06827; D07452; EN300-118704; A877139; Q201928; SR-01000721886; SR-01000721886-2; BRD-K55044200-001-03-9; BRD-K55044200-001-15-3; Z1515385072; (2S,5R,6R)-6-((R)-(-)-2-AMINO-2-(P-HYDROXYPHENYL)ACETAMIDO)-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID; (2S,5R,6R)-6-((R)-2-Amino-2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylicacid; 4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 6-((AMINO(4-HYDROXYPHENYL)ACETYL)AMINO)-3,3-DIMETHYL-7-OXO-(2S-(2.ALPHA.,5.ALPHA.,6.BETA.(S*)))-; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[amino (4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]-	Approved	Approved Drug(s)	33613	DB01060	D0F6EO	365.4	158	590	-2	25	4	7	4	C16H19N3O5S	(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid	CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C	InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1	LSQZJLSUYDQPKJ-NJBDSQKTSA-N
DN6T1K	Fluoxetine	Small molecule	fluoxetine; 54910-89-3; Prozac; Pulvules; Portal; Eufor; Animex-On; Fluoxetina; Fluval; Fluoxetina [Spanish]; Fluoxetinum; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; Fluoxetinum [INN-Latin]; Fluoxetina [INN-Spanish]; Fluoxetine-d5; Fluoxetin ratiopharm; Fluctine; Fluoxac; Fludac; Fluxil; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; CHEMBL41; dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; NSC-283480; 01K63SUP8D; 57226-07-0; DTXSID7023067; Fluoxetin; CHEBI:86990; Selfemra; NSC-758685; (+/-)-Fluoxetine; HSDB 6633; NCGC00015428-08; n-methyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; DTXCID903067; 1173147-79-9; Fluoxetine [USAN:INN:BAN]; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; Fluoxetine (TN); CAS-54910-89-3; Fluoxetine (USAN/INN); UNII-01K63SUP8D; Spectrum_001679; FLUOXETINE [MI]; SpecPlus_000723; FLUOXETINE [INN]; Prestwick0_000511; Prestwick1_000511; Prestwick2_000511; Prestwick3_000511; Spectrum2_001658; Spectrum3_001648; Spectrum4_000613; Spectrum5_001518; FLUOXETINE [USAN]; Benzenepropamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-; FLUOXETINE [VANDF]; Biomol-NT_000152; Epitope ID:224550; (+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-; SCHEMBL8353; LY-110140 free base; (+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; FLUOXETINE [WHO-DD]; Lopac0_000558; BSPBio_000461; BSPBio_003375; GTPL203; KBioGR_001166; KBioSS_002159; cid_62857; DivK1c_006819; SPBio_001815; SPBio_002382; BPBio1_000354; BPBio1_000509; CHEBI:5118; BDBM30130; KBio1_001763; KBio2_002159; KBio2_004727; KBio2_007295; KBio3_002595; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; HMS2090H14; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; AMY32526; BCP28440; HY-B0102; Tox21_110144; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; AB9783; BBL012251; MFCD00072041; NS-140; NSC283480; STK734483; AKOS003663021; Tox21_110144_1; AC-8478; CCG-204648; DB00472; NSC 283480; NSC 758685; SDCCGSBI-0050541.P004; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; FLUOXETINE [EMA EPAR VETERINARY]; NCGC00015428-06; NCGC00015428-07; NCGC00015428-10; NCGC00015428-11; NCGC00015428-12; NCGC00015428-13; NCGC00015428-15; NCGC00015428-27; NCGC00024879-03; NCGC00024879-04; AS-44989; SBI-0050541.P003; DB-015148; AB00053774; FT-0626489; D00326; EN300-199668; AB00053774-13; AB00053774-14; AB00053774_15; AB00053774_16; L000931; Q422244; BRD-A31159102-001-01-9; BRD-A31159102-003-05-6; BRD-A31159102-003-16-3; SR-01000002988-18; LY-110140;LY 110140;LY110140; N-methyl 3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; N-Methyl-3-phenyl-3-(p-trifluoromethylphenoxy)propylamine; Benzenepropanamine, N-methyl-?-[4-(trifluoromethyl)phenoxy]-; benzenepropanamine, N-methyl-gamma-[4-(trifluoromethyl)phenoxy]-; DL-N-METHYL-3-(P-TRIFLUOROMETHYLPHENOXY)-3-PHENYLPROPYLAMINE; N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine; N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine #; Benzenepropanamine, N-methyl-gamma-[4-(trifluoromethyl)phenoxy]-, (+/-)-; N-METHYL-.GAMMA.-(4-(TRIFLUOROMETHYL)PHENOXY)BENZENEPROPANAMINE; N-methyl-3-[4-(trifluoromethyl)phenoxy]-3-(3-tritiophenyl)propan-1-amine; N-methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (.+/-.)-N-Methyl-3-phenyl-3-[(.alpha.,.alpha.,.alpha.-trifluoro-p-tolyl)oxy]propylamine; (.+/-.)-N-Methyl-3-phenyl-3-[(.alpha.,la,.alpha.-trifluoro-p-tolyl)oxy]propylamine; Benzenepropanamine, N-methyl-.gamma.-[4-(trifluoromethyl)phenoxy]-, (.+/-.)-; BENZENEPROPANAMINE, N-METHYL-G-(4-(TRIFLUOROMETHYL)PHENOXY)-, (+/-)-; (+/-)-N-METHYL-3-PHENYL-3-((.ALPHA.,ALPHA.,.ALPHA.-TRIFLUORO-P-TOLYL)OXY)PROPYLAMINE	Approved	Approved Drug(s)	3386	DB00472	D0F7XT	309.33	21.3	308	4	22	1	5	6	C17H18F3NO	N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine	CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F	CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F	InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3	RTHCYVBBDHJXIQ-UHFFFAOYSA-N
DWN71O	Propofol	Small molecule	propofol; 2,6-DIISOPROPYLPHENOL; 2078-54-8; Diprivan; Disoprofol; Disoprivan; Fresofol; Diisopropylphenol; 2,6-Bis(1-methylethyl)phenol; Ampofol; Rapinovet; Phenol, 2,6-bis(1-methylethyl)-; Propofolum; Recofol; Ivofol; Propofol-Lipuro; 2,6-di(propan-2-yl)phenol; Pofol; ICI 35868; 2,6-Diisopropyl phenol; Diprifusor; Diprofol; Propovan; Phenol, 2,6-diisopropyl-; Diprivan 10; ICI-35868; Lipuro; NSC 5105; ICI 35,868; 2,6-bis(propan-2-yl)phenol; 2,6-Di-iso-propylphenol-d18; 2,6-diisopropyl-phenol; ICI35,868; MFCD00008885; CHEMBL526; YI7VU623SF; DTXSID6023523; CHEBI:44915; NSC5105; Phenol, 2,6-bis(1-methylethyl); NSC-5105; ICI 35-868; Propofolum [Latin]; NCGC00015389-08; Aquafol; CAS-2078-54-8; Diprivan Injectable emulsion; DTXCID103523; 2,6 Diisopropylphenol; Dipravan; Propoven; Aquafo; Propofol IDD-D; Diprivan (TN); SMR000059151; CCRIS 9000; Propofol(2,6-Diisopropylphenol); HSDB 7123; 2, 6-Diisopropylphenol; SR-01000075468; EINECS 218-206-6; 2,6-bis(Isopropyl)phenol; UNII-YI7VU623SF; BRN 1866484; DDS-04F; ghl.PD_Mitscher_leg0.558; AI3-26295; Propofol [USAN:USP:INN:BAN]; Propofol (Diprivan); ZD-0859; Phenol,6-diisopropyl-; PROPOFOL [HSDB]; PROPOFOL [USAN]; PROPOFOL [INN]; PROPOFOL [JAN]; PROPOFOL [MI]; PROPOFOL [VANDF]; Prestwick0_000931; Prestwick1_000931; Prestwick2_000931; Prestwick3_000931; 2,6-di isopropyl phenol; PROPOFOL [MART.]; 2,6-dipropan-2-ylphenol; Biomol-NT_000248; Lopac-D126608; PROPOFOL [USP-RS]; PROPOFOL [WHO-DD]; Propofol (JAN/USP/INN); Lopac0_000437; SCHEMBL36245; BSPBio_000862; 4-06-00-03435 (Beilstein Handbook Reference); MLS001066348; MLS001335999; MLS002454360; BIDD:GT0436; PROPOFOL [GREEN BOOK]; SPECTRUM1505022; SPBio_003031; 2,6-Diisopropylphenol, 97%; PROPOFOL [EP IMPURITY]; PROPOFOL [ORANGE BOOK]; BPBio1_000950; BPBio1_000969; GTPL5464; Phenol,6-bis(1-methylethyl)-; PROPOFOL [EP MONOGRAPH]; PROPOFOL [USP IMPURITY]; PROPOFOL [USP MONOGRAPH]; KETAFOL COMPONENT PROPOFOL; Propofol 1.0 mg/ml in Methanol; 2,6-Diisopropylphenol, >=97%; 3f33; 3p50; HMS1570L04; HMS2089O21; HMS2094E17; HMS2097L04; HMS2231E16; HMS3259E03; HMS3261G16; HMS3369I16; HMS3714L04; Pharmakon1600-01505022; ALBB-036351; BCP02920; HY-B0649; Tox21_110134; Tox21_201371; Tox21_303225; Tox21_500437; AC8633; BDBM50058046; NSC758909; Phenol, 2, 6-bis(1-methylethyl)-; AKOS009159417; Tox21_110134_1; AC-2038; AM90311; CCG-204529; CS-W020057; DB00818; LP00437; NC00449; NSC-758909; SDCCGMLS-0318084.P029; SDCCGSBI-0050422.P002; 2,6-DIISOPROPYLPHENOL; PROPOFOL; MLS-0318084; NCGC00015389-01; NCGC00015389-02; NCGC00015389-03; NCGC00015389-04; NCGC00015389-05; NCGC00015389-06; NCGC00015389-07; NCGC00015389-09; NCGC00015389-10; NCGC00015389-11; NCGC00015389-14; NCGC00015389-17; NCGC00091538-01; NCGC00091538-02; NCGC00091538-03; NCGC00091538-04; NCGC00091538-05; NCGC00091538-06; NCGC00257228-01; NCGC00260670-01; NCGC00261122-01; AS-13299; SY013479; 2,6-Diisopropylphenol, analytical standard; BCP0726000298; MLS-0318084.P017; AB00513968; D0617; EU-0100437; EN300-52468; C07523; D00549; AB00513968-07; AB00513968_08; A814898; D126608; Q422740; Q-201631; SR-01000075468-1; SR-01000075468-4; SR-01000075468-6; BRD-K82255054-001-03-5; BRD-K82255054-001-08-4; Propofol, British Pharmacopoeia (BP) Reference Standard; Propofol, European Pharmacopoeia (EP) Reference Standard; Z752915492; Propofol, United States Pharmacopeia (USP) Reference Standard; Propofol, Pharmaceutical Secondary Standard; Certified Reference Material; Propofol for peak identification, European Pharmacopoeia (EP) Reference Standard; 113981-41-2	Approved	Approved Drug(s)	4943	DB00818	D0F9VF	178.27	20.2	135	3.8	13	1	1	2	C12H18O	2,6-di(propan-2-yl)phenol	CC(C)C1=C(C(=CC=C1)C(C)C)O	CC(C)C1=C(C(=CC=C1)C(C)C)O	InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3	OLBCVFGFOZPWHH-UHFFFAOYSA-N
DSE42Z	Sapropterin	Small molecule	Sapropterin; tetrahydrobiopterin; 62989-33-7; R-THBP; Dapropterin; 6R-BH4; Sapropterina; Sapropterinum; (6R)-L-erythro-tetrahydrobiopterin; 5,6,7,8-tetrahydrobiopterin; Sapropterin [INN]; Sapropterin [MI]; 6R-5,6,7,8-Tetrahydrobiopterin; Sapropterin [VANDF]; 6R-L-5,6,7,8-Tetrahydrobiopterin; L-erythro-tetrahydrobiopterin; Sapropterin (INN); tetrahydro-l-biopterin; (6R)-5,6,7,8-Tetrahydrobiopterin; 2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-pteridinone; (-)-(6R)-2-Amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinone; CHEBI:59560; BH4; (6R)-L-erythro-5,6,7,8-Tetrahydrobiopterin; tetra-H-biopterin; (6R)-5,6,7,8-TETRAHYDRO-L-BIOPTERIN; EGX657432I; tetra-hydro-biopterin; (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-1H-pteridin-4-one; (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydropteridin-4(3H)-one; (6R)-2-Amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(1H)-pteridinone; (6R)-2-Amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydropteridin-4(1H)-one; (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydropteridin-4(1H)-one; (R)-2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydropteridin-4(1H)-one; 4(1H)-Pteridinone, (6R)-2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-; 5,6,7,8-tetra-H-biopterin; (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-3,4,5,6,7,8-hexahydropteridin-4-one; 4(1H)-Pteridinone, 2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-, (6r)-; 27070-47-9; Sapropterin [EMA EPAR]; Sapropterinum [INN-Latin]; Sapropterina [INN-Spanish]; Tetrahydrobiopterin [WHO-DD]; UNII-EGX657432I; 5,6,7,8-Tetrahydro-2-amino-6-(1,2-dihydroxypropyl)-4(1H)-pteridinone; (1R,2S)-(2-Amino-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)-1,2-propandiol; L-erythro-2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinon; 5,6,7,8-erythro-tetrahydrobiopterin; DAPROTERIN; 6R-Tetrahydrobiopterin; (6R)-Tetrahydrobiopterin; tetrahydrobiopterin (THB); bmse000911; SAPROPTERIN [WHO-DD]; THB; SCHEMBL258544; GTPL5276; CHEMBL1201774; DTXSID1041138; BCBcMAP01_000204; 2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydropteridin-4(3H)-one; Biopterin, 5,6,7,8-tetrahydro-; BCP03735; EX-A2877; HY-A0124; BDBM50373697; DB00360; SMP1_000285; NCGC00485328-01; (6r)-erythro-5,6,7,8-tet-rahydrobiopterin; CS-0014264; (6R)-5,6,7,8-Tetrahydro-L-biopterin 2HCl; C00272; C16118; D08505; EN300-262982; W-203341; W-203533; 69081654-1FB6-4B89-B9B9-823C9887EE36; 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(1H)-pteridinone; 2-Amino-6R-(1R,2S-dihydroxypropyl)-5,6,7,8-tetrahydro-4(1H)-pteridinone; (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one; (R)-2-Amino-6-((1R,2S)-1,2-dihydroxy-propyl)-5,6,7,8-tetrahydro-1H-pteridin-4-one; 4(1H)-Pteridinone,2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro; 2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-5,6,7,8-Tetrahydro-2-amino-6-(1,2-dihydroxypropyl)-4(1H)-pteridinone	Approved	Approved Drug(s)	135398654	DB00360	D0F9XO	241.25	132	405	-1.9	17	6	6	2	C9H15N5O3	(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one	CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O	C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O	InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4+,6-/m0/s1	FNKQXYHWGSIFBK-RPDRRWSUSA-N
DN6WI4	Nifurtimox	Small molecule	NIFURTIMOX; Lampit; 23256-30-6; Bayer 2502; Nifurtimoxum; (+)-Nifurtimox; BAYER-2502; CHEBI:7566; BAY 2502; Nifurtimox, (+)-; BAY-A2502; BAY-2502; DNDI1613515; UNII-1G5DD3P35C; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide; 1G5DD3P35C; M84I3K7C2O; Thiomorpholine, 3-methyl-4-((5-nitrofurfurylidene)amino)-, 1,1-dioxide; 4-Thiomorpholinamine, 3-methyl-N-[(5-nitro-2-furanyl)methylene]-, 1,1-dioxide; BAY A2502; Nifurtimox [INN:BAN]; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine 1,1-dioxide; 4-[(5-Nitrofurfurylidene)amino]-3-methylthiomorpholine 1,1-dioxide; Nifurtimoxum [INN-Latin]; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide, (+)-; 39072-15-6; CCRIS 2201; (+/-)-Nifurtimox; X4KCV4ZI9M; SR-01000838852; EINECS 245-531-0; DTXSID3045439; UNII-M84I3K7C2O; N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitrofuran-2-yl)methanimine; NCGC00016774-01; (-)-Nifurtimox; CAS-23256-30-6; Lampit (TN); Nifurtimox, (-)-; NIFURTIMOX [MI]; NIFURTIMOX [INN]; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide; Nifurtimox (USAN/INN); Prestwick2_001024; Prestwick3_001024; UNII-X4KCV4ZI9M; NIFURTIMOX [USAN]; 1-((5-Nitrofurfurylidene)amino)-2-methyltetrahydro-1,4-thiazine-4,4-dioxide; 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide; NIFURTIMOX [MART.]; NIFURTIMOX [WHO-DD]; NIFURTIMOX [WHO-IP]; Tetrahydro-3-methyl-4-((5-nitrofurfurylidene)amino)-2H-1,4-thiazine 1,1-dioxide; BSPBio_001207; BPBio1_001329; CHEMBL290960; SCHEMBL1650162; DTXCID1025439; NIFURTIMOX [ORANGE BOOK]; Nifurtimox, >=98% (HPLC); CHEBI:91472; BAY2502; KUC114565N; 39072-16-7; EX-A4624; NIFURTIMOXUM [WHO-IP LATIN]; Tox21_110604; BDBM50259708; s6459; CS-W020813; DB11820; HY-W040073; KSC-427-39-1; MS-24101; C08002; D00833; A912676; EN300-21039719; J-015055; SR-01000838852-2; SR-01000838852-3; BRD-A84020532-001-03-5; BRD-A84020532-001-04-3; (E)-3-methyl-4-(((5-nitrofuran-2-yl)methylene)amino)thiomorpholine 1,1-dioxide; 3-methyl-4-[(E)-[(5-nitrofuran-2-yl)methylidene]amino]-1lambda6-thiomorpholine-1,1-dione; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide, (-)-; N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitro-2-furyl)methanimine; TETRAHYDRO-3-METHYL-4-((5-NITROFURFURYLIDENE)AMINO)-4H-1,4-THIAZINE 1,1-DIOXIDE; (RS)-3-METHYL-N-((1E)-(5-NITRO-2-FURYL)METHYLENE)THIOMORPHOLIN-4-AMINE 1,1-DIOXIDE	Approved	Approved Drug(s)	6842999	DB11820	D0FC1J	287.29	117	467	1.3	19	0	7	2	C10H13N3O5S	(E)-N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitrofuran-2-yl)methanimine	CC1CS(=O)(=O)CCN1N=CC2=CC=C(O2)[N+](=O)[O-]	CC1CS(=O)(=O)CCN1/N=C/C2=CC=C(O2)[N+](=O)[O-]	InChI=1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3/b11-6+	ARFHIAQFJWUCFH-IZZDOVSWSA-N
D3O4VM	Folic acid	Small molecule	folic acid; 59-30-3; Folate; Pteroylglutamic acid; Vitamin M; Folacin; PteGlu; Vitamin B9; Vitamin Bc; Folacid; Folvite; Folicet; Folettes; Foliamin; Folipac; Incafolic; Millafol; Pteroyl-L-glutamic acid; Folsan; Acifolic; Cytofol; Folbal; Folsav; Vitamin Be; Foldine; Pteroyl-L-monoglutamic acid; Mittafol; Facid; Folan; Pteroylmonoglutamic acid; Antianemia factor; Factor U; Folico (Italy); Folina (Italy); Foldine [France]; Acfol (Spain); Pteroylmonoglutamate; Folcysteine; Folasic (Australia); Folcidin; Folsaure; Folaemin [Netherlands]; Nifolin [Denmark]; Folcidin (VAN); Acidum folicum; Kyselina listova [Czech]; Mission prenatal; Novofolacid [Canada]; Acide folique [INN-French]; Acido folico [INN-Spanish]; Acidum folicum [INN-Latin]; Liver Lactobacillus casei factor; PGA (VAN); Folic; Glutamic acid, pteroyl-, l-; Vitamin B11; Usaf cb-13; N-pteroyl-L-glutamic acid; Pteroyl-L-glutamate; Kyselina listova; CHEBI:27470; AI3-26387; N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L; NSC 3073; PGA; 4-Pteridinol, 2-amino-6-((p-((1,3-dicarboxypropyl)carbamoyl)anilino)methyl)-; Glutamic acid, N-(p-(((2-amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-, l-; L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-; L-Glutamic acid, N-(4-((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-; N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; DTXSID0022519; B03BB01; 935E97BOY8; NSC-3073; (2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; 112339-08-9; 112339-32-9; CAS-59-30-3; CID 5280354; Novofolacid; Folaemin; Nifolin; Folico; Folina; Acido folico; Dosfolat B activ; L-Glutamic acid, N-(4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-; N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid; N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid; FOL; DTXCID102519; Folsaeure; Megafol; Neocepri; Acide folique; MFCD00079305; C19H19N7O6; .beta.-D-Allopyranose, 1,6-anhydro-2,3-di-O-methyl-4-O-(phenylmethyl)-; 32108-06-8; (2S)-2-[[4-[(2-amino-4-hydroxypteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; .beta.-D-ribo-2-Heptulopyranose, 2,7-anhydro-1,4-dideoxy-3-O-methyl-5-O-(phenylmethyl)-; N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid; N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid; Pteroyglutamic acid; [3H]folic acid; (2S)-2-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid; SMR000471860; CCRIS 666; Folicet (TN); [3H]-folic acid; HSDB 2002; EINECS 200-419-0; Preconceive; Folicare; Lexpec; Pteroylglutamate; Folic acid [BAN:INN:JAN]; folic-acid; UNII-935E97BOY8; Bio Science; Natur Flow; (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; (S)-2-(4-((2-amino-4-oxo-1,4-dihydropteridin-6-yl)methylamino)benzamido)pentanedioic acid; L-Glutamic acid, N-(4-(((2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-; L-Glutamic acid, N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-; N-[4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzoyl]-l-glutamic acid; Folic acid [USP:INN:BAN:JAN]; NCGC00142391-03; N-(4-(((2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL)AMINO)BENZOYL)-L-GLUTAMIC ACID; PteGlu;Vitamin M;Pteroyl-L-glutamic acid; Prestwick_230; Folic Acid,(S); Folic Acid USP/BP; Pteroyl-L-monoglutamate; Spectrum_001381; 2d0k; Folic acid, crystalline; Folic acid, USP grade; FOLIC ACID [MI]; Folic acid, >=97%; Prestwick3_000627; Spectrum2_001459; Spectrum3_000749; Spectrum4_001751; Spectrum5_000602; F0043; FOLIC ACID [DSC]; FOLIC ACID [FCC]; FOLIC ACID [INN]; FOLIC ACID [JAN]; bmse000299; FOLIC ACID [HSDB]; FOLIC ACID [INCI]; FOLIC ACID [VANDF]; SCHEMBL3876; CHEMBL1622; FOLIC ACID [MART.]; BSPBio_000594; BSPBio_002338; FOLIC ACID [USP-RS]; FOLIC ACID [WHO-DD]; FOLIC ACID [WHO-IP]; KBioGR_002222; KBioSS_001861; MLS001304016; MLS001335861; MLS002548873; BIDD:ER0563; BIDD:GT0641; DivK1c_000494; SPECTRUM1502020; SPBio_001357; BPBio1_000654; Folic acid, analytical standard; GTPL4562; GTPL4563; Folic acid (JP17/USP/INN); FOLIC ACID [GREEN BOOK]; SCHEMBL20791897; HMS501I16; KBio1_000494; KBio2_001861; KBio2_004429; KBio2_006997; KBio3_001558; FOLIC ACID [EP IMPURITY]; FOLIC ACID [ORANGE BOOK]; NINDS_000494; HMS1921D20; HMS2092N17; HMS2096N16; HMS2270L05; HMS3259A05; HMS3713N16; Pharmakon1600-01502020; FOLIC ACID [USP MONOGRAPH]; (S)-2-(4-(((2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)pentanedioic acid; FOLVRON COMPONENT FOLIC ACID; Tox21_111559; Tox21_300127; BDBM50237629; BDBM50367343; CCG-38869; NSC758158; s4605; ACIDUM FOLICUM [WHO-IP LATIN]; AKOS000503224; AKOS015895671; AKOS016007919; Tox21_111559_1; DB00158; FOLIC ACID COMPONENT OF FOLVRON; GS-6860; NC00455; NSC-758158; SDCCGMLS-0066738.P001; IDI1_000494; SMP2_000137; Folic acid, tested according to Ph.Eur.; NCGC00016265-01; NCGC00016265-02; NCGC00016265-03; NCGC00016265-04; NCGC00016265-05; NCGC00016265-08; NCGC00142391-01; NCGC00254203-01; AC-11682; BP-13474; HY-16637; SBI-0051701.P002; Folic acid, meets USP testing specifications; C00504; D00070; Folic acid, Vetec(TM) reagent grade, >=97%; EN300-1667077; CALCIUM FOLINATE IMPURITY C [EP IMPURITY]; Q127060; BRD-K18673820-001-07-2; Z2042042504; Folic acid, British Pharmacopoeia (BP) Reference Standard; Folic acid, European Pharmacopoeia (EP) Reference Standard; Folic acid, United States Pharmacopeia (USP) Reference Standard; Folic acid, Pharmaceutical Secondary Standard; Certified Reference Material; N-{p-[(2-amino-4-hydroxypteridin-6-yl)methylamino]benzoyl}glutamic acid; L-glutamic acid, N-[4-[[(2-amino-4,8-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-; (2S)-2-[(4-{[(2-AMINO-4-HYDROXYPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID; (2S)-2-[(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid; Folic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=97%	Approved	Approved Drug(s)	135398658	DB00158	D0FE8F	441.4	209	767	-1.1	32	6	10	9	C19H19N7O6	(2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid	C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N	C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N	InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1	OVBPIULPVIDEAO-LBPRGKRZSA-N
DUTL50	Cobimetinib	Small molecule	Cobimetinib; 934660-93-2; GDC-0973; XL518; Xl-518; GDC 0973; RG7420; XL 518; RG 7420; Cobimetinib [USAN:INN]; UNII-ER29L26N1X; ER29L26N1X; CHEMBL2146883; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone; Cobimetinib (GDC-0973, RG7420); (S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone; [3,4-Bis(Fluoranyl)-2-[(2-Fluoranyl-4-Iodanyl-Phenyl)amino]phenyl]-[3-Oxidanyl-3-[(2s)-Piperidin-2-Yl]azetidin-1-Yl]methanone; [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]methanone; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-((2S)-2-piperidinyl)-1-azetidinyl)-; [3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-((s)-3-hydroxy-3-piperidin-2-yl-azetidin-1-yl)-methanone; EUI; Cobimetinib Butyrate; Cobimetinib [USAN]; cometinib; C21H21F3IN3O2; COBIMETINIB [MI]; COBIMETINIB [INN]; Cobimetinib (USAN/INN); COBIMETINIB [WHO-DD]; SCHEMBL189565; GTPL7626; XL518;RG7420;Cobimetinib; CHEBI:90851; DTXSID60239435; EX-A673; GDC0973; GDC0973; XL518; Cobimetinib; BDBM50391802; MFCD22124461; NSC768068; NSC781257; NSC800075; s8041; BCP9000716; CCG-264727; CS-0521; DB05239; NSC-768068; NSC-781257; NSC-800075; VS-0129; XL518 (GDC-0973); NCGC00346455-03; NCGC00346455-05; (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone; (S)-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone; HY-13064; RO-5514041; D10405; EN300-25921151; J-525162; Q15708292; ((3,4-DIFLUORO-2-(2-FLUORO-4-IODOANILINO)PHENYL)(3-HYDROXY-3-((2S)-PIPERIDIN-2-YL)AZETIDIN-1-YL)METHANONE; (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-((S)-piperidin-2-yl)cyclobutyl)methanone; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone; [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone; 1-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzoyl}-3-[(2S)-piperidin-2-yl]azetidin-3-ol	Approved	Approved Drug(s)	16222096	DB05239	D0FJ9I	531.3	64.599	624	3.9	30	3	7	4	C21H21F3IN3O2	[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone	C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O	C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O	InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1	BSMCAPRUBJMWDF-KRWDZBQOSA-N
D9B8DV	Flunisolide	Small molecule	flunisolide; 3385-03-3; Aerobid; Rhinalar; Synaclyn; Flunisolide anhydrous; Nasarel; Syntaris; Flunisolide HFA; Nasalide; Aerospan; Bronalide; Flunisolide [INN]; Flunisolida; Flunisolidum; Aerospan HFA; Lunis; RS-3999; CHEBI:5106; Flunisolide Hemihydrate; Nisolid; Soluzione; 78M02AA8KF; Aerobid M; DTXSID1045534; Pregna-1,4-diene-3,20-dione,6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6a,11b,16a)-; (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one; DTXCID9025534; Flunisolide [anhydrous]; (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one; CAS-3385-03-3; NSC-757871; Flunisolidum [INN-Latin]; Flunisolida [INN-Spanish]; Syntaris Hayfever; NCGC00016983-01; lunisolide anhydrous; Prestwick_223; EINECS 222-193-2; RS 3999; FLUNISOLIDE [MI]; Prestwick0_000643; Prestwick1_000643; Prestwick2_000643; Prestwick3_000643; SCHEMBL4351; CHEMBL1512; UNII-78M02AA8KF; BSPBio_000645; FLUNISOLIDE [WHO-DD]; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; MLS002153928; SPBio_002566; BPBio1_000711; GTPL7076; HMS1570A07; HMS2097A07; HMS2236A06; HMS3259L10; HMS3714A07; HY-B1121; Tox21_110725; BDBM50248007; AKOS025402038; Tox21_110725_1; AC-3514; BCP9000696; CCG-220643; CS-4713; DB00180; NC00716; 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; NCGC00179492-01; NCGC00179492-03; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-; SMR001233272; F0437; (6a,11b,16a)-6-Fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione; C07005; D78324; EN300-7480609; Q3746835; BRD-K49577446-001-03-1; 6.ALPHA.-FLUORO-11.BETA.,16.ALPHA.,17,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE CYCLIC 16,17-ACETAL WITH ACETONE; 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; PREGNA-1,4-DIENE-3,20-DIONE, 6-FLUORO-11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))- (6.ALPHA.,11.BETA.,16.ALPHA.)-	Approved	Approved Drug(s)	82153	DB00180	D0FM2P	434.5	93.1	910	2.5	31	2	7	2	C24H31FO6	(1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one	CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C)F)C	C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O	InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1	XSFJVAJPIHIPKU-XWCQMRHXSA-N
D4L9NG	Prazosin	Small molecule	prazosin; 19216-56-9; Furazosin; Prazosine; Prazocin; Prazosina; Prazosinum; Prazosine [INN-French]; Prazosinum [INN-Latin]; Prazosina [INN-Spanish]; [3H]-Prazosin; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; Prazosin (INN); (4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(furan-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone; CHEMBL2; Minipress (TN); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-; 4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone; Quinazoline, 4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-; HSDB 3298; CHEBI:8364; XM03YJ541D; DTXSID4049082; 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; Hypovase; Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-2-furanyl-; NCGC00016740-13; Lentopres; PRAZOSIN [INN]; CP-122991; Prazosin [INN:BAN]; DTXCID0029008; 2-[4-(Furan-2-Ylcarbonyl)piperazin-1-Yl]-6,7-Dimethoxyquinazolin-4-Amine; 2-{4-[(furan-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine; (4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)-piperazin-1-yl)(furan-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone; CAS-19216-56-9; EINECS 242-885-8; BRN 0768345; UNII-XM03YJ541D; 2-[4-(2-Furoyl)piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline; [3H]prazosin; TNP00312; [3H]-Furazosin; [3H]-Minipress; [3H]-Pratsiol; Spectrum_000822; Tocris-0623; CP-12299; PRAZOSIN [MI]; PRAZOSIN [VANDF]; Prestwick0_000947; Prestwick1_000947; Prestwick2_000947; Prestwick3_000947; Spectrum2_001289; Spectrum3_000551; Spectrum4_000483; Spectrum5_001365; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-; PRAZOSIN [WHO-DD]; [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; Oprea1_314778; SCHEMBL26524; BSPBio_000914; BSPBio_001036; BSPBio_002221; GTPL503; KBioGR_000376; KBioGR_000965; KBioSS_000376; KBioSS_001302; 5-25-13-00365 (Beilstein Handbook Reference); MLS006011888; DivK1c_000375; SPBio_001297; SPBio_003073; BPBio1_001006; GTPL5385; TERAZOSIN HCL IMPURITY K; BCBcMAP01_000227; BDBM29568; KBio1_000375; KBio2_000376; KBio2_001302; KBio2_002944; KBio2_003870; KBio2_005512; KBio2_006438; KBio3_000731; KBio3_000732; KBio3_001721; NINDS_000375; PRAZOSIN, Prazosin Hydrochloride; Bio1_000365; Bio1_000854; Bio1_001343; Bio2_000358; Bio2_000838; HMS1362D17; HMS1792D17; HMS1990D17; HMS2089G09; HMS3403D17; HMS3886H03; BCP14556; HY-B0193; Tox21_113646; BBL028799; s5780; STK301545; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine; 2-[4-(furan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; AKOS000310009; Tox21_113646_1; AF-0052; DB00457; SB17351; SDCCGSBI-0051487.P004; IDI1_000375; IDI1_002113; SMP1_000063; NCGC00016740-01; NCGC00016740-02; NCGC00016740-03; NCGC00016740-04; NCGC00016740-05; NCGC00016740-06; NCGC00016740-07; NCGC00016740-08; NCGC00016740-09; NCGC00016740-10; NCGC00016740-11; NCGC00016740-12; NCGC00016740-14; NCGC00016740-15; NCGC00016740-18; NCGC00016740-19; NCGC00016740-33; NCGC00024324-02; NCGC00024324-04; NCGC00024324-05; NCGC00024324-06; NCGC00024324-07; NCGC00024324-08; NCGC00024324-09; NCGC00024324-10; NCI60_002417; SMR001550197; SBI-0051487.P003; CAS-19237-84-4; DB-044783; AB00053528; FT-0630457; FT-0674003; C07368; D08411; EN300-229477; AB00053528-19; AB00053528_20; AB00053528_21; L000666; Q425296; W-107722; BRD-K49111258-001-02-8; BRD-K49111258-003-05-7; BRD-K49111258-003-16-4; Z275127478; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)4-(2-furoyl)piperazine; 2-[4-(2-Furoyl)-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine #; 6,7-dimethoxy-4-amino-2-[4-(2-furoyl)piperazin-1-yl]quinazoline; TERAZOSIN HYDROCHLORIDE DIHYDRATE IMPURITY K [EP IMPURITY]; 2-(4-(2-FUROYL)-1-PIPERAZINYL)-6,7-DIMETHOXY-4-QUINAZOLINAMINE; [4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](2-furyl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-furan-2-ylmethanone; 1-(4-AMINO-6,7-DIMETHOXYQUINAZOLIN-2-YL)-4-(FURAN-2-YLCARBONYL)PIPERAZINE; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8CI); XRA	Approved	Approved Drug(s)	4893	DB00457	D0G0DZ	383.4	107	544	2	28	1	8	4	C19H21N5O4	[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC	InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)	IENZQIKPVFGBNW-UHFFFAOYSA-N
D4IQ3K	Pitavastatin	Small molecule	Pitavastatin; Itavastatin; 147511-69-1; Livalo; Pitavastatin [INN]; Pitavastatin calcium; NK 104; NK-104; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; CHEBI:32020; M5681Q5F9P; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; NSC-760423; P-872441; (3R,5S,6E)-7-(2-Cyclopropyl-4-(p-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)-; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (3R,5S,6E)-; pitavastatia; pitavastatine; pitavastatinum; Itavastin; UNII-M5681Q5F9P; (3r,5s,6e)-7-[2-cyclopropyl-4-(p-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid; 121659-03-8; P 872441; NIKITA; PITAVASTATIN [MI]; SCHEMBL3369; PITAVASTATIN [VANDF]; PITAVASTATIN [MART.]; MLS006010096; PITAVASTATIN [WHO-DD]; SCHEMBL464781; GTPL3035; CHEMBL1201753; DTXSID1048384; BDBM86707; HSDB 8367; HY-B0144A; AKOS005145916; AM84440; DB08860; NSC 760423; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (S-(R*,S*-(E)))-; SMR003965244; CAS_147511-69-1; EN300-25660282; Q412677; BRD-K75958547-001-01-2; (3R,5S)-3,5-Dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-6-heptenoic acid; (+)-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy hept-6-enoic acid; (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; (E)-(3R,5S)-7-[2-Cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid; (e)-(3r,5s)-7-[2-cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6enoic acid; E-(3R,5S)-7-[2-Cyclopropyl-4-(4fluoro-phenyl)quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid	Approved	Approved Drug(s)	5282452	DB08860	D0G1WL	421.5	90.6	631	3.5	31	3	6	8	C25H24FNO4	(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid	C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F	C1CC1C2=NC3=CC=CC=C3C(=C2/C=C/[C@H](C[C@H](CC(=O)O)O)O)C4=CC=C(C=C4)F	InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1	VGYFMXBACGZSIL-MCBHFWOFSA-N
D70SDV	Rifampin	Small molecule	Rifampicin; rifampin; Rifadin; Rimactan; Rimactane; Rifamycin AMP; 13292-46-1; Rifaldazine; Rifaprodin; Rifoldin; Rifa; Rifampicinum; Riforal; Tubocin; L-5103 Lepetit; R/AMP; Archidyn; Rifadine; Rifaldin; Rifoldine; Rimactizid; Abrifam; Eremfat; Rifagen; Rimazid; Rifampicin SV; Arficin; Benemicin; Doloresum; Fenampicin; Rifaldazin; Rifamor; Rifobac; Sinerdol; Arzide; Rifcin; Rifam; Dione 21-acetate; Rifinah; Rimactazid; Ba 41166/E; Rifampicine [French]; Rifampicina; Rifapiam; Rifampicinum [INN-Latin]; Rifampicina [INN-Spanish]; BA-41166E; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; CCRIS 551; Rifadin I.V.; NSC-113926; HSDB 3181; Rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)-; L-5103; NSC113926; VJT6J7R4TR; Rifampicine; L-5103-LEPETIT; RFP; CHEBI:28077; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; NIH-10782; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; Rifamycin, 3-[[(4-methyl-1-piperazinyl)imino]methyl]-; Rifomycin SV, 8-(N-(4-methyl-1-piperazinyl)formidoyl)-; [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate; RIF; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),1(29),2,4,9,19,21,25,27-nonaen-13-yl acetate; 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione 21-acetate; Rifampin [USAN]; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; DTXSID6021244; rifamcin; [1,11,13]trienimino)naphto[2,1-b]furan-21-yl acetate; Rifomycin sv, 8-[N-(4-Methyl-1-piperazinyl)formidoyl]-; Rifamsolin; Rifampicin [INN:BAN:JAN]; Famcin; Rimactane (TN); AZT + Rifampin; Rifampin (USP); (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-Pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[[(4-methylpiperazin-1-yl)imino]methyl]-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acet; (2S,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-Pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; [pentahydroxy-methoxy-heptamethyl-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-dioxo-[?]yl] acetate; 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate; Rifampicin & EEP; Prestwick_833; EINECS 236-312-0; R-Cin; Rifadin (TN); MFCD00151389; NSC 113926; Piperine & Rifampicin; Rifampicin & Propolis; Reserpine & Rifampicin; RIFAMPIN [HSDB]; Rifampin [USAN:USP]; RIFAMPIN [MI]; RIFAMPICIN [INN]; RIFAMPICIN [JAN]; RIFAMPIN [VANDF]; Prestwick2_000525; Prestwick3_000525; Spectrum5_002018; UNII-VJT6J7R4TR; RIFAMPICIN [IARC]; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; Rifampicin (JP17/INN); 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; RIFAMPICIN [MART.]; RIFAMYCIN AMP [MI]; RIFAMPICIN [WHO-DD]; RIFAMPICIN [WHO-IP]; SCHEMBL23490; BSPBio_000509; RIFAMPIN [ORANGE BOOK]; 8CI); BPBio1_000561; CHEMBL374478; RIFAMPICIN [EP IMPURITY]; RIFAMPIN [USP MONOGRAPH]; RIFATER COMPONENT RIFAMPIN; RIFAMPICIN [EP MONOGRAPH]; RIFAMATE COMPONENT RIFAMPIN; Rifampin, Molecular Biology Grade; HMS1569J11; HMS2089F12; HMS2096J11; HMS3713J11; 845504-52-1; DRG-0109; Rifampicin, >=97.0% (HPLC); RIFAMPICINUM [WHO-IP LATIN]; Rifampicin, powder, gamma-irradiated; RIFAMPIN COMPONENT OF RIFATER; Ba 41166; BDBM50370232; GR-306; RIFAMPIN COMPONENT OF RIFAMATE; AKOS015951372; Rifampicin - CAS 13292-46-1; Rifampicin, >=97% (HPLC), powder; BA 411661E; BA-41166/E; CCG-208267; DB01045; NCGC00022678-03; NCGC00022678-04; NCGC00022678-05; NCGC00022678-06; 2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-, 21-acetate; C06688; D00211; Rifampicin, VETRANAL(TM), analytical standard; AB00383022_07; SR-05000002118; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; SR-05000002118-3; WLN: V1 WQ A&1 E&1 E1UN- AT6N DNTJ D1; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; 3-(((4-METHYL-1-PIPERAZINYL)IMINO)METHYL)RIFAMYCIN; Rifampicin, European Pharmacopoeia (EP) Reference Standard; Rifampin, United States Pharmacopeia (USP) Reference Standard; Rifampin, Pharmaceutical Secondary Standard; Certified Reference Material; Rifampicin, plant cell culture tested, BioReagent, >=97% (HPLC), crystalline; yl]-, (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl ac; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11- methoxy-3,7,12,14,16,18,22-heptamethyl-26-{(E)-[(4-methylpiperazin-1-yl)imino] methyl}-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1 (28),2,4,9,19,21,25(29),26-octaen-13-yl acetate; 2,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-, 21-acetate; 2,7-(epoxy[1,11,13]pentadecatrienoimino)naphtho[2,1-b]furan-1,11(2H)-dione, 21-(acetyloxy)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[(E)-[(4-methyl-1-piperazinyl)imino]meth; 2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-, 21-acetate (; 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-beta)furan-1,11(2H)-dione 21-acetate; 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-, 21-acetate; Rifampicin in combination with actinonin, BB-3497, hydroxylamine hydrochloride, and 1,10-phenanthroline; Stereoisomer of 5,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-he@ptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate	Approved	Approved Drug(s)	135398735	DB01045	D0G3DL	822.9	220	1620	4.9	59	6	15	5	C43H58N4O12	[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate	CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C	C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C	InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1	JQXXHWHPUNPDRT-WLSIYKJHSA-N
DP9NX3	Doxercalciferol	Small molecule	Doxercalciferol; 54573-75-0; Hectorol; 1-Hydroxyergocalciferol; 1alpha-Hydroxyergocalciferol; TSA 840; 1alpha-hydroxyvitamin D2; 1-alpha-Hydroxyvitamin D2; 1-alpha-hydroxyergocalciferol; 1-Hydroxyvitamin D2; 1.alpha.-Hydroxyvitamin D2; 1alpha-OH-D2; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; 3DIZ9LF5Y9; (1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol; CHEBI:4712; 1-.alpha.-hydroxyergocalciferol; TSA-840; GZ427397; Doxercalciferol [INN]; 1alpha-hydroxyvitamin D2 / 1alpha-hydroxyergocalciferol; (5Z,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3-diol; Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol; Vitamin D2, 1alpha-Hydroxy-; UNII-3DIZ9LF5Y9; DTXSID1034214; BRN 4716774; Doxercalciferol [USAN:INN]; Doxercalciferolum; 1alphaOHD2; MFCD00871065; 1a-hydroxyvitamin D2; 1alpha-hydroxy vitamin D2; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; Vitamin D2, 1a-Hydroxy-; 1-alpha-hydroxy-vitamin D2; DOXERCALCIFEROL [MI]; Doxercalciferol (USAN/INN); DOXERCALCIFEROL [USAN]; SCHEMBL322422; 1.alpha.-hydroxyergocalciferol; DOXERCALCIFEROL [VANDF]; GTPL2790; DOXERCALCIFEROL [MART.]; 1-ALPHA-HYDROXYVITAMIND2; CHEMBL1200810; DOXERCALCIFEROL [USP-RS]; DOXERCALCIFEROL [WHO-DD]; ACT06836; EX-A4428; DOXERCALCIFEROL [ORANGE BOOK]; HSCI1_000341; LMST03010028; AKOS005146517; CS-0395; DB06410; DOXERCALCIFEROL [USP MONOGRAPH]; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1-alpha,3-beta,5Z,7E,22E)-; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1.alpha.,3.beta.,5Z,7E,22E)-; BS-17040; HY-32348; 1a-HYDROXYERGOCALCIFEROL (ERCALCIDOL); C08211; D01009; D82103; EN300-26545978; Q5303688; Doxercalciferol, >=98% (HPLC), solubility: >10 mg/mL in DMSO; Doxercalciferol, United States Pharmacopeia (USP) Reference Standard; (5Z,7E,22E)-9,10-SECOERGOSTA-5,7,10(19),22-TETRAENE-1.ALPHA.,3.BETA.-DIOL; 7,10(19),22-TETRAENE-1,3-DIOL,(1-ALPHA,3-BETA,5Z,7E,22E)-10-SECOERGOSTA-5; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1alpha,3beta,5Z,7E,22E)-; (1R,3S,5Z)-4-Methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-7?-methyl-1-[(1R,2E)-1,4,5-trimethyl-2-hexen-1-yl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol; (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol; (1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol; (1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5R,E)-5,6-Dimethylhept-3-en-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol; 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-((2E)-2-((1R,3AS,7AR)-OCTAHYDRO-7A-METHYL-1-((1R,2E)-1,4,5-TRIMETHYL-2-HEXEN-1-YL)-4H-INDEN-4-YLIDENE)ETHYLIDENE)-, (1R,3S,5Z)-	Approved	Approved Drug(s)	5281107	DB06410	D0G5CF	412.6	40.5	712	6.3	30	2	2	5	C28H44O2	(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol	CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C	C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C	InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1	HKXBNHCUPKIYDM-CGMHZMFXSA-N
DPJM91	Calcifediol	Small molecule	Calcifediol; Calcidiol; 25-hydroxyvitamin D3; 19356-17-3; 25-Hydroxycholecalciferol; Calcifediol anhydrous; Hidroferol; Calderol; Didrogyl; Calcifediolum; Rayaldee; Ro 8-8892; 5,6-cis-25-Hydroxyvitamin D3; Calcifediol [INN]; Cholecalciferol, 25-hydroxy-; CHEBI:17933; T0WXW8F54E; (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol; 3-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANOL; Calcifidiol; Delakmin; 25-Hydroxy vitamin D3; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol; U-32070E; U 32070 E; 25-hydroxyvitamin D3 / 25-hydroxycholecalciferol / calcidiol; 25-Hydroxycholescalciferol; Calcifediolum [INN-Latin]; Rovimix Hy-D; (3b,5Z,7E)- 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol; Hy-D; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; 36149-00-5; 25-(OH)Vitamin D3; 5,6-trans-25-Hydroxycholescalciferol; UNII-T0WXW8F54E; DTXSID0022721; Ryaldee; BML2-E02; (5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol; NCGC00161326-04; 25(OH)D3; EINECS 242-990-9; MFCD00867077; U 32070E; CALCIFEDIOL [MI]; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 5,6-trans-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; Spectrum5_001931; 25-hydroxy-cholecalciferol; Vitamin D, 25-hydroxy-; CALCIFEDIOL,ANHYDROUS; SCHEMBL3296; CHEMBL1040; BSPBio_001411; CALCIFEDIOL, ANHYDROUS; (3S,5Z,7E)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol; GTPL6921; CHEBI:94743; AMY2863; BCPP000306; DM100; HMS1361G13; HMS1791G13; HMS1989G13; HMS2089L21; HMS3402G13; ACT06833; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)-; BDBM50521013; CALCIFEDIOL,ANHYDROUS [VANDF]; LMST03020246; s1469; AKOS015965097; BCP9000472; CCG-268657; CS-0800; DB00146; IDI1_033881; NCGC00161326-01; AC-31367; HY-32351; 25-Hydroxycholecalciferol, >=98% (HPLC); C01561; AB01275461-01; AB01275461_02; EN300-7413489; A923587; Q139307; SR-05000001468; SR-05000001468-1; W-201718; 25-Hydroxyvitamin D3 monohydrate, >=99.0% (HPLC); 9,10-Secocholesta-5,7,10(19)-triene-3b,25-diol; BRD-K77175907-001-01-5; B91135EC-8937-4D8B-A533-CCD82F33C1B0; Calcifediol, European Pharmacopoeia (EP) Reference Standard; (5E,7E)-9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol; Calcifediol, United States Pharmacopeia (USP) Reference Standard; (5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-3b,25-diol monohydrate; 9,10-Secocholesta-5,7,10(19)-triene-1,25-diol, (3.beta,.5Z,7E)-; (?R,1R,3aS,4E,7aR)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-?,?,?,7a-tetramethyl-1H-indene-1-pentanol; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-5-hydroxy-1,5-dimethyl-hexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol; (S,Z)-3-((E)-2-((1R,3aS,7aR)-1-((R)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-4-methylenecyclohexanol; 1H-Indene-1-pentanol, octahydro-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]-.alpha.,.alpha.,.epsilon.,7a-tetramethyl-, (.epsilon.R,1R,3aS,4E,7aR)-; 64719-49-9	Approved	Approved Drug(s)	5283731	DB00146	D0G5GY	400.6	40.5	655	6.2	29	2	2	6	C27H44O2	(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol	CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C	InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1	JWUBBDSIWDLEOM-DTOXIADCSA-N
DTF2G1	Methylene blue	Small molecule	methylene blue; 61-73-4; Basic blue 9; Methylthioninium chloride; Solvent blue 8; Swiss Blue; Chromosmon; Methylene Blue anhydrous; Methylene Blue N; Methylene Blue BB; 3,7-Bis(dimethylamino)phenothiazin-5-ium chloride; C.I. Basic Blue 9; Methylenium ceruleum; Tetramethylthionine chloride; Bleu de methylene; Methylene Blue chloride; Methylthionine chloride; External Blue 1; Methylene Blue A; Methylene Blue B; Methylene Blue D; Methylene Blue G; Calcozine Blue ZF; Methylene Blue BD; Methylene Blue BP; Methylene Blue BX; Methylene Blue BZ; Methylene Blue FZ; Methylene Blue GZ; Methylene Blue NZ; Methylene Blue SG; Methylene Blue SP; Methylene Blue ZF; Methylene Blue ZX; Tetramethylene Blue; Methylene Blue 2B; Methylene Blue BBA; Methylene Blue BPC; Methylene Blue HGG; Methylene Blue IAD; Methylene Blue JFA; Sandocryl Blue BRL; Methylenblau; Methylene Blue 2BF; Methylene Blue 2BN; Methylene Blue 2BP; M-B Tabs; Rember; Mitsui Methylene Blue; Methylthionium chloride; Leather Pure Blue HB; Modr methylenova; Schultz No. 1038; Aizen Methylene Blue BH; Aizen Methylene Blue FZ; Methylene Blue Zinc Free; C.I. 52015; Yamamoto Methylene Blue B; D And C Blue Number 1; Methylene Blue (Medicinal); Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride; Yamamoto Methylene Blue ZF; Ext D and C Blue No. 1; Methylene Blue I (Medicinal); Cloruro de metiltioninio; Methylene Blue NF (Medicinal); Methylthioninii chloridum; Hidaco Methylene Blue Salt Free; Methylene Blue BB (Zinc Free); Methylene Blue USP (Medicinal); Lowacryl blue 9; Chlorure de methylthioninium; 3,7-Bis(dimethylamino)phenazathionium chloride; 105504-42-5; Methylene Blue Chloride (Biological stain); X 138; Methylene Blue USP XII (Medicinal); MFCD00012111; 12262-49-6; CI 52015; CI-52015; 8NAP7826UB; CHEBI:6872; Methylthioninium chloride [INN]; DTXSID0023296; [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride; Urolene blue; Provayblue; NSC-215213; NSC-617593; azul de metileno; N-[7-(dimethylamino)-3H-phenothiazin-3-ylidene]-N-methylmethanaminium chloride; Ceruleum methylenum; Methylenum coeruleum; CI Basic Blue 9; DTXCID803296; Zinc free Methylene Blue; Caswell No. 567; Methylenblau [German]; Methylthionini chloridum; 3H-Phenothiazine, 3-methochloride; Trx0014; Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride (1:1); Modr Methylenova [Czech]; CHEMBL405110; Modr zasadita 9; Modr Zasadita 9 [Czech]; CAS-61-73-4; N-(7-(dimethylamino)-3H-phenothiazin-3-ylidene)-N-methylmethanaminium chloride; NSC3089; 152071-32-4; CCRIS 833; Metiltioninio cloruro [DCIT]; Metiltioninio cloruro; Modr Rozpoustedlova 8 [Czech]; 3H-Phenothiazine, 7-(dimethylamino)-3-(methylimino)-, 3-methochloride; Modr rozpoustedlova 8; NSC215213; NSC617593; C.I. 52 015; HSDB 1405; NCGC00167496-01; NCGC00167496-03; Phenothiazin-5-ium,7-bis(dimethylamino)-, chloride; EINECS 200-515-2; Methylthioninii chloridum [INN-Latin]; EPA Pesticide Chemical Code 039505; NSC 215213; Cloruro de metiltioninio [INN-Spanish]; UNII-8NAP7826UB; WLN: T C666 BS EY INJ EUK1&1 MN1&1 &G &421; Chlorure de methylthioninium [INN-French]; Methylene blue usp; Methylene Azure II; Prestwick_326; CI NO 52015; Methylene Blue (Inhibitor); SCHEMBL1351; METHYLENE BLUE [MI]; MLS000719838; METHYLENE BLUE [HSDB]; BASIC BLUE 9 [INCI]; DOG (COUCH) GRASS Powder; HMS2598O03; Pharmakon1600-01505444; NSC-3089; TRX-0014; Tox21_112497; Tox21_302087; NSC759135; s4535; STK018918; AKOS000486124; AKOS015916406; Tox21_112497_1; CCG-267696; DB09241; 4-(1-HYDROXY-ETHYL)-BENZOICACID; METHYLTHIONINIUM CHLORIDE [MART.]; NCGC00255351-01; 97130-83-1; AC-15225; AS-35256; Basic Blue 9;Tetramethylthionine chloride; HY-14536; METHYLTHIONINIUM CHLORIDE [WHO-DD]; METHYLTHIONINIUM CHLORIDE PROVEBLUE; SMR000304367; SY076497; Methylthioninium Chloride (Methylene Blue); Methylene Blue (C.I. 52015) BioChemica; METHYLTHIONINIUM CHLORIDE [EMA EPAR]; A0574; FT-0622580; M0501; M2392; C00220; M-3598; METHYLTHIONINIUM CHLORIDE [EP IMPURITY]; EN300-6504462; 3,7-Bis(dimethylamino)-5-phenothiazinium Chloride; Q422134; METHYLTHIONINIUM CHLORIDE ANHYDROUS [WHO-IP]; 3,7-bis(dimethylamino)-phenothiazin-5-ium chloride salt; Z1954806063; METHYLTHIONINII CHLORIDUM ANHYDROUS [WHO-IP LATIN]; 3,7-bis(dimethylamino)-5lambda4-phenothiazin-5-ylium chloride; 3-N,3-N,7-N,7-N-tetramethylphenothiazin-5-ium-3,7-diamine;chloride; n-(7-(dimethylamino)-3h-phenothiazin-3-ylidene)-n-methylmethanaminiumchloride; 1341-90-8; 6476-03-5	Approved	Approved Drug(s)	6099	DB09241	D0G5TF	319.9	43.9	483	.	21	0	4	1	C16H18ClN3S	[7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride	CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-]	CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-]	InChI=1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1	CXKWCBBOMKCUKX-UHFFFAOYSA-M
D5VSR7	Zanubrutinib	Small molecule	Zanubrutinib; 1691249-45-2; Brukinsa; BGB-3111; Zanubrutinib [INN]; Zanubrutinib [USAN]; AG9MHG098Z; 1691249-45-2 (S-isomer); (S)-7-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide; BGB3111; (7S)-2-(4-Phenoxyphenyl)-7-(1-(prop-2-enoyl)piperidin-4-yl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide; (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide; (7S)-2-(4-PHENOXYPHENYL)-7-[1-(PROP-2-ENOYL)PIPERIDIN-4-YL]-4H,5H,6H,7H-PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE; (7S)-4,5,6,7-Tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; Pyrazolo(1,5-a)pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-, (7S)-; Brukinsa (TN); (7S)-2-(4-Phenoxyphenyl)-7-[1-(prop-2-enoyl)piperidin-4-yl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide; ZANUBRUTINIB [MI]; Zanubrutinib (USAN/INN); Zanubrutinib [USAN:INN]; UNII-AG9MHG098Z; BGB-3111(Zanubrutinib); Zanubrutinib (BGB-3111); ZANUBRUTINIB [WHO-DD]; GTPL9861; CHEMBL3936761; SCHEMBL17842597; BDBM250082; DTXSID701026208; ZANUBRUTINIB [ORANGE BOOK]; compound 27b [US9447106]; BCP29110; EX-A3602; NSC823807; s8791; AT18252; DB15035; HY-101474A; NSC-823807; US9447106, 27b (peak 2); BS-15529; BZ168474; CS-0021869; D11422; BGB-3111; BGB 3111; BGB3111; A934931; EN300-22831096; 1651179-04-2; 7-(1-acryloyl-4-piperidinyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide	Approved	Approved Drug(s)	135565884	DB15035	D0G5XV	471.5	103	756	3.5	35	2	5	6	C27H29N5O3	(7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide	C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N	C=CC(=O)N1CCC(CC1)[C@@H]2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N	InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1	RNOAOAWBMHREKO-QFIPXVFZSA-N
DFO32E	Viltolarsen	Small molecule	Viltolarsen; Viltepso; NCNP-01; GTPL11430; NS-065	Approved	Approved Drug(s)	154562176	DB15005	D0G6DR	6925	2230	21200	-33.1	465	29	149	122	C244H381N113O88P20	1-[(2R,6S)-6-[[[(2S,6R)-2-[[[(2R,6S)-2-(2-amino-6-oxo-1H-purin-9-yl)-6-[[[(2S,6R)-2-[[[(2R,6S)-2-(2-amino-6-oxo-1H-purin-9-yl)-6-[[[(2R,6S)-2-(2-amino-6-oxo-1H-purin-9-yl)-6-[[[(2S,6R)-2-[[[(2S,6R)-2-[[[(2R,6S)-2-(2-amino-6-oxo-1H-purin-9-yl)-6-[[[(2S,6R)-2-[[[(2S,6R)-2-[[[(2S,6R)-2-[[[(2S,6R)-2-[[[(2R,6S)-2-(2-amino-6-oxo-1H-purin-9-yl)-6-[[[(2R,6S)-2-(2-amino-6-oxo-1H-purin-9-yl)-6-[[[(2R,6S)-2-(4-amino-2-oxopyrimidin-1-yl)-6-[[[(2R,6S)-2-(4-amino-2-oxopyrimidin-1-yl)-6-[[[(2S,6R)-2-[[[(2R,6S)-2-(4-amino-2-oxopyrimidin-1-yl)-6-[[[(2R,6S)-2-(4-amino-2-oxopyrimidin-1-yl)-6-(hydroxymethyl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(5-methyl-2,4-dioxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(5-methyl-2,4-dioxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(5-methyl-2,4-dioxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(4-amino-2-oxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(5-methyl-2,4-dioxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(6-aminopurin-9-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(6-aminopurin-9-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(5-methyl-2,4-dioxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(5-methyl-2,4-dioxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-4-[[(2S,6R)-6-(4-amino-2-oxopyrimidin-1-yl)morpholin-2-yl]methoxy-(dimethylamino)phosphoryl]morpholin-2-yl]-5-methylpyrimidine-2,4-dione	CC1=CN(C(=O)NC1=O)C2CN(CC(O2)COP(=O)(N3CC(OC(C3)N4C=C(C(=O)NC4=O)C)COP(=O)(N5CC(OC(C5)N6C=NC7=C6N=C(NC7=O)N)COP(=O)(N8CC(OC(C8)N9C=C(C(=O)NC9=O)C)COP(=O)(N1CC(OC(C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1CC(OC(C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1CC(OC(C1)N1C=NC2=C(N=CN=C21)N)COP(=O)(N1CC(OC(C1)N1C=NC2=C(N=CN=C21)N)COP(=O)(N1CC(OC(C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1CC(OC(C1)N1C=C(C(=O)NC1=O)C)COP(=O)(N1CC(OC(C1)N1C=CC(=NC1=O)N)COP(=O)(N1CC(OC(C1)N1C=C(C(=O)NC1=O)C)COP(=O)(N1CC(OC(C1)N1C=C(C(=O)NC1=O)C)COP(=O)(N1CC(OC(C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1CC(OC(C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1CC(OC(C1)N1C=CC(=NC1=O)N)COP(=O)(N1CC(OC(C1)N1C=CC(=NC1=O)N)COP(=O)(N1CC(OC(C1)N1C=C(C(=O)NC1=O)C)COP(=O)(N1CC(OC(C1)N1C=CC(=NC1=O)N)COP(=O)(N1CC(OC(C1)N1C=CC(=NC1=O)N)CO)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)P(=O)(N(C)C)OCC1CNCC(O1)N1C=CC(=NC1=O)N	CC1=CN(C(=O)NC1=O)[C@H]2CN(C[C@H](O2)COP(=O)(N3C[C@H](O[C@H](C3)N4C=C(C(=O)NC4=O)C)COP(=O)(N5C[C@H](O[C@H](C5)N6C=NC7=C6N=C(NC7=O)N)COP(=O)(N8C[C@H](O[C@H](C8)N9C=C(C(=O)NC9=O)C)COP(=O)(N1C[C@H](O[C@H](C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1C[C@H](O[C@H](C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1C[C@H](O[C@H](C1)N1C=NC2=C(N=CN=C21)N)COP(=O)(N1C[C@H](O[C@H](C1)N1C=NC2=C(N=CN=C21)N)COP(=O)(N1C[C@H](O[C@H](C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1C[C@H](O[C@H](C1)N1C=C(C(=O)NC1=O)C)COP(=O)(N1C[C@H](O[C@H](C1)N1C=CC(=NC1=O)N)COP(=O)(N1C[C@H](O[C@H](C1)N1C=C(C(=O)NC1=O)C)COP(=O)(N1C[C@H](O[C@H](C1)N1C=C(C(=O)NC1=O)C)COP(=O)(N1C[C@H](O[C@H](C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1C[C@H](O[C@H](C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1C[C@H](O[C@H](C1)N1C=CC(=NC1=O)N)COP(=O)(N1C[C@H](O[C@H](C1)N1C=CC(=NC1=O)N)COP(=O)(N1C[C@H](O[C@H](C1)N1C=C(C(=O)NC1=O)C)COP(=O)(N1C[C@H](O[C@H](C1)N1C=CC(=NC1=O)N)COP(=O)(N1C[C@H](O[C@H](C1)N1C=CC(=NC1=O)N)CO)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)P(=O)(N(C)C)OC[C@@H]1CNC[C@@H](O1)N1C=CC(=NC1=O)N	InChI=1S/C244H381N113O88P20/c1-140-62-343(238(378)290-213(140)359)180-94-322(447(386,298(10)11)405-110-147-60-259-61-174(425-147)337-54-48-168(245)272-232(337)372)74-153(431-180)117-412-454(393,305(24)25)325-78-157(435-183(97-325)346-65-143(4)216(362)293-241(346)381)119-414-460(399,311(36)37)331-84-163(441-189(103-331)352-134-266-197-207(352)278-226(253)284-220(197)366)125-418-457(396,308(30)31)328-80-159(437-186(100-328)349-68-146(7)219(365)296-244(349)384)121-416-462(401,313(40)41)333-87-167(445-191(105-333)354-136-268-199-209(354)280-228(255)286-222(199)368)129-424-465(404,316(46)47)336-88-165(443-194(108-336)357-139-271-202-212(357)283-231(258)289-225(202)371)127-422-459(398,310(34)35)330-81-160(438-188(102-330)351-133-265-196-204(252)261-131-263-206(196)351)122-420-458(397,309(32)33)329-82-161(439-187(101-329)350-132-264-195-203(251)260-130-262-205(195)350)123-421-463(402,314(42)43)334-85-164(442-193(106-334)356-138-270-201-211(356)282-230(257)288-224(201)370)126-419-456(395,307(28)29)327-76-155(433-185(99-327)348-67-145(6)218(364)295-243(348)383)116-411-450(389,301(16)17)320-73-152(430-178(92-320)341-58-52-172(249)276-236(341)376)114-409-453(392,304(22)23)324-77-156(434-182(96-324)345-64-142(3)215(361)292-240(345)380)118-413-455(394,306(26)27)326-79-158(436-184(98-326)347-66-144(5)217(363)294-242(347)382)120-415-461(400,312(38)39)332-86-166(444-190(104-332)353-135-267-198-208(353)279-227(254)285-221(198)367)128-423-464(403,315(44)45)335-83-162(440-192(107-335)355-137-269-200-210(355)281-229(256)287-223(200)369)124-417-451(390,302(18)19)321-71-150(428-179(93-321)342-59-53-173(250)277-237(342)377)112-407-448(387,299(12)13)318-72-151(429-177(90-318)340-57-51-171(248)275-235(340)375)113-408-452(391,303(20)21)323-75-154(432-181(95-323)344-63-141(2)214(360)291-239(344)379)115-410-449(388,300(14)15)319-70-149(427-176(91-319)339-56-50-170(247)274-234(339)374)111-406-446(385,297(8)9)317-69-148(109-358)426-175(89-317)338-55-49-169(246)273-233(338)373/h48-59,62-68,130-139,147-167,174-194,259,358H,60-61,69-129H2,1-47H3,(H2,245,272,372)(H2,246,273,373)(H2,247,274,374)(H2,248,275,375)(H2,249,276,376)(H2,250,277,377)(H2,251,260,262)(H2,252,261,263)(H,290,359,378)(H,291,360,379)(H,292,361,380)(H,293,362,381)(H,294,363,382)(H,295,364,383)(H,296,365,384)(H3,253,278,284,366)(H3,254,279,285,367)(H3,255,280,286,368)(H3,256,281,287,369)(H3,257,282,288,370)(H3,258,283,289,371)/t147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191+,192+,193+,194+,446?,447?,448?,449?,450?,451?,452?,453?,454?,455?,456?,457?,458?,459?,460?,461?,462?,463?,464?,465?/m0/s1	ZVXLKCOOOKREJD-OERAVCCFSA-N
DF0Z5B	Ibrutinib	Small molecule	Ibrutinib; 936563-96-1; PCI-32765; IMBRUVICA; PCI 32765; Ibrutinib (PCI-32765); PCI-32765 (Ibrutinib); CRA-032765; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; Pc-32765; 1X70OSD4VX; PCI-32765-00; CHEBI:76612; PCI32765; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; 1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one; 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-; C25H24N6O2; (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo-[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.; 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1- yl)prop-2-en-1-one; Ibrutinib [USAN]; Ibrutinib [USAN:INN]; UNII-1X70OSD4VX; ibrutinibum; JNJ 02; Imbruvica (TN); Ibrutinib- Bio-X; 1-{(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1- yl}prop-2-en-1-one; CRA 032765; Ibrutinib, Free Base; IBRUTINIB [INN]; IBRUTINIB [JAN]; IBRUTINIB [MI]; Ibrutinib (JAN/USAN); IBRUTINIB [VANDF]; IBRUTINIB [WHO-DD]; Imbruvica; PCI-32765; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; MLS006010041; SCHEMBL201859; GTPL6912; IBRUTINIB [ORANGE BOOK]; CHEMBL1873475; HSDB 8260; DTXSID60893450; EX-A066; AMY27873; BDBM50357312; MFCD20261150; NSC800769; AKOS022185476; DB09053; EX-5960; NSC-800769; NCGC00187912-01; NCGC00187912-02; NCGC00187912-03; NCGC00187912-12; AC-26942; BI164531; HY-10997; SMR004701213; SW218096-2; EN300-97039; D10223; A1-01649; J-523872; Q5984881; Z1302446275; (R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-ylprop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one1-[(3R)-3-[4-AMino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyriMidin-1-yl]; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IbrutinibCI-32765mbruvica(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; piperidin-1-yl]prop-2-en-1-one1-{3-[4-AMino-3-(4-phenoxy-phenyl)-pyrazolo[3,4-d]pyriMidin-1-yl]-piperidin-1-yl}-propenone	Approved	Approved Drug(s)	24821094	DB09053	D0G6JU	440.5	99.2	678	3.6	33	1	6	5	C25H24N6O2	1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one	C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N	C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N	InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1	XYFPWWZEPKGCCK-GOSISDBHSA-N
DB67QR	Delavirdine	Small molecule	Delavirdine; 136817-59-9; Delavirdine [INN]; N-(2-(4-(3-(Isopropylamino)pyridin-2-yl)piperazine-1-carbonyl)-1H-indol-5-yl)methanesulfonamide; u-90152; U 90152; Delavirdine (INN); 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine; N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide; DOL5F9JD3E; 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; DLV; CHEMBL593; DTXSID6022892; CHEBI:119573; (1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE; N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide; NCGC00168776-01; BHAP-U 90152; U 90152;BHAP-U 90152; (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; N-[2-(4-{3-[(propan-2-yl)amino]pyridin-2-yl}piperazine-1-carbonyl)-1H-indol-5-yl]methanesulfonamide; N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; DTXCID302892; UNII-DOL5F9JD3E; Rescriptor (TM); N-[2-[4-[3-(isopropylamino)-2-pyridyl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide; CAS-136817-59-9; C22H28N6O3S; Delavirdine (*Mesylate salt*); SR-05000001471; U90152S (*Mesylate salt*); PNU-90152-T; Delavirdine(U-90152) & .a.IFN; DELAVIRDINE [MI]; DELAVIRDINE [VANDF]; SCHEMBL34420; DELAVIRDINE [WHO-DD]; BDBM1944; HMS2089F20; HMS3713A14; BCP08068; Tox21_112637; AKOS015965076; Tox21_112637_1; CS-1660; DB00705; DT-0031; NCGC00168776-02; NCGC00168776-03; NCGC00168776-10; HY-10571; N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide; FT-0603115; C06941; D07782; AB01275468-01; EN300-7442125; Q370244; J-006916; SR-05000001471-1; N-{2-[(4-{3-[(propan-2-yl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide; Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]- & alpha-Interferon	Approved	Approved Drug(s)	5625	DB00705	D0G6SD	456.6	119	749	2.4	32	3	7	6	C22H28N6O3S	N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide	CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C	CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C	InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3	WHBIGIKBNXZKFE-UHFFFAOYSA-N
DO8Z3A	Meloxicam	Small molecule	meloxicam; 71125-38-7; Mobic; Metacam; Movalis; Movatec; Mobec; Mobicox; Meloxicam (Mobic); UH-AC 62XX; Meloxivet; Coxicam; Melfax; Parocin; Meloxicamum [Latin]; 4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide; Meloxicamum; Meloxidolor; Melosus; Meloxoral; Rheumocam; Vivlodex; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; RevitaCAM; Acticam; Contacera; Emdocam; Flexicam; Inflacam; Loxicom; Melovem; Meloxidyl; Recocam; C14H13N3O4S2; UNII-VG2QF83CGL; UHAC-62XX; VG2QF83CGL; CHEMBL599; UH-AC-62 XX; 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; MLS000028587; CHEBI:6741; DTXSID1020803; N-1539; NCGC00018248-04; Meloxicam 100 microg/mL in Acetonitrile; SMR000058994; N1539; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1$l^{6},2-benzothiazine-3-carboxamide; DTXCID70803; Revmoksikam; Coxflam; Melonex; Tenaron; (3E)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1lambda6,2-benzothiazin-4-one; CAS-71125-38-7; CCRIS 9139; HSDB 7741; Meloxicam [USAN:USP:INN:BAN]; Meloxicam,(S); 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1?^{6},2-benzothiazine-3-carboxamide; MFCD00868752; ANJESO; Mobic (TN); Opera_ID_2; QMIIZ ODT; Spectrum_001633; MELOXICAM [INN]; MELOXICAM [JAN]; MELOXICAM [MI]; MELOXICAM [HSDB]; MELOXICAM [USAN]; Spectrum2_000941; Spectrum3_000649; Spectrum4_000787; Spectrum5_001813; MELOXICAM [VANDF]; Meloxicam impurity standard; MELOXICAM [MART.]; MELOXICAM [USP-RS]; MELOXICAM [WHO-DD]; SCHEMBL3576; Meloxicam (JAN/USP/INN); Lopac0_000766; SCHEMBL33369; BSPBio_002257; KBioGR_001234; KBioSS_002113; MLS001304725; MLS001306413; MLS006011422; BIDD:GT0726; SCHEMBL713100; SPECTRUM1504150; SPBio_000902; MELOXICAM [GREEN BOOK]; GTPL7220; MELOXICAM [ORANGE BOOK]; CHEMBL1741042; MELOXICAM [EP MONOGRAPH]; SCHEMBL23589638; KBio2_002113; KBio2_004681; KBio2_007249; KBio3_001477; ETI-511; MELOXICAM [USP MONOGRAPH]; ZELERIS COMPONENT MELOXICAM; HMS1922D19; HMS2089B18; HMS2096I19; HMS2234P07; HMS2236C09; HMS3259H06; HMS3372C13; HMS3372P18; HMS3655K06; HMS3713I19; HMS3744K09; HMS3884G08; ZYNRELEF COMPONENT MELOXICAM; ALBB-027268; AMY40407; BCP11928; HY-B0261; Tox21_111734; Tox21_113192; Tox21_201689; Tox21_302756; BBL029076; BDBM50056998; CCG-39098; HSCI1_000045; s1734; STK620505; Meloxicam - CAS 71125-38-7; MELOXICAM COMPONENT OF ZELERIS; AKOS000279442; AKOS026749959; MELOXICAM COMPONENT OF ZYNRELEF; Tox21_111734_1; AC-1325; DB00814; KS-1084; MELOXICAM [EMA EPAR VETERINARY]; NC00698; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide; SMP2_000133; NCGC00018248-01; NCGC00018248-02; NCGC00018248-03; NCGC00018248-05; NCGC00018248-06; NCGC00018248-07; NCGC00018248-08; NCGC00018248-10; NCGC00018248-23; NCGC00018248-25; NCGC00018248-26; NCGC00022924-03; NCGC00022924-04; NCGC00256316-01; NCGC00259238-01; NCGC00263878-02; (E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2,3-dihydro-4H-benzo[e][1,2]thiazin-4-one 1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide; BH164661; SMR000718800; Meloxicam 1000 microg/mL in Acetonitrile; DB-055490; Meloxicam 1.0 mg/ml in Dimethyl Sulfoxide; FT-0628193; M1959; SW219562-1; EN300-52507; C08169; D00969; F20356; AB00383033-17; AB00383033-18; AB00383033_20; A837087; AN-668/13244001; Q414028; SR-01000003132-10; F2173-0387; Z1695493323; 4-hydroxy-2-methyl-N-(5-methy-2-thiazolyl)-2H-1,2-benzothiazine-3-caboxamide-1,1-dioxide; (3Z)-2-methyl-3-[[(5-methyl-1,3-thiazol-2-yl)amino]-oxidanyl-methylidene]-1,1-bis(oxidanylidene)-1$l^{6},2-benzothiazin-4-one; (3Z)-3-[hydroxy-[(5-methyl-2-thiazolyl)amino]methylidene]-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazin-4-one; 133687-22-6; 3-{hydroxy[(5-methyl-1,3-thiazol-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1lambda6,2-benzothiazine-1,1,4-trione; 4-Hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide; 4-Hydroxy-2-methyl-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-2-thiazole)-2H-1,2-benzothiazine-3 -carboxamide 1,1-dioxide; 4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide1,1-dioxide	Approved	Approved Drug(s)	54677470	DB00814	D0G7FJ	351.4	136	628	3	23	2	7	2	C14H13N3O4S2	4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide	CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O	CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O	InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)	ZRVUJXDFFKFLMG-UHFFFAOYSA-N
D2K0WC	Cyclosporin A	Small molecule	cyclosporin A; cyclosporine; Ciclosporin; 59865-13-3; Sandimmune; Cyclosporine A; Neoral; Cyclosporin; Sandimmun; Ramihyphin A; Ciclosporine; Equoral; Gengraf; Neoplanta; Sang-35; Ciclosporinum; Sandimmun Neoral; Zinograf ME; Ciclosporina; Consupren; Mitogard; Optimmune; Ciclosporin A; NeuroSTAT; Atopica; Antibiotic S 7481F1; Ciclosporin [INN]; SangCyA; Cyclosporine microemulsion; CSA; 83HN0GTJ6D; SDZ-OXL-400; MLS001333756; CHEBI:4031; ANTIBIOTIC S-7481F1; DTXSID0020365; S-Neoral; Cipol N; Sigmasporin Microoral; NSC-290193; OL-27-400; MFCD00274558; Ciclosporin (Ciclosporin A); (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; SDZ-OXL 400; DTXCID00365; OL 27-400; Abrammune; Imusporin; Seciera; Vekacia; Papilock Mini; Arpimune ME; Sandimmune Neoral; Ciclosporina Germed; Cyclosporine;Ciclosporin; (R-(R*,R*-(E)))-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl); CYA; Cyclo(((E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl); SMR000058578; Cicloral (antibiotic); Cyclosporine [USAN]; Debio088; Sang 35; Cyclosporine [USAN:USP]; UNII-83HN0GTJ6D; Ciclosporine [INN-French]; Ciclosporinum [INN-Latin]; Ciclosporina [INN-Spanish]; Cyclospori; Sigmasporin; Cyclokat; Ikervis; Papilock; Pulminiq; Zyclorin; CicloMulsion; Ciclosporin;; CCRIS 1590; Ciclosporin DT; Consupren S; NSC290193; Modusik-A; HSDB 6881; 1cyn; 2wfj; 4jjm; Cipol-N; NCGC00016890-01; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,2; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19; (R-[R*,R*-(E)])-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl); Cyclo[[(E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl]; DRG-0275; Prestwick_731; CAS-59865-13-3; CEQUA; VERKAZIA; NSC 290193; CsA & IFN.alpha.; 1c5f; 2z6w; S 7481F1; Cyclosporine manufacturer; Prestwick2_000435; Prestwick3_000435; CICLOSPORIN [JAN]; CHEMBL160; Sang-2000; CYCLOSPORINE [HSDB]; CYCLOSPORINE [IARC]; CYCLOSPORIN A [MI]; SCHEMBL3491; SCHEMBL4442; CICLOSPORIN [MART.]; CYCLOSPORINE [VANDF]; Nova-22007; BSPBio_000450; CICLOSPORIN [WHO-DD]; CICLOSPORIN [WHO-IP]; Cyclosporin A & IFN.alpha.; MLS000028376; MLS002153454; MLS002207033; CYCLOSPORINE [USP-RS]; BPBio1_000496; GTPL1024; CHEBI:92233; ATH-002; CYCLOSPORINE [GREEN BOOK]; OLO-400; CB-01-09 MMX; CICLOSPORIN [EP MONOGRAPH]; CYCLOSPORINE [ORANGE BOOK]; HMS1569G12; HMS2089A09; HMS2096G12; HMS2230M14; HMS3713G12; CYCLOSPORINE [USP IMPURITY]; 1,11-cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(E)-(2S,3R,4R)-2-amino-3-hydroxy-N,4-dimethyloct-6-enoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine]; 30-Ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone; 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl)-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl); EX-A4110; HY-B0579; CYCLOSPORINE [USP MONOGRAPH]; Tox21_110667; Tox21_301849; BDBM50022815; CICLOSPORINUM [WHO-IP LATIN]; DE-076; ST-603; Cyclosporin A, >=98.5% (TLC); AKOS015969287; Tox21_110667_1; CCG-208184; DB00091; KS-1257; SDCCGSBI-0050230.P004; NCGC00093704-12; NCGC00164258-01; NCGC00164258-02; NCGC00164258-03; NCGC00255232-01; BC164336; BP-28432; Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl); OL-27400; SBI-0050230.P003; C2408; M01532; A832514; Cyclosporin A, VETRANAL(TM), analytical standard; Q367700; SR-01000780563; Q-200913; SR-01000780563-3; BRD-K03222093-001-01-8; BRD-K13533483-001-03-0; Ciclosporin, European Pharmacopoeia (EP) Reference Standard; Cyclosporin A, from Tolypocladium inflatum, >=95% (HPLC), solid; Cyclosporine, United States Pharmacopeia (USP) Reference Standard; Ciclosporin for system suitability, European Pharmacopoeia (EP) Reference Standard; Cyclosporin A, from Tolypocladium inflatum, BioReagent, for molecular biology, >=95%; Cyclosporine, Pharmaceutical Secondary Standard; Certified Reference Material; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-((1R,2R,E)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-pent-3-enyl]-3,6,9,18,24-pentaisobutyl-21-isopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32; (R-(R*,R*-(E)))-CYCLIC(L-ALANYL-D-ALANYL-N-METHYL-L-LEUCYL-N-METHYL-L-LEUCYL-N-METHYL-L-VALYL-3-HYDROXY-N,4-DIMETHYL-L-2-AMINO-6-OCTENOYL-L-.ALPHA.-AMINOBUTYRYL-N-METHYLGLYCYL-N-METHYL-L-LEUCYL-L-VALYL-N-METHYL-L-LEUCYL); 104250-72-8; 30-Ethyl-33-((E)-1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,28-octamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone	Approved	Approved Drug(s)	5284373	DB00091	D0G7UX	1202.6	279	2330	7.5	85	5	12	15	C62H111N11O12	(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone	CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C	CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C	InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1	PMATZTZNYRCHOR-CGLBZJNRSA-N
DW0DQ2	Letermovir	Small molecule	Letermovir; 917389-32-3; AIC246; Prevymis; AIC-246; MK-8228; AIC 246; 1H09Y5WO1F; 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid; 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic acid; 4-Quinazolineacetic acid, 8-fluoro-3,4-dihydro-2-(4-(3-methoxyphenyl)-1-piperazinyl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-, (4S)-; (S)-2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetic acid; Letermovir [INN]; Letermovir [USAN:INN]; UNII-1H09Y5WO1F; Prevymis (TN); (S)-[8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazoline-4-yl]acetic acid; (S)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazoline-4-yl}acetic acid; MK-8828; Letermovir(AIC246); LETERMOVIR [MI]; LETERMOVIR [JAN]; LETERMOVIR [USAN]; LETERMOVIR [WHO-DD]; Letermovir (JAN/USAN/INN); SCHEMBL379403; CHEMBL1241951; LETERMOVIR [ORANGE BOOK]; DTXSID40238683; EX-A1871; s8873; CS-1571; DB12070; AIC246;AIC 246;AIC-246; NCGC00378936-01; NCGC00378936-02; AC-35698; AS-56206; HY-15233; J3.556.145E; D10801; D71052; A902281; EN300-18167086; Q15409407; (4S)-2-{8-Fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid; (4S)-8-Fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetic acid; (S)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydro-quinazolin-4-yl}acetic acid; (S)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazolin-4-yl}acetic acid; 2-[(4S)-8-fluoro-3-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3,4-dihydroquinazolin-4-yl]acetic acid	Approved	Approved Drug(s)	45138674	DB12070	D0G8PA	572.5	77.8	931	4.6	41	1	10	7	C29H28F4N4O4	2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid	COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O	COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O	InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1	FWYSMLBETOMXAG-QHCPKHFHSA-N
DC94ZH	Rifapentine	Small molecule	RIFAPENTINE; Priftin; 61379-65-5; Rifapentin; Cyclopentylrifampicin; MDL 473; Rifamycin AF/ACPP; Prifitin; MDL-473; 3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Priftin (TN); CHEBI:45304; DL-473; KTC 1; KTC-1; ANTIBIOTIC DL-473IT; XJM390A33U; R-773; Cyclopentyl rifampin; DL 473; R 77-3; R-77-3; Rifapentina; Rifapentinum; [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-[(E)-(4-cyclopentylpiperazin-1-yl)iminomethyl]-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate; 3-[N-(4-Cyclopentyl-1-piperazinyl)formimidoyl]rifamycin; Rifamycin, 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)-; Antibiotic DL 473IT; DL 473;Cyclopentylrifampicin; MDL473; 3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin; DTXSID8041115; Rifapentinum [Latin]; Rifapentina [Spanish]; RIFAPENTINE [MI]; RIFAPENTINE [INN]; Rifapentine (USAN/INN); RIFAPENTINE [USAN]; 3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV; RIFAPENTINE [VANDF]; CHEMBL1660; RIFAPENTINE [MART.]; UNII-XJM390A33U; SCHEMBL41590; RIFAPENTINE [WHO-DD]; Rifapentine [USAN:INN:BAN]; RIFAPENTINE [ORANGE BOOK]; DL473; HMS3713M16; DRG-0283; EINECS 262-743-9; BDBM50248298; MFCD00866806; AKOS024255723; CCG-220467; DB01201; KS-1409; R773; C08059; D00879; AB01209744-01; AB01209744-03; AB01209744_04; M000473; Rifapentine, Antibiotic for Culture Media Use Only; W-105162; 3-((4-CYCLOPENTYL-1-PIPERAZINYL)IMINO)METHYL)RIFAMYCIN; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-8-{(E)-[(4-cyclopentylpiperazin-1-yl)imino]methyl}-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-{(E)-[(4-cyclopentylpiperazin-1-yl)imino]methyl}-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),1(29),2,4,9,19,21,25,27-nonaen-13-yl acetate; [[(E)-(4-cyclopentylpiperazin-1-yl)iminomethyl]-pentahydroxy-methoxy-heptamethyl-dioxo-[?]yl] acetate; 1279038-35-5; RPE	Approved	Approved Drug(s)	135403821	DB01201	D0G9IU	877	220	1730	6.7	63	6	15	6	C47H64N4O12	[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-[(E)-(4-cyclopentylpiperazin-1-yl)iminomethyl]-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate	CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C6CCCC6)C	C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C	InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1	WDZCUPBHRAEYDL-GZAUEHORSA-N
D57SKN	Colestipol	Small molecule	COLESTIPOL; Alseroxylon; 50925-79-6; 8001-95-4; 26658-42-4; Colestipolum [INN-Latin]; N1-(2-aminoethyl)-N2-(2-((2-aminoethyl)amino)ethyl)ethane-1,2-diamine compound with 2-(chloromethyl)oxirane (1:1); Rautensin; U 26597A; Egalin; Rau-Tab; Alseroxylon [JAN]; SCHEMBL1649962; DTXSID00965206; Tetraethylenepentamine,3-epoxypropane; NSC147003; NSC-147003; U 26,597A; C06925; Q3294635; N'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;2-(chloromethyl)oxirane; N~1~,N~1'~-[Azanediyldi(ethane-2,1-diyl)]di(ethane-1,2-diamine)--2-(chloromethyl)oxirane (1/1)	Approved	Approved Drug(s)	62816	DB00375	D0GJ8R	281.83	101	117	.	18	5	6	11	C11H28ClN5O	N'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;2-(chloromethyl)oxirane	C1C(O1)CCl.C(CNCCNCCNCCN)N	C1C(O1)CCl.C(CNCCNCCNCCN)N	InChI=1S/C8H23N5.C3H5ClO/c9-1-3-11-5-7-13-8-6-12-4-2-10;4-1-3-2-5-3/h11-13H,1-10H2;3H,1-2H2	GMRWGQCZJGVHKL-UHFFFAOYSA-N
DYU8W9	Talazoparib	Small molecule	Talazoparib; 1207456-01-6; BMN-673; BMN 673; Talzenna; Talazoparib (BMN 673); BMN673; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one; LT-673; Talazoparib(BMN-673); 9QHX048FRV; (8s,9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1h-1,2,4-Triazol-5-Yl)-2,7,8,9-Tetrahydro-3h-Pyrido[4,3,2-De]phthalazin-3-One; 3H-Pyrido(4,3,2-de)phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-, (8S,9R)-; (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one; Talazoparib [USAN:INN]; UNII-9QHX048FRV; 4pjt; 2YQ; TALAZOPARIB [MI]; TALAZOPARIB [INN]; Talazoparib (USAN/INN); TALAZOPARIB [USAN]; Talazoparib (BMN-673); TALAZOPARIB [WHO-DD]; (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one; GTPL8313; SCHEMBL2299348; CHEMBL3137320; BMN673,BMN-673; DTXSID001025928; AMY27900; EX-A1356; BDBM50084621; MFCD22666357; NSC767125; CS-0937; DB11760; NSC-767125; NCGC00390231-01; AC-30927; AS-57491; HY-16106; LT 00673; S7048; SW219655-1; D10732; A892079; EN300-20176329; Q25100990; Q27453411; (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(1-methyl-1H-1,2,4-triazol-5-yl)-2,3,10-triazatricyclo[7.3.1.0,5,13]trideca-1,5,7,9(13)-tetraen-4-one; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one;BMN-673	Approved	Approved Drug(s)	135565082	DB11760	D0GV8J	380.4	84.2	654	2.3	28	2	7	2	C19H14F2N6O	(11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one	CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F	CN1C(=NC=N1)[C@@H]2[C@H](NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F	InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1	HWGQMRYQVZSGDQ-HZPDHXFCSA-N
D6IQU4	Toremifene	Small molecule	toremifene; 89778-26-7; Farestone; Z-Toremifene; Toremifeno; Toremifenum; Chlortamoxifen; GTx 006; (E)-Toremifene; GTx-006; Toremiphene; Toremifene (INN); 7NFE54O27T; CHEBI:9635; Toremifenum [Latin]; Toremifeno [Spanish]; 89778-26-7 (free base); 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; Ethanamine, 2-(4-((1Z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-; J33.157K; TOREMIFENE [INN]; Toremifene Base; Toremifene [INN:BAN]; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; 89778-29-0; Estrimex; (2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine; UNII-7NFE54O27T; CCRIS 8745; {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); TOREMIFENE [MI]; TOREMIFENE [IARC]; TOREMIFENE [VANDF]; SCHEMBL7465; CHEMBL1655; TOREMIFENE [WHO-DD]; BIDD:PXR0202; BIDD:ER0222; BIDD:GT0211; TOREMIFENE [EMA EPAR]; GTPL4325; DTXSID3023689; BDBM58492; cid_3005572; HY-B0005A; HMS2090B22; HMS3714P06; DL-519; MFCD00801070; STK626445; AKOS005559276; AC-1751; CCG-220952; CS-1268; DB00539; 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenyl-but-1-enyl]phenoxy]-N,N-dimethyl-ethanamine; Ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-; MRF-0000351; NCGC00160530-02; NCGC00160530-13; SBI-0206902.P001; C08166; D08620; AB00698360-07; AB00698360-09; AB00698360-10; AB00698360_11; AB00698360_12; A843306; EN300-22411559; Q3993743; SR-01000763502-5; BRD-K51350053-048-06-6; 2-[4-[(Z)-4-chloro-1,2-di(phenyl)but-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenyl-but-1-enyl]phenoxy]ethyl-dimethyl-amine;citric acid; ETHANAMINE, 2-(4-((1Z)-4-CHLORO-1,2-DIPHENYL-1-BUTEN-1-YL)PHENOXY)-N,N-DIMETHYL-; 2-[4-[(Z)-4-chloranyl-1,2-diphenyl-but-1-enyl]phenoxy]-N,N-dimethyl-ethanamine;2-oxidanylpropane-1,2,3-tricarboxylic acid; 275360-73-1; T0R	Approved	Approved Drug(s)	3005573	DB00539	D0GZ8Q	406	12.5	483	7.2	29	0	2	9	C26H28ClNO	2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine	CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3	CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3	InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-	XFCLJVABOIYOMF-QPLCGJKRSA-N
DHXC93	Ponatinib	Small molecule	PONATINIB; 943319-70-8; AP24534; Ponatinib (AP24534); AP 24534; AP-24534; 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; CHEMBL1171837; CHEBI:78543; 943319-70-8 (free base); 4340891KFS; 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide; 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide; 3-(Imidazo[1,2-B]pyridazin-3-Ylethynyl)-4-Methyl-N-{4-[(4-Methylpiperazin-1-Yl)methyl]-3-(Trifluoromethyl)phenyl}benzamide; Benzamide, 3-(2-imidazo(1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methyl-1- piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-; 3-(2-(Imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1- yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide.; Ponatinib [USAN]; Ponatinib [USAN:INN]; ponatinibum; UNII-4340891KFS; HSDB 8184; 0LI; 3-(2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; 3-(2-{imidazo[1,2-b]pyridazin-3-yl}ethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide; 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzam ide; 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide; Ponatinib, Free Base; AP24534,Ponatinib; PONATINIB [INN]; PONATINIB [MI]; Ponatinib (USAN/INN); PONATINIB [VANDF]; AP24534 - Ponatinib; PONATINIB [WHO-DD]; MLS006010166; SCHEMBL589260; GTPL5890; DTXSID50241426; EX-A067; BCPP000397; HMS3295I23; HMS3654H16; BCP02037; BDBM50322535; MFCD17215203; NSC758487; NSC800855; AKOS015995214; AM81261; BCP9000307; CCG-264900; CS-0204; DB08901; NSC-758487; NSC-800855; PB34916; NCGC00263152-01; NCGC00263152-02; NCGC00263152-12; NCGC00263152-14; AC-26973; AS-19133; HY-12047; SMR004701274; FT-0660376; S1490; SW218091-2; A24930; D09950; AB01565847_03; EN300-6733072; Q198728; BRD-K44227013-001-02-3; Z1828098700; 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-benzamide; BENZAMIDE, 3-(2-IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL-1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL]-; Ponatinib;3-(2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide	Approved	Approved Drug(s)	24826799	DB08901	D0H0EQ	532.6	65.8	910	4.1	39	1	8	6	C29H27F3N6O	3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5	InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)	PHXJVRSECIGDHY-UHFFFAOYSA-N
DHM74N	Riluzole	Small molecule	riluzole; 1744-22-5; Rilutek; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 2-Amino-6-(trifluoromethoxy)benzothiazole; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; RP-54274; 2-amino-6-trifluoromethoxybenzothiazole; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-Benzothiazolamine, 6-(trifluoromethoxy)-; C8H5F3N2OS; PK-26124; RP 54274; Tiglutik; 2-Amino-6-(trifluoromethoxy)-benzothiazole; Amino-2 trifluoromethoxy-6 benzothiazole; MLS000069369; 6-(trifluoromethoxy)-2-benzothiazolamine; 6-Trifluoromethoxy-benzothiazol-2-ylamine; CHEMBL744; NSC-753433; NSC-759823; SMR000058231; 7LJ087RS6F; CHEBI:8863; DTXSID3045192; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; BENZOTHIAZOLE, 2-AMINO-6-TRIFLUOROMETHOXY-; BHV-0223; NCGC00015882-09; Riluzol; Riluzolum; Riluzol [INN-Spanish]; Riluzolum [INN-Latin]; DTXCID1025192; Rilutek (TN); CAS-1744-22-5; 2-Benzothiazolamine,6-(trifluoromethoxy)-; Amino-2 trifluoromethoxy-6 benzothiazole [French]; UNII-7LJ087RS6F; 2-amino-6-(trifluoromethoxyl)benzothiazole; Riluzole, solid; Riluzole [USAN:USP:INN:BAN]; Riluzole- Bio-X; BF-37; ALBB-006046; Riluzole (Rilutek); MFCD00210213; Prestwick-03A08; EXSERVAN; PK26124; Tocris-0768; PK 26124; 6-trifluoromethoxybenzothiazole-2-yl-amine; Opera_ID_548; RILUZOLE [USAN]; Lopac-R-116; RILUZOLE [INN]; RILUZOLE [JAN]; RILUZOLE [MI]; Prestwick0_000167; Prestwick1_000167; Prestwick2_000167; Prestwick3_000167; Spectrum2_000550; RILUZOLE [MART.]; Biomol-NT_000245; RILUZOLE [USP-RS]; RILUZOLE [WHO-DD]; cid_5070; Riluzole (JAN/USP/INN); RILUZOLE [EMA EPAR]; Lopac0_001064; SCHEMBL78905; BSPBio_000033; BIDD:GT0055; SPBio_000599; SPBio_001954; RILUZOLE [ORANGE BOOK]; BPBio1_000037; BPBio1_000837; GTPL2326; RILUZOLE [USP IMPURITY]; RILUZOLE [USP MONOGRAPH]; BDBM30705; Bio1_000416; Bio1_000905; Bio1_001394; HMS1773G08; HMS2089O19; HMS2094G07; HMS2233E14; HMS3263E10; HMS3371A09; HMS3657E13; Pharmakon1600-01505348; AMY14166; BCP02142; HY-B0211; Riluzole - CAS 1744-22-5; Tiglutik (thickened oral suspension); Tox21_110252; Tox21_501064; AC-730; BBL013272; CCG-39528; HB6093; NSC753433; NSC759823; s1614; STK503686; AKOS000265071; Tox21_110252_1; DB00740; KS-5231; LP01064; NSC 753433; NSC 759823; SDCCGSBI-0051034.P003; 2-amino-6-trifluoromethoxy-benzothiazole; 6-trifluoromethoxy-2-amino-benzothiazole; NCGC00015882-01; NCGC00015882-02; NCGC00015882-03; NCGC00015882-04; NCGC00015882-05; NCGC00015882-06; NCGC00015882-07; NCGC00015882-08; NCGC00015882-10; NCGC00015882-11; NCGC00015882-12; NCGC00015882-13; NCGC00015882-15; NCGC00015882-28; NCGC00023141-02; NCGC00023141-04; NCGC00023141-05; NCGC00023141-06; NCGC00261749-01; 6-(trifluoromethoxy)-2-aminobenzothiazole; 6-trifluoromethoxybenzo[d]thiazol-2-amine; BR164340; SBI-0051034.P002; 2-Amino-6-(Trifluoromethoxy) Benzothiazole; DB-030335; EU-0101064; FT-0611194; R1174; SW196805-4; EN300-23782; 6-trifluoromethoxy-1,3-benzothiazol-2-ylamine; C07937; D00775; VU0239571-11; Q415744; SR-01000002997-3; BRD-K21283037-001-02-5; BRD-K21283037-003-03-9; BRD-K21283037-003-06-2; F3282-0020; Z164707762; Riluzole, United States Pharmacopeia (USP) Reference Standard; 2-Amino-6-(trifluoromethoxy)-1,3-benzothiazole;2-AMINO-6-(TRIFLUOROMETHOXY)BENZOTHIAZOLE	Approved	Approved Drug(s)	5070	DB00740	D0H0KB	234.2	76.4	238	3.6	15	1	7	1	C8H5F3N2OS	6-(trifluoromethoxy)-1,3-benzothiazol-2-amine	C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N	C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N	InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)	FTALBRSUTCGOEG-UHFFFAOYSA-N
DB5T8M	Simvastatin	Small molecule	simvastatin; 79902-63-9; Zocor; Synvinolin; MK-733; Sinvacor; Denan; Lipex; Sivastin; Lodales; Simvastatine; Cholestat; Colemin; Simovil; Medipo; Pantok; Simvastatina; Simvastatinum; Velostatin; Zocord; Zorced; Simvastatin (Zocor); Simvastatin lactone; Lipovas; Simcard; Simvacor; Simvoget; Rechol; Simlup; MK-0733; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; MK 733; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; AGG2FN16EV; NSC-758706; CHEBI:9150; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Labistatin; Coledis; Corolin; DTXSID0023581; Nivelipol; Rendapid; Vasotenal; C10AA01; Simvastatine [French]; Simvastatinum [Latin]; Simvastatina [Spanish]; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; DTXCID103581; Zosta; Simvast CR; DRG-0320; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; SMR000718785; MK 0733; CCRIS 7558; Zocor (TN); HSDB 7208; Simvastatin & Primycin; MK733; SR-05000001894; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; UNII-AGG2FN16EV; L 644128-000U; BRN 4768037; Kolestevan; Lipinorm; Modutrol; Simvotin; Sinvascor; Valemia; Eucor; Nor-Vastina; Simvastatin,(S); simvastatin predrug; (+)-Simvastatin; NCGC00016940-01; inactive simvastatin; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one; Simvastatin [USAN:USP:INN:BAN]; TNP00259; Prestwick_171; Simvastatin- Bio-X; CAS-79902-63-9; KS-1113; Spectrum_001717; SpecPlus_000895; SIMVASTATIN [MI]; Prestwick0_000865; Prestwick1_000865; Prestwick2_000865; Prestwick3_000865; Spectrum2_001671; Spectrum3_000669; Spectrum4_000632; Spectrum5_001428; SIMVASTATIN [INN]; SIMVASTATIN [JAN]; SIMVASTATIN [HSDB]; SIMVASTATIN [USAN]; SIMVASTATIN [VANDF]; SCHEMBL2471; CHEMBL1064; SIMVASTATIN [MART.]; BSPBio_000909; BSPBio_002337; KBioGR_001244; KBioSS_002197; SIMVASTATIN [USP-RS]; SIMVASTATIN [WHO-DD]; MLS001304029; MLS001333077; MLS001333078; MLS002154038; MLS006011866; BIDD:GT0769; DivK1c_006991; SPECTRUM1504236; SPBio_001881; SPBio_002830; BPBio1_001001; GTPL2955; Simvastatin (JP17/USP/INN); Simvastatin, analytical standard; BCBcMAP01_000007; KBio1_001935; KBio2_002197; KBio2_004765; KBio2_007333; KBio3_001557; RYMZZMVNJRMUDD-HGQWONQESA-; SIMVASTATIN [ORANGE BOOK]; HMS1570N11; HMS1922H13; HMS2089D12; HMS2093E06; HMS2097N11; HMS2231N22; HMS3259B12; HMS3412P08; HMS3676P08; HMS3714N11; HMS3884G10; Pharmakon1600-01504236; SIMVASTATIN [EP MONOGRAPH]; SIMCOR COMPONENT SIMVASTATIN; SIMVASTATIN [USP MONOGRAPH]; BUTANOIC ACID, 2,2-DIMETHYL-, 1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-(TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL ESTER, (1S-(1.ALPHA.,3.ALPHA.,7.BETA.,8.BETA.(2S*,4S*),8A.BETA.))-; VYTORIN COMPONENT SIMVASTATIN; Tox21_110696; Tox21_300400; BBL024390; BDBM50139181; CCG-39069; NSC633782; NSC758706; s1792; STK801938; AKOS005111006; AKOS015842733; SIMVASTATIN COMPONENT OF SIMCOR; Simvastatin, >=97% (HPLC), solid; Tox21_110696_1; AC-1530; DB00641; NC00719; NSC 758706; NSC-633782; SIMVASTATIN COMPONENT OF VYTORIN; MRF-0000729; NCGC00017324-01; NCGC00017324-02; NCGC00017324-03; NCGC00017324-04; NCGC00017324-05; NCGC00017324-07; NCGC00017324-08; NCGC00017324-09; NCGC00254418-01; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; BS164407; Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta))-; HY-17502; SBI-0206773.P001; Simvastatin 100 microg/mL in Acetonitrile; S0509; EN300-52503; D00434; AB00053395-07; AB00053395-08; AB00053395-10; AB00053395_11; AB00053395_13; A839783; Q670131; SR-05000001894-1; SR-05000001894-2; BRD-K22134346-001-05-8; BRD-K22134346-001-11-6; BRD-K22134346-001-15-7; Z754918914; Simvastatin, British Pharmacopoeia (BP) Reference Standard; Simvastatin, European Pharmacopoeia (EP) Reference Standard; Simvastatin, United States Pharmacopeia (USP) Reference Standard; Simvastatin, Pharmaceutical Secondary Standard; Certified Reference Material; Simvastatin for peak identification, European Pharmacopoeia (EP) Reference Standard; (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyly-2,2-dimethyl butanoate; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbu; (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate	Approved	Approved Drug(s)	54454	DB00641	D0H0ND	418.6	72.8	706	4.7	30	1	5	7	C25H38O5	[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate	CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C	CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C	InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1	RYMZZMVNJRMUDD-HGQWONQESA-N
DJT53U	Lanthanum carbonate	Small molecule	Lanthanum Carbonate; 587-26-8; Foznol; Lanthanum sesquicarbonate; Phosbloc; Carbonic acid, lanthanum(3+) salt (3:2); lanthanum(3+);tricarbonate; Lanthanum(3+) carbonate; Lanthanum (III) carbonate; lanthanum carbonate (2:3); Lanthanum carbonate anhydrous; 0M78EU4V9H; Dilanthanum tricarbonate; Carbonic acid,lanthanum(3+) salt (3:2), octahydrate (8CI,9CI); Lanthanum(3 ) carbonate; EINECS 209-599-5; lanthanum(3+) tricarbonate; UNII-0M78EU4V9H; HSDB 7758; Carbonato de lantano; Carbonate de lanthane; Carbonato de lantanio; Carbonato di lantanio; lanthanum(iii) carbonate; Lanthanum Carbonate powder; EC 209-599-5; Lanthanum(3+) salt (3:2); LANTHANUM CARBONATE [MI]; DTXSID30890512; Lanthanum carbonate (la2(co3)3); LANTHANUM CARBONATE [WHO-DD]; DB06792; LANTHANUM(3 ) CARBONATE [HSDB]; Q421317; Carbonic acid,lanthanum(3+) salt (3:2), hydrate (9CI)	Approved	Approved Drug(s)	168924	DB06792	D0H1LO	457.84	190	18.8	.	14	0	9	0	C3La2O9	lanthanum(3+);tricarbonate	C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].[La+3].[La+3]	C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].[La+3].[La+3]	InChI=1S/3CH2O3.2La/c3*2-1(3)4;;/h3*(H2,2,3,4);;/q;;;2*+3/p-6	NZPIUJUFIFZSPW-UHFFFAOYSA-H
DFN6V9	Aripiprazole	Small molecule	Aripiprazole; 129722-12-9; Abilify; Abilitat; OPC-14597; Abilify Discmelt; Opc 14597; OPC 31; Aripiprex; Abilify Maintena; Abilify MyCite; OPC-31; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; AriprazoleImpurity; 7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE; NSC-759266; CHEMBL1112; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone; Discmelt; DTXSID3046083; CHEBI:31236; 82VFR53I78; 129722-12-9 (free base); 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; MFCD00892072; 2(1H)-Quinolinone, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; aripiprazol; NCGC00159510-02; Aripiprazole [USAN]; 2(1H)-Quinolinone, 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-; 1026778-41-5; DTXCID1026083; aripiprazolum; 7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-quinol in-2-one; SMR000466383; Abilify (TN); Abilify Maintena Kit; CAS-129722-12-9; HSDB 7320; SR-01000759353; UNII-82VFR53I78; Abilify Digital; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; Aripiprazole [USAN:INN:BAN]; 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy)-3,4-dihydrocarbostyril; 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril; Abilify OD; 7-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy)-3,4-dihydroquinolin-2(1H)-one; Aripiprazole Depot; 9SC; Aripiprazole- Bio-X; BMS-337039; KS-1030; Aripiprazole (Abilify); CPD000466383; ABILIFY MYCITE KIT; ARIPIPRAZOLE [MI]; ARIPIPRAZOLE [INN]; ARIPIPRAZOLE [JAN]; GTPL34; ARIPIPRAZOLE [HSDB]; Aripiprazole-d8(butyl-d8); SCHEMBL8255; ARIPIPRAZOLE [VANDF]; ARIPIPRAZOLE [MART.]; MLS000759517; MLS001165779; MLS001195621; MLS001424078; MLS006011892; ARIPIPRAZOLE [USP-RS]; ARIPIPRAZOLE [WHO-DD]; Aripiprazole (JAN/USP/INN); SCHEMBL5335696; ARIPIPRAZOLE [EMA EPAR]; Aristada (aripiprazole lauroxil); SCHEMBL12961254; ARIPIPRAZOLE [ORANGE BOOK]; HMS2051I18; HMS2089M20; HMS2093F22; HMS2230M18; HMS3373D04; HMS3393I18; HMS3657K13; HMS3715J07; HMS3744A13; HMS3884E18; Pharmakon1600-01505851; ARIPIPRAZOLE [EP MONOGRAPH]; ACT03221; BCP04902; ARIPIPRAZOLE [USP MONOGRAPH]; Tox21_111728; BBL029082; BDBM50130293; DL-178; NSC759266; s1975; STK625160; AKOS005558247; Tox21_111728_1; AB07660; AC-1554; BCP9000317; CCG-100891; CS-0766; DB01238; NC00141; NSC 759266; Aripiprazole 1.0 mg/ml in Acetonitrile; NCGC00159510-03; NCGC00159510-04; NCGC00159510-05; BA164218; HY-14546; SY053146; SBI-0206870.P001; AM20090766; FT-0600352; FT-0662278; FT-0662279; SW197521-3; A19454; D01164; EN300-119521; AB00639935-09; AB00639935_10; AB00639935_11; L001339; Q411188; J-005707; SR-01000759353-4; SR-01000759353-6; BRD-K70358946-001-06-6; Z1521553846; 7-[4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone; 7-[4-[4-(2,3-Dichlorophenyl)-1-Piperazinyl]Butoxy]3,4-Dihydro-2(1H)-Quinolinone; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-quinolin-2(1H)-one; 7-{4-[-4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril; 7-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3, 4-dihydrocarbostyril; 7-{4-[4-(2,3-dichlorophenyl)piperazino]butoxy}-3,4-dihydro-2(1H)-quinolinone; aripiprazole; 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; 24-29-3	Approved	Approved Drug(s)	60795	DB01238	D0H3HM	448.4	44.8	559	4.6	30	1	4	7	C23H27Cl2N3O2	7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one	C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl	C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl	InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)	CEUORZQYGODEFX-UHFFFAOYSA-N
DL47HJ	Desflurane	Small molecule	DESFLURANE; 57041-67-5; Suprane; 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane; Desflurano [INN-Spanish]; difluoromethyl 1,2,2,2-tetrafluoroethyl ether; Desfluranum [INN-Latin]; I-653; 1,2,2,2-Tetrafluoroethyl difluoromethyl ether; (+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; CRS35BZ94Q; CHEBI:4445; 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane; Desfluranum; Desflurano; Ethane, 2-(difluoromethoxy)-1,1,1,2-tetrafluoro-, (+-)-; (+/-)-2-difluoromethyl 1,2,2,2-tetrafluoroethyl ether; I 653; Suprane (TN); UNII-CRS35BZ94Q; Desflurane (JAN/USP/INN); Desfluran-O; HSDB 8058; Desflurane [USAN:USP:INN:BAN]; Ethane, 2-(difluoromethoxy)-1,1,1,2-tetrafluoro-; CHF2OCHFCF3; DESFLURANE [MI]; DESFLURANE [INN]; DESFLURANE [JAN]; DESFLURANE [USAN]; DESFLURANE [VANDF]; DESFLURANE [MART.]; DESFLURANE [USP-RS]; DESFLURANE [WHO-DD]; SCHEMBL62917; GTPL7156; CHEMBL1200733; DESFLURANE [ORANGE BOOK]; DESFLURANE [EP MONOGRAPH]; DTXSID80866606; DESFLURANE [USP MONOGRAPH]; MFCD00236716; AKOS006228397; DB01189; DB-053001; Difluoromethyl1,2,2,2-tetrafluoroethylether; FT-0624525; C07519; D00546; EN300-7635854; Q419383; ETHANE, 2-(DIFLUOROMETHOXY)-1,1,1,2-TETRAFLUORO-, (+/-)-; 1351959-69-7	Approved	Approved Drug(s)	42113	DB01189	D0H4GN	168.04	9.2	97.7	2.6	10	0	7	2	C3H2F6O	2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane	C(C(F)(F)F)(OC(F)F)F	C(C(F)(F)F)(OC(F)F)F	InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H	DPYMFVXJLLWWEU-UHFFFAOYSA-N
D8UG5H	Asparaginase	Small molecule	asparaginate; asparagine anion; 2,4-diamino-4-oxobutanoate; Asparaginase; Asp(-); CHEBI:32660; Q27115042	Approved	Approved Drug(s)	5460875	DB00023	D0H5XB	131.11	109	128	-2.8	9	2	4	2	C4H7N2O3-	2,4-diamino-4-oxobutanoate	C(C(C(=O)[O-])N)C(=O)N	C(C(C(=O)[O-])N)C(=O)N	InChI=1S/C4H8N2O3/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H2,6,7)(H,8,9)/p-1	DCXYFEDJOCDNAF-UHFFFAOYSA-M
D9WKR5	Indapamide	Small molecule	indapamide; 26807-65-8; Noranat; Veroxil; Tertensif; Lozol; Indaflex; Arifon; Fludex; Indamol; Bajaten; Ipamix; Tandix; Natrilix; Damide; Pressurai; Indapamida; Indapamidum; Natrix; Indapamidum [INN-Latin]; Indapamida [INN-Spanish]; SE-1520; flupamid; indamide; 1-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; Indapamide (Lozol); Fludin; Lorvas; 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide; S-1520; Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-; 4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide; FLUBEST; Metindamide; Cormil; NSC-757075; N-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; 4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzamide; MLS000028554; CHEBI:5893; DTXSID7044633; 26807-65-8(free base); KYD-041; BENZAMIDE, 4-CHLORO-N-(2-METHYL-1-INDOLINYL)-3-SULFAMOYL-; F089I0511L; NCGC00018172-03; SMR000058829; 4-CHLORO-N-(2-METHYLINDOLIN-1-YL)-3-SULFAMOYLBENZAMIDE; DTXCID5024633; SE 1520; RHC 2555; USV 2555; Natrix (TN); Lozol (TN); SR-01000003079; EINECS 248-012-7; MFCD00079375; BRN 1604026; UNII-F089I0511L; Hypen SR; 3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide; Indapamide [USAN:USP:INN:BAN:JAN]; Spectrum_000917; INDAPAMIDE [MI]; Opera_ID_110; INDAPAMIDE [INN]; INDAPAMIDE [JAN]; Prestwick3_000220; Spectrum2_000980; Spectrum3_000467; Spectrum4_000017; Spectrum5_000866; INDAPAMIDE [USAN]; S1520; INDAPAMIDE [VANDF]; CHEMBL406; Indapamide (JP17/USP); INDAPAMIDE [MART.]; INDAPAMIDE [USP-RS]; INDAPAMIDE [WHO-DD]; SCHEMBL41303; BSPBio_000239; BSPBio_002174; KBioGR_000393; KBioSS_001397; 5-20-06-00348 (Beilstein Handbook Reference); MLS001148152; MLS002222229; MLS006011900; DivK1c_000508; SPECTRUM1500349; SPBio_001019; BPBio1_000263; GTPL7203; INDAPAMIDE [EP IMPURITY]; INDAPAMIDE [ORANGE BOOK]; BDBM25901; HMS501J10; KBio1_000508; KBio2_001397; KBio2_003965; KBio2_006533; KBio3_001394; INDAPAMIDE [EP MONOGRAPH]; NINDS_000508; HMS1920F19; HMS2090M16; HMS2091N07; HMS2095L21; HMS2231G13; HMS3259C14; HMS3369J20; HMS3655E06; HMS3712L21; HMS3748K05; INDAPAMIDE [USP MONOGRAPH]; Pharmakon1600-01500349; Indapamide 1.0 mg/ml in Methanol; AMY31945; BCP04140; HY-B0259; Tox21_110775; Tox21_113182; Tox21_302687; CCG-40198; NSC757075; s1730; STL257105; STL455045; 3-(Aminosulfonyl)-4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)benzamide; AKOS015888148; Tox21_110775_1; AB03037; AC-2073; DB00808; KS-5219; NC00568; NSC 757075; Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-l-yl)-; IDI1_000508; NCGC00018172-02; NCGC00018172-04; NCGC00018172-06; NCGC00018172-08; NCGC00018172-09; NCGC00089727-02; NCGC00089727-03; NCGC00256884-01; SBI-0051415.P003; DB-047020; AB00052021; I0730; SW198686-2; A23574; D00345; EN300-117260; AB00052021-14; AB00052021-15; AB00052021_16; AB00052021_17; Indapamide, analytical standard, for drug analysis; J-016554; Q1078392; SR-01000003079-2; SR-01000003079-3; BRD-A95869247-001-04-6; BRD-A95869247-001-14-5; Z1501485351; Indapamide, British Pharmacopoeia (BP) Reference Standard; Indapamide, European Pharmacopoeia (EP) Reference Standard; Indapamide, United States Pharmacopeia (USP) Reference Standard; 3-aminosulfonyl-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide; 4-chloro-3-aminosulphonyl-N-(2,3-dihydro2-methyl-1H-indol-1-yl)benzamide; Indapamide, Pharmaceutical Secondary Standard; Certified Reference Material; 3-(aminosulphonyl)-4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1--yl)benzamide; 3-(aminosulphonyl)-4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)benzamide; 4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzenecarboximidic acid	Approved	Approved Drug(s)	3702	DB00808	D0H8FH	365.8	101	580	2.9	24	2	5	3	C16H16ClN3O3S	4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide	CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N	CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N	InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)	NDDAHWYSQHTHNT-UHFFFAOYSA-N
D1POI5	Lomitapide	Small molecule	Lomitapide; 182431-12-5; AEGR-733; Juxtapid; BMS-201038; AEGR 733; Lojuxta; BMS 201038; AEGR733; BMS201038; AEGR-733(Lomitapide); Lomitapide free base; AEGR-733;BMS-201038; BMS-201038-01; CHEMBL354541; CHEBI:72297; 82KUB0583F; 182431-12-5 (free base); n-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoromethyl)biphenyl-2-ylcarboxamido)piperidin-1-yl)butyl)-9h-fluorene-9-carboxamide; 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-(4-(4-(((4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl)amino)-1-piperidinyl)butyl)-; N-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamido)piperidin-1-yl)butyl)-9H-fluorene-9-carboxamide; N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide; N-(2,2,2-trifluoroethyl)-9-{4-[4-({[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)piperidin-1-yl]butyl}-9H-fluorene-9-carboxamide; Lomitapide [USAN]; Lomitapide [USAN:INN]; BMS 201238; lomitapida; lomitapidum; BMS 201038-01; UNII-82KUB0583F; HSDB 8218; 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-; N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDE; N-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-ylcarboxamido)piperidin-1-yl)butyl)-9H-fluorene-9-carboxamide; N-(2,2,2-Trifluoroethyl)-9-[4-[4-[4'-(trifluoromethyl)-[1,1'-biphenyl]-2-ylcarboxamido]piperidin-1-yl]butyl]-9H-fluorene-9-carboxamide; LOMITAPIDE [MI]; LOMITAPIDE [INN]; Lomitapide (USAN/INN); LOMITAPIDE [VANDF]; LOMITAPIDE [WHO-DD]; AEGR773; SCHEMBL304604; AEGR 773; AEGR-773; GTPL7439; Lomitapide, >=98% (HPLC); DTXSID50171294; HMS3653B17; HMS3743K11; AMY38746; BCP06821; BDBM50098320; MFCD16620494; s7635; AKOS025149590; CCG-270380; CS-3423; DB08827; SB16780; s11708; NCGC00386364-01; NCGC00386364-05; AC-32635; AS-75234; HY-14667; DB-065402; FT-0750236; L0298; SW220160-1; D09637; J-690250; Q1268941; Z1696860003; 9-(4-{4-[(4''''-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-piperidin-1-yl}-butyl)-9H-fluorene-9-carboxylic acid (2,2,2-trifluoro-ethyl)-amide; 9-(4-{4-[(4''-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-piperidin-1-yl}-butyl)-9H-fluorene-9-carboxylic acid (2,2,2-trifluoro-ethyl)-amide; N-(2,2,2-TRIFLUOROETHYL)-9-(4-{4-[4'-(TRIFLUOROMETHYL)-[1,1'-BIPHENYL]-2-AMIDO]PIPERIDIN-1-YL}BUTYL)-9H-FLUORENE-9-CARBOXAMIDE; N-(2,2,2-trifluoroethyl)-9-[4-(4-{2-[4-(trifluoromethyl)phenyl]benzamido}piperidin-1-yl)butyl]-9H-fluorene-9-carboxamide; N-(2,2,2-trifluoroethyl)-9-{4-(4-({(4'-(trifluoromethyl)biphenyl-2- yl)carbonyl}amino)piperidin-1-yl)butyl}-9H-fluorene-9-carboxamide	Approved	Approved Drug(s)	9853053	DB08827	D0H8VY	693.7	61.4	1110	8.6	50	2	9	10	C39H37F6N3O2	N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide	C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F	C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F	InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)	MBBCVAKAJPKAKM-UHFFFAOYSA-N
DSB74U	Acebutolol	Small molecule	acebutolol; 37517-30-9; Acetobutolol; dl-Acebutolol; Neptal; Acebutololo; Sectral; Acebutololum; (+-)-Acebutolol; N-(3-Acetyl-4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)butyramide; 5'-Butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone; CHEBI:2379; 3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 1-(2-Acetyl-4-n-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane; N-(3-acetyl-4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)butanamide; N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide; N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide; C07AB04; 67P356D8GH; N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide; Acebrutololum; Monitan; (-)-ACEBUTOLOL; N-{3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}butanamide; 28197-63-9; Acebutololum [INN-Latin]; Acebrutololum [INN-Latin]; Acetobutolol [INN-Spanish]; Acebutolol [USAN:INN:BAN]; Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-; Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-, (.+/-.)-; (+/-)-acebutolol; CCRIS 9214; RP 21823; Acebutolol (USAN/INN); EINECS 253-539-0; BRN 2162244; UNII-67P356D8GH; 3'-Acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)butyranilid; 3'-(Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; (+-)-3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; (+-)-N-(3-Acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)butanamide; Sectral (Salt/Mix); Wesfalin (Salt/Mix); Spectrum_000491; ACEBUTOLOL [MI]; ACEBUTOLOL [INN]; Prestwick0_000069; Prestwick1_000069; Prestwick2_000069; Prestwick3_000069; Spectrum2_001340; Spectrum3_000573; Spectrum4_000802; Spectrum5_001399; (.+/-.)-Acebutolol; ACEBUTOLOL [USAN]; ACEBUTOLOL [VANDF]; CHEMBL642; Epitope ID:146105; ACEBUTOLOL [MART.]; SCHEMBL3772; ACEBUTOLOL [WHO-DD]; Butanamide, N-(3-acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, (+-)-; BSPBio_000257; BSPBio_001986; KBioGR_001283; KBioSS_000971; DivK1c_000612; SPBio_001499; SPBio_002178; BPBio1_000283; GTPL7107; IL 17803A (Salt/Mix); Discontinued. See: A123800; DTXSID2048539; BDBM25755; KBio1_000612; KBio2_000971; KBio2_003539; KBio2_006107; KBio3_001486; NINDS_000612; MFCD00599435; AKOS015963037; DB01193; DS-3129; IDI1_000612; NCGC00018215-02; HY-17497; SBI-0051584.P003; DB-069556; AB00053574; CS-0009240; FT-0660954; C06803; D02338; AB00053574_13; AB00053574_14; EN300-7398930; A935714; L000998; Q418857; BRD-A29260609-003-05-4; BRD-A29260609-003-15-3; 1-[2-Acetyl-4-(butyrylamino)phenoxy]-3-(isopropylamino)-2-propanol; (.+/-.)-3'-Acetyl-4'-[2-hydroxy-3-(isopropylamino)propoxy]butyranilide; N-(3-Acetyl-4-(2-hydroxy-3-(isopropylamino)-propoxy)phenyl)butyramide; N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide #; N-[3-Acetyl-4-(2-hydroxy-3-propan-2-ylaminopropoxy)-phenyl] butanamide; (+/-)-3'-ACETYL-4'-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)BUTYRANILIDE; (.+/-.)-3'-Acetyl-4'-[2-hydroxy-3-(1-methylethylamino)propoxy]butyranilide; (.+/-.)-N-(3-Acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)butanamide; N-(3-acetyl-4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)butanimidic acid; BUTANAMIDE, N-(3-ACETYL-4-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)PHENYL)-, (+/-)-; Butanamide, N-(3-acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-,monohydrochloride,(+-)-	Approved	Approved Drug(s)	1978	DB01193	D0HD9K	336.4	87.7	401	1.7	24	3	5	10	C18H28N2O4	N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide	CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C	CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C	InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)	GOEMGAFJFRBGGG-UHFFFAOYSA-N
D1TG9D	Amifampridine	Small molecule	3,4-DIAMINOPYRIDINE; 54-96-6; pyridine-3,4-diamine; Amifampridine; 3,4-Pyridinediamine; 3,4-DAP; 4,5-Diaminopyridine; Diamino-3,4 pyridine; amifampridin; Ruzurgi; Pyridine, 3,4-diamino-; 3,4 Diaminopyridine; Dynamine; 3-amino-4-pyridinylamine; NSC-521760; RU4S6E2G0J; 54-96-6 (free base); CHEMBL354077; DTXSID6046715; NCGC00167560-01; DTXCID4026715; CAS-54-96-6; SMR000752913; Amifampridine [INN]; EINECS 200-220-9; UNII-RU4S6E2G0J; NSC 521760; BRN 0110232; Amifampridine [USAN:INN:BAN]; Ruzurgi (TN); MFCD00006401; Pyridine,4-diamino-; 3,4-diamino pyridine; 3,4-diamino-pyridine; 3,4-Diammoniopyridinium; AMIFAMPRIDINE [MI]; WLN: T6NJ CZ DZ; Amifampridine (USAN/INN); 4-DAP; AMIFAMPRIDINE [USAN]; SCHEMBL21273; 5-22-11-00266 (Beilstein Handbook Reference); MLS001304911; MLS001333181; MLS001333182; AMIFAMPRIDINE [MART.]; AMIFAMPRIDINE [WHO-DD]; GTPL8032; AMIFAMPRIDINE [EMA EPAR]; CHEBI:135948; HMS2233K06; AMIFAMPRIDINE [ORANGE BOOK]; ACT01546; ALBB-005969; BCP22343; Amifampridin (3,4-Diaminopyridine); Tox21_112555; 3,4 DIAMINOPYRIDINE [VANDF]; BBL013269; BDBM50416493; CL0116; NSC521760; NSC790505; s4622; STK503647; AKOS000672436; Tox21_112555_1; CCG-304141; DB11640; NSC-790505; PB48915; PS-9273; NCGC00167560-02; BP-12781; HY-14946; DB-011105; A7976; AM20070030; D1149; FT-0614203; EN300-69695; D10228; AC-907/34116043; Q411707; J-610017; W-105592; F0001-1409; Z385438794; L89	Approved	Approved Drug(s)	5918	DB11640	D0HE0Y	109.13	64.9	74.1	-0.5	8	2	3	0	C5H7N3	pyridine-3,4-diamine	C1=CN=CC(=C1N)N	C1=CN=CC(=C1N)N	InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)	OYTKINVCDFNREN-UHFFFAOYSA-N
DHM23C	Ambroxol	Small molecule	ambroxol; 18683-91-5; 107814-37-9; rac-cis-Ambroxol; 36557-04-7; Ambroxol Base; 4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol; Ambroxolum; Bisolvon metabolite VIII; 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol; Bromhexine-metabolite VIII; NA-872; Tabcin; trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol; Ambroxol, cis-; cis-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol; Ambroxol [INN]; Cyclohexanol, 4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-, trans-; 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol; trans-4-((2-Amino-3,5-dibromobencil)amino)ciclohexanol; trans-4-((2-Amino-3,5-dibromobenzyl)amine)cyclohexanol; QH6ZT6J071; Cyclohexanol, 4-((2-amino-3,5-dibromobenzyl)amino)- (E)-; N-(2-Amino-3,4-dibromocyclohexyl)-trans-4-aminocyclohexanol; 4-Hydroxydemethylbromhexine, cis-; N-(trans-4-Hydroxycyclohexyl)-(2-amino-3,5-dibromobenzyl)-amine; N-(trans-p-Hydroxycyclohexyl)-(2-amino-3,5-dibromobenzyl)amine; Ambroxol (INN); Cyclohexanol, 4-(((2-amino-3,5-dibromophenyl)methyl)amino)-, trans-; 200168S0CL; trans-4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol; N-(2-Amino-3,4-dibromociclohexil)-trans-4-aminociclohexanol; N-(trans-4-Hidroxiciclohexil)-(2-amino-3,5-dibromobencil)amina; 1217679-83-8; Ambroxol [INN:BAN]; cis-4-(((2-Amino-3,5-dibromophenyl)methyl)amino)cyclohexanol; Ambroxolum [INN-Latin]; Cyclohexanol, 4-(((2-amino-3,5-dibromophenyl)methyl)amino)-, cis-; Cyclohexanol, 4-(((2-amino-3,5-dibromophenyl)methyl)amino)-, trans- (9CI); Bromhexine Metabolite VIII; NCGC00016781-04; EINECS 242-500-3; CAS-23828-92-4; Amboxol; cis-Ambroxol; SR-05000001463; UNII-200168S0CL; Tabcin (TN); Spectrum_001346; AMBROXOL [MI]; rac-cis-Ambroxol-[d5]; Prestwick0_000366; Prestwick1_000366; Prestwick2_000366; Prestwick3_000366; Spectrum2_001518; Spectrum3_000955; Spectrum4_001068; Spectrum5_001021; trans-4-((2-Amino-3,5-dibromobencil)amino)ciclohexanol [Spanish]; N-(2-Amino-3,4-dibromociclohexil)-trans-4-aminociclohexanol [Spanish]; AMBROXOL [WHO-DD]; EC 242-500-3; N-(trans-4-Hidroxiciclohexil)-(2-amino-3,5-dibromobencil)amina [Spanish]; UNII-QH6ZT6J071; Oprea1_766685; SCHEMBL18702; BSPBio_000491; KBioGR_001396; KBioSS_001826; MLS001306470; DivK1c_000027; SCHEMBL423712; SPBio_001595; SPBio_002412; BPBio1_000541; CHEMBL153479; SCHEMBL7855003; 4-[(2-amino-3,5-dibromo-phenyl)methylamino]cyclohexanol; CHEMBL1477775; DTXSID8022583; SCHEMBL21765132; BCBcMAP01_000092; CHEBI:92994; GTPL10692; KBio1_000027; KBio2_001826; KBio2_004394; KBio2_006962; KBio3_002050; DTXSID60860228; CHEBI:135590; NINDS_000027; 4-{[(2-amino-3,5-dibromophenyl)methyl]amino}cyclohexan-1-ol; Cyclohexanol, 4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-; HMS2089D06; HMS2231B19; HMS3373J22; HMS3886M18; ALBB-022461; BCP04489; HY-B1039; BBL009896; BDBM50395322; MFCD00242702; MFCD28143339; s5710; STK711075; AKOS005530704; AKOS015889660; AKOS027338704; AC-8362; Ambroxol hydrochloride impurity D [EP]; BCP9000283; CCG-207907; CS-4558; DB06742; SB17463; SB82866; IDI1_000027; SMP1_000014; NCGC00016781-01; NCGC00016781-02; NCGC00016781-08; NCGC00159399-02; NCGC00371077-02; AS-56023; SMR000718792; VS-02240; 4-HYDROXYDEMETHYLBROMHEXINE, TRANS-; BCP0726000066; SBI-0051766.P002; AB00514663; CS-0323348; FT-0622261; FT-0630430; FT-0661549; D07442; 4-(2-amino-3,5-dibromobenzylamino)cyclohexanol; AB00053639_13; AB01275465-01; A813089; EN300-18524079; Q221637; SR-05000001463-1; AMBROXOL HYDROCHLORIDE IMPURITY D [EP IMPURITY]; BRD-K11223672-003-03-7; BRD-K11223672-003-04-5; BRD-K56558538-003-02-8; 4-[(2-amino-3,5-dibromophenyl)methylamino-]cyclohexanol; 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexanol; (1s,4s)-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol; 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol, trans-; (1r,4r)-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol; trans-4-{[(2-amino-3,5-dibromophenyl)methyl]amino}cyclohexanol; (1r,4r)-4-{[(2-Amino-3,5-dibromophenyl)methyl]amino}cyclohexan-1-ol; Cyclohexanol, 4-[[(2-amino-3,5-dibromo-phenyl)methyl]amino]-, trans	Approved	Approved Drug(s)	2132	DB06742	D0HR5H	378.1	58.3	259	2.6	18	3	3	3	C13H18Br2N2O	4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol	C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O	C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O	InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2	JBDGDEWWOUBZPM-UHFFFAOYSA-N
DM30ER	Miglustat	Small molecule	Miglustat; 72599-27-0; N-Butyldeoxynojirimycin; Zavesca; NB-DNJ; Butyldeoxynojirimycin; N-Butylmoranoline; (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol; N-butyl-1-deoxynojirimycin; BuDNJ; n-Butyl deoxynojirimycin; N-(n-Butyl)deoxynojirimycin; OGT 918; SC-48334; OGT-918; N-Butyl-DNJ; SC 48334; 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3r,4R,5S)-; N-Butyldeoxynojirimycin.HCl; ADN3S497AZ; CHEMBL1029; DTXSID6045618; CHEBI:50381; 72599-27-0 (free base); n-Butyl dnj; Miglustat [USAN]; DTXCID4025618; miglustatum; Vevesca; Zavesca (TN); CAS-72599-27-0; N-Bu-DNJ; N-Butyl-deoxynojirimycin; NBV; UNII-ADN3S497AZ; SC48334; Brazaves; N-(n-butyl)deoxy-nojirimycin; Miglustat [USAN:INN:BAN]; D-Glucitol, 1,5-(butylimino)-1,5-dideoxy-; NCGC00018140-02; Brazaves (TN); MFCD00272581; MIGLUSTAT [INN]; MIGLUSTAT [JAN]; MIGLUSTAT [MI]; 1,5-Dideoxy-1,5-N-butylimino-D-glucitol; N-Butyldeoxynojirimycin;NB-DNJ;OGT918; MIGLUSTAT [VANDF]; MIGLUSTAT [MART.]; MIGLUSTAT [WHO-DD]; N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol; MIGLUSTAT [EMA EPAR]; Miglustat (JAN/USAN/INN); SCHEMBL246893; OGT918N-Butyldeoxynojirimycin; GTPL4841; OGT918; MIGLUSTAT [ORANGE BOOK]; BDBM18355; HMS2090N20; Tox21_110830; AKOS028109118; Tox21_110830_1; DB00419; 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-; NCGC00024452-03; NCGC00024452-04; HY-17020; N-(n-Butyl)-1-deoxynojirimycin min. 99%; N-Butyldeoxynojirimycin, film (dried in situ); D05032; P16976; AB00489939-10; 1,5-(BUTYLIMINO)-1,5 DIDEOXY,D-GLUCITOL; A850985; Q425911; SR-01000000043; SR-01000000043-2; W-203639; Z2379810058; 1,5-(Butylimino)-1,5-dideoxy-D-glucitol(2R,3R,4R,5S)-1-Butyl-2-(hydroxymethyl)-3,4,5-piperidinetriol; 134282-77-2	Approved	Approved Drug(s)	51634	DB00419	D0HR8Z	219.28	84.2	190	-0.6	15	4	5	4	C10H21NO4	(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol	CCCCN1CC(C(C(C1CO)O)O)O	CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O	InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1	UQRORFVVSGFNRO-UTINFBMNSA-N
DXU91J	Mycophenolate mofetil	Small molecule	mycophenolate mofetil; 128794-94-5; CellCept; 115007-34-6; RS 61443; Myfenax; RS-61443; TM-MMF; myclausen; Mycophenylate mofetil; Mycophenolic acid morpholinoethyl ester; Mycophenolatemofetil; Mycophenolate mofetil Teva; CHEBI:8764; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate; Cellcept (TN); (E)-2-Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate; NSC-724229; NSC-758905; 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; DTXSID3023340; Mycophenolate mofetil (CellCept); 9242ECW6R0; 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (E)-; Munoloc; Mycophenolate mofetil 100 microg/mL in Acetonitrile; DTXCID103340; MYCOPHENOLIC ACID 2-(4-MORPHOLINYL)ETHYL ESTER; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; 2-Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)-; SMR002544686; MMF CellCept(TM); CAS-128794-94-5; HSDB 7436; ME-MPA; SR-05000001485; Mycophenolate mofetil [USAN]; Arzip; UNII-9242ECW6R0; Mycophenolatmofetil; Mycophenolate mofetil [USAN:USP]; NCGC00159459-02; (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester; mycophenolate-mofetil; Mofetil mycophenolate; MFCD00867568; RS61443; R-99; SCHEMBL4195; CHEMBL1456; MLS003915627; MLS004774133; MLS006011929; SCHEMBL218782; GTPL6831; CHEBI:93612; Mycophenolate mofetil (JAN/USP); HMS2090A03; Pharmakon1600-01504567; MYCOPHENOLATE MOFETIL [JAN]; 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester; ACT01993; ALBB-027273; HY-B0199; MYCOPHENOLATE MOFETIL [HSDB]; Tox21_111686; BBL029073; BDBM50248299; MYCOPHENOLATE MOFETIL [VANDF]; NSC724229; NSC758905; s1501; STL146382; MYCOPHENOLATE MOFETIL [MART.]; AKOS005720900; MYCOPHENOLATE MOFETIL [USP-RS]; MYCOPHENOLATE MOFETIL [WHO-DD]; Tox21_111686_1; AC-1562; BCP9000969; CCG-213315; DB00688; KS-1209; NSC 724229; NSC 758905; MYCOPHENOLATE MOFETIL [EMA EPAR]; Mycophenolate mofetil, >=98% (HPLC); NCGC00159459-03; NCGC00159459-04; 140401-05-4; 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-hex-4-enoate; BM164622; LS-15013; SMR004703518; MYCOPHENOLATE MOFETIL [ORANGE BOOK]; MYCOPHENOLATE MOFETIL [EP MONOGRAPH]; M2387; MYCOPHENOLATE MOFETIL [USP MONOGRAPH]; Mycophenolate mofetil for peak identification; SW219893-1; C07908; D00752; W18801; AB01274794-01; AB01274794-02; AB01274794_03; AB01274794_04; EN300-1705962; A803280; A805863; A888971; J-005626; Q-101316; Q4567614; SR-05000001485-1; SR-05000001485-2; BRD-K92428153-001-01-0; Z2568665233; MYCOPHENOLIC ACID 2-(4-MORPHOLINYL)ETHYL ESTER [MI]; Mycophenolate mofetil, European Pharmacopoeia (EP) Reference Standard; Mycophenolate mofetil, United States Pharmacopeia (USP) Reference Standard; Mycophenolate mofetil for peak identification, European Pharmacopoeia (EP) Reference Standard; Mycophenolate Mofetil, Pharmaceutical Secondary Standard; Certified Reference Material; (1s,3r,4s)-2-amino-9-[4-(benzyloxy)-3-(benzyloxymethyl)-2-methylidene-cyclopentyl]-3h-purin-6-one; (E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic Acid 2-(4-Morpholinyl)ethyl Ester; 2-(4-MORPHOLINO)ETHYL (E)-6-(1,3-DIHYDRO-4-HYDROXY-6-METHOXY-7-METHYL)-3-OXO-5-ISOBENZOFURANYL)-4-METHYL-4-HEXENOATE; 2-(4-Morpholinyl)ethyl (E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate; 2-morpholin-4-ylethyl (E)-6-(6-methoxy-7-methyl-4-oxidanyl-3-oxidanylidene-1H-2-benzofuran-5-yl)-4-methyl-hex-4-enoate; 4-Hexenoic acid,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E); 6-((7-hydroxy-5-methoxy-4-methyl-1-oxo-3h-isobenzofuran-6-yl))-4-methyl-hex-4-enoic acid 2-morpholinoethyl ester; 6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester; morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate; Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)- 4-methylhex-4-enoate; Morpholinoethyl E-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate; Morpholinoethyl E-6-(1,3-dihydro-4-hydroxy-6-methoxy-7methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate	Approved	Approved Drug(s)	5281078	DB00688	D0HV6R	433.5	94.5	646	3.2	31	1	8	10	C23H31NO7	2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate	CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)OCCN3CCOCC3)O	CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O	InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+	RTGDFNSFWBGLEC-SYZQJQIISA-N
D4QE8J	Raltegravir	Small molecule	Raltegravir; 518048-05-0; MK-0518; Isentress; Raltegravir (MK-0518); MK0518; Raltegravir (INN); MK 0518; N-(2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide; DTXSID2048660; 22VKV8053U; 518048-05-0 (free); 4-Pyrimidinecarboxamide, N-((4-fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-; N-(2-(4-(4-Fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide; NCGC00184997-01; RALTEGRAVIR [INN]; N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-yl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide; DTXCID5028586; Isentress(TM); N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide; CAS-518048-05-0; Raltegravir [USAN:INN]; raltegravirum; UNII-22VKV8053U; HSDB 8124; N-(4-FLUOROBENZYL)-5-HYDROXY-1-METHYL-2-(1-METHYL-1-(((5-METHYL-1,3,4-OXADIAZOL-2-YL)CARBONYL)AMINO)ETHYL)-6-OXO-1,6-DIHYDROPYRIMIDINE-4-CARBOXAMIDE; N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-di hydropyrimidine-4-carboxamide; N-(4-Fluorobenzyl)-5-Hydroxy-1-Methyl-2-(1-Methyl-1-{[(5-Methyl-1,3,4-Oxadiazol-2-Yl)carbonyl]amino}ethyl)-6-Oxo-1,6-Dihydropyrimidine-4-Carboxamide; RLT; Raltegravir- Bio-X; RALTEGRAVIR [MI]; N-[1-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxo-pyrimidin-2-yl]-1-methyl-ethyl]-5-methyl-1,3,4-oxadiazole-2-carboxamide; Raltegravir; MK-0518; K-0518; RALTEGRAVIR [VANDF]; Raltegravir - MK-0518; RALTEGRAVIR [MART.]; hydropyrimidine-4-carboxamide; SCHEMBL51817; RALTEGRAVIR [WHO-DD]; MLS006011985; SCHEMBL996804; RALTEGRAVIR [EMA EPAR]; CHEMBL254316; SCHEMBL2112870; BDBM25351; CHEBI:82960; GTPL11571; BCPP000093; HMS3655B09; BCP01394; EX-A2147; Tox21_113019; MFCD10698872; NSC762522; s2005; AKOS015902444; AKOS025149884; AKOS032960305; Tox21_113019_1; AC-5261; CCG-269170; DB06817; NSC-762522; PB13312; SB20935; NCGC00274066-01; NCGC00274066-05; AS-16992; BR164312; HY-10353; SMR003601806; FT-0649660; SW220138-1; A25486; D06676; EN300-120882; MK-0518;MK 0518;MK0518; yl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide; AB01566833_01; A828788; Q421552; BRD-K05658747-237-01-1; [(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-; N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-; Z1532717445; (Z)-N-(2-(4-(((4-Fluorophenyl)(methyl)amino)(hydroxy)methylene)-1-methyl-5,6-dioxo-1,4,5,6-tetrahydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide; MK-0518;N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxamide Potassium Salt; N-(2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1, 6-dihydropyrimidin-2-yl)propan-2-yl) -5-methyl-1,3,4-oxadiazole-2- carboxamide; N-(2-(4-(4-FLUOROBENZYLCARBAMOYL)-5-HYDROXY-1-METHYL-6-OXO-1,6- DIHYDROPYRIMIDIN-2-YL)PROPAN-2-YL)-5-METHYL-1,3,4-OXADIAZOLE-2-CARBOXAMIDE; N-(2-(4-(4-Fluorobenzylcarbamoyl)-5-OH-1-Me-6-oxo-pyrimidin-2-yl)propan-2-yl)-5-Me-1,3,4-oxadiazole-2-carboxamide; N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}propan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide; N-[2-(4-{[(4-fluorophenyl)methyl]carbamoyl}-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide	Approved	Approved Drug(s)	54671008	DB06817	D0I1FQ	444.4	150	836	1.1	32	3	9	6	C20H21FN6O5	N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide	CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F	CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F	InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)	CZFFBEXEKNGXKS-UHFFFAOYSA-N
D6QY3F	Dasatinib	Small molecule	Dasatinib; 302962-49-8; Sprycel; BMS-354825; Dasatinib anhydrous; BMS 354825; BMS354825; Dasatinib (BMS-354825); Dasatinib (anhydrous); N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; anh. dasatinib; anhydrous dasatinib; dasatinib (anh.); CHEMBL1421; X78UG0A0RN; DTXSID4040979; CHEBI:49375; NSC732517; NSC-732517; NSC-759877; NCGC00181129-01; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-; DTXCID2020979; dasatinibum; BMS-354825 HYDRATE; C22H26ClN7O2S; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-; SMR002529551; CAS-302962-49-8; 302962-49-8 pound not863127-77-9; Dasatinib [USAN:INN]; UNII-X78UG0A0RN; BMS Dasatinib; 1N1; Kinome_3650; Dasatinib (JAN/INN); DASATINIB [INN]; DASATINIB [MI]; n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; Sprycel (Bristol Meyers); DASATINIB [WHO-DD]; SCHEMBL8226; Dasatinib,BMS-354825; MLS003915609; MLS004774145; MLS006010904; Dasatinib - BMS-354825; GTPL5678; BDBM13216; cid_3062316; EX-A401; 5-Thiazolecarboxamide, monohydrate; BCPP000263; HMS2043N05; HMS3244A05; HMS3244A06; HMS3244B05; HMS3265C19; HMS3265C20; HMS3265D19; HMS3265D20; HMS3654K05; HMS3744C11; Pharmakon1600-01502275; BCP01797; Tox21_112736; MFCD11046566; NSC759877; NSC800087; s1021; AKOS015902363; Tox21_112736_1; BCP9000589; BMS 345825; CCG-264779; CS-0100; DB01254; GS-6548; NSC-800087; SB17284; NCGC00181129-02; NCGC00181129-03; NCGC00181129-05; NCGC00181129-06; NCGC00181129-07; NCGC00181129-12; NCGC00181129-14; NCGC00181129-22; NCGC00481571-01; 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide; AC-22749; BCB03_000715; BMS 35482513; HY-10181; N-(2-chloro-6-methyl-phenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl]amino]thiazole-5-carboxamide; AM20080877; D5949; FT-0650671; SW208076-5; EC-000.2122; D-3307; D03658; EN300-123025; AB01273956-01; AB01273956-02; AB01273956_03; AR-270/43507994; Q419940; SR-00000000554; Q-101345; SR-00000000554-5; BRD-K49328571-001-05-1; BRD-K49328571-001-07-7; BMS-354825;BMS354825;BMS 354825; Z1546610486; N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl}amino)-1,3-thiazole-5-carboxamide; N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide	Approved	Approved Drug(s)	3062316	DB01254	D0I1PS	488	135	642	3.6	33	3	9	7	C22H26ClN7O2S	N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO	InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)	ZBNZXTGUTAYRHI-UHFFFAOYSA-N
DVUW42	Metoprolol	Small molecule	metoprolol; 51384-51-1; (RS)-Metoprolol; Beatrolol; dl-Metoprolol; Spesicor; 37350-58-6; Seroken; Toprol; Metohexal; Preblok; Meijoprolol; Metoprololum; Presolol; Selo-Zok; rac Metoprolol-d7; Loresor; TOPROL-XL; 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol; CGP 2175; CGP-2175; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol; (+/-)-Metoprolol; Metoprolol slow release; CHEMBL13; 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol; GEB06NHM23; CHEBI:6904; Betalok; DTXSID2023309; Spesikor; 51384-51-1 (free base); 2-Propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)-; Lopresoretic; 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-; H-93/26; Metoprololum [INN-Latin]; Metoprolol [USAN:INN:BAN]; Neobloc; Metrol; {2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl}(propan-2-yl)amine; 1-[4-(2-methoxyethyl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol; 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-, (.+/-.)-; LOPRESSIDONE; CCRIS 4198; HSDB 6531; CGP2175; Metoprolol (USAN/INN); UNII-GEB06NHM23; 1-(4-(2-methoxyethyl)phenoxy)-3-(propan-2-ylamino)propan-2-ol; metoprolol tartarate; EINECS 257-166-4; Lopresol (Salt/Mix); METOPROLOL [MI]; Lopresoretic (Salt/Mix); METOPROLOL [INN]; (.+/-.)-Metoprolol; METOPROLOL [HSDB]; METOPROLOL [USAN]; METOPROLOL [VANDF]; METOPROLOL [MART.]; SCHEMBL4093; METOPROLOL [WHO-DD]; GTPL553; 1-(Isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]-2-propanol; H 93/26 (Salt/Mix); DTXCID503309; BDBM25756; METOPROLOL, (+/-)-; HMS2090B15; HMS3886O04; BCA38451; BCP09038; GP-2175E; Tox21_303972; MFCD00599534; s5430; STL301858; AKOS005927923; BG-0006; CCG-204813; CS-3159; DB00264; SDCCGSBI-0050706.P005; NCGC00021148-03; NCGC00021148-04; NCGC00021148-05; NCGC00021148-21; NCGC00356981-01; 54163-88-1; AC-19022; HY-17503; SBI-0050706.P004; 3-BROMO-4,5-DIHYDROXYBENZYLALCOHOL; CAS-51384-51-1; DB-049097; A2878; AB00053499; FT-0602794; FT-0672382; FT-0672383; FT-0672385; C07202; D02358; EN300-317058; AB00053499-21; AB00053499_22; AB00053499_23; A823609; A871296; L000669; Q409468; Q-201400; SR-01000003148-2; BRD-A03623303-045-02-0; BRD-A03623303-045-05-3; Z398538014; 1-Isopropylamino-3-[p-(2-methoxyethyl)phenoxy]-2-propanol; 1-(Isopropylamino)-3-[p-(2-methoxyethyl)phenoxy]-2-propanol; 1-Isopropylamino-3-[4-(2-methoxy-ethyl)-phenoxy]-propan-2-ol; (+/-)-1-(Isopropylamino)-3-(p-(beta-methoxyethyl)phenoxy)-2-propanol; 1-(4-(2-Methoxyethyl)-phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-(4-(2-METHOXYETHYL)PHENOXY)-3-((1-METHYLETHYL)AMINO)-2-PROPANOL; (2R,3R)-2,3-dihydroxysuccinic acid;1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol	Approved	Approved Drug(s)	4171	DB00264	D0I2MK	267.36	50.7	215	1.9	19	2	4	9	C15H25NO3	1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol	CC(C)NCC(COC1=CC=C(C=C1)CCOC)O	CC(C)NCC(COC1=CC=C(C=C1)CCOC)O	InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3	IUBSYMUCCVWXPE-UHFFFAOYSA-N
DUL5M0	Levamlodipine	Small molecule	Levamlodipine; (S)-Amlodipine; 103129-82-4; S-Amlodipine; Levamlodipine [INN]; Amlodipine, (s)-; Levoamlodipine; CHEBI:53796; 0P6NLP6806; (4S)-2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic Acid 3-Ethyl 5-Methyl Ester; Levoamlodipine Besylate; 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, (4S)-; 3-Ethyl 5-methyl (4S)-2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl (4S)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl (S)-2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; (-)-Amlodipine; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, (4S)-; UNII-0P6NLP6806; S-Amlodipine Besylate; SCHEMBL41283; LEVAMLODIPINE [WHO-DD]; CHEMBL2111097; DTXSID50904504; HMS3885M19; BCP22052; MFCD09832686; s3674; AKOS015896087; AM90308; BCP9000849; CCG-268748; DB09237; AGSAV301 COMPONENT LEVAMLODIPINE; BS-42190; HY-14744; CS-0003533; A14935; D97381; A800681; EN300-19633977; Q-101935; Q6534831; 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-3-ethoxy-carbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 3-O-ethyl 5-O-methyl (4S)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate	Approved	Approved Drug(s)	9822750	DB09237	D0I2WV	408.9	99.9	647	3	28	2	7	10	C20H25ClN2O5	3-O-ethyl 5-O-methyl (4S)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN	CCOC(=O)C1=C(NC(=C([C@@H]1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN	InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3/t17-/m0/s1	HTIQEAQVCYTUBX-KRWDZBQOSA-N
DSQL43	Quinapril	Small molecule	quinapril; 85441-61-8; Quinaprilum [Latin]; Quinaprilum; Accuretic; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; CHEBI:8713; CI-906; C09AA06; Quinapril (INN); RJ84Y44811; 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, (3S)-; QUINAPRIL [INN]; CI-906 (free acid); Quinapril [USP:INN:BAN]; UNII-RJ84Y44811; Quinapril (Korec); Spectrum_001597; QUINAPRIL [MI]; Spectrum2_000825; Spectrum3_001551; Spectrum4_000727; Spectrum5_001075; QUINAPRIL [VANDF]; QUINAPRIL [WHO-DD]; CHEMBL1592; SCHEMBL15813; BSPBio_003022; KBioGR_000994; KBioSS_002077; (3S)-2-{N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; BIDD:GT0797; DivK1c_000710; SPBio_000749; Quinapril Hydrochloride Hydrate; GTPL6350; DTXSID4023547; QUINAPRIL [USP IMPURITY]; HMS502D12; KBio1_000710; KBio2_002077; KBio2_004645; KBio2_007213; KBio3_002522; NINDS_000710; HMS2090L05; BDBM50368166; AKOS015950821; DB00881; IDI1_000710; NCGC00167962-01; NCGC00167962-02; NCGC00167962-03; NCGC00167962-05; (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; (3S)-2-{(2S)-2-[(1S)-1-ethoxycarbonyl-3-phenylpropylamino]propanoyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; 3-Isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-, (3S-(2(R*(R*)),3R*))-; SBI-0051931.P002; C07398; D03752; AB00053714-07; AB00053714_08; AB00053714_09; A841331; Q596022; BRD-K72222507-003-03-6; BRD-K72222507-003-07-7; (3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-{N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-{N-[(2S)-1-ethoxycarbonyl-4-phenylbutan-2-yl]-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (S)-2-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; 90243-99-5	Approved	Approved Drug(s)	54892	DB00881	D0I7SZ	438.5	95.9	648	1.2	32	2	6	10	C25H30N2O5	(3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid	CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC=CC=C3CC2C(=O)O	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O	InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1	JSDRRTOADPPCHY-HSQYWUDLSA-N
D5ZBX9	Isoproterenol	Small molecule	isoproterenol; Isoprenaline; Novodrin; Isopropydrin; 7683-59-2; Bellasthman; Isoprenalin; Norisodrine; Aludrine; Asiprenol; Asmalar; Assiprenol; Respifral; Neodrenal; Proternol; neo-Epinine; Isopropylarterenol; Saventrine; Aludrin; Isadrine; Isonorin; Isorenin; N-Isopropylnoradrenaline; Isonorene; Isopropyladrenaline; Lomupren; N-Isopropylnorepinephrine; Isopropylnorepinephrine; Vapo-N-iso; Isupren; DL-ISOPROTERENOL; Isopropylnoradrenaline; Isopropyl noradrenaline; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Epinephrine isopropyl homolog; Isoprenalinum; Aleudrin; Aleudrine; (+-)-Isoprenaline; Isoprenalina; 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol; Dihydroxyphenylethanolisopropylamine; WIN 5162; 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 149-53-1; ICI 46399; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; alpha-(Isopropylaminomethyl)protocatechuyl alcohol; 1,2-Benzenediol, 4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; Isoprenaline (INN); Isoprenaline [INN]; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-; NSC-9975; NSC-33791; CHEMBL434; 4-(1-Hydroxy-2-(isopropylamino)ethyl)benzene-1,2-diol; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; Isoproterenolum; DTXSID4023175; CHEBI:64317; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; L628TT009W; 7683-59-2 (free); NSC33791; 3,4-dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; NCGC00015558-06; 3,4-Dihydroxy-.alpha.-(isopropylaminomethyl)-benzyl alcohol; A-21; Isoproterenol [JAN]; Protocatechuyl alcohol,-; DL(+-)-Isoproterenol; Isoprenalinum [INN-Latin]; .alpha.-(Isopropylaminomoethyl)protocatechuyl alcohol; DTXCID603175; Isoprenalina [INN-Spanish]; Isoproterenol Chloride; WLN: QR BQ DYQ1MY1&1; 3,4-Dihydroxy-.alpha.-[(isopropylamino)methyl]benzyl alcohol; 4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; CAS-7683-59-2; ISOPROP; CCRIS 3081; NSC 9975; 1, 4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-; EINECS 231-687-7; NSC 33791; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; 4-[1-hydroxy-2-(isopropylamino)ethyl]benzene-1,2-diol; BRN 2213857; Benzyl alcohol,4-dihydroxy-.alpha.-[(isopropylamino)methyl]-; Isoproterenol-l; Isoproterenol;; UNII-L628TT009W; 3,4-DIHYDROXY-.ALPHA.-((ISOPROPYLAMINO)METHYL)BENZYL ALCOHOL; 4-[1-Hydroxy-2-(isopropylamino)ethyl]-1,2-benzenediol; Isoproterenol (-); Isoproterenol,(+); Protocatechuyl alcohol, alpha-(isopropylaminomethyl)-; ISOPROTERONOL; Isoproterenol dl-form; Isuprel (Salt/Mix); Izadrin (Salt/Mix); Euspiran (Salt/Mix); L-Isoproterenol; Levisoprenaline; Proternol L; (+/-)-isoprenaline; (+/-)-isoproterenol; Spectrum_000949; Prestwick0_001097; Prestwick1_001097; Prestwick2_001097; Spectrum2_001061; Spectrum3_000474; Spectrum4_000024; Spectrum5_000880; (.+/-.)-Isoprenaline; ISOPROTERENOL [MI]; (.+/-.)-Isoproterenol; SCHEMBL4165; DL(.+/-.)-Isoproterenol; Lopac0_000711; Oprea1_009434; BSPBio_002208; GTPL536; ISOPRENALINE [MART.]; ISOPROTERENOL [VANDF]; KBioGR_000427; KBioSS_001429; 3-13-00-02387 (Beilstein Handbook Reference); DivK1c_000894; ISOPRENALINE [WHO-DD]; SPBio_001042; SPBio_003057; SGCUT00015; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; BDBM25392; KBio1_000894; KBio2_001429; KBio2_003997; KBio2_006565; KBio3_001428; NSC9975; NINDS_000894; HMS2089A12; HMS3742A11; ISOPROTERENOL DL-FORM [MI]; BCP09043; Benzyl alcohol, 3,4-dihydroxy-alpha-((isopropylamino)methyl)-; to_000062; (A+/-)-Isoproterenol hydrochloride; Tox21_110172; PDSP1_001425; PDSP2_001409; STL558077; AKOS015913894; Tox21_110172_1; CCG-204727; CCG-204796; DB01064; SDCCGSBI-0050620.P003; SDCCGSBI-0050689.P005; IDI1_000894; NCGC00015558-04; NCGC00015558-05; NCGC00015558-07; NCGC00015558-08; NCGC00015558-09; NCGC00015558-10; NCGC00015558-11; NCGC00015558-12; NCGC00015558-14; NCGC00015558-25; NCGC00016665-02; NCGC00025274-03; NCGC00025274-04; NCGC00162220-01; SBI-0050689.P004; HY-108353; CS-0028436; FT-0724367; C07056; D08090; EN300-148243; AB00053487-09; AB00053487-10; AB00053487_11; AB00053487_12; AG-219/03618046; L000936; Q415550; .alpha.-(Isopropylaminomethyl)protocatechuyl alcohol; Protocatechuyl alcohol,.alpha.-(isopropylamino-methyl),-; 4-[1-Hydroxy-2-(isopropylamino)ethyl]-1,2-benzenediol #; N-Isopropyl-.beta.-dihydroxyphenyl-.beta.-hydroxyethylamine; 4-[1-hydroxy-2-(isopropylamino)ethyl]pyrocatechol;hydrochloride; 4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol, 2; Benzyl alcohol, 3,4-dihydroxy-.alpha.-((isopropylamino)methyl)-; 114-45-4; Iso	Approved	Approved Drug(s)	3779	DB01064	D0I8FI	211.26	72.7	187	-0.6	15	4	4	4	C11H17NO3	4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol	CC(C)NCC(C1=CC(=C(C=C1)O)O)O	CC(C)NCC(C1=CC(=C(C=C1)O)O)O	InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3	JWZZKOKVBUJMES-UHFFFAOYSA-N
DJ0EI7	Cabozantinib	Small molecule	Cabozantinib; 849217-68-1; XL184; Cometriq; XL-184; BMS-907351; XL 184; BMS 907351; XL-184 free base; Cabozantinib (XL184, BMS-907351); Cabozantinib [USAN]; CHEBI:72317; BMS907351; 1C39JW444G; BMS-907351 FREE BASE; MFCD20926324; Cabozantinib (USAN); N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE; XL-184 (Cabozantinib,BMS907351); Cabometyx (TN); Cometriq (TN); 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; 1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-; N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; XL184 cpd; Cabozantinib [USAN:INN]; Carbozantinib; UNII-1C39JW444G; 1,1-CYCLOPROPANEDICARBOXAMIDE, N'-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N-(4-FLUOROPHENYL)-; XL184 free base; Cabozantinib (free base); CABOZANTINIB [MI]; CABOZANTINIB [INN]; CABOZANTINIB [VANDF]; CABOZANTINIB [WHO-DD]; SCHEMBL360795; GTPL5887; Cabozantinib (BMS-907351); CHEMBL2105717; DTXSID10233968; EX-A075; XL184 free base - Cabozantinib; BCPP000308; HMS3654G06; XL-184 free base (Cabozantinib); BCP02591; 849217-68-1 (free base); BDBM50021574; NSC761068; NSC800066; s1119; AKOS025142112; BCP9000470; CCG-264678; CS-0278; DB08875; NSC-761068; NSC-800066; SB20062; XL-184,Cabozantinib, BMS-907351; NCGC00263164-01; NCGC00263164-14; NCGC00263164-17; 1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-; AC-25082; AS-16277; HY-13016; N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide; SY097158; DB-023624; FT-0664184; SW218093-3; D10062; AB01565831_02; Q795057; SR-01000941569; J-523016; SR-01000941569-1; BRD-K51544265-001-01-8; 1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-; 1,1-CYCLOPROPANEDICARBOXAMIDE, N-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)-; cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide; cyclopropane-1,1-dicarboxylic acid[4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide; N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4 fluorophenyl)cyclopropane-1,1-dicarboxamide; N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; N-[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]-N inverted exclamation mark -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Approved	Approved Drug(s)	25102847	DB08875	D0IQ6P	501.5	98.8	795	5.4	37	2	7	8	C28H24FN3O5	1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F	InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)	ONIQOQHATWINJY-UHFFFAOYSA-N
DS9BF1	Dexamethasone	Small molecule	dexamethasone; 50-02-2; Decadron; Maxidex; Dexamethazone; Hexadecadrol; Dexasone; Hexadrol; Decaspray; Millicorten; Oradexon; Prednisolone F; Fluormethylprednisolone; Aeroseb-Dex; Cortisumman; Desametasone; Dexacortal; Dexacortin; Fortecortin; Gammacorten; Superprednol; Visumetazone; Auxiron; Calonat; Decaderm; Dexacort; Dexason; Azium; Dexone; Deltafluorene; Desamethasone; Mediamethasone; Aphtasolon; Decasone; Dectancyl; Dekacort; Dergramin; Desadrene; Desameton; Dexadeltone; Dexalona; Dexameth; Dexapolcort; Dextelan; Dinormon; Loverine; Luxazone; Mymethasone; Turbinaire; Corsone; Decalix; Mexidex; Dexa-Cortidelt; Dexa-Cortisyl; Dexa-Scheroson; Prednisolon F; Dexa-sine; Isopto-Dex; Aeroseb-D; SK-Dexamethasone; Anaflogistico; Decacortin; Deseronil; Dexafarma; Dexaprol; Dexinolon; Dexinoral; Policort; Spoloven; Decagel; Deronil; Dezone; Sunia Sol D; Bisu DS; Dexa Mamallet; Hexadrol Elixir; Lokalison F; Ocu-trol; Dex-ide; Hl-dex; Dexamethasonum; Dexone 4; Fluorocort; Decaject; Decameth; Fluormone; Corson; Dexpak; Pet Derm III; Dxms; Dexamethasone alcohol; Hexadrol Tablets; Dexamethasone Intensol; Methylfluorprednisolone; Desametasone [DCIT]; Dexone 0.5; Dexone 1.5; Dexone 0.75; Dexametasona; Ozurdex; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexapos; Decadron Tablets, Elixir; 9alpha-Fluoro-16alpha-methylprednisolone; Azium (Veterinary); Dexamethansone; Dextenza; Posurdex; Prodex; OTO-104; MK 125; (3H)-Dexamethasone; Azimycin (Veterinary); NSC 34521; Dexametasone; Naquasone (Veterinary); Tresaderm (Veterinary); Dexycu; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; DexaSite; 16alpha-Methyl-9alpha-fluoroprednisolone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; delta1-9alpha-Fluoro-16alpha-methylcortisol; MFCD00064136; Decacort; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; Dexamethasone (GMP); DTXSID3020384; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; ISV-305; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; (11beta,16alpha)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; NSC-34521; Dexamethasone (DHAP); 7S5I7G3JQL; MLS001332507; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; CHEBI:41879; 9-Fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; [3H]-dexamethasone; Decaject-L.A.; (1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one; Aphthasolone; Dexamonozon; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; Osurdex; Dexamethasone Base; Decadron (TN); (8S,9R,10S,11S,13S,14S,16R,17R)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]ph; SMR000857119; DXM [Steroid]; CCRIS 7067; HSDB 3053; dexamethasone (tetramethyl-rhodamine conjugated ); Prednisolone, 9.alpha.-fluoro-16.alpha.-methyl-; EINECS 200-003-9; UNII-7S5I7G3JQL; Solurex; .delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol; 16.alpha.-Methyl-9.alpha.-fluoro-.delta.(sup1)-hydrocortisone; Diodex; NSC34521; AI3-50934; .gamma.corten; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; Apo-dexamethasone; Prednisolone, 9alpha-fluoro-16alpha-methyl-; Dexasone 4mg; Zema-Pak; PHL-dexamethasone; PMS-dexamethasone; [3H]dexamethasone; Dexamethasone-omega; NCGC00091019-08; Dexasone 0.5mg; Dexamethasone [USP:INN:BAN:JAN]; Dexasone 0.75mg; Sandoz Dexamethasone; HEMADY; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-; Dexamethasone, topical; Maxidex Ont 0.1%; Maxidex Sus 0.1%; dexamethasone-17-acetate; Spectrum5_002019; DEXAMETHASONE [MI]; MolMap_000018; DEXAMETHASONE [INN]; DEXAMETHASONE [JAN]; SCHEMBL3774; 16-alpha-Methyl-9-alpha-fluoro-1,4-pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; 16-alpha-Methyl-9-alpha-fluoro-11-beta,17-alpha,21-trihydroxypregna-1,4-diene-3,20-dione; 4-alpha-Fluoro-16-alpha-methyl-11-beta,17,21-trihydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-methyl-1,4-pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; DEXAMETHASONE [HSDB]; BIDD:PXR0060; BSPBio_000995; DEXAMETHASONE [VANDF]; MLS001055412; MLS001332508; BIDD:ER0494; DEXAMETHASONE [MART.]; DTXCID10384; sustained-release dexamethasone; DEXAMETHASONE [USP-RS]; DEXAMETHASONE [WHO-DD]; DEXAMETHASONE [WHO-IP]; CHEMBL384467; GTPL2768; GTPL3447; SGCUT00126; 9-Fluoro-16-methylprednisolone; Ak Dex Oph Otic Soln 0.1%; DEXAMETHASONE [EMA EPAR]; BDBM18207; Dexamethasone (anti-inflammatory); Dexamethasone (JP17/USP/INN); 1p93; DEXAMETHASONE [GREEN BOOK]; HMS1792A17; HMS1990A17; HMS2089N13; HMS2235F08; HMS3039L11; HMS3259N11; HMS3403A17; DEXAMETHASONE [ORANGE BOOK]; AMY28815; to_000038; DEXAMETHASONE [EP MONOGRAPH]; Tox21_200122; DEXAMETHASONE [USP MONOGRAPH]; Dexamethasone, >=97.0% (HPLC); HB2521; HY-14648G; IBI-10090; MK-125; s1322; Dexamethasone 1.0 mg/ml in Methanol; DEXAMETHASONUM [WHO-IP LATIN]; PMS Dexamethasone Elixir 0.5mg/5ml; AKOS005259009; AKOS015895509; CIPRODEX COMPONENT DEXAMETHASONE; Decadron phosphate, Decdan, Dexacort,; MAXITROL COMPONENT DEXAMETHASONE; TOBRADEX COMPONENT DEXAMETHASONE; CCG-264887; CS-1505; DB01234; KS-1451; NC00645; alpha -Fluoro-16-alpha -methylcortisol; CAS-50-02-2; DEXACIDIN COMPONENT DEXAMETHASONE; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-16alpha-methyl-; SMP1_000092; Dexamethasone, >=98% (HPLC), powder; DEXASPORIN COMPONENT DEXAMETHASONE; NCGC00091019-01; NCGC00091019-02; NCGC00091019-03; NCGC00091019-04; NCGC00091019-05; NCGC00091019-06; NCGC00091019-07; NCGC00091019-23; NCGC00257676-01; (11beta,16alpha)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione labeled with tritium; 23495-06-9; 9alpha-fluoro-16alpha-methyl-Prednisolone; AC-11056; DEXAMETHASONE COMPONENT OF CIPRODEX; DEXAMETHASONE COMPONENT OF MAXITROL; DEXAMETHASONE COMPONENT OF TOBRADEX; HY-14648; NCI60_003067; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, labeled with tritium, (11beta,16alpha)-; SMR001227192; TOBRADEX ST COMPONENT DEXAMETHASONE; DEXAMETHASONE COMPONENT OF DEXACIDIN; 16alpha -Methyl-9alpha -fluoroprednisolone; 9alpha -Fluoro-16alpha -methylprednisolone; DEXAMETHASONE COMPONENT OF DEXASPORIN; Dexamethasone, tested according to Ph.Eur.; CS-0626118; DEXAMETHASONE COMPONENT OF TOBRADEX ST; BETAMETHASONE IMPURITY A [EP IMPURITY]; EN300-52607; D00292; Dexamethasone, meets USP testing specifications; Prednisolone, 9alpha -fluoro-16alpha -methyl-; 9.alpha.-Fluoro-16.alpha.-methyl-1,20-dione; AB00918428-05; AB00918428-08; AB00918428-09; AB00918428_10; 16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol; Dexamethasone, VETRANAL(TM), analytical standard; Q422252; Q-200939; BRD-K38775274-001-02-3; BRD-K38775274-001-06-4; DEXAMETHASONE ACETATE IMPURITY A [EP IMPURITY]; 1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone; 9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione; Dexamethasone, British Pharmacopoeia (BP) Assay Standard; Z756391748; Pregna-1,4-diene-3,20-dione, 9-fluoro-11alpha -methyl-; Dexamethasone, European Pharmacopoeia (EP) Reference Standard; WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1; Dexamethasone, powder, BioReagent, suitable for cell culture, >=97%; Dexamethasone, United States Pharmacopeia (USP) Reference Standard; 16-.alpha.-Methyl-9-.alpha.-fluoro-1,17-.alpha.,21-triol-3,20-dione; 4.alpha.-Fluoro-16.alpha.-methyl-11.beta.-17,4-diene-3,20-dione; Pregna-1,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-16.alpha.-methyl-; 16.alpha.-Methyl-9.alpha.-fluoro-11.beta.-17.alpha.-21-trihydroxypregna-1,20-dione; 9-Fluoro-11.beta.,21-trihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione; 9-fluoro-16alpha-methyl-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.-17.alpha.- 21-trihydroxy-16.alpha.-methylpregna-1,20-dione; Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard; Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard; Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material; Dexamethasone, powder, gamma-irradiated, BioXtra, suitable for cell culture, >=80% (HPLC); Pregna-1,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11.beta.,16.alpha.)-; (11.BETA.,16.ALPHA.)-9-FLUORO-11,17,21-TRIHYDROXY-16-METHYLPREGNA-1,4-DIENE-3,20-DIONE; (1R,2R,3aS,3bS,9aS,9bR,10S,11aS)-9b-fluoro-1,10-dihydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one; (1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo-; (1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-5-one; 1050677-47-8; 9.alpha.-Fluoro-16.alpha.-methyl-11.beta.,21.beta.-trihydroxy-pregna-1,4-diene-3,20-dione; PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,17,21-TRIHYDROXY-16-METHYL-,(11.BETA.,16.ALPHA.)-9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE	Approved	Approved Drug(s)	5743	DB01234	D0IT2G	392.5	94.8	805	1.9	28	3	6	2	C22H29FO5	(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one	CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C	InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1	UREBDLICKHMUKA-CXSFZGCWSA-N
DCJ2O5	Idelalisib	Small molecule	Idelalisib; 870281-82-6; CAL-101; Zydelig; GS-1101; CAL 101; CAL101; (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 1146702-54-6; Idelalisib (CAL-101); CAL-101 (Idelalisib, GS-1101); GS 1101; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; YG57I8T5M0; CHEMBL2216870; CHEBI:82701; Idelalisib; CAL-101; 5-fluoro-3-phenyl-2-((1s)-1-(9h-purin-6-ylamino)propyl)-4(3h)-quinazolinone; 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one; 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one; 5-Fluoro-3-Phenyl-2-[(1s)-1-(7h-Purin-6-Ylamino)propyl]quinazolin-4(3h)-One; 1453810-72-4; Idelalisib [INN]; Idelalisib [USAN:INN]; UNII-YG57I8T5M0; Idealisib; C22H18FN7O; Zydelig (TN); IDELALISIB [MI]; IDELALISIB [JAN]; IDELALISIB [USAN]; IDELALISIB [VANDF]; IDELALISIB [WHO-DD]; MLS006010985; Idelalisib (JAN/USAN/INN); SCHEMBL356400; GTPL6741; IDELALISIB [ORANGE BOOK]; SCHEMBL16782604; HSDB 8408; AMY9239; CAL-101/CAL101; EX-A330; GS-11CAL-101; BCPP000307; DTXSID701007266; BCP02532; EX-A1242; BDBM50403068; MFCD19443647; NSC759224; NSC762828; NSC800771; s2226; AKOS022186334; Idelalisib (CAL-101,GS-1101); BCP9000471; CCG-264949; CS-0256; DB09054; NSC-759224; NSC-762828; NSC-800771; CAL-101 (GS-1101); NCGC00262603-01; NCGC00262603-02; NCGC00262603-04; AC-28394; AC-36641; HY-13026; IC489666; SMR004702787; SW219823-1; A-1138; D10560; EN300-7412931; J-517532; Q5908266; BRD-K60866521-001-01-4; (S)-5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one; 4(3H)-QUINAZOLINONE, 5-FLUORO-3-PHENYL-2-((1S)-1-(1H-PURIN-6-YLAMINO)PROPYL)-; 4(3H)-QUINAZOLINONE, 5-FLUORO-3-PHENYL-2-((1S)-1-(9H-PURIN-6-YLAMINO)PROPYL)-; 4(3H)-Quinazolinone,5-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]-; 5-fluoro-3-phenyl-2-[(1S)-1-[(9H-purin-6-yl)amino]propyl]-3,4-dihydroquinazolin-4-one; 40L	Approved	Approved Drug(s)	11625818	DB09054	D0J5VR	415.4	99.2	685	3.7	31	2	7	5	C22H18FN7O	5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one	CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5	CC[C@@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5	InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1	IFSDAJWBUCMOAH-HNNXBMFYSA-N
DS74IA	Fosphenytoin	Small molecule	Fosphenytoin; 93390-81-9; Cerebyx; (3-Phosphoryloxymethyl)phenytoin; Fosfenitoina [INN-Spanish]; Fosphenytoine [INN-French]; Fosphenytoinum [INN-Latin]; (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate; Fosphenytoin (INN); CHEBI:5165; DTXSID9044299; NP-06; B4SF212641; Fosfenitoina; Fosphenytoine; Fosphenytoinum; 2,4-Imidazolidinedione, 5,5-diphenyl-3-((phosphonooxy)methyl)-; FOSPHENYTOIN [INN]; Fosphenytoin [INN:BAN]; [(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methoxy]phosphonic acid; Sesquient; UNII-B4SF212641; HSDB 7523; FOSPHENYTOIN [MI]; 2,4-Imidazolidinedione, 5,5-diphenyl-3-((phosphonooxy)methyl)-, (SP-4-2)-; FOSPHENYTOIN [HSDB]; FOSPHENYTOIN [VANDF]; SCHEMBL94254; BIDD:GT0220; FOSPHENYTOIN [WHO-DD]; GTPL7190; CHEMBL1201336; DTXCID7024299; HY-B1657; Tox21_113670; DB01320; NCGC00249894-01; CAS-93390-81-9; CS-0013613; FT-0738599; C07840; D07993; EN300-18563827; Q5473363; 3-(HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN, PHOSPHATE (ESTER); [(2-hydroxy-5-oxo-4,4-diphenyl-4,5-dihydro-1H-imidazol-1-yl)methoxy]phosphonic acid	Approved	Approved Drug(s)	56339	DB01320	D0J5YC	362.27	116	547	0.6	25	3	6	5	C16H15N2O6P	(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate	C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3	C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3	InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)	XWLUWCNOOVRFPX-UHFFFAOYSA-N
DU0JB1	Lenalidomide	Small molecule	Lenalidomide; 191732-72-6; Revlimid; Revimid; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; CC-5013; Lenalidomide (CC-5013); Lenadoamide; CDC 501; CDC-501; IMiD3; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; CC 5013; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; C13H13N3O3; Revlimid (TN); NSC-747972; (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; DTXSID8046664; CHEBI:63791; F0P408N6V4; SYP-1512; MFCD07772307; 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; NCGC00167491-01; Lenalidomide [USAN]; 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione; DTXCID6026664; Revlimid (lenalidomide); 3-(4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione; CAS-191732-72-6; Lenalidomide (USAN/INN); UNII-F0P408N6V4; Lenalidomide [USAN:INN:BAN]; ENMD 0997; ENMD-0997; HSDB 8220; IMID-5013; CDC-5013; ALBB-015321; LENALIDOMIDE [MI]; LENALIDOMIDE [INN]; LENALIDOMIDE [JAN]; CHEMBL848; Revlimid (TN) (Celgene); LENALIDOMIDE [VANDF]; SCHEMBL32978; LENALIDOMIDE [MART.]; MLS003899194; LENALIDOMIDE [WHO-DD]; GTPL7331; SCHEMBL1980410; LENALIDOMIDE [EMA EPAR]; 3-(4-Amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione; BDBM65454; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; BCPP000186; HMS3654G07; HMS3674C05; LENALIDOMIDE [ORANGE BOOK]; BCP01390; HY-A0003; Revlimid, Lenalidomide, CC-5013; Tox21_112492; AC-914; NSC747972; s1029; STK639603; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-; AKOS005146276; AKOS005174869; Tox21_112492_1; BCP9000847; CCG-264781; CS-0125; DB00480; KS-1207; NSC 747972; SB66166; NCGC00167491-02; NCGC00167491-03; NCGC00167491-04; 443912-14-9; BL164614; BP-27972; SMR002529986; SY047646; AM20050439; FT-0659651; FT-0670758; FT-0670759; SW218084-2; EC-000.2340; D04687; EN300-118706; AB01273975-01; AB01273975-02; AB01273975_03; Q425681; SR-01000883999; Q-101410; SR-01000883999-1; Z1515385074; 2, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(4-amino-1,3-dihydro-1-oxo-2h-isoindol-2-yl)-2,6-piperidinedione; 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-dioxopiperidine; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione; 4-amino-2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindol-1-one	Approved	Approved Drug(s)	216326	DB00480	D0J7KR	259.26	92.5	437	-0.5	19	2	4	1	C13H13N3O3	3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione	C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N	C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N	InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)	GOTYRUGSSMKFNF-UHFFFAOYSA-N
D2RJD8	Eliglustat	Small molecule	ELIGLUSTAT; 491833-29-5; Genz 99067; Genz-99067; GENZ-112638; Eliglustat free base; N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide; DR40J4WA67; N-[(1r,2r)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide; CHEBI:82752; 491833-29-5 (free base); Eliglustat (Tartrate); N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]octanamide; Eliglustat [USAN:INN]; UNII-DR40J4WA67; MFCD19443735; ELIGLUSTAT [MI]; ELIGLUSTAT [INN]; Eliglustat (USAN/INN); ELIGLUSTAT [USAN]; ELIGLUSTAT [VANDF]; Eliglustat(Genz-99067); Eliglustat; Genz 99067; ELIGLUSTAT [WHO-DD]; SCHEMBL421755; GTPL7536; CHEMBL2110588; DTXSID20964175; GLXC-90436; EX-A2301; N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1- pyrrolidinyl)-2-propanyl]octanamide;eliglustat tartrate; s7852; AKOS022185521; CCG-101413; CS-5424; DB09039; NCGC00509905-01; AC-35323; BS-17368; HY-14885; N-((1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(pyrrolidin-1-ylmethyl)ethyl)octanamide; Octanamide, N-((1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl)-; D09893; EN300-259910; F53213; Q21011224; 1000191-50-3; N-((1R,2R)-2-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-2-HYDROXY-1-(PYRROLIDIN-1- YLMETHYL)ETHYL)OCTANAMIDE; N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamide; N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-7-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide; N-[(1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]octanamide; OCTANAMIDE, N-((1R,2R)-2-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-2-HYDROXY-1-(1- PYRROLIDINYLMETHYL)ETHYL)-	Approved	Approved Drug(s)	23652731	DB09039	D0J8IJ	404.5	71	484	3.7	29	2	5	11	C23H36N2O4	N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide	CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O	InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1	FJZZPCZKBUKGGU-AUSIDOKSSA-N
D9Z8HA	Olaparib	Small molecule	Olaparib; 763113-22-0; AZD2281; Lynparza; KU-0059436; AZD-2281; AZD 2281; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine; OLAPARIB cpd; Olaparib (AZD-2281); 4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; KU-59436; Olaparib (AZD2281, Ku-0059436); Olaparib [USAN:INN]; UNII-WOH1JD9AR8; WOH1JD9AR8; 4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one; C24H23FN4O3; AZ2281; MFCD13185161; NSC-747856; CHEBI:83766; 4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one; AZ-2281; KEYLYNK-010 COMPONENT OLAPARIB; KU59436; OLAPARIB COMPONENT OF KEYLYNK-010; Olaparib [INN]; 4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one; Olaparib (AZD2281; Ku-0059436); Olaparib (AZD2281); Olaparibum; AZD221; 4-[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2H)-one; Olaparib- Bio-X; Lynparza (TN); 09L; 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one; KU 59436; OLAPARIB [USAN]; OLAPARIB [JAN]; KU0059436; OLAPARIB [MI]; OLAPARIB [VANDF]; Olaparib - AZD2281; OLAPARIB [MART.]; OLAPARIB [WHO-DD]; AZD-2281 (Olaparib); Olaparib (JAN/USAN/INN); MLS006010185; SCHEMBL426568; OLAPARIB [ORANGE BOOK]; CHEMBL521686; GTPL7519; BDBM27566; DTXSID60917988; EX-A002; BCPP000360; HMS3295I09; HMS3426C03; HMS3654G13; HMS3746K07; HMS3870H03; AMY10295; BCP01872; 763113-22-0, Lynparza,; NSC747856; NSC753686; s1060; AKOS005145764; AC-7939; BCP9000363; CCG-264799; CS-0075; DB09074; EX-7210; NSC 747856; NSC-753686; SB14617; SS-4573; AZD2281,Olaparib, KU-0059436; NCGC00238451-01; NCGC00238451-02; NCGC00238451-08; NCGC00238451-09; NCGC00238451-11; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2H)-phthalazinone; 4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one; BO164169; HY-10162; SMR004701291; SY040527; Olaparib(AZD2281,KuDOSKU-0059436); A9666; BB 0260909; FT-0651458; SW218142-2; EC-000.2324; D09730; EN300-7542225; J-503540; Q7083106; BRD-K02113016-001-08-9; BRD-K02113016-001-09-7; Z2227698469; 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine; 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; (2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-; 1(2H)-PHTHALAZINONE, 4-((3-((4-(CYCLOPROPYLCARBONYL)-1-PIPERAZINYL)CARBONYL)-4-FLUOROPHENYL)METHYL)-; 1021843-02-6; 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one; PIPERAZINE, 1-(CYCLOPROPYLCARBONYL)-4-(5-((3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL)-2-FLUOROBENZOYL)-	Approved	Approved Drug(s)	23725625	DB09074	D0J9HW	434.5	82.1	790	1.9	32	1	5	4	C24H23FN4O3	4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one	C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F	C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F	InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)	FDLYAMZZIXQODN-UHFFFAOYSA-N
D2Z5DN	Torsemide	Small molecule	Torasemide; TORSEMIDE; 56211-40-6; Demadex; Luprac; Torasemida; Torasemidum; Torasemidum [INN-Latin]; Torasemida [INN-Spanish]; Unat; AC-4464; Torasemide anhydrous; JDL 464; BM-02015; AC4464; N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; Soaanz; Upcard; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; AC 4464; JDL-464; BM 02015; 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea; Torasemide [INN]; Torsemide (Demadex); Torasemide, Anhydrous; BM02.015; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; BM-02.015; MLS001165687; CHEBI:9637; W31X2H97FB; DTXSID2023690; 3-Pyridinesulfonamide, N-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-; Torsemide [USAN]; NCGC00016879-01; SMR000466313; Toradiur; CAS-56211-40-6; 1-{4-[(3-methylphenyl)amino]pyridine-3-sulfonyl}-3-(propan-2-yl)urea; N-[(isopropylamino)carbonyl]-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; 3-Pyridinesulfonamide, N-[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-; DTXCID203690; Dilutol; Torocard; Sutril; Torrem; Torasemide N; 4-[(3-methylphenyl)amino]-N-(propan-2-ylcarbamoyl)pyridine-3-sulfonamide; N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; Torsemide (USP); Demadex (TN); Luprac (TN); CCRIS 6736; Torasemide (JAN/INN); Torsemide [USAN:USP]; GJ-1090; BRN 0498515; UNII-W31X2H97FB; MFCD00866166; KS-1123; PW-2132; Spectrum_001776; TORSEMIDE [MI]; TORASEMIDE [JAN]; Prestwick0_001030; Prestwick1_001030; Prestwick2_001030; Prestwick3_001030; Spectrum2_001142; Spectrum3_001832; Spectrum4_000290; Spectrum5_001699; TORSEMIDE [VANDF]; TORASEMIDE [MART.]; TORSEMIDE [USP-RS]; CHEMBL1148; TORASEMIDE [WHO-DD]; SCHEMBL41184; BSPBio_001219; BSPBio_003503; KBioGR_000820; KBioSS_002257; cid_41781; MLS000759418; MLS001195611; MLS001424121; MLS006010744; BIDD:GT0623; SPECTRUM1505211; SPBio_001063; SPBio_003080; BPBio1_001341; GTPL7312; TORSEMIDE [ORANGE BOOK]; TORSEMIDE [USP IMPURITY]; BDBM64107; KBio2_002256; KBio2_004824; KBio2_007392; KBio3_003008; Torasemide for system suitability; TORASEMIDE [EP MONOGRAPH]; TORSEMIDE [USP MONOGRAPH]; HMS1571M21; HMS1922N05; HMS2051L21; HMS2098M21; HMS2234N14; HMS3373G20; HMS3393L21; HMS3715M21; HMS3744G19; ALBB-027267; BCP07286; HY-B0247; Tox21_110662; CCG-40257; s1698; STL388026; Torsemide, >=98% (HPLC), solid; AKOS015894937; Tox21_110662_1; BM02015; DB00214; NC00238; NCGC00016879-02; NCGC00016879-03; NCGC00016879-04; NCGC00016879-06; NCGC00016879-07; NCGC00095141-01; NCGC00095141-02; NCGC00095141-03; AC-18762; AB00514011; FT-0630689; FT-0675300; T2538; D00382; EN300-118719; T72621; AB00514011-09; AB00514011_10; AB00514011_11; A830961; Q419948; SR-01000759362; TORASEMIDE ANHYDROUS [EMA EPAR VETERINARY]; Q-201846; SR-01000759362-5; BRD-K30480208-001-05-2; Z1515385087; Torsemide, United States Pharmacopeia (USP) Reference Standard; 1-ISOPROPYL-3-((4-M-TOLUIDINO-3-PYRIDYL)SULPHONYL)UREA; 4-(3-methylanilino)-N-(propan-2-ylcarbamoyl)pyridine-3-sulfonamide; Torasemide anhydrous, European Pharmacopoeia (EP) Reference Standard; 1-({4-[(3-methylphenyl)amino]pyridin-3-yl}sulfonyl)-3-(propan-2-yl)urea; 1-isopropyl-3-[[4-(3-methylanilino)-3-pyridyl]sulfonyl]urea;Torsemide; N-(isopropylcarbamoyl)-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; N-[(propan-2-yl)carbamoyl]-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; N-({4-[(3-methylphenyl)imino]-1,4-dihydropyridin-3-yl}sulfonyl)propane-2-carbamimidic acid; Torasemide for system suitability, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	41781	DB00214	D0J9XZ	348.4	109	518	2.7	24	3	5	5	C16H20N4O3S	1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea	CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C	CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C	InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)	NGBFQHCMQULJNZ-UHFFFAOYSA-N
D1BGM3	Rosuvastatin	Small molecule	Rosuvastatin; 287714-41-4; Creston; Rosuvastatin calcium; ZD4522; Rosuvastatin [INN]; X-Plended; ZD-4522; Rosuvastatin (INN); CHEMBL1496; CHEBI:38545; 413KH5ZJ73; ZD 4522; (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5R)-Rosuvastatin; (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid; (E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid; 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-; Creston (TN); Rosuvastatin [INN:BAN]; UNII-413KH5ZJ73; HSDB 7317; (3R,5S,6E)-7-(4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(METHYL(METHYLSULFONYL)AMINO)PYRIMIDIN-5-YL)-3,5-DIHYDROXYHEPT-6-ENOIC ACID; 6-HEPTENOIC ACID, 7-(4-(4-FLUOROPHENYL)-6-(1-METHYLETHYL)-2-(METHYL(METHYLSULFONYL)AMINO)-5-PYRIMIDINYL)-3,5-DIHYDROXY-, (3R,5S,6E)-; Spectrum5_001695; ROSUVASTATIN [MI]; ROSUVASTATIN [HSDB]; SCHEMBL2520; ROSUVASTATIN [VANDF]; BSPBio_003429; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); ROSUVASTATIN [WHO-DD]; SCHEMBL154400; SPECTRUM1505213; GTPL2954; DTXSID8048492; BDBM18372; CHEBI:93454; HMS1922N09; CCG-40119; HY-17504A; MFCD18783208; AKOS000280777; AM84890; DB01098; NCGC00178070-01; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; AC-30585; AS-12247; SBI-0206727.P001; S5072; A24862; D08492; EN300-370268; EN300-20321882; Q415159; BRD-K82941592-001-01-3; BRD-K82941592-238-02-9; (3R,5S)-7-[4-(4-fluorophenyl)-2-(methyl-methylsulfonylamino)-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-trans-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[4-(4-Fluorophenyl)-2-[(methanesulfonyl)(methyl)amino]-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6enoic acid; (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid; 1354641-88-5; 7-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl-methylsulfonyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoic acid;Rosuvastatin;Rosuvastatin Acid; E-(7-{2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-yl}-(3R,5S)-3,5-dihydroxy-hept-6-enoic acid]; E-7-[2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid; FBI	Approved	Approved Drug(s)	446157	DB01098	D0JE2E	481.5	149	767	1.6	33	3	10	10	C22H28FN3O6S	(E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid	CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C	CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C	InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1	BPRHUIZQVSMCRT-VEUZHWNKSA-N
DMC1U3	Fulvestrant	Small molecule	Fulvestrant; 129453-61-8; Faslodex; ICI 182,780; Ici 182780; ICI-182780; ZM 182780; ZD-9238; ZM-182780; ZD9238; Fulvestrant (Faslodex); Fulvestrant S enantiomer; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; ZD 9238; CHEMBL1358; (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; DTXSID4022369; CHEBI:31638; 22X328QOC4; NSC-759879; Estra-1,3,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-, (7alpha,17beta)-; Fulvestrant [USAN]; C32H47F5O3S; (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; DTXCID202369; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; ZD 182780; Faslodex (TN); (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; Estra-1,3,5(10)-triene-3,17-diol, 7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-, (7alpha,17beta)-; CAS-129453-61-8; ICI182780; fulvestrantum; Fluvestrant; UNII-22X328QOC4; CCRIS 8741; Faslodex(ICI 182,780); HSDB 7658; NCGC00024964-02; 1316849-17-8; Fulvestrant [USAN:USP:INN:BAN]; MFCD00903953; ZD-182780; FULVESTRANT [MI]; FULVESTRANT [INN]; FULVESTRANT [JAN]; FULVESTRANT [VANDF]; SCHEMBL8209; FULVESTRANT [MART.]; BIDD:PXR0136; FULVESTRANT [USP-RS]; FULVESTRANT [WHO-DD]; MLS006010187; BIDD:ER0348; Fulvestrant (JAN/USP/INN); FULVESTRANT [EMA EPAR]; Fulvestrant, >98% (HPLC); GTPL1015; EX-A959; FULVESTRANT [ORANGE BOOK]; ICI 182,780 (Fulvestrant); ICI 182780- Bio-X; FULVESTRANT [EP MONOGRAPH]; FULVESTRANT [USP IMPURITY]; HMS2090N22; HMS3260G10; HMS3712A06; FULVESTRANT [USP MONOGRAPH]; Tox21_110939; Tox21_202604; Tox21_303656; Tox21_500114; BDBM50169743; HB2501; NSC719276; AKOS015895669; Tox21_110939_1; AC-4693; BCP9000707; CCG-220082; CCG-221418; CS-1267; DB00947; LP00114; NSC 759879; NSC-719276; SDCCGSBI-0633685.P001; ICI 182 780; ICI 182,789; NCGC00164789-02; NCGC00164789-04; NCGC00257357-01; NCGC00260152-01; NCGC00260799-01; NCGC00386134-10; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; AS-13024; BI167222; HY-13636; SMR001456109; BCP0726000227; F1144; S1191; Fulvestrant, Vetec(TM) reagent grade, >98%; D01161; EN300-120628; AB01273957-01; AB01273957-02; AB01273957-03; AB01273957_04; J-005680; Q5508491; BRD-A85667082-001-12-7; Fulvestrant, European Pharmacopoeia (EP) Reference Standard; Fulvestrant, United States Pharmacopeia (USP) Reference Standard; Fulvestrant for system suitability, European Pharmacopoeia (EP) Reference Standard; (13S,17S)-13-Methyl-7-[9-(4,4,5,5,5-pentafluoro-pentane-1-sulfinyl)-nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (1S,3aS,3bR,4R,9bS,11aS)-11a-methyl-4-[9-(4,4,5,5,5-pentafluoropentanesulfinyl)nonyl]-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-diol; (7?,17?)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol; (7R,13S,17S)-13-Methyl-7-[9-(4,4,5,5,5-pentafluoro-pentane-1-sulfinyl)-nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentyldihydrosulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-Methyl-7-[9-(4,4,5,5,5-pentafluoro-pentane-1-sulfinyl)-nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,9S,13S,14S,17S)-13-Methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 13-Methyl-7-[9-(4,4,5,5,5-pentafluoro-pentane-1-sulfinyl)-nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 13-Methyl-7-[9-(4,5,5,5-pentafluoropentylsulfinyl)nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 7.ALPHA.-(9-(4,4,5,5,5-PENTAFLUOROPENTYLSULPHINYL)NONYL)ESTRA-1,3,5(10)-TRIENE-3,17.BETA.-DIOL; 7alpha,17beta-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol; 7alpha-[9-(4,4,5,5,5-pentafluoro-pentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9-[(RS)-(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17beta-diol; ESTRA-1,3,5(10)-TRIENE-3,17-DIOL, 7-(9-((4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL)NONYL)-, (7.ALPHA.,17.BETA.)-; Estra-1,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-, (7.alpha.,17.beta.)-	Approved	Approved Drug(s)	104741	DB00947	D0JO7Y	606.8	76.7	854	9.2	41	2	9	14	C32H47F5O3S	(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol	CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F	InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1	VWUXBMIQPBEWFH-WCCTWKNTSA-N
DY4PZ3	Lofexidine	Small molecule	Lofexidine; 31036-80-3; 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole; Lofexidina; Lofexidinum; Lofexidinum [INN-Latin]; Lofexidina [INN-Spanish]; 2-[1-(2,6-dichlorophenoxy)ethyl]-2-imidazoline; Britlofex; 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline; 2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole; 1H-Imidazole, 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-; Lofexidine (INN); Lucemyra; CHEMBL17860; DTXSID7023221; CHEBI:51368; 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-; UI82K0T627; 31036-80-3 (free base); Baq-168;MDL-14042; LOFEXIDINE [INN]; Lofexidine [INN:BAN]; (R)-Lofexidine; SR-01000763628; 2-(1-(2,6-DICHLOROPHENOXY)ETHYL)-2-IMIDAZOLINE; UNII-UI82K0T627; (+)-Lofexidine; (S)-(+)-Lofexidine; LOFEXIDINE [MI]; LOFEXIDINE [VANDF]; LOFEXIDINE [WHO-DD]; Lofexidinum pound>>Britlofex; SCHEMBL48960; 2-Imidazoline 2-(1-(2,6-dichlorophenoxy)ethyl)-; DTXCID703221; GTPL9868; HY-B1052A; HMS2090C03; HMS3713J03; 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole; BCP30596; Tox21_113963; BDBM50019646; ZB0288; AKOS015900265; CCG-220521; DB04948; NCGC00271513-02; BS-22292; CAS-31036-80-3; DB-047957; CS-0013650; FT-0627970; FT-0670834; FT-0670835; A51269; D08141; AB00698543-05; AB00698543-07; AB00698543_08; AB00698543_09; EN300-7392995; A820699; J-507626; Q3836403; SR-01000763628-3; SR-01000763628-4; (+)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene; (-)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene	Approved	Approved Drug(s)	30668	DB04948	D0K0MW	259.13	33.6	263	2.6	16	1	2	3	C11H12Cl2N2O	2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole	CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl	CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl	InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)	KSMAGQUYOIHWFS-UHFFFAOYSA-N
D3ZYB1	Sertraline	Small molecule	sertraline; 79617-96-2; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; (+)-Sertraline; Sertralina; Sertralinum; Zoloft; Cp 51974; Sertraline (INN); (1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine; cis-(+)-sertraline; (1S,4S)-sertraline; QUC7NX6WMB; CHEMBL809; CHEBI:9123; Sertralinum [Latin]; Sertralina [Spanish]; SERTRALINE [INN]; Sertraline [INN:BAN]; TBA-2010_Sertraline_1; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-tetralin-1-amine; MLS001401398; 1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S,4S)-; C17H17Cl2N; SMR000596516; SRE; HSDB 7037; UNII-QUC7NX6WMB; NCGC00092386-03; 79617-95-1; SMR000466298; BRN 5753709; SERTRALINE [MI]; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine;hydrochloride; Prestwick3_001014; Spectrum2_000493; Spectrum3_001079; Spectrum4_001232; SERTRALINE [HSDB]; SERTRALINE [VANDF]; SERTRALINE [WHO-DD]; BIDD:PXR0193; SCHEMBL28701; BSPBio_001167; BSPBio_002698; KBioGR_001724; cid_63009; MLS001195647; MLS002222308; BIDD:GT0768; REGID_for_CID_68617; SPBio_000385; BPBio1_001285; GTPL4798; DTXSID6023577; BDBM79021; KBio3_001918; cp-51974; HMS2098K09; HMS2231I09; HMS3715K09; BDBM50028094; NCGC00092386; AKOS016842914; CCG-221014; DB01104; SDCCGSBI-0206734.P002; 1-Naphthalenamine, 1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-, (1S-cis)-; NCGC00092386-04; NCGC00092386-05; NCGC00092386-06; NCGC00092386-07; NCGC00092386-08; NCGC00092386-09; NCGC00092386-10; NCGC00092386-12; NCGC00092386-27; AC-15639; SBI-0206734.P001; CP-519741; AB00514002; FT-0630872; C07246; D02360; EN300-150167; AB00514002_17; AB00514002_18; A839725; Q407617; SR-01000759296; SR-01000759296-5; BRD-K82036761-003-02-1; BRD-K82036761-003-07-0; BRD-K82036761-003-20-3; [(1S,4S)-4-(3,4-dichlorophenyl)tetralin-1-yl]-methyl-amine;hydrochloride; syn-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-naphthalenamine; 219736-80-8	Approved	Approved Drug(s)	68617	DB01104	D0K0TC	306.2	12	322	4.8	20	1	1	2	C17H17Cl2N	(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine	CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl	CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl	InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1	VGKDLMBJGBXTGI-SJCJKPOMSA-N
D2J0QK	Mafenide	Small molecule	mafenide; 138-39-6; 4-(Aminomethyl)benzenesulfonamide; 4-Aminomethylbenzenesulfonamide; Ambamide; Emilene; Sulfamylon; Homonal; Homosul; Benzamsulfonamide; Malfamin; Maphenid; Maphenide; Homosulfanilamide; Benzenesulfonamide, 4-(aminomethyl)-; Marprontil; Mesudin; Mesudrin; Neofamid; Paramenyl; Septicid; 4-Homosulfanilamide; 4-(aminomethyl)benzene-1-sulfonamide; p-(Aminomethyl)benzenesulfonamide; Marfanil; 4-sulfamoylbenzylamine; 4-(aminosulfonyl)benzylamine; NSC-34632; .alpha.-Amino-p-toluenesulfonamide; CHEMBL419; alpha-Amino-p-toluenesulfonamide; p-Aminomethylbenzenesulfonamide; CHEBI:6633; D06BA03; NSC34632; p-Toluenesulfonamide, .alpha.-amino-; 58447S8P4L; Homosulfaminum; Bensulfamide; Mafenida; Mafenidum; Mafenidum [INN-Latin]; Mafenida [INN-Spanish]; 4-(Aminomethyl)Benzene-1-Sulfonamide Hydrochloride; Mafenide [USAN:INN:BAN]; NCGC00016403-01; CAS-138-37-4; EINECS 205-326-9; NSC 34632; Maphenidum; UNII-58447S8P4L; 4-Homosufanilamide; p-Toluenesulfonamide, alpha-amino-; Masudin (Salt/Mix); Marfanil (Salt/Mix); Spectrum_000885; MAFENIDE [USAN]; Mafenide (USAN/INN); MAFENIDE [INN]; MAFENIDE [MI]; 4-sulfamoyl-benzyl-amine; MAFENIDE [VANDF]; Prestwick0_000166; Prestwick1_000166; Prestwick2_000166; Prestwick3_000166; Spectrum2_000095; Spectrum3_000482; Spectrum4_000034; Spectrum5_000916; Homosulfamine (Salt/Mix); MAFENIDE [MART.]; MAFENIDE [WHO-DD]; Oprea1_593766; Oprea1_661906; SCHEMBL41628; BSPBio_000031; BSPBio_001943; KBioGR_000467; KBioSS_001365; BIDD:GT0346; DivK1c_000363; SPBio_000050; SPBio_001952; aromatic sulfonamide compound 6; BPBio1_000035; 4-Aminomethyl-benzenesulfonamide; 4-aminomethyl-benzenesulphonamide; DTXSID6047860; BDBM10860; KBio1_000363; KBio2_001365; KBio2_003933; KBio2_006501; KBio3_001443; NINDS_000363; BCPP000172; HY-B0614; aromatic/heteroaromatic sulfonamide 5; BBL012326; MFCD00072084; STK083032; TQ0026; AKOS001074998; BCP9000891; DB06795; GS-4341; SDCCGMLS-0003097.P003; IDI1_000363; NCGC00016403-02; NCGC00016403-03; NCGC00016403-04; NCGC00016403-11; BCP0726000212; SBI-0051431.P003; DB-002011; AB00053492; AM20050422; FT-0682668; EN300-35248; C07106; D02351; AB00053492_18; A886248; Q3843044; alpha-aminotoluene-4-sulphonamide; maphenide;Mafenide; 6LH	Approved	Approved Drug(s)	3998	DB06795	D0K1QD	186.23	94.6	224	-0.7	12	2	4	2	C7H10N2O2S	4-(aminomethyl)benzenesulfonamide	C1=CC(=CC=C1CN)S(=O)(=O)N	C1=CC(=CC=C1CN)S(=O)(=O)N	InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)	TYMRLRRVMHJFTF-UHFFFAOYSA-N
D1T3AE	Revefenacin	Small molecule	Revefenacin; 864750-70-9; TD-4208; Yupelri; GSK-1160724; GSK1160724; Revefenacin [INN]; Revefenacin [WHO-DD]; G2AE2VE07O; 864750-70-9 (free base); [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate; 1-(2-(4-((4-Carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl N-((1,1'-biphenyl)-2-yl)carbamate; 1-(2-(3-((4-carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate; Biphenyl-2-ylcarbamic acid, 1-(2-((4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl)methylamino)ethyl)piperidin-4-yl ester; Carbamic acid, N-(1,1'-biphenyl)-2-yl-, 1-(2-((4-((4-(aminocarbonyl)-1-piperidinyl)methyl)benzoyl)methylamino)ethyl)-4-piperidinyl ester; TD-4208; GSK-1160724;[1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate; REVEFENACIN [MI]; Revefenacin (USAN/INN); Revefenacin [USAN:INN]; REVEFENACIN [USAN]; UNII-G2AE2VE07O; Revefenacin;GSK1160724; SCHEMBL356480; CHEMBL3833319; GTPL10129; REVEFENACIN [ORANGE BOOK]; DTXSID701027775; HMS3886K17; Revefenacin [USAN:INN:WHO-DD]; AMY16789; BCP15793; EX-A1722; s5258; TD4208; AKOS037649398; CCG-270187; CS-7743; DB11855; SB17262; BS-18189; HY-15851; Revefenacin; TD-4208; GSK-1160724; D10978; A903445; EN300-20352165; Q27278649; Revefenacin;  TD 4208; TD4208; GSK-1160724; GSK1160724; GSK 1160724; 1-(2-(4-((4-Carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate; 1-[2-(1-{4-[(4-carbamoylpiperidin-1-yl)methyl]phenyl}-N-methylformamido)ethyl]piperidin-4-yl N-{[1,1'-biphenyl]-2-yl}carbamate; 1211931-83-7; TD-4208; TD 4208; TD4208; GSK-1160724; GSK1160724;1-(2-(4-((4-Carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl N-((1,1'-biphenyl)-2-yl)carbamate	Approved	Approved Drug(s)	11753673	DB11855	D0K1ST	597.7	108	918	4.1	44	2	6	11	C35H43N5O4	[1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate	CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N	CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N	InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)	FYDWDCIFZSGNBU-UHFFFAOYSA-N
DED8R7	Hydralazine	Small molecule	hydralazine; 1-Hydrazinophthalazine; 86-54-4; 1-Hydrazinylphthalazine; Hypophthalin; Hydralazin; Hydrazinophthalazine; Apresoline; Apresolin; Apressin; Aprezolin; Hidralazin; Idralazina; phthalazin-1-ylhydrazine; 6-Hydralazine; Hidralazina; Hipoftalin; Hydrallazine; 1(2H)-Phthalazinone, hydrazone; 1-Phthalazinylhydrazine; 59275-69-3; Hydralazinum; Hydrazone 1(2H)-phthalazinone; (E)-1-Hydrazono-1,2-dihydrophthalazine; Ciba 5968; Apressin (pharmaceutical); Phthalazine, 1-hydrazino-; BA 5968; Praparat 5968; (2H)-Phthalazinone hydrazone; C-5968; (1Z)-1(2H)-Phthalazinone hydrazone; C 5968; Hydralazine (INN); NSC 126699; CHEBI:5775; NSC-126699; 26NAK24LS8; Apresolin; Apresoline; Apressin; C-5068; Idralazina [DCIT]; Idralazina [Italian]; Hidralazina [Spanish]; HYDRALAZINE [INN]; Hydralazine [INN:BAN]; Hydralazinum [INN-Latin]; Hidralazina [INN-Spanish]; 1(2H)-Phthalazinone hydrazone; Hidral; Hidral (TN); CCRIS 5385; NCGC00015501-02; CAS-304-20-1; EINECS 201-680-3; BRN 0132615; UNII-26NAK24LS8; phthalazone hydrazone; Hydralazine polistirex; 1-hydrazonophthalazine; Spectrum_000875; (1E)-1-Hydrazono-1,2-dihydrophthalazine; HYDRALAZINE [MI]; Prestwick0_000169; Prestwick1_000169; Prestwick2_000169; Spectrum2_000969; Spectrum3_000455; Spectrum4_000005; Spectrum5_000822; Lopac-H-1753; EC-000.1838; HYDRALAZINE [IARC]; Epitope ID:137349; HYDRALAZINE [VANDF]; SCHEMBL7810; NCIOpen2_001484; Lopac0_000593; Oprea1_207681; Oprea1_416878; BSPBio_002130; HYDRALAZINE [WHO-DD]; KBioGR_000349; KBioSS_001355; WLN: T66 CNNJ BMZ; 5-25-17-00412 (Beilstein Handbook Reference); DivK1c_000117; SPBio_000977; SPBio_001958; Discontinued See: H716531; CHEMBL276832; GTPL7326; DTXSID4023129; BDBM81461; HY-B0464A; KBio1_000117; KBio2_001355; KBio2_003923; KBio2_006491; KBio3_001350; RPTUSVTUFVMDQK-UHFFFAOYSA-; 1(2H)-Phthalazinone hydrazone #; NINDS_000117; NSC_3637; NSC126699; STK246900; AKOS000122609; AKOS016843064; AKOS028109138; CCG-204682; DB01275; SDCCGSBI-0050575.P005; CAS_86-54-4; IDI1_000117; 1-hydrazinylidene-1,2-dihydrophthalazine; NCGC00015501-01; NCGC00015501-03; NCGC00015501-04; NCGC00015501-05; NCGC00015501-06; NCGC00015501-07; NCGC00015501-17; NCGC00162199-01; HLZ; LS-13412; SBI-0050575.P004; CS-0013620; FT-0669282; EN300-34025; (1E)-1-hydrazinylidene-1,2-dihydrophthalazine; C07040; D08044; AB00053483_03; AB01274815-01; AB01274815_02; A914301; A916276; Q419987; BRD-K82103381-003-03-7	Approved	Approved Drug(s)	3637	DB01275	D0K1XK	160.18	63.8	150	0.7	12	2	4	1	C8H8N4	phthalazin-1-ylhydrazine	C1=CC=C2C(=C1)C=NN=C2NN	C1=CC=C2C(=C1)C=NN=C2NN	InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)	RPTUSVTUFVMDQK-UHFFFAOYSA-N
D4MD0H	Eplerenone	Small molecule	Eplerenone; Epoxymexrenone; Inspra; 107724-20-9; SC-66110; Selara; Cgp 30083; CGP-30083; CHEMBL1095097; DTXSID2046094; CHEBI:31547; SC-6611O; 6995V82D0B; 9,11alpha-Epoxy-17-hydroxy-3-oxo-17alpha-pregn-4-ene-7alpha,21-dicarboxylic acid, gamma-lactone, methyl ester; NCGC00159559-02; (+)-Eplerenone; methyl (1'R,2R,2'S,9'R,10'R,11'S,15'S,17'R)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0^{1,17}.0^{2,7}.0^{11,15}]octadecan]-6'-ene-9'-carboxylate; Eplerenone [USAN]; DTXCID0026094; Epleremone; methyl (1'R,2S,2'S,9'R,10'R,11'S,15'S,17'R)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0^{1,17}.0^{2,7}.0^{11,15}]octadecan]-6'-ene-9'-carboxylate; Inspra (TN); CAS-107724-20-9; HSDB 7522; Eplerenone [USAN:INN:BAN]; UNII-6995V82D0B; Eplerenone- Bio-X; SC 6110; EPLERENONE [MI]; EPLERENONE [INN]; EPLERENONE [JAN]; EPLERENONE [HSDB]; EPLERENONE [VANDF]; EPLERENONE [MART.]; EPLERENONE [USP-RS]; EPLERENONE [WHO-DD]; SCHEMBL21515; GTPL2876; Eplerenone (JP17/USAN/INN); EPLERENONE [ORANGE BOOK]; Eplerenone, >=98% (HPLC); EPLERENONE [EP MONOGRAPH]; HMS3413K08; HMS3677K08; HY-B0251; Tox21_111746; BDBM50318300; HB2527; MFCD05662207; s1707; AKOS015962307; Tox21_111746_1; AC-4213; CCG-268820; DB00700; KS-1406; 7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone; NCGC00159559-03; BE164415; Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, gamma-lactone, methyl ester, (7alpha,11alpha,17alpha)-; Spiro(cyclopenta(7,8)phenanthro(4b,5-b)oxirene-7(3H),2'(3'H)-furan)-10-carboxylic acid, 2,4,4',4a,5',5a,6,6a,8,9,9a,9b,10,11-tetradecahydro-4a,6a-dimethyl-2,5'-dioxo-, methyl ester, (4aS,4bR,5aR,6aS,7 R,9aS,9bR,10R)-; E0905; D01115; AB01274707-01; AB01274707_02; EN300-6492952; A895400; Q423804; SR-01000942233; SR-01000942233-1; methyl dimethyl-5'-dioxo-spiro[[?]-[?],2'-tetrahydrofuran]carboxylate; (7?,11?,17?)-9,11-Epoxy-17-hydroxy-3-oxo-pregn-4-ene-7,21-dicarboxylic acid ?-lactone methyl ester; 9,11alpha-Epoxy-17-hydroxy-3-oxo-17alpha-pregn-4-ene-7alpha,21-dicarboxylic Acid gamma-Lactone Methyl Ester; PREGN-4-ENE-7,21-DICARBOXYLIC ACID, 9,11-EPOXY-17-HYDROXY-3-OXO-, G-LACTONE, METHYL ESTER, (7.ALPHA.,11.ALPHA.,17.ALPHA)-; YNU	Approved	Approved Drug(s)	443872	DB00700	D0K2KR	414.5	82.2	907	1.4	30	0	6	2	C24H30O6	methyl (1R,2S,9R,10R,11S,14R,15S,17R)-2,15-dimethyl-5,5'-dioxospiro[18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-ene-14,2'-oxolane]-9-carboxylate	CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC	C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC	InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1	JUKPWJGBANNWMW-VWBFHTRKSA-N
DA0QG6	Bisoprolol	Small molecule	BISOPROLOL; 66722-44-9; Bisoprololum; Bisoprolol fumarate; Concor; Zebeta; Bisoprolol hemifumarate; 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol; EMD-33512; EMD 33 512; CL-297939; (RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol; (+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol; Y41JS2NL6U; CHEBI:3127; Bisocor; Bisoprololum [Latin]; 1-(4-((2-isopropoxyethoxy)methyl)phenoxy)-3-(isopropylamino)propan-2-ol; [2-hydroxy-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propyl](propan-2-yl)amine; 2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-; Bisoprolol fumerate; 1310012-16-8; Bisoprolol hemifumarate salt; (+/-)-Bisoprolol (hemifumarate); 1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol; 1-(propan-2-ylamino)-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propan-2-ol; NCGC00024868-03; UNII-Y41JS2NL6U; Bisoprolol [USAN:INN:BAN]; CL 297939; SR-01000597980; BISOPROLOL [MI]; BISOPROLOL [INN]; BISOPROLOL [JAN]; 104344-23-2; Prestwick0_000330; Prestwick1_000330; Prestwick2_000330; Prestwick3_000330; BISOPROLOL [USAN]; BISOPROLOL [VANDF]; CHEMBL645; BISOPROLOL [WHO-DD]; SCHEMBL20960; BSPBio_000339; Bisoprolol (JAN/USAN/INN); SPBio_002260; Bisoprolol, analytical standard; BPBio1_000373; GTPL7129; DTXSID6022682; BDBM25751; HSDB 8316; BCPP000332; BCP02461; EX-A5544; MFCD00865795; s5942; STL355996; AKOS005110983; BCP9000418; DB00612; SDCCGSBI-0206894.P002; NCGC00024868-02; NCGC00024868-04; NCGC00024868-05; NCGC00024868-06; NCGC00024868-08; NCGC00024868-21; 1-[(1-methylethyl)amino]-3-({4-[({2-[(1-methylethyl)oxy]ethyl}oxy)methyl]phenyl}oxy)propan-2-ol; 2-Propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)-; AC-18540; AS-35262; SBI-0206894.P001; HY-129029; AB00514681; BB 0262613; CS-0103208; Bisoprolol - from tablet donated by Watson -; C06852; D02342; AB00514681-08; AB00514681_09; AB00514681_10; EN300-18386635; L000133; Q412515; Q-200728; SR-01000597980-1; BRD-A89175223-051-05-6; 1-(4-[(2-Isopropoxyethoxy)methyl]phenoxy)-3-(isopropylamino)-2-propanol #; 1-[ISOPROPYLAMINO]-3-[ISOPROPOXYETHOXYMETHYLPHENOXY]-2-PROPANOL; (+/-)-1-((.ALPHA.-(2-ISOPROPOXYETHOXY)-P-TOLYL)OXY)-3-(ISOPROPYLAMINO)-2-PROPANOL; (.+/-.)-1-[[.alpha.-(2-Isopropoxyethoxy)-p-tolyl]oxy]-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan- 2-ol; 1-[(propan-2-yl)amino]-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propan-2-ol; 1-[4-[2-(1-methylethoxy)ethoxymethyl]phenoxy]-3-(1-methylethylamino)propan-2-ol; 1-{4-{[2-(1-Methylethoxy)ethoxy]methyl}phenoxy}-3-[(1-methylethyl)amino]-2-propanol; 2-PROPANOL, 1-(4-((2-(1-METHYLETHOXY)ETHOXY)METHYL)PHENOXY)-3-((1-METHYLETHYL)AMINO)-, (+/-)-; 2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-, (.+/-.)-	Approved	Approved Drug(s)	2405	DB00612	D0K3ZR	325.4	60	278	1.9	23	2	5	12	C18H31NO4	1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol	CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O	CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O	InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3	VHYCDWMUTMEGQY-UHFFFAOYSA-N
D7Q5MO	Albuterol	Small molecule	Salbutamol; albuterol; 18559-94-9; Proventil; Ventoline; Volmax; Broncovaleas; dl-Salbutamol; dl-Albuterol; Ventolin Inhaler; Sultanol; Ventolin; Proventil HFA; Cobutolin; Salbulin; Salbutamolum; Salbuvent; Saventol; Asmaven; Spreor; Asmol; Aerolin; Sultanol N; Proventil Inhaler; Novosalmol; Salbuhexal; Salbutalan; Servitamol; Ventiloboi; Ventodisks; Almotex; Anebron; Asmadil; Asmanil; Asmasal; Asmatol; Asmidon; Bronter; Bugonol; Butamol; Butohaler; Butotal; Butovent; Dilatamol; Farcolin; Gerivent; Grafalin; Libretin; Medolin; Parasma; Pneumolat; Respolin; Sabutal; Salbetol; Salbron; Salbupur; Salbusian; Salbutan; Salbutol; Salbuven; Sallbupp; Salmaplon; Salomol; Salvent; Suprasma; Theosal; Tobybron; Vencronyl; Ventamol; Ventilan; Zaperin; Bumol; Mozal; Respax; Suxar; Asthalin; Buventol; Alti-Salbutamol; Salamol; Broncho-Spray; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Salbu-Fatol; Buto-Asma; Asmol Uni-Dose; Ventolin Rotacaps; Salbutamol sulfate; Salbu-BASF; Volare easi-breathe; Arubendol-Salbutamol; Volare albuterol HFA; Salbutamol Sulphate; Airomir; ALBUTEROL (+/-); Etinoline; AH 3365; (l)-albuterol; 4-(2-(tert-Butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; 1219798-60-3; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; SCH-13949W; Proventil (TN); (+/-)-Albuterol-d3; 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; NSC-757417; alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; QF8SVZ843E; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; CHEBI:2549; 35763-26-9; DTXSID5021255; Ventalin inhaler; SCH 13949W; Albuterol [USAN]; NCGC00015955-09; Solbutamol; 1,3-Benzenedimethanol, .alpha.1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; Salbutamolum [INN-Latin]; DTXCID001255; Eolene; 2-(tert-Butylamino)-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethanol; Albuterol (USP); Salbutamol (hemisulfate); HSDB 7206; AH-3365; alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; SR-01000075161; Albuterol [USAN:USP]; EINECS 242-424-0; MFCD00148978; UNII-QF8SVZ843E; BRN 2213614; racemic salbutamol; Salamol EB; Albuterol-[d3]; Prestwick_665; CAS-18559-94-9; Salbutamol Free Base; (R)-Albuterol;(R)-Salbutamol;Levosalbutamol; Salbutamol,(+/-); Venetlin (Salt/Mix); Spectrum_000200; Albuterol (hemisulfate);AH-3365 (hemisulfate); ALBUTEROL [MI]; Salbutamol [INN:BAN]; ALBUTEROL [HSDB]; SALBUTAMOL [INN]; Prestwick0_000198; Prestwick1_000198; Prestwick2_000198; Prestwick3_000198; Spectrum2_001350; Spectrum4_000887; Spectrum5_001059; ALBUTEROL [VANDF]; m-Xylene-alpha,alpha'-diol, alpha-((tert-butylamino)methyl)-4-hydroxy-; CHEMBL714; 1,3-Benzenedimethanol, alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-; EC 242-424-0; S 8260; ALBUTEROL [USP-RS]; SALBUTAMOL [MART.]; SCHEMBL4913; SALBUTAMOL [WHO-DD]; SALBUTAMOL [WHO-IP]; Lopac0_001090; Lopac0_001098; BSPBio_000155; GTPL558; KBioGR_001294; KBioSS_000680; DivK1c_000943; SPECTRUM1500677; SPBio_001539; SPBio_002076; BPBio1_000171; SGCUT00011; ALBUTEROL [ORANGE BOOK]; SALBUTAMOL [EP IMPURITY]; SCHEMBL10025126; BCBcMAP01_000116; BDBM25769; HMS502P05; KBio1_000943; KBio2_000680; KBio2_003248; KBio2_005816; ALBUTEROL [USP MONOGRAPH]; SALBUTAMOL [EP MONOGRAPH]; NINDS_000943; Bio1_000446; Bio1_000935; Bio1_001424; HMS1568H17; HMS1921C04; HMS2089I19; HMS2092I08; HMS2095H17; HMS3712H17; HMS3886I08; KUC106739N; Pharmakon1600-01500677; 4-[2-(tert-butylamino)-1-hydroxy-ethyl]-2-(hydroxymethyl)phenol; AMY38245; BCP28423; HY-B1037; Salbutamol-(tert-butyl-d9) acetate; SALBUTAMOLUM [WHO-IP LATIN]; to_000081; Tox21_110266; Tox21_200800; 4-{2-[(tert-butyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; CCG-39288; NSC757417; PDSP1_000623; PDSP2_000620; s5494; AKOS007930174; m-Xylene-alpha,alpha'-diol, alpha'-((tert-butylamino)methyl)-4-hydroxy-; Tox21_110266_1; CS-4556; DB01001; KS-5209; NSC 757417; SB19749; SDCCGSBI-0051060.P006; 1,3-Benzenedimethanol, alpha(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-; IDI1_000943; SMP1_000268; NCGC00015955-04; NCGC00015955-05; NCGC00015955-06; NCGC00015955-07; NCGC00015955-08; NCGC00015955-10; NCGC00015955-11; NCGC00015955-12; NCGC00015955-13; NCGC00015955-14; NCGC00015955-16; NCGC00015955-28; NCGC00024698-02; NCGC00024698-03; NCGC00024698-04; NCGC00024698-05; NCGC00024698-06; NCGC00024698-07; NCGC00258354-01; AC-10286; BA164143; KSC-11-222-1; Salbutamol 100 microg/mL in Acetonitrile; SBI-0051060.P005; AB00052154; EU-0101090; FT-0661467; FT-0770967; VU0243312-5; D02147; EN300-365894; F15026; Salbutamol, VETRANAL(TM), analytical standard; AB00052154-08; AB00052154-09; AB00052154_10; AB00052154_11; (+)-5,6-O-CYCLOHEXYLIDENE-L-ASCORBICACID; A812971; L000531; Q410358; Q-201695; Q-201696; SR-01000075161-3; SR-01000075161-4; SR-01000075161-5; SR-01000075161-8; BRD-A88254928-001-04-6; BRD-A88254928-001-05-3; SR-01000075161-11; Z2301287926; Salbutamol, British Pharmacopoeia (BP) Reference Standard; Salbutamol, European Pharmacopoeia (EP) Reference Standard; Albuterol, United States Pharmacopeia (USP) Reference Standard; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol #; 4-[2-(tert-butylamino)-1-oxidanyl-ethyl]-2-(hydroxymethyl)phenol; 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-.alpha.1,.alpha.3-diol; 4-Hydroxy-3-hydroxymethyl-.alpha.-((tert-butylamino)methyl)benzyl alcohol; alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha1-diol; .alpha.'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-.alpha.,.alpha.'-diol; .alpha.1'-[[(1,1-Dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol, hemisulfate; .alpha.1-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-.alpha.,.alpha.'-diol; 1,3-Benzenedimethanol, .alpha.(1)-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-; m-Xylene-.alpha.,.alpha.'-diol, .alpha.'-((tert-butylamino)methyl)-4-hydroxy-; m-Xylene-.alpha.,.alpha.-diol, .alpha.-1-((tert-butylamino)methyl)-4-hydroxy-; (+/-)-1,3-BENZENEDIMETHANOL, .ALPHA.(SUP 1)-(((1,1-DIMETHYLETHYL)AMINO)METHYL)-4-HYDROXY-; 1,3-BENZENEDIMETHANOL, .ALPHA.(SUP 1)-(((1,1-DIMETHYLETHYL)AMINO)METHYL)-4-HYDROXY-; 148563-15-9	Approved	Approved Drug(s)	2083	DB01001	D0K5CB	239.31	72.7	227	0.3	17	4	4	5	C13H21NO3	4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol	CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O	CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O	InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3	NDAUXUAQIAJITI-UHFFFAOYSA-N
DDV6Q9	Enasidenib	Small molecule	Enasidenib; 1446502-11-9; AG-221; IDHIFA; AG-221 (Enasidenib); Enasidenib [INN]; CC-90007 Free Base; AG 221; 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol; AG-221(Enasidenib); 3T1SS4E7AG; 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol; 2-Methyl-1-[(4-[6-(Trifluoromethyl)pyridin-2-Yl]-6-{[2-(Trifluoromethyl)pyridin-4-Yl]amino}-1,3,5-Triazin-2-Yl)amino]propan-2-Ol; 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol; 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-; 2-Propanol, 2-methyl-1-[[4-[6-(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]-; 2-methyl-1-({4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl}amino)propan-2-ol; UNII-3T1SS4E7AG; enasidenibum; AG221; AG-221; Enasidenib; Enasidenib; AG-221; ENASIDENIB [MI]; Enasidenib (USAN/INN); Enasidenib [USAN:INN]; ENASIDENIB [USAN]; ENASIDENIB [WHO-DD]; GTPL8960; CHEMBL3989908; SCHEMBL15102202; EX-A654; CHEBI:145374; DTXSID801027942; HMS3873D03; AMY38698; BCP16041; BDBM50503251; MFCD29472245; NSC788120; s8205; AKOS026750439; CCG-269476; CS-5017; DB13874; NSC-788120; SB19193; NCGC00479249-03; NCGC00479249-05; AC-31318; AS-75164; HY-18690; FT-0700204; D10901; A857662; EN300-21679954; J-690181; Q27077182; B0084-470859; AG-221; AG 221; AG221; CC-90007; CC 90007; CC90007; 1802003-09-3; 69Q	Approved	Approved Drug(s)	89683805	DB13874	D0K7FT	473.4	109	635	3.5	33	3	14	6	C19H17F6N7O	2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol	CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O	CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O	InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)	DYLUUSLLRIQKOE-UHFFFAOYSA-N
DL4D9W	Saxagliptin	Small molecule	Saxagliptin; Onglyza; 361442-04-8; BMS-477118; Saxagliptin [INN]; BMS 477118; OPC-262; Saxagliptin anhydrous; 8I7IO46IVQ; CHEMBL385517; DTXSID7048580; CHEBI:71272; BMS477118; (1S,3S,5S)-2-((2S)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile; (1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile; (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 945667-22-1; (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; UNII-8I7IO46IVQ; Saxagliptine; HSDB 8199; OPC 262; NCGC00242597-01; (1S,3S,5S)-2-[(2S)-2-amino-2-[(1r,3R,5R,7S)-3-hydroxyadamantan-1-yl]acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; SAXAGLIPTIN [MI]; Saxagliptin (USAN/INN); SCHEMBL17168; SAXAGLIPTIN [WHO-DD]; MLS006011223; GTPL6316; Saxagliptin - BMS-477118; DTXCID3028506; SCHEMBL20243458; BDBM11542; HMS3264P11; Pharmakon1600-01502500; Tox21_112908; BDBM50225074; MFCD12756398; NSC760407; s1540; Saxagliptin (BMS-477118,Onglyza); AKOS015896547; AC-6008; CCG-213084; CCG-267647; CS-0650; DB06335; EX-7795; NCGC00242597-02; NCGC00242597-10; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)-; HY-10285; SMR004702984; AM20090693; CAS-361442-04-8; D08996; EN300-761487; AB01562984_01; AB01562984_02; Q3121121; BRD-A81513827-001-03-6; Z2235802036; (S)-3-Hydroxyadamantylglycine-L-cis-4,5-methanoprolinenitrile TFA salt; (1S,6S)-2-(2-adamantan-1-yl-2-amino-acetyl)-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile; (1S,3S,5S)-2-((2S)-AMINO(3-HYDROXYTRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YL)ACETYL)-2-AZABICYCLO(3.1.0)HEXANE-3-CARBONITRILE; (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2,2,2-trifluoroacetic acid; (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-1-oxoethyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; (1S,3S,5S)-2-[(S)-2-amino-2-(3-hydroxy-adamantan-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile; 2-AZABICYCLO(3.1.0)HEXANE-3-CARBONITRILE, 2-((2S)-AMINO(3-HYDROXYTRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YL)ACETYL), (1S,3S,5S)-; 2-Azabicyclo(3.1.0)hexane-3-carbonitrile, 2-((2S)-amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl) , (1S,3S,5S)-; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile,2-[(2S)-amino(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)-	Approved	Approved Drug(s)	11243969	DB06335	D0K9MY	315.4	90.4	609	0.7	23	2	4	2	C18H25N3O2	(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile	C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N	C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N	InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1	QGJUIPDUBHWZPV-SGTAVMJGSA-N
D7I8TK	Imatinib	Small molecule	Imatinib; 152459-95-5; STI571; Imatinib (STI571); Imatinib free base; N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Cgp 57148; Glamox; STI 571; Imatinib (INN); Imatinib Methansulfonate; 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE; CGP-57148; 152459-95-5 (free base); BKJ8M8G5HI; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; CHEMBL941; NSC-743414; NSC-759854; CHEBI:45783; MFCD05662257; NSC743414; N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide; IMATINIB [INN]; Imatinib [INN:BAN]; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide; 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide; Benzamide, 4-((4-methyl)-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-; STI; alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-; Glamox (TN); CCRIS 9076; SR-01000763561; NCGC00159456-02; UNII-BKJ8M8G5HI; ST1571; ST 1571; imatinib-CD3; 1iep; 1xbb; Gleevec(TM); 4-[(4-methyl-1-piperazinyl)-methyl]-N-{4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl)-benzamide; 4-[(4-methyl-1-piperazinyl)-methyl]-N-{4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide; Imatinib (Gleevec); Imatinib - Gleevec; Imatinib, 21; Imatinib, Free base; alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide; Kinome_3724; 112GI019; IMATINIB [MI]; IMATINIB [VANDF]; IMATINIB [WHO-DD]; Gleevec (TN) (Novartis); cid_5291; SCHEMBL3827; IMATINIB [EMA EPAR]; STI-571; IMATINIB; BIDD:GT0047; GTPL5687; DTXSID3037125; BDBM13530; EX-A063; BCPP000205; CGP057148B; HMS2089D03; HMS3244P06; HMS3244P10; HMS3244P14; HMS3656K04; HMS3715P03; Pharmakon1600-01502276; BCP01542; AC-524; NSC759854; NSC800772; STK617705; VCC905240; AKOS000280662; BCP9000775; CCG-101289; CS-0964; DB00619; ES-0058; NSC 743414; NSC 759854; NSC-800772; SB17306; ST-1571; MRF-0000449; NCGC00159456-01; NCGC00159456-03; NCGC00159456-04; NCGC00159456-05; NCGC00159456-06; NCGC00159456-07; NCGC00159456-09; NCGC00159456-16; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; BI164570; HY-15463; N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; N-[4-Methyl-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]benzamide; SY028029; AM20090646; FT-0651483; I0906; S2475; SW197805-5; D08066; EN300-123057; AB00698388-07; AB00698388-10; AB00698388-11; AB00698388-12; AB00698388-13; AB00698388_15; AB00698388_16; A809313; Q177094; Q-201231; SR-01000763561-4; SR-01000763561-6; BRD-K92723993-066-02-9; BRD-K92723993-066-04-5; Z1546624232; 1080014-82-9; 4-(4-Me-piperazin-1-ylmethyl)-N-[4-Me-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3- pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-n[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide; BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINOPHENYL)-; Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI); methanesulfonic acid; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide	Approved	Approved Drug(s)	5291	DB00619	D0KG3Y	493.6	86.3	706	3.5	37	2	7	7	C29H31N7O	4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5	InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)	KTUFNOKKBVMGRW-UHFFFAOYSA-N
DA0K2D	Eribulin	Small molecule	Eribulin; 253128-41-5; Eribulin [INN]; ER 086526; CHEBI:63587; LR24G6354G; 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one; (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one; ER-086526; (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-bis(methylene)-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.1(3,32).1(3,33).1(6,9).1(12,16).0(18,22).0(29,36).0(31,35)]hentetracontan-24-one; NSC-707389; UNII-LR24G6354G; ERIBULIN [MI]; ERIBULIN [VANDF]; B1939;E7389;ER-086526; ERIBULIN [MART.]; ERIBULIN [WHO-DD]; B 1939; e7389-lf; GTPL6813; CHEMBL1683590; SCHEMBL15783821; EX-A4873D; DTXSID101009321; AT36513; DB08871; NCGC00510497-02; BP-29357; HY-13442; MS-31267; Q408717; (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-o	Approved	Approved Drug(s)	11354606	DB08871	D0KK2E	729.9	146	1380	1.1	52	2	12	4	C40H59NO11	(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one	CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O	C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O	InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1	UFNVPOGXISZXJD-JBQZKEIOSA-N
DK36EB	Entecavir	Small molecule	Entecavir; 142217-69-4; Baraclude; anhydrous entecavir; Entecavir anhydrous; BMS 200475; BMS-200475; entecavir (anhydrous); SQ-34676; CHEBI:473990; 209216-23-9; SQ34676; BMS-200475-01; SQ 34676; Entecavir [USAN:INN]; NNU2O4609D; 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; DTXSID4046446; Entecavir (INN); Entecavir [INN]; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-; 1333204-94-6; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 2-amino-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-1,9-dihydro-6H-purin-6-one; 2-AMINO-9-((1S,3R,4S)-4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL)-1H-PURIN-6(9H)-ONE; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-3H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one; SQ 34,676; UNII-NNU2O4609D; HSDB 7334; NCGC00164563-01; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylene-cyclopentyl]-1H-purin-6-one; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-; MFCD00907887; ENTECAVIR [MI]; ENTECAVIR [HSDB]; CHEMBL713; ENTECAVIR [WHO-DD]; (1R,3S,4S)-Entecavir; SCHEMBL28648; DTXCID2026446; Entecavir, >=98% (HPLC); SCHEMBL15198001; 188399-46-4; Tox21_112192; BDBM50248008; BMS200475; AKOS015854916; AKOS015920226; AKOS025312554; AC-1593; CCG-267218; CS-3160; DB00442; GS-6386; NCGC00164563-04; NCGC00164563-06; NCGC00164563-09; NCGC00164563-13; HY-13623; AM20080880; CAS-142217-69-4; E0899; S5246; D07896; A807868; AR-270/43507901; EN300-37158607; Q418586; BRD-K08206212-001-01-2; 9-[(1S,3R,4S)-4-Hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]guanine; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1R,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylene-cyclopentyl]-3H-purin-6-one hydrate;Entecavir; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one hydrate (1:1); 2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-3,9-dihydro-purin-6-one; 2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]	Approved	Approved Drug(s)	135398508	DB00442	D0KR2J	277.28	126	480	-1.3	20	4	5	2	C12H15N5O3	2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one	C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N	C=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2N=C(NC3=O)N	InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1	QDGZDCVAUDNJFG-FXQIFTODSA-N
DTL24D	Vilanterol	Small molecule	Vilanterol; 503068-34-6; GW642444x; GW-642444x; UNII-028LZY775B; CHEBI:75037; GW642444; GW-642444; 028LZY775B; Vilanterol (USAN); 4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; 4-[(1R)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; VILANTEROL [USAN]; 4-((1R)-2-((6-(2-((2,6-dichlorophenyl)methoxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; Vilanterol [USAN:INN]; vilanterolum; GW 642444; 4-{(1R)-2-[(6-{2-[(2,6-Dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; VILANTEROL [INN]; VILANTEROL [VANDF]; VILANTEROL [WHO-DD]; SCHEMBL142630; GTPL7353; CHEMBL1198857; AMY6916; DTXSID80198318; BCP25897; EX-A2177; BDBM50416060; MFCD18782703; AKOS032950047; CS-1680; DB09082; GW 642444X; 1,3-Benzenedimethanol, alpha1-(((6-(2-((2,6-dichlorophenyl)methoxy)ethoxy)hexyl)amino)methyl)-4-hydroxy-, (alpha1R)-; 4-(2-((6-((2-(((2,6-Dichlorophenyl)methyl)oxy)ethyl)oxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; AC-33108; AS-35120; HY-14300; Vilanterol; GW642444X; GW642444; Vilanterol (GW642444; GW 642444X); D09696; EN300-20321625; Q15053666; GW 642444X;GW 642444;GW642444X;GW642444;GW-642444X;GW-642444; 1,3-BENZENEDIMETHANOL, .ALPHA.1-(((6-(2-((2,6-DICHLOROPHENYL)METHOXY)ETHOXY)HEXYL)AMINO)METHYL)-4-HYDROXY-, (.ALPHA.1R)-; 4-((R)-2-{6-[2-(2,6-Dichlorobenzyloxy)-ethoxy]-hexylamino}-1-hydroxyethyl)-2-hydroxymethyl-phenol; 4-((R)-2-{6-[2-(2,6-Dichlorobenzyloxy)-ethoxy]-hexylamino}-1-hydroxyethyl)-2-hydroxymethylphenol; 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol	Approved	Approved Drug(s)	10184665	DB09082	D0L0GM	486.4	91.2	466	3.8	32	4	6	16	C24H33Cl2NO5	4-[(1R)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol	C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl	C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNC[C@@H](C2=CC(=C(C=C2)O)CO)O)Cl	InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1	DAFYYTQWSAWIGS-DEOSSOPVSA-N
D2QX6H	Insulin degludec	Small molecule	Insulin degludec; Degludec; Tresiba; 844439-96-9; Insulin degludec [USAN:INN]; UNII-54Q18076QB; NN 1250; NN1250; 54Q18076QB; B29N(epsilon)-omega-carboxypentadecanoyl-gamma-L-glutamyl desB30 human insulin; (1A-21A),(1B-29B)-Insulin (human), 29B-(N6-(N-(15-carboxy-1-oxopentadecyl)-L-gamma- glutamyl)-L-lysine)-	Approved	Approved Drug(s)	118984462	DB09564	D0L2CI	6104	2510	15300	-4.9	426	79	92	197	C274H411N65O81S6	16-[[(1S)-4-[[(5S)-5-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-carboxypentyl]amino]-1-carboxy-4-oxobutyl]amino]-16-oxohexadecanoic acid	CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCC(=O)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN	CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCC(=O)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN	InChI=1S/C274H411N65O81S6/c1-28-146(23)223(331-210(357)119-275)268(412)335-222(145(21)22)264(408)305-172(89-97-218(369)370)234(378)300-169(84-92-204(279)351)238(382)326-198-131-424-425-132-199-259(403)323-193(126-341)256(400)312-177(103-138(7)8)241(385)313-183(110-154-66-74-160(345)75-67-154)244(388)301-167(82-90-202(277)349)235(379)308-176(102-137(5)6)239(383)303-171(88-96-217(367)368)237(381)320-189(116-205(280)352)251(395)316-185(112-156-70-78-162(347)79-71-156)247(391)327-197(258(402)322-191(273(419)420)118-207(282)354)130-423-422-129-196(231(375)290-122-211(358)295-166(86-94-215(363)364)233(377)299-165(62-53-99-288-274(283)284)229(373)289-123-212(359)297-181(108-152-57-45-41-46-58-152)243(387)315-182(109-153-59-47-42-48-60-153)246(390)317-186(113-157-72-80-163(348)81-73-157)254(398)338-226(150(27)344)270(414)339-100-54-63-201(339)262(406)306-173(271(415)416)61-51-52-98-287-208(355)93-85-174(272(417)418)296-209(356)64-49-38-36-34-32-30-31-33-35-37-39-50-65-214(361)362)329-266(410)221(144(19)20)334-252(396)179(105-140(11)12)310-245(389)184(111-155-68-76-161(346)77-69-155)314-240(384)175(101-136(3)4)307-227(371)148(25)294-232(376)170(87-95-216(365)366)304-263(407)220(143(17)18)333-253(397)180(106-141(13)14)311-249(393)188(115-159-121-286-135-293-159)319-255(399)192(125-340)298-213(360)124-291-230(374)195(128-421-426-133-200(328-260(198)404)261(405)337-225(149(26)343)269(413)324-194(127-342)257(401)336-224(147(24)29-2)267(411)330-199)325-242(386)178(104-139(9)10)309-248(392)187(114-158-120-285-134-292-158)318-236(380)168(83-91-203(278)350)302-250(394)190(117-206(281)353)321-265(409)219(142(15)16)332-228(372)164(276)107-151-55-43-40-44-56-151/h40-48,55-60,66-81,120-121,134-150,164-201,219-226,340-348H,28-39,49-54,61-65,82-119,122-133,275-276H2,1-27H3,(H2,277,349)(H2,278,350)(H2,279,351)(H2,280,352)(H2,281,353)(H2,282,354)(H,285,292)(H,286,293)(H,287,355)(H,289,373)(H,290,375)(H,291,374)(H,294,376)(H,295,358)(H,296,356)(H,297,359)(H,298,360)(H,299,377)(H,300,378)(H,301,388)(H,302,394)(H,303,383)(H,304,407)(H,305,408)(H,306,406)(H,307,371)(H,308,379)(H,309,392)(H,310,389)(H,311,393)(H,312,400)(H,313,385)(H,314,384)(H,315,387)(H,316,395)(H,317,390)(H,318,380)(H,319,399)(H,320,381)(H,321,409)(H,322,402)(H,323,403)(H,324,413)(H,325,386)(H,326,382)(H,327,391)(H,328,404)(H,329,410)(H,330,411)(H,331,357)(H,332,372)(H,333,397)(H,334,396)(H,335,412)(H,336,401)(H,337,405)(H,338,398)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,369,370)(H,415,416)(H,417,418)(H,419,420)(H4,283,284,288)/t146-,147-,148-,149+,150+,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,219-,220-,221-,222-,223-,224-,225-,226-/m0/s1	FYZPCMFQCNBYCY-WIWKJPBBSA-N
DN8H3V	Fluoxymesterone	Small molecule	fluoxymesterone; 76-43-7; Halotestin; Fluoximesterone; Fluoxymestrone; Androfluorene; Androfluorone; Fluotestin; Android-f; Ora-Testryl; Androsterolo; Fluosterone; Flusteron; Flutestos; Oralsterone; Oratestin; Testoral; Ultandren; Ultandrene; Fluoximesteronum; Neo-Ormonal; Ora Testryl; Fluoximesterona; Fluossimesterone [DCIT]; Fluoxymesteronum; Fluoxymesteronum [INN-Latin]; Fluoximesterona [INN-Spanish]; NSC-12165; Fluoxymesteron; (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone; 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one; Fluoxymesterone ciii; U 6040; NSC 10704; NSC-10704; Testosterone, 9-fluoro-11beta-hydroxy-17-methyl-; 9JU12S4YFY; CHEBI:5120; FXM; DTXSID8033512; Anadroid-F; 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone; component of Halodrin; Fluossimesterone; (11beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one; 9.alpha.-Fluoro-11.beta.-hydroxy-17-methyltestosterone; DTXCID6013512; Androxy; 9alpha-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one; 9.alpha.-Fluoro-11.beta.,17.beta.-dihydroxy-17.alpha.-methyl-4-androstene-3-one; CAS-76-43-7; Halotestin (TN); (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; CCRIS 9036; HSDB 3333; EINECS 200-961-8; Testosterone, 9-fluoro-11.beta.-hydroxy-17-methyl-; UNII-9JU12S4YFY; BRN 2008796; 9-alpha-Fluoro-11-beta-hydroxy-17-methyltestosterone; 17-alpha-Methyl-9-alpha-fluoro-11-beta-hydroxytesterone; AI3-52940; 9-Fluoro-11-beta,17-beta-dihydroxy-17-methylandrost-4-en-3-one; Androst-4-en-3-one, 9-fluoro-11,17-dihydroxy-17-methyl-, (11.beta.,17.beta.)-; 9alpha-Fluoro-17alpha-methyl-11beta,17-dihydroxy-4-androsten-3-one; NCGC00182970-01; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one; 9-alpha-Fluoro-17-alpha-methyl-11-beta,17-dihydroxy-4-androsten-3-one; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methyl-4-androstene-3-one; Androxy (TN); 11-beta,17-beta-Dihydroxy-9-alpha-fluoro-17-alpha-methyl-4-androster-3-one; 9-alpha-Fluoro-11-beta,17-beta-dihydroxy-17-alpha-methyl-4-androstene-3-one; Androst-4-en-3-one, 9-fluoro-11,17-dihydroxy-17-methyl-, (11beta,17beta)-; Fluoxymesterone [USP:INN:BAN:JAN]; Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3 [French]; Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-; Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3; SCHEMBL5096; CHEMBL1445; FLUOXYMESTERONE [MI]; FLUOXYMESTERONE [INN]; FLUOXYMESTERONE [JAN]; 4-08-00-02057 (Beilstein Handbook Reference); MLS001055414; FLUOXYMESTERONE [HSDB]; FLUOXYMESTERONE [VANDF]; GTPL2861; FLUOXYMESTERONE [MART.]; FLUOXYMESTERONE [WHO-DD]; BDBM18189; Fluoxymesterone (JAN/USP/INN); HMS2272B06; BCP10776; NSC10704; NSC12165; Tox21_113158; Tox21_200854; 9-fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; FLUOXYMESTERONE [ORANGE BOOK]; LMST02020025; FLUOXYMESTERONE CIII [USP-RS]; AKOS015895109; Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl- (VAN); DB01185; FLUOXYMESTERONE [USP MONOGRAPH]; Fluoxymesterone, solid (photosensitive); NCGC00091037-01; NCGC00091037-02; NCGC00258408-01; AC-29744; SMR000686158; Fluoxymesterone 1.0 mg/ml in Acetonitrile; D00327; A838701; Q410663; W-104363; (1R,2S,10S,11S,14S,15S,17S)-1-fluoro-14,17-dihydroxy-2,14,15-trimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-6-en-5-one; (8S,9R,10S,11S,13S,14S,17S)-9-fluoranyl-10,13,17-trimethyl-11,17-bis(oxidanyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one	Approved	Approved Drug(s)	6446	DB01185	D0L2LS	336.4	57.5	630	2.4	24	2	4	0	C20H29FO3	(8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one	CC12CCC(=O)C=C1CCC3C2(C(CC4(C3CCC4(C)O)C)O)F	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@]4(C)O)C)O)F	InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1	YLRFCQOZQXIBAB-RBZZARIASA-N
DLFE95	Nelfinavir	Small molecule	nelfinavir; 159989-64-7; Viracept; AG-1343; Viracept (TN); Nelfinavir (INN); HO3OGH5D7I; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; NSC-747167; CHEBI:7496; 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; NLF; NELFINAVIR [INN]; Nelfinavir [INN:BAN]; NFV; (3S,4aS,8aS)-N-(tert-Butyl)-2-((2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl)decahydroisoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamide; CHEMBL1205; AG1341; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methyl-benzoyl)amino]-4-phenylsulfanyl-butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-((2R,3R)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S,4aS,8aS)-; SMR000596515; NSC722664; NCGC00090782-03; NELFINAVIR MESYLATE AG1343; UNII-HO3OGH5D7I; Met-SDF-1.beta. & Nelfinavir; 1ohr; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; NELFINAVIR [MI]; NELFINAVIR [VANDF]; CHEMBL584; NELFINAVIR [WHO-DD]; BIDD:PXR0143; SCHEMBL38218; MLS001195634; MLS001304729; N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-; BIDD:GT0395; NELFINAVIR [EMA EPAR]; DTXSID5035080; GTPL11090; HMS2232I04; Met-Stromal Cell-derived Factor-1.beta. (Human) & Nelfinavir; BDBM50061306; MFCD01938163; NSC747167; AKOS000280862; AM84529; CS-0677; DB00220; NSC 747167; MRF-0000208; NCGC00090782-04; NCGC00090782-05; NCGC00090782-17; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2-(2S*,3S*),3-alpha,4a-beta,8a-beta))-; AC-20032; AS-75258; HY-15287; C07257; C73027; D08259; AB00698259-15; A810095; A810096; EN300-18530973; Q423366; (3S, 4aS, 8aS)-2-[(2R, 3R)-2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide; (3S, 4aS, 8aS)-2-[(2R, 3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide; (3S,4abeta,8abeta)-N-tert-Butyl-2-[(2R,3R)-2-hydroxy-3-(2-methyl-3-hydroxybenzoylamino)-4-(phenylthio)butyl]decahydroisoquinoline-3alpha-carboxamide; (3S,4aS,8aS)-2-[(2R,3R)-2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylsulfanyl-butyl]-decahydro-isoquinoline-3-carboxylic acid tert-butylamide; compound with methanesulfonic acid; (3S,4aS,8aS)-2-[(2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)-oxomethyl]amino]-4-(phenylthio)butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-3-[(2-methyl-3-oxidanyl-phenyl)carbonylamino]-2-oxidanyl-4-phenylsulfanyl-butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2- [(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; 3-Isoquinolinecarboxamide,1-dimethyl ethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; 3-Isoquinolinecarboxamide,1-dimethylethyl)decahydro-2-[2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, [3S-[2(2S*,3S*),3.alpha.,4a.beta.,8a.beta.]]-; N-(tert-Butyl)-2-(2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl)decahydroisoquinoline-3-carboxamide	Approved	Approved Drug(s)	64143	DB00220	D0L3MP	567.8	127	830	5.7	40	4	6	10	C32H45N3O4S	(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide	CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O	CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O	InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1	QAGYKUNXZHXKMR-HKWSIXNMSA-N
DKGB30	Salmeterol	Small molecule	Salmeterol; 89365-50-4; Serevent; Astmerole; Aeromax; Salmeterolum [Latin]; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol; GR 33343X; SALMATEROL; SN408D; GR 33343 X; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; 2I4BC502BT; DTXSID6023571; CHEBI:64064; GR-33343-X; Salmeterolum; 4-(1-hydroxy-2-(6-(4-phenylbutoxy)hexylamino)ethyl)-2-(hydroxymethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; 4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-2-(hydroxymethyl)phenol; SMR000466295; HSDB 7315; SR-01000076139; Salmeterol (USAN/INN); UNII-2I4BC502BT; Salmeterol [USAN:INN:BAN]; NCGC00025247-01; Fluticasonepropiponate; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; CPD000466295; SALMETEROL [MI]; SALMETEROL [INN]; Prestwick3_000945; Salmeterol Dimer Impurity; SALMETEROL [HSDB]; SALMETEROL [USAN]; SALMETEROL [VANDF]; S 2692; SCHEMBL4767; CHEMBL1263; SALMETEROL [WHO-DD]; Lopac0_001100; BSPBio_000910; GTPL559; MLS000759000; MLS001424322; BPBio1_001002; DTXCID803571; Salmeterol Xinafoate Impurity 1; BDBM25771; HMS2052H13; HMS2090E17; HMS2097N12; HMS3268K19; HMS3394H13; HMS3412P13; HMS3714N12; HMS3886G10; AMY37616; BCP04199; EX-A4409; GR33343XGR33343X; Tox21_113584; MFCD00867037; s5527; STK629186; AKOS005561914; CCG-101194; CCG-205176; DB00938; NC00444; SDCCGSBI-0633788.P001; 1,3-Benzenedimethanol, 4-hydroxy-.alpha.1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-; 1,3-Benzenedimethanol, 4-hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-; MRF-0000468; NCGC00015938-03; NCGC00025247-02; 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-; 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl-, (+-)-; AS-56157; HY-14302; Salmeterol 100 microg/mL in Acetonitrile; CAS-89365-50-4; AB00513972; FT-0674508; FT-0674509; C07241; C77008; D05792; AB00513972-07; EN300-18530979; L000532; Q424333; Q-101428; SR-01000076139-2; SR-01000076139-6; BRD-A01320529-001-05-9; 2-hydroxymethyl-4-{1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl}phenol; 5-[2-[6-(4-Phenylbutoxy)hexylamino]-1-hydroxyethyl]-2-hydroxybenzenemethanol; ( inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; GR 33343X; 1-hydroxy-2-naphthoic acid;4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]-2-methylol-phenol	Approved	Approved Drug(s)	5152	DB00938	D0L5YV	415.6	82	403	3.9	30	4	5	16	C25H37NO4	2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol	C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O	C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O	InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2	GIIZNNXWQWCKIB-UHFFFAOYSA-N
DA20FU	Insulin lispro	Small molecule	Insulin lispro; 133107-64-9; INSULIN LISPRO (5.97 MG); Insulin-lispro; DTXSID90157956	Approved	Approved Drug(s)	16132438	DB00046	D0L6JE	5814	2310	13000	.	405	84	89	185	C257H389N65O77S6	(4S)-4-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R)-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[[(2R)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid;(4S)-4-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[(2S)-2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid	CCC(C)C(C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CS)C(=O)NC(CS)C(=O)NC(C(C)O)C(=O)NC(CO)C(=O)NC(C(C)CC)C(=O)NC(CS)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)N)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CS)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)CN.CC(C)CC(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CS)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC4=CC=C(C=C4)O)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)O)C(=O)O)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC6=CN=CN6)NC(=O)C(CO)NC(=O)CNC(=O)C(CS)NC(=O)C(CC(C)C)NC(=O)C(CC7=CN=CN7)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC8=CC=CC=C8)N	CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN.C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC8=CC=CC=C8)N)O	InChI=1S/C158H234N40O42S2.C99H155N25O35S4/c1-79(2)57-104(181-131(213)86(15)173-136(218)102(50-53-125(211)212)179-152(234)127(84(11)12)194-148(230)107(60-82(7)8)184-145(227)113(67-95-70-166-78-172-95)189-150(232)115(74-199)176-123(208)73-170-134(216)116(75-241)191-140(222)105(58-80(3)4)182-144(226)112(66-94-69-165-77-171-94)188-138(220)101(48-51-119(161)204)178-146(228)114(68-120(162)205)190-153(235)126(83(9)10)193-132(214)98(160)61-89-31-21-18-22-32-89)139(221)185-110(64-92-40-44-96(202)45-41-92)142(224)183-106(59-81(5)6)147(229)195-128(85(13)14)154(236)192-117(76-242)135(217)169-71-121(206)174-100(49-52-124(209)210)137(219)177-99(38-29-55-167-158(163)164)133(215)168-72-122(207)175-108(62-90-33-23-19-24-34-90)141(223)186-109(63-91-35-25-20-26-36-91)143(225)187-111(65-93-42-46-97(203)47-43-93)149(231)196-129(87(16)200)155(237)180-103(37-27-28-54-159)156(238)198-56-30-39-118(198)151(233)197-130(88(17)201)157(239)240;1-12-46(9)77(121-73(134)36-100)97(156)122-76(45(7)8)95(154)108-56(25-29-75(137)138)80(139)105-54(23-27-70(102)131)83(142)117-66(40-161)93(152)119-68(42-163)94(153)124-79(48(11)127)98(157)116-64(38-126)90(149)123-78(47(10)13-2)96(155)120-67(41-162)92(151)115-63(37-125)89(148)110-58(31-44(5)6)85(144)111-59(32-49-14-18-51(128)19-15-49)86(145)106-53(22-26-69(101)130)81(140)109-57(30-43(3)4)84(143)107-55(24-28-74(135)136)82(141)113-61(34-71(103)132)88(147)112-60(33-50-16-20-52(129)21-17-50)87(146)118-65(39-160)91(150)114-62(99(158)159)35-72(104)133/h18-26,31-36,40-47,69-70,77-88,98-118,126-130,199-203,241-242H,27-30,37-39,48-68,71-76,159-160H2,1-17H3,(H2,161,204)(H2,162,205)(H,165,171)(H,166,172)(H,168,215)(H,169,217)(H,170,216)(H,173,218)(H,174,206)(H,175,207)(H,176,208)(H,177,219)(H,178,228)(H,179,234)(H,180,237)(H,181,213)(H,182,226)(H,183,224)(H,184,227)(H,185,221)(H,186,223)(H,187,225)(H,188,220)(H,189,232)(H,190,235)(H,191,222)(H,192,236)(H,193,214)(H,194,230)(H,195,229)(H,196,231)(H,197,233)(H,209,210)(H,211,212)(H,239,240)(H4,163,164,167);14-21,43-48,53-68,76-79,125-129,160-163H,12-13,22-42,100H2,1-11H3,(H2,101,130)(H2,102,131)(H2,103,132)(H2,104,133)(H,105,139)(H,106,145)(H,107,143)(H,108,154)(H,109,140)(H,110,148)(H,111,144)(H,112,147)(H,113,141)(H,114,150)(H,115,151)(H,116,157)(H,117,142)(H,118,146)(H,119,152)(H,120,155)(H,121,134)(H,122,156)(H,123,149)(H,124,153)(H,135,136)(H,137,138)(H,158,159)/t86-,87+,88+,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,126-,127-,128-,129-,130-;46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-,77-,78-,79-/m00/s1	WNRQPCUGRUFHED-DETKDSODSA-N
D2MW5P	Probenecid	Small molecule	probenecid; 57-66-9; 4-(Dipropylsulfamoyl)benzoic acid; Benemid; Probenecid acid; Probecid; Probalan; Benecid; Probenemid; Benuryl; p-(Dipropylsulfamoyl)benzoic acid; Probexin; Prolongine; Tubophan; Uricosid; Apurina; Proben; Synergid R; Probenecidum; Probenecida; Probenecide; 4-[(dipropylamino)sulfonyl]benzoic acid; 4-((Dipropylamino)sulfonyl)benzoic acid; 4-(Di-n-propylsulfamoyl)benzoesaeure; 4-(N,N-Dipropylsulfamoyl)benzoesaeure; NCI-C56097; Benzoic acid, 4-[(dipropylamino)sulfonyl]-; Benzoic acid, p-(dipropylsulfamoyl)-; Probenate; 4-(N,N-Dipropylsulfamoyl)benzoic Acid; p-(Dipropylsulfamyl)benzoic acid; Benzoic acid, 4-((dipropylamino)sulfonyl)-; NSC 18786; CHEBI:8426; NSC-18786; CHEMBL897; MLS000028496; 4-Dipropylsulfamoyl-benzoic acid; Benemide; DTXSID9021188; Probenid; Robenecid; PO572Z7917; CAS-57-66-9; probenicid; NCGC00016251-08; SMR000058280; Probenecide [INN-French]; Probenecidum [INN-Latin]; Probenecida [INN-Spanish]; DTXCID901188; Benemid (TN); CCRIS 3643; HSDB 3387; SR-01000003108; EINECS 200-344-3; MFCD00038402; BRN 2815775; AI3-50078; UNII-PO572Z7917; Probenecid [USP:INN:BAN:JAN]; Prestwick_809; Probenecid (Benemid); Spectrum_000834; ColBenemid (Salt/Mix); Opera_ID_677; PROBENECID [MI]; PROBENECID [INN]; PROBENECID [JAN]; Prestwick0_000542; Prestwick1_000542; Prestwick2_000542; Prestwick3_000542; Spectrum2_001294; Spectrum3_000554; Spectrum4_000486; Spectrum5_001419; PROBENECID [HSDB]; Benemid; Benecid; Benuryl; Epitope ID:180853; PROBENECID [MART.]; SCHEMBL3663; PROBENECID [USP-RS]; PROBENECID [WHO-DD]; PROBENECID [WHO-IP]; BIDD:PXR0092; Oprea1_416955; WLN: QVR DSWN3&3; BSPBio_000583; BSPBio_002227; KBioGR_000971; KBioSS_001314; MLS001076472; BIDD:GT0626; DivK1c_000056; SPECTRUM1500502; SPBio_001327; SPBio_002504; BPBio1_000643; GTPL4357; Probenecid (JP17/USP/INN); PROBENECID [EP IMPURITY]; PROBENECID [ORANGE BOOK]; HMS500C18; KBio1_000056; KBio2_001314; KBio2_003882; KBio2_006450; KBio3_001727; AMY8947; PROBENECID [EP MONOGRAPH]; PROBENECID [USP IMPURITY]; NINDS_000056; HMS1569N05; HMS1920J22; HMS2092C03; HMS2096N05; HMS2233N05; HMS3259G04; HMS3369L18; HMS3652O17; HMS3713N05; HMS3743E07; HMS3885I18; p-(Dipropylsulfamoyl) benzoic acid; Pharmakon1600-01500502; PROBENECID [USP MONOGRAPH]; ALBB-025846; BCP21785; HY-B0545; NSC18786; PROBENECIDUM [WHO-IP LATIN]; STR06053; PROBEN-C COMPONENT PROBENECID; Tox21_110328; Tox21_202110; Tox21_302928; BDBM50206509; CCG-39232; NSC757292; s4022; STL229614; COLBENEMID COMPONENT PROBENECID; 4-Dipropylsulfamoyl-benzoic acid anion; AKOS000165123; PROBAMPACIN COMPONENT PROBENECID; Tox21_110328_1; AC-2023; DB01032; HC 5006; NC00530; NSC-757292; SB17360; IDI1_000056; PROBENECID COMPONENT OF PROBEN-C; NCGC00016251-01; NCGC00016251-02; NCGC00016251-03; NCGC00016251-04; NCGC00016251-05; NCGC00016251-06; NCGC00016251-07; NCGC00016251-09; NCGC00016251-10; NCGC00016251-13; NCGC00016251-17; NCGC00023829-03; NCGC00023829-04; NCGC00023829-05; NCGC00023829-06; NCGC00023829-07; NCGC00256441-01; NCGC00259659-01; PROBENECID COMPONENT OF COLBENEMID; BP166195; COL-PROBENECID COMPONENT PROBENECID; PROBENECID COMPONENT OF PROBAMPACIN; 4-(N,N-dipropylaminosulphonyl)benzoic acid; SBI-0051492.P003; 4-Dipropylsulfamoyl-benzoic acid(probenecid); AB00052080; P1975; PROBENECID COMPONENT OF COL-PROBENECID; SW196943-3; EN300-69677; C07372; D00475; D92177; AB00052080_15; AB00052080_16; Q900898; Q-201621; SR-01000003108-2; SR-01000003108-3; BRD-K95237249-001-05-9; BRD-K95237249-001-15-8; Z53037954; Probenecid, European Pharmacopoeia (EP) Reference Standard; Probenecid, United States Pharmacopeia (USP) Reference Standard	Approved	Approved Drug(s)	4911	DB01032	D0L7FM	285.36	83.1	374	3.2	19	1	5	7	C13H19NO4S	4-(dipropylsulfamoyl)benzoic acid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O	InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)	DBABZHXKTCFAPX-UHFFFAOYSA-N
D7LW9N	Romidepsin	Small molecule	Romidepsin; Depsipeptide; Istodax; FK228; Chromadax; 128517-07-7; Antibiotic FR 901228; FR901228; FK 228; FK-228; FR 901228; FR-901228; NSC-630176; CHEMBL343448; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; CHEBI:61080; NSC 630176; NSC630176; NSC754143; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; C24H36N4O6S2; Istodax (TN); Romidepsin [USAN]; CX3T89XQBK; HDInhib_000006; romidepsina; romidepsine; romidepsinum; OXA-12,8,20,23-TETRAZABICYCLO[8.7.6]TRICOSANE, CYCLIC PEPTIDE DERIV.; Romidepsin (FK228); Romidepsin; FK-228; ROMIDEPSIN [MI]; FK-901228; ROMIDEPSIN [INN]; ROMIDEPSIN [JAN]; ROMIDEPSIN [VANDF]; Probes1_000153; Probes2_000337; ROMIDEPSIN [MART.]; ROMIDEPSIN [WHO-DD]; DEPSIPEPTIDE [WHO-DD]; Romidepsin (JAN/USAN/INN); SCHEMBL677497; GTPL7006; ROMIDEPSIN [ORANGE BOOK]; Romidepsin, >=98% (HPLC); BDBM19151; Romidepsin (FK228 ,depsipeptide); (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (3->5)-disulfide; HB1386; MFCD18433404; s3020; API0005301; CS-0985; DB06176; NSC-754143; HY-15149; D06637; AB01273968-01; EN300-22844947; SR-01000941579; Q7363205; SR-01000941579-1; L-Valine,3-didehydro-2- aminobutanoyl-,.xi.-lactone, cyclic (1.fwdarw.2)-disulfide; L-Valine,3-didehydro-2-aminobutanoyl-,.xi.-lactone, cyclic (1.fwdarw.2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7- ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23- tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(1methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16ene-3,6,9,19,22-pentone; (E)-(1S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2- oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (E)-(1S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2- oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; CYCLO((2Z)-2-AMINO-2-BUTENOYL-L-VALYL-(3S,4E)-3-HYDROXY-7-MERCAPTO-4-HEPTENOYL-D-VALYL-D-CYSTEINYL), CYCLIC (3->5)-DISULPHIDE; Cyclo[(2Z)-2-amino-2-butenoyl-L-val yl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valy l-D-cysteinyl], cyclic (3-5) disulfide; Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl], cyclic (3-5) disulfide	Approved	Approved Drug(s)	5352062	DB06176	D0L7LC	540.7	193	905	2.2	36	4	8	2	C24H36N4O6S2	(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone	CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C	C/C=C\1/C(=O)N[C@H](C(=O)O[C@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C	InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1	OHRURASPPZQGQM-GCCNXGTGSA-N
DD31TQ	Voclosporin	Small molecule	Voclosporin; 515814-01-4; Lupkynis; Luveniq; ISAtx-247; Voclosporin [USAN]; ISATX247; ISA-247; ISA247; LX211; LX-211; R 1524; R-1524; ISA(TX)247; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dienyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; 515814-00-3; 2PN063X6B1; trans-ISA 247; Voclera; ISA 247; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-((1R,2R,E)-1-hydroxy-2-methylhepta-4,6-dien-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone; trans-ISA-247; Voclosporin (USAN/INN); Voclosporin [USAN:INN]; ISATX 247; UNII-2PN063X6B1; 3odi; LX-214; ISAtx-247; Luveniq; VOCLOSPORIN [MI]; VOCLOSPORIN [INN]; VOCLOSPORIN [MART.]; VOCLOSPORIN [WHO-DD]; E-ISA247; SCHEMBL12632344; GTPL11388; VOCLOSPORIN [ORANGE BOOK]; CHEBI:135957; DTXSID401030488; (E)-ISA-247; EX-A5922; AT27977; DB11693; MS-32055; HY-106638; CS-0026210; R1524; D09033; Q7939256; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dien-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone; 1,11-anhydro[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl- N-methyl-L-valyl-[(2S,3R,4R,6E)-3-hydroxy-4-methyl- 2-(methylamino)nona-6,8-dienoyl][(2S)-2-aminobutanoyl]- N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine]; CYCLO (((E,Z)-(2S,3R,4R)-3-HYDROXY-4-METHYL-2-(METHYLAMINO)NONA-6,8-DIENOYL)-L-2-AMINOBYTYRL-N-METHYL-GLYCYL-N-METHYL-L-LEUCYL-L-VALYL-N-METHYL-L-LEUCYL-L-ALANYL-D-ALANYL-N-METHYL-L-LEUCYL-N-METHYL-L-LEUCYL-N-METHYL-L-VALYL); CYCLO(L-ALANYL-D-ALANYL-N-METHYL-L-LEUCYL-N-METHYL-L-LEUCYL-N-METHYL-L-VALYL- ((2S,3R,4R,6E)-3-HYDROXY-4-METHYL-2-(METHYLAMINO)NONA-6,8-DIENOYL)-(2S)-2- AMINOBUTANOYL-N-METHYLGLYCYL-N-METHYL-L-LEUCYL-L-VALYL-N-METHYL-L-LEUCYL); CYCLOSPORIN A, 6-((2S,3R,4R,6E)-3-HYDROXY-4-METHYL-2-(METHYLAMINO)-6,8- NONADIENOIC ACID)-	Approved	Approved Drug(s)	6918486	DB11693	D0L9HX	1214.6	279	2380	7.9	86	5	12	16	C63H111N11O12	(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dienyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone	CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C	CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C	InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1	BICRTLVBTLFLRD-PTWUADNWSA-N
DF2PE3	Gentamicin	Small molecule	gentamicin; Garamycin; Gentavet; Gentamicins; 1403-66-3; Gentacycol; Gentamycin C1; Cidomycin; Gentamicinum; Gentamycinum; 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; Refobacin TM; Gentamicina; Gentamicine; Gentamycin-creme; Gentamycins; Gentamicin sulphate sterile; Gentamicine [INN-French]; Gentamicinum [INN-Latin]; Gentamycin-creme [German]; Gentamicina [INN-Spanish]; Centicin; Gentamicin (TN); Gentamicin (BAN); Gentamicin [INN]; HSDB 3087; Gentamicin [INN:BAN]; EINECS 215-765-8; UNII-T6Z9V48IKG; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside; T6Z9V48IKG; SCHEMBL537630; CHEMBL329592; GTPL2427; SCHEMBL19996168; STL454325; AKOS015961211; DB00798; J4.074F; 2-[4,6-diamino-3-[3-amino-6-(1-methylaminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-methylaminooxane-3,5-diol; AC-13386; FT-0626646; FT-0668965; D08013; EN300-19875459; Q422482; 1294497-75-8; 2-{[4,6-diamino-3-({3-amino-6-[1-(methylamino)ethyl]oxan-2-yl}oxy)-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol	Approved	Approved Drug(s)	3467	DB00798	D0L9UU	477.6	200	636	-4.1	33	8	12	7	C21H43N5O7	2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol	CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC	CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC	InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3	CEAZRRDELHUEMR-UHFFFAOYSA-N
DSK2L6	Fluticasone	Small molecule	fluticasone; 90566-53-3; Fluticasonum; Fluticasona; Fluticaps (TN); Fluticasone (INN); CUT2W21N7U; CHEBI:5134; S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate; FLUTICASONE [INN]; Fluticasone, Inhaled; Fluticasonum [Latin]; Fluticasona [Spanish]; Fluticasone [INN:BAN]; UNII-CUT2W21N7U; HSDB 7740; Fluticasone, topical; FLUTICASONE [HSDB]; FLUTICASONE [VANDF]; SCHEMBL4069; FLUTICASONE [MART.]; FLUTICASONE [WHO-DD]; BIDD:GT0819; GTPL6699; CHEMBL1201396; DTXSID0044022; BDBM589230; EX-A4418; HY-B0603; AC-456; DB13867; CS-0009547; C07815; D07981; US11554172, Compound Fluticasone-Propionate; EN300-19800841; Q1002165; (1R,2R,3aS,3bS,5S,9aS,9bR,10S,11aS)-5,9b-difluoro-1-{[(fluoromethyl)sulfanyl]carbonyl}-1,10-dihydroxy-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one; Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)-; S-(FLUOROMETHYL) (6.ALPHA.,11.BETA.,16.ALPHA.,17.ALPHA.)-6,9-DIFLUORO-11,17-DIHYDROXY-16-METHYL-3-OXOANDROSTA-1,4-DIENE-17-CARBOTHIOATE; S-(fluoromethyl) (6alpha,11beta,16alpha,17alpha)-6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate	Approved	Approved Drug(s)	5311101	DB13867	D0LC6K	444.5	99.9	861	3.2	30	2	8	3	C22H27F3O4S	S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate	CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)O)C)O)F)C)F	C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)O)C)O)F)C)F	InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1	MGNNYOODZCAHBA-GQKYHHCASA-N
D0E6KJ	Budesonide	Small molecule	budesonide; Pulmicort; Entocort; Rhinocort; 51333-22-3; Preferid; Rhinocort Aqua; Entocort EC; Uceris; Pulmicort Respules; Budeson; Pulmicort Flexhaler; Cortivent; Micronyl; Respules; Spirocort; Bidien; S-1320; MAP-0010; CHEBI:3207; 51372-29-3; Q3OKS62Q6X; MLS000028507; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; Budesonide MMX; Budesonidum; DTXSID8020202; Rhinocort alpha; MAP0010; R01AD05; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16A(R),17-(BUTYLIDENEBIS(OXY))-11B,21-DIHYDROXYPREGNA-1,4-DIENE-3,20-DIONE; NSC-757788; Budenofalk; Budesonido; SMR000058337; Budecort Inhaler; Budesonidum [INN-Latin]; Budesonido [INN-Spanish]; DTXCID50820058; (R)-Budesonide; Inflammide; Budiair; Miflonide; Pulmaxan; Fvolir; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; (22R)-Budesonide; Budesonide [USAN:INN:BAN:JAN]; Rhinocort Allergy; Pulmaxan turbohaler; Pulmicort (TN); Pulmicort Topinasal; Rhinocort (TN); (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one; Pulmicort turbuhaler; Budesonide Easyhaler; S 1320; CCRIS 5230; Entocort EC (TN); SR-01000000101; EINECS 257-139-7; MFCD00083259; UNII-Q3OKS62Q6X; Jorveza; Eltair; Ultesa; Noex; Giona Easyhaler; 16?,17-[(1RS)-Butylidenebis(oxy)]-11?,21-dihydroxypregna-1,4-diene-3,20-dione; NCGC00016862-01; Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-, (11.beta.,16.alpha.)-; Prestwick_840; CAS-51333-22-3; Uceris (TN); ORTIKOS; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; Budesonide, >=99%; BUDESONIDE [MI]; BUDESONIDE [INN]; BUDESONIDE [JAN]; Opera_ID_1696; Prestwick0_000518; Prestwick1_000518; Prestwick2_000518; Prestwick3_000518; BUDESONIDE [USAN]; BUDESONIDE [VANDF]; Epitope ID:161750; B 7777; SCHEMBL4096; (+)-16alpha,17alpha-Butylidenedioxy-11beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; BUDESONIDE [USP-RS]; BUDESONIDE [WHO-DD]; CHEMBL1370; Pregna-1,4-diene-3,20-dione,16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11beta,16alpha)-; Lopac0_000174; BSPBio_000475; Budesonide (JAN/USP/INN); MLS001077323; MLS002207112; Budesonide (anti-inflammatory); SPBio_002396; BPBio1_000523; GTPL7434; BUDESONIDE [ORANGE BOOK]; HSDB 8279; BUDESONIDE [EP MONOGRAPH]; UCERIS COMPONENT BUDESONIDE; BUDESONIDE [USP MONOGRAPH]; HMS1569H17; HMS2096H17; HMS2232D17; HMS3259H07; HMS3260D09; HMS3413B08; HMS3413P17; HMS3677B08; HMS3677P17; HMS3713H17; BREZTRI COMPONENT BUDESONIDE; 5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; ACT03247; AIRSUPRA COMPONENT BUDESONIDE; BCP05589; Eohilia (budesonide oral suspension); Tox21_110653; Tox21_201827; Tox21_302815; Tox21_500174; BDBM50354850; SYMBICORT COMPONENT BUDESONIDE; BUDESONIDE COMPONENT OF UCERIS; AKOS015969655; BUDESONIDE COMPONENT OF BREZTRI; AC-4697; BUDESONIDE COMPONENT OF AIRSUPRA; CCG-204269; CS-2063; DB01222; KS-1162; LP00174; NC00626; NSC 757788; SDCCGSBI-0050162.P002; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; BUDESONIDE COMPONENT OF SYMBICORT; NCGC00021318-05; NCGC00021318-06; NCGC00021318-08; NCGC00021318-18; NCGC00089747-04; NCGC00256415-01; NCGC00259376-01; NCGC00260859-01; BB164267; Budesonide 100 microg/mL in Acetonitrile; CPD000058337; HY-13580; Pregna-1,4-diene-3,20-dione, 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11-beta,16-alpha)-; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; B3909; EU-0100174; D00246; T70986; EN300-19737584; Q422212; J-504150; Q-101375; SR-01000000101-2; SR-01000000101-6; BRD-A34299591-001-03-4; Budesonide, European Pharmacopoeia (EP) Reference Standard; Budesonide, United States Pharmacopeia (USP) Reference Standard; Budesonide, Pharmaceutical Secondary Standard; Certified Reference Material; (11?,16?)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-6b-Glycoloyl-5-hydroxy-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one	Approved	Approved Drug(s)	5281004	DB01222	D0LG6A	430.5	93.1	862	2.5	31	2	6	4	C25H34O6	(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one	CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C	CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C	InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1	VOVIALXJUBGFJZ-KWVAZRHASA-N
DQ92WL	Ephedrine	Small molecule	Ephedrine; l-Ephedrine; (-)-Ephedrine; 299-42-3; Ephedrin; Ephedrol; Mandrin; Sanedrine; Fedrin; L(-)-Ephedrine; 1-Sedrin; (1R,2S)-2-(methylamino)-1-phenylpropan-1-ol; Ephedrital; Ephedrosan; Ephedrotal; Ephedsol; Ephendronal; Ephoxamin; Kratedyn; Lexofedrin; Manadrin; Vencipon; Efedrin; Zephrol; Nasol; Xenadrine; I-Sedrin; racephedrine; Ephedrine, anhydrous; l-alpha-(1-Methylaminoethyl)benzyl alcohol; l-Erythro-2-(methylamino)-1-phenylpropan-1-ol; NCI-C55652; Norephedrine, N-methyl-; GN83C131XS; Biophedrin; Ephedremal; Eciphin; Ephedral; (1R,2S)-2-methylamino-1-phenylpropan-1-ol; CHEBI:15407; (1R,2S)-1-phenyl-1-hydroxy-2-methylaminopropane; (1R,2S)-2-(methylamino)-1-phenyl-propan-1-ol; NSC-8971; 1-Phenyl-2-methylaminopropanol; NSC-170951; l-2-Methylamino-1-phenylpropanol; Ephedrine, L-(-)-; Sal-Phedrine; Ephedrine l-form; Ephedrine [USAN:BAN]; 1-Hydroxy-2-methylamino-1-phenylpropane; (-)-Ephedrine hemisulfate; (L)-EPHEDRINE; (-)-(1R,2S)-Ephedrine; Ephedrine (TN); Ephedrine (USP); HSDB 3072; 1-2-Methylamino-1-phenylpropanol; 2-Methylamino-1-phenyl-1-propanol; NSC 8971; EINECS 206-080-5; NSC 170951; UNII-GN83C131XS; 1-Phenyl-1-hydroxy-2-methylaminopropane; alpha-Hydroxy-beta-methylaminopropylbenzene; 1-alpha-(1-Methylaminoethyl)benzyl alcohol; AI3-02761; alpha-(1-(Methylamino)ethyl)benzenemethanol; NSC170951; alpha-Hydroxy-beta-methyl amine propylbenzene; (-)-alpha-(1-Methylaminoethyl)benzyl alcohol; 1(-)ephedrine; Ephedrinum, anhydrous; EPHEDRINE [MI]; EPHEDRINE [HSDB]; Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (R-(R*,S*))-; EPHEDRINE [VANDF]; DEA Code 8113; EPHEDRINE [MART.]; EC 206-080-5; EPHEDRINE [WHO-DD]; SCHEMBL4785; Lopac0_000501; GTPL556; (1r, 2s)-(-)-ephedrine; CHEMBL211456; Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (-)-; DTXSID0022985; EPHEDRINE [EP MONOGRAPH]; EPHEDRINE [USP MONOGRAPH]; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alphaR)-; HY-B1195; Benzenemethanol, .alpha.-[(1S)-1-(methylamino)ethyl]-, (.alpha.R)-; PDSP2_001327; PDSP2_001330; (1R,2S)-(-)-Ephedrine, 98%; AKOS016011257; Emerphed (ephedrine sulfate injection); EPHEDRINE, ANHYDROUS [WHO-IP]; CCG-204592; CS-4802; DB01364; NCGC00162174-01; NCGC00162174-02; SBI-0051362.P003; EPHEDRINUM, ANHYDROUS [WHO-IP LATIN]; (1R,2S)-2-Methylamino-1-phenyl-1-propanol; C01575; D00124; (1R*,2S*)-2-methylamino-1-phenyl-1-propanol; (1R,2S)-2-(methylamino)-1-phenyl-1-propanol; AB00375843_06; A820118; Q219626; SR-01000075166; (1R,2S)-(-)-2-Methylamino-1-phenyl-1-propanol; J-500280; SR-01000075166-1; (1R,2S)-(-)-2-(N-methylamino)-1-phenylpropan-1-ol; (1R,2S)-(-)-alpha-(1-Methylaminoethyl)benzenemethanol; PSEUDOEPHEDRINE HYDROCHLORIDE IMPURITY A [EP IMPURITY]; BENZENEMETHANOL, .ALPHA.-(1-(METHYLAMINO)ETHYL)-, (R-(R*,S*))-; (R-(R*,S*))-.ALPHA.-(1-(METHYLAMINO)ETHYL)BENZENEMETHANOL [WHO-IP]	Approved	Approved Drug(s)	9294	DB01364	D0LG8E	165.23	32.299	121	0.9	12	2	2	3	C10H15NO	(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol	CC(C(C1=CC=CC=C1)O)NC	C[C@@H]([C@@H](C1=CC=CC=C1)O)NC	InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1	KWGRBVOPPLSCSI-WPRPVWTQSA-N
D3KG5Y	Varenicline	Small molecule	Varenicline; 249296-44-4; 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-; 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene; CP-526555; 7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline; Varenicline (INN); CHEMBL556954; NCGC00247735-01; NCGC00247735-02; CHEMBL1396; SCHEMBL225687; (6R,10S)-7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline; DTXSID40861516; CP 526555; Champix; Chantix; BCP01413; BDBM50166908; s6985; AKOS005145561; CS-0396; DB01273; SB17430; NCGC00247735-03; HY-10019; MS-23161; DB-015064; D08669; AB01568242_01; EN300-1695307; A849621; J-501695; Q56433825; 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine; 7,8,9,10-tetrahydro- 6,10-methano- 6H-pyrazino (2,3-h)(3) benzazepine; 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino-[2,3-h][3]benzazepine; 5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2(11),3,5,7,9-pentaene; 5,8,14-Triazatetracyclo[10.3.1.02, 11.04,9]hexadeca-2(11),3,5,7,9-pentaene; 5,8,14-Triazatetracyclo[10.3.1.02,11,04,9]hexadeca-2(11),3,5,7,9-pentaene; 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene; 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9pentaene; 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9-pentaene; 6,10-Methano-7,8,9,10-tetrahydro-1,4,8-triaza-6H-cyclohepta[b]naphthalene; 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine(Varenicline); 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9-pentaene; dihydrochloride	Approved	Approved Drug(s)	170361	DB01273	D0LM4A	211.26	37.8	254	0.8	16	1	3	0	C13H13N3	5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene	C1C2CNCC1C3=CC4=NC=CN=C4C=C23	C1C2CNCC1C3=CC4=NC=CN=C4C=C23	InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2	JQSHBVHOMNKWFT-UHFFFAOYSA-N
DDE1L6	Glycopyrrolate	Small molecule	GLYCOPYRROLATE; 596-51-0; Glycopyrrolate bromide; Robinul; glycopyrronium bromide; Gastrodyn; Nodapton; Tarodyl; Tarodyn; Asecryl; Cuvposa; Glycopyrronii bromidum; Robanul; AHR-504; Bromuro de glicopirronio; Bromure de glycopyrronium; NVA-237; Robinal; Seebri Neohaler; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide alpha-cyclopentylmandelate; Seebri; DTXSID6023109; 1,1-Dimethyl-3-hydroxypyrrolidinium bromide alpha-cyclopentylmandelate; 1-Methyl-3-pyrrolidyl alpha-phenylcyclopentaneglycolate methobromide; 3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidin-1-ium bromide; Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-,bromide; AD-237; PT-001; NSC-250836; NSC-251251; NSC-251252; Copyrrolate; 3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium Bromide; threo-Glycopyrronium bromide; (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate bromide; Glycopyrronium (bromide);Glycopyrrolate (bromide); DTXCID103109; NVA237; 475468-09-8; ROBINUL FORTE; Pyrrolidinium,1-dimethyl-, bromide; Seebri Breezhaler; 53808-86-9; (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide; SMR000469282; Glycopyrrolate, erythro-; NSC 250836; NSC 251251; NSC 251252; Org-NC-45; NSC250836; NSC251251; NSC251252; (2S,3'S)-glycopyrrolate; AHR 504; Glycopyrronium (as bromide); NVA 237; Glycopyrronii bromidum [INN-Latin]; NCGC00179456-02; WLN: T5KTJ A1 A1 COVXQR&- AL5TJ &Q &E; EINECS 209-887-0; MFCD00072137; Bromure de glycopyrronium [INN-French]; Bromuro de glicopirronio [INN-Spanish]; CHF5259; Glycopyrrolate [USAN:USP]; PT001; CHF-5259; Lonhala Magnair; Pyrrolidinium,1-dimethyl-, bromide, .alpha.-cyclopentylmandelate; 1,1-Dimethyl-3-hydroxypyrrolidinium bromide .alpha.-cyclopentylmandelate; 1-Methyl-3-pyrrolidinyl .alpha.-phenylcyclopentaneglycolate methobromide; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide-.alpha.-cyclopentylmandelate; Mandelic acid, ester with 3-hydroxy-1,1-dimethylpyrrolidinium bromide; Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-, bromide, [S-(R*,S*)]-; Cuvposa (TN); Robinul (TN); Glycopyrrolate (USP); .beta.-1-Methyl-3-pyrrolidyl-.alpha.-cyclopentylmandelate methobromide; Seebri breezhaler (TN); CAS-596-51-0; GLYCOPYRRONE BROMIDE; SCHEMBL41436; Glycopyrronium Bromide ,(S); MLS001424112; MLS002222301; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide .alpha.-cyclopentylmandelate; CHEMBL1201027; CHEBI:90972; Glycopyrrolate, >=98% (HPLC); Glycopyrronium bromide (JAN/INN); HMS1570E14; HMS2051P12; HMS2094A05; HMS2097E14; HMS2235F12; HMS3259P04; HMS3369F10; HMS3393P12; HMS3714E14; HMS3885P14; Pharmakon1600-01505753; AMY22352; BCP07110; BCP33298; CHF-5992; EX-A4155; Tox21_113144; Tox21_113145; NSC759238; s4660; AKOS015962136; Pyrrolidinium, 1,1-dimethyl-3-hydroxy-, bromide, alpha-cyclopentylmandelate; Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate; Tox21_113144_1; CCG-101030; CCG-213543; CS-1763; NC00280; NC00694; NSC-759238; NCGC00179456-04; AC-23382; HY-17465; Glycopyrrolate Erythro Isomer (SS-Isomer); FT-0626787; G0392; D00540; EN300-7405787; A832400; SR-01000763650; SR-01000763650-3; Q27162963; Glycopyrrolate, United States Pharmacopeia (USP) Reference Standard; Glycopyrronium bromide, European Pharmacopoeia (EP) Reference Standard; Glycopyrronium impurity N, European Pharmacopoeia (EP) Reference Standard; 3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidin-1-iumbromide; 3-[(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidin-1-ium bromide; 3-{[cyclopentyl(hydroxy)phenylacetyl]oxy}-1,1-dimethylpyrrolidin-1-ium bromide; Glycopyrronium for peak identification, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	11693	DB00986	D0M0AM	398.3	46.5	424	.	24	1	4	5	C19H28BrNO3	(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide	C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]	C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]	InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1	VPNYRYCIDCJBOM-UHFFFAOYSA-M
DTI73R	Insulin glulisine	Small molecule	Apidra; Apidra solostar; Insulin glulisine; UNII-7XIY785AZD; B3-lysyl-B29-glutamylinsulin; Insulin, Lys(B3)-Glu(B29)-; HMR 1964; Insulin glulisine [USAN:INN:JAN]; Insulin, lysyl(B3)-glutamyl(B29)-; 7XIY785AZD; Insulin (human), 3B-L-lysine-29B-L-glutamic acid-; 207748-29-6; (3(sup B)-L-Lysine,29(sup B)-L-glutamic acid)insulin (human); Insulin (human),3(sup B)-L-lysine,29(sup B)-L-glutamic acid-	Approved	Approved Drug(s)	16136701	DB01309	D0M2XE	5823	2450	14600	-12.1	406	78	90	180	C258H384N64O78S6	(4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-4-carboxy-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid	CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCC(=O)O)C(=O)NC(C(C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN	CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN	InChI=1S/C258H384N64O78S6/c1-29-132(23)206(313-193(338)105-260)253(394)317-205(131(21)22)250(391)289-160(75-83-200(348)349)219(360)283-157(71-79-190(264)335)223(364)308-184-117-404-405-118-185-244(385)305-179(112-324)241(382)295-164(90-124(7)8)227(368)296-170(97-141-53-61-147(329)62-54-141)230(371)284-156(70-78-189(263)334)220(361)291-163(89-123(5)6)225(366)285-159(74-82-199(346)347)222(363)303-176(103-191(265)336)236(377)299-172(99-143-57-65-149(331)66-58-143)233(374)309-183(243(384)304-177(256(397)398)104-192(266)337)116-403-402-115-182(215(356)273-108-194(339)278-154(72-80-197(342)343)218(359)281-152(51-42-86-271-258(267)268)213(354)272-109-195(340)279-168(95-139-46-36-32-37-47-139)229(370)298-169(96-140-48-38-33-39-49-140)232(373)300-173(100-144-59-67-150(332)68-60-144)239(380)320-209(136(27)327)255(396)322-87-43-52-187(322)247(388)286-161(76-84-201(350)351)224(365)321-210(137(28)328)257(399)400)311-251(392)204(130(19)20)316-237(378)166(92-126(11)12)293-231(372)171(98-142-55-63-148(330)64-56-142)297-226(367)162(88-122(3)4)290-211(352)134(25)277-216(357)158(73-81-198(344)345)288-249(390)203(129(17)18)315-238(379)167(93-127(13)14)294-235(376)175(102-146-107-270-121-276-146)302-240(381)178(111-323)280-196(341)110-274-214(355)181(114-401-406-119-186(310-245(184)386)246(387)319-208(135(26)326)254(395)306-180(113-325)242(383)318-207(133(24)30-2)252(393)312-185)307-228(369)165(91-125(9)10)292-234(375)174(101-145-106-269-120-275-145)301-221(362)155(69-77-188(262)333)282-217(358)153(50-40-41-85-259)287-248(389)202(128(15)16)314-212(353)151(261)94-138-44-34-31-35-45-138/h31-39,44-49,53-68,106-107,120-137,151-187,202-210,323-332H,29-30,40-43,50-52,69-105,108-119,259-261H2,1-28H3,(H2,262,333)(H2,263,334)(H2,264,335)(H2,265,336)(H2,266,337)(H,269,275)(H,270,276)(H,272,354)(H,273,356)(H,274,355)(H,277,357)(H,278,339)(H,279,340)(H,280,341)(H,281,359)(H,282,358)(H,283,360)(H,284,371)(H,285,366)(H,286,388)(H,287,389)(H,288,390)(H,289,391)(H,290,352)(H,291,361)(H,292,375)(H,293,372)(H,294,376)(H,295,382)(H,296,368)(H,297,367)(H,298,370)(H,299,377)(H,300,373)(H,301,362)(H,302,381)(H,303,363)(H,304,384)(H,305,385)(H,306,395)(H,307,369)(H,308,364)(H,309,374)(H,310,386)(H,311,392)(H,312,393)(H,313,338)(H,314,353)(H,315,379)(H,316,378)(H,317,394)(H,318,383)(H,319,387)(H,320,380)(H,321,365)(H,342,343)(H,344,345)(H,346,347)(H,348,349)(H,350,351)(H,397,398)(H,399,400)(H4,267,268,271)/t132-,133-,134-,135+,136+,137+,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,202-,203-,204-,205-,206-,207-,208-,209-,210-/m0/s1	RCHHVVGSTHAVPF-ZPHPLDECSA-N
DAQ73X	Lanreotide	Small molecule	Lanreotide; Lanreotide acetate; 127984-74-1; 108736-35-2; 10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; Somatuline; 10-(4-Aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide; Angiopeptin acetate; DC 13-116; 3-(2-Naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2-->7)-disulfide; SCHEMBL34091; GTPL2031; SCHEMBL14802383; CFA98474; DB06791; Somatuline; Lanreotidum; BIM 23014C; NCGC00181321-01; BS-42393; A857302; EN300-26911522; L000343; (4S,7S,10S,13R,16S,19S)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-(naphthalen-2-yl)propanamido)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-10-(4-aminobutyl)-16-(4-hydroxybenzyl)-7-isopropyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate; 2-({19-[2-amino-3-(naphthalen-2-yl)propanamido]-10-(4-aminobutyl)-16-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-6,9,12,15,18-pentaoxo-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}formamido)-3-hydroxybutanamide; 3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2 inverted exclamation marku7)-disulfide acetate; Angiopeptin; 3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2-7)-disulfide acetate;Lanreotide; Lanreotide; Angiopeptin; 3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2-7)-disulfide; 127984-74-1	Approved	Approved Drug(s)	71349	DB06791	D0M2YE	1096.3	406	2000	2.5	77	13	14	17	C54H69N11O10S2	10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide	CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N	CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N	InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)	PUDHBTGHUJUUFI-UHFFFAOYSA-N
D1DY6U	Obeticholic acid	Small molecule	Obeticholic acid; 459789-99-2; 6-ECDCA; INT-747; 6-Ethylchenodeoxycholic acid; Ocaliva; Obetichloic acid; 6alpha-Ethyl-chenodeoxycholic acid; INT747; INT 747; DSP-1747; 6-Ethyl-CDCA; (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; 6-ETHYL-CHENODEOXYCHOLIC ACID; Obeticholic acid (INT-747); 6alpha-ethylchenodeoxycholic acid; 0462Z4S4OZ; 6alpha-ethyl-3alpha,7alpha-dihydroxy-5beta-cholan-24-oic acid; 6ECDCA; (4R)-4-[(1S,2S,5R,7S,8R,9R,10S,11S,14R,15R)-8-ethyl-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanoic acid; UNII-0462Z4S4OZ; 6-Et CDCA; Obeticholic acid [USAN]; Obeticholic acid [USAN:INN]; 1osv; DSP1747; Ocaliva (TN); 6-ethyl-3,7-dihydroxycholan-24-oic acid; 6-ECDCA; Obeticholic acid; OBETICHOLIC ACID [MI]; SCHEMBL715823; OBETICHOLIC ACID [INN]; OBETICHOLIC ACID [JAN]; CHEMBL566315; GTPL3435; (3alpha,5beta,6alpha,7alpha)-6-Ethyl-3,7-dihydroxycholan-24-oic acid; BDBM21675; CHEBI:43602; DTXSID20196671; EX-A387; 6-alpha-ethylchenodeoxycholic acid; OBETICHOLIC ACID [WHO-DD]; Obeticholic acid (JAN/USAN/INN); AMY16595; HB3731; MFCD16621104; AKOS024259126; Cholan-24-oic acid, 6-ethyl-3,7-dihydroxy-, (3alpha,5beta,6alpha,7alpha)-; OBETICHOLIC ACID [ORANGE BOOK]; CS-3813; DB05990; GS-6103; NCGC00480885-01; HY-12222; D09360; P16663; A854341; EN300-20332085; Q15708271; 3A, 7A -DIHYDROXY-6A -ETHYL-5B-CHOLAN-24-OIC ACID; 3alpha,7alpha-dihydroxy-6alpha-ethyl-5beta-cholan-24-oic acid; (3alpha,5beta,6alpha,7alpha,8xi)-6-Ethyl-3,7-dihydroxycholan-24-oic acid; (3.ALPHA.,5.BETA.,6.ALPHA.,7.ALPHA.)-6-ETHYL-3,7-DIHYDROXYCHOLAN-24-OIC ACID; (4R)-4-[(1R,3aS,3bS,4R,5R,5aS,7R,9aS,9bS,11aR)-5-ethyl-4,7-dihydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanoic acid; (R)-4-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; (R)-4-((3R,7R,8S,9S,10S,13R,14S,17R)-6-Ethyl-3,7-dihydroxy-10,13-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; CHOLAN-24-OIC ACID, 6-ETHYL-3,7-DIHYDROXY-, (3.ALPHA.,5.BETA.,6.ALPHA.,7.ALPHA.)-	Approved	Approved Drug(s)	447715	DB05990	D0M4WA	420.6	77.8	649	5.7	30	3	4	5	C26H44O4	(4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid	CCC1C2CC(CCC2(C3CCC4(C(C3C1O)CCC4C(C)CCC(=O)O)C)C)O	CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)O	InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1	ZXERDUOLZKYMJM-ZWECCWDJSA-N
DRPG43	Omacetaxine mepesuccinate	Small molecule	homoharringtonine; Omacetaxine mepesuccinate; 26833-87-4; Ceflatonin; Myelostat; Synribo; CGX-635; Omapro; Homoharringtonin; (-)-homoharringtonine; NSC-141633; C29H39NO9; CHEBI:71019; (2'R,3S,4S,5R)-(-)-homoharringtonine; Omacetaxine (homoharringtonine); Omacetaxine mepesuccinate [USAN]; 6FG8041S5B; NSC 141633; 1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate; Cephalotaxine 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate; Omacetaxine mepesuccinate (USAN); Tekinex; Synribo (TN); Cephalotaxine, 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester); Omacetaxine mepesuccinate;HHT; UNII-6FG8041S5B; NSC141633; NCGC00025155-01; Omacetaxine mepesuccinate [USAN:INN]; BRN 5687925; omacetaxini mepesuccinas; ZJ-C; mepesuccinate d'omacetaxine; mepesuccinato de omacetaxina; Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester); MLS001424293; CHEMBL46286; HOMOHARRINGTONINE [MI]; CGX-635-14 (formulation); GTPL7454; SCHEMBL12745687; HMS3267H22; HMS3414N05; HMS3678N03; AMY33459; Homoharringtonine, >=98% (HPLC); BDBM50480293; HB4660; MFCD05618221; NSC758253; s9015; AKOS024456585; CCG-269981; DB04865; NC00395; NSC-758253; OMACETAXINE MEPESUCCINATE [INN]; NCGC00025155-02; NCGC00025155-03; NCGC00025155-04; NCGC00025155-07; OMACETAXINE MEPESUCCINATE [MART.]; OMACETAXINE MEPESUCCINATE [VANDF]; HY-14944; NCI60_000917; OMACETAXINE MEPESUCCINATE [WHO-DD]; SMR000469230; H1775; D08956; OMACETAXINE MEPESUCCINATE [ORANGE BOOK]; AB00642561-02; EN300-22161068; SR-01000597562; Q7089373; SR-01000597562-1; BRD-K76674262-001-01-7; BRD-K76674262-001-02-5; Cephalotaxine, 3-[4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate]; Cephalotaxine, 4-methyl-, 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester); (2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0^{2,6}.0^{6,10}.0^{15,19}]icosa-1(13),4,14,19-tetraen-3-yl 1-methyl (3R)-3-hydroxy-3-(4-hydroxy-4-methylpentyl)butanedioate; (S)-1-((11bS,12S,14aR)-13-methoxy-2,3,5,6,11b,12-hexahydro-1H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]cyclopenta[b]pyrrolo[1,2-a]azepin-12-yl) 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)succinate; 1-((1S,3aR,14bS)-2-Methoxy-1,5,6,8,9,14b-hexahydro-4H- cyclopenta(a)(1,3)dioxolo(4,5-h)pyrrolo(2,1-b)(3)benzazepin-1-yl) 4-methyl (2R)-2- hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate; 1-[(1S,3aR,14bS)-2-Methoxy-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[a][1,3]dioxolo[4,5-H]pyrrolo[2,1-b][3]benzazepin-1-yl] 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate	Approved	Approved Drug(s)	285033	DB04865	D0M4XY	545.6	124	968	0.8	39	2	10	11	C29H39NO9	1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate	CC(C)(CCCC(CC(=O)OC)(C(=O)OC1C2C3=CC4=C(C=C3CCN5C2(CCC5)C=C1OC)OCO4)O)O	CC(C)(CCC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O	InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1	HYFHYPWGAURHIV-JFIAXGOJSA-N
DT8US1	Trandolapril	Small molecule	trandolapril; 87679-37-6; Mavik; Gopten; Odrik; Trandolaprilum [Latin]; RU-44570; RU 44570; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; 1T0N3G9CRC; RU44570; DTXSID2023692; NSC-758939; NCGC00182079-02; Trandolaprilum; Udrik; (2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; DTXCID003692; Odric; Preran; (2S)-1-[(2R)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aR,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid; CAS-87679-37-6; CCRIS 6594; Mavik (TN); UNII-1T0N3G9CRC; Trandolapril [USP:INN:BAN]; NCGC00095153-01; (2S,3aR,7aS)-1-[(S)-N-[(S)-1-Carboxy-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; MFCD00865776; TRANDOLAPRIL [MI]; TRANDOLAPRIL [INN]; TRANDOLAPRIL [JAN]; CHEMBL1519; TRANDOLAPRIL [VANDF]; SCHEMBL16610; TRANDOLAPRIL [MART.]; BIDD:GT0804; TRANDOLAPRIL [USP-RS]; TRANDOLAPRIL [WHO-DD]; Trandolapril (JAN/USP/INN); CHEBI:9649; GTPL6453; HSDB 8392; HMS3262J10; TRANDOLAPRIL [ORANGE BOOK]; TARKA COMPONENT TRANDOLAPRIL; TRANDOLAPRIL [EP MONOGRAPH]; HY-B0592; Tox21_111453; Tox21_113152; Tox21_500924; TRANDOLAPRIL [USP MONOGRAPH]; BDBM50369775; s6468; AKOS015843316; AKOS015896050; TRANDOLAPRIL COMPONENT OF TARKA; CCG-222228; DB00519; KS-1467; LP00924; NSC 758939; SDCCGSBI-0633768.P001; NCGC00182079-03; NCGC00261609-01; (2S,3aR,7aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydro-1H-indole-2-carboxylic acid; (2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid; 1H-Indole-2-carboxylic acid, 1-((2S)-2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S,3aR,7aS)-; 1H-Indole-2-carboxylic acid, octahydro-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (2S-(1(R*(R*)),2-alpha,3a-alpha,7a-beta))-; Trandolapril, >=98% (HPLC), white powder; D00383; W18796; EN300-7481395; A842336; Q929420; SR-02000000917; SR-02000000917-2; BRD-K28550399-001-01-4; Trandolapril, European Pharmacopoeia (EP) Reference Standard; Trandolapril, United States Pharmacopeia (USP) Reference Standard; (2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-Ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; 1H-INDOLE-2-CARBOXYLIC ACID, OCTAHYDRO N-((2S)-1-ETHOXY-1-OXO-4-PHENYLBUTAN-2-YL)-1-ALANYL (2S,3AR,7AS); 2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid, Mavik; Trandolapril/(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-Ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylicacid	Approved	Approved Drug(s)	5484727	DB00519	D0M5OC	430.5	95.9	634	2	31	2	6	10	C24H34N2O5	(2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid	CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCCC3CC2C(=O)O	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(=O)O	InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1	VXFJYXUZANRPDJ-WTNASJBWSA-N
DYI1A2	Iloperidone	Small molecule	Iloperidone; 133454-47-4; Zomaril; Fanapt; Fanapta; HP 873; HP-873; Iloperidone (Fanapt); C24H27FN2O4; 4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone; 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone; VPO7KJ050N; CHEMBL14376; 1-(4-(3-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propoxy)-3-methoxyphenyl)ethanone; DTXSID6049060; CHEBI:65173; Ethanone, 1-(4-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)propoxy)-3-methoxyphenyl)-; NCGC00188864-01; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone; 1-(4-{3-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-propoxy}-3-methoxy-phenyl)-ethanone; DTXCID7028986; Fiapta; 1-(4-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)propoxy)-3-methoxyphenyl)ethanone; 1-(4-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy}-3-methoxyphenyl)ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-phenyl]ethanone; SMR002529575; Fanapt (TN); CAS-133454-47-4; Iloperidone (USAN/INN); UNII-VPO7KJ050N; iloperidona; iloperidonum; Iloperidone [USAN:INN:BAN]; HSDB 8207; ILO-522; Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-; ILOPERIDONE [MI]; ILOPERIDONE [INN]; ILOPERIDONE [USAN]; GTPL87; ILOPERIDONE [VANDF]; ILOPERIDONE [MART.]; ILOPERIDONE [USP-RS]; ILOPERIDONE [WHO-DD]; MLS004774132; MLS006011943; SCHEMBL115755; Iloperidone, >=98% (HPLC); ILOPERIDONE [ORANGE BOOK]; BCPP000206; HMS3604B21; HMS3654J14; HMS3884A19; HP873; (non-Isotopelabelled)Iloperidone-d6; ACT02698; BCP02042; Tox21_113610; BDBM50034043; MFCD00866688; PDSP1_000514; PDSP1_000515; PDSP2_000512; PDSP2_000513; s1483; AKOS005146266; Tox21_113610_1; AC-3482; BCP9000774; CCG-268962; CS-1236; DB04946; NCGC00188864-02; NCGC00188864-10; 1-(4-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propoxy)-3-methoxyphenyl)ethan-1-one; HY-17410; AM20090764; FT-0631148; FT-0670284; I0926; SW219279-1; D02666; EN300-119522; AB01274793-01; AB01274793_02; A806617; L001176; SR-01000940095; J-503185; Q4199443; SR-01000940095-2; Z1521553906; Iloperidone, United States Pharmacopeia (USP) Reference Standard; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-piperidinyl]propoxy]-3-methoxyphenyl]ethanone; 1-(4-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy}-3-methoxyphenyl)ethan-1-one; 1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)piperidin-1-yl]-propoxy}-3-methoxy-phenyl)-ethanone; 1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)piperidin-1-yl]propoxy}-3-methoxy-phenyl)-ethanone; 1-[4-[3-[4(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoranyl-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxy-phenyl]ethanone; 1-[4-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoro-1,2- benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3- methoxyphenyl]ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperdinyl]propoxy]-3-methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]- propoxy]-3-methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxyl]-3-methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl] ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3methoxyphenyl]ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1piperidinyl]-propoxy]-3-methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-piperidinyl]propoxy]-3-methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)1-piperidinyl]-propoxy]-3-methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3yl)-1-piperidinyl]propoxy]-3-methoxyphenyl] ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanone; 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-(trideuteriomethoxy)phenyl]ethanone	Approved	Approved Drug(s)	71360	DB04946	D0M8VE	426.5	64.8	586	4.1	31	0	7	8	C24H27FN2O4	1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone	CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC	CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC	InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3	XMXHEBAFVSFQEX-UHFFFAOYSA-N
DP7OL2	Chlorothiazide	Small molecule	chlorothiazide; 58-94-6; Diuril; Chlorothiazid; Chlorthiazide; Chlotride; Chlortiazid; Thiazide; Chlorosal; Chlorurit; Saluretil; Warduzide; Alurene; Clotride; Diuresal; Diurilix; Diurite; Diutrid; Salisan; Salunil; Saluric; Yadalan; Flumen; Minzil; Urinex; Neo-Dema; Sk-chlorothiazide; Chlorothiazidum; Clorotiazida; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; component of Aldoclor; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; NSC 25693; NSC-25693; Diuril (TN); MLS000028398; CHEBI:3640; Chlorthiazid; Chlorthiazidum; DTXSID0022800; NSC25693; 77W477J15H; CAS-58-94-6; NCGC00015242-04; Clorotiazide; Chloriazid; Chlrosal; SMR000058429; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Clorotiazide [DCIT]; Diuril Boluses; 6-chloro-1,1-dioxo-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide; 6-chloro-1,1-dioxo-4H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide; Diuril Boluses, Veterinary; Clorotiazida [INN-Spanish]; DTXCID802800; Chlorothiazidum [INN-Latin]; CCRIS 5999; HSDB 3030; SR-01000075604; EINECS 200-404-9; MFCD00058576; 6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide; 6-chloro-1,1-dioxo-2H-1?^{6},2,4-benzothiadiazine-7-sulfonamide; Chlorothiazide (JAN/USP/INN); Chlorothiazide [USP:INN:BAN]; UNII-77W477J15H; Prestwick_56; Diupres (Salt/Mix); Aldoclor (Salt/Mix); Spectrum_000134; Prestwick0_000251; Prestwick1_000251; Prestwick2_000251; Prestwick3_000251; Spectrum2_000154; Spectrum3_000342; Spectrum4_000280; Spectrum5_001446; Lopac-C-4911; CHEMBL842; C 4911; CHLOROTHIAZIDE [MI]; cid_2720; CHLOROTHIAZIDE [INN]; CHLOROTHIAZIDE [JAN]; Lopac0_000254; SCHEMBL22329; BSPBio_000062; BSPBio_002003; CHLOROTHIAZIDE [HSDB]; KBioGR_000780; KBioSS_000594; BIDD:GT0635; CHLOROTHIAZIDE [VANDF]; DivK1c_000675; SPECTRUM1500180; SPBio_000288; SPBio_002281; CHLOROTHIAZIDE [MART.]; BPBio1_000070; GTPL4835; CHLOROTHIAZIDE [WHO-DD]; CHEMBL3392493; BDBM39351; Chlorothiazide, thiazide diuretic; HMS502B17; KBio1_000675; KBio2_000594; KBio2_003162; KBio2_005730; KBio3_001223; NINDS_000675; HMS1568D04; HMS1920K15; HMS2091C18; HMS2095D04; HMS2232N22; HMS3259K15; HMS3260D10; HMS3370A15; HMS3655M13; HMS3712D04; Pharmakon1600-01500180; CHLOROTHIAZIDE [GREEN BOOK]; BCP24474; HY-B0224; CHLOROTHIAZIDE [EP IMPURITY]; CHLOROTHIAZIDE [ORANGE BOOK]; Tox21_110107; Tox21_200972; Tox21_500254; WLN: T66 BSWM ENJ HG ISZW; 6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide; 6-chloro-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide; CCG-38953; CHLOROTHIAZIDE [USP IMPURITY]; NSC756682; s1641; CHLOROTHIAZIDE [USP MONOGRAPH]; AKOS015896601; AKOS024319450; Tox21_110107_1; DB00880; LP00254; NC00500; NSC-756682; SDCCGSBI-0050242.P005; IDI1_000675; NCGC00015242-01; NCGC00015242-02; NCGC00015242-03; NCGC00015242-05; NCGC00015242-06; NCGC00015242-07; NCGC00015242-08; NCGC00015242-09; NCGC00015242-10; NCGC00015242-12; NCGC00015242-13; NCGC00015242-19; NCGC00091042-01; NCGC00091042-02; NCGC00091042-03; NCGC00091042-04; NCGC00091042-05; NCGC00258525-01; NCGC00260939-01; AC-18732; AS-11760; SBI-0050242.P004; C2259; EU-0100254; FT-0664953; Hydrochlorothiazide impurity, chlorothiazide-; SW219268-1; Chlorothiazide 100 microg/mL in Acetonitrile; C07461; D00519; D89501; AB00051940-04; AB00051940_05; AB00051940_06; HYDROCHLOROTHIAZIDE IMPURITY A [EP IMPURITY]; Q2603363; SR-01000075604-1; SR-01000075604-3; SR-01000075604-5; W-105353; BRD-K88682005-001-05-9; BRD-K88682005-001-07-5; Z1501480416; 6-Chloro-7-sulfamoyl-2H-1,4-benzothiadiazine 1,1-dioxide; 6-Chloro-2H-1,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-chloro-4H-1,2,4-benzathiadiazine-7-sulfonamide-1,1-dioxide; Chlorothiazide, European Pharmacopoeia (EP) Reference Standard; 2H-1,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-chloro-1,1-dioxo-4H-1$l^{6,2,4-benzothiadiazine-7-sulfonamide; 6-chloro-2H-benzo[e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide; Chlorothiazide, United States Pharmacopeia (USP) Reference Standard; HYDROCHLOROTHIAZIDE IMPURITY, CHLOROTHIAZIDE- [USP IMPURITY]; 6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide; Chlorothiazide, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	2720	DB00880	D0M9WM	295.7	135	532	-0.2	17	2	6	1	C7H6ClN3O4S2	6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide	C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2	C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2	InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)	JBMKAUGHUNFTOL-UHFFFAOYSA-N
D8LW1F	Sodium nitrite	Small molecule	SODIUM NITRITE; 7632-00-0; Nitrous acid, sodium salt; sodium;nitrite; Nitrite, sodium; Natrium nitrit; Nitrito sodico; Nitrite de sodium; Natrum nitrosum; Nitrous acid soda; NaNO2; Sodium nitrite [USP]; MFCD00011118; CHEMBL93268; INS NO.250; M0KG633D4F; DTXSID0020941; CHEBI:78870; INS-250; NSC-77391; Sodium Nitrite-18O2 (10% 16O2); Sodium nitrite (USP); DTXCID00941; Caswell No. 782; Dusitan sodny [Czech]; Azotyn sodowy [Polish]; Azotyn sodowy; Natrium nitrit [German]; Nitrito sodico [Spanish]; Nitrite de sodium [French]; CCRIS 559; CAS-7632-00-0; HSDB 757; EINECS 231-555-9; NSC 77391; UN1500; EPA Pesticide Chemical Code 076204; UNII-M0KG633D4F; natrium nitrite; sodium nitrit; Natrii nitris; Sodium nitrite (TN); Sodium nitrite ACS grade; EC 231-555-9; SODIUM NITRITE [MI]; SODIUM NITRITE [FCC]; SODIUM NITRITE [HSDB]; SODIUM NITRITE [INCI]; NATRUM NITROSUM [HPUS]; SODIUM NITRITE [VANDF]; SODIUM NITRITE [MART.]; Sodium nitrite, AR, >=98%; Sodium nitrite, LR, >=98%; SODIUM NITRITE [USP-RS]; SODIUM NITRITE [WHO-DD]; SODIUM NITRITE [WHO-IP]; HMS3652K08; Nitrous acid, sodium salt (1:1); Sodium nitrite, analytical standard; Sodium nitrite, granular, 99.5%; Sodium nitrite, Trace metals grade; Tox21_202155; Tox21_300025; s4074; SODIUM NITRITE [ORANGE BOOK]; NATRII NITRIS [WHO-IP LATIN]; SODIUM NITRITE [EP MONOGRAPH]; AKOS024427981; SODIUM NITRITE [USP MONOGRAPH]; CCG-266007; NCGC00090737-01; NCGC00090737-02; NCGC00254137-01; NCGC00259704-01; Sodium nitrite [UN1500]  [Oxidizer]; BP-31053; E250; NITHIODOTE COMPONENT SODIUM NITRITE; Sodium nitrite, ACS reagent, >=97.0%; Sodium nitrite, p.a., ACS reagent, 99%; FT-0645124; S0565; SODIUM NITRITE COMPONENT OF NITHIODOTE; Sodium nitrite, 99.5%, super free-flowing; Sodium nitrite, ReagentPlus(R), >=99.0%; SW219150-1; Sodium nitrite, 99.999% trace metals basis; Sodium nitrite, SAJ first grade, >=97.0%; D05865; E78844; Sodium nitrite, >=99.99% trace metals basis; Sodium nitrite, JIS special grade, >=98.5%; Sodium nitrite, purum p.a., >=98.0% (RT); Q339975; Sodium nitrite, puriss. p.a., ACS reagent, >=99.0% (RT); Sodium nitrite, United States Pharmacopeia (USP) Reference Standard; Sodium nitrite, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=97%; Sodium nitrite, puriss. p.a., ACS reagent, reag. Ph. Eur., >=99%	Approved	Approved Drug(s)	23668193	DB09112	D0MA7C	68.995	52.5	13.5	.	4	0	3	0	NNaO2	sodium;nitrite	N(=O)[O-].[Na+]	N(=O)[O-].[Na+]	InChI=1S/HNO2.Na/c2-1-3;/h(H,2,3);/q;+1/p-1	LPXPTNMVRIOKMN-UHFFFAOYSA-M
DJ81VA	Dapsone	Small molecule	dapsone; 80-08-0; 4,4'-Sulfonyldianiline; Diaphenylsulfone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenylsulfone; Dapson; 4-Aminophenyl sulfone; Diaphenylsulfon; Novophone; Sulfona; DADPS; Bis(4-aminophenyl) sulfone; Avlosulfone; Diphenasone; Sulfadione; Sulphadione; Dapsonum; Disulone; Aczone; Udolac; p-Aminophenyl sulfone; Avlosulfon; Croysulfone; Dumitone; Diphone; Eporal; Diaphenylsulphon; Diaphenylsulphone; Metabolite C; Sumicure S; Bis(p-aminophenyl) sulfone; Sulphonyldianiline; p,p-Sulphonylbisbenzamine; Sulfona-MAE; Avlosulphone; Croysulphone; Dubronax; 4,4'-Dapsone; Diaminodiphenyl sulfone; Tarimyl; p,p-Sulphonylbisbenzenamine; Sulfone ucb; Sulfonyldianiline; 4,4'-Sulfonylbisaniline; p,p'-Diaminodiphenyl sulfone; 4-(4-aminophenyl)sulfonylaniline; Dapsona; NSC-6091; Benzenamine, 4,4'-sulfonylbis-; Diaminodiphenylsulfone; Bis(4-aminophenyl)sulfone; Di(p-aminophenyl) sulfone; p,p-Sulphonyldianiline; 4,4'-Sulfonylbisbenzamine; Di(4-aminophenyl) sulfone; p,p'-sulfonyldianiline; 4,4'-Sulfonylbisbenzenamine; p,p-Sulfonylbisbenzamine; Diaminodifenilsulfona; DDS, pharmaceutical; Di(p-aminophenyl)sulphone; p,p-Sulfonylbisbenzenamine; Araldite HT 976; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl)sulphone; Bis(4-aminophenyl)sulphone; p,p-Diaminodiphenyl sulphone; N,N'-Diphenyl sulfondiamide; 1,1'-Sulfonylbis(4-aminobenzene); 4,4'-Sulphonyldianiline; DDS; Servidapson; 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; 4,4'-Diaminodiphenyl sulphone; WR 448; 4,4-Diaminodifenylsulfon; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; NSC 6091D; NCI-C01718; 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); Aniline, 4,4'-sulfonyldi-; HT 976; 4,4'-diamino diphenyl sulphone; F 1358; 4,4'-Sulfonyldianiline (Dapsone); 1358F; 4-[(4-aminobenzene)sulfonyl]aniline; 4,4'-Sulfonylbisbenzeneamine; DTXSID4020371; 4,4'-Sulfonyldianilin; Diaphenylsulfone (JAN); CHEMBL1043; MLS000069409; CHEBI:4325; NSC-6091D; Sulfanona-mae; J04BA02; NSC6091; Sulfon-mere; 4,4'-DDS; 4,4'-Diaminodiphenyl-13C12-sulfone; 1632119-29-9; Di(4-aminophenyl)sulfone; 4-(4-amino-benzenesulfonyl)-phenylamine; NCGC00016322-08; SMR000059064; Hardener HT 976; DDS (pharmaceutical); Sulphon-mere; 8W5C518302; 4,4'-DIAMINO-15N2-DIPHENYL SULFONE; Dapsonum [INN-Latin]; Dapsona [INN-Spanish]; DSS (VAN); DIAPHENYLSULFONE [JAN]; DTXCID00371; 4-Aminophenylsulfone; 4 4-Diamino Diphenyl Sulfone 99.5%min Cas:80-08-8; DDS, diaphenylsulfone; 4,4'-Diaminodiphenyl suphone; Atrisone; Diaminodifenilsulfona [Spanish]; 4,4-Diaminodifenylsulfon [Czech]; CAS-80-08-0; HY 976; CCRIS 192; Dapsone (USP); Aczone (TN); HSDB 5073; SR-01000002976; NSC 6091; 4-[(4-aminophenyl)sulfonyl]aniline; Sulfone, diphenyl, 4,4'-diamino-; EINECS 201-248-4; (4-sulfanilylphenyl)amine; MFCD00007887; AZT + Dapsone cominbation; BRN 0788055; AI3-08087; Diaphenyl sulfone; Dapsone [USAN:USP:INN:BAN]; 4-(4-aminobenzenesulfonyl)aniline; UNII-8W5C518302; Dapsone,(S); Prestwick_152; ALBB-005917; Dapsone-d8(major); Dapsone-[d4]; IN-201; BIS SULFONE; 4,4''-dapsone; 4-[(4-Aminophenyl)sulfonyl]phenylamine; Dapsone-[15N2]; Spectrum_000888; DAPSONE [VANDF]; Aniline,4'-sulfonyldi-; DAPSONE [HSDB]; DAPSONE [IARC]; DAPSONE [USAN]; DAPSONE [INN]; DAPSONE [MI]; DAPSONE [MART.]; Opera_ID_1950; Prestwick0_000035; Prestwick1_000035; Prestwick2_000035; Prestwick3_000035; Spectrum2_001133; Spectrum3_000375; Spectrum4_000310; Spectrum5_000825; WLN: ZR DSWR DZ; 4,4''-sulfonyldianiline; DAPSONE [USP-RS]; DAPSONE [WHO-DD]; DAPSONE [WHO-IP]; 4,4''-sulfonylbisaniline; EC 201-248-4; 4,4'-Sulfonyldiphenylamine; Benzenamine,4'-sulfonylbis-; Oprea1_143052; SCHEMBL21428; BSPBio_000129; BSPBio_002129; CBDivE_013582; Dianiline, 4,4'-sulfonyl-; KBioGR_000900; KBioSS_001368; MLS001055349; MLS001076146; 4,4''-Sulfonylbisbenzenamine; 4,4'-Sulfonylbis[benzamine]; 4-Aminophenyl sulfone, 97%; BIDD:GT0770; DAPSONE [EP IMPURITY]; DAPSONE [ORANGE BOOK]; DivK1c_000573; p,p''-diaminodiphenyl sulfone; SPECTRUM1500222; SPBio_001025; SPBio_002050; DAPSONE [EP MONOGRAPH]; 4,4''-diaminodiphenyl sulfone; 4,4'-diamino diphenyl sulfone; BPBio1_000143; DAPSONE [USP MONOGRAPH]; DAPSONUM [WHO-IP LATIN]; GTPL10934; HMS501M15; KBio1_000573; KBio2_001368; KBio2_003936; KBio2_006504; KBio3_001349; 4-(4-aminophenylsulfonyl)aniline; NINDS_000573; HMS1568G11; HMS1920C14; HMS2091K04; HMS2095G11; HMS2231G09; HMS3259C13; HMS3369B11; HMS3712G11; Pharmakon1600-01500222; Dapson 100 microg/mL in Methanol; ACT07431; AMY40781; HY-B0688; 1,1''-sulfonylbis(4-aminobenzene); Tox21_110371; Tox21_201347; Tox21_300558; 4-(4-aminophenylsulfonyl)benzenamine; BBL002412; BDBM50029764; CCG-40260; NSC756716; s4612; STK387118; AKOS000119322; Tox21_110371_1; DB00250; HT 9664; KS-1450; NC00488; NSC-756716; IDI1_000573; NCGC00016322-01; NCGC00016322-02; NCGC00016322-03; NCGC00016322-04; NCGC00016322-05; NCGC00016322-06; NCGC00016322-07; NCGC00016322-09; NCGC00016322-10; NCGC00016322-13; NCGC00023946-03; NCGC00023946-04; NCGC00023946-05; NCGC00023946-06; NCGC00254533-01; NCGC00258899-01; AC-10922; 4-[(4-Aminophenyl)sulfonyl]phenylamine #; SBI-0051331.P003; DB-056406; AB00051962; D0089; Dapsone, VETRANAL(TM), analytical standard; FT-0624447; FT-0665473; 4 inverted exclamation marka-Sulfonyldianiline; EN300-19042; C07666; D00592; AB00051962_19; A839828; Q422226; 4 inverted exclamation marka-Diaminodiphenyl sulfone; 4,4 inverted exclamation mark(R)-Sulfonyldianiline; Q-200435; SR-01000002976-2; SR-01000002976-4; BRD-K62363391-001-05-8; BRD-K62363391-001-15-7; SULFACETAMIDE SODIUM IMPURITY D [EP IMPURITY]; Dapsone, British Pharmacopoeia (BP) Reference Standard; Dapsone, European Pharmacopoeia (EP) Reference Standard; F0266-3067; Z104472374; 2-(PIPERAZIN-1-YL)-ACETICACIDN-(2-PHENYLETHYL)-AMIDE; 4-(4-aminophenyl)sulfonylaniline;4,4'-Diaminodiphenyl sulfone; Dapsone, United States Pharmacopeia (USP) Reference Standard; Dapsone, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	2955	DB00250	D0MA9N	248.3	94.6	306	1	17	2	4	2	C12H12N2O2S	4-(4-aminophenyl)sulfonylaniline	C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N	C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N	InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2	MQJKPEGWNLWLTK-UHFFFAOYSA-N
DD3M0I	Adefovir dipivoxil	Small molecule	ADEFOVIR DIPIVOXIL; 142340-99-6; Hepsera; Preveon; Adefovir pivoxil; bis-POM PMEA; GS-0840; GS 0840; GS 840; GS-840; [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; Adefovir dipivoxil [USAN]; Adefovir pivoxil (JAN); Adefovir di(pivaloyloxymethyl) ester; Adefovir dipivoxil (USAN); 9-(2-((Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; (((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) 2,2-dimethylpropanoate; DTXSID5046487; U6Q8Z01514; Propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) ester; NCGC00164624-01; Adefovirdipivoxl; ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid, diester with hydroxymethyl pivalate; ((((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphoryl)bis(oxy))bis(methylene) bis(2,2-dimethylpropanoate); ADEFOVIR PIVOXIL [JAN]; DTXCID3026487; 9-[2-[Bis(pivaloyloxymethoxy)phosphorylmethoxy]ethyl]adenine; YouHeDing; Adefovir dipivoxyl; [({[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}({[(2,2-dimethylpropanoyl)oxy]methoxy})phosphoryl)oxy]methyl 2,2-dimethylpropanoate; Bis(pom)PMEA; SMR002530072; Hepsera (TM); Hepsera (TN); Piv2PMEA; CAS-142340-99-6; Bis(POM)-PMEA; 9-(2-((-Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; UNII-U6Q8Z01514; adefovir-dipivoxil; [[2-(6-Amino-9H-purin-9-yl)ethoxy]methyl]phosphonic acid, diester with hydroxymethyl pivalate; MFCD00869897; Adefovir dipivoxil- Bio-X; CHEMBL922; SCHEMBL29729; MLS003915635; MLS004774124; CHEBI:31175; 9-(2[bis(Pivaloyloxymethoxy)phosphorylmethoxy]ethyl)adenine; Bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine; ADEFOVIR DIPIVOXIL [VANDF]; BCPP000434; HMS3604F09; HMS3655I04; ADEFOVIR DIPIVOXIL [MART.]; ADEFOVIR DIPIVOXIL [WHO-DD]; BCP22959; HY-B0255; Tox21_112243; BDBM50248359; s1718; STL257088; ADEFOVIR DIPIVOXIL [EMA EPAR]; Adefovir Dipivoxil (Preveon, Hepsera); AKOS005145737; Tox21_112243_1; AB07592; AC-1693; BCP9000232; CCG-269700; DB00718; GS-3604; ADEFOVIR DIPIVOXIL [ORANGE BOOK]; NCGC00164624-02; NCGC00164624-03; NCGC00164624-11; BA164139; BCP0726000157; FT-0631164; SW219933-1; D01655; AB01274706-01; AB01274706_02; A807894; ADEFOVIR DI(PIVALOYLOXYMETHYL) ESTER [MI]; Adefovir dipivoxil 100 microg/mL in Acetonitrile; SR-01000931258; Q-101927; SR-01000931258-2; BRD-K96159438-001-03-0; Z1546616202; Adefovir dipivoxil, Antibiotic for Culture Media Use Only; BIS(PIVALOYLOXYMETHYL)-9-[2-(PHOSPHONOMETHOXY)ETHYL]ADENINE; ((((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphoryl)-bis(oxy))bis(methylene) bis(2,2-dimethylpropanoate); (((2-(6-AMINO-9H-PURIN-9-YL)ETHOXY)METHYL)PHOSPHORYL)BIS(OXY)BIS(METHYLENE) BIS(2,2-DIMETHYLPROPANOATE); ({[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}phosphoryl)bis(oxymethanediyl) bis(2,2-dimethylpropanoate); 2,2-dimethylpropanoic acid [2-(6-aminopurin-9-yl)ethoxymethyl-[(2,2-dimethyl-1-oxopropoxy)methoxy]phosphoryl]oxymethyl ester;Adefovir dipivoxyl; 3-{[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}-8,8-dimethyl-3-oxido-7-oxo-2,4,6-trioxa-3?5-phosphanon-1-yl 2,2-dimethylpropanoate; 3-{[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}-8,8-dimethyl-3-oxido-7-oxo-2,4,6-trioxa-3lambda~5~-phosphanon-1-yl 2,2-dimethylpropanoate; Adefovir di(pivaloyloxymethyl) ester;Bis(POM)PMEA; GS-0840; Piv2PMEA;9-[2-(Bis[(pivaloyloxy)-methoxy]phosphinylmethoxy)ethyl]adenine	Approved	Approved Drug(s)	60871	DB00718	D0ML1F	501.5	167	706	1.8	34	1	12	15	C20H32N5O8P	[2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate	CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N=CN=C21)N)OCOC(=O)C(C)(C)C	CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N=CN=C21)N)OCOC(=O)C(C)(C)C	InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)	WOZSCQDILHKSGG-UHFFFAOYSA-N
DL13YN	Migalastat	Small molecule	Migalastat; 1-deoxygalactonojirimycin; 108147-54-2; (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; galafold; 1-Deoxygalactostatin; D-Galactitol, 1,5-dideoxy-1,5-imino-; C4XNY919FW; DEOXYGALACTONOJIRIMYCIN; CHEMBL110458; GR181413A; 108147-54-2 (free base); Amigal; DDIG; 1,5-Dideoxy-1,5-iminogalactitol; Migalastat [INN]; 1,5-Dideoxy-1,5-imino-D-galactitol; Migalastat [USAN:INN]; UNII-C4XNY919FW; DGJ; D-Galactitol, 1,5-dideoxy-1,5-imino; NSC658776; Tocris-1258; MIGALASTAT [MI]; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R,3S,4R,5S)-; Migalastat (USAN/INN); MIGALASTAT [USAN]; MIGALASTAT [WHO-DD]; D-galacto-1-Deoxynojirimycin; 2-(Hydroxymethyl)-3,4,5-piperidinetriol hydrochloride; SCHEMBL1479364; GTPL10200; CHEBI:135923; DTXSID201022520; BDBM50163440; 1,5-didesoxy-l,5-imino-D-galactitol; DB05018; GR-181413A; NCGC00025085-01; NCGC00686698-01; HY-14929; CS-0003641; D10359; EN300-255537; A937322; Q161613; (2R,3S,4R,5S)-2-Hydroxymethyl-piperidine-3,4,5-triol	Approved	Approved Drug(s)	176077	DB05018	D0MU9L	163.17	93	132	-2.3	11	5	5	1	C6H13NO4	(2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol	C1C(C(C(C(N1)CO)O)O)O	C1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)O	InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5+,6-/m1/s1	LXBIFEVIBLOUGU-DPYQTVNSSA-N
DVMN62	Niacin	Small molecule	nicotinic acid; niacin; 59-67-6; Pyridine-3-carboxylic acid; 3-pyridinecarboxylic acid; 3-Carboxypyridine; wampocap; Niaspan; Acidum nicotinicum; vitamin B3; nicolar; Apelagrin; Pellagrin; Akotin; Daskil; Efacin; Pelonin; Linic; nicamin; nicobid; nicocap; Enduracin; Nicodelmine; Niconacid; Nicotinipca; Pellagramin; Direktan; Nicacid; Nicangin; Peviton; Bionic; Diacin; Nicyl; Nyclin; Niac; Vitaplex N; Davitamon PP; Nico-Span; Tega-Span; Nicocidin; Nicocrisina; Niconazid; Nicoside; Nicotamin; Nicotene; Nicovasan; Nicovasen; Nipellen; SK-Niacin; Naotin; Niacor; Nicodon; Niconat; Nicosan 3; Nicosyl; Nicotil; Tinic; 3-Carboxylpyridine; Nicotine acid; Slo-niacin; NICO; 3-Picolinic acid; Nicotinsaure; Nico-400; Acide nicotinique; Pyridine-beta-carboxylic acid; Nicagin; anti-Pellagra vitamin; Caswell No. 598; PP Factor; Kyselina nikotinova; P.P. factor; Pellagra preventive factor; S115; Nicotinsaure [German]; Acido nicotinico; 3-Pyridylcarboxylic acid; m-Pyridinecarboxylic acid; Kyselina nikotinova [Czech]; MFCD00006391; niacine; CCRIS 1902; Pyridine-carboxylique-3; EPA Pesticide Chemical Code 056701; Acide nicotinique [INN-French]; Acido nicotinico [INN-Spanish]; Acidum nicotinicum [INN-Latin]; HSDB 3134; Pyridine-carboxylique-3 [French]; AI3-18994; Pyridinecarboxylic acid, 3-; Niacin [USP]; SR 4390; BRN 0109591; Niacin extended release; Nicotinic acid [INN]; NAH; CHEMBL573; beta-pyridinecarboxylic acid; NSC-169454; MLS000069603; Pyridine-.beta.-carboxylic acid; DTXSID1020932; CHEBI:15940; Niacin (USP); 2679MF687A; P.P. factor-pellagra preventive factor; CAS-59-67-6; NCGC00016268-02; SMR000059024; [5, 6-3H]-niacin; DTXCID10932; Niacin [USAN]; Nicotinicacid; NIO; Niacin (nicotinic acid); SR-01000722017; 36321-41-2; EINECS 200-441-0; NIASPAN TITRATION STARTER PACK; NSC 169454; pellagra; Nikotinsaeure; Ncotnc acd; UNII-2679MF687A; preventative factor; antipellagra vitamin; Niaspan (TN); 3PyrCOOH; [3H]nicotinic acid; Niacor (TN); Nicotinic Acid,(S); [3H]-Nicotinic acid; Spectrum_001063; 3-Pyridinecarboxylicacid; Nicotinic acid, Ph Eur; NIACIN [VANDF]; NIACIN [HSDB]; NIACIN [INCI]; Nicotinic acid (Niacin); 5-pyridinecarboxylic acid; NIACIN [FCC]; NIACIN [USP-RS]; Opera_ID_1346; Prestwick0_000881; Prestwick1_000881; Prestwick2_000881; Prestwick3_000881; Pyridine-3-carbonic acid; Spectrum2_000006; Spectrum3_000515; Spectrum4_000965; Spectrum5_001287; VITAMIN B-3; 3-Pyridyl carboxylic acid; Nicotinic acid-d3(major); WLN: T6NJ CVQ; 3-pyridine carboxylic acid; bmse000104; Nicotinic acid, >=98%; Nicotinic acid, USP grade; EC 200-441-0; SCHEMBL1433; NICOTINIC ACID [MI]; Oprea1_514398; VITAMIN B3 [VANDF]; BSPBio_000662; BSPBio_002069; KBioGR_001309; KBioSS_001543; NIACIN [ORANGE BOOK]; NICOTINIC ACID [JAN]; 5-22-02-00057 (Beilstein Handbook Reference); Nicotinic acid (Vitamin B3); BIDD:GT0644; DivK1c_000695; Nicotinic acid (JP17/INN); SIMCOR COMPONENT NIACIN; SPECTRUM1500430; .beta.-Pyridinecarboxylic acid; SPBio_000011; SPBio_002881; ADVICOR COMPONENT NIACIN; NIACIN [USP MONOGRAPH]; NICOTINIC ACID [VANDF]; BPBio1_000730; GTPL1588; GTPL1594; NICOTINIC ACID [MART.]; NICOTINIC ACID [WHO-DD]; NICOTINIC ACID [WHO-IP]; BDBM23515; HMS502C17; KBio1_000695; KBio2_001543; KBio2_004111; KBio2_006679; KBio3_001569; ABT-919; NIACIN COMPONENT OF SIMCOR; NICOTINIC ACID [EMA EPAR]; NINDS_000695; HMS1570B04; HMS1920P17; HMS2091H22; HMS2097B04; HMS2236A05; HMS3259K21; HMS3371E07; HMS3655K08; HMS3714B04; NIACIN COMPONENT OF ADVICOR; Pharmakon1600-01500430; Nicotinic acid, analytical standard; BCP16301; HY-B0143; STR00112; Tox21_110337; Tox21_201420; Tox21_302904; AC8691; BBL037343; CCG-38340; NICOTINIC ACID [EP IMPURITY]; Nicotinic acid, for synthesis, 99%; NSC169454; NSC757241; s1744; STK301803; NICOTINIC ACID [EP MONOGRAPH]; AKOS000118980; Nicotinic acid, >=99.5% (HPLC); Tox21_110337_1; AM81316; CS-1946; DB00627; NC00524; Nicotinic Acid 1.0 mg/ml in Methanol; NSC-757241; PS-4255; SDCCGMLS-0066610.P001; IDI1_000695; NCGC00016268-01; NCGC00016268-03; NCGC00016268-04; NCGC00016268-05; NCGC00016268-08; NCGC00016268-09; NCGC00094734-01; NCGC00094734-02; NCGC00256537-01; NCGC00258971-01; AC-22484; ACIDUM NICOTINICUM [WHO-IP LATIN]; BP-21419; NCI60_001041; Nicotinic acid, NIST(R) SRM(R) 148; Nicotinic acid, plant cell culture tested; SY011111; SBI-0051456.P003; DB-007765; Nicotinic Acid [Matrix for MALDI-TOF/MS]; AB00052050; FT-0600004; FT-0672715; FT-0672716; FT-0672717; FT-0672718; FT-0773496; N0082; N1103; Nicotinic acid 10 microg/mL in Acetonitrile; Nicotinic acid, purum, >=99.0% (HPLC); SW197229-3; EN300-16693; C00253; D00049; Nicotinic acid, SAJ special grade, >=99.5%; AB00052050-13; AB00052050_14; AB00052050_15; Nicotinic acid, meets USP testing specifications; AC-907/25014105; L001199; METHYL NICOTINATE IMPURITY A [EP IMPURITY]; Nicotinic acid, Vetec(TM) reagent grade, >=98%; Q134658; J-523605; SR-01000722017-2; SR-01000722017-3; SR-01000722017-4; Z56755709; 3DDB011E-F3A6-45B6-A2D2-77B2A6E8936E; F2191-0082; Niacin, United States Pharmacopeia (USP) Reference Standard; Nicotinic acid, certified reference material, TraceCERT(R); Nicotinic acid, European Pharmacopoeia (EP) Reference Standard; Nicotinic acid, matrix substance for MALDI-MS, >=99.5% (HPLC); Nicotinic acid, for inorganic trace analysis, >=99.999% (metals basis); Niacin (Nicotinic Acid), Pharmaceutical Secondary Standard; Certified Reference Material; 101113-41-1; Nicotinic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=98%	Approved	Approved Drug(s)	938	DB00627	D0N0ES	123.11	50.2	114	0.4	9	1	3	1	C6H5NO2	pyridine-3-carboxylic acid	C1=CC(=CN=C1)C(=O)O	C1=CC(=CN=C1)C(=O)O	InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)	PVNIIMVLHYAWGP-UHFFFAOYSA-N
D5A3SO	Deferiprone	Small molecule	deferiprone; 30652-11-0; 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone; Ferriprox; 3-hydroxy-1,2-dimethylpyridin-4(1H)-one; CP20; 1,2-dimethyl-3-hydroxy-4-pyridone; 1,2-Dimethyl-3-hydroxypyrid-4-one; APO-66; 1,2-Dimethyl-3-hydroxypyridine-4-one; 4(1H)-Pyridinone, 3-hydroxy-1,2-dimethyl-; APO-066; DN-180-01-AF; 3-hydroxy-1,2-dimethylpyridin-4-one; Deferipron; MFCD00134497; Deferiprone (INN); PL-1; L1; CHEBI:68554; 1,2-Dimethyl-3-hydroxy-4(1H)-pyridinone; CP-20; DN-18001AF; NSC-758880; 2BTY8KH53L; MLS000069481; HK-1; PL1; DTXSID6040666; 4(1H)-Pyridinone, 1,2-dimethyl-3-hydroxy-; SMR000059136; DEFERIPRONE [INN]; L-1; CP20 (Chelating agent); Ferriprox (TN); UNII-2BTY8KH53L; BRN 1447108; Deferidone; Deferiprona; Deferum; Deferiprone [USAN:INN:BAN]; CCRIS 8318; 1,2-dimethyl-3-hydroxy-4-pyridinone; 3-Hydroxy-1,2-dimethyl-4-pyridinone; L-1[chelating agent]; Opera_ID_366; 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone; DEFERIPRONE [MI]; 4(1H)-Pyridone, 3-hydroxy-1,2-dimethyl-; Deferiprone (USAN/INN); DEFERIPRONE [USAN]; DEFERIPRONE [VANDF]; DEFERIPRONE [MART.]; SCHEMBL94474; DEFERIPRONE [WHO-DD]; MLS000758227; MLS001424029; MLS006011689; CHEMBL70927; DEFERIPRONE [EMA EPAR]; CRMD-001; GTPL7456; DTXCID4020666; HSDB 8335; TZXKOCQBRNJULO-UHFFFAOYSA-; DEFERIPRONE [ORANGE BOOK]; EX-A972; CP020; DEFERIPRONE [EP MONOGRAPH]; HMS2051C05; HMS2232E24; HMS3264P17; HMS3393C05; HMS3873L13; Pharmakon1600-01504512; BCP09606; HY-B0568; 3-hydroxy-1,2-dimethylpyrid-4-one; Tox21_112429; BBL036482; BDBM50525976; CGP-37391; NSC758880; s4067; STL559018; 1,2-dimetyl-3-hydroxy-4-pyridinone; AKOS015902286; CCG-100760; CS-5240; DB08826; DS-5493; NC00010; NSC 758880; 3-hydroxy-1,2-dimethyl-4- pyridinone; 3-hydroxy-1,2-dimethyl-pyridin-4-one; NCGC00090548-01; NCGC00090548-02; NCGC00090548-04; NCGC00090548-05; AC-33026; BP-12415; SY052576; SBI-0207041.P001; CAS-30652-11-0; DB-047826; 1,2-Dimethyl-3-hydroxy-4-pyridone, 99+%; FT-0606424; H0944; D07416; 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone, 98%; AB00572605_11; AB00572605_12; EN300-1718313; 3-hydroxy-1,2-dimethyl-1,4-dihydropyridin-4-one; A820470; Q749664; SR-01000721891; Deferiprone 1,2-DIMETHYL-3-HYDROXY-4-PYRIDONE; SR-01000721891-4; Z1255390865	Approved	Approved Drug(s)	2972	DB08826	D0N0OU	139.15	40.5	228	0.5	10	1	3	0	C7H9NO2	3-hydroxy-1,2-dimethylpyridin-4-one	CC1=C(C(=O)C=CN1C)O	CC1=C(C(=O)C=CN1C)O	InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3	TZXKOCQBRNJULO-UHFFFAOYSA-N
DA0BX1	Paricalcitol	Small molecule	Paricalcitol; 131918-61-1; Zemplar; Compound 49510; 19-Nor-1alpha,25-dihydroxyvitamin D2; Paracalcin; Compound-49510; (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; CHEBI:7931; DTXSID4048640; 6702D36OG5; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; NCGC00182706-01; Paricalcitol [USAN]; (1R,3R)-5-(2-((1R,3aS,7aR,E)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol; 19-Nor-1,25-(OH)2D2; Zemplar (TN); 19-Nor-1-alpha,25-dihydroxyvitamin D2; HSDB 7360; Paricalcitol [USAN:USP:INN]; UNII-6702D36OG5; ABT-358; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; PARICALCITOL [MI]; PARICALCITOL [JAN]; (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; PARICALCITOL [HSDB]; SCHEMBL3655; PARICALCITOL [VANDF]; PARICALCITOL [MART.]; BIDD:GT0330; PARICALCITOL [USP-RS]; PARICALCITOL [WHO-DD]; Paricalcitol (JAN/USP/INN); GTPL2791; CHEMBL1200622; DTXCID7028566; AMY2878; BDBM233195; PARICALCITOL [ORANGE BOOK]; PARICALCITOL [USP IMPURITY]; ACT07192; EX-A4434; PARICALCITOL [USP MONOGRAPH]; Tox21_112987; LMST04030163; s6681; AKOS005145562; BCP9001050; CS-0705; DB00910; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1alpha,3beta,7E,22E)-; HY-50919; MS-27260; CAS-131918-61-1; C08127; D00930; A937163; Q155746; (1.ALPHA.3.BETA.,7E,22E)-19-NOR-9,10-SECOERGOSTA-5,7,22-TRIENE-1,3,25-TRIOL; (7E,22E)-19-NOR-9,10-SECOERGOSTA-5,7,22-TRIENE-1.ALPHA.,3.BETA.,25-TRIOL; (1R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol; 1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-	Approved	Approved Drug(s)	5281104	DB00910	D0N1TP	416.6	60.7	676	5	30	3	3	5	C27H44O3	(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol	CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C	C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C	InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1	BPKAHTKRCLCHEA-UBFJEZKGSA-N
DWR29G	Voriconazole	Small molecule	Voriconazole; 137234-62-9; Vfend; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; UK-109496; Voriconzole; (+/-)-Voriconazole; Voriconazole Vfend; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; UK-109,496; UK 109496; VCZ; Voriconazole, (+/-)-; CHEMBL638; NSC-759888; JFU09I87TR; USG4B1CD29; CPD000466350; C16H14F3N5O; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-; CHEBI:10023; MFCD00905717; 173967-54-9; VRC; Voriconazol; (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-((1H)-1,2,4-triazol-1-yl)-butan-2-ol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))-; 188416-29-7; Voriconazolum; Vorikonazole; Voriconazole [USAN:INN:BAN]; DRG-0301; SMR000466350; Vfend (TN); VFEND I.V.; UNII-JFU09I87TR; DTXSID5046485; Pfizer; Voriconazole- Bio-X; Voriconazole - Vfend; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; Voriconazole in combination with MGCD290; VORICONAZOLE [MI]; VORICONAZOLE [INN]; VORICONAZOLE [JAN]; UNII-USG4B1CD29; VORICONAZOLE [USAN]; VORICONAZOLE [VANDF]; SCHEMBL36233; VORICONAZOLE [MART.]; MLS000759464; MLS001424082; MLS006010028; VORICONAZOLE [USP-RS]; VORICONAZOLE [WHO-DD]; VORICONAZOLE [EMA EPAR]; Voriconazole (JP17/USP/INN); AMY8903; Voriconazole, >=98% (HPLC); BCPP000019; DTXSID201019420; HMS2051N09; HMS3260M22; HMS3713F12; Pharmakon1600-01502346; VORICONAZOLE [ORANGE BOOK]; VORICONAZOLE [EP MONOGRAPH]; Tox21_500150; VORICONAZOLE [USP MONOGRAPH]; Voriconazole 2.0 mg/ml in Methanol; AC-823; BDBM50333117; NSC759888; s1442; AKOS005145705; CCG-100941; CS-1227; DB00582; HY-W337569; KS-1157; NC00191; NSC 759888; NCGC00164622-04; NCGC00164622-06; NCGC00260835-01; BV164532; HY-76200; ( inverted exclamation markA)-Voriconazole; CS-0448910; SW197571-2; V0116; C07622; D00578; EN300-119515; AB00639948-04; AB00639948-06; AB00639948_07; AB00639948_08; Voriconazole, VETRANAL(TM), analytical standard; A807215; Q412236; J-006986; Z1521553720; Voriconazole, European Pharmacopoeia (EP) Reference Standard; Voriconazole, United States Pharmacopeia (USP) Reference Standard; (2R,3S)-2,3-bis(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; 2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol; 4-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methylene]-1-oxo-1,3-thiazolidin-5-one; Voriconazole, Pharmaceutical Secondary Standard: Certified Reference Material; (.ALPHA.R,.BETA.S)-A-(2,4-DIFLUOROPHENYL)-5-FLUORO-.BETA.-METHYL-.ALPHA.-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-4-PYRIMIDINEETHANOL; (2R,3S)-2-(2,4-Difluoro-phenyl)-3-(5-fluoro-pyrimidin-4-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol; (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol; (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol; 2R,3S-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol-4-Pyrimidineethanol, ?-(2,4-difluorophenyl)-5-fluoro-?-methyl-?-(1H-1,2,4-triazol-1-ylmethyl)-,?(?R,?S)-; 4-PYRIMIDINEETHANOL, .ALPHA.-(2,4-DIFLUOROPHENYL)-5-FLUORO-.BETA.-METHYL-.ALPHA.-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-, (.ALPHA.R,.BETA.S)-REL-; 4-PYRIMIDINEETHANOL, A-(2,4-DIFLUOROPHENYL)-5-FLUORO-.BETA.-METHYL-.ALPHA.-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-, (.ALPHA.R,.BETA.S)-; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-rel-	Approved	Approved Drug(s)	71616	DB00582	D0N3VR	349.31	76.7	448	1.5	25	1	8	5	C16H14F3N5O	(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol	CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O	C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O	InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1	BCEHBSKCWLPMDN-MGPLVRAMSA-N
DWIJ07	Repaglinide	Small molecule	Repaglinide; 135062-02-1; Prandin; NovoNorm; GlucoNorm; AG-EE 623 ZW; AG-EE 388 ZW; Repaglinidum [INN-Latin]; Repaglinida [INN-Spanish]; AGEE-623ZW; (S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; C27H36N2O4; AG-EE 623ZW; AG-EE-623ZW; AG-EE-623-ZW; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; NSC-759893; CHEMBL1272; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-ethoxy-4-(2-(3-methyl-1-(2-(piperidin-1-yl)phenyl)butylamino)-2-oxoethyl)benzoic acid; CHEBI:8805; DTXSID3023552; A10BX02; (-)-Repaglinide; 668Z8C33LU; NCGC00016978-01; Repaglinida; Repaglinidum; Repaglinide [USAN]; CAS-135062-02-1; 2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; Actulin; Surepost; Reglin; MFCD00906179; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; SMR000466305; Prandin (TN); Repaglinide (JAN/USP/INN); UNII-668Z8C33LU; AG-EE-623 ZW; AG-EE-388; Repaglinide,(S); SMP-508; Surepost (TN); (S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid; BJX; Repaglinide [USAN:USP:INN:BAN]; Repaglinide- Bio-X; NN-623; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; 2-Ethoxy-4-[2-[[(1S)-3-Methyl-1-[2-(1-Piperidinyl)Phenyl]Butyl]Amino]-2-Oxoethyl]Benzoic Acid; 111GE012; REPAGLINIDE [MI]; Prestwick0_001046; Prestwick1_001046; Prestwick2_001046; Prestwick3_001046; REPAGLINIDE [INN]; REPAGLINIDE [JAN]; REPAGLINIDE [VANDF]; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; REPAGLINIDE [MART.]; SCHEMBL16137; BSPBio_000972; REPAGLINIDE [USP-RS]; REPAGLINIDE [WHO-DD]; MLS000759407; MLS001076684; MLS001424111; MLS006011560; BIDD:GT0338; SPBio_002906; REPAGLINIDE [EMA EPAR]; BPBio1_001070; DTXCID603552; GTPL6841; REPAGLINIDE [ORANGE BOOK]; Repaglinide for system suitability; HMS1571A14; HMS2051N08; HMS2094C07; HMS2098A14; HMS2231M21; HMS3414D09; HMS3678D09; HMS3715A14; Pharmakon1600-01506035; REPAGLINIDE [EP MONOGRAPH]; REPAGLINIDE [USP MONOGRAPH]; BCP04250; Tox21_110721; AC-726; BDBM50153520; HB1106; NSC759893; s1426; STK629501; AKOS005561792; Repaglinide, >=98% (HPLC), solid; BS-1010; CCG-101013; CS-0979; DB00912; NC00263; NSC 759893; NCGC00016978-02; NCGC00016978-04; NCGC00016978-05; Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-, (S)-; BR164332; HY-15209; SBI-0206942.P001; AB00514019; AM20090697; R0179; SW197344-4; C07670; D00594; F15001; AB00514019-09; AB00514019_10; AB00514019_11; A806877; SR-01000759404; Q-201663; Q2195995; SR-01000759404-4; BRD-K82846253-001-03-0; Z1501485370; Repaglinide, European Pharmacopoeia (EP) Reference Standard; Repaglinide, United States Pharmacopeia (USP) Reference Standard; (s)-(+)-2-ethoxy-4-(2-oxo-2-[(alpha-isobutyl-2-piperidinobenzyl)amino]ethyl)-benzoic acid; Repaglinide for system suitability, European Pharmacopoeia (EP) Reference Standard; (+)-2-ETHOXY-.ALPHA.-(((S)-.ALPHA.-ISOBUTYL-O-PIPERIDINOBENZYL)CARBAMOYL)-P-TOLUIC ACID; (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-guanidino-pentanoyl]amino]-4-carboxy-butanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]acetyl]amino]-4-methyl-pentanoyl]amino]-3-methyl-pe;(S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid; (S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoicacid; (S)-2-ETHOXY-4-(2-(METHYL-1-(2-(1-PIPERIDINYL)PHENYL)BUTYLAMINO)-2-OXOETHYL)-BENZOIC ACID; (S)-2-Ethoxy-4-[2-[[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid; (S)-2-Ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-aminocarbonylmethyl]-benzoic acid; 2-Ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benz oic acid; 2-Ethoxy-4-{[(S)-3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid; Benzoic acid, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-	Approved	Approved Drug(s)	65981	DB00912	D0N5YA	452.6	78.9	619	5.2	33	2	5	10	C27H36N2O4	2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid	CCOC1=C(C=CC(=C1)CC(=O)NC(CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O	CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O	InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1	FAEKWTJYAYMJKF-QHCPKHFHSA-N
DXU36A	Maraviroc	Small molecule	Maraviroc; 376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; MD6P741W8A; CHEMBL256907; CHEMBL584744; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; MVC; CHEMBL1201187; DTXSID8048949; CHEBI:63608; NCGC00183109-02; 4,4-difluoro-N-((1S)-3-((1R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide; Cyclohexanecarboxamide, 4,4-difluoro-N-((1S)-3-((3-exo)-3-(3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)-; Celsentri(TM); Selzentry(TM); [3H]maraviroc; 2414315-81-2; 4,4-difluoro-N-((1S)-3-((1R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,3S,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; 4,4-Difluoro-N-[(1s)-3-{(3-Exo)-3-[3-Methyl-5-(Propan-2-Yl)-4h-1,2,4-Triazol-4-Yl]-8-Azabicyclo[3.2.1]oct-8-Yl}-1-Phenylpropyl]cyclohexanecarboxamide; PRO 140 & Maraviroc; maravirocum; Maraviroc [INN:BAN:JAN]; UNII-MD6P741W8A; Rel-Maraviroc; HSDB 8021; Maraviroc, endo-; 4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide; Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-; UK-427,857 maraviroc (MVC); MARAVIROC [INN]; MARAVIROC [JAN]; MARAVIROC [MI]; [3H]UK 427,857; [3H]UK-427,857; MARAVIROC [VANDF]; A3C7SRV8DV; MARAVIROC [MART.]; (non-labelled)Maraviroc-d6; MARAVIROC [WHO-DD]; SCHEMBL51991; GTPL803; GTPL806; MARAVIROC [EMA EPAR]; 4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; MLS006011960; SCHEMBL2177194; SCHEMBL4576508; MARAVIROC [ORANGE BOOK]; DTXCID5028875; Maraviroc, >=98% (HPLC); EX-A200; CHEBI:184662; AMY12578; Tox21_113369; AC-558; BDBM50334986; BDBM50464147; BDBM50583789; AKOS025402143; AKOS032960315; CS-0366; DB04835; NCGC00183109-01; AS-75265; exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; HY-13004; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; SMR004703532; CAS-376348-65-1; EN300-128501; EN300-7367238; EN300-22828861; Q421369; SR-01000942244; J-521678; SR-01000942244-1; BRD-A23284911-001-02-4; Z1614451557; 4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[(1S,5S)-3-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-1-phenyl-propyl}-amide; 4,4-difluoro-N-((1S)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-Difluoro-N-((S)-3-((1R,3R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide; 4,4-difluoro-N-((S)-3-((1S,3R,5R)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-((S)-3-((1S,3S,5R)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-((S)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,3R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; 4,4-Difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboximidic acid; 4,4-Difluoro-N-[(1S)-3-[(3-endo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide; 4,4-difluoro-N-{(1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide; 4,4-diluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[(3-endo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-; Cyclohexanecarboxamide,4,4-difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-; MRV	Approved	Approved Drug(s)	3002977	DB04835	D0NR6S	513.7	63	751	5.1	37	1	6	8	C29H41F2N5O	4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide	CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C	CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C	InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1	GSNHKUDZZFZSJB-HLMSNRGBSA-N
DD97BF	Donepezil	Small molecule	donepezil; 120014-06-4; Aricept; 2-((1-Benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one; donepezilo; Donaz; 2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one; HSDB 7743; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one; 142057-79-2; CHEMBL502; CHEBI:53289; 8SSC91326P; Donepezil (INN); 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one; DONEPEZIL [INN]; D-797; 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-; Donepezil [INN:BAN]; (RS)-2-[(1-BENZYL-4-PIPERIDYL)METHYL]-5,6-DIMETHOXYINDAN-1-ONE; 142057-80-5; 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-; 1H-Inden-1-one,2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-,(2S)-; 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1h-inden-1-one; NSC 737535; NSC 758882; NCGC00167537-01; (S)-E2020 (free base); donepezilum; Domepezil; UNII-8SSC91326P; 2-((1-benzyl-4-piperidyl)methyl)-5,6-dimethoxy-2,3-dihydroinden-1-one; 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-1h-inden-1-one; Donaz (TN); Spectrum_001664; DONEPEZIL [JAN]; DONEPEZIL [MI]; DONEPEZIL [HSDB]; Spectrum5_001662; DONEPEZIL [VANDF]; DONEPEZIL [WHO-DD]; SCHEMBL2149; Oprea1_188452; KBioSS_002144; BDBM8960; GTPL6599; SCHEMBL8265876; DTXSID8048317; KBio2_002144; KBio2_004712; KBio2_007280; AMY8939; CHEBI:145499; BCPP000253; HMS3886M11; BCP07590; MFCD00912833; s5073; STK003905; AKOS000277311; AKOS016842349; AC-6969; BCP9000622; CCG-268401; DB00843; MRF-0000323; D797; HY-14566; SBI-0206789.P001; FT-0601545; D07869; EN300-267872; AB00640013-07; AB00640013-08; AB00640013_09; AB00640013_10; Q415081; Q-100098; BRD-A49160188-003-04-4; Z1741977105; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one; (+/-)-2-((1-BENZYL-4-PIPERIDYL)METHYL)-5,6-DIMETHOXY-1-INDANONE; (+/-)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-indan-1-one; 2-[(1-benzyl-4-piperidyl)methyl]- 5,6-dimethoxy-2,3-dihydroinden-1-one; 2,3-dihydro-5,6-dimethoxy-2 [[1-(phenyl methyl)-4-piperidinyl]methyl]-1H-inden-1-one; 2,3-dihydro-5,6-dimethoxy-2[[1-(phenyl methyl)-4-piperidinyl]methyl]-1H-inden-1-one; 5,6-dimethoxy-2-[[1-(phenylmethyl)piperidin-4-yl]methyl]-2,3-dihydroinden-1-one; 5,6-DIMETHOXY-2-((1-(PHENYLMETHYL)-4-PIPERIDINYL)METHYL)-2,3-DIHYDRO-1H-INDEN-1-ONE	Approved	Approved Drug(s)	3152	DB00843	D0NS6H	379.5	38.8	510	4.3	28	0	4	6	C24H29NO3	2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one	COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC	COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC	InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3	ADEBPBSSDYVVLD-UHFFFAOYSA-N
DG9L8K	Belzutifan	Small molecule	Belzutifan; PT2977; 1672668-24-4; MK-6482; Welireg; MK6482; Belzutifan [INN]; Belzutifan [USAN]; PT-2977; 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile; 7K28NB895L; 3-[[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1H-inden-4-yl]oxy]-5-fluorobenzonitrile; 3-{[(1s,2s,3r)-2,3-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-((1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl)oxy-5-fluoro-benzonitrile; Benzonitrile, 3-(((1S,2S,3R)-2,3-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; Belzutifan [USAN:INN]; BELZUTIFAN [WHO-DD]; UNII-7K28NB895L; BELZUTIFAN [ORANGE BOOK]; CHEMBL4585668; SCHEMBL16560918; GTPL11251; PT 2977 [WHO-DD]; BDBM373040; DTXSID201334517; Pt 2977; EX-A4441; US9896418, Compound 289; XRC66824; NSC825217; WHO 11196; AT14994; Belzutifan (PT2977, MK-6482); compound 2 [PMID: 31282155]; NSC-825217; MK-6482; PT2977; AC-35183; MS-26288; HY-125840; CS-0101119; A935088; Q27456641; 3-(((1S,2S,3R)-2,3-DIFLUORO-1-HYDROXY-7-(METHANESULFONYL)-2,3-DIHYDRO-1H-INDEN-4-YL)OXY)-5-FLUOROBENZONITRILE; 3-((1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yloxy)-5-fluorobenzonitrile; 72Q	Approved	Approved Drug(s)	117947097	DB15463	D0NU8J	383.3	95.8	675	2	26	1	8	3	C17H12F3NO4S	3-[[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1H-inden-4-yl]oxy]-5-fluorobenzonitrile	CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O	CS(=O)(=O)C1=C2[C@@H]([C@@H]([C@@H](C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O	InChI=1S/C17H12F3NO4S/c1-26(23,24)12-3-2-11(13-14(12)17(22)16(20)15(13)19)25-10-5-8(7-21)4-9(18)6-10/h2-6,15-17,22H,1H3/t15-,16-,17+/m1/s1	LOMMPXLFBTZENJ-ZACQAIPSSA-N
DY3FU8	Erdafitinib	Small molecule	Erdafitinib; 1346242-81-6; JNJ-42756493; Balversa; 890E37NHMV; N1-(3,5-dimethoxyphenyl)-N2-isopropyl-N1-(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)ethane-1,2-diamine; JNJ42756493; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine; Erdafitinib [INN]; Erdafitinib [USAN:INN]; UNII-890E37NHMV; Balversa (TN); ERDAFITINIB [MI]; ERDAFITINIB [JAN]; Erdafitinib (USAN/INN); ERDAFITINIB [USAN]; ERDAFITINIB [WHO-DD]; GTPL9039; SCHEMBL2583760; CHEMBL3545376; ERDAFITINIB [ORANGE BOOK]; Erdafitinib(JNJ-42756493); Erdafitinib; JNJ-42756493; DTXSID001027936; JNJ-42756493 (Erdafitinib); AMY31119; BCP20346; EX-A2564; BDBM50525939; MFCD28502040; NSC781556; s8401; compound 4 [WO2011135376]; CCG-269200; CS-4988; DB12147; NSC-781556; SB16854; NCGC00475735-01; AC-30222; AS-35040; HY-18708; JNJ 42756493; N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine; D10927; A857165; Q27077213; B0084-470835; PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493; 5SF; N-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-N-{2-[(propan-2-yl)amino]ethyl}quinoxalin-6-amine; N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine;Erdafitinib	Approved	Approved Drug(s)	67462786	DB12147	D0NW0T	446.5	77.3	583	3.2	33	1	7	9	C25H30N6O2	N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine	CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC	CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC	InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3	OLAHOMJCDNXHFI-UHFFFAOYSA-N
DJ3PF4	Entrectinib	Small molecule	Entrectinib; 1108743-60-7; RXDX-101; NMS-E628; Rozlytrek; Entrectinib (RXDX-101); Entrectinib(rxdx-101); L5ORF0AN1I; N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide; N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide; N-{5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl}-4-(4-methylpiperazin-1-yl)-2-[(oxan-4-yl)amino]benzamide; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Entrectinib [INN]; UNII-L5ORF0AN1I; Entrectinib [USAN:INN]; Rozlytrek (TN); YMX; Entrectinib, 95%; Kinome_2659; ENTRECTINIB [MI]; ENTRECTINIB [JAN]; Entrectinib; NMS-E628; ENTRECTINIB [USAN]; ENTRECTINIB [WHO-DD]; Entrectinib (JAN/USAN/INN); GTPL8290; SCHEMBL3512601; CHEMBL1983268; NMS-E-628; ENTRECTINIB [ORANGE BOOK]; NMS-E628;RXDX-101; DTXSID101026450; HMS3886H21; BCP16174; EX-A2261; MFCD28129099; NSC774769; NSC800095; s7998; CCG-270048; DB11986; NSC-774769; NSC-800095; SB17194; NCGC00484067-01; NCGC00484067-02; NCGC00484067-03; AC-31286; AS-75092; DA-47850; HY-12678; FT-0736318; D10926; EN300-7376549; A856078; Q25323953; RXDX101; RXDX 101; RXDX-101; NMS E628; NMS-E628;NMS E628; N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide; N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide; N-[5-(3,5-Difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide	Approved	Approved Drug(s)	25141092	DB11986	D0O0LS	560.6	85.5	847	5.7	41	3	8	7	C31H34F2N6O2	N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide	CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6	CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6	InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)	HAYYBYPASCDWEQ-UHFFFAOYSA-N
DP49JT	Nevirapine	Small molecule	nevirapine; 129618-40-2; Viramune; BI-RG-587; Nevirapine anhydrous; BIRG 0587; NVP; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; Viramune XR; BI-RG 587; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; Nevirapine, anhydrous; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; Nevirapine teva; BIRG-0587; NSC 641530; CHEMBL57; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-CYCLOPROPYL-4-METHYL-5H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6(11H)-ONE; MFCD00866928; NEV; NSC-641530; 99DK7FVK1H; 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-; MLS000084585; DTXSID7031797; CHEBI:63613; NSC641530; NCGC00065890-02; SMR000048458; BIRG587; DTXCID9010787; Viramune(TM); Viramune (TN); 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one; CAS-129618-40-2; HSDB 7164; Nevirapine & CD4-IgG; Nevirapine & PRO 140; UNII-99DK7FVK1H; Nevirapine (JAN/USP/INN); Nevirapine); 11-cyclopropyl-4-methyl-5H-dipyrido[[?],[?]][1,4]diazepin-6-one; BIRG 587; BIRG-587; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; 11-cyclopropyl-4-methyl-5H-dipyrido[2,3-b:3',2'-e][1,4]diazepin-6-one; Viramune IR; 1vrt; 2hny; Nevirapine,(S); Nevirapine [USAN:USP:INN:BAN]; BI-RG-587 & CD4-IgG; 6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-; Nevirapinum anhydrous; Nevirapine (Viramune); Nevirapine (anhydrous); NEVIRAPINE [MI]; Opera_ID_934; NEVIRAPINE [INN]; NEVIRAPINE [JAN]; NEVIRAPINE [HSDB]; NEVIRAPINE [USAN]; NEVIRAPINE [VANDF]; NEVIRAPINE [MART.]; SCHEMBL3318; NEVIRAPINE [WHO-DD]; MLS000759409; MLS001055309; MLS001201730; MLS001424058; MLS006011423; BIDD:GT0326; NEVIRAPINE [EMA EPAR]; BDBM1434; NEVIRAPINE [ORANGE BOOK]; NEVIRAPINE [EP MONOGRAPH]; NEVIRAPINE [USP IMPURITY]; Nevirapine for peak identification; HMS2051J09; HMS2231O23; HMS3264D21; HMS3371E03; HMS3393J09; HMS3655I08; HMS3715B10; NEVIRAPINE [USP MONOGRAPH]; Pharmakon1600-01503842; ALBB-027264; BCP05587; Tox21 110982; Tox21_110982; Tox21_200770; AC-643; AC1280; BBL010768; NSC759902; STK580320; NEVIRAPINE ANHYDROUS [USP-RS]; NEVIRAPINE ANHYDROUS [WHO-IP]; AKOS005504351; Tox21_110982_1; AB07544; CCG-100939; DB00238; KS-5019; NC00189; NSC-759902; NCGC00065890-03; NCGC00065890-04; NCGC00065890-05; NCGC00065890-07; NCGC00065890-14; NCGC00258324-01; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one; HY-10570; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; Nevirapine 100 microg/mL in Acetonitrile; SY009679; BI-RG 587;NSC 641530;NVP; DB-041930; FT-0607215; FT-0672686; N0922; NEVIRAPINUM ANHYDROUS [WHO-IP LATIN]; S1742; SW197569-2; C07263; D00435; EN300-119500; AB00393001-13; AB00393001-15; AB00393001_16; AB00393001_17; Q263713; F2173-0607; Z1521553473; BI-RG-587; BIRG 0587; BIRG587; HSDB 7164; NSC 641530; NVP; Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard; Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard; Nevirapine, Pharmaceutical Secondary Standard; Certified Reference Material; 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b :2',3'-e][1,4 ]diazepin-6-one; 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2', 3'-e][1,4]diazepin-6-one; 6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-; Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2 inverted exclamation mark ,3 inverted exclamation mark -e][1,4]diazepin-6-one; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0,3,8]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one	Approved	Approved Drug(s)	4463	DB00238	D0O2EM	266.3	58.1	397	2	20	1	4	1	C15H14N4O	2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one	CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4	CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4	InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)	NQDJXKOVJZTUJA-UHFFFAOYSA-N
DW0A3R	Losartan	Small molecule	losartan; 114798-26-4; DUP 89; allisartan; Lortaan; Hyzaar; Cozaar; Angizaar; Losartic; LOSARTAN POTASSIUM; Lozap; Losartan (INN); CHEBI:6541; DUP-89; DTXSID7023227; DuP-753; NSC-758699; JMS50MPO89; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; MK-954; HGP1405; HGP-1405; (1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol; (1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol; NCGC00095125-01; LOSARTAN [INN]; Losartan [INN:BAN]; 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl)methyl)-; 1H-imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; DTXCID103227; (1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol; [3H]losartan; Losartic (TN); [2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; 2-BUTYL-4-CHLORO-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-IMIDAZOLE-5-METHANOL; [3H]-losartan; CAS-114798-26-4; SR-01000763170; UNII-JMS50MPO89; lorastan; [2-butyl-5-chloro-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; MFCD00865831; Dup89; Spectrum_001713; LOSARTAN [MI]; SCHEMBL60; LOSARTAN [VANDF]; Spectrum2_001677; Spectrum3_000998; Spectrum4_001126; Spectrum5_001466; Epitope ID:140137; LOSARTAN [WHO-DD]; EC 601-329-8; Oprea1_644635; US9624243, Losartin; BSPBio_002695; GTPL590; KBioGR_001611; KBioSS_002193; BIDD:GT0286; SPECTRUM1504268; SPBio_001893; GTPL3941; BDBM82258; HSDB 7043; KBio2_002193; KBio2_004761; KBio2_007329; KBio3_001915; BCPP000183; BDBM318822; EX 89; HMS1922J13; HMS2093E22; HMS3715L11; Pharmakon1600-01504268; BCP27731; NSC_3961; Tox21_111435; CCG-39095; NSC758699; s5067; STL419984; 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol; AKOS015917390; AKOS015994740; Tox21_111435_1; AB07507; BCP9000861; DB00678; KS-5004; NSC 758699; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole; NCGC00095125-02; NCGC00095125-03; NCGC00095125-05; NCGC00095125-08; NCGC00095125-15; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol; 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol; BL164640; HY-17512; SBI-0206766.P001; CAS_114798-26-4; FT-0631074; L0378; C07072; D08146; EN300-311953; AB01563296_01; A803239; L000351; Q410074; Q-201321; SR-01000763170-3; SR-01000763170-4; BRD-K76205745-001-02-5; BRD-K76205745-001-04-1; F2173-0506; Z2417557127; 2-BUTYL-4-CHLORO-1-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)IMIDAZOLE-5-METHANOL; 2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)-biphenyl-4-yl)methyl]imidazole; 2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; (1-((2'-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1h-imidazol-5-yl)methanol; (2-butyl-4-chloro-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol; (2-butyl-4-chloro-1-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; [2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol; {2-Butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-yl}-methanol; 1H-IMIDAZOLE-5-METHANOL, 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI); 2-butyl-4-chloro-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-methanol; 2-butyl-4-chloro-1-[2'-(2H-tetrazol-5-yl)-1,1'-biphenyl-4-ylmethyl]-1H- imidazole-5-methanol; 2-butyl-4-chloro-5-(hydroxymethyl)-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole	Approved	Approved Drug(s)	3961	DB00678	D0O2WJ	422.9	92.5	520	4.3	30	2	5	8	C22H23ClN6O	[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol	CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl	CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl	InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)	PSIFNNKUMBGKDQ-UHFFFAOYSA-N
DD9I2G	Docetaxel	Small molecule	docetaxel; 114977-28-5; Taxotere; Docetaxel anhydrous; Docetaxol; RP-56976; Docetaxel Winthrop; Docetaxel [INN]; EmDOC; Docefrez; NSC 628503; N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol; RP 56976; DTXSID0040464; TXL; Taxotere (TN); NSC-628503; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; CHEBI:4672; 699121PHCA; NSC628503; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; Docetaxel, Trihydrate; DTXCID8020464; taxotel; Docetaxolum; Taxoel; Docetaxel Kabi; Docetaxel intermediate; BIND 014; Taxotere(R); CKD-810; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate; CAS-114977-28-5; Docetaxolum [INN-Latin]; Docecad; UNII-699121PHCA; Docetaxel Teva; Docetaxel Accord; MFCD00871399; docetaxel 114977-28-5; HSDB 6965; XRP-6976L; ANX-514; SDP-014; SID 530; Docetaxel (TN); Docetaxel- Bio-X; NCGC00181306-01; NCGC00181306-02; 5?,20-Epoxy-1,7?,10?-trihydroxy-9-oxotax-11-ene-2?,4,13?-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-3-phenylpropanoate]; Taxotere (Aventis); Docetaxel, anhydrous; CID148124; N-debenzoyl-N-Boc-10-deacetyl taxol; Docetaxel - Taxotere; DOCETAXEL MYLAN; RP56976; bind-014; Docetaxel (JAN/INN); DOCETAXEL [JAN]; DOCETAXEL [MI]; CHEMBL92; DOCETAXEL [HSDB]; SCHEMBL4419; DOCETAXEL TEVA PHARMA; GTPL6809; BIND 014 [WHO-DD]; BDBM36351; SYP-0704A; ZDZOTLJHXYCWBA-VCVYQWHSSA-; AMY4356; 114977-28-5, Docetaxel; HMS2089K08; EX-A1206; HY-B0011; Tox21_112781; Tox21_113088; AC-383; DOCETAXEL ANHYDROUS [WHO-DD]; AKOS015960718; AKOS024457953; Tox21_112781_1; CS-1144; DB01248; KS-1452; Docetaxel, purum, >=97.0% (HPLC); NCGC00181306-04; NCGC00242509-01; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; BD164373; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; CABAZITAXEL METABOLITE (RP56976); D4102; D07866; EN300-123047; AB01273941-01; AB01273941-02; Q420436; SR-01000003023; W-60384; Q-100074; SR-01000003023-5; BRD-K30577245-001-04-3; BRD-K30577245-341-01-9; Z1546621742; Anhydrous Docetaxel, European Pharmacopoeia (EP) Reference Standard; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate; (2R,3S)-N-CARBOXY-3-PHENYLISOSERINE, N-TERT-BUTYL ESTER, 13-ESTER WITH 5.BETA.,20-EPOXY-1,2.ALPHA.,4,7.BETA.,10.BETA.,13.ALPHA.-HEXAHYDROXYTAX-11-EN-9-ONE 4-ACETATE 2-BENZOATE; [2aR-[2a?,4?,4a?,6?,9?(?R*,?S*),11?,12?,12a?,12b?]]-?-[[(1,1-Dimethylethoxy)carbonyl]amino]-?-hydroxy-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester benzenepropanoic acid; [acetoxy-[(2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenyl-propanoyl]oxy-trihydroxy-tetramethyl-oxo-[?]yl] benzoate; 114915-20-7; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-; Benzenepropanoic acid,1-dimethylethoxy)carbonyl]amino]-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)	Approved	Approved Drug(s)	148124	DB01248	D0O5WP	807.9	224	1660	1.6	58	5	14	13	C43H53NO14	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O	InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1	ZDZOTLJHXYCWBA-VCVYQWHSSA-N
DWYO48	Pemigatinib	Small molecule	Pemigatinib; 1513857-77-6; Pemazyre; INCB054828; Pemigatinib [INN]; Fgfr inhibitor INCB054828; Pemigatinib [USAN]; INCB-054828; Y6BX7BL23K; INCB54828; INCB-54828; 1513857-77-6 (free base); 2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-; 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-1,3,4,6-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(morpholin-4-yl)methyl]-1,3,4,7-tetrahydro-2Hpyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; Pemazyre (TN); 3-(2,6-DIFLUORO-3,5-DIMETHOXYPHENYL)-1-ETHYL-8-(MORPHOLIN-4-YLMETHYL)-1,3,4,7-TETRAHYDRO-2H-PYRROLO(3',2':5,6)PYRIDO(4,3-D)PYRIMIDIN-2-ONE; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; PEMIGATINIB [MI]; PEMIGATINIB [JAN]; Pemigatinib [USAN:INN]; UNII-Y6BX7BL23K; PEMIGATINIB [WHO-DD]; Pemigatinib (JAN/USAN/INN); GTPL9767; Pemigatinib (INCB054828); CHEMBL4297522; SCHEMBL15556271; PEMIGATINIB [ORANGE BOOK]; BDBM301310; DTXSID501027955; INCB 54828; EX-A4049; NSC816556; US10131667, Example 126; AT15587; DB15102; INCB054828INCB054828; NSC-816556; AC-36489; AS-78489; example 126 [WO2014007951]; HY-109099; CS-0039499; D11417; A936247; EN300-22847362; 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one; 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-[(morpholin-4-yl)methyl]-5,7,11,13-tetraazatricyclo[7.4.0.0,2,6]trideca-1(9),2(6),3,7-tetraen-12-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3'',2'':5,6]pyrido[4,3-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-3,4-dihydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2(7H)-one	Approved	Approved Drug(s)	86705695	DB15102	D0O6UY	487.5	83.2	731	1.8	35	1	8	6	C24H27F2N5O4	11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one	CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5	CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5	InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)	HCDMJFOHIXMBOV-UHFFFAOYSA-N
D80SCP	Histrelin	Small molecule	histrelin; 76712-82-8; Histrelin acetate; Histrelinum; ORF 17070; RWJ 17070; Histrelina; Histreline; Supprelin; Vantas; ORF-17070; CHEBI:5739; H50H3S3W74; RWJ-17070; ORF 17070RWJ 17070; Vantaas; Vantas (TN); Histreline [French]; Histrelinum [Latin]; Histrelina [Spanish]; Histrelin [USAN:INN]; 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide; 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-N(tau)-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide; L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-N(im)-benzyl-histidyl-L-leucyl-L-arginyl-L-proline ethylamide; BRN 4290557; UNII-H50H3S3W74; HSDB 7657; ((ImBl)-D-His(sub 6),Pro(sub 9)-NEt)LHRH; HISTRELIN [INN]; HISTRELIN [MI]; Histrelin (USAN/INN); HISTRELIN [HSDB]; HISTRELIN [USAN]; Supprelin LASupprelin LA; HISTRELIN [VANDF]; HISTRELIN [MART.]; HISTRELIN [WHO-DD]; SCHEMBL17881; 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-N(sup tau)-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide; GTPL3884; CHEMBL1201255; SCHEMBL19409305; SCHEMBL19712198; SCHEMBL22288995; DTXSID50227543; HY-P0056; NCGC00181758-01; des-gly10,(D-his(bzl)6)-lh-rh*ethylamide; CS-0015085; (Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH; D02369; Q5871149; 5-OXO-L-PROLYL-L-HISTIDYL-L-TRYPTOPHYL-L-SERYL-L-TYROSYL-NT-BENZYL-D-HISTIDYL-L-LEUCYL-L-ARGINYL-N-ETHYL-L-PROLINAMIDE; L-Prolinamide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-(phenylmethyl)-D-histidyl-L-leucyl-L-arginyl-N-ethyl-	Approved	Approved Drug(s)	25077993	DB06788	D0O7DG	1323.5	449	2660	0.7	96	15	15	34	C66H86N18O12	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-3-(1-benzylimidazol-4-yl)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide	CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC2=CN(C=N2)CC3=CC=CC=C3)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CN(C=N2)CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8	InChI=1S/C66H86N18O12/c1-4-70-64(95)55-17-11-25-84(55)65(96)48(16-10-24-71-66(67)68)76-58(89)49(26-38(2)3)77-62(93)53(30-43-34-83(37-74-43)33-40-12-6-5-7-13-40)81-59(90)50(27-39-18-20-44(86)21-19-39)78-63(94)54(35-85)82-60(91)51(28-41-31-72-46-15-9-8-14-45(41)46)79-61(92)52(29-42-32-69-36-73-42)80-57(88)47-22-23-56(87)75-47/h5-9,12-15,18-21,31-32,34,36-38,47-55,72,85-86H,4,10-11,16-17,22-30,33,35H2,1-3H3,(H,69,73)(H,70,95)(H,75,87)(H,76,89)(H,77,93)(H,78,94)(H,79,92)(H,80,88)(H,81,90)(H,82,91)(H4,67,68,71)/t47-,48-,49-,50-,51-,52-,53+,54-,55-/m0/s1	HHXHVIJIIXKSOE-QILQGKCVSA-N
DMJE60	Osimertinib	Small molecule	osimertinib; 1421373-65-0; AZD-9291; AZD9291; Mereletinib; AZD 9291; Osimertinib [USAN]; UNII-3C06JJ0Z2O; N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide; 3C06JJ0Z2O; AZD-9291 FREE BASE; N-(2-{[2-(Dimethylamino)ethyl](Methyl)amino}-4-Methoxy-5-{[4-(1-Methyl-1h-Indol-3-Yl)pyrimidin-2-Yl]amino}phenyl)prop-2-Enamide; MereletinibAZD-9291,Osimertinib; N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide; 2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-; N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide; Mereletinib [INN]; osimertinibum; N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)acrylamide; OSIMERTINIB [MI]; OSIMERTINIB [INN]; Osimertinib (AZD9291); Osimertinib; AZD-9291; mereletinib (obsolete INN); OSIMERTINIB [WHO-DD]; GTPL7719; CHEMBL3353410; SCHEMBL14660911; CHEBI:90943; AMY9161; EX-A314; DTXSID501025961; HMS3653E10; HMS3672M05; BCP08626; BDBM50029668; MFCD27988062; NSC779217; NSC781254; NSC800812; s7297; AKOS025290756; CCG-264683; CS-2018; DB09330; NSC-779217; NSC-781254; NSC-800812; SB22952; NCGC00378622-03; NCGC00378622-04; NCGC00378622-10; AC-29019; AS-16943; HY-15772; 4714B; SW219863-1; EN300-7382438; A854509; Q21506464; N(2{[2(diMethylaMino)ethyl](Methyl)aMino}4Methoxy5{[4(1Methyl1Hindol3yl)pyriMidin2yl]aMino}phenyl)prop2enaMide;Osimertinib; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide; N-(2-{2-Dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide	Approved	Approved Drug(s)	71496458	DB09330	D0O8GK	499.6	87.6	752	3.7	37	2	7	10	C28H33N7O2	N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide	CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC	CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC	InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)	DUYJMQONPNNFPI-UHFFFAOYSA-N
DML68I	Umbralisib	Small molecule	Umbralisib; 1532533-67-7; TGR-1202; rp-5264; TGR1202; TGR-1202 free base; Umbralisib [USAN]; RP5264; TGR-1202 base; TGR 1202; Ukoniq; (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one; 38073MQB2A; UNII-38073MQB2A; TGR 1202 [WHO-DD]; 2-[(1S)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one; 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one; UMBRALISIB [INN]; Umbralisib (USAN/INN); UMBRALISIB [WHO-DD]; GTPL8916; CHEMBL3948730; SCHEMBL15557416; BDBM184556; DTXSID601337137; BCP24686; EX-A1645; MFCD28386165; NSC793696; NSC800405; s8194; example A1 [US2014011819]; CCG-270101; CS-5243; DB14989; NSC-793696; NSC-800405; RP 5264; AC-33183; AS-52257; HY-12279; US9150579, B1; D11322; P14656; A901657; Q27088612; (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one;RP-5264; 4H-1-BENZOPYRAN-4-ONE, 2-((1S)-1-(4-AMINO-3-(3-FLUORO-4-(1-METHYLETHOXY)PHENYL)-1H-PYRAZOLO(3,4-D)PYRIMIDIN-1-YL)ETHYL)-6-FLUORO-3-(3-FLUOROPHENYL)-	Approved	Approved Drug(s)	72950888	DB14989	D0O8SJ	571.5	105	1020	5.8	42	1	10	6	C31H24F3N5O3	2-[(1S)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one	CC(C)OC1=C(C=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)C4=C(C(=O)C5=C(O4)C=CC(=C5)F)C6=CC(=CC=C6)F)F	C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=NC=NC(=C5C(=N4)C6=CC(=C(C=C6)OC(C)C)F)N	InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1	IUVCFHHAEHNCFT-INIZCTEOSA-N
DWV6I8	Bosutinib	Small molecule	Bosutinib; 380843-75-4; SKI-606; Bosutinib (SKI-606); SKI 606; BOSULIF; SKI606; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (USAN); Bosutinib [USAN]; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; SK-606; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; BOSUTINIB ISOMER 1; CHEMBL288441; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; CHEBI:39112; 5018V4AEZ0; SKI-606); Bosutinib (as monohydrate); Bosutinib [USAN:INN]; NCGC00241107-01; UNII-5018V4AEZ0; MFCD07367846; Bosutinib,SKI-606; BOSUTINIB [INN]; Bosutinib (SKI606); BOSUTINIB [MI]; BOSUTINIB [VANDF]; PF-5208763; Bosutinib - SKI-606; BOSUTINIB [MART.]; EC 700-455-1; BOSUTINIB [WHO-DD]; MLS006011212; SCHEMBL158390; AMY266; BDBM4552; GTPL5710; Bosutinib, >=98% (HPLC); DTXSID10861568; EX-A391; BCPP000318; HMS2043A22; HMS3244A03; HMS3244A04; HMS3244B03; HMS3651C03; HMS3672K11; HMS3743E09; 2-PYRIDIN-2-YLETHYLACETATE; K00615a; BCP01782; HB1323; NSC765694; NSC799367; SK 606; AKOS015902521; AC-2413; BCP9000446; CCG-208129; CS-0118; DB06616; NSC-765694; NSC-799367; PB30881; NCGC00241107-03; NCGC00241107-05; 4-(2,4-dichloro-5-methoxy-anilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; AS-11064; HY-10158; SMR002530350; FT-0656231; S1014; SKI606; SKI 606; SK-I606; SW220197-1; A25014; D03252; AB01565836_03; EN300-7565041; Q894611; SR-01000941572; J-519931; Q-200745; SR-01000941572-1; BRD-K99964838-001-01-0; BRD-K99964838-001-06-9; Z2216885221; 3-Quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-; 3-QUINOLINECARBONITRILE, 4-((2,4-DICHLORO-5-METHOXYPHENYL)AMINO)-6-METHYL-1-PIPERAZINYL)PROPOXY)-; 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrile; SKI-606;4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile	Approved	Approved Drug(s)	5328940	DB06616	D0OB0F	530.4	82.9	734	5.4	36	1	8	9	C26H29Cl2N5O3	4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile	CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC	CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC	InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)	UBPYILGKFZZVDX-UHFFFAOYSA-N
DM95SR	Mivacurium	Small molecule	Mivacurium; Mivacron; MIVACURIUM CHLORIDE; Mivacurium cation; BW-B109OU; 133814-19-4; BW B109OU; bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate; CHEBI:6958; DTXSID6048333; BWB109OU; (1R)-2-(3-{[(4E)-8-{3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propoxy}-8-oxooct-4-enoyl]oxy}propyl)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium; NCGC00167469-01; Mivacurium ion; UNII-77D66S9Q93; NCGC00183094-01; GTPL7243; CHEMBL1182833; DTXCID7028308; SCHEMBL10014476; SCHEMBL10666872; Tox21_112909; 77D66S9Q93; DB01226; NCGC00167469-02; CAS-133814-19-4; C07550; Q413877; Isoquinolinium, 2,2'-((1,8-dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl)-, (1R-(1R*(E(1'R*))))-	Approved	Approved Drug(s)	5281042	DB01226	D0OB2M	1029.3	145	1550	8.7	74	0	14	30	C58H80N2O14+2	bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate	C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CCC=CCCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C	C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C	InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1	ILVYCEVXHALBSC-OTBYEXOQSA-N
DN54QD	Pralsetinib	Small molecule	Pralsetinib; BLU-667; 2097132-94-8; Pralsetinib free base; Gavreto; Blu667; trans-Pralsetinib; Pralsetinib [INN]; Pralsetinib [USAN]; BLU123244; BLU-667 (Pralsetinib); 1WPE73O1WV; N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide; X581238; 2097132-94-8 (free base); BLU-123244; X-581238; 2097132-93-7; (cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide; cis-N-{(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl}-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide; Cyclohexanecarboxamide, N-((1S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)-3-pyridinyl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)-, cis-; cyclohexanecarboxamide, N-[(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)-3-pyridinyl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]-, cis-; Q4J; Blu667Blu667; cis-BLU-667; Pralsetinib (USAN/INN); Pralsetinib [USAN:INN]; UNII-1WPE73O1WV; PRALSETINIB [WHO-DD]; CHEMBL4582651; SCHEMBL18789228; SCHEMBL18789229; SCHEMBL18806610; SCHEMBL24492860; GTPL10033; BDBM435009; BDBM435010; DTXSID901336540; AMY16875; EX-A1944; EX-A3347; NSC811429; s8716; US10584114, Compound 129; US10584114, Compound 130; WHO 11004; AKOS037648884; HY-112301A; NSC-811429; RG 6396; AC-35657; BS-15942; HY-112301; CS-0043448; CS-0044766; D11712; EN300-24493835; (1r,4r)-N-[(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide; (1s,4R)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide; cis-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)cyclohexanecarboxamide; N-[(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide	Approved	Approved Drug(s)	129073603	DB15822	D0OD2I	533.6	136	816	3.1	39	3	9	8	C27H32FN9O2	N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide	CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)NC(C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC	CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC	InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1	GBLBJPZSROAGMF-SIYOEGHHSA-N
DH8EI2	Bexagliflozin	Small molecule	Bexagliflozin; 1118567-05-7; EGT1442; EGT-1442; THR-1442; Bexagliflozin [USAN]; EGT0001442; BRENZAVVY; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; EGT-0001442; EY00JF42FV; CHEMBL1808388; THR1442; (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; Bexagliflozin (USAN); D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; UNII-EY00JF42FV; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-({4-[2-(cyclopropyloxy)ethoxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-, (1S)-; EGT1442; Bexagliflozin; BEXAGLIFLOZIN [INN]; SCHEMBL302200; BEXAGLIFLOZIN [WHO-DD]; GTPL12335; Bexagliflozin(THR1442EGT1442); EX-A2332; BDBM50349249; Bexagliflozin(THR1442EGT1442); ; CS-5702; DB12236; compound 29 [PMID: 21737266]; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-D-glucitol; AC-33643; AS-55919; HY-17604; C71393; D10865; J-500393; Q27277423	Approved	Approved Drug(s)	25195624	DB12236	D0OR3G	464.9	109	569	2.4	32	4	7	9	C24H29ClO7	(2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol	C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl	C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl	InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1	BTCRKOKVYTVOLU-SJSRKZJXSA-N
DI17AC	Brexpiprazole	Small molecule	BREXPIPRAZOLE; 913611-97-9; OPC-34712; Rexulti; 7-(4-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one; OPC 34712; Brexpiprazole-d8; Brexpiprazole(OPC34712); 2J3YBM1K8C; 7-(4-(4-(1-Benzothiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one; 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one; 1427049-19-1; C25H27N3O2S; Brexpiprazole [USAN]; UNII-2J3YBM1K8C; Brexpiprazole [USAN:INN]; Rxulti; Rexulti (TN); Brexpiprazole.2H2O; Brexpiprazole-[d8]; BREXPIPRAZOLE [MI]; BREXPIPRAZOLE [INN]; BREXPIPRAZOLE [JAN]; Brexpiprazole; OPC-34712; BREXPIPRAZOLE [WHO-DD]; GTPL7672; SCHEMBL1037592; Brexpiprazole (JAN/USAN/INN); CHEMBL2105760; SCHEMBL14772509; AMY6914; DTXSID40238527; CHEBI:134716; HMS3885P12; BREXPIPRAZOLE [ORANGE BOOK]; BCP10218; BCP24077; EX-A2639; OPC34712; MFCD27987920; s4639; AKOS025291100; AKOS037515802; CCG-269055; DB09128; SB16735; NCGC00378574-01; NCGC00378574-02; AC-30404; AS-56467; DA-35913; HY-15780; FT-0712292; A13527; D10309; EN300-311582; Q2924764; Z2373117814; 2(1H)-Quinolinone, 7-(4-(4-benzo(b)thien-4-yl-1-piperazinyl)butoxy)-; 7-[4-(4-benzo[b]thien-4-yl-1-piperazinyl)butoxy]- 2(1H)-Quinolinone; 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one; 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one; 7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one; 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}-1,2-dihydroquinolin-2-one	Approved	Approved Drug(s)	11978813	DB09128	D0P0OU	433.6	73	636	4.7	31	1	5	7	C25H27N3O2S	7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one	C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4	C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4	InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)	ZKIAIYBUSXZPLP-UHFFFAOYSA-N
DTEI47	Dronabinol	Small molecule	Dronabinol; TETRAHYDROCANNABINOL; Marinol; delta9-Tetrahydrocannabinol; delta9-THC; delta-9-tetrahydrocannabinol; Abbott 40566; 1972-08-3; Deltanyne; delta-9-THC; delta(9)-THC; Dronabinolum; THC; delta(1)-Tetrahydrocannabinol; delta1-THC; 1-trans-delta-9-Tetrahydrocannabinol; delta(sup 1)-Thc; delta(sup 9)-Thc; QCD 84924; SP 104; Namisol; (-)-delta9-trans-Tetrahydrocannabinol; 9-tetrahydrocannabinol; delta(9)-Tetrahydrocannabinol; 1-trans-delta9-Tetrahydrocannabinol; QCD-84924; delta1-Tetrahydrocannabinol; delta(9)-Tetrahydrocannibinol; .DELTA.9-Tetrahydrocannabinol; Syndros; delta(sup 1)-Tetrahydrocannabinol; delta(sup 9)-Tetrahydrocannabinol; .DELTA.1-THC; .DELTA.9-THC; L-delta1-trans-Tetrahydrocannabinol; Cannabinol, delta1-tetrahydro-; CCRIS 4726; CHEBI:66964; 3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol; (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; 6465-30-1; CHEMBL465; Tetrahydrocannabinols (-)-delta1-3,4-trans-form; NSC-134454; (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol; .delta.-9-tetrahydrocannabinol; ABBOTT-40566; DTXSID6021327; Cannabinol, 1-trans-delta(sup 9)-tetrahydro-; J882F; 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; trans-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; SP-104; 6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-; 7J8897W37S; Dronabinolum [Latin]; Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; 6,6,9-Trimethyl-3-pentyl-7,8,9,10-tetrahydro-6H-dibenzo(b,d)pyran-1-ol; Tetrahydrocannabinols (-)-trans-.delta.9-form; 6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR,10aR)-; 6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, trans-; (-)-.DELTA.9-THC; Compassia; Relivar; (L)-.delta.1-Tetrahydrocannabinol; (-)-.DELTA.1-Tetrahydrocannabinol; (-)-.DELTA.9-Tetrahydrocannabinol; L-.delta.1-trans-Tetrahydrocannabinol; L-trans-.delta.9-Tetrahydrocannabinol; (6aR,10aR)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; (6aR,10aR)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; (6aR-trans)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; 6H-dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR,10aR)-; (-)-.DELTA.9-trans-Tetrahydrocannabinol; (-)-trans-.DELTA.9-Tetrahydrocannabinol; Marinol (TN); DEA No. 7369; delta1-Tetrahydrocannabinol (VAN); delta9-Tetrahydrocannabinol (VAN); Dronabinol (USP/INN); .DELTA.1-Tetrahydrocannabinol; Tetrahydrocannabinol delta9; (-)-trans-Delta9-THC; (l)-delta(sup 1)-Tetrahydrocannabinol; Cannabinol, .DELTA.1-tetrahydro-; 1-trans-delta(sup 9)-Tetrahydrocannabinol; .DELTA.9-trans-Tetrahydrocannabinol; (l)-delta1-Tetrahydrocannabinol; L-.delta.1-Tetrahydrocannabinol; (-)-delta1-Tetrahydrocannabinol; (-)-delta9-Tetrahydrocannabinol; delta9-trans-Tetrahydrocannabinol; HSDB 6471; trans-delta9-Tetrahydrocannabinol; (6aR-trans)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; CAT-310; L-trans-delta9-Tetrahydrocannabinol; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol; 6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-; DRG-0138; TCI; 14C-.DELTA.1-Tetrahydrocannabinol; trans-.DELTA.9-Tetrahydrocannabinol; (-)-trans-Delta1-Tetrahydrocannabinol; (-)-trans-delta9-Tetrahydrocannabinol; NSC 134454; .delta.-9-THC; 1-trans-delta(sup9)-tetrahydrocannabinol; Dronabinol (Synthetic); .delta.(sup9)-THC; 3ls4; DRONABINOL [INN]; (-)-3,4-trans-Delta1-Tetrahydrocannabinol; 1-trans-.delta.(sup9)-tetrahydrocannabinol; DRONABINOL [HSDB]; DRONABINOL [USAN]; (-)-.delta.(sup9)-trans-Tetrahydrocannabinol; DRONABINOL [VANDF]; Epitope ID:224552; DRONABINOL [MART.]; SCHEMBL4609; delta 9-Tetrahydrocannabinol; delta-9 Tetrahydrocannabinol; DRONABINOL [WHO-DD]; BIDD:GT0427; Dronabinol [USAN:USP:INN]; SCI-110 component dronabinol; DTXCID101327; GTPL2424; Cannabinol, tetrahydro- (6CI); DRONABINOL [ORANGE BOOK]; UNII-7J8897W37S; BDBM60994; delta-Tetrahydrocannabinol (THC); DRONABINOL [USP MONOGRAPH]; DTXSID001038830; US9416103, Delta9-THC; (+/-)-delta9-Tetrahydrocannabinol; INT-0010; Tox21_112616; BDBM50007391; NSC134454; PDSP2_000714; Cannabinol, Delta1-tetrahydro- (7CI); DB00470; INT-0010/06; CAS-1972-08-3; TETRAHYDROCANNABINOL, DELTA-9 TRANS; C06972; Cannabinol, 1-trans-.delta.(sup9)-tetrahydro-; D00306; Q190067; (-)-.DELTA.1-3,4-TRANS-TETRAHYDROCANNABINOL; (-)-Delta9-THC (Dronabinol) 0.1 mg/ml in Methanol; (-)-Delta9-THC (Dronabinol) 1.0 mg/ml in Methanol; (-)-Delta9-THC (Dronabinol) 5.0 mg/ml in Methanol; Delta9-Tetrahydrocannabinol 250 microg/mL in Acetonitrile; TETRAHYDROCANNABINOLS (-)-TRANS-.DELTA.9-FORM [MI]; 6H-Dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-; (-)-Delta9-Tetrahydrocannabinol (Delta9-THC) 100 microg/mL in Methanol; (-)-Delta9-Tetrahydrocannabinol (Delta9-THC) 1000 microg/mL in Methanol; 6,9-Trimethyl-3-pentyl-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-ol; 6H-Dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, trans-; (-)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol(l)-delta(sup 1)-Tetrahydrocannabinol; (10R,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; (6AR,10AR)-6,6,9-TRIMETHYL-3-PENTYL-6H,6AH,7H,8H,10AH-BENZO[C]ISOCHROMEN-1-OL; (S)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol(DeltaE-9-THC); 6H-Dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-; Delta-9-Tetrahydrocannabinol, United States Pharmacopeia (USP) Reference Standard; (6AR,10AR)-6,6,9-TRIMETHYL-3-PENTYL-6A,7,8,10A-TETRAHYDRO-6H-DIBENZO(B,D)PYRAN-1-OL; 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol(delta9-THC(delta9-tetrahydrocannabinol)); 8,8-Dimethyl-11-methylene-5-pentyl-3,4,8a,9,10,11,12,12a-octahydro-2H,8H-1,7-dioxa-benzo[c]phenanthrene	Approved	Approved Drug(s)	16078	DB00470	D0P1FO	314.5	29.5	439	7	23	1	2	4	C21H30O2	(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol	CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O	CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O	InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1	CYQFCXCEBYINGO-IAGOWNOFSA-N
DHE84J	Venlafaxine	Small molecule	venlafaxine; 93413-69-5; D,L-Venlafaxine; Elafax; Venlafaxina; 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol; Venlafaxinum; Efectin; Effexor; velafax; Trevilor; 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; Kanghong; Venlor; Venlafaxine (INN); GRZ5RCB1QG; NSC-758676; CHEBI:9943; DTXSID6023737; Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-; Venlafaxine [INN:BAN]; NCGC00095109-01; Venlafaxinum [INN-Latin]; Venlafaxina [INN-Spanish]; VENLAFAXINE [INN]; DTXCID403737; Venlafaxin; Venlafexine; Efectin (TN); CAS-93413-69-5; SR-01000762930; UNII-GRZ5RCB1QG; 1-(2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexan-1-ol; DL-Venlafaxine; Venflaxine EP; CYCLOHEXANOL, 1-(2-(DIMETHYLAMINO)-1-(4-METHOXYPHENYL)ETHYL)-; HSDB 6699; Spectrum_001671; SpecPlus_000842; VENLAFAXINE [MI]; Spectrum2_000542; Spectrum3_000989; Spectrum4_001115; Spectrum5_001516; Venlafaxine EP Impurity H; CHEMBL637; EC 618-944-2; VENLAFAXINE [VANDF]; SCHEMBL35154; BSPBio_002657; KBioGR_001590; KBioSS_002151; VENLAFAXINE [WHO-DD]; MLS006011859; DivK1c_006938; SPECTRUM1504171; SPBio_000583; GTPL7321; BDBM82071; KBio1_001882; KBio2_002151; KBio2_004719; KBio2_007287; KBio3_001877; HMS1922F05; HMS2090F04; HMS2093A12; HMS3714K11; HMS3886K14; Pharmakon1600-01504171; 1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol; AMY39116; HY-B0196; Tox21_111425; CCG-39577; MFCD00864385; N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine; NSC_62923; NSC758676; s5655; STK621394; AKOS005555049; Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, (+-)-; Tox21_111425_1; Wy 45030Wy 45030; AC-1547; DB00285; NSC 758676; SDCCGSBI-0052740.P003; NCGC00095109-02; NCGC00095109-03; NCGC00095109-04; NCGC00095109-05; NCGC00095109-06; NCGC00095109-08; NCGC00095109-20; AS-76254; SMR002204138; WY-45655; SBI-0052740.P002; CAS_93413-69-5; CAS_99300-78-4; DB-057399; FT-0642242; FT-0675793; FT-0675795; C07187; D08670; D82446; EN300-708795; AB00053751-08; AB00053751-10; AB00053751-11; AB00053751_12; AB00053751_13; Q898407; SR-01000762930-3; SR-01000762930-4; BRD-A51714012-001-02-3; BRD-A51714012-003-01-1; 1-[2-dimethylamino-1-(4-methoxylphenyl)ethyl]cyclohexanol; (RS)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; (+/-)-1-(.ALPHA.-((DIMETHYLAMINO)METHYL)-P-METHOXYBENZYL)CYCLOHEXANOL; 540726-98-5	Approved	Approved Drug(s)	5656	DB00285	D0P1UX	277.4	32.7	279	2.9	20	1	3	5	C17H27NO2	1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol	CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O	CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O	InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3	PNVNVHUZROJLTJ-UHFFFAOYSA-N
D8WEY5	Tiotropium	Small molecule	Tiotropium; Spiriva; tiotropium cation; Tiotropium ion; BA-679 BR; BA-679-BR; 186691-13-4; CHEMBL4650755; 0EB439235F; [3H]tiotropium; (1r,2r,4s,5s,7s)-7-{[hydroxy(Dithiophen-2-Yl)acetyl]oxy}-9,9-Dimethyl-3-Oxa-9-Azoniatricyclo[3.3.1.0~2,4~]nonane; NCGC00167971-01; UNII-0EB439235F; (1R,2R,4S,5S)-7-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium; 0HK; TIOTROPIUM [VANDF]; TIOTROPIUM [WHO-DD]; GTPL367; GTPL8592; SCHEMBL4662461; CHEMBL1900528; CHEMBL3305968; CHEBI:90960; BDBM50066861; BDBM50581209; DB01409; AB01274813-01; AB01274813-02; AB01274813-03; Q424316; Q27088996; (1alpha,2beta,4beta,5alpha,7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane; (1beta,5beta)-3beta-[[Hydroxybis(2-thienyl)acetyl]oxy]-8,8-dimethyl-6beta,7beta-epoxy-8-azoniabicyclo[3.2.1]octane; [(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate; 3-OXA-9-AZONIATRICYCLO(3.3.1.02,4)NONANE, 7-((2-HYDROXY-2,2-DI-2-THIENYLACETYL)OXY)-9,9-DIMETHYL-, (1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.)-; 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane	Approved	Approved Drug(s)	5487427	DB01409	D0P1WA	392.5	116	564	2.3	26	1	6	5	C19H22NO4S2+	[(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate	C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C	C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C	InChI=1S/C19H22NO4S2/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15/h3-8,11-13,16-17,22H,9-10H2,1-2H3/q+1/t11?,12-,13+,16-,17+	LERNTVKEWCAPOY-FPISHFTHSA-N
D21CKJ	Glucarpidase	Small molecule	Glucarpidase; 9074-87-7; Q5572303	Approved	Approved Drug(s)	21195079	DB08898	D0P4PZ	261.5	0	0	.	4	0	0	0	Zn4+8	zinc(2+)	[Zn+2].[Zn+2].[Zn+2].[Zn+2]	[Zn+2].[Zn+2].[Zn+2].[Zn+2]	InChI=1S/4Zn/q4*+2	LZQXMCNBQHANEY-UHFFFAOYSA-N
DGQ4L7	Terazosin	Small molecule	terazosin; 63590-64-7; Terazosine; Hytrin; Terazosina; Terazosinum; Flumarc; Vasomet; Terazosine [INN-French]; Terazosinum [INN-Latin]; Terazosina [INN-Spanish]; Terazosabb; Terazosin (INN); 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; C19H25N5O4; CHEMBL611; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; MLS000069703; CHEBI:9445; 141269-44-5; Terazosin (hydrochloride); 8L5014XET7; 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine; 141269-45-6; SMR000058309; TERAZOSIN [INN]; Terazosin [INN:BAN]; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; Abbott 45975; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-{(tetnaphydro-2-furanyl)carbonyl}piperazine; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine; Terazosabb (TN); 6,7-Dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine hydrochloride; terazosin a; UNII-8L5014XET7; terazosinhydrochloride; TERAZOSIN [MI]; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride; Opera_ID_1910; Prestwick0_000751; Prestwick1_000751; Prestwick2_000751; Prestwick3_000751; TERAZOSIN [VANDF]; SCHEMBL6528; TERAZOSIN [WHO-DD]; Lopac0_001138; REGID_for_CID_5401; BSPBio_000762; MLS001201836; MLS006011889; SPBio_002701; BPBio1_000840; GTPL7302; DTXSID3023639; HMS2090P21; HMS2232N21; HMS3259F04; HMS3369P14; HMS3371E20; HMS3742I09; HY-B0371; BBL010743; BDBM50033111; STK567029; AKOS005266642; CCG-205212; DB01162; NC00689; SDCCGSBI-0051105.P002; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-; NCGC00016026-04; NCGC00016026-05; NCGC00016026-08; NCGC00016026-11; NCGC00025191-03; AC-11120; LS-14728; FT-0630739; C07127; D08569; EN300-119614; A834201; L000692; Q280786; BRD-A22256192-003-03-7; BRD-A22256192-003-14-4; Z1172269406; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-piperazine; 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]-3,4-dihydroquinazolin-4-imine; 6,7-Dimethoxy-2-[4-(tetrahydro-2-furanylcarbonyl)-1-piperazinyl]-4-quinazolinamine #; 6,7-dimethoxy-2-{4-[(oxolan-2-yl)carbonyl]piperazin-1-yl}quinazolin-4-amine; 1-(4-AMino-6,7-diMethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-piperazinehydrochloride; 1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)-2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine	Approved	Approved Drug(s)	5401	DB01162	D0P9RF	387.4	103	544	1.4	28	1	8	4	C19H25N5O4	[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC	InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)	VCKUSRYTPJJLNI-UHFFFAOYSA-N
DR91QF	Risedronic acid	Small molecule	Risedronic acid; Risedronate; 105462-24-6; Atelvia; Risedronic acid monohydrate; Ridron; Benet; NE-58095; (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid; Risedronic acid (INN); Risedronic acid [INN]; (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; Risedronic acid (Actonel); CHEMBL923; CHEBI:8869; Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-; Phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-; 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID; M05BA07; KM2Z91756Z; RIS; Acido risedronico; Acide risedronique; Acidum risedronicum; Risedronic acid [INN:BAN]; (1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl)bis(phosphonic acid); Acide risedronique [INN-French]; Acido risedronico [INN-Spanish]; Acidum risedronicum [INN-Latin]; Bisphosphonate 1; [1-hydroxy-1-phosphono-2-(3-pyridyl)ethyl]phosphonic acid; Ridron (TN); MFCD00867080; NE 58019; HSDB 7326; Risdronate; UNII-KM2Z91756Z; Risedronate acid; SR-05000001495; (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid; RISEDRONATE [VANDF]; SCHEMBL18378; RISEDRONIC ACID [MI]; 2-(3-pyridinyl)-1-hydroxyethane diphosphonic acid; BIDD:GT0010; RISEDRONIC ACID [HSDB]; GTPL3176; JMC515594 Compound 64; DTXSID2023563; RISEDRONIC ACID [MART.]; BDBM12576; AMY3524; RISEDRONIC ACID [WHO-DD]; HMS2090C21; HMS3741A17; (1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid); BCP13805; HY-B0148; s1874; AKOS015892564; AC-1295; CS-1964; DB00884; NCGC00386377-01; AS-13584; FT-0642593; C08233; D08484; EN300-117266; AB01275490-01; AB01275490_02; A801245; Q408724; SR-05000001495-1; 2-(3-pyridyl)-1-hydroxyethane-1,1-bisphosphonic acid; Z1501485357; (1-Hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid; 1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyldiphosphonic acid; Phosphonic acid, P,P'-[1-hydroxy-2-(3-pyridinyl)ethylidene]bis-; 1-Hydroxy-2-(3-pyridinyl)ethylidenebisphosphonicacidmonohydrate;Risedronic acid monohydrate	Approved	Approved Drug(s)	5245	DB00884	D0PA5S	283.11	148	339	-3.1	17	5	8	4	C7H11NO7P2	(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid	C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O	C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O	InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)	IIDJRNMFWXDHID-UHFFFAOYSA-N
DH2UG9	Furosemide	Small molecule	furosemide; 54-31-9; Frusemide; Lasix; Furanthril; Furosemid; Errolon; Fusid; Aisemide; Beronald; Desdemin; Frusemin; Fuluvamide; Furanthryl; Furantril; Fursemide; Lowpstron; Macasirool; Prefemin; Rosemide; Trofurit; Fulsix; Furesis; Katlex; Lasilix; Radonna; Seguril; Transit; Lasex; Salix; Urex; Marsemide; Eutensin; Frusetic; Fursemid; Logirene; Oedemex; Promedes; Frusid; Lazix; Mirfat; Frusemid; Frusenex; Furanturil; Furosedon; Profemin; Urosemide; Aluzine; Diural; Dryptal; Impugan; Nicorol; Rusyde; Uremide; Uresix; Yidoli; Disal; Laxur; Urian; Apo-Frusemide; Hydro-rapid; Anfuramaide; Arasemide; Bioretic; Disemide; Diurapid; Diurolasa; Diusemide; Durafurid; Fluidrol; Frusedan; Fuluvamine; Furobeta; Furodiurol; Furodrix; Furorese; Furosemidum; Furosemix; Furoside; Furosifar; Furovite; Fursemida; Hissuflux; Hydroled; Jenafusid; Lasiletten; Lowpston; Moilarorin; Novosemide; Protargen; Radisemide; Selectofur; Sigasalur; Spirofur; Synephron; Zafimida; Aldalix; Aquarid; Aquasin; Cetasix; Dirine; Discoid; Diurin; Diusil; Diuzol; Dranex; Edemid; Edenol; Endural; Farsix; Franyl; Frumex; Frumide; Frusema; Furetic; Furfan; Furmid; Furocot; Furomen; Furomex; Furosan; Furose; Furosix; Furoter; Fursol; Hydrex; Kofuzon; Kolkin; Kutrix; Lasemid; Liside; Luscek; Nelsix; Odemase; Odemex; Promide; Puresis; Radouna; Salinex; Salurex; Salurid; Uridon; Uritol; Aldic; Depix; Desal; Eliur; Fluss; Furex; Furix; Golan; Hydro; Nadis; Retep; Rosis; Vesix; Mita; Apo-Furosemide; Furo-puren; Lasix Retard; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid; less Diur; Neo-renal; Furo-Basan; Furosemidu; Urex-M; Nephron; Furomide M.D.; Furosemida; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid; LB 502; 5-(Aminosulfonyl)-4-chloro-2-[(2-furylmethyl)amino]benzoic acid; 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; LB-502; NCI-C55936; Lasix (TN); Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]-; Diumide-K; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid; 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid; 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid; Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure; Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl-; CHEMBL35; 4-Chloro-2-((furan-2-ylmethyl)amino)-5-sulfamoylbenzoic acid; NSC-269420; Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)-; 7LXU5N7ZO5; DTXSID6020648; CHEBI:47426; Furosemidu [Polish]; 5-(Aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)benzoic acid; 5-(Aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoic acid; CAS-54-31-9; Furosemidum [INN-Latin]; Furosemida [INN-Spanish]; NCGC00016241-06; Sal diureticum; Furosemide 'mita'; FUN; DTXCID80648; Furosemide mita; Furosemide oral; 4-chloro-2-{[(furan-2-yl)methyl]amino}-5-sulfamoylbenzoic acid; 4-CHLORO-N-FURFURYL-5-SULFAMOYLANTHRANILIC ACID pound>>Furosemide; 5-(Aminosulfonyl)-4-chloro-2-([2-furanylmethyl]amino)benzoic acid; 5-(aminosulfonyl)-4-chloro-2-[(furan-2-ylmethyl)amino]benzoic acid; SMR000058202; CCRIS 1951; furosemide ''mita''; HSDB 3086; SR-01000765380; EINECS 200-203-6; Hoe-058A; UNII-7LXU5N7ZO5; NSC 269420; BRN 0840915; Neosemid; Zafurida; Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]; 5-(AMINOSULFONYL)-4-CHLORO-2-((2-FURYLMETHYL)AMINO)BENZOIC ACID; Furosemide, 4; Urex M; furosemide (lasix); Prestwick_752; Frumil (Salt/Mix); MFCD00010549; FUROSCIX; Furosemide [USAN:USP:INN:BAN:JAN]; Spectrum_001100; 1z9y; FUROSEMIDE [MI]; FUROSEMIDE [INN]; FUROSEMIDE [JAN]; Prestwick0_000341; Prestwick1_000341; Prestwick2_000341; Prestwick3_000341; Spectrum2_001005; Spectrum3_000437; Spectrum4_000560; Spectrum5_000744; FUROSEMIDE [HSDB]; FUROSEMIDE [IARC]; FUROSEMIDE [USAN]; F0182; FUROSEMIDE [VANDF]; UPCMLD-DP022; FUROSEMIDE [MART.]; SCHEMBL9811; FUROSEMIDE [USP-RS]; FUROSEMIDE [WHO-DD]; FUROSEMIDE [WHO-IP]; Oprea1_667724; BSPBio_000401; BSPBio_002054; KBioGR_001259; KBioSS_001580; 5-18-09-00555 (Beilstein Handbook Reference); MLS001066374; MLS001306403; MLS002548896; BIDD:GT0139; DivK1c_000575; SPECTRUM1500310; SPBio_001129; SPBio_002322; BPBio1_000443; Furosemide (JP17/USP/INN); GTPL4839; FUROSEMIDE [GREEN BOOK]; FUROSEMIDE [ORANGE BOOK]; UPCMLD-DP022:001; BDBM25902; HMS501M17; KBio1_000575; KBio2_001580; KBio2_004148; KBio2_006716; KBio3_001274; 4-chloro-2-(2-furylmethylamino)-5-sulfamoyl-benzoic acid; 4-chloro-2-[(2-furylmethyl)amino]-5-sulfamoylbenzoic acid; FUROSEMIDE [EP MONOGRAPH]; NINDS_000575; FUROSEMIDE [USP MONOGRAPH]; HMS1569E03; HMS1920B03; HMS2090K06; HMS2091H05; HMS2096E03; HMS2233H03; HMS3259M03; HMS3370J22; HMS3655E09; HMS3713E03; HMS3874G03; Pharmakon1600-01500310; FUROSEMIDUM [WHO-IP LATIN]; ALBB-019200; HY-B0135; Tox21_110322; Tox21_202213; Tox21_302971; BBL027780; CCG-40223; NSC269420; NSC757039; STK177334; WLN: T5OJ B1MR CG FVQ DSZW; AKOS000266625; Tox21_110322_1; BCP9000708; CS-1915; DB00695; KS-1226; NC00453; NSC-757039; IDI1_000575; SMP1_000129; NCGC00016241-01; NCGC00016241-02; NCGC00016241-03; NCGC00016241-04; NCGC00016241-05; NCGC00016241-07; NCGC00016241-08; NCGC00016241-10; NCGC00016241-11; NCGC00090893-01; NCGC00090893-02; NCGC00090893-03; NCGC00090893-05; NCGC00090893-06; NCGC00256523-01; NCGC00259762-01; AC-11067; BF166384; BP-13261; SBI-0051389.P003; DB-052536; AB00052001; SW196894-3; C07017; D00331; D87719; EN300-126738; AB00052001-10; AB00052001-11; AB00052001_12; AB00052001_13; A830094; Q388801; SR-01000765380-2; SR-01000765380-3; SR-01000765380-7; BRD-K78010432-001-05-8; BRD-K78010432-001-10-8; Z275128584; 4-chloro-2-(2-furanylmethylamino)-5-sulfamoylbenzoic acid; Furosemide, British Pharmacopoeia (BP) Reference Standard; Furosemide, European Pharmacopoeia (EP) Reference Standard; 4-chloranyl-2-(furan-2-ylmethylamino)-5-sulfamoyl-benzoic acid; Furosemide, United States Pharmacopeia (USP) Reference Standard; 4-CHLORO-N-FURFURYL-5-SULFAMOYLANTHRANILIC ACID Furosemide; 5-(Aminosulfamyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoic acid; 5-(Aminosulfonyl)-4-chloro-2-[(2-furylmethyl)amino]benzoic acid #; Furosemide, Pharmaceutical Secondary Standard; Certified Reference Material; Furosemide for peak identification, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	3440	DB00695	D0PQ3G	330.74	131	481	2	21	3	7	5	C12H11ClN2O5S	4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid	C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl	C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl	InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)	ZZUFCTLCJUWOSV-UHFFFAOYSA-N
DJN4A5	Ertugliflozin	Small molecule	Ertugliflozin; 1210344-57-2; PF-04971729; Steglatro; PF04971729; MK-8835; (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; CHEMBL1770248; PF-04971729-00; 6C282481IP; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; (1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; beta-L-Idopyranose, 1,6-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-5-C-(hydroxymethyl)-; beta-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-; PF 04971729; Ertugliflozin [USAN:INN]; UNII-6C282481IP; (1s,2s,3s,4r,5s)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; ERTUGLIFLOZIN [MI]; ERTUGLIFLOZIN [INN]; Ertugliflozin (USAN/INN); ERTUGLIFLOZIN [USAN]; PF 04971729-00; SCHEMBL181047; ERTUGLIFLOZIN [WHO-DD]; GTPL8376; PF-04971729;Ertugliflozin; DTXSID40153120; EX-A407; CHEBI:188719; ERTUGLIFLOZIN [ORANGE BOOK]; AMY32613; BDBM50342885; MFCD21609259; s5413; AKOS025404928; CCG-269087; CS-0976; DB11827; 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol; AC-29007; AS-35204; HY-15461; D10313; EN300-7393259; J-504029; Q27077223; (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-(hydroxymethyl)-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (1S,5S)-1-(Hydroxymethyl)-5-[3-(4-ethoxybenzyl)-4-chlorophenyl]-6,8-dioxabicyclo[3.2.1]octane-2beta,3alpha,4beta-triol	Approved	Approved Drug(s)	44814423	DB11827	D0Q3VE	436.9	109	586	1.7	30	4	7	6	C22H25ClO7	(1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@@]34[C@@H]([C@H]([C@@H]([C@@](O3)(CO4)CO)O)O)O)Cl	InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1	MCIACXAZCBVDEE-CUUWFGFTSA-N
DI6HN2	Cevimeline	Small molecule	Cevimeline; 107233-08-9; 1035535-90-0; cevimeline trans-sulfoxide; BIDD:GT0265; SCHEMBL188381; CHEMBL1201267; DTXSID2023777; DTXSID401338115; AKOS025294043; CS-0397; AS-56166; HY-70020; D07667; EN300-814007; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]; cis-2-Methyl-1'-azaspiro[[1,3]oxathiolane-5,3'-bicyclo[2.2.2]octane]; (2'R,3R)-2'-Methylspiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane]; (2R,5'R)-5'-methyl-4-azaspiro[bicyclo[2.2.2]octane-2,2'-[1,4]oxathiolane]; (3R,2'R)-2'-Methylspiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane]	Approved	Approved Drug(s)	83898	DB00185	D0Q4CS	199.32	37.8	215	1.5	13	0	3	0	C10H17NOS	(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]	CC1OC2(CN3CCC2CC3)CS1	C[C@@H]1O[C@]2(CN3CCC2CC3)CS1	InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1	WUTYZMFRCNBCHQ-PSASIEDQSA-N
DB6WX2	Deferasirox	Small molecule	Deferasirox; 201530-41-8; Exjade; ICL 670; ICL670A; ICL-670A; ICL 670A; ICL670; ICL-670; Deferasiroxum; Deferasiroxum [INN-Latin]; Jadenu; 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid; Osveral; Jadenu Sprinkle; 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; 4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid; CGP-72670; Deferasirox (Exjade); CHEBI:49005; 1044764-54-6; V8G4MOF2V9; DTXSID1048596; Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-; NCGC00181754-01; Benzoic acid, 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)-; DTXCID1028522; 4-[bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; 4-{3,5-bis[(1E)-6-oxocyclohexa-2,4-dien-1-ylidene]-1,2,4-triazolidin-1-yl}benzoic acid; SMR002544689; CAS-201530-41-8; UNII-V8G4MOF2V9; Deferasirox [USAN:INN:JAN]; HSDB 7844; 4-(3,5-Bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid; 4-[3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid; Deferasirox [INN]; Exjade (TN); Jadenu (TN); Deferasirox, ICL670; DEFERASIROX [MI]; DEFERASIROX [JAN]; DEFERASIROX [HSDB]; DEFERASIROX [USAN]; DEFERASIROX [VANDF]; 4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid; DEFERASIROX [MART.]; SCHEMBL61756; SCHEMBL62042; DEFERASIROX [USP-RS]; DEFERASIROX [WHO-DD]; MLS003915634; MLS006010080; Deferasirox (JAN/USAN/INN); DEFERASIROX [EMA EPAR]; CHEMBL550348; SCHEMBL1071867; 4-[3,5-bis(2-hydroxyphenyl); DEFERASIROX [ORANGE BOOK]; DEFERASIROX [EP MONOGRAPH]; HMS3655A04; BCP05341; EX-A4091; Tox21_112926; BDBM50088376; MFCD09751362; MFCD09951804; s1712; AKOS015855839; AKOS015902587; AKOS025312553; Tox21_112926_1; AC-8972; BCP9000594; CCG-268337; CS-0901; DB01609; KE-0220; SB18926; NCGC00263572-01; HY-17359; Deferasirox 100 microg/mL in Acetonitrile; D5905; FT-0601564; FT-0665569; SW219752-1; D03669; AB01565800_02; A814288; EN300-26907573; SR-01000931971; J-013060; Q5251502; SR-01000931971-2; F0001-2380; Z3041510169; 4-[3,5-Bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; 4-(3,5-Bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoicacid; 4-((3E,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid; 4-[(3Z,5E)-3,5-Bis(6-Oxo-2,4-cyclohexadien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid, AldrichCPR; 4-[(3z,5e)-3,5-bis(6-oxocyclohexa-2,4-dien-1ylidene)-1,2,4-triazolidin-1-yl] benzoic acid; 4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; CGP-72670; ICL-670; ICL-670A; JBL	Approved	Approved Drug(s)	214348	DB01609	D0Q5UQ	373.4	109	540	3.8	28	3	6	4	C21H15N3O4	4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid	C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O	C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O	InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)	BOFQWVMAQOTZIW-UHFFFAOYSA-N
DHVG05	Succinylcholine	Small molecule	succinylcholine; Suxamethonium; Succinyldicholine; Succinocholine; Succinoylcholine; Dicholine succinate; Succinylbischoline; 306-40-1; Quelicin; Anectine; Ditilin; suxamethonium chloride; Ditiline; Sucostrin; Suxamethonium ion; 2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM); Succinylcholine ion; Suxamethonium cation; Scoline; Succinylcholine cation; CHEBI:45652; CHEMBL703; trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium; J2R869A8YF; Diacetylcholine; Succinyl choline; Ethanaminium, 2,2'-((1,4-dioxo-1,4-butanediyl)bis(oxy))bis(N,N,N-trimethyl-; Choline, succinyl-; Choline, succinate (ester); Succinic acid, diester with choline; trimethyl[2-({4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl}oxy)ethyl]azanium; Choline, succinate (2:1) (ester); HSDB 3254; BRN 1805311; UNII-J2R869A8YF; .Succinylcholin; diester with choline; succinylcholine-chloride; 2ha2; 2ha6; Lopac-S-8251; Epitope ID:116045; Lopac0_001080; SCHEMBL41537; 4-04-00-01451 (Beilstein Handbook Reference); MLS001183716; SUCCINYLCHOLINE [HSDB]; SUCCINYLCHOLINE [VANDF]; SUXAMETHONIUM [WHO-DD]; GTPL4004; DTXSID7048455; AXOIZCJOOAYSMI-UHFFFAOYSA-; HMS2090P14; BDBM50061568; STK177290; AKOS022084126; CCG-205157; DB00202; ETHANAMINIUM,2,2'-[(1,4-DIOXO-1,4-BUTANEDIYL)BIS(OXY)]BIS[N,N,N-TRIMETHYL-; trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio; NCGC00015971-01; NCGC00015971-02; NCGC00015971-03; NCGC00015971-04; NCGC00015971-07; NCGC00162336-01; SMR000677912; C07546; AB00375912-06; L000926; Q424378; 2,2''-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)	Approved	Approved Drug(s)	5314	DB00202	D0Q7ZQ	290.4	52.6	284	0.6	20	0	4	11	C14H30N2O4+2	trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2	AXOIZCJOOAYSMI-UHFFFAOYSA-N
DF4BY5	Tiludronic acid	Small molecule	Tiludronic Acid; Tiludronate; 89987-06-4; Skelid; Tiludronicacid; Acide tiludronique [INN-French]; Acido tiludronico [INN-Spanish]; Acidum tiludronicum [INN-Latin]; SR-41319; [(4-chlorophenyl)sulfanyl-phosphonomethyl]phosphonic acid; SR 41319; 6PNS59HP4Y; CHEBI:9598; Tiludronic acid (INN); Acide tiludronique; Acidum tiludronicum; TILUDRONIC ACID [INN]; {[(4-chlorophenyl)sulfanyl](phosphono)methyl}phosphonic acid; Acido tiludronico; Tiludronic acid [INN:BAN]; UNII-6PNS59HP4Y; CIPsMBP; (4-Chlorophenylthio)methylenediphosphonic acid; C08141; TILUDRONATE [VANDF]; CHEMBL1350; SCHEMBL18988; TILUDRONIC ACID [MI]; (((p-Chlorophenyl)thio)methylene)diphosphonic acid; BIDD:GT0814; GTPL7604; TILUDRONIC ACID [MART.]; Tiludronate disodium salt hydrate; DTXSID10237966; TILUDRONIC ACID [WHO-DD]; HY-A0213; BDBM50442524; DB01133; CS-0017560; FT-0630969; D08599; EN300-18567910; Q2823312; BRD-K10845183-382-01-2	Approved	Approved Drug(s)	60937	DB01133	D0Q8CS	318.61	140	324	-0.3	17	4	7	4	C7H9ClO6P2S	[(4-chlorophenyl)sulfanyl-phosphonomethyl]phosphonic acid	C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl	C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl	InChI=1S/C7H9ClO6P2S/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14/h1-4,7H,(H2,9,10,11)(H2,12,13,14)	DKJJVAGXPKPDRL-UHFFFAOYSA-N
DB1Z2F	Neratinib	Small molecule	Neratinib; 698387-09-6; HKI-272; Neratinib (HKI-272); Nerlynx; HKI 272; PB-272; JJH94R3PWB; (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide; (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; CHEMBL180022; CDP-820; 698387-09-6 (free base); HKI272; WAY-179272; (2E)-N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; (E)-N-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; 876310-02-0; N-(4-(3-Chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide; (2e)-n-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-; Neratinib [USAN]; Neratinib(HKI-272); Neratinib [USAN:INN]; UNII-JJH94R3PWB; Neratinib- Bio-X; (2E)-N-[4-({3-chloro-4-[(pyridin-2-yl)methoxy]phenyl}amino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide; PB 272; NERATINIB [INN]; NERATINIB [MI]; Neratinib (USAN/INN); Neratinib - HKI-272; NERATINIB [MART.]; NERATINIB [WHO-DD]; SCHEMBL571762; SCHEMBL571763; GTPL5686; CHEBI:61397; AMY9255; DTXSID70220132; EX-A062; BCPP000151; BDBM50161957; MFCD09752958; NSC757439; NSC800803; s2150; WAY-179272-B; AKOS005146340; AKOS025149637; BCP9000984; CCG-270036; DB11828; NSC-757439; NSC-800803; NCGC00241101-01; NCGC00241101-03; NCGC00241101-09; AC-25073; AS-16279; BN164645; HY-32721; N1062; EC-000.2260; A25338; D08950; EN300-7386009; Q-101402; Q6995920; BRD-K85606544-001-01-8; (2e)-n-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide                                              neratinib; (2E)-N-[4-[[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide; (E)-4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide; 4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide; HKI-272; PB272;;(2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;HKI-272; N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)butanamide	Approved	Approved Drug(s)	9915743	DB11828	D0Q9CY	557	112	881	4.9	40	2	8	11	C30H29ClN6O3	(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide	CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C	CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C	InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+	JWNPDZNEKVCWMY-VQHVLOKHSA-N
DNH3P5	Insulin detemir	Small molecule	Insulin detemir; 169148-63-4; NN-304; Levemir; Levemir Flexpen; Levemir Innolet; Levemir Insulin; Levemir Penfill; UNII-4FT78T86XV; Detemir; Insulin detemir [USAN:INN:BAN]; NN304; NN 304; Insulin,detemir,human; 4FT78T86XV; CHEMBL2104391; INSULIN DETEMIR RECOMBINANT; 29B-(N6-Myristoyl-L-lysine)-30B-de-L-threonineinsulin (human); 29(sup B)-(N(sup 6)-Myristoyl-L-lysine)-30(sup B)-de-L-threonineinsulin (human); 29(sup B)-(N(sup 6)-(1-Oxotetradecyl)-L-lysine)-(1(sup A)-21(sup A)),(1(sup B)-29(sup B))-insulin (human)	Approved	Approved Drug(s)	16137271	DB01307	D0QE5U	5917	2400	14700	-3.5	413	76	87	189	C267H402N64O76S6	(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-6-(tetradecanoylamino)hexanoic acid	CCCCCCCCCCCCCC(=O)NCCCCC(C(=O)O)NC(=O)C1CCCN1C(=O)C(C(C)O)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC4=CC=CC=C4)NC(=O)CNC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C5CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C6CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N5)C(C)C)CC(C)C)CC7=CC=C(C=C7)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC8=CNC=N8)CO)NC(=O)C(CC(C)C)NC(=O)C(CC9=CNC=N9)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC1=CC=CC=C1)N)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N6)C(C)CC)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN)CO)CC(C)C)CC1=CC=C(C=C1)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC1=CC=C(C=C1)O)C(=O)NC(CC(=O)N)C(=O)O	CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]5CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)C(C)C)CC(C)C)CC7=CC=C(C=C7)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC8=CNC=N8)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC9=CNC=N9)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N6)[C@@H](C)CC)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN)CO)CC(C)C)CC1=CC=C(C=C1)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O	InChI=1S/C267H402N64O76S6/c1-29-32-33-34-35-36-37-38-39-40-50-64-204(347)280-95-52-51-61-170(265(404)405)298-256(395)197-63-54-97-331(197)264(403)220(147(28)336)330-248(387)182(110-154-71-79-160(340)80-72-154)309-240(379)178(106-150-59-48-43-49-60-150)307-237(376)177(105-149-57-46-42-47-58-149)289-207(350)120-282-223(362)162(62-53-96-281-267(276)277)291-227(366)163(84-91-209(352)353)288-206(349)119-283-225(364)192-126-409-410-127-193(252(391)314-187(266(406)407)115-203(275)346)319-241(380)181(109-153-69-77-159(339)78-70-153)308-245(384)185(113-201(273)344)312-231(370)168(86-93-211(356)357)295-233(372)172(99-134(6)7)300-229(368)164(81-88-198(270)341)293-238(377)179(107-151-65-73-157(337)74-66-151)305-235(374)173(100-135(8)9)304-250(389)189(123-333)315-253(392)195-129-412-411-128-194(318-232(371)166(83-90-200(272)343)292-228(367)169(87-94-212(358)359)297-258(397)216(142(22)23)327-262(401)217(143(24)30-2)323-205(348)116-268)254(393)320-196(255(394)329-219(146(27)335)263(402)316-190(124-334)251(390)328-218(144(25)31-3)261(400)322-195)130-413-408-125-191(317-236(375)174(101-136(10)11)301-242(381)183(111-155-117-278-131-285-155)310-230(369)165(82-89-199(271)342)294-244(383)186(114-202(274)345)313-259(398)213(139(16)17)324-222(361)161(269)104-148-55-44-41-45-56-148)224(363)284-121-208(351)290-188(122-332)249(388)311-184(112-156-118-279-132-286-156)243(382)303-176(103-138(14)15)247(386)325-214(140(18)19)257(396)296-167(85-92-210(354)355)226(365)287-145(26)221(360)299-171(98-133(4)5)234(373)306-180(108-152-67-75-158(338)76-68-152)239(378)302-175(102-137(12)13)246(385)326-215(141(20)21)260(399)321-192/h41-49,55-60,65-80,117-118,131-147,161-197,213-220,332-340H,29-40,50-54,61-64,81-116,119-130,268-269H2,1-28H3,(H2,270,341)(H2,271,342)(H2,272,343)(H2,273,344)(H2,274,345)(H2,275,346)(H,278,285)(H,279,286)(H,280,347)(H,282,362)(H,283,364)(H,284,363)(H,287,365)(H,288,349)(H,289,350)(H,290,351)(H,291,366)(H,292,367)(H,293,377)(H,294,383)(H,295,372)(H,296,396)(H,297,397)(H,298,395)(H,299,360)(H,300,368)(H,301,381)(H,302,378)(H,303,382)(H,304,389)(H,305,374)(H,306,373)(H,307,376)(H,308,384)(H,309,379)(H,310,369)(H,311,388)(H,312,370)(H,313,398)(H,314,391)(H,315,392)(H,316,402)(H,317,375)(H,318,371)(H,319,380)(H,320,393)(H,321,399)(H,322,400)(H,323,348)(H,324,361)(H,325,386)(H,326,385)(H,327,401)(H,328,390)(H,329,394)(H,330,387)(H,352,353)(H,354,355)(H,356,357)(H,358,359)(H,404,405)(H,406,407)(H4,276,277,281)/t143-,144-,145-,146+,147+,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,213-,214-,215-,216-,217-,218-,219-,220-/m0/s1	UGOZVNFCFYTPAZ-IOXYNQHNSA-N
D6J2VE	Oxcarbazepine	Small molecule	OXCARBAZEPINE; 28721-07-5; Trileptal; Oxcarbamazepine; Oxcarbazepina; Oxcarbazepinum; GP 47680; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide; KIN-493; GP-47680; Oxtellar XR; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; SPN-804; 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo-; MLS000084586; 9-oxo-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide; 5H-Dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10-oxo-; NSC-758693; CHEMBL1068; SMR000048684; CHEBI:7824; VZI5B1W380; DTXSID0045703; Timox; NCGC00065934-02; Oxcarbazepine [INN]; Oxcarbazepinum [INN-Latin]; Oxcarbazepina [INN-Spanish]; DTXCID8025703; Oxcarbazepime; Epilexter; Epliga; Trileptal (TN); CAS-28721-07-5; SR-01000612612; EINECS 249-188-8; UNII-VZI5B1W380; Oxcarbazepin; HSDB 7524; Oxtellar (TN); Oxcarbazepine [USAN:USP:INN:BAN]; MFCD00865307; OCBZ; Oxcarbazepine- Bio-X; Spectrum_001675; Opera_ID_818; regid866068; Spectrum2_000483; Spectrum3_001669; Spectrum4_000634; Spectrum5_001869; O0363; OXCARBAZEPINE [MI]; OXCARBAZEPINE [JAN]; OXCARBAZEPINE [HSDB]; OXCARBAZEPINE [USAN]; SCHEMBL35129; BSPBio_003457; KBioGR_001248; KBioSS_002155; OXCARBAZEPINE [VANDF]; cid_34312; MLS000759520; MLS001201742; MLS001424025; MLS006011855; BIDD:GT0078; OXCARBAZEPINE [MART.]; SPECTRUM1504243; SPBio_000345; OXCARBAZEPINE [USP-RS]; OXCARBAZEPINE [WHO-DD]; GTPL7254; Oxcarbazepine (JAN/USP/INN); BDBM34179; KBio2_002155; KBio2_004723; KBio2_007291; KBio3_002677; Oxcarbazepine, analytical standard; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; HMS1922H17; HMS2051O04; HMS2090F13; HMS2093E10; HMS2231B12; HMS3369J22; HMS3393O04; HMS3657O11; HMS3713I10; HMS3884K13; Pharmakon1600-01504243; OXCARBAZEPINE [ORANGE BOOK]; BCP28260; BCP33398; HY-B0114; OXCARBAZEPINE [EP MONOGRAPH]; Tox21_110983; CCG-39509; NSC758693; OXCARBAZEPINE [USP MONOGRAPH]; s1391; STK594696; AKOS005516529; Tox21_110983_1; AC-3483; CS-1869; DB00776; KS-5197; NC00088; NSC 758693; Oxcarbazepine, >=98% (HPLC), solid; NCGC00065934-03; NCGC00065934-04; NCGC00065934-05; NCGC00065934-06; BO164187; SBI-0206772.P001; GP-47-680; AM20040094; FT-0630543; FT-0673414; SW197468-3; A13943; C07492; D00533; EN300-123538; M06310; AB00393017-12; AB00393017-14; AB00393017_15; AB00393017_16; Q176301; SR-01000612612-4; SR-01000612612-6; W-107033; BRD-K04196797-001-12-9; Z1551967555; 10-oxo-10,11-dihydro-5H-dibenz(b,f)azepin-5-carboxamide; 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepin-5-carbonsaeureamid; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide #; Oxcarbazepine, European Pharmacopoeia (EP) Reference Standard; 10,11-Dihydro-10-oxo-5H-dibenzo(Z)[b,f]azepine-5-carboxamide; Oxcarbazepine, United States Pharmacopeia (USP) Reference Standard; 10-Oxo carbazepine; Oxecarb; 10,11-Dihdyro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; 9-oxo-2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxamide; Oxcarbazepine, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	34312	DB00776	D0QL3P	252.27	63.4	382	1.7	19	1	2	0	C15H12N2O2	5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide	C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N	C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N	InChI=1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)	CTRLABGOLIVAIY-UHFFFAOYSA-N
DE17HC	Nitrofurantoin	Small molecule	nitrofurantoin; 67-20-9; Macrodantin; Furadantin; 5-Nitrofurantoin; Furadonine; Furadantine; Furadantoin; Furadoine; Furadontin; Furantoin; Nifurantin; Furalan; Nitrofuradantin; Nitrofurantoine; Berkfurin; Chemiofuran; Furachel; Furadonin; Furatoin; Furobactina; Macrobid; Novofuran; Orafuran; Parfuran; Trantoin; Urantoin; Urofurin; Welfurin; Zoofurin; Cyantin; Cystit; Furina; Ituran; Nitoin; Urizept; Urodin; Urolong; Furadantine mc; Uro-Tablinen; Fur-ren; Macrofuran; Nitrofurantoina; Benkfuran; Dantafur; Furaloid; Nierofu; Macpac; Nitrex; Nitrofurantoinum; Fua Med; N-Toin; Usaf ea-2; 1-(5-Nitro-2-furfurylideneamino)hydantoin; 1-[(5-Nitrofurfurylidene)amino]hydantoin; N-(5-Nitrofurfurylidene)-1-aminohydantoin; NITROFURANTOIN, MACROCRYSTALLINE; 1-((5-Nitrofurfurylidene)amino)hydantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; Nitrofurantoin anhydrous; NCI-C55196; NSC 2107; NITROFURANTOIN MACROCRYSTALLINE; NSC 44150; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; NSC-2107; Furadoninum; Nitrofurantoin macrocrystal; 1-(((5-Nitrofuran-2-yl)methylene)amino)imidazolidine-2,4-dione; 2,4-Imidazolidinedione, 1-[[(5-nitro-2-furanyl)methylene]amino]-; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; Nitrofurantoin, macrocrystals; MLS000028500; Cistofuran; Macrodantina; Macrofurin; Nifuretten; Alfuran; Berkfuran; Ceduran; Furabid; Furedan; Gerofuran; Phenurin; Siraliden; Uerineks; Urofuran; Urolisa; CHEBI:71415; Hydantoin, 1-((5-nitrofurfurylidene)amino)-; PiyEloseptyl; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; Furadantina MC; Furadantine-MC; 2,4-Imidazolidinedione, 1-(((5-nitro-2-furanyl)methylene)amino)-; Furophen T; Nitrofur-C; Ro-Antoin; Furadantin Retard; Uro-Selz; Ivadantin; 927AH8112L; NCGC00091505-01; NCGC00091505-07; SMR000058271; 1-(((5-Nitrofuran-2-yl)methylene)-amino)imidazolidine-2,4-dione; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; Nitrofurantoina [DCIT]; 178170-37-1; DTXCID90972; Nitrofurantoine [INN-French]; Nitrofurantoinum [INN-Latin]; Furodantin; 1-((5-nitro-2-furanyl)methylene)amino-2,4-imidazolidenedione; Fuamed; 1-{[(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; 1-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; NSC-44150; Furadantin (TN); Macrobid (TN); CCRIS 1192; 1516934-90-9; Hydantoin, 1-[(5-nitrofurfurylidene)amino]-; HSDB 3135; SR-05000001681; EINECS 200-646-5; DTXSID7020972; NSC2107; Furantoina; Furadoin; Uvamin; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; NSC44150; AI3-26388; (E)-1-(((5-Nitrofuran-2-yl)methylene)amino)imidazolidine-2,4-dione; Nitrofurantoin (JAN/USP/INN); UNII-927AH8112L; Furophen T-Caps; CAS-67-20-9; Prestwick_358; Nitrofurantoin Macro; 5-Nitrofurantoindorn; J01XE01; Nitrofurantoin [USP:INN:BAN:JAN]; MFCD00003224; ND-3320; ND-7248; Nitrofurantoin, 97%; Nitrofurantoinum anhydrous; Prestwick2_000168; Prestwick3_000168; Spectrum5_001367; Nitrofurantoin, crystalline; CHEMBL572; NITROFURANTOIN [MI]; Nitrofurantoin Macrocrystals; cid_4509; NITROFURANTOIN [INN]; NITROFURANTOIN [JAN]; SCHEMBL29470; SCHEMBL29472; BSPBio_000035; BSPBio_002073; NITROFURANTOIN [HSDB]; NITROFURANTOIN [IARC]; BIDD:GT0181; NITROFURANTOIN [VANDF]; SPECTRUM1500433; NITROFURANTOIN [MART.]; BPBio1_000039; NITROFURANTOIN [USP-RS]; NITROFURANTOIN [WHO-DD]; BDBM57045; CHEBI:95222; HMS500L06; HMS1568B17; HMS1920P21; HMS2091H16; HMS2095B17; HMS3712B17; Pharmakon1600-01500433; NITROFURANTOIN [GREEN BOOK]; 1-[(E)-(5-nitro-2-furyl)methyleneamino]imidazolidine-2,4-dione; HY-A0090; NITROFURANTOIN [ORANGE BOOK]; Tox21_111142; Tox21_201924; Tox21_300602; 2,4-Imidazolidenedione, 1-(((5-nitro-2-furanyl)methylene)amino)-; CCG-40108; NITROFURANTOIN [EP MONOGRAPH]; NSC757243; s4536; STK009471; STL454163; NITROFURANTOIN [USP MONOGRAPH]; AKOS001678301; Tox21_111142_1; DB00698; NSC-757243; IDI1_000224; MACROBID COMPONENT NITROFURANTOIN; NCGC00091505-03; NCGC00091505-04; NCGC00091505-05; NCGC00091505-06; NCGC00091505-08; NCGC00091505-09; NCGC00091505-10; NCGC00254547-01; NCGC00259473-01; NITROFURANTOIN ANHYDROUS [WHO-IP]; LS-13402; 1-((5-nitrofurfurylidene)amino)-hydantoin; NITROFURANTOIN COMPONENT OF MACROBID; SBI-0051457.P003; AB00513815; BB 0310231; N0883; NITROFURANTOIN MACROCRYSTALLINE [VANDF]; A16008; C07268; D00439; AB00052052_03; EN300-7466667; NITROFURANTOINUM ANHYDROUS [WHO-IP LATIN]; A835659; EN300-18241497; Hydantoin, n-(5-nitro-2-furfurylidene)-1-amino-; Nitrofurantoin, VETRANAL(TM), analytical standard; Q-201479; SR-05000001681-1; SR-05000001681-2; SR-05000001681-3; SR-05000001681-4; BRD-K76927775-001-05-0; Nitrofurantoin, Antibiotic for Culture Media Use Only; Z57152561; Hydantoin, 1-[(5-nitrofurfurylidene)amino]- (7CI,8CI); MACROBID COMPONENT NITROFURANTOIN, MACROCRYSTALLINE; 1-{[(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; NITROFURANTOIN, MACROCRYSTALLINE COMPONENT OF MACROBID; (E)-1-[(5-nitro-2-furyl)methylideneamino]imidazolidine-2,4-dione; 1-([(5-Nitro-2-furyl)methylidene]amino)-2,4-imidazolidinedione #; 1-[(E)-(5-nitro-2-furanyl)methylideneamino]imidazolidine-2,4-dione; Nitrofurantoin, United States Pharmacopeia (USP) Reference Standard; 1-[(E)-[(5-nitrofuran-2-yl)methylidene]amino]imidazolidine-2,4-dione; 1-{[(E)-1-(5-nitro-2-furyl)methylidene]amino}-1H-imidazole-2,4(3H,5H)-dione; 4-hydroxy-1-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}-1,5-dihydro-2H-imidazol-2-one; N-(5-Nitro-2-furfurylidine)-1-aminohydantoin; N-(5-Nitrofurfurylidene)-1aminohydantoin; Nitrofurantoin, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	6604200	DB00698	D0R0BX	238.16	121	390	-0.5	17	1	6	2	C8H6N4O5	1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione	C1C(=O)NC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-]	C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]	InChI=1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+	NXFQHRVNIOXGAQ-YCRREMRBSA-N
D5LUR3	Lenvatinib	Small molecule	Lenvatinib; 417716-92-8; E7080; E7080 (Lenvatinib); 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide; Lenvatinib (E7080); E-7080; E 7080; ER-203492-00; Lenvatinib free base; 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide; 4-{3-Chloro-4-[(Cyclopropylcarbamoyl)amino]phenoxy}-7-Methoxyquinoline-6-Carboxamide; UNII-EE083865G2; C21H19ClN4O4; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide; CHEMBL1289601; CHEBI:85994; 417716-92-8 (free base); EE083865G2; 4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide; 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide; Lenvatinib [USAN]; Lenvatinib [USAN:INN]; Kisplyx; 4-(3-CHLORO-4-((CYCLOPROPYLCARBAMOYL)AMINO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE; 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; LEV; Lenvatinib; E7080; LENVATINIB [MI]; Lenvatinib base- Bio-X; LENVATINIB [INN]; Lenvatinib (USAN/INN); LENVATINIB [WHO-DD]; MLS006011239; SCHEMBL864638; GTPL7426; AMY9240; DTXSID50194605; EX-A249; BCPP000247; HMS3244A07; HMS3244A08; HMS3244B07; HMS3654A14; BCP01799; BDBM50331094; MFCD16038644; NSC755980; NSC800781; s1164; AKOS025401742; BCP9000633; CCG-264842; CS-0109; DB09078; NSC-755980; NSC-800781; SB16580; NCGC00263198-01; NCGC00263198-04; NCGC00263198-07; AC-25047; AS-16203; BL164616; HY-10981; SMR004702999; DB-070219; FT-0700727; SW219259-1; D09919; EN300-7418350; A825653; J-513372; Q6523413; BRD-K39974922-001-02-7; Z2235801899; 4-[3-chloranyl-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide; N-(4-((6-CARBAMOYL-7-METHOXYQUINOLIN-4-YL)OXY)-2-CHLOROPHENYL)-N'-CYCLOPROPYLUREA; 4-[3-chloro-4-[[(cyclopropylamino)-oxomethyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide; 6-Quinolinecarboxamide, 4-(3-chloro-4-     (((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-; 6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)- 7-METHOXY-; 6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)-7-METHOXY-	Approved	Approved Drug(s)	9823820	DB09078	D0R0FO	426.9	116	634	2.8	30	3	5	6	C21H19ClN4O4	4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide	COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl	COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl	InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)	WOSKHXYHFSIKNG-UHFFFAOYSA-N
D28PUR	Sunitinib	Small molecule	Sunitinib; 557795-19-4; Sutent; SU11248; SU-11248; 342641-94-5; Sunitinib Base; Su-011248; sunitinibum; N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; SU 11248; (Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Sunitinib (INN); Sunitinib [INN]; N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide; SU011248; CHEMBL535; NSC-750690; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; C22H27FN4O2; CHEBI:38940; NSC750690; Sunitinib, Free base; NSC-736511; V99T50803M; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-; n-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide; (E)-N-[2-(Diethylamono)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indole-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; Sunitinib (free base); Sunitinib [INN:BAN]; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; NCGC00164631-01; MFCD09260778; UNII-V99T50803M; HSDB 7932; (Z)-Sunitinib; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; 5-(5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; N-(2-(DIETHYLAMINO)ETHYL)-5-((Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE; Sutent (free base); KS-5022; SUNITINIB [MI]; 1126641-10-8; SUNITINIB [VANDF]; SCHEMBL8081; SUNITINIB [WHO-DD]; SUNITINIB [EMA EPAR]; BDBM4814; GTPL5713; Sutent, Sunitinib, SU11248; CHEBI:91430; EX-A553; BCPP000057; K00588a; HY-10255A; NSC800937; s7781; AKOS015908193; AKOS025312424; CCG-268638; CS-1670; DB01268; NSC 736511; NSC 750690; NSC-800937; NCGC00164631-02; NCGC00164631-04; BD164426; 1,2,4,5-tetramethylpyrrole-3-carboxamide; AM20090630; D08552; EN300-323230; AB01273976-01; AB01273976-02; AB01273976_04; A822143; A830806; Q417542; SR-00000000005; SR-00000000005-2; Q27163278; Z2568722545; 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylamino-ethyl)-amide; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1 pound not2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2 pound not4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(Diethylamino)ethyl]-5-(2-oxo-5-fluoroindoline-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	Approved	Approved Drug(s)	5329102	DB01268	D0R0MW	398.5	77.2	636	2.6	29	3	4	7	C22H27FN4O2	N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C	CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C	InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-	WINHZLLDWRZWRT-ATVHPVEESA-N
D8I0MG	Sunitinib malate	Small molecule	Sunitinib malate; 341031-54-7; Sutent; SU011248 L-malate salt; Sunitinib malate [USAN]; PHA-290940AD; SU010398; sunitinib L-malate; SU-011248 L-malate salt; LVX8N1UT73; SUNITINIB MALEATE; SU-010398; DTXSID4046492; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate; SU 11248; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate; DTXCID801476195; (2S)-2-hydroxybutanedioic acid; N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide; CAS-341031-54-7; SU 011248; NCGC00164631-01; UNII-LVX8N1UT73; MFCD08282795; PDGF TK antagonist; Sutent (TN); Sunitinib malate- Bio-X; Sutent (TN) (Pfizer); Sunitinib Malate (Sutent); CHEMBL1567; SU 11248 (Malate); SU-11248 L-malate salt; SUNITINIB MALATE [MI]; Sunitinib malate (JAN/USAN); SUNITINIB MALATE [JAN]; SCHEMBL1258610; SCHEMBL1772213; SUNITINIB MALATE [VANDF]; SUNITINIB MALATE [MART.]; PNU-290940AD; SUNITINIB MALATE [WHO-DD]; HMS3261H09; Sunitinib malate, >=98% (HPLC); Tox21_112249; Tox21_500514; NSC736511; s1042; SU-11248J; AKOS005145765; AKOS025149097; Sunitinib Malate (Sunitinib L-Malate); SUNITINIB MALATE [ORANGE BOOK]; Tox21_112249_1; CCG-221818; CS-0177; KS-5023; NCGC00164631-05; NCGC00261199-01; BS164428; HY-10255; AM20090634; SW219407-1; D06402; A822079; J-019449; Q27283213; Sunitinib Malate; 341031-54-7; Sutent; SU-11248; Sunitinib; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide(S)-2-hydroxysuccinate; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-,     (2S)-hydroxybutanedioate (1:1); 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1); 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1); 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, malate salt; N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioate salt	Approved	Approved Drug(s)	6456015	DB01268	D0R0MW	532.6	172	765	.	38	6	9	10	C26H33FN4O7	N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid	CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=O)O	CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C.C([C@@H](C(=O)O)O)C(=O)O	InChI=1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1	LBWFXVZLPYTWQI-IPOVEDGCSA-N
DGW70K	Doravirine	Small molecule	Doravirine; 1338225-97-0; MK-1439; Pifeltro; Doravirine (MK-1439); 3-Chloro-5-((1-((4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benzonitrile; 3-chloro-5-[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile; MK1439; Mk-1439a; 3-Chloro-5-({1-[(4-Methyl-5-Oxo-4,5-Dihydro-1h-1,2,4-Triazol-3-Yl)methyl]-2-Oxo-4-(Trifluoromethyl)-1,2-Dihydropyridin-3-Yl}oxy)benzonitrile; 913P6LK81M; Benzonitrile, 3-chloro-5-((1-((4,5-dihydro-4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl)-1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl)oxy)-; Doravirine [USAN]; Doravirine [USAN:INN]; UNII-913P6LK81M; 4ncg; Pifeltro (TN); 2KW; MK 1439; DORAVIRINE [MI]; DORAVIRINE [INN]; DORAVIRINE [JAN]; Doravirine; MK-1439; MK-1439(Doravirine); DORAVIRINE [WHO-DD]; C17H11ClF3N5O3; Doravirine (JAN/USAN/INN); SCHEMBL2509885; CHEMBL2364608; DORAVIRINE [ORANGE BOOK]; DTXSID30158386; AMY16781; BCP02296; EX-A1968; BDBM50508293; DELSTRIGO COMPONENT DORAVIRINE; MFCD22417167; s6492; AKOS030528603; CS-5924; DB12301; SB17104; DORAVIRINE COMPONENT OF DELSTRIGO; NCGC00508866-01; AC-33637; HY-16767; MS-27504; DB-091410; D10624; F53303; A856128; EN300-20050128; Q6885419; 3-chloro-5-[[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-3-pyridyl]oxy]benzonitrile	Approved	Approved Drug(s)	58460047	DB12301	D0R0TS	425.7	98	860	2.1	29	1	8	4	C17H11ClF3N5O3	3-chloro-5-[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile	CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F	CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F	InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)	ZIAOVIPSKUPPQW-UHFFFAOYSA-N
D2G4OW	Vigabatrin	Small molecule	vigabatrin; 4-aminohex-5-enoic acid; 60643-86-9; Sabril; 68506-86-5; 4-Amino-5-hexenoic acid; gamma-Vinyl GABA; Vigabatrine; 5-Hexenoic acid, 4-amino-; gamma-Vinyl-GABA; gamma Vinyl GABA; Vigabatrinum; MDL-71754; 4-Aminohexenoic acid; gamma-Vinyl-gamma-Aminobutyric Acid; RMI-71754; CPP-109; GVG; MDL 71,754; CPP109; (+/-)-Vigabatrin; VINYL GAMMA-AMINOBUTYRIC ACID; GR120KRT6K; (+/-)-gamma-Vinyl GABA; CHEMBL89598; DTXSID4041153; CHEBI:63638; Vigabatrine [French]; Vigabatrinum [Latin]; (+/-)-4-aminohex-5-enoic acid; Vigabatrina [Spanish]; NCGC00016087-06; Vigabatrina; Sabrilex; Sabril (TN); Vigabatrin [USAN:INN:BAN]; RMI-71890; MDL 71754; RMI 71754; 4-aminohex-5-enoic acid/S(+)-Gamma-VIGABATRIN; Hexenoic acid, 4-amino; SR-01000075653; UNII-GR120KRT6K; (+-)-gamma-Vinyl GABA; 4-Amino-hex-5-enoic acid; (+/-)-gamma-Vinyl-GABA; Kigabeq; rac-Vigabatrin; MFCD00274076; (1)-4-Aminohex-5-enoic acid; CPP 109; Vigabatrin [INN]; Prestwick_837; EINECS 270-929-6; MFCD00274577; .gamma.-vinyl GABA; .gamma.-Vinyl-GABA; Spectrum_000368; 4-amino-5-hexenoicacid; SpecPlus_000664; VIGABATRIN [MI]; (y)-gamma-Vinyl GABA; VIGABATRIN [JAN]; Prestwick0_000501; Prestwick1_000501; Prestwick2_000501; Prestwick3_000501; Spectrum3_001825; VIGABATRIN [USAN]; (?)-gamma-Vinyl GABA; VIGABATRIN [VANDF]; Biomol-NT_000247; V 8261; VIGABATRIN [MART.]; VIGABATRIN [USP-RS]; VIGABATRIN [WHO-DD]; Lopac0_001277; M071754; SCHEMBL26714; BSPBio_000421; BSPBio_003469; KBioSS_000848; Vigabatrin (JAN/USP/INN); (A+/-)-gamma-Vinyl GABA; DivK1c_006760; SPECTRUM1502036; (+/-)-?-Vinyl GABA; SPBio_002342; BPBio1_000465; BPBio1_000925; GTPL4821; DTXCID2021153; VIGABATRIN [ORANGE BOOK]; Vinyl .gamma.-aminobutyric Acid; HSDB 8395; KBio1_001704; KBio2_000848; KBio2_003416; KBio2_005984; KBio3_002973; VIGABATRIN, (+/-)-; AMY6474; VIGABATRIN [EP MONOGRAPH]; S(+)-4-AMINOHEXENOICACID; HMS1569F03; HMS2094M21; HMS2096F03; HMS3263P16; VIGABATRIN [USP MONOGRAPH]; BCP16220; Tox21_110301; Tox21_501277; BDBM50118886; HB0868; AKOS015854596; CCG-205350; CS-0791; DB01080; LP01277; SDCCGSBI-0051243.P004; .gamma.-Vinyl-.gamma.-aminobutyric acid; NCGC00016087-03; NCGC00016087-04; NCGC00016087-05; NCGC00016087-07; NCGC00016087-08; NCGC00016087-09; NCGC00016087-11; NCGC00016087-22; NCGC00024802-02; NCGC00024802-03; NCGC00024802-04; NCGC00024802-05; NCGC00024802-06; NCGC00261962-01; AS-11778; HY-15399; SY263247; SBI-0051243.P003; ( inverted question mark)-gamma-Vinyl GABA; CAS-68506-86-5; DB-117820; AB00053309; EU-0101277; FT-0675811; FT-0675812; FT-0700968; gamma-Vinyl GABA; 4-Amino-5-hexenoic acid; C07500; D00535; EN300-245587; AB00053309_04; A853593; Q421663; Q-201924; SR-01000075653-1; SR-01000075653-4; SR-01000075653-6; BRD-A07893380-001-01-6; Z1255431434; Vigabatrin, European Pharmacopoeia (EP) Reference Standard; Vigabatrin, United States Pharmacopeia (USP) Reference Standard	Approved	Approved Drug(s)	5665	DB01080	D0R3QY	129.16	63.3	112	-2.2	9	2	3	4	C6H11NO2	4-aminohex-5-enoic acid	C=CC(CCC(=O)O)N	C=CC(CCC(=O)O)N	InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)	PJDFLNIOAUIZSL-UHFFFAOYSA-N
DJ8NA2	Clofarabine	Small molecule	Clofarabine; 123318-82-1; Clolar; Evoltra; Clofarex; CAFdA; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; C1-F-Ara-A; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; CHEBI:681569; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; (2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; 762RDY0Y2H; DTXSID5046437; 9H-Purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-; (2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; NSC-759857; Clofarabine [USAN]; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; CFB; C10H11ClFN5O3; DTXCID3026437; clofarabina; clofarabinum; Cl-F-araA; MFCD00871077; 2-Chloro-9-(2-Deoxy-2-Fluoro-B -D-Arabinofuranosyl)-9h-Purin-6-Amine; (2R,3R,4S,5R)-5-(6-amino-2-chloro-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; Clolar (TN); CAS-123318-82-1; 2-Cl-2'-F-araA; UNII-762RDY0Y2H; Clofarabine [USAN:INN:BAN]; NCGC00164553-01; CLOFARABINE [MI]; CLOFARABINE [INN]; CLOFARABINE [JAN]; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine; CLOFARABINE [VANDF]; Clofarabine,Clolar, Evoltra; SCHEMBL9040; CHEMBL1750; CLOFARABINE [MART.]; CLOFARABINE [WHO-DD]; MLS003915615; Clofarabine (JAN/USAN/INN); CLOFARABINE [EMA EPAR]; GTPL6802; Clofarabine, >=98% (HPLC); CLOFARABINE [ORANGE BOOK]; HMS2090A07; HMS3413J15; HMS3677J15; ACT05522; BCP23422; HY-A0005; Tox21_112182; AC-274; BDBM50247921; s1218; AKOS005063562; AKOS015919355; Tox21_112182_1; BCP9000540; CCG-264865; CS-0373; DB00631; NSC 759857; SAR-393590; NCGC00164553-02; NCGC00164553-05; AS-12958; SMR002530055; BCP0726000280; SW218080-2; D03546; EN300-123437; AB00430247-03; AB00430247-04; AB00430247_06; SR-01000930565; Q5134875; SR-01000930565-3; Z1551900487; 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-adenine; 2-Chloro-9-(2-deoxy-2-fluoro-?-D-arabinofuranosyl)-9H-purin-6-amine; 9H-Purine-6-amine,2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-; 2-CHLORO-9-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL)-9H-PURIN-6-AMINE; 9H-PURIN-6-AMINE, 2-CHLORO-9-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL); (2R,3R,4S,5R)-5-(6-Amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol 2-chloro-2''-arabino-fluoro-2''-deoxyadenosine	Approved	Approved Drug(s)	119182	DB00631	D0R5RR	303.68	119	370	0.9	20	3	8	2	C10H11ClFN5O3	(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol	C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N	C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N	InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1	WDDPHFBMKLOVOX-AYQXTPAHSA-N
DM7OF6	Fenoldopam	Small molecule	fenoldopam; 67227-56-9; Fenoldopamum [Latin]; Fenoldopamum; SKF 82526; Carlacor; Fenoldopam (INN); 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; INU8H2KAWG; 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; CHEBI:5002; DTXSID0043896; 1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-; NCGC00015444-04; FENOLDOPAM [INN]; Fenoldopam [INN:BAN]; DTXCID8023896; MLS001401388; Carlacor (TN); SK&F-82526; CAS-67227-56-9; SK-82526-J; UNII-INU8H2KAWG; SMR000469190; FENOLDOPAM [MI]; FENOLDOPAM [VANDF]; Biomol-NT_000042; CHEMBL588; C07693; FENOLDOPAM [WHO-DD]; Lopac0_000556; SCHEMBL34250; GTPL939; cid_49659; BPBio1_001265; SCHEMBL13287212; BDBM60917; HMS2090G16; HMS3715H14; HMS3742O09; HY-B0735; Tox21_110152; PDSP1_001661; PDSP2_001645; AKOS015906543; Tox21_110152_1; CCG-204646; DB00800; SDCCGSBI-0050539.P002; NCGC00015444-03; NCGC00015444-05; NCGC00015444-06; NCGC00015444-07; NCGC00015444-17; NCGC00025246-02; NCGC00025246-03; SK-82526; DB-054998; FT-0641107; D07946; EN300-119508; AB00698256-13; AB00698256-15; AB00698256_16; L000254; Q2357007; BRD-A50684349-001-01-5; BRD-A50684349-003-01-1; 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol;mesylic acid; 1092382-99-4; 9-chloranyl-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol;methanesulfonic acid	Approved	Approved Drug(s)	3341	DB00800	D0R6BI	305.75	72.7	348	2.4	21	4	4	1	C16H16ClNO3	9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol	C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O	C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O	InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2	TVURRHSHRRELCG-UHFFFAOYSA-N
D75KGF	Sotorasib	Small molecule	Sotorasib; AMG-510; 2296729-00-3; AMG510; Lumakras; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; Sotorasib [INN]; Sotorasib [USAN]; 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; Kras mutant-targeting AMG 510; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; sotorasibum; Lumykras; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-; PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE, 6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-1-(4-METHYL-2-(1-METHYLETHYL)-3-PYRIDINYL)-4-((2S)-2-METHYL-4-(1-OXO-2-PROPEN-1-YL)-1-PIPERAZINYL)-, (1R)-; Pyrido[2,3-d]pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-, (1R)-; AMG510 racemate; AMG 510 racemate; AMG-510(racemate); SOTORASIB [JAN]; Sotorasib [USAN:INN]; SOTORASIB RACEMATE; UNII-2B2VM6UC8G; SOTORASIB [WHO-DD]; SOTORASIB [ORANGE BOOK]; SCHEMBL20560375; GTPL10678; CHEBI:178199; AMG 510 pound>>AMG-510; DTXSID001099260; GLXC-25372; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; AKOS037649138; DB15569; NSC-818433; AC-35168; BA172505; BA172506; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; D70074; D77975; A930071; A934531; AMG510 ; AMG 510; AMG-510; AMG510; (1R)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; (1RA)-6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-4-((2S)-2-METHYL-4-(1-OXOPROP-2-EN-1-YL)PIPERAZIN-1-YL)-1-(4-METHYL-2-(PROPAN-2-YL)PYRIDIN-3-YL)PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE; 6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-(1M)-1-(4-METHYL-2-(PROPAN-2-YL)PYRIDIN-3-YL)-4-((2S)-2-METHYL-4-(PROP-2-ENOYL)PIPERAZIN-1-YL)PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(2-propanyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl]pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]-1H,2H-pyrido[2,3-d]pyrimidin-2-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one	Approved	Approved Drug(s)	137278711	DB15569	D0R7LD	560.6	102	1030	4	41	1	7	5	C30H30F2N6O3	6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one	CC1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C	C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C	InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1	NXQKSXLFSAEQCZ-SFHVURJKSA-N
DNUW02	Tepotinib	Small molecule	Tepotinib; 1100598-32-0; EMD-1214063; EMD 1214063; Tepotinib [INN]; EMD1214063; MSC2156119; MSC-2156119J; Tepmetko; Tepotinib [USAN]; MSC-2156119; MSC2156119J; 3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile; 1IJV77EI07; Tepotinib(EMD-1214063); Tepotinib (EMD 1214063); 3-(1-(3-(5-((1-methylpiperidin-4-yl)methoxy)pyrimidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo-3-pyridazinyl)-; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; 3-[1-(3-{5-[(1-Methylpiperidin-4-Yl)methoxy]pyrimidin-2-Yl}benzyl)-6-Oxo-1,6-Dihydropyridazin-3-Yl]benzonitrile; UNII-1IJV77EI07; Tepotinib (USAN/INN); Tepotinib [USAN:INN]; TEPOTINIB [WHO-DD]; MLS006010785; GTPL8293; SCHEMBL1296895; CHEMBL3402762; DTXSID70149132; EX-A394; WHO 9934; BDBM50065457; MFCD18452823; NSC758244; NSC781256; NSC800945; s7067; CCG-269632; CS-0647; DB15133; NSC-758244; NSC-781256; NSC-800945; SB16609; compound 22 [PMID: 25736998]; NCGC00345793-01; NCGC00345793-08; AC-35185; AS-16915; HY-14721; SMR004701471; D11717; J-002366; Q27088961; 1100598-30-8; 3-(1-(3-(5-((1-Methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)benzyl)-6-oxo-1,6-dihydro-3-pyridazinyl)benzonitrile; 3-(1-{3-[5-(1-methylpiperidin-4-yl-methoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile; 3-(1-{3-[5-(1-methylpiperidin-4-ylmethoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile; 3-[1,6-Dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]benzonitrile; 3E8	Approved	Approved Drug(s)	25171648	DB15133	D0R8QG	492.6	94.7	880	3.4	37	0	7	7	C29H28N6O2	3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile	CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N	CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N	InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3	AHYMHWXQRWRBKT-UHFFFAOYSA-N
D3TKH0	Galantamine	Small molecule	galanthamine; Galantamine; 357-70-0; (-)-Galanthamine; Lycoremin; Lycoremine; Jilkon; (-)-Galantamine; Razadyne; (+/-)-Galantamine; Razadyne ER; Bodamine; (+/-)-Galanthamine; Galantamina; Reminyl (TN); Galantamine, (+/-)-; Galanthamine, (+/-)-; CHEMBL659; 0D3Q044KCA; Galanthaminum; CHEBI:42944; 1T835Z585R; NSC-100058; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol; 23173-12-8; Galantaminum; Galantaminum [INN-Latin]; GNT; Galantamina [INN-Spanish]; (1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12}.0^{6,17}]heptadeca-6,8,10(17),15-tetraen-14-ol; (1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol; (4aS,6R,8aS)-3-Methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4aH-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol; 6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aR,6S,8aR)-rel-; 6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-; 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-; NSC 100058; BRN 0093736; HSDB 7361; Galantamine (USAN/INN); UNII-0D3Q044KCA; Galantamine [USAN:INN:BAN]; SR-05000001783; 1qti; Galanthamine, 12; Spectrum_001271; 1dx6; GALANTAMINE [MI]; Prestwick0_000588; Prestwick1_000588; Prestwick2_000588; Prestwick3_000588; Spectrum3_001738; Spectrum4_000839; Spectrum5_001673; GALANTAMINE [INN]; GALANTAMINE [HSDB]; GALANTAMINE [USAN]; Probes1_000055; Probes2_000395; GALANTAMINE [VANDF]; SCHEMBL2577; BSPBio_000436; BSPBio_003416; GALANTAMINE [WHO-DD]; KBioGR_001417; KBioSS_001751; 4-27-00-02184 (Beilstein Handbook Reference); BIDD:GT0517; DivK1c_000590; SPBio_002655; BPBio1_000480; GTPL6693; SCHEMBL3293474; UNII-1T835Z585R; ASUTZQLVASHGKV-JDFRZJQESA-; BDBM10404; KBio1_000590; KBio2_001751; KBio2_004319; KBio2_006887; KBio3_002636; NINDS_000590; HMS2089H03; HMS3885C10; Pharmakon1600-01501202; MFCD00867189; NSC759861; s3866; AKOS015965330; AM62710; CCG-212961; CS-1217; DB00674; NSC-759861; SDCCGMLS-0066737.P001; IDI1_000590; SMP1_000131; NCGC00017256-05; NCGC00017256-11; NCGC00017256-17; NCGC00024731-02; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofurol[3a,3,2,-ef][2]benzazepin-6-ol; AC-20240; AC-34328; AS-56354; HY-76299; SBI-0051689.P002; C08526; D04292; EN300-708805; AB00053614-09; AB00053614_10; Q412690; SR-05000001783-4; BRD-K49481516-004-03-5; BRD-K49481516-004-04-3; BRD-K49481516-004-09-2; (1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12}.0^{6,17}]heptadeca-6(17),7,9,15-tetraen-14-ol; (4aS,6R,8aS)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol; 1008759-59-8; 6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4A.ALPHA.,6.BETA.,8AR*)-; 6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aalpha,6beta,8ar*)-; 6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)	Approved	Approved Drug(s)	9651	DB00674	D0R9VR	287.35	41.9	440	1.8	21	1	4	1	C17H21NO3	(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol	CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O	CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O	InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1	ASUTZQLVASHGKV-JDFRZJQESA-N
DBVF87	Mirvetuximab soravtansine	Small molecule	Mirvetuximab soravtansine; huMov 19; UNII-98DE7VN88D; IMGN853; IMGN 853; Mirvetuximab soravtansine [USAN]; mirvetuximab-soravtansine; 98DE7VN88D; IMGN-853; SCHEMBL16447449; 1453084-37-1; Immunoglobulin G1, anti-(human folate receptor alpha) (human-Mus musculus monoclonal M9346A heavy chain), disulfide with human-Mus musculus monoclonal M9346A light chain, dimer, tetraamide with N2'-(4-((3-carboxy-3-sulfopropyl)dithio)-4-methyl-1-oxopentyl)-N2'-deacetylmaytansine; Q27272114	Approved	Approved Drug(s)	91810695	DB12489	D0RP2W	977.6	313	1890	1.8	64	4	16	16	C42H61ClN4O14S3	1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid	CC1C2CC(C(C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)CC(C4(C1O4)C)OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(=O)N)S(=O)(=O)O)C)C)OC)(NC(=O)O2)O	C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(=O)N)S(=O)(=O)O)C)\C)OC)(NC(=O)O2)O	InChI=1S/C42H61ClN4O14S3/c1-23-12-11-13-31(58-10)42(53)22-29(59-39(52)45-42)24(2)36-41(6,61-36)32(21-34(49)47(8)27-19-26(18-23)20-28(57-9)35(27)43)60-38(51)25(3)46(7)33(48)14-16-40(4,5)63-62-17-15-30(37(44)50)64(54,55)56/h11-13,19-20,24-25,29-32,36,53H,14-18,21-22H2,1-10H3,(H2,44,50)(H,45,52)(H,54,55,56)/b13-11+,23-12+/t24-,25+,29+,30?,31-,32+,36+,41+,42+/m1/s1	ZOHXWSHGANNQGO-DSIKUUPMSA-N
D5PVR4	Ipratropium	Small molecule	ipratropium; 60205-81-4; Ipratropium ion; Ipratropium cation; N-Isopropylatropine; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane; [(1S,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; Ipatropium Bromide; SCHEMBL3125; CHEBI:5956; SCHEMBL7862886; CHEMBL1621597; CHEMBL1740585; DTXSID9048437; SCHEMBL19665229; SCHEMBL19665230; BDBM228865; HMS2089K19; US9333195, IPRATROPIUM; BDBM50581210; DB00332; NCGC00022819-04; NCGC00089786-02; C07052; BRD-A47449001-004-13-7; (1S,5R)-3alpha-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-isopropyl-8-azoniabicyclo[3.2.1]octane; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; 8-Azoniabicyclo[3.2.1]octane,3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-,(endo,syn)-	Approved	Approved Drug(s)	657309	DB00332	D0S0AS	332.5	46.5	430	2.6	24	1	3	6	C20H30NO3+	[(1S,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate	CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C	CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C	InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17+,18?,19?,21?	OEXHQOGQTVQTAT-BZQJJPTISA-N
DA6V1P	Maribavir	Small molecule	Maribavir; 176161-24-3; Benzimidavir; livtencity; 1263W94; (2S,3S,4R,5S)-2-(5,6-dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; Camvia; BW-1263W94; GW-257406X; GW-1263; PTB4X93HE1; (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol; 5,6-Dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole; 1263-W-94; GW257406X; G1263; Maribavir [USAN]; UNII-PTB4X93HE1; Maribavir [USAN:INN:BAN]; Camvia(TM); Camvia (TN); BW 1263W94; MARIBAVIR [INN]; Maribavir (USAN/INN); 1263W94;BW1263W94;GW257406X; MARIBAVIR [WHO-DD]; SCHEMBL791309; CHEMBL515408; GTPL12049; DTXSID60170091; BW1263W94; 5,6-Dichloro-2-(isopropylamino)-1-(beta-L-ribofuranosyl)-1H-benzimidazole; AKOS015962194; DB06234; GW 1263; GW 257406X; 5,6-Dichloro-N-(1-methylethyl)-1-beta-L-ribofuranosyl-1H-benzimidazol-2-amine; NCGC00378559-03; AC-22286; AS-49903; HY-16305; VP-41263; D04859; O10059; Q6762512; Maribavir (1263W94, benzimidazole D-ribose derivative); 5,6-Dichloro-2-(isopropylamino)-1-beta-L-ribofuranosylbenzimidazole; 5,6-Dichloro-2-(isopropylamino)-1-(.beta.-L-ribofuranosyl)benzimidazole; 5,6-dichloro-2-isopropylamino-1-(beta-l-ribofuranosyl)-1h-benzimidazole; 1H-BENZIMIDAZOL-2-AMINE, 5,6-DICHLORO-N-(1-METHYLETHYL)-1-.BETA.-L-RIBOFURANOSYL-; 1H-Benzimidazol-2-amine, 5,6-dichloro-N-(1-methylethyl)-1-beta-L-ribofuranosyl-; 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-.BETA.-L-RIBOFURANOSYLBENZIMIDAZOLE; 5,6-DICHLORO-N-(1-METHYLETHYL)-1-.BETA.-L-RIBOFURANOSYL-1H-BENZIMIDAZOL-2-AMINE; (2S,3S,4R,5S)-2-(5,6-Dichloro-2-(isopropylamino)-1H-benzo[d]-imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5S)-2-[5,6-dichloro-2-(isopropylamino)benzimidazol-1-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol	Approved	Approved Drug(s)	471161	DB06234	D0S1QY	376.2	99.8	447	2.2	24	4	6	4	C15H19Cl2N3O4	(2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol	CC(C)NC1=NC2=CC(=C(C=C2N1C3C(C(C(O3)CO)O)O)Cl)Cl	CC(C)NC1=NC2=CC(=C(C=C2N1[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)Cl)Cl	InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)/t11-,12-,13-,14-/m0/s1	KJFBVJALEQWJBS-XUXIUFHCSA-N
D4TL3N	Selegiline	Small molecule	selegiline; L-Deprenalin; Emsam; 14611-51-9; (-)-selegiline; Eldepryl; L-Deprenyl; Zelapar; Jumex; Selegilinum; Selegilina; L-Selegiline; (2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine; Selegilinum [INN-Latin]; Selegilina [INN-Spanish]; CHEMBL972; CHEBI:9086; N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine; Carbex; 2K1V7GP655; Otrasel; (-)-Deprenil; methyl[(2R)-1-phenylpropan-2-yl](prop-2-yn-1-yl)amine; selgene; Anipryl; (-)-(N)-Methyl-N-((1R)-1-methyl-2-phenylethyl)prop-2-yn-1-amine; (R)-N-Methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine; Zalapar; l-E 250; (R)-(-)-Selegiline; Selegene; Selegiline [USAN:INN:BAN]; UNII-2K1V7GP655; (R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine; Emsam (TN); (R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-; SELEGILINE [MI]; SELEGILINE [INN]; Prestwick0_000552; Prestwick1_000552; Prestwick2_000552; Prestwick3_000552; Selegiline (USAN/INN); SELEGILINE [USAN]; SELEGILINE [VANDF]; SELEGILINE [WHO-DD]; SCHEMBL22232; US8633208, Deprenyl; BSPBio_000623; BSPBio_001589; SPBio_002544; BPBio1_000687; GTPL6639; DTXSID6023575; SELEGILINE [ORANGE BOOK]; BDBM15579; Benzeneethanamine, N,alpha-methyl-N-2-propynyl-, (alphaR)-; HMS1791P11; HMS1989P11; HMS2089D09; HMS3402P11; STK640578; AKOS000281115; DB01037; NCGC00024994-01; NCGC00024994-02; NCGC00024994-03; NCGC00024994-04; C07245; D03731; EN300-4271449; (r)-(-)-n,2-dimethyl-n-2-propynylphenethylamine; BRD-K86434416-001-02-7; BRD-K86434416-003-03-1; BRD-K86434416-003-06-4; Q47495783; methyl[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-ylamine; N-methyl-N-[(1R)-1-methyl-2-phenylethyl]prop-2-yn-1-amine; BENZENEETHANAMINE, N,.ALPHA.-METHYL-N-2-PROPYNYL-, (.ALPHA.R)-; 102741-42-4	Approved	Approved Drug(s)	26757	DB01037	D0S2UG	187.28	3.2	195	2.8	14	0	1	4	C13H17N	(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine	CC(CC1=CC=CC=C1)N(C)CC#C	C[C@H](CC1=CC=CC=C1)N(C)CC#C	InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1	MEZLKOACVSPNER-GFCCVEGCSA-N
D1I2NF	Nisoldipine	Small molecule	nisoldipine; 63675-72-9; Sular; Nisocor; Baymycard; Nisoldipin; Zadipina; Bay k 5552; Nisoldipinum; Syscor; 3-Isobutyl 5-methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Nisoldipinum [INN-Latin]; Nisoldipino [INN-Spanish]; Bay-k-5552; BAY-k 5552; Geomatrix 16e; Nisoldipine (stn); CHEBI:76917; 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; NSC-759106; 4I8HAB65SZ; methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; CHEMBL441428; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester; Nisoldipino; DTXSID0023371; Nisoldipine 100 microg/mL in Methanol; NCGC00164633-01; DTXCID403371; 1219795-47-7; 3-methyl 5-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; SMR000466370; CAS-63675-72-9; Sular (TN); SR-05000002009; EINECS 264-407-7; MFCD00478055; UNII-4I8HAB65SZ; BRN 0454188; Nisoldipine (JAN/USAN/INN); Nisoldipine;; Nisoldipine,(S); Nisoldipine [USAN:INN:BAN:JAN]; (+-)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate; Isobutyl 1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3-pyridincarboxylat; Nisoldipine, ~97%; NISOLDIPINE [MI]; NISOLDIPINE [INN]; NISOLDIPINE [JAN]; (.+/-.)-Nisoldipine; NISOLDIPINE [USAN]; NISOLDIPINE [VANDF]; Baymycard, Norvasc, Syscor; CHEMBL1726; NISOLDIPINE [MART.]; SCHEMBL39779; (+/-)-NISOLDIPINE; NISOLDIPINE [USP-RS]; NISOLDIPINE [WHO-DD]; 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2-methylpropyl ester; MLS000759498; MLS001424102; MLS002153943; BIDD:GT0684; GTPL2524; CHEMBL3192341; Nisoldipine, >=98% (HPLC); NISOLDIPINE [ORANGE BOOK]; HMS2051O18; HMS2089K20; HMS2093F15; HMS2097E13; HMS2231L20; HMS3393O18; HMS3651K17; HMS3714E13; HMS3744O19; HMS3884I08; Pharmakon1600-01505390; BCP22696; Tox21_112251; Tox21_302365; AC-987; BBL028683; BDBM50101963; BDBM50227259; DL-255; NSC759106; s1748; STK631543; AKOS005563632; AKOS037515714; Tox21_112251_1; CCG-100894; CCG-213412; CS-1131; DB00401; KS-5188; NC00144; NSC 759106; Bay K 5552;BAY-K 5552;Sular; Isobutyl Methyl 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate; O5-isobutyl O3-methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; NCGC00164633-02; NCGC00164633-03; NCGC00255136-01; 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic Acid Isobutyl Methyl Ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester, (+-)-; 6-BROMO-2,3-DIMETHOXYBENZOICACID; BN164147; HY-17402; (+/-)-BAY-K-5552; SBI-0206830.P001; FT-0601599; N0900; SW219237-1; C07699; D00618; EN300-119517; AB01275444-01; AB01275444_02; A834466; Q3342150; SR-05000002009-1; SR-05000002009-2; SR-05000002009-3; BRD-A84465106-001-01-2; Z277942268; 3-Isobutyl5-methyl2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; isobutyl methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (.+/-.)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(2-NITROPHENYL)-, 3-METHYL 5-(2-METHYLPROPYL) ESTER; 3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(2-NITROPHENYL)-, METHYL 2-METHYLPROPYL ESTER, (+/-)-; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester, (.+/-.)-; 3-Isobutyl 5-methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate #; METHYL 2-METHYLPROPYL-1,4-DIHYDRO-2,6-DIMETHYL-4-(2-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE, DL-; O5-isobutyl O3-methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;Nisoldipine; O5-methyl O3-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate	Approved	Approved Drug(s)	4499	DB00401	D0S5CU	388.4	110	704	3.3	28	1	7	7	C20H24N2O6	3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate	CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC	CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC	InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3	VKQFCGNPDRICFG-UHFFFAOYSA-N
D2TDX9	Copanlisib	Small molecule	Copanlisib; 1032568-63-0; BAY 80-6946; BAY-80-6946; Aliqopa; BAY80-6946; WI6V529FZ9; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide; Copanlisib (BAY 80-6946); 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide; 2-Amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazolin-5-yl]-5-pyrimidinecarboxamide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide; Copanlisib [INN]; BAY 80-6946 (Copanlisib); copanlisibum; UNII-WI6V529FZ9; 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDE; Copanlisib tris-HCl; COPANLISIB [MI]; Copanlisib (USAN/INN); Copanlisib [USAN:INN]; COPANLISIB [USAN]; COPANLISIB [WHO-DD]; Copanlisib(BAY80-6946); GTPL7875; SCHEMBL1655478; BAY 80-6946; Copanlisib; BAY-80-6946 tris-HCl; Copanlisib; BAY-80-6946; CHEMBL3218576; SCHEMBL13084037; DTXSID00145728; CHEBI:173077; BCP04754; EX-A2005; BDBM50204093; MFCD18633201; NSC760443; NSC800076; NSC809693; NSC816437; s2802; AKOS025290222; BAY-806946; CS-0741; DB12483; NSC-760443; NSC-800076; NSC-809693; NSC-816437; PB22956; VS-0128; NCGC00346457-01; NCGC00346457-02; NCGC00346457-04; 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide; AC-28438; BAY 80-6946?; BC164810; HY-15346; D10867; Q19903876; 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1.2-c]quinazolin-5-yl]pyrimidine-5-carboxamide; 2-amino-N-{7-methoxy-8-[3-(morpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide; 5-PYRIMIDINECARBOXAMIDE, 2-AMINO-N-(2,3-DIHYDRO-7-METHOXY-8-(3-(4-MORPHOLINYL)PROPOXY)IMIDAZO(1,2-C)QUINAZOLIN-5-YL)-	Approved	Approved Drug(s)	135565596	DB12483	D0S5LD	480.5	140	974	0.3	35	2	9	7	C23H28N8O4	2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide	COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5	COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5	InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27)	MWYDSXOGIBMAET-UHFFFAOYSA-N
D0JEC6	Macitentan	Small molecule	Macitentan; 441798-33-0; Opsumit; ACT-064992; ACT 064992; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; ACT064992; Z9K9Y9WMVL; 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine; N-(5-(4-Bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-N'-propylsulfamide; CHEBI:76607; Macitentan (Actelion-1,ACT-064992); Actelion-1; {[5-(4-BROMOPHENYL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]SULFAMOYL}(PROPYL)AMINE; Macitentan [INN]; N-(5-(4-Bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)-N'-propylsulfamide; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'- propylsulfamide; Macitentan [USAN:INN]; UNII-Z9K9Y9WMVL; macitentanum; SULFAMIDE, N-(5-(4-BROMOPHENYL)-6-(2-((5-BROMO-2-PYRIMIDINYL)OXY)ETHOXY)-4-PYRIMIDINYL)-N'-PROPYL-; Sulfamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propyl-; Macitentan- Bio-X; Opsumit (TN); MACITENTAN [MI]; MACITENTAN [JAN]; Macitentan (JAN/USAN); MACITENTAN [USAN]; MACITENTAN [VANDF]; (non-labelled)Macitentan-d7; MACITENTAN [WHO-DD]; MLS006011174; GTPL7352; SCHEMBL1445625; CHEMBL2103873; MACITENTAN [ORANGE BOOK]; DTXSID50196063; EX-A544; HMS3653N06; HMS3747E09; cas:441798-33-0;Macitentan; BCP05309; BDBM50395626; MFCD17167076; s8051; AKOS024463406; AM81244; CCG-270155; CS-0686; DB08932; SB14841; NCGC00346456-01; NCGC00346456-05; AC-30102; AS-74590; BM162771; HY-14184; n-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-n'-propylaminosulfonamide; SMR004702943; DB-070519; FT-0696675; SW219473-1; ACT 064992; ACT-064992; D10135; EN300-7404089; Q6724151; N-(5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXI)ETHOXY)PYRIMIDIN-4-YL)-N'-PROPYLSULFURIC DIAMIDE; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)-oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; n-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-n'-propyl-sulfamide; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'-propylsulfuric diamide	Approved	Approved Drug(s)	16004692	DB08932	D0S7JH	588.3	137	642	3.7	32	2	10	11	C19H20Br2N6O4S	5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine	CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br	CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br	InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)	JGCMEBMXRHSZKX-UHFFFAOYSA-N
D5LHS2	Flibanserin	Small molecule	Flibanserin; 167933-07-5; Bimt-17; Bimt 17; Addyi; Ectris; Girosa; Filbanserin.; BIMT 17 BS; BIMT-17-BS; 1-(2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)-1H-benzo[d]imidazol-2(3H)-one; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 37JK4STR6Z; Female Viagra [Street Name]; 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one; 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-; 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one; Female Viagra (Street Name); Flibanserin [USAN]; 1,3-Dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one; Flibanserin [USAN:INN]; UNII-37JK4STR6Z; Addyi (TN); FLIBANSERIN [MI]; FLIBANSERIN [INN]; Flibanserin (USAN/INN); BIMT 17BS; BIMT-17BS; 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; FLIBANSERIN [MART.]; FLIBANSERIN [WHO-DD]; Girosa (proposed trade name); SCHEMBL247579; CHEMBL231068; GTPL8182; CHEBI:90865; HSDB 8278; FLIBANSERIN [ORANGE BOOK]; HMS3885K21; BCP02131; EX-A2807; HY-A0095; BDBM50476735; MFCD00918402; s3716; AKOS005146139; Flibanserin; BIMT-17; BIMT-17BS; AM84577; CCG-268528; CS-4671; DB04908; 1-(2-(4-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; NCGC00386567-01; NCGC00386567-02; NCGC00386567-03; F1239; FT-0659246; D02577; A810922; EN300-18167232; L001463; Q415996; 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-(piperazinyl)ethyl)-2-benzimidazolinone; 1-[2-[4-(3-trifluoromethylphenyl)piperazin-1-yl]ethyl]benzimidazol-[1H]-2-one; 3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-1H-benzimidazol-2-one; 1-(2-(4-(.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)-1-PIPERAZINYL)ETHYL)-2-BENZIMIDAZOLINONE; 1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-2,3-dihydro-1H-1,3-benzodiazol-2-one	Approved	Approved Drug(s)	6918248	DB04908	D0S9CB	390.4	38.8	550	3.3	28	1	6	4	C20H21F3N4O	3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one	C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F	C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F	InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)	PPRRDFIXUUSXRA-UHFFFAOYSA-N
DQ19JW	Clobazam	Small molecule	Clobazam; Frisium; Urbanyl; Chlorepin; Clorepin; Urbadan; 22316-47-8; Onfi; LM-2717; HR 376; Clobazamum; Mystan; LM 2717; H-4723; RU-4723; H 4723; 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione; HR-376; 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione; NSC 336279; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine; CHEBI:31413; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione; NSC-336279; 2MRO291B4U; DTXSID2046759; NSC336279; NCGC00168249-01; Caastilium; Noiafren; Urbanil; Odipam; Clobazamum [INN-Latin]; Clobazepam; 7-Chloro-1-methyl-5-phenyl-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione; 7-chloro-1-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-2,4-dione; Mystan (TN); CCRIS 7506; EINECS 244-908-7; BRN 0758410; UNII-2MRO291B4U; Clobazam (JAN/USAN/INN); Clobazam [USAN:INN:BAN]; Colbazam; Perizam; Tapclob; Urbanol; DEA No. 2751; SYMPAZAN; Onfi (TN); CLOBAZAM [USAN]; CLOBAZAM [INN]; CLOBAZAM [JAN]; CLOBAZAM [MI]; CLOBAZAM [VANDF]; COLBAZAM [VANDF]; CLOBAZAM [MART.]; CLOBAZAM [WHO-DD]; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-diketo-3H-1,5-benzodiazepine; SCHEMBL43038; 5-24-08-00034 (Beilstein Handbook Reference); MLS003899217; CHEMBL70418; CLOBAZAM [ORANGE BOOK]; GTPL7149; CLOBAZAM [EP MONOGRAPH]; DTXCID0026759; HSDB 8343; Clobazam 0.1 mg/ml in Methanol; Clobazam 1.0 mg/ml in Methanol; HY-A0041; Tox21_112608; BDBM50247888; AKOS025401921; CS-6756; DB00349; SMR000058811; WLN: T67 GNV JVN IHJ CG G1 KR; CAS-22316-47-8; DB-045870; C-2991; D01253; Q412164; SR-01000937603; SR-01000937603-2; 7-Chloro-1-methyl-5-phenyl-1H-1,4(3H,5H)-dione; 7-Chloro-1-methyl-5-phenyl-1H-1,4-(3H,5H)-dione; 1H-1,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; 7-Chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4(3H)-dione; 1-phenyl 5-methyl 8-chloro 1,2,4,5-tetrahydo 2,4-dioxo 3H-1,5-benzodiazepine; 1-phenyl 5-methyl 8-chloro 1,2,4,5-tetrahydro 2,4-dioxo 3H-1,5-benzodiazepine; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1, 5-benzodiazepine; 1-Phenyl-5-methyl-8-chloro-1,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine	Approved	Approved Drug(s)	2789	DB00349	D0S9MC	300.74	40.6	423	2.1	21	0	2	1	C16H13ClN2O2	7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione	CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3	CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3	InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3	CXOXHMZGEKVPMT-UHFFFAOYSA-N
DDV5R1	Emtricitabine	Small molecule	Emtricitabine; 143491-57-0; Emtriva; Coviracil; (-)-FTC; 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; 143491-54-7; 524W91; BW-524W91; FTC; Racivir; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; BW524W91; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; FTC-(-); BW 524W91; (-)-emtricitabine; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; CHEBI:31536; Emtricitabine, (-)-; PSI-5004; 145213-48-5; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; G70B4ETF4S; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; ULS8902U4O; Emtritabine; DTXSID0040129; BW1592; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; NCGC00164564-01; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, rel-; 524-W-91; PSI 5004; MFCD00870151; Ftc, dl-; Coviracil(TM); DRG-0208; 4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one; rel-4-Amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; Emtriva(TM); 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, rel-; Emtricitabine (Emtriva); SMR002533604; C8H10FN3O3S; BW 1592; 2',3',5-FTC; Emtricitabine, (+/-)-; HSDB 7337; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one; FTC, (-)-; UNII-G70B4ETF4S; Emtricitabine [USAN:INN]; (-)-.beta.-L-FTC; UNII-ULS8902U4O; Emtricitabinum; (+/-)-FTC; 5-Fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 2(1h)-pyrimidinone,4-amino-5-fluoro-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-; 2(1H)-Pyrimidinone,4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-; Emtricitabine- Bio-X; EMTRICITABINE [MI]; CHEMBL885; EMTRICITABINE [INN]; EMTRICITABINE [JAN]; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-; EMTRICITABINE [HSDB]; EMTRICITABINE [USAN]; SCHEMBL39708; EMTRICITABINE [VANDF]; MLS003882429; MLS006011556; MLS006011987; EMTRICITABINE [MART.]; EMTRICITABINE [USP-RS]; EMTRICITABINE [WHO-DD]; EMTRICITABINE [WHO-IP]; DTXCID8020129; EMTRICITABINE [EMA EPAR]; GTPL11244; EX-A150; HMS2089I05; HMS3713L12; EMTRICITABINE [ORANGE BOOK]; Tox21_112193; ((-))-FTC; BDBM50107843; CS1125; FTC-((-)); NSC804863; s1704; ATRIPLA COMPONENT EMTRICITABINE; DESCOVY COMPONENT EMTRICITABINE; EMTRICITABINUM [WHO-IP LATIN]; ODEFSEY COMPONENT EMTRICITABINE; TRUVADA COMPONENT EMTRICITABINE; AKOS015853098; AKOS015894950; EVIPLERA COMPONENT EMTRICITABINE; STRIBILD COMPONENT EMTRICITABINE; AM84393; CCG-220615; CS-1370; DB00879; NSC-804863; 2',3'-Dideoxy-3-thia-5-fluorocytidine; DESCOVY COMPONENT OF EMTRICITABINE; EMTRICITABINE COMPONENT OF ATRIPLA; EMTRICITABINE COMPONENT OF DESCOVY; EMTRICITABINE COMPONENT OF GENVOYA; EMTRICITABINE COMPONENT OF ODEFSEY; EMTRICITABINE COMPONENT OF TRUVADA; NCGC00164564-06; NCGC00164564-09; NCGC00164564-10; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-(+-)-; AS-14099; BE165946; EMTRICITABINE COMPONENT OF EVIPLERA; EMTRICITABINE COMPONENT OF STRIBILD; HY-17427; CAS-143491-57-0; E1007; Emtricitabine 100 microg/mL in Acetonitrile; SW220172-1; D01199; D72669; EN300-119501; ent-Emtricitabine; Emtricitabine IP Impurity D; AB01275429-01; Q422604; W-201247; W-201248; 2',3'-DIDEOXY-5-FLUORO-3'-THIACYTIDINE, DL-; Z1521553474; .beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 5-FLUORO-1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)CYTOSINE (2R,5S); 2(1H)-PYRIMIDINONE, 4-AMINO-5-FLUORO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)-; 4-Amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; (+)-2'-Deoxy-3'-thia-5-fluorocytidine; (2S-cis)-4-Amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone	Approved	Approved Drug(s)	60877	DB00879	D0S9SD	247.25	113	374	-0.6	16	2	5	2	C8H10FN3O3S	4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one	C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F	C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F	InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1	XQSPYNMVSIKCOC-NTSWFWBYSA-N
D1FW4H	Mercaptopurine	Small molecule	6-Mercaptopurine; mercaptopurine; 50-44-2; Purinethol; Mercapurin; 6-Thiopurine; Leukerin; Leupurin; Mercaleukin; 7H-purine-6-thiol; 6-Thioxopurine; Puri-Nethol; Purinethiol; Ismipur; Mern; 6-Thiohypoxanthine; 6-Mercaptopurin; 6-Purinethiol; Purimethol; 9H-Purine-6-thiol; 6-MP; 1,9-dihydro-6H-purine-6-thione; Purine-6-thiol; 3H-Purine-6-thiol; 6 MP; Mercaleukim; 3,7-dihydropurine-6-thione; 1,7-Dihydro-6H-purine-6-thione; Hypoxanthine, thio-; Mercaptopurine (6-MP); Mercaptopurine anhydrous; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Merkaptopuryna; 6H-Purine-6-thione, 1,7-dihydro-; Xaluprine; 6-Merkaptopurin; Purine, 6-mercapto-; 9H-Purine-6(1H)-thione; Purine-6(1H)-thione; NCI-C04886; 7-Mercapto-1,3,4,6-tetrazaindene; 1H-Purine, 6-mercapto-; NSC 755; U-4748; 1,9-dihydropurine-6-thione; Purixan; Mercaptopurine;6-MP; NSC755; NSC-755; Mercaptopurine (INN); 3,7-dihydro-6H-purine-6-thione; Purinethol (TN); PKK6MUZ20G; 1H-purine-6(7H)-thione.; CHEBI:2208; DTXSID0020810; 157930-11-5; Mercaptopurine (VAN); Mercaptopurin [German]; Merkaptopuryna [Polish]; 6-Merkaptopurin [Czech]; MERCAPTOPURINE [INN]; Mercaptopurine (anhydrous); DTXCID00810; Mercaptopurinum [INN-Latin]; Mercaptopurina [INN-Spanish]; thiohypoxanthine; Purine-6-thiol, monohydrate; CAS-50-44-2; SMR000544948; Mercaptopurine, 6-; CCRIS 2761; HSDB 3235; SR-05000001925; 1194-62-3; EINECS 200-037-4; UNII-PKK6MUZ20G; NCIMech_000025; 9H-Purin-6-yl hydrosulfide; a thiopurine; Mercaptopurine [USAN:USP:INN]; 157930-13-7; Spectrum_000921; Spectrum2_000060; Spectrum3_000491; Spectrum4_000857; Spectrum5_000950; M0063; H-Purine-6(1H)-thione; Azathioprine EP Impurity B; SCHEMBL3893; CHEMBL1425; BSPBio_001981; KBioGR_001493; KBioGR_002363; KBioSS_001401; KBioSS_002366; MERCAPTOPURINE [HSDB]; AG-670/31547064; MLS001066623; MLS001304020; MLS001304953; MLS006011869; DivK1c_000493; SPECTRUM1500387; SPBio_000219; 6-MERCAPTOPURINE [MI]; GTPL7226; SCHEMBL2790086; 7H-Purin-6-yl hydrosulfide #; 6-MERCAPTOPURINE [IARC]; SCHEMBL12683725; CHEBI:50667; CHEBI:94796; HMS501I15; KBio1_000493; KBio2_001401; KBio2_002363; KBio2_003969; KBio2_004931; KBio2_006537; KBio2_007499; KBio3_001481; KBio3_002842; 7-Mercapto-1,4,6-tetrazaindene; cMAP_000033; NINDS_000493; 6,7-dihydro-3H-purine-6-thione; HMS1920L07; HMS2091B20; HMS2236L06; HMS3259N03; HMS3369M05; HMS3651G07; HMS3713N10; HMS3747A17; HMS3872N13; Pharmakon1600-01500387; ACT11542; DISCONTINUED, see M225450; Tox21_111158; Tox21_202591; BDBM50423778; CCG-35344; CCG-39915; MFCD00233552; NSC759614; NSC817004; s1305; SK5357; STK727062; STL257085; 6-Mercaptopurine, analytical standard; WLN: T56 BM DN FN HNJ ISH; AKOS000170222; AKOS000275858; AKOS005224624; AKOS008901311; AKOS016903205; Tox21_111158_1; AM81386; CCG-266232; CS-1499; DB01033; NC00613; NSC-817004; IDI1_000493; MERCAPTOPURINE ANHYDROUS [WHO-DD]; NCGC00091641-02; NCGC00091641-03; NCGC00091641-04; NCGC00091641-16; NCGC00094717-01; NCGC00094717-02; NCGC00094717-03; NCGC00094717-05; NCGC00094717-06; NCGC00188973-01; NCGC00188973-02; NCGC00260139-01; AC-11464; AS-13109; HY-13677; NCI60_041653; SMR004703503; SBI-0051437.P004; DB-026398; AZATHIOPRINE IMPURITY B [EP IMPURITY]; BB 0241023; FT-0621175; SW199090-2; EN300-61517; C01756; C02380; D04931; AB00171799_05; AB00641894-03; AB00641894-04; AB00641894_05; AB00876276-13; A828129; Q418529; SR-05000001925-1; SR-05000001925-2; W-105961; purine antimetabolite: inhibits nucleic acid replication; 1,9-Dihydropurine-6-thione DISCONTINUED, see M225450; Mercaptopurine; 7H-Purine-6-thiol; Azathioprine BP Impurity B	Approved	Approved Drug(s)	667490	DB01033	D0SD1L	152.18	85.2	190	0	10	2	2	0	C5H4N4S	3,7-dihydropurine-6-thione	C1=NC2=C(N1)C(=S)N=CN2	C1=NC2=C(N1)C(=S)N=CN2	InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)	GLVAUDGFNGKCSF-UHFFFAOYSA-N
DQK97E	Bortezomib	Small molecule	Bortezomib; 179324-69-7; Velcade; PS-341; LDP-341; Bortezomib (PS-341); radiciol; Ps 341; ((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid; DPBA; C19H25BN4O4; LDP 341; Bortezomib accord; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; NSC-681239; Bortezomib (Velcade); N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; MG 341; MG-341; Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-; NSC 681239; 69G8BD63PP; CHEMBL325041; Peptide boronate; DTXSID3040980; CHEBI:52717; NSC681239; NCGC00242506-02; S1013; DTXCID1020980; Pyz-Phe-boroLeu; (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid; Boronic acid, ((1R)-3-methyl-1-(((2S)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-; N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide; Velcade (TN); CAS-179324-69-7; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; PS 341 (pharmaceutical); UNII-69G8BD63PP; Brotezamide; PROSCRIPT BORONIC ACID; Bortezomib [USAN:INN:BAN]; HSDB 7666; Bortezomib hydrate; Bortezomib,Velcade; LPD 341; LPD-341; NCGC00168751-01; NCGC00181022-01; ((1R)-3-Methyl-1-(((2S)-3-phenyl-2-((pyrazinylcarbonyl)amino)propanoyl)amino)butyl)boronic acid; [(1R)-3-Methyl-1-[[(2S)-3-phenyl-2-[(pyrazinylcarbonyl)amino]propanoyl]amino]butyl]boronic acid; Bortezomib- Bio-X; Bortezomib [USAN]; MFCD09056737; Velcade (Millenium); 3mg0; BORTEZOMIB [MI]; BORTEZOMIB [INN]; BORTEZOMIB [JAN]; BORTEZOMIB [HSDB]; PS-341 [Bortezomib]; BORTEZOMIB [VANDF]; BORTEZOMIB [MART.]; BORTEZOMIB [WHO-DD]; MLS004774142; Bortezomib (JAN/USAN/INN); BORTEZOMIB [EMA EPAR]; SCHEMBL192129; GTPL6391; BORTEZOMIB [ORANGE BOOK]; BORTEZOMIB HYDRATE [JAN]; Tox21_112630; Tox21_112672; BDBM50069989; HB4036; NSC756655; AKOS015909706; Tox21_112672_1; AM81235; CCG-268449; CS-1039; DB00188; NSC-756655; Bortezomib (Velcade,MG-341,PS-341); NCGC00242506-01; NCGC00242506-06; NCGC00242506-07; AS-15721; BB164258; HY-10227; NCI60_029010; SMR003500787; B5741; SW208077-3; A18332; D03150; EN300-657180; AB01273951-01; AB01273951-02; AB01273951_03; Q419319; SR-01000939863; SR-01000939863-2; BRD-K88510285-001-02-0; Z2213886907; ((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronicacid; (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-6-carboxamido)propanamido)butylboronic acid; [(1R)-3-methyl-1-[(2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamido]butyl]boronic acid; (1R)-3-Methyl-1-({(2S)-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propanoyl}amino)butylboronic acid, AldrichCPR; (R)-3-METHYL-1-((S)-3-PHENYL-2-(PYRAZINE-2-CARBOXAMIDO)PROPANAMIDO)BUTAN-2-YLBORONIC ACID; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]-butyl]boronic acid; 1610526-91-4; Boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (S-(R*,S*))-; Boronic acid, [(1(R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-; N-((1S)-1-benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)2-oxoethylpyrazinecarboxamide; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide	Approved	Approved Drug(s)	387447	DB00188	D0SH3I	384.2	124	500	.	28	4	6	9	C19H25BN4O4	[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid	B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O	B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O	InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1	GXJABQQUPOEUTA-RDJZCZTQSA-N
D1SRI3	Pirbuterol	Small molecule	PIRBUTEROL; 38677-81-5; Maxair; Pirbuterolum [INN-Latin]; (+/-)-Pirbuterol; Pirbuterol (INN); 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol; OG645J8RVW; CHEBI:8245; ARA-211; Ethanol, 2-tert-butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)-; 38677-81-5 (free base); Pirbuterolum; PIRBUTEROL [INN]; Pirbuterol [INN:BAN]; 64856-15-1; (+/-)-Pirbuterol; ARA 211; 2,6-Pyridinedimethanol,a6-[[(1,1-dimethylethyl)amino]methyl]-3-hydroxy-; NSC355078; UNII-OG645J8RVW; 2-tert-Butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)ethanol; PIRBUTEROL [MI]; 38029-10-6; 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)-3-pyridinol; PIRBUTEROL [VANDF]; PIRBUTEROL [MART.]; SCHEMBL4819; PIRBUTEROL [WHO-DD]; ()-Pirbuterol; ARA 211; GTPL7272; CHEMBL1094966; DTXSID0046937; Pirbuterol-[d9] Dihydrochloride; DB01291; NCI60_003197; CP-2431414; C07807; D08387; EN300-23818614; L013424; Q1236526; 2-(hydroxymethyl)-6-(1-hydroxy-2-tert-butylaminoethyl)pyridin-3-ol; (RS)-6-(2-(TERT-BUTYLAMINO)-1-HYDROXYETHYL)-2-(HYDROXYMETHYL)PYRIDIN-3-OL; .ALPHA.6-(((1,1-DIMETHYLETHYL)AMINO)METHYL)-3-HYDROXY-2,6-PYRIDINEDIMETHANOL; 2,6-PYRIDINEDIMETHANOL, .ALPHA.6-(((1,1-DIMETHYLETHYL)AMINO)METHYL)-3-HYDROXY-; 77145-72-3	Approved	Approved Drug(s)	4845	DB01291	D0SS4P	240.3	85.6	230	-0.1	17	4	5	5	C12H20N2O3	6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol	CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O	CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O	InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3	VQDBNKDJNJQRDG-UHFFFAOYSA-N
D5BA7Z	Primaquine	Small molecule	PRIMAQUINE; 90-34-6; Primachin; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; Neo-Quipenyl; Primaquin; Primachinum; Primaquinum; Primaquina; Kanaprim; (+/-)-Primaquine; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-; 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; SN 13,272; Maliride; S. N. 13272; NSC 27296; Primaquine (INN); WR 2975; CHEBI:8405; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; NSC-27296; MVR3634GX1; (+)-Primaquine; (-)-Primaquine; NSC27296; 1,4-Pentanediamine, N(4)-(6-methoxy-8-quinolinyl)-; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline; WR-2975; N-[(S)-4-Amino-1-methylbutyl]-6-methoxy-8-quinolinamine; Primachina [DCIT]; Primachina; SN-13272; dl-Primaquine; PRIMAQUINE [INN]; Primaquine [INN:BAN]; BRN 0019337; Maliride; NSC 27296; Neo-Quipenyl; Primachin; N4-(6-methoxy-8-quinolyl)pentane-1,4-diamine; Primaquinum [INN-Latin]; Primaquina [INN-Spanish]; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; Quinoline, 8-((4-amino-1-methylbutyl)amino)-6-methoxy-; CHEMBL506; MLS001334045; Kanaprim (TN); CCRIS 4109; HSDB 6516; 4-22-00-05817 (Beilstein Handbook Reference); NCGC00178754-06; N~4~-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; SMR000875314; EINECS 201-987-2; 6-Methoxy-8-((4-amino-1-methylbutyl)amino)quinoline; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-; UNII-MVR3634GX1; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; (RS)-primaquine; TG1-296; TG1-297; Spectrum_000830; PRIMAQUINE [MI]; Prestwick0_000476; Prestwick1_000476; Prestwick2_000476; Prestwick3_000476; Spectrum2_000887; Spectrum3_000552; Spectrum4_000484; Spectrum5_001363; PRIMAQUINE [VANDF]; Epitope ID:131792; PRIMAQUINE [WHO-DD]; Oprea1_546209; SCHEMBL22207; BSPBio_000612; BSPBio_002223; KBioGR_000967; KBioSS_001310; DivK1c_000806; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; SPBio_000674; SPBio_002551; (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; BPBio1_000674; cid_359247; GTPL9952; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy-; DTXSID8023509; BDBM71542; KBio1_000806; KBio2_001310; KBio2_003878; KBio2_006446; KBio3_001723; NINDS_000806; HMS2090J17; BCP29271; BBL011330; HY-12651A; MFCD00598906; STL146416; 1, N4-(6-methoxy-8-quinolinyl)-; AKOS005721199; DB01087; WLN: T66 BNJ HO1 JMY1&3Z; IDI1_000806; SMP1_000263; NCGC00178754-01; NCGC00178754-02; NCGC00178754-03; AC-23007; AS-30679; NCI60_001035; NCI60_005887; SBI-0051491.P003; AB00053529; CS-0013754; FT-0687514; C07627; D08420; EN300-144245; AB00053529-11; AB00053529_12; AB00053529_14; N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; A843518; N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; Q419834; BRD-A55913614-316-06-2; SR-05000001864-11; N4-(6-methoxy-8-quinolyl)pentane-1,4-diamine;Primaquine; N4-(6-Methoxyquinolin-8-yl)pentane-1,4-diamine (2 H3PO4); N4-(6-methoxy-8-quinolinyl)pentane-1,4-diamine;phosphoric acid; N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine;phosphoric acid; (4-amino-1-methyl-butyl)-(6-methoxy-8-quinolyl)amine;phosphoric acid	Approved	Approved Drug(s)	4908	DB01087	D0T1LK	259.35	60.2	262	2.2	19	2	4	6	C15H21N3O	4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine	CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2	CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2	InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3	INDBQLZJXZLFIT-UHFFFAOYSA-N
D0CAZ5	Meclizine	Small molecule	meclizine; Meclozine; 569-65-3; Parachloramine; Chiclida; Bonine; Sea-Legs; Histamethine; Histamethizine; Histametizine; Histametizyne; Bonadettes; Calmonal; Itinerol; Monamine; Navicalm; Peremesin; Postafene; Suprimal; Travelon; Vomisseis; Ancolan; Ravelon; Sabari; Siguran; Marex; Neo-istafene; Neo-suprimal; Neo-suprimel; Antivert; Vomissels; Ancolon; 1-((4-Chlorophenyl)(phenyl)methyl)-4-(3-methylbenzyl)piperazine; Meclizine hydrochloride; UCB 5062; Meclozine [INN]; Bonamine; Diadril; UCB 170; U.C.B. 5062; 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)diethylenediamine; NSC 169189; UCB 5052; NSC-169189; U. C. B. 5062; CHEBI:6709; (+-)-Meclizine; 1-(p-Chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)piperazine; Piperazine, 1-(p-chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)-; Dramamine II; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)-; Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)piperazine; 3L5TQ84570; Meclozina; Meclozinum; Subari; Piperazine,1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-; Meclizine [INN:BAN]; Meclozinum [INN-Latin]; Meclozina [INN-Spanish]; Piperazine, 1-(p-chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)-; Nevidoxine (TN); Meclozine (BAN); HSDB 3113; EINECS 209-323-3; 1-p-Chlorobenzhydryl-4-m-methylbenzylpiperazine; BRN 0332002; Meclozin; 1-[(4-Chlorophenyl)(phenyl)methyl]-4-(3-methylbenzyl)piperazine; UNII-3L5TQ84570; 1-(p-Chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-((4-Chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)piperazine; Diadril (Salt/Mix); Bonamine (Salt/Mix); Bonadoxin (Salt/Mix); Vertizine (Salt/Mix); Spectrum_000891; MECLIZINE [MI]; MECLIZINE [HSDB]; (.+/-.)-Meclizine; Prestwick0_000457; Prestwick1_000457; Prestwick2_000457; Prestwick3_000457; Spectrum2_000110; Spectrum3_000485; Spectrum4_000037; Spectrum5_000919; MECLIZINE [VANDF]; MECLOZINE [WHO-DD]; SCHEMBL4649; CHEMBL1623; BSPBio_000534; BSPBio_001949; KBioGR_000473; KBioSS_001371; 4-Methyl-2-chloroacetophenone; DivK1c_000407; SPBio_000100; SPBio_002473; BPBio1_000588; GTPL2757; DTXSID0023242; BDBM81467; KBio1_000407; KBio2_001371; KBio2_003939; KBio2_006507; KBio3_001449; NINDS_000407; Meclizine;Meclozine; Parachloramine; BCP28339; NSC_4034; MFCD00242697; NSC169189; AKOS015951354; DB00737; IDI1_000407; NCGC00018296-02; NCGC00018296-04; NCGC00018296-08; BS-17628; CAS_569-65-3; SBI-0051433.P003; WLN: T6N DNTJ AYR&R DG& D1R C1; AB00053493; FT-0659103; EN300-58334; C07116; D08163; D81963; AB00053493_14; AB00053493_15; L001136; Q386441; BRD-A50311610-300-05-4; BRD-A50311610-300-06-2; Z53003552; 1-[(4-Chlorophenyl)(phenyl)methyl]-4-(3-methylbenzyl)piperazine #	Approved	Approved Drug(s)	4034	DB00737	D0T1XW	390.9	6.5	448	5.8	28	0	2	5	C25H27ClN2	1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine	CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl	CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl	InChI=1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3	OCJYIGYOJCODJL-UHFFFAOYSA-N
DS5T1A	Rilpivirine	Small molecule	Rilpivirine; 500287-72-9; TMC278; Edurant; Rilpivirine free base; R278474; TMC 278; TMC-278; (E)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenylamino)pyrimidin-2-ylamino)benzonitrile; Rilpivirine Z-Isomer HCl; R 278474; (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile; 4-{[4-({4-[(E)-2-Cyanoethenyl]-2,6-Dimethylphenyl}amino)pyrimidin-2-Yl]amino}benzonitrile; 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile; CHEBI:68606; FI96A8X663; 500287-72-9 (free base); 4-[[4-[[4-[(E)-2-Cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile; DB08864; Rilpivirine(R 278474, TMC 278); R-278474; Rilpivirine [INN]; Rilpivirine [USAN:INN]; Rilpivirina; UNII-FI96A8X663; HSDB 8153; Edurant(TM); 4-((4-((4-((1E)-2-Cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile; 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile; T27; RILPIVIRINE [MI]; RILPIVIRINE [JAN]; RILPIVIRINE [USAN]; RILPIVIRINE [VANDF]; RILPIVIRINE [MART.]; RILPIVIRINE [WHO-DD]; SCHEMBL384696; SCHEMBL385113; Rilpivirine (JAN/USAN/INN); CHEMBL175691; GTPL11387; DTXSID10198189; EX-A245; RILPIVIRINE [ORANGE BOOK]; BDBM222178; BCP03563; CABENUVA COMPONENT RILPIVIRINE; MFCD11046372; s7303; STL484047; AKOS015901680; BCP9000016; CCG-268241; CS-0440; KE-0036; R278474;TMC278; 4-[[4-[4-[(E)-2-cyanovinyl]-2,6-dimethyl-anilino]pyrimidin-2-yl]amino]benzonitrile; RILPIVIRINE COMPONENT OF CABENUVA; NCGC00319175-03; NCGC00319175-08; AC-30619; HY-10574; BCP0726000192; SW220232-1; D09720; A827939; EN300-21682062; Q421547; W-202888; 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]pyrimidine-2-yl]amino]benzonitrile; 4-[[4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]-2-pyrimidinyl]amino]benzonitrile; 4-{4-[4-((E)-2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-pyrimidin-2-ylamino}-benzonitrile; (E)-3-{4-[2-(p-Cyanophenylamino)-4-pyrimidinylamino]-3,5-xylyl}acrylonitrile; 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzenecarbonitrile; 4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile; 4-{[4-({4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile; BENZONITRILE, 4-((4-((4-((1E)-2-CYANOETHENYL)-2,6-DIMETHYLPHENYL)AMINO)-2- PYRIMIDINYL)AMINO)-; Benzonitrile, 4-((4-((4-((1E)-2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)-	Approved	Approved Drug(s)	6451164	DB08864	D0T6WN	366.4	97.4	607	4.5	28	2	6	5	C22H18N6	4-[[4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile	CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)C=CC#N	CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)/C=C/C#N	InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+	YIBOMRUWOWDFLG-ONEGZZNKSA-N
D2WLF0	Pantoprazole	Small molecule	pantoprazole; 102625-70-7; Pantozol; Protonix; Pantoprazol; Pantoprazolum; Pantoloc; BY-1023; SK&F-96022; SK&F 96022; BY 1023; SKF-96022; Controloc Control; Altopan; Zovanta; Protonix I.V.; (+)-(R)-Pantoprazole; (S)-Pantoprazole; Pantoprazole-d3; Somac Control; Pantoloc Control; Pantozol Control; SK-96022; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole; 1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-; BY1023; NSC-759257; CHEMBL1502; CHEBI:7915; D8TST4O562; DTXSID4023416; Pantoprazole sodium hydrate; 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; NCGC00095188-01; Pantoprazol [INN-Spanish]; Pantoprazolum [INN-Latin]; 6-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole; DTXCID803416; (R)-Pantoprazole; Panyocid; apo-Pantoprazole; Pantecta Control; PANTOPRAZOLE SODIUM SALT; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole; (S)-(-)-Pantoprazole; CAS-102625-70-7; HSDB 7292; Pantoprazole (USAN/INN); UNII-D8TST4O562; Pantoprazole [USAN:INN:BAN]; 5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole; 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]benzimidazole; SKF96022; Pantoprazole (Protonix); PANTOPRAZOLE [MI]; PANTOPRAZOLE [INN]; EC 600-331-6; PANTOPRAZOLE [HSDB]; PANTOPRAZOLE [USAN]; PANTOPRAZOLE [VANDF]; SCHEMBL29465; BSPBio_002320; PANTOPRAZOLE [MART.]; MLS003882559; (+/-)-PANTOPRAZOLE; BIDD:GT0003; PANTOPRAZOLE [WHO-DD]; SPECTRUM1505818; GTPL7260; PANTOPRAZOLE [EMA EPAR]; HMS1922H20; HMS2090H03; HMS2093F14; Pharmakon1600-01505818; BCP20279; BCP21400; Tox21_111477; AC-679; BDBM50241342; NSC759257; s2105; STL451032; AKOS015894910; AKOS034831879; Tox21_111477_1; CCG-213558; CCG-268437; CS-3161; DB00213; NSC 759257; SB17368; 5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; NCGC00095188-02; NCGC00095188-03; NCGC00095188-04; NCGC00095188-05; NCGC00389443-01; BS-14224; HY-17507; SMR002533625; SBI-0206873.P001; FT-0602547; P2262; D05353; AB01275513-01; AB01275513_02; A800593; A901011; EN300-19767202; Q286846; SR-01000763715; J-000744; SR-01000763715-3; 5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl); BRD-A22380646-001-01-5; BRD-A22380646-001-02-3; (R)-(+)-Pantoprazole;(+)-(R)-Pantoprazole;Pantoprazole Isomer(R) Impurity; 2-(((3,4-Dimethoxy-2-pyridinyl)methyl)-sulfinyl)-5-methyl-1H-1,3-benzimidazole; 2-(((3,4-DIMETHOXYPYRIDIN-2-YL)METHYL)SULFINYL)-5-DIFLUOROMETHOXY-1H-BENZIMIDAZOLE; 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole; 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole; 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole; 5-Difluoromethoxy-2-(3,4-dimethoxy-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole; 5-Difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole; 6-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; 6-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methane]sulfinyl}-1H-1,3-benzodiazole; (R)-(+)-Pantoprazole;R-enantiomer of Pantoprazole;(R)-Pantoprazole;5-(Difluoromethoxy)-2-[(R)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole ;5-(Difluoromethoxy)-2-[(R)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole. - See more at: https://www.clearsynth.com/en/CST38666.html#sthash.yGNPTXpx.dpuf; 154644-14-1; 1H-BENZIMIDAZOLE, 5-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDYL)METHYL)SULFINYL)-; 5-(DIFLUOROMETHOXY)-2-[[(3,4-DIMETHOXY-2-PYRIDINYL)METHYL]SULFINYL]-1H-BENZIMIDAZOLE(Sodium salt form); 6-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE	Approved	Approved Drug(s)	4679	DB00213	D0T6XX	383.4	106	490	2.4	26	1	9	7	C16H15F2N3O4S	6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole	COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC	COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC	InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)	IQPSEEYGBUAQFF-UHFFFAOYSA-N
D98FDV	Pegvaliase	Small molecule	Pegvaliase; rAvPAL-PEG; PEG-PAL; Pegvaliase-pqpz; 1585984-95-7; Pegvaliase [INN]; UNII-N6UAH27EUV; Phenylase; BMN 165; N6UAH27EUV; DTXSID501336362; DB12839; EN300-33416974; (2S)-2-amino-6-[6-(2-methoxyethoxy)hexanamido]hexanoic acid; 2714339-04-3	Approved	Approved Drug(s)	86278362	DB12839	D0T8HZ	318.41	111	300	-2.3	22	3	6	15	C15H30N2O5	(2S)-2-amino-6-[6-(2-methoxyethoxy)hexanoylamino]hexanoic acid	COCCOCCCCCC(=O)NCCCCC(C(=O)O)N	COCCOCCCCCC(=O)NCCCC[C@@H](C(=O)O)N	InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1	NPOCDVAOUKODSQ-ZDUSSCGKSA-N
DL54BI	Lusutrombopag	Small molecule	LUSUTROMBOPAG; 1110766-97-6; mulpleta; S-888711; (S,E)-3-(2,6-Dichloro-4-((4-(3-(1-(hexyloxy)ethyl)-2-methoxyphenyl)thiazol-2-yl)carbamoyl)phenyl)-2-methylacrylic acid; LusutrombopagS-888711; 6LL5JFU42F; RSC888711; (E)-3-[2,6-dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid; (2E)-3-{2,6-dichloro-4-[(4-{3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl}-1,3-thiazol-2-yl)carbamoyl]phenyl}-2-methylprop-2-enoic acid; Lusutrombopag [INN]; UNII-6LL5JFU42F; Lusutrombopag [USAN:INN]; Mulpleta (TN); (2E)-3-(2,6-Dichloro-4-((4-(3-((1S)-1-(hexyloxy)ethyl)-2-methoxyphenyl)-1,3-thiazol-2-yl)carbamoyl)phenyl)-2-methylprop-2-enoic acid; 2-Propenoic acid, 3-(2,6-dichloro-4-(((4-(3-((1S)-1-(hexyloxy)ethyl)-2-methoxyphenyl)-2-thiazolyl)amino)carbonyl)phenyl)-2-methyl-, (2E)-; 2-Propenoic acid, 3-[2,6-dichloro-4-[[[4-[3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-, (2E)-; S 888711; LUSUTROMBOPAG [MI]; LUSUTROMBOPAG [JAN]; LUSUTROMBOPAG [USAN]; LUSUTROMBOPAG [WHO-DD]; SCHEMBL3062080; SCHEMBL3062084; CHEMBL2107831; Lusutrombopag (JAN/USAN/INN); GTPL10032; CHEBI:136051; BDBM430660; DTXSID701027951; LUSUTROMBOPAG [ORANGE BOOK]; EX-A1290; MFCD28502075; s6988; CS-6137; DB13125; NCGC00522464-01; (2E)-3-(2,6-Dichloro-4-((4-(3-((1S)-1-(hexyloxy)ethyl)- 2-methoxyphenyl)-1,3-thiazol-2-yl)carbamoyl)phenyl)-2-methylprop-2-enoic acid; AC-30601; AS-52368; HY-19883; J3.505.027B; D10476; EN300-7383464; A927042; S888711; Q27265116; (E)-3-[2,6-Dichloro-4-[4-[3-[(S)-1-hexyloxyethyl]-2-methoxyphenyl]thiazol-2-ylcarbamoyl]phenyl]-2-methylacrylic acid	Approved	Approved Drug(s)	49843517	DB13125	D0TD1R	591.5	126	822	7.7	39	2	7	13	C29H32Cl2N2O5S	(E)-3-[2,6-dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid	CCCCCCOC(C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)C=C(C)C(=O)O)Cl	CCCCCCO[C@@H](C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)/C=C(\C)/C(=O)O)Cl	InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1	NOZIJMHMKORZBA-KJCUYJGMSA-N
DHY27C	Diclofenac	Small molecule	diclofenac; Diclofenac acid; 15307-86-5; dichlofenac; Diclofenacum; Diclophenac; 2-(2-((2,6-Dichlorophenyl)amino)phenyl)acetic acid; Diclofenaco; Diclofenac resinate; Voltarol; 2-(2,6-Dichloroanilino)phenylacetic Acid; 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid; Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-; 2-[2-(2,6-dichloroanilino)phenyl]acetic acid; Diclofenac free acid; 2-((2,6-Dichlorophenyl)amino)benzeneacetic acid; Solaraze; CHEBI:47381; Voltaren-XR; Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-; 2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid; CHEMBL139; 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID; ACETIC ACID, (o-(2,6-DICHLOROANILINO)PHENYL)-; [2-(2,6-Dichloroanilino)phenyl]acetic acid; 144O8QL0L1; {2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid; LAS41007; Arthrotec; 15307-86-5 (free); ProSorb-D; Olfen; LAS-41007; MFCD00056694; Solaraze (TN); 2-[(2,6-dichlorophenyl)amino]-benzeneacetic acid; Enfenamic acid; N-Phenethylanthranilic acid; RH 8; 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetic acid; Zorovolex; Zorvolex; 2-[2-[(2,6-Dichlorophenyl)amino]phenyl]acetic Acid (Diclofenac); Diclofenamic acid; Diclofenacum [INN-Latin]; Diclofenaco [INN-Spanish]; DIF; HSDB 7234; EINECS 239-348-5; (2-((2,6-Dichlorophenyl)amino-phenyl)acetic acid (HD); BRN 2146636; (2-((2,6-DICHLOROPHENYL)AMINO)PHENYL)ACETIC ACID; Diclofenac [USAN:INN:BAN]; UNII-144O8QL0L1; ISV-205; Zorvolex (TN); Spectrum_000930; DICLOFENAC [MI]; DICLOFENAC [INN]; 128402-48-2; Diclofenac (USAN/INN); Prestwick0_000594; Prestwick1_000594; Prestwick2_000594; Prestwick3_000594; Spectrum2_000991; Spectrum3_000385; Spectrum4_000506; Spectrum5_000867; DICLOFENAC [HSDB]; DICLOFENAC [USAN]; DICLOFENAC [VANDF]; Epitope ID:116873; EC 239-348-5; DICLOFENAC [MART.]; SCHEMBL2799; DICLOFENAC [WHO-DD]; Lopac0_000441; Oprea1_011155; BSPBio_000468; BSPBio_002169; KBioGR_001051; KBioGR_002306; KBioSS_001410; KBioSS_002308; MLS006011795; BIDD:GT0380; DivK1c_000272; DivK1c_000402; 2-[2-(2,6-dichlorophenyl)aminophenyl]ethanoic acid; SPBio_001081; SPBio_002687; BPBio1_000516; GTPL2714; DICLOFENAC [ORANGE BOOK]; DTXSID6022923; BDBM13066; HMS501E04; KBio1_000272; KBio1_000402; KBio2_001410; KBio2_002306; KBio2_003978; KBio2_004874; KBio2_006546; KBio2_007442; KBio3_001389; KBio3_002786; 2b17; cMAP_000014; NINDS_000272; NINDS_000402; HMS2090C10; HMS3886F09; BCP09087; BCP13860; s6073; STK984493; AKOS001579542; DB00586; KS-1258; IDI1_000272; IDI1_000402; NCGC00021125-01; NCGC00021125-02; NCGC00021125-11; AC-27673; HY-15036; o-(2,6-dichloroanilino)phenylacetic acid; SMR001550371; SY038623; SBI-0051341.P003; Diclofenac 1000 microg/mL in Acetonitrile; ACECLOFENAC IMPURITY A [EP IMPURITY]; D3748; FT-0624731; FT-0666643; UNM000001216103; [2-(2,6-Dichloroanilino)phenyl]acetic acid #; C01690; D07816; EN300-119509; H10425; [o-(2,6-dichloro-anilino)-phenyl]-acetic acid; 2-[(2,6-dichlorophenyl)amino]phenylacetic acid; 2-[2-(2,6-dichloroanilino)phenyl]acetic acid.; AB01275502-01; AB01275502_02; 2-(2-(2,6-dichlorophenylamino)phenyl)acetic acid; 2-[(2,6-dichlorophenyl)amino]-phenyl-acetic acid; Q244408; (O-(2,6-DICHLOROANILINO)PHENYL)ACETIC ACID; [2-(2,6-dichloro-phenylamino)-phenyl]-acetic acid; 2-[(2,6-dichlorophenyl)-amino]-benzeneacetic acid; 2-[(2,6-dichlorophenyl)-amino]-phenyl-acetic acid; 2-[2-(2,6-dichlorophenylamino)phenyl]-acetic acid; SR-01000003041-3; 2-[2-(2,6-dichlorophenylamino)-phenyl]-acetic acid; BRD-K08252256-236-05-6; BRD-K08252256-236-17-1; Z57664869; F0722-0745	Approved	Approved Drug(s)	3033	DB00586	D0TG1H	296.1	49.3	304	4.4	19	2	3	4	C14H11Cl2NO2	2-[2-(2,6-dichloroanilino)phenyl]acetic acid	C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl	C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl	InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)	DCOPUUMXTXDBNB-UHFFFAOYSA-N
D0T2AN	Encorafenib	Small molecule	Encorafenib; LGX818; 1269440-17-6; LGX-818; Braftovi; Encorafenib (LGX818); NVP-LGX818-NXA; LGX-818(Encorafenib); NVP-LGX-818-NXA; NVP-LGX818; 8L7891MRB6; methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate; Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester; Methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate; Encorafenib [USAN:INN]; UNII-8L7891MRB6; LGX 818; Braftovi (TN); CARBAMIC ACID, N-((1S)-2-((4-(3-(5-CHLORO-2-FLUORO-3-((METHYLSULFONYL)AMINO)PHENYL)-1-(1-METHYLETHYL)-1H-PYRAZOL-4-YL)-2-PYRIMIDINYL)AMINO)-1-METHYLETHYL)-, METHYL ESTER; ENCORAFENIB [MI]; Encorafenib(LGX-818); ENCORAFENIB [INN]; ENCORAFENIB [JAN]; ENCORAFENIB [USAN]; ENCORAFENIB [WHO-DD]; Encorafenib (JAN/USAN/INN); GTPL7908; SCHEMBL8228295; CHEMBL3301612; DTXSID00155347; ENCORAFENIB [ORANGE BOOK]; BDBM221688; BCP08458; EX-A1587; MFCD25976758; NSC778304; NSC800093; s7108; CCG-269960; DB11718; NSC-778304; NSC-800093; NCGC00378599-03; AC-30230; AS-35201; HY-15605; A13226; D11053; US9314464, 9; EN300-24699278; Q15409405; (S)-Methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate; METHYL N-((2S)-1-((4-(3-(5-CHLORO-2-FLUORO-3-(METHANESULFONAMIDO)PHENYL)(-1-(PROPAN-2-YL)-1H-PYRAZOL-4-YL(PYRIMIDIN-2-YL)AMINO)PROPAN-2-YL)CARBAMATE	Approved	Approved Drug(s)	50922675	DB11718	D0TK7R	540	149	836	2.7	36	3	10	10	C22H27ClFN7O4S	methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate	CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC	C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=C(C(=CC(=C3)Cl)NS(=O)(=O)C)F)C(C)C)NC(=O)OC	InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1	CMJCXYNUCSMDBY-ZDUSSCGKSA-N
DCEP76	Pasireotide	Small molecule	Pasireotide; 396091-73-9; SOM-230; SOM 230; SOM230; Pasireotide free base; Signifor LAR; Pasireotide [USAN:INN]; CHEBI:72312; UNII-98H1T17066; 98H1T17066; CHEMBL3349607; 396091-73-9 (free base); Cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L-phenylalanyl-); Pasireotide diaspartate; cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-); (3S,6R,9S,12S,15S,19R,20aS)-6-((1H-indol-3-yl)methyl)-9-(4-aminobutyl)-15-benzyl-12-(4-(benzyloxy)benzyl)-1,4,7,10,13,16-hexaoxo-3-phenylicosahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecin-19-yl (2-aminoethyl)carbamate; cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-benzyl-L-tyrosyl-L-phenylalanyl-(4R)-4-{[(2-aminoethyl)carbamoyl]oxy}-L-prolyl]; Pasireotide [INN]; PASIREOTIDE [USAN]; pasireotida; pasireotidum; PASIREOTIDE [MI]; PASIREOTIDE [VANDF]; PASIREOTIDE [MART.]; PASIREOTIDE [WHO-DD]; GTPL2018; SCHEMBL12462108; SOM 320; BDBM50474236; DB06663; NCGC00378682-03; HY-16381; EN300-23849528; Q3896970; (3S,6R,9S,12S,15S,19R,20aS)-9-(4-aminobutyl)-15-benzyl-12-{[4-(benzyloxy)phenyl]methyl}-6-[(1H-indol-3-yl)methyl]-1,4,7,10,13,16-hexaoxo-3-phenyl-icosahydropyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-19-yl N-(2-aminoethyl)carbamate; [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[[4-(phenylmethoxy)phenyl]methyl]-3-(phenylmethyl)-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate; [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate	Approved	Approved Drug(s)	9941444	DB06663	D0TV0C	1047.2	281	1940	4.7	77	9	11	18	C58H66N10O9	[(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate	C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN	C1[C@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN	InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1	VMZMNAABQBOLAK-DBILLSOUSA-N
D1AH5E	Sitagliptin	Small molecule	Sitagliptin; 486460-32-6; Xelevia; MK-0431; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; LEZ763; QFP0P1DV7Z; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; CHEBI:40237; LEZ-763; Sitagliptin (Metformin,MK-0431); (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; 790712-60-6; Sitagliptin [INN]; MK0431; Sitagliptin (Prop.INN); UNII-QFP0P1DV7Z; sitagliptina; sitagliptine; sitagliptinum; SR-05000001748; C16H15F6N5O; HSDB 7516; LEZ 763; (2R)-4-OXO-4-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO(1,2,4)TRIAZOLO(4,3-A)PYRAZIN-7(8H)-YL)-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-A MINE; Sitagliptin (13); (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; Sitagliptin; MK0431; SITAGLIPTIN [MI]; SITAGLIPTIN [HSDB]; SITAGLIPTIN [USAN]; EC 690-730-1; SITAGLIPTIN [VANDF]; CHEMBL1422; SCHEMBL17783; BSPBio_002262; SITAGLIPTIN [WHO-DD]; MLS006011959; SITAGLIPTIN [EMA EPAR]; Sitagliptin [USAN:INN:BAN]; GTPL6286; BDBM11162; AMY6930; DTXSID70197572; 1x70; HMS2093F20; (3R)-3-amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;(R)-3-amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one; ACT02665; EX-A2816; WHO 8692; MFCD09838015; NSC813215; AKOS015888724; CCG-268731; DB01261; NSC-813215; NCGC00178734-03; NCGC00178734-06; NCGC00178734-13; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; 7-((3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)buyl)-5,6,7,8-tetrahydro-3-trifluoromethyl)-1,4-triazolo(4,3-a); AS-19118; HY-13749; SMR002546724; SBI-0206871.P001; Sitagliptin 100 microg/mL in Acetonitrile; S5079; A14377; A25516; D08516; EN300-119510; AB01563393_01; AR-270/43507782; Q419832; Q-101366; Q-201711; SR-05000001748-1; BRD-K19416115-001-01-2; BRD-K19416115-001-03-8; Z1521553713; (1R)-3-oxo-3-[3-(trifluoroethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorobenzyl)propylamine; (2r)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8h)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine; (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-alpha]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine; (3R)-3-amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[3,4-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one hydrochloride; (R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine; 1,2,4-Triazolo(4,3-a)pyrazine, 7-((3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-5,6,7,8-tetrahydor-3-(trifluoromethyl)-; 1,2,4-TRIAZOLO(4,3-A)PYRAZINE-7(8H)-PROPANAMINE, 5,6-DIHYDRO-.GAMMA.-OXO-3-(TRIFLUOROMETHYL)-.ALPHA.-((2,4,5-TRIFLUOROPHENYL)METHYL)-, (.ALPHA.R)-; 1,2,4-Triazolo[4,3-a]pyrazine,7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-; 3-oxo-1-(2,4,5-trifluorobenzyl)-3-(3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)propylamine; 7-[(3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine	Approved	Approved Drug(s)	4369359	DB01261	D0U2JP	407.31	77	566	0.7	28	1	10	4	C16H15F6N5O	(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one	C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N	C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N	InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1	MFFMDFFZMYYVKS-SECBINFHSA-N
DD24TH	Dexmedetomidine	Small molecule	DEXMEDETOMIDINE; 113775-47-6; Dexmedetomidinum; MPV 1440; 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; MPV-1440; Dexmedetomidina; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole; Medetomidine, (s)-; (S)-5-(1-(2,3-Dimethylphenyl)ethyl)-1H-imidazole; Precedex (TN); CHEMBL778; 67VB76HONO; CHEBI:4466; 113775-47-6 (free base); 1H-Imidazole, 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-; (S)-4-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole; 4-[(1~{S})-1-(2,3-dimethylphenyl)ethyl]-1~{H}-imidazole; (S)-4-(1-(2,3-dimethylphenyl)ethyl)-1H-imidazole; UNII-67VB76HONO; Dexmedetomidine (USAN/INN); Dexmedetomidinum [INN-Latin]; Dexmedetomidina [INN-Spanish]; MFCD00880557; Dexmedetomidine [USAN:INN:BAN]; Dexdor (TN); Tocris-2023; NCGC00025347-01; DEXMEDETOMIDINE [MI]; SCHEMBL26433; DEXMEDETOMIDINE [INN]; GTPL521; DEXMEDETOMIDINE [USAN]; DEXMEDETOMIDINE [VANDF]; (+)-(S)-4-[1-(2,3-dimethylphenyl) ethyl]-1H -imidazole monohydrochloride; DEXMEDETOMIDINE [WHO-DD]; DexmedetomidineHclC13H16N2.Hcl; DTXSID10873388; TPU 006; HMS3885M07; DEXMEDETOMIDINE [GREEN BOOK]; BDBM50085683; s3075; AKOS025149503; AKOS026750524; CCG-266586; DB00633; Igalmi (dexmedetomidine sublingual film); NCGC00371080-02; NCGC00371080-09; AS-68685; HY-12719; CS-0012295; SW219607-1; C07450; D00514; EN300-127736; AB01566872_01; AB01566872_02; Q412133; 4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazol; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-3H-imidazole; 1H-Imidazole, 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-; 4-[(s)-1-(2,3-dimethyl-phenyl)-ethyl]-1h-imidazole; (+)-4-((S)-.ALPHA.,2,3-TRIMETHYLBENZYL)IMIDAZOLE	Approved	Approved Drug(s)	5311068	DB00633	D0U3DU	200.28	28.7	205	3.1	15	1	1	2	C13H16N2	5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole	CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C	CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C	InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1	CUHVIMMYOGQXCV-NSHDSACASA-N
DU90QV	Alectinib	Small molecule	Alectinib; 1256580-46-7; CH5424802; Alecensa; AF-802; CH 5424802; AF802; RO5424802; Alectinib (CH5424802); UNII-LIJ4CT1Z3Y; 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile; CH-5424802; 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile; AF 802; LIJ4CT1Z3Y; CH5424802(Alectinib); 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile; 9-Ethyl-6,6-Dimethyl-8-[4-(Morpholin-4-Yl)piperidin-1-Yl]-11-Oxo-6,11-Dihydro-5h-Benzo[b]carbazole-3-Carbonitrile; CHEMBL1738797; RO-5424802; ARQ-761; 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile; Alectinib [INN]; 9-ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-5h-benzo(b)carbazole-3-carbonitrile; Alectinib [USAN:INN]; 5H-BENZO(B)CARBAZOLE-3-CARBONITRILE, 9-ETHYL-6,11-DIHYDRO-6,6-DIMETHYL-8-(4-(4-MORPHOLINYL)-1-PIPERIDINYL)-11-OXO-; 5H-Benzo[b]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-; Alectinib free base; EMH; ALECTINIB [MI]; Alectinib (USAN/INN); ALECTINIB [USAN]; ALECTINIB [WHO-DD]; ch 5424802, Alectinib; MLS006010971; SCHEMBL896753; GTPL7739; CHEBI:90936; AMY3288; DTXSID50154840; EX-A406; CH-5424802 HCl; HMS3672C13; HMS3744I17; BCP02589; BDBM50362781; MFCD19440988; NSC764040; NSC764821; NSC794611; NSC799328; s2762; 1256580-46-7 (free base); AKOS025290737; BCP9000514; CS-0518; DB11363; NSC-764040; NSC-764821; NSC-794611; NSC-799328; RG-7853; SB16515; NCGC00346688-01; NCGC00346688-03; NCGC00346688-04; 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-; AC-29020; AS-17008; HY-13011; SMR004702775; FT-0748626; CH-5424802/RG-7853; D10542; EN300-7407832; J-005256; J-519506; Q21099132; CH5424802,CAS:1256580-46-7; 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrileCH5424802; 9-Ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile; 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5h-benzo[b]carbazol-3-carbonitril; 9-ETHYL-6,6-DIMETHYL-8-[4-(MORPHOLIN-4-YL)PIPERIDIN-1-YL]-11-OXO-5H,6H,11H-BENZO[B]CARBAZOLE-3-CARBONITRILE	Approved	Approved Drug(s)	49806720	DB11363	D0U3SY	482.6	72.4	867	5.2	36	1	5	3	C30H34N4O2	9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile	CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C	CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C	InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3	KDGFLJKFZUIJMX-UHFFFAOYSA-N
D4ZX9H	Bosentan	Small molecule	Bosentan; 147536-97-8; Tracleer; Actelion; bosentan anhydrous; Ro 47-0203; Ro-47-0203; Anhydrous bosentan; Bosentan [USAN:INN:BAN]; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide; p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; Bosentan (INN); 4-(tert-butyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide; CHEMBL957; XUL93R30K2; N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide; DTXSID7046627; CHEBI:51450; 147536-97-8 (free); 174227-18-0; Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-; NCGC00167440-01; BOSENTAN [INN]; 1174918-31-0; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; 4-tert-butyl-N-[6-(2-hydroxyethyloxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]benzenesulfonamide; Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-; DTXCID5026627; bosentanum; Ro-47-0203/029; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide; CAS-147536-97-8; Ro 47-0203/039; SR-05000001532; Ro-470203029; Ro-47-0203-029; UNII-XUL93R30K2; 4-tert-butyl-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide; KS-5062; starbld0043886; BOSENTAN [MI]; Ro-47-0203/039; BOSENTAN [WHO-DD]; SCHEMBL4218; GTPL3494; HMS2090N14; HMS3652F15; HMS3715N05; HMS3750A13; BCP05202; HY-A0013; Tox21_112444; AC-148; BDBM50061101; PDSP1_001731; PDSP2_001714; s4220; AKOS015852063; Tox21_112444_1; AM84442; BCP9000445; CCG-221182; CS-0381; DB00559; SB17356; NCGC00167440-02; BB164259; B5118; FT-0658809; SW199648-3; D07538; EN300-120648; W18800; AB01275536-01; A808658; L001086; Q419769; J-008366; SR-05000001532-1; SR-05000001532-2; SR-05000001532-4; Z1530532762; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2''-bipyrimidin)-4-yl) benzenesulfornamide; 4-(1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide; 4-(tert-Butyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide; 4-tert butyl-N-[4-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-6-yl]benzenesulphonamide; 4-tert-Butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl]benzene-1-sulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2''-bipyrimidin-4-yl]benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide; 4-tert-Butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzenesulfonamide; K86	Approved	Approved Drug(s)	104865	DB00559	D0U4CE	551.6	154	839	3.8	39	2	11	11	C27H29N5O6S	4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC	InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)	GJPICJJJRGTNOD-UHFFFAOYSA-N
D17XOY	Hydrochlorothiazide	Small molecule	hydrochlorothiazide; 58-93-5; HCTZ; Esidrix; Hypothiazide; Hidrotiazida; Idrotiazide; Megadiuril; Newtolide; Servithiazid; Oretic; Vetidrex; Chlorosulthiadil; Esidrex; Dichlotiazid; Hydrochlorothiazid; Hydrochlorthiazide; Hydrodiuretic; Hydrosaluric; Apresazide; Aquarills; Aquarius; Carozide; Dichlotride; Diclotride; Disalunil; Hypothiazid; Maschitt; Thiuretic; Drenol; Hidril; Hydril; Nefrix; Hidrochlortiazid; HydroDIURIL; Hydro-Diuril; Hydro-Aquil; Dihydrochlorothiazide; Jen-Diril; Dihydrochlorothiazid; Lotensin HCT; Dihydrochlorothiazidum; Chlorzide; Dichlorosal; Hidroronol; Hydrothide; Hydrozide; Microzide; Moduretic; Neoflumen; Urodiazin; Bremil; Cidrex; Diaqua; Direma; Dyazide; Fluvin; Ivaugan; Panurin; Ro-hydrazide; Neo-codema; Acuretic; Caplaril; Hydrocot; Pantemon; Thlaretic; Timolide; Unipres; Ziac; Zide; Dihydrochlorurite; Aquazide H; 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Hydro-D; 3,4-Dihydrochlorothiazide; Hydrochlorothiazidum; Thiaretic; Apo-Hydro; Lopressor HCT; Inderide; Dihydrochlorurit; Hidroclorotiazida; Su 5879; Aldactazide; Maxzide; Prinzide; Hydrochlorothiazide Intensol; NCI-C55925; component of Cyclex; component of Esimil; Esidrix (TN); Ser-Ap-Es; component of Aldoril; component of Dyazide; component of Caplaril; HCZ; Chlorsulfonamidodihydrobenzothiadiazine dioxide; component of Aldactazide; Copalia-hct; Exforge-hct; Imprida-hct; Rasilez-hct; Dafiro-hct; Hydrochlorothiaizide; component of Butizide Prestabs; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide; NSC-53477; Diu-melusin; 0J48LPH2TH; 6-Chloro-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; MLS000069619; CHEBI:5778; Chlorizide; Disothiazid; HCT; Hidrosaluretil; Novodiurex; Spironazide; Acesistem; Acuilix; Aldazida; Briazide; Catiazida; Chlothia; Clorana; Condiuren; Dihydran; Diurogen; Dixidrasi; DTXSID2020713; Esoidrina; H.H. 25/25; H.H. 50/50; Hyclosid; Indroclor; Manuril; Medozide; Mictrin; Mikorten; Modurcen; Natrinax; Saldiuril; Selozide; Tandiur; Urozide; Didral; Hytrid; Nefrol; Unazid; Hidro-Niagrin; Hydro-Saluric; Raunova Plus; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide; Concor Plus; Aquazide-H; Neo-Flumen; Neo-Minzil; 6-Chloro-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; Hydro Par; NSC53477; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide; Hydro-T; Hydrochlorthiazidum; HCT-Isis; SU-5879; CAS-58-93-5; Mazide 25 mg; NCGC00015508-08; Hydrochlorat; Hydrochlorot; SMR000035778; Idroclorotiazide; Diu 25 Vigt; Hydrex-semi; Aldactazide 25/25; Aldectazide 50/50; Dihydroxychlorothiazidum; Inderide 80/25; Hydrochlorothiazide form II; 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; 6-chloro-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide; Idroclorotiazide [DCIT]; DTXCID80713; Hydrochlorzide; Ezide; Hydrozide Injection, Veterinary; Hidroclorotiazida [INN-Spanish]; Hydrochlorothiazidum [INN-Latin]; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide; Microzide (TN); CCRIS 2082; 1190006-03-1; HSDB 3096; SR-01000000119; EINECS 200-403-3; NSC 53477; UNII-0J48LPH2TH; BRN 0625101; Hydrokraft; Idrodiuvis; Aquazide; Manschitt; Urirex; 6-Chloro-3,4-dihydro-(2H)-1,2,4-benzothiadiazine-7-sulfonamide 1,1-Dioxide; HydroPar; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1?^{6},2,4-benzothiadiazine-7-sulfonamide; 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; Prestwick_263; Hydrochloro Thiazide; Hyzaar (Salt/Mix); MFCD00051765; Aldoril (Salt/Mix); Dutoprol (Salt/Mix); Inderide (Salt/Mix); Prinzide (Salt/Mix); Accuretic (Salt/Mix); Hydropres (Salt/Mix); Thiazide, hydrochloro-; Hydrochlorothiazide [USP:INN:BAN:JAN]; Spectrum_000877; Opera_ID_168; Maybridge1_004336; Prestwick0_000009; Prestwick1_000009; Prestwick2_000009; Prestwick3_000009; Spectrum2_001040; Spectrum3_000456; Spectrum4_000006; Spectrum5_000824; Lopac-H-4759; CHEMBL435; Tekturna HCT (Salt/Mix); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1, 1-dioxide; H 4759; cid_3639; SCHEMBL9349; Lopac0_000614; Oprea1_357174; BSPBio_000017; BSPBio_002132; KBioGR_000351; KBioSS_001357; 8049-49-8; AF-614/30832002; BIDD:GT0153; DivK1c_000289; SPECTRUM1500335; BMCL182567 Compound 6a; SPBio_001259; SPBio_001938; BPBio1_000019; GTPL4836; Hydrochlorothiazide, crystalline; HYDROCHLOROTHIAZIDE [MI]; BDBM13076; component of Dyazide (Salt/Mix); HMS500O11; HMS553N04; HYDROCHLOROTHIAZIDE [INN]; HYDROCHLOROTHIAZIDE [JAN]; KBio1_000289; KBio2_001357; KBio2_003925; KBio2_006493; KBio3_001352; HYDROCHLOROTHIAZIDE [HSDB]; HYDROCHLOROTHIAZIDE [IARC]; component of Caplaril (Salt/Mix); NINDS_000289; HMS1568A19; HMS1920D19; HMS2091L05; HMS2095A19; HMS2235I09; HMS3259O17; HMS3261L10; HMS3370P11; HMS3428A05; HMS3655M21; HMS3712A19; HYDROCHLOROTHIAZIDE [VANDF]; Pharmakon1600-01500335; HYDROCHLOROTHIAZIDE [MART.]; HYDROCHLOROTHIAZIDE COMPONENT; BCP22001; HY-B0252; JFD00715; HYDROCHLOROTHIAZIDE [USP-RS]; HYDROCHLOROTHIAZIDE [WHO-DD]; HYDROCHLOROTHIAZIDE [WHO-IP]; Tox21_110165; Tox21_201565; Tox21_300292; Tox21_500614; 3,4-dihydro-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; CCG-40240; NSC757059; s1708; STK315354; 3,2,4-benzothiadiazine-1,1-dioxide; Hydrochlorothiazide (JP17/USP/INN); HYDROCHLOROTHIAZIDE [EMA EPAR]; AKOS000121373; Tox21_110165_1; AC-8114; DB00999; LP00614; NC00510; NSC-757059; PS-3162; SDCCGSBI-0050596.P005; HYDROCHLOROTHIAZIDE [GREEN BOOK]; IDI1_000289; WLN: T66 BSWM EM DHJ HG ISZW; HYDROCHLOROTHIAZIDE [EP IMPURITY]; HYDROCHLOROTHIAZIDE [ORANGE BOOK]; NCGC00015508-01; NCGC00015508-02; NCGC00015508-03; NCGC00015508-04; NCGC00015508-05; NCGC00015508-06; NCGC00015508-07; NCGC00015508-09; NCGC00015508-10; NCGC00015508-11; NCGC00015508-12; NCGC00015508-13; NCGC00015508-14; NCGC00015508-16; NCGC00015508-17; NCGC00015508-25; NCGC00021906-03; NCGC00021906-04; NCGC00021906-05; NCGC00021906-06; NCGC00021906-07; NCGC00021906-08; NCGC00254017-01; NCGC00259114-01; NCGC00261299-01; ZIAC COMPONENT HYDROCHLOROTHIAZIDE; BH164522; HH-50/50; HYDROCHLOROTHIAZIDE [EP MONOGRAPH]; NCI60_004317; component of Butizide Prestabs (Salt/Mix); ESIMIL COMPONENT HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE [USP MONOGRAPH]; Hydrochlorothiazide 1.0 mg/ml in Methanol; HYDROCHLOROTHIAZIDUM [WHO-IP LATIN]; HYZAAR COMPONENT HYDROCHLOROTHIAZIDE; SBI-0050596.P004; ALDORIL COMPONENT HYDROCHLOROTHIAZIDE; AVALIDE COMPONENT HYDROCHLOROTHIAZIDE; DYAZIDE COMPONENT HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE COMPONENT OF ZIAC; MAXZIDE COMPONENT HYDROCHLOROTHIAZIDE; RIPRAZO COMPONENT HYDROCHLOROTHIAZIDE; UNIPRES COMPONENT HYDROCHLOROTHIAZIDE; AB00052012; DUTOPROL COMPONENT HYDROCHLOROTHIAZIDE; EU-0100614; FT-0650564; H1274; PRINZIDE COMPONENT HYDROCHLOROTHIAZIDE; RASITRIO COMPONENT HYDROCHLOROTHIAZIDE; SW196569-3; UNIRETIC COMPONENT HYDROCHLOROTHIAZIDE; ACCURETIC COMPONENT HYDROCHLOROTHIAZIDE; AMTURNIDE COMPONENT HYDROCHLOROTHIAZIDE; APRESAZIDE COMPONENT HYDROCHLOROTHIAZIDE; CAM-AP-ES COMPONENT HYDROCHLOROTHIAZIDE; EN300-16641; H.R.-50 COMPONENT HYDROCHLOROTHIAZIDE; HYDRAP-ES COMPONENT HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZDE COMPONENT OF TOULOMI; HYDROCHLOROTHIAZIDE COMPONENT OF ESIMIL; HYDROCHLOROTHIAZIDE COMPONENT OF HYZAAR; HYDROPRES COMPONENT HYDROCHLOROTHIAZIDE; KERVEZIDE COMPONENT HYDROCHLOROTHIAZIDE; KINZALKOMB COMPONENT HYDROCHLOROTHIAZIDE; MODURETIC COMPONENT HYDROCHLOROTHIAZIDE; NORMOZIDE COMPONENT HYDROCHLOROTHIAZIDE; PRITORPLUS COMPONENT HYDROCHLOROTHIAZIDE; QUINARETIC COMPONENT HYDROCHLOROTHIAZIDE; SER-A-GEN COMPONENT HYDROCHLOROTHIAZIDE; SER-AP-ES COMPONENT HYDROCHLOROTHIAZIDE; TOLUCOMBI COMPONENT HYDROCHLOROTHIAZIDE; TRIBENZOR COMPONENT HYDROCHLOROTHIAZIDE; VASERETIC COMPONENT HYDROCHLOROTHIAZIDE; VISKAZIDE COMPONENT HYDROCHLOROTHIAZIDE; ZESTORETIC COMPONENT HYDROCHLOROTHIAZIDE; 6-Chloro-3,2,4-benzothiadiazine 1,1-dioxide; A19550; ALDACTAZIDE COMPONENT HYDROCHLOROTHIAZIDE; BENICAR HCT COMPONENT HYDROCHLOROTHIAZIDE; C07041; D00340; DIOVAN HCT COMPONENT HYDROCHLOROTHIAZIDE; EXFORGE HCT COMPONENT HYDROCHLOROTHIAZIDE; H10742; HYDRA-ZIDE COMPONENT HYDROCHLOROTHIAZIDE; HYDRO-RIDE COMPONENT HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE COMPONENT OF ALDORIL; HYDROCHLOROTHIAZIDE COMPONENT OF AVALIDE; HYDROCHLOROTHIAZIDE COMPONENT OF DUTOPROL; HYDROCHLOROTHIAZIDE COMPONENT OF DYAZIDE; HYDROCHLOROTHIAZIDE COMPONENT OF MAXZIDE; HYDROCHLOROTHIAZIDE COMPONENT OF PRINZIDE; HYDROCHLOROTHIAZIDE COMPONENT OF RASITRIO; HYDROCHLOROTHIAZIDE COMPONENT OF RIPRAZO; HYDROCHLOROTHIAZIDE COMPONENT OF UNIPRES; HYDROCHLOROTHIAZIDE COMPONENT OF UNIRETIC; IFIRMACOMBI COMPONENT HYDROCHLOROTHIAZIDE; SPRIMEO-HCT COMPONENT HYDROCHLOROTHIAZIDE; TEVETEN HCT COMPONENT HYDROCHLOROTHIAZIDE; AB00052012-15; AB00052012_16; AB00052012_17; HYDRO-RESERP COMPONENT HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE COMPONENT OF AMTURNIDE; HYDROCHLOROTHIAZIDE COMPONENT OF H.R.-50; HYDROCHLOROTHIAZIDE COMPONENT OF HYDRAP-ES; HYDROCHLOROTHIAZIDE COMPONENT OF HYDROPRES; HYDROCHLOROTHIAZIDE COMPONENT OF MODURETIC; HYDROCHLOROTHIAZIDE COMPONENT OF NORMOZIDE; HYDROCHLOROTHIAZIDE COMPONENT OF TRIBENZOR; HYDROCHLOROTHIAZIDE COMPONENT OF VASERETIC; HYDROCHLOROTHIAZIDE COMPONENT OF VISKAZIDE; LOTENSIN HCT COMPONENT HYDROCHLOROTHIAZIDE; MICARDIS HCT COMPONENT HYDROCHLOROTHIAZIDE; MICARDISPLUS COMPONENT HYDROCHLOROTHIAZIDE; MONOPRIL HCT COMPONENT HYDROCHLOROTHIAZIDE; TEKTURNA HCT COMPONENT HYDROCHLOROTHIAZIDE; Hydrochlorothiazide 100 microg/mL in Acetonitrile; HYDROCHLOROTHIAZIDE COMPONENT OF ALDACTAZIDE; HYDROCHLOROTHIAZIDE COMPONENT OF APRESAZIDE; HYDROCHLOROTHIAZIDE COMPONENT OF BENICAR HCT; HYDROCHLOROTHIAZIDE COMPONENT OF CAM-AP-ES; HYDROCHLOROTHIAZIDE COMPONENT OF DIOVAN HCT; HYDROCHLOROTHIAZIDE COMPONENT OF EXFORGE HCT; HYDROCHLOROTHIAZIDE COMPONENT OF HYDRA-ZIDE; HYDROCHLOROTHIAZIDE COMPONENT OF HYDRO-RIDE; HYDROCHLOROTHIAZIDE COMPONENT OF IFIRMACOMBI; HYDROCHLOROTHIAZIDE COMPONENT OF KINZALKOMB; HYDROCHLOROTHIAZIDE COMPONENT OF QUINARETIC; HYDROCHLOROTHIAZIDE COMPONENT OF RASILEZ-HCT; HYDROCHLOROTHIAZIDE COMPONENT OF SER-A-GEN; HYDROCHLOROTHIAZIDE COMPONENT OF SER-AP-ES; HYDROCHLOROTHIAZIDE COMPONENT OF SPRIMEO-HCT; HYDROCHLOROTHIAZIDE COMPONENT OF TEVETEN HCT; HYDROCHLOROTHIAZIDE COMPONENT OF ZESTORETIC; LOPRESSOR HCT COMPONENT HYDROCHLOROTHIAZIDE; ORETICYL FORTE COMPONENT HYDROCHLOROTHIAZIDE; Q423930; HYDROCHLOROTHIAZIDE COMPONENT OF HYDR	Approved	Approved Drug(s)	3639	DB00999	D0U4UQ	297.7	135	494	-0.1	17	3	7	1	C7H8ClN3O4S2	6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide	C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl	C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl	InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)	JZUFKLXOESDKRF-UHFFFAOYSA-N
DQV0N9	Capsaicin	Small molecule	Capsaicin; 404-86-4; (E)-Capsaicin; Zostrix; Qutenza; CAPSAICINE; Axsain; Styptysat; Isodecenoic acid vanillylamide; E-CAPSAICIN; Ausanil; trans-Capsaicin; NGX-4010; trans-8-Methyl-N-vanillyl-6-nonenamide; Mioton; (E)-8-Methyl-N-vanillyl-6-nonenamide; FEMA No. 3404; C18H27NO3; Capsaicinoid; ALGRX 4975; Dolenon; Transacin; Ovocap; 8-Methyl-N-vanillyl-trans-6-nonenamide; Capzasin-hp; Togarashi orenji; (Z)-Capsaicin; NCI-C56564; MFCD00017259; NSC 56353; Ratden pe 40; CHEBI:3374; (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; trans-Capsaicin-d3; Capsaicin (JAN/USP); 6-Nonenamide, 8-methyl-N-vanillyl-, (E)-; NGX-1998; ZOSTRIX (TN); (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; N-(4-Hydroxy-3-methoxybenzyl)-8-methylnon-trans-6-enamide; NSC-56353; 1217899-52-9; Cntx-4975; (6E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)-; (e)-n-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; ALGRX-4975; CHEMBL294199; S07O44R1ZM; DTXSID9020241; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (E)-; NSC56353; Capsaicin [in oleoresin of capsicum]; N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; NCGC00017337-02; 8-Methyl-N-Vanillyl-6-Nonenamide; 8-Methyl-N-vanillyl-(trans)-6-nonenamide; (E)-N-((4-Hydroxy-3-methoxyphenyl)-methyl)-8-methyl-6-nonenamide; (E)-N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide; 6-Nonenamide, (E)-N-((4-hydroxy-3-methoxy-phenyl)methyl)-8-methyl; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (E)-; 7553-53-9; (E)-N-[(4-HYDROXY-3-METHOXYPHENYL)METHYL]-8-METHYL-6-NONENAMIDE; Capsaicin [USAN]; DTXCID30241; Caswell No. 158; Capsicine; Vanilloid; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-; Capsaicin (in oleoresin of capsicum); (6E)-N-{[4-hydroxy-3-(methyloxy)phenyl]methyl}-8-methylnon-6-enamide; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (6E)-; NGX 4010; CCRIS 1588; HSDB 954; SR-05000001861; EINECS 206-969-8; EPA Pesticide Chemical Code 070701; BRN 2816484; neurotoxic; UNII-S07O44R1ZM; Isodecenoate; Zucapsaicin;Civamide;cis-Capsaicin; N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; Adlea; 8-Methyl-N-vanillyl-6-nonenamide, (E)-; TNP00277; (E)-N-[(4-Hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide; epsilon-capsaicin; capsacin(E); Qutenza;Vanilloid; Zostrix HP; Capsaicin,(S); 4DY; CAS-404-86-4; Prestwick_204; Capsaicin (Natural); depletes Substance P; CAPSAICINOIDS; Citrus Aurantium 30%; starbld0019180; Capsaicin [USP:INN]; CAPSAICIN [INN]; CAPSAICIN [JAN]; CAPSAICIN [MI]; isoamyl4-methoxycinnamate; 6-Nonenamide, (E)-; CAPSAICIN [HSDB]; CAPSAICIN [INCI]; Prestwick2_000879; Prestwick3_000879; Spectrum5_000538; CAPSAICIN [VANDF]; CAPSAICIN, NATURAL; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide, (E)-; CITRUS AURANTIUM PE; CAPSAICIN [MART.]; UPCMLD-DP092; CAPSAICIN [USP-RS]; CAPSAICIN [WHO-DD]; SCHEMBL8085; SCHEMBL8086; MR3H3; BSPBio_000957; BSPBio_001548; BSPBio_002917; CAPSAICIN [EMA EPAR]; MLS002154049; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; Capsaicin, analytical standard; SPECTRUM1501128; BPBio1_001053; GTPL2486; MEGxp0_001448; CAPSAICIN [ORANGE BOOK]; Methyl-N-vanillyl-6-noneneamide; UPCMLD-DP092:001; UPCMLD-DP092:002; BDBM20461; BDBM86537; CHEBI:94524; HMS501B16; CAPSAICIN [USP MONOGRAPH]; HMS1361N10; HMS1570P19; HMS1791N10; HMS1921H11; HMS1989N10; HMS2089N11; HMS2092D21; HMS2097P19; HMS2230O23; HMS3402N10; HMS3414F11; HMS3649N15; HMS3678F11; Pharmakon1600-01501128; 8-Methyl-N-vanillyl-6E-nonenamide; AMY25669; NGX-3781; NGX-7325; NSC_2548; Tox21_110817; Tox21_200315; BBL027836; CCG-39657; CCG-39908; EI-125; HB1179; HY-10448A; LMFA08020085; NSC757844; s1990; STL372889; (E)8-methyl-N-vanillyl-6-Nonenamide; AKOS007930159; CS-1518; DB06774; KS-5181; NSC-757844; SDCCGMLS-0066678.P001; TQ-1018; Capsaicin 10 microg/mL in Acetonitrile; Capsaicin, >=95%, from Capsicum sp.; IDI1_000354; IDI1_034018; SMP2_000337; NCGC00017337-03; NCGC00017337-04; NCGC00017337-05; NCGC00017337-06; NCGC00017337-07; NCGC00017337-08; NCGC00017337-09; NCGC00017337-10; NCGC00017337-11; NCGC00017337-12; NCGC00017337-13; NCGC00017337-17; NCGC00017337-18; NCGC00090853-01; NCGC00090853-02; NCGC00090853-03; NCGC00090853-04; NCGC00090853-06; NCGC00090853-07; NCGC00090853-08; NCGC00090853-09; NCGC00090853-10; NCGC00090853-11; NCGC00090853-12; NCGC00257869-01; AC-10114; CAS_404-86-4; HY-10448; LS-14673; SMR000718774; SBI-0052593.P002; CS-0181240; M1149; (E)-8-Methyl-N-vanillyl-6-nonenamide(8cl); Capsaicin (8-Methyl-N-vanillyl-6-nonenamide); C-1700; C06866; D00250; AB00053098-11; AB00053098_12; Capsaicin, from Capsicum sp., >=50% (HPLC); EN300-7544118; CAPSAICIN (CONSTITUENT OF CAPSICUM) [DSC]; Q273169; SR-05000001861-1; SR-05000001861-4; SR-05000001861-5; SR-05000001861-6; SR-05000001861-9; BRD-K37056290-001-01-1; BRD-K50590187-001-06-6; Capsaicin, certified reference material, TraceCERT(R); N-(3-Methoxy-4-hydroxybenzyl)-8-methyl-6-nonenamide; Capsaicin, European Pharmacopoeia (EP) Reference Standard; (6E)-N-(4-Hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide #; Capsaicin, United States Pharmacopeia (USP) Reference Standard; Capsaicin; 8-Methyl-N-vanillyl-trans-6-nonenamide; NGX-4010; N-[(4-hydroxy-3-methoxyphenyl)methyl]-6E-8-methyl-nonenamide; N-(4-HYDROXY-3-METHOXYBENZYL)-8-METHYL-6-NONENAMIDE [FHFI]; trans-N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; 6-nonenamide,n-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-,(6e)-; Capsaicin, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	1548943	DB06774	D0U5CE	305.4	58.6	341	3.6	22	2	3	9	C18H27NO3	(E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide	CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC	CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC	InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+	YKPUWZUDDOIDPM-SOFGYWHQSA-N
D9TL1W	Leuprolide	Small molecule	Leuprorelin; leuprolide; 53714-56-0; Leuproreline; Leuprorelinum; Leuporelin; Leuprorelin acetate; (-)-leuprolide; Leuprorelina; Leuprorelin slow release; EFY6W0M8TG; TAP-144 FREE BASE; CHEBI:6427; CKD-841; ABBOTT-43818 FREE BASE; NSC-377526; pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHC2H5; Leuprorelin acetate (JAN); Leuprolide acetate (USAN); LEUPRORELIN [INN]; Leuprorelin [INN:BAN]; UNII-EFY6W0M8TG; Leuproreline [INN-French]; Leuprorelinum [INN-Latin]; Leuprorelina [INN-Spanish]; CCRIS 8462; HSDB 6518; LH-RH Leuprolide; 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide; NSC 377526; LEUPROLIDE [MI]; LEUPROLIDE [HSDB]; LEUPROLIDE [VANDF]; SCHEMBL4585; LEUPRORELIN [MART.]; LEUPRORELIN [WHO-DD]; GTPL1175; CHEMBL1201199; DTXSID50872411; LEUPRORELIN [EP MONOGRAPH]; (D-Leu(sup 6),des-gly-NH2(sup 10),pro-ethylamide(sup 9))-GNRH; (D-Leu(sup 6),des-gly-NH2(sup 10),pro-ethylamide(sup 9))-LHRH; BDBM50369395; MFCD00167544; AKOS015892744; AKOS030213246; AKOS037515838; CCG-270656; CS-4947; DB00007; HS-2016; NCGC00485984-01; HY-12553; Leuprolide acetate salt, >=98% (HPLC); C75519; pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt; BISPHENOLA-(3-CHLORO-2-HYDROXYPROPYL)-&; EN300-7481165; Fensolvi (leuprolide acetate injectable suspension); Q907160; Leuprolide acetate, United States Pharmacopeia (USP) Reference Standard; (2S)-1-[(2S)-5-carbamimidamido-2-[(2S)-2-[(2R)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-4-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]-4-methylpentanamido]-4-methylpentanamido]pentanoyl]-N-ethylpyrrolidine-2-carboxamide; (S)-N-ethyl-1-(((S)-5-oxopyrrolidine-2-carbonyl)-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl)pyrrolidine-2-carboxamide; 5-OXO-L-PROLYL-L-HISTIDYL-L-TRYPTOPHYL-L-SERYL-L-TRYOSYL-D-LEUCYL-L-LEUCYL-L-ARGINYL-N-ETHYL-L-PROLINAMIDE; L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide	Approved	Approved Drug(s)	657181	DB00007	D0U5FF	1209.4	432	2390	0.7	87	15	14	32	C59H84N16O12	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide	CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6	InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1	GFIJNRVAKGFPGQ-LIJARHBVSA-N
DC27QH	Cisplatin	Small molecule	cisplatin; 14913-33-8; trans-Dichlorodiamineplatinum(II); azane;dichloroplatinum; Platinum, diamminedichloro-, (SP-4-1)-; trans-Diamminedichloro platinum(II); trans-Platinum(II)diammine dichloride; MFCD00011623; CACP; trans-Dichlorodiamineplatinum(II);Transplatin; SR-05000001586; IA call; Trans-Platinum diammine dichloride; Cisplatin in water; Cisplatin,(S); Cisplatin in DMSO; CPDC; DDP-H; PLATINOL (TN); SPECTRUM1502107; Cisplatin (JP17/USP/INN); cis-Diaminodichloroplatinum(II); cis-Dichlorodiamine platinum(II); HMS502M12; HMS1921J18; HMS2092D04; BCP01792; BCP18182; CCG-39901; AKOS005137969; NCGC00094962-01; NCGC00094962-02; NCGC00094962-03; FT-0777996; C06911; D00275; cis-Diammineplatinum(II) dichloride, crystalline; Q412415; SR-01000076254; SR-01000076254-1; SR-05000001586-1; SR-05000001586-3; Z3182781436; Cisplatin, European Pharmacopoeia (EP) Reference Standard; Cisplatin, United States Pharmacopeia (USP) Reference Standard; cis-Diamineplatinum(II) dichloride, >=99.9% trace metals basis; Cisplatin impurity A, European Pharmacopoeia (EP) Reference Standard; Transplatin, United States Pharmacopeia (USP) Reference Standard; Cisplatin, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	5702198	DB00515	D0U5HU	300.05	2	2.8	.	5	2	2	0	Cl2H6N2Pt	azane;dichloroplatinum	N.N.Cl[Pt]Cl	N.N.Cl[Pt]Cl	InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2	LXZZYRPGZAFOLE-UHFFFAOYSA-L
DH2Q4T	Acetaminophen	Small molecule	acetaminophen; Paracetamol; 4-Acetamidophenol; 103-90-2; Tylenol; N-(4-Hydroxyphenyl)acetamide; APAP; Panadol; N-Acetyl-p-aminophenol; 4'-Hydroxyacetanilide; Acetaminofen; Datril; p-Hydroxyacetanilide; p-Acetamidophenol; Algotropyl; Lonarid; Naprinol; Doliprane; Injectapap; Acamol; Acenol; Anelix; Multin; p-Acetaminophenol; Abensanil; Acetagesic; Acetalgin; Biocetamol; Clixodyne; Gelocatil; Liquagesic; Pyrinazine; Servigesic; Acephen; Alvedon; Anaflon; Apamide; Dymadon; Febridol; Febrilix; Febrolin; Finimal; Homoolan; Lestemp; Paracet; Tabalgin; Tralgon; Tussapap; Valadol; Valgesic; Vermidon; Alpiny; Amadil; Anhiba; Calpol; Dirox; Eneril; Fendon; Hedex; Lyteca; Neopap; Pacemo; Panets; Parmol; Tapar; Tempra; Acetamide, N-(4-hydroxyphenyl)-; Paracetamolo; Dafalgan; Dolprone; Momentum; Ortensan; Paldesic; Banesin; Captin; Disprol; Enelfa; Salzone; Exdol; p-Acetylaminophenol; Febro-Gesic; NEBS; Paracetamolum; Dolgesic; Elixodyne; Febrectal; Phenaphen; Tempanal; Abenol; Apacet; Apadon; Cetadol; Fensum; Janupap; Minoset; Napafen; Neodol; Nobedon; Pacemol; Panodil; Parapan; Pedric; Phendon; Rounox; Suppap; Korum; Pinex; Temlo; 4-(Acetylamino)phenol; Ben-u-ron; Dial-A-Gesic; Anacin-3; Calmanticold; Codoliprane; Demogripal; Dolegrippin; Doloreduct; Dristancito; Duracetamol; Eu-Med; Grippostad; Gynospasmine; Medocodene; Paedialgon; Paracetanol; Parakapton; Pediapirin; Phenipirin; Phogoglandin; Predualito; Sanicopyrine; Scentalgyl; Sunetheton; Tachiprina; Termalgine; Treuphadol; Abrolet; Acertol; Acetamol; Acetofen; Afebrin; Afebryl; Aferadol; Algesidal; Algomol; Alpinyl; Analter; Antidol; Apitrelal; Atralidon; Babikan; Bacetamol; Cadafen; Calapol; Causalon; Cefalex; Codabrol; Codalgin; Codapane; Codicet; Codisal; Cofamol; Cosutone; Cuponol; Curadon; Custodial; Darocet; Daygrip; Deminofen; Democyl; Desfebre; Dimindol; Dolefin; Dolofugin; Dolorfug; Dolorstop; Dolotec; Dorocoff; Dularin; Durapan; Ecosetol; Excipain; Fanalgic; Farmadol; Febranine; Febrectol; Febricet; Febrinol; Fepanil; Finiweh; Fluparmol; Geluprane; Ildamol; Inalgex; Infadrops; Kataprin; Labamol; Lekadol; Lemgrip; Lupocet; Magnidol; Malidens; Maxadol; Mexalen; Minafen; Miralgin; Nealgyl; Neodolito; Neotrend; Neuridon; Nodolex; Ofirmev; Oralgan; Oxycocet; Pacimol; Panacete; Panadeine; Panadiene; Panaleve; Panamax; Panasorbe; Panofen; Pantalgin; Paracemol; Paracenol; Paracetol; Paracin; Paracod; Paracodol; Parador; Paradrops; Paralen; Paralief; Paralink; Paralyoc; Paramol; Paramolan; Paranox; Parasedol; Parasin; Paraspen; Parcetol; Parogal; Pediatrix; Perfalgan; Piramin; Pirinasol; Polmofen; Predimol; Prontina; Puernol; Pulmofen; Pyrigesic; Pyromed; Remedol; Rivalgyl; Rubophen; Rupemol; Sanicet; Schmerzex; Sedalito; Semolacin; Seskamol; Setakop; Setamol; Sifenol; Sinaspril; Sinedol; Stanback; Stopain; Supofen; Tazamol; Termacet; Termalgin; Termofren; Titralgan; Tricoton; Upsanol; Utragin; Veralgina; Viruflu; Vivimed; Zatinol; Abrol; Algina; Anapap; Andox; Asetam; Asomal; Aspac; Asplin; Benmyo; Curpol; Dhamol; Dolcor; Dolko; Dresan; Dypap; Febrex; Febrin; Lemsip; Malgis; Oltyl; Paceco; Pacet; Paedol; Painex; Pamol; Panex; Parake; Paroma; Plicet; Prodol; Reliv; Scanol; Setol; Sinmol; Tiffy; Tylex; Tylol; Tymol; Verpol; Volpan; Zolben; NeoCitran; NilnOcen; Nina; RubieMol; Vips; Supadol mono; Treupel mon; Bickie-mol; Fortalidon P; Gattaphen T; Gripin Bebe; Influbene N; Lonarid Mono; Panadeine Co; Dymadon Co; Toximer P; Treupel N; Accu-Tap; 4-Acetaminophenol; Helon N; Malex N; Spalt N; Tylex CD; N-Acetyl-4-aminophenol; SK-Apap; Paracetamole; Conacetol; Darvocet; Empracet; Panasorb; A-Per; Apamid; Parelan; Prompt; Vicodin; Fevor; Freka-cetamol; Codisal Forte; Croix Blanche; Dolorol Forte; Dymadon Forte; Junior Disprol; Kinder Finimal; Liquigesic Co; Mono Praecimed; Percocet-Demi; Perdolan Mono; Rockamol Plus; Viclor Richet; Actifed Plus; Kratofin simplex; Neo-Fepramol; Paracetamol AL; Paracetamol BC; Paracetamol PB; Acetanilide, 4'-hydroxy-; Claradol Codeine; Geralgine-P; Melabon Infantil; Migraleve Yellow; Paracetamol Saar; Pyregesic-C; Anti-Algos; Para-Suppo; Pasolind N; Supramol-M; No-Febril; Panado-Co; Para-Tabs; Paracetamol Hexal; Paracetamol Raffo; Paracetamol Rosch; Paracetamol Stada; Dol-Stop; Anadin dla dzieci; p-Hydroxyphenolacetamide; Percocet-5; Cod-Acamol Forte; Contra-Schmerz P; Hy-Phen; Medinol Paediatric; Paracetamol Basics; Panado-Co Caplets; Paracetamol von ct; Pe-Tam; Paracetamol Fecofar; Paracetamol Harkley; Paracetamol Heumann; Paracetamol Nycomed; Codral Pain Relief; Paracetamol Hanseler; Paracetamol Winthrop; 4-Hydroxyacetanilide; Phenaphen W/Codeine; Spalt fur die nacht; A.F. Anacin; Paracetamol Genericon; Anexsia; Demilets; Efferalgan; Endecon; Intensin; Naldegesic; Propacet; Resfenol; Theraflu; Wygesic; Paracetamol Ratiopharm; Coricidin Sinus; Paracetamol Italfarmaco; Sudafed Sinus; Coricidin D; Paracetamol DC; Quiet World; Paracetamol Antipanin P; St Joseph Aspirin-Free; New Cortal for Children; INFANTS' FEVERALL; St. Joseph Fever Reducer; Midol Teen Formula; Paracetamol Dr. Schmidgall; Acetamide, N-(p-hydroxyphenyl)-; p-hydroxy-acetanilid; Aspirin-Free Anacin; Children's Tylenol Chewable; NCI-C55801; PCM Paracetamol Lichtenstein; Tylenol Allergy Sinus; p-(Acetylamino)phenol; Rhinex D-Lay Tablets; acetaminophene; Midol Regular Strength; Paracetamol SmithKline Beecham; Scherzatabletten Rezeptur 534; Percogesic with Codeine; 4-Hydroxyanilid kyseliny octove; Bayer Select Head Cold; Bayer Select Allergy-Sinus; Bayer Select Headache Pain; Dristan Cold No Drowsiness; Prestwick_13; St Joseph Aspirin-Free for Children; 4-acetylaminophenol; Children's Acetaminophen Elixir Drops; MFCD00002328; Midol PM Night Time Formula; Triaminic Sore Throat Formula; N-(4-hydroxyphenyl)ethanamide; Bayer Select Sinus Pain Relief; DTXSID2020006; Phenol, p-acetamido-; Sine-Off Sinus Medicine Caplets; CHEBI:46195; Roxicet 5/500; Tocris-1706; NSC-3991; N-acetyl-para-aminophenol; 4-(N-Acetylamino)phenol; Acetaminophen (4-hydroxyacetanilide); Bayer Select Menstrual Multi-Symptom; Acetaco; n-acetyl-4-hydroxyaniline; St. Joseph Cold Tablets for Children; CHEMBL112; NSC-109028; N-(4-Hydroxyphenyl)acetamide (Tylenol); Acetaminophen-13C2,15N1; N-(4-hydroxyphenyl)-acetamide; 362O9ITL9D; Aminofen; Atasol; Duaneo; Duorol; component of Dialog; component of Dilone; Fever All; Paracetamol (INN); component of Endecon; component of Percocet; component of Phenaphen; TYL; component of Percogesic; NCGC00016361-07; Acetominophen; Actamin; CAS-103-90-2; Pasolind; Redutemp; Robigesic; Valorin; Aceta Elixir; PARACETAMOL [INN]; Dafalgan Codeine; DTXCID606; Jin Gang; WLN: QR DMV1; component of Hycomine Compound; 360769-21-7; Acetavance; Paracetamolo [Italian]; Calonal; Flexsure; Acenol (pharmaceutical); N-(4-Hydroxyphenyl)acetanilide; n-(4-hydroxyphenyl-2,3,5,6-d4)acetamide-2,2,2-d3; Drixoral Sinus; Aceta Tablets; Paracetamol [INN:BAN]; Valorin Extra; CCRIS 3; Snaplets-FR; Oraphen-PD; Phenaphen Caplets; Paracetamolum [INN-Latin]; Tylenol (caplet); Tylenol (geltab); Tylenol 8-Hour; SMR000112065; Tavist Allergy/Sinus/Headache; Dapa X-S; Drixoral Cold & Flu; HSDB 3001; SR-01000597517; EINECS 203-157-5; 222 AF; Acetaminophen [USP:JAN]; paracetamol (acetaminophen); NSC 109028; acetominophene; UNII-362O9ITL9D; 4-Hydroxyanilid kyseliny octove [Czech]; Claratal; Daphalgan; Resprin; Apacet Capsules; Atasol Caplets; Atasol Tablets; Tempra Caplets; Tylenol Caplets; Tylenol Elixir; Tylenol Gelcaps; Tylenol Tablets; Actamin Extra; Actamin Super; Aminofen Max; ANEXSIA 10/660; Apacet Elixir; Atasol Drops; Exdol Strong; p-Acetoaminophen; Tempra Drops; Tylenol Drops; alpha-Per; Citramon P; Excedrin Caplets; Dial-alpha-gesic; Apo-Acetaminophen; 4-acetominophenol; Genebs X-Tra; Paracetamol;Tylenol; 4-acetamido phenol; 4-acetamido-phenol; Tempra D.S; APAP, Paracetamol; p-hydroxyacetoanilide; Tylenol (TN); Supac (Salt/Mix); Tylox (Salt/Mix); Zydone (Salt/Mix); Atasol Forte Caplets; Atasol Forte Tablets; para-acetylaminophenol; Anexsia (Salt/Mix); Endecon (Salt/Mix); Sinubid (Salt/Mix); Talacen (Salt/Mix); Vicodin (Salt/Mix); Wygesic (Salt/Mix); Acetaminophen Uniserts; Datril Extra-Strength; Tylenol Infants Drops; Demilets (Salt/Mix); Empracet (Salt/Mix); Intensin (Salt/Mix); Propacet (Salt/Mix); Suppap-120; Suppap-325; Suppap-650; Panadol Extra Strength; TheraFlu (Salt/Mix); Coricidin (Salt/Mix); Liquiprin (Salt/Mix); Hy-Phen (Salt/Mix); IV-APAP; phenol derivative, 11; Spectrum_000016; Tempra Chewable Tablets; Naldegesic (Salt/Mix); Actimol Chewable Tablets; Feverall Junior Strength; Darvocet-N (Salt/Mix); Anacin-3 Extra Strength; Liquiprin Infants' Drops; N-acetyl para aminophenol; Prestwick0_000868; Prestwick1_000868; Prestwick2_000868; Prestwick3_000868; Spectrum2_000085; Spectrum3_000283; Spectrum4_000140; Spectrum5_000736; Coricidin D (Salt/Mix); Quiet World (Salt/Mix); Genapap Children's Elixir; Tylenol Children's Elixir; 4-Acetamidophenol, 98%; Actifed Plus (Salt/Mix); ACETAMINOPHEN [MI]; PARACETAMOL [IARC]; Epitope ID:117710; Genapap Children's Tablets; Sudafed Sinus (Salt/Mix); ACETAMINOPHEN [JAN]; EC 203-157-5; Actimol Infants' Suspension; Drixoral Sinus (Salt/Mix); Liquiprin Children's Elixir; SCHEMBL3480; Acetaminophen (JP17/USP); ACETAMINOPHEN [HSDB]; ACETAMINOPHEN [INCI]; Coricidin Sinus (Salt/Mix); N-(4-hydroxyfenyl)ethanamid; PARACETAMOL [MART.]; ACETAMINOPHEN [VANDF]; BSPBio_000915; BSPBio_001786; DDS-06A; KBioGR_000560; KBioSS_000356; PARACETAMOL [WHO-DD]; PARACETAMOL [WHO-IP]; 4-13-00-01091 (Beilstein Handbook Reference); Actimol Children's Suspension; Apacet Extra Strength Caplets; Apacet Extra Strength Tablets; Aspirin-Free Excedrin Caplets; Genebs Extra Strength Caplets; MLS001146925; MLS001331684; MLS002154041; BIDD:GT0005; DivK1c_000660; SPECTRUM1500101; Genapap Extra Strength Caplets; Genapap Extra Strength Tablets; SPBio_000010; SPBio_002836; Tapanol Extra Strength Caplets; Tapanol Extra Strength Tablets; Tylenol Extra Strength Caplets; Tylenol Extra Strength Gelcaps; Tylenol Extra Strength Tablets; ACETAMINOPHEN [USP-RS]; Actimol Junior Strength Caplets; Apacet Regular Strength Tablets; BPBio1_001007; Excedrin Extra Strength Caplets; Genebs Regular Strength Tablets; GTPL5239; Panadol Junior Strength Caplets; SGCUT00014; Tylenol Junior Strength Caplets; Midol Teen Formula (Salt/Mix); Genapap Regular Strength Tablets; Panadol Maximum Strength Caplets; Panadol Maximum Strength Tablets; SCHEMBL19474893; Tylenol Regular Strength Caplets; Tylenol Regular Strength Tablets; Aspirin-Free Anacin (Salt/Mix); BDBM26197; HMS502A22; KBio1_000660; KBio2_000356; KBio2_002924; KBio2_005492; KBio3_001286; NSC3991; Tylenol Arthritis Extended Relief; Acetaminophen, analytical standard; NINDS_000660; Tyleno	Approved	Approved Drug(s)	1983	DB00316	D0U5QK	151.16	49.3	139	0.5	11	2	2	1	C8H9NO2	N-(4-hydroxyphenyl)acetamide	CC(=O)NC1=CC=C(C=C1)O	CC(=O)NC1=CC=C(C=C1)O	InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)	RZVAJINKPMORJF-UHFFFAOYSA-N
D06MSQ	Pegaspargase	Small molecule	Pegaspargase; NSC382000; MLS002701709; 116218-49-6; 2-Propen-1-one, 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)-; CHEMBL1705708; SCHEMBL15245121; DTXSID80331167; 2-(dimethylaminomethyl)-1-(2,4-dimethylphenyl)prop-2-en-1-one; NCI60_003626; SMR001565306; 1-(2,4-Dimethylphenyl)-2-(dimethylaminomethyl)-2-propene-1-one; 2-((Dimethylamino)methyl)-1-(2,4-dimethylphenyl)-2-propen-1-one	Approved	Approved Drug(s)	436058	DB00059	D0U8JN	217.31	20.3	270	2.8	16	0	2	4	C14H19NO	2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one	CC1=CC(=C(C=C1)C(=O)C(=C)CN(C)C)C	CC1=CC(=C(C=C1)C(=O)C(=C)CN(C)C)C	InChI=1S/C14H19NO/c1-10-6-7-13(11(2)8-10)14(16)12(3)9-15(4)5/h6-8H,3,9H2,1-2,4-5H3	QXLQZLBNPTZMRK-UHFFFAOYSA-N
D6RF8X	Elagolix	Small molecule	Elagolix; 834153-87-6; (R)-Elagolix; Elagolix sodium; NBI-56418; 5B2546MB5Z; NBI56418; 834153-87-6 (free acid); Orilissa; (R)-4-((2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl)amino)butanoic acid; 4-[[(1R)-2-[5-(2-fluoranyl-3-methoxy-phenyl)-3-[[2-fluoranyl-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-bis(oxidanylidene)pyrimidin-1-yl]-1-phenyl-ethyl]amino]butanoic acid; 4-{[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl]-1-phenylethyl]amino}butanoic acid; Elagolix [USAN]; Elagolix [USAN:INN]; UNII-5B2546MB5Z; 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid; ELA gOLIX; Elagolix (USAN/INN); ELAGOLIX [INN]; ELAGOLIX [MI]; ELAGOLIX [WHO-DD]; GTPL8362; SCHEMBL1642523; CHEMBL1208155; ABT-620; DTXSID40232348; CHEBI:177453; AMY16504; BCP08827; EX-A1765; CS-5329; DB11979; compound 10b [PMID 19006286]; NBI-56418NBI-56418; AC-30676; HY-14789; MS-30861; D09335; EN300-19807339; Q21098999; 4-(((1R)-2-(5-(2-FLUORO-3-METHOXYPHENYL)-3-((2-FLUORO-6-(TRIFLUOROMETHYL)PHENYL)METHYL)- 4-METHYL-2,6-DIOXO-3,6-DIHYDROPYRIMIDIN-1(2H)-YL)-1-PHENYLETHYL)AMINO)BUTANOIC ACID; 4-(((1R)-2-(5-(2-Fluoro-3-methoxyphenyl)-3-((2-fluoro-6-(trifluoromethyl)phenyl)methyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl)amino)butanoic acid; 4-[[(1R)-2-[5-(2-luoro-3-methoxyphenyl)-3-[[2-luoro-6-(triluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid; BUTANOIC ACID, 4-(((1R)-2-(5-(2-FLUORO-3-METHOXYPHENYL)-3-((2-FLUORO-6-(TRIFLUOROMETHYL)PHENYL)METHYL)-3,6-DIHYDRO-4-METHYL-2,6-DIOXO-1(2H)-PYRIMIDINYL)-1- PHENYLETHYL)AMINO)-; Butanoic acid, 4-(((1R)-2-(5-(2-fluoro-3-methoxyphenyl)-3-((2-fluoro-6-(trifluoromethyl)phenyl)methyl)-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl)-1-phenylethyl)amino)-; F5O	Approved	Approved Drug(s)	11250647	DB11979	D0UI3T	631.6	99.2	1080	2.6	45	2	11	12	C32H30F5N3O5	4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid	CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F	CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F	InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1	HEAUOKZIVMZVQL-VWLOTQADSA-N
DKI81B	Hydroxychloroquine	Small molecule	hydroxychloroquine; 118-42-3; Plaquenil; Oxichloroquine; Polirreumin; Hidroxicloroquina; Hydroxychloroquinum; oxichlorochine; WIN 1258; 2-((4-((7-Chloroquinolin-4-yl)amino)pentyl)(ethyl)amino)ethanol; 2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol; 7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline; Oxychlorochin; CHEBI:5801; 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol; 2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol; 7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline; Hydroxychloroquine (INN); Oxichlorochinum; 4QWG6N8QKH; HCQ; 2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol; 7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline; NSC4375; 2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol; Ethanol, 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethylamino)-; Ethanol, 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]ethylamino]-; MFCD00242707; Idrossiclorochina [DCIT]; Idrossiclorochina; Hidroxicloroquina [INN-Spanish]; Hydroxychloroquinum [INN-Latin]; HYDROXYCHLOROQUINE [INN]; Hydroxychloroquine [INN:BAN]; 2-[[4-[(7-chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol; 2-{N-[4-(7-Chloro-4-quinolylamino)pentyl]-N-ethylamino}ethanol; Ethanol, 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)-; 7-chloro-4-[4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline; 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline; Polirreumin (TN); NCGC00159483-02; EINECS 204-249-8; UNII-4QWG6N8QKH; BRN 0253894; Dolquine; Ethanol, 2-[[4-[(7-chloro-4-quinolyl)amino]pentyl]ethylamino]-; R-Hydroxychloroquine; Ercoquin (Salt/Mix); Ethanol, 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]ethylamino]-, sulfate (1:1); (+-)-hydroxychloroquine; Spectrum2_001238; Spectrum5_001697; HYDROXY CHLOROQUINE; Z0188; (+/-)-hydroxychloroquine; SCHEMBL8170; CHEMBL1535; 5-22-10-00280 (Beilstein Handbook Reference); (.+/-.)-Hydroxychloroquine; DivK1c_000942; SPBio_001116; HYDROXYCHLOROQUINE [MI]; GTPL7198; DTXSID8023135; HMS502P04; KBio1_000942; HYDROXYCHLOROQUINE [VANDF]; Win 1258-2; NINDS_000942; 2-[4-[(7-chloro-4-quinolyl)amino]pentyl-ethyl-amino]ethanol; HYDROXYCHLOROQUINE [WHO-DD]; 2-[[4-[(7-Chloro-4-quinolyl)amino]pentyl](ethyl)amino]ethanol; ALBB-022466; BCP30197; 2-({4-[(7-chloro(4-quinolyl))amino]pentyl}ethylamino)ethan-1-ol; BDBM50467780; STL429829; AKOS015997886; AT13123; CCG-208059; DB01611; DT-0016; HY-W031727; SB73036; IDI1_000942; NCGC00159483-03; NCGC00159483-06; SY270913; SBI-0052759.P002; CS-0075751; FT-0627143; FT-0669455; FT-0669456; C07043; D08050; EN300-122642; AB00053257_02; Q421094; BRD-A99117172-065-01-6; BRD-A99117172-065-02-4; F2173-0553; 2-((4-(7-chloroquinolin-4-ylamino)pentyl)(ethyl)amino)ethanol; 2-[(4-[(7-Chloro-4-quinolinyl)amino]pentyl)(ethyl)amino]ethanol #; 7-chloro-4-[4-[ethyl(2-hydroxyethyl)amino]1-methylbutylamino]-quinoline; 7-chloro-4-[4-[ethyl(2-hydroxyethyl)amino]1-methylbutylamino]quinoline; (+/-)-2-((4-((7-CHLORO-4-QUINOLYL)AMINO)PENTYL)ETHYLAMINO)ETHANOL; 7-Chloro-4-(4-(N-ethyl-N-.beta.-hydroxyethylamino)-1-methylbutylamino)quinoline; ETHANOL, 2-((4-((7-CHLORO-4-QUINOLINYL)AMINO)PENTYL)ETHYL)AMINO-, (+/-)-; Oxichloroquine;Oxychlorochin;2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol	Approved	Approved Drug(s)	3652	DB01611	D0UK3A	335.9	48.4	331	3.6	23	2	4	9	C18H26ClN3O	2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol	CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO	CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO	InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)	XXSMGPRMXLTPCZ-UHFFFAOYSA-N
D0WX8Y	Avapritinib	Small molecule	Avapritinib; BLU-285; 1703793-34-3; Ayvakit; Avapritinib [INN]; BLU285; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; BLU-285 (Avapritinib); 513P80B4YJ; C-366; 70C366; X720776; X-720776; (1S)-1-(4-fluorophenyl)-1-(2-{4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl}pyrimidin-5-yl)ethan-1-amine; Ayvakyt; MFCD31544325; Ayvakit (TN); AVAPRITINIB [MI]; Avapritinib (USAN/INN); AVAPRITINIB [USAN]; Avapritinib (BLU-285); AVAPRITINIB [WHO-DD]; UNII-513P80B4YJ; CHEMBL4204794; SCHEMBL16652297; GTPL10368; AVAPRITINIB [ORANGE BOOK]; BLU 285; BDBM469269; DTXSID301027935; AMY16753; EX-A1366; US10807985, Compound 44; NSC801082; s8553; AKOS037648993; CCG-269677; CS-7577; DB15233; NSC-801082; (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethan-1-amine; AC-31598; BB166456; BS-16206; HY-101561; D11279; EN300-25382569; Q29213676; (1S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo(2,1-f)(1,2,4)triazin-4-yl)-1-piperazinyl)-5-pyrimidinyl)ethanamine; (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO(2,1-F)(1,2,4)TRIAZIN-4-YL)PIPERAZIN-YL)PYRIMIDIN-5-YL)ETHAN-1-AMINE; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine; 5-PYRIMIDINEMETHANAMINE, .ALPHA.-(4-FLUOROPHENYL)-.ALPHA.-METHYL-2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO(2,1-F)(1,2,4)TRIAZIN-4-YL)-1-PIPERAZINYL)-, (.ALPHA.S)-	Approved	Approved Drug(s)	118023034	DB15233	D0UO2P	498.6	106	752	1.9	37	1	9	5	C26H27FN10	(1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine	CC(C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N	C[C@](C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N	InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1	DWYRIWUZIJHQKQ-SANMLTNESA-N
DX38BR	Chlorhexidine gluconate	Small molecule	CHLORHEXIDINE DIGLUCONATE; 18472-51-0; Chlorhexidine gluconate; Hibiclens; Peridex; Dyna-hex; Bioscrub; Chlorhexidine D-digluconate; Exidine; Microderm; Periochip; Periogard; Unisept; Brian Care; Steri-Stat; Cida-Stat; Hibistat; Pharmaseal Scrub Care; CHG SCRUB; Prevacare; Chlorhexidine di-D-gluconate; MOR84MUD8E; NSC-753971; Hibiscrub; Hibitane; 1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide), digluconate; 1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide) di-D-gluconate; Bacticlens; Chlorhexamed; Kleersight; Corsodyl; Disteryl; Hibident; Hibidil; Orahexal; Plurexid; Septeal; Abacil; Fight bac; Plac out; Prevacare R; Arlacide G; Hibitane 5; 2,4,11,13-Tetraazatetradecanediimidamide, N,N''-bis(4-chlorophenyl)-3,12-diimino-, di-D-gluconate; Chlorhexidin glukonatu; Peridex (antiseptic); Bactoshield CHG 2%; Caswell No. 481G; 55-56-1; UNII-MOR84MUD8E; PwrioChip; Chlorhexidin glukonatu [Czech]; 1,6-Bis(N5-[p-chlorophenyl]-N1-biguanido)hexane; pHiso-Med; Hibitane gluconate; Hibiclens (TN); Periogard (TN); DRG-0091; EINECS 242-354-0; Peridex (TN); MFCD00083599; Chlohexidine gluconate; EPA Pesticide Chemical Code 045504; READYPREP CHG; Chlorhexidine gluconate [USAN:USP:JAN]; EC 242-354-0; SCHEMBL34468; 1,6-Bis(5-(p-chlorophenyl)biguandino)hexane digluconate; CHEMBL4297088; DTXSID5034519; CHEBI:28312; 1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide) gluconate; 1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide)digluconate; Biguanide, 1,1'-hexamethylenebis(5-(p-chlorophenyl)-, digluconate; Chlorhexidine gluconate (JP17/USP); CHLORHEXIDINE GLUCONATE [JAN]; CHLORHEXIDINE GLUCONATE [USAN]; AKOS015896303; AKOS025310696; CHLORHEXIDINE GLUCONATE [MART.]; CHLORHEXIDINE GLUCONATE [VANDF]; NSC 753971; CHLORHEXIDINE D-DIGLUCONATE [MI]; CHLORHEXIDINE DIGLUCONATE [INCI]; CHLORHEXIDINE GLUCONATE [WHO-DD]; D-Gluconic acid, compound with N,N''-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediamidine (2:1); C3105; CHLORHEXIDINE GLUCONATE [ORANGE BOOK]; CHLORHEXIDINE GLUCONATE [USP IMPURITY]; AVAGARD COMPONENT CHLORHEXIDINE GLUCONATE; C08038; D00858; SOLUPREP COMPONENT CHLORHEXIDINE GLUCONATE; CHLORAPREP COMPONENT CHLORHEXIDINE GLUCONATE; CHLORHEXIDINE GLUCONATE COMPONENT OF AVAGARD; CHLORHEXIDINE GLUCONATE COMPONENT OF SOLUPREP; J-011837; CHLORHEXIDINE GLUCONATE COMPONENT OF CHLORAPREP; 1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide] Digluconate; Chlorhexidine digluconate, Pharmaceutical Secondary Standard; Certified Reference Material; 1,1'-Hexamethylenebis[5-(p-chlorophenyl)biguanide] (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid(1:2); 1-(4-chlorophenyl)-3-[N-[6-[[N-[N-(4-chlorophenyl)carbamimidoyl]carbamimidoyl]amino]hexyl]carbamimidoyl]guanidine; (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid; 2,4,11,13-Tetraazatetradecanediimidamide, N,N''-bis(4-chlorophenyl)-3,12-diimino-, digluconate; 2,4,11,13-Tetraazatetradecanediimidamide, N,N'-bis(4-chlorophenyl)-3,12-diimino-, di-D-gluconate; D-Gluconic acid, compd with N,N''-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide (2:1); N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]--D-gluconic acid (1/2)	Approved	Approved Drug(s)	9552081	DB00878	D0V4GY	897.8	455	819	.	60	18	16	23	C34H54Cl2N10O14	(1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid	C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl.C(C(C(C(C(C(=O)O)O)O)O)O)O.C(C(C(C(C(C(=O)O)O)O)O)O)O	C1=CC(=CC=C1N/C(=N/C(=NCCCCCCN=C(/N=C(/NC2=CC=C(C=C2)Cl)\N)N)N)/N)Cl.C(O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O.C(O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O	InChI=1S/C22H30Cl2N10.2C6H12O7/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18;2*7-1-2(8)3(9)4(10)5(11)6(12)13/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34);2*2-5,7-11H,1H2,(H,12,13)/t;2*2-,3-,4+,5-/m.11/s1	YZIYKJHYYHPJIB-UUPCJSQJSA-N
DF5Z0B	Olanzapine	Small molecule	olanzapine; 132539-06-1; Zyprexa; Olansek; Zalasta; Zyprexa Zydis; Zyprexa Velotab; Zyprexa Intramuscular; Zolafren; Zypadhera; LY-170053; Olanzapine Mylan; 2-Methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; Olzapin; Lanzac; Oferta; Olazax; Olanzapine Teva; Olazax Disperzi; LY 170053; Olanzapine Glenmark; C17H20N4S; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; Olanzapine cipla; LY170053; Olanzapine apotex; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine; 10H-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; CHEMBL715; N7U69T4SZR; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; CHEBI:7735; DTXSID9023388; olanzapina; NCGC00096077-03; 10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene; DTXCID503388; olanzapinum; Midax; 2-methyl-4-(4-methyl-1-piperazinyl)-5H-thieno[3,2-c][1,5]benzodiazepine; Olanzapine  Teva; SMR000466345; Olanzapine Neopharma; CAS-132539-06-1; SR-01000759343; Olanzapine Glenmark Europe; UNII-N7U69T4SZR; Olanzapin; ALKS-7921; HSDB 8155; Olanzapine [USAN:USP:INN:BAN]; Olanzapine- Bio-X; MFCD00866702; Olanzapine (Zyprexa); KS-1090; OLANZAPINE [MI]; OLANZAPINE [INN]; OLANZAPINE [JAN]; OLANZAPINE [USAN]; OLANZAPINE [VANDF]; GTPL47; 2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine; OLANZAPINE [MART.]; OLANZAPINE [USP-RS]; OLANZAPINE [WHO-DD]; BIDD:PXR0138; SCHEMBL28763; Olanzapine (JAN/USP/INN); US8802672, Olanzapine; MLS000759457; MLS001165781; MLS001195646; MLS001424057; BIDD:GT0332; OLANZAPINE [EMA EPAR]; SCHEMBL117695; SPECTRUM1505024; Olanzapine (LY-170053); OLANZAPINE [ORANGE BOOK]; Olanzapine, >=98% (HPLC); BDBM35254; BDBM82479; CHEBI:94534; AMY7709; OLANZAPINE [EP MONOGRAPH]; HMS2051H05; HMS2089M04; HMS2093I04; HMS2233F24; HMS3374L02; HMS3393H05; HMS3657I15; HMS3714J03; HMS3743A09; HMS3884J21; OLANZAPINE [USP MONOGRAPH]; LYBALVI COMPONENT OLANZAPINE; SYMBYAX COMPONENT OLANZAPINE; ACT03231; ALBB-027265; BCP04917; NSC_4585; Tox21_111556; AC-665; HB1786; NSC754829; NSC801187; s2493; STK634338; STL388024; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; AKOS000282888; AKOS005566122; Olanzapine 1.0 mg/ml in Acetonitrile; OLANZAPINE COMPONENT OF LYBALVI; OLANZAPINE COMPONENT OF SYMBYAX; Tox21_111556_1; BCP9001021; CCG-100922; CS-1114; DB00334; NC00172; NSC-754829; NSC-801187; NCGC00096077-01; NCGC00096077-04; NCGC00096077-05; NCGC00096077-06; NCGC00096077-18; NCGC00389791-02; BO164166; HY-14541; SBI-0206786.P001; CAS_132539-06-1; FT-0673219; O0393; SW220248-1; C07322; D00454; EN300-119499; AB00639907-06; AB00639907-07; AB00639907_08; AB00639907_09; A806453; L000455; L005958; Q201872; J-006186; SR-01000759343-4; SR-01000759343-6; Z1521553472; Olanzapine, European Pharmacopoeia (EP) Reference Standard; Olanzapine, United States Pharmacopeia (USP) Reference Standard; Olanzapine, Pharmaceutical Secondary Standard; Certified Reference Material; (E)-2-methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine; 2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene; 2-methyl-4-(4-methyl-1-piperazinyl) -10h-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine #; 2-Methyl-4-(4-methylpiperazin-1-yl)-10H- thieno[2,3-b][1,5]benzodiazepin; Olanzapine for system suitability, European Pharmacopoeia (EP) Reference Standard; Olanzapine-d8, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0,3,7]tetradeca-1(10),3(7),5,8,11,13-hexaene	Approved	Approved Drug(s)	135398745	DB00334	D0V4QS	312.4	59.1	432	2.9	22	1	4	1	C17H20N4S	2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine	CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C	CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C	InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3	KVWDHTXUZHCGIO-UHFFFAOYSA-N
DP0DH5	Lurbinectedin	Small molecule	Lurbinectedin; 497871-47-3; PM01183; Tryptamicidin; Zepzelca; PM-01183; PM-1183; 2CN60TN6ZS; PM 01183; PM1183; [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate; zepsyre; Lurbinectedin [INN]; UNII-2CN60TN6ZS; LURBINECTEDIN [MI]; Lurbinectedin [USAN:INN]; LURBINECTEDIN [USAN]; LURBINECTEDIN [WHO-DD]; CHEMBL4297516; SCHEMBL16152477; GTPL10681; DTXSID30198065; LURBINECTEDIN [ORANGE BOOK]; EX-A4316; WHO 9397; NSC826275; s9603; AT22223; CS-6323; DB12674; NSC-826275; HY-16293; MS-31432; J3.531.659K; J3.652.626B; PM01183;PM-1183;LY-01017;ryptamicidin; EN300-23257233; Q27254568; (1'R,6R,6AR,7R,13S,14S,16R)-8,14-DIHYDROXY-6',9-DIMETHOXY-4,10,23-TRIMETHYL-19-OXO-2',3',4',6,7,9',12,13,14,16-DECAHYDRO-6AHSPIRO(7,13-AZANO-6,16-(EPITHIOPROPANOOXYMETHANO)(1,3)DIOXOLO(7,8)ISOQUINOLINO(3,2-B)(3)BENZAZOCINE-20,1'-PYRIDO(3,4-B)INDOL)-5-YL ACETATE; (1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxo-2',3',4',9'-tetrahydro-17,19,28-trioxa-24-thia-13,30-diazaspiro[heptacyclo[12.9.6.1^{3,11}.0^{2,13}.0^{4,9}.0^{15,23}.0^{16,20}]triacontane-26,1'-pyrido[3,4-b]indole]-4(9),5,7,15(23),16(20),21-hexaen-22-yl acetate; [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22; SPIRO(6,16-(EPITHIOPROPANOXYMETHANO)-7,13-IMINO-12H-1,3-DIOXOLO(7,8)ISOQUINO(3,2-B)(3)BENZAZOCINE-20,1'-(1H)PYRIDO(3,4-B)INDOL)-19-ONE, 5-(ACETYLOXY)-2',3',4',6,6A,7,9',13,14,16-DECAHYDRO-8,14-DIHYDROXY-6',9-DIMETHOXY-4,10,23-TRIMETHYL-, (1'R,6R,6AR,7R,13S,14S,16R)-	Approved	Approved Drug(s)	57327016	DB12674	D0V6OA	784.9	190	1530	3.9	56	4	14	4	C41H44N4O10S	[(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate	CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O	CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O	InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1	YDDMIZRDDREKEP-HWTBNCOESA-N
DS19UO	Fostamatinib	Small molecule	Fostamatinib; 901119-35-5; R788; Fostamatinib (R788); Tavalisse; Fostamatinib(R788); R-788 Free acid; R788 FREE ACID; R-935788 Free acid; [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate; Fostamatinib [USAN]; R935788 FREE ACID; R 788; R-788; SQ8A3S5101; R7935788; Fostamatinib (USAN); 2H-Pyrido(3,2-b)-1,4-oxazin-3(4H)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-; Tavlesse; [6-({5-Fluoro-2-[(3,4,5-Trimethoxyphenyl)amino]pyrimidin-4-Yl}amino)-2,2-Dimethyl-3-Oxo-2,3-Dihydro-4h-Pyrido[3,2-B][1,4]oxazin-4-Yl]methyl Dihydrogen Phosphate; R788 compound; Fostamatinib [USAN:INN]; UNII-SQ8A3S5101; R-935788; (6-((5-FLUORO-2-((3,4,5-TRIMETHOXYPHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-PYRIDO(3,2-B)(1,4)OXAZIN-4-YL)METHYL DIHYDROGEN PHOSPHATE; 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-; R 788 compound; R788 (Fostamatinib); FOSTAMATINIB [MI]; FOSTAMATINIB [INN]; FOSTAMATINIB [WHO-DD]; GTPL7796; SCHEMBL1201371; CHEMBL2103830; EX-A108; BCPP000226; DTXSID401009170; HMS3651H09; BCP01871; BDBM50431381; HY-13038A; MFCD16628163; NSC800102; s2625; AKOS025404920; AM81257; BCP9000704; CCG-270128; DB12010; NSC-800102; PB25570; NCGC00346622-01; NCGC00346622-02; [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxo-pyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate; AC-30126; AS-56399; FT-0699180; SW219234-1; D09347; A857764; EN300-20332957; J-517972; Q5473550; Z2235801948; R788;R7935788;R 788;R 7935788;R-788;R-7935788; (6-((5-Fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl dihydrogen phosphate; (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2,3-dihydropyrido[3,2-b][1,4]oxazin-4-yl)methyl dihydrogen phosphate; [6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[2,3-e][1,4]oxazin-4-yl]methyl dihydrogen phosphate; {[6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-3-oxo-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-4-yl]methoxy}phosphonic acid; 2RC; 6-((5-Fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-2h-pyrido(3,2-b)-1,4-oxazi n-3(4h)-one; 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one; R 788; 6-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one	Approved	Approved Drug(s)	11671467	DB12010	D0V8HJ	580.5	187	904	1.6	40	4	15	10	C23H26FN6O9P	[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate	CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C	CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C	InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)	GKDRMWXFWHEQQT-UHFFFAOYSA-N
D53LTN	Viloxazine	Small molecule	viloxazine; 46817-91-8; Viloxazin; 2-((2-ETHOXYPHENOXY)METHYL)MORPHOLINE; 2-[(2-ethoxyphenoxy)methyl]morpholine; Viloxazina; Morpholine, 2-((2-ethoxyphenoxy)methyl)-; 2-(2-Ethoxyphenoxymethyl)tetrahydro-1,4-oxazine; Morpholine, 2-[(2-ethoxyphenoxy)methyl]-; CHEMBL306700; 5I5Y2789ZF; Viloxazine (INN); Qelbree; VILOXAZINE [INN]; ICI-58834; Viloxazinum; Viloxazine [INN:BAN]; Viloxazinum [INN-Latin]; Viloxazina [INN-Spanish]; CCRIS 9180; EINECS 256-281-7; ICI-58,834; UNII-5I5Y2789ZF; 2-(o-ethoxyphenoxymethyl)morpholine; VILOXAZINE [MI]; VILOXAZINE [VANDF]; VILOXAZINE [WHO-DD]; Oprea1_394269; SCHEMBL34168; DivK1c_001019; DTXSID6057900; CHEBI:94405; GTPL11502; KBio1_001019; NINDS_001019; BDBM50025691; MFCD00865384; 2-[(o-Ethoxyphenoxy)methyl]morpholine; AKOS013400287; 2-(2-Ethoxy-phenoxymethyl)-morpholine; DB09185; HY-W380450; IDI1_001019; CS-0491105; D08673; EN300-253642; 2-(2-Ethoxy-phenoxymethyl)-morpholine(viloxazine); Q907148; (+/-)-2-(O-ETHOXYPHENOXYMETHYL)MORPHOLINE; 2-(2-Ethoxy-phenoxymethyl)-morpholine (viloxazine); BRD-A59198242-003-01-1; Z1235945951	Approved	Approved Drug(s)	5666	DB09185	D0V9JR	237.29	39.7	213	1.5	17	1	4	5	C13H19NO3	2-[(2-ethoxyphenoxy)methyl]morpholine	CCOC1=CC=CC=C1OCC2CNCCO2	CCOC1=CC=CC=C1OCC2CNCCO2	InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3	YWPHCCPCQOJSGZ-UHFFFAOYSA-N
DQ6WD8	Ribavirin	Small molecule	ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Copegus; Ribasphere; Vilona; Ribavirine; Viramid; RTCA; Cotronak; Ribamide; Ribamidil; Ribavirina; Ribavirinum; Ribavirine [INN-French]; Ribavirinum [INN-Latin]; ICN-1229; Ribavirina [INN-Spanish]; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; Ribavirin Mylan; Ribavirin Teva; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; Ribavirin BioPartners; SCH 18908; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboxamide; RBV; MFCD00058564; Ribamidyl; Ribavirin (Copegus); 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; Rebetron; Varazid; NSC-163039; Ribavirin Capsules; 1H-1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-; DTXSID8023557; CHEBI:63580; 49717AWG6K; SCH-18908; 1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide; Rebretron; Virazid; Virazide; 1H-1,2,4-Triazole-3-carboxamide, 1-.beta.-D-ribofuranosyl-; Ribav; DTXCID603557; RTC; Ravanex; Ribacine; C-Virin; DRG-0028; Ribasphere (TN); Virazole (TN); 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,2,4-triazole-3-carboxamide; SMR000058315; Copegus (TN); Rebetol (TN); HSDB 6513; SR-01000076112; BRN 0892462; Ribavirin Teva Pharma B.V.; UNII-49717AWG6K; Ribavirine;; NSC163039; Ribavirin [USAN:USP:INN:BAN]; Ribavirin,(S); NCGC00015904-02; 66510-90-5; Ribavirin, antiviral; CAS-36791-04-5; RG-964; Ro-20-9963; Spectrum_001826; 4pb1; RIBAVIRIN [INN]; RIBAVIRIN [JAN]; RIBAVIRIN [MI]; ribofluranosyl carboxamide; RIBAVIRIN [HSDB]; RIBAVIRIN [USAN]; Prestwick3_000993; Spectrum3_001876; Spectrum4_001252; Spectrum5_002075; RIBAVIRIN [VANDF]; R-964; RIBAVIRIN [MART.]; R 9644; RIBAVIRIN [USP-RS]; RIBAVIRIN [WHO-DD]; SCHEMBL3727; 1-.beta.-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; CHEMBL1643; Lopac0_001063; BSPBio_001085; BSPBio_003352; KBioGR_001804; KBioSS_002331; RIBAVIRIN [EMA EPAR]; cid_37542; MLS000028486; MLS002222317; DivK1c_000782; SPECTRUM1503938; Ribavirin (JP17/USP/INN); BPBio1_001195; GTPL6842; RIBAVIRIN [ORANGE BOOK]; 1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-; 1-(beta-D-Ribofuranosyl)-1,2,4-triazole-3-carboxamide; 1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; RIBAVIRIN [EP MONOGRAPH]; HMS502H04; KBio1_000782; KBio2_002328; KBio2_004896; KBio2_007464; KBio3_002854; RIBAVIRIN [USP MONOGRAPH]; NINDS_000782; HMS2090L15; HMS2094O09; HMS2098G07; HMS2232P07; HMS3263E08; HMS3715G07; Pharmakon1600-01503938; HY-B0434; Tox21_110259; Tox21_200967; Tox21_501063; BDBM50154375; CCG-38985; HB4522; NSC758650; s2504; AKOS001715163; Tox21_110259_1; DB00811; GS-3572; LP01063; NSC-758650; SDCCGSBI-0051033.P004; IDI1_000782; SMP1_000261; NCGC00090726-01; NCGC00090726-03; NCGC00090726-04; NCGC00090726-05; NCGC00090726-06; NCGC00090726-07; NCGC00090726-08; NCGC00090726-09; NCGC00090726-12; NCGC00090726-25; NCGC00090726-30; NCGC00258520-01; NCGC00261748-01; 252269-50-4; AS-34178; BCP0726000138; RIBAVIRIN COMPONENT OF PEGINTERFERON; SBI-0051033.P003; AB00430481; EU-0101063; R0077; EN300-59237; D00423; AB00430481-15; AB00430481-16; AB00430481_17; AB00430481_18; 1-beta-Ribofuranosyl-1,2,4-triazole-3-carboamide; A823370; Q421862; Ribavirin 100 microg/mL in Acetonitrile:Methanol; SR-01000721904; 1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide; 1-ss-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; SR-01000076112-2; SR-01000076112-3; SR-01000076112-4; SR-01000721904-2; BRD-K60369935-001-02-7; BRD-K60369935-001-18-3; SR-01000076112-11; 1-?-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; Ribavirin, British Pharmacopoeia (BP) Reference Standard; Z594284196; 1-(beta -D-ribofuranosyl)-1,2,4-triazole-3-carboxamide; Ribavirin, European Pharmacopoeia (EP) Reference Standard; Ribavirin, United States Pharmacopeia (USP) Reference Standard; Ribavirin, Pharmaceutical Secondary Standard; Certified Reference Material; 1-beta-<span class='DL'>D</span>-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; 1-[(2R,3S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,2,4-triazole-3-carboxamide	Approved	Approved Drug(s)	37542	DB00811	D0VI8H	244.2	144	304	-1.8	17	4	7	3	C8H12N4O5	1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide	C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N	C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N	InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1	IWUCXVSUMQZMFG-AFCXAGJDSA-N
DXP13T	Aclidinium	Small molecule	Aclidinium; Aclidinium ion; Aclidinium cation; K17VY42F6C; CHEBI:65346; 727649-81-2; CHEMBL551466; (3R)-3-[2-hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; UNII-K17VY42F6C; (3R)-3-(2-HYDROXY(DI-2-THIENYL)ACETOXY)-1-(3-PHENOXYPROPYL)-1-AZONIABICYCLO(2.2.2)OCTANE; (3R)-3-{[Hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide; ACLIDINIUM [VANDF]; ACLIDINIUM [WHO-DD]; SCHEMBL72141; GTPL7449; CHEMBL1194325; SCHEMBL15096073; DTXSID00223070; BDBM50296331; DB08897; NCGC00386257-02; AB01565828_02; Q521173; 1-(3-Phenoxypropyl)-3alpha-[hydroxybis(2-thienyl)acetyloxy]-1-azoniabicyclo[2.2.2]octane; [(8R)-1-[3-(phenoxy)propyl]-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-di(thiophen-2-yl)acetate; 1-AZONIABICYCLO(2.2.2)OCTANE, 3-((HYDROXYDI-2-THIENYLACETYL)OXY)-1-(3-PHENOXYPROPYL)-, (3R)-	Approved	Approved Drug(s)	11434515	DB08897	D0VP1V	484.7	112	647	4.7	33	1	6	10	C26H30NO4S2+	[(3R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate	C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5	C1C[N+]2(CCC1[C@H](C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5	InChI=1S/C26H30NO4S2/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2/q+1/t20?,22-,27?/m0/s1	ASMXXROZKSBQIH-VITNCHFBSA-N
D9UPO8	Conivaptan	Small molecule	Conivaptan; 210101-16-9; Conivaptan [INN]; YM087; Conivaptan (INN); N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; CHEBI:681850; 0NJ98Y462X; 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide; (1,1'-biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-; [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-; CONIVAPTAN [MI]; CONIVAPTAN [VANDF]; CHEMBL1755; CONIVAPTAN [WHO-DD]; SCHEMBL49815; UNII-0NJ98Y462X; GTPL2203; BDBM85095; DTXSID80175220; HMS3745C21; BCP07817; PDSP1_001735; PDSP2_001718; AKOS015917893; CAS_151171; DB00872; NSC_151171; NCGC00345881-02; NCGC00345881-03; NCGC00345881-04; NCGC00345881-05; AC-30626; N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide; DB-066404; AM20090722; FT-0724257; D07748; AB01565868_02; EN300-6481317; L001073; L001531; Q5161126; Z2588038959; (1,1'-Biphenyl)-2-carboxamide, N-(4-(4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-; 4''-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide; 4'-[(2-Methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide; N-(4-{4-methyl-3,5,9-triazatricyclo[8.4.0.0,2,6]tetradeca-1(10),2(6),3,11,13-pentaene-9-carbonyl}phenyl)-[1,1'-biphenyl]-2-carboxamide; N-[4-({4-methyl-3,5,9-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),2(6),3,11,13-pentaen-9-yl}carbonyl)phenyl]-2-phenylbenzamide; N-[4-(2-methyl4,5-dihydro-3H-imidazo[5,4-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; N-[4-[(4,5-Dihydro-2-methylimidazo[4,5-d][benzazepin-6(1H)-yl)carbonyl]phenyl-[1,1'-biphenyl]-2-carboxamide hydrochloride	Approved	Approved Drug(s)	151171	DB00872	D0VU2X	498.6	78.1	820	5.7	38	2	3	4	C32H26N4O2	N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide	CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6	CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6	InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)	IKENVDNFQMCRTR-UHFFFAOYSA-N
DQU71M	Anastrozole	Small molecule	anastrozole; 120511-73-1; Arimidex; anastrazole; ZD1033; Anastrozol; 2,2'-(5-((1H-1,2,4-triazol-1-yl)methyl)-1,3-phenylene)bis(2-methylpropanenitrile); ICI D1033; ZD-1033; ICI-D1033; 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile; alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; NSC-719344; NSC-759855; 2Z07MYW1AZ; CHEMBL1399; CHEBI:2704; DTXSID9022607; Rvg-106400; NSC719344; 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); NCGC00164619-01; Asiolex; 2-[3-(1-cyano-1-methylethyl)-5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile; alpha1,alpha1,alpha3,alpha3-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile; DTXCID202607; ZD 1033; Arimidex (TN); SMR000466301; CAS-120511-73-1; HSDB 7462; ICI-D 1033; SR-01000759390; UNII-2Z07MYW1AZ; CCRIS 9352; Anastrozole [USAN:USP:INN:BAN]; Anastrozole- Bio-X; Arimidex (AstraZeneca); ANASTROZOLE [MI]; ANASTROZOLE [INN]; ANASTROZOLE [JAN]; ANASTROZOLE [HSDB]; ANASTROZOLE [USAN]; SCHEMBL9726; ANASTROZOLE [MART.]; ANASTROZOLE [USP-RS]; ANASTROZOLE [WHO-DD]; 1,3-Benzenediacetonitrile, alpha,alpha,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-; MLS000759396; MLS001424217; MLS006011961; Anastrozole (JAN/USP/INN); GTPL5137; BDBM10015; ANASTROZOLE [ORANGE BOOK]; ANASTROZOLE [EP MONOGRAPH]; ANASTROZOLE [USP IMPURITY]; BCPP000401; HMS2052M11; HMS2089N10; HMS2235M06; HMS3369K05; HMS3394M11; HMS3654I18; HMS3715B05; HMS3742O21; HMS3866K03; Pharmakon1600-01502278; ANASTROZOLE [USP MONOGRAPH]; ACT03222; AMY42020; BCP02090; Tox21_112238; Tox21_303568; MFCD00866298; NSC759855; s1188; STL451008; AKOS015894980; Tox21_112238_1; AC-4234; BCP9000301; CCG-101109; CS-0716; DB01217; KS-5052; NC00359; NSC 719344; NSC 759855; SB17304; 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); NCGC00164619-02; NCGC00164619-04; NCGC00257356-01; BT164176; HY-14274; SW197739-4; C08159; D00960; EN300-118709; AB00639929-06; AB00639929-08; AB00639929-09; AB00639929-10; AB00639929_11; AB00639929_13; A804526; Q419143; SR-01000759390-4; SR-01000759390-5; Z1515385077; 3-AMINO-3-(4-DIETHYLAMINO-2-HYDROXY-PHENYL)-PROPIONICACID; 1,.alpha.,alpha.,alpha.',.alpha.'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-; 2,2'-[5-(1H-1,2,4-triazol-1-yl-methyl)-1,3-phenylene]-di(2-methyl propionitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropiononitrile); 2,2'-[5-(1H-1,2,4-triazole-1-yl-methyl)-1,3-phenylene]di(2-methyl propionitrile); 2-[3-(2-cyano-2-propyl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropiononitrile; 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methyl-propanenitrile; .alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; .ALPHA.,.ALPHA.,.ALPHA.',.ALPHA.'-TETRAMETHYL-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-M-BENZENEDIACETONITRILE; 1,3-BENZENEDIACETONITRILE,.ALPHA.,.ALPHA.,.ALPHA.',.ALPHA.'-TETRAMETHYL-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-; 2-[3-(1-cyano-1-methylethyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]phenyl]-2-methylpropanenitrile; alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile	Approved	Approved Drug(s)	2187	DB01217	D0W0BF	293.4	78.3	456	2.1	22	0	4	4	C17H19N5	2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile	CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N	CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N	InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3	YBBLVLTVTVSKRW-UHFFFAOYSA-N
DS2XJ6	Avatrombopag	Small molecule	AVATROMBOPAG; 570406-98-3; AKR-501; Doptelet; E5501; YM477; Avatrombopag free base; YM-477; 3H8GSZ4SQL; 570406-98-3 (free base); 1-[3-chloro-5-[[[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbonyl]-2-pyridinyl]-4-piperidinecarboxylic acid; E5501;AKR-501;YM477; YM-301477; E-5501; 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid; (1-(3-chloro-5-((4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid); 1-(3-chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)pyridin-2-yl)piperidine-4-carboxylic acid; Avatrombopag [USAN]; AKR 501; UNII-3H8GSZ4SQL; Avatrombopag [USAN:INN]; 1-(3-CHLORO-5-{[4-(4-CHLOROTHIOPHEN-2-YL)-5-(4-CYCLOHEXYLPIPERAZIN-1-YL)-1,3-THIAZOL-2-YL]CARBAMOYL}PYRIDIN-2-YL)PIPERIDINE-4-CARBOXYLIC ACID; 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl)piperidine-4-carboxylic acid; E5501 compound; YM 477; AVATROMBOPAG [MI]; AS 1670542; Avatrombopag (USAN/INN); AVATROMBOPAG [INN]; E 5501; AVATROMBOPAG [WHO-DD]; SCHEMBL289354; AKR501; GTPL9953; CHEMBL2103883; DTXSID30205667; AMY40535; BCP28031; EX-A6599; VXA40698; s6624; CS-3397; DB11995; SB16846; HY-13463; MS-30955; DB-072238; FT-0728753; A14087; D10306; F85065; AKR-501;E5501;AS1670542; EN300-18167306; Q27257213; 1-(3-chloro-5-((4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid; 1-(3-CHLORO-5-((4-(4-CHLOROTHIOPHEN-2-YL)-5-(4-CYCLOHEXYLPIPERAZIN-1-YL)THIAZOL-2-YL)CARBAMOYL)-2-PYRIDYL)PIPERIDINE-4-CARBOXYLIC ACID; 1-[3-Chloro-5-[[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazino)-2-thiazolyl]carbamoyl]-2-pyridyl]piperidine-4-carboxylic acid; 4-Piperidinecarboxylic acid, 1-(3-chloro-5-(((4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl)amino)carbonyl)-2-pyridinyl)-	Approved	Approved Drug(s)	9852519	DB11995	D0W1DI	649.7	158	935	4	42	2	10	7	C29H34Cl2N6O3S2	1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid	C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl	C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl	InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38)	OFZJKCQENFPZBH-UHFFFAOYSA-N
DW24XA	Lonafarnib	Small molecule	Lonafarnib; 193275-84-2; Sarasar; Sch66336; Sch 66336; Sch-66336; Zokinvy; CHEMBL298734; Lonafarnib [USAN]; IOW153004F; (+)-4-(2-(4-(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-piperidin-1-yl))-2-oxoethyl)-piperidine-1-carboxamide; (R)-4-(2-(4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl)-2-oxoethyl)piperidine-1-carboxamide; 1-Piperidinecarboxamide, 4-(2-(4-((11R-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-; 1-PIPERIDINECARBOXAMIDE, 4-[2-[4-[(11R)-3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL]-1-PIPERIDINYL]-2-OXOETHYL]-; 4-[2-[4-(6,15-Dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl)piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide; 4-[2-[4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide; 1-Piperidinecarboxamide, 4-(2-(4-((11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-; SMR004701448; Lonafarnib (USAN/INN); Lonafarnib [USAN:INN]; Lonafarnib (SCH66336); lonafarnibum; UNII-IOW153004F; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide; SCH-066336; 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide; 1o5m; LONAFARNIB [MI]; LONAFARNIB [INN]; (non-labelled)Lonafarnib-d9; LONAFARNIB [WHO-DD]; SCHEMBL19032; MLS006010423; MLS006011106; GTPL8024; LONAFARNIB [ORANGE BOOK]; Lonafarnib, >=98% (HPLC); BDBM14459; CHEBI:47097; DTXSID90172927; BCP07027; EX-A1630; NSC719467; s2797; AKOS005145760; CCG-270312; CS-0792; DB06448; NSC-719467; NCGC00346707-01; AC-32661; AS-56182; HY-15136; SW220034-1; C73675; D04768; EN300-18167093; J-514232; Q3258910; (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidin-yl]-2-oxo-ethyl]-1-piperidinecarboxamide; (+)-4[2-[4-(8-Chloro-3,11-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]-pyridin-11(R)-yl-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide; 4-(2-{4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperidin-1-yl}-2-oxoethyl)piperidine-1-carboxamide; 4-(2-{4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]piperidin-1-yl}-2-oxoethyl)piperidine-1-carboxamide; 4-(2-{4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-2-yl]piperidin-1-yl}-2-oxoethyl)piperidine-1-carboxamide; 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[1,2]cyclohepta[2,4-b]pyridin-11-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide; 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5h-Benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-Piperidinyl]-2-oxoethyl]-1-Piperidi necarboxamide	Approved	Approved Drug(s)	148195	DB06448	D0W4HZ	638.8	79.5	790	4.8	36	1	3	3	C27H31Br2ClN4O2	4-[2-[4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide	C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N	C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N	InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1	DHMTURDWPRKSOA-RUZDIDTESA-N
DSK62X	Sorafenib	Small molecule	Sorafenib; 284461-73-0; Nexavar; BAY 43-9006; 4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N-METHYLPICOLINAMIDE; sorafenibum; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; Sorafenib free base; 100012-18-8; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; 284461-73-0 (free base); MFCD06411450; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; BAY-43-9006; 9ZOQ3TZI87; CHEMBL1336; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; DTXSID7041128; CHEBI:50924; Sorafenib [INN]; 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; Sorafenib (Nexavar); 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; Donafenib (Sorafenib D3); 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-; BAX; 1210608-86-8; NSC-724772; NCGC00167488-01; UNII-9ZOQ3TZI87; Sorafenib [USAN:INN:BAN]; SR-00000000529; HSDB 8173; 1uwh; 3gcs; 3heg; 4asd; Hit compound, 8; Sorafenib, 4; 4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N(SUP 2)-METHYLPYRIDINE-2-CARBOXAMIDE; Manganese(4+), chloro[[4,4',4'',4'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis[1-methylpyridiniumato]](2-)]-, chloride (1:4), (SP-5-12)-; BAY 439006; BAY43-9006; Kinome_766; SORAFENIB BASE; SORAFENIB [MI]; Sorafenib (USAN/INN); Sorafenib-[13C,d3]; SORAFENIB [USAN]; Nexavar (TN) (Bayer); SORAFENIB [VANDF]; SORAFENIB [MART.]; EC 608-209-4; SCHEMBL8218; SORAFENIB [WHO-DD]; SORAFENIB [EMA EPAR]; BAY 43-9006; Sorafenib; cid_216239; GTPL5711; BDBM16673; BCPP000064; HMS2043A18; HMS3244A15; HMS3244A16; HMS3244B15; HMS3656N20; K00597a; ACT06732; BCP01767; BCP34023; EX-A2894; BAY439006; NSC747971; NSC800934; s7397; STK627350; AKOS005560229; AC-1674; BAY-439006; CCG-269400; CS-1590; DB00398; NSC-747971; NSC-800934; PB14443; SB19942; SF-0529; BAY-43-0006; Sorafenib free base (BAY-43-9006); NCGC00167488-02; NCGC00167488-03; NCGC00167488-04; NCGC00167488-05; NCGC00167488-07; NCGC00167488-14; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; BS164413; HY-10201; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; SY009239; AM20090614; FT-0650736; FT-0674632; SW202562-4; D08524; EN300-120647; AB00933189-05; AB00933189-06; AB00933189_08; A819449; Q421136; Q-201728; SR-00000000529-1; BRD-K23984367-001-01-8; Z89277543; BAY 439006; BAY439006; BAY-439006; Sorafenib (D3); CM-4307; CM 4307; CM4307;Bay 43-9006 (D3); 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido) phenoxy)-N-methylpicolinamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido)phenoxy)-N-methylpicolinamide; N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)- N-methylpyridine-2-carboxamide; 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-picolinamide;tosylic acid; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methyl-pyridine-2-carboxamide; Manganese(4+), chloro[[4,4',4'',4'''-(21H,23H-porphine-5,10,15,20-tetrayl-N21,N22,N23,N24)tetrakis[1-methylpyridiniumato]](2-)]-, chloride (1:4), (SP-5-12)-; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea	Approved	Approved Drug(s)	216239	DB00398	D0W5HK	464.8	92.4	646	4.1	32	3	7	5	C21H16ClF3N4O3	4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide	CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F	CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F	InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)	MLDQJTXFUGDVEO-UHFFFAOYSA-N
DJ6E1C	Alpelisib	Small molecule	alpelisib; 1217486-61-7; BYL-719; BYL719; Piqray; NVP-BYL719; Vijoice; Alpelisib (BYL719); BYL 719; UNII-08W5N2C97Q; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; 08W5N2C97Q; Alpelisib [USAN:INN]; CHEMBL2396661; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; 1,2-Pyrrolidinedicarboxamide, N1-(4-methyl-5-(2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl)-2-thiazolyl)-, (2S)-; (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide; (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-(2-(2,2,2-trifluoro-1,1-dimethylethyl)-pyridin-4-yl)thiazol-2-yl)amide; 1,2-PYRROLIDINEDICARBOXAMIDE, N1-[4-METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYLETHYL)-4-PYRIDINYL]-2-THIAZOLYL]-, (2S)-; Alpelisib [INN]; (2s)-N~1~-{4-Methyl-5-[2-(1,1,1-Trifluoro-2-Methylpropan-2-Yl)pyridin-4-Yl]-1,3-Thiazol-2-Yl}pyrrolidine-1,2-Dicarboxamide; (S)-N1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide.; 4jps; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; 1LT; Alpelisib [USAN]; Piqray (TN); ALPELISIB [JAN]; ALPELISIB [MI]; ALPELISIB [WHO-DD]; Alpelisib (JAN/USAN/INN); GTPL7955; SCHEMBL1911869; ALPELISIB [ORANGE BOOK]; CHEBI:93752; DTXSID70153355; EX-A405; BYL 719; BYL719; BDBM50436459; MFCD22417085; NSC765974; NSC800065; s2814; AKOS022186315; CCG-269139; CS-0663; DB12015; NSC-765974; NSC-800065; NCGC00346717-03; NCGC00346717-06; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidine; 1217486-47-9; AC-37083; AS-16349; HY-15244; SW220128-1; cas:1217486-61-7;BYL-719; D11011; A855666; EN300-23810842; J-004627; Q27074391; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-diMethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxaMide;Alpelisib; (2S)-N1-{4-Methyl-5-[1-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide; (2S)-N1-{4-METHYL-5-[2-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)PYRIDIN-4-YL]-1,3-THIAZOL-2-YL}PYRROLIDINE-1,2-DICARBOXAMIDE	Approved	Approved Drug(s)	56649450	DB12015	D0W7HE	441.5	129	663	3.2	30	2	8	4	C19H22F3N5O2S	(2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide	CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F	CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F	InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1	STUWGJZDJHPWGZ-LBPRGKRZSA-N
D4EB9A	Ivacaftor	Small molecule	Ivacaftor; 873054-44-5; VX-770; Kalydeco; Ivacaftor (VX-770); N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; VX 770; Ivacaftor-d18; N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide; 1413431-05-6; CHEBI:66901; Ivacaftor (4-tertbutyl-d9); N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide; 1Y740ILL1Z; 3-Quinolinecarboxamide, N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxo-; VX770; 3-Quinolinecarboxamide, N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-; N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; Kalydeco (TN); Ivacaftor [USAN]; Ivacaftor [USAN:INN]; ivacaftorum; UNII-1Y740ILL1Z; N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-4-oxo-1,4-dihydroquinoline-3-carboxamide; VX7; IVACAFTOR [INN]; IVACAFTOR [MI]; Ivacaftor (USAN/INN); VX-770 - Ivacaftor; IVACAFTOR [VANDF]; IVACAFTOR [WHO-DD]; MLS006011119; SCHEMBL351373; GTPL4342; IVACAFTOR [ORANGE BOOK]; VX-770, Ivacaftor, Kalydeco; CHEMBL2010601; DTXSID00236281; EX-A441; ORKAMBI COMPONENT IVACAFTOR; SYMKEVI COMPONENT IVACAFTOR; BCPP000199; HMS3654E10; HMS3744K05; TRIKAFTA COMPONENT IVACAFTOR; BCP19794; BDBM50032693; MFCD17171361; s1144; IVACAFTOR COMPONENT OF ORKAMBI; AKOS015994762; AKOS032950001; IVACAFTOR COMPONENT OF TRIKAFTA; BCP9000799; CCG-268562; CS-0497; DB08820; EX-7211; LE-0002; SB16815; NCGC00242480-01; NCGC00242480-03; AC-28324; HY-13017; SMR004702900; FT-0696681; SW219620-1; EC-000.2478; A25626; D09916; AB01565806_02; EN300-7400944; Q6095693; Z2146566713; CTP-656; CTP-656; CTP-656; d9-ivacaftor;VX-561; Cystic Fibrosis Transmembrane Conductance Regulator Potentiator; N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide; N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; N-(5-Hydroxy-2,4-bis(2-methyl-2-propanyl)phenyl]-4-oxo-1,4-dihydro-3-quinolinecarboxamide; N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide; 1134822-00-6; Ivacaftor;N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide;Ivacaftor	Approved	Approved Drug(s)	16220172	DB08820	D0W7WC	392.5	78.4	671	5.6	29	3	4	4	C24H28N2O3	N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide	CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C	CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C	InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)	PURKAOJPTOLRMP-UHFFFAOYSA-N
DL26OU	Guanfacine	Small molecule	GUANFACINE; 29110-47-2; Estulic; Guanfacinum [INN-Latin]; Guanfacina [INN-Spanish]; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-; N-amidino-2-(2,6-dichlorophenyl)acetamide; 30OMY4G3MK; CHEBI:5558; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; Guanfacine (INN); NSC-759121; SPD 503; GUANFACINE [INN]; Guanfacina; Guanfacinum; Guanfacine [INN:BAN]; NCGC00015469-05; EINECS 249-442-8; CAS-29110-48-3; UNII-30OMY4G3MK; Estulic (TN); Tenex (Salt/Mix); Estulic (Salt/Mix); Tocris-1030; GUANFACINE [MI]; Prestwick0_000339; Prestwick1_000339; Prestwick2_000339; Prestwick3_000339; Lopac-G-1043; GUANFACINE [VANDF]; CHEMBL862; GUANFACINE [WHO-DD]; LON 798 (Salt/Mix); Lopac0_000519; SCHEMBL35094; BSPBio_000377; GTPL522; RASPBERRYKETONEGLUCOSIDE; SPBio_002298; BPBio1_000415; DTXSID9046944; BDBM81984; BCP09647; NSC_3519; Guanfacine hydrochloride (Salt/Mix); HY-17416A; (2,6-dichlorophenylacetyl)-guanidine; [(2,6-dichlorophenyl)acetyl]guanidine; AKOS030255657; CCG-204609; DB01018; NSC 759121; SDCCGSBI-0050502.P002; MRF-0000019; NCGC00015469-01; NCGC00015469-02; NCGC00015469-03; NCGC00015469-04; NCGC00015469-06; NCGC00015469-07; NCGC00024950-01; NCGC00024950-02; NCGC00024950-03; CAS_29110-47-2; FT-0669067; FT-0669068; C07037; D08031; EN300-243924; AB01563079_01; A902647; A918619; L000286; L013430; J-017394; Q5613599; BRD-K32830106-003-03-0; BRD-K32830106-003-11-3; N-(Diaminomethyliden)-2-(2,6-dichlorophenyl)acetamid; [(2,6-Dichlorophenyl)acetyl]guanidine hydrochloride;Guanfacine HCl	Approved	Approved Drug(s)	3519	DB01018	D0WD8M	246.09	81.5	256	2	15	2	1	2	C9H9Cl2N3O	N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide	C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl	C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl	InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)	INJOMKTZOLKMBF-UHFFFAOYSA-N
DH2DX5	Saquinavir mesylate	Small molecule	Saquinavir mesylate; 149845-06-7; Invirase; Fortovase; Saquinavir mesilate; Saquinavir, Mesylate; Ro 31-8959/003; Saquinavir methanesulfonate salt; UHB9Z3841A; Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)-, methanesulfonate (1:1); DTXSID9023835; CHEBI:32121; (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide;methanesulfonic acid; (S)-N1-((2S,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-phenylbutan-2-yl)-2-(quinoline-2-carboxamido)succinamide methanesulfonate; NCGC00091469-01; Ro-318959003; Ro-31-8959/003; Saquinavir mesilate (JAN); DTXCID803835; SAQUINAVIR MESILATE [JAN]; Ro 31-8959; Saquinavir mesylate [USAN]; Saquinavir monomethanesulfonate salt; UNII-UHB9Z3841A; Saquinavir mesylate [USAN:USP]; Invirase (TN); N1-{(1S,2R)-1-benzyl-3-[(3S,4aS,8aS)-3-[(tert-butylamino)carbonyl]octahydroisoquinolin-2(1H)-yl]-2-hydroxypropyl}-N2-(quinolin-2-ylcarbonyl)-L-aspartamide methanesulfonate (salt); CAS-149845-06-7; Saquinavir mesylate (AIDS Initiative); SQV; Saquinavir mesylate (USP); Saquinavir mesylate- Bio-X; SCHEMBL42352; (S)-N-((alphaS)-alpha-((1R)-2-((3S,4aS,8aS)-3-(tert-Butylcarbamoyl)octahydro-2(1H)-isoquinolyl)-1-hydroxyethyl)phenethyl)-2-quinaldamidosuccinamide monomethanesulfonate (salt); MLS001401395; CHEMBL282042; HMS1571O10; HMS2051D04; HMS2098O10; HMS2231C15; HMS3715O10; SAQUINAVIR MESYLATE [VANDF]; SAQUINAVIR MESILATE [MART.]; Tox21_111137; Tox21_202533; SAQUINAVIR MESILATE [WHO-DD]; SAQUINAVIR MESILATE [WHO-IP]; SAQUINAVIR MESYLATE [USP-RS]; AKOS015962362; AC-1333; CCG-100992; KS-1110; NC00242; NCGC00260082-01; SAQUINAVIR MESYLATE [ORANGE BOOK]; (2S)-N1[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-Dimethylethyl)amino]carbonyl]octahydro-2-(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]butanediamide Mesylate; BS164392; Butanediamide, N(sup 1)-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3S-(2(1R*(R*),2S*),3alpha,4abeta,8abeta))-, monomethanesulfonate (salt); Butanediamide, N1-((1S,2R)-3-((3S,4aS,8aS)-3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2S)-, monomethanesulfonate (salt); R-56; SAQUINAVIR MESILATE [EP MONOGRAPH]; SAQUINAVIR MESYLATE [USP IMPURITY]; SMR000469290; SAQUINAVIR MESYLATE [USP MONOGRAPH]; SAQUINAVIR METHANESULFONATE SALT [MI]; Ro-31-8959-003; Saquinavir mesylate, >=98% (HPLC), powder; D01160; F84902; SR-01000763454; J-008634; SR-01000763454-4; Q27114794; Saquinavir mesilate, European Pharmacopoeia (EP) Reference Standard; Saquinavir mesylate, United States Pharmacopeia (USP) Reference Standard; Saquinavir for system suitability, European Pharmacopoeia (EP) Reference Standard; (2S)-N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]butanediamide methanesulfonate; (S)-N-((.ALPHA.S)-.ALPHA.-((1R)-2-((3S,4AS,8AS)-3-(TERT-BUTYLCARBAMOYL)OCTAHYDRO-2(1H)-ISOQUINOLYL)-1-HYDROXYETHYL)PHENETHYL)-2-QUINALDAMIDOSUCCINAMIDE MONOMETHANESULFONATE; (S)-N-((.ALPHA.S)-.ALPHA.-((1R)-2-((3S,4AS,8AS)-3-(TERT-BUTYLCARBAMOYL)OCTAHYDRO-2(1H)-ISOQUINOLYL)-1-HYDROXYETHYL)PHENETHYL)-2-QUINALDAMIDOSUCCINAMIDE MONOMETHANESULPHONATE; BUTANEDIAMIDE, N(SUP 1)-(3-(3-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)OCTAHYDRO-2(1H)-ISOQUINOLINYL)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-2-((2-QUINOLINYLCARBONYL)AMINO)-, (3S-(2(1R*(R*),2S*),3.ALPHA.,4A.BETA.,8A.BETA.))-, MONOMETHANESULFONATE; BUTANEDIAMIDE, N(SUP 1)-(3-(3-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)OCTAHYDRO-2(1H)-ISOQUINOLINYL)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-2-((2-QUINOLINYLCARBONYL)AMINO)-, (3S-(2(1R*(R*),2S*),3.ALPHA.,4A.BETA.,8A.BETA.))-, MONOMETHANESULPHONATE; N-t-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide methanesulphonate	Approved	Approved Drug(s)	60934	DB01232	D0WI3T	766.9	230	1230	.	54	6	10	13	C39H54N6O8S	(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide;methanesulfonic acid	CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O.CS(=O)(=O)O	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O.CS(=O)(=O)O	InChI=1S/C38H50N6O5.CH4O3S/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29;1-5(2,3)4/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49);1H3,(H,2,3,4)/t26-,27+,30-,31-,32-,33+;/m0./s1	IRHXGOXEBNJUSN-YOXDLBRISA-N
D9P8VD	Felodipine	Small molecule	felodipine; 72509-76-3; Plendil; Flodil; Renedil; Feloday; Munobal; Splendil; dl-Felodipine; Perfudal; Prevex; Hydac; Modip; Agon; Felodipina; Felodipinum; Felodipinum [INN-Latin]; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; Felodipina [INN-Spanish]; H 154/82; Felodipine (Plendil); CGH-869; Plendil ER; 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester; 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; Felogard; MFCD00868316; Penedil; Preslow; Munobal Retard; NSC-760343; Plendil Retard; H-154/82; Plendil Depottab; (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; MLS000069629; OL961R6O2C; DTXSID4023042; C08CA02; CHEBI:585948; Felodur ER; AGON SR; 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate; NCGC00015455-03; Plandil; SMR000058204; C18H19Cl2NO4; (R)-(+)-Felodipine-d5; ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; DTXCID303042; Felodipine [USAN:BAN:INN]; Logimax; Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; (+/-)-ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; (RS)-3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; Plendil (TN); SR-01000075890; 1217744-87-0; BRN 4331472; UNII-OL961R6O2C; Perfuda; Plendil;Renedil; Felodipine, solid; Felodipine,(S); Felodipine [USAN:USP:INN:BAN]; 1217716-73-8; 3,5-dicarboxylate; Felodipine- Bio-X; Prestwick_797; CAS-72509-76-3; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester; Felodipine (dl form); FELODIPINE [MI]; FELODIPINE [INN]; FELODIPINE [JAN]; Opera_ID_1873; Prestwick0_000478; Prestwick1_000478; Prestwick2_000478; Prestwick3_000478; (.+/-.)-Felodipine; FELODIPINE [USAN]; FELODIPINE [VANDF]; F 9677; FELODIPINE [MART.]; 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester; CHEMBL1480; FELODIPINE [USP-RS]; FELODIPINE [WHO-DD]; Lopac0_000508; SCHEMBL26398; BSPBio_000616; AE-641/11429675; MLS001077361; MLS001333735; MLS002153409; MLS002153832; MLS003876820; BIDD:GT0733; SPBio_002555; BPBio1_000678; Felodipine (JP17/USP/INN); GTPL4190; (R)-(+)-Felodipine-[d5]; CHEMBL3196476; FELODIPINE [ORANGE BOOK]; SCHEMBL13460298; FELODIPINE [EP MONOGRAPH]; FELODIPINE [USP IMPURITY]; LEXXEL COMPONENT FELODIPINE; BDBM189379; FELODIPINE [USP MONOGRAPH]; HMS1569O18; HMS2089J05; HMS2096O18; HMS2232D24; HMS3259F12; HMS3261F17; HMS3651O21; HMS3713O18; HMS3884I14; Pharmakon1600-01505887; BCP02192; BCP22685; HY-B0309; 2,6-dimethyl-1,4-dihydropyridine-; Tox21_110155; Tox21_500508; CA-236; HB1222; NSC760343; s1885; FELODIPINE COMPONENT OF LEXXEL; AKOS015891545; Tox21_110155_1; AC-2124; BCP9000680; CCG-204599; DB01023; KS-1264; LP00508; NC00721; NSC 760343; SDCCGSBI-0050492.P002; O5-ethyl O3-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; NCGC00015455-04; NCGC00015455-05; NCGC00015455-06; NCGC00015455-07; NCGC00015455-08; NCGC00015455-10; NCGC00015455-24; NCGC00024087-02; NCGC00093906-01; NCGC00093906-02; NCGC00261193-01; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, (+-)-; 4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester; AC-24403; BF164445; Felodipine 100 microg/mL in Acetonitrile; SMR002529504; SY053174; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-; EU-0100508; F0814; FT-0626393; FT-0660933; FT-0668475; SW219299-1; EN300-70726; D00319; Q420644; SR-01000075890-1; SR-01000075890-4; BRD-A30815329-001-03-0; Z239864852; Felodipine, European Pharmacopoeia (EP) Reference Standard; Felodipine, United States Pharmacopeia (USP) Reference Standard; 3-ethyl5-methyl4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (.+/-.) Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 3,5-PYRIDINEDICARBOXYLIC ACID 4-(2,3-DICHLOROPHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-, ETHYL METHYL ESTER, (+/-)-; 3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-ethyl-5-methylester; 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate #	Approved	Approved Drug(s)	3333	DB01023	D0WN0U	384.2	64.599	614	3.9	25	1	5	6	C18H19Cl2NO4	5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate	CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C	CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C	InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3	RZTAMFZIAATZDJ-UHFFFAOYSA-N
DWY60C	Mepivacaine	Small molecule	mepivacaine; 96-88-8; N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide; Carbocaine; DL-Mepivacaine; Scandicaine; Mepivacaina; Mepivacainum; Mepicaine; 22801-44-1; Mepivicaine; Polocaine; Mepivacainum [INN-Latin]; Mepivacaina [INN-Spanish]; tevacaine; (+-)-1-Methyl-2',6'-pipecoloxylidide; 1-METHYL-2',6'-PIPECOLOXYLIDIDE; Carboplyin Dental; 2',6'-Pipecoloxylidide, 1-methyl-; Carbocain; N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide; Polocaine-Mpf; 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-; Mepisv; N-Methyl-2-pipecolic acid, 2,6-xylidide; Mepivacaine (INN); N-Methyl-2-pipecolic acid, 2,6-dimethylanilide; CHEBI:6759; N-Methylhexahydro-2-picolinic acid, 2,6-dimethylanilide; B6E06QE59J; APF-135; Mepihexal; Scandicane; S-Ropivacaine Mesylate; MEPIVACAINE [INN]; BRN 0211230; Mepivacaine [INN:BAN]; (+/-)-Mepivacaine; Carboplyin Dental (TN); 5-22-01-00223 (Beilstein Handbook Reference); EINECS 202-543-0; UNII-B6E06QE59J; Spectrum_001480; SpecPlus_000874; MEPIVACAINE [MI]; Spectrum2_001656; Spectrum3_001629; Spectrum4_000596; Spectrum5_001354; (.+/-.)-Mepivacaine; Epitope ID:122686; MEPIVACAINE [VANDF]; CHEMBL1087; SCHEMBL25314; BSPBio_003297; KBioGR_001092; KBioSS_001960; MEPIVACAINE [WHO-DD]; MLS006011662; DivK1c_006970; SPBio_001811; GTPL7224; DTXSID9023259; KBio1_001914; KBio2_001960; KBio2_004528; KBio2_007096; KBio3_002517; HMS3886E04; HY-B0517; BDBM50417964; MFCD00243006; s5392; AKOS015889304; AC-9857; CCG-266926; DB00961; FS-3679; NCGC00018284-02; NCGC00018284-03; NCGC00018284-05; NCGC00018284-06; NCGC00089774-02; SMR004703413; SBI-0052814.P002; CS-0009492; FT-0653428; (.+/-.)-1-Methyl-2',6'-pipecoloxylidide; C07528; D08181; AB00053769_12; AB00053769_13; EN300-7359348; (+/-)-1-METHYL-2',6'-PIPECOLOXYLIDIDE; A816361; A858662; Q416760; Q-100290; BRD-A03216249-003-02-9; BRD-A03216249-003-12-8; Z1741980843; N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide #; N-(2,6-dimethylphenyl)-1-methyl-piperidine-2-carboxamide; N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboximidic acid; 2-PIPERIDINECARBOXAMIDE, N-(2,6-DIMETHYLPHENYL)-1-METHYL-, (+/-)-	Approved	Approved Drug(s)	4062	DB00961	D0WO8W	246.35	32.299	282	1.9	18	1	2	2	C15H22N2O	N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide	CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C	CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C	InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)	INWLQCZOYSRPNW-UHFFFAOYSA-N
DGI56H	Rivastigmine	Small molecule	rivastigmine; 123441-03-2; Exelon; ENA 713 free base; Prometax; Rivastigmine Teva; Nimvastid; S-Rivastigmine; rivastigmine hexal; (S)-Rivastigmine; (S)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate; Rivastigmine sandoz; SDZ-ENA-713; SDZ-212-713; 3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate; m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; (S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; CHEMBL636; [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate; PKI06M3IW0; CHEBI:8874; ENA-713D; ONO-2540; SDZ-212713; Exelon Patch; Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester; 3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate; (S)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate; SR-05000001475; UNII-PKI06M3IW0; SDZ 212-713; Rivastigmine Transdermal System; Prometax (TN); Rivastigmine [USAN:INN:BAN:JAN]; Rivastigmine.tartrate; Rivastigmine impurity D; 3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; RIVASTIGMINE [MI]; RIVASTIGMINE [INN]; RIVASTIGMINE [JAN]; Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester; RIVASTIGMINE [USAN]; SCHEMBL2764; RIVASTIGMINE [VANDF]; RIVASTIGMINE [MART.]; ethylmethylcarbamic acid 3-[1-(dimethylamino)ethyl]phenyl ester; MLS003876822; BIDD:GT0316; RIVASTIGMINE [USP-RS]; RIVASTIGMINE [WHO-DD]; Rivastigmine (JAN/USP/INN); GTPL6602; RIVASTIGMINE [EMA EPAR]; RIVASTIGMINE 1 A PHARMA; DTXSID7023564; BDBM10620; BDBM11682; AMY3808; HMS2089H18; HMS3715P15; HMS3885B18; RIVASTIGMINE [ORANGE BOOK]; RIVASTIGMINE [EP MONOGRAPH]; RIVASTIGMINE [USP MONOGRAPH]; MFCD00871496; AKOS015896334; Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-; AC-8250; CCG-221197; CS-0946; DB00989; RIVASTIGMINE 3M HEALTH CARE LTD; NCGC00167531-03; NCGC00167531-17; AS-73448; HY-17368; SMR002203623; R0250; S4687; (R)-Rivastigmine (Rivastigmine EP Impurity D); D03822; D82061; AB01275472-01; AB01275472_02; AB01275472_03; EN300-7403044; Q411887; SR-05000001475-1; SR-05000001475-2; W-200966; [3-[(1S)-1-dimethylaminoethyl]phenyl] N-ethyl-N-methylcarbamate; 3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl N-methyl carbamate; Ethyl-methyl-carbamic acid 3-(1-dimethylamino-ethyl)-phenyl ester; Ethyl-methyl-carbamic acid 3-((R)-1-dimethylamino-ethyl)-phenyl ester; Ethyl-methyl-carbamic acid 3-((S)-1-dimethylamino-ethyl)-phenyl ester; Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester; 2,3-dihydroxybutanedioic acid; 3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate	Approved	Approved Drug(s)	77991	DB00989	D0WY5Q	250.34	32.8	269	2.3	18	0	3	5	C14H22N2O2	[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate	CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C	CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C	InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1	XSVMFMHYUFZWBK-NSHDSACASA-N
DG4RP9	Ganaxolone	Small molecule	GANAXOLONE; 38398-32-2; CCD 1042; Ztalmy; CCD-1042; 3alpha-Hydroxy-3beta-methyl-5alpha-pregnan-20-one; 1-((3R,5S,8R,9S,10S,13S,14S,17S)-3-Hydroxy-3,10,13-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone; 98WI44OHIQ; 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone; DTXSID6046503; DEA NO. 2401; C22H36O2; Pregnan-20-one, 3-hydroxy-3-methyl-, (3a,5a)-; NCGC00165802-02; (3alpha,5alpha)-3-hydroxy-3-methyl-pregnan-20-one; DTXCID4026503; 1-((3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethan-1-one; CAS-38398-32-2; Ganaxolone [USAN]; Ganaxolone [USAN:INN]; UNII-98WI44OHIQ; Ganaxolone, solid; GANAXOLONE [MI]; GANAXOLONE [INN]; Ganaxolone (USAN/INN); GANAXOLONE [WHO-DD]; SCHEMBL144522; (3alpha,5alpha)-3-Hydroxy-3-methylpregnan-20-one; CHEMBL1568698; GTPL11942; CCD1042; CHEBI:177658; HMS3261K19; AMY38916; Tox21_112264; Tox21_500379; BDBM50369240; HB0938; MFCD09971088; AKOS027327586; Tox21_112264_1; CCG-221683; DB05087; LP00379; SDCCGSBI-0633706.P001; NCGC00165802-03; NCGC00261064-01; NCGC00263545-01; AS-35253; (3?,5?)-3-Hydroxy-3-methyl-pregnan-20-one; 3alpha-Hydroxy-3-methyl-5alpha-pregnan-20-one; D04300; A901692; Q3758034; 3.ALPHA.-HYDROXY-3-METHYL-5.ALPHA.-PREGNAN-20-ONE; Pregnan-20-one, 3-hydroxy-3-methyl-, (3alpha,5alpha)-; PREGNAN-20-ONE, 3-HYDROXY-3-METHYL-, (3.ALPHA.,5.ALPHA.)-; 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone.	Approved	Approved Drug(s)	6918305	DB05087	D0X0CH	332.5	37.3	542	5	24	1	2	1	C22H36O2	1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone	CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)(C)O)C)C	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C	InChI=1S/C22H36O2/c1-14(23)17-7-8-18-16-6-5-15-13-20(2,24)11-12-21(15,3)19(16)9-10-22(17,18)4/h15-19,24H,5-13H2,1-4H3/t15-,16-,17+,18-,19-,20+,21-,22+/m0/s1	PGTVWKLGGCQMBR-FLBATMFCSA-N
DXQ4U9	Phenoxybenzamine	Small molecule	phenoxybenzamine; Dibenylin; Dibenyline; Dibenzyline; 59-96-1; Bensylyt; Benzylyt; Fenoxibenzamina; Fenossibenzamina [DCIT]; Fenossibenzamina; Fenoxibenzamina [INN-Spanish]; Phenoxybenzaminum [INN-Latin]; N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine; 688A; Benzenemethanamine, N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine; A 688; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine; Dibenylene; 2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane; Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine; Phenoxybenzamine (INN); NSC 37448; Benzylamine, N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-; CHEMBL753; 0TTZ664R7Z; CHEBI:8077; 59-96-1 (free); DTXSID0023458; benzyl(2-chloroethyl)(1-phenoxypropan-2-yl)amine; NCGC00015121-08; Bensylyte; Phenoxybenzaminum; N-Phenoxyisopropyl-N-benzyl-.beta.-chloroethylamine; PHENOXYBENZAMINE [INN]; DTXCID803458; Phenoxybenzamine [INN:BAN]; CAS-59-96-1; 102737-84-8; CCRIS 505; HSDB 4005; EINECS 200-446-8; N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine; BRN 2129697; UNII-0TTZ664R7Z; Spectrum_000378; Prestwick0_000944; Prestwick1_000944; Prestwick2_000944; Prestwick3_000944; Spectrum2_001815; Spectrum4_000769; Spectrum5_001370; SCHEMBL5722; Lopac0_000235; BSPBio_000908; BSPBio_001278; BSPBio_002356; KBioGR_000618; KBioGR_001158; KBioSS_000618; KBioSS_000858; PHENOXYBENZAMINE [MI]; 4-12-00-02204 (Beilstein Handbook Reference); DivK1c_000800; SPBio_001829; SPBio_003067; PHENOXYBENZAMINE [HSDB]; BPBio1_001000; GTPL7268; PHENOXYBENZAMINE [VANDF]; (+/-)-PHENOXYBENZAMINE; KBio1_000800; KBio2_000618; KBio2_000858; KBio2_003186; KBio2_003426; KBio2_005754; KBio2_005994; KBio3_001095; KBio3_001096; PHENOXYBENZAMINE [WHO-DD]; NINDS_000800; Bio2_000479; Bio2_000959; HMS1362P19; HMS1792P19; HMS1990P19; HMS2089J09; HMS3403P19; HY-B0431; N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine; Tox21_110087; BDBM50017679; AKOS015961144; Tox21_110087_1; CCG-204330; DB00925; SB82886; SDCCGSBI-0050223.P004; IDI1_000800; IDI1_002234; MRF-0000619; NCGC00015121-03; NCGC00015121-04; NCGC00015121-05; NCGC00015121-06; NCGC00015121-07; NCGC00015121-09; NCGC00015121-11; NCGC00015121-12; NCGC00015121-13; NCGC00015121-14; NCGC00015121-16; NCGC00015121-17; NCGC00089748-03; NCGC00089748-04; NCGC00089748-05; NCGC00089748-07; AC-13214; SBI-0050223.P003; AB00053702; CS-0255342; FT-0778642; EN300-57590; C07435; D08358; AB00053702-12; AB00053702_13; AB00053702_14; L001197; Q419824; Q-201556; N-benzyl-N-(2-chloroethyl)-1-phenoxy-propan-2-amine; N-Benzyl-N-(2-chloroethyl)-1-phenoxy-2-propanamine #; Benzyl-(2-chloro-ethyl)-(1-methyl-2-phenoxy-ethyl)-amine	Approved	Approved Drug(s)	4768	DB00925	D0X2DK	303.8	12.5	262	4.4	21	0	2	8	C18H22ClNO	N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine	CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2	CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2	InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3	QZVCTJOXCFMACW-UHFFFAOYSA-N
DM0FP1	Mirabegron	Small molecule	Mirabegron; 223673-61-8; Myrbetriq; Betanis; Betmiga; YM178; Mirabegron (YM178); YM-178; YM 178; 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide; MVR3JL3B2V; CHEBI:65349; 2-Amino-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-thiazoleacetamide; (R)-2-(2-aminothiazol-4-yl)-N-(4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)acetamide; 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide; 4-Thiazoleacetamide, 2-amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)-; Myrbetriq (TN); 2-(2-azanyl-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-oxidanyl-2-phenyl-ethyl]amino]ethyl]phenyl]ethanamide; Mirabegron [USAN:INN]; UNII-MVR3JL3B2V; 2-(2-AMINO-1,3-THIAZOL-4-YL)-N-(4-(2-(((2R)-2-HYDROXY-2-PHENYLETHYL)AMINO)ETHYL)PHENYL)ACETAMIDE; MIRABEGRON [MI]; MIRABEGRON [INN]; MIRABEGRON [JAN]; Mirabegron (USAN/JAN); MIRABEGRON [USAN]; MIRABEGRON [VANDF]; MIRABEGRON [MART.]; MIRABEGRON [WHO-DD]; SCHEMBL904788; GTPL7445; CHEMBL2095212; MIRABEGRON [ORANGE BOOK]; AMY1800; DTXSID101021648; HMS3714I09; HMS3885M16; 2-(2-AMINO-1,3-THIAZOL-4-YL)-N-(4-{2-[(2-HYDROXY-2-PHENYLETHYL)AMINO]ETHYL}PHENYL)ACETAMIDE; EX-A1050; MFCD11100356; s4009; AKOS016340341; CCG-268611; CS-0915; DB08893; KS-1398; 2-(2-Aminothiazol-4-yl)-4'-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)acetanilide; N-(4-(2-(2-hydroxy-2-phenylethylamino)ethyl)phenyl)-2-(2-aminothiazol-4-yl)acetamide; NCGC00386239-01; HY-14773; SW220301-1; D09535; AB01565808_02; A816162; AR-270/43507997; Q3702534; Z1980444597; (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide; (R)-2-(2-aminothiazol-4-yl)-4-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide; (R)-2-(2-aminothiazol-4-yl)-N-(4-(2-(2-hydroxy-2-phenylethylamino)ethyl)phenyl)acetamide; 2-(2-Aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide; H6U; YM 178;2-(2-aminothiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenyl-ethyl]amino]ethyl]phenyl]acetamide	Approved	Approved Drug(s)	9865528	DB08893	D0X5UN	396.5	129	467	2.1	28	4	6	9	C21H24N4O2S	2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide	C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O	C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O	InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1	PBAPPPCECJKMCM-IBGZPJMESA-N
DTJ6M3	Ambrisentan	Small molecule	Ambrisentan; 177036-94-1; Letairis; Volibris; LU-208075; BSF 208075; BSF-208075; (S)-2-(4,6-Dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid; LU 208075; (S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; GSK1325760A; GSK-1325760A; HW6NV07QEC; GSK1325760; GSK-1325760; CHEMBL1111; DTXSID4046282; C22H22N2O4; (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid; Ambrisentan [INN]; DTXCID2026282; LU208075; (s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropionic acid; CAS-177036-94-1; UNII-HW6NV07QEC; Ambrisentan [INN:BAN:JAN]; NCGC00160662-01; Letairis (TN); Volibris (TN); Ambrisentan- Bio-X; BSF 208075;LU 208075; Ambrisentan (JAN/INN); AMBRISENTAN [MI]; AMBRISENTAN [JAN]; AMBRISENTAN [VANDF]; SCHEMBL3679; AMBRISENTAN [MART.]; AMBRISENTAN [WHO-DD]; AMBRISENTAN, (+)-; MLS006010218; AMBRISENTAN [EMA EPAR]; GTPL3951; AMBRISENTAN [ORANGE BOOK]; CHEBI:135949; EX-A3315; Tox21_111967; BDBM50146710; FD7219; MFCD09842330; s2097; AKOS015994540; Tox21_111967_1; AC-9015; CCG-268386; CS-0447; DB06403; DE-0223; (+)-(2S)-2-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; NCGC00160662-02; NCGC00346730-01; BA164153; Benzenepropanoic acid, alpha-[(4,6-dimethyl-2-pyrimidinyl)oxy]-beta-methoxy-beta-phenyl-, (alphaS)-; HY-13209; SMR004701307; SW219060-1; D07077; AB01566890_01; EN300-7368573; Q410789; J-519579; (?S)-?-[(4,6-Dimethyl-2-pyrimidinyl)oxy]-?-methoxy-?-phenylbenzenepropanoic acid; (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid; (2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy- 3,3-diphenylpropanoic acid; (S)-2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid	Approved	Approved Drug(s)	6918493	DB06403	D0X5ZI	378.4	81.5	475	3.8	28	1	6	7	C22H22N2O4	(2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid	CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C	CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C	InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1	OUJTZYPIHDYQMC-LJQANCHMSA-N
D5FW0T	Carboplatin	Small molecule	41575-94-4; Carboplatin; Paraplatin; Cbdca; Carboplatinum; MFCD00070464; NSC-241240; cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); 1,1-Cyclobutanedicarboxylate diammine platinum(II); cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; DTXSID3046742; CHEBI:31355; NSC241240; NSC-201345; Platinum(II),1-cyclobutanedicarboxylato)diammine-, cis-; Platinum,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-; Platinum,1-cyclobutanedicarboxylato(2-)-O,O']-, (SP-4-2)-; Epitope ID:194801; SCHEMBL4964; 1,1-Cyclobutanedicarboxylatodiammineplatinum(II); Paraplatin (Bristol Meyers); Lopac0_000230; DTXCID201476080; HMS3269H03; Pharmakon1600-01502106; NSC201345; NSC758182; STL451040; Tox21_112586_1; NSC-758182; NCGC00167800-01; NCGC00263858-02; BP-25385; SY075575; CAS-41575-94-4; EN300-123065; AB01273939-01; azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+); 7,7-diamino-6,8-dioxa-7-platinaspiro[3.5]nonane-5,9-dione; diamino[cyclobutane-1,1-dicarboxylato(2-)-kappa~2~O~1~,O~1~]platinum; Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-.kappa.O,.kappa.O'']-, (SP-4-2)-	Approved	Approved Drug(s)	426756	DB00958	D0X7HM	371.25	76.6	177	.	13	4	6	0	C6H12N2O4Pt	azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+)	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]	InChI=1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2	VSRXQHXAPYXROS-UHFFFAOYSA-N
DK9P2V	Fosinopril	Small molecule	fosinopril; 98048-97-6; Fosinopril impurity C; (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; CHEBI:5163; (4S)-4-cyclohexyl-1-({[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)-L-proline; 474519-28-3; (2S,4S)-4-cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid; SR-05000001490; starbld0017934; 8B3FLG23GN; SCHEMBL15626; CHEMBL3306578; DTXSID1023079; HMS2089P08; HMS3715N21; (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxy-propoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; YDA04897; AKOS015961605; AC-8775; CCG-221190; EN300-118722; AB01275481-01; FOSINOPRIL SODIUM IMPURITY C [EP IMPURITY]; SR-05000001490-1; SR-05000001490-2; ((4S)-4-Cyclohexyl-1-[(R)-[(S)-1-hydroxy-2-methylpropoxy](4-phenylbutyl)phosphinyl]acetyl-D-proline Propionate (Ester) Hemibarium Sa lt Sesquihydrate); (2S,4S)-4-CYCLOHEXYL-1-(((SR)-((1SR)-2-METHYL-1-(1-OXOPROPOXY)PROPOXY)(4-PHENYLBUTYL)PHOSPHORYL)ACETYL)PYRROLIDINE-2-CARBOXYLIC ACID; (2S,4S)-4-Cyclohexyl-1-(2-((2-methyl-1-(propionyloxy)propoxy)(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-carboxylic acid; (4S)-4-cyclohexyl-1-{[{[2-methyl-1-(propanoyloxy)propyl]oxy}(4-phenylbutyl)phosphoryl]acetyl}-L-proline; (S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid; 4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxy-propoxy)-(4-phenylbutyl)phosphoryl]acetyl] FOSINOPRIL, (4S)-4-CYCLOHEXYL-1-[(RS)-2-METHYL-1-(PROPIONYLOXY)PROPOXY]-(4-PHENYLBUTYL)PHOSPHINYLACETYL-L-PROLINE L-Proline, 4-cyclohexyl-1-(R)-(1S)-2-methyl-1-(1-oxopropoxy)propoxy(4-phenylbutyl)phosphinylacetyl-, (4S)-fosenopril	Approved	Approved Drug(s)	55891	DB00492	D0X8KY	563.7	110	850	6.2	39	1	7	15	C30H46NO7P	(2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid	CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2CC(CC2C(=O)O)C3CCCCC3	CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)O)C3CCCCC3	InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1	BIDNLKIUORFRQP-FKDWWROVSA-N
D4UBL6	Telaprevir	Small molecule	Telaprevir; 402957-28-2; VX-950; Incivek; Telaprevir (VX-950); Incivo; MP-424; VX 950; LY-570310; Telavic; MP 424; VRT 111950; VRT-111950; LY 570310; CHEMBL231813; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; CHEBI:68595; 655M5O3W0U; (3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-6-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide; S-Telaprevir; (1S,3aR,6aS)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamide; VX950 cpd; Telaprevir [USAN:INN]; UNII-655M5O3W0U; HSDB 8125; Incivek(TM); 569364-34-7; Incivek (TN); Incivo (TN); Telaprevir,VX-950; TELAPREVIR [MI]; TELAPREVIR [INN]; TELAPREVIR [JAN]; (1S,3aR,6aS)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-1-carboxamide; TELAPREVIR [USAN]; VX-950 (Telaprevir); TELAPREVIR [VANDF]; TELAPREVIR [MART.]; TELAPREVIR [WHO-DD]; SCHEMBL183996; Telaprevir (JAN/USAN/INN); GTPL7871; TELAPREVIR [ORANGE BOOK]; DTXSID40193304; EX-A006; AIDS213006; AIDS-213006; BDBM50326056; FD7166; MFCD11616089; s1538; VRT111950; AKOS005145815; CCG-270366; CS-0285; DB05521; NCGC00346545-03; (3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethyl-butanoyl]-N-[(1S)-1-[2-(cyclopropylamino)-2-oxo-acetyl]butyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; AS-16995; HY-10235; WO-00218369; D09012; EN300-26212550; Q408557; Q-101417; Z2235802141; (1S,3aR,6aS)-(2S)-2-Cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydrocyclopenta[c]pyrrole-1-carboxamide; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxo-hexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cydopropylamino)-1,2-dioxo-hexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-3-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide; (1S,3aR,6aS)-2-[(2S)-2-({(2S)-2-cyclohexyl-2-[(pyrazin-2-ylcarbonyl)amino]acetyl}amino)-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]octahydrocyclopenta[c]pyrrole-1-carboxamide; (1S,3aR,6aS)-2-[(2S)-2-[[(2S)-Cyclohexyl[(pyrazinylcarbonyl)amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl] octahydrocyclopenta[c]pyrrole-1-carboxamide; (1S,3aR,6aS)-N-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S)-3-{[(1S,3aR,6aS)-2-[(2S)-2-[(2S)-2-cyclohexyl-2-(pyrazin-2-ylformamido)acetamido]-3,3-dimethylbutanoyl]-octahydrocyclopenta[c]pyrrol-1-yl]formamido}-N-cyclopropyl-2-oxohexanamide; (3S)-3-{[(1S,3aR,6aS)-2-[(2S)-2-[(2S)-2-cyclohexyl-2-[(pyrazin-2-yl)formamido]acetamido]-3,3-dimethylbutanoyl]-octahydrocyclopenta[c]pyrrol-1-yl]formamido}-N-cyclopropyl-2-oxohexanamide; 2-(2-{2-Cyclohexyl-2-[(pyrazine-2-carbonyl)-amino]-acetylamino}-3,3-dimethyl-butyryl)-octahydro-cyclopenta[c]pyrrole-1-carboxylic acid (1-cyclopropylaminooxalyl-butyl)-amide	Approved	Approved Drug(s)	3010818	DB05521	D0X9CH	679.8	180	1240	4.2	49	4	8	14	C36H53N7O6	(3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide	CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5	CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=NC=CN=C5	InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1	BBAWEDCPNXPBQM-GDEBMMAJSA-N
DQB07O	Pyrazinamide	Small molecule	pyrazinamide; pyrazinecarboxamide; 98-96-4; pyrazine-2-carboxamide; Zinamide; Aldinamide; pyrazinoic acid amide; 2-Pyrazinecarboxamide; Pirazinamid; Aldinamid; Tebrazid; Unipyranamide; Farmizina; Pirazimida; Eprazin; Novamid; Pyrafat; pyrazine carboxylamide; Pyrazineamide; 2-Carbamylpyrazine; Isopas; Pyrazinecarboxylic acid amide; Pyrazinamidum; Pyrazide; Rozide; Pirazinamide; Pyrazine carboxamide; D-50; C5H5N3O; pyramizade; MK 56; PZA; NCI-C01785; MFCD00006132; NSC 14911; .alpha.-pyrazinamide; T 165; Pirazinamida; Pyrazinamide (Pyrazinoic acid amide); Pyrazinamide-15N,d3; NSC-14911; Tisamid; 2KNI5N06TI; MLS000069730; DTXSID9021215; Pezetamid; Piraldina; CHEBI:45285; NSC14911; NCGC00015833-09; Pyrazinamdie; SMR000036662; 1246817-81-1; Pirazinamide [DCIT]; Pyrazinamidum [INN-Latin]; DTXCID801215; Pirazinamida [INN-Spanish]; Rifafour; D-50 (VAN); DRG 0124; CAS-98-96-4; CCRIS 545; Pyrazinamide (TN); Rifafour e-200; HSDB 3576; SR-01000076077; EINECS 202-717-6; UNII-2KNI5N06TI; BRN 0112306; pyrazinamida; Pyrizinamide; pyrazine amide; AZT + Pyrazinamide combination; Pyrazine-2-carboxylic acid amide; Pyrazinamide,(S); Pyrazinamide [USP:INN:BAN:JAN]; Prestwick_811; Pyranzinoic acid amide; 2-pyrazine carboxamide; Spectrum_000902; Opera_ID_735; Prestwick0_000514; Prestwick1_000514; Prestwick2_000514; Prestwick3_000514; Spectrum2_001305; Spectrum3_001046; Spectrum4_001186; Spectrum5_001026; Lopac-P-7136; PYRAZINAMIDE [MI]; PYRAZINAMIDE [INN]; PYRAZINAMIDE [JAN]; CHEMBL614; P 7136; PYRAZINAMIDE [HSDB]; WLN: T6N DNJ BVZ; PYRAZINAMIDE [VANDF]; pyrazine-2-carboximidic acid; Lopac0_001011; SCHEMBL24102; BSPBio_000467; BSPBio_002572; KBioGR_001851; KBioSS_001382; PYRAZINAMIDE [MART.]; 5-25-04-00178 (Beilstein Handbook Reference); MLS002222347; BIDD:GT0228; DivK1c_000241; PYRAZINAMIDE [USP-RS]; PYRAZINAMIDE [WHO-DD]; PYRAZINAMIDE [WHO-IP]; SPECTRUM1500518; SPBio_001369; SPBio_002388; BPBio1_000515; GTPL7287; HMS500M03; KBio1_000241; KBio2_001382; KBio2_003950; KBio2_006518; KBio3_001792; Pyrazinamide (JP17/USP/INN); NINDS_000241; BDBM228814; HMS1569H09; HMS1920N08; HMS2092E09; HMS2096H09; HMS2235G17; HMS3259O04; HMS3263K03; HMS3371G09; HMS3655A10; HMS3713H09; KUC109577N; Pharmakon1600-01500518; PYRAZINAMIDE [ORANGE BOOK]; PYRAZINAMIDE [EP MONOGRAPH]; PYRAZINAMIDE [USP IMPURITY]; ACT01761; AMY14180; BCP30257; HY-B0271; KSC-27-052E; Pyrazine-[d3]-carboxamide-[15N]; PYRAZINAMIDE [USP MONOGRAPH]; Tox21_110237; Tox21_202059; Tox21_302771; Tox21_501011; CCG-39243; NSC757304; PYRAZINAMIDUM [WHO-IP LATIN]; RIFATER COMPONENT PYRAZINAMIDE; s1762; STK801661; AKOS000120280; Tox21_110237_1; DB00339; LP01011; NC00534; NSC-757304; Pyrazinecarboxamide, analytical standard; SDCCGSBI-0050984.P005; IDI1_000241; PYRAZINAMIDE COMPONENT OF RIFATER; NCGC00015833-01; NCGC00015833-02; NCGC00015833-03; NCGC00015833-04; NCGC00015833-05; NCGC00015833-06; NCGC00015833-07; NCGC00015833-08; NCGC00015833-10; NCGC00015833-11; NCGC00015833-12; NCGC00015833-15; NCGC00015833-16; NCGC00015833-25; NCGC00090695-01; NCGC00090695-03; NCGC00090695-04; NCGC00090695-05; NCGC00090695-06; NCGC00090695-07; NCGC00256336-01; NCGC00259608-01; NCGC00261696-01; Pyrazinoic acid amide; pyrazinamide; PZA; CAS- 98-96-4; SY013550; TS-01626; SBI-0050984.P004; DB-002866; AB00052083; BB 0253141; EU-0101011; FT-0659757; P0633; SW196945-3; EN300-15621; C01956; D00144; D70481; 1,2-dihydro-1,2,4-triazol-3-one;Pyrazinamide; AB00052083-16; AB00052083_17; AB00052083_18; A845937; AC-907/25014068; Q417571; SR-01000076077-1; SR-01000076077-4; SR-01000076077-6; W-100059; Z33546644; Pyrazinamide, British Pharmacopoeia (BP) Reference Standard; Pyrazinamide, European Pharmacopoeia (EP) Reference Standard; 2-Carbamylpyrazine ;Aldinamid ;Aldinamide; Pyrazinoic acid amide; Pyrazinamide, United States Pharmacopeia (USP) Reference Standard; Pyrazinamide, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	1046	DB00339	D0XF8W	123.11	68.9	115	-0.6	9	1	3	1	C5H5N3O	pyrazine-2-carboxamide	C1=CN=C(C=N1)C(=O)N	C1=CN=C(C=N1)C(=O)N	InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)	IPEHBUMCGVEMRF-UHFFFAOYSA-N
DDP62L	Lisinopril	Small molecule	lisinopril; Prinivil; 76547-98-3; Zestril; Linopril; Lisipril; Lysinopril; Tensopril; 83915-83-7; Lisinopril anhydrous; Acercomp; Inhibril; Noperten; Presiten; Sinopril; Acerbon; Carace; Vivatec; Coric; Alapril; Inopril; Lisinal; Lisoril; Lispril; Novatec; Sinopryl; Cipral; Cipril; Linvas; Lipril; Loril; Prinil; Tensyn; Tersif; Lisinoprilum; Longes; Hipril; MK-521; Lisinopril (INN); Lisinopril [INN]; [N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE; N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; Zestril (TN); 7Q3P4BS2FD; CHEBI:43755; Qbrelis; NSC-751176; NSC-758151; (S)-1-((S)-6-Amino-2-(((S)-1-carboxy-3-phenylpropyl)amino)hexanoyl)pyrrolidine-2-carboxylic acid; LPR; L-Proline, N2-((1S)-1-carboxy-3-phenylpropyl)-L-lysyl-; (S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline; Nanopril; Lisinoprilum [Latin]; (S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline; CHEMBL1237; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid; Lizinopril; Diroton; Lisitec; Lisopril; Listril; Lizonoton; Optimon; Prinvil; Skopryl; Vitopril; Amicor; Doneka; Irumed; Laaven; MLS002154258; MK 521; MK 522; SMR000544473; CCRIS 3568; SMR001233519; EINECS 278-488-1; UNII-7Q3P4BS2FD; BRN 4276619; lysinopryl; (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline; L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-; N-(1(S)-Carboxy-3-phenylpropyl)-L-lysyl-L-proline; N2-((S)-1-Carboxy-3-phenylpropyl)-L-lysyl-L-proline; LisiprilPrinivil; HSDB 6852; (S)-1-(N(sup 2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline; (2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid; 77726-95-5; (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate; Lisinopril (Zestril); 1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline; Spectrum_000497; LISINOPRIL [MI]; Prestwick0_000301; Prestwick1_000301; Prestwick2_000301; Prestwick3_000301; Spectrum2_001456; Spectrum3_000941; Spectrum4_001040; Spectrum5_000995; (S)-Lisinopril Dihydrate; LISINOPRIL [WHO-DD]; SCHEMBL15680; BSPBio_000262; KBioGR_001599; KBioSS_000977; (2S)-1-[(2S)-6-amino-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid; MLS001306436; MLS001306481; BIDD:GT0755; DivK1c_001037; SPECTRUM1501217; SPBio_001351; SPBio_002481; BPBio1_000290; GTPL6360; ICI-209K; DTXSID6040537; BDBM66979; HMS503O15; KBio1_001037; KBio2_000977; KBio2_003545; KBio2_006113; KBio3_002002; L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-; N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; cid_22887897; NINDS_001037; HMS1921B14; HMS2090O14; HMS2092L21; HMS2850N20; Pharmakon1600-01501217; 1-[Nalpha-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline; L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-, (S)-; BDBM50367879; CCG-39190; DL-434; NSC751176; NSC758151; s2076; AKOS015836369; AKOS015894970; L-Proline, 1-(N(sup 2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-, (S)-; BCP9000856; DB00722; IDI1_001037; NCGC00179623-01; NCGC00179623-07; HY-18206; SBI-0051692.P002; L0220; C76449; D08131; AB00052250-13; AB00052250_14; AB00052250_15; A838743; Q412208; SR-05000001786; SR-05000001786-1; BRD-K67966701-335-03-5; Z1515376765; N-[N2 (1(S)-carboxy-3-phenylpropyl)-L-lysyl]-L-proline; N-[N2 -(1(S)-carboxy-3-phenylpropyl)-L-lysyl]-L-proline; 1-(N(SUP 2)-((S)-1-CARBOXY-3-PHENYLPROPYL)-L-LYSYL)-L-PROLINE; L-PROLINE, 1-(N(SUP 2)-(1-CARBOXY-3-PHENYLPROPYL)-L-LYSYL)-; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenyl-propyl]amino]hexanoyl]proline;hydrate; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenyl-propyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;Lisinopril; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxohexyl]-2-pyrrolidinecarboxylic acid;hydrate; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate; (2S)-1-[(2S)-6-azanyl-2-[[(2S)-1-oxidanyl-1-oxidanylidene-4-phenyl-butan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate; (S)-1-((S)-6-amino-2-((S)-1-carboxy-3-phenylpropylamino)hexanoyl)pyrrolidine-2-carboxylic acid	Approved	Approved Drug(s)	5362119	DB00722	D0XS1W	405.5	133	550	-2.9	29	4	7	12	C21H31N3O5	(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid	C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O	C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O	InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1	RLAWWYSOJDYHDC-BZSNNMDCSA-N
D5VIN3	Belinostat	Small molecule	Belinostat; 414864-00-9; PXD101; Belinostat (PXD101); 866323-14-0; Beleodaq; PXD-101; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; NSC726630; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; PX-105684; PX105684; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; NSC-726630; F4H96P17NZ; PXD 101; CHEBI:61076; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; 2-Propenamide, N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; N-hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide; 2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide.; E-Belinostat; 2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, (2E)-; Belinostat [USAN]; Belinostat [USAN:INN]; N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; UNII-F4H96P17NZ; (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE; N-HYDROXY-3-(3-((PHENYLAMINO)SULFONYL)PHENYL)-2-PROPENAMIDE; PXD101;PX105684; Belinostat Ph3; Beleodaq (TN); N-Hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; BELINOSTAT [MI]; Belinostat - PXD101; BELINOSTAT [INN]; Belinostat (USAN/INN); BELINOSTAT [VANDF]; N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]-2-propenamide; BELINOSTAT [WHO-DD]; N-Hydroxy-3-(3-phenylsulphamoylphenyl)acrylamide; MLS006011091; CHEMBL408513; GTPL7496; BELINOSTAT [ORANGE BOOK]; BDBM25150; CHEBI:94531; AMY1792; DTXSID60194378; EX-A180; (E)-3-[3-(phenylsulfamoyl)phenyl]prop-2-enehydroxamic acid; BCPP000351; BCP01741; Belinostat,PXD101, PX105684; MFCD08064035; NSC758774; s1085; AKOS025401741; BCP9000386; CCG-208758; DB05015; NSC-758774; NCGC00263155-02; NCGC00263155-05; AC-25046; AC-35365; AS-17068; SMR004702879; B5888; SW219445-1; EC-000.2286; A25012; D08870; EN300-7361191; J-523584; Q4882925; BRD-K17743125-001-01-9; N-Hydroxy-3-[(phenylamino)sulfonyl]-trans-cinnamamide; (E)-N-Hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide; 5OG	Approved	Approved Drug(s)	6918638	DB05015	D0XT6W	318.3	104	492	1.7	22	3	5	5	C15H14N2O4S	(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide	C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO	C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO	InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+	NCNRHFGMJRPRSK-MDZDMXLPSA-N
D3FC7W	Mitomycin C	Small molecule	mitomycin C; Mitomycin; 50-07-7; Ametycine; Mutamycin; Mitomycin-C; Mitocin-C; Mytozytrex; Ametycin; Mitomycinum; Mytomycin; Mitozytrex; Mitamycin; Mitosol; MMC; NSC-26980; Muamycin; 7-Amino-9alpha-methoxymitosane; C15H18N4O5; NSC 26980; Mitomycyna C; NCI-C04706; Mito-C; NSC26980; Mit-C; Mitomycinum C; Mitocin C; DTXSID2020898; CHEBI:27504; RCRA waste number U010; UGN-101; UGN-102; 50SG953SK6; Mitomycyna C [Polish]; [(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.0^{2,7}.0^{4,6}]trideca-1(9),11-dien-8-yl]methyl carbamate; 6-Amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione carbamate (ester); Mitomycin (TN); Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)-; DTXCID00898; CAS-50-07-7; Muamycin (TN); ((1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl carbamate; [(1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)-; CCRIS 414; HSDB 3239; Mitomycin (USP/INN); MLS002702984; (amino-methoxy-methyl-dioxo-[?]yl)methyl carbamate; EINECS 200-008-6; RCRA waste no. U010; 7-Amino-9.alpha.-methoxymitosane; Mitonco; Mitoplus; MitoExtra; UNII-50SG953SK6; AI3-26199; Mitomycin [USAN:USP:INN:BAN]; NCGC00095258-01; [(1aS,8S,8aR,8bS)-6-Amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2'',3'':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; [(1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-, carbamate (ester); Jelmyto (TN); MFCD00078109; JELMYTO; Mitomycin C- Bio-X; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS-(1aalpha,8beta,8aalpha,8balpha))-; Mitomycin C from Streptomyces caespitosus; MITOMYCIN [INN]; Mitomycin C (JP17); MITOMYCIN [HSDB]; MITOMYCIN [USAN]; MITOMYCIN [VANDF]; MITOMYCIN C [MI]; CHEMBL105; MITOMYCIN [MART.]; MITOMYCIN C [JAN]; MITOMYCIN [USP-RS]; MITOMYCIN [WHO-DD]; MITOMYCIN C [IARC]; SCHEMBL3760; CBiol_001927; BSPBio_001267; KBioGR_000607; KBioSS_000607; Mitomycin C (4% in NaCl); MLS001332654; Mitozytrex (TN) (Supergene); 50-07-7 (non-salt); AMETYCIN pound notmitomycin C; GTPL7089; MITOMYCIN [ORANGE BOOK]; MITOMYCIN [EP MONOGRAPH]; KBio2_000607; KBio2_003175; KBio2_005743; KBio3_001073; KBio3_001074; EX-A501; MITOMYCIN [USP MONOGRAPH]; BCPP000410; Bio1_000213; Bio1_000702; Bio1_001191; Bio2_000464; Bio2_000944; HMS1362O09; HMS1792O09; HMS1990O09; HMS2089F16; HMS3403O09; AMY10316; AZIRINO(2',3':3,4)PYRROLO(1,2-A)INDOLE-4,7-DIONE, 6-AMINO-8-(((AMINOCARBONYL)OXY)METHYL)-1,1A,2,8,8A,8B-HEXAHYDRO-8A-METHOXY-5-METHYL-, (1AS-(1A.ALPHA.,8.BETA.,8A.ALPHA.,8B.ALPHA.))-; Tox21_111493; AC-918; BDBM50428658; GR-311; HB4458; s8146; AKOS015895703; Tox21_111493_1; BCP9000285; CCG-208564; CS-0564; DB00305; KS-5148; IDI1_002219; SMP1_000307; Mitomycin 100 microg/mL in Acetonitrile; NCGC00163468-02; NCGC00163468-03; NCGC00163468-05; NCGC00163468-06; [1aS-(1aalpha,8beta,8aalpha,8balpha)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; 1404-00-8; BM164668; HY-13316; SMR000058401; BCP0726000181; M2320; C06681; D00208; D91590; AB00918689-03; AB00918689-04; EN300-7405455; Mitomycin C, Antibiotic for Culture Media Use Only; Q-201410; BRD-K59670716-001-02-6; BRD-K59670716-001-06-7; Q19856779; WLN: T D3 B556 BN EM JV MVTTT&J GO1 H1OVZ KZ L1; Mitomycin C from Streptomyces caespitosus, >=970 mug/mg (USP XXIV); Mitomycin C from Streptomyces caespitosus, powder, BioReagent, suitable for cell culture; Mitomycin C from Streptomyces caespitosus, powder, contains NaCl as solubilizer; [1aS-(1a?,8?,8a?,8b?)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a- methoxy-5-methyl-, carbamate (ester); Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b- hexahydro-8a-methoxy-5-methyl-, [1aR-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-; Mitomycin C from Streptomyces caespitosus, >=98% (HPLC), potency: >=970 mug per mg (USP XXIV), gamma-irradiated, suitable for cell culture	Approved	Approved Drug(s)	5746	DB00305	D0Y0GH	334.33	147	757	-0.4	24	3	8	4	C15H18N4O5	[(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate	CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N	CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N	InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1	NWIBSHFKIJFRCO-WUDYKRTCSA-N
D3U8IX	Flutamide	Small molecule	flutamide; 13311-84-7; Eulexin; Niftolide; Niftholide; Sch 13521; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; NFBA; niftolid; Drogenil; Flutamin; Cebatrol, veterinary; Flutamida; Flutamidum; Sch-13521; 4'-Nitro-3'-trifluoromethylisobutyranilide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; N-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)ISOBUTYRAMIDE; SCH13521; MFCD00072009; NSC 215876; alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; CHEMBL806; Propanamide, 2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-; Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-; NSC-215876; 4-Nitro-3-(trifluoromethyl)isobutyranilide; CHEBI:5132; DTXSID7032004; 76W6J0943E; NCGC00015452-09; Eulexine; Chimax; 4'-Nitro-3'-trifluoromethylisobutyramilide; CAS-13311-84-7; Ham's F-12 medium; Flutamidum [INN-Latin]; Flutamida [INN-Spanish]; Flutamide USP25; N-[4-Nitro-3-(trifluoromethyl)phenyl]isobutyramide; DTXCID9011121; Prostandril; Odyne; .alpha.,.alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; SMR000058187; Eulexin (TN); CCRIS 7246; m-Propionotoluidide,.alpha.,.alpha.-trifluoro-; SR-01000075888; EINECS 236-341-9; BRN 2157663; .alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; m-Propionotoluidide,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-; UNII-76W6J0943E; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; Flutamide [USAN:USP:INN:BAN]; Flutamide,(S); Prestwick_228; Flutamide (Eulexin); NK-601; Spectrum_001210; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; CPD000058187; FLUTAMIDE [INN]; FLUTAMIDE [JAN]; FLUTAMIDE [MI]; FLUTAMIDE [USAN]; Prestwick0_000180; Prestwick1_000180; Prestwick2_000180; Prestwick3_000180; Spectrum2_001201; Spectrum3_001421; Spectrum4_000829; Spectrum5_001450; Lopac-F-9397; F0663; Flutamide (pubertal study); FLUTAMIDE [MART.]; F 9397; FLUTAMIDE [USP-RS]; FLUTAMIDE [WHO-DD]; SCHEMBL3934; Lopac0_000557; BSPBio_000079; BSPBio_003122; KBioGR_001377; KBioSS_001690; MLS000069634; MLS001065596; MLS002548892; DivK1c_000459; SPECTRUM1500995; SPBio_000982; SPBio_002000; Flutamide (JP17/USP/INN); BPBio1_000087; GTPL6943; FLUTAMIDE [EP IMPURITY]; FLUTAMIDE [ORANGE BOOK]; CHEMBL4759307; FLUTAMIDE [EP MONOGRAPH]; SCHEMBL12932289; HMS501G21; KBio1_000459; KBio2_001690; KBio2_004258; KBio2_006826; KBio3_002342; FLUTAMIDE [USP MONOGRAPH]; NINDS_000459; HMS1568D21; HMS1921O16; HMS2090I18; HMS2092O14; HMS2095D21; HMS2230P19; HMS3259I03; HMS3261P15; HMS3373C12; HMS3655G22; HMS3712D21; Pharmakon1600-01500995; AMY32524; BCP23006; HY-B0022; Tox21_110154; Tox21_202169; Tox21_300536; Tox21_500557; BDBM50131270; CCG-39105; m-Propionotoluidide, 2-methyl-4'-nitro-alpha,alpha,alpha-triflouro-; m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-; NSC147834; NSC215876; NSC757817; s1908; AKOS001025465; AKOS025243203; m-Propionotoluidide, .alpha.,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-; Tox21_110154_1; AB02835; DB00499; KS-5091; LP00557; NC00451; NSC-147834; NSC-757817; SDCCGSBI-0050540.P004; IDI1_000459; NCGC00015452-01; NCGC00015452-02; NCGC00015452-03; NCGC00015452-04; NCGC00015452-05; NCGC00015452-06; NCGC00015452-07; NCGC00015452-08; NCGC00015452-10; NCGC00015452-11; NCGC00015452-12; NCGC00015452-13; NCGC00015452-14; NCGC00015452-15; NCGC00015452-16; NCGC00015452-19; NCGC00015452-20; NCGC00015452-32; NCGC00091460-01; NCGC00091460-02; NCGC00091460-03; NCGC00091460-04; NCGC00091460-05; NCGC00091460-06; NCGC00091460-07; NCGC00091460-08; NCGC00091460-09; NCGC00254495-01; NCGC00259718-01; NCGC00261242-01; AC-24192; BF166239; SY036411; SBI-0050540.P003; DB-042163; 3'-Trifluoromethyl-4'-Nitro-Isobutyranilide; AB00052188; EU-0100557; FT-0626493; FT-0668764; SW196536-4; 4''-nitro-3''-trifluoromethylisobutyranilide; C07653; D00586; EN300-119548; AB00052188-09; AB00052188_10; AB00052188_11; A806562; Q418669; Q-201131; SR-01000075888-1; SR-01000075888-6; SR-01000075888-7; SR-01000075888-9; BRD-K28307902-001-05-0; Flutamide, certified reference material, TraceCERT(R); Z56755651; a,a,a-Trifluoro-2-methyl-4'-nitro- m-propionotoluidide; Flutamide, European Pharmacopoeia (EP) Reference Standard; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide #; Flutamide, United States Pharmacopeia (USP) Reference Standard; 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide;Flutamide; alpha,alpha,alpha-trifluoro-2-methyl-4''-nitro-m-propionotoluidide; m-Propionotoluidide, 2-methyl-4'-nitro-.alpha.,.alpha.,.alpha.-trifluoro-; Flutamide for system suitability, European Pharmacopoeia (EP) Reference Standard; 37209-54-4	Approved	Approved Drug(s)	3397	DB00499	D0Y0SW	276.21	74.9	352	3.3	19	1	6	2	C11H11F3N2O3	2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide	CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F	CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F	InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)	MKXKFYHWDHIYRV-UHFFFAOYSA-N
D5S3JK	Minoxidil	Small molecule	minoxidil; 38304-91-5; Rogaine; Loniten; Minoximen; Regaine; Theroxidil; Alopexil; Alostil; Tricoxidil; Lonolox; Normoxidil; Prexidil; Minodyl; Pierminox; RiUP; Mintop; 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide; U-10858; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine; CHEBI:6942; 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide; U-10,858; 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine; NSC-757106; MLS000028566; DTXSID9040685; Minossidile [Italian]; Minoxidilum [INN-Latin]; NCGC00015673-08; Minoxidilum; SMR000058963; 6-amino-2-imino-4-(piperidin-1-yl)-1,2-dihydropyrimidin-1-ol; CAS-38304-91-5; Apo-Gain; U10858; 6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide; 2,6-diamino-4-(piperidin-1-yl)pyrimidin-1-ium-1-olate; DTXCID7020685; Neoxidil; Avacor and Mintop; SMR000326812; Loniten (TN); Rogaine (TN); Riup (TN); 2,4-Diamino-6-piperidinopyrimidine 3-oxide; SR-01000075331; SR-05000001479; MFCD00063409; 3-oxido-6-piperidin-1-ylpyrimidin-3-ium-2,4-diamine; Kopdil; Regaine For Men; Minoxidil,(S); Regaine For Women; Prestwick_521; 3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine; TM-160; Men''''s Rogaine; Women''''s rogaine; Rogaine Extra Strength; pyrimidin-1(2H)-ol; Spectrum_000969; Tocris-0583; MINOXIDIL [INN]; MINOXIDIL [JAN]; MINOXIDIL [MI]; Minoxidil Extra Strength; MINOXIDIL [HSDB]; MINOXIDIL [INCI]; MINOXIDIL [USAN]; regid855572; Opera_ID_1150; Prestwick0_000020; Prestwick1_000020; Prestwick2_000020; Prestwick3_000020; Spectrum2_001053; Spectrum3_000509; Spectrum4_000063; Spectrum5_001299; Lopac-M-4145; MINOXIDIL [VANDF]; M1389; CHEMBL802; MINOXIDIL [MART.]; M 4145; MINOXIDIL [USP-RS]; MINOXIDIL [WHO-DD]; Minoxidil (U-10858); Minoxidil (JAN/USP/INN); CBiol_001798; Lopac0_000786; SCHEMBL29698; BSPBio_000059; BSPBio_001385; BSPBio_002037; KBioGR_000105; KBioGR_000585; KBioSS_000105; KBioSS_001449; 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide; MLS000859953; MLS001077294; DivK1c_000160; SCHEMBL232565; SPECTRUM1500415; SPBio_001006; SPBio_001980; BPBio1_000065; CHEMBL609587; GTPL4254; Minoxidil, >=99% (TLC); SGCUT00112; MINOXIDIL [ORANGE BOOK]; 6-amino-2-imino-4-(piperidin-1-yl)pyrimidin-1(2H)-ol; CHEMBL1372483; MINOXIDIL [EP MONOGRAPH]; BCBcMAP01_000193; BDBM81463; CHEBI:92128; HMS500H22; KBio1_000160; KBio2_000105; KBio2_001449; KBio2_002673; KBio2_004017; KBio2_005241; KBio2_006585; KBio3_000209; KBio3_000210; KBio3_001537; MINOXIDIL [USP MONOGRAPH]; NINDS_000160; BCPP000162; Bio1_000084; Bio1_000573; Bio1_001062; Bio2_000105; Bio2_000585; HMS1361F07; HMS1568C21; HMS1791F07; HMS1920P03; HMS1989F07; HMS2089L08; HMS2091F20; HMS2095C21; HMS2233E04; HMS2235N21; HMS3259P21; HMS3262M14; HMS3266O06; HMS3371E15; HMS3372M19; HMS3402F07; HMS3411G16; HMS3675G16; HMS3712C21; Pharmakon1600-01500415; ACT04612; BCP01409; CAS_4201; HY-B0112; NSC_4201; to_000070; Tox21_110193; Tox21_500786; BDBM50237593; CCG-40112; HB1094; NSC757106; s1383; STL453211; AKOS015920078; AKOS016339636; Tox21_110193_1; 6-amino-2-imino-4-(piperidin-1-yl); AC-5271; BCP9000929; CCG-220020; CS-1867; DB00350; GS-3605; KS-5164; LP00786; NC00686; SDCCGSBI-0050764.P005; IDI1_000160; IDI1_033855; SMP1_000192; NCGC00015673-01; NCGC00015673-02; NCGC00015673-03; NCGC00015673-04; NCGC00015673-05; NCGC00015673-06; NCGC00015673-07; NCGC00015673-09; NCGC00015673-10; NCGC00015673-11; NCGC00015673-13; NCGC00015673-20; NCGC00018278-01; NCGC00018278-02; NCGC00018278-03; NCGC00018278-04; NCGC00024666-01; NCGC00024666-02; NCGC00024666-03; NCGC00024666-04; NCGC00024666-05; NCGC00024666-06; NCGC00024666-07; NCGC00024666-08; NCGC00179672-01; NCGC00261471-01; 16317-69-4; BD164673; SBI-0050764.P004; 2,6-Diamino-4-piperidinopyrimidine 1-Oxide; 5965120SH1; AB00513797; EU-0100786; FT-0620793; D00418; EN300-121204; H10337; O10620; 6-(1-Piperidinyl)-2,4-pyrimidinediamine3-oxide; AB00052047-08; AB00052047_09; AB00052047_10; AB00513797-02; A824098; Q424165; Q-201408; SR-01000075331-1; SR-01000075331-3; SR-01000075331-5; SR-05000001479-1; SR-05000001479-2; 2,4-DIAMINO-6-PIPERIDINOPYRIMIDINE 3-OXIDE.; 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine; BRD-K06902185-001-05-2; BRD-K06902185-001-10-2; BRD-K14888893-001-02-3; Minoxidil, British Pharmacopoeia (BP) Reference Standard; Z1541638524; Minoxidil, European Pharmacopoeia (EP) Reference Standard; 2-azanylidene-3-oxidanyl-6-piperidin-1-yl-pyrimidin-4-amine; 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidino-pyrimidine; Minoxidil, United States Pharmacopeia (USP) Reference Standard; Minoxidil for system suitability, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	4201	DB00350	D0Y2CJ	209.25	88.9	329	1.2	15	3	3	1	C9H15N5O	3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine	C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O	C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O	InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2	ZIMGGGWCDYVHOY-UHFFFAOYSA-N
D5AQ0Y	Valproic acid	Small molecule	VALPROIC ACID; 2-Propylpentanoic acid; 99-66-1; 2-Propylvaleric acid; Dipropylacetic acid; Depakene; Depakine; Valproate; Ergenyl; Di-n-propylacetic acid; Mylproin; Propylvaleric acid; Pentanoic acid, 2-propyl-; 4-Heptanecarboxylic acid; n-Dipropylacetic acid; Myproic Acid; n-DPA; Dipropylacetate; Convulex; Depakin; Di-n-propylessigsaure; Avugane; Baceca; Stavzor; Acido valproico; Kyselina 2-propylvalerova; Acide valproique; 2-n-Propyl-n-valeric acid; Acidum valproicum; Acetic acid, dipropyl-; 2,2-di-n-propylacetic acid; Valproinsaeure; Savicol; Depakine chrono; Depakin chrono; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; 2-PROPYL-PENTANOIC ACID; Di-n-propylessigsaure [German]; Valeric acid, 2-propyl-; divalproex; Epilim; Kyselina 2-propylvalerova [Czech]; Di-n-propylessigsaeure; VPA; VPA;2-Propylpentanoic Acid; NSC 93819; Delepsine; Sprinkle; Valcote; Valparin; Epilex; PEAC; Depakene (TN); pentanoic acid, 2-propyl; Vupral; CHEMBL109; (n-C3H7)2CHCOOH; Valproic acid extended release; 614OI1Z5WI; DTXSID6023733; CHEBI:39867; Valerin; NSC-93819; NCGC00091149-01; Deproic; Alti-Valproic; Novo-Valproic; Penta-Valproic; Dom-Valproic; Med Valproic; Nu-Valproic; Valproic acid USP; PMS-Valproic Acid; DTXCID803733; Valproic acid (USP); Valproic Acid Semisodium Salt; CAS-99-66-1; Depakote (TM); SMR000499581; HSDB 3582; 2 PP (base); EINECS 202-777-3; MFCD00002672; BRN 1750447; UNII-614OI1Z5WI; valproic-acid; Novo-divalproex; Sandoz valproic; Dom-valproate; Gen-divalproex; Apo-valproic; AI3-10500; APO-divalproex; DOM-divalproex; Epival er; PHL-valproate; PMS-valproate; PMS-Divalproex; Erganyl; Stavzor; Dom-valproic acid; PHL-valproic acid; Epiject I.V.; 2-propyl-Pentanoate; Epical (TM); Epilim (Salt/Mix); Valproic acid [USAN:USP:INN:BAN]; VALPROICACID; Depacon (Salt/Mix); Convulex (Salt/Mix); Eurekene (Salt/Mix); G2M-777; Valparin (Salt/Mix); Novo-Valproic - ECC; Spectrum_000521; Divalproex (Salt/Mix); Ratio-Valproic - ECC; Valdisoval (Salt/Mix); 2 -propylpentanoic acid; di-n-propyl acetic acid; S(-)-4-En-valproate; Spectrum2_000946; Spectrum3_001733; Spectrum4_000376; DOM-valproic acid E.C.; PHL-valproic acid E.C.; PMS-valproic acid E.C.; Novo-valproic soft gel cap; EC 202-777-3; SCHEMBL2275; VALPROIC ACID [MI]; VALPROIC ACID [INN]; S-2-n-Propyl-4-pentenoate; (S)-2-propyl-4-pentanoate; KBioGR_000871; KBioGR_002277; KBioSS_001001; KBioSS_002278; VALPROIC ACID [HSDB]; VALPROIC ACID [INCI]; VALPROIC ACID [USAN]; MLS001076682; MLS001335927; MLS001335928; MLS002415770; BIDD:GT0858; DivK1c_000273; VALPROIC ACID [VANDF]; SPBio_000912; VALPROIC ACID [MART.]; GTPL7009; VALPROIC ACID [USP-RS]; VALPROIC ACID [WHO-DD]; WLN: QVY3 & 3; KBio1_000273; KBio2_001001; KBio2_002277; KBio2_003569; KBio2_004845; KBio2_006137; KBio2_007413; KBio3_002626; KBio3_002757; NIJJYAXOARWZEE-UHFFFAOYSA-; Valproic acid [USAN:BAN:INN]; NINDS_000273; HMS2089J06; HMS2231E06; HMS3259C18; HMS3370C21; HMS3715B15; HMS3885G14; ACT05281; ALBB-032973; BCP33204; NSC93819; VALPROIC ACID [EP IMPURITY]; VALPROIC ACID [ORANGE BOOK]; Tox21_111091; Tox21_201963; Tox21_300603; BDBM50003616; LMFA01020291; s3944; STL445581; VALPROIC ACID [EP MONOGRAPH]; VALPROIC ACID [USP IMPURITY]; VALPROIC ACID [USP MONOGRAPH]; AKOS009156895; Tox21_111091_1; Valproic Acid 1.0 mg/ml in Methanol; CCG-221127; CS-1765; DB00313; NC00584; SDCCGSBI-0050864.P004; NCGC00091149-02; NCGC00091149-03; NCGC00091149-04; NCGC00091149-05; NCGC00091149-06; NCGC00091149-08; NCGC00091149-09; NCGC00091149-26; NCGC00162288-07; NCGC00254365-01; NCGC00259512-01; AS-11354; HY-10585; SBI-0050864.P003; FT-0609289; FT-0675769; P0823; EN300-64925; A19450; C07185; D00399; AB00698315-06; Q240642; Q-200321; Sodium valproate; 2-Propylpentanoic acid sodium salt; SR-01000075242-7; F2191-0115; Z756391526; Valproic acid, European Pharmacopoeia (EP) Reference Standard; Valproic acid, United States Pharmacopeia (USP) Reference Standard; Valproic acid for system suitability, European Pharmacopoeia (EP) Reference Standard; Valproic acid, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	3121	DB00313	D0Y3KG	144.21	37.3	93.4	2.8	10	1	2	5	C8H16O2	2-propylpentanoic acid	CCCC(CCC)C(=O)O	CCCC(CCC)C(=O)O	InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)	NIJJYAXOARWZEE-UHFFFAOYSA-N
D2O9KA	Oxaliplatin	Small molecule	oxaliplatin; DTXSID0036760; Oxalato(trans-l-1,2-cyclohexanediamine)platinum(II); cis-oxalato-trans-l-1,2-diaminocyclohexaneplatinum(II); DTXCID8016760; CAS-61825-94-3; Oxaliplatin [USAN:INN:BAN]; NCGC00167798-01; SCHEMBL19511; HMS3269F19; Tox21_112585; Tox21_112629; AKOS005766023; AKOS015855804; CS-0992; BP-25383; HY-17371; [(1S,2S)-2-azanidylcyclohexyl]azanide; oxalate; platinum(4+)	Approved	Approved Drug(s)	9887053	DB00526	D0Y3ME	397.29	76.6	191	.	15	4	6	0	C8H14N2O4Pt	[(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+)	C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]	C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]	InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1	DRMCATBEKSVAPL-BNTLRKBRSA-N
D0D7SB	Amikacin	Small molecule	amikacin; 37517-28-5; Amicacin; Amikin; Amikacinum; Lukadin; amikacine; Amikacina; Amikacillin; Antibiotic BB-K 8; Potentox; Amukin; Amikacine [INN-French]; Amikacinum [INN-Latin]; Amikacina [INN-Spanish]; Amikacin Base; BB-K8; Kaminax; 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A; BAY 41-6551; Amikacin free base; Briclin; Amikavet; CHEBI:2637; Amikacin hydrate; Amiglyde-V; Arikace; N1-[(S)-4-Amino-2-hydroxybutyryl]kanamycin A; ANTIBIOTIC BB-K8; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; DTXSID3022586; Mikavir; 84319SGC3C; 37517-28-5 (free base); Amikacin Dihydrate; NSC177001; NSC-177001; BB-K 8; NCGC00093350-02; (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide; (S)-4-amino-N-((1R,2S,3S,4R,5S)-5-amino-2-(((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4-(((2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide; AMK; DTXCID002586; Amikozit; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-{[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-{[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide; HSDB 3583; Amikacin (USP/INN); EINECS 253-538-5; NSC 177001; Amikacin [USP:INN:BAN]; UNII-84319SGC3C; SR-01000722004; Arikayce liposomal; NCGC00093350-05; Amikacin,(S); (2S)-N-[(1R,2S,3S,4R,5S)-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5-azanyl-2-[(2S,3R,4S,5S ,6R)-4-azanyl-6-(hydroxymethyl)-3,5-bis(oxidanyl)oxan-2-yl]oxy-3-oxidanyl-cyclohexyl]-4-azanyl-2-oxidanyl-butanamide; (2s)-N-[(1r,2s,3s,4r,5s)-4-[(2r,3r,4s,5s,6r)-6-(Aminomethyl)-3,4,5-Tris(Oxidanyl)oxan-2-Yl]oxy-5-Azanyl-2-[(2s,3r,4s,5s,6r)-4-Azanyl-6-(Hydroxymethyl)-3,5-Bis(Oxidanyl)oxan-2-Yl]oxy-3-Oxidanyl-Cyclohexyl]-4-Azanyl-2-Oxidanyl-Butanamide; AKN; Amikin (Disulfate); MFCD00883675; BAY41-6551; Amikacin (free base); O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; nktr-061; AMIKACIN [HSDB]; AMIKACIN [INN]; AMIKACIN [JAN]; AMIKACIN [MI]; AMIKACIN [VANDF]; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]; Prestwick3_000395; AMIKACIN [MART.]; AMIKACIN [USP-RS]; AMIKACIN [WHO-DD]; AMIKACIN [WHO-IP]; CHEMBL177; SCHEMBL2985; CAS-37517-28-5; BSPBio_000609; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-; BPBio1_000671; AMIKACIN [EP MONOGRAPH]; AMIKACIN [USP MONOGRAPH]; 37517-28-5 (anhydr; GTPL10894; HY-B0509A; MAT2501; AMIKACINUM [WHO-IP LATIN]; Tox21_111201; BDBM50237603; STK039706; AKOS005383276; Tox21_111201_1; BAY 416651; DB00479; NCGC00093350-03; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide; AS-76985; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; AB00513828; C06820; D02543; AB00513828_06; Amikacin, Antibiotic for Culture Media Use Only; EN300-7481440; A823716; Q408529; SR-01000722004-6; W-106531; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxy-tetrahydropyran-2-yl]oxy-3-hydroxy-cyclohexyl]-2-hydroxy-butanamide; (S)-4-amino-N-((1R,2S,3S,4R,5S)-5-amino-2-((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-4-((2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yloxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide; D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-N(SUP 1)-(4-AMINO-2-HYDROXY-1-OXOBUTYL)-2-DEOXY-, (S)-; D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy-; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.4))-N1-((2S)-4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-; O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6))-N(SUP 3)-(4-AMINO-L-2-HYDROXYBUTYRYL)-2-DEOXY-L-STREPTAMINE	Approved	Approved Drug(s)	37768	DB00479	D0Y3MO	585.6	332	819	-7.9	40	13	17	10	C22H43N5O13	(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide	C1C(C(C(C(C1NC(=O)C(CCN)O)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(C(C(C(O3)CN)O)O)O)N	C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N	InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1	LKCWBDHBTVXHDL-RMDFUYIESA-N
D8F2GA	Pemetrexed	Small molecule	Pemetrexed; 137281-23-3; LY231514; Alimta; CHEBI:63616; LY-231514; (S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid; NSC-698037; 04Q9AIZ7NO; N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; Pemetrexed (INN); LY 231514; LY-2315; N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; PEMETREXED [INN]; Alimta (TN); (S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo-[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid; (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID; (2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; LYA; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid; Pemetrexed [INN:BAN]; UNII-04Q9AIZ7NO; HSDB 7316; 1juj; Pemetrexed (TN); N-(4-(2-(2-AMINO-4,7-DIHYDRO-4-OXO-1H-PYRROLO(2,3-D)PYRIMIDIN-5-YL)ETHYL)BENZOYL)-L-GLUTAMIC ACID; N-(4-[2-(2-amino-4,7-Dihydro-4-Oxo-1H-Pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl)-L-Glutamic Acid; Pemetrexed- Bio-X; PEMFEXY; PEMETREXED [MI]; Alimta (TN) (Lilly); PEMETREXED [HSDB]; PEMETREXED [VANDF]; SCHEMBL7968; PEMETREXED [WHO-DD]; US9422297, Pemetrexed; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; PEMETREXED [EMA EPAR]; CHEMBL225072; DTXSID2048329; PEMETREXED [ORANGE BOOK]; Premetrexed [Common mis-spelling]; BDBM50027656; NSC698037; s5971; AKOS015896253; AKOS016842348; AC-1701; CS-1297; DB00642; NCGC00166414-11; NCGC00167517-01; NCGC00242485-01; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; AS-30680; BP164240; HY-10820; L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-; N-[4-[2(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; DB-024764; P2288; D07472; AB01273937-01; EN300-7396246; A807228; Q415220; J-502393; L-Glutamic acid,3-d]pyrimidin-5-yl]ethyl]benzoyl]-; (2S)-2-{[4-(2-{2-amino-4-oxo-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioic acid; 1006872-74-7; N-(P-(2-(2-AMINO-4,7-DIHYDRO-4-OXO-1H-PYRROLO(2,3-D)PYRIMIDIN-5-YL)ETHYL)BENZOYL)-L-GLUTAMATE; N-[4-[2(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7h-pyrrolo[2,3-d]pyrimi-din-5-yl)ethyl]benzoyl]l-glutamic acid; N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt;Pemetrexed; N-[4-[2-[2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl]ethyl]benzoyl]glutamic acid	Approved	Approved Drug(s)	135410875	DB00642	D0Y4GO	427.4	187	748	0.2	31	6	7	9	C20H21N5O6	(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid	C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O	C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O	InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
D2JS6G	Bedaquiline	Small molecule	Bedaquiline; 843663-66-1; TMC207; TMC-207; Sirturo; R207910; TMC 207; Bedaquiline [USAN:INN]; AIDS-222089; R 207910; R-207910; CHEBI:72292; HSDB 8217; UNII-78846I289Y; (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol; 654653-93-7; (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol; 843663-66-1 (free base); MMV689758; 1-(6-Bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol; 78846I289Y; (alphaS,betaR)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol; (alphaR,betaS)-rel-Bedaquiline; (1R,2S)-1-(6-Bromo-2-methoxy-3-quinolyl)-4-dimethylamino-2-(1-naphthyl)-1-phenyl-butan-2-ol; (1R,2S)-1-(6-Bromo-2-methoxy-quinolin-3-yl)-4-methyl-amino-2-naphthalen-1-yl-1-phenyl-butan-2-ol; (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(1-naphthyl)-1-phenylbutan-2-ol; BDQ; Bedaquiline [USAN]; bedaquilina; bedaquilinum; (1R,2S)-1-(6-bromo-2-methoxy-3-quinolyl)-4-(dimethylamino)-2-(1-naphthyl)-1-phenyl-butan-2-ol; BQ1; AIDS 222089; BEDAQUILINE [MI]; BEDAQUILINE [INN]; Bedaquiline (USAN/INN); (; AS,; AR)-Bedaquiline; BEDAQUILINE [VANDF]; BEDAQUILINE [WHO-DD]; C32H31BrN2O2; SCHEMBL295482; CHEMBL376488; GTPL11171; DTXSID80903989; DTXSID101027810; EX-A4133; BDBM50063995; MFCD22628872; s5623; AKOS022186476; CCG-270030; DB08903; bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol; compound 1a [PMID: 17496888]; NCGC00348215-01; NCGC00348215-03; NCGC00348215-04; 3-Quinolineethanol, 6-bromo-alpha-(2-(dimethylamino)ethyl)-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-, (alphaR,betaS)-rel-; AC-28385; HY-14881; D09872; SR-05000022473; J-500265; Q1257318; SR-05000022473-1; R403323; TMC207; R207910; (1R)-(6-Bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2(S)-(1-naphthyl)-1-phenylbutan-2-ol; (1R,2S) 6-BROMO-ALPHA-(2-(DIMETHYLAMINO)ETHYL)-2-METHOXY-ALPHA-(1-NAPHTHYL)-BETA-PHENYL-3-QUINOLINEETHANOL; (1R,2S)-1-(6-BROMO-2-METHOXYQUINOLIN-3-YL)-4-(DIMETHYLAMINO)-2-(NAPHTHALEN-1-YL)-1- PHENYLBUTAN-2-OL; 1-(1R)-(6-Bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-(2S)-(naphthalen-1-yl)-1-phenyl-butan-2-ol; 3-QUINOLINEETHANOL, 6-BROMO-.ALPHA.-(2-(DIMETHYLAMINO)ETHYL)-2-METHOXY-.ALPHA.-1-NAPHTHALENYL-.BETA.-PHENYL-, (.ALPHA.S,.BETA.R)-; 3-Quinolineethanol, 6-bromo-alpha-(2-(dimethylamino)ethyl)-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-, (alphaS,betaR)-; rel-(1R,2S)-1-(6-Bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol	Approved	Approved Drug(s)	5388906	DB08903	D0Y4QG	555.5	45.6	715	7.2	37	1	4	8	C32H31BrN2O2	(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol	CN(C)CCC(C1=CC=CC2=CC=CC=C21)(C(C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O	CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O	InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3/t30-,32-/m1/s1	QUIJNHUBAXPXFS-XLJNKUFUSA-N
DM7ST0	Darifenacin	Small molecule	Darifenacin; Enablex; 133099-04-4; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; UK-88525; Darifenacin extended release; APG9819VLM; CHEMBL1346; (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; CHEBI:391960; [3H]darifenacin; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide; NCGC00168775-01; UK-88525 (hydrobromide); Darifenacin (USAN/INN); UNII-APG9819VLM; Darifenacin [USAN:INN:BAN]; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-di(phenyl)acetamide; Darifenacin [USAN]; DARIFENACIN [MI]; DARIFENACIN [INN]; DARIFENACIN [VANDF]; DARIFENACIN [MART.]; SCHEMBL56574; DARIFENACIN [WHO-DD]; GTPL319; GTPL321; MLS003876823; DTXSID2048290; AMY40857; HY-A0033; AC-302; BDBM50109647; AKOS015907962; CS-1168; DB00496; NCGC00168775-07; 3-(S)-(-)-(1-carbamoyl-1,1-diphenylmethyl)-1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]pyrrolidine; SMR002533186; D03654; AB01566824_01; EN300-19768793; Q166476; (s)-1-[2-(2,3-dihydro-5-benzofuranyl) ethyl]-alpha,alpha-diphenyl-3-pyrrolidine acetamide; (S)-2-{1-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-pyrrolidin-3-yl}-2,2-diphenyl-acetamide; (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide; 2-((3S)-1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide; 2-((3S)-1-(2-(2,3-DIHYDROBENZOFURAN-5-YL)ETHYL)PYRROLIDIN-3-YL)-2,2-DIPHENYLACETAMIDE.; 2-{1-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-pyrrolidin-3-yl}-2,2-diphenyl-acetamide (Darifenacin); 3-(S)-(-)-(1-carbamoyl-1,1-diphenylmethyl)-1-[2-(2,3-dihydrobenzofuran-5-y l)ethyl]pyrrolidine; 3-PYRROLIDINEACETAMIDE, 1-(2-(2,3-DIHYDRO-5-BENZOFURANYL)ETHYL)-.ALPHA.,.ALPHA.-DIPHENYL-, (3S)-; 3-Pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, (3S)-	Approved	Approved Drug(s)	444031	DB00496	D0Y5AM	426.5	55.6	607	4.6	32	1	3	7	C28H30N2O2	2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide	C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5	C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5	InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1	HXGBXQDTNZMWGS-RUZDIDTESA-N
DV50AM	Citalopram	Small molecule	citalopram; 59729-33-8; Nitalapram; Celexa; Cipram; Bonitrile; Citadur; 1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile; [3H]Citalopram; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; Lu-10-171; CHEMBL549; 1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; 0DHU5B8D6V; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; CHEBI:77397; [3H]-Citalopram; Citalopramum [INN-Latin]; Citalopramum; 5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-; 5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-; 5-Isobenzofurancarbonitrile,1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-; 1219908-84-5; Perrigo citalopram; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile; SMR000465669; Citadur (TN); Citalopram (USP/INN); EINECS 261-891-1; UNII-0DHU5B8D6V; Citalopram [USP:INN:BAN]; 1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile; [3H]Cytalopram; 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile; [3H]Escitalopram; Citalopram-[d4]; Citalopram-[d6]; [3H]Lexapro; 1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile; Escitalopram Impurity A; CITALOPRAM [MI]; CITALOPRAM [INN]; Prestwick3_000692; SCHEMBL946; CITALOPRAM [VANDF]; CITALOPRAM [MART.]; CITALOPRAM [WHO-DD]; Lopac0_000258; BSPBio_000843; MLS000028578; MLS006011858; BPBio1_000929; GTPL4621; GTPL7547; DTXSID8022826; BDBM25870; HSDB 7042; WSEQXVZVJXJVFP-UHFFFAOYSA-; CITALOPRAM [USP IMPURITY]; HMS2090O09; HMS2093A14; HMS3259B10; ACT02666; BBL029066; LU-10171B; STL058639; AKOS005711003; AC-8894; CCG-204353; DB00215; NC00711; SDCCGSBI-0050246.P003; 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carb onitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-isobenzofuran-5-carbonitrile; 5-Isobenzofurancarbonitrile, 1,3-dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-; MRF-0000302; NCGC00015267-04; NCGC00015267-05; NCGC00015267-07; NCGC00015267-09; NCGC00015267-11; NCGC00015267-12; NCGC00015267-20; NCGC00025160-02; AS-76503; SBI-0050246.P002; HY-121203; AB00513896; C3149; CS-0081223; FT-0657967; FT-0660873; C07572; D07704; EN300-304884; AB00513896-09; AB00513896-11; AB00513896_12; AB00513896_13; A832440; L001223; Q409672; SR-01000003129-8; BRD-A47598013-004-02-0; BRD-A47598013-004-06-1; 1-(3'-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile; 1-(3-(dimethylamino)propyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile; 1-(3-Dimethylamino-propyl)-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile; 1-[3-(dimethylamino) propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzo[b]furancarbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro[3,4]benzofuran-5-carbonitrile; 5-Cyano-1-(4-fluorophenyl)-1-(3-dimethylaminopropyl)-1,3-dihydro-isobenzofuran	Approved	Approved Drug(s)	2771	DB00215	D0Y5DO	324.4	36.3	466	3.2	24	0	4	5	C20H21FN2O	1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile	CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F	CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F	InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3	WSEQXVZVJXJVFP-UHFFFAOYSA-N
D1ELG3	Amitriptyline	Small molecule	amitriptyline; 50-48-6; Amitriptylin; Damitriptyline; Seroten; Triptanol; Flavyl; Proheptadiene; Elavil; Damilen; Lantron; Adepress; Triptisol; Tryptanol; Adepril; Amitriprolidine; Amitryptiline; Triptilin; Laroxyl; Redomex; Damilan; Ro 4-1575; Sarotex; MK 230; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; Amitriptyline (INN); HSDB 3007; CHEMBL629; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 5H-Dibenzo(a,d)cycloheptene-delta5,gamma-propylamine, 10,11-dihydro-N,N-dimethyl-; CHEBI:2666; Amytriptylin; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; Limbitrol; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(sup 5),gamma-propylamine; 1806D8D52K; Amitriptilina; Amitriptylinum; Amitryptyline; Amytriptiline; Laroxil; Elanil; Amitriptylin [German]; Amitriptilina [Italian]; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; AMITRIPTYLINE [INN]; 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine; Amitriptyline [INN:BAN]; Amitriptylinum [INN-Latin]; Amitriptilina [INN-Spanish]; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; 5H-Dibenzo[a,d]cycloheptene-.delta.5,.gamma.-propylamine, 10,11-dihydro-N,N-dimethyl-; Laroxyl (TN); CCRIS 9174; NSC169910; N 750; NCGC00015095-09; CAS-549-18-8; EINECS 200-041-6; BRN 2217885; UNII-1806D8D52K; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; Domical (Salt/Mix); Laroxyl (Salt/Mix); Lentizol (Salt/Mix); Vanatrip (Salt/Mix); Triptizol (Salt/Mix); Spectrum_000044; Prestwick0_000074; Prestwick1_000074; Prestwick2_000074; Prestwick3_000074; Spectrum2_000101; Spectrum3_000298; Spectrum4_000146; Spectrum5_000806; Lopac-A-8404; AMITRIPTYLINE [MI]; EC 200-041-6; SCHEMBL7824; Lopac0_000112; Oprea1_479304; AMITRIPTYLINE [VANDF]; BSPBio_000287; BSPBio_001836; GTPL200; KBioGR_000592; KBioGR_002261; KBioSS_000424; KBioSS_002262; AMITRIPTYLINE [MART.]; BIDD:GT0115; DivK1c_000766; SPBio_000082; SPBio_002208; AMITRIPTYLINE [WHO-DD]; BPBio1_000317; DTXSID7022594; KBio1_000766; KBio2_000424; KBio2_002261; KBio2_002992; KBio2_004829; KBio2_005560; KBio2_007397; KBio3_001336; KBio3_002741; cMAP_000001; NINDS_000766; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; BCP09083; AMITRIPTYLINE [USP IMPURITY]; BDBM50020712; PDSP1_001564; PDSP2_001548; s5947; STK525215; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; AKOS000512694; CCG-204207; DB00321; SDCCGSBI-0050100.P005; 3-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethyl-1-propanamine; 5H-Dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-N,N-dimethyl-; IDI1_000766; MRF-0000533; NCGC00015095-01; NCGC00015095-02; NCGC00015095-03; NCGC00015095-04; NCGC00015095-05; NCGC00015095-06; NCGC00015095-07; NCGC00015095-08; NCGC00015095-10; NCGC00015095-11; NCGC00015095-12; NCGC00015095-14; NCGC00015095-26; NCGC00024433-04; NCGC00183047-01; dimethyl({3-[(2Z)-tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene]propyl})amine; N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine; SBI-0050100.P004; AB00514631; AmitriptylineMK-230, N-750, Ro41575; BB 0305430; FT-0653242; C06824; D07448; Q58397; AB00053417-12; AB00053417_13; AB00053417_14; L001041; W-109252; BRD-K53737926-003-05-4; BRD-K53737926-003-14-6; NORTRIPTYLINE HYDROCHLORIDE IMPURITY F [EP IMPURITY]; 5-(.gamma.-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(.gamma.-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 10,11-Dihydro-5-(.gamma.-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-dihydro-N,N-dimethl-5H-dibenzo[a,d]cycloheptene-(delta(5, gamma))-propylamine; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-.DELTA.5,.gamma.-propylamine; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta5,gamma-propylamine; 3-(5,6-dihydrodibenzo[[?],[?]][7]annulen-11-ylidene)-N,N-dimethyl-propan-1-amine; 5-(.gamma.-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(.gamma.-Dimethylaminopropylidene)-5H-dibenzo(a,d)-10,11-dihydrocycloheptene; 3-(10,11-Dihydro-5H-dibenzo-[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine, hydrochloride; 5H-Dibenzo(a,d)cycloheptene-.delta.(sup 5),.gamma.-propylamine, 10,11-dihydro-N,N-dimethyl-; 5H-Dibenzo[a,d]cycloheptene-Delta5,gamma-propylamine, 10,11-dihydro-N,N-dimethyl- (6CI,8CI) 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene; dimethyl({3-[(2E)-tricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene]propyl})amine	Approved	Approved Drug(s)	2160	DB00321	D0Y5UG	277.4	3.2	331	5	21	0	1	3	C20H23N	N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine	CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31	CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31	InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3	KRMDCWKBEZIMAB-UHFFFAOYSA-N
DODT56	Fingolimod	Small molecule	Fingolimod; 162359-55-9; 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; 2-Amino-2-(4-octylphenethyl)propane-1,3-diol; Fty-720; Fingolimod [INN]; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propandiol; 1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-; Gilenya (TN); 3QN8BYN5QF; 1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-; CHEMBL314854; C19H33NO2; CHEBI:63115; Fingolimod (INN); 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol; FTY-720A; UNII-3QN8BYN5QF; 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol; fingolimodum; FingoliMod Base; Fingolimod- Bio-X; FINGOLIMOD [MI]; FINGOLIMOD [VANDF]; FINGOLIMOD [MART.]; SCHEMBL7445; FINGOLIMOD [WHO-DD]; 2-(4-octylphenylethyl)-2-aminopropane-1,3-diol; GTPL2407; FINGOLIMOD [ORANGE BOOK]; DTXSID40167363; HMS3743O13; AMY22173; BCP05969; BDBM50158336; NSC755643; s5950; STL445699; AKOS015999594; DB05286; DB08868; NSC-755643; NCGC00188399-01; NCGC00188399-03; NCGC00188399-04; NCGC00188399-06; NCGC00188399-16; AC-25899; AS-68987; BF164460; HY-11063; DB-064455; FT-0660847; 2-(4-octylphenethyl)-2-aminopropane-1,3-diol; D10001; D70458; 2-amino-2-(4-octylphenyl)ethylpropane-1,3-diol; EN300-18802383; Q425137; 2-amino-2-hydroxymethyl-4-(4-(octyl)phenyl)butanol; BRD-K88025533-003-01-7; 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol	Approved	Approved Drug(s)	107970	DB08868	D0Y6VW	307.5	66.5	258	4.2	22	3	3	12	C19H33NO2	2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol	CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N	CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N	InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3	KKGQTZUTZRNORY-UHFFFAOYSA-N
DLRA04	Phenobarbital	Small molecule	phenobarbital; Phenobarbitone; Luminal; Phenobarbitol; 50-06-6; Phenylethylbarbiturate; Phenobarbituric acid; Phenylethylmalonylurea; Fenobarbital; Gardenal; Phenemal; Adonal; Phenylethylbarbituric acid; Nunol; Gardepanyl; Neurobarb; Phenaemal; Dormiral; Hysteps; Aphenylbarbit; Aphenyletten; Dezibarbitur; Lepinaletten; Lumofridetten; Aephenal; Agrypnal; Amylofene; Barbenyl; Barbiphenyl; Barbipil; Barbivis; Barbonal; Barbophen; Bialminal; Cabronal; Calmetten; Calminal; Cardenal; Codibarbita; Coronaletta; Cratecil; Doscalun; Ensobarb; Ensodorm; Episedal; Epsylone; Eskabarb; Fenbital; Fenylettae; Glysoletten; Haplopan; Hennoletten; Hypnaletten; Hypnette; Hypnogen; Hypnolone; Hypnoltol; Liquital; Lixophen; Lubergal; Lubrokal; Lumesettes; Luphenil; Nirvonal; Parkotal; Pharmetten; Phenemalum; Phenobal; Phenobarbyl; Phenoluric; Phenolurio; Phenomet; Phenonyl; Phenoturic; Phenyletten; Phenyral; Polcominal; Promptonal; Sedizorin; Sedonettes; Sedophen; Solfoton; Sombutol; Somnolens; Somnoletten; Somnosan; Spasepilin; Starifen; Starilettae; Teolaxin; Versomnal; Barbita; Bardorm; Bartol; Chinoin; Duneryl; Epanal; Epidorm; Epilol; Etilfen; Euneryl; Fenemal; Fenosed; Haplos; Henotal; Leonal; Lepinal; Linasen; Lumesyn; Luramin; Molinal; Noptil; Sedabar; Sedicat; Sedlyn; Sedofen; Sedonal; Sevenal; Somonal; Lumen; Seda-Tablinen; 5-Ethyl-5-phenylbarbituric acid; Blu-phen; Nova-Pheno; Solu-Barb; Hypno-Tablinetten; Stental Extentabs; Phen-Bar; PHOB; Phenobarb; Talpheno; Triabarb; Triphenatol; 5-Phenyl-5-ethylbarbituric acid; Phenobarbitalum; Tridezibarbitur; Zadoletten; Barbinal; Barbiphen; Damoral; Dormina; Lefebar; Lephebar; Stental; Teoloxin; Theoloxin; Zadonal; 5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione; SK-Phenobarbital; Thenobarbital; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl-; Dormital; Phenylethylbarbitursaeure; 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione; Phenylaethylbarbitursaeure; Barbituric acid, 5-ethyl-5-phenyl-; 5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione; 5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; Barbilehae (barbilettae); component of Tedral; Sedonal (sedative); component of Slowten; CHEBI:8069; component of Antrocol; component of Hecadrol; component of Bronkotabs; 5-Ethyl-5-phenyl-2,4,6-(1H,3H,5H)pyrimidinetrione; PHENOBARBITAL CIV; component of Primatene P; NSC-9848; CHEMBL40; NSC-128143; component of Valpin 50-PB; YQE403BP4D; Austrominal; Phenobarbitonum; DTXSID5021122; NCGC00159493-02; Fenobarbitale; Fenobarbitale [DCIT]; Elixir of phenobarbital; Phenobarbitalum [INN]; Chardonna-2; Phenylethyl barbituric acid; DTXCID701122; Fenobarbital [INN-Spanish]; Phenyl-ethyl-barbituric acid; Phenobarbitalum [INN-Latin]; WLN: T6VMVMV FHJ F2 FR; Barbinol; Fenemal recip; CAS-50-06-6; Levsin PB Drops and Tablets; CCRIS 502; Luminal (TN); phenobarbital (PB); Acido 5-fenil-5-etilbarbiturico; HSDB 3157; Acido 5-fenil-5-etilbarbiturico [Italian]; 5-Ethyl-5-phenyl-2,6(1H,3H,5H)-pyrimidinetrione; EINECS 200-007-0; UNII-YQE403BP4D; 2,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl-; NSC 128143; Phenobar; AI3-02726; Phenobarbital [USP:INN:BAN:JAN]; Tedral (Salt/Mix); Primidone Impurity B; TEDRIGEN; THEOPHED; Kinesed (Salt/Mix); Antrocol (Salt/Mix); Donnatal (Salt/Mix); Donnazyme (Salt/Mix); Quadrinal (Salt/Mix); Mephobarbital M (nor); Barbidonna (Salt/Mix); Bronkotabs (Salt/Mix); TEDRAL SUSPENSION; Chardonna-2 (Salt/Mix); PHENOBARBITAL [MI]; Epitope ID:116048; PHENOBARBITAL [INN]; PHENOBARBITAL [JAN]; PHENOBARBITAL [HSDB]; PHENOBARBITAL [IARC]; BIDD:PXR0061; Oprea1_384816; SCHEMBL16583; 5-ethyl-5-phenyl-hexahydropyrimidine-2,4,6-trione; Methylphenobarbital, M(nor-); MLS001240232; DivK1c_000987; PHENOBARBITAL [MART.]; PHENOBARBITALUM [HPUS]; PHENOBARBITAL [WHO-DD]; PHENOBARBITAL [WHO-IP]; GTPL2804; SCHEMBL11114624; HMS503E15; KBio1_000987; NSC9848; Phenobarbital (JP17/USP/INN); NINDS_000987; HMS2272G06; PHENOBARBITAL [EP IMPURITY]; PHENOBARBITAL CIV [USP-RS]; PHENOBARBITAL [EP MONOGRAPH]; Tox21_111713; Tox21_200510; BDBM50021437; NSC128143; PHENOBARBITAL [USP MONOGRAPH]; STL367898; component of Primatene P (Salt/Mix); Phenobarbital 0.1 mg/ml in Methanol; Phenobarbital 1.0 mg/ml in Methanol; AKOS000605404; AKOS015964976; Barbituric acid, 5-ethyl-5-phenyl-,; PHENOBARBITALUM [WHO-IP LATIN]; AB02704; DB01174; component of Valpin 50-PB (Salt/Mix); IDI1_000987; NSC-128143-; Levsin PB Drops and Tablets (Salt/Mix); NCGC00159493-03; NCGC00159493-04; NCGC00258064-01; SMR000058986; PRIMIDONE IMPURITY B [EP IMPURITY]; DB-051722; C07434; D00506; A827956; Q407241; SR-01000313151; METHYLPHENOBARBITAL IMPURITY A [EP IMPURITY]; SR-01000313151-1; Phenobarbital, United States Pharmacopeia (USP) Reference Standard; 11097-06-6; UQA	Approved	Approved Drug(s)	4763	DB01174	D0Y7RW	232.23	75.3	339	1.5	17	2	3	2	C12H12N2O3	5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione	CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2	CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2	InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)	DDBREPKUVSBGFI-UHFFFAOYSA-N
DJ7O3D	Vemurafenib	Small molecule	Vemurafenib; 918504-65-1; PLX4032; Zelboraf; 1029872-54-5; PLX-4032; N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide; RG7204; PLX 4032; RG 7204; Vemurafenib (PLX4032, RG7204); N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide; RO 5185426; Vemurafenib (PLX4032); RO5185426; RG-7204; 207SMY3FQT; RO-5185426; CHEBI:63637; MFCD18074504; NSC761431; N-(3-((5-(4-Chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4- difluorophenyl)propane-1-sulfonamide; Vemurafenib;PLX-4032; RO-51-85426; 1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3- yl)carbonyl)-2,4-difluorophenyl)-; 1-PROPANESULFONAMIDE, N-[3-[[5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL]-2,4-DIFLUOROPHENYL]-; N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-PropanesulfonaMide; N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide; N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide; Zelboraf (TN); 1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-; 1415041-85-8; n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-1-propanesulfonamide; Vemurafenib [USAN]; Vemurafenib [USAN:INN]; UNII-207SMY3FQT; vemurafenibum; C23H18ClF2N3O3S; Ro 51-85426; HSDB 8143; N-(3-{(5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl}-2,4- difluorophenyl)propane-1-sulfonamide; 3og7; VEMURAFENIB [MI]; Vemurafenib; PLX4032; VEMURAFENIB [INN]; VEMURAFENIB [JAN]; PLX4032 - Vemurafenib; VEMURAFENIB [VANDF]; VEMURAFENIB [MART.]; VEMURAFENIB [WHO-DD]; SCHEMBL298931; Vemurafenib (JAN/USAN/INN); GTPL5893; CHEMBL1229517; DTXSID50238710; EX-A053; VEMURAFENIB [ORANGE BOOK]; HMS3265M03; HMS3265M04; HMS3265N03; HMS3265N04; HMS3654P09; HMS3748G15; BCP25783; EX-A1335; BDBM50396483; NSC800964; s1267; AKOS007930804; AM81259; CCG-264883; CS-0216; DB08881; ME-0096; NSC-761431; NSC-800964; PB11741; NCGC00250399-01; NCGC00250399-05; NCGC00250399-08; AC-25010; HY-12057; N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide; SY067868; FT-0660388; FT-0675792; FT-0689782; SW218095-2; A25476; A25742; D09996; R-7204; AB01273970-01; AB01273970_03; EN300-23265091; Q423111; SR-01000941568; carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide; J-522975; J-690009; SR-01000941568-1; BRD-K56343971-001-02-3; BRD-K56343971-001-05-6; PLX4032,Vemurafenib, RG7204, RO5185426, Zelboraf; N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6 -dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl]methanone; N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)-propane-1-sulfonamide; propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide	Approved	Approved Drug(s)	42611257	DB08881	D0Y9EW	489.9	100	790	5	33	2	7	7	C23H18ClF2N3O3S	N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide	CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F	CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F	InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)	GPXBXXGIAQBQNI-UHFFFAOYSA-N
D0ACH3	Teriparatide	Small molecule	Forteo; Parathar; 52232-67-4; Teriparatida; Teriparatidum; Teriparatidum [Latin]; Teriparatida [Spanish]; Human PTH (1-34); UNII-10T9CSU89I; MN 10T; HSDB 7367; hPTH (1-34); MN 10-T; Teriparatide [USAN:INN:BAN:JAN]; HPTH- (1-34); ZT 034; 10T9CSU89I; CHEBI:135983; AKOS015994659; HS-2025	Approved	Approved Drug(s)	16133850	DB06285	D0YA2L	4118	1800	9740	-18.7	289	60	62	146	C181H291N55O51S2	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid	CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N	InChI=1S/C181H291N55O51S2/c1-21-96(18)146(236-160(267)114(48-53-141(250)251)212-174(281)132(84-239)232-177(284)143(93(12)13)233-147(254)103(185)82-237)178(285)216-111(45-50-134(187)241)155(262)219-119(65-90(6)7)163(270)213-116(55-62-289-20)158(265)224-124(71-100-79-196-86-203-100)167(274)226-126(73-135(188)242)169(276)217-117(63-88(2)3)148(255)201-81-138(245)205-105(39-27-30-56-182)149(256)223-123(70-99-78-195-85-202-99)166(273)221-121(67-92(10)11)164(271)225-128(75-137(190)244)171(278)231-131(83-238)173(280)214-115(54-61-288-19)157(264)210-112(46-51-139(246)247)153(260)208-109(43-34-60-199-181(193)194)159(266)234-144(94(14)15)175(282)215-113(47-52-140(248)249)156(263)222-122(69-98-77-200-104-38-26-25-37-102(98)104)165(272)220-120(66-91(8)9)161(268)209-108(42-33-59-198-180(191)192)151(258)206-106(40-28-31-57-183)150(257)207-107(41-29-32-58-184)152(259)218-118(64-89(4)5)162(269)211-110(44-49-133(186)240)154(261)228-129(76-142(252)253)172(279)235-145(95(16)17)176(283)229-125(72-101-80-197-87-204-101)168(275)227-127(74-136(189)243)170(277)230-130(179(286)287)68-97-35-23-22-24-36-97/h22-26,35-38,77-80,85-96,103,105-132,143-146,200,237-239H,21,27-34,39-76,81-84,182-185H2,1-20H3,(H2,186,240)(H2,187,241)(H2,188,242)(H2,189,243)(H2,190,244)(H,195,202)(H,196,203)(H,197,204)(H,201,255)(H,205,245)(H,206,258)(H,207,257)(H,208,260)(H,209,268)(H,210,264)(H,211,269)(H,212,281)(H,213,270)(H,214,280)(H,215,282)(H,216,285)(H,217,276)(H,218,259)(H,219,262)(H,220,272)(H,221,273)(H,222,263)(H,223,256)(H,224,265)(H,225,271)(H,226,274)(H,227,275)(H,228,261)(H,229,283)(H,230,277)(H,231,278)(H,232,284)(H,233,254)(H,234,266)(H,235,279)(H,236,267)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,286,287)(H4,191,192,198)(H4,193,194,199)/t96-,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,143-,144-,145-,146-/m0/s1	OGBMKVWORPGQRR-UMXFMPSGSA-N
DC9SW1	Selumetinib	Small molecule	Selumetinib; 606143-52-6; AZD6244; ARRY-142886; AZD 6244; 5-[(4-BROMO-2-CHLOROPHENYL)AMINO]-4-FLUORO-N-(2-HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE; AZD-6244; Selumetinib (AZD6244); ARRY 142886; ARRY-886; AZD6244 (Selumetinib); Selumetinib [USAN:INN]; 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide; Koselugo; UNII-6UH91I579U; 6UH91I579U; 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benzo[d]iMidazole-6-carboxaMide; CHEMBL1614701; DTXSID3048944; CHEBI:90227; NSC741078; NCGC00189073-01; NCGC00189073-02; 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; DTXCID0028870; 1H-Benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide; 6-[(4-bromo-2-chlorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; AZD 6244;5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide;6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; CAS-606143-52-6; ARRY142886; C17H15BrClFN4O3; selumetinibum; 3EW; SELUMETINIB [MI]; SELUMETINIB [INN]; Selumetinib (USAN/INN); SELUMETINIB [USAN]; AZD6244 - Selumetinib; SELUMETINIB [WHO-DD]; SCHEMBL155456; GTPL5665; EX-A020; BCPP000367; HMS3244G03; HMS3244G04; HMS3244H03; HMS3265K01; HMS3265K02; HMS3265L01; HMS3265L02; HMS3654O03; NSC 741O78; BCP01739; Tox21_113362; BDBM50355497; MFCD11977472; NSC800882; s1008; AKOS015904255; Tox21_113362_1; BCP9000354; CCG-264774; CS-0059; DB11689; EX-8621; NSC-741078; NSC-800882; SB14707; NCGC00189073-07; 6-(4-bromo-2-chloro-anilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-benzimidazole-5-carboxamide; AC-25059; AM808016; AZD6244,Selumetinib, ARRY-142886; HY-50706; Selumetinib (ARRY142886/AZD6244); AZD6244 (Selumetinib,ARRY-142886); A8446; FT-0674552; SW202561-3; D09666; EN300-18166787; Q-101405; Q7448840; BRD-K57080016-001-01-9; 1H-BENZIMIDAZOLE-6-CARBOXAMIDE, 5-((4-BROMO-2-CHLOROPHENYL)AMINO)-4-FLUORO-N-(2- HYDROXYETHOXY)-1-METHYL-; 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy -ethoxy)-amide; 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide; 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxy-ethoxy)-amide; 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide; 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxyethoxy)-amide; 6-(4-bromo-2chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide	Approved	Approved Drug(s)	10127622	DB11689	D0YN5T	457.7	88.4	523	3.6	27	3	6	6	C17H15BrClFN4O3	6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO	InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)	CYOHGALHFOKKQC-UHFFFAOYSA-N
DVTL63	Setmelanotide	Small molecule	Setmelanotide; 920014-72-8; RM-493; BIM-22493; Setmelanotide acetate; Setmelanotide (RM-493); N7T15V1FUY; (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide; 1504602-49-6; L-Cysteinamide, N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2->8)-disulfide; UNII-N7T15V1FUY; Setmelanotide [USAN:INN]; Setmelanotide [USAN]; SETMELANOTIDE [INN]; SETMELANOTIDE [WHO-DD]; GTPL9272; RM-493; BIM-22493; IRC-022493; CHEMBL3301624; SCHEMBL21840385; EX-A5542; BDBM50581319; AT23144; CS-6399; DB11700; IRC-022493; HY-19870; Q21098917; N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinamide, cyclic (2-8)-disulfide	Approved	Approved Drug(s)	11993702	DB11700	D0YP7B	1117.3	500	2130	-2.5	78	15	14	18	C49H68N18O9S2	(4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide	CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)N1)NC(=O)C(CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5	C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5	InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)/t26-,33+,34+,35-,36+,37+,38+,39+/m1/s1	HDHDTKMUACZDAA-PHNIDTBTSA-N
DD7R3A	Sparsentan	Small molecule	sparsentan; 254740-64-2; Sparsentan (RE-021); RE-021; Sparsentan [USAN]; PS433540; FILSPARI; PS-433540; 9242RO5URM; CHEMBL539423; 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide; 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide; retrophin; (1,1'-Biphenyl)-2-sulfonamide, 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-; [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-; UNII-9242RO5URM; DARA; compound 7 [PMID 15634011]; DARA-a; PS 33540; SPARSENTAN [INN]; Sparsentan (USAN/INN); Sparsentan(PS433540); SPARSENTAN [WHO-DD]; SCHEMBL535109; GTPL8448; AMY38147; BCP23969; EX-A3048; BDBM50175523; s6665; CS-7947; DB12548; SB16876; DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors); PS-433540;RE-021;DARA; AC-35179; HY-17621; MS-30544; Sparsentan (PS-433540,RE-021,DARA); D11776; F77045; A858308; L023324; Q27088845; 4''''-(2-Butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''''-ethoxymethyl-biphenyl-2-sulfonic acid (4,5-dimethyl-isoxazol-3-yl)-amide; 4''-(2-Butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''-ethoxymethyl-biphenyl-2-sulfonic acid (4,5-dimethyl-isoxazol-3-yl)-amide; 4'-((2-BUTYL-4-OXO-1,3-DIAZASPIRO(4.4)NON-1-EN-3-YL)METHYI)-N-(4,5- DIMETHYLISOXAZOL-3-YL)-2'-(ETHOXYMETHYL)BIPHENYL-2-SULFONAMIDE; 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-2-biphenylsulfonamide; 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide	Approved	Approved Drug(s)	10257882	DB12548	D0YS1U	592.8	123	1060	5	42	1	8	12	C32H40N4O5S	2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC	InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)	WRFHGDPIDHPWIQ-UHFFFAOYSA-N
DI0J3M	Carglumic acid	Small molecule	Carglumic acid; 1188-38-1; N-Carbamyl-L-glutamic acid; (S)-2-ureidopentanedioic acid; Carbaglu; N-Carbamylglutamate; N-Carbamoyl-L-glutamic acid; Ureidoglutaric acid; Carbamylglutamic acid; (2S)-2-(carbamoylamino)pentanedioic acid; Carbamino-L-glutamic acid; L-N-Carbamoylglutamic acid; N-Carbamyl-L-glutamate; N-Carbamyl-glutamic Acid; L-Glutamic acid, N-(aminocarbonyl)-; OE-312; 5L0HB4V1EW; N-carbamoyl-L-glutamate; DTXSID7046706; CHEBI:71028; OE312; n-carbamoylglutamate; OE 312; NSC-760124; OE 312 (LABORATORY CODE DESIGNATION); DTXCID5026706; Carglumic acid [INN]; carbamylglutamate; Carbaglu (TN); CAS-1188-38-1; N-(Aminocarbonyl)-L-glutamic acid(carglumic acid); UNII-5L0HB4V1EW; Carglumic acid [USAN:INN]; carglumic-acid; acido carglumico; acide carglumique; acidum carglumicum; Glutamic acid, N-carbamoyl-, L-; NCGC00167549-01; CARGLUMIC ACID [MI]; CARGLUMIC ACID [JAN]; CARGLUMIC ACID [USAN]; SCHEMBL373546; CARGLUMIC ACID [VANDF]; GTPL7458; CARBAMYL-L-GLUTAMIC ACID; CARGLUMIC ACID [MART.]; CARGLUMIC ACID [USP-RS]; CARGLUMIC ACID [WHO-DD]; CHEMBL1201780; Carglumic acid (JAN/USAN/INN); CARGLUMIC ACID [EMA EPAR]; BCP16753; HY-B0711; Tox21_112544; CARGLUMIC ACID [ORANGE BOOK]; MFCD00047874; s5301; AKOS010384789; N-carbamyl-L-glutamic acid crystalline; Tox21_112544_1; CS-8208; DB06775; NSC 760124; NCGC00274073-01; DS-17934; C-1805; C05829; D07130; EN300-122612; A804117; Q822884; J-507608; Z756468010; Carglumic Acid, United States Pharmacopeia (USP) Reference Standard	Approved	Approved Drug(s)	121396	DB06775	D0Z0MG	190.15	130	227	-2.4	13	4	5	5	C6H10N2O5	(2S)-2-(carbamoylamino)pentanedioic acid	C(CC(=O)O)C(C(=O)O)NC(=O)N	C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N	InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1	LCQLHJZYVOQKHU-VKHMYHEASA-N
DER83M	Clozapine	Small molecule	clozapine; 5786-21-0; Leponex; CLOZARIL; Clozapin; Fazaclo; Clorazil; Iprox; Clozapina; Clozapinum; HF 1854; HF-1854; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; W-801; 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; 5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)-; Clozapine (Clozaril); LX 100-129; CHEMBL42; J60AR2IKIC; NSC-757429; 3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzo[b][1,4]benzodiazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 5H-Dibenzo(b,e)(1,4)diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)-; MLS000028472; CHEBI:3766; Asaleptin; DTXSID5022855; Lepotex; 3-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine; Fazaclo ODT; NCGC00015254-12; SMR000058365; CAS-5786-21-0; 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; Clozapinum [INN-Latin]; Clozapina [INN-Spanish]; DTXCID302855; Azaleptine; Versacloz; Clozaril (TN); 1333667-72-3; CCRIS 9171; HSDB 6478; SR-01000000096; EINECS 227-313-7; UNII-J60AR2IKIC; MFCD00153785; BRN 0764984; Clozapine (JAN/USP/INN); Clozapine, solid; Clozapine (udl); Clozapine (ivax); Clozapine (teva); LEX-123; Clozapine [USAN:USP:INN:BAN]; Clozapine (mylan); 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine; Clozapine (caraco); Prestwick_693; Clozapine (fazaclo); Clozapine - Bio-X; Clozapine (versacloz); KS-1166; Spectrum_000139; Tocris-0444; CPD000058365; CLOZAPINE [INN]; CLOZAPINE [JAN]; Opera_ID_482; CLOZAPINE [MI]; CLOZAPINE [HSDB]; CLOZAPINE [USAN]; Prestwick0_000350; Prestwick1_000350; Spectrum2_000919; Spectrum3_001828; Spectrum4_000898; CLOZAPINE [VANDF]; Lopac-C-6305; CLOZAPINE [MART.]; GTPL38; C 6305; CLOZAPINE [USP-RS]; CLOZAPINE [WHO-DD]; SCHEMBL8397; REGID_for_CID_2818; SCHEMBL33323; KBioGR_000310; KBioGR_001336; KBioSS_000310; KBioSS_000599; MLS001077282; DivK1c_000343; SPECTRUM1500685; SPBio_000798; SPBio_002340; CLOZAPINE [ORANGE BOOK]; CLOZAPINE [EP MONOGRAPH]; BDBM22869; CHEBI:92657; Clozapine for peak identification; HMS501B05; KBio1_000343; KBio2_000310; KBio2_000599; KBio2_002878; KBio2_003167; KBio2_005446; KBio2_005735; KBio3_000619; KBio3_000620; KBio3_002979; CLOZAPINE (UDL) [VANDF]; CLOZAPINE [USP MONOGRAPH]; CLOZAPINE (IVAX) [VANDF]; CLOZAPINE (TEVA) [VANDF]; NINDS_000343; Bio1_000436; Bio1_000925; Bio1_001414; Bio2_000310; Bio2_000790; DTXSID401020663; HMS1361P12; HMS1569E21; HMS1791P12; HMS1921C16; HMS1989P12; HMS2089L13; HMS2092I16; HMS2096E21; HMS2235E19; HMS3259J17; HMS3260H14; HMS3266A10; HMS3371H05; HMS3402P12; HMS3414F09; HMS3657E15; HMS3678F09; HMS3713E21; HMS3742K03; Pharmakon1600-01500685; CLOZAPINE (MYLAN) [VANDF]; BCP25196; CLOZAPINE (CARACO) [VANDF]; CLOZAPINE (FAZACLO) [VANDF]; Tox21_110113; Tox21_500276; BDBM50001884; CCG-39881; HB1607; NSC757429; s2459; CLOZAPINE (CLOZARIL) [VANDF]; Clozapine 1.0 mg/ml in Acetonitrile; 8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; AKOS005064444; AKOS026749900; CLOZAPINE (VERSACLOZ) [VANDF]; Tox21_110113_1; CS-0644; DB00363; LP00276; NC00667; NSC 757429; SDCCGSBI-0050264.P005; NCGC00015254-01; NCGC00015254-02; NCGC00015254-03; NCGC00015254-04; NCGC00015254-05; NCGC00015254-06; NCGC00015254-07; NCGC00015254-08; NCGC00015254-09; NCGC00015254-10; NCGC00015254-11; NCGC00015254-13; NCGC00015254-14; NCGC00015254-15; NCGC00015254-16; NCGC00015254-17; NCGC00015254-18; NCGC00015254-20; NCGC00015254-31; NCGC00022902-02; NCGC00022902-04; NCGC00022902-05; NCGC00022902-06; NCGC00022902-07; NCGC00022902-08; NCGC00022902-09; NCGC00022902-10; NCGC00022902-11; NCGC00022902-12; NCGC00022902-13; NCGC00188978-01; NCGC00260961-01; BC164328; HY-14539; SBI-0050264.P004; DB-053121; C2547; D-107; EU-0100276; SW220247-1; EN300-52510; C06924; D00283; H10436; AB00052158-13; AB00052158-14; AB00052158_15; AB00052158_16; Clozapine, drug standard, 1.0 mg/mL in methanol; L000195; L013417; Q221361; SR-01000000096-2; SR-01000000096-4; SR-01000000096-5; SR-01000000096-8; W-105432; BRD-K37289225-001-09-1; BRD-K37289225-001-23-2; Clozapine, British Pharmacopoeia (BP) Reference Standard; Z754926488; Clozapine, European Pharmacopoeia (EP) Reference Standard; Clozapine, United States Pharmacopeia (USP) Reference Standard; 8-Chloro-11-(4-methylpiperazino)-5H-dibenzo[b,e][1,4]diazepine; (E)-8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; 3-chloro-6-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-10H-dibenzo[b,e][1,4]diazepine; 8-chloro-11-(4-methyl-piperazin-1-yl)-10H-dibenzo[b,e][1,4]diazepine; 3-Hydroxy-2-phenyl-propionic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester; 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine (Clozapine); 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine( Clozepine ); 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine(Ciozapine); 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine(Clopazine); Clozapine for peak identification, European Pharmacopoeia (EP) Reference Standard; CLOZAPINE, 8-CHLORO-11-(4-METHYL-PIPERAZIN-1-YL)-5H-DIBENZO[B,E][1,4]DIAZEPINE; 6-chloro-10-(4-methylpiperazin-1-yl)-2,9-diazatricyclo[9.4.0.0,3,8]pentadeca-1,3(8),4,6,10,12,14-heptaene; 6-chloro-10-(4-methylpiperazin-1-yl)-2,9-diazatricyclo[9.4.0.0^{3,8}]pentadeca-1,3(8),4,6,10,12,14-heptaene; 6-chloro-10-(4-methylpiperazin-1-yl)-2,9-diazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,9,12,14-heptaene	Approved	Approved Drug(s)	135398737	DB00363	D0Z1RV	326.8	30.9	446	3.1	23	1	3	1	C18H19ClN4	3-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine	CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42	CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42	InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3	QZUDBNBUXVUHMW-UHFFFAOYSA-N
DTJ5A4	Nebivolol	Small molecule	Nebivolol; 99200-09-6; 2,2'-Azanediylbis(1-(6-fluorochroman-2-yl)ethanol); Narbivolol; (-)-Nebivolol; (Rac)-Nebivolol; See N387903; 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol; CHEBI:64019; Nebivololum [Latin]; (S,R,R,S)-Nebivolol; 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]; 118457-14-0; R 74714; (alphaR,alpha'R,2R,2'S)-alpha,alpha'-[Iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]; R-65824; 1-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-{[2-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-hydroxyethyl]amino}ethan-1-ol; (-)-Nebivolol; Levonebivolol; l-Nebivolol; rac Nebivolol-[d8]; 2H-1-Benzopyran-2-methanol, alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro-; SCHEMBL19863; R 67138;d-Nebivolol;(+)-Nebivolol; (S,R,R,R)-Nebivolol; CHEMBL434394; GTPL7246; DTXSID9040556; BDBM84735; HY-B0203B; HMS3604L09; MFCD00865796; NSC_71301; PDSP1_000244; PDSP2_000243; Ro-67555; AKOS015895102; AC-1611; CCG-357228; DB04861; AS-77015; CAS_99200-09-6; DB-057766; CS-0143939; FT-0631000; FT-0672663; FT-0672664; FT-0672665; FT-0672666; FT-0700072; EN300-7392989; A845981; L001284; Q418130; SR-01000883933; SR-01000883933-1; 2,2-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]; alpha,alpha'-(iminodimethylene)bis-(6-fluoro-2-chromanmethanol); 1,1'-bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol; 1,1'-[bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol; 1-(6-fluorochroman-2-yl)-2-[[2-(6-fluorochroman-2-yl)-2-hydroxyethyl]amino]ethanol; alpha,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol); alpha,alpha'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]; alpha,alpha'[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]; 9920-09-6	Approved	Approved Drug(s)	71301	DB04861	D0Z1UA	405.4	71	483	3	29	3	7	6	C22H25F2NO4	1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol	C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O	C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O	InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2	KOHIRBRYDXPAMZ-UHFFFAOYSA-N
D5RIU7	Methyltestosterone	Small molecule	methyltestosterone; 17-Methyltestosterone; 58-18-4; Testred; Metandren; Android; Virilon; Androsan; Androsten; Mesterone; 17alpha-Methyltestosterone; Malestrone; Mastestona; Synandrets; Synandrotabs; Andrometh; Anertan; Dumogran; Homandren; Hormale; Malogen; Masenone; Metestone; Metrone; Nabolin; Oraviron; Steronyl; Syndren; Testora; Oreton Methyl; Glosso-sterandryl; Oreton-M; M.T.Mucorettes; Neo-Hombreol-M; Nu-man; Android 5; Android 10; Android 25; Methitest; NSC-9701; Orchisterone-M; Testovis Depot; Homandren, tablets; 17beta-Hydroxy-17-methylandrost-4-en-3-one; Metiltestosterona; Methyltestosteronum; RU 24400; 17-Methyltestosteron; CDB 110; Anertan, tablets; 17-Hydroxy-17-methyl-3-keto-androstene-4; 17alpha-Methyl-3-oxo-4-androsten-17beta-ol; 17-beta-Hydroxy-17-methylandrost-4-en-3-one; 17.alpha.-Methyltestosterone; 4-Androstene-17alpha-methyl-17beta-ol-3-one; Methyltestosterone ciii; L 589.372; 17; A-Methyltestosterone; METHYL TESTOSTERONE; U 2842; V9EFU16ZIF; 17alpha-Methyl-delta-androsten-17beta-ol-3-one; NSC-139965; DTXSID1033664; CHEBI:27436; Oreton M; Androsan, tablets; CDB-110; component of Estan; Neo-Hombreol [M]; Neo-Homobreol (M); Neo-Homobreol [M]; component of Gynetone; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; Androst-4-en-3-one, 17-hydroxy-17-methyl-, (17b)-; NCGC00091009-03; Androst-4-en-3-one, 17-hydroxy-17-methyl-, (17.beta.)-; component of Tylosterone; Estratest; RU-24400; Glosso sterandryl; Testosterone, 17-methyl-; U-2842; Anertan (tablets); Homandren (VAN); Testovis (tablet); 17.alpha.-Methyl-3-oxo-4-androsten-17.beta.-ol; Androsan (tablets); Androsan (VAN); Testoviron (VAN); Anertan (VAN); (17beta)-17-hydroxy-17-methylandrost-4-en-3-one; 4-Androstene-17.alpha.-methyl-17.beta.-ol-3-one; Androst-4-en-3-one, 17.beta.-hydroxy-17-methyl-; L-589372; Testoviron (tablet); L-589.372; DTXCID9013664; Oretron; Metiltestosterone; Estan (Salt/Mix); Metiltestosterone [DCIT]; CAS-58-18-4; Estratest (Salt/Mix); SMR000058528; Android (TN); CCRIS 3723; Methyltestosteronum [INN-Latin]; Metiltestosterona [INN-Spanish]; HSDB 3365; WLN: L E5 B666 OV MUTJ A E FQ F -B&AEF; EINECS 200-366-3; UNII-V9EFU16ZIF; NSC 139965; 17-alpha-Methyltestosterone; BRN 2057425; component of Gynetone (Salt/Mix); Premarin with methyltestosterone; 4-Androstene-17-alpha-methyl-17-beta-ol-3-one; NCGC00091009-04; NCGC00091009-05; Androst-4-en-3-one, 17beta-hydroxy-17-methyl-; Testred (TN); (17-beta)-17-Hydroxy-17-methylandrost-4-en-3-one; Premarin with Methyltestosterone (Salt/Mix); 17(alpha)-Methyl-delta4-androsten-17(beta)-ol-3-one; 17-Hydroxy-17-methylandrost-4-en-3-one #; 17a-methyltestosterone; Methyltestosterone [USP:INN:BAN:JAN]; 17-.beta.-Hydroxy-17-methylandrost-4-en-3-one; Androst-4-en-3-on-17.beta.-ol, 17.alpha.-methyl; Androst-4-ene-17.alpha.-methyl-17.beta.-ol-3-one; 17.beta.-Hydroxy-17.alpha.-methylandrost-4-en-3-one; 17.alpha.-methyl-.DELTA.4-androsten-17.beta.-ol-3-one; CHEMBL1395; SCHEMBL18657; 4-08-00-01010 (Beilstein Handbook Reference); Androst-4-en-3-one, 17-beta-hydroxy-17-methyl-; MLS000759474; MLS001424040; MLS002174282; GTPL6945; METHYLTESTOSTERONE [INN]; METHYLTESTOSTERONE [JAN]; METHYLTESTOSTERONE [HSDB]; .ALPHA.-METHYLTESTOSTERONE; METHYLTESTOSTERONE [VANDF]; NSC9701; 17-MT; HMS2051A14; HMS2272A06; METHYLTESTOSTERONE [MART.]; METHYLTESTOSTERONE [USP-RS]; METHYLTESTOSTERONE [WHO-DD]; METHYLTESTOSTERONE [WHO-IP]; 17-METHYLTESTOSTERONE [MI]; HY-A0121; Tox21_113161; Tox21_113162; Tox21_400058; BDBM50410531; LMST02020029; Methyltestosterone (JP17/USP/INN); NSC139965; AKOS015917317; Tox21_113162_1; CCG-100871; CS-5099; DB06710; GS-6594; NC00121; METHYLTESTOSTERONE [ORANGE BOOK]; METHYLTESTOSTERONE [EP MONOGRAPH]; NCGC00091009-01; NCGC00091009-06; NCGC00091009-07; Oxandrolone impurity, methyltestosterone-; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one; METHYLTESTOSTERONE [USP MONOGRAPH]; METHYLTESTOSTERONUM [WHO-IP LATIN]; SMR001261452; M0435; 17alpha-Methyltestosterone, >=97.0% (HPLC); C07198; D00408; Methyltestosterone (17alpha-Methyltestosterone); AB00443683-06; AB00443683-09; 17alpha-methyl-Delta4-androsten-17beta-ol-3-one; 17alpha-Methyltestosterone, solid (photosensitive); Q421768; 17alpha-methyl-Delta(4)-androsten-17beta-ol-3-one; 17(alpha)-methyl-Delta(4)-androsten-17(beta)-ol-3-one; 17-alpha-Methyltestosterone 100 microg/mL in Acetonitrile; 17alpha-Methyltestosterone, VETRANAL(TM), analytical standard; OXANDROLONE IMPURITY, METHYLTESTOSTERONE- [USP IMPURITY]; Methyltestosterone, European Pharmacopoeia (EP) Reference Standard; Methyltestosterone (17alpha-Methyltestosterone) 1.0 mg/ml in Acetonitrile; Methyltestosterone, United States Pharmacopeia (USP) Reference Standard; Methyltestosterone for system suitability, European Pharmacopoeia (EP) Reference Standard; (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,14,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one; (1S,3aS,3bR,9aR,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one; (8R,10R,13S,17S)-17-Hydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one	Approved	Approved Drug(s)	6010	DB06710	D0Z1XD	302.5	37.3	550	3.4	22	1	2	0	C20H30O2	(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one	CC12CCC(=O)C=C1CCC3C2CCC4(C3CCC4(C)O)C	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C	InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1	GCKMFJBGXUYNAG-HLXURNFRSA-N
D86ZSC	Clarithromycin	Small molecule	clarithromycin; 81103-11-9; Biaxin; 6-O-Methylerythromycin; Klaricid; 6-O-Methylerythromycin a; Abbott-56268; Clarithromycine; Clathromycin; Macladin; Klacid; Veclam; Erythromycin, 6-O-methyl-; Mavid; Naxy; A-56268; TE-031; Clarith; Cyllind; Kofron; Zeclar; Clarithromycinum; Clarithromycin identity; Biaxin XL; TE031; NSC-758704; CHEBI:3732; H1250JIK0A; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-12,13-dihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; DTXSID3022829; Claritromicina; Abbotic; Astromen; Bicrolid; Clacine; Clambiotic; Claribid; Claricide; Claridar; Claripen; Fromilid; Heliclar; Klaciped; Mabicrol; Clacee; Clacid; Clarem; Crixan; Cyllid; Klabax; Klarid; Klarin; Maclar; Helas; Adel; Biaxin filmtab; Klax; Biaxin HP; Biaxin xl filmtab; Klaricid Pediatric; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; Clarithromycin extended release; DTXCID40820062; DRG-0099; Klaricid H.P.; CTY; SMR000466382; Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; CAS-81103-11-9; SR-05000001992; clarithromycina; UNII-H1250JIK0A; Clarosip; CCRIS 8833; Klaricid XL; HSDB 8055; (14R)-14-Hydroxyclarithromycin; NCGC00095117-01; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy; Clarithromycin,(S); Biaxin (TN); Spectrum_000089; CPD000466382; Clarithromycin [USAN:USP:INN:BAN:JAN]; SpecPlus_000559; 6-O-methyl erythromycin; O(6)-methylerythromycin; Spectrum2_001668; Spectrum3_001667; Spectrum4_000629; Spectrum5_001729; 6-0-methylerythromycin A; A56268; CLARITHROMYCIN [MI]; CHEMBL1741; CLARITHROMYCIN [INN]; CLARITHROMYCIN [JAN]; SCHEMBL38125; BSPBio_003453; KBioGR_001218; KBioSS_000509; MLS000759516; MLS001201751; MLS001424066; BIDD:GT0200; CLARITHROMYCIN [VANDF]; DivK1c_006655; SPECTRUM1504231; SPBio_001855; CLARITHROMYCIN [MART.]; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; CLARITHROMYCIN [USP-RS]; CLARITHROMYCIN [WHO-DD]; Clarithromycin (Biaxin, Klacid); Clarithromycin & Interleukin-12; CLM & IL-12; GTPL10903; KBio1_001599; KBio2_000509; KBio2_003077; KBio2_005645; KBio3_002673; ANX-015; SDP-015; Clarithromycin (JP17/USP/INN); Clarithromycin, >=95% (HPLC); Clarithromycin, >=98% (HPLC); HMS1922H09; HMS2051G18; HMS2090O11; HMS2094M05; HMS2231A08; HMS3715J17; Pharmakon1600-01504231; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dion; CLARITHROMYCIN [ORANGE BOOK]; Tox21_111429; Tox21_202903; BDBM50404044; CCG-39086; CLARITHROMYCIN [EP MONOGRAPH]; CLARITHROMYCIN [USP IMPURITY]; LMPK04000014; NSC758704; s2555; CLARITHROMYCIN [USP MONOGRAPH]; AKOS015894242; PREVPAC COMPONENT CLARITHROMYCIN; CS-2576; DB01211; NC00140; NSC 758704; CLARITHROMYCIN IDENTITY [USP-RS]; NCGC00178054-01; NCGC00178054-06; NCGC00260449-01; CLARITHROMYCIN COMPONENT OF PREVPAC; HY-17508; SBI-0206716.P001; C2220; Clarithromycin 100 microg/mL in Acetonitrile; C06912; D00276; F14975; AB00053394-10; AB00053394-12; AB00053394-13; AB00053394_14; AB00053394_15; A840042; Q118551; Q-200870; SR-05000001992-1; SR-05000001992-2; BRD-K49668410-001-07-1; BRD-K49668410-001-18-8; Z1515385076; Clarithromycin, European Pharmacopoeia (EP) Reference Standard; Clarithromycin, United States Pharmacopeia (USP) Reference Standard; Clarithromycin Identity, United States Pharmacopeia (USP) Reference Standard; Clarithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard; Clarithromycin, Pharmaceutical Secondary Standard; Certified Reference Material; (3R,4S,5R,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4R,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacy; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-14-ethyl-12,13-dihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11S, 12R,13S,14S)-6-{[(2S,3R,4S,6R)- 4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy- 4-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-4,6- dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1- oxacyclotetradecane-2,10-dione	Approved	Approved Drug(s)	84029	DB01211	D0Z1ZM	748	183	1190	3.2	52	4	14	8	C38H69NO13	(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione	CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O	CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O	InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1	AGOYDEPGAOXOCK-KCBOHYOISA-N
D82LFO	Glipizide	Small molecule	glipizide; 29094-61-9; Glucotrol; Glydiazinamide; Melizide; Glibenese; Glucozide; Glupizide; Sucrazide; Dipazide; Glupitel; Mindiab; Minidiab; Minodiab; Napizide; Ozidia; Glucotrol XL; Glibetin; Glucolip; Aldiab; Digrin; Glican; Glidiab; Glipid; Minidab; Glyde; Gluco-Rite; Glipizida; Glipizidum; Glipizidum [INN-Latin]; K 4024; Glipizida [INN-Spanish]; N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)phenethyl)-5-methylpyrazine-2-carboxamide; CP 28720; K-4024; CP-28720; TK 1320; CP 28,720; N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide; Glipizide slow release; CP-28,720; 1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea; Glide; NSC-759120; CHEMBL1073; X7WDT95N5C; MLS000069386; Pyrazinecarboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-; CHEBI:5384; CP 28720;K 4024; DTXSID0040676; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide; NCGC00015462-07; SMR000058455; CAS-29094-61-9; 1-cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl]sulfonyl]urea; Urea, 1-cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)-; 29094-66-4; DTXCID8020676; 1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea; N-{4-[beta-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylurea; Glucotrol (TN); Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-; Glipizide (USP/INN); SR-01000000010; EINECS 249-427-6; MFCD00072159; UNII-X7WDT95N5C; BRN 0903495; Glipizide, solid; N-(4-[N-(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-5-methylpyrazine-2-carboxamide; Glipizide [USAN:USP:INN:BAN]; glipizide/glucotrol; Glipizide,(S); Prestwick_242; KS-1068; Metaglip (Salt/Mix); Glipizide (Glucotrol); GLIPIZIDE [INN]; GLIPIZIDE [JAN]; GLIPIZIDE [MI]; Lopac-G-117; GLIPIZIDE [USAN]; Opera_ID_1908; Prestwick0_000131; Prestwick1_000131; Prestwick2_000131; Prestwick3_000131; GLIPIZIDE [VANDF]; G-117; GLIPIZIDE [MART.]; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea; GLIPIZIDE [USP-RS]; GLIPIZIDE [WHO-DD]; CBiol_001788; Lopac0_000621; SCHEMBL17094; BSPBio_000202; BSPBio_001349; KBioGR_000069; KBioSS_000069; MLS001148176; BIDD:GT0476; SPBio_002141; BPBio1_000224; GTPL6821; GLIPIZIDE [ORANGE BOOK]; GLIPIZIDE [EP MONOGRAPH]; KBio2_000069; KBio2_002637; KBio2_005205; KBio3_000137; KBio3_000138; GLIPIZIDE [USP MONOGRAPH]; Bio1_000074; Bio1_000563; Bio1_001052; Bio2_000069; Bio2_000549; HMS1361D11; HMS1568K04; HMS1791D11; HMS1989D11; HMS2089C21; HMS2093J09; HMS2095K04; HMS2233N11; HMS3259K12; HMS3261N04; HMS3369L12; HMS3402D11; HMS3655G04; HMS3712K04; Pharmakon1600-01505433; METAGLIP COMPONENT GLIPIZIDE; BCP09195; HY-B0254; Tox21_110156; Tox21_301834; Tox21_500621; BBL028143; BDBM50012956; NSC759120; NSC813218; s1715; STK631952; AKOS005564405; GLIPIZIDE COMPONENT OF METAGLIP; N-[4-(3-Cyclohexylureidosulfonyl)phenethyl]-5-methyl-2-pyrazinecarboxamide; Tox21_110156_1; CCG-204710; DB01067; LP00621; NC00564; NSC 759120; NSC-813218; SDCCGSBI-0050603.P003; IDI1_033819; N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-pyrazine-2-carboxamide; Glipizide 100 microg/mL in Acetonitrile; NCGC00015462-01; NCGC00015462-02; NCGC00015462-03; NCGC00015462-04; NCGC00015462-05; NCGC00015462-06; NCGC00015462-08; NCGC00015462-09; NCGC00015462-10; NCGC00015462-11; NCGC00015462-12; NCGC00015462-14; NCGC00015462-23; NCGC00016802-01; NCGC00023748-03; NCGC00023748-04; NCGC00023748-05; NCGC00023748-06; NCGC00023748-07; NCGC00255522-01; NCGC00261306-01; AC-15789; SBI-0050603.P002; EU-0100621; FT-0626714; FT-0659737; G0369; SW196549-3; D00335; Q3108899; SR-01000000010-2; SR-01000000010-5; W-107005; BRD-K12219985-001-04-8; BRD-K12219985-001-15-4; Z1575081877; Glipizide, European Pharmacopoeia (EP) Reference Standard; Glipizide, United States Pharmacopeia (USP) Reference Standard; Glipizide, Pharmaceutical Secondary Standard; Certified Reference Material; 1-cyclohexyl-3-(4-(2-(2-methylpyrazine-5-carboxamido)ethyl)phenylsulfonyl)urea; 1-Cyclohexyl-3-{{p=[2-[5-methylpyrazine-carboxamido)-ethyl]phenyl}sulphonyl}urea; N-(4-(.beta.-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; 172964-66-8; 2-Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-; N-(2-[4-(([(Cyclohexylamino)carbonyl]amino)sulfonyl)phenyl]ethyl)-5-methyl-2-pyrazinecarboxamide	Approved	Approved Drug(s)	3478	DB01067	D0Z4SB	445.5	139	697	1.9	31	3	6	7	C21H27N5O4S	N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide	CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3	CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3	InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)	ZJJXGWJIGJFDTL-UHFFFAOYSA-N
D15ARO	Isradipine	Small molecule	isradipine; 75695-93-1; DynaCirc; Isradipin; Lomir; Isrodipine; Prescal; Esradin; Dynacirc CR; Clivoten; PN 200-110; Dynacrine; Isradipinum [Latin]; Isradipino [Spanish]; PN-200-110; Rebriden; DynaCire; DynaCire CR; (+/-)-Isradipine; PN 200; Isradipine (Dynacirc); 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; C19H21N3O5; (+-)-Isradipine; 3-isopropyl 5-methyl 4-(benzo[c][1,2,5]oxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 131970-21-3; 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; NSC-759892; YO1UK1S598; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; DTXSID4023179; Isradipinum; Isradipino; DTXCID203179; Icaz; 3-methyl 5-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,1,3-Benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid methyl 1-methylethyl ester; SMR000466320; SMR002529690; DynaCirc (TN); Isradipine (USP/INN); SR-01000597526; MFCD00153820; UNII-YO1UK1S598; Isradipine [USAN:USP:INN:BAN]; NCGC00016931-01; (-)-Isradipine; (plusmn)-isradipine; CAS-75695-93-1; PN200-110; Isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Spectrum_000218; ISRADIPINE [MI]; PN-200110; ISRADIPINE [INN]; Prestwick0_001021; Prestwick1_001021; Prestwick2_001021; Prestwick3_001021; (.+/-.)-Isradipine; ISRADIPINE [USAN]; ISRADIPINE [VANDF]; ISRADIPINE [MART.]; CHEMBL1648; ISRADIPINE [USP-RS]; ISRADIPINE [WHO-DD]; SCHEMBL34555; BSPBio_001201; KBioSS_000698; 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; MLS000759425; MLS001424076; MLS002154106; MLS003915633; MLS006010138; O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; SPBio_003062; BPBio1_001323; CHEBI:6073; CHEMBL315436; GTPL4488; CHEMBL3211306; ISRADIPINE [ORANGE BOOK]; KBio2_000698; KBio2_003266; KBio2_005834; ISRADIPINE [EP MONOGRAPH]; HMS1571M03; HMS2051J12; HMS2098M03; HMS2235O12; HMS3268D21; HMS3393J12; HMS3413A15; HMS3655C17; HMS3677A15; HMS3715M03; HMS3884E06; ISRADIPINE [USP MONOGRAPH]; Pharmakon1600-02300234; (non-Isotopelabelled)Isradipine-d7; ACT02697; BCP06719; HY-B0233; Benzo[1,2,5]oxadiazol-4-aldehyde; Tox21_110690; BDBM50436176; HB1223; NSC759892; s1662; AKOS015895129; Isradipine, >=98% (HPLC), solid; Tox21_110690_1; AC-8539; CCG-101027; CCG-213711; DB00270; HS-0085; NC00277; NSC 759892; Isopropyl Methyl 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; NCGC00025341-01; NCGC00025341-02; NCGC00025341-03; NCGC00025341-06; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9CI); 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, (+-)-; 4-(2,1,3-Benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester; 4-(4-Benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate; methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; DB-055981; AB00514007; FT-0627542; I0876; SW220017-1; D00349; AB00514007_02; AB00514007_03; EN300-19741623; Q414873; J-513454; SR-01000597526-1; SR-01000597526-2; SR-01000597526-8; BRD-A90799790-001-03-3; BRD-A90799790-001-10-8; Isradipine, European Pharmacopoeia (EP) Reference Standard; Isradipine, United States Pharmacopeia (USP) Reference Standard; Isopropyl Methyl 4-(2,1,3-Benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimet; 3,5-PYRIDINEDICARBOXYLIC ACID, 4-(4-BENZOFURAZANYL)-1,4-DIHYDRO-2,6-DIMETHYL-, METHYL 1-METHYLETHYL ESTER, (+/-)-; 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, (.+/-.)-; 3-Isopropyl 5-methyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate #; 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic Acid Isopropyl Methyl Ester; ISOPROPYL METHYL (+/-)-4-(4-BENZOFURAZANYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5-PYRIDINEDICARBOXYLATE; Isopropyl methyl (.+/-.)-4-(4-benzfurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Isopropyl methyl (.+/-.)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate	Approved	Approved Drug(s)	3784	DB00270	D0Z7KE	371.4	104	685	4.3	27	1	8	6	C19H21N3O5	3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate	CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC	CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC	InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3	HMJIYCCIJYRONP-UHFFFAOYSA-N
DS97TG	Mycophenolic acid	Small molecule	mycophenolic acid; 24280-93-1; Mycophenolate; Myfortic; Melbex; Mycophenolsaeure; 483-60-3; Lilly-68618; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; NSC-129185; Acido micofenolico; Micofenolico acido; Acide mycophenolique; Acidum mycophenolicum; (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; CCRIS 5565; NSC 129185; Ly 68618; (E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoic acid; (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; MFCD00036814; Lilly 68618; CHEMBL866; HU9DX48N0T; 6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methylhex-4-enoic acid; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (E)-; DTXSID4041070; CHEBI:168396; TNP00198; RS-61443 [AS MOFETIL]; NSC129185; 4-Hexenoic acid, 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-, (E)-; 4-Methyl-5-methoxy-7-hydroxy-6-(5-carboxy-3-methylpent-2-en-1-yl)-phthalide (E)-; 6-(1,3-Dihydro-7-hydroxy-5-methoxy-4-methyl-1-oxoisobenzofuran-6-yl)-4-methyl-4-hexanoic acid; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid (E)-; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)-; NCGC00016786-01; CAS-24280-93-1; Mycophenolic acid 100 microg/mL in Acetonitrile; 6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid; DTXCID2021070; Mycophenoic acid; 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-4-hexenoic acid; Micofenolico acido [Spanish]; (4E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoic Acid (Mycophenolic Acid); (E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid; 4-Hexenoic acid,6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)-; 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoic acid; MOA; SMR000471887; Acido micofenolico [INN-Spanish]; 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; Acide mycophenolique [INN-French]; Acidum mycophenolicum [INN-Latin]; SR-01000597602; EINECS 246-119-3; UNII-HU9DX48N0T; mycophenolic-acid; Prestwick_817; EINECS 207-595-8; Mycophenolic acid [USAN:INN:BAN]; Tocris-1505; (Z)-Mycophenolic Acid; 1jr1; starbld0040186; Mycophenolic acid (TN); Prestwick2_000556; Prestwick3_000556; Spectrum5_001654; Mycophenolic Acid (MPA); UPCMLD-DP028; 4-Hexenoic acid, (E)-; EC 246-119-3; Mycophenolate;RS-61443; SCHEMBL4549; Mycophenolic (Mycophenolate); Mycophenolic acid, >=98%; BSPBio_000631; BSPBio_002534; MYCOPHENOLATE [VANDF]; MLS001074701; MLS002222265; MLS002695945; BIDD:GT0456; SPECTRUM1500674; MYCOPHENOLIC ACID [MI]; BPBio1_000695; GTPL6832; MEGxm0_000120; Mycophenolic acid (USAN/INN); Myfortic (mycophenolate sodium); SCHEMBL2514376; MYCOPHENOLIC ACID [INN]; MYCOPHENOLIC ACID [USAN]; UPCMLD-DP028:001; ACon0_000960; ACon1_000496; BDBM19264; CHEBI:92545; HMS500H08; EX-A975; MYCOPHENOLIC ACID [VANDF]; MYCOPHENOLIC ACID [MART.]; HMS1569P13; HMS1921A18; HMS2089A17; HMS2092G22; HMS2096P13; HMS2268H22; HMS3403P09; HMS3412F09; HMS3676F09; Pharmakon1600-01500674; MYCOPHENOLIC ACID [WHO-DD]; ACT02623; AMY40494; BCP05321; HY-B0421; Tox21_110610; BBL034696; CCG-39914; HB3987; NSC757424; s2487; STL419986; Mycophenolic acid, analytical standard; AKOS015888214; Tox21_110610_1; AC-4491; BCP9000970; DB01024; DS-1638; MYCOPHENOLIC ACID [ORANGE BOOK]; NSC-757424; SDCCGMLS-0066618.P001; (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid; IDI1_000146; NCGC00016786-02; NCGC00016786-03; NCGC00016786-04; NCGC00016786-05; NCGC00016786-06; NCGC00016786-07; NCGC00016786-08; NCGC00016786-09; NCGC00016786-10; NCGC00016786-11; NCGC00016786-12; NCGC00016786-15; NCGC00025190-01; NCGC00025190-02; NCGC00025190-03; NCGC00025190-04; NCGC00025190-05; NCGC00025190-07; NCGC00025190-08; NCGC00025190-09; NCGC00025190-10; (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxohydroisobenzofuran-5-yl)-4-methylhex -4-enoic acid; BM164624; Mycophenolic Acid - CAS 24280-93-1; SBI-0051945.P003; A-249; M2216; SW196951-2; C20380; D05096; EN300-122327; M 5255; M02087; AB00052466-13; AB00052466-14; AB00052466_15; AB00052466_16; EN300-1273238; A817192; Mycophenolate mofetil impurity, mycophenolic acid-; Q420553; SR-01000597602-1; SR-01000597602-3; SR-01000597602-4; BRD-K63750851-001-06-6; BRD-K63750851-001-13-2; MYCOPHENOLATE MOFETIL IMPURITY F [EP IMPURITY]; Z2315575694; MYCOPHENOLATE MOFETIL IMPURITY, MYCOPHENOLIC ACID- [USP IMPURITY]; Mycophenolic acid, powder, BioReagent, suitable for cell culture, >=98%; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid;NSC 129185; 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthanlanyl)-4-methyl-4-hexanoic acid; (E)-6-(1,3-dihydro-4-hydroxy-6- methoxy-7-methyl-3-oxoisobenzofuran-5-yl)-4-methyl-4-hexenoic acid; (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran-5-yl)-4-methyl-4-hexenoic acid; 1162256-90-7; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (9CI); 4-Hexenoic acid, 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-, (E)- (8CI); 4-Hexenoic acid,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-, (E)-; 4-Methyl-6-[3-oxo-7-methyl-4-hydroxy-6-methoxy-1,3-dihydroisobenzofuran-5-yl]-4-hexenoic acid; E-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid	Approved	Approved Drug(s)	446541	DB01024	D0Z8EV	320.3	93.1	486	3.2	23	2	6	6	C17H20O6	(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid	CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O	CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O	InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+	HPNSFSBZBAHARI-RUDMXATFSA-N
D7BYC0	Stavudine	Small molecule	stavudine; 3056-17-5; sanilvudine; Zerit; 2',3'-Didehydro-3'-deoxythymidine; Stavudinum; Zerit Xr; d4T; BMY-27857; Estavudina; Stavudinum [INN-Latin]; Estavudina [INN-Spanish]; Thymidine, 2',3'-didehydro-3'-deoxy-; 3'-Deoxy-2'-thymidinene; ddeThd; 2',3'-Didehydro-3'-deoxythimidine; 3'-Deoxy-2',3'-didehydrothymidine; BMY 27857; 1-((2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; Dideoxydidehydrothymidine; 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine; NSC 163661; Sanilvudine (JAN); BO9LE4QFZF; STV; CHEMBL991; NSC-759897; Zerut XR; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; MLS000028546; D-4T; DTXSID1023819; CHEBI:63581; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione; NSC-163661; NCGC00023212-07; SMR000058350; D 4T (nucleoside); SANILVUDINE [JAN]; 1-[(2R,5S)-5-(HYDROXYMETHYL)-2,5-DIHYDROFURAN-2-YL]-5-METHYL-1,2,3,4-TETRAHYDROPYRIMIDINE-2,4-DIONE; DTXCID803819; Stavudine [USAN:BAN:INN]; 1-(2,3-Dideoxy-.beta.-D-glycero-pent-2-enofuranosyl)thymine; D 4T; ddeTyd; 1-(cis-5-(Hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; 220020-60-0; CAS-3056-17-5; Zerit(TM); Zerit (TN); HSDB 7338; SR-01000075802; UNII-BO9LE4QFZF; Stavudine (USAN/INN); BRN 0618327; D4T & GM-CSF; 2'-Thymidinene, 3'-deoxy-; NSC163661; Stavudine [USAN:USP:INN:BAN]; Stavudine (dt4); Stavudine- Bio-X; D4TMBY-27857-3; STAVUDINE [INN]; STAVUDINE [MI]; STAVUDINE [HSDB]; STAVUDINE [USAN]; Opera_ID_1281; 3'-deoxythymidin-2'-ene; STAVUDINE [MART.]; D 1413; cid_5155; STAVUDINE [USP-RS]; STAVUDINE [WHO-DD]; STAVUDINE [WHO-IP]; 1-((2R,5S)-5-Hydroxymethyl-2,5-dihydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; 3''-deoxy-2''-thymidine; Lopac0_000336; SCHEMBL38661; STAVUDINE [EMA EPAR]; cid_18283; MLS000759504; MLS001055348; MLS001077292; MLS001424091; MLS006011922; BIDD:GT0082; 2',3'-Anhydrothymidine; d4T; STAVUDINE [EP IMPURITY]; STAVUDINE [ORANGE BOOK]; STAVUDINE [EP MONOGRAPH]; 1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine; STAVUDINE [USP MONOGRAPH]; STAVUDINUM [WHO-IP LATIN]; HMS2051O20; HMS2234C10; HMS3039O05; HMS3259L21; HMS3261C13; HMS3428C07; HMS3714N22; Pharmakon1600-01502339; STAVUDINE (D4T) [VANDF]; STAVUDINE (DT4) [VANDF]; BCP02952; HY-B0116; Tox21_110886; Tox21_201393; Tox21_300583; Tox21_500336; BBL033763; BDBM50013111; NSC759897; STK801888; AKOS005622554; Tox21_110886_1; AC-5263; CCG-100902; CS-1872; DB00649; KS-1115; LP00336; NC00152; NC00684; SDCCGSBI-0050324.P002; ZIDOVUDINE IMPURITY A [WHO-IP]; 2'',3''-didehydro-3''-deoxythymidine; 3''-deoxy-2'',3''-didehydrothymidine; NCGC00023212-03; NCGC00023212-04; NCGC00023212-05; NCGC00023212-08; NCGC00023212-09; NCGC00023212-10; NCGC00023212-11; NCGC00023212-12; NCGC00023212-13; NCGC00023212-14; NCGC00023212-25; NCGC00023212-30; NCGC00254372-01; NCGC00258944-01; NCGC00261021-01; Stavudine 100 microg/mL in Acetonitrile; 1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2; BD164571; SMR000673569; Thymidine, 2',3'-didehydro-, 3'-deoxy-; ZIDOVUDINE IMPURITY A [EP IMPURITY]; D3580; EU-0100336; 2'',3''-dideoxy-2'',3''-didehydrothymidine; C07312; D00445; EN300-120634; AB00383018_18; Q423984; J-700246; Q-201742; SR-01000075802-1; SR-01000075802-4; 2',3'-Didehydro-3'-deoxythymidine, >=98% (TLC); Z1530425068; Stavudine, European Pharmacopoeia (EP) Reference Standard; Stavudine, United States Pharmacopeia (USP) Reference Standard; Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)-; 1-(5-Hydroxymethyl-2,5-dihydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; 1-(5-Hydroxymethyl-2,5-dihydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (ddeThd); 1-[(2R,5S)-2,5-Dihydro-5-(hydroxymethyl)-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione; 3'- Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor; Stavudine for system suitability, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	18283	DB00649	D0Z8EX	224.21	78.9	388	-0.8	16	2	4	2	C10H12N2O4	1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione	CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO	CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO	InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1	XNKLLVCARDGLGL-JGVFFNPUSA-N
DR80BH	Clomipramine	Small molecule	clomipramine; Chlorimipramine; 303-49-1; Monochlorimipramine; 3-Chloroimipramine; Hydiphen; Anafranil base; Clomicalm; Anafranil (free base); Clomipramina; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; Clomipraminum [INN-Latin]; Clomipramina [INN-Spanish]; Anapramine; NSC 169865; 3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; Clomipramine (INN); 3-Chloro-Iminodibenzyl; 5H-Dibenz[b,f]azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl-; 5H-Dibenz(b,f)azepine, 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-; Anafranil (TN); NSC-169865; 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl-; NUV44L116D; DTXSID6022844; CHEBI:47780; G 34586; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; N,N-Dimethyl-7-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine-5-propanamine-2,4-D2; 2241983-11-7; NCGC00015264-08; Clomipraminum; CLOMIPRAMINE [INN]; Clomipramine [INN:BAN]; Anapramine; Chlorimipramine;G 34586; NSC 169865; DTXCID602844; 3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine; 3-CHLORO-10,11-DIHYDRO-N,N-DIMETHYL-5H-DIBENZ[B,F]AZEPINE-5-PROPANAMINE; CAS-303-49-1; EINECS 206-144-2; CAS-17321-77-6; BRN 1323477; UNII-NUV44L116D; 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz[b,f]azepine; HSDB 7746; 5H-Dibenz[b,f]azepine, 3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-; CLOMIPRIMINE; Spectrum_000444; Tocris-0457; Prestwick0_000269; Prestwick1_000269; Prestwick2_000269; Prestwick3_000269; Spectrum2_001729; Spectrum3_001707; Spectrum4_000350; Spectrum5_001235; CLOMIPRAMINE [MI]; Lopac-C-7291; Biomol-NT_000151; CHEMBL415; CLOMIPRAMINE [HSDB]; CLOMIPRAMINE [VANDF]; BIDD:PXR0151; Lopac0_000307; Oprea1_312582; SCHEMBL35423; BSPBio_000118; BSPBio_003294; KBioGR_000759; KBioSS_000924; 5-20-08-00103 (Beilstein Handbook Reference); cid_68539; CLOMIPRAMINE [WHO-DD]; DivK1c_000797; SPBio_001778; SPBio_002337; BPBio1_000130; BPBio1_000661; GTPL2398; BDBM77970; HY-B0457A; KBio1_000797; KBio2_000924; KBio2_003492; KBio2_006060; KBio3_002514; NINDS_000797; HMS3428J14; AMY32531; Tox21_110117; MFCD00242755; MFCD31699980; NSC169865; PDSP1_000241; PDSP2_000240; STK534842; 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine; AKOS001487687; Tox21_110117_1; AB05476; CCG-110307; DB01242; DS-6718; SDCCGSBI-0050295.P004; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethyl-propan-1-amine; IDI1_000797; NCGC00015264-01; NCGC00015264-02; NCGC00015264-03; NCGC00015264-04; NCGC00015264-05; NCGC00015264-06; NCGC00015264-07; NCGC00015264-09; NCGC00015264-10; NCGC00015264-13; NCGC00015264-25; NCGC00024355-02; NCGC00024355-04; NCGC00024355-05; CLOMIPRAMINE [EMA EPAR VETERINARY]; SY246341; SBI-0050295.P003; 2-Bromo-3-ethoxy-6-fluorophenylboronicacid; AB00053695; CS-0012495; C06918; C74557; D07727; Q58713; AB00053695-14; AB00053695_15; AB00053695_16; EN300-6733614; L000890; 3-Chloro-5-[3-(dimethylamino)propyl]-10,f]azepine; 5H-Dibenz[b, 3-chloro-10,11-dihydro-N,N-dimethyl-; BRD-K52989797-001-01-1; BRD-K52989797-003-05-8; BRD-K52989797-003-16-5; WLN: T C676 BN & T & J B3N1 & 1 EG; 5H-Dibenz[b, 10,11-dihydro-3-chloro-5-[3-(dimethylamino)propyl]-; 5H-Dibenz[b, 3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl-dimethyl-amine;hydrochloride; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine #; 3-(9-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro- (8CI); N-[3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]-N,N-dimethylamine; (3-{5-chloro-2-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine; (3-{5-chloro-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine; 3-(2-chloranyl-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethyl-propan-1-amine;hydrochloride; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethyl-1-propanamine;hydrochloride	Approved	Approved Drug(s)	2801	DB01242	D0ZS8P	314.9	6.5	346	5.2	22	0	2	4	C19H23ClN2	3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine	CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl	CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl	InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3	GDLIGKIOYRNHDA-UHFFFAOYSA-N
DZE7M4	Ritonavir	Small molecule	ritonavir; 155213-67-5; Norvir; ABT-538; A-84538; Abbott 84538; ABBOTT-84538; Empetus; Ritomune; Ritovir; Viekirax; Viriton; RTV; ABT 538; CHEBI:45409; 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate; NSC-693184; DTXSID1048627; O3J8G9O825; NSC693184; 2,7,10,12-Tetraazatridecanoic acid, 4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (3S,4S,6S,9S)-; thiazol-5-ylmethyl ((2S,3S,5S)-3-hydroxy-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-yl)carbamate; Ritonavir [USAN]; NCGC00159462-02; NCGC00183130-01; Norvir Softgel; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; RIT; DTXCID8028553; ABT538; C37H48N6O5S2; MFCD00927142; DRG-0244; 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (5S-(5R*,8R*,10R*,11R*))-; SMR000466395; thiazol-5-ylmethyl (2S,3S,5S)-3-hydroxy-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-ylcarbamate; thiazol-5-ylmethyl N-[(1S,2S,4S)-1-benzyl-2-hydroxy-4-[[(2S)-2-[[(2-isopropylthiazol-4-yl)methyl-methyl-carbamoyl]amino]-3-methyl-butanoyl]amino]-5-phenyl-pentyl]carbamate; Norvir (TM); Norvir (TN); CAS-155213-67-5; HSDB 7160; 1,3-Thiazol-5-ylmethyl N-[(2S,3S,5R)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenyl-hexan-2-yl]carbamate; Ritonavirum; TMC 114r; UNII-O3J8G9O825; 1hxw; 3prs; 3tne; 4eyr; Ritonavir [USAN:USP:INN:BAN]; Ritonavir- Bio-X; 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]-; 2,7,10,12-TETRAAZATRIDECANOIC ACID, 4-HYDROXY-12-METHYL-9-(1-METHYLETHYL)-13-(2-(1-METHYLETHYL)-4-THIAZOLYL)-8,11-DIOXO-3,6-BIS(PHENYLMETHYL)-, 5-THIAZOLYLMETHYL ESTER, (3S,4S,6S,9S)-; 5-Thiazolylmethyl [(alphaS)-alpha-[(1S,3S)-1-hydroxy-3-[(2S)-2-[3-[(2-isopropyl-4-thiazolyl)methyl]-3-methylureido]-3-methylbutyramido]-4-phenylbutyl]phenethyl]carbamate; Ritonavir & PLGA; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; Norvir, Norvir Softgel; 1sh9; RITONAVIR [INN]; RITONAVIR [JAN]; RITONAVIR [MI]; RITONAVIR [HSDB]; RITONAVIR [VANDF]; Abbot 84538; CHEMBL163; RITONAVIR [MART.]; RITONAVIR [USP-RS]; RITONAVIR [WHO-DD]; RITONAVIR [WHO-IP]; SCHEMBL6679; Ritonavir (JAN/USP/INN); BIDD:PXR0023; RITONAVIR [EMA EPAR]; MLS000759541; MLS001424063; MLS006011764; BIDD:GT0387; GTPL8804; RITONAVIR [ORANGE BOOK]; RITONAVIR [USP IMPURITY]; Ritonavir, >=98% (HPLC); RITONAVIR [USP MONOGRAPH]; KALETRA COMPONENT RITONAVIR; HMS2051B08; HMS2235O10; HMS3715L22; Pharmakon1600-01502391; PAXLOVID COMPONENT RITONAVIR; RITONAVIRUM [WHO-IP LATIN]; VIEKIRAX COMPONENT RITONAVIR; Tox21_112969; Tox21_113431; AC-733; BDBM50088504; HB6070; NSC760369; s1185; STK634209; RITONAVIR COMPONENT OF KALETRA; AKOS000280930; RITONAVIR COMPONENT OF VIEKIRAX; Tox21_112969_1; CCG-101007; CS-0432; DB00503; KS-5017; NC00257; NSC 693184; NSC 760369; NSC-760369; MRF-0000287; NCGC00159462-03; NCGC00159462-04; NCGC00159462-07; NCGC00159462-20; Ritonavir 100 microg/mL in Acetonitrile; BR164353; HY-90001; N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; MLS000759541-02; R0116; SW197637-2; C07240; D00427; EN300-119505; AB00639991-06; AB00639991-08; AB00639991_09; AB00639991_10; A 84538; A904691; Q422618; J-009178; BRD-K51485625-001-07-6; Z1521553599; (1,3-thiazol-5-yl)methyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate; (2S, 3S, 5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinvl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S )-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl) methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-MethyI-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino )-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1 .6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3hydroxyhexane; (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane; 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate; 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-di(phenyl)hexan-2-yl]carbamate; 2,4,7,12-TETRAAZATRIDECAN-13-OIC ACID, 10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-(2-(1-METHYLETHYL)-4-THIAZOLYL)-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-5-THIAZOLYLMETHYL ESTER (5S-(5R*,8R*,10R*,11R*))-; 5-Thiazolylmethyl   (3S,4S,6S,9S)-4-hydroxy-12-methyl-9-  (1-methylethyl)-13-[2-  (1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis  (phenylmethyl)-2,7,10,12-tetraazatridecanoate; 5-Thiazolylmethyl (3S,4S,6S,9S)-4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-2,7,10,12-tetraazatridecanoate; N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N(2)-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; N1-((1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentyl)-N2-{[[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)amino]carbonyl}-L-valinamide; thiazol-5-ylmethyl((2S,3S,5S)-3-hydroxy-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-yl)carbamate	Approved	Approved Drug(s)	392622	DB00503	D0ZU9R	720.9	202	1040	6	50	4	9	18	C37H48N6O5S2	1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate	CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O	CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O	InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1	NCDNCNXCDXHOMX-XGKFQTDJSA-N
DQA65U	Valbenazine	Small molecule	Valbenazine; 1025504-45-3; Ingrezza; NBI-98854; Mt-5199; ValbenazineNBI-98854; NBI 98854; 54K37P50KH; (2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl L-valinate; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester; Valbenazine [USAN]; Valbenazine [USAN:INN]; UNII-54K37P50KH; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester; VALBENAZINE [MI]; VALBENAZINE [INN]; Valbenazine (USAN/INN); VALBENAZINE [WHO-DD]; GTPL8694; CHEMBL2364639; SCHEMBL15932979; DTXSID801026306; EX-A2002; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester;L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester; BDBM50573733; MFCD28963976; CS-5908; DB11915; NCGC00522306-02; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate; AC-30929; AS-35294; HY-16771; Valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester; D10675; EN300-7482951; NBI-98854;NBI98854;NBI 98854; Q27089118; (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate; (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-yl (2S)-2-amino-3-methylbutanoate; (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl] (2S)-2-amino-3-methylbutanoate; 2401901-99-1; L-Valine (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester	Approved	Approved Drug(s)	24795069	DB11915	D63WMQ	418.6	74	569	4.3	30	1	6	8	C24H38N2O4	[(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate	CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1OC(=O)C(C(C)C)N)OC)OC	CC(C)C[C@@H]1CN2CCC3=CC(=C(C=C3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC	InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1	GEJDGVNQKABXKG-CFKGEZKQSA-N
DWD01Z	Tirzepatide	Small molecule	Tirzepatide; Mounjaro; 2023788-19-2; CHEBI:194186; LY-3298176	Approved	Approved Drug(s)	163285897	DB15171	DA69JF	4813	1790	11700	-6.8	341	58	70	163	C225H348N48O68	20-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2-methylpropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid	CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N	InChI=1S/C225H348N48O68/c1-23-126(10)183(264-198(311)146(64-50-52-88-226)246-202(315)157(109-180(297)298)252-199(312)152(103-124(6)7)261-223(337)225(21,22)269-217(330)185(128(12)25-3)266-209(322)163(120-278)257-200(313)153(107-138-74-78-141(282)79-75-138)250-203(316)158(110-181(299)300)253-207(320)162(119-277)259-216(329)187(134(18)280)267-206(319)155(106-136-60-44-41-45-61-136)254-215(328)186(133(17)279)262-174(289)114-237-193(306)147(83-87-179(295)296)260-222(336)224(19,20)268-192(305)143(227)104-137-72-76-140(281)77-73-137)214(327)242-131(15)190(303)244-148(80-84-168(228)283)196(309)245-145(65-51-53-89-231-175(290)121-340-100-99-339-97-91-233-176(291)122-341-101-98-338-96-90-232-170(285)86-82-150(221(334)335)243-171(286)70-46-38-36-34-32-30-28-26-27-29-31-33-35-37-39-47-71-178(293)294)195(308)240-130(14)191(304)248-154(105-135-58-42-40-43-59-135)205(318)263-182(125(8)9)212(325)247-149(81-85-169(229)284)197(310)251-156(108-139-111-234-144-63-49-48-62-142(139)144)201(314)249-151(102-123(4)5)204(317)265-184(127(11)24-2)213(326)241-129(13)189(302)236-112-172(287)235-115-177(292)270-92-54-66-164(270)210(323)258-161(118-276)208(321)256-160(117-275)194(307)238-113-173(288)239-132(16)218(331)272-94-56-68-166(272)220(333)273-95-57-69-167(273)219(332)271-93-55-67-165(271)211(324)255-159(116-274)188(230)301/h40-45,48-49,58-63,72-79,111,123-134,143,145-167,182-187,234,274-282H,23-39,46-47,50-57,64-71,80-110,112-122,226-227H2,1-22H3,(H2,228,283)(H2,229,284)(H2,230,301)(H,231,290)(H,232,285)(H,233,291)(H,235,287)(H,236,302)(H,237,306)(H,238,307)(H,239,288)(H,240,308)(H,241,326)(H,242,327)(H,243,286)(H,244,303)(H,245,309)(H,246,315)(H,247,325)(H,248,304)(H,249,314)(H,250,316)(H,251,310)(H,252,312)(H,253,320)(H,254,328)(H,255,324)(H,256,321)(H,257,313)(H,258,323)(H,259,329)(H,260,336)(H,261,337)(H,262,289)(H,263,318)(H,264,311)(H,265,317)(H,266,322)(H,267,319)(H,268,305)(H,269,330)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,334,335)/t126-,127-,128-,129-,130-,131-,132-,133+,134+,143-,145-,146-,147-,148-,149-,150+,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,182-,183-,184-,185-,186-,187-/m0/s1	BTSOGEDATSQOAF-SMAAHMJQSA-N
DW5M0A	Odevixibat	Small molecule	Odevixibat; 501692-44-0; AZD8294; A4250; AR-H064974; Odevixibat [USAN]; A-4250; 2W150K0UUC; AZD-8294; Odevixibat (USAN); (2S)-2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid; (S)-2-((R)-2-(2-((3,3-Dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)acetamido)-2-(4-hydroxyphenyl)acetamido)butanoic acid; Butanoic acid, 2-(((2R)-((((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)(4-hydroxyphenyl)acetyl)amino)-, (2S)-; Butanoic acid, 2-(((2R)-2-((2-((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino)-, (2S)-; ODEVIXIBAT [INN]; ODEVIXIBAT [WHO-DD]; UNII-2W150K0UUC; SCHEMBL946468; CHEMBL4297588; ODEVIXIBAT [ORANGE BOOK]; BDBM77040; GTPL11194; DTXSID601336860; EX-A5384; example 5 [US9694018B1]; WHO 10706; AT28924; BO181253; MS-31290; HY-109120; CS-0078340; D11716; US9694018, 5; (2S)-2-(((2R)-2-((((3,3-Dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino)butanoic acid	Approved	Approved Drug(s)	10153627	DB16261	DEWC27	740.9	208	1230	6.8	51	5	11	17	C37H48N4O8S2	(2S)-2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)N1)OCC(=O)NC(C3=CC=C(C=C3)O)C(=O)NC(CC)C(=O)O)SC)C4=CC=CC=C4)CCCC	CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)N1)OCC(=O)N[C@H](C3=CC=C(C=C3)O)C(=O)N[C@@H](CC)C(=O)O)SC)C4=CC=CC=C4)CCCC	InChI=1S/C37H48N4O8S2/c1-5-8-19-37(20-9-6-2)24-41(26-13-11-10-12-14-26)29-21-31(50-4)30(22-32(29)51(47,48)40-37)49-23-33(43)39-34(25-15-17-27(42)18-16-25)35(44)38-28(7-3)36(45)46/h10-18,21-22,28,34,40,42H,5-9,19-20,23-24H2,1-4H3,(H,38,44)(H,39,43)(H,45,46)/t28-,34+/m0/s1	XULSCZPZVQIMFM-IPZQJPLYSA-N
D5HCD8	Mobocertinib	Small molecule	Mobocertinib; 1847461-43-1; TAK-788; AP32788; TAK788; Mobocertinib [INN]; AP-32788; Mobocertinib [USAN]; Mobocertinib(TAK-788); propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate; 39HBQ4A67L; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; 1-Methylethyl 2-[[4-[[2-(dimethylamino)ethyl]methylamino]-2-methoxy-5-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]-4-(1-methyl-1H-indol-3-yl)-5-pyrimidinecarboxylate; Exkivity; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib (TAK788); Mobocertinib [USAN:INN]; UNII-39HBQ4A67L; MOBOCERTINIB [WHO-DD]; CHEMBL4650319; SCHEMBL17373133; GTPL10468; BDBM368374; DTXSID201336749; BCP31045; EX-A3392; US10227342, Example 10; XYC46143; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; AT30193; NSC-825519; AC-36436; example 94 [WO2015195228A1]; MS-30474; HY-135815; CS-0114256; D81621; A934607; TAK-788;TAK 788; TAK788; AP32788; AP-32788; AP 32788; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[(4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)phenyl)amino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate	Approved	Approved Drug(s)	118607832	DB16390	DI4HA7	585.7	114	935	4.4	43	2	9	13	C32H39N7O4	propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate	CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC	CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC	InChI=1S/C32H39N7O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36)	AZSRSNUQCUDCGG-UHFFFAOYSA-N
DQF9H2	Asciminib	Small molecule	asciminib; 1492952-76-7; ABL-001; ABL001; Asciminib free base; ABL001-NX; NVP-ABL001; Asciminib [USAN]; (R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; Example 9; L1F3R18W77; 1492952-76-7 (free base); 3-Pyridinecarboxamide, N-(4-(chlorodifluoromethoxy)phenyl)-6-((3R)-3-hydroxy-1-pyrrolidinyl)-5-(1H-pyrazol-3-yl)-; N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide; 3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(1H-pyrazol-3-yl)-; ASCIMINIB [INN]; Asciminib (ABL001); Asciminib (USAN/INN); ASCIMINIB [WHO-DD]; UNII-L1F3R18W77; GTPL8962; CHEMBL4208229; SCHEMBL15388306; TQP0925; EX-A3030; BDBM50459091; NSC789925; s8555; AT30330; CCG-269232; compound 1 [PMID: 30137981]; CS-7655; DB12597; NSC-789925; (R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide; BA166957; BS-15538; HY-104010; D11403; A910986; Q27074535; (R)-N-(4-(Chloro difluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; (R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-3-yl)nicotinamide; AY7; N-(4-(CHLORODIFLUOROMETHOXY)PHENYL)-6-((3R)-3- HYDROXYPYRROLIDIN-1-YL)-5-(1H-PYRAZOL-3-YL)PYRIDINE- 3-CARBOXAMIDE; N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-3-yl)pyridine-3-carboxamide	Approved	Approved Drug(s)	72165228	DB12597	DSHT18	449.8	103	626	3	31	3	8	6	C20H18ClF2N5O3	N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide	C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4	C1CN(C[C@@H]1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4	InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1	VOVZXURTCKPRDQ-CQSZACIVSA-N
DT2E6D	Adagrasib	Small molecule	MRTX849; Adagrasib; 2326521-71-3; MRTX-849; Adagrasib [USAN]; KRAZATI; Kras G12C inhibitor MRTX849; 8EOO6HQF8Y; 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; 2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-; 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-; ADAGRASIB [INN]; UNII-8EOO6HQF8Y; ADAGRASIB [WHO-DD]; CHEMBL4594350; SCHEMBL20974691; GTPL10888; DTXSID801336759; BCP31538; EX-A3258; MRTX-849; MRTX 849; BDBM50539763; MFCD32263433; NSC831453; s8884; WHO 11519; AKOS037648997; AT23561; NSC-831453; compound 20 [PMID: 32250617]; AC-35659; BM177692; BS-16211; HY-130149; CS-0105265; A936721; EN300-26953032; Z4145344023; ((2S)-4-(7-(8-CHLORONAPHTHALEN-1-YL)-2-(((2S)-1- METHYLPYRROLIDIN-2-YL)METHOXY)-5,6,7,8- TETRAHYDROPYRIDO(3,4-D)PYRIMIDIN-4-YL)-1-(2-FLUOROPROP2-ENOYL)PIPERAZIN-2-YL)ACETONITRILE; [(2S)-4-[7-(8-Chloro-1-naphthyl)-2-{[(2S)-1-methyl-2-pyrrolidinyl]methoxy}-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroacryloyl)-2-piperazinyl]acetonitrile	Approved	Approved Drug(s)	138611145	DB15568	DUQV41	604.1	88.8	1060	5	43	0	9	7	C32H35ClFN7O2	2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile	CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F	CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F	InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1	PEMUGDMSUDYLHU-ZEQRLZLVSA-N
D5Q6OT	Pirtobrutinib	Small molecule	Pirtobrutinib; LOXO-305; 2101700-15-4; JAYPIRCA; Pirtobrutinib [USAN]; JNA39I7ZVB; (S)-5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide; LY3527727; RXC-005; LY-3527727; 1H-Pyrazole-4-carboxamide, 5-amino-3-(4-(((5-fluoro-2-methoxybenzoyl)amino)methyl)phenyl)-1-((1S)-2,2,2-trifluoro-1-methylethyl)-; 1H-Pyrazole-4-carboxamide, 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(1S)-2,2,2-trifluoro-1-methylethyl]-; Y7W; BTK inhibitor 16; UNII-JNA39I7ZVB; PIRTOBRUTINIB [INN]; PIRTOBRUTINIB [JAN]; LOXO305; Pirtobrutinib (LOXO-305); PIRTOBRUTINIB [WHO-DD]; MCL133; RXC005; CHEMBL4650485; SCHEMBL19014257; GTPL11628; GLXC-25733; EX-A5016; WHO 11681; BL180882; MS-28909; HY-131328; CS-0133286; LOXO-305;LY 3527727; RXC-005; 5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-((2S)-1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE; 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide	Approved	Approved Drug(s)	129269915	DB17472	DXP04H	479.4	125	719	3.3	34	3	9	7	C22H21F4N5O3	5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide	CC(C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N	C[C@@H](C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N	InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1	FWZAWAUZXYCBKZ-NSHDSACASA-N
D3L9CK	Glycerol	Small molecule	glycerol; glycerin; 56-81-5; Glycerine; PROPANE-1,2,3-TRIOL; 1,2,3-Propanetriol; Glycyl alcohol; Trihydroxypropane; Glyceritol; Propanetriol; 1,2,3-trihydroxypropane; Osmoglyn; Grocolene; Glysanin; Glyrol; Glycerin, synthetic; Dagralax; Glycerinum; Ophthalgan; Vitrosupos; Glycerin, anhydrous; Synthetic glycerin; Synthetic glycerine; Optim; Moon; Star; Incorporation factor; Glycerolum; 90 Technical glycerine; 25618-55-7; Glycerin mist; Glycerin (mist); Citifluor AF 2; Bulbold; Cristal; Glicerina [DCIT]; Glycerine mist; Caswell No. 469; Glycerin [JAN]; FEMA No. 2525; Propanetriol (VAN); Glycerin base; Tryhydroxypropane; Glycerin, natural; Glycerin,anhydrous; Glicerol [INN-Spanish]; Glycerolum [INN-Latin]; Clyzerin, wasserfrei; Pricerine 9091; Clyzerin, wasserfrei [German]; Emery 916; CCRIS 2295; HSDB 492; Monoctanoin Component D; EPA Pesticide Chemical Code 063507; Collyrium Fresh-Eye Drops; AI3-00091; NSC 9230; Glycerol [INN]; BRN 0635685; IFP; di-o-tolylphenylphosphine; DYNASTIN 7; NSC-9230; GLYCEROL-(OD)3; MFCD00004722; PDC6A3C0OX; 1,2,3-trihydroxypropanol; INS NO.422; DTXSID9020663; CHEBI:17754; INS-422; NSC9230; Glycerol (INN); M 314429; 101662-08-2; 144086-03-3; PZN 7474853; NCGC00090950-03; Diacylglycerol(35:0); E-422; 107283-02-3; 153050-05-6; 18803-09-3; 1H-Thieno[3,4-d]iMidazole-4-pentanaMide, hexahydro-2-oxo-N-[6-oxo-6-(2-propenylaMino)hexyl]-, (3aS,4; DTXCID40662; Glycerol; Propane-1,2,3-Triol; Glicerina; Glicerol; Heterochromatin-specific nonhistone chromosomal protein HP-1; DAG 31:3; DAG 35:0; DAG(35:0); Glycerol, ACS reagent, >=99.5%; Glyceol Opthalgan; DG 31:3; DG 35:0; CAS-56-81-5; DG(31:3); DG(35:0); GOL; Mackstat H 66; WURCS=2.0/1,1,0/[h2h]/1/; Glycerin [USP:JAN]; RG-S; EINECS 200-289-5; UNII-PDC6A3C0OX; Neutracett; Glyceol; Glyzerin; Oelsuess; glycerine usp; Artifical tears; D-glycerol; L-glycerol; Organic Glycerin; Organic Glycerine; Glycerine (crude); 1,3-Propanetriol; Glycerol, ultrapure; Glycerin USP grade; Glycerine 96%; Glycerol 85%; diacylglycerol 31:3; diacylglycerol 35:0; 8043-29-6; Glycerin 99.5%; Glycerine 96% USP; 1,3-Trihydroxypropane; 90 Technical glycerin; Emery 912; diacylglycerol(31:3); GLYCERIN [HSDB]; GLYCERIN [INCI]; GLYCEROL [FHFI]; GLYCERIN [II]; GLYCEROL [MI]; GLYCERIN [VANDF]; GLYCERINUM [HPUS]; E 422; Glycerin (JP17/USP); Glycerin 99.5% USP; Glycerine 99.7% USP; GLYCEROL [MART.]; bmse000184; bmse000807; bmse000856; CHEMBL692; GLYCERIN [USP-RS]; GLYCEROL [WHO-DD]; GLYCEROL [WHO-IP]; MolMap_000024; EC 200-289-5; Glycerol, >=99.5%; Glycerol, biochemical grade; Glycerin Reagent Grade ACS; WLN: Q1YQ1Q; Glycerine (Fragrance Grade); 2-hydroxylpropane-1,3-diol; Glycerol, LR, >=98%; Glycerol, analytical standard; 4-01-00-02751 (Beilstein Handbook Reference); 8013-25-0; Glycerol, Cell Culture Grade; Glycerol-[1,3-13C2]; Glycerol min 98%, anhydrous; Glycerol, >=99% (GC); GLYCERIN [ORANGE BOOK]; GLYCEROL [EP IMPURITY]; GTPL5195; QSPL 181; GLYCEROL [EP MONOGRAPH]; GLYCERIN [USP MONOGRAPH]; Glycerol, AR, >=99.5%; Pentrioxido sulfurico glycerincol; Glycerol, >99%, FCC, FG; Glycerol, technical grade, 95%; Glycerol, ultrapure, HPLC Grade; 2w97; CHEBI:131416; CHEBI:178017; CHEBI:189439; GLYCEROL 85% [WHO-DD]; Glycerol, ACS reagent, 99.5%; Glycerol, Molecular Biology Grade; GLYCEROLUM [WHO-IP LATIN]; GLYCERIN,ANHYDROUS [VANDF]; Pharmakon1600-01300020; Glycerol, Vetec(TM) reagent grade; HY-B1659; STR02073; Glycerine 912 (96% CP/USP); Tox21_111043; Tox21_202077; Tox21_300144; c0066; DAG(31:3); Glycerol, BioXtra, >=99% (GC); Glycerol, ReagentPlus(R), >=99%; NSC759633; s2766; STL199174; 2-PROPANOL, 1,3-DIHYDROXY-; AKOS000120102; CS-6964; DB09462; Glycerol, USP, 99.0-101.0%; NSC-759633; SB83762; GLYCERIN; PROPANE-1,2,3-TRIOL; Glycerolglycerin; Propane-1,2,3-Triol; Glycerol, SAJ first grade, >=98.0%; NCGC00090950-01; NCGC00090950-02; NCGC00090950-04; NCGC00090950-05; NCGC00253975-01; NCGC00259626-01; BP-31039; E422; Glycerol, for molecular biology, >=99%; Glycerol, JIS special grade, >=99.0%; Glycerol, Vetec(TM) reagent grade, 99%; Glycerin, meets USP testing specifications; FT-0626742; FT-0669018; FT-0697060; G0316; Glycerol, ultrapure, Spectrophotometric Grade; EN300-19328; Glycerol, ReagentPlus(R), >=99.0% (GC); Glycerol, spectrophotometric grade, >=99.5%; C00116; D00028; D92249; A831186; Glycerol, tested according to Ph.Eur., anhydrous; Q132501; BRD-K73866522-001-02-6; Glycerol-Gelatine, for mounting (histochemical slides); F0001-1470; 8DFDFCD7-1ED2-4373-845E-054F5AD00089; Glycerin, United States Pharmacopeia (USP) Reference Standard; Glycerin, Pharmaceutical Secondary Standard; Certified Reference Material; Glycerol, BioUltra, for molecular biology, anhydrous, >=99.5% (GC); Glycerol, p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 98.0-101.0%; Glycerol, puriss. p.a., ACS reagent, anhydrous, dist., >=99.5% (GC); 26403-55-4; Glycerol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, >=99% (GC); Glycerol, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E422, anhydrous, 99.0-101.0% (alkalimetric)	Approved	Approved Drug(s)	753	DB09462	.	92.09	60.7	25.2	-1.8	6	3	3	2	C3H8O3	propane-1,2,3-triol	C(C(CO)O)O	C(C(CO)O)O	InChI=1S/C3H8O3/c4-1-3(6)2-5/h3-6H,1-2H2	PEDCQBHIVMGVHV-UHFFFAOYSA-N
DGR7F9	Sacituzumab govitecan	Small molecule	Satralizumab linker; Sacituzumab govitecan [USAN]; 1491917-83-9; Sacituzumab govitecan; hRS7-SN38; UNII-M9BYU8XDQ6; hRS 7SN38; IMMU 132; IMMU-132; sacituzumab-govitecan; M9BYU8XDQ6; DA64T2C2IO; CYSTEINYL CL2A-SN-38; SN-38 CYSTEINYL CONJUGATE; DTXSID401335985; EX-A4354; GOVITECAN CYSTEINYL CONJUGATE; F82944	Approved	Approved Drug(s)	91668186	DB12893	.	1601.8	498	3150	-3.3	113	8	30	54	C76H104N12O24S	(2R)-2-amino-3-[1-[[4-[[1-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[2-[2-[[(2S)-6-amino-1-[4-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxycarbonyloxymethyl]anilino]-1-oxohexan-2-yl]amino]-2-oxoethoxy]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]methylcarbamoyl]cyclohexyl]methyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)CC(C8=O)SCC(C(=O)O)N)C2=NC9=C1C=C(C=C9)O	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)[C@H](CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)CC(C8=O)SC[C@@H](C(=O)O)N)C2=NC9=C1C=C(C=C9)O	InChI=1S/C76H104N12O24S/c1-3-55-56-37-54(89)16-17-61(56)83-68-57(55)43-87-63(68)38-59-58(71(87)95)45-110-74(99)76(59,4-2)112-75(100)111-44-50-10-14-52(15-11-50)81-70(94)62(7-5-6-18-77)82-66(91)47-109-46-65(90)79-19-21-101-23-25-103-27-29-105-31-33-107-35-36-108-34-32-106-30-28-104-26-24-102-22-20-86-42-53(84-85-86)40-80-69(93)51-12-8-49(9-13-51)41-88-67(92)39-64(72(88)96)113-48-60(78)73(97)98/h10-11,14-17,37-38,42,49,51,60,62,64,89H,3-9,12-13,18-36,39-41,43-48,77-78H2,1-2H3,(H,79,90)(H,80,93)(H,81,94)(H,82,91)(H,97,98)/t49?,51?,60-,62-,64?,76-/m0/s1	ULRUOUDIQPERIJ-PQURJYPBSA-N
D7E8HJ	Ferric oxyhydroxide	Small molecule	Ferric oxyhydroxide; Iron hydroxide oxide; iron(3+);oxygen(2-);hydroxide; Iron Oxide Hydroxide; Iron hydroxide Nanorods; FERRIC OXY-HYDROXIDE; FERRIC HYDROXIDE [MI]; DTXSID3042057; FERRIC OXYHYDROXIDE (FEO2H); FERRIC HYDROXIDE OXIDE (FEOOH); DB14695; IRON HYDROXIDE OXIDE (FEO(OH))	Approved	Approved Drug(s)	9793696	DB14695	.	88.85	2	0	.	3	1	2	0	FeHO2	iron(3+);oxygen(2-);hydroxide	[OH-].[O-2].[Fe+3]	[OH-].[O-2].[Fe+3]	InChI=1S/Fe.H2O.O/h;1H2;/q+3;;-2/p-1	IEECXTSVVFWGSE-UHFFFAOYSA-M
D65JPW	Chlorambucil	Small molecule	chlorambucil; 305-03-3; Ambochlorin; Leukeran; Chloroambucil; Chloraminophen; Chlorbutin; Chloraminophene; Chlorobutine; Amboclorin; Ecloril; Chlorbutine; Chlorobutin; Lympholysin; Chlocambucil; Linfolizin; Linfolysin; Elcoril; Phenylbutyric acid nitrogen mustard; Leukersan; Leukoran; Chlorambucilum; NSC-3088; 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoic acid; Cb l348; CB 1348; Phenylbuttersaeure-lost; 4-(4-(Bis(2-chloroethyl)amino)phenyl)butanoic acid; Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-; NSC 3088; Rcra waste number U035; CB-1348; NCI-C03485; 4-[p-[Bis(2-chloroethyl)amino]phenyl]butyric acid; 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid; N,N-Di-2-chloroethyl-gamma-p-aminophenylbutyric acid; 4-(Bis(2-chloroethyl)amino)benzenebutanoic acid; p-(N,N-Di-2-chloroethyl)aminophenyl butyric acid; 4-(p-Bis(beta-chloroethyl)aminophenyl)butyric acid; Benzenebutanoic acid, 4-(bis(2-chloroethyl)amino)-; CHEBI:28830; NSC3088; 4-[Bis(2-chloroethyl)amino]benzenebutyric acid; 4-[Bis(2-chloroethyl)amino]benzenebutanoic acid; CHEMBL515; 4-(p-(Bis(2-chloroethyl)amino)phenyl)butyric acid; gamma-[p-Di(2-chloroethyl)aminophenyl]butyric acid; MLS000028443; Chloorambucol; Chlorbutinum; DTXSID7020263; Elcorin; 4-(Bis(2-chloroethyl)amino)phenylbutyric acid; NCI-3088; gamma-(p-Di(2-chloroethyl)aminophenyl)butyric acid; Butyric acid, 4-(p-bis(2-chloroethyl)aminophenyl)-; 18D0SL7309; Kyselina 4-(N,N-bis-(2-chlorethyl)-p-aminofenyl)maselna; NCGC00015199-08; Clorambucile; Clorambucilo; CAS-305-03-3; SMR000058372; Clorambucile [DCIT]; Leukeran tablets; 4-[Bis(2-chloroethyl)amino]phenylbutyric acid; DTXCID30263; 4-(4-[Bis(2-chloroethyl)amino]phenyl)butyric acid; .gamma.-[p-Di(2-chloroethyl)aminophenyl]butyric acid; Butyric acid, 4-[p-[bis(2-chloroethyl)amino]phenyl]-; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; p-N,N-Di-(.beta.-chloroethyl)aminophenyl butyric acid; N,N-Di-2-chloroethyl-.gamma.-p-aminophenylbutyric acid; CCRIS 126; Phenylbuttersaeure-lost [German]; HSDB 3026; SR-01000000062; LEUKERAN (TN); 4-[4-[Bis(2-chloroethyl)amino]phenyl]butyric Acid; EINECS 206-162-0; .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyric acid; .gamma.-[p-bis(2-chloroethyl)aminophenyl]butyric acid; 4-(p-Bis(.beta.-chloroethyl)aminophenyl)butyric acid; 4-[p-Bis(.beta.-chloroethyl)aminophenyl]butyric acid; RCRA waste no. U035; Butyric acid, 4-(p-[bis(2-chloroethyl)amino]phenyl)-; BRN 0999011; chlorambucilddv; Chlorambucil [USP:INN:BAN]; AI3-26083; UNII-18D0SL7309; p-(N,N-Di-2-chlorethylaminophenyl)butyric acid; para-(Di(2-chloroethyl)aminophenyl)butyric acid; Chlorambucil,(S); gamma-(p-bis(2-chloroethyl)aminophenyl)butyricacid; Butanoic acid, 4-(bis(2-chloroethyl)amino) benzene; gamma-(p-Bis(2-chloroethyl)aminophenyl)butyric acid; phenyl)butanoic acid; MFCD00021783; p-N,N-Di-(beta-chloroethyl)aminophenyl butyric acid; Butyric acid, 4-(p-(bis(2-chloroethyl)amino)phenyl); para-N,N-Di(beta-chloroethyl)aminophenyl butyric acid; N,N-Di-2-chloroethyl-gamma-para-aminophenyl butyric acid; Opera_ID_51; Spectrum_000118; Kyselina 4-(N,N-bis-(2-chlorethyl)-p-aminofenyl)maselna [Czech]; Prestwick0_001079; Prestwick1_001079; Prestwick2_001079; Prestwick3_001079; Spectrum2_000065; Spectrum3_000336; Spectrum4_000273; Spectrum5_000677; CHLORAMBUCIL [MI]; Lopac-C-0253; CHLORAMBUCIL [INN]; CHLORAMBUCIL [JAN]; Epitope ID:139977; CHLORAMBUCIL [HSDB]; CHLORAMBUCIL [IARC]; SCHEMBL4308; CHLORAMBUCIL [VANDF]; Chlorambucil with impurity G; Lopac0_000227; WLN: QV3R DN2G2G; BSPBio_001098; BSPBio_001971; CHLORAMBUCIL [MART.]; KBioGR_000766; KBioSS_000558; 4-14-00-01715 (Beilstein Handbook Reference); MLS001076130; CHLORAMBUCIL [USP-RS]; CHLORAMBUCIL [WHO-DD]; CHLORAMBUCIL [WHO-IP]; DivK1c_000688; SPECTRUM1500171; Chlorambucil (JAN/USP/INN); SPBio_000249; SPBio_002999; BPBio1_001208; GTPL7143; HMS502C10; KBio1_000688; KBio2_000558; KBio2_003126; KBio2_005694; KBio3_001191; NINDS_000688; CHLORAMBUCIL [ORANGE BOOK]; Chlorambucil for system suitability; HMS1571G20; HMS1920M15; HMS2090M19; HMS2091A22; HMS2098G20; HMS2235A04; HMS3259I10; HMS3372O04; HMS3652P08; Pharmakon1600-01500171; 4-(4-(bis(2-chloroethyl)amino); CHLORAMBUCIL [EP MONOGRAPH]; AMY33445; BCP28394; CHLORAMBUCIL [USP MONOGRAPH]; Tox21_110096; Tox21_201390; Tox21_302996; BDBM50003677; CCG-39872; NSC756674; s4288; CHLORAMBUCILUM [WHO-IP LATIN]; AKOS024319346; Tox21_110096_1; Chlorambucil, purum, >=98.0% (T); CS-3118; DB00291; GS-6200; LP00227; NC00555; NSC-756674; SDCCGSBI-0050215.P005; IDI1_000688; NCGC00015199-01; NCGC00015199-02; NCGC00015199-03; NCGC00015199-04; NCGC00015199-05; NCGC00015199-06; NCGC00015199-07; NCGC00015199-09; NCGC00015199-10; NCGC00015199-11; NCGC00015199-12; NCGC00015199-13; NCGC00015199-14; NCGC00015199-15; NCGC00015199-16; NCGC00015199-17; NCGC00015199-19; NCGC00015199-20; NCGC00023250-00; NCGC00023250-03; NCGC00023250-04; NCGC00023250-05; NCGC00023250-06; NCGC00023250-07; NCGC00023250-08; NCGC00023250-09; NCGC00023250-10; NCGC00256464-01; NCGC00258941-01; BP-24028; HY-13593; NCI60_002639; SBI-0050215.P004; DB-047794; WR-139013; AB00051938; C2939; EU-0100227; FT-0617365; SW197258-4; A14252; A18607; C 0253; C06900; D00266; EN300-123640; H10484; AB00051938-14; AB00051938-15; AB00051938_16; Q415939; 4-(4-(Bis(2-chloroethyl)amino)phenyl)butanoicacid; 4[p-Bis(.beta.-chloroethyl)aminophenyl]butyric acid; Butanoic acid, 4-(bis(2-chloroethyl)amino)benzene-; SR-01000000062-2; SR-01000000062-4; SR-01000000062-7; W-106940; .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyricacid; BRD-K29458283-001-04-2; BRD-K29458283-001-05-9; BRD-K29458283-001-17-4; 4-(4-[Bis(2-chloroethyl)amino]phenyl)butanoic acid #; Z1552153009; 4-[4-(N,N-bis(2-chloroethyl)-amino]phenyl)butanoic acid; Chlorambucil, European Pharmacopoeia (EP) Reference Standard; Chlorambucil, United States Pharmacopeia (USP) Reference Standard; Chlorambucil for system suitability, European Pharmacopoeia (EP) Reference Standard	Approved	Approved Drug(s)	2708	DB00291	D0V8QT	304.2	40.5	250	1.7	19	1	3	9	C14H19Cl2NO2	4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid	C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl	C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl	InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)	JCKYGMPEJWAADB-UHFFFAOYSA-N
DIA08B	Vinorelbine	Small molecule	vinorelbine; 71486-22-1; Vinorelbine base; Navelbine; Vinorelbinum; Exelbine; Vinorelbina; Navelbin; Nor-5'-anhydrovinblastine; KW-2307 base; Vinorelbine (INN); Vinorelbinum [Latin]; Vinorelbina [Spanish]; Navelbine base; CHEBI:480999; Q6C979R91Y; C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-; NSC-760087; VINORELBINE [INN]; Navelbine (TN); Eunades; Vinorelbine [INN:BAN]; KW 2307 base; methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; SR-05000001504; UNII-Q6C979R91Y; HSDB 7665; ANX-530; SDP-012; 5'-Noranhydrovinblastine; VINORELBINE [MI]; VINORELBINE [HSDB]; VINORELBINE [VANDF]; SCHEMBL4765; VINORELBINE [WHO-DD]; CHEMBL553025; GTPL7105; DTXSID8040640; VINORELBINE [ORANGE BOOK]; HMS2090E13; AKOS024457606; CCG-208616; DB00361; NSC 760087; NCGC00165966-03; methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; FT-0657343; 4-DEOXY-3,4-DIDEHYDROVINCALEUKOBLASTINE; D08680; AB01275493-01; AB01566877_01; EN300-19767066; SR-05000001504-1; SR-05000001504-2; VINORELBINE TARTRATE IMPURITY J [EP IMPURITY]; ASPIDOSPERMIDINE-3-CARBOXYLIC ACID, 4-(ACETYLOXY)-6,7-DIDEHYDRO-15-((2R,6R,8S)-4-ETHYL-1,3,6,7,8,9-HEXAHYDRO-8-(METHOXYCARBONYL)-2,6-METHANO-2H-AZECINO(4,3-B)INDOL-8-YL)-3-HYDROXY-16-METHOXY-1-METHYL-, METHYL ESTER, (2.BETA.,3.BETA.,4.BETA.,5.ALPHA.,12R,19.ALPHA.)-; Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12beta,19alpha)-; Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12R,19alpha)-; methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0^{3,11}.0^{4,9}]octadeca-3(11),4(9),5,7,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2,4,6,13-tetraene-10-carboxylate; methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate	Approved	Approved Drug(s)	5311497	DB00361	D01HTL	778.9	134	1690	3.6	57	2	11	10	C45H54N4O8	methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate	CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC	CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC	InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1	GBABOYUKABKIAF-IELIFDKJSA-N
DJ2G8Z	Vinblastine	Small molecule	vinblastine; 865-21-4; Vincaleucoblastin; Vincaleukoblastine; Vinblastina; Velban; Velbe; Vinblastinum; Vinblastin; CHEMBL159; 5V9KLZ54CY; Vincoblastine; Rozevin; (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; Nincaluicolflastine; NSC-47842; Vinblastina [DCIT]; Vinblastine [INN:BAN]; methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate; Vinblastinum [INN-Latin]; VR-8; VLB; CCRIS 9002; VINBLASTINE [INN]; HSDB 3263; NCI-C04842; NDC 0002-1452-01; EINECS 212-734-0; NSC 47842; UNII-5V9KLZ54CY; cid_5388983; 2'-Epivinblastine; [3H]-Vinblastine; 1z2b; VINBLASTINE [MI]; (2'R)-Vincaleukoblastine; VINBLASTINE [HSDB]; VINBLASTINE [VANDF]; SCHEMBL3628; BIDD:PXR0201; BSPBio_001228; VINBLASTINE [WHO-DD]; (3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid, 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-, methyl ester, (3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-; GTPL6851; 132142-72-4; 72401-36-6; methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((5S,7R,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate; BDBM50012278; NSC816570; AKOS015965500; CS-1336; DB00570; NSC-816570; NCGC00022585-04; NCGC00022585-05; NCGC00485975-02; AC-24191; AS-15821; HY-17418; EN300-19874057; VINDESINE SULFATE IMPURITY B [EP IMPURITY]; VINCRISTINE SULFATE IMPURITY H [EP IMPURITY]; BRD-K01188359-001-02-0; BRD-K01188359-065-02-5; (2ALPHA,2''''BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca-4(12),5(10),6,8-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2,4,6,13-tetraene-10-carboxylate	Approved	Approved Drug(s)	13342	DB00570	D0W9MM	811	154	1700	3.7	59	3	12	10	C46H58N4O9	methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate	CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O	CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O	InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1	JXLYSJRDGCGARV-CFWMRBGOSA-N
D5N1BK	Leucovorin	Small molecule	folinic acid; leucovorin; 5-Formyltetrahydrofolic acid; 58-05-9; Folinic acid-SF; Welcovorin; Acide folinique; 5-Formyl-5,6,7,8-tetrahydrofolic acid; folinate; N5-Formyltetrahydrofolic acid; Leucal; N5-Formyl-5,6,7,8-tetrahydrofolic acid; Q573I9DVLP; 5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid; 5-formyltetrahydrofolate; 10-Formyl-7,8-dihydrofolic acid; CHEBI:15640; (5-formyl-5,6,7,8-tetrahydropteroyl)glutamate; L-Glutamic acid, N-(4-(((2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-; HSDB 6544; N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid; Leucoverin; 1492-18-8; [3H]folinic acid; NSC3590; Leucovorinum (acid); Leucovorin [USAN]; CHEMBL69905; UNII-Q573I9DVLP; 5-Formyl-tetrahydrofolate; Leucovorinum; 5-Formyltetrahydropteroylglutamic acid; Citrovoeum factor; EINECS 200-361-6; L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid; L-(+)-Folinic acid; Spectrum_000859; Prestwick0_000738; Prestwick1_000738; Prestwick2_000738; Prestwick3_000738; Spectrum2_000116; Spectrum3_000479; Spectrum4_000031; Spectrum5_000910; LEUCOVORIN [HSDB]; LEUCOVORIN [VANDF]; FOLINIC ACID [MI]; SCHEMBL8349; CHEMBL1679; 5-formyltetrahydro-folic acid; BSPBio_000696; BSPBio_002218; KBioGR_000461; KBioSS_001339; DivK1c_000222; FOLINIC ACID [MART.]; SPBio_000132; SPBio_002635; FOLINIC ACID [WHO-DD]; BPBio1_000766; GTPL4816; GTPL6690; DTXSID0048216; SCHEMBL10068238; KBio1_000222; KBio2_001339; KBio2_003907; KBio2_006475; KBio3_001438; NINDS_000222; DW385; BDBM50039121; MFCD00867488; s5790; AKOS015961207; DB00650; IDI1_000222; AC-13429; HY-17556; SBI-0051427.P003; SD-204098; D93089; EN300-27068710; BRD-A75919782-238-01-8; Q45435667; (2S)-2-(4-((2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methylamino)benzamido)pentanedioic acid; (2S)-2-[(4-{[(2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid; (2S)-2-[(4-{[(2-amino-5-formyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid; (2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; (S)-2-{4-[(2-Amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydro-pteridin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid; 2-{4-[(2-Amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydro-pteridin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid; Glutamic acid, N-(p-(((2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-, L-; L-Glutamic acid, N-[4-[[(2-amino-5-formyl-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-; N-(P-((((6RS)-2-AMINO-5-FORMYL-5,6,7,8-TETRAHYDRO-4-HYDROXY-6-PTERIDINYL)METHYL)AMINO)BENZOYL)-L-GLUTAMATE; N-[4-({[2-amino-5-formyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid; N-[4-[[(2-Amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6(RS)-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid	Approved	Approved Drug(s)	135403648	DB00650	D0R4PS	473.4	216	911	-1.2	34	7	10	9	C20H23N7O7	(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid	C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O	C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O	InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12?,13-/m0/s1	VVIAGPKUTFNRDU-ABLWVSNPSA-N
D6BRZ9	Dacarbazine	Small molecule	dacarbazine; 4342-03-4; DTIC; DTIC-Dome; Deticene; Biocarbazine; Biocarbazine R; Decarbazine; ICDMT; Dacarbazinum; Imidazole carboxamide; NSC-45388; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; NSC45388; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; ICDT; Dacarbasine; Dicarbazine; Di-me-triazenoimidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; NSC 45388; DTIE; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; NCI-C04717; Dacarbazinum [INN-Latin]; Dacarbazino [INN-Spanish]; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; Dtic-Dome (TN); 4-(Dimethyltriazeno)imidazole-5-carboxamide; 7GR28W0FJI; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; NCI C04717; Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)-; NCGC00091861-01; 1H-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-; DTXCID20369; 5-(dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; HSDB 3219; 4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide; Dacarbazino; 5-[(1E)-dimethyltriaz-1-en-1-yl]-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; CAS-4342-03-4; SR-05000001598; MFCD00057167; DTXSID0020369; CCRIS 190; Dacarbazine (JAN/USP/INN); 5-(Dimethyltriazeno)imidazole-4-carboximide; (E)-Dacarbazine; Dimethyltriazenoimidazolecarboxamide; 750512-03-9; EINECS 224-396-1; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; AI3-52825; DACARBAZINE [MI]; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; DACARBAZINE [INN]; DACARBAZINE [JAN]; Dacarbazine (DTIC-Dome); DACARBAZINE [HSDB]; DACARBAZINE [IARC]; DACARBAZINE [USAN]; CHEMBL476; UNII-7GR28W0FJI; DACARBAZINE [VANDF]; SCHEMBL5560; SCHEMBL5561; DACARBAZINE [MART.]; DACARBAZINE [USP-RS]; DACARBAZINE [WHO-DD]; DACARBAZINE [WHO-IP]; SPECTRUM1500218; SCHEMBL1014331; Carboxamide, 5-(3,3-dimethyl-1-triazeno)imidazole-4-; CHEBI:94587; HMS501A08; DACARBAZINE [ORANGE BOOK]; Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-; CHEBI:177836; BDBM233149; DACARBAZINE [EP MONOGRAPH]; HMS2090A20; HMS2091I20; Pharmakon1600-01500218; DACARBAZINE [USP MONOGRAPH]; DACARBAZINUM [WHO-IP LATIN]; HY-B0078; Tox21_111171; Tox21_201010; CCG-35381; CCG-36068; CCG-40272; NSC759610; NSC799994; s1221; WLN: T5M CNJ DVZ ENUNN1&1; AKOS005220502; AKOS015850745; AKOS026750028; Tox21_111171_1; CS-1772; DB00851; KS-5186; NSC-759610; NSC-799994; Dacarbazine [USAN:USP:INN:BAN:JAN]; NCGC00091861-02; NCGC00091861-03; NCGC00091861-04; NCGC00091861-05; NCGC00091861-07; NCGC00188955-01; NCGC00258563-01; SBI-0051328.P003; C06936; Carboxamide,3-dimethyl-1-triazeno)imidazole-4-; D00288; EN300-7357020; Imidazole-4-carboxamide,3-dimethyl-1-triazeno)-; A826278; SR-05000001598-1; SR-05000001598-3; W-106228; 1H-Imidazole-4-carboxamide,3-dimethyl-1-triazenyl)-; 4-[(E)-dimethylaminoazo]-1H-imidazole-5-carboxamide; BRD-K35520305-001-04-5; BRD-K35520305-001-07-8; (5E)-5-(dimethylaminohydrazono)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazono)imidazole-4-carboxamide; 5- (3,3-Dimethyl-1-triazenyl) imidazole-4-carboxamide; Imidazole-4(or 5)-carboxamide,3-dimethyl-1-triazeno)-; Z2289761610; 5-(3,3-Dimethyltriaz-1-enyl)-1H-imidazole-4-carboxamide; 5-[(E)-dimethylaminodiazenyl]-1H-imidazole-4-carboxamide; Dacarbazine, British Pharmacopoeia (BP) Reference Standard; Dacarbazine, European Pharmacopoeia (EP) Reference Standard; (5E)-5-(dimethylaminohydrazinylidene)-4-imidazolecarboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or  4)-carboxamide; Dacarbazine, United States Pharmacopeia (USP) Reference Standard; Dacarbazine, Pharmaceutical Secondary Standard; Certified Reference Material	Approved	Approved Drug(s)	135398738	DB00851	D0Y7ZU	182.18	99.7	215	-0.6	13	2	5	3	C6H10N6O	4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide	CN(C)N=NC1=C(NC=N1)C(=O)N	CN(C)/N=N/C1=C(NC=N1)C(=O)N	InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+	FDKXTQMXEQVLRF-ZHACJKMWSA-N
DDB7X9	Azacitidine	Small molecule	5-azacytidine; Azacitidine; 320-67-2; Ladakamycin; Azacytidine; Vidaza; Mylosar; 5-azacitidine; Azacitidinum; Azacitidina; Azacitidinum [INN-Latin]; 5-AZAC; Azacitidina [INN-Spanish]; C8H12N4O5; NSC-102816; U-18496; Onureg; NSC 102816; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; NSC102816; 5AzaC; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; Antibiotic U 18496; 4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one; CHEBI:2038; M801H13NRU; DTXSID9020116; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; U-18,496; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one; WR-183027; NCGC00090851-04; U 18496; DTXCID10116; 1,3,5-Triazin-2(1H)-one, 4-amino-1-.beta.-D-ribofuranosyl-; MFCD00006539; CCRIS 60; SMR000857239; Vidaza (TN); HSDB 6879; 5-aza-CR; SR-01000075662; EINECS 206-280-2; Azacitidine;5-AzaC;Ladakamycin; BRN 0620461; UNII-M801H13NRU; Azacitidine (JAN/USAN/INN); Azacitidine [USAN:INN:BAN]; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; NS-17; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one; CAS-320-67-2; Azacitidine (Vidaza); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; Antibiotic U18496; U18496; Spectrum_001262; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; AZACITIDINE [MI]; Spectrum2_000786; Spectrum3_001509; Spectrum4_000922; Spectrum5_001166; AZACITIDINE [INN]; AZACITIDINE [JAN]; AZACITIDINE [HSDB]; AZACITIDINE [IARC]; AZACITIDINE [USAN]; MolMap_000062; 4-Amino-1-.beta.-D-ribofuranosyl-s-triazin-2(1H)-one; A 2385; AZACITIDINE [VANDF]; SCHEMBL3741; AZACITIDINE [MART.]; CHEMBL1489; Azacitidine (5-Azacytidine); Lopac0_000035; AZACITIDINE [USP-RS]; AZACITIDINE [WHO-DD]; BSPBio_003157; KBioGR_001444; KBioGR_002556; KBioSS_001742; KBioSS_002565; MLS001333121; MLS001333122; MLS002153249; MLS002548894; DivK1c_000125; SPECTRUM1502111; SPBio_000892; AZACITIDINE [EMA EPAR]; GTPL6796; s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-; BCBcMAP01_000083; HMS500G07; KBio1_000125; KBio2_001742; KBio2_002556; KBio2_004310; KBio2_005124; KBio2_006878; KBio2_007692; KBio3_002657; KBio3_003034; NMUSYJAQQFHJEW-KVTDHHQDSA-; AZACITIDINE [ORANGE BOOK]; pyrimidine antimetabolite: inhibits nucleic acid replication; cMAP_000082; NINDS_000125; HMS1921J22; HMS2092D08; HMS2231F15; HMS3259D19; HMS3260G11; Pharmakon1600-01502111; 5-Azacytidine, >=98% (HPLC); Tox21_111032; Tox21_302985; Tox21_500035; BDBM50424715; CCG-39046; HB1374; NSC758186; s1782; Onureg (CC-486; oral azacitidine); AKOS015896938; Tox21_111032_1; AM83944; CS-1287; DB00928; LP00035; NC00672; NSC-758186; NSC103-627; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; IDI1_000125; NCGC00090851-01; NCGC00090851-02; NCGC00090851-03; NCGC00090851-05; NCGC00090851-06; NCGC00090851-07; NCGC00090851-08; NCGC00090851-10; NCGC00090851-14; NCGC00090851-22; NCGC00178234-01; NCGC00256541-01; NCGC00260720-01; AS-13697; HY-10586; SRI-10756_10; SRI-10756_12; WR183027; DB-006955; SL-000003; EU-0100035; D03021; EN300-118700; F10504; A821115; Q416451; J-700085; SR-01000075662-1; SR-01000075662-3; SR-01000075662-7; BRD-K03406345-001-02-1; BRD-K03406345-001-27-8; 4-Amino-1-?-D-ribofuranosyl-1,3,5-triazin-2(1H)-one; Z1515383340; 4-Amino-1-(bet.-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-tr iazin-2(1H)-one; Azacitidine, United States Pharmacopeia (USP) Reference Standard; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Ladakamycin; Azacitidine, Pharmaceutical Secondary Standard; Certified Reference Material; 1401238-97-8; 5-Azacytidine, Hybri-Max(TM), gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma; 5AE; 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-1,3,5-triazin-3-ium-2-one	Approved	Approved Drug(s)	9444	DB00928	D09FAZ	244.2	141	384	-2.2	17	4	5	2	C8H12N4O5	4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one	C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N	C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N	InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1	NMUSYJAQQFHJEW-KVTDHHQDSA-N
DICZ61	Cytarabine	Small molecule	cytarabine; 147-94-4; Ara-C; Cytosine arabinoside; Arabinocytidine; Aracytin; Depocyt; Cytosar-U; Aracytine; Tarabine; Udicil; 1-beta-D-Arabinofuranosylcytosine; Arabinofuranosylcytosine; Aracytidine; DepoCyte; Cytarabinoside; Cytosar; arabinocytosine; Cytarabinum; Arabinosylcytosine; Cytarabin; Cytosine beta-D-arabinofuranoside; Spongocytidine; Cytosinearabinoside; 4-Amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; Citarabina; Alexan; beta-D-Arabinosylcytosine; Cytarabinum [INN-Latin]; Citarabina [INN-Spanish]; AraC; Cytosine beta-D-arabinoside; Arabitin; Cytarabina; Arafcyt; Erpalfa; Iretin; Cytosine-1-beta-D-arabinofuranoside; 1beta-D-Arabinosylcytosine; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; Cytosine arabinose; 1beta-Arabinofuranasylcytosine; Cytosine 1-beta-D-arabinofuranoside; cytarabine liposome; 1beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; U 19920A; Cytosine-beta-D-arabinofuranoside; Cytosine arabinofuranoside; Depocyt (liposomal); 1-Arabinofuranosylcytosine; U-19,920; 1-beta-D-Arabinosylcytosine; Arabinoside C; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one; CHEMBL803; U-19920; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one; C9H13N3O5; 2(1H)-Pyrimidinone, 4-amino-1-.beta.-D-arabinofuranosyl-; AR3; Cytonal; DTXSID3022877; CHEBI:28680; CHX 3311; 04079A1RDZ; 1-beta-D-arabinofuranosyl-cytosine; CCRIS 913; beta-Ara C; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; NSC-287459; Cytosine, 1-beta-D-arabinosyl-; HSDB 3049; (beta-D-Arabinofuranosyl)cytosine; NCGC00093356-03; 2(1H)-Pyrimidinone, 4-amino-1-y-D-arabinofuranosyl- [CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; MFCD00066487; Cytosine, 1-beta-D-arabinofuranosyl-; NSC 287459; AC-1075; AI3-52329; Cytosine arabinoside (VAN); 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-; DTXCID702877; beta-Arabinosylcytosine; Beta-cytosine arabinoside; Cytosine-beta-arabinoside; 69-74-9; Ara-Cytidine; cytarabine liposome injection; Arabinosyl Cytosine; Cytosine, beta-D-arabinoside; CAS-147-94-4; SMR000449317; Depocyt (TN); Cytosine b-D-arabinofuranoside; EINECS 205-705-9; 1-(arabinofuranosyl)cytosine; Cytartbine; UNII-04079A1RDZ; 1-beta-arabinofuranosylcytosine; 1-.beta.-D-Arabinofuranosylcytosine; SR-01000075773; NSC287459; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 1-.beta.-D-arabinofuranosyl-cytosine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; Cytarabine [USAN:USP:INN:BAN:JAN]; MK 8242; beta -arabinosylcytosine; CYTARABINE [MI]; CYTARABINE [INN]; CYTARABINE [JAN]; CYTARABINE [HSDB]; CYTARABINE [USAN]; beta -cytosine arabinoside; beta -D-arabinosylcytosine; Cytosine-beta -arabinoside; CYTARABINE [VANDF]; CYTARABINE [MART.]; SCHEMBL3140; 1beta -D-Arabinosylcytosine; CYTARABINE [USP-RS]; CYTARABINE [WHO-DD]; CYTARABINE [WHO-IP]; BIDD:PXR0139; Lopac0_000316; MLS000758310; MLS001066340; MLS001424023; 1-beta-D-Arabinosyl-Cytosine; BIDD:GT0371; CYTARABINE [EMA EPAR]; Cytosine, beta -D-arabinoside; 1beta -Arabinofuranasylcytosine; Cytarabine (JP17/USP/INN); GTPL4827; 1-ss-D-Arabinofuranosylcytosine; CYTARABINE [ORANGE BOOK]; SCHEMBL22591193; SCHEMBL23152019; 1beta -D-Arabinofuranosylcytosine; CYTARABINE [EP MONOGRAPH]; CYTARABINE [USP IMPURITY]; Cytosine, 1-beta -D-arabinosyl-; VYXEOS COMPONENT CYTARABINE; 1-beta -d-arabinofuranosylcytosine; 1-beta-D-arabinofuranosyl cytosine; CYTARABINE [USP MONOGRAPH]; Cytosine-beta -D-arabinofuranoside; HMS2051K19; HMS2090A18; HMS2230M16; HMS3713N12; 1-beta -D-Arabinofaranosylcytosine; CYTARABINE LIPOSOME [VANDF]; CYTARABINUM [WHO-IP LATIN]; BCP02876; Tox21_111203; Tox21_301971; BDBM50087289; CCG-51297; s1648; (non-labelled)Cytarabine-13C-15N2; AKOS007930145; AKOS015896896; AM84428; Cytosine, 1-beta -D-arabinofuranosyl-; DB00987; KS-5063; NC00070; SDCCGSBI-0050304.P002; NCGC00093356-04; NCGC00093356-05; NCGC00093356-06; NCGC00093356-19; NCGC00142483-02; NCGC00255381-01; BA164339; HY-13605; SRI-10828-19; SRI-10828-20; SRI-10828_24; SL-000002; C2035; SW197450-5; C02961; D00168; EN300-118320; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; ARA-C; A808710; Q180983; SR-01000721860; J-520199; J-700005; J-700166; SR-01000075773-3; SR-01000075773-5; SR-01000721860-6; 1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl; BRD-K33106058-001-07-7; BRD-K33106058-003-20-6; 2(1H)-Pyrimidinone, 4-amino-1beta -D-arabinofuranosyl-; Cytosine -D-arabinofuranoside;Cytosine Arabinoside;Ara-C; Z1511499171; 2(1H)-Pyrimidinone, 4-amino-1-beta -D-arabinofuranosyl-; Cytarabine, European Pharmacopoeia (EP) Reference Standard; Cytarabine, United States Pharmacopeia (USP) Reference Standard; Cytosine beta-D-arabinofuranoside, crystalline, >=90% (HPLC); Cytosine beta-D-arabinofuranoside, Vetec(TM) reagent grade, 90%; Cytarabine, Pharmaceutical Secondary Standard; Certified Reference Material; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; Cytosine -D-arabinofuranoside hydrochloride;Cytosine Arabinoside hydrochloride;Ara-C hydrochloride	Approved	Approved Drug(s)	6253	DB00987	D07XSN	243.22	129	383	-2.1	17	4	5	2	C9H13N3O5	4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one	C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O	C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O	InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1	UHDGCWIWMRVCDJ-CCXZUQQUSA-N
DVK0W6	Melphalan	Small molecule	melphalan; 148-82-3; Alkeran; Melfalan; L-PAM; Phenylalanine mustard; L-Sarcolysine; L-Phenylalanine mustard; L-Sarcolysin; p-L-Sarcolysin; Melphalanum; Melfalano; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; Phenylalanine nitrogen mustard; Levofalan; p-Di-(2-chloroethyl)amino-L-phenylalanine; CB 3025; NCI-C04853; Levopholan; Levofolan; p-Bis(beta-chloroethyl)aminophenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; L-Sarkolysin; p-N-Bis(2-chloroethyl)amino-L-phenylalanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; Alanine Nitrogen Mustard; CB-3025; SK 15673; SK-15673; Sarcolycin, l-; NSC-8806; Evomela; L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-; CHEBI:28876; p-N,N-bis(2-chloroethyl)amino-L-phenylalanine; CHEMBL852; ALKERAN (TN); Rcra waste number U150; DTXSID6020804; Q41OR9510P; Alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-, L-; Alanine, 3-[p-[bis(2-chloroethyl)amino]phenyl]-, L-; NSC-241286; 8057-25-8; NCGC00090757-02; (2S)-2-azaniumyl-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate; L-Phenylalanine, 4-[bis(2-chloroethyl)amino]-; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; DTXCID00804; Phenylalanine, 4-[bis(2-chloroethyl)amino]-; (S)-2-amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; (2S)-2-amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoic acid; (S)-2-Amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid; NSC8806; CAS-148-82-3; SMR000058720; CCRIS 374; HSDB 3234; EINECS 205-726-3; RCRA waste no. U150; NSC 241286; BRN 2816456; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; Phelinun; UNII-Q41OR9510P; NSC241286; Melphalan, powder; Prestwick_1006; Melphalan [USAN:USP:INN:BAN:JAN]; Spectrum_000397; MELPHALAN [INN]; MELPHALAN [JAN]; MELPHALAN [MI]; 3025 C.B.; MELPHALAN [HSDB]; MELPHALAN [IARC]; MELPHALAN [USAN]; Spectrum2_000074; Spectrum3_000684; Spectrum4_000882; Spectrum5_001601; MELPHALAN [VANDF]; DL-Melphalan hydrochloride; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; Epitope ID:141802; MELPHALAN [MART.]; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine; MELPHALAN [WHO-DD]; SCHEMBL5872; BSPBio_002407; KBioGR_001284; KBioSS_000877; 1217854-43-7; 4-14-00-01689 (Beilstein Handbook Reference); MLS001333666; MLS002153368; BIDD:GT0044; DivK1c_000653; SPECTRUM1500382; SPBio_000287; Melphalan (JP17/USP/INN); GTPL7620; MELPHALAN [ORANGE BOOK]; MELPHALAN [EP MONOGRAPH]; NIOSH/AY3360000; HMS502A15; KBio1_000653; KBio2_000877; KBio2_003445; KBio2_006013; KBio3_001627; L-phenylalanine mustard (L-PAM); MELPHALAN [USP MONOGRAPH]; NINDS_000653; HMS2090B09; HMS2091B16; HMS2235D21; Pharmakon1600-01500382; Tox21_111010; Tox21_202522; BDBM50025837; CCG-39704; DL-442; MFCD00057717; NSC757098; s8266; AKOS015895374; Tox21_111010_1; CS-3120; DB01042; NSC-757098; IDI1_000653; Phenylalanine,4-[bis(2-chloroethyl)amino]-, hydrochloride (1:1); SMP2_000174; NCGC00090757-01; NCGC00090757-03; NCGC00090757-04; NCGC00090757-05; NCGC00090757-06; NCGC00260071-01; AS-13314; HY-17575; SBI-0052787.P003; AY33600000; 4-[bis(2-chloroethyl)-amino]-L-phenylalanine; 4-[bis(2-chloroethyl)-amino]-l-phenyl-alanine; 4-[bis(2-chloroethyl)amino]-(L)-phenylalanine; C07122; D00369; AB00053282-07; AB00053282-08; AB00053282_09; EN300-7479343; A808810; Alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-; SR-05000001667; Q2298283; SR-05000001667-1; W-108096; BRD-K87827419-001-02-8; 2-amino-3-[4-bis(2-chloroethyl)amino]phenylpropanoic acid; (2S)-2-azanyl-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; 2-Amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid; 2-Amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid(L-PAM); 2-Amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid (Melphalan); 2-Amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid(Melphalan)	Approved	Approved Drug(s)	460612	DB01042	D00FGO	305.2	66.6	265	-0.5	19	2	4	8	C13H18Cl2N2O2	(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid	C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl	C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl	InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1	SGDBTWWWUNNDEQ-LBPRGKRZSA-N
DF96HE	Bicalutamide	Small molecule	bicalutamide; 90357-06-5; Casodex; Bicalutamide (CDX); Calutide; ICI 176334; ICI-176334; N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; ICI 176,334; C18H14F4N2O4S; Cosudex; A0Z3NAU9DP; CHEMBL409; NSC-759816; DTXSID2022678; N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide; ICI176,334-1; Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-; DTXCID00209197; Raffolutil; Kalumid; SMR000466329; Casodex (TN); CAS-90357-06-5; SR-01000759410; 1217769-79-3; 1217826-87-3; UNII-A0Z3NAU9DP; BRN 5364666; Bicalutamine; Bicalutamide (JAN/USP/INN); Propanamide,; CCRIS 8728; HSDB 7655; NCGC00167487-01; Bicalutamide [USAN:USP:INN:BAN]; MFCD00869971; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; KS-1161; Bicalutamide (Casodex); Bicalutamide - Casodex; CPD000466329; BICALUTAMIDE [MI]; BICALUTAMIDE [INN]; BICALUTAMIDE [JAN]; BICALUTAMIDE [HSDB]; BICALUTAMIDE [USAN]; SCHEMBL3611; BICALUTAMIDE [VANDF]; BICALUTAMIDE [MART.]; MLS000759437; MLS001424047; Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-; S-(+)-Bicalutamide-[d4]; BICALUTAMIDE [USP-RS]; BICALUTAMIDE [WHO-DD]; GTPL2863; BDBM18525; CHEBI:91617; EX-A962; CHEBI:144093; BCPP000337; BICALUTAMIDE [ORANGE BOOK]; HMS2051B13; HMS2089N12; HMS2232H03; HMS3263M13; HMS3372K05; HMS3393B13; HMS3654K18; HMS3714P13; Pharmakon1600-01504827; BICALUTAMIDE [EP MONOGRAPH]; BICALUTAMIDE [USP IMPURITY]; ACT06291; AMY33430; BCP02110; BICALUTAMIDE [USP MONOGRAPH]; Tox21_112488; Tox21_303560; Tox21_501026; NSC722665; NSC759816; s1190; AKOS015895073; AC-4232; BCP9000408; CCG-100951; CCG-220876; CCG-222330; CS-1296; DB01128; LP01026; NC00201; NSC 759816; NSC-722665; SB17301; SDCCGSBI-0633779.P001; N-(4-cyano-3-(trifluoromethyl)phenyl); NCGC00167977-01; NCGC00167977-02; NCGC00167977-03; NCGC00167977-09; NCGC00167977-20; NCGC00257459-01; NCGC00261711-01; HY-14249; DB-041165; B3206; FT-0618286; FT-0631069; FT-0663100; SW197581-4; Bicalutamide (CDX), >=98% (HPLC), powder; C08160; D00961; AB00639963-06; AB00639963-08; AB00639963-09; AB00639963_10; EN300-1715981; A803039; A843528; Q1988832; SR-01000759410-4; SR-01000759410-5; BRD-A29485665-001-03-7; Z2108698963; Bicalutamide, British Pharmacopoeia (BP) Reference Standard; Bicalutamide, European Pharmacopoeia (EP) Reference Standard; Bicalutamide, United States Pharmacopeia (USP) Reference Standard; 4'-cyano-3-[(4- fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide; 4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide; Bicalutamide for system suitability, European Pharmacopoeia (EP) Reference Standard; Bicalutamide, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-4'-CYANO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-3-((P-FLUOROPHENYL)SULFONYL)-2-METHYL-M-LACTOTOLUIDIDE; N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-N-phenylpropanamide; N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorobenzenesulfonyl)-2-hydroxy-2-methylpropanamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-methyl-2-oxidanyl-propanamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorobenzene)sulfonyl]-2-hydroxy-2-methylpropanamide; N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropionamide; N-[4-cyano-3-trifluoromethyl-phenyl]-3-[4-fluorophenyl-sulfonyl]-2-hydroxy-2-methyl-propionamide; PROPANAMIDE, N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-3-((4-FLUOROPHENYL)SULFONYL)-2-HYDROXY-2-METHYL-, (+/-)-	Approved	Approved Drug(s)	2375	DB01128	D0V9BD	430.4	116	750	2.3	29	2	9	5	C18H14F4N2O4S	N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide	CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O	CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O	InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)	LKJPYSCBVHEWIU-UHFFFAOYSA-N
DN8A5Q	Kanamycin	Small molecule	kanamycin; KANAMYCIN A; 59-01-8; Kanamycin sulfate; Kanamycin Base; Kanamicina; Kanamycine; 8063-07-8; KanamycinA; CHEBI:17630; Kanamycin A monosulfate; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; EQK9Q303C5; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; KAN; Kanamycinum; Kanamicina [Italian]; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycine [INN-French]; Kanamycinum [INN-Latin]; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-3-{[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}oxane-3,4,5-triol; 2-(aminomethyl)-6-[4,6-diamino-3-[4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; HSDB 3107; EINECS 200-411-7; BRN 0061647; UNII-EQK9Q303C5; Kanamycins; Kanamycin,(S); Liposomal Kanamycin; (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]tetrahydropyran-3,4,5-triol; Amikacin EP Impurity D; Prestwick3_000394; Kantrex (1:1 sulfate); Klebcil (1:1 sulfate); KANAMYCIN A [MI]; KANAMYCIN A [HSDB]; SCHEMBL2735; CHEMBL1384; Glucopyranoside, 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-, D-; BSPBio_000607; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1,4))-2-deoxy-; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-2-deoxy-; DivK1c_000024; KANAMYCIN A [WHO-IP]; BPBio1_000669; DTXSID3023184; GTPL12132; KBio1_000024; NINDS_000024; BDBM50031282; AKOS025293505; DB01172; IDI1_000024; SMP2_000007; NCGC00179506-01; NCGC00179506-05; AS-14003; D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1.fwdarw.6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1.fwdarw.4)]-2-deoxy-; HY-16566; AB00513827; CS-0006792; C01822; K-0250; EN300-19735925; BRD-K08327065-065-01-9; Q27094615; Kanamycin sulfate, Antibiotic for Culture Media Use Only; (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-((1R,2R,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-2-hydroxycyclohexyloxy)tetrahydro-2H-pyran-3,4,5-triol; D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-2-DEOXY-; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.4))-2-deoxy-; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine	Approved	Approved Drug(s)	6032	DB01172	D0YV1Q	484.5	283	638	-6.9	33	11	15	6	C18H36N4O11	(2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol	C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)O)O)OC3C(C(C(C(O3)CO)O)N)O)N	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N	InChI=1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1	SBUJHOSQTJFQJX-NOAMYHISSA-N
DQBK97	Idarubicin	Small molecule	IDARUBICIN; 58957-92-9; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; Idarubicine; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Idarubicina [INN-Spanish]; Idarubicin (INN); NSC 256439; ZRP63D75JW; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; Idarubicina; CHEBI:42068; 5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)-; Idarubicinum; IDARUBICIN [INN]; Idarubicin [INN:BAN]; Idarubicinhydrochloride; (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,9,11-trihydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; DM5; MLS001401448; Daunomycin, 4-demethoxy-; NSC256439; (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; Zavedos (TN); CCRIS 5083; NCGC00093976-03; SMR000466355; UNII-ZRP63D75JW; 4-DMD; SR-01000075934; IDARUBICIN [MI]; IDARUBICIN [VANDF]; I 1656; SCHEMBL3750; CHEMBL1117; IDARUBICIN [WHO-DD]; Lopac0_000600; KBioSS_002388; Idarubicin hydrochloride, solid; cid_636362; GTPL7083; 4-DEMETHOXY-DAUNORUBICIN; DTXSID7023142; IDARUBICIN(Hydrochloride form); BDBM58490; BCPP000207; HMS2089D05; HMS3261H22; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; Tox21_500600; HY-17381A; AKOS015895563; AC-9384; BCP9000773; CCG-204689; DB01177; LP00600; SDCCGSBI-0050582.P002; NCGC00093976-01; NCGC00093976-02; NCGC00093976-04; NCGC00093976-05; NCGC00093976-18; NCGC00261285-01; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-, (7S-cis)-; CS-0007534; EU-0100600; D08062; AB00698511-06; AB00698511-08; AB00698511-09; AB00698511-10; AB00698511_11; EN300-7479233; A832088; A935911; Q1063862; SR-01000075934-1; BRD-K69650333-001-01-1; BRD-K69650333-001-02-9; BRD-K69650333-003-14-0; Idarubicin, United States Pharmacopeia (USP) Reference Standard; (1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE; (7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-9-ethanoyl-6,9,11-tris(oxidanyl)-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-9-ethanoyl-6,9,11-tris(oxidanyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (7S,9S)-9-Acetyl-7-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (7S,9S)-9-acetyl-7-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride; (7S,9S)-9-acetyl-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-, (7S-cis)-; 5,12-NAPHTHACENEDIONE, 9-ACETYL-7-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,9,11-TRIHYDROXY-, (7S,9S)-	Approved	Approved Drug(s)	42890	DB01177	D01XDL	497.5	177	912	1.9	36	5	10	3	C26H27NO9	(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione	CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O	InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1	XDXDZDZNSLXDNA-TZNDIEGXSA-N
DK3T1U	Lapatinib 	Small molecule	Lapatinib; 231277-92-2; Lapatinib Ditosylate; Tykerb; GW572016; GW 572016; Lapatinib [INN]; Lapatinib base; Tyverb; 388082-78-8; Lapatinib (INN); Lapatinib free base; N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; Lapatinib (free base); 231277-92-2 (free base); GSK572016; FMM; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine; CHEMBL554; GW-572016; DTXSID7046675; CHEBI:49603; 0VUA21238F; NSC745750; GSK-572016; GW-572016X; 1210608-87-9; NCGC00167507-01; DTXCID5026675; 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-; 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-; N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine; n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine; GSK 572016; CAS-231277-92-2; GW-2016; Lapatinib [INN:BAN]; MFCD09264194; GW 282974X; C29H26ClFN4O4S; UNII-0VUA21238F; HSDB 8209; 1xkk; N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; Lapatinib, Free base; nchembio866-comp20; Kinome_3684; Kinome_3685; Lapatinib base- Bio-X; LAPATINIB [MI]; LAPATINIB [VANDF]; LAPATINIB [WHO-DD]; SCHEMBL8100; Lapatinib (GW572016); LAPATINIB [EMA EPAR]; BDBM5445; cid_208908; GTPL5692; EX-A402; BCPP000188; BCPP000189; HMS2089H10; HMS3244N06; HMS3244N10; HMS3244N14; HMS3744K11; Tykerb (TN) (Glaxo Smith Kline); BCP01874; Tox21_112505; NSC800780; AKOS005145766; Tox21_112505_1; AC-1314; BCP9000837; BCP9000838; CCG-270133; DB01259; NSC-745750; NSC-800780; SB16918; NCGC00167507-02; NCGC00167507-03; NCGC00167507-04; NCGC00167507-09; 913989-15-8; AS-14065; BC164610; HY-50898; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; AM20090641; FT-0659650; L0360; SW199101-5; A25184; D08108; EN300-117254; AB01273965-01; AB01273965-02; AB01273965-03; AB01273965_04; AB01273965_05; Q420323; Q-101353; SR-05000001472-1; BRD-K19687926-001-01-7; BRD-K19687926-379-02-5; GW572016;GW-572016;GW 572016; 1092929-10-6; GW-2016;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl] quinazolin-4-amine; N-{3-chloro-4-[(3-fluoro-benzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N3-Chloro-4-(3-fluorophenyl)methoxyphenyl-6-5-(2-methylsulfonylethylamino)methyl-2-furylquinazolin-4-amine	Approved	Approved Drug(s)	208908	DB01259	D08CDI	581.1	115	898	5.1	40	2	9	11	C29H26ClFN4O4S	N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl	InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)	BCFGMOOMADDAQU-UHFFFAOYSA-N
DV29CU	Decitabine	Small molecule	Decitabine; 5-Aza-2'-deoxycytidine; 2353-33-5; Dacogen; 2'-Deoxy-5-azacytidine; 5-Azadeoxycytidine; AzadC; 5-aza-CdR; 5-aza-dC; Dezocitidine; NSC 127716; Dac; 5-Aza-deoxycytidine; Alpha-Decitibine; 4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one; NSC-127716; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5A2dc; C8H12N4O4; 5-aza-2-deoxycytidine; MFCD00043011; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; MLS001332587; DTXSID7030432; CHEBI:50131; 776B62CQ27; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one; SMR000857076; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one; 4-amino-1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; DTXCID5010432; 5-AZAdC; NSC127716; 2-deoxyazacytidine; Dacogen (TN); CAS-2353-33-5; 2-Desoxy-5-azacytidine; NCGC_5ADOC; Decitabine (USAN/INN); Decitabine [USAN:INN:BAN]; CCRIS 8227; UNII-776B62CQ27; 5-Aza-2'-deoxycytidine;NSC 127716; NCGC00166088-01; 22432-95-7; Decitabine- Bio-X; deoxy-5-azacytidine; EINECS 219-089-4; BRN 0617982; Decitabine, Free Base; JNJ 30979754; JNJ-30979754; DECITABINE [MI]; DECITABINE [INN]; DECITABINE [USAN]; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; DECITABINE [VANDF]; MolMap_000063; E-7373; DECITABINE [MART.]; SCHEMBL4006; DECITABINE [WHO-DD]; MLS001332588; MLS006010136; ASTX-727; cid_451668; GTPL6805; CHEMBL1201129; DECITABINE [ORANGE BOOK]; BDBM96274; EX-A961; INQOVI COMPONENT DECITABINE; HMS2235O03; HMS3413L07; HMS3677L07; 105597-46-4; 4-Amino-1-((2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one; ACT00147; AMY33354; BCP02870; HY-A0004; 5-Aza-2'-deoxycytidine, >=97%; Tox21_112311; ASTX727 COMPONENT DECITABINE; HB1356; s1200; 5-aza-2'-deoxycytidine (Decitabine); DECITABINE COMPONENT OF INQOVI; 4-Amino-1-(2-deoxy-?-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; AKOS015895047; ASTX-727 COMPONENT DECITABINE; Inqovi  (decitabine +  cedazuridine); Tox21_112311_1; AC-1135; BCP9000593; CCG-208143; CS-0372; DB01262; 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-; ASTX727 (decitabine +  cedazuridine); Decitabine (NSC127716; 5AZA-CdR); NCGC00166088-02; NCGC00166088-05; AS-17558; BA164359; BCP0726000271; DB-029060; SW218076-2; D03665; EN300-269341; AB00918337-07; AB00918337_08; SR-01000838879; J-700084; Q1181878; SR-01000838879-4; Z2467077030; decitabine (2 inverted exclamation marka-deoxy-5-azacytidine).cd; s-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-; 1,3, 5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy--D-erythro-pentofuranosyl)-; 4-AMINO-1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-S-TRIAZIN-2(1H)-ONE; 4-Amino-1-(2-deoxy-beta-D-erythro-pento furanosyl)-1,3,5-triazin-2(1H)-one	Approved	Approved Drug(s)	451668	DB01262	D0X5XU	228.21	121	356	-1.2	16	3	4	2	C8H12N4O4	4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one	C1C(C(OC1N2C=NC(=NC2=O)N)CO)O	C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O	InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1	XAUDJQYHKZQPEU-KVQBGUIXSA-N
DS6W7Q	Ixabepilone	Small molecule	Ixabepilone; Azaepothilone B; 219989-84-1; Ixempra; BMS-247550; Ixempra kit; Aza-epothilone B; BMS 247550-1; BMS 247550-01; NSC-747973; CHEBI:63605; BMS-247550-01; K27005NP0A; NSC747973; BMS 247550; 17-oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-((1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-, (1S,3S,7S,10R,11S,12S,16R)-; 1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-((1E)-1-methyl-2-(2-methylthiazol-4-yl)ethenyl)-17-oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione; Ixabepilone [INN]; (1~{S},3~{S},7~{S},10~{R},11~{S},12~{S},16~{R})-8,8,10,12,16-pentamethyl-3-[(~{E})-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-7,11-bis(oxidanyl)-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione; Ixempra (TN); (1R,5S,6S,7R,10S,14S,16S)-6,10-DIHYDROXY-1,5,7,9,9-PENTAMETHYL-14-((E)-1-(2-METHYL-1,3-THIAZOL-4-YL)PROP-1-EN-2-YL)-17-OXA-13-AZABICYCLO(14.1.0)HEPTADECANE-8,12-DIONE; (1R,5S,6S,7R,10S,14S,16S)-6,10-dihydroxy-1,5,7,9,9-pentamethyl-14-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-13-azabicyclo[14.1.0]heptadecane-8,12-dione; Ixempra (TM); 16-Aza-epothilone B; IXABEPILONE [MI]; IXABEPILONE [JAN]; IXABEPILONE [HSDB]; IXABEPILONE [USAN]; IXABEPILONE [VANDF]; SCHEMBL8386; IXABEPILONE [MART.]; IXABEPILONE [USP-RS]; IXABEPILONE [WHO-DD]; UNII-K27005NP0A; Ixabepilone (JAN/USAN/INN); Ixabepilone [USAN:INN:JAN]; GTPL6824; SCHEMBL1890345; Ixabepilone (BMS-247550); CHEMBL1201752; CHEBI:95095; HSDB 7738; DTXSID70870252; IXABEPILONE [ORANGE BOOK]; IXABEPILONE [USP MONOGRAPH]; EX-A1245; BDBM50564768; MFCD04307791; s7930; AKOS025401600; CCG-269752; CS-0551; DB04845; NSC 747973; NSC-710428; NCGC00378665-02; AC-22618; HY-10222; D04645; AB01273979-01; Azaepothilone B;BMS 247550;BMS 247550-1; SR-01000941577; J-014409; SR-01000941577-1; Q11711607; (1r,5s,6s,7r,10s,14s,16s)-6,10-dihydroxy-1,5,7,9,9-pentamethyl-14-[[e]-1-(2-methyl-1,3-thiazol-4-yl]prop-1-en-2-yl)-17-oxa-13-azabicyclo(14,1,0)heptadecane-8,12-dione; (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione; (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione; 7-Oxa-4-azabicyclo[14.1.0]heptadecane -5, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)-; GZX	Approved	Approved Drug(s)	6445540	DB04845	D0W2EK	506.7	140	817	3.6	35	3	7	2	C27H42N2O5S	(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione	CC1CCCC2(C(O2)CC(NC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C	C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](NC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)C)/C)C	InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1	FABUFPQFXZVHFB-PVYNADRNSA-N
DS4YD5	Vismodegib	Small molecule	Vismodegib; 879085-55-9; GDC-0449; Erivedge; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide; Vismodegib (GDC-0449); HhAntag691; GDC0449; GDC 0449; NSC-747691; NSC-755986; 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide; CHEMBL473417; CHEBI:66903; 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide; 25X868M3DS; NSC755986; 2-chloro-n-[4-chloro-3-(pyridin-2-yl)phenyl]-4-methanesulfonylbenzamide; 2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide; 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide; 2-chloro-N-(4-chloro-3-pyridin-2-yl-phenyl)-4-methanesulfonyl-benzamide; Benzamide, 2-chloro-N-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-; 2-Chloranyl-~{n}-(4-Chloranyl-3-Pyridin-2-Yl-Phenyl)-4-Methylsulfonyl-Benzamide; GDC-0449 (Vismodegib); Erivedge (TN); Vismodegib [USAN]; Vismodegib [USAN:INN]; NSC 747691; vismodegibum; UNII-25X868M3DS; HSDB 8130; R 3616; VIS; NSC747691; Hh-Antag691; HhAntag 691; Vismodegib, free base; RG 3616; RG-3616; methanesulfonylbenzamide; VISMODEGIB [MI]; VISMODEGIB [INN]; Vismodegib (USAN/INN); VISMODEGIB [VANDF]; Vismodegib; GDC-0449; R-3616; VISMODEGIB [WHO-DD]; GDC-0449 - Selumetinib; MLS006012035; SCHEMBL302587; GTPL6975; VISMODEGIB [ORANGE BOOK]; CUR-691; DTXSID40236689; GDC-449; BCPP000223; HMS3604K16; HMS3654E17; BCP01715; EX-A2178; BDBM50249522; MFCD12407408; NSC755809; s1082; GDC-0449,Vismodegib, HhAntag691; 2-Chloro-N-(4-chloro-3-(pyridin-2-yl)-phenyl)-4-(methylsulfonyl)benzamide; AKOS015966534; BCP9000713; CCG-264811; CS-0255; DB08828; NSC-755809; PB15086; NCGC00242497-01; NCGC00242497-02; NCGC00242497-06; NCGC00242497-12; AC-26969; AS-14066; HY-10440; SMR004703564; FT-0675833; SW218087-2; EC-000.2333; D09992; V-4050; AB01565813_02; EN300-7413185; SR-01000941574; 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-; J-509076; Q2070286; SR-01000941574-1; 2-Chloro-N-(4-chloro-3-(2-pyridl)phenyl)-4-(methylsulfonyl)benzamide; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methyl sulfonyl)benzamide; 2-chloro-N~1~-[4-chloro-3-(2-pyridyl)phenyl]-4-(methylsulfonyl)benzamide; 2-CHLORO-N-(4-CHLORO-3-PYRIDIN-2-YL)PHENYL)-4-(METHYLSULFONYL)BENZAMIDE; 2-CHLORO-N-[4-CHLORO-3-(2-PYRIDINYL)PHENYL]-4-(METHYLSULFONYL)-BENZAMIDE	Approved	Approved Drug(s)	24776445	DB08828	D03EDQ	421.3	84.5	625	3.8	27	1	4	4	C19H14Cl2N2O3S	2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide	CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl	CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl	InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)	BPQMGSKTAYIVFO-UHFFFAOYSA-N
D31OCV	Benzalkonium	Small molecule	Benzalkonium; 47309-59-1; Benzyldimethyltridecylammonium; N-Benzyl-N,N-dimethyltridecan-1-aminium; benzyl-dimethyl-tridecylazanium; SPBio_001472; Benzalkonium ion; Benzalkonium cation; Spectrum_001442; Spectrum2_001566; Spectrum3_001597; Spectrum4_000861; Spectrum5_001097; Benzyldimethyltridecylaminium; BSPBio_003194; KBioGR_001521; KBioSS_001922; DivK1c_000825; SCHEMBL7125738; CHEMBL1187417; KBio1_000825; KBio2_001922; KBio2_004490; KBio2_007058; KBio3_002694; CHEBI:188978; NINDS_000825; IDI1_000825; QTL1_000011; NCGC00178214-01; NCGC00178214-02; NCGC00178214-04; SBI-0051833.P002; FT-0622628; AB00053823_02	Approved	Approved Drug(s)	2330	DB11105	.	318.6	0	253	7.9	23	0	0	14	C22H40N+	benzyl-dimethyl-tridecylazanium	CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1	CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1	InChI=1S/C22H40N/c1-4-5-6-7-8-9-10-11-12-13-17-20-23(2,3)21-22-18-15-14-16-19-22/h14-16,18-19H,4-13,17,20-21H2,1-3H3/q+1	VVZBFOKBSDGVGZ-UHFFFAOYSA-N
D8U5SI	Curcumin	Small molecule	curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Indian saffron; Kacha haldi; Curcuma; Gelbwurz; Haldar; Curcumin I; Souchet; Haidr; Halad; Halud; Terra Merita; Yellow Ginger; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Safran d'Inde; C.I. Natural Yellow 3; Yo-Kin; Golden seal; Curcumine; Hydrastis; Yellow puccoon; Diferaloylmethane; Kurkumin [Czech]; Tumeric yellow; 8024-37-1; CI Natural Yellow 3; C.I. 75300; Zlut prirodni 3 [Czech]; Cucurmin; Curcumin (synthetic); Tumeric oleoresin; 94875-80-6; E 100; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Curcurmin; CI 75300; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; NSC32982; MFCD00008365; NSC 32982; CHEBI:3962; MLS000069631; NSC-32982; 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione; CHEMBL140; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-; SMR000058237; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-; IT942ZTH98; DTXSID8031077; (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; NSC687842; NSC-687842; NCGC00017159-05; Kurkumin; (1E,6E)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione; (1E,6E)-1,7-bis[4-hydroxy-3-(methyloxy)phenyl]hepta-1,6-diene-3,5-dione; Zlut prirodni 3; DTXCID901421; CAS-458-37-7; FEMA No. 3085; FEMA No. 3086; CCRIS 3257; CCRIS 5804; HSDB 4334; 1,5-Di(vanillyliden)acetylaceton; NCI-C61325; SR-01000000149; 1,5-Divanillyliden-2,4-pentandion; EINECS 207-280-5; NSC 687842; BRN 2306965; UNII-IT942ZTH98; E 100 (Dye); Curcumin,(S); (E/Z)-Curcumin; trans,trans-Curcumin; starbld0017234; CURCUMIN [HSDB]; CURCUMIN [INCI]; CURCUMIN [MI]; Opera_ID_1627; CURCUMIN [MART.]; CURCUMIN [USP-RS]; CURCUMIN [WHO-DD]; SCHEMBL8440; SCHEMBL8441; Curcumin, analytical standard; 4-08-00-03697 (Beilstein Handbook Reference); MLS001148449; BIDD:ER0479; CU-01000001305-2; cid_969516; GTPL7000; SCHEMBL13521974; SCHEMBL23884885; SCHEMBL23884886; SCHEMBL23884892; SCHEMBL23884893; BDBM29532; cid_5281767; cMAP_000052; CI 75300 [INCI]; HMS2233K04; HMS3649K06; 2,7-Nonadiene-4,6-dione, 1,9-bis(4-hydroxy-3-methoxyphenyl)-; 91884-86-5; AMY33436; BCP04695; Tox21_110803; Tox21_111505; Tox21_201116; BBL027711; BDBM50067040; BDBM50140172; CCG-36020; CCG-36107; STL371943; AKOS001305497; BCP9000557; DB11672; NCGC00017159-04; NCGC00017159-06; NCGC00017159-07; NCGC00017159-09; NCGC00017159-10; NCGC00017159-11; NCGC00017159-12; NCGC00023332-03; NCGC00023332-04; NCGC00023332-05; NCGC00258668-01; AC-24238; AS-72202; BP-25396; BCP0726000035; DB-002681; WLN: 1OR BQ E1U1V1V1U1R DQ CO1; C-230; C2302; CS-0149275; 1,3-Di(3-methoxy-4-hydroxystyryl)propanedial; EN300-21494; F21478; K00009; Curcumin, Curcuma longa L. - CAS 458-37-7; A826902; Curcumin, primary pharmaceutical reference standard; Q312266; 1,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; SR-01000000149-2; SR-01000000149-5; BRD-K07572174-001-02-2; BRD-K07572174-001-19-6; BRD-K07572174-001-22-0; Z104500108; Curcumin, >=94% (curcuminoid content), >=80% (Curcumin); 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione; 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadiene-3,5-dione; Curcumin, matrix substance for MALDI-MS, >=99.5% (HPLC); Curcumin, United States Pharmacopeia (USP) Reference Standard; 1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); (1E,6E)-1,7-bis(3-methoxy-4-oxidanyl-phenyl)hepta-1,6-diene-3,5-dione; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione #; (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione.; (1E,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; (1Z,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, (E,E)-; 1,7-BIS-(4-HYDROXY-3-METHOXYPHENYL)-HEPTA-1,6-DIENE-3,5-DIONE; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one; 5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; (1E,4Z,6E)-5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one	Approved	Approved Drug(s)	969516	DB11672	D07SDQ	368.4	93.1	507	3.2	27	2	6	8	C21H20O6	(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione	COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O	COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O	InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+	VFLDPWHFBUODDF-FCXRPNKRSA-N
DB0CL6	Alpha1-proteinase inhibitor	Protein	.	Approved	Approved Drug(s)	.	DB00058	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DLF94V	Synthetic conjugated estrogens, A	Protein	.	Approved	Approved Drug(s)	.	DB09317	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D1SHJ9	Tebentafusp	Protein	.	Approved	Approved Drug(s)	.	DB15283	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DRU1F4	Interferon alpha-2b	Protein	.	Approved	Approved Drug(s)	.	DB00105	D00EFO	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DTX7M2	Nitroprusside	Protein	.	Approved	Approved Drug(s)	.	DB00325	D00PLV	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D18LGH	Romiplostim	Protein	.	Approved	Approved Drug(s)	.	DB05332	D01PZD	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DIXK81	Dulaglutide	Protein	.	Approved	Approved Drug(s)	.	DB09045	D03NAW	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DS85LC	Follitropin	Protein	.	Approved	Approved Drug(s)	.	DB00066	D05HAJ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D41EAQ	Cerliponase alfa	Protein	.	Approved	Approved Drug(s)	.	DB13173	D06CAS	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DH36JU	Pegloticase	Protein	.	Approved	Approved Drug(s)	.	DB09208	D06ZIT	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DLK8Z5	Alglucosidase alfa	Protein	.	Approved	Approved Drug(s)	.	DB01272	D07DUU	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DBFR86	Rasburicase	Protein	.	Approved	Approved Drug(s)	.	DB00049	D08LJP	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D3JX5L	Peginterferon alfa-2b	Protein	.	Approved	Approved Drug(s)	.	DB00022	D08NWC	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D0JHL8	Pancrelipase	Protein	.	Approved	Approved Drug(s)	.	DB00085	D0A5DJ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D6B2JO	Filgrastim	Protein	.	Approved	Approved Drug(s)	.	DB00099	D0AT8C	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D3GWR1	Calaspargase pegol	Protein	.	Approved	Approved Drug(s)	.	DB14730	D0C9DA	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DLO32V	Sebelipase alfa	Protein	.	Approved	Approved Drug(s)	.	DB11563	D0CH4A	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DX1Y8Z	Interferon beta-1b	Protein	.	Approved	Approved Drug(s)	.	DB00068	D0CQ2O	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DEH2O7	Alglucerase	Protein	.	Approved	Approved Drug(s)	.	DB00088	D0D4HM	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D3N1IL	Pegvisomant	Protein	.	Approved	Approved Drug(s)	.	DB00082	D0D6VE	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DO6D1M	Abatacept	Protein	.	Approved	Approved Drug(s)	.	DB01281	D0EW4L	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DF9EQ3	Velaglucerase alfa	Protein	.	Approved	Approved Drug(s)	.	DB06720	D0G5ET	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D0ULA5	Taliglucerase alfa	Protein	.	Approved	Approved Drug(s)	.	DB08876	D0G6HA	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DWAK54	Etanercept	Protein	.	Approved	Approved Drug(s)	.	DB00005	D0I5QX	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DUMV30	Denileukin diftitox	Protein	.	Approved	Approved Drug(s)	.	DB00004	D0J3RY	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DZK19M	Bacitracin	Protein	.	Approved	Approved Drug(s)	.	DB00626	D0M1IO	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DM9CI7	Imiglucerase	Protein	.	Approved	Approved Drug(s)	.	DB00053	D0QW9H	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D54XRY	Oprelvekin	Protein	.	Approved	Approved Drug(s)	.	DB00038	D0T1IJ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DF83ZO	Andexanet alfa	Protein	.	Approved	Approved Drug(s)	.	DB14562	D0T4MK	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DN2X1T	Desmopressin	Protein	.	Approved	Approved Drug(s)	.	DB00035	D0U7SH	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DOUN83	Choriogonadotropin alfa	Protein	.	Approved	Approved Drug(s)	.	DB00097	D0W6SS	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DGU87Q	Sargramostim	Protein	.	Approved	Approved Drug(s)	.	DB00020	D0XT5Y	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DAJH64	Peginterferon alfa-2a	Protein	.	Approved	Approved Drug(s)	.	DB00008	D0Y8OK	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D6Q7KT	Interferon gamma	Protein	.	Approved	Approved Drug(s)	.	DB15753	D0Z1KC	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DD87PE	Lutropin alfa	Protein	.	Approved	Approved Drug(s)	.	DB00044	D0Z2CM	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DW3QM0	Metreleptin	Protein	.	Approved	Approved Drug(s)	.	DB09046	D0Z9EO	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DVTO07	Asparaginase Escherichia coli	Protein	.	Approved	Approved Drug(s)	.	DB00023	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DBPA23	Natalizumab	Antibody	.	Approved	Approved Drug(s)	.	DB00108	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9IGV3	Aducanumab	Antibody	.	Approved	Approved Drug(s)	.	DB12274	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DM4J9E	Lecanemab	Antibody	.	Approved	Approved Drug(s)	.	DB14580	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D2PL6Q	Teclistamab	Antibody	.	Approved	Approved Drug(s)	.	DB16655	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DTJ8R2	Ibritumomab tiuxetan	Antibody	.	Approved	Approved Drug(s)	.	DB00078	D01TVQ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DG74DX	Margetuximab	Antibody	.	Approved	Approved Drug(s)	.	DB14967	D01YYP	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D5V8FZ	Alemtuzumab	Antibody	.	Approved	Approved Drug(s)	.	DB00087	D01ZYG	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D3LVD0	Omalizumab	Antibody	.	Approved	Approved Drug(s)	.	DB00043	D02GEC	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DMYA92	Mepolizumab	Antibody	.	Approved	Approved Drug(s)	.	DB06612	D03EOF	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DE6TY2	Brentuximab vedotin	Antibody	.	Approved	Approved Drug(s)	.	DB08870	D03TIS	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D1B6CU	Ravulizumab	Antibody	.	Approved	Approved Drug(s)	.	DB11580	D04FOP	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DNE3R2	Trastuzumab	Antibody	.	Approved	Approved Drug(s)	.	DB00072	D04WFL	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D67YJR	Polatuzumab vedotin	Antibody	.	Approved	Approved Drug(s)	.	DB12240	D05QOL	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D6XC4K	Fam-Trastuzumab deruxtecan	Antibody	.	Approved	Approved Drug(s)	.	DB14962	D06BHB	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9ZN6H	Gemtuzumab ozogamicin	Antibody	.	Approved	Approved Drug(s)	.	DB00056	D06EWO	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DWK90Q	Pembrolizumab	Antibody	.	Approved	Approved Drug(s)	.	DB09037	D08ANZ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DUO7J6	Eculizumab	Antibody	.	Approved	Approved Drug(s)	.	DB01257	D08SPH	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D70RZS	Denosumab	Antibody	.	Approved	Approved Drug(s)	.	DB06643	D08WSY	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D70CXH	Ramucirumab	Antibody	.	Approved	Approved Drug(s)	.	DB05578	D09HVD	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DA0Q2N	Olaratumab	Antibody	.	Approved	Approved Drug(s)	.	DB06043	D09QZS	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D97EFT	Ustekinumab	Antibody	.	Approved	Approved Drug(s)	.	DB05679	D0A2UV	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D97YBO	Tisotumab vedotin	Antibody	.	Approved	Approved Drug(s)	.	DB16732	D0A4GQ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DA6WG2	Idarucizumab	Antibody	.	Approved	Approved Drug(s)	.	DB09264	D0B9FW	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DHMY23	Pertuzumab	Antibody	.	Approved	Approved Drug(s)	.	DB06366	D0CI4E	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D3WS2P	Burosumab	Antibody	.	Approved	Approved Drug(s)	.	DB14012	D0DJ9D	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D2SAQ6	Ibalizumab	Antibody	.	Approved	Approved Drug(s)	.	DB12698	D0E7AD	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D8I7NC	Bevacizumab	Antibody	.	Approved	Approved Drug(s)	.	DB00112	D0FX3U	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DY50IT	Naxitamab	Antibody	.	Approved	Approved Drug(s)	.	DB15965	D0HI5D	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9YUT7	Panitumumab	Antibody	.	Approved	Approved Drug(s)	.	DB01269	D0HU9H	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DWN49Q	Tositumomab and iodine I 131 tositumomab	Antibody	.	Approved	Approved Drug(s)	.	DB00081	D0I2AV	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D58YCD	Ipilimumab	Antibody	.	Approved	Approved Drug(s)	.	DB06186	D0J2AJ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DPW9S4	Nivolumab	Antibody	.	Approved	Approved Drug(s)	.	DB09035	D0J2AJ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D8J0GN	Tremelimumab	Antibody	.	Approved	Approved Drug(s)	.	DB11771	D0J6DQ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DD9W8J	Isatuximab	Antibody	.	Approved	Approved Drug(s)	.	DB14811	D0JB2J	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D69EXI	Blinatumomab	Antibody	.	Approved	Approved Drug(s)	.	DB09052	D0K4RK	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DLE51P	Avelumab	Antibody	.	Approved	Approved Drug(s)	.	DB11945	D0K7SX	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DKG42T	Infliximab	Antibody	.	Approved	Approved Drug(s)	.	DB00065	D0KC1H	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DTVH39	Adalimumab	Antibody	.	Approved	Approved Drug(s)	.	DB00051	D0KC1N	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9K2IH	Cemiplimab	Antibody	.	Approved	Approved Drug(s)	.	DB14707	D0KG4Q	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DIV91X	Durvalumab	Antibody	.	Approved	Approved Drug(s)	.	DB11714	D0LS9E	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DBW13Z	Satralizumab	Antibody	.	Approved	Approved Drug(s)	.	DB15762	D0MD0T	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DH7JB4	Cetuximab	Antibody	.	Approved	Approved Drug(s)	.	DB00002	D0N5OV	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D85NSK	Efgartigimod alfa	Antibody	.	Approved	Approved Drug(s)	.	DB15270	D0P0LD	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D35DZJ	Retifanlimab	Antibody	.	Approved	Approved Drug(s)	.	DB15766	D0PG5O	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D59EKN	Secukinumab	Antibody	.	Approved	Approved Drug(s)	.	DB09029	D0Q0OD	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DEX71H	Tafasitamab	Antibody	.	Approved	Approved Drug(s)	.	DB15044	D0R3PY	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D67SHM	Tocilizumab	Antibody	.	Approved	Approved Drug(s)	.	DB06273	D0R8WT	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DIR19L	Daratumumab	Antibody	.	Approved	Approved Drug(s)	.	DB09331	D0RV4P	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DB4N9D	Ado-Trastuzumab emtansine	Antibody	.	Approved	Approved Drug(s)	.	DB05773	D0UG0K	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D0X3RC	Inebilizumab	Antibody	.	Approved	Approved Drug(s)	.	DB12530	D0XH3V	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DI5A0R	Ofatumumab	Antibody	.	Approved	Approved Drug(s)	.	DB06650	D0Y8ZN	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DE62LI	Atezolizumab	Antibody	.	Approved	Approved Drug(s)	.	DB11595	D0YM2K	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D4E2HW	Rituximab	Antibody	.	Approved	Approved Drug(s)	.	DB00073	D0YM7U	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D30CMJ	Mosunetuzumab	Antibody	.	Approved	Approved Drug(s)	.	DB15434	D2HDB8	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DV4YN0	Belantamab mafodotin	Antibody	.	Approved	Approved Drug(s)	.	DB15719	D52NZX	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D40FWP	Loncastuximab tesirine	Antibody	.	Approved	Approved Drug(s)	.	DB16222	D8L5PA	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DC30YO	Sintilimab	Antibody	.	Approved	Approved Drug(s)	.	DB15765	DFLK16	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D2QIG4	Dostarlimab	Antibody	.	Approved	Approved Drug(s)	.	DB15627	DGQU43	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DA4KD9	Enfortumab vedotin	Antibody	.	Approved	Approved Drug(s)	.	DB13007	DORB45	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DT4I8S	Amivantamab	Antibody	.	Approved	Approved Drug(s)	.	DB16695	DQ5X1Z	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR8MS1	Eteplirsen	Antisense oligonucleotide	.	Approved	Approved Drug(s)	.	DB06014	D04AIV	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DFQ14C	Golodirsen	Antisense oligonucleotide	.	Approved	Approved Drug(s)	.	DB15593	D0M6ER	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D6VRA2	Casimersen	Antisense oligonucleotide	.	Approved	Approved Drug(s)	.	DB14984	D0R1GJ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D85NPI	Axicabtagene ciloleucel	CAR T cell therapy	.	Approved	Approved Drug(s)	.	DB13915	D0DK5R	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DFHV26	Tisagenlecleucel	CAR T cell therapy	.	Approved	Approved Drug(s)	.	DB13881	D0IM6T	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D5X7OB	Brexucabtagene autoleucel	CAR T cell therapy	.	Approved	Approved Drug(s)	.	DB15699	D18SHN	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DNY28G	Lumasiran	Small interfering RNA	.	Approved	Approved Drug(s)	.	DB15935	DD1GK8	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D14IZK	Bexsero	Vaccine	Meningococcal Group B Vaccine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D16YQA	Ixiaro	Vaccine	Japanese Encephalitis Vaccine, Inactivated, Adsorbed	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D16ZAV	Menveo	Vaccine	.	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D69UWD	Ynneos	Vaccine	Smallpox and Monkeypox Vaccine, Live, Non replicating	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D8ZP3F	Gardasil 9	Vaccine	Human Papillomavirus 9-valent Vaccine, Recombinant	Approved	Approved Drug(s)	.	.	D0ZK8H	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9MP4T	Recombivax HB	Vaccine	Hepatitis B vaccine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D7RP5C	Kedrab	Vaccine	Rabies Immune Globulin	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DFT21Q	Prevnar 13	Vaccine	Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DK61IR	Vaxneuvance	Vaccine	Pneumococcal 15-valent Conjugate Vaccine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DPJE80	Daptacel	Vaccine	Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DQ3ZA0	Infanrix	Vaccine	Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DQX4M2	Prevnar 20	Vaccine	Pneumococcal 20-valent Conjugate Vaccine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D3KER5	Fluad	Vaccine	.	Approved	Approved Drug(s)	.	.	D0W0DY	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D7RZT4	BioThrax	Vaccine	Anthrax Vaccine Adsorbed	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D8QI0C	IPOL	Vaccine	Poliovirus Vaccine Inactivated	Approved	Approved Drug(s)	.	.	D05EHJ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DGA17D	ACAM2000	Vaccine	Smallpox (Vaccinia) Vaccine, Live	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DJRC34	Fluzone	Vaccine	.	Approved	Approved Drug(s)	.	.	D09LNI	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DQKO51	MenQuadfi	Vaccine	Meningococcal (Groups A, C, Y, W) Conjugate Vaccine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DQZF56	Hiberix	Vaccine	Haemophilus B Conjugate Vaccine (Tetanus Toxoid Conjugate)	Approved	Approved Drug(s)	.	.	D0QF9P	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DRBH61	Afluria	Vaccine	.	Approved	Approved Drug(s)	.	.	D0I3TJ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DTB6A0	RabAvert	Vaccine	Rabies Vaccine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DWY42C	Imovax	Vaccine	Rabies Vaccine	Approved	Approved Drug(s)	.	.	D05EHJ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DXPN13	Adace	Vaccine	Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DZ32WE	Pneumovax 23	Vaccine	Pneumococcal vaccine polyvalent	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DLPM64	Prehevbrio	Vaccine	Hepatitis B Vaccine Recombinant	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DM89OL	Flublok	Vaccine	.	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DRF9Q5	Flucelvax quadrivalent	Vaccine	.	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DS8K1U	Fluad quadrivalent	Vaccine	.	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DY65FH	Flulaval	Vaccine	.	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DZ0K7T	Fluarix	Vaccine	.	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DZ85YK	Audenz	Vaccine	.	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D4U9LJ	YF-Vax	Vaccine	Yellow Fever Vaccine	Approved	Approved Drug(s)	.	DB10805	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D4CQN8	Vaqta	Vaccine	Hepatitis A Vaccine, Inactivated	Approved	Approved Drug(s)	.	DB10989	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D6JTI0	Havrix	Vaccine	Hepatitis A Vaccine	Approved	Approved Drug(s)	.	DB10989	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D7XJ3P	Agriflu	Vaccine	.	Approved	Approved Drug(s)	.	DB11003	D0Q6BH	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DPVJ63	Heplisav-B	Vaccine	Hepatitis B Vaccine	Approved	Approved Drug(s)	.	DB11627	D0H8ZY	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DQAS62	Engerix-B	Vaccine	.	Approved	Approved Drug(s)	.	DB11627	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DIC73J	Andexxa	Vaccine	coagulation factor xa (recombinant), inactivated-zhzo	Approved	Approved Drug(s)	.	DB14711	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9GT2P	Ticovac	Vaccine	Tick-Borne Encephalitis Vaccine	Approved	Approved Drug(s)	.	DB16611	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D02WAO	Epclusa	Combination drug	sofosbuvir; velpatasvir	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D0EH9S	Combivir	Combination drug	lamivudine; zidovudine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D2O4AQ	Symtuza	Combination drug	cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D3NU8J	Orkambi	Combination drug	Ivacaftor and Lumacaftor	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D5D0PE	Moviprep	Combination drug	Ascorbic acid, PEG-3350, potassium chloride, Sodium ascorbate, Sodium chloride, and Sodium sulfate	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D73UXT	Darzalex	Combination drug	Daratumumab and hyaluronidase	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D7SO8P	Symfi	Combination drug	efavirenz; lamivudine; tenofovir disoproxil fumarate	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9C5WN	VAXELIS	Combination drug	Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9VFJ7	Zepatier	Combination drug	elbasvir; grazoprevir	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DA87LW	Evotaz	Combination drug	atazanavir sulfate; cobicistat	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DAE8F3	Truvada	Combination drug	emtricitabine; tenofovir disoproxil fumarate	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DB5NR3	Symdeko	Combination drug	Ivacaftor and Tezacaftor	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DC38OZ	Complera	Combination drug	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DE9XS1	Temixys	Combination drug	lamivudine; tenofovir disoproxil fumarate	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DENJ97	Trikafta	Combination drug	Elexacaftor, Ivacaftor, and Tezacaftor	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DEQ4H5	Orabloc	Combination drug	Articaine and Epinephrine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DEZ32W	Kovanaze	Combination drug	Oxymetazoline and Tetracaine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DI5PF6	Pediazole	Combination drug	Erythromycin and Sulfisoxazole	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DJ82VE	Harvoni	Combination drug	ledipasvir; sofosbuvir	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DJLS54	Bactrim	Combination drug	Sulfamethoxazole and Trimethoprim	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DL9T7O	Biktarvy	Combination drug	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DO84MC	Odefsey	Combination drug	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DP3EQ5	Genvoya	Combination drug	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR14OV	Dovato	Combination drug	dolutegravir sodium; lamivudine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DS79QD	Cimduo	Combination drug	lamivudine; tenofovir disoproxil fumarate	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DV5KM4	Epzicom	Combination drug	abacavir sulfate; lamivudine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DWH81Z	Triumeq	Combination drug	abacavir sulfate; dolutegravir sodium; lamivudine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DXCH37	Atripla	Combination drug	efavirenz; emtricitabine; tenofovir disoproxil fumarate	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DY4BE5	Synera	Combination drug	Lidocaine and Tetracaine	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DYTN87	Stribild	Combination drug	cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DW9X3Y	Amoxicillin-clavulanate	Combination drug	.	Approved	Approved Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DD68NS	Bijuva	Combination drug	Estradiol and Progesterone	Approved	Approved Drug(s)	.	.	D02BAE	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D68VFQ	Descovy	Combination drug	emtricitabine; tenofovir alafenamide fumarate	Approved	Approved Drug(s)	.	.	D0A2CP	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DU13GV	Trizivir	Combination drug	abacavir sulfate; lamivudine; zidovudine	Approved	Approved Drug(s)	.	.	D0A4IJ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D6SMR3	Mavyret	Combination drug	glecaprevir; pibrentasvir	Approved	Approved Drug(s)	.	.	D0C4DH	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D76AUE	Juluca	Combination drug	dolutegravir sodium; rilpivirine hydrochloride	Approved	Approved Drug(s)	.	.	D0CU1O	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9Q8DH	Kaletra	Combination drug	lopinavir; ritonavir	Approved	Approved Drug(s)	.	.	D0J9EI	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D4TF3X	Oraqix	Combination drug	Lidocaine and Prilocaine	Approved	Approved Drug(s)	.	.	D0OH4N	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D7BMU2	Vosevi	Combination drug	sofosbuvir; velpatasvir; voxilaprevir	Approved	Approved Drug(s)	.	.	D0RM5Z	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D0CM8Z	Prezcobix	Combination drug	cobicistat; darunavir	Approved	Approved Drug(s)	.	.	D0V9HC	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D4WBO5	Delstrigo	Combination drug	doravirine; lamivudine; tenofovir disoproxil fumarate	Approved	Approved Drug(s)	.	.	D0WG2R	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D3YH8N	Sodium polystyrene sulfonate	.	.	Approved	Approved Drug(s)	.	DB01344	D0DS5U	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9IO6U	Patiromer	.	.	Approved	Approved Drug(s)	.	DB09263	D0Z2YQ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9QXE4	Daunorubicin	.	BI 2536; 755038-02-9; BI-2536; BI2536; (R)-4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; (R)-BI-2536; 4LJG22T9C6; CHEMBL513909; 4-{[(7r)-8-Cyclopentyl-7-Ethyl-5-Methyl-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxy-N-(1-Methylpiperidin-4-Yl)benzamide; 4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; 4-{[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino}-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; Benzamide, 4-(((7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl)amino)-3-methoxy-N-(1-methyl-4-piperidinyl)-; US8598172, 5; UNII-4LJG22T9C6; R78; MLS006011060; SCHEMBL372489; GTPL5666; BDBM25121; DTXSID20226442; BI 2536 [WHO-DD]; BCPP000342; AMY24180; EX-A2350; MFCD10565924; NSC755983; NSC799359; s1109; BCP9000402; CCG-264824; CS-0071; EX-8611; NSC-755983; NSC-799359; NCGC00253438-01; 4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methyl-4-piperidyl)benzamide; AC-32625; AS-16191; BP-23384; HY-50698; SMR004702852; SW218289-2; A19139; EN300-18167228; BRD-K64890080-001-01-3; Q27075215; ((R)-4-[(8-Cyclopentyl-7-Et-5,6,7,8-tetrahydro-5-Me-6-oxo-2-pteridinyl)amino]-3-methoxy-N-(1-Me-4-piperidinyl)benzamide; (R)-4-((8-CYCLOPENTYL-7-ETHYL-5,6,7,8-TETRAHYDRO-5-METHYL-6-OXO-2-PTERIDINYL)AMINO)-3-METHOXY-N-(1-METHYL-4-PIPERIDINYL)BENZAMIDE; (R)-4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; 4-((R)-8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydro-pteridin-2-ylamino)-3-methoxy-N-(1-methyl-piperidin-4-yl)-benzamide	Approved	Approved Drug(s)	30323	DB00694	D01XWG	521.7	103	816	3.7	38	2	8	7	C28H39N7O3	4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide	CCC1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C	CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C	InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1	XQVVPGYIWAGRNI-JOCHJYFZSA-N
D82OTN	Nitrendipine	.	PHA-767491; 845714-00-3; PHA 767491; 2-pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one; CAY10572; 1,5,6,7-Tetrahydro-2-(4-pyridinyl)-4H-pyrrolo[3,2-c]pyridin-4-one; CAY10572(PHA-767491); 5M2GUN688C; 2-(pyridin-4-yl)-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-one; PHA-767491A; CAY-10572; PHA767491; compound 8 [PMID: 17480064]; 2-Pyridin-4-yl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one; 2-Pyridin-4-yl-1,5,6,7-tetrahydropyrrolo(3,2-C)pyridin-4-one; 1,5,6,7-Tetrahydro-2-(4-pyridinyl)-4H-pyrrolo(3,2-C)pyridin-4-one; 2-Pyridin-4-yl-1,5,6,7-tetrahydro-pyrrolo(3,2-C)pyridin-4-one; 4H-Pyrrolo(3,2-C)pyridin-4-one, 1,5,6,7-tetrahydro-2-(4-pyridinyl)-; Pyrrolopyridinone, 1; Cdc7/Cdk9; Kinome_2973; UNII-5M2GUN688C; JMC502647 Compound 8; MLS006011036; CHEMBL225519; GTPL8763; SCHEMBL4767679; BDBM27344; CHEBI:95058; DTXSID50471069; HMS3229B21; HMS3656P19; HMS3672G07; HMS3742O19; AMY16364; BCP02855; s2742; CCG-266672; CS-1208; SB19465; NCGC00346723-01; AC-32849; HY-13461; SMR004702829; DB-044973; FT-0700494; SW219878-1; A864080; Q27076833; 2-(4-pyridyl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one; 2-(pyridin-4-yl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one; 1,5,6,7-Tetrahydro-2-(4-pyridinyl)-4H-pyrrolo[3,2-c]pyridin-4-one hydrochloride;PHA-767491	Approved	Approved Drug(s)	4507	DB01054	D0A1DH	213.23	57.8	275	0.6	16	2	2	1	C12H11N3O	2-pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one	C1CNC(=O)C2=C1NC(=C2)C3=CC=NC=C3	C1CNC(=O)C2=C1NC(=C2)C3=CC=NC=C3	InChI=1S/C12H11N3O/c16-12-9-7-11(8-1-4-13-5-2-8)15-10(9)3-6-14-12/h1-2,4-5,7,15H,3,6H2,(H,14,16)	DKXHSOUZPMHNIZ-UHFFFAOYSA-N
D14ZIA	Solifenacin	.	WZ8040; 1214265-57-2; WZ-8040; N-(3-((5-chloro-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)thio)phenyl)acrylamide; N-[3-[5-chloro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]sulfanylphenyl]prop-2-enamide; N-[3-[[5-Chloro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]thio]phenyl]-2-propenamide; WZ 8040; SCHEMBL93523; MLS006011280; CHEMBL1643989; DTXSID40659652; HMS3654M16; BCP02320; EX-A4023; s1179; CCG-269557; CS-0171; SB19363; NCGC00346497-01; NCGC00346497-02; AC-32056; HY-12029; MS-28946; SMR004703030; FT-0728045; SW219395-1; A25636; F82898; J-523324; N-[3-({5-Chloro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl}sulfanyl)phenyl]prop-2-enamide	Approved	Approved Drug(s)	154059	DB01591	D0L4YD	481	98.7	640	4.8	33	2	7	7	C24H25ClN6OS	N-[3-[5-chloro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]sulfanylphenyl]prop-2-enamide	CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)SC4=CC=CC(=C4)NC(=O)C=C)Cl	CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)SC4=CC=CC(=C4)NC(=O)C=C)Cl	InChI=1S/C24H25ClN6OS/c1-3-22(32)27-18-5-4-6-20(15-18)33-23-21(25)16-26-24(29-23)28-17-7-9-19(10-8-17)31-13-11-30(2)12-14-31/h3-10,15-16H,1,11-14H2,2H3,(H,27,32)(H,26,28,29)	KIISCIGBPUVZBF-UHFFFAOYSA-N
DP0NH9	Raltitrexed	Small molecule	Raltitrexed; Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694; D-1694; D1694; ICI D1694; ZD-16; CHEBI:5847; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; Raltitrexed (Tomudex); FCB9EGG971; ZD 1694; CHEMBL225071; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; DTXSID0046482; ICI-D-1694; NSC-639186; N-(5-(((3,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thenoyl)-L-glutamic acid; NCGC00229704-01; (2S)-2-[(5-{methyl[(2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)formamido]pentanedioic acid; (S)-2-(5-(Methyl((2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)-methyl)amino)thiophene-2-carboxamido)pentanedioic acid; (S)-2-(5-(methyl((2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid; L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl)-; N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid; DTXCID8026482; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; D16; Tomudex (TN); D 1694; CAS-112887-68-0; UNII-FCB9EGG971; Raltitrexed (JAN/USAN/INN); 1hvy; 2kce; 2tsr; ZN-D1694; KS-5069; ZD1694; Raltitrexed; RALTITREXED [MI]; RALTITREXED [INN]; RALTITREXED [JAN]; RALTITREXED [USAN]; SCHEMBL7438; RALTITREXED [MART.]; RALTITREXED [WHO-DD]; MLS001424225; MLS006010125; Raltitrexed [USAN:INN:BAN]; GTPL7403; BDBM18795; 1i00; HMS2052I03; HMS3715P08; (S)-2-(5-(methyl((2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid; AMY42113; N-(5-(N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid;(S)-2-(5-(Methyl((2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid; Tox21_112237; BDBM50027655; MFCD00864168; NSC639186; s1192; AKOS015894877; AKOS015994729; Tox21_112237_1; CCG-101075; CCG-221273; DB00293; NC00325; NCGC00263534-02; HY-10821; L-Glutamic acid, N-[[5-[[(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-; NCI60_013008; SMR000469217; SMR002529608; BCP0726000267; R0208; SW197705-2; D01064; AB00698356-05; EN300-27032179; SR-01000763351; J-524216; SR-01000763351-3; BRD-K89839824-001-01-2; Q15304877; N-[[5-[[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic acid	Approved outisde USA	Approved Drug(s)	135400182	DB00293	D01KKQ	458.5	177	790	1.4	32	4	9	9	C21H22N4O6S	(2S)-2-[[5-[methyl-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid	CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1	CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)N1	InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1	IVTVGDXNLFLDRM-HNNXBMFYSA-N
D7P9FG	Lumiracoxib	Small molecule	Lumiracoxib; 220991-20-8; Prexige; COX-189; Lumaricoxib; COX 189; COX189; Prexige;COX 189; 2-(2-((2-chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid; CHEMBL404108; DTXSID9049035; CHEBI:73044; {2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid; V91T9204HU; CGS-35189; NCGC00181795-01; Joicela; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid; Benzeneacetic acid, 2-((2-chloro-6-fluorophenyl)amino)-5-methyl-; DTXCID4028961; 2-(2-(2-chloro-6-fluorophenylamino)-5-methylphenyl)acetic acid; 2-{2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid; Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-; CAS-220991-20-8; Lumiracoxib (USAN/INN); lumiracoxibum; 2-[(2-Chloro-6-fluorophenyl)amino]-5-methylphenyl]acetic acid; 2-[2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl]acetic acid; 4llz; 4oty; LUR; Lumiracoxib- Bio-X; Prexige, Lumiracoxib; 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid; 2-(2-(2-chloro-6-fluorophenylamino)-5-methylphenyl)aceticacid; LUMIRACOXIB [MI]; LUMIRACOXIB [INN]; LUMIRACOXIB [USAN]; Lumiracoxib (COX-189); SCHEMBL4479; LUMIRACOXIB [MART.]; LUMIRACOXIB [WHO-DD]; MLS003882594; UNII-V91T9204HU; Lumiracoxib [USAN:INN:BAN]; GTPL2897; HMS3264F19; HMS3651H08; HMS3884J22; (S)-Methyl2,3-dihydroxypropanoate; 2-[2-(2-chloro-6-fluoro-anilino)-5-methyl-phenyl]acetic acid; BCP06134; Tox21_113566; BDBM50207446; s2903; STL239146; AKOS015895138; Tox21_113566_1; AC-1738; CCG-213068; DB01283; KS-1302; SB19319; NCGC00181795-02; NCGC00181795-03; BL164650; HY-13507; SMR002529582; CS-0007130; FT-0601568; SW219769-1; D03714; D71097; AB01563279_01; A815920; EN300-24116087; Q413744; SR-01000930684; J-014493; SR-01000930684-2; 2-(2-((2-chloro-6-fluorophenyl)amino)-5-methylphenyl)aceticacid; 2-[2-[(2-Chloro-6-Fluoro-Phenyl)Amino]-5-Methyl-Phenyl]Acetic Acid	Approved outside USA	Approved Drug(s)	151166	DB01283	D04YMH	293.72	49.3	342	4.2	20	2	4	4	C15H13ClFNO2	2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid	CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O	CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O	InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)	KHPKQFYUPIUARC-UHFFFAOYSA-N
D1NJ9O	Reboxetine	Small molecule	Reboxetine; 71620-89-8; 98769-81-4; Reboxetine [INN]; (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; 105017-38-7; 947S0YZ36I; Reboxetine (INN); Norebox; (2r)-2-[(R)-(2-Ethoxyphenoxy)(Phenyl)methyl]morpholine; Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,R*)-; Reboxitine; Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-; (R)-2-((R)-(2-ethoxyphenoxy)(phenyl)methyl)morpholine; Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-; Reboxetine [INN:BAN]; UNII-947S0YZ36I; R,R-reboxetine; Reboxe- tine; HSDB 7701; Edronax (TN); (R,R)-Reboxetine; 2-[(2-ethoxyphenoxy)-phenyl-methyl]morpholine; REBOXETINE [MI]; REBOXETINE [HSDB]; REBOXETINE [VANDF]; (R,R)-(-)-Reboxetine; REBOXETINE [WHO-DD]; SCHEMBL34533; CHEMBL383921; DTXSID1048257; CHEBI:135342; BDBM388642; DTXSID401315414; BCP12060; AKOS015966368; DB00234; AS-56251; US9944618, Compound ID No. 178; D08472; D95753; AB00920697_06; A837261; EN300-19659906; (+/-)-(2R*)-2-((.ALPHA.R*)-.ALPHA.-(O-ETHOXYPHENOXY)BENZYL)MORPHOLINE; 41X	Approved outside USA	Approved Drug(s)	127151	DB00234	D0N8FQ	313.4	39.7	333	3	23	1	4	6	C19H23NO3	(2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine	CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3	CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3	InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1	CBQGYUDMJHNJBX-RTBURBONSA-N
DT7S9I	Flucloxacillin	Small molecule	Flucloxacillin; FLOXACILLIN; 5250-39-5; Floxapen; flucloxacilina; Flucloxacilline; Flucloxacillinum; Floxacillin [USAN]; flucloxacillin sodium; Flucloxacilina [INN-Spanish]; Flucloxacilline [INN-French]; Flucloxacillinum [INN-Latin]; BRL 2039; 3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin; Flucloxacillin-Sodium; CHEBI:5098; Floxacillin (USAN); Flucloxacillin (INN); Flucloxacillin [INN]; BRL-2039; Floxapen (TN); (2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 43B2M34G2V; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-amido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; Floxacillin sodium anhydrous; Flucloxacillin sodium anhydrous; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,6-[[[3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-,(2S,5R,6R)-; MFIPC; NSC-277175; EINECS 226-051-0; UNII-43B2M34G2V; 6-[3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolecarboxamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Flucloxacillin,(S); FLOXACILLIN [MI]; Epitope ID:117416; SCHEMBL3823; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S(2alpha,5alpha,6beta)); FLUCLOXACILLIN [MART.]; CHEMBL222645; FLUCLOXACILLIN [WHO-DD]; DTXSID8023056; GTPL10910; BRL2039; HY-A0246; BDBM50370590; DB00301; NCGC00485420-01; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido]-2,2-dimethylpenam-3alpha-carboxylic acid; NCI60_002254; CS-0017591; D04196; EN300-19766067; Q1994556; W-105817; BRD-K27871792-001-01-8; Flucloxacillin, Antibiotic for Culture Media Use Only; (2S,5R,6R)-6-(3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 6-(((3-(2-CHLORO-6-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLYL)CARBONYL)AMINO)-3,3-DIMETHYL-7-OXO-, (2S(2.ALPHA.,5.ALPHA.,6.BETA.))	Approved outside USA	Approved Drug(s)	21319	DB00301	D0Q2AT	453.9	138	758	2.6	30	2	8	4	C19H17ClFN3O5S	(2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid	CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O	CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O	InChI=1S/C19H17ClFN3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1	UIOFUWFRIANQPC-JKIFEVAISA-N
D3J2GL	Cyproterone acetate	Small molecule	CYPROTERONE ACETATE; 427-51-0; Androcur; Cyproterone 17-O-acetate; Cyproteroneacetate; Cyproteron acetate; Cyproteron-R acetate; SH 714; Cyprostat; NSC-81430; Cyprosterone acetate; SH-714; SH 80714; 4KM2BN5JHF; Cyproterone 17.alpha.-acetate; MLS000859908; CHEMBL139835; 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-; DTXSID5020366; CHEBI:50743; NSC81430; 6-Chloro-1beta,2beta-dihydro-17-hydroxy-3'H-cyclopropa(1,2)-pregna-1,4,6-triene-3,20-dione acetate; NCGC00091032-03; (1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate; 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1.beta.,2.beta.)-; DTXCID30366; Cyproterone (acetate); 6-chloro-3,20-dioxo-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-dien-17-yl acetate; (2aR,3aS,3bS,3cS,5aS,6R,8aS,8bR)-6-acetyl-10-chloro-3b,5a-dimethyl-2-oxo-2,2a,3,3a,3b,3c,4,5,5a,6,7,8,8a,8b-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-6-yl acetate; SMR000326769; CCRIS 4385; HSDB 3592; SR-01000075755; EINECS 207-048-3; UNII-4KM2BN5JHF; NSC 81430; Cyprostat&reg; cyproterone-acetate; (1?,2?)-17-(Acetyloxy)-6-chloro-1,2-dihydro-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione; 3'H-CYCLOPROPA(1,2)PREGNA-1,4,6-TRIENE-3,20-DIONE, 17-(ACETYLOXY)-6-CHLORO-1,2-DIHYDRO-, (1.BETA.,2.BETA.)-; CAS-427-51-0; MFCD00864671; 2oz7; 6-Chloro-delta-6-1,2alpha-methylene-17alpha-hydroxyprogesterone acetate; 1,2-alpha-Methylene-6-chloro-delta(sup 6)-17-alpha-hydroxyprogesterone acetate; 1,2-alpha-Methylene-6-chloro-pregna-4,6-diene-3,20-dione 17-alpha-acetate; 6-Chloro-1,2-alpha-methylene-6-dehydro-17-alpha-hydroxyprogesterone acetate; 6-Chloro-delta(sup 6)-1,2-alpha-methylene-17-alpha-hydroxyprogesterone acetate; cid_9880; SCHEMBL5936; 1,2-alpha-Methylene-6-chloro-(sup 4,6)-pregnadiene-17-alpha-ol-3,20-dione 17-alpha-acetate; 17-alpha-Acetoxy-6-chloro-1-alpha,2-alpha-methylenepregna-4,6-diene-3,20-dione; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteronacetat [German]; 6-Chloro-1,2-alpha-methylene-17-alpha-hydroxy-delta(sup 6)-progesterone acetate; 6-Chloro-17-hydroxy-1-alpha,2-alpha-methylenepregna-4,6-diene-3,20-dione acetate; Pregna-4,6-diene-3,20-dione, 6-chloro-17-hydroxy-1-alpha,2-alpha-methylene-, acetate; BIDD:PXR0052; Lopac0_000301; MLS001055462; MLS001066353; MLS002207305; MLS006011110; Cyproterone acetate, >=98%; (non-d)Cyproterone acetate-d5; GTPL2865; CYPROTERONE ACETATE [MI]; CYPROTERONE ACETATE [JAN]; Cyproterone acetate Assay Standard; CYPROTERONE ACETATE [HSDB]; CYPROTERONE ACETATE [USAN]; HMS2090A14; HMS2233J06; HMS3260N04; CYPROTERONE ACETATE [MART.]; Tox21_111064; Tox21_201686; Tox21_302941; Tox21_500301; AC-929; BDBM50094569; CYPROTERONE ACETATE [WHO-DD]; DL-368; s2042; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteronacetat; AKOS008901350; AKOS015895238; Tox21_111064_1; CCG-204396; DB04839; LP00301; SDCCGSBI-0050289.P002; NCGC00091032-01; NCGC00091032-04; NCGC00091032-05; NCGC00091032-09; NCGC00091032-12; NCGC00256442-01; NCGC00259235-01; NCGC00260986-01; NCGC00262575-02; Progesterone,2.alpha.-methylene, acetate; (1S,2S,3S,12S,16S,5R,11R,15R)-15-acetyl-9-chloro-2,16-dimethyl-6-oxopentacyclo [9.7.0.0<2,8>.0<3,5>.0<12,16>]octadeca-7,9-dien-15-yl acetate; 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 6-chloro-1-beta,2-beta-dihydro-17-hydroxy-, acetate; 6-Chloro-1-beta,2-beta-dihydro-17-hydroxy-3'H-cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione 17-acetate; CYPROTERONE ACETATE [EP MONOGRAPH]; SMR000686068; Cyproterone acetate for peak identification; Progesterone,2.alpha.-methylene-, acetate; (acetyl-chloro-dimethyl-oxo-[?]yl) acetate; 1,6-diene-3,20-dione 17.alpha.-acetate; C2942; EU-0100301; C 3412; D01368; AB00698312-08; 1,6)-pregnadeine-17.alpha.-3,20-dione acetate; EN300-19765943; Q426185; SR-01000075755-1; SR-01000075755-4; SR-01000075755-6; W-106262; 1,6)-pregnadiene-17.alpha.-ol-3,20-dione acetate; BRD-K41141507-001-16-2; WLN: L F3 E6 D665 IV JU LUTJ A1 E1 RV1 RQ; 17.alpha.-Acetoxy-6-chloro-1.alpha.,6-diene-3,20-dione; 6-Chloro-17-hydroxy-1.alpha.,6-diene-3,20-dione acetate; 1,6)-pregnadiene-17.alpha.-ol-3,20-dione 17alpha-acetate; 6-Chloro-1.beta.,2]pregna-1,4,6-triene-3,20-dione acetate; Cyproterone acetate, European Pharmacopoeia (EP) Reference Standard; 6-chloro-17-acetoxy-1alpha,2alpha-methylene-4,6-pregnadiene-3,20-dione; 1,2.alpha.-Methylene-6-chloro-.delta.(sup 6)-17.alpha.-hydroxyprogesterone acetate; 17alpha-acetoxy-6-chloro-1alpha,2alpha-methylene-4,6-pregnadiene-3,20-dione; 6-Chloro-.delta.(sup 6)-1,2.alpha.-methylene-17.alpha.-hydroxyprogesterone acetate; 6-Chloro-1,2.alpha.-methylene-17.alpha.-hydroxy-.delta.(sup 6)-progesterone acetate; 6-Chloro-1,2.alpha.-methylene-6-dehydro-17.alpha.-hydroxyprogesterone acetate; Cyproterone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard; Pregna-4,20-dione, 6-chloro-17-hydroxy-1.alpha.,2.alpha.-methylene-, acetate; (1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxopentacyclo[9.7.0.0^{2,8}.0^{3,5}.0^{12,16}]octadeca-7,9-dien-15-yl acetate; 3'H-Cyclopropa[1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1.beta.,2.beta.)-; 3'H-Cyclopropa[1,4,6-triene-3,20-dione, 6-chloro-1.beta.,2.beta.-dihydro-17-hydroxy-, acetate; 3'H-Cyclopropa[1,4,6-triene-3,20-dione, 6-chloro-1.beta.,2.beta.-dihydro-17-hydroxy-,acetate; 6-CHLORO-1.BETA.,2.BETA.-DIHYDRO-17-HYDROXY-3'H-CYCLOPROPA(1,2)-PREGNA-1,4,6-TRIENE-3,20-DIONE ACETATE; 6-chloro-3,20-dioxo-1beta,2beta-dihydro-3''H-cyclopropa[1,2]pregna-4,6-dien-17-yl acetate; acetic acid (8R,9S,10S,13S,14S,17R)-17-acetyl-6-(S)-chloro-10,13-dimethyl-3-(R)-oxo-1,2,3,8,9,10,11,12,13,14,15,16,17,20-tetradecahydro-cyclopropa[1,2]cyclopenta[a]phenanthren-17-yl ester	Phase 3	Drugs in Phase 3 Trial	9880	DB04839	.	416.9	60.4	903	3.6	29	0	4	3	C24H29ClO4	[(1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxo-15-pentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dienyl] acetate	CC(=O)C1(CCC2C1(CCC3C2C=C(C4=CC(=O)C5CC5C34C)Cl)C)OC(=O)C	CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C	InChI=1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1	UWFYSQMTEOIJJG-FDTZYFLXSA-N
DL0MJ4	Bitopertin	Small molecule	Bitopertin; 845614-11-1; Paliflutine; RG1678; RO-4917838; RO4917838; RG-1678; R-1678; Q8L6AN59YY; CHEMBL1171829; (S)-(4-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)(5-(methylsulfonyl)-2-((1,1,1-trifluoropropan-2-yl)oxy)phenyl)methanone; RO-4917939; (4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methylsulfonyl-2-(((S)-2,2,2-trifluoro-1-methylethyl)oxy)phenyl)methanone; (S)-(4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-(methanesulfonyl)-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone; [4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-[(2S)-1,1,1-trifluoropropan-2-yl]oxyphenyl]methanone; [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-Methylsulfonyl-2-[((S)-2,2,2-trifluoro-1-methylethyl)oxy]phenyl]methanone; Piperazine, 1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)-4-(5-(methylsulfonyl)-2-((1S)-2,2,2-trifluoro-1-methylethoxy)benzoyl)-; Paliflutine [INN]; Bitopertin [USAN:INN]; UNII-Q8L6AN59YY; RG 1678; METHANONE, (4-(3-FLUORO-5-(TRIFLUOROMETHYL)-2-PYRIDINYL)-1-PIPERAZINYL)(5-(METHYLSULFONYL)-2-((1S)-2,2,2-TRIFLUORO-1-METHYLETHOXY)PHENYL)-; Methanone, [4-[3-fluoro-5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl][5-(methylsulfonyl)-2-[(1S)-2,2,2-trifluoro-1-methylethoxy]phenyl]-; Ro 4917939; BITOPERTIN [INN]; BITOPERTIN [JAN]; Bitopertin (JAN/USAN); BITOPERTIN [USAN]; RO 4917838; R 1678; BITOPERTIN [WHO-DD]; SCHEMBL562490; GTPL7546; DTXSID80233556; HMS3886D08; BDBM50322423; MFCD18251496; s8219; AKOS022185256; BCP9001046; CCG-269972; CS-0939; DB12426; NCGC00379029-01; AC-33092; AS-75194; Bitopertin (RG1678,RO-4917838); HY-10809; Methanone, (4-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)-1-piperazinyl)(5-(methylsulfonyl)-2-((1s)-2,2,2-trifluoro-1-methylethoxy)phenyl)-palmitoyl oligopeptide; Methanone, [4-[3-fluoro-5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl][5-(methylsulfonyl)-2-[(1S)-2; A15021; D10186; Q4918919; (4-(3-FLUORO-5-(TRIFLUOROMETHYL)PYRIDIN-2-YL)PIPERAZIN-1-YL)(5-(METHANESULFONYL)-2-(((2S)-1,1,1-TRIFLUOROPROPAN-2-YL)OXY)PHENYL)METHANONE; (4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone; (S)-4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl]-methanone; 1-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]-4-(5-methanesulfonyl-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzoyl)piperazine	Phase 3	Drugs in Phase 3 Trial	24946690	DB12426	.	543.5	88.2	872	4	36	0	13	5	C21H20F7N3O4S	[4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-[(2S)-1,1,1-trifluoropropan-2-yl]oxyphenyl]methanone	CC(C(F)(F)F)OC1=C(C=C(C=C1)S(=O)(=O)C)C(=O)N2CCN(CC2)C3=C(C=C(C=N3)C(F)(F)F)F	C[C@@H](C(F)(F)F)OC1=C(C=C(C=C1)S(=O)(=O)C)C(=O)N2CCN(CC2)C3=C(C=C(C=N3)C(F)(F)F)F	InChI=1S/C21H20F7N3O4S/c1-12(20(23,24)25)35-17-4-3-14(36(2,33)34)10-15(17)19(32)31-7-5-30(6-8-31)18-16(22)9-13(11-29-18)21(26,27)28/h3-4,9-12H,5-8H2,1-2H3/t12-/m0/s1	YUUGYIUSCYNSQR-LBPRGKRZSA-N
DQW21R	Ziritaxestat	Small molecule	Ziritaxestat; 1628260-79-6; GLPG-1690; GLPG1690; 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile; GLPG-1690(Ziritaxestat); Ziritaxestat [USAN]; CHEMBL3828074; G451990; I02418V13W; G-451990; 2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]-methylamino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile; 5-Thiazolecarbonitrile, 2-((2-ethyl-6-(4-(2-(3-hydroxy-1-azetidinyl)-2-oxoethyl)-1-piperazinyl)-8-methylimidazo(1,2-a)pyridin-3-yl)methylamino)-4-(4-fluorophenyl)-; Ziritaxestatn; 2-[[2-Ethyl-8-Methyl-6-[4-[2-(3-Oxidanylazetidin-1-Yl)-2-Oxidanylidene-Ethyl]piperazin-1-Yl]imidazo[1,2-A]pyridin-3-Yl]-Methyl-Amino]-4-(4-Fluorophenyl)-1,3-Thiazole-5-Carbonitrile; Ziritaxestat (USAN/INN); ZIRITAXESTAT [INN]; Ziritaxestat (GLPG1690); GTPL9561; SCHEMBL16051264; UNII-I02418V13W; BCP20895; EX-A1646; BDBM50187686; MFCD31544330; s8895; WHO 11017; CS-7634; DB15403; SB19736; compound 11 [PMID: 28414242]; AC-36149; HY-101772; J3.652.431F; D11844; A902613; Q23075652; 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;GLPG1690; 42-ETHYL-14-FLUORO-83-HYDROXY-3,48-DIMETHYL-7-OXO-3-AZA-4(3,6)-IMIDAZO(1,2-A)PYRIDINA-5(1,4)-PIPERAZINA-2(4,2)-(1,3)THIAZOLA-8(1)-AZETIDINA-1(1)-BENZENAOCTAPHANE-25-CARBONITRILE	Phase 3	Drugs in Phase 3 Trial	90420193	DB15403	.	588.7	133	995	4.8	42	1	10	7	C30H33FN8O2S	2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]-methylamino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile	CCC1=C(N2C=C(C=C(C2=N1)C)N3CCN(CC3)CC(=O)N4CC(C4)O)N(C)C5=NC(=C(S5)C#N)C6=CC=C(C=C6)F	CCC1=C(N2C=C(C=C(C2=N1)C)N3CCN(CC3)CC(=O)N4CC(C4)O)N(C)C5=NC(=C(S5)C#N)C6=CC=C(C=C6)F	InChI=1S/C30H33FN8O2S/c1-4-24-29(35(3)30-34-27(25(14-32)42-30)20-5-7-21(31)8-6-20)39-15-22(13-19(2)28(39)33-24)37-11-9-36(10-12-37)18-26(41)38-16-23(40)17-38/h5-8,13,15,23,40H,4,9-12,16-18H2,1-3H3	REQQVBGILUTQNN-UHFFFAOYSA-N
DS1M9L	E2609	Small molecule	Elenbecestat; 1388651-30-6; E-2609; E2609; Elenbecestat [INN]; Elenbecestat [USAN]; RXJ96XL94H; N-[3-[(4aS,5R,7aS)-2-amino-5-methyl-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-(difluoromethyl)pyrazine-2-carboxamide; 2-Pyrazinecarboxamide, N-(3-((4aS,5R,7aS)-2-amino-5,7-dihydro-5-methyl-4H-furo(3,4-d)(1,3)thiazin-7a(4ah)-yl)-4-fluorophenyl)-5-(difluoromethyl)-; N-(3-((4aS,5R,7aS)-2-Amino-5-methyl-4a,5-dihydro-4H-furo(3,4-d)(1,3)thiazin-7a(7H)-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide; N-{3-[(4aS,5R,7aS)-2-Amino-5-methyl-4a,5-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(7H)-yl]-4-fluorophenyl}-5-(difluoromethyl)pyrazine-2-carboxamide; Elenbecestat; E2609; Elenbecestat (JAN/USAN); ELENBECESTAT [JAN]; Elenbecestat [USAN:INN]; UNII-RXJ96XL94H; EMAPALUMAB [WHO-DD]; ELENBECESTAT [WHO-DD]; GTPL9818; SCHEMBL2620149; CHEMBL4204869; EX-A3151; BDBM50510823; s8600; DB15391; AC-36887; MS-27836; HY-109055; CS-0031645; E2609E2609; D11509; D87146; E 2609	Phase 3	Drugs in Phase 3 Trial	57827330	.	D08MHD	437.4	128	687	1.4	30	2	9	4	C19H18F3N5O2S	N-[3-[(4aS,5R,7aS)-2-amino-5-methyl-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-(difluoromethyl)pyrazine-2-carboxamide	CC1C2CSC(=NC2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(N=C4)C(F)F)F)N	C[C@@H]1[C@H]2CSC(=N[C@]2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(N=C4)C(F)F)F)N	InChI=1S/C19H18F3N5O2S/c1-9-12-7-30-18(23)27-19(12,8-29-9)11-4-10(2-3-13(11)20)26-17(28)15-6-24-14(5-25-15)16(21)22/h2-6,9,12,16H,7-8H2,1H3,(H2,23,27)(H,26,28)/t9-,12-,19-/m1/s1	AACUJFVOHGRMTR-DPXNYUHVSA-N
DW4VH6	SAR439859	Small molecule	Amcenestrant; SAR439859; 2114339-57-8; SAR-439859; Amcenestrant [INN]; Amcenestrant [USAN]; TBF1NHY02O; (S)-8-(2,4-Dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid; 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid; 8-(2,4-Dichlorophenyl)-9-[4-[[(3S)-1-(3-fluoropropyl)-3-pyrrolidinyl]oxy]phenyl]-6,7-dihydro-5H-benzocycloheptene-3-carboxylic acid; 5H-Benzocycloheptene-3-carboxylic acid, 8-(2,4-dichlorophenyl)-9-(4-(((3S)-1-(3-fluoropropyl)-3-pyrrolidinyl)oxy)phenyl)-6,7-dihydro-; 6-(2,4-dichlorophenyl)-5-[4-[(3~{S})-1-(3-fluoranylpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7~{H}-benzo[7]annulene-2-carboxylic acid; 8-(2,4-Dichlorophenyl)-9-(4-(((3S)-1-(3-fluoropropyl)-3-pyrrolidinyl)oxy)phenyl)-6,7-dihydro-5H-benzocycloheptene-3-carboxylic acid; UNII-TBF1NHY02O; AMCENESTRANT [JAN]; Amcenestrant [USAN:INN]; AMCENESTRANT [WHO-DD]; CHEMBL4475463; SCHEMBL19131426; US9714221, Example 51; BDBM263716; EX-A4678; NSC827675; s9609; WHO 11312; NSC-827675; MS-30114; HY-133017; CS-0109407; Q66885452; 8-(2,4-DICHLOROPHENYL)-9-(4-(((3S)-1-(3-FLUOROPROPYL)PYRROLIDIN-3-YL)OXY)PHENYL)-6,7-DIHYDRO-5H-BENZO(7)ANNULENE-3-CARBOXYLIC ACID; L5B	Phase 3	Drugs in Phase 3 Trial	130232326	.	D0O1TJ	554.5	49.8	832	5.3	38	1	5	8	C31H30Cl2FNO3	6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid	C1CC2=C(C=CC(=C2)C(=O)O)C(=C(C1)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)OC5CCN(C5)CCCF	C1CC2=C(C=CC(=C2)C(=O)O)C(=C(C1)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)O[C@H]5CCN(C5)CCCF	InChI=1S/C31H30Cl2FNO3/c32-23-8-12-27(29(33)18-23)28-4-1-3-21-17-22(31(36)37)7-11-26(21)30(28)20-5-9-24(10-6-20)38-25-13-16-35(19-25)15-2-14-34/h5-12,17-18,25H,1-4,13-16,19H2,(H,36,37)/t25-/m0/s1	KISZAGQTIXIVAR-VWLOTQADSA-N
DA42NC	Tramiprosate	Small molecule	Homotaurine; 3-Amino-1-propanesulfonic acid; Tramiprosate; 3687-18-1; 3-aminopropane-1-sulfonic acid; 3-aminopropanesulphonic acid; Alzhemed; 3APS; 1-Propanesulfonic acid, 3-amino-; 3-Aminopropane sulfonic acid; 3-aminopropanesulfonic acid; Cerebril; NC-758; Tramiprosate [USAN]; 3-Aminopropanesulfonate; NSC-77071; 5K8EAX0G53; CHEBI:1457; CHEMBL149082; 3-aminopropane-d6-sulfonic acid; NSC77071; MFCD00008225; Tramiprosate (USAN); 3-Aminopropane-1-sulfonic Acid (Homotaurine); 3-aminopropylsulfonic acid; 3-APS; NSC 77071; 3-Aminopropane-1-sulphonic acid; EINECS 222-977-4; 3-Aminopropiosulfonic Acid; Tramiprosate [USAN:INN]; UNII-5K8EAX0G53; AI3-52544; NC-531; Aminopropanesulfonic-3; Acamprosate impurity A; Spectrum_001340; Spectrum2_001409; Spectrum3_000924; Spectrum4_001023; Spectrum5_001319; TRAMIPROSATE [MI]; TRAMIPROSATE [INN]; EC 222-977-4; Lopac0_000066; SCHEMBL26759; 3-ammoniopropane-1-sulfonate; KBioGR_001545; KBioSS_001820; MLS000028639; 3-aminopropane-1-sulfonicacid; DivK1c_000348; SPECTRUM1501125; TRAMIPROSATE [WHO-DD]; SPBio_001458; 3-amino-1-propanesulphonic acid; 3-amino-1-propane sulfonic acid; HMS501B10; KBio1_000348; KBio2_001820; KBio2_004388; KBio2_006956; KBio3_001928; 3-Amino-propane-1-sulfonic acid; DTXSID80190352; NINDS_000348; HMS1921H05; HMS2235L19; HMS3372L06; AMY23443; BDBM50281573; CCG-39012; CPD-11725; HB0866; s5131; ZINC01529636; AKOS006221419; 3-Amino-1-propanesulfonic acid, 97%; CS-5741; DB06527; GS-3103; IDI1_000348; NCGC00094904-01; NCGC00094904-02; HY-14602; SMR000059181; SY006704; 3-AMINOPROPANE SULFONIC ACID [INCI]; DB-049023; FT-0614911; EN300-94821; C03349; D06202; AB00052207_13; A823416; ACAMPROSATE CALCIUM IMPURITY A [EP IMPURITY]; Q-200354; Q5891790; Z1203578094; Acamprosate impurity A, European Pharmacopoeia (EP) Reference Standard; A20	Phase 3	Drugs in Phase 3 Trial	1646	DB06527	D09DLP	139.18	88.8	133	-3.8	8	2	4	3	C3H9NO3S	3-aminopropane-1-sulfonic acid	C(CN)CS(=O)(=O)O	C(CN)CS(=O)(=O)O	InChI=1S/C3H9NO3S/c4-2-1-3-8(5,6)7/h1-4H2,(H,5,6,7)	SNKZJIOFVMKAOJ-UHFFFAOYSA-N
DG15CA	LY-333531	Small molecule	Ruboxistaurin; 169939-94-0; LY-333531; Ruboxistaurin [INN]; LY 333531; LY333531; 721809WQCP; K00587a; (18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione; CHEMBL432130; 9H,18H-5,21:12,17-Dimethenodibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecine-18,20(19H)-dione, 9-((dimethylamino)methyl)-6,7,10,11-tetrahydro-, (9S)-; UNII-721809WQCP; 13-((Dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione; (9R)-9-[(DIMETHYLAMINO)METHYL]-6,7,10,11-TETRAHYDRO-9H,18H-5,21:12,17-DIMETHENODIBENZO[E,K]PYRROLO[3,4-H][1,4,13]OXADIAZACYCLOHEXADECINE-18,20-DIONE; 9H,18H-5,21:12,17-Dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione, 9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-, (9S)-; LY4; 1uu3; RUBOXISTAURIN [MI]; LY333531;LY-333531;LY 333531; Ruboxistaurin; LY333531; RUBOXISTAURIN [VANDF]; CHEMBL91829; RUBOXISTAURIN [MART.]; RUBOXISTAURIN [WHO-DD]; cid_153999; GTPL5263; SCHEMBL2496701; BDBM17055; DTXSID00168775; EX-A2313; BDBM50128281; NSC800873; DB11829; NSC-800873; ZACYCLOHEXADECINE-18,20-DIONE; (9S)-9-((Dimethylamino)methyl)-6,7,10,11-tetrahydro-9H,19H-5,21:12,17-dimethenodibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-18,20-dione; (S)-9-[(Dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione; AC-35844; HY-10195; MS-28648; CS-0002500; LY-333,531; A12399; A902568; Q7376181; (18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.1;{7,14}.0;{2,6}.0;{8,13}.0;{22,27}]nonacosa-1(28),2(6),7(29),8(13),9,11,22(27),23,25-nonaene-3,5-dione; (9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione; 18-dimethylaminomethyl-(18S)-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8(13),9,11,22(27),23,25-nonaene-3,5-dione; methane sulphonic acid salt	Phase 3	Drugs in Phase 3 Trial	153999	DB11829	D0W3LI	468.5	68.5	872	2.7	35	1	4	2	C28H28N4O3	(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione	CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O	CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O	InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1	ZCBUQCWBWNUWSU-SFHVURJKSA-N
DWM46E	Phenserine	Small molecule	Phenserine; 101246-66-6; (-)-Phenserine; (-)-Eseroline phenylcarbamate; (+/-)-Phenserine; Phenserine, (+/-)-; posiphen; Phenserine (racemate) [MI]; SUE285UG3S; CHEMBL74926; (3as,8ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate; N8142NV8UM; 101246-66-6 (free base); 159652-53-6; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-phenylcarbamate), (3aR,8aS)-rel-; pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-phenylcarbamate), (3aS,8aR)-; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, phenylcarbamate (ester), cis-(+/-)-; phenserine.tartaric acid; Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-phenylcarbamate), (3aS,8aR)-; N-phenylcarbamoyleseroline; N-phenylcarbamoyl eseroline; UNII-SUE285UG3S; UNII-N8142NV8UM; MFCD00672748; PHENSERINE [MI]; BUNTANETAP, (-)-; SCHEMBL1537384; BDBM10958; BUNTANETAP, (+/-)-; DTXSID00906018; HMS3261J07; Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-phenylcarbamate), (3aR,8aS)-; Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-phenylcarbamate), (3aS,8aR)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1);Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-phenylcarbamate), (3aS,8aR)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1); Tox21_500523; AKOS015967321; Phenserine, >=98% (HPLC), solid; CCG-221827; DB04892; LP00523; SDCCGSBI-0633726.P001; [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate; NCGC00163250-01; NCGC00163250-02; NCGC00163250-05; NCGC00261208-01; MS-25129; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, phenylcarbamate (ester), (3aS-cis)-; HY-103374; CS-0027770; J-000348; BRD-K46580984-001-01-0; Q27095557; (3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol 5-(N-phenylcarbamate); (3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate	Phase 3	Drugs in Phase 3 Trial	192706	DB04892	D07CIN	337.4	44.8	507	2.3	25	1	4	3	C20H23N3O2	[(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate	CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C	C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C	InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m1/s1	PBHFNBQPZCRWQP-QUCCMNQESA-N
D36TGU	Resiniferatoxin	Small molecule	Resiniferatoxin; 57444-62-9; Lopain; RTX; (+)-resiniferatoxin; Resiniferatoxin [USAN]; Mtx-071; A5O6P1UL4I; MTX-71; Reciniferatoxin; Benzeneacetic acid, 4-hydroxy-3-methoxy-, ((2S,3aR,3bS,6aR,9aR,9bR,10R,11aR)-3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7-oxo-2-(phenylmethyl)-7H-2,9b-epoxyazuleno(5,4-e)-1,3-benzodioxol-5-yl)methyl ester; 4-hydroxy-3-methoxy-benzeneacetic acid, [(2S,3aR,3bS,6aR,9aR,9bR,10R,11aR)-3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7-oxo-2-(phenylmethyl)-7H-2,9b-epoxyazuleno[5,4-e]-1,3-benzodioxol-5-yl]methyl ester; [3H]resiniferatoxin; CHEMBL448382; UNII-A5O6P1UL4I; resinferatoxin; Resiniferatoxin(RTX); RESINIFERATOXIN [INN]; 6,7-Deepoxy-6,7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)daphnetoxin 20-(3-hydroxy-5-methoxybenzeneacetate); CHEMBL17976; CHEBI:8809; GTPL2491; GTPL4091; RESINIFERATOXIN [WHO-DD]; SCHEMBL17792942; DTXSID00894764; BDBM50052442; WHO 11485; AKOS024456409; DB06515; NCGC00162396-01; Q3277888; (4-Hydroxy-3-methoxy-phenyl)-acetic acid (2R,3S,3aR,5R,5aR,8bR,11aR)-3b-benzyloxy-11a-hydroxy-5a-isopropenyl-2,4-dimethyl-1-oxo-1,3a,3b,4,5,5a,8a,8b,11,11a-decahydro-6,8-dioxa-indeno[5,4-e]azulen-10-ylmethyl ester; [(1R,2R,6R,10S,11R,13S,15R,17R)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-prop-1-en-2-yl-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxy-3-methoxyphenyl)acetate; [(2S,3aR,3bS,6aR,9aR,9bR,10R,11aR)-2-Benzyl-6a-hydroxy-8,10-dimethyl-11a-(prop-1-en-2-yl)-7-oxo-3a,6,6a,7,9a,10,11,11a-octahydro-3bH-2,9b-epoxyazuleno[5,4-E]-1,3-benzodioxol-5-yl]methyl 2-(4-hydroxy-3-methoxyphenyl)acetate; [(2S,3aR,3bS,6aR,9aR,9bR,10R,11aR)-2-benzyl-6a-hydroxy-8,10-dimethyl-7-oxo-11a-(prop-1-en-2-yl)-3a,6,6a,7,9a,10,11,11a-octahydro-3bH-2,9b-epoxyazuleno[4',5':5,6]benzo[1,2-d][1,3]dioxol-5-yl]methyl (4-hydroxy-3-methoxyphenyl)acetate; 13-benzyl-6-hydroxy-15-isopropenyl-4,17-dimethyl-5-oxo-(1R,2S,6R,10S,11R,13S,15R,17R)-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-ylmethyl 2-(4-hydroxy-3-methoxyphenyl)acetate; 13-benzyl-6-hydroxy-15-isopropenyl-4,17-dimethyl-5-oxo-(1R,2S,6R,10S,11R,15R,17R)-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-ylmethyl 2-(4-hydroxy-3-methoxyphenyl)acetate; 13-benzyl-6-hydroxy-15-isopropenyl-4,17-dimethyl-5-oxo-(2S,6R,10S,11R,15R,17R)-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-ylmethyl 2-(4-hydroxy-3-methoxyphenyl)acetate; 4-Hydroxy-3-methoxy-[(2S,3aR,3bS,6aR,9aR,9bR,10R,11aR) -3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7-oxo-2-(phenylmethyl)-7H-2,9b-epoxyazuleno[5,4-e]-1,3-benzodioxol-5-yl]benzeneacetate	Phase 3	Drugs in Phase 3 Trial	5702546	DB06515	D05XJW	628.7	121	1330	4.5	46	2	9	9	C37H40O9	[(1R,2R,6R,10S,11R,13S,15R,17R)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-prop-1-en-2-yl-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxy-3-methoxyphenyl)acetate	CC1CC2(C3C4C1(C5C=C(C(=O)C5(CC(=C4)COC(=O)CC6=CC(=C(C=C6)O)OC)O)C)OC(O3)(O2)CC7=CC=CC=C7)C(=C)C	C[C@@H]1C[C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5(CC(=C4)COC(=O)CC6=CC(=C(C=C6)O)OC)O)C)O[C@](O3)(O2)CC7=CC=CC=C7)C(=C)C	InChI=1S/C37H40O9/c1-21(2)35-17-23(4)37-27(33(35)44-36(45-35,46-37)19-24-9-7-6-8-10-24)14-26(18-34(41)30(37)13-22(3)32(34)40)20-43-31(39)16-25-11-12-28(38)29(15-25)42-5/h6-15,23,27,30,33,38,41H,1,16-20H2,2-5H3/t23-,27+,30-,33-,34-,35-,36-,37-/m1/s1	DSDNAKHZNJAGHN-MXTYGGKSSA-N
D5I0EV	Beloranib	Small molecule	Beloranib; 251111-30-5; Beloranib [INN]; ZGN-433; ZGN-440; CKD-732; ZGN 440; O-[4-(2-Dimethylaminoethoxy)-trans-cinnamoyl]fumagillol; FI471K8BU6; (3R,4S,5S,6R)-5-Methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro(2.5)octan-6-yl (2E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)prop-2-enoate; O-(4-(2-Dimethylaminoethoxy)-trans-cinnamoyl)fumagillol; 609845-93-4; UNII-FI471K8BU6; ZGN 433; ZGN-440(Beloranib); O-(4-Dimethylaminoethoxycinnamoyl)fumagillol; BELORANIB [WHO-DD]; GTPL8445; US9682965, Compound A; CHEMBL4297504; SCHEMBL14648763; DTXSID40179800; BDBM148430; ZGN-440;CDK-732; DB12671; (3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl)-1-oxaspiro(2.5)oct-6-yl (2E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)acrylate; HY-14811; CS-0003572; A13870; Q4884554; [(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (E)-3-[4-(2-dimethylaminoethoxy)phenyl]prop-2-enoate; 3-[4-[2-(Dimethylamino)ethoxy]phenyl]acrylic acid (3R)-4beta-[(2R,3R)-2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-5alpha-methoxy-1-oxaspiro[2.5]octane-6alpha-yl ester	Phase 3	Drugs in Phase 3 Trial	6918502	DB12671	D0E4VQ	499.6	73.1	815	4.4	36	0	7	12	C29H41NO6	[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (E)-3-[4-[2-(dimethylamino)ethoxy]phenyl]prop-2-enoate	CC(=CCC1C(O1)(C)C2C(C(CCC23CO3)OC(=O)C=CC4=CC=C(C=C4)OCCN(C)C)OC)C	CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)/C=C/C4=CC=C(C=C4)OCCN(C)C)OC)C	InChI=1S/C29H41NO6/c1-20(2)7-13-24-28(3,36-24)27-26(32-6)23(15-16-29(27)19-34-29)35-25(31)14-10-21-8-11-22(12-9-21)33-18-17-30(4)5/h7-12,14,23-24,26-27H,13,15-19H2,1-6H3/b14-10+/t23-,24-,26-,27-,28+,29+/m1/s1	ZEZFKUBILQRZCK-MJSCXXSSSA-N
D1GL2R	Ximelagatran	Small molecule	Ximelagatran; Exanta; 192939-46-1; H 376/95; H 37695; DTXSID5049075; H 376-95; NCGC00183598-01; Exarta; xi-melagatran; ethyl ((R)-1-cyclohexyl-2-((S)-2-((4-((Z)-N'-hydroxycarbamimidoyl)benzyl)carbamoyl)azetidin-1-yl)-2-oxoethyl)glycinate; Ximelagatran [USAN:INN]; Exanta (proposed); H-376/95; 1243838-77-8; ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate; ethyl 2-{[(1R)-1-cyclohexyl-2-[(2S)-2-({[4-(N-hydroxycarbamimidoyl)phenyl]methyl}carbamoyl)azetidin-1-yl]-2-oxoethyl]amino}acetate; Exanta (TN); ximelagatranum; Ximelagatran (JAN/USAN/INN); UNII-49HFB70472; 49HFB70472; H 376 95; Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-, ethyl ester; Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; ximelagatran (oxime form); SCHEMBL4845; SCHEMBL4846; Ethyl (((1R)-1-cyclohexyl-2-((2S)-2-((4-(hydroxycarbamimidoyl)benzyl)carbamoyl)azetidin-1-yl-2-oxoethyl)amino)acetate; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-((hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ester ester; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ethyl ester; glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; SCHEMBL8039753; DTXCID5029001; ximelagatran (hydroxylamine form); CHEBI:136702; Tox21_113633; DB04898; NCGC00183598-02; ethyl 2-[[(1R)-1-cyclohexyl-2-[(2S)-2-[[4-[(Z)-N'-hydroxycarbamimidoyl]phenyl]methylcarbamoyl]azetidin-1-yl]-2-oxoethyl]amino]acetate; HY-10787; MS-28784; CAS-192939-46-1; CS-0002822; D01981; A880297; EN300-22104206; J-012490; ethyl ({(1R)-1-cyclohexyl-2-[(2S)-2-({[4-(N-hydroxycarbamimidoyl)phenyl]methyl}carbamoyl)azetidin-1-yl]-2-oxoethyl}amino)acetate; ethyl 2-{[(1R)-1-cyclohexyl-2-[(2S)-2-[({4-[(Z)-N'-hydroxycarbamimidoyl]phenyl}methyl)carbamoyl]azetidin-1-yl]-2-oxoethyl]amino}acetate; ethyl N-{(1R)-1-cyclohexyl-2-[(2S)-2-{[4-(N'-hydroxycarbamimidoyl)benzyl]carbamoyl}azetidin-1-yl]-2-oxoethyl}glycinate	Phase 3	Drugs in Phase 3 Trial	9574101	DB04898	D0JQ7Y	473.6	146	731	2.2	34	4	7	11	C24H35N5O5	ethyl 2-[[(1R)-1-cyclohexyl-2-[(2S)-2-[[4-[(Z)-N'-hydroxycarbamimidoyl]phenyl]methylcarbamoyl]azetidin-1-yl]-2-oxoethyl]amino]acetate	CCOC(=O)CNC(C1CCCCC1)C(=O)N2CCC2C(=O)NCC3=CC=C(C=C3)C(=NO)N	CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N2CC[C@H]2C(=O)NCC3=CC=C(C=C3)/C(=N/O)/N	InChI=1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1	ZXIBCJHYVWYIKI-PZJWPPBQSA-N
DM1CU9	Davunetide	Small molecule	Davunetide; 211439-12-2; AL-108; AL-208; L-Asparaginyl-L-alanyl-L-prolyl-L-valyl-L-seryl-L-isoleucyl-L-prolyl-L-glutamine; NAP peptide; D-NAP peptide; L-Glutamine, L-asparaginyl-L-alanyl-L-prolyl-L-valyl-L-seryl-L-isoleucyl-L-prolyl-; NAPVSIPQ peptide; (2S)-5-amino-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid; AL108 cpd; AL208 cpd; 132031-50-6; NAP (peptide); AL 108; AL 208; AL-408; Davunetide (USAN); NAPVSIPQ; Davunetide [USAN:INN]; UNII-GF00K3IIWE; GF00K3IIWE; SCHEMBL239737; CHEMBL2103826; CHEBI:177706; Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln; DB12613; L-Glutamine,L-asparaginyl-L-alanyl-L-prolyl-L-valyl-L-seryl-L-isoleucyl-L-prolyl-; BN172353; MS-31531; HY-105066; CS-0024867; D09401; Influenza pr8 hemagglutinin peptide(110-119); Influenza PR8 Hemagglutinin Peptide (110-119); J-013876; Q27279075; H2N-L-Asn-L-Ala-L-Pro-L-Val-L-Ser-L-Ile-L-Pro-L-Gln-COOH; Human activity-dependent neuroprotective protein (ADNP)-(354-361)-peptide	Phase 3	Drugs in Phase 3 Trial	9832404	DB12613	D0V1FF	824.9	356	1560	-5.6	58	10	13	22	C36H60N10O12	(2S)-5-amino-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid	CCC(C)C(C(=O)N1CCCC1C(=O)NC(CCC(=O)N)C(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(C)NC(=O)C(CC(=O)N)N	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)N	InChI=1S/C36H60N10O12/c1-6-18(4)28(35(56)46-14-8-9-23(46)31(52)41-21(36(57)58)11-12-25(38)48)44-30(51)22(16-47)42-33(54)27(17(2)3)43-32(53)24-10-7-13-45(24)34(55)19(5)40-29(50)20(37)15-26(39)49/h17-24,27-28,47H,6-16,37H2,1-5H3,(H2,38,48)(H2,39,49)(H,40,50)(H,41,52)(H,42,54)(H,43,53)(H,44,51)(H,57,58)/t18-,19-,20-,21-,22-,23-,24-,27-,28-/m0/s1	DWLTUUXCVGVRAV-XWRHUKJGSA-N
DW8Z6B	Semagacestat	Small molecule	Semagacestat; 425386-60-3; LY450139; Semagacestat (LY450139); LY-450139; LY 450139; 866488-53-1; (S)-2-hydroxy-3-methyl-N-((S)-1-((S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ylamino)-1-oxopropan-2-yl)butanamide; 3YN0602W4W; (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide; (S)-2-Hydroxy-3-methyl-N-((S)-1-(((S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl)amino)-1-oxopropan-2-yl)butanamide; (2S)-2-Hydroxy-3-methyl-N-[(2S)-1-{[(1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]amino}-1-oxopropan-2-yl]butanamid; Butanamide, 2-hydroxy-3-methyl-N-((1S)-1-methyl-2-oxo-2-(((1S)-2,3,4,5-tetrahydro-3- methyl-2-oxo-1H-3-benzazepin-1-yl)amino)ethyl)-, (2S)-; Semagacestat [USAN]; Semagacestat [USAN:INN]; UNII-3YN0602W4W; SEMAGACESTAT [MI]; Semagacestat (USAN/INN); SEMAGACESTAT [INN]; Semagacestat; LY450139; MLS006010180; SCHEMBL417581; SEMAGACESTAT [WHO-DD]; CHEMBL520733; GTPL6978; BDBM28944; DTXSID10235740; CHEBI:131158; BCPP000174; HMS3884G21; AMY36446; EX-A2257; MFCD09970409; NSC755982; s1594; AKOS015924574; BCP9000888; CCG-268180; CS-0292; DB12463; EX-1762; NSC-755982; NCGC00346556-01; NCGC00346556-07; (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-2-oxo-ethyl]butanamide; (2S)-2-HYDROXY-3-METHYL-N-[(1S)-1-METHYL-2-OXO-2-[[(1S)-2,3,4,5-TETRAHYDRO-3-METHYL-2-OXO-1H-3-BENZAZEPIN-1-YL]AMINO]ETHYL]BUTANAMIDE; AC-24396; AS-42018; HY-10009; SMR004701288; A25230; D09377; LY450139, >=98% (HPLC); Q426010; J-501018; L-450139; (2S)-2-HYDROXY-3-METHYL-N-((2S)-1-(((1S)-3-METHYL-2-OXO-2,3,4,5-TETRAHYDRO-1H-3- BENZAZEPIN-1-YL)AMINO)-1-OXOPROPAN-2-YL)BUTANAMIDE; (2S)-2-hydroxy-3-methyl-N-[(1S)-1-{[(1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]carbamoyl}ethyl]butanamide; (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide; (2S)-2-Hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]butanamid e; (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(1S)-3-methyl-2-oxo-4,5-dihydro-1H-3-benzazepin-1-yl]amino]-1-oxopropan-2-yl]butanamide; (N)-((S)-2-HYDROXY-3-METHYL-BUTYRYL)-1-(L-ALANINYL)-(S)-1-AMINO-3-METHYL-2,3,4,5- TETRAHYDRO-1H-3-BENZAZEPIN-2-ONE; (N)-((S)-2-Hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one; BUTANAMIDE, 2-HYDROXY-3-METHYL-N-((1S)-1-METHYL-2-OXO-2-(((1S)-2,3,4,5-TETRAHYDRO-3-METHYL-2-OXO-1H-3-BENZAZEPIN-1-YL)AMINO)ETHYL)-, (2S)-; ESF; N(SUP 2)-((2S)-2-HYDROXY-3-METHYLBUTANOYL)-N(SUP 1)-((1S)-3-METHYL-2-OXO-2,3,4,5-TETRAHYDRO-1H-3- BENZAZEPIN-1-YL)-L-ALANINAMIDE; N2-((2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-laninamide; N2-((2S)-2-Hydroxy-3-methylbutanoyl)-N1-((1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl)-L-alaninamide; Semagacestat;(S)-2-hydroxy-3-methyl-N-((S)-1-((S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ylamino)-1-oxopropan-2-yl)butanamide	Phase 3	Drugs in Phase 3 Trial	9843750	DB12463	D01LXD	361.4	98.7	537	1.3	26	3	4	5	C19H27N3O4	(2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide	CC(C)C(C(=O)NC(C)C(=O)NC1C2=CC=CC=C2CCN(C1=O)C)O	C[C@@H](C(=O)N[C@H]1C2=CC=CC=C2CCN(C1=O)C)NC(=O)[C@H](C(C)C)O	InChI=1S/C19H27N3O4/c1-11(2)16(23)18(25)20-12(3)17(24)21-15-14-8-6-5-7-13(14)9-10-22(4)19(15)26/h5-8,11-12,15-16,23H,9-10H2,1-4H3,(H,20,25)(H,21,24)/t12-,15-,16-/m0/s1	PKXWXXPNHIWQHW-RCBQFDQVSA-N
D5QS8I	AFQ056	Small molecule	Mavoglurant; 543906-09-8; AFQ056; AFQ-056; (3ar,4s,7ar)-octahydro-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-1h-indole-1-carboxylic acid methyl ester; GT0I9SV4F6; methyl (3aR,4S,7aR)-4-hydroxy-4-(m-tolylethynyl)octahydro-1H-indole-1-carboxylate; 1H-Indole-1-carboxylic acid, octahydro-4-hydroxy-4-(2-(3-methylphenyl)ethynyl)-, methyl ester, (3aR,4S,7aR)-; methyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate; (-)-(3aR,4S,7aR)-4-hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester; Mavoglurant [INN]; Mavoglurant [USAN:INN]; UNII-GT0I9SV4F6; AFQ 056; Mavoglurant racemate; 4oo9; Mavoglurant, AFQ056; MAVOGLURANT [USAN]; MAVOGLURANT [WHO-DD]; SCHEMBL989279; GTPL7586; CHEMBL3087515; DTXSID30202777; BCP20624; EX-A1564; BDBM50443085; CS-5245; DB13004; AS-79009; HY-15257; DB-102250; F85319; F85489; Q6589598; (3aR,4S,7aR)-Methyl 4-hydroxy-4-(m-tolylethynyl)octahydro-1H-indole-1-carboxylate; 1636881-61-2; 1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-; 2U8; Methyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]octahydro-1H-indole-1-carboxylate	Phase 3	Drugs in Phase 3 Trial	9926832	DB13004	D0G5PF	313.4	49.8	519	2.9	23	1	3	3	C19H23NO3	methyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate	CC1=CC(=CC=C1)C#CC2(CCCC3C2CCN3C(=O)OC)O	CC1=CC(=CC=C1)C#C[C@@]2(CCC[C@@H]3[C@H]2CCN3C(=O)OC)O	InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1	ZFPZEYHRWGMJCV-ZHALLVOQSA-N
DW8KZ9	Odanacatib	Small molecule	Odanacatib; 603139-19-1; MK-0822; Odanacatib (MK-0822); MK0822; MK 0822; Odanacatib (MK0822); Odanacatib (MK 0822); CHEMBL481611; N673F6W2VH; (S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-(((S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)ethyl)amino)pentanamide; (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]pentanamide; (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; (S)-N-(1-CYANOCYCLOPROPYL)-4-FLUORO-4-METHYL-2-((S)-2,2,2-TRIFLUORO-1-(4'-(METHYLSULFONYL)BIPHENYL-4-YL)ETHYLAMINO)PENTANAMIDE; Odanacatib [USAN]; Odanacatib [USAN:INN]; UNII-N673F6W2VH; C25H27F4N3O3S; (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)pentanamide; MK-0822A; ODANACATIB [MI]; ODANACATIB [INN]; ODANACATIB [JAN]; Odanacatib (JAN/USAN); ODANACATIB [MART.]; ODANACATIB [WHO-DD]; MLS006010197; GTPL6478; L-1037536; SCHEMBL1496266; DTXSID40209075; EX-A552; BCPP000141; cas:603139-19-1;Odanacatib; BDBM50255753; MFCD11042419; NSC766811; s1115; AKOS015900719; BCP9001020; CCG-269888; CS-0277; DB06670; NSC-766811; NCGC00346637-01; AC-27468; AS-19562; HY-10042; SMR004676504; SW219669-1; D08955; MK-0822;MK 0822;MK0822; J-690332; Q2014070; N-(1-Cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide; N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methyl sulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; Pentanamide, N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)-, (2S)-	Phase 3	Drugs in Phase 3 Trial	10152654	DB06670	D0J6AU	525.6	107	934	4.1	36	2	9	9	C25H27F4N3O3S	(2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide	CC(C)(CC(C(=O)NC1(CC1)C#N)NC(C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F	CC(C)(C[C@@H](C(=O)NC1(CC1)C#N)N[C@@H](C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F	InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1	FWIVDMJALNEADT-SFTDATJTSA-N
D9AGL4	Tivantinib	Small molecule	Tivantinib; 905854-02-6; ARQ-197; ARQ 197; (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib (ARQ 197); ARQ197; 905853-99-8; PJ4H73IL17; 1000873-98-2; rel-(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolidinedione; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [INN]; Tivantinib [USAN:INN]; UNII-PJ4H73IL17; Tivantinib; ARQ197; TIVANTINIB [MI]; TIVANTINIB [JAN]; TIVANTINIB [USAN]; ARQ 197 (Tivantinib); TIVANTINIB [WHO-DD]; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; DTXSID60920316; ARQ-197,Tivantinib, ARQ197; ARQ197; ARQ-197;Tivantinib; BCPP000042; BCP02529; EX-A2169; CAS:905854-02-6;Tivantinib; BDBM50146168; MFCD11977596; NSC758242; NSC800951; s2753; AKOS022182739; CCG-268285; DB12200; NSC-758242; NSC-800951; (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; AC-25009; AC-35963; AS-16991; HY-50686; J3.496.311H; C77073; D10173; E82820; A857990; J-501255; BRD-K33379087-001-01-8; Q17123902; Z2242166213; (+/-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1H-indol-3-yl)pyrrolidine-2,5-dione; (+/-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2,5-dione; (+/-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; (_)-trans-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1h-indol-3-yl)pyrrolidine-2,5-dione; (3R,4R)-3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; (3R,4R)-3-(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-pyrrolidine-2,5-dione; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1-yl)-4-(1H-indole-3-yl)pyrrolidine-2,5-dione; 2,5-Pyrrolidinedione, 3-(5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R,4R)-; 2,5-Pyrrolidinedione,3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-,(3R,4R)-rel-; TIV; trans 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-pyrrolidine-2,5-dione	Phase 3	Drugs in Phase 3 Trial	11494412	DB12200	D0ZI1F	369.4	66.9	666	2.9	28	2	2	2	C23H19N3O2	(3R,4R)-3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione	C1CC2=C3C(=CC=C2)C(=CN3C1)C4C(C(=O)NC4=O)C5=CNC6=CC=CC=C65	C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65	InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1	UCEQXRCJXIVODC-PMACEKPBSA-N
D1PWQ5	Anacetrapib	Small molecule	Anacetrapib; 875446-37-0; MK-0859; MK0859; Anacetrapib (MK-0859); (4s,5r)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one; P7T269PR6S; CHEMBL1800807; MK 0859; (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-3-((4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)methyl)-4-methyloxazolidin-2-one; (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)methyl)-4-methyloxazolidin-2-one.; (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one; Anacetrapib [USAN]; Anacetrapib [USAN:INN]; UNII-P7T269PR6S; Anacetrapib-[d3]; MFCD16294903; ANACETRAPIB [MI]; ANACETRAPIB [INN]; ANACETRAPIB [JAN]; Anacetrapib (JAN/USAN); 15?-Hydroxy Testosterone; Anacetrapib - MK-0859; ANACETRAPIB [MART.]; ANACETRAPIB [WHO-DD]; (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one; MLS006010190; SCHEMBL531448; GTPL8400; DTXSID90236452; EX-A420; BCPP000402; AMY19494; BCP02374; BDBM50348228; s2748; AKOS025290725; BCP9000299; CCG-270307; CS-0636; DB06630; NCGC00346671-01; AC-25517; AS-19552; HY-12090; SMR004701293; A24886; D08855; J-501484; Q4750639; (4S,5R)-5-(3,5-bis(Trifluoromethyl)phenyl)-3-((4'-fluoro-2'-methoxy-5'-(propan-2- yl)-4-(trifluoromethyl)(1,1'-biphenyl)-2-yl)methyl)-4-methyl-1,3-oxazolidin-2-one; (4S,5R)-5-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-3-((4'-FLUORO-2'-METHOXY-5'-(PROPAN-2-YL)-4-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)METHYL)-4-METHYL-1,3-OXAZOLIDIN-2-ONE; (4S,5r)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl)methyl)-4-methyl-1 ,3-oxazolidin-2-one; (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl)methyl)-4-methyloxazolidin-2-one; (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-2'-methoxy-5'-(1-methylethyl)-4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-4-methyl-2-Oxazolidinone; (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-5'isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one; (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-5'isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl}4-methyl-1,3-oxazolidin-2-one; 2-Oxazolidinone, 5-(3,5-bis(trifluoromethyl)phenyl)-3-((4'-fluoro-2'-methoxy-5'-(1- methylethyl)-4-(trifluoromethyl)(1,1'-biphenyl)-2-yl)methyl)-4-methyl-, (4S,5R)-; MK-0859;(4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one	Phase 3	Drugs in Phase 3 Trial	11556427	DB06630	D07HLS	637.5	38.8	964	8.8	44	0	13	6	C30H25F10NO3	(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one	CC1C(OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F	C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F	InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1	MZZLGJHLQGUVPN-HAWMADMCSA-N
D7F3TW	Motesanib	Small molecule	Motesanib; 453562-69-1; AMG 706; AMG-706; N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide; AMG706; N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide; Motesanib [USAN]; N-(2,3-Dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide; U1JK633AYI; CHEBI:51098; Motesanib (USAN); 453562-69-1 (free base); N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide; N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide; 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-; N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4- ylmethyl)amino]pyridine-3-carboxamide; Motesanib [USAN:INN]; UNII-U1JK633AYI; N-(3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-carboxamide; AMG706/ Motesanib; MOTESANIB [INN]; MOTESANIB [MI]; Motesanib (AMG-706); MOTESANIB [MART.]; MOTESANIB [WHO-DD]; SCHEMBL187470; CHEMBL572881; GTPL5660; BDBM24773; DTXSID10196488; EX-A487; cid_11667893; BCPP000407; HMS3244A09; HMS3244A10; HMS3244B09; HMS3265G19; HMS3265G20; HMS3265H19; HMS3265H20; BCP01982; AMG 706; AMG-706; MFCD10567689; NSC760843; NSC800801; s5793; AKOS005146333; N-(3,3-dimethylindolin-6-yl)-2-((pyridin-4-ylmethyl)amino)nicotinamide; BCP9000289; DB05575; EX-8571; NSC-760843; NSC-800801; SB14621; NCGC00263205-01; NCGC00263205-06; AC-32664; AS-16212; HY-10228; FT-0706483; A19395; D06678; J-522983; Q6917202; BRD-K99616396-316-01-2; N-(3,3-dimethylindolin-6-yl)-2-(4-pyridylmethylamino)nicotinamide; N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)-3-pyridinecarboxamide; N-(3,3-DIMETHYL-2,3-DIHYDRO-1H-INDOL-6-YL)-2-((PYRIDIN-4-YLMETHYL)AMINO)NICOTINAMIDE	Phase 3	Drugs in Phase 3 Trial	11667893	DB05575	D00DQX	373.5	78.9	533	3.9	28	3	5	5	C22H23N5O	N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide	CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C	CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C	InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)	RAHBGWKEPAQNFF-UHFFFAOYSA-N
DNC8M0	Alisertib	Small molecule	Alisertib; 1028486-01-2; MLN8237; MLN-8237; MLN 8237; MLN8237 (Alisertib); 4-((9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic acid; Alisertib [USAN]; 4-[[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid; CHEMBL483158; T66ES73M18; Alisertib (USAN); 4-((9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic acid; Benzoic acid, 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido(5,4-d)(2)benzazepin-2-yl)amino)-2-methoxy-; Alisertib [USAN:INN]; UNII-T66ES73M18; 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid; MLN8237,Alisertib; Kinome_3770; ALISERTIB [INN]; Alisertib; MLN8237; Alisertib (MLN8237); MLN8237 - Alisertib; ALISERTIB [WHO-DD]; MLS006011041; SCHEMBL855823; GTPL7790; DTXSID30145539; EX-A024; MIN8237; CHEBI:125628; HMS3654E08; HMS3673I07; HMS3743E17; AMY24201; BCP01823; BDBM50277545; MFCD16621243; NSC759677; NSC799329; s1133; AKOS015924647; BCP9000956; CCG-264832; CS-0106; DB05220; MLN 8237 (Contain 10% DMSO); NSC-759677; NSC-799329; SB16658; NCGC00263271-01; NCGC00263271-02; NCGC00263271-10; 4-(9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-2-methoxybenzoic acid; AC-25236; AS-17005; HY-10971; SMR004702834; FT-0672433; SW219771-1; D10085; EN300-6482023; J-514220; BRD-K75295174-001-03-5; Q15633917; Z2037281068; 4-((9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-yl)amino)-2-methoxy MLN 8237 (Contain 10% DMSO); 4-(9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[e]pyrimido[5,4-c]azepin-2-ylamino)-2-methoxybenzoic acid; 4-{[13-chloro-10-(2-fluoro-6-methoxyphenyl)-3,5,9-triazatricyclo[9.4.0.0,2,7]pentadeca-1(11),2(7),3,5,9,12,14-heptaen-4-yl]amino}-2-methoxybenzoic acid; 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl) -5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid; 4-{[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxy-benzoic acid; A5B	Phase 3	Drugs in Phase 3 Trial	24771867	DB05220	D0S4JK	518.9	106	836	5	37	2	9	6	C27H20ClFN4O4	4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid	COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC	COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC	InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)	ZLHFILGSQDJULK-UHFFFAOYSA-N
D8YN1O	Quizartinib	Small molecule	Quizartinib; 950769-58-1; AC220; Quizartinib (AC220); AC-220; AC 220; Quizartinib HCl; AC010220; Quizartinib freebase; AC 010220; ASP-2689; 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea; 7LA4O6Q0D3; CHEMBL576982; N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea; CHEBI:90217; 950769-58-1 (free base); AC-010220; 1132827-21-4 (HCl); 1-(5-Tert-Butyl-1,2-Oxazol-3-Yl)-3-(4-{7-[2-(Morpholin-4-Yl)ethoxy]imidazo[2,1-B][1,3]benzothiazol-2-Yl}phenyl)urea; 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea; n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride; CHEMBL2386811; 1-(5-(tert-Butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)-benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea; N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1- b)benzothiazol-2-yl)phenyl)urea; N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)urea; Urea, N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-N'-(4-(7-(2-(4-morpholinyl)ethoxy) imidazo(2,1-b)benzothiazol-2-yl)phenyl)-; AC220 compound; AC220,Quizartinib; Quizartinib [USAN]; Quizartinib [USAN:INN]; quizartinibum; UNII-7LA4O6Q0D3; 1-(5-TERT-BUTYL-1,2-OXAZOL-3-YL)-3-(4-(7-(2-(MORPHOLIN-4-YL)ETHOXY)IMIDAZO(2,1-B)(1,3)BENZOTHIAZOL-2-YL)PHENYL)UREA; N-(5-TERT-BUTYLISOXAZOL-3-YL)-N'-(4-(7-(2-(MORPHOLIN-4-YL)ETHOXY)IMIDAZO(2,1-B)(1,3)BENZOTHIAZOL-2-YL)PHENYL)UREA; N-(5-tert-Butylisoxazol-3-yl)-N'-[4-[7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea; Quizartinib, 95%; Quizartinib, ac220; Quizartinib, Free Base; AC220 - Quizartinib; QUIZARTINIB [MI]; Quizartinib; PLX3397; QUIZARTINIB [INN]; Quizartinib (USAN/INN); SCHEMBL72923; QUIZARTINIB [WHO-DD]; MLS006011240; GTPL5658; DTXSID70241746; BCPP000443; HMS3244K09; HMS3244K10; HMS3244L09; HMS3265G09; HMS3265G10; HMS3265H09; HMS3265H10; HMS3654J20; HMS3743G21; BCP02224; BDBM50300690; MFCD18074524; NSC756647; NSC799659; NSC800857; s1526; AKOS015891557; BCP9000223; CCG-264906; CS-0211; DB12874; NSC-756647; NSC-799659; NSC-800857; SB16610; NCGC00242493-01; NCGC00242493-02; NCGC00242493-07; AS-16178; HY-13001; SMR004703000; FT-0687630; SW218131-2; D09955; J-524214; Q7272714; BRD-K93918653-001-01-4; 3-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4-{10-[2-(morpholin-4-yl)ethoxy]-7-thia-2,5-diazatricyclo[6.4.0.0^{2,6}]dodeca-1(12),3,5,8,10-pentaen-4-yl}phenyl)urea; N-(5-tert-Butyl-isoxazol-3-yl)-N''-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea; N-(5-Tert-butyl-isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-ylethoxy)imidazo(2,1-b) (1,3)benzothiazol-2-yl)phenyl)urea; N-(5-tert-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea; N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea	Phase 3	Drugs in Phase 3 Trial	24889392	DB12874	D07KYT	560.7	134	849	5.6	40	2	8	8	C29H32N6O4S	1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea	CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3	CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3	InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)	CVWXJKQAOSCOAB-UHFFFAOYSA-N
D38VPS	Navitoclax	Small molecule	Navitoclax; 923564-51-6; ABT-263; ABT 263; ABT263; ABT-263 (Navitoclax); Navitoclax (ABT-263); UNII-XKJ5VVK2WD; XKJ5VVK2WD; A-855071.0; CHEMBL443684; (R)-4-(4-((4'-Chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide; (R)-4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(4-(4-morpholino-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)phenylsulfonyl)benzamide; 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide; (R)-4-(4-((2-(4-Chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(4-(4-morpholino-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)p; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-En-1-Yl]methyl}piperazin-1-Yl)-N-[(4-{[(2r)-4-(Morpholin-4-Yl)-1-(Phenylsulfanyl)butan-2-Yl]amino}-3-[(Trifluoromethyl)sulfonyl]phenyl)sulfonyl]benzamide; Navitoclax [USAN]; Navitoclax [USAN:INN]; navitoclaxum; Novitoclax; C47H55ClF3N5O6S3; 4-(4-((2-(4-CHLOROPHENYL)-5,5-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((4-(((2R)-4-(MORPHOLIN-4-YL)-1-(PHENYLSULFANYL)BUTAN-2-YL)AMINO)-3-((TRIFLUOROMETHYL)SULFONYL)PHENYL)SULFONYL)BENZAMIDE; ABT-263,Navitoclax; NAVITOCLAX [MI]; ABT-263 In Bulk; Navitoclax, ABT-263; Navitoclax; ABT-263; NAVITOCLAX [INN]; NAVITOCLAX [JAN]; Navitoclax (USAN/INN); ABT-263 - Navitoclax; NAVITOCLAX [WHO-DD]; MLS006011021; SCHEMBL522847; GTPL8319; DTXSID2042640; CHEBI:94128; EX-A055; CHEBI:131174; BDBM50270877; MFCD12756219; NSC759659; s1001; AKOS015896297; DB12340; NSC-759659; RG-7433; NCGC00188344-01; NCGC00188344-02; NCGC00188344-03; NCGC00188344-05; NCGC00188344-08; 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-mo; 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(1R)-3-morpholino-1-(phenylsulfanylmethyl)propyl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonyl-benzamide; AC-31055; AS-16690; HY-10087; SMR004702817; 4-[4-[[2-(4-chlorophenyl)-5,5-dimet; SW218055-2; D09935; J-519525; BRD-K82746043-001-01-1; BRD-K82746043-001-02-9; BRD-K82746043-001-03-7; BRD-K82746043-001-04-5; Q18002993; (R)-4-(4-((4-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-CHLOROPHENYL)-5,5-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-(4-(((2R)-4-(MORPHOLIN-4-YL)-1-(PHENYLSULFANYL)BUTAN-2-YL)AMINO)-3-(TRIFLUOROMETHANESULFONYL)BENZENESULFONYL)BENZAMIDE; 4-(4-{[2-(4-Chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-(morpholin-4-yl)-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide;ABT 263;Benzamide, 4-(4-((2-(4-chlorophenyl)-5,5-dime; 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}-N-[(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]benzamide; BENZAMIDE, 4-(4-((2-(4-CHLOROPHENYL)-5,5-DIMETHYL-1-CYCLOHEXEN-1-YL)METHYL)-1- PIPERAZINYL)-N-((4-(((1R)-3-(4-MORPHOLINYL)-1-((PHENYLTHIO)METHYL)PROPYL)AMINO)-3-((TRIFLUOROMETHYL)SULFONYL)PHENYL)SULFONYL)-; Benzamide, 4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylthio)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)-; N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethyl-cyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-4-((r)-3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-3-trifluoromethanesulfonyl-benzenesulfonamide	Phase 3	Drugs in Phase 3 Trial	24978538	DB12340	D06ETI	974.6	170	1800	9.6	65	2	14	16	C47H55ClF3N5O6S3	4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide	CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C	CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C	InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1	JLYAXFNOILIKPP-KXQOOQHDSA-N
D9V5TS	Pyrotinib	Small molecule	Pyrotinib; 1269662-73-8; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8 (free base); (R,E)-N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; Pyrotinib Racemate; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; UNII-CJN36EQM0H; Airuini; 1246089-97-3; Pyrotinib(SHR-1258); PYROTINIB [WHO-DD]; GTPL9662; SCHEMBL9948753; CHEMBL3647420; BDBM139991; BCP29458; WZB08997; s8852; CS-7940; DB14993; compound 12 [PMID: 28115222]; MS-30445; HY-104065; 4679B; A17068; US8901140, 5; SHR-1258; SHR1258; SHR 1258; Q27275495; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide	Phase 3	Drugs in Phase 3 Trial	51039030	DB14993	D0M8YM	583.1	112	960	5.4	42	2	8	10	C32H31ClN6O3	(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide	CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CC5CCCN5C	CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/[C@H]5CCCN5C	InChI=1S/C32H31ClN6O3/c1-3-41-30-17-27-25(16-28(30)38-31(40)12-10-24-8-6-14-39(24)2)32(21(18-34)19-36-27)37-22-9-11-29(26(33)15-22)42-20-23-7-4-5-13-35-23/h4-5,7,9-13,15-17,19,24H,3,6,8,14,20H2,1-2H3,(H,36,37)(H,38,40)/b12-10+/t24-/m1/s1	SADXACCFNXBCFY-IYNHSRRRSA-N
DP3IM9	MK-8931	Small molecule	Verubecestat; 1286770-55-5; MK-8931; Verubecestat Free Base; SCH-900931; SCH900931; SCH 900931; Verubecestat (MK-8931); J1I0P6WT7T; N-[3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-6H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide; C17H17F2N5O3S; (R)-N-(3-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoropicolinamide; 2-Pyridinecarboxamide, N-(3-((5R)-3-amino-5,6-dihydro-2,5-dimethyl-1,1-dioxido-2H-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoro-; 2-Pyridinecarboxamide, N-[3-[(5R)-3-amino-5,6-dihydro-2,5-dimethyl-1,1-dioxido-2H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoro-; N-{3-[(5r)-3-Amino-2,5-Dimethyl-1,1-Dioxido-5,6-Dihydro-2h-1,2,4-Thiadiazin-5-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; Verubecestat [USAN:INN]; UNII-J1I0P6WT7T; example 25 (US8940748); VerubecestatFreeBase; 66F; Verubecestat [USAN]; VERUBECESTAT [INN]; VERUBECESTAT [JAN]; Verubecestat; MK-8931; VERUBECESTAT [WHO-DD]; GTPL8699; Verubecestat (JAN/USAN/INN); CHEMBL3301601; SCHEMBL10328722; SCHEMBL17507398; BDBM143220; DTXSID301020622; HMS3886D12; BCP15722; EX-A2003; BDBM50580216; MFCD28963974; s8564; CCG-268756; CS-5823; DB12285; SB19728; NCGC00522475-03; AC-33091; AS-35038; HY-16759; J3.514.620B; A16113; D10739; US8940748, 25; A858066; Q27089141; MK 8931;MK-8931;SCH 900931;SCH900931;SCH-900931;MK8931; N-(3-((5R)-3-amino-2,5-dimethyl-1,1-dioxo-1,2,5,6-tetrahydro-1lambda6,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoropyridine-2-carboxamide; N-(3-((5R)-3-amino-2,5-dimethyl-1,1-dioxo-5,6-dihydro-2H-1lambda6,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoropyridine-2-carboxamide; N-(3-(3-amino-5,6-dihydro-2,5-dimethyl-1,1-dioxido-2H-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide	Phase 3	Drugs in Phase 3 Trial	51352361	DB12285	D0R4KK	409.4	126	744	0.6	28	2	7	3	C17H17F2N5O3S	N-[3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-6H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide	CC1(CS(=O)(=O)N(C(=N1)N)C)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)F)F	C[C@]1(CS(=O)(=O)N(C(=N1)N)C)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)F)F	InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1	YHYKUSGACIYRML-KRWDZBQOSA-N
DO75XV	Venglustat	Small molecule	Ibiglustat; Venglustat; 1401090-53-6; Genz-682452; SAR402671; GZ/SAR402671; Genz-682452-AA; Venglustat [USAN]; GZ402671; BLP1XA3FZA; Ibiglustat(Genz-682452; (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate; SAR-402671; [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate; GZ-402671; Carbamic acid, N-(1-(2-(4-fluorophenyl)-4-thiazolyl)-1-methylethyl)-, (3S)-1-azabicyclo(2.2.2)oct-3-yl ester; (1R,3S,4R)-1-azabicyclo[2.2.2]octan-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate; (3S)-1-Azabicyclo(2.2.2)octan-3-yl N-(2-(2-(4-fluorophenyl)-1,3-thiazol-4-yl)propan-2-yl)carbamate; Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester; Ibiglustat [INN]; UNII-BLP1XA3FZA; (3S)-1-AZABICYCLO[2.2.2]OCTAN-3-YL N-{2-[2-(4-FLUOROPHENYL)-1,3-THIAZOL-4-YL]PROPAN-2-YL}CARBAMATE; VENGLUSTAT [INN]; Venglustat (USAN/INN); VENGLUSTAT [WHO-DD]; CHEMBL4297611; SCHEMBL12615329; GTPL11550; GZ/SAR-402671; AMY19519; BGC09053; EX-A1870; MFCD28502073; NSC823013; WHO 10063; AKOS027337125; CS-6512; DB14966; NSC-823013; AC-35551; AS-52367; HY-16743; D11633; P14969; Q27274745; Z2327390275; (S)-quinuclidin-3-yl 2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-ylcarbamate; (S)-Quinuclidin-3-yl(2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate; KYF	Phase 3	Drugs in Phase 3 Trial	60199242	DB14966	D07WEN	389.5	82.7	533	3.5	27	1	6	5	C20H24FN3O2S	[(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate	CC(C)(C1=CSC(=N1)C2=CC=C(C=C2)F)NC(=O)OC3CN4CCC3CC4	CC(C)(C1=CSC(=N1)C2=CC=C(C=C2)F)NC(=O)O[C@@H]3CN4CCC3CC4	InChI=1S/C20H24FN3O2S/c1-20(2,17-12-27-18(22-17)14-3-5-15(21)6-4-14)23-19(25)26-16-11-24-9-7-13(16)8-10-24/h3-6,12-13,16H,7-11H2,1-2H3,(H,23,25)/t16-/m1/s1	YFHRCLAKZBDRHN-MRXNPFEDSA-N
DLE0R6	Dovitinib	Small molecule	Dovitinib; 405169-16-6; CHIR-258; TKI-258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; Chir 258; Dovitinib [INN]; Dovitinib (TKI-258, CHIR-258); CHIR258; TKI258; 804551-71-1; Dovitinib lactate; TKI 258; CHEMBL522892; GFKI-258; CHEMBL4578973; I35H55G906; 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one; 4-Amino-5-Fluoro-3-(6-(4-Methylpiperazin-1-yl)-1H-Benzo[D]Imidazol-2-yl)Quinolin-2(1H)-One; 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; (3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one; 1027263-12-2; 4-AMINO-5-FLUORO-3-[ 5- (4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]QUINOLIN-2(1H)-ONE; Dovitinib, Free Base; UNII-I35H55G906; 38O; MFCD10565680; TK-258; Kinome_1513; Dovitinib (TKI-258); DOVITINIB [WHO-DD]; NVP-TKI258; MLS006009991; SCHEMBL172687; GTPL5962; SCHEMBL9975396; SCHEMBL20399550; SCHEMBL23876106; BDBM25118; CHEBI:91395; BCPP000286; BDBM153731; CHIR-258(Dovitinib,TKI258); Dovitinib,TKI258, CHIR-258; DTXSID901025925; HMS3295E21; HMS3651E03; BCP01981; EX-A2051; CHIR-258, TKI258, Dovitinib; BDBM50507579; NSC759661; NSC800092; NSC807408; s1018; Dovitinib; TKI-258; CHIR-258; AKOS005146311; AKOS015951093; BCP9000518; CCG-264778; CS-0120; DB05928; NSC-759661; NSC-800092; NSC-807408; PB13248; SB20297; NCGC00249685-01; NCGC00249685-02; NCGC00249685-11; (3E)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one; AC-32059; AS-19556; HY-50905; SMR004701066; FT-0667782; SW219787-1; EC-000.2257; A24080; C75053; TKI-258;CHIR-258;Unii-I35H55G906; 1,3-benzodiazol-2-yl]-1,2-dihydroquinolin-2-one; J-514396; BRD-K85402309-001-01-7; Q27077102; Q27163255; Q27453625; 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-; B2693-091881; 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2 (1h)-one; 4-amino-5-fluoro-3-[6(4-methyl-1-piperazinyl)-1h-benzimidazol-2-yl]-2(1h)-quinolinone; 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one; (3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazino)-1,3-dihydrobenzimidazol-2-ylidene]carbostyril; 4-AMINO-5-FLUORO-3-(6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL)QUINOLIN-2(1H)-ONE; 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydrobenzimidazol-2-ylidene]-2-quinolinone; 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-ylidene]-2,3-dihydroquinolin-2-one; 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-1,3-benzodiazol-2-yl]-1,2-dihydroquinolin-2-one	Phase 3	Drugs in Phase 3 Trial	135398510	DB05928	D07OZR	392.4	90.3	678	1.6	29	3	6	2	C21H21FN6O	4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one	CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N	CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N	InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)	PIQCTGMSNWUMAF-UHFFFAOYSA-N
DB57GK	Triptolide	Small molecule	triptolide; 38748-32-2; Triptolid; PG490; NSC 163062; NSC-163062; 19ALD1S53J; CHEBI:9747; CHEMBL463763; PG-490; (1S,2S,4S,5S,7R,8R,9S,11S,13S)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one; (5bS,6aS,7aS,8R,8aR,9aS,9bS,10aS,10bS)-8-Hydroxy-8a-isopropyl-10b-methyl-1,5,5b,6,6a,8,8a,9a,9b,10b-decahydrotris(oxireno)[2',3':4b,5;2'',3'':6,7;2''',3''':8a,9]phenanthro[1,2-c]furan-3(2H)-one; (6aS,7aS,8R,8aR,9aS,9bS,10aS,10bS)-8-hydroxy-8a-isopropyl-10b-methyl-1,5,5b,6,6a,8,8a,9a,9b,10b-decahydrotris(oxireno)[2',3':4b,5;2'',3'':6,7;2''',3''':8a,9]phenanthro[1,2-c]furan-3(2H)-one.; SMR000466307; UNII-19ALD1S53J; NSC163062; Triptolide, 1; (3BS,4AS,5AS,6R,6AR,7AS,7BS,8AS,8BS)-3B,4,4A,6,6A,7A,7B,8B,9,10-DECAHYDRO-6-HYDROXY-8B-METHYL-6A-(1-METHYLETHYL)TRISOXIRENO(4B,5:6,7:8A,9)PHENANTHRO(1,2-C)FURAN-1(3H)-ONE; (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-3b,4,4a,6,6a,7a,7b,8b,9,10-Decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one; Trisoxireno[6,7:8a,9:4b,5]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; MFCD00210565; CPD000466307; TRIPTOLIDE [MI]; TRIPTOLIDE [WHO-DD]; BSPBio_001595; KBioGR_000315; KBioSS_000315; MLS000759410; MLS001424107; MLS006010844; SCHEMBL413634; DTXSID5041144; KBio2_000315; KBio2_002883; KBio2_005451; KBio3_000629; KBio3_000630; Bio2_000315; Bio2_000795; HMS1361P17; HMS1791P17; HMS1989P17; HMS2051N13; HMS3402P17; 144539-79-7; TPL; BDBM50241049; NSC839303; s3604; AKOS022168197; AM84923; CCG-100957; CS-0286; DB12025; NC00207; NSC-839303; IDI1_034065; NCGC00163411-01; NCGC00163411-02; NCGC00163411-03; NCGC00163411-07; BP-25386; BS-16697; HY-32735; NCI60_001223; PG490;PG 490;PG-490; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; T2899; C09204; AB00639938-06; AB00639938-08; Q906351; Q-100450; BRD-K39484304-001-02-5; BRD-K39484304-001-06-6; BRD-K39484304-001-16-5; Triptolide, Tripterygium wilfordii - CAS 38748-32-2; (1S,2S,4S,5S,7R,8R,9S,11S)-8-Hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one; (3BS,4AS,5AS,6R,6AR,7AS,7BS,8AS,8BS)-3B,4,4A,6,6A,7A,7B,8B,9,10-DECAHYDRO-6-HYDROXY-6A-ISOPROPYL-8B-METHYLTRISOXIRENO(6,7:8A,9:4B,5)PHENANTHRO(1,2-C)FURAN-1(3H)-ONE; (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-6-hydroxy-8b-methyl-6a-(propan-2-yl)-3b,4,4a,6,6a,7a,7b,8b,9,10-decahydrotrisoxireno[6,7:8a,9:4b,5]phenanthro[1,2-c]furan-1(3H)-one; (5bS,6aS,7aS,8R,8aR,9aS,9bS,10aS,10bS)-8-hydroxy-8a-isopropyl-10b-methyl-2,5,5b,6,6a,8,8a,9a,9b,10b-decahydrotris(oxireno)[2',3':4b,5;2'',3'':6,7;2''',3''':8a,9]phenanthro[1,2-c]furan-3(1H)-one; Trisoxireno[4b,7:8a,9]phenanthro[1,2-c]furan-(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, [3bR-(3b.alpha.,4a.alpha.,5aS*,6.beta.,6a.beta.,7a.beta.,7b.alpha.,8aS*,8b.beta.)]-; Trisoxireno[4b,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, [3bR-(3b.alpha.,4a.alpha.,5aS*,6.beta.,6a.beta.,7a.beta.,7b.alpha.,8aS*,8b.beta.)]-	Phase 3	Drugs in Phase 3 Trial	107985	DB12025	D0I6LH	360.4	84.1	819	0.2	26	1	6	1	C20H24O6	(1S,2S,4S,5S,7R,8R,9S,11S,13S)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one	CC(C)C12C(O1)C3C4(O3)C5(CCC6=C(C5CC7C4(C2O)O7)COC6=O)C	CC(C)[C@@]12[C@@H](O1)[C@H]3[C@@]4(O3)[C@]5(CCC6=C([C@@H]5C[C@H]7[C@]4([C@@H]2O)O7)COC6=O)C	InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1	DFBIRQPKNDILPW-CIVMWXNOSA-N
D85GMV	Gossypol	Small molecule	gossypol; 303-45-7; 90141-22-3; (-)-Gossypol; Pogosin; (+)-Gossypol; Tash 1; (R)-Gossypol; (R)-(-)-Gossypol; No Fertil; AT 101; (+/-)-Gossypol; 20300-26-9; 7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde; BL 193; AT101; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; NSC 56817; Gossypol, (R)-; Gossypol, (S)-; NSC56817; NSC-56817; XNA7DR63CQ; NSC-624336; BRN 1917878; 8DY2X8LXW4; CHEMBL51483; KAV15B369O; DTXSID5023110; 303-45-7 (free); 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); BL-193; NSC624336; NSC-726190; (2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-, (+)-; 7-[8-formyl-1,6,7-trihydroxy-3-methyl-5-(propan-2-yl)naphthalen-2-yl]-2,3,8-trihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carbaldehyde; NCGC00016423-03; CAS-303-45-7; racemic-Gossypol; (2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-; [2,2'-Binaphthalene]-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-; [2,2'-Binaphthalene]-8,8'-dicarboxaldehyde,1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (2R)-; 4-08-00-03754 (Beilstein Handbook Reference); DTXCID803110; (+-)-Gossypol; 7-(8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methyl-2-naphthyl)-2,3,8-trihydroxy-4-isopropyl-6-methyl-naphthalene-1-carbaldehyde; Gossypol Sodium Salt; CCRIS 2689; Gissypol, (R)-; NSC-19048; Sodium Salt, Gossypol; (S)-(+)-Gossypol; Gossypol, (+)-Isomer; Gossypol, (-)-Isomer; SR-01000597521; Gossypol Dipotassium Salt; UNII-XNA7DR63CQ; Gossypol, (+-)-Isomer; Dipotassium Salt, Gossypol; UNII-8DY2X8LXW4; NSC 624336; ssypol; UNII-KAV15B369O; Thespesin; AI3-22957; HSDB 7872; Gossypol, 4; (S)-Gossypol; MFCD00017352; Prestwick_1031; R-(-)-gossypol; Pogosin; AT101; Spectrum_000359; Spectrum_001521; Tocris-1964; ST065835; SpecPlus_000602; GOSSYPOL [MI]; GOSSYPOL [VANDF]; GOSSYPOL, R-; Prestwick0_000677; Prestwick1_000677; Prestwick2_000677; Prestwick3_000677; Spectrum2_001472; Spectrum2_001624; Spectrum3_001102; Spectrum3_001516; Spectrum4_000846; Spectrum4_001931; Spectrum5_000693; Spectrum5_001035; 8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methyl-2,2'-bisnaphthalene; GOSSYPOL [MART.]; Gossypol from cotton seeds; UPCMLD-DP103; NCIMech_000271; cid_3503; SCHEMBL3939; BSPBio_000773; BSPBio_002804; BSPBio_003191; GOSSYPOL, (+)-; KBioGR_001451; KBioGR_002303; KBioSS_000839; KBioSS_002001; (2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (-)-; MLS000028490; DivK1c_000173; DivK1c_006698; GOSSYPOL R-FORM [MI]; GOSSYPOL S-FORM [MI]; SPECTRUM1504019; SPBio_001423; SPBio_001687; SPBio_002694; BPBio1_000851; cid_227456; GTPL4204; UPCMLD-DP103:001; UPCMLD-DP103:002; BDBM23223; BDBM46555; KBio1_000173; KBio1_001642; KBio2_000839; KBio2_002001; KBio2_003407; KBio2_004569; KBio2_005975; KBio2_007137; KBio3_002024; KBio3_002691; EX-A068; NINDS_000173; HMS1570G15; HMS2097G15; HMS3262J15; HMS3268O22; HMS3413L10; HMS3651C18; HMS3677L10; HMS3868F13; (+/-)-Gossypol from cotton seeds; ALBB-033351; BCP03607; Tox21_110434; Tox21_500847; CCG-35400; HB0304; NSC726190; NSC728875; s6852; STK063457; (2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahyd; AKOS002140475; Tox21_110434_1; AT25344; BCP9000332; CS-0966; DB13044; LMPR0103330002; LP00847; NSC 726190; NSC-728875; SB17342; SDCCGSBI-0051726.P004; IDI1_000173; SMP2_000170; NCGC00016423-01; NCGC00016423-02; NCGC00016423-04; NCGC00016423-05; NCGC00016423-06; NCGC00016423-07; NCGC00016423-08; NCGC00016423-09; NCGC00016423-10; NCGC00016423-12; NCGC00016423-14; NCGC00016423-15; NCGC00016423-17; NCGC00016423-34; NCGC00025331-01; NCGC00025331-02; NCGC00025331-03; NCGC00025331-04; NCGC00025331-06; NCGC00025331-07; NCGC00261532-01; (2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-; 7-[8-formyl-1,6,7-trihydroxy-3-methyl-5-(methylethyl)(2-naphthyl)]-2,3,8-trihy droxy-6-methyl-4-(methylethyl)naphthalenecarbaldehyde; AC-20251; AC-30274; AC-34521; AS-55885; BP-25397; HY-13407; HY-15464; NCI60_001588; NCI60_004391; SMR000058386; BCP0726000183; DB-047766; AB00052921; FT-0631917; SW197103-2; A15004; C07667; A820340; Q411882; J-017920; SR-01000597521-1; SR-01000597521-5; SR-01000597521-6; (+/-)-Gossypol from cotton seeds, >=95% (HPLC); BRD-K19295594-001-06-9; BRD-K19295594-001-10-1; BRD-K19295594-015-02-8; ( inverted exclamation markA)-GOSSYPOL FROM COTTON SEEDS; 8-Formyl-1,7-trihydroxy-5-isopropyl-3-methyl-2,2'-bisnaphthalene; (-)-2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); (2,8'-dicarboxaldehyde, 1,1',6,6'7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-; (R)-2,2'-BIS(8-FORMYL-1,6,7-TRIHYDROXY-5-ISOPROPYL-3-METHYLNAPHTHALENE); [2,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-; (+)1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)[2,2'-binaphthalene]-8,8'-dicarboxaldehyde; (-)-1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-[2,2'-binaphthalene]-8,8'-dicarboxaldehyde; (-)-1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)[2,2'-binaphthalene]-8,8'-dicarboxaldehyde; (2,2'-BINAPHTHALENE)-8,8'-DICARBOXALDEHYDE, 1,1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-5,5'-BIS(1-METHYLETHYL)-, (2S)-; (2,2'-BINAPHTHALENE)-8,8'-DICARBOXALDEHYDE, 1,1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-5,5'-BIS(1-METHYLETHYL)-, (S)-; [2,8'-dicarboxaldehyde, 1,1',6,6',7,7'- hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (2R)-; [2,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1- methylethyl)-; [2,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-; 1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-[2,2'-binaphthalene]-8,8'-dicarboxaldehyde; 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-2,2'-binaphthalene-8,8'-dicarbaldehyde; 1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)[2,2'-binaphthalene]-8,8'-dicarboxaldehyde; 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalene-8,8'-dicarbaldehyde; 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-2,2'-binaphthalene-8,8'-dicarbaldehyde; 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-2,2'-binaphthyl-8,8'-dicarbaldehyde; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 1,1',6,6'-Tetrahydroxy-3,3'-dimethyl-5,5'-diisopropyl-8,8'-bis(hydroxymethylene)-2,2'-binaphthalene-7,7'(8H,8'H)-dione; 7-(8-Formyl-1,6,7-trihydroxy-3-methyl-5-(methylethyl)(2-naphthyl))-2,3,8-trihydroxy-6-methyl-4-(methylethyl)naphthalenecarbaldehyde; acetic acid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-yl-2-naphthalenyl)-2,3,8-trihydroxy-6-methyl-4-propan-2-yl-1-naphthalenecarboxaldehyde; acetic acid;7-(8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methyl-2-naphthyl)-2,3,8-trihydroxy-4-isopropyl-6-methyl-naphthalene-1-carbaldehyde; ethanoic acid;7-[8-methanoyl-3-methyl-1,6,7-tris(oxidanyl)-5-propan-2-yl-naphthalen-2-yl]-6-methyl-2,3,8-tris(oxidanyl)-4-propan-2-yl-naphthalene-1-carbaldehyde	Phase 3	Drugs in Phase 3 Trial	3503	DB13044	D0Z0HH	518.6	156	780	6.9	38	6	8	5	C30H30O8	7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde	CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O	CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O	InChI=1S/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3	QBKSWRVVCFFDOT-UHFFFAOYSA-N
DCZE91	Immunoglobulin	Protein	.	Phase 3	Drugs in Phase 3 Trial	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D6EIX2	Interferon alfa	Protein	.	Phase 3	Drugs in Phase 3 Trial	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D09FZQ	Interleukin 2	Protein	.	Phase 3	Drugs in Phase 3 Trial	.	.	D04OJM	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR73OC	Intranasal insulin	Protein	.	Phase 3	Drugs in Phase 3 Trial	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D5W2MQ	Toripalimab	Antibody	.	Phase 3	Drugs in Phase 3 Trial	.	DB15043	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DX6IH3	BIIB059	Antibody	.	Phase 3	Drugs in Phase 3 Trial	.	.	D0M0TV	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DE0GU3	Bapineuzumab	Antibody	.	Phase 3	Drugs in Phase 3 Trial	.	DB11715	D0A1MX	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DP8ET7	Onartuzumab	Antibody	.	Phase 3	Drugs in Phase 3 Trial	.	DB11746	D0H9PT	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DOZM46	Solanezumab	Antibody	.	Phase 3	Drugs in Phase 3 Trial	.	DB11756	D00CZT	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DS6N4E	Crenezumab	Antibody	.	Phase 3	Drugs in Phase 3 Trial	.	DB11959	D0R7EQ	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR8I2D	BAN2401	Antibody	.	Phase 3	Drugs in Phase 3 Trial	.	DB14580	D06XVR	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D8WXR9	SRK-015	Antibody	.	Phase 3	Drugs in Phase 3 Trial	.	DB16096	DN5J9R	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D1KFH4	LY3002813	Antibody	.	Phase 3	Drugs in Phase 3 Trial	.	DB16647	D0SD7G	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D8B0HX	Psoralen	Small molecule	Psoralen; 66-97-7; Ficusin; 7H-Furo[3,2-g]chromen-7-one; Furocoumarin; Psoralene; 7H-Furo[3,2-g][1]benzopyran-7-one; furo[3,2-g]chromen-7-one; Psorline-P; 6,7-Furanocoumarin; Furo[3,2-g]coumarin; Furo(2',3',7,6)coumarin; Furo(3,2-g)-coumarin; Furo(4',5',6,7)coumarin; NSC 404562; 7H-Furo[3,2-g]benzopyran-7-one; Furo[2',3':7,6]coumarin; Furo[4',5':6,7]coumarin; 7H-Furo(3,2-g)(1)benzopyran-7-one; Furo[2'.3':7.6]coumarin; KTZ7ZCN2EX; 6-Hydroxy-5-benzofuranacrylic acid beta-lactone; NSC-404562; 5-Benzofuranacrylic acid, 6-hydroxy-, delta-lactone; CHEMBL164660; CHEBI:27616; 2H-furo[3,2-g]chromen-2-one; 6-hydroxy-5-benzofuranacrylic acid delta-lactone; TNP00293; 6-hydroxy-5-benzofuranacrylic acid gamma-lactone; 3-(6-hydroxy-5-benzofuranyl)-2-propenoic acid delta-lactone; C11H6O3; CCRIS 4343; HSDB 3528; UNII-KTZ7ZCN2EX; EINECS 200-639-7; BRN 0152784; Manaderm; furano[3,2-g]chromen-2-one; Psoralene (DCF); Manaderm (TN); Psoralen,(S); MFCD00010520; Psoralen, 97%; Furo[4',7]coumarin; PHYTOALEXIN-CMPD; PSORALEN [HSDB]; PSORALEN [MI]; 2-Propenoic acid, 3-(6-hydroxy-5-benzofuranyl)-, delta-lactone; PSORALEN [USP-RS]; PSORALEN [WHO-DD]; Oprea1_841692; SCHEMBL17835; Psoralen, analytical standard; 5-19-04-00445 (Beilstein Handbook Reference); MLS001304059; MEGxp0_001172; Psoralen, >=99% (HPLC); ACon1_001579; pyrano[5,6-f]benzofuran-7-one; DTXSID00216205; 7-furo[3,2-g][1]benzopyranone; HMS2267L05; BCP04177; HY-N0053; 7H-Furo[3,2-g]chromen-7-one #; BDBM50331544; NSC404562; s4737; STL564822; AKOS004110987; AC-7968; CCG-266472; CS-3756; NCGC00017351-01; NCGC00017351-02; NCGC00017351-03; NCGC00017351-07; NCGC00142529-01; AS-59034; SMR000112587; FT-0603268; P2077; 7H-Furo[3,2-g][1]benzopyran-7-one, 9CI; C09305; D08450; P-7850; A835599; Q417788; BRD-K47264279-001-01-4; 5-Benzofuranacrylic acid, 6-hydroxy-, .delta.-lactone; Z1201617131; 6-HYDROXY-5-BENZOFURANACRYLIC ACID .DELTA.-LACTONE; 2-Propenoic acid, 3-(6-hydroxy-5-benzofuranyl)-, .delta.-lactone	Phase 2	Drugs in Phase 2 Trial	6199	.	D00VUI	186.16	39.4	284	2.3	14	0	3	0	C11H6O3	furo[3,2-g]chromen-7-one	C1=CC(=O)OC2=CC3=C(C=CO3)C=C21	C1=CC(=O)OC2=CC3=C(C=CO3)C=C21	InChI=1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H	ZCCUUQDIBDJBTK-UHFFFAOYSA-N
DMDG38	LEO 29102	Small molecule	LEO-29102; JKP2Z098S2; 1035572-38-3; UNII-JKP2Z098S2; CHEMBL3315088; J3.342.853G; N-Propyl-2-(2-((3,5-dichloro-4-pyridyl)acetyl)-5,6-dimethoxyphenoxy)acetamide; 2-(6-(2-(3,5-Dichloropyridin-4-yl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide; Acetamide, 2-(6-(2-(3,5-dichloro-4-pyridinyl)acetyl)-2,3-dimethoxyphenoxy)-N-propyl-; N-Propyl-2-[2-[(3,5-dichloro-4-pyridyl)acetyl]-5,6-dimethoxyphenoxy]acetamide; SCHEMBL885153; LEO29102; BDBM50048446; Q27281554	Phase 2	Drugs in Phase 2 Trial	66829720	.	D04XVJ	441.3	86.8	529	3.5	29	1	6	10	C20H22Cl2N2O5	2-[6-[2-(3,5-dichloropyridin-4-yl)acetyl]-2,3-dimethoxyphenoxy]-N-propylacetamide	CCCNC(=O)COC1=C(C=CC(=C1OC)OC)C(=O)CC2=C(C=NC=C2Cl)Cl	CCCNC(=O)COC1=C(C=CC(=C1OC)OC)C(=O)CC2=C(C=NC=C2Cl)Cl	InChI=1S/C20H22Cl2N2O5/c1-4-7-24-18(26)11-29-19-12(5-6-17(27-2)20(19)28-3)16(25)8-13-14(21)9-23-10-15(13)22/h5-6,9-10H,4,7-8,11H2,1-3H3,(H,24,26)	HOKIHKLKOZWCRY-UHFFFAOYSA-N
DYE0R4	ARQ 087	Small molecule	Derazantinib; 1234356-69-4; ARQ-087; ARQ087; Derazantinib [USAN]; ARQ 087; Derazantinib (ARQ 087); N9B0H171MJ; (6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine; (6R)-6-(2-fluorophenyl)-N-(3-{2-[(2-methoxyethyl)amino]ethyl}phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine; (R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine; Benzo(H)quinazolin-2-amine, 6-(2-fluorophenyl)-5,6-dihydro-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-, (6R)-; Benzo[h]quinazolin-2-amine, 6-(2-fluorophenyl)-5,6-dihydro-N-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-, (6R)-; Derazantinib(ARQ-087); DERAZANTINIB [INN]; UNII-N9B0H171MJ; DERAZANTINIB [WHO-DD]; GTPL9785; CHEMBL4297187; SCHEMBL13273847; ARQ-087ARQ-087; AMY16754; BCP29103; EX-A1717; s8609; WHO 10488; AKOS037648596; CS-7922; DB14889; AC-30343; BS-14785; HY-19981; A16825; C71924; (6R)-6-(2-fluorophenyl)-5,6-dihydro-N-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-Benzo[h]quinazolin-2-amine; 1814961-15-3	Phase 2	Drugs in Phase 2 Trial	46834118	.	D07PQJ	468.6	59.1	638	5.3	35	2	6	9	C29H29FN4O	(6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine	COCCNCCC1=CC(=CC=C1)NC2=NC=C3CC(C4=CC=CC=C4C3=N2)C5=CC=CC=C5F	COCCNCCC1=CC(=CC=C1)NC2=NC=C3C[C@H](C4=CC=CC=C4C3=N2)C5=CC=CC=C5F	InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1	KPJDVVCDVBFRMU-AREMUKBSSA-N
D4X9BM	SAR100842	Small molecule	SAR-100842; 1195941-38-8; Edg-2 receptor inhibitor 1; FIPAXALPARANT; CZN001; Y76WZ464EY; CZN-001; HZN-825; 2-(4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino)-indan-2-carboxylic acid; 2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indane-2-carboxylic acid; 2-(4-Methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid; 2-[[4-methoxy-3-[2-(3-methylphenyl)ethoxy]benzoyl]amino]-1,3-dihydroindene-2-carboxylic acid; 2-{4-methoxy-3-[2-(3-methylphenyl)ethoxy]benzamido}-2,3-dihydro-1H-indene-2-carboxylic acid; 1H-Indene-2-carboxylic acid, 2,3-dihydro-2-((4-methoxy-3-(2-(3-methylphenyl)ethoxy)benzoyl)amino)-; FIPAXALPARANT [INN]; UNII-Y76WZ464EY; SCHEMBL1560214; CHEMBL3621969; GTPL11315; AMY9033; VXB94138; SAR100842; DB-121933; HY-100185; CS-0018180; EN300-265974; Z2492413932; 2-(4-methoxy-3-(2-m-tolyl-ethoxy)benzoylamino)indane-2-carboxylic acid; 2,3-Dihydro-2-[[4-methoxy-3-[2-(3-methylphenyl)ethoxy]benzoyl]amino]-1H-Indene-2-carboxylic Acid	Phase 2	Drugs in Phase 2 Trial	44481866	.	D07WCT	445.5	84.9	667	4.9	33	2	5	8	C27H27NO5	2-[[4-methoxy-3-[2-(3-methylphenyl)ethoxy]benzoyl]amino]-1,3-dihydroindene-2-carboxylic acid	CC1=CC(=CC=C1)CCOC2=C(C=CC(=C2)C(=O)NC3(CC4=CC=CC=C4C3)C(=O)O)OC	CC1=CC(=CC=C1)CCOC2=C(C=CC(=C2)C(=O)NC3(CC4=CC=CC=C4C3)C(=O)O)OC	InChI=1S/C27H27NO5/c1-18-6-5-7-19(14-18)12-13-33-24-15-20(10-11-23(24)32-2)25(29)28-27(26(30)31)16-21-8-3-4-9-22(21)17-27/h3-11,14-15H,12-13,16-17H2,1-2H3,(H,28,29)(H,30,31)	SOJDTNUCCXWTMG-UHFFFAOYSA-N
DTNS97	AZD2423	Small molecule	AZD-2423; AZD2423; 1229603-37-5; AZD 2423 [WHO-DD]; 4-((2R)-4-tert-Butylpiperazine-2-carbonyl)-N-(4-chloro-3-fluorophenyl)piperazine-1-carboxamide; 4-[(2R)-4-tert-butylpiperazine-2-carbonyl]-N-(4-chloro-3-fluorophenyl)piperazine-1-carboxamide; 1W47471992; SCHEMBL2492309; UNII-1W47471992; MS-27510; HY-135891; CS-0116098; 1449698-98-9	Phase 2	Drugs in Phase 2 Trial	46213922	.	D0E5NY	425.9	67.9	594	1.5	29	2	5	3	C20H29ClFN5O2	4-[(2R)-4-tert-butylpiperazine-2-carbonyl]-N-(4-chloro-3-fluorophenyl)piperazine-1-carboxamide	CC(C)(C)N1CCNC(C1)C(=O)N2CCN(CC2)C(=O)NC3=CC(=C(C=C3)Cl)F	CC(C)(C)N1CCN[C@H](C1)C(=O)N2CCN(CC2)C(=O)NC3=CC(=C(C=C3)Cl)F	InChI=1S/C20H29ClFN5O2/c1-20(2,3)27-7-6-23-17(13-27)18(28)25-8-10-26(11-9-25)19(29)24-14-4-5-15(21)16(22)12-14/h4-5,12,17,23H,6-11,13H2,1-3H3,(H,24,29)/t17-/m1/s1	SRWQVWAIVQXPJY-QGZVFWFLSA-N
DRK8Y3	NP001	Small molecule	.	Phase 2	Drugs in Phase 2 Trial	.	.	D1LU7W	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DRB2G3	ELND005	Small molecule	inositol; myo-inositol; Scyllo-inositol; epi-Inositol; Muco-Inositol; Allo-inositol; i-Inositol; 87-89-8; meso-Inositol; Neo-inositol; 1D-Chiro-inositol; 1L-Chiro-inositol; D-(+)-chiro-Inositol; cis-Inositol; 643-12-9; 488-59-5; D-chiro-Inositol; Myoinositol; Scyllitol; 6917-35-7; Cyclohexane-1,2,3,4,5,6-hexaol; cyclohexane-1,2,3,4,5,6-hexol; 488-58-4; Quercinitol; mesoinositol; Cocositol; 551-72-4; Meat sugar; Myoinosite; Dambose; chiro-inositol; Inositene; Inositina; L-chiro-Inositol; Phaseomannite; Inosital; Inosite; Iso-inositol; Cyclohexitol; Phaseomannitol; 41546-34-3; Inositol, myo-; Mesoinosit; Mesoinosite; Scyllite; Mesovit; Nucite; Mesol; 643-10-7; 488-55-1; Cyclohexanehexol; Inositol, meso-; cis-1,2,3,5-trans-4,6-Cyclohexanehexol; D-myo-Inositol; D-chiro Inositol; 488-54-0; Bios I; Insitolum; Isoinositol; L-(-)-chiro-Inositol; (-)-Inositol; 576-63-6; d-Inositol; L-Inositol; L-myo-Inositol; Inositol, allo-; Inositol, muco-; Inositol, i-; Inositol, scyllo-; Inositol (VAN); alloinositol; neoinositol; Hexahydroxycyclohexane; scyllo-Cyclohexanehexol; 1D-myo-Inositol; 1L-myo-Inositol; Inositol, cis-; Inositol, epi-; Inositol, neo-; epi-Cyclohexanehexol; (+)-Inositol; 1,2,3,4,5,6-Cyclohexanehexol; (-)-chiro-Inositol; ELND005; Rat antispectacled eye factor; Levoinositol; CCRIS 6745; 1,2,3,5-trans-4,6-Cyclohexanehexol, cis-; AZD 103; Chiro-inositol, (-)-; Inositol, myo; (1R,2R,3S,4R,5r,6S)-cyclohexane-1,2,3,4,5,6-hexaol; 38876-99-2; MFCD00077932; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexol; 1,3,5/2,4,6-Hexahydroxycyclohexane; (1R,2R,3R,4R,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; (1R,2R,3S,4S,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; 1-L-chiro-Inositol; Inositol, D-chiro-; (+)-Chiro-Inositol; CHEBI:17268; AI3-16111; NSC8101; 1,3,5/2,4,6-cyclohexanehexol; 1,2,3,5/4,6-Cyclohexanehexol; NSC 8101; NSC-8101; Chiro-inositol, (+)-; (1r,2R,3S,4r,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1R,2R,3R,4S,5S,6s)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2R,3S,4S,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; 1,2,3,4,5,6-HEXAHYDROXY-CYCLOHEXANE; NSC-25142; NSC-55551; NSC404118; myo-Inositol;meso-Inositol; NSC 404118; NSC-404118; J101.890F; J101.891D; (1s,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol; 63GQX5QW03; 8LQ63P85IC; 9O6Y5O4P9W; ELND-005; R1Y9F3N15A; (1R,2R,3R,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1r,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1s,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; DTXSID7023146; CHEBI:10642; CHEBI:23927; CHEBI:27372; CHEBI:27987; AZD-103; 4661D3JP8D; 6R79WV4R10; M94176HJ2F; Inositol (VAN8C; NSC45517; NSC55551; NSC55552; NSC-55552; NSC-55558; 1VS4X81277; NSC-103959; NSC-127230; INS; NCGC00159409-02; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; 4L6452S749; 587A93P465; Inositol, myo- (8CI); MYO-INOSITOL-1,2,3,4,5,6-D6; 1,3,4,5,6-Cyclohexanehexol; 1,3,5/4,6-Cyclohexanehexol; DTXCID2065254; 1,2,4/3,5,6-cyclohexanehexol; rel-(1r,2r,3r,4r,5r,6r)-Cyclohexane-1,2,3,4,5,6-hexaol; rel-(1R,2r,3S,4R,5s,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; Mouse antialopecia factor; 1,2,3,4,5,6-Cyclohexanehexol #; cis-1,2,3,4,5,6-cyclohexanehexol; CAS-87-89-8; cis-1,3,5-trans-4,6-Cyclohexanehexol; SMR000857145; SMR000857319; SMR000857320; Inositol NF 12; ELND 005; SR-05000001655; EINECS 201-781-2; MFCD00065455; 1,2,3,4,5,6-Hexahydroxycyclohexane; inositols; UNII-63GQX5QW03; UNII-8LQ63P85IC; UNII-9O6Y5O4P9W; UNII-R1Y9F3N15A; an inositol; Inositol [Nonspecific isomer]; UNII-4661D3JP8D; UNII-6R79WV4R10; UNII-M94176HJ2F; Muscle sugar; inositol myo-; D-muco-Inositol; UNII-1VS4X81277; Inositol FCC; 4irx; Inositol, chiro-; rac-chiro-inositol; UNII-4L6452S749; UNII-587A93P465; Inosital (TN); Inositol (NF); CBU; EINECS 207-681-5; EINECS 207-682-0; EINECS 209-000-7; EINECS 211-393-5; EINECS 211-394-0; EINECS 230-024-9; NSC 25142; EPIINOSITOL; (+)-Epi-Inositol; CHIRO-INOSITOLS; Epi-inositol, 98%; allo-Inositol, 97%; Inositol [USAN:NF]; INOSITOL, MESO; Spectrum_001595; 2os9; INOSITOL [INCI]; INOSITOL [USAN]; INOSITOL [FCC]; INOSITOL [INN]; orthorhombic myo-inositol; D-(+)-Chiro Inositol; DL-CHIRO-INOSITOL; INOSITOL [MI]; INOSITOL (D); INOSITOL (L); INOSITOL [VANDF]; Spectrum3_001053; Spectrum4_001193; Spectrum5_000961; myo-Inositol, >=99%; INOSITOL [MART.]; bmse000102; bmse000103; bmse000113; bmse000901; bmse000922; Epitope ID:144993; INOSITOL [USP-RS]; INOSITOL [WHO-DD]; scyllo-Inositol, >=98%; SCHEMBL5831; SCHEMBL5832; SCHEMBL5969; NCIOpen2_008191; BSPBio_002606; KBioGR_001885; KBioSS_002075; MLS001332377; MLS001332378; MLS001335965; MLS001335966; MLS001335967; MLS001335968; SCHEMBL187278; SCHEMBL187397; SCHEMBL187796; SCHEMBL188106; SCHEMBL188237; SCHEMBL491333; SCHEMBL959404; SCHEMBL959405; CHEMBL278373; CHEMBL468154; GTPL4495; GTPL4645; GTPL4648; GTPL4649; MEGxp0_001817; SCHEMBL1055883; SCHEMBL4748543; SCHEMBL6378921; SCHEMBL6468882; SCHEMBL6791918; CHEMBL1222251; CHEMBL1231671; CHEMBL1950780; CHEMBL3976780; SCHEMBL12371461; SCHEMBL12377889; SCHEMBL12411898; SCHEMBL12711208; SCHEMBL12735687; SCHEMBL13058696; SCHEMBL13114115; SCHEMBL13114116; SCHEMBL13114128; SCHEMBL13207905; SCHEMBL13580047; SCHEMBL14542470; SCHEMBL21388397; ACon1_002457; CHEBI:22357; CHEBI:23311; CHEBI:24848; CHEBI:25492; CHEBI:27374; D-(+)-chiro-Inositol, 95%; KBio2_002075; KBio2_004643; KBio2_007211; KBio3_001826; L-(-)-chiro-Inositol, 95%; DTXSID30110000; DTXSID50905091; myo-Inositol, p.a., 98.0%; 1,2,3,4,5/6-cyclohexanehexol; 1,2,3,4/5,6-cyclohexanehexol; 1,2,3/4,5,6-cyclohexanehexol; 1,2,4,5/3,6-cyclohexanehexol; DTXSID101028818; DTXSID101028820; DTXSID201028823; DTXSID301028826; DTXSID601028825; DTXSID901028824; HMS2091N13; HMS2230N03; HMS2235H05; HMS2235M23; HMS3369B06; HMS3369F20; HMS3373E05; Pharmakon1600-01500352; D-CHIRO-INOSITOL [USP-RS]; D-CHIRO-INOSITOL [WHO-DD]; 1,2,3,4,5,6-Cyclohexanehexaol; BCP25172; HY-B1411; HY-N3021; MYO-INOSITOL [EP MONOGRAPH]; NSC25142; NSC55558; D-myo-Inositol, Cell Culture Grade; Tox21_111642; Tox21_302035; CCG-36096; cis-Inositol, >=98.0% (TLC); MFCD00003863; MFCD00272608; MFCD00799555; MFCD00799556; MFCD01321249; NSC 55552; NSC 55558; NSC-45517; NSC103959; NSC127230; NSC757076; s4530; STL453612; epi-Inositol, >=98.0% (HPLC); 1,2,3,4,5,6/0-cyclohexanetetrol; AKOS006240678; AKOS006332036; AKOS015895894; AKOS015912905; AKOS015912934; AKOS015960429; AKOS015960633; AKOS015994742; AKOS024318869; Tox21_111642_1; CS-4782; CS-W010757; CS-W017225; DB03106; DB13178; DB15350; HY-W010041; HY-W016509; HY-W021265; HY-W127726; J9.771C; KS-1284; KS-1420; NSC 103959; NSC 127230; NSC-757076; SB44732; SB45039; SB46764; SB46855; D-chiro-Inositol, >=98.0% (HPLC); NCGC00159409-03; NCGC00159409-04; NCGC00169828-01; NCGC00178580-01; NCGC00178580-03; NCGC00255362-01; AC-11070; AS-10616; AS-68396; AS-68424; cyclohexane-1R,2R,3S,4S,5R,6S-hexol; LS-13189; NCI60_041778; SY060836; myo-Inositol, purum, >=98.0% (HPLC); rac-chiro-1,2,3,4,5,6-cyclohexanehexol; SBI-0051369.P003; cis-1,2,4-trans-3,5,6-Cyclohexanehexol; DB-051583; DB-051584; DB-054642; HY-121962; J101.888D; J101.889B; J101.892B; myo-Inositol, for microbiology, >=99.0%; CS-0023004; CS-0083766; CS-0369552; FT-0627237; FT-0632208; FT-0632209; FT-0632730; FT-0652045; FT-0670351; FT-0670357; FT-0693444; FT-0693614; I0040; I0628; I0629; I0630; I0631; I0632; I0633; S6176; EN300-82941; myo-Inositol, BioUltra, >=99.5% (HPLC); myo-Inositol, SAJ special grade, >=99.0%; myo-Inositol, Vetec(TM) reagent grade, 99%; C00137; C06151; C06152; C06153; C19891; D08079; D78450; D91187; D91188; D91189; E78671; EN300-658805; F19572; I-6500; M01914; T72516; AB00051982_13; EN300-7361851; EN300-7411506; A834712; A836375; A866896; EN300-19631206; EN300-19632288; EN300-25914216; Q407997; Q743661; Q-201583; Q2838375; Q2974313; Q3011024; Q3023527; Q3205874; Q3331426; Q3347078; Q3589114; SR-05000001655-1; SR-05000001655-5; W-202861; W-202862; W-203081; W-203168; W-203392; 1,2,4/3,5,6-Cyclohexane-1,2,3,4,5,6-hexol; 7B0CEF84-D9CE-4A88-AA7D-EC50C89387A5; 1D7A27BF-6060-4FA9-AC46-3BD18DBA406E; 220128F1-89BF-442D-AD6D-E6D1EA7BA625; Z1486007281; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2S,3r,4R,5S,6r)-cyclohexane-1,2,3,4,5,6-hexol; (1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol; (1R,2S,3s,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol; D-MYO-INOSITOL-1,2,5,6-TETRAPHOSPHATE SODIUM SALT; Inositol, United States Pharmacopeia (USP) Reference Standard; myo-Inositol, European Pharmacopoeia (EP) Reference Standard; (1R,2R,3S,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; 1,2,3,4,5,6-Cyclohexanehexol, (cis,cis,cis,trans,cis,trans)- #; 1,2,3,4,5,6-cyclohexanehexol, (1alpha,2alpha,3alpha,4beta,5alpha,6beta); Inositol, Pharmaceutical Secondary Standard; Certified Reference Material; 1.ALPHA.,2.ALPHA.,3.BETA.,4.ALPHA.,5.BETA.,6.BETA.-CYCLOHEXANEHEXOL; 2H3; myo-Inositol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture	Phase 2	Drugs in Phase 2 Trial	892	DB03106	D03SHD	180.16	121	104	-3.7	12	6	6	0	C6H12O6	cyclohexane-1,2,3,4,5,6-hexol	C1(C(C(C(C(C1O)O)O)O)O)O	C1(C(C(C(C(C1O)O)O)O)O)O	InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H	CDAISMWEOUEBRE-UHFFFAOYSA-N
DK68QF	Flupirtine	Small molecule	Flupirtine; 56995-20-1; ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate; C15H17FN4O2; D 9998; MOH3ET196H; Flupirtine (INN); FLUPIRTINE [INN]; W-2964; Flupirtino; Flupirtinum; Flupirtine [INN:BAN]; MLS002153180; Flupirtinum [INN-Latin]; Flupirtino [INN-Spanish]; Carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester; NCGC00015451-03; SMR001230672; EINECS 260-503-8; UNII-MOH3ET196H; Flupirtinte; Flupirtin; Ethyl (2-amino-6-((4-fluorobenzyl)amino)pyridin-3-yl)carbamate; ethyl {2-amino-6-[(4-fluorobenzyl)amino]pyridin-3-yl}carbamate; Carbamic acid, [2-amino-6-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]-, ethyl ester; NCGC00015451-01; ethyl 2-amino-6-((p-fluorobenzyl)amino)-3-pyridinecarbamate; FLUPIRTINE [MI]; Lopac-F-8927; FLUPIRTINE [VANDF]; FLUPIRTINTE [VANDF]; FLUPIRTINE [WHO-DD]; Lopac0_000547; SCHEMBL25009; Flupirtine, analytical standard; CHEMBL255044; GTPL2598; DTXSID4048436; BDBM81199; CHEBI:94646; ethyl 2-amino-6-(4-fluorobenzylamino)pyridin-3-ylcarbamate; cid_25162978; HY-17001A; STL483409; AKOS024457318; CCG-204637; CS-1746; DB06623; SDCCGSBI-0050530.P002; NCGC00015451-02; NCGC00015451-04; NCGC00015451-06; NCGC00015451-17; NCGC00162182-01; AS-56215; D07978; Q415403; 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine; (Z)-but-2-enedioate;ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate; N-[2-amino-6-[(4-fluorobenzyl)amino]-3-pyridyl]carbamic acid ethyl ester;maleate; N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester; (Z)-but-2-enedioate;ethyl N-[2-azanyl-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate; 1198579-27-9; CARBAMIC ACID, (2-AMINO-6-(((4-FLUOROPHENYL)METHYL)AMINO)-3-PYRIDINYL)-, ETHYL ESTER, (Z)-2-; N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester;(Z)-2-butenedioate	Phase 2	Drugs in Phase 2 Trial	53276	DB06623	D0SD9V	304.32	89.3	350	2.4	22	3	6	6	C15H17FN4O2	ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate	CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N	CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N	InChI=1S/C15H17FN4O2/c1-2-22-15(21)19-12-7-8-13(20-14(12)17)18-9-10-3-5-11(16)6-4-10/h3-8H,2,9H2,1H3,(H,19,21)(H3,17,18,20)	JUUFBMODXQKSTD-UHFFFAOYSA-N
DM70FZ	5-fluoro-2'-deoxycytidine	Small molecule	10356-76-0; 2'-Deoxy-5-fluorocytidine; 5-FLUORO-2'-DEOXYCYTIDINE; FdCyd; 5-Fluorodeoxycytidine; FCdR; 4-amino-5-fluoro-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 5-Fluoro-2-deoxycytidine; NSC-48006; Cytidine, 2'-deoxy-5-fluoro-; Ro 5-1090; KUA4693H5W; CHEMBL1076257; 5-Fluor-desoxycytidin; 2'-Deoxy-5-fluorcytidine; UNII-KUA4693H5W; 2'-deoxy-5-fluoro-Cytidine; 5-Fluor-desoxycytidin [German]; 3ipx; MFCD00077348; NSC 48006; BRN 0619209; 5-Fluoro 2'-deoxycytidine; SCHEMBL8345; 2''-deoxy-5-fluorocytidine; Cytidine, 2'-deoxy-5-fluoro-;Cytidine, 2'-deoxy-5-fluoro-; MLS006010723; Cytidine,2'-deoxy-5-fluoro-; DTXSID2030437; BCP18422; BDBM50311540; s2477; ZB1480; AKOS015853117; AKOS016002166; DB12957; 4-amino-5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; NCGC00346830-01; AC-32303; AS-74677; BP-58661; SMR004701686; HY-116217; RO-5-1090; CS-0064397; D3642; A800762; 5-Fluoro-2'-deoxycytidine, >=98% (HPLC), powder; Q27282447; 4-amino-1-[2-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 4-Amino-5-fluoro-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; 4-amino-5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one; 4-amino-5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; B86	Phase 2	Drugs in Phase 2 Trial	515328	DB12957	D0D1LS	245.21	108	398	-1.5	17	3	5	2	C9H12FN3O4	4-amino-5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one	C1C(C(OC1N2C=C(C(=NC2=O)N)F)CO)O	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=NC2=O)N)F)CO)O	InChI=1S/C9H12FN3O4/c10-4-2-13(9(16)12-8(4)11)7-1-5(15)6(3-14)17-7/h2,5-7,14-15H,1,3H2,(H2,11,12,16)/t5-,6+,7+/m0/s1	IDYKCXHJJGMAEV-RRKCRQDMSA-N
DLO34J	Telatinib	Small molecule	Telatinib; 332012-40-5; Bay 57-9352; Telatinib (BAY 57-9352); Telatinib [INN]; BAY-579352; 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide; 4-[[4-(4-Chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methyl-pyridine-2-carboxamide; BAY57-9352; BAY-57-9352; CHEMBL2079588; 18P7197Q7J; 4-(((4-((4-chlorophenyl)amino)furo[2,3-d]pyridazin-7-yl)oxy)methyl)-N-methylpicolinamide; 4-((4-(4-chlorophenylamino)furo[2,3-d]pyridazin-7-yloxy)methyl)-N-methylpicolinamide; UNII-18P7197Q7J; TELATINIB [WHO-DD]; MLS006010950; SCHEMBL1250560; Bay 57-9352 (Telatinib); GTPL10476; Telatinib - BAY 57-9352; DTXSID70954809; EX-A007; BCPP000050; HMS3655F14; BCP02409; BAY579352; BDBM50399538; MFCD18251453; NSC776017; NSC800944; s2231; AKOS015909525; BAY 579352; CCG-264951; CS-3722; DB15393; EX-8672; NSC-776017; NSC-800944; PB30302; SB13250; NCGC00249392-01; NCGC00249392-05; 2-Pyridinecarboxamide, 4-(((4-((4-chlorophenyl)amino)furo(2,3-d)pyridazin-7-yl)oxy)methyl)-N-methyl-; AC-25239; example 14 [WO2001023375A2]; HY-10527; MS-27057; SMR004702754; FT-0674832; SW220176-1; A25614; J-524317; Q27252023; 4-(((4-((4-CHLOROPHENYL)AMINO)FURO(2,3-D)PYRIDAZIN-7-YL)OXY)METHYL)-N-METHYLPYRIDINE-2-CARBOXAMIDE; 4-({[4-(4-Chloroanilino)furo[2,3-d]pyridazin-7-yl]oxy}methyl)-N-methylpyridine-2-carboxamide	Phase 2	Drugs in Phase 2 Trial	9808844	DB15393	D07NOI	409.8	102	548	3.1	29	2	7	6	C20H16ClN5O3	4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide	CNC(=O)C1=NC=CC(=C1)COC2=NN=C(C3=C2OC=C3)NC4=CC=C(C=C4)Cl	CNC(=O)C1=NC=CC(=C1)COC2=NN=C(C3=C2OC=C3)NC4=CC=C(C=C4)Cl	InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)	QFCXANHHBCGMAS-UHFFFAOYSA-N
DK2N6E	CHF5074	Small molecule	749269-83-8; CHF 5074; Itanapraced; CHF-5074; CHF5074; 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid; 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid; C35RF1MWQZ; CHEMBL196945; CSP-1103; CHF5074;CSP-1103; 1-(3',4'-Dichloro-2-Fluorobiphenyl-4-Yl)cyclopropanecarboxylic Acid; Cyclopropanecarboxylic acid, 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)-; UNII-C35RF1MWQZ; GHF-5074; H50; ITANAPRACED [INN]; ITANAPRACED [WHO-DD]; SCHEMBL407631; GTPL7339; CSP1103; DTXSID30225901; HMS3886F13; BCP30410; EX-A1963; ZEB26983; BDBM50172482; s7323; AKOS026750398; CS-5022; SB16945; NCGC00408905-01; AC-36860; AS-16850; DA-34983; HY-14399; FT-0708261; Q27075958; 1-(3'',4''-Dichloro-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid; 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropane carboxylic acid; CHF-5074; CHF5074; Itanapraced; CSP-1103; CSP1103; CSP 1103; 1-(3',4'-dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid	Phase 2	Drugs in Phase 2 Trial	9996409	DB16825	D03MFQ	325.2	37.3	413	4.7	21	1	3	3	C16H11Cl2FO2	1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid	C1CC1(C2=CC(=C(C=C2)C3=CC(=C(C=C3)Cl)Cl)F)C(=O)O	C1CC1(C2=CC(=C(C=C2)C3=CC(=C(C=C3)Cl)Cl)F)C(=O)O	InChI=1S/C16H11Cl2FO2/c17-12-4-1-9(7-13(12)18)11-3-2-10(8-14(11)19)16(5-6-16)15(20)21/h1-4,7-8H,5-6H2,(H,20,21)	LIYLTQQDABRNRX-UHFFFAOYSA-N
DW7CG2	PBT2	Small molecule	PBT-1033; 747408-78-2; 5,7-dichloro-2-[(dimethylamino)methyl]quinolin-8-ol; PBT-2; PBT2; 8-Quinolinol, 5,7-dichloro-2-((dimethylamino)methyl)-; PB 1033; Q7K6GJQ4O4; PBT 1033; 5,7-Dichloro-2-((dimethylamino)methyl)quinolin-8-ol; PBT2 Compound; PBT 2; PBT 2 (anti-Alzheimer agent); UNII-Q7K6GJQ4O4; 5,7-dichloro-2-(dimethylaminomethyl)quinolin-8-ol; SCHEMBL8342589; CHEMBL3634131; GTPL11108; PBT1033; DTXSID701029571; BCP19805; EX-A4581; MFCD30749371; AKOS037644486; DB05565; 1123760-88-2; AS-53797; HY-105321; CS-0025730; EN300-305718; P17129; 5,7-Dichloro-2-(dimethylaminomethyl)-8-quinolinol; Q7118446; 5,7-Dichloro-2-[(dimethylamino)methyl]-8-quinolinol; PBT-2; PBT1033; PBT2; PBT 1033; PBT 2; Z2525155501	Phase 2	Drugs in Phase 2 Trial	10016012	DB05565	D00GXL	271.14	36.4	265	3	17	1	3	2	C12H12Cl2N2O	5,7-dichloro-2-[(dimethylamino)methyl]quinolin-8-ol	CN(C)CC1=NC2=C(C=C1)C(=CC(=C2O)Cl)Cl	CN(C)CC1=NC2=C(C=C1)C(=CC(=C2O)Cl)Cl	InChI=1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3	YZPOQCQXOSEMAZ-UHFFFAOYSA-N
D6RLC1	AZD8848	Small molecule	AZD8848; AZD-8848; DSP-3025; 866269-28-5; 322ZMR6920; UNII-322ZMR6920; 866269-28-5 (free base); methyl 2-(3-(((3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl)(3-morpholinopropyl)amino)methyl)phenyl)acetate; Benzeneacetic acid, 3-(((3-(6-amino-2-butoxy-7,8-dihydro-8-oxo-9H-purin-9-yl)propyl)(3-(4-morpholinyl)propyl)amino)methyl)-, methyl ester; Methyl 2-(3-(((3-(6-amino-2-butoxy-8-oxo-7H-purin-9(8H)-yl)propyl)(3-morpholinopropyl)amino)methyl)phenyl)acetate; GTPL9256; CHEMBL4297356; SCHEMBL12047493; AZD 8848 [WHO-DD]; AZD 8848; DB14868; MS-30302; HY-111269; CS-0034794; Q27074812; 1310826-85-7; Methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate; methyl 2-[3-[[3-(6-amino-2-butoxy-8-oxo-7H-purin-9-yl)propyl-(3-morpholin-4-ylpropyl)amino]methyl]phenyl]acetate	Phase 2	Drugs in Phase 2 Trial	11592228	DB14868	D04XCO	569.7	135	802	2.3	41	2	10	17	C29H43N7O5	methyl 2-[3-[[3-(6-amino-2-butoxy-8-oxo-7H-purin-9-yl)propyl-(3-morpholin-4-ylpropyl)amino]methyl]phenyl]acetate	CCCCOC1=NC(=C2C(=N1)N(C(=O)N2)CCCN(CCCN3CCOCC3)CC4=CC=CC(=C4)CC(=O)OC)N	CCCCOC1=NC(=C2C(=N1)N(C(=O)N2)CCCN(CCCN3CCOCC3)CC4=CC=CC(=C4)CC(=O)OC)N	InChI=1S/C29H43N7O5/c1-3-4-16-41-28-32-26(30)25-27(33-28)36(29(38)31-25)13-7-12-35(11-6-10-34-14-17-40-18-15-34)21-23-9-5-8-22(19-23)20-24(37)39-2/h5,8-9,19H,3-4,6-7,10-18,20-21H2,1-2H3,(H,31,38)(H2,30,32,33)	FEFIBEHSXLKJGI-UHFFFAOYSA-N
DLK3P0	AZD1386	Small molecule	azd1386; 946080-23-5; AZD 1386; CID 24752296; 5'-chloro-7'-methyl-1'-[[3-(trifluoromethyl)phenyl]methyl]spiro[imidazolidine-5,3'-indole]-2,2',4-trione; 5/'-chloro-7/'-methyl-1/'-[[3-(trifluoromethyl)phenyl]methyl]spiro[imidazolidine-5,3/'-indole]-2,2/',4-trione; GTPL7820; SCHEMBL4257077; CHEMBL3545039; KB-270807; AZ12457709; Q27074708	Phase 2	Drugs in Phase 2 Trial	24752296	DB15333	D04PMM	423.8	78.5	733	3.2	29	2	6	2	C19H13ClF3N3O3	5'-chloro-7'-methyl-1'-[[3-(trifluoromethyl)phenyl]methyl]spiro[imidazolidine-5,3'-indole]-2,2',4-trione	CC1=CC(=CC2=C1N(C(=O)C23C(=O)NC(=O)N3)CC4=CC(=CC=C4)C(F)(F)F)Cl	CC1=CC(=CC2=C1N(C(=O)C23C(=O)NC(=O)N3)CC4=CC(=CC=C4)C(F)(F)F)Cl	InChI=1S/C19H13ClF3N3O3/c1-9-5-12(20)7-13-14(9)26(16(28)18(13)15(27)24-17(29)25-18)8-10-3-2-4-11(6-10)19(21,22)23/h2-7H,8H2,1H3,(H2,24,25,27,29)	DXDVSYALLVVBOV-UHFFFAOYSA-N
DA5O8G	PF-04457845	Small molecule	PF-04457845; 1020315-31-4; PF 04457845; PF04457845; N-pyridazin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxamide; H4C81M8YYW; CHEMBL1651534; PF-4457845; 1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-; N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; N-Pyridazin-3-yl-4-[(3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl)methylidene]piperidine-1-carboxamide; 1-Piperidinecarboxamide, N-3-pyridazinyl-4-((3-((5-(trifluoromethyl)-2-pyridinyl)oxy)phenyl)methylene)-; 1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-;1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-; N-(pyridazin-3-yl)-4-[(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)methylidene]piperidine-1-carboxamide; N-3-Pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-1-piperidinecarboxamide; N-Pyridazin-3-yl-4-((3-(5-(trifluoromethyl)pyridin-2-yl)oxyphenyl)methylidene)piperidine-1-carboxamide; UNII-H4C81M8YYW; compound 23 [PMID: 21666860]; GTPL6694; SCHEMBL1010408; DTXSID00144539; BCP05805; EX-A2309; BDBM50335377; MFCD18782721; s2421; AKOS027338651; CS-0868; DB12012; SB17493; NCGC00378983-01; NCGC00378983-03; AC-36022; AS-74797; HY-14376; A855972; PF-04457845, >=98% (HPLC); Q7119045; N-pyridazin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxami	Phase 2	Drugs in Phase 2 Trial	24771824	DB12012	D0JT5I	455.4	80.2	680	3.3	33	1	8	4	C23H20F3N5O2	N-pyridazin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxamide	C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4	C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4	InChI=1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32)	BATCTBJIJJEPHM-UHFFFAOYSA-N
D08PWS	SAR125844	Small molecule	SAR125844; 1116743-46-4; SAR-125844; XH93U6NIJE; CHEMBL4461070; 1-(6-((6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)thio)benzo[d]thiazol-2-yl)-3-(2-morpholinoethyl)urea; Urea, N-[6-[[6-(4-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]thio]-2-benzothiazolyl]-N'-[2-(4-morpholinyl)ethyl]-; 1-(6-((6-(4-Fluorophenyl)(1,2,4)triazolo(4,3-b)pyridazin-3-yl)sulfanyl)-1,3-benzothiazol-2-yl)-3-(2-(morpholin-4-yl)ethyl)urea; Urea, N-(6-((6-(4-fluorophenyl)-1,2,4-triazolo(4,3-b)pyridazin-3-yl)thio)-2-benzothiazolyl)-N'-(2-(4-morpholinyl)ethyl)-; UNII-XH93U6NIJE; 1-(6-{[6-(4-Fluorophenyl)[1,2,4]triazolo[4,3-B]pyridazin-3-Yl]sulfanyl}-1,3-Benzothiazol-2-Yl)-3-[2-(Morpholin-4-Yl)ethyl]urea; SCHEMBL2801192; DTXSID901031348; BCP28183; EX-A2198; BDBM50532757; NSC771652; s7564; SAR125884; DB15382; NSC-771652; SAR 125844; SB16715; AC-35976; BS-14459; HY-16446; CS-0006341; J3.534.595G; N17079; SAR 125844; SAR-125844; 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulphanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea; 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulphanyl}-1,3-benzothiazol-2-yl)-3-[2-(morpholin-4-yl)ethyl]urea; 1-[6-[[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea; 2-(4-Fluorophenyl)-7-[[2-[[[(2-morpholinoethyl)amino]carbonyl]amino]benzothiazole-6-yl]thio]-5,6-diazapyrrolo[1,2-b]pyridazine	Phase 2	Drugs in Phase 2 Trial	25182860	DB15382	D07ARN	550.6	163	791	3.4	38	2	10	7	C25H23FN8O2S2	1-[6-[[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea	C1COCCN1CCNC(=O)NC2=NC3=C(S2)C=C(C=C3)SC4=NN=C5N4N=C(C=C5)C6=CC=C(C=C6)F	C1COCCN1CCNC(=O)NC2=NC3=C(S2)C=C(C=C3)SC4=NN=C5N4N=C(C=C5)C6=CC=C(C=C6)F	InChI=1S/C25H23FN8O2S2/c26-17-3-1-16(2-4-17)19-7-8-22-30-31-25(34(22)32-19)37-18-5-6-20-21(15-18)38-24(28-20)29-23(35)27-9-10-33-11-13-36-14-12-33/h1-8,15H,9-14H2,(H2,27,28,29,35)	ODIUNTQOXRXOIV-UHFFFAOYSA-N
DMO7C2	AZD2014	Small molecule	AZD2014; 1009298-59-2; Vistusertib; AZD-2014; Vistusertib [INN]; AZD 2014; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib (AZD-2014); Vistusertib [USAN]; vistusertib (AZD2014); 0BSC3P4H5X; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; CHEMBL2336325; C25H30N6O3; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; Benzamide, 3-(2,4-bis((3S)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-N-methyl-; 3-(2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido(5,6-e)pyrimidin-7-yl)-N-methylbenzamide; UNII-0BSC3P4H5X; cc-551; Benzamide, 3-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-N-methyl-; Vistusertib (JAN/INN); VISTUSERTIB [JAN]; Vistusertib [USAN:INN]; VISTUSERTIB [WHO-DD]; MLS006011011; SCHEMBL290672; GTPL7699; DTXSID20143584; EX-A155; AMY24188; BCP05748; BDBM50429701; MFCD22628784; NSC767189; NSC780879; NSC787289; NSC799345; s2783; AKOS024464879; BCP9000362; CCG-269370; CS-0701; DB11925; NSC-767189; NSC-780879; NSC-787289; NSC-799345; NCGC00346698-04; NCGC00346698-11; NCGC00346698-12; AC-28425; AS-16302; HY-15247; SMR004702809; SW219704-1; D10887; J-000268; Q27089147; 3-[2,4-Bis-[(3S)-3-methyl-4-morpholinyl]-pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; 3-[2,4-Bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide	Phase 2	Drugs in Phase 2 Trial	25262792	DB11925	D0Z2UQ	462.5	92.7	698	2.8	34	1	8	4	C25H30N6O3	3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide	CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOCC5C	C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOC[C@@H]5C	InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1	JUSFANSTBFGBAF-IRXDYDNUSA-N
DL7MA6	Foretinib	Small molecule	Foretinib; 849217-64-7; GSK1363089; XL880; EXEL-2880; Foretinib (GSK1363089); GSK089; XL-880; GSK 1363089; XL 880; EXEL 2880; GSK-1363089; Foretinib(XL880); GSK-089; GSK1363089G; 81FH7VK1C4; GSK-1363089G; 937176-80-2; N-[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; 88Z; n-(3-fluoro-4-((6-methoxy-7-(3-(4-morpholinyl)propoxy)-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; N-(3-Fluoro-4-{[6-Methoxy-7-(3-Morpholin-4-Ylpropoxy)quinolin-4-Yl]oxy}phenyl)-N'-(4-Fluorophenyl)cyclopropane-1,1-Dicarboxamide; N-[3-fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl]oxy)phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; xl-880, Foretinib; FORETINIB [INN]; Foretinib (USAN/INN); Foretinib [USAN:INN]; FORETINIB [USAN]; FORETINIB [WHO-DD]; UNII-81FH7VK1C4; MLS006010302; SCHEMBL371804; Foretinib - GSK1363089; GTPL5679; CHEMBL1230609; CHEBI:91418; DTXSID20918193; EX-A050; BCPP000236; HMS3295K13; HMS3654G04; BCP02231; BDBM50399540; GSK 1363089G; MFCD16038048; NSC755775; NSC800101; s1111; Foretinib,XL880, GSK1363089; AKOS015904319; BCP9000675; CCG-270292; CS-0153; DB12307; NSC-755775; NSC-800101; PB27007; SB20469; Foretinib (GSK1363089, XL880); NCGC00263104-01; NCGC00263104-10; AC-25081; AS-16268; HY-10338; SMR003599144; SW219390-1; EC-000.2326; A25642; D09618; J-523004; Q5469311; BRD-K03449891-001-01-1; 1,1-CYCLOPROPANEDICARBOXAMIDE, N-(3-FLUORO-4-((6-METHOXY-7-(3-(4- MORPHOLINYL)PROPOXY)-4-QUINOLINYL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)-; 1,1-Cyclopropanedicarboxamide, N-(3-fluoro-4-((6-methoxy-7-(3-(4-morpholinyl)propoxy)-4-quinolinyl)oxy)phenyl)-N'-(4-fluorophenyl)-; 1-N'-[3-fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; 1-N'-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; GSK1363089;EXEL-2880;Foretinib;N-[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide;Foretinib; N-(3-FLUORO-4-((6-METHOXY-7-(3-(MORPHOLIN-4-YL)PROPOXY)QUINOLIN-4-YL)OXY) PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE; N-(4-(7-(3-MORPHOLINOPROPOXY)-6-METHOXYQUINOLIN-4-YLOXY)-3-FLUOROPHENYL)-N-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE; N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin 4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Phase 2	Drugs in Phase 2 Trial	42642645	DB12307	D0D1GF	632.7	111	1010	5.5	46	2	10	12	C34H34F2N4O6	1-N'-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F	COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F	InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)	CXQHYVUVSFXTMY-UHFFFAOYSA-N
D4F7WP	GSK2245035	Small molecule	GSK2245035; 1207629-49-9; GSK-2245035; 5L3SX16QBQ; 6-amino-2-[(2S)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7H-purin-8-one; 6-amino-7,9-dihydro-2-[(1S)-1-methylbutoxy]-9-[5-(1-piperidinyl)pentyl]-8H-purin-8-one; 8H-Purin-8-one, 6-amino-7,9-dihydro-2-((1S)-1-methylbutoxy)-9-(5-(1-piperidinyl)pentyl)-; UNII-5L3SX16QBQ; SCHEMBL565847; GTPL9254; CHEMBL4297492; compound 32 [PMID: 26861551]; MS-26512; HY-118250; CS-0065520; J3.609.218A; F3409-0744; (S)-6-amino-2-(pentan-2-yloxy)-9-(5-(piperidin-1-yl)pentyl)-7,9-dihydro-8H-purin-8-one; 6-amino-2-[(2S)-pentan-2-yloxy]-9-[5-(piperidin-1-yl)pentyl]-8,9-dihydro-7H-purin-8-one; 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl) pentyl]-7,9-dihydro-8H-purin-8-one; 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one; 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9[5-(1-piperidinyl) pentyl]-7,9-dihydro-8H-purin-8-one	Phase 2	Drugs in Phase 2 Trial	44623937	DB16076	D04PAU	390.5	96.6	487	3	28	2	6	10	C20H34N6O2	6-amino-2-[(2S)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7H-purin-8-one	CCCC(C)OC1=NC(=C2C(=N1)N(C(=O)N2)CCCCCN3CCCCC3)N	CCC[C@H](C)OC1=NC(=C2C(=N1)N(C(=O)N2)CCCCCN3CCCCC3)N	InChI=1S/C20H34N6O2/c1-3-10-15(2)28-19-23-17(21)16-18(24-19)26(20(27)22-16)14-9-5-8-13-25-11-6-4-7-12-25/h15H,3-14H2,1-2H3,(H,22,27)(H2,21,23,24)/t15-/m0/s1	LFMPVTVPXHNXOT-HNNXBMFYSA-N
D3SPF1	BMS-708163	Small molecule	Avagacestat; 1146699-66-2; BMS-708163; BMS 708163; BMS-708163-01; BMS-708163 (Avagacestat); Avagacestat (BMS-708163); Avagacestat [USAN:INN]; UNII-TQ44WWY45Q; TQ44WWY45Q; Avagacestat [USAN]; BMS708163; BMS-70816301; MFCD13195458; Avagacestat (USAN); (2R)-2-(N-((4-Chlorophenyl)sulfonyl)-N-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoropentanamide; (2R)-2-[N-[(4-CHLOROPHENYL)SULFONYL]-N-[2-FLUORO-4-(1,2,4-OXADIAZOL-3-YL)BENZYL]AMINO]-5,5,5-TRIFLUOROPENTANAMIDE; (2R)-2-[(4-Chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoro-pentanamide; (2R)-5,5,5-trifluoro-2-(N-{[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl}4-chlorobenzenesulfonamido)pentanamide; (2R)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoranyl-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-tris(fluoranyl)pentanamide; (2R)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide; (2R)-2-[[(4-Chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide; (R)-2-(4-Chloro-N-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)-phenylsulfonamido)-5,5,5-trifluoropentanamide; PENTANAMIDE, 2-(((4-CHLOROPHENYL)SULFONYL)((2-FLUORO-4-(1,2,4-OXADIAZOL-3-YL)PHENYL)METHYL)AMINO)-5,5,5-TRIFLUORO-, (2R)-; Pentanamide, 2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoro-, (2R)-; AVAGACESTAT [INN]; AVAGACESTAT [WHO-DD]; MLS006011074; SCHEMBL310019; Avagacestat; BMS-708163; GTPL6489; CHEMBL1090771; Avagacestat, >=98% (HPLC); DTXSID40150811; CHEBI:177493; BCPP000327; HMS3884O07; (2R)-2-[[(4-Chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoro-pentanamide; BCP01770; EX-A2871; BBL102113; BDBM50458169; NSC761217; s1262; STL555912; AKOS005146523; AKOS016016280; BCP9000429; CCG-269860; CS-0180; DB11893; NSC-761217; MRF-0000009; NCGC00346504-01; AS-75078; HY-50845; SMR004676648; BCP0726000124; DB-024955; SW218162-2; C71464; D09869; A894166; Q27074630; (2R)-2-[(4-chlorophenyl)sulonyl-[[2-luoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-triluoropentanamide; (R)-2-((4-Chloro-N-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)phenyl)sulfonamido)-5,5,5-trifluoropentanamide; BMS-708163;(R)-2-(4-chloro-N-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)phenylsulfonamido)-5,5,5-trifluoropentanamide; EN9; N~2~-[(4-chlorophenyl)sulfonyl]-5,5,5-trifluoro-N~2~-[2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl]-D-norvalinamide	Phase 2	Drugs in Phase 2 Trial	46883536	DB11893	D02JOH	520.9	128	792	4	34	1	11	9	C20H17ClF4N4O4S	(2R)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide	C1=CC(=CC=C1S(=O)(=O)N(CC2=C(C=C(C=C2)C3=NOC=N3)F)C(CCC(F)(F)F)C(=O)N)Cl	C1=CC(=CC=C1S(=O)(=O)N(CC2=C(C=C(C=C2)C3=NOC=N3)F)[C@H](CCC(F)(F)F)C(=O)N)Cl	InChI=1S/C20H17ClF4N4O4S/c21-14-3-5-15(6-4-14)34(31,32)29(17(18(26)30)7-8-20(23,24)25)10-13-2-1-12(9-16(13)22)19-27-11-33-28-19/h1-6,9,11,17H,7-8,10H2,(H2,26,30)/t17-/m1/s1	XEAOPVUAMONVLA-QGZVFWFLSA-N
D91JRB	Nemiralisib	Small molecule	nemiralisib; 1254036-71-9; GSK-2269557 free base; GSK2269557; Nemiralisib [USAN]; OEP8JJ3OZR; GSK2269557A; 2-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole; CHEMBL2216859; GSK2269557 (free base); PI3Kdelta inhibitor GS2269557; GSK-2269557A; 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole; 1H-Indazole, 6-(1H-indol-4-yl)-4-(5-((4-(1-methylethyl)-1-piperazinyl)methyl)-2-oxazolyl)-; 1H-indazole, 6-(1H-indol-4-yl)-4-[5-[[4-(1-methylethyl)-1-piperazinyl]methyl]-2-oxazolyl]-; 6-(1H-Indol-4-yl)-4-(5-((4-(1-methylethyl)-1-piperazinyl)methyl)-1,3-oxazol-2-yl)-1H-indazole; UNII-OEP8JJ3OZR; NEMIRALISIB [INN]; Nemiralisib (USAN/INN); GSK2269557 free base; NEMIRALISIB [WHO-DD]; SCHEMBL109919; GTPL9425; EX-A5754; BDBM50004529; HY-19535A; s7937; CCG-269127; compound 2 [PMID: 26301626]; CS-5683; AC-35584; DA-36928; MS-27918; FT-0716060; D11267; Q27467143; 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole; 4-(5-(4-Isopropyl-1-piperazinyl)methyl-2-oxazolyl)-6-(1H-indole-4-yl)-1H-indazole; 6-(1H-INDOL-4-YL)-4-(5-((4-(1-METHYLETHYL)-1-PIPERAZINYL)METHYL)-2-OXAZOLYL)-1H-INDAZOLE; VVX	Phase 2	Drugs in Phase 2 Trial	49784002	DB16253	D06GUA	440.5	77	655	3.9	33	2	5	5	C26H28N6O	2-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole	CC(C)N1CCN(CC1)CC2=CN=C(O2)C3=C4C=NNC4=CC(=C3)C5=C6C=CNC6=CC=C5	CC(C)N1CCN(CC1)CC2=CN=C(O2)C3=C4C=NNC4=CC(=C3)C5=C6C=CNC6=CC=C5	InChI=1S/C26H28N6O/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30)	MCIDWGZGWVSZMK-UHFFFAOYSA-N
DDQV57	LY2886721	Small molecule	LY2886721; 1262036-50-9; LY-2886721; N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; LY 2886721; 2CQ62IWB67; CHEMBL2396989; n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide; UNII-2CQ62IWB67; N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; N-[3-[(4aS,7aS)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide; MLS006011070; SCHEMBL966802; GTPL6475; DTXSID70155117; EX-A029; HMS3884J09; BCP02507; BDBM50012647; MFCD22124078; s2156; AKOS027422646; BCP9000879; CCG-268530; CS-0458; DB12547; AC-33097; AS-56127; HY-13240; SMR004702860; A889495; J-522974; LY 2886721;LY-2886721; Q27082776; 2-PYRIDINECARBOXAMIDE, N-(3-((4AS,7AS)-2-AMINO-4A,5-DIHYDRO-4H-FURO(3,4-D)(1,3)THIAZIN-7A(7H)-YL)-4-FLUOROPHENYL)-5-FLUORO-; 3YS; N-{3-[(4aS,7aS)-2-amino-4H,4aH,5H,7H,7aH-furo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide	Phase 2	Drugs in Phase 2 Trial	49837968	DB12547	D0F8GK	390.4	115	610	1.5	27	2	7	3	C18H16F2N4O2S	N-[3-[(4aS,7aS)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide	C1C2CSC(=NC2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)F)F)N	C1[C@H]2CSC(=N[C@]2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)F)F)N	InChI=1S/C18H16F2N4O2S/c19-11-1-4-15(22-6-11)16(25)23-12-2-3-14(20)13(5-12)18-9-26-7-10(18)8-27-17(21)24-18/h1-6,10H,7-9H2,(H2,21,24)(H,23,25)/t10-,18-/m0/s1	NIDRNVHMMDAAIK-YPMLDQLKSA-N
D3XYJ9	CC-292	Small molecule	AVL-292; spebrutinib; 1202757-89-8; cc-292; Btk inhibitor CC-292; AVL292; Spebrutinib [USAN:INN]; UNII-DRU6NG543J; DRU6NG543J; N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide; N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide; Spebrutinib (AVL-292); n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide; C22H22FN5O3; AVL 292; N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide; 2-Propenamide, N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)-4-pyrimidinyl)amino)phenyl)-; CC-292 (AVL-292); N-{3-[(5-FLUORO-2-{[4-(2-METHOXYETHOXY)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENYL}PROP-2-ENAMIDE; N-(3-((5-Fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)-4-pyrimidinyl)amino)phenyl)-2-propenamide; SPEBRUTINIB [INN]; Spebrutinib (USAN/INN); SPEBRUTINIB [USAN]; SPEBRUTINIB [WHO-DD]; SCHEMBL626216; GTPL7837; CHEMBL3301625; AMY9065; EX-A255; LMK-435; DTXSID101026012; HMS3653E15; HMS3674E05; BCP07702; BDBM50161162; CC 292; MFCD25976876; NSC780020; s7173; AKOS026670200; AKOS032949981; CCG-268921; CS-1482; DB11764; NSC-780020; SB14609; NCGC00386306-03; NCGC00386306-06; AC-32618; AS-16998; DA-35316; HY-18012; FT-0751022; SW219474-1; D10730; Q27088846; 3-(5-FLUORO-2-(4-(2-METHOXYETHOXY)PHENYLAMINO)PYRIMIDIN-4-YLAMINO)PHENYL)ACRYLAMIDE; N-(3-((5-fluoro-2-((4-(2-methoxyethoxyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide; N-(3-{5-fluoro-2-[4-(2-methoxy-ethoxy)-phenylamino]-pyrimidin-4-ylamino}-phenyl)-acrylamide	Phase 2	Drugs in Phase 2 Trial	59174488	DB11764	D04BFC	423.4	97.4	561	3.6	31	3	8	10	C22H22FN5O3	N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	COCCOC1=CC=C(C=C1)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)NC(=O)C=C)F	COCCOC1=CC=C(C=C1)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)NC(=O)C=C)F	InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)	KXBDTLQSDKGAEB-UHFFFAOYSA-N
DP75BE	RO5459072	Small molecule	Petesicatib; 1252637-35-6; RG7625; Petesicatib [INN]; RG-7625; Petesicatib [USAN]; RO-5459072; RO5459072; A26QO95U37; Petesicatib (USAN); (2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methylpyrazol-4-yl)-2-(trifluoromethyl)phenyl]sulfonyl-1-[1-(trifluoromethyl)cyclopropanecarbonyl]pyrrolidine-2-carboxamide; 2-Pyrrolidinecarboxamide, N-(1-cyanocyclopropyl)-4-((4-(1-methyl-1H-pyrazol-4-yl)-2-(trifluoromethyl)phenyl)sulfonyl)-1-((1-(trifluoromethyl)cyclopropyl)carbonyl)-, (2S,4R)-; Petesicatib [USAN:INN]; PETESICATIB [WHO-DD]; SCHEMBL700776; UNII-A26QO95U37; GTPL9855; CHEMBL4297638; EX-A3136; AT32881; DB15297; MS-30641; HY-109069; CS-0033436; D11376; (2s,4r)-4-[4-(1-methyl-1h-pyrazol-4-yl)-2-trifluoromethyl-benzenesulfonyl]-1-(1-trifluoromethyl-cyclopropanecarbonyl)-pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide; (2S,4R)-N-(1-CYANOCYCLOPROPYL)-4-(4-(1-METHYL-1H-PYRAZOL-4-YL)-2-(TRIFLUOROMETHYL)BENZENESULFONYL)-1-(1-(TRIFLUOROMETHYL)CYCLOPROPANE-1-CARBONYL)PYRROLIDINE-2-CARBOXAMIDE; (4R)-N-(1-Cyanocyclopropyl)-4-((4-(1-methyl-1H-pyrazol-4-yl)-2-(trifluoromethyl)phenyl)sulfonyl)-1-((1-(trifluoromethyl)cyclopropyl)carbonyl)-L-prolinamide	Phase 2	Drugs in Phase 2 Trial	59543597	DB15297	D0DQ2D	603.5	134	1230	2.6	41	1	12	6	C25H23F6N5O4S	(2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methylpyrazol-4-yl)-2-(trifluoromethyl)phenyl]sulfonyl-1-[1-(trifluoromethyl)cyclopropanecarbonyl]pyrrolidine-2-carboxamide	CN1C=C(C=N1)C2=CC(=C(C=C2)S(=O)(=O)C3CC(N(C3)C(=O)C4(CC4)C(F)(F)F)C(=O)NC5(CC5)C#N)C(F)(F)F	CN1C=C(C=N1)C2=CC(=C(C=C2)S(=O)(=O)[C@@H]3C[C@H](N(C3)C(=O)C4(CC4)C(F)(F)F)C(=O)NC5(CC5)C#N)C(F)(F)F	InChI=1S/C25H23F6N5O4S/c1-35-11-15(10-33-35)14-2-3-19(17(8-14)24(26,27)28)41(39,40)16-9-18(20(37)34-22(13-32)4-5-22)36(12-16)21(38)23(6-7-23)25(29,30)31/h2-3,8,10-11,16,18H,4-7,9,12H2,1H3,(H,34,37)/t16-,18+/m1/s1	KXAAIORSMACJSI-AEFFLSMTSA-N
D9OFV8	GSK2586881	Protein	.	Phase 2	Drugs in Phase 2 Trial	.	DB15736	D0ET2T	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DE5DN3	PRX002	Antibody	.	Phase 2	Drugs in Phase 2 Trial	.	.	D4N2JV	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DKNE81	CAN04	Antibody	.	Phase 2	Drugs in Phase 2 Trial	.	.	DB5UO0	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D94VCE	Blosozumab	Antibody	.	Phase 2	Drugs in Phase 2 Trial	.	DB12560	D07TFL	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DM3TC8	BIIB092	Antibody	.	Phase 2	Drugs in Phase 2 Trial	.	DB15376	D0I8FS	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DAS98L	BIIB054	Antibody	.	Phase 2	Drugs in Phase 2 Trial	.	DB16127	D0TU9W	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D3Z5DV	ISIS 443139	Antisense oligonucleotide	.	Phase 2	Drugs in Phase 2 Trial	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D0CZ7B	CDR132L	Antisense oligonucleotide	.	Phase 2	Drugs in Phase 2 Trial	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D1FXY7	BI 2536	.	Solifenacin; 242478-37-1; Solifenacin succinate; Solifenacin (INN); [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; A8910SQJ1U; YM 905; NSC-759144; SOLIFENACIN [INN]; (3R)-1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate; Soliten; Solifenacin [INN:BAN]; CHEMBL1200803; (+)-Solifenacin; YM905 (free base); NCGC00168778-01; UNII-A8910SQJ1U; ((8r)-1-azabicyclo(2.2.2)octan-8-yl) (1s)-1-phenyl-3,4-dihydro-1h-isoQUINOLINE-2-carboxylate; [(8R)-1-azabicyclo[2.2.2]octan-8-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; solifenacin-succinate; SOLIFENACIN [MI]; SOLIFENACIN [VANDF]; CHEMBL1734; SOLIFENACIN [WHO-DD]; SCHEMBL188493; GTPL7483; SCHEMBL9971260; DTXSID3048289; CHEBI:135530; HMS3886O15; HY-A0034; BDBM50344284; BDBM50370682; s5238; AKOS015896445; CCG-268199; CS-8096; DB01591; NSC 759144; NCGC00168778-06; DB-001095; A16947; D08522; D95831; AB01565949_02; EN300-20176688; EN300-20343692; (S)-(R)-Quinuclidin-3-yl 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate; ((8R)-1-azabicyclo(2.2.2)octan-8-yl)(1S)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate; (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate; [(3r)-1-azabicyclo[2.2.2]octan-3-yl](1s)-1-phenyl-3,4-dihydro-1hisoquinoline-2-carboxylate; 1172613-99-8; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)-; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1-azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-	Phase 2	Drugs in Phase 1 Trial	11364421	DB16107	D0O0LQ	362.5	32.8	525	4	27	0	3	3	C23H26N2O2	[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate	C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5	C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5	InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1	FBOUYBDGKBSUES-VXKWHMMOSA-N
DZVJ52	AZD5634	Small molecule	.	Phase 1	Drugs in Phase 1 Trial	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DB7H4I	PF-05297909	Small molecule	.	Phase 1	Drugs in Phase 1 Trial	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DAZ83V	LMP776	Small molecule	INDIMITECAN; 915360-05-3; V5T7S4HP8A; NSC-725776; 20-(3-imidazol-1-ylpropyl)-15,16-dimethoxy-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione; UNII-V5T7S4HP8A; LMP776; SCHEMBL7712896; CHEMBL1196228; DTXSID90238618; LMP-776; Indimitecan hydrochloride (LMP-776); SB16794; 5H-(1,3)Dioxolo(4',5':5,6)indeno(1,2-c)isoquinoline-5,12(6H)-dione, 6-(3-(1H-imidazol-1-xyl)propyl)-2,3-dimethoxy-; HY-18350; MS-28413; CS-0007474; Q27291563; 5H-(1,3)DIOXOLO(4',5':5,6)INDENO(1,2-C)ISOQUINOLINE-5,12(6H)-DIONE, 6-(3-(1H-IMIDAZOL-1-YL)PROPYL)-2,3-DIMETHOXY-	Phase 1	Drugs in Phase 1 Trial	11519397	.	.	459.4	92.1	864	2.2	34	0	7	6	C25H21N3O6	20-(3-imidazol-1-ylpropyl)-15,16-dimethoxy-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione	COC1=C(C=C2C(=C1)C3=C(C4=CC5=C(C=C4C3=O)OCO5)N(C2=O)CCCN6C=CN=C6)OC	COC1=C(C=C2C(=C1)C3=C(C4=CC5=C(C=C4C3=O)OCO5)N(C2=O)CCCN6C=CN=C6)OC	InChI=1S/C25H21N3O6/c1-31-18-8-14-17(11-19(18)32-2)25(30)28(6-3-5-27-7-4-26-12-27)23-15-9-20-21(34-13-33-20)10-16(15)24(29)22(14)23/h4,7-12H,3,5-6,13H2,1-2H3	GCILEJUNEYIABW-UHFFFAOYSA-N
DQ2U8F	ACT-389949	Small molecule	ACT-389949; 1258417-54-7; UNII-JH0PQ88XA2; JH0PQ88XA2; N-[2-[[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide; 4-Oxazolecarboxamide, N-(2-((4-(1,1-difluoroethyl)-2-oxazolyl)methyl)-2H-1,2,3-triazol-4-yl)-2-methyl-5-(3-methylphenyl)-; N-(2-((4-(1,1-Difluoroethyl)-2-oxazolyl)methyl)-2H-1,2,3-triazol-4-yl)-2-methyl-5-(3-methylphenyl)-4-oxazolecarboxamide; GTPL9511; SCHEMBL1704153; EX-A3740; AT24816; AC-36738; MS-27575; HY-124071; CS-0084095; 2-Methyl-5-m-tolyl-oxazole-4-carboxylic Acid {2-[4-(1,1-difluoro-ethyl)-oxazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}-amide; N-(2-((4-(1,1-Difluoroethyl)oxazol-2-yl)methyl)-2H-1,2,3-triazol-4-yl)-2-methyl-5-(m-tolyl)oxazole-4-carboxamide; N-(2-{[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl}-2H-1,2,3-triazol-4-yl)-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide	Phase 1	Drugs in Phase 1 Trial	49834265	.	.	428.4	112	644	3.5	31	1	9	6	C20H18F2N6O3	N-[2-[[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide	CC1=CC(=CC=C1)C2=C(N=C(O2)C)C(=O)NC3=NN(N=C3)CC4=NC(=CO4)C(C)(F)F	CC1=CC(=CC=C1)C2=C(N=C(O2)C)C(=O)NC3=NN(N=C3)CC4=NC(=CO4)C(C)(F)F	InChI=1S/C20H18F2N6O3/c1-11-5-4-6-13(7-11)18-17(24-12(2)31-18)19(29)26-15-8-23-28(27-15)9-16-25-14(10-30-16)20(3,21)22/h4-8,10H,9H2,1-3H3,(H,26,27,29)	PBTWPEDVIMHJEO-UHFFFAOYSA-N
DG57XY	GDC-0334	Small molecule	GDC-0334; CZ9KU41DVB; UNII-CZ9KU41DVB; CHEMBL4865238; (4R,5S)-4-fluoro-1-[(4-fluorophenyl)sulfonyl]-5-methyl-N-({5-(trifluoromethyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]pyridin-4-yl}methyl)-L-prolinamide; 1984824-54-5; 2-Pyrrolidinecarboxamide, 4-fluoro-1-((4-fluorophenyl)sulfonyl)-5-methyl-N-((5-(trifluoromethyl)-2-(2-(trifluoromethyl)-5-pyrimidinyl)-4-pyridinyl)methyl)-, (2S,4R,5S)-; SCHEMBL18018280; GTPL12568; GDC0334; BDBM50573115; HY-115877; CS-0371271; (2S,4R,5S)-4-fluoro-1-(4-fluorophenyl)sulfonyl-5-methyl-N-[[5-(trifluoromethyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]pyridin-4-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R,5S)-4-fluoro-1-(4-fluorophenylsulfonyl)-5-methyl-N-((5-(trifluoromethyl)-2-(2-(trifluoromethyl)pyrimidin-5-yl)pyridin-4-yl)methyl)pyrrolidine-2-carboxamide; LXY	Phase 1	Drugs in Phase 1 Trial	122490062	.	.	609.5	114	1010	3.7	41	1	15	6	C24H19F8N5O3S	(2S,4R,5S)-4-fluoro-1-(4-fluorophenyl)sulfonyl-5-methyl-N-[[5-(trifluoromethyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]pyridin-4-yl]methyl]pyrrolidine-2-carboxamide	CC1C(CC(N1S(=O)(=O)C2=CC=C(C=C2)F)C(=O)NCC3=CC(=NC=C3C(F)(F)F)C4=CN=C(N=C4)C(F)(F)F)F	C[C@H]1[C@@H](C[C@H](N1S(=O)(=O)C2=CC=C(C=C2)F)C(=O)NCC3=CC(=NC=C3C(F)(F)F)C4=CN=C(N=C4)C(F)(F)F)F	InChI=1S/C24H19F8N5O3S/c1-12-18(26)7-20(37(12)41(39,40)16-4-2-15(25)3-5-16)21(38)34-8-13-6-19(33-11-17(13)23(27,28)29)14-9-35-22(36-10-14)24(30,31)32/h2-6,9-12,18,20H,7-8H2,1H3,(H,34,38)/t12-,18+,20-/m0/s1	RGXNECXVRZKGGH-UOXRKKOCSA-N
DJV5F1	ACT-1004-1239	Small molecule	ACT-1004-1239; CHEMBL4782111; SCHEMBL21211623; GLXC-25595; BDBM50555343; 2178049-58-4; HY-142617; CS-0370816; N-[(3S,4S)-1-(Cyclopropylmethyl)-3-[(1-pyrimidin-2-ylcyclopropyl)carbamoyl]piperidin-4-yl]-5-(2,4-difluorophenyl)-1,2-oxazole-3-carboxamide	Phase 1	Drugs in Phase 1 Trial	139360137	.	.	522.5	113	868	2.8	38	2	9	8	C27H28F2N6O3	N-[(3S,4S)-1-(cyclopropylmethyl)-3-[(1-pyrimidin-2-ylcyclopropyl)carbamoyl]piperidin-4-yl]-5-(2,4-difluorophenyl)-1,2-oxazole-3-carboxamide	C1CC1CN2CCC(C(C2)C(=O)NC3(CC3)C4=NC=CC=N4)NC(=O)C5=NOC(=C5)C6=C(C=C(C=C6)F)F	C1CN(C[C@@H]([C@H]1NC(=O)C2=NOC(=C2)C3=C(C=C(C=C3)F)F)C(=O)NC4(CC4)C5=NC=CC=N5)CC6CC6	InChI=1S/C27H28F2N6O3/c28-17-4-5-18(20(29)12-17)23-13-22(34-38-23)25(37)32-21-6-11-35(14-16-2-3-16)15-19(21)24(36)33-27(7-8-27)26-30-9-1-10-31-26/h1,4-5,9-10,12-13,16,19,21H,2-3,6-8,11,14-15H2,(H,32,37)(H,33,36)/t19-,21-/m0/s1	IIDSHAJKXPUYSL-FPOVZHCZSA-N
DN4T8U	ACT-1014-6470	Small molecule	2-(2,2-difluoropropyl)-5-[1-(2-fluoro-6-methylphenyl)piperidin-4-yl]-7-[[2-(trifluoromethyl)phenyl]methyl]-4H-pyrazolo[3,4-d]pyrimidin-6-one; Ic-58; SCHEMBL22653891; GTPL12326; ACT-1014-6470; example 172 [WO2019137927A1]	Phase 1	Drugs in Phase 1 Trial	142620206	.	.	565.6	44.6	884	5.7	40	0	9	6	C28H29F6N5O	2-(2,2-difluoropropyl)-5-[1-(2-fluoro-6-methylphenyl)piperidin-4-yl]-7-[[2-(trifluoromethyl)phenyl]methyl]-4H-pyrazolo[3,4-d]pyrimidin-6-one	CC1=C(C(=CC=C1)F)N2CCC(CC2)N3CC4=CN(N=C4N(C3=O)CC5=CC=CC=C5C(F)(F)F)CC(C)(F)F	CC1=C(C(=CC=C1)F)N2CCC(CC2)N3CC4=CN(N=C4N(C3=O)CC5=CC=CC=C5C(F)(F)F)CC(C)(F)F	InChI=1S/C28H29F6N5O/c1-18-6-5-9-23(29)24(18)36-12-10-21(11-13-36)38-16-20-14-37(17-27(2,30)31)35-25(20)39(26(38)40)15-19-7-3-4-8-22(19)28(32,33)34/h3-9,14,21H,10-13,15-17H2,1-2H3	YPWBQOVYMUEXJT-UHFFFAOYSA-N
D90PYQ	Carbendazim	Small molecule	Carbendazim; 10605-21-7; Carbendazole; Bavistin; Mecarzole; Thicoper; Carbendazime; Carbendazol; Bavistan; Derosal; Medamine; Funaben; Methyl 2-benzimidazolecarbamate; BMK (fungicide); Carbendazym; Equitdazin; Garbenda; Kemdazin; Supercarb; Agrizim; Battal; Bengard; Bitosen; Custos; Delsene; Karben; Kolfugo; Stempor; Myco; Methyl benzimidazol-2-ylcarbamate; Bavistin 3460; carbendazine; Falicarben; Pillarstin; Fungisol; methyl 1H-benzo[d]imidazol-2-ylcarbamate; Triticol; methyl N-(1H-benzimidazol-2-yl)carbamate; Stein; Spin; Bercema-Bitosen; Carbamic acid, 1H-benzimidazol-2-yl-, methyl ester; Kolfugo Extra; Preventol BCM; Antibac MF; Carben VL; Funaben 3; BCM (fungicide); METHYL 1H-BENZIMIDAZOL-2-YLCARBAMATE; 2-MBC; IPO Y; Methyl benzimidazolylcarbamate; Benzimidazolecarbamic; Funaben 50; Mercarzole; Jkatein; Preparation G 665; 2-(Methoxycarbamoyl)benzimidazole; A 118 (pesticide); 2-(Carbomethoxyamino)benzimidazole; Methyl 1H-benzimidazole-2-carbamate; 1H-Benzimidazole-2-carbamic acid, methyl ester; Kolfugo 25 FW; Lignasan; 2-(Methoxycarbonylamino)-benzimidazole; BAS 67054F; 2-(Methoxycarbonylamino)benzimidazole; 2-Benzimidazolecarbamic acid, methyl ester; Carbendazim [BSI:ISO]; BMK (VAN); Methyl N-2-benzimidazolecarbamate; 1H-Benzimidazol-2-ylcarbamic acid methyl ester; Methyl benzimidazolecarbamate; BAS-3460; CTR 6669; Benzimidazole-2-carbamic acid, methyl ester; EK 578; HOE 17411; G 665; Derroprene; Zhiweiling; Bavistine; CCRIS 1553; Fungoxan; Jkstein; Protek; Sarfun; Subeej; 2-(Methoxy-carbonylamino)-benzimidazol; HSDB 6581; U 32104; Bavistin FL; Carbendazim D3; Spin (pesticide); Karben flo Stefes; Karben Stefes Flo; Olgin (fungicide); BA 67054F; Bavistin 25SD; Bavistin 50SD; Delsene 10; Derosal 60PM; Kolfugo 25FW; 2-[(Methoxycarbonyl)amino]benzimidazole; Methyl 2-benzimidazolylcarbamate; 105268-95-9; BMK; BAS 3460F; Methyl 1H-benzimidazolylcarbamate; Benzimidazole carbamate de methyle; IPO 1250; BAS-67054; FB-642; 1H-Benzimidazol-2-ylcarbamic acid, methyl ester; NSC-109874; U-32.104; Carbamic acid, N-1H-benzimidazol-2-yl-, methyl ester; CHEMBL70971; 2-Methyl benzimidazolecarbamate; MLS002701961; CHEBI:3392; A 118; DTXSID4024729; Methyl 1H-benzimidazol-2-ylcarbamate (9CI); 2-(Methoxy-carbonylamino)-benzimidazol [German]; BAS-67054F; Carbamic acid, 1H-benzimidazolyl-, methyl ester; H75J14AA89; 2-(Methoxycarboxamido)benzimidazole; BAS 3460; EK-578; 2-Bezimidazolecarbamic acid methyl ester; carbendazin; carbendazyme; mekarzole; methyl N-(1H-1,3-benzodiazol-2-yl)carbamate; 1H-Benzimidazol-2-yl-carbamic acid, methyl ester; 37953-07-4; 39413-19-9; DTXCID004729; MBC (VAN); Carbendazime [ISO-French]; IPO-1250; Carbamic acid, N-1H-benzimidazol-2-yl-, methyl ester;Methyl 1H-benzo[d]imidazol-2-ylcarbamate; Carbendazim (MBC); Carbendazim [ISO]; CAS-10605-21-7; methyl 2-benzimidazil carbamate; methyl-2-benzimidazole carbamate; methylbenzimidazole-2-ylcarbamate; 2-(Methoxy-carbonylamino)-benzimidazol (GERMAN); benzimidazolecarbamate methyl ester; BAS 3460 F; methoxybenzimidazole-2-carbamic acid; EINECS 234-232-0; methyl-N-(2-benzimidazolyl)carbamate; RCRA waste no. U372; EPA Pesticide Chemical Code 115001; EPA Pesticide Chemical Code 128872; NSC 109874; 2-benzimidazolecarbamic acid methyl ester; Carbate; UNII-H75J14AA89; Benzimidazole carbamate de methyle [French]; Benomyl metabolite; Carbendazol, JMAF; CTR-6669; Tripart defensor FL; N-benzimidazol-2-ylmethoxycarboxamide; Carbendazim, 97%; Turfclear (Salt/Mix); BMC?; CARBENDAZIM [MI]; ChemDivAM_000201; ChemDiv1_000052; 1h-benzimidazole-2-carbamic acid methyl ester; CARBENDAZIM [HSDB]; SCHEMBL21051; CARBENDAZIM [WHO-DD]; N-1H-Benzimidazol-2-yl-carbamic Acid Methyl Ester; BIDD:ER0282; Carbendazim, analytical standard; 2-carbomethoxyamino-benzimidazole; methyl benzimidazole-2-carbamate; SCHEMBL19926051; HMS587C08; methyl 2-benzimidazolyl-carbamate; KID PEST PROJECT (CARBENDAZIM) (SEE ALSO CARBENDAZIM); AMY22465; Tox21_202295; Tox21_300478; 2-(carbomethoxy-amino)-benzimidazole; BDBM50116313; HOE-17411; Methyl 1H-2-benzimidazolecarbaminate; Methyl N-benzimidazol-2-yl-carbamate; MFCD00055390; NSC109874; AKOS002384358; Carbendazim 100 microg/mL in Methanol; CCG-101273; CS-8030; DB13009; KS-5360; 2-(Methoxy-carbonylamino)-benzimidazole; NCGC00090706-01; NCGC00090706-02; NCGC00090706-03; NCGC00090706-04; NCGC00254328-01; NCGC00259844-01; A118; AC-10590; BP-21318; HY-13582; NCI60_000240; SMR000304463; 1H-Benzimidazol-2-ylcarbamicacidmethylester; DB-040676; Methyl 1H-benzimidazol-2-ylcarbamate, 9CI; ALBENDAZOLE IMPURITY E [EP IMPURITY]; FT-0602933; FT-0664246; S3676; Carbendazim, PESTANAL(R), analytical standard; E78626; EN300-180487; METHYL N-1H-BENZIMIDAZOL-2-YLCARBAMATE; A801368; AF-962/00515023; Q418607; SR-01000390861; (1H-Benzoimidazol-2-yl)-carbamic acid methyl ester; J-001536; SR-01000390861-1; Carbendazim, certified reference material, TraceCERT(R); F0266-0908; Z752774256; Fenbendazole impurity A, European Pharmacopoeia (EP) Reference Standard; 102040-01-7; 110342-67-1; 212384-28-6	Phase 1	Drugs in Phase 1 Trial	25429	DB13009	.	191.19	67	222	1.5	14	2	3	2	C9H9N3O2	methyl N-(1H-benzimidazol-2-yl)carbamate	COC(=O)NC1=NC2=CC=CC=C2N1	COC(=O)NC1=NC2=CC=CC=C2N1	InChI=1S/C9H9N3O2/c1-14-9(13)12-8-10-6-4-2-3-5-7(6)11-8/h2-5H,1H3,(H2,10,11,12,13)	TWFZGCMQGLPBSX-UHFFFAOYSA-N
D5MGE0	J147	Small molecule	j147; J-147; 1146963-51-0; UNII-Z41H3C5BT9; Z41H3C5BT9; 1807913-16-1; J 147; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N-((E)-(3-methoxyphenyl)methylideneamino)acetamide; Acetic acid, 2,2,2-trifluoro-, (2E)-1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; N-(2,4-DIMETHYLPHENYL)-2,2,2-TRIFLUORO-N'-[(1E)-(3-METHOXYPHENYL)METHYLIDENE]ACETOHYDRAZIDE; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; CHEMBL2387144; SCHEMBL12995834; SCHEMBL21294999; 2,2,2-Trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; CHEBI:192601; DTXSID501045787; HMS3886O17; EX-A2235; MFCD25976644; s5269; AKOS024458485; CCG-268030; CS-3688; DB13957; AC-35232; AS-16718; HY-13779; EC-000.2544; A15953; A894156; (E)-N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-triluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide	Phase 1	Drugs in Phase 1 Trial	25229652	DB13957	.	350.3	41.9	481	4.7	25	0	6	4	C18H17F3N2O2	N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide	CC1=CC(=C(C=C1)N(C(=O)C(F)(F)F)N=CC2=CC(=CC=C2)OC)C	CC1=CC(=C(C=C1)N(C(=O)C(F)(F)F)/N=C/C2=CC(=CC=C2)OC)C	InChI=1S/C18H17F3N2O2/c1-12-7-8-16(13(2)9-12)23(17(24)18(19,20)21)22-11-14-5-4-6-15(10-14)25-3/h4-11H,1-3H3/b22-11+	HYMZAYGFKNNHDN-SSDVNMTOSA-N
D0YGC4	PHA-665752	Small molecule	PHA-665752; 477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; (R,Z)-5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; 2H-Indol-2-one, 5-(((2,6-dichlorophenyl)methyl)sulfonyl)-3-((3,5-dimethyl-4-(((2R)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (3Z)-; PHA-665752 hydrate; (2R)-1-[[5-[(Z)-[5-[[(2,6-Dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]c arbonyl]-2-(1-pyrrolidinylmethyl)pyrrolidine; SCHEMBL93654; GTPL5700; DTXSID30197270; EX-A019; BCPP000112; HMS3269N19; HMS3413B20; HMS3677B20; AMY24192; BDBM50242737; MFCD07772270; NSC748798; NSC766271; PHA 665752 [WHO-DD]; AKOS015896678; CCG-264805; CS-0137; NSC-748798; NSC-766271; (3Z)-5-[(2,6-dichlorophenyl)methanesulfonyl]-3-({3,5-dimethyl-4-[(2R)-2-[(pyrrolidin-1-yl)methyl]pyrrolidine-1-carbonyl]-1H-pyrrol-2-yl}methylidene)-2,3-dihydro-1H-indol-2-one; AC-30914; HY-11107; S1070; EC-000.2429; A15588; 1Y-7008; J-500906; BRD-K95435023-001-01-0; BRD-K95435023-001-10-1; Q27088356; (3Z)-5-[(2,6-dichlorobenzyl)sulfonyl]-3-[(3,5-dimethyl-4-{[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; (3Z)-5-[[(2,6-Dichlorophenyl)methyl]sulfonyl]-3-[[3,5-dimethyl-4-[[(2R)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]-1H-pyrrol-2-yl]methylene]-1,3-dihydro-2H-indol-2-one; (3Z)-5-{[(2,6-dichlorophenyl)methane]sulfonyl}-3-[(3,5-dimethyl-4-{[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)methylidene]-2,3-dihydro-1H-indol-2-one; 5-(2,6-dichloro-phenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-((r)-2-pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-1h-pyrrol-2-yl]-meth-(z)-ylidene]-1,3-dihydro-indol-2-one	Phase 1	Drugs in Phase 1 Trial	10461815	.	D00TBD	641.6	111	1180	5	43	2	5	7	C32H34Cl2N4O4S	(3Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-3-[[3,5-dimethyl-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]-1H-pyrrol-2-yl]methylidene]-1H-indol-2-one	CC1=C(NC(=C1C(=O)N2CCCC2CN3CCCC3)C)C=C4C5=C(C=CC(=C5)S(=O)(=O)CC6=C(C=CC=C6Cl)Cl)NC4=O	CC1=C(NC(=C1C(=O)N2CCC[C@@H]2CN3CCCC3)C)/C=C\4/C5=C(C=CC(=C5)S(=O)(=O)CC6=C(C=CC=C6Cl)Cl)NC4=O	InChI=1S/C32H34Cl2N4O4S/c1-19-29(35-20(2)30(19)32(40)38-14-6-7-21(38)17-37-12-3-4-13-37)16-24-23-15-22(10-11-28(23)36-31(24)39)43(41,42)18-25-26(33)8-5-9-27(25)34/h5,8-11,15-16,21,35H,3-4,6-7,12-14,17-18H2,1-2H3,(H,36,39)/b24-16-/t21-/m1/s1	OYONTEXKYJZFHA-SSHUPFPWSA-N
D4LT0E	ETC-159	Small molecule	ETC-159; 1638250-96-0; ETC-1922159; 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide; ETC159; 2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide; CHEMBL3633802; 5L854240DQ; 2-(1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide; 7H-Purine-7-acetamide, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-N-(6-phenyl-3-pyridazinyl)-; UNII-5L854240DQ; SCHEMBL17626176; GTPL11168; ETC 159; BCP20688; EX-A2302; BDBM50133866; NSC809251; CS-5162; ETC1922159; NSC-809251; SB18869; AC-35482; AS-74458; HY-18988; S6616; A857431; 1,2,3,6-TETRAHYDRO-1,3-DIMETHYL-2,6-DIOXO-N-(6-PHENYL-3-PYRIDAZINYL)-7H-PURINE-7-ACETAMIDE	Phase 1	Drugs in Phase 1 Trial	86280523	.	D05FKU	391.4	113	654	0.5	29	1	6	4	C19H17N7O3	2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide	CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)NC3=NN=C(C=C3)C4=CC=CC=C4	CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)NC3=NN=C(C=C3)C4=CC=CC=C4	InChI=1S/C19H17N7O3/c1-24-17-16(18(28)25(2)19(24)29)26(11-20-17)10-15(27)21-14-9-8-13(22-23-14)12-6-4-3-5-7-12/h3-9,11H,10H2,1-2H3,(H,21,23,27)	QTRXIFVSTWXRJJ-UHFFFAOYSA-N
DP5UY2	BI 894999	Small molecule	BRD4 Inhibitor-10; 1660117-38-3; 2,4-dimethyl-6-[6-(oxan-4-yl)-1-[(1S)-1-phenylethyl]imidazo[4,5-c]pyridin-2-yl]pyridazin-3-one; BI 894999; (S)-2,4-Dimethyl-6-(1-(1-phenylethyl)-6-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)pyridazin-3(2H)-one; 3(2H)-Pyridazinone, 2,4-dimethyl-6-[1-[(1S)-1-phenylethyl]-6-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl]-; CHEMBL3787279; SCHEMBL16489493; BDBM215738; DTXSID001105413; EX-A4092; s8574; MS-27618; US9296748, II-25; BI-898999; HY-117491; CS-0066215	Phase 1	Drugs in Phase 1 Trial	90647162	.	D06QBV	429.5	72.6	755	3	32	0	5	4	C25H27N5O2	2,4-dimethyl-6-[6-(oxan-4-yl)-1-[(1S)-1-phenylethyl]imidazo[4,5-c]pyridin-2-yl]pyridazin-3-one	CC1=CC(=NN(C1=O)C)C2=NC3=CN=C(C=C3N2C(C)C4=CC=CC=C4)C5CCOCC5	CC1=CC(=NN(C1=O)C)C2=NC3=CN=C(C=C3N2[C@@H](C)C4=CC=CC=C4)C5CCOCC5	InChI=1S/C25H27N5O2/c1-16-13-21(28-29(3)25(16)31)24-27-22-15-26-20(19-9-11-32-12-10-19)14-23(22)30(24)17(2)18-7-5-4-6-8-18/h4-8,13-15,17,19H,9-12H2,1-3H3/t17-/m0/s1	QNFGQQDKBYVNAS-KRWDZBQOSA-N
D2M3SX	ABBV-075	Small molecule	Mivebresib; 1445993-26-9; ABBV-075; ABBV075; Mivebresib [INN]; Mivebresib [USAN]; Mivebresib(ABBV-075; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; VR86R11J7J; N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; Ethanesulfonamide, N-(4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo(2,3-C)pyridin-4-yl)phenyl)-; N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro- 1H-pyrrolo(2,3-C)pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Ethanesulfonamide, N-[4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-; Mivebresib (USAN/INN); Mivebresib [USAN:INN]; Mivebresib; ABBV-075; ABBV-075 (Mivebresib); Mivebresib (ABBV-075); MIVEBRESIB [WHO-DD]; UNII-VR86R11J7J; ABBV 075; GTPL9117; CHEMBL3987016; SCHEMBL15068241; BDBM220447; AMY16732; BCP18592; EX-A1082; MFCD30377200; NSC793103; s8400; AKOS030628486; CCG-269326; CS-5815; NSC-793103; SB19768; Example 36 [WO2013097601]; AC-29897; AS-75006; BA166577; HY-100015; D11479; US9296741, 36; A857556; Q27291978; N-[4-(2,4-difluorophenoxy)-3-{6-methyl-7-oxo-1H,6H,7H-pyrrolo[2,3-c]pyridin-4-yl}phenyl]ethane-1-sulfonamide	Phase 1	Drugs in Phase 1 Trial	71600087	.	D0M2TS	459.5	99.9	834	2.9	32	2	7	6	C22H19F2N3O4S	N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide	CCS(=O)(=O)NC1=CC(=C(C=C1)OC2=C(C=C(C=C2)F)F)C3=CN(C(=O)C4=C3C=CN4)C	CCS(=O)(=O)NC1=CC(=C(C=C1)OC2=C(C=C(C=C2)F)F)C3=CN(C(=O)C4=C3C=CN4)C	InChI=1S/C22H19F2N3O4S/c1-3-32(29,30)26-14-5-7-19(31-20-6-4-13(23)10-18(20)24)16(11-14)17-12-27(2)22(28)21-15(17)8-9-25-21/h4-12,25-26H,3H2,1-2H3	RDONXGFGWSSFMY-UHFFFAOYSA-N
DZ0A1N	LMP744	Small molecule	LMP744; 308246-52-8; LMP-744; MJ-III-65; NSC-706744; LMP744 free base; NSC-706743; 29BY7HQV0T; NCI60_037977; CHEMBL126159; Topoisomerase-1 inhibitor lmp744; 308246-52-8 (free base); 6-(3-((2-hydroxyethyl)amino)propyl)-2,3-dimethoxy-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione; 5H-(1,3)Dioxolo(5,6)indeno(1,2-C)isoquinoline-5,12(6H)-dione, 6-(3-((2-hydroxyethyl)amino)propyl)-2,3-dimethoxy-; UNII-29BY7HQV0T; SCHEMBL4162998; DTXSID30327954; BCP34017; EX-A3021; BDBM50237809; HY-U00248; NSC706743; CS-7432; AC-35733; MS-28221; Q27894415; 20-[3-(2-Hydroxyethylamino)propyl]-15,16-dimethoxy-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione; 5H-[1,6]indeno[1,2-c]isoquinoline- 5,12(6H)-dione,6-[3-[(2-hydroxyethyl)amino]propyl]-2,3-dimethoxy-; 6-[3-(2-Hydroxyethyl)aminopropyl]-5,11-diketo-2,3-dimethoxy-8,9-(methylenedioxy)- 11H-indeno[1,2-c]isoquinoline; 863126-39-0	Phase 1	Drugs in Phase 1 Trial	397888	.	DDXH71	452.5	107	802	1.4	33	2	8	8	C24H24N2O7	20-[3-(2-hydroxyethylamino)propyl]-15,16-dimethoxy-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione	COC1=C(C=C2C(=C1)C3=C(C4=CC5=C(C=C4C3=O)OCO5)N(C2=O)CCCNCCO)OC	COC1=C(C=C2C(=C1)C3=C(C4=CC5=C(C=C4C3=O)OCO5)N(C2=O)CCCNCCO)OC	InChI=1S/C24H24N2O7/c1-30-17-8-13-16(11-18(17)31-2)24(29)26(6-3-4-25-5-7-27)22-14-9-19-20(33-12-32-19)10-15(14)23(28)21(13)22/h8-11,25,27H,3-7,12H2,1-2H3	QCSDJDQOJBQTDV-UHFFFAOYSA-N
DB3QA9	CVN058	Small molecule	.	Phase 1	Drugs in Phase 1 Trial	.	.	DO2P5G	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D12EAG	LMP400	Small molecule	INDOTECAN; 915303-09-2; NSC-724998; LMP-400; Indotecan(LMP400); BTA69L5M8D; 2,3-dimethoxy-6-(3-morpholinopropyl)-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione; UNII-BTA69L5M8D; LMP400; NSC724998; Indotecan (LMP400); CHEMBL216462; SCHEMBL7712572; DTXSID90238613; BCP34018; EX-A3020; Indotecan hydrochloride (LMP-400); ZB1545; NSC-724998LMP-400; SB16793; AC-35734; HY-18351; MS-28890; CS-0007476; LMP400; LMP-400; LMP 400; Q27274872; 15,16-dimethoxy-20-(3-morpholin-4-ylpropyl)-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione; 3-[(Morpholine)-1-propyl]-5,3-dimethoxy-8,9-meth ylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline; 5H-(1,3)DIOXOLO(4',5':5,6)INDENO(1,2-C)ISOQUINOLINE-5,12(6H)-DIONE, 2,3-DIMETHOXY-6-(3-(4-MORPHOLINYL)PROPYL)-	Phase 1	Drugs in Phase 1 Trial	11533060	.	DV3WF1	478.5	86.8	872	2.2	35	0	8	6	C26H26N2O7	15,16-dimethoxy-20-(3-morpholin-4-ylpropyl)-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione	COC1=C(C=C2C(=C1)C3=C(C4=CC5=C(C=C4C3=O)OCO5)N(C2=O)CCCN6CCOCC6)OC	COC1=C(C=C2C(=C1)C3=C(C4=CC5=C(C=C4C3=O)OCO5)N(C2=O)CCCN6CCOCC6)OC	InChI=1S/C26H26N2O7/c1-31-19-10-15-18(13-20(19)32-2)26(30)28(5-3-4-27-6-8-33-9-7-27)24-16-11-21-22(35-14-34-21)12-17(16)25(29)23(15)24/h10-13H,3-9,14H2,1-2H3	FMFIFGLHVOZDEL-UHFFFAOYSA-N
DK87RJ	Cinnamaldehyde	Small molecule	cinnamaldehyde; trans-Cinnamaldehyde; 104-55-2; 14371-10-9; Cinnamic aldehyde; 3-Phenylacrylaldehyde; Cinnamal; (E)-Cinnamaldehyde; Zimtaldehyde; (2E)-3-phenylprop-2-enal; 3-Phenylpropenal; 2-Propenal, 3-phenyl-; Phenylacrolein; trans-Cinnamic aldehyde; Cinnamylaldehyde; (E)-3-phenylprop-2-enal; (E)-3-Phenylpropenal; (E)-3-Phenyl-2-propenal; Cassia aldehyde; 3-Phenylacrolein; 3-phenylprop-2-enal; 3-Phenyl-2-propenal; Cinnemaldehyde; 2-propenal, 3-phenyl-, (2E)-; Cinnamyl aldehyde; Abion CA; Cinnamaldehyde, (E)-; trans-Cinnamylaldehyde; Benzylideneacetaldehyde; beta-Phenylcrolein; 3-Phenyl-2-propenaldehyde; Acrolein, 3-phenyl-; 3-Fenylpropenal; FEMA No. 2286; 3-Phenyl-2-propen-1-al; trans-3-Phenyl-2-propenal; (E)-Cinnamic aldehyde; NCI-C56111; 2-Propenal, 3-phenyl-, (E)-; (2E)-3-phenylacrylaldehyde; .beta.-phenylacrolein; CHEBI:16731; Cinnamaldehyde, trans-; (E)-3-Phenyl-propenal; MFCD00007000; NSC-16935; NSC-40346; SR60A3XG0F; (3E)-3-phenylprop-2-enal; (2E)-3-Phenyl-2-propenal; CHEMBL293492; Aldehyd skoricovy; DTXSID6024834; XC-800; NCGC00091512-04; NSC 16935; WLN: VH1U1R; DTXCID504834; Caswell No. 221A; FEMA Number 2286; 3-Fenylpropenal [Czech]; Aldehyd skoricovy [Czech]; Cinnamic aldehyde (natural); Hefty Dog and Cat Repellent; CAS-14371-10-9; CCRIS 3189; CCRIS 6222; Cinnamaldehyde [NF]; HSDB 209; EINECS 203-213-9; UNII-SR60A3XG0F; DTXSID1024835; EPA Pesticide Chemical Code 040506; BRN 0605737; BRN 1071571; e-cinnamaldehyde; AI3-00473; AI3-33275; transcinnamaldehyde; trans cinnamaldehyde; Nat. Cinnamaldehyde; CNMA; (trans)-cinnamaldehyde; trans cinnamic aldehyde; trans-3-Phenylacrolein; Cinnamaldehyde, Natural; CINNAMAL [INCI]; trans-3-phenyl-propenal; (E)-phenylvinyl aldehyde; (E)-3-phenylacrylaldehyde; bmse010257; Epitope ID:150921; CINNAMALDEHYDE [II]; CINNAMALDEHYDE [MI]; EC 203-213-9; trans-3-Phenylacrylaldehyde; Trans-Cinnamaldehyde ,(S); SCHEMBL3441; trans-Cinnamaldehyde, 99%; (E)-3-phenyl-acrylaldehyde; CINNAMALDEHYDE [FCC]; trans-Cinnamaldehyde; trans-3-Phenylacrylaldehyde; Cinnamaldehyde (trans), neat; CINNAMALDEHYDE [FHFI]; CINNAMALDEHYDE [HSDB]; 2-07-00-00273 (Beilstein Handbook Reference); 4-07-00-00984 (Beilstein Handbook Reference); MLS002454394; CINNAMALDEHYDE (TRANS); trans-Cinnamaldehyde, >=99%; DTXCID904835; GTPL2423; (E)-cinnamaldehyde (incorrect); CINNAMALDEHYDE [USP-RS]; CINNAMALDEHYDE [WHO-DD]; NATURAL CINNAMIC ALDEHYDE; trans-cinnamaldehyde (incorrect); CHEBI:142921; HMS2268O08; HMS3885E04; HY-N0609; NSC16935; NSC40346; Tox21_111144; Tox21_200272; Tox21_201804; Tox21_303271; BDBM50203065; s3763; STK397371; AKOS000119171; Cinnamaldehyde, natural, >=95%, FG; CCG-266119; DB14184; Cinnamaldehyde min. 98%, for synthesis; Cinnamaldehyde 100 microg/mL in Toluene; NCGC00091512-01; NCGC00091512-02; NCGC00091512-05; NCGC00091512-06; NCGC00091512-07; NCGC00257017-01; NCGC00257826-01; NCGC00259353-01; trans-Cinnamaldehyde, analytical standard; AS-12078; AS-75456; CAS-104-55-2; SMR000112334; trans-Cinnamaldehyde, >=98%, FCC, FG; (E)-3-phenyl-2-propenal(E)-cinnamaldehyde; DB-003796; AM20060482; CS-0009609; EN300-19160; A14480; C00903; Cinnamaldehyde, Vetec(TM) reagent grade, 93%; D72477; EN300-735819; A801001; Q204036; W-205597; B99DD6C7-1C6D-4FE3-A172-54BFDB987683; Z3219847383; CINNAMALDEHYDE (CONSTITUENT OF CINNAMOMUM VERUM BARK) [DSC]; Cinnamaldehyde, United States Pharmacopeia (USP) Reference Standard; TRANS-CINNAMALDEHYDE (CONSTITUENT OF CINNAMOMUM CASSIA BARK) [DSC]	Phase 1	Drugs in Phase 1 Trial	637511	DB14184	D0PJ3M	132.16	17.1	121	1.9	10	0	1	2	C9H8O	(E)-3-phenylprop-2-enal	C1=CC=C(C=C1)C=CC=O	C1=CC=C(C=C1)/C=C/C=O	InChI=1S/C9H8O/c10-8-4-7-9-5-2-1-3-6-9/h1-8H/b7-4+	KJPRLNWUNMBNBZ-QPJJXVBHSA-N
D9E5UB	LY2811376	Small molecule	LY2811376; 1194044-20-6; (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine; LY-2811376; LY 2811376; UR18YJ97SJ; CHEMBL2333941; J3.079.793K; (4s)-4-[2,4-Difluoro-5-(Pyrimidin-5-Yl)phenyl]-4-Methyl-5,6-Dihydro-4h-1,3-Thiazin-2-Amine; (4S)-4-[2,4-Difluoro-5-(5-pyrimidinyl)phenyl]-5,6-dihydro-4-methyl-4H-1,3-thiazin-2-amine; (4S)-4-[2,4-DIFLUORO-5-(PYRIMIDIN-5-YL)PHENYL]-4-METHYL-5,6-DIHYDRO-1,3-THIAZIN-2-AMINE; (4S)-4-(2,4-Difluoro-5-(5-pyrimidinyl)phenyl)-5,6-dihydro-4-methyl-4H-1,3-thiazine-2-amine; 4H-1,3-Thiazin-2-amine, 4-(2,4-difluoro-5-(5-pyrimidinyl)phenyl)-5,6-dihydro-4-methyl-, (4S)-; 4H-1,3-Thiazin-2-amine, 4-[2,4-difluoro-5-(5-pyrimidinyl)phenyl]-5,6-dihydro-4-methyl-, (4S)-; UNII-UR18YJ97SJ; MLS006011069; GTPL6936; SCHEMBL1422085; DTXSID10658051; EX-A094; LY2811376; BACE inhibitor; HMS3654L20; HMS3884I19; BCP02221; BDBM50012632; MFCD18074525; s1528; AKOS016003393; BCP9000876; CCG-267708; CS-0987; DB13065; NCGC00346719-01; NCGC00346719-02; NCGC00390720-01; AC-32718; AM807940; AS-31771; HY-10472; SMR004702859; SW219874-1; J-501480; Q27082743; (S)-4-(2,4-Difluoro-5-pyrimidin-5-yl-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]thiazin-2-ylamine; 4B2	Phase 1	Drugs in Phase 1 Trial	44251605	DB13065	D0N1BF	320.4	89.5	430	2.1	22	1	6	2	C15H14F2N4S	(4S)-4-(2,4-difluoro-5-pyrimidin-5-ylphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine	CC1(CCSC(=N1)N)C2=C(C=C(C(=C2)C3=CN=CN=C3)F)F	C[C@]1(CCSC(=N1)N)C2=C(C=C(C(=C2)C3=CN=CN=C3)F)F	InChI=1S/C15H14F2N4S/c1-15(2-3-22-14(18)21-15)11-4-10(12(16)5-13(11)17)9-6-19-8-20-7-9/h4-8H,2-3H2,1H3,(H2,18,21)/t15-/m0/s1	MJQMRGWYPNIERM-HNNXBMFYSA-N
DTAB68	AZD5153	Small molecule	AZD5153; AZD-5153; 1869912-39-9; C7C7U6YEAO; CHEMBL4078100; AZD 5153 [WHO-DD]; AZD 5153; 1869912-39-9 (free base); (R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)-1,3-dimethylpiperazin-2-one; (3~{r})-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-B]pyridazin-6-Yl)piperidin-4-Yl]phenoxy]ethyl]-1,3-Dimethyl-Piperazin-2-One; 2-Piperazinone, 4-(2-(4-(1-(3-methoxy-1,2,4-triazolo(4,3-b)pyridazin-6-yl)-4-piperidinyl)phenoxy)ethyl)-1,3-dimethyl-, (3R)-; UNII-C7C7U6YEAO; SCHEMBL17477306; AMY16812; BCP20057; EX-A1317; AZD5153, 6-hydroxy-2-naphthoate; BDBM50260093; MFCD30530420; NSC797938; AKOS030627661; AZD-5153, 6-hydroxy-2-naphthoate; NSC-797938; AC-31599; AS-35242; J3.544.368A; Q27467599; (3r)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one; (3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-dimethylpiperazin-2-one; XNH	Phase 1	Drugs in Phase 1 Trial	118693659	DB17018	D0PH9I	479.6	88.3	699	2.4	35	0	8	7	C25H33N7O3	(3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-dimethylpiperazin-2-one	CC1C(=O)N(CCN1CCOC2=CC=C(C=C2)C3CCN(CC3)C4=NN5C(=NN=C5OC)C=C4)C	C[C@@H]1C(=O)N(CCN1CCOC2=CC=C(C=C2)C3CCN(CC3)C4=NN5C(=NN=C5OC)C=C4)C	InChI=1S/C25H33N7O3/c1-18-24(33)29(2)14-15-30(18)16-17-35-21-6-4-19(5-7-21)20-10-12-31(13-11-20)23-9-8-22-26-27-25(34-3)32(22)28-23/h4-9,18,20H,10-17H2,1-3H3/t18-/m1/s1	RSMYFSPOTCDHHJ-GOSISDBHSA-N
DBC9V3	CB-5083	Small molecule	CB-5083; 1542705-92-9; CB5083; CB 5083; 1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide; 591IV6UL6J; 1-[4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl]-2-methylindole-4-carboxamide; 1-(7,8-Dihydro-4-((phenylmethyl)amino)-5H-pyrano(4,3-d)pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide; 1-[4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl]-2-methyl-1H-indole-4-carboxamide; 1H-Indole-4-carboxamide, 1-(7,8-dihydro-4-((phenylmethyl)amino)-5H-pyrano(4,3-d)pyrimidin-2-yl)-2-methyl-; JDP; UNII-591IV6UL6J; CHEMBL3747513; SCHEMBL15421452; EX-A773; CB 5083 [WHO-DD]; DTXSID801022542; HMS3873E13; BCP23807; BDBM50500325; MFCD28963914; NSC786100; AKOS025396184; CCG-268805; CS-5405; NSC-786100; NCGC00481317-01; NCGC00481317-03; AC-29018; AS-55872; BC177445; HY-12861; CB-5083; CB 5083; FT-0700217; S8101; J3.551.815K	Phase 1	Drugs in Phase 1 Trial	73051434	DB16874	D08OOJ	413.5	95.1	627	3.1	31	2	5	5	C24H23N5O2	1-[4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl]-2-methylindole-4-carboxamide	CC1=CC2=C(C=CC=C2N1C3=NC4=C(COCC4)C(=N3)NCC5=CC=CC=C5)C(=O)N	CC1=CC2=C(C=CC=C2N1C3=NC4=C(COCC4)C(=N3)NCC5=CC=CC=C5)C(=O)N	InChI=1S/C24H23N5O2/c1-15-12-18-17(22(25)30)8-5-9-21(18)29(15)24-27-20-10-11-31-14-19(20)23(28-24)26-13-16-6-3-2-4-7-16/h2-9,12H,10-11,13-14H2,1H3,(H2,25,30)(H,26,27,28)	RDALZZCKQFLGJP-UHFFFAOYSA-N
D2S5ZD	ATR-107	Antibody	.	Phase 1	Drugs in Phase 1 Trial	.	.	D0M4MH	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DK1D5O	PF-06342674	Antibody	.	Phase 1	Drugs in Phase 1 Trial	.	.	D0Q7IX	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DJZK69	AV-203	Antibody	.	Phase 1	Drugs in Phase 1 Trial	.	.	D0Y5ED	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DP4YI0	LY3415244	Antibody	.	Phase 1	Drugs in Phase 1 Trial	.	.	DC8HR6	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DUX9O2	BITS7201A	Antibody	.	Phase 1	Drugs in Phase 1 Trial	.	.	DFU4B0	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DF4O6Z	MCAF5352A	Antibody	.	Phase 1	Drugs in Phase 1 Trial	.	DB14798	D0V9AL	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D50PMG	PD01A	Vaccine	.	Phase 1	Drugs in Phase 1 Trial	.	.	D68PVB	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DZM7H6	A357300	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DV67OR	CRD-733	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D7AHX5	EQ-6	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DW8B9A	GSK2292767A	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D2QVL9	MK-4710	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DAD39Z	NP260	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DF7XB9	OKI-005	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D2J8GO	QM385	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DL8OV4	RA283	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DCV45F	RA334	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DT8W6Y	S217879	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D8J2UR	SLR080811	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D6QR1C	Trimethyltin	Small molecule	TRIMETHYLTIN; Stannane, trimethyl-; Stannyl, trimethyl-; 1631-73-8; 17272-57-0; (CH3)3SnH; DTXSID6035102; DTXSID801315666; ZN8	Investigative	Investigative Drug(s)	5358116	.	.	163.81	0	8	.	4	0	0	0	C3H9Sn	NULL	C[Sn](C)C	C[Sn](C)C	InChI=1S/3CH3.Sn/h3*1H3;	LYRCQNDYYRPFMF-UHFFFAOYSA-N
DSK29G	LRRK2-IN1	Small molecule	LRRK2-IN-1; 1234480-84-2; LRRK2IN1; LRRK2-IN1; 2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one; 2-((2-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)phenyl)-amino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one; 2-((2-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)phenyl)amino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one; CHEMBL2012582; CHEBI:78413; 5,11-Dihydro-2-[[2-methoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one; 2-[(2-methoxy-4-{[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}phenyl)amino]-5,11-dimethyl-5,11-dihydro-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one; BDBM50379529; 2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)phenyl)amino)-5,11-dimethyl-5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one; LRRK-2IN1; 4K4; LRRK2-IN 1; LRRK2-TN-1; MLS003230940; SCHEMBL616761; GTPL9396; DTXSID70676751; EX-A644; BDBM482157; HMS3265O17; HMS3265O18; HMS3265P17; HMS3265P18; BCP14860; s7584; AKOS024458067; CCG-270098; CS-0246; SB18523; NCGC00346807-01; NCGC00346807-04; AC-35378; AS-56177; HY-10875; SMR001913505; FT-0700139; J-004944; BRD-K01436366-001-01-6; BRD-K01436366-001-14-9; Q27147815; 2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)phenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one; 2-{2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino}-5,11-dimethyl-5,11-dihydro-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one	Investigative	Investigative Drug(s)	46843906	.	.	570.7	97.4	939	3	42	1	9	5	C31H38N8O3	2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one	CN1CCN(CC1)C2CCN(CC2)C(=O)C3=CC(=C(C=C3)NC4=NC=C5C(=N4)N(C6=CC=CC=C6C(=O)N5C)C)OC	CN1CCN(CC1)C2CCN(CC2)C(=O)C3=CC(=C(C=C3)NC4=NC=C5C(=N4)N(C6=CC=CC=C6C(=O)N5C)C)OC	InChI=1S/C31H38N8O3/c1-35-15-17-38(18-16-35)22-11-13-39(14-12-22)29(40)21-9-10-24(27(19-21)42-4)33-31-32-20-26-28(34-31)36(2)25-8-6-5-7-23(25)30(41)37(26)3/h5-10,19-20,22H,11-18H2,1-4H3,(H,32,33,34)	IWMCPJZTADUIFX-UHFFFAOYSA-N
DGKR94	SPRi3	Small molecule	SPR inhibitor 3; SPRi3; 1292285-54-1; N-[2-(5-hydroxy-2-methyl-1H-indol-3-yl)ethyl]-2-methoxyacetamide; SPRi 3; N-[2-(5-hydroxy-2-methyl-1H-indol-3-yl)ethyl]-2-methoxy-acetamide; CHEMBL3948731; SCHEMBL12720826; GTPL10130; BDBM187258; example 23 [WO2011047156]; MS-23695; HY-115510; CS-0087277; US9169234, 23; Q27454383; 43O	Investigative	Investigative Drug(s)	52911386	.	.	262.3	74.4	311	1.6	19	3	3	5	C14H18N2O3	N-[2-(5-hydroxy-2-methyl-1H-indol-3-yl)ethyl]-2-methoxyacetamide	CC1=C(C2=C(N1)C=CC(=C2)O)CCNC(=O)COC	CC1=C(C2=C(N1)C=CC(=C2)O)CCNC(=O)COC	InChI=1S/C14H18N2O3/c1-9-11(5-6-15-14(18)8-19-2)12-7-10(17)3-4-13(12)16-9/h3-4,7,16-17H,5-6,8H2,1-2H3,(H,15,18)	YBXBWBBVLXZQBJ-UHFFFAOYSA-N
DE40CM	Wnt-C59	Small molecule	Wnt-C59; 1243243-89-1; 2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl)acetamide; C25H21N3O; 2-[4-(2-Methyl-pyridin-4-yl)-phenyl]-N-(4-pyridin-3-yl-phenyl)-acetamide; Wnt-C59 (C59); CHEMBL2139947; 2-[4-(2-methylpyridin-4-yl)phenyl]-N-(4-pyridin-3-ylphenyl)acetamide; MFCD22201167; C59; 4-(2-Methyl-4-pyridinyl)-N-[4-(3-pyridinyl)phenyl]benzeneacetamide; 2-[4-(2-methylpyridin-4-yl)phenyl]-n-[4-(pyridin-3-yl)phenyl]acetamide; WNTC59; MLS006011203; SCHEMBL1724609; GTPL12020; DTXSID60727009; EX-A289; HMS3652D18; BCP07008; BDBM50133864; CS2235; HB3155; s7037; AKOS024458516; CCG-268399; CS-1420; SB19435; NCGC00263085-01; AC-30233; AS-72497; DA-28367; HY-15659; SMR004702972; FT-0700434; SW220173-1; J-690095; 2-[4-(2-Methyl-4-pyridyl)phenyl]-N-[4-(3-pyridyl)phenyl]acetamide; 4-(2-Methyl-4-pyridinyl)-N-[4-(3-py ridinyl)phenyl]benzeneacetamide; 4-(2-Methyl-4-pyridinyl)-N-[4-(3-pyridinyl)phenyl]-benzeneacetamide; Benzeneacetamide, 4-(2-methyl-4-pyridinyl)-N-[4-(3-pyridinyl)phenyl]-	Investigative	Investigative Drug(s)	57519544	.	.	379.5	54.9	508	4.2	29	1	3	5	C25H21N3O	2-[4-(2-methylpyridin-4-yl)phenyl]-N-(4-pyridin-3-ylphenyl)acetamide	CC1=NC=CC(=C1)C2=CC=C(C=C2)CC(=O)NC3=CC=C(C=C3)C4=CN=CC=C4	CC1=NC=CC(=C1)C2=CC=C(C=C2)CC(=O)NC3=CC=C(C=C3)C4=CN=CC=C4	InChI=1S/C25H21N3O/c1-18-15-22(12-14-27-18)20-6-4-19(5-7-20)16-25(29)28-24-10-8-21(9-11-24)23-3-2-13-26-17-23/h2-15,17H,16H2,1H3,(H,28,29)	KHZOJCQBHJUJFY-UHFFFAOYSA-N
D9RJT7	GSK2578215A	Small molecule	GSK2578215A; 1285515-21-0; 2-(benzyloxy)-5-(2-fluoropyridin-4-yl)-N-(pyridin-3-yl)benzamide; GSK-2578215A; GSK257821A; 5-(2-fluoropyridin-4-yl)-2-phenylmethoxy-N-pyridin-3-ylbenzamide; itor GSK2578215A; Benzamide, 5-(2-fluoro-4-pyridinyl)-2-(phenylmethoxy)-N-3-pyridinyl-; Q641JSF42X; CHEMBL2204495; LRRK2 inhib1285515-21-0; BDBM50401284; LRRK2-kinase inhibitor; UNII-Q641JSF42X; SCHEMBL10321469; BDBM482159; HMS3740I09; BCP07701; EX-A1118; GSK 257821A; GSK-257821A; GSK 2578215A; GSK2578215-A; MFCD22665702; s7664; AKOS024458262; CCG-268642; CS-3516; NCGC00370783-04; NCGC00370783-06; NCGC00370783-10; AC-35433; AS-72347; DA-33593; HY-13237; FT-0700156; F50677; J-005608; Q27287044; 5-(2-Fluoro-4-pyridinyl)-2-(phenylmethoxy)-N-3-pyridinylbenzamide; 5-(2-Fluoro-4-pyridinyl)-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide	Investigative	Investigative Drug(s)	68107965	.	.	399.4	64.099	543	4.1	30	1	5	6	C24H18FN3O2	5-(2-fluoropyridin-4-yl)-2-phenylmethoxy-N-pyridin-3-ylbenzamide	C1=CC=C(C=C1)COC2=C(C=C(C=C2)C3=CC(=NC=C3)F)C(=O)NC4=CN=CC=C4	C1=CC=C(C=C1)COC2=C(C=C(C=C2)C3=CC(=NC=C3)F)C(=O)NC4=CN=CC=C4	InChI=1S/C24H18FN3O2/c25-23-14-19(10-12-27-23)18-8-9-22(30-16-17-5-2-1-3-6-17)21(13-18)24(29)28-20-7-4-11-26-15-20/h1-15H,16H2,(H,28,29)	WCIGMFCFPXZRMQ-UHFFFAOYSA-N
D6WJ5G	MLi-2	Small molecule	MLI-2; 1627091-47-7; MLi-2 - Bio-X; (2~{r},6~{s})-2,6-Dimethyl-4-[6-[5-(1-Methylcyclopropyl)oxy-1~{h}-Indazol-3-Yl]pyrimidin-4-Yl]morpholine; (2S,6R)-2,6-dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine; Merck lrrk2 inhibitor-2; CHEMBL4098877; SCHEMBL16022474; GTPL11663; CHEBI:132484; EX-A4118; AKOS030210950; AT22709; compound 1 [PMID: 28245354]; CS-6349; AC-36550; AS-76747; HY-100411; S9694; J3.645.913A; Q27225595; cis-2,6-dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine; (2R,6S)-2,6-dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine; (2R,6S)-2,6-dimethyl-4-[6-[5-(1-methylcyclopropyl)oxy-1H-indazol-3-yl]pyrimidin-4-yl]morpholine; 5-(1-Methylcyclopropane-1-yloxy)-3-[6-(2beta,6beta-dimethylmorpholine-4-yl)pyrimidine-4-yl]-1H-indazole; A1N; rel-(2S,6R)-2,6-Dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine; rel-3-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-4-pyrimidyl]-5-[(1-methylcyclopropyl)oxy]-1H-indazole	Investigative	Investigative Drug(s)	78319901	.	.	379.5	76.2	549	3.2	28	1	6	4	C21H25N5O2	(2R,6S)-2,6-dimethyl-4-[6-[5-(1-methylcyclopropyl)oxy-1H-indazol-3-yl]pyrimidin-4-yl]morpholine	CC1CN(CC(O1)C)C2=NC=NC(=C2)C3=NNC4=C3C=C(C=C4)OC5(CC5)C	C[C@@H]1CN(C[C@@H](O1)C)C2=NC=NC(=C2)C3=NNC4=C3C=C(C=C4)OC5(CC5)C	InChI=1S/C21H25N5O2/c1-13-10-26(11-14(2)27-13)19-9-18(22-12-23-19)20-16-8-15(28-21(3)6-7-21)4-5-17(16)24-25-20/h4-5,8-9,12-14H,6-7,10-11H2,1-3H3,(H,24,25)/t13-,14+	ATUUNJCZCOMUKD-OKILXGFUSA-N
D3YG8I	SHIN2	Small molecule	(Rac)-SHIN2; SHIN2; SCHEMBL19958329; EX-A5815; HY-134978; CS-0168616; 2204289-53-0	Investigative	Investigative Drug(s)	134335035	.	.	406.5	128	773	3.1	30	4	6	6	C23H26N4O3	6-amino-4-[3-(hydroxymethyl)-5-(5-hydroxypent-1-ynyl)phenyl]-3-methyl-4-propan-2-yl-2H-pyrano[2,3-c]pyrazole-5-carbonitrile	CC1=C2C(=NN1)OC(=C(C2(C3=CC(=CC(=C3)C#CCCCO)CO)C(C)C)C#N)N	CC1=C2C(=NN1)OC(=C(C2(C3=CC(=CC(=C3)C#CCCCO)CO)C(C)C)C#N)N	InChI=1S/C23H26N4O3/c1-14(2)23(19(12-24)21(25)30-22-20(23)15(3)26-27-22)18-10-16(7-5-4-6-8-28)9-17(11-18)13-29/h9-11,14,28-29H,4,6,8,13,25H2,1-3H3,(H,26,27)	IWUCUJZMKDHLOF-UHFFFAOYSA-N
D1Y0DP	Inosine	Small molecule	inosine; 58-63-9; Hypoxanthosine; Ribonosine; Atorel; Oxiamin; Hypoxanthine riboside; Trophicardyl; Selfer; Pantholic-L; Panholic-L; beta-Inosine; Hypoxanthine D-riboside; (-)-Inosine; Hypoxanthine ribonucleoside; 9-beta-D-Ribofuranosylhypoxanthine; Hypoxanthine nucleoside; INO 495; Inosina; Inosinum; Inosie; iso-prinosine; Inosine [INN:JAN]; Inosinum [INN-Latin]; Inosina [INN-Spanish]; hypoxanthine-ribose; NSC 20262; Hypoxanthine, 9-beta-D-ribofuranosyl-; Inosin; Inotin; INO; AI3-52241; Hypoxanthine 9-beta-D-ribofuranoside; beta-D-Ribofuranoside, hypoxanthine-9; HXR; Hypoxanthine-9-beta-D-ribofuranoside; MLS000028518; DTXSID2045993; CHEBI:17596; 5A614L51CT; 9.beta.-D-Ribofuranosylhypoxanthine; 9-.beta.-D-Ribofuranosylhypoxanthine; NSC-20262; 9-beta-D-ribofuranosyl-9H-purin-6-ol; CID 5274258; SMR000058316; MFCD00066770; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one; 1,9-Dihydro-9-beta-D-ribofuranosyl-6H-purin-6-one; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one; DTXCID0025993; .beta.-Inosine; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-hydroxypurin-9-yl)oxolane-3,4-diol; 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3H-purin-6-one; 9-[(2S,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; CAS-58-63-9; SR-01000721862; EINECS 200-390-4; Catacol; NSC20262; UNII-5A614L51CT; 3h-inosine; 2ada; 2fqw; .beta.-D-Ribofuranoside, hypoxanthine-9; NCGC00095787-01; Hypoxanthine, 9-.beta.-D-ribofuranosyl-; Inosine,(S); Inotin (TN); Inosine (JAN/INN); 1a4m; INOSINE [INCI]; Inosine (8CI,9CI); INOSINE [INN]; INOSINE [JAN]; INOSINE [MI]; INOSINE [MART.]; Opera_ID_1628; INOSINE [WHO-DD]; INOSINE [WHO-IP]; bmse000098; bmse000888; bmse000978; cid_6021; CHEMBL1556; SCHEMBL15804; KBioGR_002560; KBioSS_002569; INOSINE [USP IMPURITY]; GTPL4554; 9-b-D-Ribofuranosylhypoxanthine; Hypoxanthine-9-D-ribofuranoside; Inosine, >=99% (HPLC); 9beta-D-Ribofuranosylhypoxanthine; BDBM22104; KBio2_002560; KBio2_005128; KBio2_007696; KBio3_003038; 9-b-D-ribofuranosyl-Hypoxanthine; cMAP_000084; HMS2235I17; Hypoxanthine-9-delta-ribofuranoside; 9-beta-D-ribofuranosyl-Hypoxanthine; AMY30713; HY-N0092; 9beta-delta-Ribofuranosylhypoxanthine; Tox21_111522; BDBM50366815; beta-D-Ribofuranoside hypoxanthine-9; hypoxanthine-9 beta-D-Ribofuranoside; s2442; 9-beta-delta-Ribofuranosylhypoxanthine; AKOS015969695; AKOS015995607; AKOS024462561; Atorel; HXR; Hypoxanthine D-riboside; Tox21_111522_1; 9-beta-delta-ribofuranosyl-Hypoxanthine; AM83935; CCG-267127; CS-5845; DB04335; DIDANOSINE IMPURITY B [WHO-IP]; beta-delta-Ribofuranoside hypoxanthine-9; Hypoxanthine 9-beta-delta-ribofuranoside; hypoxanthine-9 beta-delta-Ribofuranoside; Hypoxanthine-9-beta-delta-ribofuranoside; SMP1_000165; NCGC00095787-05; NCGC00096119-02; NCGC00096119-03; AS-11754; BP-51105; 9-(beta-D-ribofuranosyl)-9H-purin-6-ol; ADENOSINE IMPURITY G [EP IMPURITY]; DB-029916; DIDANOSINE IMPURITY B [EP IMPURITY]; I0037; C00294; D00054; EN300-310328; 1,9-dihydro-9-b-D-ribofuranosyl-6H-Purin-6-one; Q422564; SR-01000721862-2; SR-01000721862-3; AC89F8E4-FD89-45EE-8B41-94DFC07AB42F; BRD-K79612754-001-21-7; 1,9-Dihydro-9-beta-delta-ribofuranosyl-6H-purin-6-one; 6H-Purin-6-one, 1,9-dihydro-9-beta-D-ribofuranosyl-; Z2681890654; 9-.BETA.-D-RIBOFURANOSYL-1,9-DIHYDRO-6H-PURIN-6-ONE; 9-beta-D-Ribofuranosyl-1,9-dihydro-6H-purin-6-one (Inosine); 9-.BETA.-D-RIBOFURANOSYL-1,9-DIHYDRO-6H-PURIN-6-ONE [WHO-IP]; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-hydroxy-9H-purin-9-yl)tetrahydrofuran-3,4-diol; 9-(3,4-DIHYDROXY-5-HYDROXYMETHYL-TETRAHYDRO-FURAN-2-YL)-1,9-DIHYDRO-PURIN-6-ONE; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one; 9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one	Investigative	Investigative Drug(s)	135398641	.	.	268.23	129	405	-1.3	19	4	7	2	C10H12N4O5	9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one	C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)CO)O)O	C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O	InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1	UGQMRVRMYYASKQ-KQYNXXCUSA-N
DBV69K	GA-607	Small molecule	(6-(5-amino)-ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline hydrochloride	Investigative	Investigative Drug(s)	156025349	.	.	268.78	47.3	311	.	18	3	3	2	C14H21ClN2O	1-[(2,2,4-trimethyl-1H-quinolin-6-yl)oxy]ethanamine;hydrochloride	CC1=CC(NC2=C1C=C(C=C2)OC(C)N)(C)C.Cl	CC1=CC(NC2=C1C=C(C=C2)OC(C)N)(C)C.Cl	InChI=1S/C14H20N2O.ClH/c1-9-8-14(3,4)16-13-6-5-11(7-12(9)13)17-10(2)15;/h5-8,10,16H,15H2,1-4H3;1H	AHRRMMGKGPSJGG-UHFFFAOYSA-N
D51GUE	PNA5	Small molecule	PNA5; UNII-N6H8CV85UW; N6H8CV85UW; PNA-5; ANG-1-6-o-Ser-glc-NH2; 2186644-51-7	Investigative	Investigative Drug(s)	162623682	.	.	1050.1	494	1910	-6.6	74	17	19	30	C45H71N13O16	(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-[(2S,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)NC(COC2C(C(C(C(O2)CO)O)O)O)C(=O)N)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)CO)O)O)O)C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N	InChI=1S/C45H71N13O16/c1-5-21(4)33(43(72)55-28(14-23-16-50-19-52-23)40(69)56-29(37(47)66)18-73-44-36(65)35(64)34(63)30(17-59)74-44)58-41(70)27(13-22-8-10-24(60)11-9-22)54-42(71)32(20(2)3)57-39(68)26(7-6-12-51-45(48)49)53-38(67)25(46)15-31(61)62/h8-11,16,19-21,25-30,32-36,44,59-60,63-65H,5-7,12-15,17-18,46H2,1-4H3,(H2,47,66)(H,50,52)(H,53,67)(H,54,71)(H,55,72)(H,56,69)(H,57,68)(H,58,70)(H,61,62)(H4,48,49,51)/t21-,25-,26-,27-,28-,29-,30-,32-,33-,34-,35+,36-,44-/m0/s1	MREIEXHOTNPVMV-XHNKTLSDSA-N
DSGV56	Puromycin	Small molecule	puromycin; 53-79-2; Stylomycin; Puromycine; Puromicina; Puromycinum; P-638; 3123L; Puromycin dihydrochloride; CHEBI:17939; GNF-PF-2016; CL 13,900; Stillomycin; CL-13900; 4A6ZS6Q2CL; 3'-(L-alpha-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine; (S)-3'-((2-Amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyladenosine; NSC 3055; Puromycin (USAN); PUROMYCIN [USAN]; NSC-3055; 3123-L; 9-{3-deoxy-3-[(O-methyl-L-tyrosyl)amino]-beta-D-xylofuranosyl}-N,N-dimethyl-9H-purin-6-amine; Adenosine, 3'-(((2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyl-; Adenosine, 3'-((2-amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyl-, (S)-; (S)-2-amino-N-((2S,3S,4R,5R)-5-(6-(dimethylamino)-9H-purin-9-yl)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)-3-(4-methoxyphenyl)propanamide; Achromycin (purine derivative); P 638; TCMDC-123493; 3'-deoxy-N,N-dimethyl-3'-(O-methyl-L-tyrosinamido)adenosine; 3'-[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-diemthyladenosine; CL 16536; NSC3055; CL 13900; 58-58-2; Puromycine [INN-French]; Puromycinum [INN-Latin]; Puromicina [INN-Spanish]; UNII-4A6ZS6Q2CL; Puromycin [USAN:INN:BAN]; 3'-deoxy-N,N-dimethyl-3'-[(O-methyl-L-tyrosyl)amino]adenosine; (S)-3'-[[2-Amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyladenosine; Adenosine, 3'-[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyl-; PUY; CL13900; PUROMYCIN [INN]; PUROMYCIN [MI]; Prestwick3_000480; Epitope ID:140945; PUROMYCIN [WHO-DD]; SCHEMBL4570; BSPBio_000620; BPBio1_000682; CHEMBL469912; DTXSID8036788; 3'-(L-.alpha.-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine; HMS2089F18; HY-B1743; CL 16,536 (*Dihydrochloride*); BDBM50277158; MFCD00866328; AKOS030485964; CCG-208505; CS-6500; DB08437; 6-Dimethylamino-9-(3'-(p-methoxy-L-phenylalanylamino)-beta-D-ribofuranosyl)-purine; Puromycin, 10 mg/ml in distilled water; NCGC00179500-01; NCGC00179500-07; NCGC00179500-14; (2S)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide; AB00514661; C01610; D05653; AB00514661-07; Q424696; BRD-K36007650-001-01-9; BRD-K36007650-300-02-3; Q27167243; Adenosine, 3'-(alpha-amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyl-, L-; (2S)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]-3-(4-methoxyphenyl)propanamide; 2-amino-N-[5-[6-(dimethylamino)-9-purinyl]-4-hydroxy-2-(hydroxymethyl)-3-oxolanyl]-3-(4-methoxyphenyl)propanamide; Adenosine, 3'-(-amino-p-methoxyhydrocinnamamido)-3'-deoxy-N, N-dimethyl-, dihydrochloride, L-	Investigative	Investigative Drug(s)	439530	DB08437	.	471.5	161	680	0	34	4	10	8	C22H29N7O5	(2S)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide	CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)NC(=O)C(CC4=CC=C(C=C4)OC)N)O	CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)NC(=O)[C@H](CC4=CC=C(C=C4)OC)N)O	InChI=1S/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)/t14-,15+,16+,18+,22+/m0/s1	RXWNCPJZOCPEPQ-NVWDDTSBSA-N
DQYT98	Antimycin A	Small molecule	Antimycin A; Antimycin A1b; Antipiricullin; Fintrol; Virosin; antimycin A1; 1397-94-0; Antimycin-A; Caswell No. 052B; CCRIS 924; HSDB 6417; 116095-18-2; EPA Pesticide Chemical Code 006314; 75G3NMU1TS; CHEMBL211501; CHEBI:22584; (2R,3S,6S,7R,8R)-3-[(3-formamido-2-hydroxybenzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl 3-methylbutanoate; [(2R,3S,6S,7R,8R)-3-[(3-formamido-2-hydroxybenzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] 3-methylbutanoate; [(2r,3s,6s,7r,8r)-3-[(3-Formamido-2-Oxidanyl-Phenyl)carbonylamino]-8-Hexyl-2,6-Dimethyl-4,9-Bis(Oxidanylidene)-1,5-Dioxonan-7-Yl] 3-Methylbutanoate; Butanoic acid, 3-methyl-, 3-((3-(formylamino)-2-hydroxybenzoyl)amino)-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl ester, (2R-(2R*,3S*,6S*,7R*,8R*))-; SR-05000002233; UNII-75G3NMU1TS; UNII-8S75R39Y6J; AWB; SCHEMBL218354; CHEBI:2762; DTXSID3058668; 8S75R39Y6J; AIDS032154; BDBM50191588; AKOS015889205; BCP9000305; CCG-208457; NCGC00017338-02; NCGC00017338-03; NCGC00017338-04; NCGC00017338-05; NCGC00142516-01; NCGC00142516-02; NCGC00142516-03; HY-107406; CS-0028420; SR-05000002233-2; SR-05000002233-3; [(2R,3S,6S,7R,8R)-3-[(3-formamido-2-hydroxy-benzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] 3-methylbutanoate; 2(or 3)-Methylbutanoic acid, (2R,3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl ester; 3-Methylbutanoic acid 3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl ester; BUTANOIC ACID, 3-METHYL-, (2R,3S,6S,7R,8R)-3-((3-(FORMYLAMINO)-2-HYDROXYBENZOYL)AMINO)-8-HEXYL-2,6-DIMETHYL-4,9-DIOXO-1,5-DIOXONAN-7-YL ESTER; isovaleric acid 8-ester with 3-formamido-N-(7-hexyl-8-hydroxy-4,9-dimethyl-2,6-dioxo-1,5-dioxonan-3-yl)salicylamide	Investigative	Investigative Drug(s)	14957	.	D04LBT	548.6	157	849	5.3	39	3	9	12	C28H40N2O9	[(2R,3S,6S,7R,8R)-3-[(3-formamido-2-hydroxybenzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] 3-methylbutanoate	CCCCCCC1C(C(OC(=O)C(C(OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C	CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C	InChI=1S/C28H40N2O9/c1-6-7-8-9-11-20-25(39-22(32)14-16(2)3)18(5)38-28(36)23(17(4)37-27(20)35)30-26(34)19-12-10-13-21(24(19)33)29-15-31/h10,12-13,15-18,20,23,25,33H,6-9,11,14H2,1-5H3,(H,29,31)(H,30,34)/t17-,18+,20-,23+,25+/m1/s1	UIFFUZWRFRDZJC-SBOOETFBSA-N
DN71BM	NVP-ADW742	Small molecule	NVP-ADW742; 475488-23-4; 475489-15-7; ADW-742; ADW742; cis-NVP-ADW742; 5-(3-phenylmethoxyphenyl)-7-[3-(pyrrolidin-1-ylmethyl)cyclobutyl]pyrrolo[2,3-d]pyrimidin-4-amine; GSK 621659A; GSK-552602A; NVP ADW 742; CHEMBL399021; MXS2N5862L; 5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(Benzyloxy)phenyl)-7-(cis-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 7H-Pyrrolo(2,3-d)pyrimidin-4-amine, 5-(3-(phenylmethoxy)phenyl)-7-(trans-3-(1-pyrrolidinylmethyl)cyclobutyl)-; UNII-MXS2N5862L; Kinome_2540; SCHEMBL95142; SCHEMBL1983470; SCHEMBL1983472; CHEMBL1988370; DTXSID70431367; NVP-ADW742;ADW-742; HMS3654M17; BCP25985; EX-A2114; GSK 552602A; BDBM50219355; GSK-552602-A; NSC767746; s1088; ADW742;GSK 552602A; AKOS024458545; AKOS026750356; BCP9001005; CCG-269275; CS-0450; NSC-767746; SB19377; NCGC00346485-01; NCGC00386129-03; AC-32801; AS-56233; DA-42361; HY-10252; DB-070828; FT-0698450; FT-0707043; SW219932-1; C15838; J-516157; BRD-K15179513-001-01-8; Q27284280; 5-(3-(benzyloxy)phenyl)-7-(3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine/NVP-ADW742; 5-[3-(Phenylmethoxy)phenyl]-7-[trans-3-(1-pyrrolidinylmethyl)cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine; ADW	Investigative	Investigative Drug(s)	9825149	.	D06NMZ	453.6	69.2	645	4.6	34	1	5	7	C28H31N5O	5-(3-phenylmethoxyphenyl)-7-[3-(pyrrolidin-1-ylmethyl)cyclobutyl]pyrrolo[2,3-d]pyrimidin-4-amine	C1CCN(C1)CC2CC(C2)N3C=C(C4=C(N=CN=C43)N)C5=CC(=CC=C5)OCC6=CC=CC=C6	C1CCN(C1)CC2CC(C2)N3C=C(C4=C(N=CN=C43)N)C5=CC(=CC=C5)OCC6=CC=CC=C6	InChI=1S/C28H31N5O/c29-27-26-25(22-9-6-10-24(15-22)34-18-20-7-2-1-3-8-20)17-33(28(26)31-19-30-27)23-13-21(14-23)16-32-11-4-5-12-32/h1-3,6-10,15,17,19,21,23H,4-5,11-14,16,18H2,(H2,29,30,31)	LSFLAQVDISHMNB-UHFFFAOYSA-N
DPQ5S6	SCH772984	Small molecule	SCH772984; 942183-80-4; SCH-772984; (R)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)piperazin-1-yl)ethyl)-N-(3-(pyridin-4-yl)-1H-indazol-5-yl)pyrrolidine-3-carboxamide; SCH 772984; CHEMBL3590107; (3R)-1-[2-Oxo-2-[4-[4-(2-pyrimidinyl)phenyl]-1-piperazinyl]ethyl]-N-[3-(4-pyridinyl)-1H-indazol-5-yl]-3-pyrrolidinecarboxamide; (3~{R})-1-[2-oxidanylidene-2-[4-(4-pyrimidin-2-ylphenyl)piperazin-1-yl]ethyl]-~{N}-(3-pyridin-4-yl-1~{H}-indazol-5-yl)pyrrolidine-3-carboxamide; (3r)-1-(2-Oxo-2-{4-[4-(Pyrimidin-2-Yl)phenyl]piperazin-1-Yl}ethyl)-N-[3-(Pyridin-4-Yl)-2h-Indazol-5-Yl]pyrrolidine-3-Carboxamide; (3R)-1-[2-oxo-2-[4-(4-pyrimidin-2-ylphenyl)piperazin-1-yl]ethyl]-N-(3-pyridin-4-yl-1H-indazol-5-yl)pyrrolidine-3-carboxamide; 38Z; GTPL8056; SCHEMBL12151489; EX-A296; CHEBI:167670; BDBM50094464; MFCD11878503; NSC775636; s7101; AKOS025402018; CS-1421; NSC-775636; NCGC00350780-05; NCGC00350780-10; NCGC00350780-11; (R)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)piperazin-1-yl)ethyl)-N-(3-(pyridin-4-yl)-1H-indazol-5-y; (R)-1-{2-Oxo-2-[4-(4-pyrimidin-2-yl-phenyl)-piperazin-1-yl]-ethyl}-pyrrolidine-3-carboxylic acid (3-pyridin-4-yl-1H-indazol-5-yl)-amide; AC-28198; CID 24866313; HY-50846; F31041; A859514; Q27088760; Z2037279765; (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL)PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-1H-INDAZOL-5-YL]PYRROLIDINE-3-CARBOXAMIDE; (R)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)piperazin-1-yl)ethyl)-N-(3-(pyridin-4-yl)-1H-indazol-5-; F3Z	Investigative	Investigative Drug(s)	24866313	.	D08XVZ	587.7	123	957	2.5	44	2	8	7	C33H33N9O2	(3R)-1-[2-oxo-2-[4-(4-pyrimidin-2-ylphenyl)piperazin-1-yl]ethyl]-N-(3-pyridin-4-yl-1H-indazol-5-yl)pyrrolidine-3-carboxamide	C1CN(CC1C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC=NC=C4)CC(=O)N5CCN(CC5)C6=CC=C(C=C6)C7=NC=CC=N7	C1CN(C[C@@H]1C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC=NC=C4)CC(=O)N5CCN(CC5)C6=CC=C(C=C6)C7=NC=CC=N7	InChI=1S/C33H33N9O2/c43-30(42-18-16-41(17-19-42)27-5-2-24(3-6-27)32-35-11-1-12-36-32)22-40-15-10-25(21-40)33(44)37-26-4-7-29-28(20-26)31(39-38-29)23-8-13-34-14-9-23/h1-9,11-14,20,25H,10,15-19,21-22H2,(H,37,44)(H,38,39)/t25-/m1/s1	HDAJDNHIBCDLQF-RUZDIDTESA-N
DB58DF	CP55,940	Small molecule	CP55940; CP-55940; 83003-12-7; 2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol; 83002-04-4; CP55,940; CP 55,940; CP-55,940; 8YX8JK1BQG; KFY70972J5; Phenol, 5-(1,1-dimethylheptyl)-2-((1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-, rel-; 5-(1,1-Dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; [3H]CP55940; Phenol,5-(1,1-dimethylheptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-, rel-(-)-; 5-(1,1-Dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol; SR-01000075740; UNII-8YX8JK1BQG; CP 56667; UNII-KFY70972J5; CP-56,667; 2-((1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-5-(2-methyloctan-2-yl)phenol; Phenol, 5-(1,1-dimethylheptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-; 9GF; PHENOL, 5-(1,1-DIMETHYLHEPTYL)-2-((1R,2R,5R)-5-HYDROXY-2-(3-HYDROXYPROPYL)CYCLOHEXYL)-; Lopac-C-1112; Lopac0_000189; GTPL730; GTPL734; ChEMBL_75020; MLS002153159; CHEMBL48552; SCHEMBL120410; CHEMBL559612; DTXSID80875516; DTXSID401017713; HMS2236E04; HMS3649D17; BDBM50072775; NSC792743; PDSP2_000199; PDSP2_000671; AKOS024458710; CCG-204284; LP00189; NSC-792743; SDCCGSBI-0050177.P002; (-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol; 5-(1,1-Dimethylheptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol; NCGC00015212-01; NCGC00024896-02; NCGC00024896-03; NCGC00024896-04; NCGC00024896-05; Phenol, 5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-, (1alpha,2beta,5alpha)-; SMR001230653; CP-55940 [(-)-AC],XIV; CP-55940, >98% (HPLC), powder; J259.891D; EU-0100189; (-)-CP-55940; (?)-CP-55940; C 1112; (+-)-CP 55940; (+/-)-CP 55,940; (+/-)-CP-55940; SR-01000597481; CP-55940, (+/-)-; SR-01000075740-1; SR-01000075740-4; SR-01000597481-1; (1r,3r,4r)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol; 5-(1,1-Dimethyl-heptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxy-propyl)-cyclohexyl]-phenol; rel-5-(1,1-dimethylheptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol; 5-(1,1-Dimethyl-heptyl)-2-[(4R,6R)-5-hydroxy-2-((R)-3-hydroxy-propyl)-cyclohexyl]-phenol; PHENOL, 5-(1,1-DIMETHYLHEPTYL)-2-(5-HYDROXY-2-(3-HYDROXYPROPYL)CYCLOHEXYL)-, (1.ALPHA.,2.BETA.,5.ALPHA.)-	Investigative	Investigative Drug(s)	104895	.	D0D6OH	376.6	60.7	408	6.1	27	3	3	10	C24H40O3	2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol	CCCCCCC(C)(C)C1=CC(=C(C=C1)C2CC(CCC2CCCO)O)O	CCCCCCC(C)(C)C1=CC(=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O)O	InChI=1S/C24H40O3/c1-4-5-6-7-14-24(2,3)19-11-13-21(23(27)16-19)22-17-20(26)12-10-18(22)9-8-15-25/h11,13,16,18,20,22,25-27H,4-10,12,14-15,17H2,1-3H3/t18-,20-,22-/m1/s1	YNZFFALZMRAPHQ-SYYKKAFVSA-N
DXG13A	CI-1044	Small molecule	CI-1044; 197894-84-1; O4T475XIIY; PD-189659; UNII-O4T475XIIY; CI 1044; CHEMBL342285; DTXSID5047291; (+)-CI-1044; N-(9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro(1,4)diazepino(6,7,1-hi)indol-3-yl)nicotinamide; 3-Pyridinecarboxamide, N-((3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-; 3-Pyridinecarboxamide, N-(9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-, (R)-; (R)-N-(9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-3-yl)nicotinamide; SCHEMBL6441242; DTXCID3027291; Tox21_300455; BDBM50473083; NCGC00248057-01; NCGC00254387-01; MS-26706; HY-100246; CS-0018397; Q27285326; N-[(11R)-6-amino-12-oxo-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl]pyridine-3-carboxamide	Investigative	Investigative Drug(s)	9843744	.	D0DL6J	397.4	101	704	2	30	2	5	3	C23H19N5O2	N-[(11R)-6-amino-12-oxo-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl]pyridine-3-carboxamide	C1CN2C(=O)C(N=C(C3=CC(=CC1=C32)N)C4=CC=CC=C4)NC(=O)C5=CN=CC=C5	C1CN2C(=O)[C@@H](N=C(C3=CC(=CC1=C32)N)C4=CC=CC=C4)NC(=O)C5=CN=CC=C5	InChI=1S/C23H19N5O2/c24-17-11-15-8-10-28-20(15)18(12-17)19(14-5-2-1-3-6-14)26-21(23(28)30)27-22(29)16-7-4-9-25-13-16/h1-7,9,11-13,21H,8,10,24H2,(H,27,29)/t21-/m0/s1	XGXOSJSGDNPEEF-NRFANRHFSA-N
DOZK57	PP242	Small molecule	PP242; 1092351-67-1; TORKinib; PP-242; PP 242; Torkinib (PP242); 2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol; 2-[4-Amino-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-1H-indol-5-ol; H5669VNZ7V; DTXSID5048685; CHEBI:90679; 2-(4-Amino-1-isopropyl-1H-pyrazolo(3,4-d)pyrimidin-3-yl)-1H-indol-5-ol; 2-[4-Amino-1-(Propan-2-Yl)-1h-Pyrazolo[3,4-D]pyrimidin-3-Yl]-1h-Indol-5-Ol; (2E)-2-(4-amino-1-propan-2-yl-2H-pyrazolo[3,4-d]pyrimidin-3-ylidene)indol-5-ol; 1H-Indol-5-ol, 2-(4-amino-1-(1-methylethyl)-1H-pyrazolo(3,4-d)pyrimidin-3-yl)-; 2-[4-Amino-1-(1-methylethyl)-1H-pyrazolo-[3,4-d]pyrimidin-3-yl]-1H-indol-5-ol; DTXCID5028611; CAS-1092351-67-1; UNII-H5669VNZ7V; EX-7207; MLS006011184; SCHEMBL298922; GTPL5704; CHEMBL1241674; CHEMBL3988893; SCHEMBL21381567; BDBM36409; CHEBI:95099; EX-A034; HMS3655B12; AMY23716; BCP02319; Tox21_113072; MFCD12196869; NSC764515; s2218; AKOS024458060; AKOS026750472; Tox21_113072_1; CCG-267563; CS-0247; NSC-764515; CID24905147; NCGC00188346-02; NCGC00188346-03; NCGC00387863-04; AC-28392; AS-16317; HY-10474; SMR004702953; FT-0696781; SW220211-1; A25462; J-507663; BRD-K87112191-001-02-9; Q27088430; Q27166867; 2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-5-ol; 2-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol; 2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol, PP242; 2-(4-amino-1-propan-2-yl-2H-pyrazolo[3,4-d]pyrimidin-3-ylidene)-5-indolol; P2X	Investigative	Investigative Drug(s)	135565635	.	D0H2CM	308.34	106	435	2	23	3	5	2	C16H16N6O	2-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol	CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(N3)C=CC(=C4)O)N	CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(N3)C=CC(=C4)O)N	InChI=1S/C16H16N6O/c1-8(2)22-16-13(15(17)18-7-19-16)14(21-22)12-6-9-5-10(23)3-4-11(9)20-12/h3-8,20,23H,1-2H3,(H2,17,18,19)	MFAQYJIYDMLAIM-UHFFFAOYSA-N
D5C1JU	PD0166285	Small molecule	PD0166285; 185039-89-8; PD166285; PD-166285; TCMDC-140940; CHEMBL49120; 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one; PD-0166285; 6-(2,6-dichlorophenyl)-2-((4-(2-(diethylamino)ethoxy)phenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one; C26H27Cl2N5O2; 6-(2,6-Dichloro-phenyl)-2-[4-(2-diethylamino-ethoxy)-phenylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-({4-[2-(diethylamino)ethoxy]phenyl}amino)-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 6-(2,6-Dichlorophenyl)-2-({4-[2-(Diethylamino)ethoxy]phenyl}amino)-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Kinome_3263; SCHEMBL133914; BDBM3096; GTPL8183; DTXSID501019043; BCP20228; EX-A4179; s8148; CCG-269785; NCGC00242490-01; NCGC00242490-02; AC-35457; BS-16163; HY-13925; CS-0008610; C73566; 2-aminopyrido[2,3-d]pyrimidin-7(8H)-one deriv.; Q27088273; 6-(2,6-dichlorophenyl)-2-[[4-(2-diethylaminoethoxy)phenyl]amino]-8-methylpyrido[6,5-d]pyrimidin-7-one; 6-(2,6-Dichlorophenyl)-2-[4-(2-diethylaminoethoxy)-phenylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one; 6-(2,6-Dichlorophenyl)-2-[4-(2-diethylaminoethoxy)phenylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one, Dihydrochloride; 96M	Investigative	Investigative Drug(s)	5311382	.	D0H8KG	512.4	70.6	719	5.6	35	1	6	9	C26H27Cl2N5O2	6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one	CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl	CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl	InChI=1S/C26H27Cl2N5O2/c1-4-33(5-2)13-14-35-19-11-9-18(10-12-19)30-26-29-16-17-15-20(25(34)32(3)24(17)31-26)23-21(27)7-6-8-22(23)28/h6-12,15-16H,4-5,13-14H2,1-3H3,(H,29,30,31)	IFPPYSWJNWHOLQ-UHFFFAOYSA-N
DF0QP4	Desmethylclomipramine	Small molecule	Desmethylclomipramine; 303-48-0; Norclomipramine; 01DN47PPQG; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5H-Dibenz[b,f]azepine-5-propanamine, 3-chloro-10,11-dihydro-N-methyl-; N-Desmethylclomipramine; 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N-methyl-; Demethylchlorimipramine; N-Demethylclomipramine; Desmethylchlorimipramine; Norchlorimipramine; UNII-01DN47PPQG; AMINOGUANIDINECARBONATE; SCHEMBL11384662; DTXSID70952663; CHEBI:124969; DESMETHYLCLOMIPRAMINE [WHO-DD]; AS-80832; GP-38025; BRD-K52696183-003-01-0; Q27215299; 3-Chloro-10,11-dihydro-N-methyl-5H-dibenz(b,f)azepine-5-propanamine; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methyl-1-propanamine #; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine	Investigative	Investigative Drug(s)	622606	.	D0L4CI	300.8	15.3	322	4.7	21	1	2	4	C18H21ClN2	3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine	CNCCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl	CNCCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl	InChI=1S/C18H21ClN2/c1-20-11-4-12-21-17-6-3-2-5-14(17)7-8-15-9-10-16(19)13-18(15)21/h2-3,5-6,9-10,13,20H,4,7-8,11-12H2,1H3	VPIXQGUBUKFLRF-UHFFFAOYSA-N
DOA1M0	ELND006	Small molecule	ELND006; ELND-006; 1333990-84-3; ELND0006; 959997-22-9; 7F5QGV49GL; CHEMBL2396778; (R)-4-Cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo(4,3-c)quinoline; 1H-Pyrazolo(4,3-c)quinoline, 4-cyclopropyl-7,8-difluoro-4,5-dihydro-5-((4-(trifluoromethyl)phenyl)sulfonyl)-, (4R)-; (4R)-4-cyclopropyl-7,8-difluoro-5-[4-(trifluoromethyl)phenyl]sulfonyl-1,4-dihydropyrazolo[4,3-c]quinoline; (R)-4-cyclopropyl-7,8-difluoro-5-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline; UNII-7F5QGV49GL; (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline; SCHEMBL486044; GTPL7337; DTXSID40242063; BDBM50492093; Q27077173; (4R)-4-cyclopropyl-7,8-difluoro-5-[4-(trifluoromethyl)benzenesulfonyl]-1H,4H,5H-pyrazolo[4,3-c]quinoline; 4,5-Dihydro-4beta-cyclopropyl-7,8-difluoro-5-[4-(trifluoromethyl)phenylsulfonyl]-1,2-diaza-2H-cyclopenta[c]quinoline	Investigative	Investigative Drug(s)	53308121	.	D0Q6ZQ	455.4	74.4	779	4	31	1	9	3	C20H14F5N3O2S	(4R)-4-cyclopropyl-7,8-difluoro-5-[4-(trifluoromethyl)phenyl]sulfonyl-1,4-dihydropyrazolo[4,3-c]quinoline	C1CC1C2C3=C(C4=CC(=C(C=C4N2S(=O)(=O)C5=CC=C(C=C5)C(F)(F)F)F)F)NN=C3	C1CC1[C@@H]2C3=C(C4=CC(=C(C=C4N2S(=O)(=O)C5=CC=C(C=C5)C(F)(F)F)F)F)NN=C3	InChI=1S/C20H14F5N3O2S/c21-15-7-13-17(8-16(15)22)28(19(10-1-2-10)14-9-26-27-18(13)14)31(29,30)12-5-3-11(4-6-12)20(23,24)25/h3-10,19H,1-2H2,(H,26,27)/t19-/m1/s1	XODSHWXKSMPDRP-LJQANCHMSA-N
D6DC8W	NVP-TAE684	Small molecule	761439-42-3; NVP-TAE684; TAE684; NVP-TAE 684; TAE-684; 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; TAE684 (NVP-TAE684); TAE 684; NVT-TAE-684; 5-Chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-2,4-pyrimidinediamine; CHEMBL509032; EH1713MN4K; BDBM50242742; 5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine; 5-Chloro-N-[2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl)piperidin-1-Yl]phenyl]-N'-(2-Propan-2-Ylsulfonylphenyl)pyrimidine-2,4-Diamine; UNII-EH1713MN4K; NVP-TAE684-TAE 684; GUI; Kinome_1205; Nv--tae684; MLS006010970; SCHEMBL282775; GTPL5714; CHEBI:91338; DTXSID30227001; EX-A427; BCPP000143; BDBM482158; HMS3265E03; HMS3265E04; HMS3265F03; HMS3265F04; BCP01828; MFCD11977634; NSC764041; s1108; AKOS005145672; BCP9001015; CCG-270242; ES-0036; NSC-764041; SB19385; NCGC00238453-01; NCGC00238453-02; NCGC00238453-07; 5-chloro-2-N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-4-N-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine; AC-33167; HY-10192; SMR004702774; A9654; FT-0700362; EC-000.2345; J-517400; BRD-K50140147-001-01-0; Q27088117; 5-CHLORO-N-[2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL)PIPERIDIN-1-YL]PHENYL]-N''-(2-PROPAN-2-YLSULFONYLPHENYL)PYRIMIDINE-2,4-DIAMINE; 5-Chloro-n2-[2-Methoxy-4-[4-(4-Methyl-1-piperazinyl)-1-Piperidinyl]phenyl]-n4-[2-[(1-Methylethyl)sulfonyl]phenyl]-2,4-pyrimidinediam ine; 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-pyperidinyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-2,4-Pyrimidinediamine	Investigative	Investigative Drug(s)	16038120	.	D0R2WK	614.2	111	940	5.7	42	2	10	9	C30H40ClN7O3S	5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC	CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC	InChI=1S/C30H40ClN7O3S/c1-21(2)42(39,40)28-8-6-5-7-26(28)33-29-24(31)20-32-30(35-29)34-25-10-9-23(19-27(25)41-4)37-13-11-22(12-14-37)38-17-15-36(3)16-18-38/h5-10,19-22H,11-18H2,1-4H3,(H2,32,33,34,35)	QQWUGDVOUVUTOY-UHFFFAOYSA-N
D1LX3J	PF-06447475	Small molecule	PF-06447475; 1527473-33-1; PF06447475; 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile; 3-(4-morpholino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile; CHEMBL3393348; PF 06447475; 3-(4-(morpholin-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile; 3FE; GTPL8054; SCHEMBL15401353; EX-A560; BCP14890; 3-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile; BDBM50059277; MFCD28347838; s8202; AKOS025404704; CCG-267523; CS-3553; SB17260; NCGC00390733-02; AC-35246; AS-56286; DA-44137; HY-12477; FT-0700214; A883883; J-690197; PF-06447475, >=98% (HPLC); Q27088322; 3-[4-(4-Morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile	Investigative	Investigative Drug(s)	72706840	.	D0WK9R	305.33	77.8	457	2.1	23	1	5	2	C17H15N5O	3-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile	C1COCCN1C2=NC=NC3=C2C(=CN3)C4=CC=CC(=C4)C#N	C1COCCN1C2=NC=NC3=C2C(=CN3)C4=CC=CC(=C4)C#N	InChI=1S/C17H15N5O/c18-9-12-2-1-3-13(8-12)14-10-19-16-15(14)17(21-11-20-16)22-4-6-23-7-5-22/h1-3,8,10-11H,4-7H2,(H,19,20,21)	BHTWDJBVZQBRKP-UHFFFAOYSA-N
D0VPI1	Clioquinol	Small molecule	clioquinol; 130-26-7; 5-Chloro-7-iodoquinolin-8-ol; Iodochlorhydroxyquin; Chinoform; Chloroiodoquin; 5-Chloro-7-iodo-8-quinolinol; Chloroiodoquine; 5-Chloro-8-hydroxy-7-iodoquinoline; Vioform; Iodochloroxyquinoline; Cliquinol; Iodochlorohydroxyquinoline; Chlorojodochin; Enteroquinol; Iodochloroquine; Iodochloroxine; Iodoenterol; 7-Iodo-5-chloroxine; Entero-Vioform; Iodochlorhydroxyquinoline; 5-Chloro-7-iodo-8-hydroxyquinoline; Iodoxyquinoline; Alchloquin; Barquinol; Budoform; Cifoform; Dermaform; Dioquinol; Domeform; Eczecidin; Enteroseptol; Enterozol; Enterseptol; Entrokin; Iodenterol; Lekosept; Mycoquin; Quinambicide; Quinoform; Rheaform; Amebil; Amoenol; Bactol; Emaform; Nioform; Rometin; Entero-Bioform; Iodochlorohydroxyquin; Hi-Enterol; Iodochlorhydroxyquinol; Hydriodide-enterol; Quin-O-Creme; Entero-Septol; Enterum locorten; 5-Chloro-7-iodo-quinolin-8-ol; Domeform-HC; 8-Quinolinol, 5-chloro-7-iodo-; 7-Iodo-5-chloro-8-hydroxyquinoline; Clioquinolum; Chloro-8-hydroxyiodoquinoline; Quinoform (antiseptic); Vioform n.n.r.; Quinoline, chloro-8-hydroxyiodo-; 5-Chlor-7-jod-8-hydroxy-chinolin; Rheaform boluses; iodochlorhydroxyquinolone; NSC-3531; Chinoformum; Cliochinolum; 7BHQ856EJ5; Enterovalodon; Alioform; DTXSID7022837; Enteritan; Jodchloroxychinolinum; Oralcer; CHEBI:74460; Corque; Cortin; Iodochloroxychinolinum; Cremo-quin; Entero-bio form; Entero-Vioformio; Ala-Quin; UAD Lotion; NSC-74938; NCGC00016391-05; Cliochinolo; CAS-130-26-7; Cliochinolo [DCIT]; TG2-36-2; Caswell No. 193; Formtone-HC; PBT-1; Quinoform (VAN); Clioquinolum [INN-Latin]; DTXCID502837; loquinol; Vioformio; Hi-eneterol; Iodochlorhydroxyquin Cream; Vioform-Hydrocortisone Mild; 22112-03-4; SMR000058282; Rheaform Boluses (Veterinary); CCRIS 6050; HSDB 6843; 5-Chlor-7-jod-8-hydroxy-chinolin [German]; SR-01000002987; NSC 3531; EINECS 204-984-4; EPA Pesticide Chemical Code 024001; BRN 0153637; UNII-7BHQ856EJ5; Linolasept; Clioquinol [USP:INN:BAN]; Cloquinol; AI3-16451; Clioquinol (CQ); component of Hyquin; MFCD00006787; NSC 74938; Nystaform (Salt/Mix); Clioquinol (USP/INN); CLIOQUINOL [INN]; component of Formtone-HC; component of Heb-Cort V; Prestwick0_000886; Prestwick1_000886; Prestwick2_000886; Prestwick3_000886; CLIOQUINOL [HSDB]; Formtone-HC (Salt/Mix); CLIOQUINOL [VANDF]; CHEMBL497; EC 204-984-4; cid_2788; CLIOQUINOL [MART.]; SCHEMBL3967; CLIOQUINOL [USP-RS]; CLIOQUINOL [WHO-DD]; NCIOpen2_009062; Oprea1_438281; BSPBio_000672; BSPBio_002466; 5-21-03-00294 (Beilstein Handbook Reference); ksc-8-192; MLS000069389; MLS002454410; SPECTRUM1505114; SPBio_002891; BPBio1_000740; CLIOQUINOL [ORANGE BOOK]; component of Hyquin (Salt/Mix); BDBM32188; IODOCHLORHYDROXYQUIN [MI]; CLIOQUINOL [EP MONOGRAPH]; NSC3531; WLN: T66 BNJ GG II JQ; CLIOQUINOL [USP MONOGRAPH]; HMS1570B14; HMS1648J07; HMS2093I12; HMS2097B14; HMS2230I20; HMS3372J20; HMS3714B14; KUC105859N; Pharmakon1600-01505114; ALBB-031653; component of Cort-Quin (Salt/Mix); Tox21_110416; Tox21_200291; NSC759822; NYSTAFORM COMPONENT CLIOQUINOL; s4601; STK399761; 5-chloro-8-hydroxy-7-iodo-quinoline; component of Heb-Cort V (Salt/Mix); AKOS000120779; Tox21_110416_1; AC-6792; CCG-213339; DB04815; FD10468; NSC-759822; CLIOQUINOL COMPONENT OF NYSTAFORM; SMP1_000073; IODOCHLORHYDROXYQUIN [GREEN BOOK]; NCGC00016391-01; NCGC00016391-02; NCGC00016391-03; NCGC00016391-04; NCGC00016391-06; NCGC00016391-07; NCGC00016391-08; NCGC00016391-09; NCGC00016391-10; NCGC00016391-13; NCGC00021665-03; NCGC00021665-04; NCGC00021665-05; NCGC00257845-01; S4601 5-Chloro-8-hydroxy-7-iodoquin; AS-14597; BC167259; HY-14603; SBI-0206782.P001; DB-041956; AB00384254; FT-0603209; 4-stearylamino-phenyl-trimethylam. metilsulf.; EN300-20836; A16461; Clioquinol, VETRANAL(TM), analytical standard; component of Vioform-Hydrocortisone (Salt/Mix); D03538; AB00384254_17; 5-Chloro-7-iodo-8-quinolinol, >=95.0% (HPLC); CU-01000000767-2; Q-200875; Q5134338; SR-01000002987-2; SR-01000002987-3; SR-01000002987-4; BRD-K09255212-001-04-2; Z104483432; Clioquinol, British Pharmacopoeia (BP) Reference Standard; Clioquinol, European Pharmacopoeia (EP) Reference Standard; Clindamycin phosphate, Antibiotic for Culture Media Use Only; Clioquinol, United States Pharmacopeia (USP) Reference Standard; CQL	Investigative	Investigative Drug(s)	2788	DB04815	D06ABW	305.5	33.1	193	3.5	13	1	2	0	C9H5ClINO	5-chloro-7-iodoquinolin-8-ol	C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1	C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1	InChI=1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H	QCDFBFJGMNKBDO-UHFFFAOYSA-N
DUI6Y3	L-serine	Small molecule	L-serine; serine; 56-45-1; (S)-2-Amino-3-hydroxypropanoic acid; (S)-Serine; H-Ser-OH; beta-Hydroxyalanine; L-ser; L-(-)-Serine; (2S)-2-amino-3-hydroxypropanoic acid; Serine, L-; L-Serin; Serinum [Latin]; Serina [Spanish]; Serine (VAN); L-3-Hydroxy-alanine; (-)-Serine; beta-Hydroxy-L-alanine; L-2-Amino-3-hydroxypropionic acid; Serine [USAN:INN]; SER (IUPAC abbrev); alpha-Amino-beta-hydroxypropionic acid; 2-Amino-3-hydroxypropionic acid; L-3-Hydroxy-2-aminopropionic acid; (S)-2-Amino-3-hydroxypropionic acid; HSDB 680; (S)-(-)-Serine; 2-Amino-3-hydroxypropanoic acid, (S)-; ser; Propanoic acid, 2-amino-3-hydroxy-, (S)-; MFCD00064224; BRN 1721404; CHEBI:17115; (S)-alpha-Amino-beta-hydroxypropionic acid; (2S)-2-amino-3-hydroxy-propanoic acid; Serine (L-Serine); 452VLY9402; NSC-118365; (S)-2-amino-3-hydroxy-Propanoic acid; 6898-95-9; (S)-(+)-2-Amino-3-hydroxypropionic acid; Serinum; Serene; Serina; .beta.-Hydroxyalanine; b-Hydroxy-L-alanine; EINECS 200-274-3; NSC 118365; rac-serine; Racemic serine; 2-amino-3-hydroxypropanoate; UNII-452VLY9402; 3h-l-serine; L-Serine;; H-Ser; (S)-a-Amino-b-hydroxypropionic acid; Serine (USP); 3-hydroxy-L-Alanine; L-Serine,(S); Tocris-0226; Tocris-0227; L-Serine (JP17); SERINE [VANDF]; SERINE [HSDB]; SERINE [INCI]; SERINE [USAN]; L-Alanine, 3-hydroxy-; SERINE [INN]; SERINE [WHO-DD]; Lopac-S-4250; SERINE [II]; SERINE [MI]; L-SERINE [FCC]; L-SERINE [JAN]; SERINE [MART.]; (L)-SERINE; bmse000048; bmse000809; bmse000867; bmse000885; Epitope ID:150900; EC 200-274-3; SCHEMBL1775; L-SERINE [USP-RS]; GTPL726; 4-04-00-03118 (Beilstein Handbook Reference); CHEMBL11298; SERINE [EP MONOGRAPH]; L-3-Hydroxy-2-aminopropionate; SERINE [USP MONOGRAPH]; (S)-a-Amino-b-hydroxypropionate; (S)-b-Amino-3-hydroxypropionate; DTXSID60883230; (S)-2-Amino-3-hydroxypropanoate; DTXSID301031857; Pharmakon1600-01301010; L-Serine - CAS 56-45-1; (S)-2-amino-3-hydroxy-Propanoate; ACT08366; HY-N0650; L-2-Amino-3-hydroxypropanoic Acid; L-Serine, Vetec(TM), 98.5%; STR02557; (S)-beta-Amino-3-hydroxypropionate; Fmoc-(2-aminomethylphenyl)aceticacid; l-2-Amino-3-hydroxy-propanoic acid; L-Serine, >=99.0% (NT); BDBM50357212; NSC760115; (S)-b-Amino-3-hydroxypropionic acid; AKOS015854115; (S)-alpha-Amino-beta-hydroxypropionate; AC-1190; CCG-266038; CS-W020136; DB00133; NSC-760115; (S)-beta-Amino-3-hydroxypropionic acid; L-Serine, tested according to Ph.Eur.; (2S)-2-amino-3-hydroxypropanoic acid.; NCGC00015952-01; NCGC00024507-01; NCGC00024507-02; BP-13282; L-Serine, BioUltra, >=99.5% (NT); SY002847; 2-Amino-3-hydroxypropanoic acid-, (S)-; DB-029983; Propanoic acid, 2-amino-3-hydroxy-, (S); AM20100375; S0035; S9353; EN300-52635; L-Serine, ReagentPlus(R), >=99% (HPLC); L-Serine, Vetec(TM) reagent grade, >=99%; A20660; C00065; D00016; L-Serine, Cell Culture Reagent (H-L-Ser-OH); Q183290; SR-01000597708; .alpha.-Amino-.beta.-hydroxypropionic acid-, (S)-; SR-01000597708-1; L-Serine, certified reference material, TraceCERT(R); F1905-7047; Serine, European Pharmacopoeia (EP) Reference Standard; Z756440058; 3AB40D3A-043A-488F-8361-D1BF309F842C; L-Serine, United States Pharmacopeia (USP) Reference Standard; (s)-2-amino-3-hydroxypropanoicacid;2-Amion-3-hydroxypropionicacid; L-Serine, Pharmaceutical Secondary Standard; Certified Reference Material; L-Serine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%	Investigative	Investigative Drug(s)	5951	DB00133	D0T6GM	105.09	83.6	72.6	-3.1	7	3	4	2	C3H7NO3	(2S)-2-amino-3-hydroxypropanoic acid	C(C(C(=O)O)N)O	C([C@@H](C(=O)O)N)O	InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m0/s1	MTCFGRXMJLQNBG-REOHCLBHSA-N
DPM2S4	Phencyclidine	Small molecule	PHENCYCLIDINE; 1-(1-Phenylcyclohexyl)piperidine; Angel dust; Piperidine, 1-(1-phenylcyclohexyl)-; 77-10-1; Fenciclidina; PCP (Anesthetic); Phencyclidinum; Cl-395; Elephant tranquilizer; Peace pill; Phencycline; Phenylcyclidine; CHEBI:8058; J1DOI7UV76; 1-(PHENYL-1-CYCLOHEXYL)PIPERIDINE; Supergrass; Cadillac; Crystal; Stardust; GP 121; Surfer; Tranks; HOG; Whack; Killer weed; Magic mist; Zombie dust; Busy bee; J4.441E; DEA No. 7471; PCP hydrochloride; Cycline; Cyclones; Scuffle; Sherman; Superjoint; Superweed; Sheets; Snorts; Aurora borealis; Peace; Selma; Crystal joints; Goon; Pits; Horse tracks; Monkey dust; Whacky weed; Wobble weed; Angel hair; Angel mist; Peace weed; Gorilla biscuits; Mint weed; Mint dew; Super Kool; Green tea leaves; Hog Dust; Horse tranquilizer; Kay Jay; Animal tranquilizer; Monkey tranquilizer; Fenciclidina [INN-Spanish]; Phencyclidinum [INN-Latin]; MLS002320664; Phencyclidine [INN:BAN]; Good [Street Name]; HSDB 6472; SMR001338811; CL 395; UNII-J1DOI7UV76; Rocket fuel [Street Name]; BRN 1287039; Phencylidine; 2pcp; Tic Tac; Sernyl (Salt/Mix); Elysion (Salt/Mix); CJs; Sernylan (Salt/Mix); PHENCYCLIDINE [MI]; Epitope ID:180852; PHENCYCLIDINE [INN]; PHENCYCLIDINE [HSDB]; Oprea1_593450; SCHEMBL42022; PHENCYCLIDINE [VANDF]; 101887-87-0; 5-20-02-00078 (Beilstein Handbook Reference); LBJ; PHENCYCLIDINE [WHO-DD]; CHEMBL275528; GTPL4282; DTXSID6023446; BDBM83449; cid_9795678; PDSP1_001675; PDSP2_001658; AKOS015902745; Phencyclidine hydrochloride (Salt/Mix); DB03575; NCGC00247332-01; Phencyclidine (PCP) 1.0 mg/ml in Methanol; 1-(1-phenylcyclohexyl)piperidine;hydrochloride; C07575; Q407324	Investigative	Investigative Drug(s)	6468	DB03575	D0Q5PC	243.4	3.2	242	3.6	18	0	1	2	C17H25N	1-(1-phenylcyclohexyl)piperidine	C1CCC(CC1)(C2=CC=CC=C2)N3CCCCC3	C1CCC(CC1)(C2=CC=CC=C2)N3CCCCC3	InChI=1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2	JTJMJGYZQZDUJJ-UHFFFAOYSA-N
DJL50Y	Platinum	Small molecule	7440-06-4; Platinum; Pt; Platinum Black; Platin; Platinum sponge; Platinum powder; Platinum on carbon; Platinum, elemental; platine; platino; Platinum metallicum; Platinum on alumina; platinum(3+); 78Pt; Platinum foil; Platinum wire; 49DFR088MY; C.I. 77795; CHEBI:33364; MFCD00011179; Platinum (on  carbon); Platinum, metal; Platinum asbestos; Platin [German]; Liquid bright platinum; Platinum foil, 0.1mm (0.004in) thick, Premion?; Platinum foil, 0.25mm (0.01in) thick, Premion?; platinum metal; platinum/carbon; Platinum hydride; Platina l; platinum/charcoal; Pt on charcoal; Metallic platinum; Pt on alumina; Pt on carbon; HSDB 6479; Platinum Nanorods; Platinum Standard; Platinum Nanostars; platinum(0); Platinum on silica; Platinum, 1m; Platinum, 2m; Platinum, 5m; Platinum-on-carbon; Platinum Dispersion; Platinum Nanoprisms; platinum-on-alumina; EINECS 231-116-1; platinum on charcoal; platinum(3+) ion; Platinum, nanopowder; platinum(iv) hydride; Platinum, 0.5m; Platinum Nano Powder; platinum(III) cation; Pt-C; Pt/C; PLATINUM [HSDB]; PLATINUM [INCI]; PLATINUM [MI]; Conductive Platinum Paste; Platinum, 5% on alumina; Platinium Rod, 5mmx50mm; PLATINUM [MART.]; Platinum Standard Solution; Epitope ID:114076; PLATINUM [WHO-DD]; Platinum Hollow Nanospheres; Platinum on Barium Sulfate; Platinum, 10% on carbon; Platinum, 5% on graphite; Pt(S)/C; sulfided platinum on carbon; Platinum Sponge, 60 Mesh; sulphided platinum on carbon; Platinum powder, -22 mesh; Platinum sponge, -60 mesh; UNII-49DFR088MY; Platinum, 0.5% on alumina; Platinum 5% on Carbon, wet; Platinum powder, -200 mesh; Platinum powder, -325 mesh; Platinum(5%) water(71%); Platinum, sulfided, on carbon; Pt(0); Platinum, Powder -200 Mesh; PLATINUM POWDER [INCI]; Platinum, 0.5m, 0.05mm; Platinum, 5% on carbon, dry; Trichloro(Ethene)platinate(Ii); DTXSID9064681; PLATINUM  ON CARBON 1%; Platinum paste, screen printable; CHEBI:33398; CHEBI:33400; HSDB 6997; Pt(3+); Platinum black, S.A. 10m 2/g; PLATINUM METALLICUM [HPUS]; AMY22528; Platinum 10% on carbon dry powder; Platinum powder, -200+400 mesh; Platinum, 10% on alumina, reduced; AKOS005259052; DB12257; Platinum, 5% on alumina paste, 5R94; Platinum foil, 0.5mm (0.02in) thick; Platinum wire, 0.3mm (0.012in) dia; Platinum, 5% on alumina powder, reduced; Platinum, nominally 20% on carbon black; Platinum, nominally 40% on carbon black; Platinum, p.a., 99.0-101.0%; BP-21259; Platinum foil, 0.25mm thick, 25x25mm; Platinum sponge, 2mm (0.08in) & down; Platinum foil, 0.25mm (0.01in) thick; Platinum wire, 0.25mm (0.010in) dia; Platinum, 2% on 2.5mm alumina triblobes; Platinum powder, amorphous, APS <3 micron; Platinum wire, 0.01mm (0.0004in) dia; Platinum wire, 0.025mm (0.001in) dia; CS-0016071; Platinum foil, 0.025mm (0.001in) thick; Platinum foil, 0.127mm (0.005in) thick; Platinum foil, 0.203mm (0.008in) thick; Platinum foil, 0.635mm (0.025in) thick; Platinum wire, 0.5mm (0.02in) dia, hard; Platinum wire, 1.0mm (0.04in) dia, hard; Platinum, 0.5% on granular carbon, reduced; Molybdenum Boride (Mo2B5) Sputtering Targets; Platinum black, low surface area, >=99.9%; Platinum shot, 0.1-3mm (0.004-0.1in); Platinum wire, 0.6mm (0.024in) dia, hard; Platinum wire, 1.5mm (0.059in) dia, hard; Platinum-Pt @ 1000 microg/mL in 20% HCl; Platinum wire, 0.762mm (0.03in) dia, hard; Platinum wire, 1.0mm (0.04in) dia, Premion; Platinum, 1% on gamma alumina powder, reduced; Platinum, powder, 99.995% trace metals basis; Platinum, sponge, >=99.9% trace metals basis; Platinum rod, 6.35mm (0.25in) dia, Premion; Platinum wire, 0.127mm (0.005in) dia, hard; Platinum wire, 0.5mm (0.02in) dia, annealed; Platinum wire, 1.0mm (0.04in) dia, annealed; Platinum wire, 2.0mm (0.08in) dia, annealed; Platinum, rod, 2mm, diameter 2.0mm, 99.95%; Magnetic susceptibility standard-Platinum cylinder; Platinum Standard: Pt @ 10 microg/mL in 5% HCl; Platinum wire, 0.0508mm (0.002in) dia, hard; Platinum wire, 0.1mm (0.004in) dia, Premion?; Platinum wire, 0.25mm (0.01in) dia, Premion?; Platinum wire, 0.368mm (0.0145in) dia, hard; Platinum, rod, 10mm, diameter 2.0mm, 99.95%; Platinum, rod, 10mm, diameter 3.0mm, 99.95%; Platinum, rod, 10mm, diameter 4.0mm, 99.95%; Platinum, rod, 10mm, diameter 5.0mm, 99.95%; Platinum, rod, 25mm, diameter 1.0mm, 99.95%; Platinum, rod, 25mm, diameter 1.6mm, 99.95%; Platinum, rod, 25mm, diameter 2.0mm, 99.95%; Platinum, rod, 25mm, diameter 3.0mm, 99.95%; Platinum, rod, 50mm, diameter 1.0mm, 99.95%; Platinum, rod, 50mm, diameter 1.6mm, 99.95%; Platinum, rod, 50mm, diameter 2.0mm, 99.95%; Platinum foil, 0.5mm (0.02in) thick, Premion(R); Platinum foil, 1.0mm (0.04in) thick, Premion(R); Platinum wire, 0.5mm (0.02in) dia, Premion(R); Platinum(0) black high surface area (> 32 m(2)); Platinum, nanopowder, <50 nm particle size (TEM); Platinum, rod, 100mm, diameter 1.0mm, 99.95%; Platinum, rod, 100mm, diameter 1.6mm, 99.95%; Platinum, rod, 200mm, diameter 1.0mm, 99.95%; Platinum, rod, 25mm, diameter 1.25mm, 99.95%; Platinum, rod, 50mm, diameter 1.25mm, 99.95%; Platinum, wire, diam. 0.25 mm, thermocouple grade; Platinum foil, 0.025mm (0.001in) thick, Premion?; Platinum foil, 0.05mm (0.002in) thick, Premion??; Platinum foil, 0.127mm (0.005in) thick, Premion?; Platinum wire, 0.404mm (0.0159in) dia, annealed; Platinum, 0.5% on 1/8 in alumina pellets, reduced; Platinum, gauze, 52 mesh, 99.9% trace metals basis; Platinum, rod, 100mm, diameter 1.25mm, 99.95%; Platinum, rod, 200mm, diameter 1.25mm, 99.95%; Platinum, rod, 6.5mm, diameter 6.0mm, 99.99+%; Q27115637; Q27882222; D017671000; Platinum insulated wire, 2m, CD 0.05mm, IT 0.009mm; Platinum, gauze, 100 mesh, 99.9% trace metals basis; Platinum, powder (coarse), 99.99% trace metals basis; Platinum, powder, <=10 mum, 99.9% trace metals basis; Platinum, shot, <=3 mm, >=99.9% trace metals basis; Platinum AA Standard: Pt @ 1000 microg/mL in 20% HCl; Platinum boat, Thickness (mm), 0.05, Length (mm), 75mm; Platinum insulated wire, 0.1m, CD 0.125mm, IT 0.016mm; Platinum insulated wire, 0.2m, CD 0.025mm, IT 0.001mm; Platinum insulated wire, 0.2m, CD 0.125mm, IT 0.016mm; Platinum insulated wire, 0.5m, CD 0.125mm, IT 0.016mm; Platinum insulated wire, 1m, CD 0.125mm, IT 0.016mm; Platinum Internal Standard: Pt @ 10 microg/mL in 5% HCl; Platinum Thinfoil, 0.00125mm (0.00005in) thick, hard; Platinum wire, 0.0508mm (0.002in) dia, stress relieved; Platinum, 5% on silica powder, reduced, dry (Escat 2351); Platinum, wire reel, 10m, diameter 0.08mm, hard, 99.9%; Platinum, wire reel, 1m, diameter 0.01mm, hard, 99.9%; Platinum, wire reel, 1m, diameter 0.025mm, hard, 99.9%; Platinum, wire reel, 1m, diameter 0.05mm, hard, 99.99%; Platinum, wire reel, 1m, diameter 0.08mm, hard, 99.9%; Platinum, wire reel, 1m, diameter 0.1mm, hard, 99.99%; Platinum, wire reel, 1m, diameter 0.25mm, hard, 99.95%; Platinum, wire reel, 20m, diameter 0.08mm, hard, 99.9%; Platinum, wire reel, 2m, diameter 0.05mm, hard, 99.99%; Platinum, wire reel, 2m, diameter 0.063mm, hard, 99.9%; Platinum, wire reel, 2m, diameter 0.08mm, hard, 99.9%; Platinum, wire reel, 2m, diameter 0.1mm, hard, 99.99%; Platinum, wire reel, 2m, diameter 0.25mm, hard, 99.95%; Platinum, wire reel, 5m, diameter 0.01mm, hard, 99.9%; Platinum, wire reel, 5m, diameter 0.025mm, hard, 99.9%; Platinum, wire reel, 5m, diameter 0.05mm, hard, 99.99%; Platinum, wire reel, 5m, diameter 0.063mm, hard, 99.9%; Platinum, wire reel, 5m, diameter 0.08mm, hard, 99.9%; Platinum, wire reel, 5m, diameter 0.1mm, hard, 99.99%; Platinum, wire, diam. 0.25 mm, 99.9% trace metals basis; Platinum, wire, diam. 0.5 mm, 99.9% trace metals basis; Platinum, wire, diam. 0.5 mm, 99.99% trace metals basis; Platinum, wire, diam. 1.0 mm, 99.9% trace metals basis; Platinum, wire, diam. 1.0 mm, 99.99% trace metals basis; Platinum, wire, diam. 2.0 mm, 99.9% trace metals basis; Platinum black, fuel cell grade, >=99.9% trace metals basis; Platinum black, low bulk density, >=99.9% trace metals basis; Platinum gauze, 52 mesh woven from 0.1mm (0.004in) dia wire; Platinum Hollow Cathode Lamp: 2.0' Diameter, 4-pin, Cableless; Platinum, 5% on alumina powder, reduced, dry (Escat 2941); Platinum, foil, thickness 0.1 mm, 99.9% trace metals basis; Platinum, foil, thickness 0.1 mm, 99.99% trace metals basis; Platinum, foil, thickness 0.25 mm, 99.9% trace metals basis; Platinum, foil, thickness 0.5 mm, 99.9% trace metals basis; Platinum, foil, thickness 0.5 mm, 99.99% trace metals basis; Platinum, foil, thickness 1.0 mm, 99.99% trace metals basis; Platinum, powder, 0.5-1.2 mum, >=99.9% trace metals basis; Platinum, wire reel, 0.05m, diameter 1.0mm, hard, 99.95%; Platinum, wire reel, 0.1m, diameter 0.25mm, hard, 99.95%; Platinum, wire reel, 0.1m, diameter 1.0mm, hard, 99.95%; Platinum, wire reel, 0.2m, diameter 0.1mm, hard, 99.99%; Platinum, wire reel, 0.2m, diameter 0.25mm, hard, 99.95%; Platinum, wire reel, 0.2m, diameter 1.0mm, hard, 99.95%; Platinum, wire reel, 0.5m, diameter 0.05mm, hard, 99.99%; Platinum, wire reel, 0.5m, diameter 0.1mm, hard, 99.99%; Platinum, wire reel, 0.5m, diameter 0.25mm, hard, 99.95%; Platinum, wire reel, 10m, diameter 0.025mm, hard, 99.9%; Platinum, wire reel, 10m, diameter 0.02mm, as drawn, 99.9%; Platinum, wire reel, 10m, diameter 0.05mm, hard, 99.99%; Platinum, wire reel, 10m, diameter 0.063mm, hard, 99.9%; Platinum, wire reel, 1m, diameter 0.0125mm, hard, 99.9%; Platinum, wire reel, 1m, diameter 0.02mm, as drawn, 99.9%; Platinum, wire reel, 1m, diameter 0.40mm, as drawn, 99.99%; Platinum, wire reel, 1m, diameter 0.5mm, as drawn, 99.99+%; Platinum, wire reel, 20m, diameter 0.025mm, hard, 99.9%; Platinum, wire reel, 20m, diameter 0.02mm, as drawn, 99.9%; Platinum, wire reel, 20m, diameter 0.05mm, hard, 99.99%; Platinum, wire reel, 50m, diameter 0.025mm, hard, 99.9%; Platinum, wire reel, 5m, diameter 0.0125mm, hard, 99.9%; Platinum, wire reel, 5m, diameter 0.02mm, as drawn, 99.9%; Platinum, wire, diam. 0.10 mm, 99.99% trace metals basis; Platinum, wire, diam. 0.127 mm, 99.9% trace metals basis; Platinum, wire, diam. 0.127 mm, 99.99% trace metals basis; Platinum, wire, diam. 0.20 mm, >=99.99% trace metals basis; Platinum, wire, diam. 0.25 mm, 99.99% trace metals basis; Platinum, wire, diam. 1.5 mm, >=99.9% trace metals basis; Platinum gauze, 100 mesh woven from 0.0762mm (0.003in	Investigative	Investigative Drug(s)	23939	DB12257	D0E5FF	195.08	0	0	.	1	0	0	0	Pt	platinum	[Pt]	[Pt]	InChI=1S/Pt	BASFCYQUMIYNBI-UHFFFAOYSA-N
D9G8BJ	PI-103	Small molecule	PI-103; 371935-74-9; PI103; 3-(4-morpholinopyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol; PI 103; PIK-103; UNII-YQX02F616F; Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-; YQX02F616F; CHEBI:90524; 371935-74-9 (free base); 3-[4-(4-Morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenol; Phenol, 3-(4-(4-morpholinyl)pyrido(3',2':4,5)furo(3,2-d)pyrimidin-2-yl)-; PI-103 hydrobromide; 3-[6-(morpholin-4-yl)-8-oxa-3,5,10-triazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl]phenol; 3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol; 3-(4-(4-Morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol; 3-(4-Morpholin-4-Ylpyrido[3',2':4,5]furo[3,2-D]pyrimidin-2-Yl)phenol; X6K; PI 103 hydrobromide; Kinome_3597; 2x6k; PI 3-K Inhibitor V; mTOR Inhibitor, PI103; PI-103 HCl; MLS006010988; SCHEMBL258242; CHEMBL573339; GTPL5701; BDBM25045; cid_9884685; DTXSID40190676; EX-A039; PIK 103; 4l23; pyridofuropyrimidine derivative, 2; BCPP000107; HMS3229C15; HMS3244E11; HMS3244E12; HMS3244F11; HMS3295E19; HMS3650M10; HMS3654E09; AMY23717; BCP01923; BCP19373; MFCD11983145; NSC759676; NSC776996; s1038; AKOS024462563; CCG-101301; compound 2 [PMID: 17601739]; CS-0127; NSC-759676; NSC-776996; NCGC00187906-01; NCGC00187906-02; NCGC00187906-03; NCGC00187906-15; 3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenol; 3-[6-(morpholin-4-yl)-8-oxa-3,5,10-triazatricyclo[7.4.0.0^{2,7}]trideca-1(13),2,4,6,9,11-hexaen-4-yl]phenol; AC-31514; AS-16221; HY-10115; SMR002530603; FT-0712341; SW218117-2; EC-000.2123; SR-01000946304; SR-01000946304-1; BRD-K67868012-003-01-5; Q27088379; 3-(4-morpholinopyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol; 3-[4-(4-morpholinyl)-2-pyrido[2,3]furo[2,4-b]pyrimidinyl]phenol; 3-(4-(4-morpholinyl)pyrido[3?,2?:4,5]furo[3,2-d]pyrimidin-2- yl)phenol; 3-(4-morpholin-4-ylpyrido[3 ,2 :4,5]furo[3,2-d]pyrimidin-2-yl)phenol; 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]; 3-[4-(morpholin-4-yl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenol; 3-[6-(morpholin-4-yl)-8-oxa-3,5,10-triazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2,4,6,10,12-hexaen-4-yl]phenol	Investigative	Investigative Drug(s)	9884685	DB17046	D0W8XH	348.4	84.5	489	2.7	26	1	7	2	C19H16N4O3	3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenol	C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O	C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O	InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2	TUVCWJQQGGETHL-UHFFFAOYSA-N
DW0LB2	ABT-737	Small molecule	ABT-737; 852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; Z5NFR173NV; CHEMBL376408; (R)-4-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide; 2yxj; 4-{4-[(4'-chlorobiphenyl-2-yl)methyl]piperazin-1-yl}-N-{[4-({(1R)-3-(dimethylamino)-1-[(phenylsulfanyl)methyl]propyl}amino)-3-nitrophenyl]sulfonyl}benzamide; BENZAMIDE, 4-(4-((4'-CHLORO(1,1'-BIPHENYL)-2-YL)METHYL)-1-PIPERAZINYL)-N-((4-(((1R)-3-(DIMETHYLAMINO)-1-((PHENYLTHIO)METHYL)PROPYL)AMINO)-3-NITROPHENYL)SULFONYL)-; Benzamide, 4-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]-; N3C; SCHEMBL158942; GTPL8320; ABT 737 [WHO-DD]; DTXSID7042641; N-Benylpiperazine derivative, 2; BDBM21447; CHEBI:47575; EX-A056; MFCD12756212; NSC758873; s1002; compound 2 [PMID 17256834]; AKOS016003299; AM81254; CCG-264769; CS-0014; NSC-758873; NCGC00253562-01; NCGC00253562-02; BP-25381; HY-50907; SW218108-2; BRD-K56301217-001-01-7; Q25105040; 4-(4-((4'-chloro-1,1'-biphenyl-2-yl)methyl)-1-piperazinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfony)benzamide; 4-(4-{[2-(4-chlorophenyl)phenyl]methyl}piperazin-1-yl)-N-[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrobenzene)sulfonyl]benzamide; 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4- (dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl] sulfonylbenzamide; 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-dimethylamino-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide; 4-{4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]piperazin-1-yl}-N-(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrobenzene-1-sulfonyl)benzamide; 4-{4-[(4'-chloro[biphenyl]-2-yl)methyl]piperazin-1-yl}-N-[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrophenyl)sulfonyl]benzamide	Investigative	Investigative Drug(s)	11228183	DB17023	D0L8WH	813.4	165	1320	9	56	2	10	15	C42H45ClN6O5S2	4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide	CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]	CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]	InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1	HPLNQCPCUACXLM-PGUFJCEWSA-N
DLPR17	JQ1	Small molecule	1268524-70-4; (+)-JQ1; (+)-JQ-1; JQ1 compound; JQ1; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; JQ-1; (S)-JQ1; 1MRH0IMX0W; C23H25ClN4O2S; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate; CHEMBL1957266; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetic acid, 4-(4-chlorophenyl)-2,3,9-trimethyl-, 1,1-dimethylethyl ester, (6S)-; tert-butyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; tert-Butyl 2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate; (S)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno-[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid, 4-(4-chlorophenyl)-2,3,9-trimethyl-, 1,1-dimethylethyl ester, (6S)-; Bromodomain Inhibitor, (+)-JQ1; UNII-1MRH0IMX0W; 3mxf; 4flp; 4qzs; (6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester; tert-butyl 2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; MLS006011158; SCHEMBL881227; GTPL7511; CHEBI:95080; DTXSID20155309; EX-A457; CHEBI:137113; BDBM50365262; HB1448; NSC760183; NSC764043; s7110; AKOS016344680; (+)JQ-1; CCG-269306; CS-0581; JQ1 (+); JQ1-(+); NSC-760183; NSC-764043; NCGC00250412-01; NCGC00250412-15; NCGC00250412-21; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diaz; AC-32617; AS-16352; BP-21590; HY-13030; SMR004702930; BB 0262647; (+)-JQ1, >=98% (HPLC); EN300-7404173; A854208; Q3156953; Z2235802082; (6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]di azepine-6-acetic acid 1,1-dimethylethyl ester; tert-butyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate;(S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; tert-butyl [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetate; tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0,2,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate; tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate; tert-butyl[(S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetate	Investigative	Investigative Drug(s)	46907787	DB17021	D0D2KU	457	97.6	706	4.9	31	0	6	5	C23H25ClN4O2S	tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate	CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C	CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C	InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1	DNVXATUJJDPFDM-KRWDZBQOSA-N
DBS98R	RG2833	Small molecule	RG2833; 1215493-56-3; RG-2833; N-(6-((2-Aminophenyl)amino)-6-oxohexyl)-4-methylbenzamide; RGFP 109; RGFP-109; RGFP109; RG2833 (RGFP109); N-(6-(2-Aminophenylamino)-6-oxohexyl)-4-methylbenzamide; 17V14R89EU; N-[6-(2-aminoanilino)-6-oxohexyl]-4-methylbenzamide; N-[6-(2-aminophenylamino)-6-oxohexyl]-4-methylbenzamide; UNII-17V14R89EU; SCHEMBL529065; GTPL7501; CHEMBL3970532; DTXSID20153300; EX-A767; RG 2833 [WHO-DD]; BDBM207629; GLXC-90514; HMS3653O08; HMS3747M17; HMS3886B13; MFCD25976845; s7292; AKOS030525997; CCG-267917; CS-1526; NCGC00381565-04; AC-33034; AS-55992; HY-16425; US9265734, R01; FT-0700118; SW219374-1; A13139; A891588; J-690067; Q27088540; N-(2-aminophenyl)-6-[(4-methylphenyl)formamido]hexanamide; 3-(1H-Indol-5-yl)-5-{4-[(4-methyl-1-piperazinyl)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridine	Investigative	Investigative Drug(s)	56654642	DB16955	D0GE5B	339.4	84.2	419	2.8	25	3	3	8	C20H25N3O2	N-[6-(2-aminoanilino)-6-oxohexyl]-4-methylbenzamide	CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=CC=CC=C2N	CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=CC=CC=C2N	InChI=1S/C20H25N3O2/c1-15-10-12-16(13-11-15)20(25)22-14-6-2-3-9-19(24)23-18-8-5-4-7-17(18)21/h4-5,7-8,10-13H,2-3,6,9,14,21H2,1H3,(H,22,25)(H,23,24)	VOPDXHFYDJAYNS-UHFFFAOYSA-N
DBT1K4	Compound 11	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DW9C1F	Compound 3	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D3JN2P	Compound M	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D92OWI	Sodium lauryl sulfate	Small molecule	Sodium dodecyl sulfate; 151-21-3; SODIUM LAURYL SULFATE; Sodium dodecylsulfate; Sodium lauryl sulphate; Sodium dodecyl sulphate; Dodecyl sodium sulfate; Neutrazyme; Sodium n-dodecyl sulfate; Irium; Sulfuric acid monododecyl ester sodium salt; Dodecyl sulfate sodium salt; Dodecyl sulfate, sodium salt; Anticerumen; Duponal; Duponol; Gardinol; Sodium monododecyl sulfate; Dreft; Aquarex methyl; Duponol methyl; Solsol needles; Stepanol methyl; Duponol waqa; Stepanol wac; Stepanol waq; Duponol qx; Richonol af; Perlandrol L; Perlankrol L; Sipex sb; Sipex sd; Standapol wa-ac; Stepanol me dry; Duponol Me; Richonol A; Richonol C; Sintapon L; Duponol C; Maprofix LK; Standapol WAQ; Stepanol ME; Stepanol WA; Akyposal SDS; Carsonol SLS; Maprobix NEU; Maprofix NEU; Maprofix WAC; Aquarex ME; Dupanol WAQ; Duponol QC; Duponol WA; Duponol WA dry; Duponol WAQ; Empicol LPZ; Hexamol SLS; Melanol CL; Duponal WAQE; Duponol WAQE; Duponol WAQM; Sterling wa paste; Conco sulfate WA; Conco sulfate WN; Nikkol SLS; Orvus WA Paste; Sipex OP; Sipex SP; Sipex UB; Sipon LS; Sipon PD; Sipon WD; Detergent 66; Montopol La Paste; Sipon LSB; Maprofix WAC-LA; Sterling WAQ-CH; Cycloryl 21; Cycloryl 31; Stepanol WA Paste; Conco Sulfate WAG; Conco Sulfate WAN; Conco Sulfate WAS; Quolac EX-UB; Odoripon Al 95; sodiumdodecylsulfate; Avirol 118 conc; Cycloryl 580; Cycloryl 585N; Lauyl sodium sulfate; Maprofix 563; Sinnopon LS 95; Stepanol T 28; Sodium laurilsulfate; Steinapol NLS 90; Empicol LS 30; Empicol LX 28; Lauryl sodium sulfate; Melanol CL 30; NALS; Rewopol NLS 30; Standapol waq special; Standapol was 100; Sinnopon LS 100; Stepanol WA-100; Carsonol SLS Special; Standapol 112 conc; Stepanol ME Dry AW; Avirol 101; Emersal 6400; Monogen Y 100; Carsonol SLS Paste B; sodium;dodecyl sulfate; Stepanol methyl dry aw; Berol 452; Emal 10; EMAL O; Sipon LS 100; n-Dodecyl sulfate sodium; Sodium monolauryl sulfate; Monododecyl sodium sulfate; Sodiumlauryl ether sulfate; Lauryl sulfate sodium salt; Conco sulfate WA-1200; Conco sulfate WA-1245; Dehydag sulfate GL emulsion; MFCD00036175; Emulsifier no. 104; Texapon k 12 p; CHEBI:8984; P and G Emulsifier 104; Sodium lauryl sulfate ether; SLS; Sodium Laurylsulfate; NSC-402488; Texapon K 1296; NCI-C50191; Laurylsulfuric Acid Sodium Salt; Dodecyl alcohol, hydrogen sulfate, sodium salt; Dodecylsulfuric Acid Sodium Salt; DTXSID1026031; Sodium lauryl sulfate, synthetic; Finasol osr2; Incronol SLS; Natriumlaurylsulfat; 368GB5141J; NCGC00091020-03; E487; Jordanol SL-300; Finasol osr(sub 2); Dodecyl sulfate sodium; Monagen Y 100; Perklankrol ESD 60; Caswell No. 779; Natrium laurylsulfuricum; 12738-53-3; 12765-21-8; 1334-67-4; Laurylsiran sodny [Czech]; Lauryl sulfate, sodium salt; Dehydrag sulfate gl emulsion; DTXCID906031; Dehydag sulphate GL emulsion; Laurylsiran sodny; Rhodapon UB; Sodium lauryl sulfate 30%; CAS-151-21-3; CCRIS 6272; Lauryl sulfate sodium; HSDB 1315; Sodium lauryl sulfate, dental grade; EINECS 205-788-1; EPA Pesticide Chemical Code 079011; NSC 402488; CP 75424; Empicol; AI3-00356; UNII-368GB5141J; Sodium lauryl sulfate [JAN:NF]; sodiumlauryl sulfate; sodium dodecylsulphate; Sodium dedecyl sulfate; Sodium-dodecyl-S-SDS; IPC-SDS; sodium n-dodecyl sulphate; Sodium Lauryl Sulfate NF; SDS (20% Solution); sodium monododecyl sulphate; lauryl sulphate sodium salt; EC 205-788-1; dodecyl sulphate sodium salt; SCHEMBL1102; Sodium lauryl sulfate, SDS; sodium dodecyl sulfate (sds); Sulfuric acid monododecyl ester sodium salt (1:1); CHEMBL23393; sodium dodecyl sulphate (sds); dodecyl sulfuric acid sodium salt; HY-Y0316B; Dodecyl sulphuric acid sodium salt; Sodium lauryl sulfate (JP17/NF); SODIUM LAURYL SULFATE [II]; SODIUM LAURYL SULFATE [MI]; BCP30594; CS-B1770; SODIUM LAURYL SULFATE [FCC]; SODIUM LAURYL SULFATE [JAN]; Tox21_111059; Tox21_201614; Tox21_300149; BDBM50530482; SODIUM LAURILSULFATE [MART.]; SODIUM LAURYL SULFATE [HSDB]; SODIUM LAURYL SULFATE [INCI]; SODIUM LAURYL SULFATE [VANDF]; AKOS015897278; AKOS025147308; Tox21_111059_1; DB00815; Dodecyl sulfuric acid ester sodium salt; SODIUM LAURYL SULFATE [USP-RS]; SODIUM LAURYL SULFATE [WHO-DD]; NCGC00091020-01; NCGC00091020-02; NCGC00254225-01; NCGC00259163-01; NCGC00274082-01; AS-14730; SODIUM LAURILSULFATE [EP IMPURITY]; Lauryl Sulfate, Sodium Salt (25% Aq.); SODIUM LAURILSULFATE [EP MONOGRAPH]; D1403; FT-0603358; FT-0700721; I0352; S0588; D01045; EN300-103513; F16341; S-4600; S-4601; SODIUM DODECYL SULFATE BIOTECH GRD 100G; Q422241; Sodium n-dodecyl sulfate, 98%, for electrophoresis; F0001-0539; Z1365432828; Sodium dodecylsulfate;Sodium lauryl sulphate;Dodecyl sodium sulfate; Sodium dodecyl sulfate for Electrophoresis, inverted exclamation markY98.5%; Dodecyl sodium sulfate, Dodecyl sulfate sodium salt, Lauryl sulfate sodium salt, SDS, Sodium lauryl sulfate	Investigative	Investigative Drug(s)	3423265	DB00815	D05ATI	288.38	74.8	249	.	18	0	4	12	C12H25NaO4S	sodium;dodecyl sulfate	CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]	CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]	InChI=1S/C12H26O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15;/h2-12H2,1H3,(H,13,14,15);/q;+1/p-1	DBMJMQXJHONAFJ-UHFFFAOYSA-M
DW2JM3	SN38	Small molecule	7-Ethyl-10-hydroxycamptothecin; 86639-52-3; SN-38; SN 38; SN 38 lactone; (S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; SN38; 10-Hydroxy-7-ethylcamptothecin; 7-Ethyl-10-hydroxy-20(S)-camptothecin; NK012; NK 012; NK-012; CHEBI:8988; 113015-38-6; C22H20N2O5; IT-141; NSC673596; 0H43101T0J; (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione; CAMPTOTHECIN, 7-ETHYL-10-HYDROXY-; (+)-7-ETHYL-10-HYDROXYCAMPTOTHECIN; (4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 7-ethyl-10-hydroxy-20(s)-campthothecin; LE-SN38; Captothecin, 7-ethyl-10-hydroxy-; MFCD00871873; UNII-0H43101T0J; 110714-48-2; 1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 4,11-DIETHYL-4,9-DIHYDROXY-, (4S)-; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (4S)-; AvaChem1025; diethyl(dihydroxy)[?]dione; SN 38- Bio-X; SCHEMBL34018; GTPL6925; SN 38 [WHO-DD]; DTXSID4040399; 10-hydroxy-7-ethyl camptothecin; 10-hydroxy-7-ethyl-camptothecin; EX-A989; HMS3413B12; HMS3652P12; HMS3677B12; BCP01386; 7-Ethyl-10-hydroxy-20(S)-CPT; BDBM50418088; s4908; AKOS015920433; SN-38(NK-012); AC-1357; BCP9000200; CCG-264764; CS-1579; DB05482; NSC-673596; NCGC00167831-01; NCGC00167831-05; (4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione; AS-13533; BE164132; BP-24513; HY-13704; NCI60_026056; E0748; SW219948-1; S-(+)-7-ETHYL-10-HYDROXYCAMPOTHECIN; EN300-122379; A857464; Q-100871; Q1750127; 7-Ethyl-10-hydroxycamptothecin, >=98% (HPLC), powder; Z1541759909; (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione, AldrichCPR; (4S)-4,9-Dihydroxy-4,11-diethyl-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;SN-38; (S)-4,11-Diethyl-4,9-di-OH-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline- 3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (4S)-; 7-Ethyl-10-hydroxycamptothecin ((S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione); H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (S)-; RS4	Investigative	Investigative Drug(s)	104842	DB05482	D0B6YB	392.4	100	820	1.4	29	2	6	2	C22H20N2O5	(19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)O	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)O	InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1	FJHBVJOVLFPMQE-QFIPXVFZSA-N
D9NDE1	PLX4720	Small molecule	918505-84-7; PLX-4720; PLX4720; N-(3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide; PLX 4720; N-[3-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide; N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide; EQY31RO8HA; N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]propane-1-sulfonamide; CHEBI:90295; MFCD14635203; N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide; N-[3-({5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl}carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide; Raf Kinase Inhibitor V; UNII-EQY31RO8HA; a,a-dimethoxytoluene; 3c4c; MLS006010065; SCHEMBL133733; GTPL5703; CHEMBL1230020; BDBM25617; AMY2871; DTXSID10238711; EX-A186; HMS3244C03; HMS3244C04; HMS3244D03; HMS3265I09; HMS3265I10; HMS3265J09; HMS3265J10; HMS3654M10; HMS3750K11; HMS3884C05; ACT06829; BCP01754; PLX-4720,PLX4720; BBL102256; NSC757438; s1152; STL556055; AKOS015919071; CCG-268810; CS-0094; DB06999; NSC-757438; NCGC00187911-01; NCGC00187911-02; NCGC00187911-06; AC-23171; AS-19376; HY-51424; SMR004701225; DB-003736; FT-0673969; SW218119-2; A19411; Raf Kinase Inhibitor V - CAS 918505-84-7; J-522979; BRD-K16478699-001-01-9; Q27088418; 1-PROPANESULFONAMIDE, N-(3-((5-CHLORO-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)CARBONYL)-2,4-DIFLUOROPHENYL)-; N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]pr opane-1-sulfonamide; propane-1-sulfonic acid [3-(5-chloro-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide; Propane-1-sulfonic acid[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]-amide	Investigative	Investigative Drug(s)	24180719	DB06999	D0F5JZ	413.8	100	648	3.3	27	2	7	6	C17H14ClF2N3O3S	N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide	CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)Cl)F	CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)Cl)F	InChI=1S/C17H14ClF2N3O3S/c1-2-5-27(25,26)23-13-4-3-12(19)14(15(13)20)16(24)11-8-22-17-10(11)6-9(18)7-21-17/h3-4,6-8,23H,2,5H2,1H3,(H,21,22)	YZDJQTHVDDOVHR-UHFFFAOYSA-N
D59XJS	Isoliquiritigenin	Small molecule	isoliquiritigenin; 961-29-5; 2',4,4'-Trihydroxychalcone; (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 4,2',4'-Trihydroxychalcone; 6'-deoxychalcone; GU 17; C15H12O4; 2',4',4-Trihydroxychalcone; Isoliquiritigen; Chalcone, 2',4,4'-trihydroxy-; 13745-20-5; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (2E)-; B9CTI9GB8F; 42'4'-trihydroxychalcone; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxyphenyl)-; CHEMBL129795; GU17; CHEBI:310312; (2E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; (E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; trans-2',4,4'-trihydroxychalcone; 2-PROPEN-1-ONE, 1-(2,4-DIHYDROXYPHENYL)-3-(4-HYDROXYPHENYL)-; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (E)-; (E)-1-(2,4-Dihydroxy-phenyl)-3-(4-hydroxy-phenyl)-propenone; 1060-19-1; (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propene-1-one; GU-17; SMR000112969; CCRIS 7676; GU17;ISL;Isoliquiritigen; SR-01000075499; EINECS 237-316-5; UNII-B9CTI9GB8F; BRN 1914295; iso-Liquiritigenin; MFCD00075907; ILTG; ISLQ; Isoliquiritigenin, powder; Spectrum5_000612; (2E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; Lopac0_000681; BSPBio_003411; 1-08-00-00707 (Beilstein Handbook Reference); MLS000438943; MLS002207240; MLS006010045; BIDD:ER0235; SCHEMBL161168; SPECTRUM1504200; cid_638278; MEGxp0_001326; 2',4,4'-Trihydroxy-Chalcone; DTXSID2022466; 2'',4'',4-trihydroxychalcone; 2'',4,4''-trihydroxychalcone; ACon1_000047; CHEBI:94010; TRIHYDROXYCHALCONE [INCI]; BCPP000201; HMS2233H18; HMS3262I03; 2,4''-dihydroxy-4-hydroxychalcone; BCP02312; HY-N0102; Tox21_500681; BDBM50042944; CCG-40334; CMLD3_000056; HB4213; LMPK12120096; s2404; 2',4,4'-Trihydroxychalcone, 97%; Isoliquiritigenin, analytical standard; AKOS001590146; BCP9000795; CS-1745; DB03285; KS-5256; LP00681; SDCCGMLS-0066751.P001; SDCCGSBI-0050660.P004; NCGC00090504-01; NCGC00090504-02; NCGC00090504-03; NCGC00090504-04; NCGC00090504-05; NCGC00090504-06; NCGC00090504-07; NCGC00090504-08; NCGC00090504-24; NCGC00261366-01; AC-33981; EU-0100681; I0822; SW219658-1; C08650; I 3766; I11575; A845551; 2',4'-Dihydroxy-3-(p-hydroxyphenyl)-Acrylophenone; Q-100904; Q3155537; SR-01000075499-1; SR-01000075499-5; BRD-K33583600-001-03-9; BRD-K33583600-001-04-7; 1-(2,4-Dihydroxy-phenyl)-3-(4-hydroxy-phenyl)-propenone; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-prop-2-en-1-one; (E)-1-[2,4-bis(oxidanyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one; ILG	Investigative	Investigative Drug(s)	638278	DB03285	.	256.25	77.8	331	3.2	19	3	4	3	C15H12O4	(E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one	C1=CC(=CC=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O	C1=CC(=CC=C1/C=C/C(=O)C2=C(C=C(C=C2)O)O)O	InChI=1S/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3+	DXDRHHKMWQZJHT-FPYGCLRLSA-N
D7NS1Z	Propyl gallate	Small molecule	propyl gallate; 121-79-9; Propyl 3,4,5-trihydroxybenzoate; N-Propyl gallate; Tenox PG; Progallin P; Gallic acid, propyl ester; Nipagallin P; Gallic acid propyl ester; NIPA 49; 3,4,5-Trihydroxybenzoic acid propyl ester; Benzoic acid, 3,4,5-trihydroxy-, propyl ester; n-Propyl 3,4,5-trihydroxybenzoate; FEMA No. 2947; 3,4,5-Trihydroxybenzene-1-propylcarboxylate; Propylester kyseliny gallove; n-Propyl ester of 3,4,5-trihydroxybenzoic acid; Gallic acid n-propyl ester; NSC 2626; 3,4,5-Trihydroxybenzoic acid, propyl ester; NCI-C505888; 3,4,5-Trihydroxybenzoic acid n-propyl ester; Nipanox S 1; Propyl gallate (NF); Propyl gallate [NF]; NSC-2626; Propyl gallate (e 310); CHEMBL7983; Gallic acid, n-propyl ester; E310; 8D4SNN7V92; INS NO.310; DTXSID5021201; CHEBI:10607; INS-310; NSC2626; Anhydrous propyl gallate (e 310); NCGC00164234-01; E-310; DTXCID901201; Gallate, Propyl; Pro gallin P; CAS-121-79-9; CCRIS 541; HSDB 591; n-Propyl-3,4,5-Trihydroxybenzoate; EINECS 204-498-2; Propylester kyseliny gallove [Czech]; UNII-8D4SNN7V92; Propyl galiate; AI3-17136; l ester; n-propyl-gallate; Sustane PG; Propylgallate,(S); Propyl Gallate FCC; MFCD00002196; Propyl gallate, powder; Propyl gallate, 98%; Gallic acid-propyl ester; 3,4,5-Trihydroxy-benzoic acid propyl ester; Gallic acid propyl esterZ; PROPYL GALLATE [II]; PROPYL GALLATE [MI]; Oprea1_580415; SCHEMBL22630; CBDivE_013134; PROPYL GALLATE [FCC]; BIDD:ER0334; Propyl 3,5-trihydroxybenzoate; PROPYL GALLATE [FHFI]; PROPYL GALLATE [HSDB]; PROPYL GALLATE [INCI]; WLN: QR BQ CQ EVO3; PROPYL GALLATE [VANDF]; PROPYL GALLATE [MART.]; PROPYL GALLATE [USP-RS]; PROPYL GALLATE [WHO-DD]; FEMA 2947; n-Propyl 3,5-trihydroxybenzoate; Propyl gallate, >=98%, FCC; NCI-C50588; BCP13340; HY-N0524; Tox21_113531; Tox21_202286; Tox21_300060; BDBM50032154; s5113; 3,4,5-Trihydroxy-benzoic acid propy; PROPYL GALLATE [EP MONOGRAPH]; AKOS001603853; ANGC-121-79-9; 5-Methyl-4,5-dihydrothiazole-2-thiol; CCG-207932; DB12450; NCGC00164234-02; NCGC00164234-03; NCGC00164234-04; NCGC00254138-01; NCGC00259835-01; 3,5-Trihydroxybenzene-1-propylcarboxylate; 3,5-Trihydroxybenzoic acid, propyl ester; AC-11365; AC-34485; AS-11986; NCI60_002094; Propyl gallate, USP, 98.0-102.0%; DB-003766; Benzoic acid,4,5-trihydroxy-, propyl ester; CS-0009059; EU-0036319; FT-0626599; G0018; n-Propyl ester of 3,5-trihydroxybenzoic acid; A19435; D02382; E80666; Propyl gallate, antioxidant, >=98.0% (HPLC); Q608726; SR-01000944710; Propyl gallate, for microscopy, >=98.0% (HPLC); Q-201634; SR-01000944710-1; EFFF5FFA-651C-4DE3-A25F-D807C65D5537; N-PROPYL ESTER OF 3,4,5- TRIHYDROXYBENZOIC ACID; Propyl gallate, European Pharmacopoeia (EP) Reference Standard; Propyl gallate, United States Pharmacopeia (USP) Reference Standard; Propyl gallate, Pharmaceutical Secondary Standard; Certified Reference Material	Investigative	Investigative Drug(s)	4947	DB12450	.	212.2	87	206	1.8	15	3	5	4	C10H12O5	propyl 3,4,5-trihydroxybenzoate	CCCOC(=O)C1=CC(=C(C(=C1)O)O)O	CCCOC(=O)C1=CC(=C(C(=C1)O)O)O	InChI=1S/C10H12O5/c1-2-3-15-10(14)6-4-7(11)9(13)8(12)5-6/h4-5,11-13H,2-3H2,1H3	ZTHYODDOHIVTJV-UHFFFAOYSA-N
DI2W4H	BMS-536924	Small molecule	BMS-536924; 468740-43-4; BMS536924; BMS 536924; 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone; 40E3AZG1MX; CHEMBL401930; Insulin-like Growth Factor-1 Receptor Inhibitor; CS-0117; HY-10262; (S)-4-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)-3-(4-methyl-6-morpholino-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one; (3M)-4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(morpholin-4-yl)-1H-benzimidazol-2-yl]pyridin-2(1H)-one; UNII-40E3AZG1MX; (S)-4-((2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)-3-(4-METHYL-6-MORPHOLINO-1H-BENZO(D)IMIDAZOL-2-YL)PYRIDIN-2(1H)-ONE; 4-(((2S)-2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)-3-(7-METHYL-5-(4-MORPHOLINYL)-1H-BENZIMIDAZOL-2-YL)-2(1H)-PYRIDINONE; N6I; MLS006011171; SCHEMBL4132577; SCHEMBL15974144; BDBM27879; CHEBI:91454; BCP02116; EX-A4566; NSC761760; s1012; BMS 536924 [WHO-DD]; AKOS024458339; AKOS025149514; CCG-269544; NSC-761760; NCGC00346460-02; NCGC00346460-04; NCGC00346460-05; NCGC00346460-06; 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one; AC-32997; AS-78828; SMR004702940; SW218124-2; D94990; BMS-536924, >=98% (HPLC); J-514217; BRD-K34581968-001-01-2; Q27163296; Q27258319; 2(1H)-PYRIDINONE, 4-(((2S)-2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)-3-(7-METHYL-5-(4-MORPHOLINYL)-1H-BENZIMIDAZOL-2-YL)-; 4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[4-methyl-6-(4-morpholinyl)-1,3-dihydrobenzimidazol-2-ylidene]-2-pyridinone; 4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(morpholin-4-yl)-1H-1,3-benzodiazol-2-yl]-1,2-dihydropyridin-2-one; 4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[7-methyl-5-(morpholin-4-yl)-1H-1,3-benzodiazol-2-yl]-1,2-dihydropyridin-2-one	Investigative	Investigative Drug(s)	135440466	.	D0M4SY	480	103	801	2.7	34	4	6	6	C25H26ClN5O3	4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one	CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCOCC5	CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCOCC5	InChI=1S/C25H26ClN5O3/c1-15-11-18(31-7-9-34-10-8-31)13-20-23(15)30-24(29-20)22-19(5-6-27-25(22)33)28-14-21(32)16-3-2-4-17(26)12-16/h2-6,11-13,21,32H,7-10,14H2,1H3,(H,29,30)(H2,27,28,33)/t21-/m1/s1	ZWVZORIKUNOTCS-OAQYLSRUSA-N
DE32OX	Honokiol	Small molecule	Honokiol; 35354-74-6; 5,3'-Diallyl-2,4'-dihydroxybiphenyl; NSC 293100; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; C18H18O2; Honokiol,(S); 3',5-diallyl-2,4'-biphenyldiol; 3',5-Diallylbiphenyl-2,4'-diol; CPD000387107; CHEMBL16901; 2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol; CHEBI:5759; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; 11513CCO0N; 5,3'-Diallyl-biphenyl-2,4'-diol; MFCD00016674; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; NSC-293100; 2-[4-hydroxy-3-(prop-2-en-1-yl)phenyl]-4-(prop-2-en-1-yl)phenol; 2-(4-hydroxy-3-prop-2-enyl-phenyl)- 4-prop-2-enyl-phenol; SMR000387107; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; Purinol; (1,1'-BIPHENYL)-2,4'-DIOL, 3',5-DI-2-PROPENYL-; UNII-11513CCO0N; Honokiol, HO; 5,3&prime; Honokiol - 95%; FMLT BSASM H; HONOKIOL [INCI]; HONOKIOL [MI]; HONOKIOL [WHO-DD]; Honokiol, analytical standard; cid_72303; MLS000759481; MLS001048916; MLS001423980; MLS006011755; SCHEMBL133034; REGID_for_CID_72303; GTPL11610; DTXSID30188845; 3',1'-biphenyl)-2,4'-diol; HMS2051C12; HMS2271J07; HMS3393C12; HMS3656G03; (1,1'-BIPHENYL)-2,4'-DIOL, 3',5-DI-2-PROPEN-1-YL-; AMY40657; BCP28282; HY-N0003; 3',5'-Diallyl-2,4'-biphenyldiol; AC-486; BBL027819; BDBM50157304; HB0328; NSC293100; s2310; STK801954; 3'',5-diallylbiphenyl-2,4''-diol; Honokiol, >=98% (HPLC), powder; 3,5'-diallyl-2',4-dihydroxybiphenyl; AKOS005622639; 3',5-Diallyl-2,4'-dihydroxybiphenyl; CCG-100864; CS-1696; NC00114; 5,3''-Diallyl-biphenyl-2,4''-diol; SMP2_000040; NCGC00163567-01; NCGC00163567-02; NCGC00163567-03; NCGC00163567-08; AS-15333; XH163752; 5,3''''-Diallyl-biphenyl-2,4''''-diol; FT-0601638; H1309; SW197494-3; EN300-7399522; A822747; SR-01000758208; Q-100425; Q5896650; SR-01000758208-5; {1,1'-Biphenyl]-2,4'-diol, 3,5-di-2-propenyl-; 3'',5-di-2-propenyl-1,1''-biphenyl-2,4''-diol; BRD-K98493452-001-01-6; 3',5-Di-2-propen-1-yl[1,1'-biphenyl]-2,4'-diol; Honokiol, European Pharmacopoeia (EP) Reference Standard; Z2065671480; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propen-1-yl; 4-[2-hydroxy-5-(prop-2-en-1-yl)phenyl]-2-(prop-2-en-1-yl)phenol	Investigative	Investigative Drug(s)	72303	.	D04DQJ	266.3	40.5	325	5	20	2	2	5	C18H18O2	2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol	C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C	C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C	InChI=1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2	FVYXIJYOAGAUQK-UHFFFAOYSA-N
DE50VH	Aristolochic acid	Small molecule	Aristolochic acid; Aristolochic acid A; 313-67-7; Aristolochic acid I; Aristolochin; Tardolyt; Aristolochic acid-I; ARISTOLOCHINE; TR 1736; NSC-50413; 8-Methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid; C17H11NO7; NSC11926; 3,4-Methylenedioxy-8-methoxy-10-nitro-1-phenanthrenecarboxylic acid; NSC50413; Birthwort; 8-Methoxy-3,4-methylenedioxy-10-nitrophenanthrene-1-carboxylic acid; 8-Methoxy-6-nitrophenanthol (3,4-d) 1,3-dioxole-5-carboxylic acid; CHEMBL93353; MLS002702976; CHEBI:2825; Aristolochic acid I;TR 1736; 8-methoxy-6-nitronaphtho[2,1-g][1,3]benzodioxole-5-carboxylic acid; 94218WFP5T; Phenanthro(3,4-d)-1,3-dioxole-5-carboxylic acid, 8-methoxy-6-nitro-; Phenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid, 8-methoxy-6-nitro-; NSC-11926; Aristolochiazaeure; 8-methoxy-6-nitro-naphtho[1,2-e][1,3]benzodioxole-5-carboxylic acid; 8-METHOXY-6-NITROPHENANTHROL(3,4-D)-1,3-DIOXIDE-5-CARBOXYLIC ACID; SMR001562128; Aristolochic acid 1; CCRIS 1544; SR-05000002369; EINECS 206-238-3; NSC 11926; NSC 50413; BRN 0345159; Aristolochia; Phenanthro[3,3-dioxole-5-carboxylic acid, 8-methoxy-6-nitro-; UNII-94218WFP5T; AristolochicacidA; aris-tolochic acid; GOQ; Aristolochic-acid-A; MFCD00004996; ARISTOLOCHIA A; Spectrum_001156; SpecPlus_000448; 8-Methoxy-3,4-methylendioxxy-10-nitro-1-phenanthrencarbonsaeure; 10190-99-5; 8-methoxy-6-nitrophenanthro(3,4-d)-1,3-dioxole-5-carboxylic acid; Spectrum2_000822; Spectrum3_001114; Spectrum4_001952; Spectrum5_000729; Aristolochic acid A,(S); NCIMech_000812; Aristolochic acid I, powder; BSPBio_001440; BSPBio_002848; KBioGR_000160; KBioGR_002387; KBioSS_000160; KBioSS_001636; MLS002695974; DivK1c_006544; SCHEMBL166284; SPECTRUM1502233; SPBio_000743; ARISTOLOCHIC ACID [MI]; ARISTOLOCHIC ACID [IARC]; DTXSID0040969; GTPL12438; KBio1_001488; KBio2_000160; KBio2_001636; KBio2_002728; KBio2_004204; KBio2_005296; KBio2_006772; KBio3_000319; KBio3_000320; KBio3_002068; Bio1_000418; Bio1_000907; Bio1_001396; Bio2_000160; Bio2_000640; HMS1361H22; HMS1791H22; HMS1989H22; HMS3402H22; ARISTOLOCHIC ACID [WHO-DD]; HY-N0510; TNP00273; 8-methoxy-6-nitro-naphtho[2,1-g][1,3]benzodioxole-5-carboxylic acid; BDBM50306855; CCG-35796; CCG-36162; s9193; Mixture of Aristolochic Acid A and B; AKOS015896751; TR-1736; IDI1_033910; 2-Naphthyl Pyrovalerone-d8 Hydrochloride; NCGC00017334-01; NCGC00017334-02; NCGC00017334-03; NCGC00017334-04; NCGC00017334-05; NCGC00017334-06; NCGC00017334-07; NCGC00095981-01; NCGC00095981-02; NCGC00095981-03; NCGC00095981-04; NCGC00095981-05; 1246815-48-4; AC-34489; BS-16911; NCI60_000460; XA167153; DB-048017; CS-0009050; FT-0602867; C08469; ARISTOLOCHIC ACID, PLANTS CONTAINING [IARC]; Q-100394; SR-05000002369-2; SR-05000002369-3; Q21099362; Aristolochia, European Pharmacopoeia (EP) Reference Standard; 8-Methoxy-6-nitro-phenanthro[3,4-d][1,3]dioxole-5-carboxylic acid; Aristolochic acid I, European Pharmacopoeia (EP) Reference Standard; 8-Methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid #; Phenanthro[3,4-d]-1,3-dioxole-5-carbocylic acid, 8-methoxy-6-nitro-	Investigative	Investigative Drug(s)	2236	.	.	341.27	111	550	3.6	25	1	7	2	C17H11NO7	8-methoxy-6-nitronaphtho[2,1-g][1,3]benzodioxole-5-carboxylic acid	COC1=CC=CC2=C3C(=C(C=C21)[N+](=O)[O-])C(=CC4=C3OCO4)C(=O)O	COC1=CC=CC2=C3C(=C(C=C21)[N+](=O)[O-])C(=CC4=C3OCO4)C(=O)O	InChI=1S/C17H11NO7/c1-23-12-4-2-3-8-9(12)5-11(18(21)22)14-10(17(19)20)6-13-16(15(8)14)25-7-24-13/h2-6H,7H2,1H3,(H,19,20)	BBFQZRXNYIEMAW-UHFFFAOYSA-N
D0S9WD	AG-012986	Small molecule	486414-35-1; AG-012986; AG-12286; SPQ325890Y; 4-((4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl)amino)-N-((R)-2-dimethylamino-1-methylethyl)benzamide; Benzamide, 4-((4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl)amino)-N-((1R)-2-(dimethylamino)-1-methylethyl)-; 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-((R)-2-dimethylamino-1-methylethyl)benzamide; Benzamide, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-n-[(1r)-2-(dimethylamino)-1-methylethyl]-; UNII-SPQ325890Y; SCHEMBL6788391; P16766; Q27289330; 4-[[4-amino-5-(2,6-difluorobenzoyl)-1,3-thiazol-2-yl]amino]-N-[(2R)-1-(dimethylamino)propan-2-yl]benzamide; BENZAMIDE,4-[[4-AMINO-5-(2,6-DIFLUOROBENZOYL)-2-THIAZOLYL]AMINO]-N-[(1R)-2-(DIMETHYLAMINO)-1-METHYLETHYL]-	Investigative	Investigative Drug(s)	11259686	.	.	459.5	129	640	4.7	32	3	9	8	C22H23F2N5O2S	4-[[4-amino-5-(2,6-difluorobenzoyl)-1,3-thiazol-2-yl]amino]-N-[(2R)-1-(dimethylamino)propan-2-yl]benzamide	CC(CN(C)C)NC(=O)C1=CC=C(C=C1)NC2=NC(=C(S2)C(=O)C3=C(C=CC=C3F)F)N	C[C@H](CN(C)C)NC(=O)C1=CC=C(C=C1)NC2=NC(=C(S2)C(=O)C3=C(C=CC=C3F)F)N	InChI=1S/C22H23F2N5O2S/c1-12(11-29(2)3)26-21(31)13-7-9-14(10-8-13)27-22-28-20(25)19(32-22)18(30)17-15(23)5-4-6-16(17)24/h4-10,12H,11,25H2,1-3H3,(H,26,31)(H,27,28)/t12-/m1/s1	KFWFBALDPSVAFT-GFCCVEGCSA-N
DB9XA4	2-fluoropyrimidine	Small molecule	2-fluoropyrimidine; 31575-35-6; Pyrimidine, 2-fluoro-; 2-fluoro-pyrimidine; Pyrimidine, fluoro-; MFCD08059530; fluoropyrimidine; Pyrimidine,2-fluoro-; AMY088; DTXSID40185466; BBL103780; STL557590; AKOS005258968; CS-W018601; SB55512; AS-57144; EN300-194488; A820916; J-509528; Z1255443066	Investigative	Investigative Drug(s)	141643	.	.	98.08	25.8	51.7	0	7	0	3	0	C4H3FN2	2-fluoropyrimidine	C1=CN=C(N=C1)F	C1=CN=C(N=C1)F	InChI=1S/C4H3FN2/c5-4-6-2-1-3-7-4/h1-3H	WAVYAFBQOXCGSZ-UHFFFAOYSA-N
D1IL7H	WZ4002	Small molecule	WZ4002; 1213269-23-8; WZ-4002; N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide; WZ 4002; CHEBI:61400; N-(3-((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)acrylamide; N-{3-[(5-chloro-2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)oxy]phenyl}prop-2-enamide; CHEMBL1229592; 6BQ432Z61M; N-[3-[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]prop-2-enamide; N-[3-[[5-Chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide; SMR001913510; UNII-6BQ432Z61M; N-(3-((5-CHLORO-2-((2-METHOXY-4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-4-PYRIMIDINYL)OXY)PHENYL)-2-PROPENAMIDE; SCHEMBL93699; MLS003230945; MLS006011213; AMY370; GTPL9176; DTXSID30153230; EX-A416; HMS3265O15; HMS3265O16; HMS3265P15; HMS3265P16; HMS3654C16; BCP02515; BDBM50383274; NSC755927; s1173; AKOS025401946; CCG-264847; CS-0167; NSC-755927; SB19360; NCGC00263144-01; NCGC00263144-02; NCGC00263144-11; AC-27472; AS-19387; DA-47168; HY-12026; N-(3-((5-chloro-2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-4-pyrimidinyl)oxy)phenyl)acrylamide; WZ4002, >=98% (HPLC); FT-0730384; SW219315-1; EC-000.2280; A25634; J-004480; J-523322; Q27089236; 2-PROPENAMIDE, N-(3-((5-CHLORO-2-((2-METHOXY-4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-4-PYRIMIDINYL)OXY)PHENYL)-; N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazine-1-yl)phenylamino)pyrimidin-4yloxy)phenyl)acrylam; N-[3-[[5-Chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide HBr	Investigative	Investigative Drug(s)	44607530	.	.	495	91.8	694	4.2	35	2	8	8	C25H27ClN6O3	N-[3-[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]prop-2-enamide	CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)OC4=CC=CC(=C4)NC(=O)C=C)Cl)OC	CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)OC4=CC=CC(=C4)NC(=O)C=C)Cl)OC	InChI=1S/C25H27ClN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h4-9,14-16H,1,10-13H2,2-3H3,(H,28,33)(H,27,29,30)	ITTRLTNMFYIYPA-UHFFFAOYSA-N
DP1MN5	1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DXL93P	Deoxynucleoside	Small molecule	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DZ8IK7	FGF21	Protein	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DEMG78	Follistatin-Fc	Protein	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DW07ET	SNN0029	Protein	.	Investigative	Investigative Drug(s)	.	DB12639	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9WL6S	SNN0031	Protein	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DE32SY	C9ASO-1	Antisense oligonucleotide	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D8X1JT	C9ASO-2	Antisense oligonucleotide	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DVO01C	1928z CAR T cells	CAR T cell therapy	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D4JUQ8	Dioscorea bulbifera	Natural product	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D4E8KO	Butylated hydroxyanisole	Natural product	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D5YNO7	Carpesii fructus	Natural product	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D7AB4Q	Cistanches herba	Natural product	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DPE12Q	Clerodendrum cyrtophyllum	Natural product	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D1POC8	Fructus psoraleae	Natural product	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DT3CQ2	Largehead atractylodes rhizome	Natural product	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DK5B1U	Panax ginseng	Natural product	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D87AWG	Rhizoma sparganii	Natural product	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D46NDB	Tripterygium glycosides	Natural product	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DL5RN9	Tripterygium wilfordii	Natural product	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DX5WE9	Xiaoaiping	Natural product	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D3LI4O	PF-0259	Antibody drug conjugate	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9RDC2	Targeted neutrophil inhibitory-hirulog	Glycoprotein 	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DPO0I1	2-hydroxypropyl-beta-cyclodextrins	.	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D6MD1O	WZ8040	.	nitrendipine; 39562-70-4; Bayotensin; Baypress; Nidrel; Nitrendipin; Deiten; Bay-e-5009; Nitrendipinum; Nitrepin; BAY e 5009; Nitrendipino; Bylotensin; 3-ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Nitrendipinum [INN-Latin]; Nitrendipino [INN-Spanish]; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester; CHEBI:7582; MFCD00082255; NSC-758466; MLS000069349; DTXSID0023373; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester; 5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 9B627AW319; NCGC00015713-07; SMR000058366; ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester, (+/-)-; DTXCID203373; Baylotensin; Baypress (TN); 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-ethyl 5-methyl ester; SR-01000075334; EINECS 254-513-1; BRN 0498823; UNII-9B627AW319; Nitrendipine,(S); Nitrendipine [USAN:INN:BAN:JAN]; CAS-39562-70-4; Spectrum_001901; Opera_ID_928; SpecPlus_000742; Prestwick0_000916; Prestwick1_000916; Prestwick2_000916; Prestwick3_000916; Spectrum2_001565; Spectrum3_000968; Spectrum4_001088; Spectrum5_001655; NITRENDIPINE [MI]; N-144; (.+/-.)-Nitrendipine; NITRENDIPINE [INN]; NITRENDIPINE [JAN]; NITRENDIPINE [USAN]; (+-)-Ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; Ethyl 1,4-dihydro-5-(acetoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridincarboxylat; CBiol_001834; Lopac0_000881; Oprea1_472855; Oprea1_703261; SCHEMBL38972; BSPBio_000792; BSPBio_001399; BSPBio_002575; KBioGR_000119; KBioGR_001476; KBioSS_000119; KBioSS_002432; NITRENDIPINE [MART.]; MLS000759400; MLS001148149; MLS001424133; MLS002153303; MLS002154060; (+/-)-NITRENDIPINE; DivK1c_006838; NITRENDIPINE [WHO-DD]; Nitrendipine, >95%, powder; SPECTRUM1503609; SPBio_001470; SPBio_002981; BPBio1_000872; GTPL2334; CHEMBL3195219; KBio1_001782; KBio2_000119; KBio2_002426; KBio2_002687; KBio2_004994; KBio2_005255; KBio2_007562; KBio3_000237; KBio3_000238; KBio3_001795; BRD6392; Nitrendipine (JP17/USAN/INN); Bio1_000120; Bio1_000609; Bio1_001098; Bio2_000119; Bio2_000599; HMS1361F21; HMS1570H14; HMS1791F21; HMS1989F21; HMS2051B04; HMS2089H15; HMS2093G17; HMS2097H14; HMS2230F04; HMS3262B04; HMS3266B03; HMS3371J07; HMS3393B04; HMS3402F21; HMS3411I14; HMS3651F05; HMS3675I14; HMS3714H14; HMS3884H21; NITRENDIPINE [EP IMPURITY]; Pharmakon1600-01503609; NITRENDIPINE [EP MONOGRAPH]; BCP07540; BRD-6392; HY-B0424; Nitrendipine for peak identification; Tox21_110201; Tox21_500881; AC-648; BBL028163; BDBM50237611; CA-212; CCG-39343; NSC758466; STK368903; AKOS000622913; AKOS015894921; Tox21_110201_1; CCG-100991; DB01054; KS-1305; LP00881; NC00241; NSC 758466; SDCCGSBI-0050856.P004; IDI1_033869; NCGC00015713-04; NCGC00015713-05; NCGC00015713-06; NCGC00015713-08; NCGC00015713-09; NCGC00015713-10; NCGC00015713-11; NCGC00015713-13; NCGC00015713-26; NCGC00024013-02; NCGC00024676-02; NCGC00024676-03; NCGC00024676-04; NCGC00024676-05; NCGC00024676-06; NCGC00024676-07; NCGC00261566-01; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester, (+-)-; SY058769; (+/-)-BAY-E-5009; SBI-0050856.P003; Nitrendipine 100 microg/mL in Acetonitrile; AB00513962; EU-0100881; FT-0601600; N1186; S2491; SW219737-1; C07713; D00629; AB00053154-03; AB00053154_04; AB00053154_05; A824621; EN300-18434855; Q416584; SR-01000075334-1; SR-01000075334-2; SR-01000075334-4; SR-01000075334-6; W-106422; BRD-A02006392-001-06-5; BRD-A02006392-001-09-9; Z239859926; Nitrendipine, European Pharmacopoeia (EP) Reference Standard; (.+/-.)-Ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinecarboxylic acid ethyl methyl ester; 3-Ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate #; 3-ethyl5-methyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; Ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate; methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Nitrendipine for peak identification, European Pharmacopoeia (EP) Reference Standard; O3-ethyl O5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (+/-)-ETHYL METHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine dicarboxylic acid ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester, (.+/-.)-	Investigative	Investigative Drug(s)	44607531	.	.	360.4	110	661	2.9	26	1	7	6	C18H20N2O6	5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate	CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C	CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C	InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3	PVHUJELLJLJGLN-UHFFFAOYSA-N
D3F6WC	PHA-767491	.	daunorubicin; Daunomycin; 20830-81-3; Acetyladriamycin; Leukaemomycin C; Rubidomycin; Cerubidine; (+)-Daunomycin; DaunoXome; Daunorubicinum; Daunorubicine; RP 13057; Rubomycin C; FI 6339; Daunorubicin (INN); NSC-82151; Daunarubicinum; Daunorrubicina; DaunoXome (TN); Daunamycin; FI-6339; FI6339; RP-13057; ZS7284E0ZP; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; DTXSID7022883; CHEBI:41977; NCGC00024246-05; Anthracyline; NDC-0082-4155; DAUNORUBICIN [INN]; 5,12-Naphthacenedione,8-acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-; Daunorubicinum [INN-Latin]; DTXCID402883; MLS000069508; Daunorubicin [INN:BAN]; NSC-83142; RCRA waste no. U059; (8S,10S)-8-acetyl-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (8S,10S)-8-acetyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; CAS-20830-81-3; NSC82151; SMR000058559; CCRIS 914; SR-01000000033; SR-05000001600; HSDB 5095; NCI-C04693; EINECS 244-069-7; NSC 83142; VS-103; BRN 1445583; Tocris-1467; Daunorubicin(Daunomycin); AI3-52942; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; Prestwick3_000487; DAUNOMYCIN [IARC]; DAUNORUBICIN [MI]; CHEMBL178; DAUNORUBICIN [HSDB]; SCHEMBL3041; DAUNORUBICIN [VANDF]; EPIRUBICIN IMPURITY D; UNII-ZS7284E0ZP; BSPBio_000353; DAUNORUBICIN [MART.]; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-; cid_62770; DAUNORUBICIN [WHO-DD]; BPBio1_000389; GTPL7063; BDBM32017; EX-A1337A; Valrubicin impurity, daunorubicin; DAUNORUBICIN [ORANGE BOOK]; HMS2089H04; HMS2091K06; Pharmakon1600-01500223; VYXEOS COMPONENT DAUNORUBICIN; Tox21_110896; BDBM50368352; GR-318; HY-13062A; LMPK13050002; MFCD00866340; NSC756717; Tox21_110896_1; CCG-212559; CS-2004; DB00694; NSC-756717; NCGC00024246-06; NCGC00024246-07; NCGC00024246-09; NCGC00024246-10; NCGC00024246-12; NCGC00024246-15; NCGC00024246-18; NCGC00025173-01; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-; SBI-0206677.P002; AB00514669; C01907; D07776; Epirubicin hydrochloride impurity, daunorubicin-; AB00514669-09; AB01644616_09; AB01644616_10; EN300-7479232; A814957; Q411659; SR-01000000033-4; SR-05000001600-1; SR-05000001600-2; BRD-K43389675-001-01-3; BRD-K43389675-003-02-7; BRD-K43389675-003-03-5; BRD-K43389675-003-20-9; EPIRUBICIN HYDROCHLORIDE IMPURITY D [EP IMPURITY]; VALRUBICIN IMPURITY, DAUNORUBICIN [USP IMPURITY]; 2-HYDROXY-5-(4-NITRO-PHENYLSULFAMOYL)-BENZOICACID; DOXORUBICIN HYDROCHLORIDE IMPURITY A [EP IMPURITY]; EPIRUBICIN HYDROCHLORIDE IMPURITY, DAUNORUBICIN- [USP IMPURITY]; (1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-9-ethanoyl-4-methoxy-6,9,11-tris(oxidanyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (7S,9S)-9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione chloride; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride; (7S,9S)-9-acetyl-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (8S,10S)-8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-6,8,11-TRIHYDROXY-1-METHOXY-7,8,9,10-TETRAHYDROTETRACENE-5,12-DIONE; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 5,12-NAPHTHACENEDIONE, 8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL))OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-, (8S-CIS)-	Investigative	Investigative Drug(s)	11715767	DB17043	D03DZO	527.5	186	960	1.8	38	5	11	4	C27H29NO10	(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione	CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O	InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1	STQGQHZAVUOBTE-VGBVRHCVSA-N
D9I3VA	TRAIL	.	.	Investigative	Investigative Drug(s)	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DMIB19	Anti-C5 antibody	Antibody	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D05EIC	Anti-GDF-8 antibody	Antibody	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D5AH4U	Anti-HTT antibody	Antibody	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D7B1OZ	Anti-IP-10 antibody	Antibody	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D7M4KO	TNF-alpha-blocking antibody	Antibody	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DHT65W	PMP22-targeting antisense oligonucleotide	Antisense oligonucleotide	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D7QS6Y	Prnp-targeting antisense oligonucleotide	Antisense oligonucleotide	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DH17LE	ATXN3 siRNA	Small interfering RNA	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D7Q9YE	Thiopurine therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DPYB54	Polymyxin	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DY7SL3	Corticosteroid	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DZW63E	Fluoropyrimidine	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DO42VU	Glucocorticoids	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9PBI7	Alkylating agent chemotherapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DQH1K5	AMPK activator	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DSR7D8	Analgesic drug	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DCL2B6	Antibiotic therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DE7O1C	Antidepressant drug	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D14SCD	Antiepileptic drug	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DQ5DI8	Anti-inflammatory therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DN3I1B	Antimicrobial therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D0RSM9	Anti-PD-1 therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DKX8Q6	Anti-PD1/PD-L1 therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D7UE6N	Anti-PD-L1 therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D28LSZ	Antithyroid drug	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DX0BQ6	Anti-tuberculosis therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D3WP1K	BACE1 inhibitor	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DLX8J5	Biochemotherapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D8WO7Y	Cardiac resynchronization therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DID30V	Cardiac surgery	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DRS8H1	CAR-T cell therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DPUW10	Chemoradiotherapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DP57NU	Chemotherapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DUCN70	Contrast agent	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D8Z1LW	CTLA-4 inhibitor	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D6N5GY	Direct renin inhibitor	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D5I1SJ	DMARD	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DMZ4S2	Electroconvulsive therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DY26NC	Endocrine therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DU6HF2	Fluorinated tranylcypromine analogue	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DXQB26	Gamma secretase inhibitor	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DU62RX	Glucocerebrosidase gene therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DUO10J	Immune checkpoint therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DD78KW	Immunotherapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D1I4VP	Induction therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DBJ0Q8	Ionizing radiation	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DAFU68	Irradiation	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DFY1J9	Living donor kidney transplant	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DMGP81	LRRK2 inhibitor	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DZ06AX	Mutated isocitrate dehydrogenase inhibitor	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D43MOP	Neoadjuvant chemotherapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DJ9X3T	Neoadjuvant radiochemotherapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D6QVK2	NMDAR modulator	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D9IW3P	P2X7 antagonist	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DLTB69	P38 kinase inhibitor	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D28JIE	PDK1 inhibitor	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DJR0Q9	Pelvic radiotherapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D8N3XG	Platinum-based chemotherapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D43RXY	Radiation therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DW8KE5	Radiochemotherapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DM69TH	Secretase inhibitor	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DRB82K	SOD1 gene silence	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DEF14O	Soluble guanylate cyclase stimulator	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D52NUA	SPR inhibitor	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D4X2OK	Synaptic repair therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DYS90L	TBK1 inhibitor	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DZJO68	Thoracic radiation therapy	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D6B8IW	Transurethral resection of the prostate	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DY92WR	TRPA1 antagonist	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
D0G9ZB	Ube3a-ATS antisense oligonucleotide	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DO19HP	Wee1 inhibitor	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DFYM20	Anthracycline	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DXTG54	Statins	.	.	Unspecific	Unspecific	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
